PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Di Cesare, A; Paris, S; Albertinazzi, C; Dariozzi, S; Andersen, J; Mann, M; Longhi, R; de Curtis, I				Di Cesare, A; Paris, S; Albertinazzi, C; Dariozzi, S; Andersen, J; Mann, M; Longhi, R; de Curtis, I			p95-APP1 links membrane transport to Rac-mediated reorganization of actin	NATURE CELL BIOLOGY			English	Article							ADP-RIBOSYLATION FACTOR; BINDING PROTEIN; RAC1-INTERACTING PROTEIN; CELL LOCOMOTION; FOCAL ADHESIONS; ARF6; RHO; GTPASE; CYTOSKELETON; FAMILY	Motility requires protrusive activity at the cellular edge, where Rho family members regulate actin dynamics. Here we show that p95-APP1 (ArfGAP-putative, Pix-interacting, paxillin-interacting protein 1), a member of the GIT1/PKL family, is part of a complex that interacts with pac. Wild-type and truncated p95-APP1 induce actin-rich protrusions mediated by Rac and ADP-ribosylation factor 6 (Arf6). Distinct p95-APP1-derived polypeptides have different distributions, indicating that p95-APP1 cycles between the cell surface and endosomes. Our results show that p95-APP1 functionally interacts with pac and localizes to endosomal compartments, thus identifying p95-APP1 as a molecular link between actin organization, adhesion, and membrane transport during cell motility.	Ist Sci San Raffaele, DIBIT, Cell Adhes Unit, I-20132 Milan, Italy; Odense Univ, Ctr Expt Bioinformat, DK-5230 Odense M, Denmark; CNR, Inst Biocatalysis & Mol Recognit, I-20133 Milan, Italy	Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; University of Southern Denmark; Consiglio Nazionale delle Ricerche (CNR)	de Curtis, I (corresponding author), Ist Sci San Raffaele, DIBIT, Cell Adhes Unit, Via Olgettina 58, I-20132 Milan, Italy.	decurtis.ivan@hsr.it	Andersen, Jens S/L-2100-2015; Mann, Matthias/A-3454-2013	Andersen, Jens S/0000-0002-6091-140X; Mann, Matthias/0000-0003-1292-4799; DE CURTIS, Ivanmatteo/0000-0002-7651-1515	Telethon [1171] Funding Source: Medline	Telethon(Fondazione Telethon)		Albertinazzi C, 1998, J CELL BIOL, V142, P815, DOI 10.1083/jcb.142.3.815; Albertinazzi C, 1999, J CELL SCI, V112, P3821; Bagrodia S, 1999, TRENDS CELL BIOL, V9, P350, DOI 10.1016/S0962-8924(99)01618-9; Bagrodia S, 1998, J BIOL CHEM, V273, P23633, DOI 10.1074/jbc.273.37.23633; Bagrodia S, 1999, J BIOL CHEM, V274, P22393, DOI 10.1074/jbc.274.32.22393; Benard V, 1999, J BIOL CHEM, V274, P13198, DOI 10.1074/jbc.274.19.13198; Bokoch GM, 1998, J BIOL CHEM, V273, P8137, DOI 10.1074/jbc.273.14.8137; Bretscher MS, 1998, CURR BIOL, V8, P721, DOI 10.1016/S0960-9822(98)70281-7; Bretscher MS, 1998, CURR OPIN CELL BIOL, V10, P537, DOI 10.1016/S0955-0674(98)80070-7; Cattelino A, 1999, MOL BIOL CELL, V10, P373, DOI 10.1091/mbc.10.2.373; Chavrier P, 1999, CURR OPIN CELL BIOL, V11, P466, DOI 10.1016/S0955-0674(99)80067-2; D'Souza-Schorey C, 1997, EMBO J, V16, P5445, DOI 10.1093/emboj/16.17.5445; D'SOUZA-SCHOREY C, 1995, SCIENCE, V267, P1175, DOI 10.1126/science.7855600; Daniels RH, 1999, TRENDS BIOCHEM SCI, V24, P350, DOI 10.1016/S0968-0004(99)01442-5; DECURTIS I, 1991, J CELL BIOL, V113, P405, DOI 10.1083/jcb.113.2.405; Franco M, 1999, EMBO J, V18, P1480, DOI 10.1093/emboj/18.6.1480; Gaschet J, 1999, J BIOL CHEM, V274, P20040, DOI 10.1074/jbc.274.28.20040; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HOPKINS CR, 1994, J CELL BIOL, V125, P1265, DOI 10.1083/jcb.125.6.1265; Kanoh H, 1997, J BIOL CHEM, V272, P5421, DOI 10.1074/jbc.272.9.5421; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lamaze C, 1996, NATURE, V382, P177, DOI 10.1038/382177a0; Lievremont JP, 1997, J BIOL CHEM, V272, P30873, DOI 10.1074/jbc.272.49.30873; Malosio ML, 1997, J NEUROSCI, V17, P6717; Manser E, 1998, MOL CELL, V1, P183, DOI 10.1016/S1097-2765(00)80019-2; Mitchison TJ, 1996, CELL, V84, P371, DOI 10.1016/S0092-8674(00)81281-7; Murphy C, 1996, NATURE, V384, P427, DOI 10.1038/384427a0; Nagase T, 1995, DNA Res, V2, P167, DOI 10.1093/dnares/2.4.167; Oh WK, 1997, BIOCHEM BIOPH RES CO, V235, P794, DOI 10.1006/bbrc.1997.6875; PETERS PJ, 1995, J CELL BIOL, V128, P1003, DOI 10.1083/jcb.128.6.1003; Premont RT, 1998, P NATL ACAD SCI USA, V95, P14082, DOI 10.1073/pnas.95.24.14082; Radhakrishna H, 1996, J CELL BIOL, V134, P935, DOI 10.1083/jcb.134.4.935; Radhakrishna H, 1999, J CELL SCI, V112, P855; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Ridley AJ, 1996, CURR BIOL, V6, P1256, DOI 10.1016/S0960-9822(02)70711-2; Rottner K, 1999, CURR BIOL, V9, P640, DOI 10.1016/S0960-9822(99)80286-3; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; Song J, 1998, J CELL SCI, V111, P2257; TOMASELLI KJ, 1988, J CELL BIOL, V107, P1241, DOI 10.1083/jcb.107.3.1241; Turner CE, 1999, J CELL BIOL, V145, P851, DOI 10.1083/jcb.145.4.851; TURNER CE, 1990, J CELL BIOL, V111, P1059, DOI 10.1083/jcb.111.3.1059; VanAelst L, 1996, EMBO J, V15, P3778, DOI 10.1002/j.1460-2075.1996.tb00751.x; Vitale N, 2000, J BIOL CHEM, V275, P13901, DOI 10.1074/jbc.275.18.13901; WELSH CF, 1994, J BIOL CHEM, V269, P15583; Wilm M, 1996, NATURE, V379, P466, DOI 10.1038/379466a0; Wilm M, 1996, ANAL CHEM, V68, P1, DOI 10.1021/ac9509519	46	109	109	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	AUG	2000	2	8					521	530		10.1038/35019561	http://dx.doi.org/10.1038/35019561			10	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	341TE	10934473				2022-12-25	WOS:000088605000018
J	Lewis, J; McGowan, E; Rockwood, J; Melrose, H; Nacharaju, P; Van Slegtenhorst, M; Gwinn-Hardy, K; Murphy, MP; Baker, M; Yu, X; Duff, K; Hardy, J; Corral, A; Lin, WL; Yen, SH; Dickson, DW; Davies, P; Hutton, M				Lewis, J; McGowan, E; Rockwood, J; Melrose, H; Nacharaju, P; Van Slegtenhorst, M; Gwinn-Hardy, K; Murphy, MP; Baker, M; Yu, X; Duff, K; Hardy, J; Corral, A; Lin, WL; Yen, SH; Dickson, DW; Davies, P; Hutton, M			Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein	NATURE GENETICS			English	Article							PAIRED HELICAL FILAMENTS; TRANSGENIC MICE; FRONTOTEMPORAL DEMENTIA; NEURODEGENERATIVE DISEASES; CORTICOBASAL DEGENERATION; CYTOSKELETAL PATHOLOGY; PARKINSONISM; TAUOPATHIES; MUTATIONS; MISSENSE	Neurofibrillary tangles (NFT) composed of the microtubule-associated protein tau are prominent in Alzheimer disease (AD), Pick disease, progressive supranuclear palsy (PSP) and corticobasal degeneration(1) (CBD). Mutations in the gene (Mtapt) encoding tau protein cause frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17). thereby proving that tau dysfunction can directly result in neurodegeneration(2). Expression of human tau containing the most common(3-5) FTDP-17 mutation (P301L) results in motor and behavioural deficits in transgenic mice, with age- and gene-dose-dependent development of NFT. This phenotype occurred as early as 6.5 months in hemizygous and 4.5 months in homozygous animals. NFT and Pick-body-like neuronal lesions occurred in the amygdala, septal nuclei, pre-optic nuclei, hypothalamus, midbrain, pens, medulla, deep cerebellar nuclei and spinal cord, with tau-immunoreactive pre-tangles in the cortex, hippocampus and basal ganglia. Areas with the most NFT had reactive gliosis. Spinal cord had axonal spheroids, anterior horn cell toss and axonal degeneration in anterior spinal roots. We also saw peripheral neuropathy and skeletal muscle with neurogenic atrophy. Brain and spinal cord contained insoluble tau that co-migrated with insoluble tau from AD and FTDP-17 brains. The phenotype of mice expressing P301L mutant tau mimics features of human tauopathies and provides a model for investigating the pathogenesis of diseases with NFT.	Mayo Clin Jacksonville, Jacksonville, FL 32224 USA; Albert Einstein Coll Med, Dept Pathol, Bronx, NY USA	Mayo Clinic; Yeshiva University; Albert Einstein College of Medicine	Hutton, M (corresponding author), Mayo Clin Jacksonville, 4500 San Pablo Rd, Jacksonville, FL 32224 USA.		Hardy, John/C-2451-2009; Duff, Karen EK/C-2510-2009; Gwinn, Katrina A/C-2508-2009	Hardy, John/0000-0002-3122-0423; Duff, Karen/0000-0002-6177-868X; Dickson, Dennis W/0000-0001-7189-7917; Gwinn, Katrina/0000-0002-8277-651X	PHS HHS [R01, P01] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Borchelt DR, 1996, GENET ANAL-BIOMOL E, V13, P159, DOI 10.1016/S1050-3862(96)00167-2; Dickson DW, 1997, ANN NEUROL, V42, P541, DOI 10.1002/ana.410420403; Dumanchin C, 1998, HUM MOL GENET, V7, P1825, DOI 10.1093/hmg/7.11.1825; FEANY MB, 1995, AM J PATHOL, V146, P1388; GOTZ J, 1995, EMBO J, V14, P1304, DOI 10.1002/j.1460-2075.1995.tb07116.x; GREENBERG SG, 1992, J BIOL CHEM, V267, P564; GREENBERG SG, 1990, P NATL ACAD SCI USA, V87, P5287; Hutton M, 1998, NATURE, V393, P702, DOI 10.1038/31508; HUTTON M, 1999, NEUROSCI NEWS, V2, P73; Ikonomovic MD, 1997, J NEUROPATH EXP NEUR, V56, P1018, DOI 10.1097/00005072-199709000-00007; IQBAL K, 1991, NEUROBIOL AGING, V12, P357, DOI 10.1016/0197-4580(91)90022-C; Ishihara T, 1999, NEURON, V24, P751, DOI 10.1016/S0896-6273(00)81127-7; Jicha GA, 1997, J NEUROSCI RES, V48, P128, DOI 10.1002/(SICI)1097-4547(19970415)48:2<128::AID-JNR5>3.0.CO;2-E; Jicha GA, 1999, J NEUROSCI RES, V55, P713, DOI 10.1002/(SICI)1097-4547(19990315)55:6<713::AID-JNR6>3.0.CO;2-G; KOSIK KS, 1989, NEURON, V2, P1389, DOI 10.1016/0896-6273(89)90077-9; Mirra SS, 1999, J NEUROPATH EXP NEUR, V58, P335, DOI 10.1097/00005072-199904000-00004; Probst A, 2000, ACTA NEUROPATHOL, V99, P469, DOI 10.1007/s004010051148; Rizzu P, 1999, AM J HUM GENET, V64, P414, DOI 10.1086/302256; Sergeant N, 1999, J NEUROCHEM, V72, P1243, DOI 10.1046/j.1471-4159.1999.0721243.x; Spillantini MG, 1998, BRAIN PATHOL, V8, P387; Spillantini MG, 1998, TRENDS NEUROSCI, V21, P428, DOI 10.1016/S0166-2236(98)01337-X; Spittaels K, 1999, AM J PATHOL, V155, P2153, DOI 10.1016/S0002-9440(10)65533-2; Trojanowski JQ, 1999, BRAIN PATHOL, V9, P733	23	1017	1086	2	70	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	AUG	2000	25	4					402	405		10.1038/78078	http://dx.doi.org/10.1038/78078			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	341WY	10932182				2022-12-25	WOS:000088615000013
J	Mack, M; Kleinschmidt, A; Bruhl, H; Klier, C; Nelson, PJ; Cihak, J; Plachy, J; Stangassinger, M; Erfle, V; Schlondorff, D				Mack, M; Kleinschmidt, A; Bruhl, H; Klier, C; Nelson, PJ; Cihak, J; Plachy, J; Stangassinger, M; Erfle, V; Schlondorff, D			Transfer of the chemokine receptor CCR5 between cells by membrane-derived microparticles: A mechanism for cellular human immunodeficiency virus 1 infection	NATURE MEDICINE			English	Article							HIV-1 CORECEPTOR ACTIVITY; POLYMERASE CHAIN-REACTION; CENTRAL-NERVOUS-SYSTEM; PLATELET MICROPARTICLES; ENDOTHELIAL-CELLS; IN-VITRO; ASTROCYTES; EXPRESSION; TYPE-1; INDIVIDUALS	The release of microparticles from eukaryotic cells is a well-recognized phenomenon. We demonstrate here that the chemokine receptor CCR5, the principal co-receptor for macrophage-tropic human immunodeficiency virus (HIV)-1, can be released through microparticles from the surface of CCR5(+) Chinese hamster ovary cells and peripheral blood mononuclear cells. Microparticles containing CCR5 can transfer the receptor to CCR5(-) cells and render them CCR5(+). The CCR5 transfer to CCR5-deficient peripheral blood mononuclear cells homozygous for a 32-base-pair deletion in the CCR5 gene enabled infection of these cells with macrophage-tropic: HIV-1. In monocytes, the transfer of CCR5 could be inhibited by cytochalasin D, and transferred CCR5 could be downmodulated by chemokines. A transfer of CCR5 from peripheral blood mononuclear cells to endothelial cells during transendothelial migration could be demonstrated. Thus, the transfer of CCR5 may lead to infection of tissues without endogenous CCR5 expression. Moreover, the intercellular transfer of membrane proteins by microparticles might have broader consequences for intercellular communication beyond the effects seen for HIV-1.	Univ Munich, Med Poliklin, D-80336 Munich, Germany; GSF, Natl Res Ctr Environm & Hlth, Inst Mol Virol, D-85764 Neuherberg, Germany; Univ Munich, Inst Anim Physiol, D-80539 Munich, Germany; Acad Sci Czech Republ, Inst Mol Genet, CR-16637 Prague, Czech Republic	University of Munich; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Munich; Czech Academy of Sciences; Institute of Molecular Genetics of the Czech Academy of Sciences	Mack, M (corresponding author), Univ Munich, Med Poliklin, Pettenkoferstr 8A, D-80336 Munich, Germany.		Plachy, Jiri/G-4381-2014					Alkhatib G, 1997, VIROLOGY, V234, P340, DOI 10.1006/viro.1997.8673; ARMSTRONG MJ, 1988, BIOCHIM BIOPHYS ACTA, V946, P106, DOI 10.1016/0005-2736(88)90462-2; Bagasra O, 1996, AIDS, V10, P573, DOI 10.1097/00002030-199606000-00002; Barry OP, 1997, J CLIN INVEST, V99, P2118, DOI 10.1172/JCI119385; Barry OP, 1998, J CLIN INVEST, V102, P136, DOI 10.1172/JCI2592; BEAUDOIN AR, 1991, BIOCHIM BIOPHYS ACTA, V1071, P203, DOI 10.1016/0304-4157(91)90014-N; Berger EA, 1999, ANNU REV IMMUNOL, V17, P657, DOI 10.1146/annurev.immunol.17.1.657; Brack-Werner R, 1999, AIDS, V13, P1, DOI 10.1097/00002030-199901140-00003; Combes V, 1999, J CLIN INVEST, V104, P93, DOI 10.1172/JCI4985; Conant K, 1998, P NATL ACAD SCI USA, V95, P3117, DOI 10.1073/pnas.95.6.3117; Edinger AL, 1997, P NATL ACAD SCI USA, V94, P14742, DOI 10.1073/pnas.94.26.14742; Farzan M, 1997, J BIOL CHEM, V272, P6854, DOI 10.1074/jbc.272.11.6854; Fritsch L, 1998, VIROLOGY, V244, P542, DOI 10.1006/viro.1998.9120; GEORGE JN, 1982, BLOOD, V60, P834; Gluschankof P, 1997, VIROLOGY, V230, P125, DOI 10.1006/viro.1997.8453; Gosling J, 1997, P NATL ACAD SCI USA, V94, P5061, DOI 10.1073/pnas.94.10.5061; Husman AD, 1999, J IMMUNOL, V163, P4597; Klein RS, 1999, J IMMUNOL, V163, P1636; LEVENE RB, 1986, BLOOD, V67, P207; Lopalco L, 2000, J IMMUNOL, V164, P3426, DOI 10.4049/jimmunol.164.6.3426; Mack M, 1998, J EXP MED, V187, P1215, DOI 10.1084/jem.187.8.1215; Mallat Z, 1999, CIRCULATION, V99, P348, DOI 10.1161/01.CIR.99.3.348; Mallat Z, 2000, CIRCULATION, V101, P841, DOI 10.1161/01.CIR.101.8.841; Marechal V, 1998, J VIROL, V72, P2208; Mesri C, 1998, J IMMUNOL, V161, P4382; NUOVO GJ, 1994, AM J PATHOL, V144, P659; Oppermann M, 1999, J BIOL CHEM, V274, P8875, DOI 10.1074/jbc.274.13.8875; Ostrowski MA, 1998, J IMMUNOL, V161, P3195; POPOVIC M, 1984, SCIENCE, V224, P497, DOI 10.1126/science.6200935; Raposo G, 1996, J EXP MED, V183, P1161, DOI 10.1084/jem.183.3.1161; Ray PE, 1998, KIDNEY INT, V53, P1217, DOI 10.1046/j.1523-1755.1998.00900.x; RIEBER EP, 1992, P NATL ACAD SCI USA, V89, P10792, DOI 10.1073/pnas.89.22.10792; Rottman JB, 1997, AM J PATHOL, V151, P1341; RUBSAMENWAIGMANN H, 1989, LANCET, V2, P1155; Sabri F, 1999, VIROLOGY, V264, P370, DOI 10.1006/viro.1999.9998; Samson M, 1996, NATURE, V382, P722, DOI 10.1038/382722a0; SATTA N, 1994, J IMMUNOL, V153, P3245; Schrager LK, 1998, JAMA-J AM MED ASSOC, V280, P67, DOI 10.1001/jama.280.1.67; Segerer S, 1999, KIDNEY INT, V56, P52, DOI 10.1046/j.1523-1755.1999.00544.x; Speck RF, 1999, CURR BIOL, V9, P547, DOI 10.1016/S0960-9822(99)80241-3; WILEY CA, 1986, P NATL ACAD SCI USA, V83, P7089, DOI 10.1073/pnas.83.18.7089; WILEY CA, 1994, ANN NEUROL, V36, P673, DOI 10.1002/ana.410360422; Xiao XD, 1999, P NATL ACAD SCI USA, V96, P7496, DOI 10.1073/pnas.96.13.7496; Zitvogel L, 1998, NAT MED, V4, P594, DOI 10.1038/nm0598-594; Zwaal RFA, 1997, BLOOD, V89, P1121, DOI 10.1182/blood.V89.4.1121	45	431	450	1	20	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUL	2000	6	7					769	+		10.1038/77498	http://dx.doi.org/10.1038/77498			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	331VV	10888925				2022-12-25	WOS:000088040100033
J	Vo-Dinh, T; Alarie, JP; Cullum, BM; Griffin, GD				Vo-Dinh, T; Alarie, JP; Cullum, BM; Griffin, GD			Antibody-based nanoprobe for measurement of a fluorescent analyte in a single cell	NATURE BIOTECHNOLOGY			English	Article						nanoprobe; nanotechnology; bioprobe; antibody; benzo[a]pyrene; benzopyrene tetrol; DNA damage; DNA adduct; carcinogen; intracellular measurement	DNA; BIOSENSOR; SENSORS	We report here the application of an antibody-based nanoprobe for in situ measurements of a single cell. The nanoprobe employs antibody-based receptors targeted to a fluorescent analyte, benzopyrene tetrol (BPT), a metabolite of the carcinogen benzo[a]pyrene (BaP) and of the BaP-DNA adduct. Detection of BPT is of great biomedical interest, since this species can serve as a biomarker for monitoring DNA damage due to BaP exposure and for possible precancer diagnosis. The measurements were performed on the rat liver epithelial clone 9 cell line, which was used as the model cell system. Before making measurements, the cells were treated with BPT. Nanoprobes were inserted into individual cells, incubated 5 min to allow antigen-antibody binding, and then removed for fluorescence detection. We determined a concentration of 9.6 +/- 0.2 x 10(-11) M for BPT in the individual cells investigated. The results demonstrate the possibility of in situ measurements inside a single cell using an antibody-based nanoprobe.	Oak Ridge Natl Lab, Div Life Sci, Adv Monitoring Dev Grp, Oak Ridge, TN 37831 USA	United States Department of Energy (DOE); Oak Ridge National Laboratory	Vo-Dinh, T (corresponding author), Oak Ridge Natl Lab, Div Life Sci, Adv Monitoring Dev Grp, POB 2008, Oak Ridge, TN 37831 USA.							Alarie JP, 1996, POLYCYCL AROMAT COMP, V8, P45, DOI 10.1080/10406639608048333; ALARIE JP, 1990, ANAL CHIM ACTA, V236, P237, DOI 10.1016/S0003-2670(00)83317-6; Barker SLR, 1999, ANAL CHEM, V71, P2071, DOI 10.1021/ac9901081; BETZIG E, 1991, SCIENCE, V251, P1468, DOI 10.1126/science.251.5000.1468; Boisde G., 1996, CHEM BIOCH SENSING O; Deckert V, 1998, ANAL CHEM, V70, P2646, DOI 10.1021/ac971304f; Nakamura R.M., 1992, IMMUNOCHEMICAL ASSAY; SANTELLA RM, 1984, CARCINOGENESIS, V5, P373, DOI 10.1093/carcin/5.3.373; TAN WH, 1992, ANAL CHEM, V64, P2985, DOI 10.1021/ac00047a019; TAN WH, 1992, SCIENCE, V258, P778, DOI 10.1126/science.1439785; VO-DINH T, 1991, CLIN CHEM, V37, P532; VO-DINH T, 1987, APPL SPECTROSC, V41, P735, DOI 10.1366/0003702874448076; VODINH T, 1993, IMMUNOMETHODS, V3, P85; VODINH T, 1989, CHEM ANAL POLYCYCLIC; WOLFBEIS OS, 1991, FIBER OPTIC CHEM SEN, V1	15	108	115	5	58	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUL	2000	18	7					764	767		10.1038/77337	http://dx.doi.org/10.1038/77337			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	331YN	10888846				2022-12-25	WOS:000088046400027
J	Woolley, AT; Guillemette, C; Cheung, CL; Housman, DE; Lieber, CM				Woolley, AT; Guillemette, C; Cheung, CL; Housman, DE; Lieber, CM			Direct haplotyping of kilobase-size DNA using carbon nanotube probes	NATURE BIOTECHNOLOGY			English	Article						atomic force microscopy; haplotype; carbon nanotube; single-nucleotide polymorphism; DNA sequencing	SINGLE-NUCLEOTIDE POLYMORPHISMS; ATOMIC-FORCE MICROSCOPY; TIPS; AMPLIFICATION; GENES; SNPS	We have implemented a method for multiplexed detection of polymorphic sites and direct determination of haplotypes in 10-kilobase-size DNA fragments using single-walled carbon nanotube (SWNT) atomic force microscopy (AFM) probes. Labeled oligonucleotides are hybridized specifically to complementary target sequences in template DNA, and the positions of the tagged sequences are detected by direct SWNT tip imaging. We demonstrated this concept by detecting streptavidin and IRD800 labels at two different sequences in M13mp18. Our approach also permits haplotype determination from simple visual inspection of AFM images of individual DNA molecules, which we have done on UGT1A7, a gene under study as a cancer risk factor. The haplotypes of individuals heterozygous at two critical loci, which together influence cancer risk, can be easily and directly distinguished from AFM images. The application of this technique to haplotyping in population-based genetic disease studies and other genomic screening problems is discussed.	MIT, Ctr Canc Res, Cambridge, MA 02139 USA; Harvard Univ, Dept Chem & Biol Chem, Cambridge, MA 02138 USA	Massachusetts Institute of Technology (MIT); Harvard University	Lieber, CM (corresponding author), MIT, Ctr Canc Res, Cambridge, MA 02139 USA.		Guillemette, Chantal/J-6463-2012; Guillemette, Chantal/AAT-6246-2020; Cheung, Chin Li/B-8270-2013	Guillemette, Chantal/0000-0002-1113-1212; Cheung, Chin Li/0000-0001-8210-2833				BINNIG G, 1986, PHYS REV LETT, V56, P930, DOI 10.1103/PhysRevLett.56.930; Brookes AJ, 1999, GENE, V234, P177, DOI 10.1016/S0378-1119(99)00219-X; Cargill M, 1999, NAT GENET, V22, P231, DOI 10.1038/10290; Collins FS, 1997, SCIENCE, V278, P1580, DOI 10.1126/science.278.5343.1580; Fang Y, 1998, ANAL CHEM, V70, P2123, DOI 10.1021/ac971187o; GUILLEMETTE C, 2000, IN PRESS PHARMACOGEN; Hafner JH, 1999, J AM CHEM SOC, V121, P9750, DOI 10.1021/ja992761b; Halushka MK, 1999, NAT GENET, V22, P239, DOI 10.1038/10297; Hodge SE, 1999, NAT GENET, V21, P360, DOI 10.1038/7687; Mackenzie PI, 1997, PHARMACOGENETICS, V7, P255, DOI 10.1097/00008571-199708000-00001; Risch N, 1996, SCIENCE, V273, P1516, DOI 10.1126/science.273.5281.1516; RUANO G, 1990, P NATL ACAD SCI USA, V87, P6296, DOI 10.1073/pnas.87.16.6296; RUANO G, 1989, NUCLEIC ACIDS RES, V17, P8392, DOI 10.1093/nar/17.20.8392; Sobel E, 1996, AM J HUM GENET, V58, P1323; Sun LF, 2000, NATURE, V403, P384, DOI 10.1038/35000290; THUNDAT T, 1992, J VAC SCI TECHNOL A, V10, P630, DOI 10.1116/1.577700; Vettiger P, 1999, MICROELECTRON ENG, V46, P11, DOI 10.1016/S0167-9317(99)00006-4; Wong SS, 1998, J AM CHEM SOC, V120, P603, DOI 10.1021/ja9737735; Wong SS, 1998, APPL PHYS LETT, V73, P3465, DOI 10.1063/1.122798; Wong SS, 1998, J AM CHEM SOC, V120, P8557, DOI 10.1021/ja9817803	20	147	171	1	45	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUL	2000	18	7					760	763		10.1038/77760	http://dx.doi.org/10.1038/77760			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	331YN	10888845	Green Published			2022-12-25	WOS:000088046400026
J	Burns, K; Clatworthy, J; Martin, L; Martinon, F; Plumpton, C; Maschera, B; Lewis, A; Ray, K; Tschopp, J; Volpe, F				Burns, K; Clatworthy, J; Martin, L; Martinon, F; Plumpton, C; Maschera, B; Lewis, A; Ray, K; Tschopp, J; Volpe, F			Tollip, a new component of the IL-1RI pathway, links IRAK to the IL-1 receptor	NATURE CELL BIOLOGY			English	Article							FACTOR-KAPPA-B; INTERLEUKIN-1 RECEPTOR; ACCESSORY PROTEIN; KINASE IRAK; MYD88; ACTIVATION; ADAPTER; COMPLEX; DOMAIN; FAMILY	Interleukin-1 (IL-1) is a proinflammatory cytokine that elicits its pleiotropic effects through activation of the transcription factors NF-kappa B and AP-1. Binding of IL-1 to its receptor results in rapid assembly of a membrane-proximal signalling complex that consists of two different receptor chains (IL-1Rs), IL-1RI and IL-1RAcP, the adaptor protein MyD88, the serine/threonine kinase IRAK and a new protein, which we have named Tollip. Here we show that, before IL-1 beta treatment, Tollip is present in a complex with IRAK, and that recruitment of Tollip-IRAK complexes to the activated receptor complex occurs through association of Tollip with IL-1RAcP. Co recruited MyD88 then triggers IRAK autophosphorylation, which in turn leads to rapid dissociation of IRAK from Tollip (and IL-1Rs). As overexpression of Tollip results in impaired NF-kappa B activation, we conclude that Tollip is an important constituent of the IL-1R signalling pathway.	Univ Lausanne, Inst Biochem, BIL Biomed Res Ctr, CH-1066 Epalinges, Switzerland; Glaxo Wellcome Res & Dev Ltd, Stevenage SG1 2NY, Herts, England; Cell Biol, Stevenage SG1 2NY, Herts, England; Mol Pharmacol, Stevenage SG1 2NY, Herts, England	University of Lausanne; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline	Tschopp, J (corresponding author), Univ Lausanne, Inst Biochem, BIL Biomed Res Ctr, Chemin Boveresses 155, CH-1066 Epalinges, Switzerland.		Martinon, Fabio/A-5575-2009	Martinon, Fabio/0000-0002-6969-822X				Baud V, 1999, GENE DEV, V13, P1297, DOI 10.1101/gad.13.10.1297; Burns K, 1998, J BIOL CHEM, V273, P12203, DOI 10.1074/jbc.273.20.12203; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; Cao ZD, 1996, SCIENCE, V271, P1128, DOI 10.1126/science.271.5252.1128; Hoffmann JA, 1999, SCIENCE, V284, P1313, DOI 10.1126/science.284.5418.1313; Huang JN, 1997, P NATL ACAD SCI USA, V94, P12829, DOI 10.1073/pnas.94.24.12829; Kojima H, 1998, BIOCHEM BIOPH RES CO, V244, P183, DOI 10.1006/bbrc.1998.8236; Li XX, 1999, MOL CELL BIOL, V19, P4643; Maschera B, 1999, BIOCHEM J, V339, P227, DOI 10.1042/0264-6021:3390227; Muzio M, 1997, SCIENCE, V278, P1612, DOI 10.1126/science.278.5343.1612; Nalefski EA, 1996, PROTEIN SCI, V5, P2375, DOI 10.1002/pro.5560051201; Shen BH, 1998, DEVELOPMENT, V125, P4719; Song HY, 1997, P NATL ACAD SCI USA, V94, P9792, DOI 10.1073/pnas.94.18.9792; Volpe F, 1997, FEBS LETT, V419, P41, DOI 10.1016/S0014-5793(97)01426-9; Wesche H, 1997, IMMUNITY, V7, P837, DOI 10.1016/S1074-7613(00)80402-1; Wesche H, 1997, J BIOL CHEM, V272, P7727, DOI 10.1074/jbc.272.12.7727; Wesche H, 1999, J BIOL CHEM, V274, P19403, DOI 10.1074/jbc.274.27.19403; Wilson I, 1997, CURR BIOL, V7, pR175, DOI 10.1016/S0960-9822(97)70082-4; Yamin TT, 1997, J BIOL CHEM, V272, P21540, DOI 10.1074/jbc.272.34.21540	19	417	453	1	31	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	JUN	2000	2	6					346	351		10.1038/35014038	http://dx.doi.org/10.1038/35014038			6	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	321KE	10854325				2022-12-25	WOS:000087454000016
J	Bulman, MP; Kusumi, K; Frayling, TM; McKeown, C; Garrett, C; Lander, ES; Krumlauf, R; Hattersley, AT; Ellard, S; Turnpenny, PD				Bulman, MP; Kusumi, K; Frayling, TM; McKeown, C; Garrett, C; Lander, ES; Krumlauf, R; Hattersley, AT; Ellard, S; Turnpenny, PD			Mutations in the human Delta homologue, DLL3, cause axial skeletal defects in spondylocostal dysostosis	NATURE GENETICS			English	Article							EPIDERMAL GROWTH-FACTOR; ALAGILLE-SYNDROME; NOTCH-GENE; DROSOPHILA; EXPRESSION; SEGMENTATION; BOUNDARIES; PATTERN; COMPLEX; ENCODES	Spondylocostal dysostosis (SD, MIM 277300) is a group of vertebral malsegmentation syndromes with reduced stature resulting from axial skeletal defects. SD is characterized by mu[tiple hemivertebrae, rib fusions and deletions with a non-progressive kyphoscoliosis. Cases may be sporadic or familial, with both autosomal dominant and autosomal recessive modes of inheritance reported(1). Autosomal recessive SD maps to a 7.8cM interval on chromosome 19q13.1-q13.3 (ref, 2) that is homologous with a mouse region containing a gene encoding the Notch ligand delta-like 3 (DII3). DII3 is mutated(3) in the Xray-induced mouse mutant pudgy (pu), causing a variety of vertebrocostal defects similar to SD phenotypes. Here we have cloned and sequenced human DLL3 to evaluate it as a candidate gene for SD and identified mutations in three autosomal recessive SD families. Two of the mutations predict truncations within conserved extracellular domains. The third is a missense mutation in a highly conserved glycine residue of the fifth epidermal growth factor (EGF) repeat, which has revealed an important functional role for this domain. These represent the first mutations in a human Delta homologue, thus highlighting the critical role of the Notch signalling pathway and its components in patterning the mammalian axial skeleton.	Royal Devon & Exeter Hosp, Clin Genet, Exeter EX2 5DW, Devon, England; Sch Postgrad Med & Hlth Sci, Exeter, Devon, England; Natl Inst Med Res, Div Dev Neurobiol, London NW7 1AA, England; Birmingham Womens Hosp, Clin Genet Unit, Birmingham, W Midlands, England; Northwick Pk & St Marks Trust, Kennedy Galton Ctr, Harrow, Middx, England; Whitehead Inst Biomed Res, Cambridge, MA 02142 USA	University of Exeter; University of Exeter; MRC National Institute for Medical Research; Birmingham Women's Hospital; Massachusetts Institute of Technology (MIT); Whitehead Institute	Turnpenny, PD (corresponding author), Royal Devon & Exeter Hosp, Clin Genet, Barrack Rd, Exeter EX2 5DW, Devon, England.		Krumlauf, Robb/AAH-5012-2019; Kusumi, Kenro/J-2626-2012	Krumlauf, Robb/0000-0001-9102-7927; Kusumi, Kenro/0000-0002-1458-4540; Ellard, Sian/0000-0002-7620-5526; Hattersley, Andrew/0000-0001-5620-473X; Frayling, Timothy/0000-0001-8362-2603				ArtavanisTsakonas S, 1997, NAT GENET, V16, P212, DOI 10.1038/ng0797-212; BETTENHAUSEN B, 1995, DEVELOPMENT, V121, P2407; BONAIME JL, 1978, PEDIATRIE, V33, P173; CASAMASSIMA AC, 1981, AM J MED GENET, V8, P117, DOI 10.1002/ajmg.1320080114; Cohen B, 1997, NAT GENET, V16, P283, DOI 10.1038/ng0797-283; CONLON RA, 1995, DEVELOPMENT, V121, P1533; deAngelis MH, 1997, NATURE, V386, P717, DOI 10.1038/386717a0; DELGOFFE C, 1982, ANN PEDIATR-PARIS, V29, P135; Dunwoodie SL, 1997, DEVELOPMENT, V124, P3065; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; Evrard YA, 1998, NATURE, V394, P377, DOI 10.1038/28632; GREENWALD I, 1994, CURR OPIN GENET DEV, V4, P556, DOI 10.1016/0959-437X(94)90072-B; Johnston SH, 1997, DEVELOPMENT, V124, P2245; Joutel A, 1996, NATURE, V383, P707, DOI 10.1038/383707a0; KOPCZYNSKI CC, 1988, GENE DEV, V2, P1723, DOI 10.1101/gad.2.12b.1723; Kusumi K, 1998, NAT GENET, V19, P274, DOI 10.1038/961; LARDELLI M, 1993, EXP CELL RES, V204, P364, DOI 10.1006/excr.1993.1044; LARDELLI M, 1994, MECH DEVELOP, V46, P123, DOI 10.1016/0925-4773(94)90081-7; Li LH, 1997, NAT GENET, V16, P243, DOI 10.1038/ng0797-243; LINDSELL CE, 1995, CELL, V80, P909, DOI 10.1016/0092-8674(95)90294-5; Mortier GR, 1996, AM J MED GENET, V61, P310, DOI 10.1002/(SICI)1096-8628(19960202)61:4<310::AID-AJMG3>3.0.CO;2-Y; Oda T, 1997, NAT GENET, V16, P235, DOI 10.1038/ng0797-235; ROBBINS J, 1992, J VIROL, V66, P2594, DOI 10.1128/JVI.66.4.2594-2599.1992; Sidow A, 1997, NATURE, V389, P722, DOI 10.1038/39587; SIMPSON JM, 1995, J MED GENET, V32, P633, DOI 10.1136/jmg.32.8.633; THOMAS U, 1991, DEVELOPMENT, V111, P749; TURNPENNY PD, 1991, J MED GENET, V28, P27, DOI 10.1136/jmg.28.1.27; Turnpenny PD, 1999, AM J HUM GENET, V65, P175, DOI 10.1086/302464; WEINMASTER G, 1991, DEVELOPMENT, V113, P931; Zhang NA, 1998, NATURE, V394, P374, DOI 10.1038/28625	30	300	316	0	11	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	APR	2000	24	4					438	441		10.1038/74307	http://dx.doi.org/10.1038/74307			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	299HK	10742114				2022-12-25	WOS:000086192800029
J	Zubko, E; Scutt, C; Meyer, P				Zubko, E; Scutt, C; Meyer, P			Intrachromosomal recombination between attP regions as a tool to remove selectable marker genes from tobacco transgenes	NATURE BIOTECHNOLOGY			English	Article						resistance marker; homologous recombination; transgenic plants	COLI IHF PROTEIN; AGROBACTERIUM-TUMEFACIENS; HOMOLOGOUS RECOMBINATION; PETUNIA-HYBRIDA; BINDING-SITES; PLANTS; METHYLATION; SEQUENCES; DNA	Recombinant genes conferring resistance to antibiotics or herbicides are widely used as selectable markers in plant transformation. Once transgenic material has been selected, the marker gene is dispensable. We report a novel strategy to remove undesirable parts of a transgene after integration into the tobacco genome, This approach is based on the transfer of a vector containing a NPTII gene flanked by two 352 bp attachment P (attP) regions of bacteriophage lambda, and the identification of somatic tissue with deletion events following intrachromosomal recombination between the attP regions. This system was used to delete a 5.9 kb region from a recombinant vector that had been inserted into two different genomic regions. As the attP system does not require the expression of helper proteins to induce deletion events, or a genetic segregation step to remove recombinase genes, it should provide a useful tool to remove undesirable transgene regions, especially in vegetatively propagated species.	Univ Leeds, Fac Biol Sci, Leeds Inst Plant Biotechnol & Agr, Leeds LS2 9JT, W Yorkshire, England	University of Leeds	Meyer, P (corresponding author), Univ Leeds, Fac Biol Sci, Leeds Inst Plant Biotechnol & Agr, Leeds LS2 9JT, W Yorkshire, England.			Scutt, Charles/0000-0003-2970-3810				CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; CRAIG NL, 1984, CELL, V39, P707, DOI 10.1016/0092-8674(84)90478-1; DALE PJ, 1992, PLANT PHYSIOL, V100, P13, DOI 10.1104/pp.100.1.13; DEBLOCK M, 1991, THEOR APPL GENET, V82, P257, DOI 10.1007/BF02190610; Dellaporta SL, 1983, PLANT MOL BIOL REP, V1, P19, DOI DOI 10.1007/BF02712670; DEPICKER AG, 1988, PLANT CELL REP, V7, P63, DOI 10.1007/BF00272980; GALLIANO H, 1995, MOL GEN GENET, V247, P614, DOI 10.1007/BF00290353; GARDNER JF, 1986, J MOL BIOL, V191, P181, DOI 10.1016/0022-2836(86)90255-X; GRESSEL J, 1992, TRENDS BIOTECHNOL, V10, P382, DOI 10.1016/0167-7799(92)90277-3; HORSCH RB, 1985, SCIENCE, V227, P1229, DOI 10.1126/science.227.4691.1229; KOES RE, 1987, PLANT MOL BIOL, V10, P159, DOI 10.1007/BF00016153; KONCZ C, 1994, PLANT MOL BIOL MAN B, V2, P1; KONZ C, 1986, MOL GEN GENET, V204, P383; MATZKE MA, 1991, PLANT MOL BIOL, V16, P821, DOI 10.1007/BF00015074; Puchta H., 1994, Homologous recombination and gene silencing in plants., P123; PUCHTA H, 1991, NUCLEIC ACIDS RES, V19, P2693, DOI 10.1093/nar/19.10.2693; PUCHTA H, 1995, PLANT MOL BIOL, V28, P281, DOI 10.1007/BF00020247; Roth D., 1988, GENETIC RECOMBINATIO, P621; SWOBODA P, 1993, MOL GEN GENET, V237, P33, DOI 10.1007/BF00282781; URWIN PE, 1995, PLANT J, V8, P121, DOI 10.1046/j.1365-313X.1995.08010121.x; van Blokland R, 1998, PLANT J, V15, P543, DOI 10.1046/j.1365-313X.1998.00238.x; VELTEN J, 1984, EMBO J, V3, P2723, DOI 10.1002/j.1460-2075.1984.tb02202.x; WEISBERG RA, 1983, LAMBDA, V2, P211; YANG CC, 1989, CELL, V57, P869, DOI 10.1016/0092-8674(89)90801-5; YODER JI, 1994, BIO-TECHNOL, V12, P263, DOI 10.1038/nbt0394-263	25	115	173	0	16	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	APR	2000	18	4					442	445		10.1038/74515	http://dx.doi.org/10.1038/74515			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	303UY	10748528				2022-12-25	WOS:000086444300030
J	Kaji, K; Oda, S; Shikano, T; Ohnuki, T; Uematsu, Y; Sakagami, J; Tada, N; Miyazaki, S; Kudo, A				Kaji, K; Oda, S; Shikano, T; Ohnuki, T; Uematsu, Y; Sakagami, J; Tada, N; Miyazaki, S; Kudo, A			The gamete fusion process is defective in eggs of Cd9-deficient mice	NATURE GENETICS			English	Article							MOUSE EGG; CA2+ OSCILLATIONS; STEM-CELLS; FERTILIZATION; CD9; SPERM; CALCIUM; PROTEIN; ACTIVATION; COMPLEXES	The cell-surface molecule Cd9, a member of the transmembrane-4 superfamily(1), interacts with the integrin family(2) and other membrane proteins(3-5), and is postulated to participate in cell migration and adhesion(6-8). Expression of Cd9 enhances membrane fusion between muscle cells(9) and promotes viral infection in some cells(10,11). Fertilization also involves membrane fusion, between gametes. In mammals, the sperm binds to microvilli on the egg surface, and sperm-egg membrane fusion first occurs around the equatorial region of the sperm head(12). The fused membrane is then disrupted, and the sperm nucleus as well as the cytoplasm is incorporated into the egg. Cd9 is expressed on the plasma membrane of the mouse egg, and an anti-Cd9 monoclonal antibody inhibits sperm-egg surface interactions(13). We generated Cd9(-/-) mice and found that homozygous mutant females were infertile. Sperm-egg binding was normal, but sperm-egg fusion was almost entirely inhibited in eggs from Cd9(-/-) females. Intracellular Ca2+ oscillations, which signal fertilization, were absent in almost all mutant eggs; in rare cases, a response occurred after a long time period. In normal animals, Cd9 molecules were expressed on the egg microvilli and became densely concentrated at the sperm attachment site. Thus, our results show that Cd9 is important in the gamete fusion process at fertilization.	Tokyo Inst Technol, Dept Life Sci, Yokohama, Kanagawa 227, Japan; Tokyo Womens Med Univ, Sch Med, Dept Physiol, Tokyo, Japan; Taisho Pharmaceut Co Ltd, Med Res Labs, Omiya, Saitama, Japan; Natl Inst Physiol Sci, Dept Mol Physiol, Lab Intracellular Metab, Okazaki, Aichi 444, Japan	Tokyo Institute of Technology; Tokyo Women's Medical University; Taisho Pharmaceutical Holdings Co Ltd; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Physiological Sciences (NIPS)	Kudo, A (corresponding author), Tokyo Inst Technol, Dept Life Sci, Yokohama, Kanagawa 227, Japan.		Kudo, Akira/C-7340-2015	Kudo, Akira/0000-0001-6289-3391				ALMEIDA EAC, 1995, CELL, V81, P1095, DOI 10.1016/S0092-8674(05)80014-5; BEGG DA, 1978, J CELL BIOL, V79, P846, DOI 10.1083/jcb.79.3.846; Berditchevski F, 1996, MOL BIOL CELL, V7, P193, DOI 10.1091/mbc.7.2.193; Chen KK, 1930, MEDICINE, V9, P1, DOI 10.1097/00005792-193002000-00001; Cho CH, 1998, SCIENCE, V281, P1857, DOI 10.1126/science.281.5384.1857; FULTON BP, 1978, NATURE, V273, P149, DOI 10.1038/273149a0; HADJIARGYROU M, 1995, J NEUROSCI, V15, P574; Horvath G, 1998, J BIOL CHEM, V273, P30537, DOI 10.1074/jbc.273.46.30537; IKEYAMA S, 1993, J EXP MED, V177, P1231, DOI 10.1084/jem.177.5.1231; KLINE D, 1992, DEV BIOL, V149, P80, DOI 10.1016/0012-1606(92)90265-I; Lawrence Y, 1997, DEVELOPMENT, V124, P233; Loffler S, 1997, J VIROL, V71, P42; LONGO FJ, 1985, AM J ANAT, V174, P303, DOI 10.1002/aja.1001740310; MASELLISSMITH A, 1994, J IMMUNOL, V152, P2768; MIYAZAKI S, 1993, DEV BIOL, V158, P62, DOI 10.1006/dbio.1993.1168; NAKAMURA K, 1995, J CELL BIOL, V129, P1691, DOI 10.1083/jcb.129.6.1691; Nakano Y, 1997, MOL HUM REPROD, V3, P1087, DOI 10.1093/molehr/3.12.1087; PHILLIPS DM, 1985, AM J ANAT, V174, P357, DOI 10.1002/aja.1001740314; RUBINSTEIN E, 1994, EUR J IMMUNOL, V24, P3005, DOI 10.1002/eji.1830241213; Slupsky JR, 1997, EUR J BIOCHEM, V244, P168, DOI 10.1111/j.1432-1033.1997.00168.x; Swann K, 1997, BIOESSAYS, V19, P371, DOI 10.1002/bies.950190504; Tachibana I, 1999, J CELL BIOL, V146, P893, DOI 10.1083/jcb.146.4.893; TALBOT P, 1982, FERTIL STERIL, V37, P240; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; Whittingham D G, 1971, J Reprod Fertil Suppl, V14, P7; Willett B, 1997, J GEN VIROL, V78, P611, DOI 10.1099/0022-1317-78-3-611; WRIGHT MD, 1994, IMMUNOL TODAY, V15, P588, DOI 10.1016/0167-5699(94)90222-4; YAGI T, 1990, P NATL ACAD SCI USA, V87, P9918, DOI 10.1073/pnas.87.24.9918; Yanagimachi R., 1994, P189	29	369	389	0	9	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAR	2000	24	3					279	282		10.1038/73502	http://dx.doi.org/10.1038/73502			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	288XW	10700183				2022-12-25	WOS:000085590600020
J	Munroe, RJ; Bergstrom, RA; Zheng, QY; Libby, B; Smith, R; John, SWM; Schimenti, KJ; Browning, VL; Schimenti, JC				Munroe, RJ; Bergstrom, RA; Zheng, QY; Libby, B; Smith, R; John, SWM; Schimenti, KJ; Browning, VL; Schimenti, JC			Mouse mutants from chemically mutagenized embryonic stem cells	NATURE GENETICS			English	Article							ETHYL METHANESULFONATE; HPRT LOCUS; MICE; MUTATIONS; SPECTRUM	The drive to characterize functions of human genes on a global scale has stimulated interest in large-scale generation of mouse mutants. Conventional germ-cell mutagenesis with N-ethyl-N-nitrosourea (ENU) is compromised by an inability to monitor mutation efficiency, strain(1) and interlocus(2) variation in mutation induction, and extensive husbandry requirements. To overcome these obstacles and develop new methods for generating mouse mutants, we devised protocols to generate germline chimaeric mice from embryonic stem (ES) cells heavily mutagenized with ethylmethanesulphonate (EMS). Germline chimaeras were derived from cultures that underwent a mutation rate of up to 1 in 1,200 at the Hprt locus (encoding hypoxanthine guanine phosphoribosyl transferase). The spectrum of mutations induced by EMS and the frameshift mutagen ICR191 was consistent with that observed in other mammalian cells. Chimaeras derived from ES cells treated with EMS transmitted mutations affecting several processes, including limb development, hair growth, hearing and gametogenesis. This technology affords several advantages over traditional mutagenesis, including the ability to conduct shortened breeding schemes and to screen for mutant phenotypes directly in ES cells or their differentiated derivatives.	Jackson Lab, Bar Harbor, ME 04609 USA; Howard Hughes Med Inst, Bar Harbor, ME USA	Jackson Laboratory; Howard Hughes Medical Institute	Schimenti, JC (corresponding author), Jackson Lab, 600 Main St, Bar Harbor, ME 04609 USA.		Zheng, Qing/C-1731-2012		EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [T32HD007065] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [F32HD008441] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P30CA034196] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045415] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC004301, R01DC005827, R03DC004376] Funding Source: NIH RePORTER; Howard Hughes Medical Institute Funding Source: Medline; NCI NIH HHS [CA34196, P30 CA034196, P30 CA034196-159007] Funding Source: Medline; NICHD NIH HHS [HD07065, F32 HD008441, T32 HD007065, F32 HD008441-02] Funding Source: Medline; NIDCD NIH HHS [R01 DC005827, R01 DC004301-01, R03 DC004376-01A1, R01 DC004301, R01 DC005827-01] Funding Source: Medline; NIGMS NIH HHS [R01 GM045415-12, R01 GM045415, GM45415] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); Howard Hughes Medical Institute(Howard Hughes Medical Institute); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BODE VC, 1984, GENETICS, V108, P457; Chen YJ, 2000, NAT GENET, V24, P314, DOI 10.1038/73557; HSIE AW, 1975, SOMAT CELL GENET, V1, P247, DOI 10.1007/BF01538449; John SWM, 1998, INVEST OPHTH VIS SCI, V39, P951; KESSEL M, 1991, CELL, V67, P89, DOI 10.1016/0092-8674(91)90574-I; KLUNGLAND A, 1995, CARCINOGENESIS, V16, P1281, DOI 10.1093/carcin/16.6.1281; Rinchik EM, 1999, GENETICS, V152, P373; SEGA GA, 1984, MUTAT RES, V134, P113, DOI 10.1016/0165-1110(84)90007-1; SMITH RS, 1994, LAB ANIM SCI, V44, P551; SOLIS RR, 1995, NATURE, V378, P720; TAFT SA, 1994, ENVIRON MOL MUTAGEN, V23, P96, DOI 10.1002/em.2850230204; You Y, 1997, NAT GENET, V15, P285, DOI 10.1038/ng0397-285; Zheng QY, 1999, HEARING RES, V130, P94, DOI 10.1016/S0378-5955(99)00003-9	13	105	110	0	6	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAR	2000	24	3					318	321		10.1038/73563	http://dx.doi.org/10.1038/73563			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	288XW	10700192	Green Accepted			2022-12-25	WOS:000085590600029
J	Tamura, T; Thilbert, C; Royer, C; Kanda, T; Abraham, E; Kamba, M; Komoto, N; Thomas, JL; Mauchamp, B; Chavancy, G; Shirk, P; Fraser, M; Prudhomme, JC; Couble, P				Tamura, T; Thilbert, C; Royer, C; Kanda, T; Abraham, E; Kamba, M; Komoto, N; Thomas, JL; Mauchamp, B; Chavancy, G; Shirk, P; Fraser, M; Prudhomme, JC; Couble, P			Germline transformation of the silkworm Bombyx mori L-using a piggyBac transposon-derived vector	NATURE BIOTECHNOLOGY			English	Article						Bombyx; transgenesis; piggyBac; transposon	YELLOW-FEVER MOSQUITO; DROSOPHILA-VIRILIS; AEDES-AEGYPTI; GENE-TRANSFER; ELEMENT; MARINER	We have developed a system for stable germline transformation in the silkworm Bombyx mori L. using piggyBac, a transposon discovered in the lepidopteran Trichoplusia ni. The transformation constructs consist of the piggyBac inverted terminal repeats flanking a fusion of the B. mori cytoplasmic actin gene BmA3 promoter and the green fluorescent protein (GFP). A nonautonomous helper plasmid encodes the piggyBac transposase. The reporter gene construct was coinjected into preblastoderm eggs of two strains of B. mori. Approximately 2% of the individuals in the G1 broods expressed GFP. DNA analyses of GFP-positive G1 silkworms revealed that multiple independent insertions occurred frequently, The transgene was stably transferred to the next generation through normal Mendelian inheritance. The presence of the inverted terminal repeats of piggyBac and the characteristic TTAA sequence at the borders of all the analyzed inserts confirmed that transformation resulted from precise transposition events, This efficient method of stable gene transfer in a lepidopteran insect opens the way for promising basic research and biotechnological applications.	CNRS, Ctr Genet Mol & Cellulaire, F-69622 Villeurbanne, France; Natl Inst Sericultural & Entomol Sci, Tsukuba, Ibaraki 3058634, Japan; INRA, Unite Natl Sericicole, F-69150 La Mulatiere, France; Univ Notre Dame, Dept Biol Sci, Notre Dame, IN 46556 USA; USDA ARS, CMAVE, Gainesville, FL USA	Centre National de la Recherche Scientifique (CNRS); National Institute of Agrobiological Sciences - Japan; INRAE; University of Notre Dame; United States Department of Agriculture (USDA)	Couble, P (corresponding author), CNRS, Ctr Genet Mol & Cellulaire, F-69622 Villeurbanne, France.	couble@univ-lyon1.fr	Thibert, Chantal/D-4367-2019; Fraser, Malcolm J/C-9100-2009	Thibert, Chantal/0000-0002-1516-5671; 				CARY LC, 1989, VIROLOGY, V172, P156, DOI 10.1016/0042-6822(89)90117-7; Coates CJ, 1998, P NATL ACAD SCI USA, V95, P3748, DOI 10.1073/pnas.95.7.3748; Gomez SP, 1997, INSECT MOL BIOL, V6, P165, DOI 10.1111/j.1365-2583.1997.tb00084.x; Handler AM, 1998, P NATL ACAD SCI USA, V95, P7520, DOI 10.1073/pnas.95.13.7520; Jasinskiene N, 1998, P NATL ACAD SCI USA, V95, P3743, DOI 10.1073/pnas.95.7.3743; KANDA T, 1991, B SERIC ENTOMOL, V2, P32; Lohe AR, 1996, GENETICS, V143, P365; LOUKERIS TG, 1995, SCIENCE, V270, P2002, DOI 10.1126/science.270.5244.2002; Lozovskaya ER, 1996, GENETICS, V142, P173; Mange A, 1997, J MOL BIOL, V265, P266, DOI 10.1006/jmbi.1996.0734; MOUNIER N, 1991, INSECT BIOCHEM, V21, P523, DOI 10.1016/0020-1790(91)90106-O; NAGARAJU J, IN PRESS ENCY GENETI; OBrochta DA, 1996, INSECT BIOCHEM MOLEC, V26, P739, DOI 10.1016/S0965-1748(96)00022-7; Robertson HM, 1996, INSECT BIOCHEM MOLEC, V26, P945, DOI 10.1016/S0965-1748(96)00061-6; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; Wang H G, 1993, Insect Mol Biol, V1, P109, DOI 10.1111/j.1365-2583.1993.tb00111.x; Yamao M, 1999, GENE DEV, V13, P511, DOI 10.1101/gad.13.5.511	17	561	675	1	84	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JAN	2000	18	1					81	84		10.1038/71978	http://dx.doi.org/10.1038/71978			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	273GQ	10625397				2022-12-25	WOS:000084699900031
J	Ali, RR; Sarra, GM; Stephens, C; de Alwis, M; Bainbridge, JWB; Munro, PM; Fauser, S; Reichell, MB; Kinnon, C; Hunt, DM; Bhattacharya, SS; Thrasher, AJ				Ali, RR; Sarra, GM; Stephens, C; de Alwis, M; Bainbridge, JWB; Munro, PM; Fauser, S; Reichell, MB; Kinnon, C; Hunt, DM; Bhattacharya, SS; Thrasher, AJ			Restoration of photoreceptor ultrastructure and function in retinal degeneration slow mice by gene therapy	NATURE GENETICS			English	Article							RDS MUTANT MICE; RETINITIS-PIGMENTOSA; RESCUE; MOUSE; AMPLICONS; VECTOR; ROM-1; DEATH	The gene Prph2 encodes a photoreceptor-specific membrane glycoprotein(1), peripherin-2 (also known as peripherin/rds), which is inserted into the rims of photoreceptor outer segment discs in a complex with rom-1 (ref. 2). The complex is necessary for the stabilization of the discs, which are renewed constantly throughout life, and which contain the visual pigments necessary for photon capture(3). Mutations in Prph2 have been shown to result in a variety of photoreceptor dystrophies, including autosomal dominant retinitis pigmentosa and macular dystrophy(4). A common feature of these diseases is the loss of photoreceptor function, also seen in the retinal degeneration slow (rds or prph2(Rd2/Rd2)) mouse, which is homozygous for a null mutation in Prph2. It is characterized by a complete failure to develop photoreceptor discs and outer segments(5), downregulation of rhodopsin(6,7) and apoptotic loss of photoreceptor cells(8,9). The electroretinograms (ERGs) of Prph2(Rd2/Rd2) mice have greatly diminished a-wave and b-wave amplitudes, which decline to virtually undetectable concentrations by two months(10). Subretinal injection of recombinant adeno-associated virus (AAV) encoding a Prph2 transgene results in stable generation of outer segment structures and formation of new stacks of discs containing both perpherin-2 and rhodopsin, which in many cases are morphologically similar to normal outer segments. Moreover, the re-establishment of the structural integrity of the photoreceptor layer also results in electrophysiological correction. These studies demonstrate for the first time that a complex ultrastructural cell defect can be corrected both morphologically and functionally by in vivo gene transfer.	UCL, Inst Ophthalmol, Dept Mol Genet, London, England; UCL, Inst Child Hlth, Mol Immunol Unit, London, England; Univ Tubingen, Hosp Eye, Tubingen, Germany; Univ Leipzig, Hosp Eye, D-7010 Leipzig, Germany	University of London; University College London; University of London; University College London; Eberhard Karls University of Tubingen; Leipzig University	Ali, RR (corresponding author), UCL, Inst Ophthalmol, Dept Mol Genet, Mortimer St, London, England.	r.ali@ucl.ac.uk	Kinnon, Christine/A-1585-2010; Hunt, David M/K-6024-2012; Bhattacharya, Shom/N-2926-2016	Hunt, David M/0000-0002-9264-3948; Bhattacharya, Shom/0000-0002-1601-6344; Bainbridge, James/0000-0003-1318-8201; Ali, Robin/0000-0003-3126-6517				Ali RR, 1996, HUM MOL GENET, V5, P591, DOI 10.1093/hmg/5.5.591; BASCOM RA, 1992, NEURON, V8, P1171, DOI 10.1016/0896-6273(92)90137-3; Boursnell MEG, 1997, J INFECT DIS, V175, P16, DOI 10.1093/infdis/175.1.16; CHANG GQ, 1993, NEURON, V11, P595, DOI 10.1016/0896-6273(93)90072-Y; Gregory-Evans K, 1998, TRENDS GENET, V14, P103, DOI 10.1016/S0168-9525(98)01402-4; HILLENKAMP F, 1975, APPL PHYS, V8, P341, DOI 10.1007/BF00898368; Lewin AS, 1998, NAT MED, V4, P967, DOI 10.1038/nm0898-967; MOLDAY RS, 1994, PROG RETIN EYE RES, V13, P271, DOI 10.1016/1350-9462(94)90013-2; NIR I, 1990, EXP EYE RES, V51, P257, DOI 10.1016/0014-4835(90)90022-M; PORTERACAILLIAU C, 1994, P NATL ACAD SCI USA, V91, P974, DOI 10.1073/pnas.91.3.974; REUTER JH, 1984, NEUROSCI LETT, V48, P231, DOI 10.1016/0304-3940(84)90024-7; SANYAL S, 1981, NEUROSCI LETT, V21, P23, DOI 10.1016/0304-3940(81)90051-3; SHALKEN JJ, 1985, BIOCHIM BIOPHYS ACTA, V839, P122; Takahashi M, 1999, J VIROL, V73, P7812, DOI 10.1128/JVI.73.9.7812-7816.1999; TRAVIS GH, 1992, NEURON, V9, P113, DOI 10.1016/0896-6273(92)90226-4; TRAVIS GH, 1989, NATURE, V338, P70, DOI 10.1038/338070a0; Zhang XL, 1999, HUM GENE THER, V10, P2527, DOI 10.1089/10430349950016861; Zhang XL, 1998, J GEN VIROL, V79, P125, DOI 10.1099/0022-1317-79-1-125	18	256	277	0	18	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036			NAT GENET	Nature Genet.	JUL	2000	25	3					306	310		10.1038/77068	http://dx.doi.org/10.1038/77068			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	329RD	10888879				2022-12-25	WOS:000087920900019
J	Eriksson, ME; Israelsson, M; Olsson, O; Moritz, T				Eriksson, ME; Israelsson, M; Olsson, O; Moritz, T			Increased gibberellin biosynthesis in transgenic trees promotes growth, biomass production and xylem fiber length	NATURE BIOTECHNOLOGY			English	Article						biomass; fiber length; gibberellin biosynthesis; gibberellin 20-oxidase; Populus; transgenic	DEEP-WATER RICE; EXPRESSION; ARABIDOPSIS; POPLAR; GENE; STEM; TRANSFORMATION; ELONGATION; INITIATION; POPULUS	In most tree-breeding programs worldwide, increasing the trees' growth rates and stem volumes and shortening their rotation times are important aims. Such trees would yield more biomass per unit area. Here we show that overexpressing a key regulatory gene in the biosynthesis of the plant hormone gibberellin (GA) in hybrid aspen (Populus tremula x P. tremuloides) improves growth rate and biomass. In addition, these transgenic trees have more numerous and longer xylem fibers than unmodified wild-type (wt) plants. Long fibers are desirable in the production of strong paper, but it has not as yet proved possible to influence this trait by traditional breeding techniques. We also show that GA has an antagonistic effect on root initiation, as the transgenic lines showed poorer rooting than the control plants when potted in soil. However, the negative effect on rooting efficiencies in the initial establishment of young plantlets in the growth chamber did not significantly affect root growth at later stages.	Swedish Univ Agr Sci, Dept Forest Genet & Plant Physiol, Umea Plant Sci Ctr, SE-90183 Umea, Sweden; Univ Gothenburg, Dept Cell & Mol Biol, SE-40530 Gothenburg, Sweden	Swedish University of Agricultural Sciences; Umea University; University of Gothenburg	Moritz, T (corresponding author), Swedish Univ Agr Sci, Dept Forest Genet & Plant Physiol, Umea Plant Sci Ctr, SE-90183 Umea, Sweden.	Thomas.Moritz@genfys.slu.se	Eriksson, Maria E./AAA-7288-2020; Nordström, Maria/B-4561-2013	Eriksson, Maria E./0000-0003-2038-4892; Olsson, Olof/0000-0003-3962-9183; Moritz, Thomas/0000-0002-4258-3190				Chang S. J., 1993, Plant Molecular Biology Reporter, V11, P113, DOI 10.1007/BF02670468; CHELIAK WM, 1990, CAN J FOREST RES, V20, P452, DOI 10.1139/x90-062; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; Coles JP, 1999, PLANT J, V17, P547, DOI 10.1046/j.1365-313X.1999.00410.x; DIGBY J, 1966, ANN BOT-LONDON, V30, P539, DOI 10.1093/oxfordjournals.aob.a084095; FILLATTI JJ, 1987, MOL GEN GENET, V206, P192, DOI 10.1007/BF00333574; Hedden P, 1999, PLANT PHYSIOL, V119, P365, DOI 10.1104/pp.119.2.365; Hedden P, 1997, ANNU REV PLANT PHYS, V48, P431, DOI 10.1146/annurev.arplant.48.1.431; Hu WJ, 1999, NAT BIOTECHNOL, V17, P808, DOI 10.1038/11758; Kende H, 1997, PLANT CELL, V9, P1197, DOI 10.1105/tpc.9.7.1197; Kozlowski T.T., 1997, GROWTH CONTROL WOODY, P352; Little C. H. Anthony, 1995, P281; MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473, DOI 10.1111/j.1399-3054.1962.tb08052.x; Nilsson O, 1996, PLANT PHYSIOL, V112, P493, DOI 10.1104/pp.112.2.493; Nilsson Ove, 1992, Transgenic Research, V1, P209, DOI 10.1007/BF02524751; Peng JR, 1999, PLANT PHYSIOL, V119, P1199, DOI 10.1104/pp.119.4.1199; PHILLIPS AL, 1995, PLANT PHYSIOL, V108, P1049, DOI 10.1104/pp.108.3.1049; Regan S, 1999, PLANT J, V19, P363, DOI 10.1046/j.1365-313X.1999.00536.x; Ridoutt BG, 1996, PHYSIOL PLANTARUM, V96, P559, DOI 10.1111/j.1399-3054.1996.tb00227.x; Ross JJ, 1997, PHYSIOL PLANTARUM, V100, P550, DOI 10.1034/j.1399-3054.1997.1000317.x; ROSS JJ, 1993, PLANT PHYSIOL, V102, P603, DOI 10.1104/pp.102.2.603; SACHS RM, 1965, ANN REV PLANT PHYSIO, V16, P73, DOI 10.1146/annurev.pp.16.060165.000445; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SAUTER M, 1993, PLANTA, V190, P354, DOI 10.1007/BF00196964; SAUTER M, 1995, PLANT J, V7, P623, DOI 10.1046/j.1365-313X.1995.7040623.x; SMITH DR, 1975, J EXP BOT, V26, P193, DOI 10.1093/jxb/26.2.193; Sterky F, 1998, P NATL ACAD SCI USA, V95, P13330, DOI 10.1073/pnas.95.22.13330; TELEWSKI FW, 1996, BIOL POPULUS ITS IMP, V2, P301; TENG YX, 1993, FOREST SCI, V39, P252; Tsuge T, 1996, DEVELOPMENT, V122, P1589; TUOMINEN H, 1995, PLANT PHYSIOL, V109, P1179, DOI 10.1104/pp.109.4.1179; VanDoorsselaere J, 1995, PLANT J, V8, P855, DOI 10.1046/j.1365-313X.1995.8060855.x; VIEIRA J, 1991, GENE, V100, P189, DOI 10.1016/0378-1119(91)90365-I; VONSCHWARTZENBERG K, 1994, TREE PHYSIOL, V14, P27, DOI 10.1093/treephys/14.1.27; WALDEN R, 1990, Methods in Molecular and Cellular Biology, V1, P175; Wang GJ, 1996, TRANSGENIC RES, V5, P289, DOI 10.1007/BF01968939; WANG Q, 1995, PHYSIOL PLANTARUM, V95, P187, DOI 10.1111/j.1399-3054.1995.tb00826.x; WAREING PF, 1958, NATURE, V181, P1744, DOI 10.1038/1811744a0; WEIGEL D, 1995, NATURE, V377, P495, DOI 10.1038/377495a0; Xu YL, 1999, PLANT CELL, V11, P927, DOI 10.1105/tpc.11.5.927	40	363	413	9	99	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JUL	2000	18	7					784	788		10.1038/77355	http://dx.doi.org/10.1038/77355			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	331YN	10888850				2022-12-25	WOS:000088046400031
J	Judson, N; Mekalanos, JJ				Judson, N; Mekalanos, JJ			TnAraOut, A transposon-based approach to identify and characterize essential bacterial genes	NATURE BIOTECHNOLOGY			English	Article						essential genes; functional genomics; transposon mutagenesis; Vibrio cholerae; cholera	GRAM-NEGATIVE BACTERIA; VIBRIO-CHOLERAE; MUTAGENESIS; GENOME; SYSTEM; IDENTIFICATION; MUTATIONS; SEQUENCES; PROMOTER; ORIGIN	Identification of genes that encode essential products provides a promising approach to validation of new antibacterial drug targets. We have developed a mariner-based transposon, TnAraOut, that allows efficient identification and characterization of essential genes by transcriptionally fusing them to an outward-facing, arabinose-inducible promoter, P-BAD, located at one end of the transposon. In the absence of arabinose, such TnAraOut fusion strains display pronounced growth defects. Of a total of 16 arabinose-dependent TnAraOut mutants characterized in Vibrio cholerae, four were found to carry insertions upstream of known essential genes (gyrB, proRS, ileRS, and aspRS) whereas the other strains carried insertions upstream of known and hypothetical genes not previously shown to encode essential gene products. One of the essential genes identified by this analysis appears to be unique to V. cholerae and thus may represent an example of a species-specific drug target.	Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Mekalanos, JJ (corresponding author), Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, Boston, MA 02115 USA.				NIAID NIH HHS [AI-26289] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI026289] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Akerley BJ, 1998, P NATL ACAD SCI USA, V95, P8927, DOI 10.1073/pnas.95.15.8927; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Arigoni F, 1998, NAT BIOTECHNOL, V16, P851, DOI 10.1038/nbt0998-851; Chiang SL, 1998, MOL MICROBIOL, V27, P797, DOI 10.1046/j.1365-2958.1998.00726.x; CHOW WY, 1988, P NATL ACAD SCI USA, V85, P6468, DOI 10.1073/pnas.85.17.6468; Clayton RA, 1998, CURR OPIN MICROBIOL, V1, P562, DOI 10.1016/S1369-5274(98)80089-1; Curnow AW, 1998, P NATL ACAD SCI USA, V95, P12838, DOI 10.1073/pnas.95.22.12838; Fullner KJ, 1999, INFECT IMMUN, V67, P1393, DOI 10.1128/IAI.67.3.1393-1404.1999; GUELROS FJ, 1997, SCIENCE, V277, P753; GUELROS FJ, 1997, SCIENCE, V276, P1716; GUINEY DG, 1979, MOL GEN GENET, V176, P183, DOI 10.1007/BF00273212; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; HARLEY CB, 1987, NUCLEIC ACIDS RES, V15, P2343, DOI 10.1093/nar/15.5.2343; HEIDELBERG JF, 1999, P 35 US JAP CHOL OTH, P87; Hirokawa T, 1998, BIOINFORMATICS, V14, P378, DOI 10.1093/bioinformatics/14.4.378; Hutchison CA, 1999, SCIENCE, V286, P2165, DOI 10.1126/science.286.5447.2165; Ibba M, 1997, TRENDS BIOCHEM SCI, V22, P39, DOI 10.1016/S0968-0004(96)20033-7; IRANI MH, 1977, J BACTERIOL, V132, P398, DOI 10.1128/JB.132.2.398-410.1977; KOLTER R, 1978, CELL, V15, P1199, DOI 10.1016/0092-8674(78)90046-6; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; MEKALANOS JJ, 1983, CELL, V35, P253, DOI 10.1016/0092-8674(83)90228-3; Metcalf WW, 1996, PLASMID, V35, P1, DOI 10.1006/plas.1996.0001; Mushegian AR, 1996, P NATL ACAD SCI USA, V93, P10268, DOI 10.1073/pnas.93.19.10268; NAKAI K, 1991, PROTEINS, V11, P95, DOI 10.1002/prot.340110203; Rappleye CA, 1997, J BACTERIOL, V179, P5827, DOI 10.1128/jb.179.18.5827-5834.1997; Rubin EJ, 1999, P NATL ACAD SCI USA, V96, P1645, DOI 10.1073/pnas.96.4.1645; SAMBROOK J, 1989, MOL CLONIN LAB MANUA; SAMUELS DS, 1994, J BACTERIOL, V176, P3072, DOI 10.1128/JB.176.10.3072-3075.1994; Schimmel P, 1998, FASEB J, V12, P1599, DOI 10.1096/fasebj.12.15.1599; SCHLEIF R, 1996, ESCHERICHIA COLI SAL, V1, P1300; SCHMID MB, 1989, GENETICS, V123, P625; SIMON R, 1983, BIO-TECHNOL, V1, P784, DOI 10.1038/nbt1183-784; TAKIFF HE, 1992, J BACTERIOL, V174, P1544, DOI 10.1128/jb.174.5.1544-1553.1992; Tang CM, 1998, CURR OPIN MICROBIOL, V1, P12, DOI 10.1016/S1369-5274(98)80137-9; Trucksis M, 1998, P NATL ACAD SCI USA, V95, P14464, DOI 10.1073/pnas.95.24.14464	35	119	136	0	11	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JUL	2000	18	7					740	745		10.1038/77305	http://dx.doi.org/10.1038/77305			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	331YN	10888841				2022-12-25	WOS:000088046400022
J	Lawinger, P; Venugopal, R; Guo, ZS; Immaneni, A; Sengupta, D; Lu, WY; Rastelli, L; Carneiro, AMD; Levin, V; Fuller, GN; Echelard, Y; Majumder, S				Lawinger, P; Venugopal, R; Guo, ZS; Immaneni, A; Sengupta, D; Lu, WY; Rastelli, L; Carneiro, AMD; Levin, V; Fuller, GN; Echelard, Y; Majumder, S			The neuronal repressor REST/NRSF is an essential regulator in medulloblastoma cells	NATURE MEDICINE			English	Article							RESTRICTIVE SILENCER FACTOR; GENE-EXPRESSION; P53 MUTATIONS; TARGET GENES; REST	Medulloblastoma is the most malignant pediatric brain tumor. It is believed to originate from the undifferentiated external granule layer cells in the cerebellum, but the mechanism of tumorigenesis remains unknown(1-6). Here we studied three types of human medulloblastoma cells that express markers corresponding to different levels of neuronal differentiation. They expressed the neuronal repressor element 1 (RE1) silencing transcription factor/neuron-restrictive silencer factor (REST/NRSF; refs. 7-10) at very high levels compared with either neuronal progenitor NTera2 (NT2) cells or fully differentiated human neuron teratocarcinoma (hNT cells). To counter the effect of REST/NRSF, we used a recombinant transcription factor, REST-VP16, constructed by replacing repressor domains of REST/NRSF with the activation domain of viral protein (VP16). Transient expression of REST-VP16 in medulloblastoma cells was able to compete with the endogenous REST/NRSF for DNA binding and stimulate neuronal promoters. High-efficiency expression of REST-VP16 mediated by adenovirus vectors (Ad.REST-VP16) in medulloblastoma cells was able to counter REST/NRSF-mediated repression of neuronal promoters, stimulate expression of endogenous neuronal genes and trigger apoptosis through the activation of caspase cascades. Furthermore, intratumoral injection of Ad.REST-VP16 in established medulloblastoma tumors in nude mice inhibited their growth. Therefore, REST/NRSF may serve as a new target for therapeutic interventions for medulloblastoma through agents such as REST-VP16.	Univ Texas, MD Anderson Canc Ctr, Brain Tumor Ctr, Houston, TX 77005 USA; NCI, Surg Branch, Bethesda, MD 20892 USA; Genzyme Transgen Corp, Framingham, MA 01710 USA	University of Texas System; UTMD Anderson Cancer Center; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Sanofi-Aventis	Majumder, S (corresponding author), Univ Texas, MD Anderson Canc Ctr, Brain Tumor Ctr, 1515 Holcombe Blvd,Box 316, Houston, TX 77005 USA.		Guo, Zong Sheng/H-3098-2019	Guo, Zong Sheng/0000-0002-4624-9907; Fuller, Gregory/0000-0001-9447-2647	NCI NIH HHS [CA51255] Funding Source: Medline; NIGMS NIH HHS [GM53454] Funding Source: Medline; NATIONAL CANCER INSTITUTE [S15CA051255] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADESINA AM, 1994, CANCER RES, V54, P5649; Andres ME, 1999, P NATL ACAD SCI USA, V96, P9873, DOI 10.1073/pnas.96.17.9873; Chen ZF, 1998, NAT GENET, V20, P136, DOI 10.1038/2431; CHONG JHA, 1995, CELL, V80, P949, DOI 10.1016/0092-8674(95)90298-8; FULLER GN, 1996, PEDIAT NEOPLASIA MOR, P153; Goodrich LV, 1997, SCIENCE, V277, P1109, DOI 10.1126/science.277.5329.1109; Goussia AC, 2000, ANTICANCER RES, V20, P65; Grimes JA, 2000, J BIOL CHEM, V275, P9461, DOI 10.1074/jbc.275.13.9461; Harris CC, 1996, JNCI-J NATL CANCER I, V88, P1442, DOI 10.1093/jnci/88.20.1442; HE XM, 1989, J NEUROPATH EXP NEUR, V48, P48, DOI 10.1097/00005072-198901000-00005; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Huang YF, 1999, NAT NEUROSCI, V2, P867, DOI 10.1038/13165; JACOBSEN PF, 1985, J NEUROPATH EXP NEUR, V44, P472, DOI 10.1097/00005072-198509000-00003; Majumder S, 1997, EMBO J, V16, P1721, DOI 10.1093/emboj/16.7.1721; McMahon AP, 2000, CELL, V100, P185, DOI 10.1016/S0092-8674(00)81555-X; Perrimon N, 1999, CELL, V97, P13, DOI 10.1016/S0092-8674(00)80710-2; Provias JP, 1996, J NEURO-ONCOL, V29, P35, DOI 10.1007/BF00165516; RAFFEL C, 1993, NEUROSURGERY, V33, P301, DOI 10.1227/00006123-199308000-00018; SCHOENHERR CJ, 1995, SCIENCE, V267, P1360, DOI 10.1126/science.7871435; Schoenherr CJ, 1996, P NATL ACAD SCI USA, V93, P9881, DOI 10.1073/pnas.93.18.9881; TapiaRamirez J, 1997, P NATL ACAD SCI USA, V94, P1177, DOI 10.1073/pnas.94.4.1177; TOHYAMA T, 1992, LAB INVEST, V66, P303; Whelan HT, 1998, PEDIATR NEUROL, V18, P103, DOI 10.1016/S0887-8994(97)00221-X; Xie JW, 1997, CANCER RES, V57, P2369	24	138	141	0	8	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUL	2000	6	7					826	+		10.1038/77565	http://dx.doi.org/10.1038/77565			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	331VV	10888935				2022-12-25	WOS:000088040100043
J	Nilsson, M; Barbany, G; Antson, DO; Gertow, K; Landegren, U				Nilsson, M; Barbany, G; Antson, DO; Gertow, K; Landegren, U			Enhanced detection and distinction of RNA by enzymatic probe ligation	NATURE BIOTECHNOLOGY			English	Article							HEPATITIS-C VIRUS; POLYMERASE-CHAIN-REACTION; EMBEDDED LIVER-TISSUES; DNA-LIGASE; PADLOCK PROBES; OLIGONUCLEOTIDES; AMPLIFICATION; REPLICATION; FIDELITY; PCR		Leiden Univ, Med Ctr, Dept Mol Cell Biol, NL-2333 AL Leiden, Netherlands; Univ Uppsala Hosp, Dept Med Sci, SE-75185 Uppsala, Sweden; Dept Genet & Pathol, Rudbeck Lab, SE-75185 Uppsala, Sweden; Karolinska Hosp, Karolinska Inst, King Gustaf V Res Inst, Atherosclerosis Res Unit, SE-17176 Stockholm, Sweden	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Uppsala University; Uppsala University Hospital; Karolinska Institutet; Karolinska University Hospital	Nilsson, M (corresponding author), Leiden Univ, Med Ctr, Dept Mol Cell Biol, Wassenaarseweg 72, NL-2333 AL Leiden, Netherlands.		Landegren, Ulf D/A-8197-2019	Barbany, Gisela/0000-0003-3185-2962				Baner J, 1998, NUCLEIC ACIDS RES, V26, P5073, DOI 10.1093/nar/26.22.5073; CONNOLLY BA, 1987, TETRAHEDRON LETT, V28, P463, DOI 10.1016/S0040-4039(00)95757-5; Fahy E, 1991, PCR Methods Appl, V1, P25; FAREED GC, 1971, J BIOL CHEM, V246, P925; FIRE A, 1995, P NATL ACAD SCI USA, V92, P4641, DOI 10.1073/pnas.92.10.4641; Hsuih TCH, 1996, J CLIN MICROBIOL, V34, P501, DOI 10.1128/JCM.34.3.501-507.1996; KLEPPE K, 1970, P NATL ACAD SCI USA, V67, P68, DOI 10.1073/pnas.67.1.68; Kwiatkowski M, 1996, NUCLEIC ACIDS RES, V24, P4632, DOI 10.1093/nar/24.23.4632; LANDEGREN U, 1988, SCIENCE, V241, P1077, DOI 10.1126/science.3413476; Liu DY, 1996, J AM CHEM SOC, V118, P1587, DOI 10.1021/ja952786k; Lizardi PM, 1998, NAT GENET, V19, P225, DOI 10.1038/898; Luo JY, 1996, NUCLEIC ACIDS RES, V24, P3071, DOI 10.1093/nar/24.15.3071; Miyauchi I, 1998, PATHOL INT, V48, P428; NILSSON M, 1994, SCIENCE, V265, P2085, DOI 10.1126/science.7522346; Nilsson M, 1997, NAT GENET, V16, P252, DOI 10.1038/ng0797-252; NILSSON M, 1998, THESIS UPPSALA; Park YN, 1996, AM J PATHOL, V149, P1485; SUND C, 1988, NUCLEOS NUCLEOT, V7, P655, DOI 10.1080/07328318808056303; Tong J, 1999, NUCLEIC ACIDS RES, V27, P788, DOI 10.1093/nar/27.3.788; Tyagi S, 1996, P NATL ACAD SCI USA, V93, P5395, DOI 10.1073/pnas.93.11.5395; WU DY, 1989, GENE, V76, P245, DOI 10.1016/0378-1119(89)90165-0; Zhang DY, 1998, GENE, V211, P277	22	95	113	1	22	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUL	2000	18	7					791	793		10.1038/77367	http://dx.doi.org/10.1038/77367			3	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	331YN	10888852				2022-12-25	WOS:000088046400033
J	Zhu, XD; Kuster, B; Mann, M; Petrini, JHJ; de Lange, T				Zhu, XD; Kuster, B; Mann, M; Petrini, JHJ; de Lange, T			Cell-cycle-regulated association of RAD50/MRE11/NBS1 with TRF2 and human telomeres	NATURE GENETICS			English	Article							STRAND BREAK REPAIR; SACCHAROMYCES-CEREVISIAE; POLYACRYLAMIDE GELS; PROTEIN COMPLEX; 2 PATHWAYS; END; MRE11; IDENTIFICATION; RECOMBINATION; MAINTENANCE	Telomeres allow cells to distinguish natural chromosome ends from damaged DNA and protect the ends from degradation and fusion. In human cells, telomere protection depends on the TTAGGG repeat binding factor, TRF2 (refs 1-4), which has been proposed to remodel telomeres into large duplex loops(5) (t-loops). Here we show by nanoelectrospray tandem mass spectrometry that RAD50 protein is present in TRF2 immunocomplexes. Protein blotting showed that a small fraction of RAD50, MRE11 and the third component of the MRE11 double-strand break (DSB) repair complex, the Nijmegen breakage syndrome protein (NBS1), is associated with TRF2. Indirect immunofluorescence demonstrated the presence of RAD50 and MRE11 at interphase telomeres. NBS1 was associated with TRF2 and telomeres in S phase, but not in G1 or G2. Although the MRE11 complex accumulated in irradiation-induced foci (IRIFs) in response to gamma-irradiation, TRF2 did not relocate to IRIFs and irradiation did not affect the association of TRF2 with the MRE11 complex, arguing against a role for TRF2 in TSB repair. Instead, we propose that the MRE11 complex functions at telomeres. possibly by modulating t-loop formation.	Rockefeller Univ, New York, NY 10021 USA; Univ So Denmark, Prot Interact Lab, Odense, Denmark; Univ Wisconsin, Sch Med, Genet Lab, Madison, WI USA	Rockefeller University; University of Southern Denmark; University of Wisconsin System; University of Wisconsin Madison	de Lange, T (corresponding author), Rockefeller Univ, 1230 York Ave, New York, NY 10021 USA.		de Lange, Titia/B-8263-2011; Mann, Matthias/A-3454-2013; Kuster, Bernhard/Q-6031-2016	de Lange, Titia/0000-0002-9267-367X; Mann, Matthias/0000-0003-1292-4799; Kuster, Bernhard/0000-0002-9094-1677; Zhu, Xu-Dong/0000-0003-1859-3134	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM059413, R01GM056888, R01GM049046, R01GM059413, R37GM049046] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM49046, GM59413, GM56888] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bilaud T, 1997, NAT GENET, V17, P236, DOI 10.1038/ng1097-236; Boulton SJ, 1998, EMBO J, V17, P1819, DOI 10.1093/emboj/17.6.1819; Bressan DA, 1999, MOL CELL BIOL, V19, P7681; Broccoli D, 1997, NAT GENET, V17, P231, DOI 10.1038/ng1097-231; BRYAN TM, 1995, EMBO J, V14, P4240, DOI 10.1002/j.1460-2075.1995.tb00098.x; Carney JP, 1998, CELL, V93, P477, DOI 10.1016/S0092-8674(00)81175-7; CHONG L, 1995, SCIENCE, V270, P1663, DOI 10.1126/science.270.5242.1663; Dolganov GM, 1996, MOL CELL BIOL, V16, P4832; Griffith JD, 1999, CELL, V97, P503, DOI 10.1016/S0092-8674(00)80760-6; Haber JE, 1998, CELL, V95, P583, DOI 10.1016/S0092-8674(00)81626-8; HARLEY CB, 1995, TELOMERES, P247; Karlseder J, 1999, SCIENCE, V283, P1321, DOI 10.1126/science.283.5406.1321; Le S, 1999, GENETICS, V152, P143; Li BB, 2000, CELL, V101, P471, DOI 10.1016/S0092-8674(00)80858-2; Lim DS, 2000, NATURE, V404, P613, DOI 10.1038/35007091; Luo GB, 1999, P NATL ACAD SCI USA, V96, P7376, DOI 10.1073/pnas.96.13.7376; MANN M, 1994, ANAL CHEM, V66, P4390, DOI 10.1021/ac00096a002; Martin SG, 1999, CELL, V97, P621, DOI 10.1016/S0092-8674(00)80773-4; Maser RS, 1997, MOL CELL BIOL, V17, P6087, DOI 10.1128/MCB.17.10.6087; Miller WA, 1997, SEMIN VIROL, V8, P3, DOI 10.1006/smvy.1997.0101; Moore JK, 1996, MOL CELL BIOL, V16, P2164, DOI 10.1128/mcb.16.5.2164; Nelms BE, 1998, SCIENCE, V280, P590, DOI 10.1126/science.280.5363.590; Nugent CI, 1998, CURR BIOL, V8, P657, DOI 10.1016/S0960-9822(98)70253-2; Paull TT, 1999, GENE DEV, V13, P1276, DOI 10.1101/gad.13.10.1276; Shevchenko A, 1997, RAPID COMMUN MASS SP, V11, P1015, DOI 10.1002/(SICI)1097-0231(19970615)11:9<1015::AID-RCM958>3.0.CO;2-H; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Stewart GS, 1999, CELL, V99, P577, DOI 10.1016/S0092-8674(00)81547-0; Usui T, 1998, CELL, V95, P705, DOI 10.1016/S0092-8674(00)81640-2; van Steensel B, 1998, CELL, V92, P401, DOI 10.1016/S0092-8674(00)80932-0; vanSteensel B, 1997, NATURE, V385, P740, DOI 10.1038/385740a0; Wilm M, 1996, NATURE, V379, P466, DOI 10.1038/379466a0; Xiao YH, 1997, NUCLEIC ACIDS RES, V25, P2985, DOI 10.1093/nar/25.15.2985; Yeager TR, 1999, CANCER RES, V59, P4175	33	481	502	1	17	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUL	2000	25	3					347	352		10.1038/77139	http://dx.doi.org/10.1038/77139			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	329RD	10888888				2022-12-25	WOS:000087920900028
J	Arundel, A; Hocke, M; Tait, J				Arundel, A; Hocke, M; Tait, J			How important is genetic engineering to European seed firms?	NATURE BIOTECHNOLOGY			English	Editorial Material									Univ Maastricht, Maastricht, Netherlands; Univ Edinburgh, Scottish Univ Policy Res & Advice Network, Edinburgh, Midlothian, Scotland	Maastricht University; University of Edinburgh	Arundel, A (corresponding author), Univ Maastricht, Maastricht, Netherlands.							BUTTEL F, 1999, SOCIOLOGICAL RES ONL, V4; *EUR COMM, PL971280 TSER	2	0	0	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUN	2000	18	6					578	578		10.1038/76319	http://dx.doi.org/10.1038/76319			1	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	325EK	10835548	Bronze			2022-12-25	WOS:000087663200004
J	Bertolotti, A; Zhang, YH; Hendershot, LM; Harding, HP; Ron, D				Bertolotti, A; Zhang, YH; Hendershot, LM; Harding, HP; Ron, D			Dynamic interaction of BiP and ER stress transducers in the unfolded-protein response	NATURE CELL BIOLOGY			English	Article							ENDOPLASMIC-RETICULUM; ESCHERICHIA-COLI; TRANSCRIPTION FACTOR; KINASE; ACTIVATION; NUCLEUS; BINDING; IRE1P; DNAK; OLIGOMERIZATION	PERK and IRE1 are type-I transmembrane protein kinases that reside in the endoplasmic reticulum (ER) and transmit stress signals in response to perturbation of protein folding. Here we show that the lumenal domains of these two proteins are functionally interchangeable in mediating an ER stress response and that, in unstressed cells, both lumenal domains form a stable complex with the ER chaperone BiP. Perturbation of protein folding promotes reversible dissociation of BiP from the lumenal domains of PERK and IRE1. Loss of BiP correlates with the formation of high-molecular-mass complexes of activated PERK or IRE1, and overexpression of BiP attenuates their activation. These findings are consistent with a model in which BiP represses signalling through PERK and IRE1 and protein misfolding relieves this repression by effecting the release of BiP from the PERK and IRE1 lumenal domains.	NYU, Sch Med, Skirball Inst Biomol Med, Dept Med, New York, NY 10016 USA; NYU, Sch Med, Skirball Inst Biomol Med, Dept Cell Biol, New York, NY 10016 USA; NYU, Sch Med, Kaplan Canc Ctr, New York, NY 10016 USA; St Jude Childrens Res Hosp, Dept Tumor Cell Biol, Memphis, TN 38105 USA	New York University; New York University; New York University; St Jude Children's Research Hospital	Ron, D (corresponding author), NYU, Sch Med, Skirball Inst Biomol Med, Dept Med, New York, NY 10016 USA.		Hendershot, Linda/N-8124-2018; Longo, Kenneth A/A-5631-2010	Hendershot, Linda/0000-0002-5473-0274; Ron, David/0000-0002-3014-5636; Harding, Heather P/0000-0002-7359-7974	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047119, R37DK047119, R29DK047119] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES008681] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK47119] Funding Source: Medline; NIEHS NIH HHS [ES08681] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Bertolotti A, 1998, MOL CELL BIOL, V18, P1489, DOI 10.1128/MCB.18.3.1489; Brostrom CO, 1998, PROG NUCLEIC ACID RE, V58, P79; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; Chapman R, 1998, ANNU REV CELL DEV BI, V14, P459, DOI 10.1146/annurev.cellbio.14.1.459; DORNER AJ, 1992, EMBO J, V11, P1563, DOI 10.1002/j.1460-2075.1992.tb05201.x; FREIDEN PJ, 1992, EMBO J, V11, P63, DOI 10.1002/j.1460-2075.1992.tb05028.x; GAMER J, 1992, CELL, V69, P833, DOI 10.1016/0092-8674(92)90294-M; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; Hebert DN, 1995, COLD SPRING HARB SYM, V60, P405, DOI 10.1101/SQB.1995.060.01.045; HENDERSHOT LM, 1995, MOL BIOL CELL, V6, P283, DOI 10.1091/mbc.6.3.283; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; KOHNO K, 1993, MOL CELL BIOL, V13, P877, DOI 10.1128/MCB.13.2.877; LANGLAND JO, 1992, J BIOL CHEM, V267, P10729; LEE A S, 1992, Current Opinion in Cell Biology, V4, P267, DOI 10.1016/0955-0674(92)90042-B; LIBEREK K, 1992, P NATL ACAD SCI USA, V89, P3516, DOI 10.1073/pnas.89.8.3516; Matlack KES, 1999, CELL, V97, P553, DOI 10.1016/S0092-8674(00)80767-9; Morimoto RI, 1998, GENE DEV, V12, P3788, DOI 10.1101/gad.12.24.3788; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; Reinhard C, 1997, EMBO J, V16, P1080, DOI 10.1093/emboj/16.5.1080; Shamu CE, 1996, EMBO J, V15, P3028, DOI 10.1002/j.1460-2075.1996.tb00666.x; Shi YG, 1998, MOL CELL BIOL, V18, P7499, DOI 10.1128/MCB.18.12.7499; STRAUS DB, 1989, GENE DEV, V3, P2003, DOI 10.1101/gad.3.12a.2003; Tirasophon W, 1998, GENE DEV, V12, P1812, DOI 10.1101/gad.12.12.1812; Tomoyasu T, 1998, MOL MICROBIOL, V30, P567, DOI 10.1046/j.1365-2958.1998.01090.x; Wang XZ, 1998, EMBO J, V17, P5708, DOI 10.1093/emboj/17.19.5708; Wang XZ, 1996, MOL CELL BIOL, V16, P4273; WEI JY, 1995, J BIOL CHEM, V270, P26670, DOI 10.1074/jbc.270.44.26670; Welihinda AA, 1996, J BIOL CHEM, V271, P18181, DOI 10.1074/jbc.271.30.18181; Zou JY, 1998, CELL, V94, P471, DOI 10.1016/S0092-8674(00)81588-3	29	2001	2084	4	236	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	JUN	2000	2	6					326	332		10.1038/35014014	http://dx.doi.org/10.1038/35014014			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	321KE	10854322				2022-12-25	WOS:000087454000013
J	Horwitz, MS; La Cava, A; Fine, C; Rodriguez, E; Ilic, A; Sarvetnick, N				Horwitz, MS; La Cava, A; Fine, C; Rodriguez, E; Ilic, A; Sarvetnick, N			Pancreatic expression of interferon-gamma protects mice from lethal coxsackievirus B3 infection and subsequent myocarditis	NATURE MEDICINE			English	Article							HUMAN HEART-DISEASE; MURINE MYOCARDITIS; TRANSGENIC MICE; DILATED CARDIOMYOPATHY; B3-INDUCED MYOCARDITIS; NITRIC-OXIDE; VIRUS; PATHOGENESIS; LYMPHOCYTES; CONTRIBUTE	Cardiovascular disease is one of the leading causes of death worldwide, and has been associated with many environmental risk factors(1). Recent evidence has indicated the involvement of pathogens such as viruses as causative agents, and specifically identified the coxsackievirus B serogroup as the leading culprit(2,3). Not only has coxsackievirus B3 (CB3) been identified from patients with cardiovascular disease(4), but also infection of mice with CB3 strains can reproduce human clinical heart disease in rodents(5,6). Several mechanisms have been proposed in an attempt to distinguish between pathology mediated by direct viral destruction of cardiac muscle cells(7,8) or by the virus-induced immune response directed at infected myocytes(9-11) or at 'mimicked' epitopes shared between viral and cardiac antigens(12-14). To distinguish between these mechanisms, we infected a unique mouse that diminishes the extent of infection and spread of the virus, but allows complete immunity to the virus. Transgenic mice expressing interferon-gamma in their pancreatic beta cells failed to develop CB-3-induced myocarditis. This work challenges the idea of the function of the immune response and 'molecular mimicry' in the CB-3-induced autoimmune myocarditis model, and instead favors the idea of virus-mediated damage. These results emphasize the benefit of reducing the level of viremia early during infection, thereby reducing the incidence of virus-mediated heart damage and autoimmunity.	Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA	Scripps Research Institute	Sarvetnick, N (corresponding author), Scripps Res Inst, Dept Immunol, 10550 N Torrey Pines, La Jolla, CA 92037 USA.		/AAG-9576-2020	/0000-0002-8839-0933				Baboonian C, 1997, CURR TOP MICROBIOL, V223, P31; Baboonian C, 1997, HEART, V78, P539, DOI 10.1136/hrt.78.6.539; Badorff C, 1999, NAT MED, V5, P320, DOI 10.1038/6543; CHOW LH, 1992, LAB INVEST, V66, P24; Felker GM, 1999, MEDICINE, V78, P270, DOI 10.1097/00005792-199907000-00005; GAUNTT CJ, 1991, EUR HEART J, V12, P124, DOI 10.1093/eurheartj/12.suppl_D.124; GAUNTT CJ, 1993, CLIN IMMUNOL IMMUNOP, V68, P129, DOI 10.1006/clin.1993.1108; GODMAN GC, 1952, AM J PATHOL, V28, P223; GU DL, 1993, DEVELOPMENT, V118, P33; HASHIMOTO I, 1983, BRIT J EXP PATHOL, V64, P497; HENKE A, 1995, J VIROL, V69, P6720, DOI 10.1128/JVI.69.11.6720-6728.1995; HOHENADL C, 1994, J VIROL METHODS, V47, P279, DOI 10.1016/0166-0934(94)90025-6; Horwitz MS, 1999, J VIROL, V73, P1756, DOI 10.1128/JVI.73.3.1756-1766.1999; Horwitz MS, 1997, NAT MED, V3, P1037, DOI 10.1038/nm0997-1037; Lowenstein CJ, 1996, J CLIN INVEST, V97, P1837, DOI 10.1172/JCI118613; MARTINO TA, 1994, CIRC RES, V74, P182, DOI 10.1161/01.RES.74.2.182; MCMANUS BM, 1993, CLIN IMMUNOL IMMUNOP, V68, P159, DOI 10.1006/clin.1993.1113; Ramsingh AI, 1999, J VIROL, V73, P3080, DOI 10.1128/JVI.73.4.3080-3086.1999; ROSE NR, 1986, ANN NY ACAD SCI, V475, P146, DOI 10.1111/j.1749-6632.1986.tb20864.x; Rose NR, 1996, CLIN IMMUNOL IMMUNOP, V80, pS92, DOI 10.1006/clin.1996.0146; SARVETNICK N, 1988, CELL, V52, P773, DOI 10.1016/0092-8674(88)90414-X; Saura M, 1999, IMMUNITY, V10, P21, DOI 10.1016/S1074-7613(00)80003-5; SCHNURR DP, 1984, J GEN VIROL, V65, P1197, DOI 10.1099/0022-1317-65-7-1197; WOLFGRAM LJ, 1985, J EXP MED, V161, P1112, DOI 10.1084/jem.161.5.1112	24	117	121	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUN	2000	6	6					693	697		10.1038/76277	http://dx.doi.org/10.1038/76277			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	321CX	10835688				2022-12-25	WOS:000087438300042
J	Lee, JS; Shin, KS; Pan, JG; Kim, CJ				Lee, JS; Shin, KS; Pan, JG; Kim, CJ			Surface-displayed viral antigens on Salmonella carrier vaccine	NATURE BIOTECHNOLOGY			English	Article						Salmonella; surface display; multivalent mucosal vaccine	SERUM ANTIBODY-RESPONSES; ICE-NUCLEATION PROTEIN; COLI CELL-SURFACE; ESCHERICHIA-COLI; OUTER-MEMBRANE; PSEUDOMONAS-SYRINGAE; ATTENUATED SALMONELLA; FOREIGN POLYPEPTIDES; IMMUNE-RESPONSES; ORAL VACCINATION	We have developed a recombinant live oral vaccine using the ice-nucleation protein (Inp) from Pseudomonas syringae to display viral antigens on the surface of Salmonella spp. Fusion proteins containing viral antigens were expressed in the oral vaccine strain, Salmonella typhi Ty21a. Surface localization was verified by immunoblotting and fluorescence-activated cell sorting. The immunogenicity of surface-displayed viral antigens on the recombinant live vaccine strain was assessed in mice inoculated intranasally and intraperitoneally. Inoculation resulted in significantly higher serum antibody level than those induced by viral antigens expressed intracellularly. Thus, this multivalent mucosal live vaccine may provide an effective means for inducing mucosal or systemic immune responses against multiple viral antigens.	Chungnam Natl Univ, Coll Vet Med, Infect Dis Lab, Taejon, South Korea; KRIBB, Taejon, South Korea	Chungnam National University; Korea Research Institute of Bioscience & Biotechnology (KRIBB)	Kim, CJ (corresponding author), Chungnam Natl Univ, Coll Vet Med, Infect Dis Lab, Taejon, South Korea.	cjkim@cnu.ac.kr		Kim, Chul-Joong/0000-0001-8827-6332; Lee, Jong-Soo/0000-0001-5119-0711				AGTERBERG M, 1990, VACCINE, V8, P438, DOI 10.1016/0264-410X(90)90242-E; AGTERBERG M, 1990, GENE, V88, P37, DOI 10.1016/0378-1119(90)90057-X; Barry EM, 1996, INFECT IMMUN, V64, P4172, DOI 10.1128/IAI.64.10.4172-4181.1996; CARDENAS L, 1992, CLIN MICROBIOL REV, V5, P328; Chabalgoity JA, 1996, MOL MICROBIOL, V19, P791, DOI 10.1046/j.1365-2958.1996.426965.x; CHARBIT A, 1988, GENE, V70, P181, DOI 10.1016/0378-1119(88)90116-3; Chen G, 1996, BIOTECHNOL PROGR, V12, P572, DOI 10.1021/bp960041s; Cornelis P, 1996, BIO-TECHNOL, V14, P203, DOI 10.1038/nbt0296-203; CURTISS R, 1990, TRENDS BIOTECHNOL, V8, P237, DOI 10.1016/0167-7799(90)90184-Y; DUNNE M, 1995, INFECT IMMUN, V63, P1611, DOI 10.1128/IAI.63.4.1611-1614.1995; Galen JE, 1997, VACCINE, V15, P700, DOI 10.1016/S0264-410X(96)00227-7; Georgiou G, 1996, PROTEIN ENG, V9, P239, DOI 10.1093/protein/9.2.239; Georgiou G, 1997, NAT BIOTECHNOL, V15, P29, DOI 10.1038/nbt0197-29; GREEN RL, 1988, MOL GEN GENET, V215, P165, DOI 10.1007/BF00331320; HOFNUNG M, 1991, METHOD CELL BIOL, V34, P77; Hone DM, 1996, J BIOTECHNOL, V44, P203, DOI 10.1016/0168-1656(95)00151-4; Jung HC, 1998, NAT BIOTECHNOL, V16, P576, DOI 10.1038/nbt0698-576; Jung HC, 1998, ENZYME MICROB TECH, V22, P348, DOI 10.1016/S0141-0229(97)00224-X; KORNACKER MG, 1990, MOL MICROBIOL, V4, P1101, DOI 10.1111/j.1365-2958.1990.tb00684.x; KOZLOFF LM, 1991, J BACTERIOL, V173, P6528, DOI 10.1128/jb.173.20.6528-6536.1991; LAUKKANEN ML, 1993, PROTEIN ENG, V6, P449, DOI 10.1093/protein/6.4.449; LECLERC C, 1989, VACCINE, V7, P242, DOI 10.1016/0264-410X(89)90237-5; LU ZJ, 1995, BIO-TECHNOL, V13, P366, DOI 10.1038/nbt0495-366; Maurer J, 1997, J BACTERIOL, V179, P794, DOI 10.1128/jb.179.3.794-804.1997; MCGHEE JR, 1992, VACCINE, V10, P75, DOI 10.1016/0264-410X(92)90021-B; NEMECEKMARSHALL M, 1993, J BACTERIOL, V175, P4062, DOI 10.1128/JB.175.13.4062-4070.1993; NEWTON SMC, 1995, RES MICROBIOL, V146, P203, DOI 10.1016/0923-2508(96)80276-2; OCALLAGHAN D, 1990, RES MICROBIOL, V141, P963, DOI 10.1016/0923-2508(90)90136-E; OCALLAGHAN D, 1988, INFECT IMMUN, V56, P419, DOI 10.1128/IAI.56.2.419-423.1988; PALLESEN L, 1995, MICROBIOL-UK, V141, P2839, DOI 10.1099/13500872-141-11-2839; POHLNER J, 1987, NATURE, V325, P458, DOI 10.1038/325458a0; ROBERTS M, 1994, NOVEL DELIVERY SYSTE, P27; SCHORR J, 1991, VACCINE, V9, P675, DOI 10.1016/0264-410X(91)90194-B; Sousa C, 1996, NAT BIOTECHNOL, V14, P1017, DOI 10.1038/nbt0896-1017; SU GF, 1992, INFECT IMMUN, V60, P3345, DOI 10.1128/IAI.60.8.3345-3359.1992; Suzuki T, 1995, J BIOL CHEM, V270, P30874, DOI 10.1074/jbc.270.52.30874; WOLBER PK, 1993, ADV MICROB PHYSIOL, V34, P203, DOI 10.1016/S0065-2911(08)60030-2; WONG RSY, 1995, GENE, V158, P55, DOI 10.1016/0378-1119(95)00155-Y	38	117	164	3	34	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JUN	2000	18	6					645	648		10.1038/76494	http://dx.doi.org/10.1038/76494			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	325EK	10835603				2022-12-25	WOS:000087663200025
J	Mauri, C; Mars, LT; Londei, M				Mauri, C; Mars, LT; Londei, M			Therapeutic activity of agonistic monoclonal antibodies against CD40 in a chronic autoimmune inflammatory process	NATURE MEDICINE			English	Article							COLLAGEN-INDUCED ARTHRITIS; CELL-MEDIATED-IMMUNITY; CD4(+) T-CELLS; IN-VIVO; B-CELLS; TARGETING AUTOANTIGEN; CLONAL EXPANSION; INDUCTION; ACTIVATION; DISEASE	The use of agonistic monoclonal antibody against CD40 has emerged as one the most effective ways to boost immune responses against infectious agents or to fight cancer. Here, we report that the same monoclonal antibodies against CD40 (FGK45 and 3/23) previously used to elicit protective immune responses treated the autoimmune inflammatory process of chronic collagen-induced arthritis in DBA/1-TCR-beta transgenic mice, as well as collagen-induced arthritis in DBA/1 mice, both animal models of rheumatoid arthritis. This study indicates that agonistic monoclonal antibody against CD40 can potentially be used to treat chronic autoimmune inflammatory processes.	Imperial Coll, Sch Med, Kennedy Inst Rheumatol, London W6 8LH, England	Imperial College London; University of Oxford	Londei, M (corresponding author), Imperial Coll, Sch Med, Kennedy Inst Rheumatol, 1 Aspenlea Rd, London W6 8LH, England.		Mauri, Chiara/GXN-0766-2022; Mars, Lennart T/K-7593-2014	Mars, Lennart T/0000-0001-7997-1974; Mauri, Claudia/0000-0001-9761-2625				Abbas AK, 1996, NATURE, V383, P787, DOI 10.1038/383787a0; Balasa B, 1997, J IMMUNOL, V159, P4620; BLUESTONE JA, 1995, IMMUNITY, V2, P555, DOI 10.1016/1074-7613(95)90000-4; Cella M, 1997, CURR OPIN IMMUNOL, V9, P10, DOI 10.1016/S0952-7915(97)80153-7; Chu CQ, 1996, J IMMUNOL, V157, P2685; DAY MJ, 1992, J EXP MED, V175, P655, DOI 10.1084/jem.175.3.655; DEVRIES JE, 1995, ANN MED, V27, P537, DOI 10.3109/07853899509002465; Diehl L, 1999, NAT MED, V5, P774, DOI 10.1038/10495; Dullforce P, 1998, NAT MED, V4, P88, DOI 10.1038/nm0198-088; DURIE FH, 1993, SCIENCE, V261, P1328, DOI 10.1126/science.7689748; Faassen AE, 1995, EUR J IMMUNOL, V25, P3249, DOI 10.1002/eji.1830251208; Ferlin WG, 1998, EUR J IMMUNOL, V28, P525, DOI 10.1002/(SICI)1521-4141(199802)28:02&lt;525::AID-IMMU525&gt;3.0.CO;2-M; FINKELMAN FD, 1987, J IMMUNOL, V138, P2826; FINKELMAN FD, 1986, J IMMUNOL, V137, P2878; FIORENTINO DF, 1989, J EXP MED, V170, P2081, DOI 10.1084/jem.170.6.2081; GAJEWSKI TF, 1991, J IMMUNOL, V146, P1750; Grewal IS, 1998, ANNU REV IMMUNOL, V16, P111, DOI 10.1146/annurev.immunol.16.1.111; Griggs ND, 1996, J EXP MED, V183, P801, DOI 10.1084/jem.183.3.801; Guinan EC, 1999, NEW ENGL J MED, V340, P1704, DOI 10.1056/NEJM199906033402202; HASBOLD J, 1994, EUR J IMMUNOL, V24, P1835, DOI 10.1002/eji.1830240817; Hogaboam CM, 1997, J CLIN INVEST, V100, P2766, DOI 10.1172/JCI119823; Howard LM, 1999, J CLIN INVEST, V103, P281, DOI 10.1172/JCI5388; Kirk AD, 1999, NAT MED, V5, P686, DOI 10.1038/9536; LANZAVECCHIA A, 1985, NATURE, V314, P537, DOI 10.1038/314537a0; LENSCHOW DJ, 1992, SCIENCE, V257, P789, DOI 10.1126/science.1323143; LIBLAU RS, 1995, IMMUNOL TODAY, V16, P34, DOI 10.1016/0167-5699(95)80068-9; LIN H, 1993, J EXP MED, V178, P1801, DOI 10.1084/jem.178.5.1801; Macaulay AE, 1997, J IMMUNOL, V158, P4171; Maiuri L, 1998, GASTROENTEROLOGY, V115, P564, DOI 10.1016/S0016-5085(98)70135-0; MATZINGER P, 1994, ANNU REV IMMUNOL, V12, P991, DOI 10.1146/annurev.immunol.12.1.991; Mauri C, 1997, J IMMUNOL, V159, P5032; Mauri C, 1996, EUR J IMMUNOL, V26, P1511, DOI 10.1002/eji.1830260716; Maxwell JR, 1999, J IMMUNOL, V162, P2024; MILLER EJ, 1972, BIOCHEMISTRY-US, V11, P4903, DOI 10.1021/bi00776a005; MOHAN C, 1995, J IMMUNOL, V154, P1470; MORI L, 1992, J EXP MED, V176, P381, DOI 10.1084/jem.176.2.381; OPENSHAW P, 1995, J EXP MED, V182, P1357, DOI 10.1084/jem.182.5.1357; POWRIE F, 1993, EUR J IMMUNOL, V23, P3043, DOI 10.1002/eji.1830231147; Rolink A, 1996, IMMUNITY, V5, P319, DOI 10.1016/S1074-7613(00)80258-7; SADICK MD, 1990, J EXP MED, V171, P115, DOI 10.1084/jem.171.1.115; SAOUDI A, 1995, J EXP MED, V182, P335, DOI 10.1084/jem.182.2.335; Skok J, 1999, J IMMUNOL, V163, P4284; Sotomayor EM, 1999, NAT MED, V5, P780, DOI 10.1038/10503; Walmsley M, 1996, ARTHRITIS RHEUM-US, V39, P495, DOI 10.1002/art.1780390318; WILLIAMS RO, 1992, P NATL ACAD SCI USA, V89, P9784, DOI 10.1073/pnas.89.20.9784	46	100	107	0	4	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUN	2000	6	6					673	679		10.1038/76251	http://dx.doi.org/10.1038/76251			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	321CX	10835684				2022-12-25	WOS:000087438300038
J	Farmer, WR; Liao, JC				Farmer, WR; Liao, JC			Improving lycopene production in Escherichia coli by engineering metabolic control	NATURE BIOTECHNOLOGY			English	Article						carotenoids; isoprenoids; metabolic engineering; metabolic control; nitrogen regulon	ACETYL PHOSPHATE; EXPRESSION; PROTEIN; ACTIVATION; GLUCOSE; PATHWAY; IDENTIFICATION; ASTAXANTHIN; AROMATICS; PLASMIDS	Metabolic engineering has achieved encouraging success in producing foreign metabolites in a variety of hosts. However, common strategies for engineering metabolic pathways focus on amplifying the desired enzymes and deregulating cellular controls. As a result, uncontrolled or deregulated metabolic pathways lead to metabolic imbalance and suboptimal productivity. Here we have demonstrated the second stage of metabolic engineering effort by designing and engineering a regulatory circuit to control gene expression in response to intracellular metabolic states. Specifically, we recruited and altered one of the global regulatory systems in Escherichia coli, the Ntr regulon, to control the engineered lycopene biosynthesis pathway. The artificially engineered regulon, stimulated by excess glycolytic flux through sensing of an intracellular metabolite, acetyl phosphate, controls the expression of two key enzymes in lycopene synthesis in response to flux dynamics. This intracellular control loop significantly enhanced lycopene production while reducing the negative impact caused by metabolic imbalance. Although we demonstrated this strategy for metabolite production, it can be extended into other fields where gene expression must be closely controlled by intracellular physiology, such as gene therapy.	Univ Calif Los Angeles, Dept Chem Engn, Los Angeles, CA 90034 USA	University of California System; University of California Los Angeles	Liao, JC (corresponding author), Univ Calif Los Angeles, Dept Chem Engn, Los Angeles, CA 90034 USA.			Liao, James/0000-0002-4580-7276				BAILEY JE, 1991, SCIENCE, V252, P1668, DOI 10.1126/science.2047876; Dedhia N, 1997, BIOTECHNOL BIOENG, V53, P379, DOI 10.1002/(SICI)1097-0290(19970220)53:4<379::AID-BIT4>3.3.CO;2-V; DRATHS KM, 1992, J AM CHEM SOC, V114, P3956, DOI 10.1021/ja00036a050; Farmer WR, 1997, APPL ENVIRON MICROB, V63, P3205, DOI 10.1128/AEM.63.8.3205-3210.1997; FENG JL, 1992, J BACTERIOL, V174, P6061, DOI 10.1128/JB.174.19.6061-6070.1992; FURSTE JP, 1986, GENE, V48, P119, DOI 10.1016/0378-1119(86)90358-6; Fussenegger M, 1998, NAT BIOTECHNOL, V16, P468, DOI 10.1038/nbt0598-468; Giovannucci E, 1999, JNCI-J NATL CANCER I, V91, P317, DOI 10.1093/jnci/91.4.317; Guillouet S, 1999, APPL ENVIRON MICROB, V65, P3100; Hoch JA, 1995, 2 COMPONENT SIGNAL T; Hwang I, 1999, P NATL ACAD SCI USA, V96, P4880, DOI 10.1073/pnas.96.9.4880; Kajiwara S, 1997, BIOCHEM J, V324, P421, DOI 10.1042/bj3240421; Kim SK, 1996, MOL MICROBIOL, V22, P135, DOI 10.1111/j.1365-2958.1996.tb02663.x; Kurland CG, 1996, MOL MICROBIOL, V21, P1, DOI 10.1046/j.1365-2958.1996.5901313.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LERNER CG, 1990, NUCLEIC ACIDS RES, V18, P4631, DOI 10.1093/nar/18.15.4631; LIU J, 1995, J BACTERIOL, V177, P926, DOI 10.1128/jb.177.4.926-931.1995; MCCLEARY WR, 1994, J BIOL CHEM, V269, P31567; Miller J.H., 1992, SHORT COURSE BACTERI, P150; MISAWA N, 1990, J BACTERIOL, V172, P6704, DOI 10.1128/jb.172.12.6704-6712.1990; Miura Y, 1998, APPL ENVIRON MICROB, V64, P1226; MOCKEL B, 1994, MOL MICROBIOL, V13, P833, DOI 10.1111/j.1365-2958.1994.tb00475.x; NYSTROM T, 1994, MOL MICROBIOL, V12, P833, DOI 10.1111/j.1365-2958.1994.tb01069.x; PATNAIK R, 1992, J BACTERIOL, V174, P7527, DOI 10.1128/JB.174.23.7527-7532.1992; PATNAIK R, 1994, APPL ENVIRON MICROB, V60, P3903, DOI 10.1128/AEM.60.11.3903-3908.1994; PATNAIK R, 1995, BIOTECHNOL BIOENG, V46, P361, DOI 10.1002/bit.260460409; REITZER LJ, 1985, P NATL ACAD SCI USA, V82, P1979, DOI 10.1073/pnas.82.7.1979; Ruther A, 1997, APPL MICROBIOL BIOT, V48, P162, DOI 10.1007/s002530051032; Sies H, 1998, P SOC EXP BIOL MED, V218, P121, DOI 10.3181/00379727-218-44285a; Silhavy T.J., 1984, EXPT GENE FUSIONS; SIMONS RW, 1987, GENE, V53, P85, DOI 10.1016/0378-1119(87)90095-3; Sprenger GA, 1997, P NATL ACAD SCI USA, V94, P12857, DOI 10.1073/pnas.94.24.12857; STEWART V, 1988, J BACTERIOL, V170, P1589, DOI 10.1128/jb.170.4.1589-1597.1988; STOCK JB, 1992, J BIOL CHEM, V267, P19753; Wang CW, 1999, BIOTECHNOL BIOENG, V62, P235, DOI 10.1002/(SICI)1097-0290(19990120)62:2<235::AID-BIT14>3.0.CO;2-U	35	408	454	5	131	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAY	2000	18	5					533	537		10.1038/75398	http://dx.doi.org/10.1038/75398			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	313UK	10802621				2022-12-25	WOS:000087017500027
J	Firestine, SM; Salinas, F; Nixon, AE; Baker, SJ; Benkovic, SJ				Firestine, SM; Salinas, F; Nixon, AE; Baker, SJ; Benkovic, SJ			Using an AraC-based three-hybrid system to detect biocatalysts in vivo	NATURE BIOTECHNOLOGY			English	Article						molecular evolution; screening/selection methods; scytalone dehydratase; three-hybrid systems; artificial transcription system	IN-VITRO RECOMBINATION; SCYTALONE DEHYDRATASE; MOLECULAR EVOLUTION; PROTEIN; DESIGN; ENZYMES; SITE	Recent methods to create large libraries of proteins have greatly advanced the discovery of proteins with novel functions. However, one limitation in the discovery of new biocatalysts is the screening or selection methods employed to find enzymes from these libraries. We have developed a potentially general method termed QUEST (QUerying for EnzymeS using the Three-hybrid system), which allows the construction of an easily screened or selected phenotype for, in theory, any type of enzymatic reaction. The method couples the in vivo concentration of an enzyme's substrate to changes in the transcriptional level of a reporter operon. Using the arabinose operon activator AraC, we constructed a system capable of detecting the fungal enzyme scytalone dehydratase (SD) in bacteria, and demonstrated its sensitivity and usefulness in library screening.	Penn State Univ, Dept Chem, University Pk, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Benkovic, SJ (corresponding author), Penn State Univ, Dept Chem, 152 Davey Lab, University Pk, PA 16802 USA.							Basarab GS, 1999, BIOCHEMISTRY-US, V38, P6012, DOI 10.1021/bi982952b; BUSTOS SA, 1993, P NATL ACAD SCI USA, V90, P5638, DOI 10.1073/pnas.90.12.5638; Chen JM, 1998, BIOCHEMISTRY-US, V37, P17735, DOI 10.1021/bi981848r; Crabtree GR, 1996, TRENDS BIOCHEM SCI, V21, P418, DOI 10.1016/S0968-0004(96)20027-1; Fastrez J, 1997, MOL BIOTECHNOL, V7, P37, DOI 10.1007/BF02821543; Licitra EJ, 1996, P NATL ACAD SCI USA, V93, P12817, DOI 10.1073/pnas.93.23.12817; LUNDQVIST T, 1994, STRUCTURE, V2, P937, DOI 10.1016/S0969-2126(94)00095-6; MENON KP, 1990, P NATL ACAD SCI USA, V87, P3708, DOI 10.1073/pnas.87.10.3708; Murzin AG, 1996, CURR OPIN STRUC BIOL, V6, P386, DOI 10.1016/S0959-440X(96)80059-5; Nixon AE, 1999, P NATL ACAD SCI USA, V96, P3568, DOI 10.1073/pnas.96.7.3568; Ostermeier M, 1999, P NATL ACAD SCI USA, V96, P3562, DOI 10.1073/pnas.96.7.3562; Shao ZX, 1998, NUCLEIC ACIDS RES, V26, P681, DOI 10.1093/nar/26.2.681; STEMMER WPC, 1994, P NATL ACAD SCI USA, V91, P10747, DOI 10.1073/pnas.91.22.10747; Thompson JE, 1998, ANAL BIOCHEM, V256, P1, DOI 10.1006/abio.1997.2489; Wawrzak Z, 1999, PROTEINS, V35, P425, DOI 10.1002/(SICI)1097-0134(19990601)35:4<425::AID-PROT6>3.3.CO;2-T; Zhao HM, 1997, CURR OPIN STRUC BIOL, V7, P480, DOI 10.1016/S0959-440X(97)80110-8; Zhao HM, 1998, NAT BIOTECHNOL, V16, P258, DOI 10.1038/nbt0398-258	17	39	66	0	8	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAY	2000	18	5					544	547		10.1038/75414	http://dx.doi.org/10.1038/75414			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	313UK	10802623				2022-12-25	WOS:000087017500029
J	Li, XR; Ponten, A; Aase, K; Karlsson, L; Abramsson, A; Uutela, M; Backstrom, G; Hellstrom, M; Bostrom, H; Li, H; Soriano, P; Betscholtz, C; Heldin, CH; Alitalo, K; Ostman, A; Eriksson, U				Li, XR; Ponten, A; Aase, K; Karlsson, L; Abramsson, A; Uutela, M; Backstrom, G; Hellstrom, M; Bostrom, H; Li, H; Soriano, P; Betscholtz, C; Heldin, CH; Alitalo, K; Ostman, A; Eriksson, U			PDGF-C is a new protease-activated ligand for the PDGF alpha-receptor	NATURE CELL BIOLOGY			English	Article							FACTOR VITAMIN-B-12 RECEPTOR; FACTOR A-CHAIN; GROWTH-FACTOR; EXTRACELLULAR-MATRIX; SIGNAL-TRANSDUCTION; CELL-DEVELOPMENT; BETA-RECEPTOR; MICE; BINDING; PROTEINS	Platelet-derived growth factors (PDGFs) are important in many types of mesenchymal cell. Here we identify a new PDGF, PDGF-C, which binds to and activates the PDGF alpha-receptor. PDGF-C is activated by proteolysis and induces proliferation of fibroblasts when overexpressed in transgenic mice. In situ hybridization analysis In the murine embryonic kidney shows preferential expression of PDGF-C messenger RNA in the metanephric mesenchyme during epithelial conversion. Analysis of kidneys lacking the PDGF alpha-receptor shows selective loss of mesenchymal cells adjacent to sites of expression of PDGF-C mRNA; this is not found in kidneys from animals lacking PDGF-A or both PDGF-A and PDGF-B, indicating that PDGF-C may have a unique function.	Ludwig Inst Canc Res, Stockholm Branch, S-17177 Stockholm, Sweden; Gothenburg Univ, Dept Med Biochem, S-41390 Gothenburg, Sweden; Univ Helsinki, Haartman Inst, Mol Canc Biol Lab, SF-00014 Helsinki, Finland; Ludwig Inst Canc Res, Uppsala Branch, S-75124 Uppsala, Sweden; Fred Hutchinson Canc Res Ctr, Program Dev Biol, Div Basic Sci, Seattle, WA 98109 USA	Ludwig Institute for Cancer Research; University of Gothenburg; University of Helsinki; Ludwig Institute for Cancer Research; Fred Hutchinson Cancer Center	Eriksson, U (corresponding author), Ludwig Inst Canc Res, Stockholm Branch, Box 240, S-17177 Stockholm, Sweden.		Abramsson, Alexandra/GPX-5584-2022; Soriano, Philippe M/E-5797-2015; Alitalo, Kari K/J-5013-2014; Ehrencrona, Hans/M-5619-2014	Soriano, Philippe M/0000-0002-0427-926X; Alitalo, Kari K/0000-0002-7331-0902; Ehrencrona, Hans/0000-0002-5589-3622; Hellstrom, Mats/0000-0002-7088-9533				ANDERSSON M, 1994, J BIOL CHEM, V269, P926; Ataliotis P, 1997, INT REV CYTOL, V172, P95, DOI 10.1016/S0074-7696(08)62359-1; BETSHOLTZ C, 1984, CELL, V39, P447, DOI 10.1016/0092-8674(84)90452-5; BETSHOLTZ C, 1986, NATURE, V320, P695, DOI 10.1038/320695a0; BORK P, 1993, J MOL BIOL, V231, P539, DOI 10.1006/jmbi.1993.1305; BORK P, 1991, FEBS LETT, V282, P9, DOI 10.1016/0014-5793(91)80433-4; Bostrom H, 1996, CELL, V85, P863, DOI 10.1016/S0092-8674(00)81270-2; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P15; ERIKSSON A, 1992, EMBO J, V11, P543, DOI 10.1002/j.1460-2075.1992.tb05085.x; Eriksson U, 1999, CURR TOP MICROBIOL, V237, P41; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Fruttiger M, 1999, DEVELOPMENT, V126, P457; Giger RJ, 1998, NEURON, V21, P1079, DOI 10.1016/S0896-6273(00)80625-X; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; HAUSMANN K, 1993, ADV CELL MOL BIOL M, V2, P259; HELDIN CH, 1988, EMBO J, V7, P1387, DOI 10.1002/j.1460-2075.1988.tb02955.x; Heldin CH, 1998, BBA-REV CANCER, V1378, pF79, DOI 10.1016/S0304-419X(98)00015-8; Heldin CH, 1999, PHYSIOL REV, V79, P1283, DOI 10.1152/physrev.1999.79.4.1283; Karlsson L, 1999, DEVELOPMENT, V126, P2611; KEATING MT, 1988, SCIENCE, V239, P914, DOI 10.1126/science.2829358; Kristiansen M, 1999, J BIOL CHEM, V274, P20540, DOI 10.1074/jbc.274.29.20540; LEVEEN P, 1994, GENE DEV, V8, P1875, DOI 10.1101/gad.8.16.1875; Lindahl P, 1999, CURR TOPICS PATHOL, V93, P27; Lindahl P, 1998, CURR OPIN NEPHROL HY, V7, P21, DOI 10.1097/00041552-199801000-00004; Lindahl P, 1998, DEVELOPMENT, V125, P3313; Lindahl P, 1997, SCIENCE, V277, P242, DOI 10.1126/science.277.5323.242; Moestrup SK, 1998, J BIOL CHEM, V273, P5235, DOI 10.1074/jbc.273.9.5235; MORI S, 1991, J BIOL CHEM, V266, P21158; Nakamura F, 1998, NEURON, V21, P1093, DOI 10.1016/S0896-6273(00)80626-1; Nakayama K, 1997, BIOCHEM J, V327, P625, DOI 10.1042/bj3270625; OEFNER C, 1992, EMBO J, V11, P3921, DOI 10.1002/j.1460-2075.1992.tb05485.x; Olofsson B, 1996, P NATL ACAD SCI USA, V93, P2576, DOI 10.1073/pnas.93.6.2576; OSTMAN A, 1992, J CELL BIOL, V118, P509, DOI 10.1083/jcb.118.3.509; Ostman A, 1989, GROWTH FACTORS, V1, P271, DOI 10.3109/08977198908998003; PARK JE, 1993, MOL BIOL CELL, V4, P1317, DOI 10.1091/mbc.4.12.1317; PEKNY M, 1994, GROWTH FACTORS, V10, P77, DOI 10.3109/08977199409010981; RAINES EW, 1990, PEPTIDE GROWTH FACTO, V1, P173; Simm A, 1998, BASIC RES CARDIOL, V93, P40; Soriano P, 1997, DEVELOPMENT, V124, P2691; SORIANO P, 1994, GENE DEV, V8, P1888, DOI 10.1101/gad.8.16.1888; SUBRAMANIAM A, 1991, J BIOL CHEM, V266, P24613; Thielens NM, 1999, IMMUNOPHARMACOLOGY, V42, P3, DOI 10.1016/S0162-3109(99)00019-3; Vainio S, 1997, CELL, V90, P975, DOI 10.1016/S0092-8674(00)80363-3	43	484	527	1	17	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	MAY	2000	2	5					302	309		10.1038/35010579	http://dx.doi.org/10.1038/35010579			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	313FX	10806482				2022-12-25	WOS:000086990600020
J	Braun, KM; Degen, JL; Sandgren, EP				Braun, KM; Degen, JL; Sandgren, EP			Hepatocyte transplantation in a model of toxin-induced liver disease: variable therapeutic effect during replacement of damaged parenchyma by donor cells	NATURE MEDICINE			English	Article							ACUTE HEPATIC-FAILURE; HEPATOCELLULAR TRANSPLANTATION; GENE-THERAPY; TRANSGENIC MICE; PLASMINOGEN-ACTIVATOR; DEFICIENT RABBITS; MOUSE-LIVER; RAT; HYPERCHOLESTEROLEMIA; REGENERATION	To provide long-term therapy in patients with severe toxin-induced hepatic parenchymal damage, donor hepatocytes would need to replicate and replace a large portion of the damaged parenchyma. Using a mouse model developed to reproduce this type of hepatic injury, we found that hepatocyte transplantation only slightly improved survival after transplantation despite the fact that many non-survivors showed moderate liver repopulation by donor cells. Perhaps accounting for this outcome, donor parenchyma in non-survivors did not have typical lobular organization. These results indicate that the re-creation of functional parenchyma by transplanted hepatocytes requires time, during which donor cells proliferate and then establish normal parenchymal architecture.	Univ Wisconsin, Sch Vet Med, Dept Pathobiol Sci, Madison, WI 53706 USA; Childrens Hosp Res Fdn, Div Dev Biol, Cincinnati, OH 45229 USA	University of Wisconsin System; University of Wisconsin Madison; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation	Sandgren, EP (corresponding author), Univ Wisconsin, Sch Vet Med, Dept Pathobiol Sci, Madison, WI 53706 USA.				NIDDK NIH HHS [R01-DK49787] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049787] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAUMGARTNER D, 1983, EUR SURG RES, V15, P129, DOI 10.1159/000128344; Birraux J, 1998, EUR J PEDIATR SURG, V8, P224, DOI 10.1055/s-2008-1071159; BORRELLI E, 1988, P NATL ACAD SCI USA, V85, P7572, DOI 10.1073/pnas.85.20.7572; Brand K, 1997, CANCER GENE THER, V4, P9; BRINSTER RL, 1985, P NATL ACAD SCI USA, V82, P4438, DOI 10.1073/pnas.82.13.4438; CAMERON RG, 1996, DRUG INDUCED HEPATOT; Chowdhury JR, 1998, PEDIATRICS, V102, P647, DOI 10.1542/peds.102.3.647; CHOWDHURY JR, 1991, SCIENCE, V254, P1802, DOI 10.1126/science.1722351; CULVER KW, 1992, SCIENCE, V256, P1550, DOI 10.1126/science.1317968; Fox IJ, 1998, NEW ENGL J MED, V338, P1422, DOI 10.1056/NEJM199805143382004; FREEMAN SM, 1993, CANCER RES, V53, P5274; FULLER BJ, 1988, J HEPATOL, V7, P368, DOI 10.1016/S0168-8278(88)80010-2; GROSSMAN M, 1994, NAT GENET, V6, P335, DOI 10.1038/ng0494-335; GROTH CG, 1977, TRANSPLANT P, V9, P313; Gunsalus JR, 1997, NAT MED, V3, P48, DOI 10.1038/nm0197-48; Gupta S, 1999, J HEPATOL, V30, P162, DOI 10.1016/S0168-8278(99)80022-1; HABIBULLAH CM, 1994, TRANSPLANTATION, V58, P951, DOI 10.1097/00007890-199410270-00016; HECKEL JL, 1990, CELL, V62, P447, DOI 10.1016/0092-8674(90)90010-C; HEYMAN RA, 1989, P NATL ACAD SCI USA, V86, P2698, DOI 10.1073/pnas.86.8.2698; KAY MA, 1992, P NATL ACAD SCI USA, V89, P89, DOI 10.1073/pnas.89.1.89; Kisseberth WC, 1999, DEV BIOL, V214, P128, DOI 10.1006/dbio.1999.9417; Kiuchi T, 1999, TRANSPLANTATION, V67, P321, DOI 10.1097/00007890-199901270-00024; KLAUNIG JE, 1981, IN VITRO CELL DEV B, V17, P913; Kocken JM, 1996, TRANSPLANTATION, V62, P358, DOI 10.1097/00007890-199608150-00010; Lake JR, 1998, NEW ENGL J MED, V338, P1463, DOI 10.1056/NEJM199805143382012; LEE AH, 1994, AM J MED, V96, P35, DOI 10.1016/0002-9343(94)90113-9; LEE WM, 1995, NEW ENGL J MED, V333, P1118, DOI 10.1056/NEJM199510263331706; MAKOWKA L, 1981, CAN J SURG, V24, P39; MAKOWKA L, 1980, J SURG RES, V29, P479, DOI 10.1016/0022-4804(80)90016-5; MATAS AJ, 1976, SCIENCE, V192, P892, DOI 10.1126/science.818706; MITO M, 1993, TRANSPLANT REV, V7, P35; Moscioni AD, 1996, CELL TRANSPLANT, V5, P499, DOI 10.1016/0963-6897(95)02021-7; Oren R, 1999, HEPATOLOGY, V29, P75, DOI 10.1002/hep.510290147; Overturf K, 1997, AM J PATHOL, V151, P1273; Overturf K, 1996, NAT GENET, V12, P266, DOI 10.1038/ng0396-266; RHIM JA, 1994, SCIENCE, V263, P1149, DOI 10.1126/science.8108734; SANDGREN EP, 1991, CELL, V66, P245, DOI 10.1016/0092-8674(91)90615-6; SMITH DD, 1988, P NATL ACAD SCI USA, V85, P160, DOI 10.1073/pnas.85.1.160; SOMMER BG, 1979, TRANSPLANT P, V11, P578; Strom SC, 1997, TRANSPLANTATION, V63, P559, DOI 10.1097/00007890-199702270-00014; SUTHERLAND DER, 1977, SURGERY, V82, P124; WALLACE H, 1994, J ENDOCRINOL, V143, P107, DOI 10.1677/joe.0.1430107; WILSON JM, 1990, P NATL ACAD SCI USA, V87, P8437, DOI 10.1073/pnas.87.21.8437; ZIMMERMAN HJ, 1993, DIS LIVER, V1, P707	44	74	79	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAR	2000	6	3					320	326						7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	288TL	10700235				2022-12-25	WOS:000085580500043
J	Gayther, SA; Batley, SJ; Linger, L; Bannister, A; Thorpe, K; Chin, SF; Daigo, Y; Russell, P; Wilson, A; Sowter, HM; Delhanty, JDA; Ponder, BAJ; Kouzarides, T; Caldas, C				Gayther, SA; Batley, SJ; Linger, L; Bannister, A; Thorpe, K; Chin, SF; Daigo, Y; Russell, P; Wilson, A; Sowter, HM; Delhanty, JDA; Ponder, BAJ; Kouzarides, T; Caldas, C			Mutations truncating the EP300 acetylase in human cancers	NATURE GENETICS			English	Article							E1A-ASSOCIATED PROTEIN P300; COACTIVATORS P300; CBP; GENE; P53; BINDING; FAMILY	The EP300 protein is a histone acetyltransferase(1.2) that regulates transcription via chromatin remodelling(3) and is important in the processes of cell proliferation(4) and differentiation(5). EP300 acetylation of TP53 in response to DNA damage regulates its DNA-binding and transcription functions(6-9). A role for EP300 in cancer has been implied by the fact that it is targeted by viral oncoproteins, it is fused to MLL in leukaemia and two missense sequence alterations in EP300 were identified in epithelial malignancies(10-13). Nevertheless, direct demonstration of the role of EP300 in tumorigenesis by inactivating mutations in human cancers has been lacking. Here we describe EP300 mutations, which predict a truncated protein, in 6 (3%) of 193 epithelial cancers analysed. Of these six mutations, two were in primary tumours (a colorectal cancer and a breast cancer) and four were in cancer cell lines (colorectal, breast and pancreatic). In addition, we identified a somatic in-frame insertion in a primary breast cancer and missense alterations in a primary colorectal cancer and two cell lines (breast and pancreatic). Inactivation of the second allele was demonstrated in five of six cases with truncating mutations and in two other cases. Our data show that EP300 is mutated in epithelial cancers and provide the first evidence that it behaves as a classical tumour-suppressor gene.	Univ Cambridge, Dept Oncol, Cambridge, England; Univ Cambridge, Dept Pathol, Cambridge, England; Univ Cambridge, Strangeways Res Labs, Cambridge, England; Univ Cambridge, Canbridge Inst Med Res, Wellcome Trust Ctr Study Mol Mechanisms Dis, Cambridge, England; Univ Cambridge, Wellcome CRC Inst, Cambridge, England; Derby City Gen Hosp, Oncol Res Lab, Derby, England; Univ Cambridge, Rosie Hosp, Dept Obstet & Gynaecol, Cambridge, England; UCL, London Sch Med, Dept Obstet & Gynaecol, London, England	University of Cambridge; University of Cambridge; University of Cambridge; University of Cambridge; University of Cambridge; University of Nottingham; University of Cambridge; University of London; University College London	Caldas, C (corresponding author), Univ Cambridge, Dept Oncol, Cambridge, England.	cc234@cam.ac.uk	Thorpe, Karen/N-1159-2017; Caldas, Carlos/U-7250-2019; Caldas, Carlos/A-7543-2008	Thorpe, Karen/0000-0001-8927-4064; Caldas, Carlos/0000-0003-3547-1489; Kouzarides, Tony/0000-0002-8918-4162; Bannister, Andrew/0000-0002-6312-4436; chin, suet-feung/0000-0001-5697-1082; Daigo, Yataro/0000-0002-0915-3025				ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; ARANY Z, 1994, CELL, V77, P799, DOI 10.1016/0092-8674(94)90127-9; Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; CALDAS C, 1994, NAT GENET, V8, P410, DOI 10.1038/ng1294-410c; Foster KA, 1996, CANCER RES, V56, P3622; Gayther SA, 1997, ONCOGENE, V15, P2119, DOI 10.1038/sj.onc.1201591; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Ida K, 1997, BLOOD, V90, P4699, DOI 10.1182/blood.V90.12.4699.4699_4699_4704; Kawasaki H, 1998, NATURE, V393, P284, DOI 10.1038/30538; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; Muraoka M, 1996, ONCOGENE, V12, P1565; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Oike Y, 1999, HUM MOL GENET, V8, P387, DOI 10.1093/hmg/8.3.387; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Yao TP, 1998, CELL, V93, P361, DOI 10.1016/S0092-8674(00)81165-4	18	458	492	3	40	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAR	2000	24	3					300	303		10.1038/73536	http://dx.doi.org/10.1038/73536			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	288XW	10700188				2022-12-25	WOS:000085590600025
J	Granovsky, M; Fata, J; Pawling, J; Muller, WJ; Khokha, R; Dennis, JW				Granovsky, M; Fata, J; Pawling, J; Muller, WJ; Khokha, R; Dennis, JW			Suppression of tumor growth and metastasis in Mgat5-deficient mice	NATURE MEDICINE			English	Article							N-ACETYLGLUCOSAMINYLTRANSFERASE-V; HAMSTER-KIDNEY CELLS; BETA-1-6 BRANCHED OLIGOSACCHARIDES; ASN-LINKED OLIGOSACCHARIDES; GLCNAC-TRANSFERASE-V; PHOSPHATIDYLINOSITOL 3-KINASE; PHASEOLUS-VULGARIS; SUGAR CHAINS; HUMAN BREAST; EXPRESSION	Golgi beta 1,6N-acetylglucosaminyltransferase V (MGAT5) is required in the biosynthesis of beta 1,6GlcNAc-branched N-linked glycans attached to cell surface and secreted glycoproteins. Amounts of MGAT5 glycan products are commonly increased in malignancies, and correlate with disease progression. To study the functions of these N-glycans in development and disease, we generated mice deficient in Mgat5 by targeted gene mutation. These Mgat5(-/-) mice lacked Mgat5 products and appeared normal, but differed in their responses to certain extrinsic conditions. Mammary tumor growth and metastases induced by the polyomavirus middle T oncogene was considerably less in Mgat5(-/-) mice than in transgenic littermates expressing Mgat5. Furthermore, Mgat5 glycan products stimulated membrane ruffling and phosphatidylinositol 3 kinase-protein kinase B activation, fueling a positive feedback loop that amplified oncogene signaling and tumor growth in vivo. Our results indicate that inhibitors of MGAT5 might be useful in the treatment of malignancies by targeting their dependency on focal adhesion signaling for growth and metastasis.	Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada; Univ Toronto, Dept Mol & Med Genet, Toronto, ON, Canada; Univ Toronto, Ontario Canc Inst, Dept Med Biophys, Toronto, ON, Canada; Princess Margaret Hosp, Toronto, ON M5G 2C1, Canada; McMaster Univ, Inst Mol Biol & Biotechnol, Hamilton, ON L8S 4K1, Canada	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; McMaster University	Dennis, JW (corresponding author), Mt Sinai Hosp, Samuel Lunenfeld Res Inst, 600 Univ Ave,R988, Toronto, ON M5G 1X5, Canada.	Dennis@mshri.on.ca	Dennis, James/E-7268-2013					ASADA M, 1991, BIOCHEMISTRY-US, V30, P1561, DOI 10.1021/bi00220a017; Bronson R, 1997, P NATL ACAD SCI USA, V94, P7954, DOI 10.1073/pnas.94.15.7954; Chen L, 1998, ONCOGENE, V17, P2087, DOI 10.1038/sj.onc.1202124; Cheng AM, 1998, CELL, V95, P793, DOI 10.1016/S0092-8674(00)81702-X; CUMMINGS RD, 1982, J BIOL CHEM, V257, P13421; CUMMINGS RD, 1982, J BIOL CHEM, V257, P1230; DEMETRIOU M, 1995, J CELL BIOL, V130, P383, DOI 10.1083/jcb.130.2.383; DENNIS JW, 1989, ONCOGENE, V4, P853; DENNIS JW, 1986, CANCER RES, V46, P5131; DENNIS JW, 1987, SCIENCE, V236, P582, DOI 10.1126/science.2953071; DIAMOND MS, 1991, CELL, V65, P961, DOI 10.1016/0092-8674(91)90548-D; DILWORTH SM, 1994, NATURE, V367, P87, DOI 10.1038/367087a0; DO KY, 1994, J BIOL CHEM, V269, P23456; FERNANDES B, 1991, CANCER RES, V51, P718; GOSS PE, 1994, CANCER RES, V54, P1450; Granovsky M, 1995, GLYCOBIOLOGY, V5, P797, DOI 10.1093/glycob/5.8.797; GUY CT, 1994, GENE DEV, V8, P23, DOI 10.1101/gad.8.1.23; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; HASTY P, 1993, GENE TARGETING PRACT, P138; HUMPHRIES MJ, 1986, P NATL ACAD SCI USA, V83, P1752, DOI 10.1073/pnas.83.6.1752; Kang R, 1996, J BIOL CHEM, V271, P26706, DOI 10.1074/jbc.271.43.26706; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; King WG, 1997, MOL CELL BIOL, V17, P4406, DOI 10.1128/MCB.17.8.4406; Liu AX, 1998, CANCER RES, V58, P2973; LU Y, 1994, CLIN EXP METASTAS, V12, P47, DOI 10.1007/BF01784333; McEvoy LM, 1997, J EXP MED, V185, P1493, DOI 10.1084/jem.185.8.1493; Nakagawa H, 1996, EUR J BIOCHEM, V237, P76, DOI 10.1111/j.1432-1033.1996.0076n.x; Neznanov N, 1999, CANCER RES, V59, P4242; PIERCE M, 1986, J BIOL CHEM, V261, P772; Reif K, 1996, CURR BIOL, V6, P1445, DOI 10.1016/S0960-9822(96)00749-X; Seberger PJ, 1999, GLYCOBIOLOGY, V9, P235, DOI 10.1093/glycob/9.3.235; Seelentag WKF, 1998, CANCER RES, V58, P5559; SHOREIBAH M, 1993, J BIOL CHEM, V268, P15381; Skelton TP, 1998, J CELL BIOL, V140, P431, DOI 10.1083/jcb.140.2.431; SPECTOR I, 1989, CELL MOTIL CYTOSKEL, V13, P127, DOI 10.1002/cm.970130302; Turner CE, 1998, INT J BIOCHEM CELL B, V30, P955, DOI 10.1016/S1357-2725(98)00062-4; Verbeek BS, 1996, J PATHOL, V180, P383, DOI 10.1002/(SICI)1096-9896(199612)180:4<383::AID-PATH686>3.0.CO;2-N; Webster MA, 1998, MOL CELL BIOL, V18, P2344, DOI 10.1128/MCB.18.4.2344; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; YAMASHITA K, 1985, J BIOL CHEM, V260, P3963; YAMASHITA K, 1984, J BIOL CHEM, V259, P834	41	434	451	1	17	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2000	6	3					306	312						7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	288TL	10700233				2022-12-25	WOS:000085580500041
J	Li, BJ; Boast, S; de los Santos, K; Schieren, I; Quiroz, M; Teitelbaum, SL; Tondravi, MM; Goff, SP				Li, BJ; Boast, S; de los Santos, K; Schieren, I; Quiroz, M; Teitelbaum, SL; Tondravi, MM; Goff, SP			Mice deficient in Abl are osteoporotic and have defects in osteoblast maturation	NATURE GENETICS			English	Article							C-ABL; CLEIDOCRANIAL DYSPLASIA; BONE; DIFFERENTIATION; MOUSE; CELLS; GENE; EXPRESSION; MUTATION; CBFA1	The c-Abl protein is a non-receptor tyrosine kinase involved in many aspects of mammalian development. c-Abl kinase is widely expressed, but high levels are found in hyaline cartilage in the adult, bone tissue in newborn mice, and osteoblasts and associated neovasculature at sites of endochondrial ossification in the fetus(1,2). Mice homozygous for mutations in the gene encoding c-Abl (Abl) display increased perinatal mortality, reduced fertility, foreshortened crania and defects in the maturation of B cells in bone marrow(3,4). Here we demonstrate that Abl(-/-) mice are also osteoporotic. The long bones of mutant mice contain thinner cortical bone and reduced trabecular bone volume. The osteoporotic phenotype is not due to accelerated bone turnover-both the number and activity of osteoclasts are similar to those of control littermates-but rather to dysfunctional osteoblasts. In addition, the rate of mineral apposition in the mutant animals is reduced. Osteoblasts from both stromal and calvarial explants showed delayed maturation in vitro as measured by expression of alkaline phosphatase (ALP), induction of mRNA encoding osteocalcin and mineral deposition.	Columbia Univ Coll Phys & Surg, Howard Hughes Med Inst, New York, NY 10032 USA; Columbia Univ, Coll Phys & Surg, Dept Biochem & Mol Biophys, New York, NY USA; Washington Univ, Sch Med, Dept Pathol, St Louis, MO 63130 USA; Amer Red Cross, Dept Tissue Biol, Rockville, MD USA	Columbia University; Howard Hughes Medical Institute; Columbia University; Washington University (WUSTL); American Red Cross	Goff, SP (corresponding author), Columbia Univ Coll Phys & Surg, Howard Hughes Med Inst, New York, NY 10032 USA.	goff@cuccfa.ccc.columbia.edu	Goff, Stephen P/K-6337-2014	Goff, Stephen P/0000-0003-0693-5547; Teitelbaum, Steven/0000-0002-4054-6679	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R29AR044089, R01AR032788] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR32788, AR44089] Funding Source: Medline; NIDCR NIH HHS [DE05413] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		AUBIN JE, 1995, BONE, V17, pS77, DOI 10.1016/8756-3282(95)00183-E; BLAIR HC, 1986, J CELL BIOL, V102, P1164, DOI 10.1083/jcb.102.4.1164; Cook HC, 1974, MANUAL HISTOLOGICAL; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; Engelman VW, 1997, J CLIN INVEST, V99, P2284, DOI 10.1172/JCI119404; HARDIN JD, 1995, CELL IMMUNOL, V165, P44, DOI 10.1006/cimm.1995.1185; Kuroo M, 1997, NATURE, V390, P45, DOI 10.1038/36285; Lewis JM, 1996, P NATL ACAD SCI USA, V93, P15174, DOI 10.1073/pnas.93.26.15174; Moursi AM, 1996, J CELL SCI, V109, P1369; MULLER R, 1982, NATURE, V299, P640, DOI 10.1038/299640a0; Mundlos S, 1997, CELL, V89, P773, DOI 10.1016/S0092-8674(00)80260-3; ONeill AJ, 1997, J PATHOL, V183, P325, DOI 10.1002/(SICI)1096-9896(199711)183:3<325::AID-PATH941>3.0.CO;2-A; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; OWEN M, 1988, CIBA F SYMP, V136, P42; QUARLES LD, 1992, J BONE MINER RES, V7, P683; SAWYERS CL, 1994, CELL, V77, P121, DOI 10.1016/0092-8674(94)90240-2; SCHWARTZBERG PL, 1991, CELL, V65, P1165, DOI 10.1016/0092-8674(91)90012-N; STEIN CA, 1990, PRINCIPLES PRACT ONC, V4, P1; TAKAHASHI N, 1988, ENDOCRINOLOGY, V123, P1504, DOI 10.1210/endo-123-3-1504; Tondravi MM, 1997, NATURE, V386, P81, DOI 10.1038/386081a0; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; Wen ST, 1996, EMBO J, V15, P1583, DOI 10.1002/j.1460-2075.1996.tb00503.x	22	125	131	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAR	2000	24	3					304	308		10.1038/73542	http://dx.doi.org/10.1038/73542			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	288XW	10700189				2022-12-25	WOS:000085590600026
J	Lohrum, MAE; Ashcroft, M; Kubbutat, MHG; Vousden, KH				Lohrum, MAE; Ashcroft, M; Kubbutat, MHG; Vousden, KH			Identification of a cryptic nucleolar-localization signal in MDM2	NATURE CELL BIOLOGY			English	Article							TUMOR-SUPPRESSOR; P53; P14(ARF); PRODUCT; LOCUS; RB		NCI, Frederick Canc Res & Dev Ctr, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Vousden, KH (corresponding author), NCI, Frederick Canc Res & Dev Ctr, Room 22-96,W 17th St, Frederick, MD 21702 USA.							Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Bates S, 1999, CELL MOL LIFE SCI, V55, P28, DOI 10.1007/s000180050267; Bottger A, 1997, CURR BIOL, V7, P860, DOI 10.1016/S0960-9822(06)00374-5; CHEN JD, 1995, MOL MED, V1, P142, DOI 10.1007/BF03401562; FANG S, IN PRESS J BIOL CHEM; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; Kubbutat MHG, 1998, MOL MED TODAY, V4, P250, DOI 10.1016/S1357-4310(98)01260-X; Kubbutat MHG, 1999, CELL GROWTH DIFFER, V10, P87; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; WEBER JD, IN PRESS MOL CELL BI; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zhang YP, 1999, MOL CELL, V3, P579, DOI 10.1016/S1097-2765(00)80351-2	17	164	165	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	MAR	2000	2	3					179	181		10.1038/35004057	http://dx.doi.org/10.1038/35004057			3	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	292AE	10707090				2022-12-25	WOS:000085771300019
J	Galvin, KM; Donovan, MJ; Lynch, CA; Meyer, RI; Paul, RJ; Lorenz, JN; Fairchild-Huntress, V; Dixon, KL; Dunmore, JH; Gimbrone, MA; Falb, D; Huszar, D				Galvin, KM; Donovan, MJ; Lynch, CA; Meyer, RI; Paul, RJ; Lorenz, JN; Fairchild-Huntress, V; Dixon, KL; Dunmore, JH; Gimbrone, MA; Falb, D; Huszar, D			A role for Smad6 in development and homeostasis of the cardiovascular system	NATURE GENETICS			English	Article							TGF-BETA; FAMILY MEMBERS; MESSENGER-RNA; GENE; EXPRESSION; BONE; ENDOTHELIUM; INDUCTION; LACZ	Smad proteins are intracellular mediators of signalling initiated by Tgf-beta superfamily ligands (Tgf-beta s, activins and bone morphogenetic proteins (Bmps)). Smads 1, 2, 3, 5 and 8 are activated upon phosphorylation by specific type I receptors, and associate with the common partner Smad4 to trigger transcriptional responses(1). The inhibitory Smads (6 and 7) are transcriptionally induced in cultured cells treated with Tgf-beta superfamily ligands, and downregulate signalling in in vitro assays(2-7). Gene disruption in mice has begun to reveal specific developmental and physiological functions of the signal-transducing Smads. Here we explore the role of an inhibitory Smad in vivo by targeted mutation of Madh6 (which encodes the Smad6 protein). Targeted insertion of a LacZ reporter demonstrated that Smad6 expression is largely restricted to the heart and blood vessels, and that Madh6 mutants have multiple cardiovascular abnormalities. Hyperplasia of the cardiac valves and outflow tract septation defects indicate a function for Smad6 in the regulation of endocardial cushion transformation. The role of Smad6 in the homeostasis of the adult cardiovascular system is indicated by the development of aortic ossification and elevated broad pressure in viable mutants. These defects highlight the importance of Smad6 in the tissue-specific modulation of Tgf-beta superfamily signalling pathways in vivo.	Millennium Pharmaceut, Cambridge, MA USA; Univ Cincinnati, Coll Med, Dept Mol & Cellular Physiol, Cincinnati, OH USA; Brigham & Womens Hosp, Div Vasc Res, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Takeda Pharmaceutical Company Ltd; Millennium Pharmaceuticals; University System of Ohio; University of Cincinnati; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Galvin, KM (corresponding author), Millennium Pharmaceut, Cambridge, MA USA.							Afrakhte M, 1998, BIOCHEM BIOPH RES CO, V249, P505, DOI 10.1006/bbrc.1998.9170; BONNEROT C, 1993, METHOD ENZYMOL, V225, P451; BOSTROM K, 1995, AM J CARDIOL, V75, pB88, DOI 10.1016/0002-9149(95)80020-S; BRADLEY A, 1987, TERATOCARCINOMAS EMB; Brown CB, 1999, SCIENCE, V283, P2080, DOI 10.1126/science.283.5410.2080; COHEN RA, 1988, J PHARMACOL EXP THER, V244, P550; Dudley AT, 1997, DEV DYNAM, V208, P349; Hata A, 1998, GENE DEV, V12, P186, DOI 10.1101/gad.12.2.186; HUANG JX, 1995, ANN NY ACAD SCI, V752, P317, DOI 10.1111/j.1749-6632.1995.tb17441.x; Imamura T, 1997, NATURE, V389, P622, DOI 10.1038/39355; Ishisaki A, 1999, J BIOL CHEM, V274, P13637, DOI 10.1074/jbc.274.19.13637; Lalli J, 1997, CIRC RES, V80, P506, DOI 10.1161/01.RES.80.4.506; Marchuk D A, 1998, Curr Opin Hematol, V5, P332, DOI 10.1097/00062752-199809000-00005; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; MCBURNEY MW, 1991, NUCLEIC ACIDS RES, V19, P5755, DOI 10.1093/nar/19.20.5755; MERCER EH, 1991, NEURON, V7, P703, DOI 10.1016/0896-6273(91)90274-4; MILLAN FA, 1991, DEVELOPMENT, V111, P131; Moore CS, 1998, DEV DYNAM, V212, P548, DOI 10.1002/(SICI)1097-0177(199808)212:4<548::AID-AJA8>3.0.CO;2-H; Perrella MA, 1998, MINER ELECTROL METAB, V24, P136, DOI 10.1159/000057361; REDDI AH, 1994, CURR OPIN GENET DEV, V4, P737, DOI 10.1016/0959-437X(94)90141-O; Takase M, 1998, BIOCHEM BIOPH RES CO, V244, P26, DOI 10.1006/bbrc.1998.8200; Topper JN, 1997, P NATL ACAD SCI USA, V94, P9314, DOI 10.1073/pnas.94.17.9314	22	375	394	0	15	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	FEB	2000	24	2					171	174		10.1038/72835	http://dx.doi.org/10.1038/72835			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	280LQ	10655064				2022-12-25	WOS:000085104600019
J	Gruninger-Leitch, F; Berndt, P; Langen, H; Nelboeck, P; Dobeli, H				Gruninger-Leitch, F; Berndt, P; Langen, H; Nelboeck, P; Dobeli, H			Identification of beta-secretase-like activity using a mass spectrometry-based assay system	NATURE BIOTECHNOLOGY			English	Article						Alzheimer disease; lysosomal proteases; mass spectrometry	AMYLOID PRECURSOR PROTEIN; CATHEPSIN-E; ALZHEIMERS-DISEASE; PEPTIDES; CELLS; PURIFICATION; EXPRESSION; INHIBITION; PROTEASES; MUTANT	We describe an assay system for the identification of site-specific proteases. The assay is based on a protein substrate that is immobilized on ceramic beads. After incubation with cell homogenates, the beads are washed and digested with endoproteinase Lys-C to liberate a defined set of peptides. The peptide fragments are identified by mass spectrometry. The assay was used to screen for beta-secretase, the protease that cleaves amyloid precursor protein (APP) at the beta-site. Cathepsin D was identified as the enzyme responsible for beta-secretase-like activity in two cell lines. Subsequent analysis of the related aspartic protease, cathepsin E, revealed almost identical cleavage specificity, Both enzymes are efficient in cleaving Swedish mutant APP at the beta-site but show almost no reactivity with wild-type APP. Treatment of cell lines with pepstatin inhibited the production of amyloid peptide (A beta) when they were transfected with a construct bearing the Swedish APP mutant. However, when the cells were transfected with wildtype APP, the generation of A beta was increased. This suggests that more than one enzyme is capable of generating A beta in vivo and that an aspartic protease is involved in the processing of Swedish mutant APP.	F Hoffmann La Roche & Co Ltd, CNS Res, CH-4070 Basel, Switzerland; F Hoffmann La Roche & Co Ltd, Roche Genet, CH-4070 Basel, Switzerland	Roche Holding; Roche Holding	Dobeli, H (corresponding author), F Hoffmann La Roche & Co Ltd, CNS Res, Grenzacherstr 124, CH-4070 Basel, Switzerland.							ABRAHAM CR, 1992, ANN NY ACAD SCI, V674, P174, DOI 10.1111/j.1749-6632.1992.tb27486.x; AMANO T, 1995, EXP NEUROL, V136, P171, DOI 10.1006/exnr.1995.1094; BROWN AM, 1994, ANAL BIOCHEM, V217, P139, DOI 10.1006/abio.1994.1094; CHANG T, 1996, ANN NY ACAD SCI, V777, P189; Citron M, 1996, NEURON, V17, P171, DOI 10.1016/S0896-6273(00)80290-1; CITRON M, 1995, NEURON, V14, P661, DOI 10.1016/0896-6273(95)90323-2; Dobeli H, 1998, PROTEIN EXPRES PURIF, V12, P404, DOI 10.1006/prep.1997.0844; FINLEY EM, 1994, J BIOL CHEM, V269, P31259; Fountoulakis M, 1997, ANAL BIOCHEM, V250, P153, DOI 10.1006/abio.1997.2213; HAASS C, 1995, J BIOL CHEM, V270, P6186, DOI 10.1074/jbc.270.11.6186; HILL J, 1993, FEBS LETT, V326, P101, DOI 10.1016/0014-5793(93)81770-Z; HOCHULI E, 1987, J CHROMATOGR, V411, P177, DOI 10.1016/S0021-9673(00)93969-4; Huber G, 1999, J NEUROCHEM, V72, P1215, DOI 10.1046/j.1471-4159.1999.0721215.x; Hussain I, 1999, MOL CELL NEUROSCI, V14, P419, DOI 10.1006/mcne.1999.0811; MATAYOSHI ED, 1990, SCIENCE, V247, P954, DOI 10.1126/science.2106161; Perez RG, 1996, J BIOL CHEM, V271, P9100, DOI 10.1074/jbc.271.15.9100; Saftig P, 1996, J BIOL CHEM, V271, P27241, DOI 10.1074/jbc.271.44.27241; Sastradipura DF, 1998, J NEUROCHEM, V70, P2045; Selkoe DJ, 1998, TRENDS CELL BIOL, V8, P447, DOI 10.1016/S0962-8924(98)01363-4; Thompson A, 1997, MOL BRAIN RES, V48, P206, DOI 10.1016/S0169-328X(97)00091-0; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Younkin SG, 1998, J PHYSIOLOGY-PARIS, V92, P289, DOI 10.1016/S0928-4257(98)80035-1	23	39	40	0	7	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JAN	2000	18	1					66	70		10.1038/71944	http://dx.doi.org/10.1038/71944			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	273GQ	10625394				2022-12-25	WOS:000084699900028
J	Braha, O; Gu, LQ; Zhou, L; Lu, XF; Cheley, S; Bayley, H				Braha, O; Gu, LQ; Zhou, L; Lu, XF; Cheley, S; Bayley, H			Simultaneous stochastic sensing of divalent metal ions	NATURE BIOTECHNOLOGY			English	Article							STAPHYLOCOCCUS-AUREUS; TRANSMEMBRANE PORE; ALPHA-HEMOLYSIN; FORMING TOXINS; GROWTH CONES; BETA-BARREL; CHANNELS; PROTEIN; RELEASE; PATCHES	Stochastic sensing is an emerging analytical technique that relies upon single-molecule detection. Transmembrane pores, into which binding sites for analytes have been placed by genetic engineering, have been developed as stochastic sensing elements(1-3). Reversible occupation of an engineered binding site modulates the ionic current passing through a pore in a transmembrane potential and thereby provides both the concentration of an analyte and, through a characteristic signature, its identity(1-3). Here, we show that the concentrations of two or more divalent metal ions in solution can be determined simultaneously with a single sensor element. Further, the sensor element can be permanently calibrated without a detailed understanding of the kinetics of interaction of the metal ions with the engineered pore.	Texas A&M Univ, Dept Med Biochem & Genet, System Hlth Sci Ctr, College Stn, TX 77843 USA; Texas A&M Univ, Dept Chem, College Stn, TX 77843 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station	Braha, O (corresponding author), Texas A&M Univ, Dept Med Biochem & Genet, System Hlth Sci Ctr, College Stn, TX 77843 USA.			Bayley, Hagan/0000-0003-2499-6116				Bayley H, 2000, ADV MATER, V12, P139, DOI 10.1002/(SICI)1521-4095(200001)12:2<139::AID-ADMA139>3.3.CO;2-H; Braha O, 1997, CHEM BIOL, V4, P497, DOI 10.1016/S1074-5521(97)90321-5; Cornell BA, 1997, NATURE, V387, P580, DOI 10.1038/42432; Gouaux E, 1998, J STRUCT BIOL, V121, P110, DOI 10.1006/jsbi.1998.3959; Gu LQ, 1999, NATURE, V398, P686, DOI 10.1038/19491; Hanke W., 1993, METHODS APPL; HUME RI, 1983, NATURE, V305, P632, DOI 10.1038/305632a0; Kasianowicz JJ, 1999, BIOPHYS J, V76, P837, DOI 10.1016/S0006-3495(99)77247-4; KRAMER RH, 1990, NEURON, V4, P335, DOI 10.1016/0896-6273(90)90046-I; Motesharei K, 1997, J AM CHEM SOC, V119, P11306, DOI 10.1021/ja9727171; Olson R, 1999, NAT STRUCT BIOL, V6, P134; Pedelacq JD, 1999, STRUCTURE, V7, P277, DOI 10.1016/S0969-2126(99)80038-0; Proakis J., 2013, DIGIT SIGNAL PROCESS, V4th; Song LZ, 1996, SCIENCE, V274, P1859, DOI 10.1126/science.274.5294.1859; VIVAUDOU MB, 1991, J MEMBRANE BIOL, V122, P165, DOI 10.1007/BF01872639; YOUNG SH, 1983, NATURE, V305, P634, DOI 10.1038/305634a0	16	241	302	5	108	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	SEP	2000	18	9					1005	1007		10.1038/79275	http://dx.doi.org/10.1038/79275			3	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	350AN	10973225				2022-12-25	WOS:000089078300033
J	Li, H; Li, SH; Johnston, H; Shelbourne, PF; Li, XJ				Li, H; Li, SH; Johnston, H; Shelbourne, PF; Li, XJ			Amino-terminal fragments of mutant huntingtin show selective accumulation in striatal neurons and synaptic toxicity	NATURE GENETICS			English	Article							INTRANUCLEAR INCLUSIONS; PROJECTION NEURONS; TRANSGENIC MICE; DISEASE; PROTEIN; LOCALIZATION; APOPTOSIS; MUTATION; RECEPTOR; NUCLEAR	Huntington disease (HD) is caused by expansion of a glutamine repeat in the amino-terminal region of huntingtin. Despite its widespread expression, mutant huntingtin induces selective neuronal loss in striatal neurons. Here we report that, in mutant mice expressing HD repeats, the production and aggregation of N-terminal huntingtin fragments preferentially occur in HD-affected neurons and their processes and axonal terminals. N-terminal fragments of mutant huntingtin form aggregates and induce neuritic degeneration in cultured striatal neurons. N-terminal mutant huntingtin also binds to synaptic vesicles and inhibits their glutamate uptake in vitro. The specific processing and accumulation of toxic fragments of N-terminal huntingtin in HD-affected striatal neurons, especially in their neuronal processes and axonal terminals, may contribute to the selective neuropathology of HD.	Emory Univ, Sch Med, Dept Genet, Atlanta, GA 30322 USA; Univ Glasgow, Inst Biomed & Life Sci, Div Mol Genet, Glasgow, Lanark, Scotland; Tongi Med Univ, Dept Histol & Embryol, Wuhan, Peoples R China	Emory University; University of Glasgow; Huazhong University of Science & Technology	Li, XJ (corresponding author), Emory Univ, Sch Med, Dept Genet, Atlanta, GA 30322 USA.	xiaoli@genetics.emory.edu						ALBIN RL, 1992, ANN NEUROL, V31, P425, DOI 10.1002/ana.410310412; ALBIN RL, 1992, NEUROLOGY, V42, P733, DOI 10.1212/WNL.42.4.733; BEAL MF, 1994, NEUROBIOL AGING, V15, P275; Becher MW, 1998, NEUROBIOL DIS, V4, P387, DOI 10.1006/nbdi.1998.0168; Davies SW, 1997, CELL, V90, P537, DOI 10.1016/S0092-8674(00)80513-9; DiFiglia M, 1997, SCIENCE, V277, P1990, DOI 10.1126/science.277.5334.1990; Ellerby LM, 1999, J NEUROCHEM, V72, P185, DOI 10.1046/j.1471-4159.1999.0720185.x; FERRANTE RJ, 1993, EXP NEUROL, V119, P46, DOI 10.1006/exnr.1993.1006; Gutekunst CA, 1999, J NEUROSCI, V19, P2522; Hackam AS, 1998, J CELL BIOL, V141, P1097, DOI 10.1083/jcb.141.5.1097; Hodgson JG, 1999, NEURON, V23, P181, DOI 10.1016/S0896-6273(00)80764-3; Igarashi S, 1998, NAT GENET, V18, P111, DOI 10.1038/ng0298-111; Ivkovic S, 1999, J NEUROSCI, V19, P5409; KISH PE, 1989, METHOD ENZYMOL, V174, P9; Li H, 1999, HUM MOL GENET, V8, P1227, DOI 10.1093/hmg/8.7.1227; Li SH, 1998, J NEUROSCI, V18, P1261, DOI 10.1523/jneurosci.18-04-01261.1998; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; REINER A, 1988, P NATL ACAD SCI USA, V85, P5733, DOI 10.1073/pnas.85.15.5733; Saudou F, 1998, CELL, V95, P55, DOI 10.1016/S0092-8674(00)81782-1; Schilling G, 1999, HUM MOL GENET, V8, P397, DOI 10.1093/hmg/8.3.397; Shelbourne PF, 1999, HUM MOL GENET, V8, P763, DOI 10.1093/hmg/8.5.763; Usdin MT, 1999, HUM MOL GENET, V8, P839, DOI 10.1093/hmg/8.5.839; VONSATTEL JP, 1985, J NEUROPATH EXP NEUR, V44, P559, DOI 10.1097/00005072-198511000-00003; Wheeler VC, 2000, HUM MOL GENET, V9, P503, DOI 10.1093/hmg/9.4.503; Xia ZG, 1996, J NEUROSCI, V16, P5425	25	241	253	0	10	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	AUG	2000	25	4					385	389		10.1038/78054	http://dx.doi.org/10.1038/78054			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	341WY	10932179				2022-12-25	WOS:000088615000010
J	Park, SH; Raines, RT				Park, SH; Raines, RT			Genetic selection for dissociative inhibitors of designated protein-protein interactions	NATURE BIOTECHNOLOGY			English	Article						AIDS; chemical genetics; drug discovery; lambda repressor; peptide library	VIRUS TYPE-1 PROTEASE; HIV-1 PROTEASE; PEPTIDE INHIBITORS; ANTIRETROVIRAL THERAPY; RETROVIRAL PROTEASES; INTERFACE PEPTIDES; VIRAL INFECTIVITY; IN-VIVO; DIMERIZATION; EXPRESSION	Many biological processes rely on protein-protein interactions. These processes include signal transduction, cell cycle regulation, gene regulation, and viral assembly and replication. Moreover, many proteins and enzymes manifest their function as oligomers. We describe here an efficient means to sift through large combinatorial libraries and identify molecules that block the interaction of target proteins in vivo. The power of this approach is demonstrated by the identification of nine-residue peptides from a combinatorial library that inhibit the intracellular dimerization of HIV-1 protease. Fewer than 1 in 10(6) peptides do so. In vitro biochemical analyses of one such peptide demonstrate that it acts by dissociating HIV-1 protease into monomers, which are inactive catalysts. Inhibition is enhanced further by dimerizing the peptide. This approach enables the facile identification of new molecules that control cellular processes.	Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA; Univ Wisconsin, Dept Chem, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Raines, RT (corresponding author), Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA.		Raines, Ronald T./A-5009-2013	Raines, Ronald T./0000-0001-7164-1719	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044783] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM44783, R01 GM044783, R01 GM044783-09] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMSTERCHODER O, 1992, SCIENCE, V257, P1395, DOI 10.1126/science.1382312; BABE LM, 1995, P NATL ACAD SCI USA, V92, P10069, DOI 10.1073/pnas.92.22.10069; BABE LM, 1992, PROTEIN SCI, V1, P1244, DOI 10.1002/pro.5560011003; Bouras A, 1999, J MED CHEM, V42, P957, DOI 10.1021/jm9803976; BUNKER CA, 1995, NUCLEIC ACIDS RES, V23, P269, DOI 10.1093/nar/23.2.269; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; Condra JH, 1998, HAEMOPHILIA, V4, P610, DOI 10.1046/j.1365-2516.1998.440610.x; CONDRA JH, 1995, NATURE, V374, P569, DOI 10.1038/374569a0; CORPET F, 1988, NUCLEIC ACIDS RES, V16, P10881, DOI 10.1093/nar/16.22.10881; CWIRLA SE, 1990, P NATL ACAD SCI USA, V87, P6378, DOI 10.1073/pnas.87.16.6378; DARKE PL, 1994, BIOCHEMISTRY-US, V33, P98, DOI 10.1021/bi00167a013; Fan XD, 1998, J AM CHEM SOC, V120, P8893, DOI 10.1021/ja981306x; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Flexner C, 1998, NEW ENGL J MED, V338, P1281, DOI 10.1056/NEJM199804303381808; FRANCISKOVICH J, 1993, BIOORG MED CHEM LETT, V3, P765, DOI 10.1016/S0960-894X(01)81271-3; Geyer CR, 1999, P NATL ACAD SCI USA, V96, P8567, DOI 10.1073/pnas.96.15.8567; GRANT SK, 1992, BIOCHEMISTRY-US, V31, P9491, DOI 10.1021/bi00154a023; HOUGHTEN RA, 1993, TRENDS GENET, V9, P235, DOI 10.1016/0168-9525(93)90087-X; HU JC, 1995, STRUCTURE, V3, P431, DOI 10.1016/S0969-2126(01)00176-9; HU JC, 1990, SCIENCE, V250, P1400, DOI 10.1126/science.2147779; IDO E, 1991, J BIOL CHEM, V266, P24359; Jappelli R, 1996, J MOL BIOL, V259, P575, DOI 10.1006/jmbi.1996.0340; Klabe RM, 1998, BIOCHEMISTRY-US, V37, P8735, DOI 10.1021/bi972555l; KOHL NE, 1988, P NATL ACAD SCI USA, V85, P4686, DOI 10.1073/pnas.85.13.4686; LABEAN TH, 1993, PROTEIN SCI, V2, P1249, DOI 10.1002/pro.5560020807; Lebon F, 2000, CURR MED CHEM, V7, P455, DOI 10.2174/0929867003375146; Li TS, 1998, LANCET, V351, P1682, DOI 10.1016/S0140-6736(97)10291-4; LU ZJ, 1995, BIO-TECHNOL, V13, P366, DOI 10.1038/nbt0495-366; MATAYOSHI ED, 1990, SCIENCE, V247, P954, DOI 10.1126/science.2106161; MATTHEWS DJ, 1993, SCIENCE, V260, P1113, DOI 10.1126/science.8493554; Norman TC, 1999, SCIENCE, V285, P591, DOI 10.1126/science.285.5427.591; PABO CO, 1979, P NATL ACAD SCI USA, V76, P1608, DOI 10.1073/pnas.76.4.1608; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; Palmer S, 1999, AIDS, V13, P661, DOI 10.1097/00002030-199904160-00006; PENG C, 1989, J VIROL, V63, P2550, DOI 10.1128/JVI.63.6.2550-2556.1989; Piketty C, 1998, AIDS, V12, P745, DOI 10.1097/00002030-199807000-00011; PTASHNE M, 1993, GENETIC SWITCH PHAGE; Rockstroh J K, 1999, Eur J Med Res, V4, P271; ROSE JR, 1993, J BIOL CHEM, V268, P11939; Schinazi R. F., 1997, International Antiviral News, V5, P129; Schramm HJ, 1999, BIOL CHEM, V380, P593, DOI 10.1515/BC.1999.076; SCHRAMM HJ, 1991, BIOCHEM BIOPH RES CO, V179, P847, DOI 10.1016/0006-291X(91)91895-J; Schramm HJ, 1996, ANTIVIR RES, V30, P155, DOI 10.1016/0166-3542(96)00940-0; SCHRAMM W, 1993, OPT WITHIN LIFE SCI, V1, P194; SMITH GP, 1985, SCIENCE, V228, P1315, DOI 10.1126/science.4001944; Todd MJ, 1998, J MOL BIOL, V283, P475, DOI 10.1006/jmbi.1998.2090; Ulysse LG, 1998, BIOORG MED CHEM LETT, V8, P3281, DOI 10.1016/S0960-894X(98)00595-2; Wlodawer A, 1998, ANNU REV BIOPH BIOM, V27, P249, DOI 10.1146/annurev.biophys.27.1.249; WLODAWER A, 1989, SCIENCE, V245, P616, DOI 10.1126/science.2548279; WONDRAK EM, 1996, J BIOL CHEM, V271, P77; Zeng X, 1997, P NATL ACAD SCI USA, V94, P3673, DOI 10.1073/pnas.94.8.3673; Zeng XG, 1997, PROTEIN SCI, V6, P2218; Zhang ZW, 2000, NAT BIOTECHNOL, V18, P71, DOI 10.1038/71951; Zhang ZW, 1999, CURR BIOL, V9, P417, DOI 10.1016/S0960-9822(99)80188-2; ZHANG ZY, 1991, J BIOL CHEM, V266, P15591; Zutshi R, 1997, J AM CHEM SOC, V119, P4841, DOI 10.1021/ja962496j; Zutshi R, 1998, CURR OPIN CHEM BIOL, V2, P62, DOI 10.1016/S1367-5931(98)80036-7	57	51	58	0	8	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	AUG	2000	18	8					847	851		10.1038/78451	http://dx.doi.org/10.1038/78451			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	342VX	10932153	Green Accepted			2022-12-25	WOS:000088666800020
J	Yu, YJ; Annala, AJ; Barrio, JR; Toyokuni, T; Satyamurthy, N; Namavari, M; Cherry, SR; Phelps, ME; Herschman, HR; Gambhir, SS				Yu, YJ; Annala, AJ; Barrio, JR; Toyokuni, T; Satyamurthy, N; Namavari, M; Cherry, SR; Phelps, ME; Herschman, HR; Gambhir, SS			Quantification of target gene expression by imaging reporter gene expression in living animals	NATURE MEDICINE			English	Article							POSITRON-EMISSION-TOMOGRAPHY; TRANSLATION INITIATION; VIRUS; PET; MICROPET; SEQUENCE; THERAPY; SCANNER; INVIVO		Crump Inst Mol Imaging, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Dept Energy, Lab Struct Biol & Mol Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Inst Mol Biol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Dept Biomath, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Gambhir, SS (corresponding author), Crump Inst Mol Imaging, Los Angeles, CA 90095 USA.		Cherry, Simon/AAH-1000-2019	Cherry, Simon/0000-0002-0155-5644; Annala, Alexandra Jacqueline/0000-0002-5967-6596	NATIONAL CANCER INSTITUTE [R01CA082214] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA82214-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alauddin MM, 1998, NUCL MED BIOL, V25, P175, DOI 10.1016/S0969-8051(97)00160-1; Barrio J. R., 1997, Journal of Labelled Compounds and Radiopharmaceuticals, V40, P348; Black ME, 1996, P NATL ACAD SCI USA, V93, P3525, DOI 10.1073/pnas.93.8.3525; Cherry SR, 1997, IEEE T NUCL SCI, V44, P1161, DOI 10.1109/23.596981; Contag PR, 1998, NAT MED, V4, P245, DOI 10.1038/nm0298-245; DAVIES MV, 1992, J VIROL, V66, P1924, DOI 10.1128/JVI.66.4.1924-1932.1992; Gambhir SS, 2000, P NATL ACAD SCI USA, V97, P2785, DOI 10.1073/pnas.97.6.2785; Gambhir SS, 1998, J NUCL MED, V39, P2003; Gambhir SS, 1999, P NATL ACAD SCI USA, V96, P2333, DOI 10.1073/pnas.96.5.2333; Gambhir SS, 1999, NUCL MED BIOL, V26, P481, DOI 10.1016/S0969-8051(99)00021-9; HAMACHER K, 1986, J NUCL MED, V27, P235; JACKSON RJ, 1990, TRENDS BIOCHEM SCI, V15, P477, DOI 10.1016/0968-0004(90)90302-R; JANG SK, 1989, J VIROL, V63, P1651, DOI 10.1128/JVI.63.4.1651-1660.1989; KAUFMAN RJ, 1991, NUCLEIC ACIDS RES, V19, P4485, DOI 10.1093/nar/19.16.4485; MacLaren DC, 1999, GENE THER, V6, P785, DOI 10.1038/sj.gt.3300877; PHELPS ME, 1991, NEUROCHEM RES, V16, P929, DOI 10.1007/BF00965836; PHELPS ME, 1975, J NUCL MED, V16, P210; Qi JY, 1998, PHYS MED BIOL, V43, P1001, DOI 10.1088/0031-9155/43/4/027; Sachs AB, 1997, CELL, V89, P831, DOI 10.1016/S0092-8674(00)80268-8; SATYAMURTHY N, 1990, APPL RADIAT ISOTOPES, V41, P113; Tjuvajev JG, 1998, CANCER RES, V58, P4333; Tjuvajev Juri G., 1999, Neoplasia (New York), V1, P315, DOI 10.1038/sj.neo.7900053; Zhou Y, 1998, HUM GENE THER, V9, P287, DOI 10.1089/hum.1998.9.3-287	23	182	189	1	8	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	AUG	2000	6	8					933	937		10.1038/78704	http://dx.doi.org/10.1038/78704			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	376TX	10932234				2022-12-25	WOS:000165473800040
J	Galloway, SM; McNatty, KP; Cambridge, LM; Laitinen, MPE; Juengel, JL; Jokiranta, TS; McLaren, RJ; Luiro, K; Dodds, KG; Montgomery, GW; Beattie, AE; Davis, GH; Ritvos, O				Galloway, SM; McNatty, KP; Cambridge, LM; Laitinen, MPE; Juengel, JL; Jokiranta, TS; McLaren, RJ; Luiro, K; Dodds, KG; Montgomery, GW; Beattie, AE; Davis, GH; Ritvos, O			Mutations in an oocyte-derived growth factor gene (BMP15) cause increased ovulation rate and infertility in a dosage-sensitive manner	NATURE GENETICS			English	Article							DIFFERENTIATION FACTOR-9; X-CHROMOSOME; MESSENGER-RNA; 3-DIMENSIONAL STRUCTURE; HOMOLOG GDF-9B; SHEEP OVARY; FACTOR-BETA; FOLLICLES; FECX(1); EWES	Multiple ovulations are uncommon in humans, cattle and many breeds of sheep. Pituitary gonadotrophins and as yet unidentified ovarian factors precisely regulate follicular development so that, normally, only one follicle is selected to ovulate. The Inverdale (FecX(I)) sheep, however, carries a naturally occurring X-linked mutation that causes increased ovulation rate and twin and triplet births in heterozygotes (FecX(I)/FecX(+); ref. 1). but primary ovarian failure in homozygotes (FecX(I)/FecX(I); ref. 2). Germcell development, formation of the follicle and the earliest stages of follicular growth are normal in FecX(I)/FecX(I) sheep, but follicular development beyond the primary stage is impaired(3,4). A second family unrelated to the Inverdale sheep also has the same X-linked phenotype(5) (Hanna, FecX(H)). Crossing FecX(I) with FecXH animals produces FecX(I)/FecX(H) infertile females phenotypically indistinguishable from FecX(I)/FecX(I) females(6). We report here that the FecX(I) locus maps to an orthologous chromosomal region syntenic to human Xp11.2-11.4, which contains BMP15, encoding bone morphogenetic protein 15 (also known as growth differentiation factor 9B (GDF9B)). Whereas BMP15 is a member of the transforming growth factor beta (TGF beta) superfamily and is specifically expressed in oocytes, its function is unknown(7-9). We show that independent germline point mutations exist in FecX(I) and FecX(H) carriers. These findings establish that BMP15 is essential for female fertility and that natural mutations in an ovary-derived factor can cause both increased ovulation rate and infertility phenotypes in a dosage-sensitive manner.	AgRes, Mol Biol Unit, Dunedin, New Zealand; Univ Otago, Dept Biochem, Ctr Gene Res, Dunedin, New Zealand; AgRes, Wallaceville Anim Res Ctr, Upper Hutt, New Zealand; Biomedicum Helsinki, Programme Dev & Reprod Biol, Helsinki, Finland; Univ Helsinki, Haartman Inst, Dept Bacteriol & Immunol, Helsinki, Finland; AgRes, Invermay Agr Ctr, Mosgiel, New Zealand	AgResearch - New Zealand; University of Otago; AgResearch - New Zealand; University of Helsinki; University of Helsinki; AgResearch - New Zealand	Galloway, SM (corresponding author), AgRes, Mol Biol Unit, Dunedin, New Zealand.		Montgomery, Grant W/B-7148-2008; Jokiranta, T. Sakari/F-1906-2011; Ritvos, Olli/GWC-2442-2022	Montgomery, Grant W/0000-0002-4140-8139; Dodds, Ken/0000-0002-9347-6379; Juengel, Jennifer/0000-0002-2717-7311; Luiro, Kaisu/0000-0003-0736-2891; Ritvos, Olli/0000-0001-7017-6931				Aaltonen J, 1999, J CLIN ENDOCR METAB, V84, P2744, DOI 10.1210/jc.84.8.2744; Bodensteiner KJ, 2000, BIOL REPROD, V62, P1479, DOI 10.1095/biolreprod62.6.1479; BRAWTAL R, 1993, BIOL REPROD, V49, P895, DOI 10.1095/biolreprod49.5.895; Cambridge LM, 1997, ANIM GENET, V28, P457, DOI 10.1111/j.1365-2052.1997.tb03295.x; DAVIES AH, 1994, EUR J VASCULAR SURG, V8, P249, DOI 10.1016/S0950-821X(05)80138-0; Davies KP, 1996, ANIM GENET, V27, P382, DOI 10.1111/j.1365-2052.1996.tb00998.x; DAVIS GH, 1992, BIOL REPROD, V46, P636, DOI 10.1095/biolreprod46.4.636; DAVIS GH, 1991, BIOL REPROD, V44, P620, DOI 10.1095/biolreprod44.4.620; DAVIS R, 1995, PSYCHOLOGIST, V8, P55; Davison RM, 1999, CLIN ENDOCRINOL, V51, P673, DOI 10.1046/j.1365-2265.1999.00926.x; DOLLING CHS, 1996, MENDELIAN INHERITANC, P7; Dong LW, 1996, J MOL RECOGNIT, V9, P383, DOI 10.1002/(SICI)1099-1352(199634/12)9:5/6<383::AID-JMR269>3.0.CO;2-Z; Dube JL, 1998, MOL ENDOCRINOL, V12, P1809, DOI 10.1210/me.12.12.1809; Elvin JA, 1999, MOL ENDOCRINOL, V13, P1035, DOI 10.1210/me.13.6.1035; Galloway SM, 1996, GENOME RES, V6, P667, DOI 10.1101/gr.6.8.667; Griffith DL, 1996, P NATL ACAD SCI USA, V93, P878, DOI 10.1073/pnas.93.2.878; HANRAHAN V, 1994, ANIM GENET, V25, P287, DOI 10.1111/j.1365-2052.1994.tb00212.x; Hayashi M, 1999, ENDOCRINOLOGY, V140, P1236, DOI 10.1210/en.140.3.1236; HENDERSON KM, 1988, J REPROD FERTIL, V84, P187, DOI 10.1530/jrf.0.0840187; Hinck AP, 1996, BIOCHEMISTRY-US, V35, P8517, DOI 10.1021/bi9604946; Jaatinen R, 1999, MOL CELL ENDOCRINOL, V156, P189, DOI 10.1016/S0303-7207(99)00100-8; JOKIRANTA TS, 1995, FEBS LETT, V376, P31, DOI 10.1016/0014-5793(95)01239-7; Juengel JL, 1997, J REPROD FERTIL, V110, P291, DOI 10.1530/jrf.0.1100291; Laitinen M, 1998, MECH DEVELOP, V78, P135, DOI 10.1016/S0925-4773(98)00161-0; Lundy T, 1999, J REPROD FERTIL, V115, P251, DOI 10.1530/jrf.0.1150251; MCGRATH SA, 1995, MOL ENDOCRINOL, V9, P131, DOI 10.1210/me.9.1.131; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; SHACKELL GH, 1993, BIOL REPROD, V48, P1150, DOI 10.1095/biolreprod48.5.1150; Smith P, 1997, BIOL REPROD, V57, P1183, DOI 10.1095/biolreprod57.5.1183; TISDALL DJ, 1994, J MOL ENDOCRINOL, V12, P181, DOI 10.1677/jme.0.0120181	30	773	887	2	72	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUL	2000	25	3					279	283		10.1038/77033	http://dx.doi.org/10.1038/77033			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	329RD	10888873				2022-12-25	WOS:000087920900013
J	Gripp, KW; Wotton, D; Edwards, MC; Roessler, E; Ades, L; Meinecke, P; Richieri-Costa, A; Zackai, EH; Massague, J; Muenke, M; Elledge, SJ				Gripp, KW; Wotton, D; Edwards, MC; Roessler, E; Ades, L; Meinecke, P; Richieri-Costa, A; Zackai, EH; Massague, J; Muenke, M; Elledge, SJ			Mutations in TGIF cause holoprosencephaly and link NODAL signalling to human neural axis determination	NATURE GENETICS			English	Article							BRAIN; GENE; PROTEINS; HEDGEHOG; LAYER	Holoprosencephaly (HPE) is the most common structural defect of the developing forebrain in humans (1 in 250 conceptuses, 1 in 16,000 live-born infants(1-3)). HPE is aetiologically heterogeneous, with both environmental and genetic causes(4,5). So far, three human HPE genes are known: SHH at chromosome region 7q36 (ref. 6); ZIC2 at 13q32 (ref. 7); and SIX3 at 2p21 (ref. 8). In animal models, genes in the Nodal signalling pathway, such as those mutated in the zebrafish mutants cyclops (refs 9,10), squint (ref. Il)and one-eyed pinhead (oep: ref. 12), cause HPE. Mice heterozygous for null alleles of both Nodal and Smad2 have cyclopia(13) Here we describe the involvement of the TO-interacting factor (TGIF), a homeodomain protein, in human HPE. We mapped TGIF to the HPE minimal critical region in 18p11.3. Heterozygous mutations in individuals with HPE affect the transcriptional repression domain of TGIF, the DNA-binding domain or the domain that interacts with SMAD2. (The latter is an effector in the signalling path-way of the neural axis developmental factor NODAL, a member of the transforming growth factor-beta (TGF-beta) family.) Several of these mutations cause a loss of TGIF function. Thus, TGIF links the NODAL signalling pathway to the bifurcation of the human forebrain and the establishment of ventral midline structures.	Univ Penn, Sch Med, Childrens Hosp Philadelphia, Dept Pediat, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Childrens Hosp Philadelphia, Dept Genet & Neurol, Philadelphia, PA 19104 USA; Mem Sloan Kettering Canc Ctr, Howard Hughes Med Inst, Cell Biol Program, New York, NY 10021 USA; Baylor Coll Med, Howard Hughes Med Inst, Dept Biochem & Mol Biol, Houston, TX 77030 USA; Natl Human Genome Res Inst, Dept Mol & Human Genet, NIH, Bethesda, MD USA; Natl Human Genome Res Inst, Med Genet Branch, NIH, Bethesda, MD USA; Royal Alexandra Hosp Children, Parramatta, Australia; Altonauer Kinderkrankenhaus, Hamburg, Germany; Univ Sao Paulo, Sao Paulo, Brazil	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center; Baylor College of Medicine; Howard Hughes Medical Institute; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); Universidade de Sao Paulo	Muenke, M (corresponding author), Univ Penn, Sch Med, Childrens Hosp Philadelphia, Dept Pediat, Philadelphia, PA 19104 USA.		Ades, lionel/T-6882-2019; Richieri-Costa, Antonio/B-2514-2013	Muenke, Maximilian/0000-0002-7719-6545; Massague, Joan/0000-0001-9324-8408; Wotton, David/0000-0002-4652-5350				BARR M, 1983, J PEDIATR-US, V102, P565, DOI 10.1016/S0022-3476(83)80185-1; Bertolino E, 1995, J BIOL CHEM, V270, P31178, DOI 10.1074/jbc.270.52.31178; Bertolino E, 1996, DEV DYNAM, V205, P410, DOI 10.1002/(SICI)1097-0177(199604)205:4<410::AID-AJA5>3.0.CO;2-L; Brown SA, 1998, NAT GENET, V20, P180, DOI 10.1038/2484; Edwards MC, 1997, GENETICS, V147, P1063; Feldman B, 1998, NATURE, V395, P181, DOI 10.1038/26013; Golden JA, 1998, J NEUROPATH EXP NEUR, V57, P991, DOI 10.1097/00005072-199811000-00001; Gritsman K, 1999, CELL, V97, P121, DOI 10.1016/S0092-8674(00)80720-5; Liu F, 1998, NAT GENET, V20, P325, DOI 10.1038/3793; Luo KX, 1999, GENE DEV, V13, P2196, DOI 10.1101/gad.13.17.2196; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Ming JE, 1998, CLIN GENET, V53, P155; MUENKE M, IN PRESS METABOLIC M; Nanni L, 1999, HUM MOL GENET, V8, P2479, DOI 10.1093/hmg/8.13.2479; Nomura M, 1998, NATURE, V393, P786, DOI 10.1038/31693; OVERHAUSER J, 1995, AM J HUM GENET, V57, P1080; Rebagliati MR, 1998, P NATL ACAD SCI USA, V95, P9932, DOI 10.1073/pnas.95.17.9932; Roessler E, 1998, J INHERIT METAB DIS, V21, P481, DOI 10.1023/A:1005406719292; Roessler E, 1996, NAT GENET, V14, P357, DOI 10.1038/ng1196-357; Sampath K, 1998, NATURE, V395, P185, DOI 10.1038/26020; VARLET I, 1997, CURR OPIN GENE DEV, V7, P518; Wallis DE, 1999, NAT GENET, V22, P196, DOI 10.1038/9718; Wotton D, 1999, J BIOL CHEM, V274, P37105, DOI 10.1074/jbc.274.52.37105; Wotton D, 1999, CELL, V97, P29, DOI 10.1016/S0092-8674(00)80712-6	24	305	318	0	13	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUN	2000	25	2					205	208		10.1038/76074	http://dx.doi.org/10.1038/76074			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	321ML	10835638				2022-12-25	WOS:000087459200022
J	Nehls, S; Snapp, EL; Cole, NB; Zaal, KJM; Kenworthy, AK; Roberts, TH; Ellenberg, J; Presley, JF; Siggia, E; Lippincott-Schwartz, J				Nehls, S; Snapp, EL; Cole, NB; Zaal, KJM; Kenworthy, AK; Roberts, TH; Ellenberg, J; Presley, JF; Siggia, E; Lippincott-Schwartz, J			Dynamics and retention of misfolded proteins in native ER membranes	NATURE CELL BIOLOGY			English	Article							VESICULAR STOMATITIS-VIRUS; ENDOPLASMIC-RETICULUM; LIVING CELLS; INTERMEDIATE COMPARTMENT; INTRACELLULAR-TRANSPORT; LATERAL DIFFUSION; GOLGI-APPARATUS; QUALITY-CONTROL; GLYCOPROTEIN; OLIGOMERIZATION	When co-translationally inserted into endoplasmic reticulum (ER) membranes, newly synthesized proteins encounter the lumenal environment of the ER, which contains chaperone proteins that facilitate the folding reactions necessary for protein oligomerization, maturation and export from the ER. Here we show, using a temperature-sensitive variant of vesicular stomatitis virus G protein tagged with green fluorescent protein (VSVG-GFP), and fluorescence recovery after photobleaching (FRAP), the dynamics of association of folded and misfolded VSVG complexes with ER chaperones. We also investigate the potential mechanisms underlying protein retention in the ER. Misfolded VSVG-GFP complexes at 40 degrees C are highly mobile in ER membranes and do not reside in post-ER compartments, indicating that they are not retained in the ER by immobilization or retrieval mechanisms. These complexes are immobilized in ATP-depleted or tunicamycin-treated cells, in which VSVG-chaperone interactions are no longer dynamic, These results provide insight into the mechanisms of protein retention in the ER and the dynamics of protein-folding complexes in native ER membranes.	NICHHD, Cell Biol & Metab Branch, NIH, Bethesda, MD 20892 USA; European Mol Biol Lab, Gene Express & Cell Biol Program, Heidelberg, Germany; Rockefeller Univ, Ctr Studies Phys & Biol, New York, NY 10021 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); European Molecular Biology Laboratory (EMBL); Rockefeller University	Lippincott-Schwartz, J (corresponding author), NICHHD, Cell Biol & Metab Branch, NIH, Bldg 18T, Bethesda, MD 20892 USA.	jlippin@helix.nih.gov	Ellenberg, Jan/I-4688-2014; Snapp, Erik Lee/H-7152-2019; Ward, Theresa H./E-9650-2013	Ellenberg, Jan/0000-0001-5909-701X; Snapp, Erik Lee/0000-0001-9482-2272; Ward, Theresa H./0000-0002-9881-8649; Kenworthy, Anne/0000-0001-6567-9059	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059018] Funding Source: NIH RePORTER; NIGMS NIH HHS [R0I GM59018-01] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bergmann JE, 1989, METHOD CELL BIOL, V32, P85; BRAAKMAN I, 1992, NATURE, V356, P260, DOI 10.1038/356260a0; BRAAKMAN I, 1992, EMBO J, V11, P1717, DOI 10.1002/j.1460-2075.1992.tb05223.x; Cole NB, 1996, SCIENCE, V273, P797, DOI 10.1126/science.273.5276.797; Dayel MJ, 1999, BIOPHYS J, V76, P2843, DOI 10.1016/S0006-3495(99)77438-2; DESILVA A, 1993, J CELL BIOL, V120, P647, DOI 10.1083/jcb.120.3.647; DESILVA AM, 1990, J CELL BIOL, V111, P857, DOI 10.1083/jcb.111.3.857; DOMS RW, 1987, J CELL BIOL, V105, P1957, DOI 10.1083/jcb.105.5.1957; DOMS RW, 1988, J CELL BIOL, V107, P89, DOI 10.1083/jcb.107.1.89; DORNER AJ, 1990, P NATL ACAD SCI USA, V87, P7429, DOI 10.1073/pnas.87.19.7429; Edidin M., 1994, MOBILITY PROXIMITY B, P109; Ellenberg J, 1997, J CELL BIOL, V138, P1193, DOI 10.1083/jcb.138.6.1193; HAMMOND C, 1994, SCIENCE, V266, P456, DOI 10.1126/science.7939687; HAMMOND C, 1994, J CELL BIOL, V126, P41, DOI 10.1083/jcb.126.1.41; HAMMOND C, 1995, CURR OPIN CELL BIOL, V7, P523, DOI 10.1016/0955-0674(95)80009-3; Helenius A, 1997, TRENDS CELL BIOL, V7, P193; HELENIUS A, 1994, MOL BIOL CELL, V5, P253, DOI 10.1091/mbc.5.3.253; Helenius Ari, 1992, Trends in Cell Biology, V2, P227, DOI 10.1016/0962-8924(92)90309-B; HENDERSHOT LM, 1995, MOL BIOL CELL, V6, P283, DOI 10.1091/mbc.6.3.283; HOWARD JC, 1995, CURR OPIN IMMUNOL, V7, P69, DOI 10.1016/0952-7915(95)80031-X; HUGHES BD, 1982, BIOPHYS J, V37, P673; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; KASSENBROCK CK, 1989, EMBO J, V8, P1461, DOI 10.1002/j.1460-2075.1989.tb03529.x; KOCH GLE, 1987, J CELL SCI, V87, P491; KREIS TE, 1986, CELL, V46, P929, DOI 10.1016/0092-8674(86)90075-9; LEAVITT R, 1977, J BIOL CHEM, V252, P9018; LEFRANCOIS L, 1982, VIROLOGY, V121, P157, DOI 10.1016/0042-6822(82)90125-8; LEWIS MJ, 1992, CELL, V68, P353, DOI 10.1016/0092-8674(92)90476-S; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; MACHAMER CE, 1990, J BIOL CHEM, V265, P6879; Marguet D, 1999, IMMUNITY, V11, P231, DOI 10.1016/S1074-7613(00)80098-9; POO MM, 1974, NATURE, V247, P438, DOI 10.1038/247438a0; Presley JF, 1997, NATURE, V389, P81, DOI 10.1038/38001; Saraste J, 1992, Semin Cell Biol, V3, P343, DOI 10.1016/1043-4682(92)90020-V; SCHWEIZER A, 1990, EUR J CELL BIOL, V53, P185; Sidrauski C, 1998, TRENDS CELL BIOL, V8, P245, DOI 10.1016/S0962-8924(98)01267-7; Szczesna-Skorupa E, 1998, P NATL ACAD SCI USA, V95, P14793, DOI 10.1073/pnas.95.25.14793; TATU U, 1993, EMBO J, V12, P2151, DOI 10.1002/j.1460-2075.1993.tb05863.x; WIER M, 1988, SCIENCE, V242, P412, DOI 10.1126/science.3175663	39	217	220	1	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	MAY	2000	2	5					288	295		10.1038/35010558	http://dx.doi.org/10.1038/35010558			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	313FX	10806480				2022-12-25	WOS:000086990600018
J	Pellegata, NS; Dieguez-Lucena, JL; Joensuu, T; Lau, S; Montgomery, KT; Krahe, R; Kivela, T; Kucherlapati, R; Forsius, H; de la Chapelle, A				Pellegata, NS; Dieguez-Lucena, JL; Joensuu, T; Lau, S; Montgomery, KT; Krahe, R; Kivela, T; Kucherlapati, R; Forsius, H; de la Chapelle, A			Mutations in KERA, encoding keratocan, cause cornea plana	NATURE GENETICS			English	Article							HUMAN DECORIN GENE; SULFATE PROTEOGLYCAN; GENOMIC DNA; HUMAN DSPG3; CONGENITA; CHROMOSOME-12; ORGANIZATION; EXPRESSION; CLONING; REGION	Specialized collagens and small leucine-rich proteoglycans (SLRPs) interact to produce the transparent corneal structure(1) In cornea plana, the forward convex curvature is flattened, leading to a decrease in refraction(2). A more severe, recessively inherited form (CNA2; MIM 217300) and a milder, dominantly inherited form (CNA1; MIM 121400) exist. CNA2 is a rare disorder with a worldwide distribution, but a high prevalence in the Finnish population(3). The gene mutated in CNA2 was assigned by linkage analysis to 12q (refs 4,5), where there is a cluster of several SLRP genes(6-9). We cloned two additional SLRP genes highly expressed in cornea: KERA (encoding keratocan) in 12q and OGN (encoding osteoglycin) in 9q. Here we report mutations in KERA in 47 CNA2 patients: 46 Finnish patients are homozygous for a founder missense mutation, leading to the substitution of a highly conserved amino acid; and one American patient is homozygous for a mutation leading to a premature stop codon that truncates the KERA protein. Our data establish that mutations in KERA cause CNA2. CNA1 patients had no mutations in these proteoglycan genes.	Ohio State Univ, Ctr Comprehens Canc, Div Human Canc Genet, Columbus, OH 43210 USA; Folkhalsan Inst Genet, Helsinki, Finland; Albert Einstein Coll Med, Dept Mol Genet, Bronx, NY 10467 USA; Univ Helsinki Hosp, Dept Ophthalmol, Helsinki, Finland	James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; Yeshiva University; Albert Einstein College of Medicine; University of Helsinki; Helsinki University Central Hospital	de la Chapelle, A (corresponding author), Ohio State Univ, Ctr Comprehens Canc, Div Human Canc Genet, Columbus, OH 43210 USA.		Joensuu, Tarja/F-3059-2011; Kucherlapati, Raju/ABC-8807-2021; Kivelä, Tero/C-9241-2009; Pellegata, Natalia S/I-1256-2012	Kivelä, Tero/0000-0003-1198-4394; Pellegata, Natalia S/0000-0002-8000-7784	NATIONAL CANCER INSTITUTE [P30CA016058] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA16058] Funding Source: Medline; PHS HHS [NG1763] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Burge C, 1997, J MOL BIOL, V268, P78, DOI 10.1006/jmbi.1997.0951; Corpuz LM, 1996, J BIOL CHEM, V271, P9759, DOI 10.1074/jbc.271.16.9759; DANIELSON KG, 1993, GENOMICS, V15, P146, DOI 10.1006/geno.1993.1022; Deere M, 1999, GENOME RES, V9, P449; Deere M, 1996, GENOMICS, V38, P399, DOI 10.1006/geno.1996.0643; ERIKSSON AW, 1973, CLIN GENET, V4, P301; Forsius H, 1998, ACTA OPHTHALMOL SCAN, V76, P196, DOI 10.1034/j.1600-0420.1998.760215.x; Funderburgh JL, 1997, J BIOL CHEM, V272, P28089, DOI 10.1074/jbc.272.44.28089; Griffith M, 1999, SCIENCE, V286, P2169, DOI 10.1126/science.286.5447.2169; GROVER J, 1995, J BIOL CHEM, V270, P21942, DOI 10.1074/jbc.270.37.21942; Hocking AM, 1998, MATRIX BIOL, V17, P1; Liechti-Gallati S, 1999, EUR J HUM GENET, V7, P590, DOI 10.1038/sj.ejhg.5200338; Liu CY, 1998, J BIOL CHEM, V273, P22584, DOI 10.1074/jbc.273.35.22584; MIANO JM, 1999, MOL BIOL VASCULAR DI, P25; SiglerVillanueva A, 1997, OPHTHALMIC GENET, V18, P55, DOI 10.3109/13816819709057116; SPENCER WH, 1996, OPHTHALMIC PATHOLOGY, P159; Tahvanainen E, 1996, J MED GENET, V33, P116, DOI 10.1136/jmg.33.2.116; TAHVANAINEN E, 1995, GENOMICS, V26, P290, DOI 10.1016/0888-7543(95)80213-6; Tahvanainen E, 1996, GENOME RES, V6, P249, DOI 10.1101/gr.6.4.249; Tahvanainen E, 1995, GENOMICS, V30, P409, DOI 10.1006/geno.1995.1258; Tasheva ES, 1999, DNA SEQUENCE, V10, P67, DOI 10.3109/10425179909033939; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TRALSTAD RL, 1974, J CELL BIOL, V62, P815; UBERBACHER EC, 1991, P NATL ACAD SCI USA, V88, P11261, DOI 10.1073/pnas.88.24.11261; VETTER U, 1993, GENOMICS, V15, P161, DOI 10.1006/geno.1993.1023; WILSON FM, 1994, CORNEA, P539	26	117	124	0	6	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAY	2000	25	1					91	95		10.1038/75664	http://dx.doi.org/10.1038/75664			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	311KU	10802664				2022-12-25	WOS:000086884000024
J	Vrana, PB; Fossella, JA; Matteson, P; del Rio, T; O'Neill, MJ; Tilghman, SM				Vrana, PB; Fossella, JA; Matteson, P; del Rio, T; O'Neill, MJ; Tilghman, SM			Genetic and epigenetic incompatibilities underlie hybrid dysgenesis in Peromyscus	NATURE GENETICS			English	Article							X-CHROMOSOME INACTIVATION; PLACENTAL DEVELOPMENT; IMPRINTED GENE; HALDANES RULE; MOUSE; LOCUS; GROWTH; MAP	Crosses between the two North American rodent species Peromyscus polionotus (PO) and Peromyscus maniculatus (BW) yield parent-of-origin effects on both embryonic and placental growth(1,2). The two species are approximately the same size, but a female BW crossed with a male PO produces offspring that are smaller than either parent. In the reciprocal cross, the offspring are oversized and typically die before birth. Rare survivors are exclusively female, consistent with Haldane's rule, which states that in instances of hybrid sterility or inviability, the heterogametic sex tends to be more severely affected(3). To understand these sex- and parent-of-origin-specific patterns of overgrowth, we analysed reciprocal backcrosses. Our studies reveal that hybrid inviability is partially due to a maternally expressed X-linked PO locus and an imprinted paternally expressed autosomal BW locus. In addition, the hybrids display skewing of X-chromosome inactivation in favour of the expression of the BW X chromosome. The most severe overgrowth is accompanied by widespread relaxation of imprinting of mostly paternally expressed genes. Both genetic and epigenetic mechanisms underlie hybrid inviability in Peromyscus and hence have a role in the establishment and maintenance of reproductive isolation barriers in mammals.	Princeton Univ, Howard Hughes Med Inst, Princeton, NJ 08544 USA; Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA	Howard Hughes Medical Institute; Princeton University; Princeton University	Tilghman, SM (corresponding author), Princeton Univ, Howard Hughes Med Inst, Princeton, NJ 08544 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051460] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM51460] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; CATTANACH BM, 1970, GENET RES, V15, P183, DOI 10.1017/S0016672300001518; CATTANACH BM, 1972, GENET RES, V19, P229, DOI 10.1017/S001667230001449X; Clerc P, 1998, NAT GENET, V19, P249, DOI 10.1038/924; COYNE JA, 1989, EVOLUTION, V43, P362, DOI 10.1111/j.1558-5646.1989.tb04233.x; DARVASI A, 1995, GENETICS, V141, P1199; DAWSON WD, 1965, EVOLUTION, V19, P44, DOI 10.2307/2406294; Dawson WD, 1999, MAMM GENOME, V10, P730, DOI 10.1007/s003359901080; Dobzhansky T., 1937; Gray A. P., 1972, MAMMALIAN HYBRIDS; Haldane JBS, 1922, J GENET, V12, P101, DOI 10.1007/BF02983075; KANEKOISHINO T, 1995, NAT GENET, V11, P52, DOI 10.1038/ng0995-52; Li LL, 1999, SCIENCE, V284, P330, DOI 10.1126/science.284.5412.330; Li YH, 1998, NAT GENET, V20, P309, DOI 10.1038/3129; Lyons LA, 1997, NAT GENET, V15, P47, DOI 10.1038/ng0197-47; Manly KF, 1999, MAMM GENOME, V10, P327, DOI 10.1007/s003359900997; Marahrens Y, 1997, GENE DEV, V11, P156, DOI 10.1101/gad.11.2.156; Muller HJ, 1942, BIOL S, V6, P71; Penny GD, 1996, NATURE, V379, P131, DOI 10.1038/379131a0; Pilia G, 1996, NAT GENET, V12, P241, DOI 10.1038/ng0396-241; Relaix F, 1998, NAT GENET, V18, P287, DOI 10.1038/ng0398-287; ROGERS JF, 1970, J REPROD FERTIL, V21, P255; Shin MK, 1997, P NATL ACAD SCI USA, V94, P13105, DOI 10.1073/pnas.94.24.13105; SIMMLER MC, 1993, MAMM GENOME, V4, P523, DOI 10.1007/BF00364788; TAKAGI N, 1975, NATURE, V256, P640, DOI 10.1038/256640a0; Tilghman SM, 1999, CELL, V96, P185, DOI 10.1016/S0092-8674(00)80559-0; TURELLI M, 1995, GENETICS, V140, P389; Vrana PB, 1998, NAT GENET, V20, P362, DOI 10.1038/3833; Zechner U, 1996, NAT GENET, V12, P398, DOI 10.1038/ng0496-398; Zeng LW, 1996, GENETICS, V143, P603	30	133	137	0	12	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAY	2000	25	1					120	124		10.1038/75518	http://dx.doi.org/10.1038/75518			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	311KU	10802670				2022-12-25	WOS:000086884000030
J	Capell, A; Steiner, H; Romig, H; Keck, S; Baader, M; Grim, MG; Baumeister, R; Haass, C				Capell, A; Steiner, H; Romig, H; Keck, S; Baader, M; Grim, MG; Baumeister, R; Haass, C			Presenilin-1 differentially facilitates endoproteolysis of the beta-amyloid precursor protein and Notch	NATURE CELL BIOLOGY			English	Article							DISEASE-ASSOCIATED PRESENILIN-1; FAMILIAL ALZHEIMERS-DISEASE; IN-VIVO; CAENORHABDITIS-ELEGANS; MEMBRANE-PROTEIN; GENE; FRAGMENTS; CLEAVAGE; PEPTIDE; ACCUMULATION	Mutations in the presenilin-1 (PSI) gene are associated with Alzheimer's disease and cause increased secretion of the neurotoxic amyloid-beta peptide (A beta), Critical intramembraneous aspartates at residues 257 and 385 are required for the function of PS1 protein. Here we investigate the biological function of a naturally occurring PSI splice variant (PSI Delta exon8), which lacks the critical aspartate 257. Cell lines that stably express PS1 Delta exon8 or a PSI protein in which aspartate residue 257 is mutated secrete significant levels of A beta, whereas A beta generation is severely reduced in cells transfected with PSI containing a mutation of aspartate 385. In contrast, endoproteolytic processing of Notch is almost completely inhibited in cell lines expressing any of the PSI variants that lack one of the critical aspartates. These data indicate that PSI may differentially facilitate gamma-secretase-mediated generation of A beta and endoproteolysis of Notch.	Univ Munich, Lab Alzheimers Dis Res, Dept Biochem, Adolf Butenandt Inst, D-80336 Munich, Germany; Boehringer Ingelheim KG, CNS Res, D-55216 Ingelheim, Germany; Univ Munich, Gene Ctr, D-81377 Munich, Germany	University of Munich; Boehringer Ingelheim; University of Munich	Haass, C (corresponding author), Univ Munich, Lab Alzheimers Dis Res, Dept Biochem, Adolf Butenandt Inst, D-80336 Munich, Germany.	chaass@pbm.med.uni-muenchen.de						Baumeister R, 1997, Genes Funct, V1, P149; Brockhaus M, 1998, NEUROREPORT, V9, P1481, DOI 10.1097/00001756-199805110-00043; Capell A, 1998, J BIOL CHEM, V273, P3205, DOI 10.1074/jbc.273.6.3205; Chan YM, 1999, NEURON, V23, P201, DOI 10.1016/S0896-6273(00)80771-0; Citron M, 1997, NAT MED, V3, P67, DOI 10.1038/nm0197-67; CITRON M, 1995, NEURON, V14, P661, DOI 10.1016/0896-6273(95)90323-2; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; CLARK RF, 1995, NAT GENET, V11, P219, DOI 10.1038/ng1095-219; Cruts M, 1996, HUM MOL GENET, V5, P1449, DOI 10.1093/hmg/5.Supplement_1.1449; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; HAASS C, 1993, J BIOL CHEM, V268, P3021; HAASS C, 1994, J BIOL CHEM, V269, P17741; HAASS C, 1995, NAT MED, V1, P1291, DOI 10.1038/nm1295-1291; HAASS C, 1992, NATURE, V357, P500, DOI 10.1038/357500a0; Hartmann D, 1999, CURR BIOL, V9, P719, DOI 10.1016/S0960-9822(99)80331-5; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; Leimer U, 1999, BIOCHEMISTRY-US, V38, P13602, DOI 10.1021/bi991453n; Levitan D, 1996, P NATL ACAD SCI USA, V93, P14940, DOI 10.1073/pnas.93.25.14940; LEVITAN D, 1995, NATURE, V377, P351, DOI 10.1038/377351a0; Lichtenthaler SF, 1999, P NATL ACAD SCI USA, V96, P3053, DOI 10.1073/pnas.96.6.3053; LINSTEDT AD, 1993, MOL BIOL CELL, V4, P679, DOI 10.1091/mbc.4.7.679; Naruse S, 1998, NEURON, V21, P1213, DOI 10.1016/S0896-6273(00)80637-6; Podlisny MB, 1997, NEUROBIOL DIS, V3, P325, DOI 10.1006/nbdi.1997.0129; Prihar G, 1996, NEUROREPORT, V7, P1680, DOI 10.1097/00001756-199607080-00031; Ray WJ, 1999, J BIOL CHEM, V274, P36801, DOI 10.1074/jbc.274.51.36801; ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; Selkoe DJ, 1999, NATURE, V399, pA23, DOI 10.1038/399a023; Shen IY, 1997, SMART MATER STRUCT, V6, P89, DOI 10.1088/0964-1726/6/1/011; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; Song WH, 1999, P NATL ACAD SCI USA, V96, P6959, DOI 10.1073/pnas.96.12.6959; Steiner H, 1999, BIOCHEMISTRY-US, V38, P14600, DOI 10.1021/bi9914210; Steiner H, 1999, J BIOL CHEM, V274, P7615, DOI 10.1074/jbc.274.12.7615; Steiner H, 1998, J BIOL CHEM, V273, P32322, DOI 10.1074/jbc.273.48.32322; Steiner H, 1999, J BIOL CHEM, V274, P28669, DOI 10.1074/jbc.274.40.28669; Struhl G, 1998, CELL, V93, P649, DOI 10.1016/S0092-8674(00)81193-9; Struhl G, 1999, NATURE, V398, P522, DOI 10.1038/19091; Thinakaran G, 1997, J BIOL CHEM, V272, P28415, DOI 10.1074/jbc.272.45.28415; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; Van Broeckhoven C, 1995, NAT GENET, V11, P230; Walter J, 1997, P NATL ACAD SCI USA, V94, P5349, DOI 10.1073/pnas.94.10.5349; WildBode C, 1997, J BIOL CHEM, V272, P16085, DOI 10.1074/jbc.272.26.16085; Wolfe MS, 1999, BIOCHEMISTRY-US, V38, P4720, DOI 10.1021/bi982562p; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Wong PC, 1997, NATURE, V387, P288, DOI 10.1038/387288a0; Ye YH, 1999, NATURE, V398, P525, DOI 10.1038/19096	48	136	137	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	APR	2000	2	4					205	211		10.1038/35008626	http://dx.doi.org/10.1038/35008626			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	302ZU	10783238				2022-12-25	WOS:000086397000013
J	Sankaranarayanan, S; Ryan, TA				Sankaranarayanan, S; Ryan, TA			Real-time measurements of vesicle-SNARE recycling in synapses of the central nervous system	NATURE CELL BIOLOGY			English	Article							FROG NEUROMUSCULAR-JUNCTION; ADRENAL CHROMAFFIN CELLS; SYNAPTIC VESICLES; HIPPOCAMPAL SYNAPSES; TRANSMITTER RELEASE; MEMBRANE RETRIEVAL; ENDOCYTOSIS; CALCIUM; EXOCYTOSIS; TRANSPORT	Following the fusion of synaptic vesicles with the presynaptic plasma membrane of nerve terminals by the process of exocytosis, synaptic-vesicle components are recycled to replenish the vesicle pool. Here we use a pl l-sensitive green fluorescent protein to measure the residence time of VAMP, a vesicle-associated SNARE protein important for membrane fusion, on the surfaces of synaptic terminals of hippocampal neurons following exocytosis. The time course of VAMP retrieval depends linearly on the amount of VAMP that is added to the plasma membrane, with retrieval occurring between about 4 seconds and 90 seconds after exocytosis, and newly internalized vesicles are rapidly acidified. These data are well described by a model in which endocytosis appears to be saturable, but proceeds with an initial maximum velocity of about one vesicle per second. We also find that, following exocytosis, a portion of the newly inserted VAMP appears on the surface of the axon.	Cornell Univ, Weill Med Coll, Dept Biochem, New York, NY 10021 USA	Cornell University	Sankaranarayanan, S (corresponding author), Cornell Univ, Weill Med Coll, Dept Biochem, 1300 York Ave, New York, NY 10021 USA.		Ryan, Timothy/AAO-8286-2020	Ryan, Timothy/0000-0003-2533-9548	NINDS NIH HHS [NS24692] Funding Source: Medline	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARTALEJO CR, 1995, P NATL ACAD SCI USA, V92, P8328, DOI 10.1073/pnas.92.18.8328; CECCARELLI B, 1973, J CELL BIOL, V57, P499, DOI 10.1083/jcb.57.2.499; Eliasson L, 1996, J PHYSIOL-LONDON, V493, P755, DOI 10.1113/jphysiol.1996.sp021420; Engisch KL, 1998, J PHYSIOL-LONDON, V506, P591, DOI 10.1111/j.1469-7793.1998.591bv.x; Gaidarov I, 1999, NAT CELL BIOL, V1, P1, DOI 10.1038/8971; HEUSER JE, 1973, J CELL BIOL, V57, P315, DOI 10.1083/jcb.57.2.315; Klingauf J, 1998, NATURE, V394, P581, DOI 10.1038/29079; KOENIG JH, 1989, J NEUROSCI, V9, P3844; MAYCOX PR, 1988, J BIOL CHEM, V263, P15423; Miesenbock G, 1998, NATURE, V394, P192, DOI 10.1038/28190; Murthy VN, 1999, NAT NEUROSCI, V2, P503, DOI 10.1038/9149; Otto H, 1997, P NATL ACAD SCI USA, V94, P6197, DOI 10.1073/pnas.94.12.6197; PARSONS TD, 1994, NEURON, V13, P875, DOI 10.1016/0896-6273(94)90253-4; REGEHR WG, 1994, J NEUROSCI, V14, P523; Ryan TA, 1999, J NEUROSCI, V19, P1317; Ryan TA, 1996, P NATL ACAD SCI USA, V93, P5567, DOI 10.1073/pnas.93.11.5567; Ryan TA, 1997, NATURE, V388, P478, DOI 10.1038/41335; Ryan TA, 1996, NEURON, V17, P1035, DOI 10.1016/S0896-6273(00)80236-6; RYAN TA, 1995, NEURON, V14, P983, DOI 10.1016/0896-6273(95)90336-4; SCHELLER RH, 1995, NEURON, V14, P893; Smith C, 1997, J CELL BIOL, V139, P885, DOI 10.1083/jcb.139.4.885; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; TABB JS, 1992, J BIOL CHEM, V267, P15412; Takei K, 1996, J CELL BIOL, V133, P1237, DOI 10.1083/jcb.133.6.1237; THOMAS P, 1990, NEURON, V5, P723, DOI 10.1016/0896-6273(90)90226-6; Threadgill R, 1997, NEURON, V19, P625, DOI 10.1016/S0896-6273(00)80376-1; VALTORTA F, 1988, J CELL BIOL, V107, P2717, DOI 10.1083/jcb.107.6.2717; VONGERSDORFF H, 1994, NATURE, V367, P735, DOI 10.1038/367735a0; VONGERSDORFF H, 1994, NATURE, V370, P652, DOI 10.1038/370652a0; Wu LG, 1996, NEURON, V17, P769, DOI 10.1016/S0896-6273(00)80208-1	30	322	331	0	9	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	APR	2000	2	4					197	204		10.1038/35008615	http://dx.doi.org/10.1038/35008615			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	302ZU	10783237				2022-12-25	WOS:000086397000012
J	Sosio, M; Giusino, F; Cappellano, C; Bossi, E; Puglia, AM; Donadio, S				Sosio, M; Giusino, F; Cappellano, C; Bossi, E; Puglia, AM; Donadio, S			Artificial chromosomes for antibiotic-producing actinomycetes	NATURE BIOTECHNOLOGY			English	Article							STREPTOMYCES-COELICOLOR A3(2); BIOSYNTHETIC GENE-CLUSTER; PHYSICAL MAP; HETEROLOGOUS HOST; HUMAN DNA; EXPRESSION; FRAGMENTS; CLONING; GENOME; VECTOR		Biosearch Italia SpA, I-21040 Gerenzano, Italy; Univ Palermo, Dept Cellular & Dev Biol, I-90128 Palermo, Italy	University of Palermo	Donadio, S (corresponding author), Biosearch Italia SpA, I-21040 Gerenzano, Italy.			Sosio, Margherita/0000-0003-4297-6936				August PR, 1998, CHEM BIOL, V5, P69, DOI 10.1016/S1074-5521(98)90141-7; Birren BW, 1993, PULSED FIELD GEL ELE, DOI [10.1016/B978-0-12-101290-8.50002-X, DOI 10.1016/B978-0-12-101290-8.50002-X]; Brosch R, 1998, INFECT IMMUN, V66, P2221, DOI 10.1128/IAI.66.5.2221-2229.1998; Hamilton CM, 1996, P NATL ACAD SCI USA, V93, P9975, DOI 10.1073/pnas.93.18.9975; Hopwood D. A., 1985, GENETIC MANIPULATION; HOPWOOD DA, 1997, P GEN MOL BIOL IND M, P1; Ioannou P.A., 1996, CURRENT PROTOCOLS HU; IOANNOU PA, 1994, NAT GENET, V6, P84, DOI 10.1038/ng0194-84; KAO CM, 1994, SCIENCE, V265, P509, DOI 10.1126/science.8036492; KIESER HM, 1992, J BACTERIOL, V174, P5496, DOI 10.1128/JB.174.17.5496-5507.1992; KUHSTOSS S, 1991, J MOL BIOL, V222, P897, DOI 10.1016/0022-2836(91)90584-S; LEBLOND P, 1993, J BACTERIOL, V175, P3422, DOI 10.1128/jb.175.11.3422-3429.1993; Liu YG, 1999, P NATL ACAD SCI USA, V96, P6535, DOI 10.1073/pnas.96.11.6535; MALPARTIDA F, 1984, NATURE, V309, P462, DOI 10.1038/309462a0; MARTIN JF, 1989, ANNU REV MICROBIOL, V43, P173, DOI 10.1146/annurev.micro.43.1.173; Redenbach M, 1996, MOL MICROBIOL, V21, P77, DOI 10.1046/j.1365-2958.1996.6191336.x; Rondon MR, 1999, P NATL ACAD SCI USA, V96, P6451, DOI 10.1073/pnas.96.11.6451; SCHWECKE T, 1995, P NATL ACAD SCI USA, V92, P7839, DOI 10.1073/pnas.92.17.7839; SHIZUYA H, 1992, P NATL ACAD SCI USA, V89, P8794, DOI 10.1073/pnas.89.18.8794; Xu Y, 1997, INFECT IMMUN, V65, P4207, DOI 10.1128/IAI.65.10.4207-4215.1997	20	77	82	0	10	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAR	2000	18	3					343	345		10.1038/73810	http://dx.doi.org/10.1038/73810			3	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	292AC	10700154				2022-12-25	WOS:000085771100036
J	Rocca, B; Loeb, AL; Strauss, JF; Vezza, R; Habib, A; Li, HW; FitzGerald, GA				Rocca, B; Loeb, AL; Strauss, JF; Vezza, R; Habib, A; Li, HW; FitzGerald, GA			Directed vascular expression of the thromboxane A(2) receptor results in intrauterine growth retardation	NATURE MEDICINE			English	Article							BIRTH-WEIGHT; MICE; BIOSYNTHESIS; PREGNANCY; PLATELET; GENE	Thromboxane (Tx) A, is a platelet agonist, smooth muscle cell constrictor, and mitogen(1). Urinary Tx metabolite (Tx-M) excretion is increased in syndromes of platelet activation and early in both normal pregnancies and in pregnancy-induced hypertension(2,3). A further increment occurs in patients presenting with severe preeclampsia, in whom Tx-M correlates with other indices of disease severity(4). TxA(2) exerts its effects through a membrane receptor (TP), of which two isoforms (alpha and beta; refs. 5,6) have been cloned. Overexpression of TP in the vasculature under the control of the pre-proendothelin-1 promoter(7) results in a murine model of intrauterine growth retardation (IUGR), which is rescued by timed suppression of Tx synthesis with indomethacin. IUGR is commonly associated with maternal diabetes or cigarette smoking, both conditions associated with increased TxA(2) biosynthesis(8,9).	Univ Penn, Ctr Expt Therapeut, Philadelphia, PA 19104 USA; Univ Penn, Ctr Res Reprod & Womens Hlth, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine	FitzGerald, GA (corresponding author), Univ Penn, Ctr Expt Therapeut, Philadelphia, PA 19104 USA.		FitzGerald, Garret A/A-4222-2010; rocca, bianca/K-3922-2018	Habib, Aida/0000-0001-6027-0043	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD029946] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL054500, R01HL057847] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 57847, HL 54500] Funding Source: Medline; NICHD NIH HHS [HD 29946] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Barker M, 1997, ARCH DIS CHILD, V77, P381, DOI 10.1136/adc.77.5.381; DAVI G, 1990, NEW ENGL J MED, V322, P1769, DOI 10.1056/NEJM199006213222503; FITZGERALD DJ, 1990, LANCET, V335, P751, DOI 10.1016/0140-6736(90)90869-7; FITZGERALD DJ, 1987, AM J OBSTET GYNECOL, V157, P325, DOI 10.1016/S0002-9378(87)80162-X; FITZGERALD GA, 1995, C LOEBS TXB MED, P1187; Ghidini A, 1996, Obstet Gynecol Surv, V51, P376, DOI 10.1097/00006254-199606000-00023; HARATS D, 1995, J CLIN INVEST, V95, P1335, DOI 10.1172/JCI117784; JOHNSTON BM, 1995, REPROD FERT DEVELOP, V7, P639, DOI 10.1071/RD9950639; KREGE JH, 1995, HYPERTENSION, V25, P1111, DOI 10.1161/01.HYP.25.5.1111; Lim H, 1997, CELL, V91, P197, DOI 10.1016/S0092-8674(00)80402-X; LOEB AL, 1992, AM J PHYSIOL, V262, pH1494, DOI 10.1152/ajpheart.1992.262.5.H1494; MCCORMICK MC, 1985, NEW ENGL J MED, V312, P82, DOI 10.1056/NEJM198501103120204; NOWAK J, 1987, CIRCULATION, V76, P6, DOI 10.1161/01.CIR.76.1.6; NUSING RM, 1993, J BIOL CHEM, V268, P25253; Parent JL, 1999, J BIOL CHEM, V274, P8941, DOI 10.1074/jbc.274.13.8941; RAYCHOWDHURY MK, 1995, J BIOL CHEM, V30, P19256; Roy-Clavel E, 1999, AM J OBSTET GYNECOL, V180, P608, DOI 10.1016/S0002-9378(99)70262-0; Sugimoto Y, 1997, SCIENCE, V277, P681, DOI 10.1126/science.277.5326.681; TALAMANTES F, 1988, INT REV CYTOL, V112, P1; VANFEIJN HP, 1980, AM J OBSTET GYNECOL, V137, P43; Vezza R, 1999, J BIOL CHEM, V274, P12774, DOI 10.1074/jbc.274.18.12774; WIGGLESWORTH JS, 1964, J PATHOL BACTERIOL, V88, P1, DOI 10.1002/path.1700880102	22	41	43	0	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	FEB	2000	6	2					219	221		10.1038/72334	http://dx.doi.org/10.1038/72334			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	278YQ	10655114				2022-12-25	WOS:000085016900046
J	Wianny, F; Zernicka-Goetz, M				Wianny, F; Zernicka-Goetz, M			Specific interference with gene function by double-stranded RNA in early mouse development	NATURE CELL BIOLOGY			English	Article							ANTISENSE RNA; MOS; EXPRESSION; ACTIVATION; EMBRYOS; EGGS	The use of double-stranded (ds) RNA is a powerful way of interfering with gene expression in a range of organisms, but doubts have been raised about whether it could be successful in mammals. Here, we show that dsRNA is effective as a specific inhibitor of the function of three genes in the mouse, namely maternally expressed c-mos in the oocyte and zygotically expressed E-cadherin or a GFP transgene in the preimplantation embryo. The phenotypes observed are the same as those reported for null mutants of the endogenous genes. These findings offer the opportunity to study development and gene regulation in normal and diseased cells.	Univ Cambridge, Wellcome CRC Inst, Cambridge CB2 1QR, England; Univ Cambridge, Dept Genet, Cambridge CB2 1QR, England	University of Cambridge; University of Cambridge	Zernicka-Goetz, M (corresponding author), Univ Cambridge, Wellcome CRC Inst, Tennis Court Rd, Cambridge CB2 1QR, England.		WIANNY, Florence/K-6035-2014	WIANNY, Florence/0000-0002-1184-9208; Zernicka-Goetz, Magdalena/0000-0002-7004-2471				Alvarado AS, 1999, P NATL ACAD SCI USA, V96, P5049, DOI 10.1073/pnas.96.9.5049; BASS BL, 1987, CELL, V48, P607, DOI 10.1016/0092-8674(87)90239-X; BEVILACQUA A, 1988, P NATL ACAD SCI USA, V85, P831, DOI 10.1073/pnas.85.3.831; Clemens MJ, 1997, INT J BIOCHEM CELL B, V29, P945, DOI 10.1016/S1357-2725(96)00169-0; COLLEDGE WH, 1994, NATURE, V370, P65, DOI 10.1038/370065a0; Fire A, 1999, TRENDS GENET, V15, P358, DOI 10.1016/S0168-9525(99)01818-1; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; HASHIMOTO N, 1994, NATURE, V370, P68, DOI 10.1038/370068a0; Kennerdell JR, 1998, CELL, V95, P1017, DOI 10.1016/S0092-8674(00)81725-0; LARUE L, 1994, P NATL ACAD SCI USA, V91, P8263, DOI 10.1073/pnas.91.17.8263; LEE SB, 1994, VIROLOGY, V199, P491, DOI 10.1006/viro.1994.1151; Marcus P I, 1983, Interferon, V5, P115; Ngo H, 1998, P NATL ACAD SCI USA, V95, P14687, DOI 10.1073/pnas.95.25.14687; PAULES RS, 1989, P NATL ACAD SCI USA, V86, P5395, DOI 10.1073/pnas.86.14.5395; REBAGLIATI MR, 1987, CELL, V48, P599, DOI 10.1016/0092-8674(87)90238-8; RIETHMACHER D, 1995, P NATL ACAD SCI USA, V92, P855, DOI 10.1073/pnas.92.3.855; SEFTON M, 1992, DEVELOPMENT, V115, P313; Sharp PA, 1999, GENE DEV, V13, P139, DOI 10.1101/gad.13.2.139; Verlhac MH, 1996, DEVELOPMENT, V122, P815; Wargelius A, 1999, BIOCHEM BIOPH RES CO, V263, P156, DOI 10.1006/bbrc.1999.1343; Waterhouse PM, 1998, P NATL ACAD SCI USA, V95, P13959, DOI 10.1073/pnas.95.23.13959; Weber RJ, 1999, DEVELOPMENT, V126, P5591; Wianny F, 1998, CHROMOSOMA, V107, P430, DOI 10.1007/s004120050327; ZernickaGoetz M, 1997, DEVELOPMENT, V124, P1133; ZERNICKAGOETZ M, 1999, CELL LINEAGE FATE DE, P521	25	560	763	1	28	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	FEB	2000	2	2					70	75		10.1038/35000016	http://dx.doi.org/10.1038/35000016			6	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	281GA	10655585				2022-12-25	WOS:000085148500010
J	Bonaccorsi, S; Giansanti, MG; Gatti, M				Bonaccorsi, S; Giansanti, MG; Gatti, M			Spindle assembly in Drosophila neuroblasts and ganglion mother cells	NATURE CELL BIOLOGY			English	Article							SELF-ORGANIZATION; CENTROSOMES; MELANOGASTER; MITOSIS; POLES		Univ Rome La Sapienza, Dipartimento Genet & Biol Mol, Ist Pasteur, Fdn Cenci Bolognetti, I-00185 Rome, Italy	Fondazione Cenci Bolognetti; Sapienza University Rome	Bonaccorsi, S (corresponding author), Univ Rome La Sapienza, Dipartimento Genet & Biol Mol, Ist Pasteur, Fdn Cenci Bolognetti, Piazzale Aldo Moro 5, I-00185 Rome, Italy.		Gatti, Maurizio/S-2877-2019; Gatti, Maurizio/J-9703-2013; Giansanti, Maria Grazia/A-6739-2014	Gatti, Maurizio/0000-0003-3777-300X; Giansanti, Maria Grazia/0000-0002-6753-7262				Bonaccorsi S, 1998, J CELL BIOL, V142, P751, DOI 10.1083/jcb.142.3.751; Gaglio T, 1997, J CELL BIOL, V138, P1055, DOI 10.1083/jcb.138.5.1055; Heald R, 1997, J CELL BIOL, V138, P615, DOI 10.1083/jcb.138.3.615; Jan YN, 1998, NATURE, V392, P775, DOI 10.1038/33854; Li KJ, 1996, CELL, V85, P585, DOI 10.1016/S0092-8674(00)81258-1; Megraw TL, 1999, DEVELOPMENT, V126, P2829; Phalle BD, 1998, J CELL BIOL, V141, P1383, DOI 10.1083/jcb.141.6.1383; RIEDER CL, 1993, NATO ASI SERIES H, V72; SPANA EP, 1995, DEVELOPMENT, V121, P3187; STEFFEN W, 1986, J CELL BIOL, V102, P1679, DOI 10.1083/jcb.102.5.1679; Truman James W., 1993, P1245; Vaizel-Ohayon D, 1999, CURR BIOL, V9, P889, DOI 10.1016/S0960-9822(99)80393-5; Waters JC, 1997, CURR OPIN CELL BIOL, V9, P37, DOI 10.1016/S0955-0674(97)80149-4; ZHANG DH, 1995, J CELL BIOL, V129, P1287, DOI 10.1083/jcb.129.5.1287; ZHENG YX, 1991, CELL, V65, P817, DOI 10.1016/0092-8674(91)90389-G	15	96	97	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	JAN	2000	2	1					54	56		10.1038/71378	http://dx.doi.org/10.1038/71378			3	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	275WR	10620808				2022-12-25	WOS:000084843600020
J	Dansen, TB; Wirtz, KWA; Wanders, RJA; Pap, EHW				Dansen, TB; Wirtz, KWA; Wanders, RJA; Pap, EHW			Peroxisomes in human fibroblasts have a basic pH	NATURE CELL BIOLOGY			English	Article							PTS1 RECEPTOR; BIOGENESIS DISORDERS; GENE; IDENTIFICATION; DEFICIENCY; STABILITY; SYNTHASE; ENCODES; IMPORT		Univ Utrecht, Dept Biochem Lipids, Ctr Biomembranes & Lipid Enzymol, Inst Biomembranes, NL-3508 TB Utrecht, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Clin Chem, NL-1105 AZ Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Paediat, NL-1105 AZ Amsterdam, Netherlands	Utrecht University; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam	Dansen, TB (corresponding author), Univ Utrecht, Dept Biochem Lipids, Ctr Biomembranes & Lipid Enzymol, Inst Biomembranes, Padualaan 8,POB 80054, NL-3508 TB Utrecht, Netherlands.	k.w.a.wirtz@chem.uu.nl		Dansen, Tobias/0000-0001-5259-8815				de Vet ECJM, 1998, J BIOL CHEM, V273, P10296, DOI 10.1074/jbc.273.17.10296; Dodt G, 1996, J CELL BIOL, V135, P1763, DOI 10.1083/jcb.135.6.1763; DODT G, 1995, NAT GENET, V9, P115, DOI 10.1038/ng0295-115; GOULD SJ, 1989, J CELL BIOL, V108, P1657, DOI 10.1083/jcb.108.5.1657; Henke B, 1998, J BIOL CHEM, V273, P3702, DOI 10.1074/jbc.273.6.3702; Mihalik SJ, 1997, NAT GENET, V17, P185, DOI 10.1038/ng1097-185; Motley AM, 1997, NAT GENET, V15, P377, DOI 10.1038/ng0497-377; Subramani S, 1998, PHYSIOL REV, V78, P171, DOI 10.1152/physrev.1998.78.1.171; VANDENBOSCH H, 1992, ANNU REV BIOCHEM, V61, P157, DOI 10.1146/annurev.bi.61.070192.001105; VANROERMUND CWT, 1995, EMBO J, V14, P3480, DOI 10.1002/j.1460-2075.1995.tb07354.x; Wanders RJA, 1998, MOL ASPECTS MED, V19, P71, DOI 10.1016/S0098-2997(98)00003-X; Wanders RJA, 1999, NEUROCHEM RES, V24, P565, DOI 10.1023/A:1022592014988; WANDERS RJA, 1994, J INHERIT METAB DIS, V17, P315, DOI 10.1007/BF00711817; WANDERS RJA, 1992, J INHERIT METAB DIS, V15, P356, DOI 10.1007/BF02435975; Wouters FS, 1998, EMBO J, V17, P7179, DOI 10.1093/emboj/17.24.7179; Yahraus T, 1996, EMBO J, V15, P2914, DOI 10.1002/j.1460-2075.1996.tb00654.x	16	98	100	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	JAN	2000	2	1					51	53		10.1038/71375	http://dx.doi.org/10.1038/71375			3	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	275WR	10620807				2022-12-25	WOS:000084843600019
J	Zhu, GZ; Mallery, SR; Schwendeman, SP				Zhu, GZ; Mallery, SR; Schwendeman, SP			Stabilization of proteins encapsulated in injectable poly (lactide-co-glycolide)	NATURE BIOTECHNOLOGY			English	Article						protein delivery; aggregation; stabilization; poly(DL-lactide-co-glycolide); bovine serum albumin	FIBROBLAST GROWTH-FACTOR; BONE MORPHOGENETIC PROTEIN-2; MOISTURE-INDUCED AGGREGATION; SUSTAINED-RELEASE; BIODEGRADABLE MICROSPHERES; DEGRADATION; DELIVERY; ALBUMIN; MICROENCAPSULATION; FORMULATIONS	Controlled release from biodegradable polymers is a novel approach to replace daily painful injections of protein drugs. A major obstacle to development of these polymers is the need to retain the structure and biological activity of encapsulated proteins during months of incubation under physiological conditions. We encapsulated bovine serum albumin (BSA) in injectable poly(DL-lactide-co-glycolide) (PLGA) 50/50 cylindrical implants and determined the mechanism of BSA instability. Simulations of the polymer microclimate revealed that moisture and acidic pH (<3) triggered unfolding of encapsulated BSA, resulting in peptide bond hydrolysis and noncovalent aggregation. To neutralize the acids liberated by the biodegradable lactic/glycolic acid-based polyester we coincorporated into the polymer an antacid, Mg(OH)(2), which increased microclimate pH and prevented BSA structural losses and aggregation for over one month. We successfully applied this stabilization approach in both cylinder- and microsphere-injectable configurations and for delivery of angiogenic basic fibroblast growth factor and bone-regenerating bone morphogenetic protein-2.	Ohio State Univ, Coll Pharm, Columbus, OH 43210 USA; Ohio State Univ, Coll Dent, Columbus, OH 43210 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University	Schwendeman, SP (corresponding author), Ohio State Univ, Coll Pharm, 500 W 12Th Ave, Columbus, OH 43210 USA.				NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE012183] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE12183] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		BERSCHT PC, 1994, BIOMATERIALS, V15, P593, DOI 10.1016/0142-9612(94)90209-7; Brunner A, 1999, PHARMACEUT RES, V16, P847, DOI 10.1023/A:1018822002353; Cleland JL, 1996, PHARMACEUT RES, V13, P1464, DOI 10.1023/A:1016063109373; COHEN S, 1991, PHARMACEUT RES, V8, P713, DOI 10.1023/A:1015841715384; COSTANTINO HR, 1994, J PHARM SCI-US, V83, P1662, DOI 10.1002/jps.2600831205; Crotts G, 1997, J CONTROL RELEASE, V47, P101, DOI 10.1016/S0168-3659(96)01624-0; Davies MJ, 1997, J BIOMATER APPL, V12, P31, DOI 10.1177/088532829701200103; Dutta A. S., 1993, Pharmaceutical Medicine (London), V7, P9; EDELMAN ER, 1991, BIOMATERIALS, V12, P619, DOI 10.1016/0142-9612(91)90107-L; EDELMAN ER, 1993, P NATL ACAD SCI USA, V90, P1513, DOI 10.1073/pnas.90.4.1513; FU K, 1998, P INT S CONTROL REL, V25, P150; FUKUNAGA K, 1994, J PHARM PHARMACOL, V46, P168, DOI 10.1111/j.2042-7158.1994.tb03771.x; GABRA N, 1994, BIOCHEM BIOPH RES CO, V205, P1423, DOI 10.1006/bbrc.1994.2824; GOSPODAROWICZ D, 1986, J CELL PHYSIOL, V128, P475, DOI 10.1002/jcp.1041280317; HELLER J, 1990, BIOMATERIALS, V11, P659, DOI 10.1016/0142-9612(90)90024-K; HERRLINGER M, 1994, THESIS U HEIDELBERG; HUTCHINSON FG, 1990, J CONTROL RELEASE, V13, P279, DOI 10.1016/0168-3659(90)90018-O; Johnson OL, 1996, NAT MED, V2, P795, DOI 10.1038/nm0796-795; KENLEY RA, 1993, PHARMACEUT RES, V10, P1393, DOI 10.1023/A:1018902720816; LANGER R, 1976, NATURE, V263, P797, DOI 10.1038/263797a0; LI SM, 1990, J MATER SCI-MATER M, V1, P123, DOI 10.1007/BF00700871; LIU WR, 1991, BIOTECHNOL BIOENG, V37, P177, DOI 10.1002/bit.260370210; Mader K, 1998, PHARMACEUT RES, V15, P787, DOI 10.1023/A:1011939607573; Mader K, 1996, BIOMATERIALS, V17, P457, DOI 10.1016/0142-9612(96)89664-5; MANNING MC, 1989, PHARM RES-DORDR, V6, P903, DOI 10.1023/A:1015929109894; Mayer M, 1996, PLAST RECONSTR SURG, V98, P247, DOI 10.1097/00006534-199608000-00006; OGAWA Y, 1989, J PHARM PHARMACOL, V41, P439, DOI 10.1111/j.2042-7158.1989.tb06497.x; OKADA H, 1994, PHARM RES-DORDR, V11, P1143, DOI 10.1023/A:1018936815654; PETERS T, 1985, ADV PROTEIN CHEM, V37, P161, DOI 10.1016/S0065-3233(08)60065-0; Putney SD, 1998, NAT BIOTECHNOL, V16, P153, DOI 10.1038/nbt0298-153; Schwendeman S.P., 1996, MICROPARTICULATE SYS, P1; SCHWENDEMAN SP, 1995, P NATL ACAD SCI USA, V92, P11234, DOI 10.1073/pnas.92.24.11234; Schwendeman SP, 1998, J MICROENCAPSUL, V15, P299, DOI 10.3109/02652049809006859; Shenderova A, 1999, PHARMACEUT RES, V16, P241, DOI 10.1023/A:1018876308346; Shenderova A, 1997, PHARMACEUT RES, V14, P1406, DOI 10.1023/A:1012172722246; SOMMER A, 1989, J CELL PHYSIOL, V138, P215, DOI 10.1002/jcp.1041380129; STRUCK MM, 1994, BIO-TECHNOL, V12, P674, DOI 10.1038/nbt0794-674; SULLIVAN R, 1986, J TISSUE CULTURE MET, V10, P125; TALMADGE JE, 1993, ADV DRUG DELIVER REV, V10, P247, DOI 10.1016/0169-409X(93)90049-A; WANG EA, 1990, P NATL ACAD SCI USA, V87, P2220, DOI 10.1073/pnas.87.6.2220; Wang YJ, 1996, FORMULATION CHARACTE, P141; WATANABE H, 1991, BIOCHEM BIOPH RES CO, V175, P229, DOI 10.1016/S0006-291X(05)81224-0; Welch RD, 1998, J BONE MINER RES, V13, P1483, DOI 10.1359/jbmr.1998.13.9.1483; ZHANG XC, 1993, J CONTROL RELEASE, V25, P61, DOI 10.1016/0168-3659(93)90095-M	44	506	544	4	192	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JAN	2000	18	1					52	57		10.1038/71916	http://dx.doi.org/10.1038/71916			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	273GQ	10625391				2022-12-25	WOS:000084699900025
J	Hamon, Y; Broccardo, C; Chambenoit, O; Luciani, MF; Toti, F; Chaslin, S; Freyssinet, JM; Devaux, PF; McNeish, J; Marguet, D; Chimini, G				Hamon, Y; Broccardo, C; Chambenoit, O; Luciani, MF; Toti, F; Chaslin, S; Freyssinet, JM; Devaux, PF; McNeish, J; Marguet, D; Chimini, G			ABC1 promotes engulfment of apoptotic cells and transbilayer redistribution of phosphatidylserine.	NATURE CELL BIOLOGY			English	Article							BINDING CASSETTE TRANSPORTER-1; TANGIER-DISEASE; CYSTIC-FIBROSIS; MAMMALIAN-CELLS; ATP; MEMBRANE; PHOSPHOLIPIDS; PROTEIN; DEATH; CHOLESTEROL	ATP-binding-cassette transporter 1 (ABC1) has been implicated in processes related to membrane-lipid turnover. Here, using in vivo Toss-of-function and in vitro gain-of-function models, we show that ABC1 promotes Ca2+-induced exposure of phosphatidylserine at the membrane, as determined by a prothrombinase assay, membrane microvesiculation and measurement of transbilayer redistribution of spin-labelled phospholipids. That ABC1 promotes engulfment of dead cells is shown by the impaired ability of ABC1-deficient macrophages to engulf apoptotic preys and by the acquisition of phagocytic behaviour by ABC1 transfectants. Release of membrane phospholipids and cholesterol to apo-AI, the protein core of the cholesterol-shuttling high-density lipoprotein (HDL) particle, is also ABC1-dependent. We propose that both the efficiency of apoptotic-cell engulfment and the efflux of cellular lipids depend on ABC1-induced perturbation of membrane phosphatidylserine turnover. Transient local exposure of anionic phospholipids in the outer membrane leaflet may be sufficient to alter the general properties of the membrane and thus influence discrete physiological functions.	CNRS Marseille Luminy, INSERM, Ctr Immunol, F-13288 Marseille, France; Univ Strasbourg 1, INSERM, U143, F-67085 Strasbourg, France; Univ Strasbourg 1, Inst Hematol & Immunol, F-67085 Strasbourg, France; Inst Biol Physicochim, F-75005 Paris, France; Pfizer Inc, Cent Res, Groton, CT 06340 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Pfizer	Chimini, G (corresponding author), CNRS Marseille Luminy, INSERM, Ctr Immunol, F-13288 Marseille, France.	chimini@ciml.univ-mrs.fr	Marguet, Didier/AGO-5421-2022; HAMON, Yannick/S-3118-2019; HAMON, Yannick YH/N-5372-2016; Marguet, Didier/B-9946-2008; Freyssinet, Jean-Marie/G-2719-2013; Broccardo, Cyril/G-2796-2017	Marguet, Didier/0000-0003-3198-5095; HAMON, Yannick/0000-0002-7636-2310; HAMON, Yannick YH/0000-0002-7636-2310; Broccardo, Cyril/0000-0003-3016-6549				ANDERSON MP, 1992, SCIENCE, V257, P1701, DOI 10.1126/science.1382316; BARON U, 1995, NUCLEIC ACIDS RES, V23, P3605, DOI 10.1093/nar/23.17.3605; Becq F, 1997, J BIOL CHEM, V272, P2695, DOI 10.1074/jbc.272.5.2695; Biwersi J, 1996, P NATL ACAD SCI USA, V93, P12484, DOI 10.1073/pnas.93.22.12484; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; Bucki R, 1998, BIOCHEMISTRY-US, V37, P15383, DOI 10.1021/bi9805238; CELIS JE, 1994, CELL BIOL LAB HDB; DEVAUX PF, 1991, BIOCHEMISTRY-US, V30, P1163, DOI 10.1021/bi00219a001; ELLIS RE, 1991, GENETICS, V129, P79; Fadok VA, 1998, CELL DEATH DIFFER, V5, P551, DOI 10.1038/sj.cdd.4400404; Fellmann P, 1994, Methods Mol Biol, V27, P161; FIELDING CJ, 1995, J LIPID RES, V36, P211; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Hess KL, 1997, CYTOMETRY, V27, P145; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Kobayashi T, 1998, NATURE, V392, P193, DOI 10.1038/32440; Langmann T, 1999, BIOCHEM BIOPH RES CO, V257, P29, DOI 10.1006/bbrc.1999.0406; Lawn RM, 1999, J CLIN INVEST, V104, pR25, DOI 10.1172/JCI8119; Le Borgne R, 1998, BBA-MOL CELL RES, V1404, P195, DOI 10.1016/S0167-4889(98)00057-3; LINSTEDT AD, 1993, MOL BIOL CELL, V4, P679, DOI 10.1091/mbc.4.7.679; Luciani MF, 1996, EMBO J, V15, P226, DOI 10.1002/j.1460-2075.1996.tb00353.x; LUCIANI MF, 1994, GENOMICS, V21, P150, DOI 10.1006/geno.1994.1237; Marguet D, 1999, NAT CELL BIOL, V1, P454, DOI 10.1038/15690; McNeish J, 2000, P NATL ACAD SCI USA, V97, P4245, DOI 10.1073/pnas.97.8.4245; MERESSE S, 1995, J CELL SCI, V108, P3349; Morin X, 1997, NEURON, V18, P411, DOI 10.1016/S0896-6273(00)81242-8; Oram JF, 1996, J LIPID RES, V37, P2473; OTTO E, 2000, NAT GENET, V24, P192; Remaley AT, 1999, P NATL ACAD SCI USA, V96, P12685, DOI 10.1073/pnas.96.22.12685; ROACH ML, 1995, EXP CELL RES, V221, P520, DOI 10.1006/excr.1995.1403; Rust S, 1999, NAT GENET, V22, P352, DOI 10.1038/11921; Savill J, 1998, NATURE, V392, P442, DOI 10.1038/33025; SEIGNEURET M, 1984, P NATL ACAD SCI-BIOL, V81, P3751, DOI 10.1073/pnas.81.12.3751; Seksek O, 1996, J BIOL CHEM, V271, P15542, DOI 10.1074/jbc.271.26.15542; Southgate CD, 1996, NAT GENET, V14, P227, DOI 10.1038/ng1096-227; TARDIEUX I, 1992, CELL, V71, P1117, DOI 10.1016/S0092-8674(05)80061-3; Toti F, 1996, BLOOD, V87, P1409, DOI 10.1182/blood.V87.4.1409.bloodjournal8741409; Vallejo Abbe N., 1995, P603; vanHelvoort A, 1996, CELL, V87, P507, DOI 10.1016/S0092-8674(00)81370-7; Via LE, 1998, J CELL SCI, V111, P897; von Eckardstein A, 1998, J LIPID RES, V39, P987; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; Weng J, 1999, CELL, V98, P13, DOI 10.1016/S0092-8674(00)80602-9; Wu YC, 1998, CELL, V93, P951, DOI 10.1016/S0092-8674(00)81201-5; Yamamoto Y, 1999, DEV BIOL, V214, P60, DOI 10.1006/dbio.1999.9413; Young SG, 1999, NAT GENET, V22, P316, DOI 10.1038/11878; Zwaal RFA, 1997, BLOOD, V89, P1121, DOI 10.1182/blood.V89.4.1121	49	436	451	1	11	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	JUL	2000	2	7					399	406		10.1038/35017029	http://dx.doi.org/10.1038/35017029			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	333MK	10878804				2022-12-25	WOS:000088133700015
J	Robertson, KD; Ait-Si-Ali, S; Yokochi, T; Wade, PA; Jones, PL; Wolffe, AP				Robertson, KD; Ait-Si-Ali, S; Yokochi, T; Wade, PA; Jones, PL; Wolffe, AP			DNMT1 forms a complex with Rb, E2F1 and HDAC1 and represses transcription from E2F-responsive promoters	NATURE GENETICS			English	Article							DNA METHYLTRANSFERASE GENE; RETINOBLASTOMA PROTEIN; HISTONE DEACETYLASE; IMMUNODEFICIENCY SYNDROME; CYTOSINE METHYLATION; REPLICATION; MUTATIONS; MECP2	Methylation of CpG islands is associated with transcriptional silencing and the formation of nuclease-resistant chromatin structures enriched in hypoacetylated histones(1-3). Methyl-CpG-binding proteins, such as MeCP2, provide a link between methylated DNA and hypoacetylated histones by recruiting histone deacetylase(4,5), but the mechanisms establishing the methylation patterns themselves are unknown. Whether DNA methylation is always causal for the assembly of repressive chromatin or whether features of transcriptionally silent chromatin might target methyltransferase remains unresolved. Mammalian DNA methyltransferases show little sequence specificity in vitro, yet methylation can be targeted in vivo within chromosomes to repetitive elements(6,7), centromeress(8-10) and imprinted loci(11). This targeting is frequently disrupted in tumour cells, resulting in the improper silencing of tumour-suppressor genes associated with CpG islands(1,2). Here we show that the predominant mammalian DNA methyltransferase, DNMT1, co-purifies with the retinoblastoma (Rb) tumour suppressor gene product, E2F1. and HDAC1 and that DNMT1 cooperates with Rb to repress transcription from promoters containing E2F-binding sites. These results establish a link between DNA methylation, histone deacetylase and sequence-specific DNA binding activity, as well as a growth-regulatory pathway that is disrupted in nearly all cancer cells.	NICHD, Mol Embryol Lab, NIH, Bethesda, MD USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Wolffe, AP (corresponding author), Sangamo Biosci Inc, Point Richmond Tech Ctr, Richmond, CA USA.	awolffe@sangamo.com	Wade, Paul A/D-2374-2019	Wade, Paul A/0000-0002-6042-357X; Robertson, Keith/0000-0002-7508-3328	DIVISION OF BASIC SCIENCES - NCI [Z01BC010420] Funding Source: NIH RePORTER	DIVISION OF BASIC SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ait-Si-Ali S, 1998, NATURE, V396, P184, DOI 10.1038/24190; Chuang LSH, 1997, SCIENCE, V277, P1996, DOI 10.1126/science.277.5334.1996; DUNAIEF JL, 1994, CELL, V79, P119, DOI 10.1016/0092-8674(94)90405-7; Eden S, 1998, NATURE, V394, P842, DOI 10.1038/29680; Fuks F, 2000, NAT GENET, V24, P88, DOI 10.1038/71750; Garrick D, 1998, NAT GENET, V18, P56, DOI 10.1038/ng0198-56; Grana X, 1998, ONCOGENE, V17, P3365, DOI 10.1038/sj.onc.1202575; Hansen RS, 1999, P NATL ACAD SCI USA, V96, P14412, DOI 10.1073/pnas.96.25.14412; Hung MS, 1999, P NATL ACAD SCI USA, V96, P11940, DOI 10.1073/pnas.96.21.11940; ISSA JP, 1997, LEUKEMIA S1, V11, P7; ISSA JPJ, 1993, J NATL CANCER I, V85, P1235, DOI 10.1093/jnci/85.15.1235; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; LEONHARDT H, 1992, CELL, V71, P865, DOI 10.1016/0092-8674(92)90561-P; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; Luff B, 1999, MOL CELL, V3, P505, DOI 10.1016/S1097-2765(00)80478-5; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; MEEHAN RR, 1989, CELL, V58, P499, DOI 10.1016/0092-8674(89)90430-3; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; Roberts J.D., 1991, CONCEPT MAGNETIC RES, V3, P27, DOI [DOI 10.1002/cmr.1820030104, 10.1002/cmr.1820030104, DOI 10.1002/CMR.1820030104]; Robertson KD, 1998, MOL CELL BIOL, V18, P6457, DOI 10.1128/MCB.18.11.6457; Royzman I, 1999, GENE DEV, V13, P827, DOI 10.1101/gad.13.7.827; SMITH SS, 1992, P NATL ACAD SCI USA, V89, P4744, DOI 10.1073/pnas.89.10.4744; Sterner JM, 1998, MOL CELL BIOL, V18, P2748, DOI 10.1128/MCB.18.5.2748; Surani MA, 1998, CELL, V93, P309, DOI 10.1016/S0092-8674(00)81156-3; Xu GL, 1999, NATURE, V402, P187, DOI 10.1038/46052	28	744	789	1	38	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JUL	2000	25	3					338	342		10.1038/77124	http://dx.doi.org/10.1038/77124			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	329RD	10888886				2022-12-25	WOS:000087920900026
J	Taillon-Miller, P; Bauer-Sardina, I; Saccone, NL; Putzel, J; Laitinen, T; Cao, A; Kere, J; Pilia, G; Rice, JP; Kwok, PY				Taillon-Miller, P; Bauer-Sardina, I; Saccone, NL; Putzel, J; Laitinen, T; Cao, A; Kere, J; Pilia, G; Rice, JP; Kwok, PY			Juxtaposed regions of extensive and minimal linkage disequilibrium in human Xq25 and Xq28	NATURE GENETICS			English	Article							GAMETIC DISEQUILIBRIUM; GENOME; GENE; POPULATION	Linkage disequilibrium (LD). or the non-random association of alleles. is poorly understood in the human genome(1). Population genetic theory suggests that LD is determined by the age of the markers, population history, recombination rate, selection and genetic drift(2). Despite the uncertainties in determining the relative contributions of these factors, some groups have argued that LD is a simple function of distance between markers(3,4). Disease-gene mapping studies and a simulation study gave differing predictions on the degree of LD in isolated and general populations(5,6). In view of the discrepancies between theory and experimental observations, we constructed a high-density SNP map of the Xq25-Xq28 region(7) and analysed the male genotypes and haplotypes across this region for LD in three populations. The populations included an outbred European sample (CEPH males) and isolated population samples from Finland and Sardinia. We found two extended regions of strong LD bracketed by regions with no evidence for LD in all three samples. Haplotype analysis showed a paucity of haplotypes in regions of strong LD. Our results suggest that, in this region of the X chromosome. LD is not a monotonic function of the distance between markers, but is more a property of the particular location in the human genome.	Washington Univ, Div Dermatol, St Louis, MO 63130 USA; Washington Univ, Dept Psychiat, St Louis, MO 63130 USA; Univ Cagliari, CNR, IRTAM, Cagliari, Sardinia, Italy; Univ Helsinki, Finnish Genome Ctr, Helsinki, Finland	Washington University (WUSTL); Washington University (WUSTL); Consiglio Nazionale delle Ricerche (CNR); University of Cagliari; University of Helsinki	Kwok, PY (corresponding author), Washington Univ, Div Dermatol, St Louis, MO 63130 USA.		Kere, Juha/A-9179-2008; Kwok, Pui-Yan/F-7725-2014; Kere, Juha/AAX-9117-2021	Kere, Juha/0000-0003-1974-0271; Kwok, Pui-Yan/0000-0002-5087-3059; Kere, Juha/0000-0003-1974-0271	NATIONAL HUMAN GENOME RESEARCH INSTITUTE [P50HG000835, R01HG001439, P50HG000201] Funding Source: NIH RePORTER; NHGRI NIH HHS [R01HG1439, P50HG00835, P50HG00201] Funding Source: Medline	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		CAO A, 1994, BLOOD REV, V8, P1, DOI 10.1016/0268-960X(94)90002-7; CAVALLISFORZA LL, 1993, SCIENCE, V259, P639, DOI 10.1126/science.8430313; Chakravarti A, 1999, NAT GENET, V21, P56, DOI 10.1038/4482; Chen XN, 1997, P NATL ACAD SCI USA, V94, P10756, DOI 10.1073/pnas.94.20.10756; Hartl D., 1989, PRINCIPLES POPULATIO; HEDRICK PW, 1987, GENETICS, V117, P331; HOGLUND P, 1995, AM J HUM GENET, V57, P95; Huttley GA, 1999, GENETICS, V152, P1711; JORDE LB, 1993, AM J HUM GENET, V53, P1038; JORDE LB, 1994, AM J HUM GENET, V54, P884; KERE J, 1994, HUM GENET, V93, P162, DOI 10.1007/BF00210603; Kruglyak L, 1999, NAT GENET, V22, P139, DOI 10.1038/9642; KWOK PY, 1992, GENOMICS, V13, P935, DOI 10.1016/0888-7543(92)90004-C; KWOK PY, 1994, GENOMICS, V23, P138, DOI 10.1006/geno.1994.1469; Laitinen T, 1997, HUM MOL GENET, V6, P2069, DOI 10.1093/hmg/6.12.2069; LEWONTIN RC, 1988, GENETICS, V120, P849; TAHVANAINEN E, 1994, P NATL ACAD SCI USA, V91, P7267, DOI 10.1073/pnas.91.15.7267; Taillon-Miller P, 1999, GENOME RES, V9, P499; Taillon-Miller P, 2000, GENOMICS, V65, P195, DOI 10.1006/geno.2000.6165; TaillonMiller P, 1997, GENOMICS, V46, P307, DOI 10.1006/geno.1997.5042; WATKINS WS, 1994, AM J HUM GENET, V55, P348	21	205	214	0	3	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUL	2000	25	3					324	328		10.1038/77100	http://dx.doi.org/10.1038/77100			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	329RD	10888883				2022-12-25	WOS:000087920900023
J	Bignell, GR; Warren, W; Seal, S; Takahashi, M; Rapley, E; Barfoot, R; Green, H; Brown, C; Biggs, PJ; Lakhani, SR; Jones, C; Hansen, J; Blair, E; Hofmann, B; Siebert, R; Turner, G; Evans, DG; Schrander-Stumpel, C; Beemer, FA; van den Ouweland, A; Halley, D; Delpech, B; Cleveland, MG; Leigh, I; Leisti, J; Rasmussen, S; Wallace, MR; Fenske, C; Banerjee, P; Oiso, N; Chaggar, R; Merrett, S; Leonard, N; Huber, M; Hohl, D; Chapman, P; Burn, J; Swift, S; Smith, A; Ashworth, A; Stratton, MR				Bignell, GR; Warren, W; Seal, S; Takahashi, M; Rapley, E; Barfoot, R; Green, H; Brown, C; Biggs, PJ; Lakhani, SR; Jones, C; Hansen, J; Blair, E; Hofmann, B; Siebert, R; Turner, G; Evans, DG; Schrander-Stumpel, C; Beemer, FA; van den Ouweland, A; Halley, D; Delpech, B; Cleveland, MG; Leigh, I; Leisti, J; Rasmussen, S; Wallace, MR; Fenske, C; Banerjee, P; Oiso, N; Chaggar, R; Merrett, S; Leonard, N; Huber, M; Hohl, D; Chapman, P; Burn, J; Swift, S; Smith, A; Ashworth, A; Stratton, MR			Identification of the familial cylindromatosis tumour-suppressor gene	NATURE GENETICS			English	Article							SACCHAROMYCES-CEREVISIAE; DYNACTIN COMPLEX; DNA FRAGMENTS; CLIP-170; CYLD1; PROTEINS; SPINDLE; CELLS	Familial cylindromatosis is an autosomal dominant genetic predisposition to multiple tumours of the skin appendages. The susceptibility gene (CYLD) has previously been localized to chromosome 16q and has the genetic attributes of a tumour-suppressor gene (recessive oncogene). Here we have identified CYLD by detecting germline mutations in 21 cylindromatosis families and somatic mutations in 1 sporadic and 5 familial cylindromas. All mutations predict truncation or absence of the encoded protein. CYLD encodes three cytoskeletal-associated-protein-glycine-conserved (CAP-GLY) domains, which are found in proteins that coordinate the attachment of organelles to microtubules. CYLD also has sequence homology to the catalytic domain of ubiquitin carboxy-terminal hydrolases (UCH).	Inst Canc Res, Sect Canc Genet, Sutton, Surrey, England; Inst Canc Res, Breakthrough Breast Canc Res Ctr, London SW3 6JB, England; UCL, Royal Free & Univ Coll, Sch Med, Dept Histopathol, London, England; OHSU, Dept Surg, Portland, OR USA; Oxford Radcliffe Hosp Trust, Dept Clin Genet, Oxford, England; Univ Dusseldorf, Hautklin Med Einrichtungen, D-4000 Dusseldorf, Germany; Univ Kiel, Dept Human Genet, Kiel, Germany; Dept Clin Genet, Yorkshire Reg Genet Serv, Leeds, W Yorkshire, England; St Marys Hosp, Cent Manchester Healthcare NHS Trust, Reg Genet Serv, Manchester, Lancs, England; Acad Hosp Maastricht, Dept Clin Genet, Maastricht, Netherlands; Univ Utrecht, Med Ctr, Dept Med Genet, Utrecht, Netherlands; Erasmus Univ, Dept Clin Genet, NL-3000 DR Rotterdam, Netherlands; Ctr Henri Becquerel, Oncol Mol Lab, UPRES EA 2122, Grp Rech Inflammat & Canc, F-76038 Rouen, France; Univ Iowa, Dept Dermatol, Iowa City, IA USA; St Bartholomews & Royal London Sch Med & Dent, Ctr Cutaneous Res, London, England; Oulu Univ, Cent Hosp, Dept Clin Genet, SF-90220 Oulu, Finland; Univ Florida, Coll Med, Div Genet, Gainesville, FL USA; St George Hosp, Sch Med, Dept Med Genet, London, England; Osaka City Univ, Sch Med, Dept Dermatol, Abeno Ku, Osaka 545, Japan; Ludwig Inst Canc Res, London W1P 8BT, England; Royal Victoria Infirm, Dept Histopathol, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England; Hop Beaumont, CHUV, Serv Dermatol, Lausanne, Switzerland; Univ Newcastle, Inst Human Genet, Newcastle Upon Tyne, Tyne & Wear, England	University of London; Institute of Cancer Research - UK; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; University of London; University College London; UCL Medical School; Oregon Health & Science University; Heinrich Heine University Dusseldorf; University of Kiel; University of Manchester; Maastricht University; Maastricht University Medical Centre (MUMC); Utrecht University; Erasmus University Rotterdam; UNICANCER; Centre Henri Becquerel; University of Iowa; University of London; Queen Mary University London; University of Oulu; State University System of Florida; University of Florida; St Georges University London; Osaka Metropolitan University; Ludwig Institute for Cancer Research; Newcastle University - UK; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); Newcastle University - UK	Stratton, MR (corresponding author), Inst Canc Res, Sect Canc Genet, Sutton, Surrey, England.	mikes@icr.ac.uk	Biggs, Patrick Jon/H-3355-2014; Hohl, Daniel M/N-7554-2016; Huber, Marcel/M-8822-2016; Jones, Chris/ABE-6059-2021; Evans, D Gareth/AAB-4308-2022; Siebert, Reiner/A-8049-2010; Oiso, Naoki/H-6540-2019; Lakhani, Sunil R/I-1970-2018	Biggs, Patrick Jon/0000-0002-0285-4101; Huber, Marcel/0000-0003-3821-2378; Jones, Chris/0000-0001-8118-2296; Evans, D Gareth/0000-0002-8482-5784; Oiso, Naoki/0000-0001-5593-6496; Lakhani, Sunil R/0000-0003-4067-2760; Takahashi, Meiko/0000-0002-8344-5472; Burn, John/0000-0002-9823-2322				Abenoza P, 1990, NEOPLASMS ECCRINE DI; Antonarakis SE, 1998, HUM MUTAT, V11, P1; BERLIN V, 1990, J CELL BIOL, V111, P2573, DOI 10.1083/jcb.111.6.2573; BIGGS PJ, 1995, NAT GENET, V11, P441, DOI 10.1038/ng1295-441; Biggs PJ, 1996, ONCOGENE, V12, P1375; BILBE G, 1992, EMBO J, V11, P2103, DOI 10.1002/j.1460-2075.1992.tb05269.x; Chase DS, 1998, J MED GENET, V35, P413, DOI 10.1136/jmg.35.5.413; D'Andrea A, 1998, CRIT REV BIOCHEM MOL, V33, P337, DOI 10.1080/10409239891204251; Dujardin D, 1998, J CELL BIOL, V141, P849, DOI 10.1083/jcb.141.4.849; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; FUTREAL PA, 1994, HUM MOL GENET, V3, P1359, DOI 10.1093/hmg/3.8.1359; GANGULY A, 1993, P NATL ACAD SCI USA, V90, P10325, DOI 10.1073/pnas.90.21.10325; GERRETSEN AL, 1995, J AM ACAD DERMATOL, V33, P199, DOI 10.1016/0190-9622(95)90234-1; Hershko A, 1997, CURR OPIN CELL BIOL, V9, P788, DOI 10.1016/S0955-0674(97)80079-8; IOANNOU PA, 1994, NAT GENET, V6, P84, DOI 10.1038/ng0194-84; Kahana JA, 1998, MOL BIOL CELL, V9, P1741, DOI 10.1091/mbc.9.7.1741; Karki S, 1999, CURR OPIN CELL BIOL, V11, P45, DOI 10.1016/S0955-0674(99)80006-4; Nagase T, 1998, DNA Res, V5, P355, DOI 10.1093/dnares/5.6.355; PELLMAN D, 1995, J CELL BIOL, V130, P1373, DOI 10.1083/jcb.130.6.1373; PIERRE P, 1994, J CELL SCI, V107, P1909; PIERRE P, 1992, CELL, V70, P887, DOI 10.1016/0092-8674(92)90240-D; RIEHEMANN K, 1993, TRENDS BIOCHEM SCI, V18, P82, DOI 10.1016/0968-0004(93)90159-K; Takahashi M, 2000, HUM GENET, V106, P58, DOI 10.1007/s004399900227; Thomson SAM, 1999, HUM GENET, V105, P171, DOI 10.1007/s004399900077; VANBALKOM IDC, 1994, J MED GENET, V31, P321, DOI 10.1136/jmg.31.4.321; Verhoef S, 1998, J MED GENET, V35, P841, DOI 10.1136/jmg.35.10.841; WatermanStorer CM, 1996, J BIOL CHEM, V271, P1153, DOI 10.1074/jbc.271.2.1153	27	541	561	4	25	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JUN	2000	25	2					160	165		10.1038/76006	http://dx.doi.org/10.1038/76006			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	321ML	10835629				2022-12-25	WOS:000087459200013
J	Gangloff, S; Soustelle, C; Fabre, F				Gangloff, S; Soustelle, C; Fabre, F			Homologous recombination is responsible for cell death in the absence of the Sgs1 and Srs2 helicases	NATURE GENETICS			English	Article							WERNERS-SYNDROME GENES; STRAND BREAK REPAIR; SACCHAROMYCES-CEREVISIAE; BLOOMS-SYNDROME; DNA HELICASE; YEAST SGS1; MUTATIONS; RAD51; ALLELE; SEQUENCE	DNA helicases are involved in many aspects of DNA metabolism, including transcription, replication, recombination and repair. In the yeast Saccharomyces cerevisiae, the absence of the Sgs1 helicase results in genomic instability and accelerated ageing(1-4). In human cells, mutations in orthologues of SGS1 lead to Bloom (BS). Werner (WS) or Rothmund-Thomson (RTS) syndromes, which are rare, autosomal recessive diseases characterized by genetic instability associated with cancer predisposition(5-7). Although data concerning these human diseases are accumulating, there is still no clear idea of the function of the proteins involved. Here we show that sgs1 Delta mutants are deficient in DNA repair and are defective for induced recombination events that involve homologous chromosomes. The role of homologous recombination is further evidenced in haploid cells in which both Sgs1p and Srs2p are absent. Yeast SRS2 encodes another DNA helicase involved in the maintenance of genome integrity(8-10). Our data suggest that some defects observed in BS. WS or RTS are the consequence of unrestrained recombination.	CEA, UMR 217 CNRS, DSV, DRR,LERA, F-92265 Fontenay Aux Roses, France	CEA	Gangloff, S (corresponding author), CEA, UMR 217 CNRS, DSV, DRR,LERA, F-92265 Fontenay Aux Roses, France.	Serge.Gangloff@cea.fr; Francis.Fabre@cea.fr	Gangloff, Serge/B-2758-2008	Gangloff, Serge/0000-0003-1333-6091				ABOUSSEKHRA A, 1989, NUCLEIC ACIDS RES, V17, P7211, DOI 10.1093/nar/17.18.7211; ABOUSSEKHRA A, 1992, MOL CELL BIOL, V12, P3224, DOI 10.1128/MCB.12.7.3224; Chanet R, 1996, MOL CELL BIOL, V16, P4782; ELLIS NA, 1995, CELL, V83, P655, DOI 10.1016/0092-8674(95)90105-1; Frei C, 2000, GENE DEV, V14, P81; GANGLOFF S, 1994, MOL CELL BIOL, V14, P8391, DOI 10.1128/MCB.14.12.8391; Gangloff S, 1999, EMBO J, V18, P1701, DOI 10.1093/emboj/18.6.1701; GERMAN J, 1993, MEDICINE, V72, P393, DOI 10.1097/00005792-199311000-00003; KAYTOR MD, 1995, GENETICS, V140, P1441; Kitao S, 1999, NAT GENET, V22, P82, DOI 10.1038/8788; Lee SK, 1999, SCIENCE, V286, P2339, DOI 10.1126/science.286.5448.2339; Lu JA, 1996, NATURE, V383, P678, DOI 10.1038/383678a0; MILNE GT, 1995, GENETICS, V139, P1189; Murray JM, 1997, MOL CELL BIOL, V17, P6868, DOI 10.1128/MCB.17.12.6868; RONG L, 1991, GENETICS, V127, P75; RONG L, 1993, J BIOL CHEM, V268, P1252; Rothstein R, 1995, GENOME RES, V5, P421, DOI 10.1101/gr.5.5.421; Rothstein R, 2000, GENE DEV, V14, P1; SCHILD D, 1995, GENETICS, V140, P115; SHERMAN F, 1991, P21; Sinclair DA, 1997, SCIENCE, V277, P1313, DOI 10.1126/science.277.5330.1313; Smith J, 1999, GENETICS, V151, P447; Stewart E, 1997, EMBO J, V16, P2682, DOI 10.1093/emboj/16.10.2682; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9; Watt PM, 1996, GENETICS, V144, P935; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258	26	302	305	0	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JUN	2000	25	2					192	194		10.1038/76055	http://dx.doi.org/10.1038/76055			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	321ML	10835635				2022-12-25	WOS:000087459200019
J	Smith, SJ; Cases, S; Jensen, DR; Chen, HC; Sande, E; Tow, B; Sanan, DA; Raber, J; Eckel, RH; Farese, RV				Smith, SJ; Cases, S; Jensen, DR; Chen, HC; Sande, E; Tow, B; Sanan, DA; Raber, J; Eckel, RH; Farese, RV			Obesity resistance and multiple mechanisms of triglyceride synthesis in mice lacking Dgat	NATURE GENETICS			English	Article							CHOLESTEROL ACYLTRANSFERASE; TRIACYLGLYCEROL SYNTHESIS; GLUCOSE-METABOLISM; INSULIN-RESISTANCE; DIABETES-MELLITUS; LEPTIN; GENE; LIPODYSTROPHY; ENZYMES; FAT	Triglycerides (or triacylglycerols) represent the major form of stored energy in eukaryotes. Triglyceride synthesis has been assumed to occur primarily through acyl CoA:diacylglycerol transferase (Dgat), a microsomal enzyme that catalyses the final and only committed step in the glycerol phosphate pathway(1-3). Therefore, Dgat has been considered necessary for adipose tissue formation and essential for survival. Here we show that Dgat-deficient (Dgat(-/-)) mice are viable and can still synthesize triglycerides, Moreover, these mice are lean and resistant to diet-induced obesity. The obesity resistance involves increased energy expenditure and increased activity. Dgat deficiency also alters triglyceride metabolism in other tissues, including the mammary gland, where lactation is defective in Dgat(-/-) females. Our findings indicate that multiple mechanisms exist for triglyceride synthesis and suggest that the selective inhibition of Dgat-mediated triglyceride synthesis may be useful for treating obesity.	Univ Calif San Francisco, Gladstone Inst Cardiovasc Dis, San Francisco, CA 94141 USA; Univ Calif San Francisco, Gladstone Inst Neurol Dis, San Francisco, CA 94141 USA; Univ Calif San Francisco, Inst Cardiovasc Res, Dept Med, San Francisco, CA 94141 USA; Univ Calif San Francisco, Inst Cardiovasc Res, Dept Neurol, San Francisco, CA 94141 USA; Univ Colorado, Hlth Sci Ctr, Dept Med, Denver, CO 80262 USA	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Farese, RV (corresponding author), Univ Calif San Francisco, Gladstone Inst Cardiovasc Dis, POB 419100, San Francisco, CA 94141 USA.			Chen, Hubert/0000-0002-7599-7218				BELL RM, 1980, ANNU REV BIOCHEM, V49, P459, DOI 10.1146/annurev.bi.49.070180.002331; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Brindley D. N, 1991, BIOCH LIPIDS LIPOPRO, P171; Cases S, 1998, P NATL ACAD SCI USA, V95, P13018, DOI 10.1073/pnas.95.22.13018; Chen GX, 1996, P NATL ACAD SCI USA, V93, P14795, DOI 10.1073/pnas.93.25.14795; ERICKSON SK, 1980, J LIPID RES, V21, P930; HANKS M, 1995, SCIENCE, V269, P679, DOI 10.1126/science.7624797; Jensen DR, 1997, AM J PHYSIOL-REG I, V273, pR683, DOI 10.1152/ajpregu.1997.273.2.R683; Kamohara S, 1997, NATURE, V389, P374, DOI 10.1038/38717; LEHNER R, 1993, J BIOL CHEM, V268, P8781; Lehner R, 1996, PROG LIPID RES, V35, P169, DOI 10.1016/0163-7827(96)00005-7; MAHLEY RW, 1995, J LIPID RES, V36, P839; Meiner VL, 1996, P NATL ACAD SCI USA, V93, P14041, DOI 10.1073/pnas.93.24.14041; Moitra J, 1998, GENE DEV, V12, P3168, DOI 10.1101/gad.12.20.3168; Ogawa Y, 1999, DIABETES, V48, P1822, DOI 10.2337/diabetes.48.9.1822; Shimabukuro M, 1997, P NATL ACAD SCI USA, V94, P4637, DOI 10.1073/pnas.94.9.4637; Shimomura I, 1998, GENE DEV, V12, P3182, DOI 10.1101/gad.12.20.3182; Shimomura I, 1999, NATURE, V401, P73, DOI 10.1038/43448; [No title captured]	19	670	753	1	39	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAY	2000	25	1					87	90		10.1038/75651	http://dx.doi.org/10.1038/75651			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	311KU	10802663				2022-12-25	WOS:000086884000023
J	Wang, H; DeVries, ME; Deng, SP; Khandaker, MH; Pickering, JG; Chow, LH; Garcia, B; Kelvin, DJ; Zhong, R				Wang, H; DeVries, ME; Deng, SP; Khandaker, MH; Pickering, JG; Chow, LH; Garcia, B; Kelvin, DJ; Zhong, R			The axis of interleukin 12 and gamma interferon regulates acute vascular xenogeneic rejection	NATURE MEDICINE			English	Article							DELAYED XENOGRAFT REJECTION; IFN-GAMMA; CARDIAC XENOTRANSPLANTATION; IL-12-DEFICIENT MICE; ALLOGRAFT-REJECTION; B-CELLS; CYTOKINE; ACTIVATION; PIG; EXPRESSION	Recent advances using transgenic animals or exogenous complement inhibitors have demonstrated prevention of hyperacute rejection of vascularized organs, but not graft loss due to acute vascular rejection. Using various wild-type and cytokine-deficient mice strains, we have examined the mechanisms of acute vascular rejection. C57BL/6 mice deficient in interleukin12 or gamma interferon showed faster acute vascular rejection than did wild-type mice. Furthermore, mice defective in B-cell development showed no acute vascular rejection. These results demonstrate that the axis of interleukin 12 and gamma interferon provides a survival advantage in vascularized xenografts by delaying or preventing acute vascular rejection caused by a B cell-dependent mechanism.	London Hlth Sci Ctr, Multi Organ Transplant Program, London, ON N6A 5A5, Canada; John P Robarts Res Inst, Expt Transplantat Surg Lab, London, ON N6G 2V4, Canada; Univ Western Ontario, Dept Microbiol & Immunol, London, ON N6A 5C1, Canada; John P Robarts Res Inst, Lab Mol Immunol & Inflammat, London, ON N6G 2V4, Canada	London Health Sciences Centre; Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario)	Kelvin, DJ (corresponding author), London Hlth Sci Ctr, Multi Organ Transplant Program, 339 Windemere Rd, London, ON N6A 5A5, Canada.		Pickering, J. Geoffrey/G-3341-2011	Pickering, J. Geoffrey/0000-0001-6474-3274				ABED NS, 1994, CELL IMMUNOL, V153, P356, DOI 10.1006/cimm.1994.1034; Auchincloss H, 1998, ANNU REV IMMUNOL, V16, P433, DOI 10.1146/annurev.immunol.16.1.433; Bhatti FNK, 1999, TRANSPLANT P, V31, P958, DOI 10.1016/S0041-1345(98)01855-7; BLAKELY ML, 1994, TRANSPLANTATION, V58, P1059, DOI 10.1097/00007890-199411270-00001; Candinas D, 1996, TRANSPLANTATION, V62, P1920, DOI 10.1097/00007890-199612270-00042; CORRY RJ, 1973, TRANSPLANTATION, V16, P343, DOI 10.1097/00007890-197310000-00010; DALTON DK, 1993, SCIENCE, V259, P1739, DOI 10.1126/science.8456300; HEINZEL FP, 1989, J EXP MED, V169, P59, DOI 10.1084/jem.169.1.59; Hutchinson IV, 1999, TRANSPLANT P, V31, P734, DOI 10.1016/S0041-1345(98)01746-1; KITAMURA D, 1991, NATURE, V350, P423, DOI 10.1038/350423a0; Konieczny BT, 1998, J IMMUNOL, V160, P2059; Lauwerys BR, 1998, EUR J IMMUNOL, V28, P2017, DOI 10.1002/(SICI)1521-4141(199806)28:06<2017::AID-IMMU2017>3.0.CO;2-2; LEVENTHAL JR, 1993, TRANSPLANTATION, V56, P1, DOI 10.1097/00007890-199307000-00001; Lin JS, 1998, J BIOMED SCI, V5, P101, DOI 10.1159/000025319; Magram J, 1996, IMMUNITY, V4, P471, DOI 10.1016/S1074-7613(00)80413-6; Markees TG, 1998, J CLIN INVEST, V101, P2446, DOI 10.1172/JCI2703; MATSUMIYA G, 1994, TRANSPLANTATION, V57, P1653; MORRIS SC, 1994, J IMMUNOL, V152, P1047; Murphy B, 1996, TRANSPLANTATION, V61, P1133, DOI 10.1097/00007890-199604270-00001; Nickerson P, 1997, TRANSPLANTATION, V63, P489, DOI 10.1097/00007890-199702270-00001; NobenTrauth N, 1996, SCIENCE, V271, P987, DOI 10.1126/science.271.5251.987; Piccotti JR, 1996, J IMMUNOL, V157, P1951; Piccotti JR, 1998, J IMMUNOL, V160, P1132; PLATT JL, 1991, TRANSPLANTATION, V52, P1037, DOI 10.1097/00007890-199112000-00019; SAYEGH MH, 1995, J EXP MED, V181, P1869, DOI 10.1084/jem.181.5.1869; SYPEK JP, 1993, J EXP MED, V177, P1797, DOI 10.1084/jem.177.6.1797; TAKEUCHI T, 1992, TRANSPLANTATION, V53, P1281, DOI 10.1097/00007890-199206000-00023; TRINCHIERI G, 1995, ANNU REV IMMUNOL, V13, P251, DOI 10.1146/annurev.immunol.13.1.251; Turner D, 1997, TRANSPLANTATION, V64, P776, DOI 10.1097/00007890-199709150-00021; vandenBogaerde J, 1997, BRIT MED BULL, V53, P904; Wang H, 1999, TRANSPLANTATION, V68, P1643, DOI 10.1097/00007890-199912150-00007; Waterworth PD, 1997, TRANSPL P, V29, P899, DOI 10.1016/S0041-1345(96)00224-2; Xu H, 1998, J THORAC CARDIOV SUR, V115, P1342, DOI 10.1016/S0022-5223(98)70218-1; YOSHIDA A, 1994, BIOCHEM BIOPH RES CO, V198, P857, DOI 10.1006/bbrc.1994.1122; Yoshimoto T, 1997, P NATL ACAD SCI USA, V94, P3948, DOI 10.1073/pnas.94.8.3948; Zaidi A, 1998, TRANSPLANTATION, V65, P1584, DOI 10.1097/00007890-199806270-00008; Zhang Z, 1996, TRANSPLANTATION, V62, P1267, DOI 10.1097/00007890-199611150-00016	37	59	64	0	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAY	2000	6	5					549	555		10.1038/75029	http://dx.doi.org/10.1038/75029			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	309YB	10802711				2022-12-25	WOS:000086796200039
J	Yant, SR; Meuse, L; Chiu, W; Ivics, Z; Izsvak, Z; Kay, MA				Yant, SR; Meuse, L; Chiu, W; Ivics, Z; Izsvak, Z; Kay, MA			Somatic integration and long-term transgene expression in normal and haemophilic mice using a DNA transposon system	NATURE GENETICS			English	Article							MEDIATED GENE-TRANSFER; ADENOASSOCIATED VIRUS; MARINER TRANSPOSASE; FACTOR-IX; IN-VITRO; HEMOPHILIA-B; HUMAN ALPHA-1-ANTITRYPSIN; RECOMBINANT ADENOVIRUSES; IMMUNE-RESPONSES; MOUSE-LIVER	The development of non-viral gene-transfer technologies that can support stable chromosomal integration and persistent gene expression in vivo is desirable. Here we describe the successful use of transposon technology for the nonhomologous insertion of foreign genes into the genomes of adult mammals using naked DNA. We show that the Sleeping Beauty transposase can efficiently insert transposon DNA into the mouse genome in approximately 5-6% of transfected mouse liver cells. Chromosomal transposition resulted in long-term expression (>5 months) of human blood coagulation factor IX at levels that were therapeutic in a mouse model of haemophilia B. Our results establish DNA-mediated transposition as a new genetic tool for mammals, and provide new strategies to improve existing non-viral and viral vectors for human gene therapy applications.	Stanford Univ, Sch Med, Dept Pediat, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Genet, Stanford, CA 94305 USA; Univ Washington, Mol & Cellular Biol Program, Seattle, WA 98195 USA; Max Delbruck Ctr Mol Med, Berlin, Germany	Stanford University; Stanford University; University of Washington; University of Washington Seattle; Helmholtz Association; Max Delbruck Center for Molecular Medicine	Kay, MA (corresponding author), Stanford Univ, Sch Med, Dept Pediat, Stanford, CA 94305 USA.	markay@stanford.edu	Wilson, Matthew H/K-3193-2013	Kay, Mark/0000-0002-2799-2615; Yant, Stephen R,/0000-0002-4444-7483	NIDDK NIH HHS [DK49022] Funding Source: Medline; NIGMS NIH HHS [T32 GM07270] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049022] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007270] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALINO SF, 1994, BIOCHEM BIOPH RES CO, V204, P1023, DOI 10.1006/bbrc.1994.2565; CAPLEN NJ, 1995, NAT MED, V1, P39, DOI 10.1038/nm0195-39; Choate KA, 1997, HUM GENE THER, V8, P1659, DOI 10.1089/hum.1997.8.14-1659; Coates CJ, 1998, P NATL ACAD SCI USA, V95, P3748, DOI 10.1073/pnas.95.7.3748; Gordon Erlinda M., 1994, Current Opinion in Biotechnology, V5, P611, DOI 10.1016/0958-1669(94)90083-3; Hartl DL, 1997, TRENDS GENET, V13, P197, DOI 10.1016/S0168-9525(97)01087-1; Hernandez YJ, 1999, J VIROL, V73, P8549, DOI 10.1128/JVI.73.10.8549-8558.1999; Ivics Z, 1997, CELL, V91, P501, DOI 10.1016/S0092-8674(00)80436-5; Kafri T, 1997, NAT GENET, V17, P314, DOI 10.1038/ng1197-314; KAY MA, 1995, HEPATOLOGY, V21, P815, DOI 10.1002/hep.1840210331; Kay MA, 1997, P NATL ACAD SCI USA, V94, P4686, DOI 10.1073/pnas.94.9.4686; KAY MA, 1993, SCIENCE, V262, P117, DOI 10.1126/science.8211118; Kay MA, 1997, MOL MED TODAY, V3, P108, DOI 10.1016/S1357-4310(96)10062-9; Koeberl DD, 1997, P NATL ACAD SCI USA, V94, P1426, DOI 10.1073/pnas.94.4.1426; Kovesdi I, 1997, CURR OPIN BIOTECH, V8, P583, DOI 10.1016/S0958-1669(97)80033-X; Lampe DJ, 1996, EMBO J, V15, P5470, DOI 10.1002/j.1460-2075.1996.tb00930.x; Lampe DJ, 1998, GENETICS, V149, P179; Latchman David S., 1994, Molecular Biotechnology, V2, P179, DOI 10.1007/BF02824809; Li K, 1997, J MOL CELL CARDIOL, V29, P1499, DOI 10.1006/jmcc.1997.0389; Lieber A, 1996, J VIROL, V70, P8944, DOI 10.1128/JVI.70.12.8944-8960.1996; Lin HF, 1997, BLOOD, V90, P3962, DOI 10.1182/blood.V90.10.3962; Liu F, 1999, GENE THER, V6, P1258, DOI 10.1038/sj.gt.3300947; Lohe AR, 1997, P NATL ACAD SCI USA, V94, P1293, DOI 10.1073/pnas.94.4.1293; Lohe AR, 1996, GENETICS, V144, P1087; Luo GB, 1998, P NATL ACAD SCI USA, V95, P10769, DOI 10.1073/pnas.95.18.10769; Miao CH, 1998, NAT GENET, V19, P13, DOI 10.1038/ng0598-13; Miao CH, 2000, J VIROL, V74, P3793, DOI 10.1128/JVI.74.8.3793-3803.2000; Mumper RJ, 1996, PHARMACEUT RES, V13, P701, DOI 10.1023/A:1016039330870; Nakai H, 1999, J VIROL, V73, P5438, DOI 10.1128/JVI.73.7.5438-5447.1999; Naldini L, 1998, CURR OPIN BIOTECH, V9, P457, DOI 10.1016/S0958-1669(98)80029-3; Park F, 2000, NAT GENET, V24, P49, DOI 10.1038/71673; PERALES JC, 1994, EUR J BIOCHEM, V226, P255, DOI 10.1111/j.1432-1033.1994.tb20049.x; Plasterk RHA, 1999, TRENDS GENET, V15, P326, DOI 10.1016/S0168-9525(99)01777-1; Plasterk RHA, 1996, CURR TOP MICROBIOL, V204, P125; Rabinowitz JE, 1998, CURR OPIN BIOTECH, V9, P470, DOI 10.1016/S0958-1669(98)80031-1; Raz E, 1998, CURR BIOL, V8, P82, DOI 10.1016/S0960-9822(98)70038-7; REINER AP, 1995, METABOLIC MOL BASIS; Rutledge EA, 1997, J VIROL, V71, P8429, DOI 10.1128/JVI.71.11.8429-8436.1997; Schouten GJ, 1998, NUCLEIC ACIDS RES, V26, P3013, DOI 10.1093/nar/26.12.3013; Sherman A, 1998, NAT BIOTECHNOL, V16, P1050, DOI 10.1038/3497; Snyder RO, 1999, NAT MED, V5, P64, DOI 10.1038/4751; Vos JC, 1996, GENE DEV, V10, P755, DOI 10.1101/gad.10.6.755; Walter J, 1996, P NATL ACAD SCI USA, V93, P3056, DOI 10.1073/pnas.93.7.3056; WOLFF JA, 1990, SCIENCE, V247, P1465, DOI 10.1126/science.1690918; Xiao WD, 1998, J VIROL, V72, P10222, DOI 10.1128/JVI.72.12.10222-10226.1998; YANG YP, 1995, J VIROL, V69, P2004, DOI 10.1128/JVI.69.4.2004-2015.1995; Yew NS, 1997, HUM GENE THER, V8, P575, DOI 10.1089/hum.1997.8.5-575; Zhang GF, 1999, HUM GENE THER, V10, P1735, DOI 10.1089/10430349950017734; Zhang LN, 1998, NUCLEIC ACIDS RES, V26, P3687, DOI 10.1093/nar/26.16.3687; Zhu JD, 1999, HUM GENE THER, V10, P113, DOI 10.1089/10430349950019246	50	403	444	0	21	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAY	2000	25	1					35	41		10.1038/75568	http://dx.doi.org/10.1038/75568			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	311KU	10802653				2022-12-25	WOS:000086884000013
J	Bodmer, JL; Holler, N; Reynard, S; Vinciguerra, P; Schneider, P; Juo, P; Blenis, J; Tschopp, J				Bodmer, JL; Holler, N; Reynard, S; Vinciguerra, P; Schneider, P; Juo, P; Blenis, J; Tschopp, J			TRAIL receptor-2 signals apoptosis through FADD and caspase-8	NATURE CELL BIOLOGY			English	Article							CYTOTOXIC LIGAND TRAIL; IDENTIFICATION; PROTEINS; FAMILY; FORM		Univ Lausanne, Inst Biochem, BIL Biomed Res Ctr, CH-1066 Epalinges, Switzerland; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA	University of Lausanne; Harvard University; Harvard Medical School	Tschopp, J (corresponding author), Univ Lausanne, Inst Biochem, BIL Biomed Res Ctr, Chemin des Boveresses 155, CH-1066 Epalinges, Switzerland.		Juo, Peter/CJY-3695-2022	Juo, Peter/0000-0002-3039-2266; Schneider, Pascal/0000-0003-0677-9409				Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; BORDIER C, 1981, J BIOL CHEM, V256, P1604; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Juo P, 1999, CELL GROWTH DIFFER, V10, P797; Juo P, 1998, CURR BIOL, V8, P1001, DOI 10.1016/S0960-9822(07)00420-4; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; MacFarlane M, 1997, J BIOL CHEM, V272, P25417, DOI 10.1074/jbc.272.41.25417; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Schneider P, 1997, IMMUNITY, V7, P831, DOI 10.1016/S1074-7613(00)80401-X; Schneider P, 1997, FEBS LETT, V416, P329, DOI 10.1016/S0014-5793(97)01231-3; Schneider P, 1998, J EXP MED, V187, P1205, DOI 10.1084/jem.187.8.1205; Screaton GR, 1997, CURR BIOL, V7, P693, DOI 10.1016/S0960-9822(06)00297-1; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; Wajant H, 1998, CURR BIOL, V8, P113, DOI 10.1016/S0960-9822(98)70042-9; Walczak H, 1997, EMBO J, V16, P5386, DOI 10.1093/emboj/16.17.5386; Wang J, 1999, CELL, V98, P47, DOI 10.1016/S0092-8674(00)80605-4; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954	19	569	602	0	17	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	APR	2000	2	4					241	243		10.1038/35008667	http://dx.doi.org/10.1038/35008667			3	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	302ZU	10783243				2022-12-25	WOS:000086397000018
J	Boorsma, M; Nieba, L; Koller, D; Bachmann, MF; Bailey, JE; Renner, WA				Boorsma, M; Nieba, L; Koller, D; Bachmann, MF; Bailey, JE; Renner, WA			A temperature-regulated replicon-based DNA expression system	NATURE BIOTECHNOLOGY			English	Article						temperature-inducible gene expression; Sindbis virus; alphavirus; DNA vector; stable expression; toxic protein	INDUCIBLE GENE-EXPRESSION; SINDBIS-VIRUS; MAMMALIAN-CELLS; TRANSGENIC MICE; VECTORS; RNA; ALPHAVIRUSES; TRANSLATION	We present a temperature-regulated, alphavirus replicon-based DNA expression system. The system is regulated by a viral temperature-sensitive RNA-dependent RNA replicase, creating a temperature-dependent RNA amplification loop. Because of this positive feedback, the system exhibits both low background and high inducibility. We observed 700-fold induction in transiently transfected cells, and over 10(4)-fold induction in stably transfected cells. The high stringency of inducibility allowed the generation of stable cell lines expressing a highly toxic protein upon temperature shift. These data suggest that the present expression system could simplify bioprocess engineering strategies, especially in situations where the cloned protein has detrimental effects on host cell metabolism.	Cytos Biotechnol AG, CH-8952 Zurich, Switzerland; ETH Zurich, Inst Biotechnol, CH-8093 Zurich, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich	Renner, WA (corresponding author), Cytos Biotechnol AG, Wagistr 21, CH-8952 Zurich, Switzerland.		Taylor, Graham/A-4027-2012					Agapov EV, 1998, P NATL ACAD SCI USA, V95, P12989, DOI 10.1073/pnas.95.22.12989; BERGER J, 1988, GENE, V66, P1, DOI 10.1016/0378-1119(88)90219-3; Berglund P, 1996, TRENDS BIOTECHNOL, V14, P130, DOI 10.1016/0167-7799(96)10019-6; BREDENBEEK PJ, 1993, J VIROL, V67, P6439, DOI 10.1128/JVI.67.11.6439-6446.1993; CREGG JM, 1993, BIO-TECHNOL, V11, P905, DOI 10.1038/nbt0893-905; Dryga SA, 1997, VIROLOGY, V228, P74, DOI 10.1006/viro.1996.8364; Dubensky TW, 1996, J VIROL, V70, P508, DOI 10.1128/JVI.70.1.508-519.1996; FROLOV I, 1994, J VIROL, V68, P8111, DOI 10.1128/JVI.68.12.8111-8117.1994; Fussenegger M, 1998, NAT BIOTECHNOL, V16, P468, DOI 10.1038/nbt0598-468; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; HAHN YS, 1989, J VIROL, V63, P1194, DOI 10.1128/JVI.63.3.1194-1202.1989; HERWEIJER, 1995, HUM GENE THER, V6, P1495; Jordan M, 1996, NUCLEIC ACIDS RES, V24, P596, DOI 10.1093/nar/24.4.596; LILJESTROM P, 1991, BIO-TECHNOL, V9, P1356, DOI 10.1038/nbt1291-1356; Liljestrom Peter, 1994, Current Opinion in Biotechnology, V5, P495, DOI 10.1016/0958-1669(94)90063-9; Makrides SC, 1996, MICROBIOL REV, V60, P512, DOI 10.1128/MMBR.60.3.512-538.1996; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; No D, 1996, P NATL ACAD SCI USA, V93, P3346, DOI 10.1073/pnas.93.8.3346; Rossi FMV, 1998, CURR OPIN BIOTECH, V9, P451, DOI 10.1016/S0958-1669(98)80028-1; Saez E, 1997, CURR OPIN BIOTECH, V8, P608, DOI 10.1016/S0958-1669(97)80037-7; SCHLESINGER S, 1993, TRENDS BIOTECHNOL, V11, P18, DOI 10.1016/0167-7799(93)90070-P; SJOBERG EM, 1994, BIO-TECHNOL, V12, P1127, DOI 10.1038/nbt1194-1127; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; STRAUSS JH, 1994, MICROBIOL REV, V58, P491, DOI 10.1128/MMBR.58.3.491-562.1994; Umana P, 1999, NAT BIOTECHNOL, V17, P176, DOI 10.1038/6179; XIONG C, 1989, SCIENCE, V243, P1188, DOI 10.1126/science.2922607	26	68	76	1	3	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	APR	2000	18	4					429	432		10.1038/74493	http://dx.doi.org/10.1038/74493			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	303UY	10748525				2022-12-25	WOS:000086444300027
J	Thurston, G; Rudge, JS; Ioffe, E; Zhou, H; Ross, L; Croll, SD; Glazer, N; Holash, J; McDonald, DM; Yancopoulos, GD				Thurston, G; Rudge, JS; Ioffe, E; Zhou, H; Ross, L; Croll, SD; Glazer, N; Holash, J; McDonald, DM; Yancopoulos, GD			Angiopoietin-1 protects the adult vasculature against plasma leakage	NATURE MEDICINE			English	Article							ENDOTHELIAL GROWTH-FACTOR; PERMEABILITY FACTOR; ADENOVIRUS VECTORS; TRANSGENIC MICE; TIE2 RECEPTOR; ANGIOGENESIS; GENE; SKIN; HYPERPERMEABILITY; VASCULOGENESIS	Pathological increases in vascular leakage lead to edema and swelling, causing serious problems in brain tumors, in diabetic retinopathy, after strokes, during sepsis and also in inflammatory conditions such as rheumatoid arthritis and asthma. Although many agents and disease processes increase vascular leakage, no known agent specifically makes vessels resistant to leaking. Vascular endothelial growth factor(1) (VEGF) and the angiopoietins(2) function together during vascular development, with VEGF acting early during vessel formation(3-5), and angiopoietin-1 acting later during vessel remodeling, maturation and stabilization(6-9). Although VEGF was initially called vascular permeability factor(10,11), there has been less focus on its permeability actions and more effort devoted to its involvement in vessel growth and applications in ischemia and cancer. Recent transgenic approaches have confirmed the profound permeability effects of VEGF (refs. 12-14), and have shown that transgenic angiopoietin-1 acts reciprocally as an anti-permeability factor when provided chronically during vessel formation(14) although it also profoundly affects vascular morphology when thus delivered(14,15). To be useful clinically angiopoietin-1 would have to inhibit leakage when acutely administered to adult vessels, and this action would have to be uncoupled from its profound angiogenic capabilities. Here we show that acute administration of angiopoietin-1 does indeed protect adult vasculature from leaking, countering the potentially lethal actions of VEGF and inflammatory agents.	Regeneron Pharmaceut Inc, Tarrytown, NY 10591 USA; Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA	Regeneron; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Thurston, G (corresponding author), Regeneron Pharmaceut Inc, 777 Old Saw Mill River Rd, Tarrytown, NY 10591 USA.			Croll, Susan/0000-0002-3949-1877; Thurston, Gavin/0000-0002-4105-5919; Glazer, Nicole/0000-0002-6397-609X	NHLBI NIH HHS [HL59157, HL24136] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059157, P01HL024136] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BERKNER KL, 1988, BIOTECHNIQUES, V6, P616; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; COLLINS PD, 1993, BRIT J PHARMACOL, V109, P195, DOI 10.1111/j.1476-5381.1993.tb13553.x; Davis S, 1996, CELL, V87, P1161, DOI 10.1016/S0092-8674(00)81812-7; Davis S, 1999, CURR TOP MICROBIOL, V237, P173; Detmar M, 1998, J INVEST DERMATOL, V111, P1, DOI 10.1046/j.1523-1747.1998.00262.x; DUMONT DJ, 1994, GENE DEV, V8, P1897, DOI 10.1101/gad.8.16.1897; Dvorak HF, 1999, CURR TOP MICROBIOL, V237, P97; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; Ferrara N, 1999, CURR TOP MICROBIOL, V237, P1; Hehir KM, 1996, J VIROL, V70, P8459, DOI 10.1128/JVI.70.12.8459-8467.1996; HERZ J, 1993, P NATL ACAD SCI USA, V90, P2812, DOI 10.1073/pnas.90.7.2812; JANCSO G, 1993, AGENTS ACTIONS, V39, P31, DOI 10.1007/BF01975711; Larcher F, 1998, ONCOGENE, V17, P303, DOI 10.1038/sj.onc.1201928; LIPPE IT, 1993, EUR J PHARMACOL, V232, P113, DOI 10.1016/0014-2999(93)90735-Z; MASSIE B, 1986, MOL CELL BIOL, V6, P2872, DOI 10.1128/MCB.6.8.2872; Muzzin P, 1996, P NATL ACAD SCI USA, V93, P14804, DOI 10.1073/pnas.93.25.14804; SATO TN, 1995, NATURE, V376, P70, DOI 10.1038/376070a0; SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9; Suri C, 1998, SCIENCE, V282, P468, DOI 10.1126/science.282.5388.468; Thurston G, 1996, AM J PHYSIOL-HEART C, V271, pH2547, DOI 10.1152/ajpheart.1996.271.6.H2547; Thurston G, 1999, SCIENCE, V286, P2511, DOI 10.1126/science.286.5449.2511; WILLNOW TE, 1994, SCIENCE, V264, P1471, DOI 10.1126/science.7515194	25	1019	1113	2	48	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	APR	2000	6	4					460	463		10.1038/74725	http://dx.doi.org/10.1038/74725			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	376UA	10742156				2022-12-25	WOS:000165474100043
J	Cutrona, G; Carpaneto, EM; Ulivi, M; Roncella, S; Landt, O; Ferrarini, M; Boffa, LC				Cutrona, G; Carpaneto, EM; Ulivi, M; Roncella, S; Landt, O; Ferrarini, M; Boffa, LC			Effects in live cells of a c-myc anti-gene PNA linked to a nuclear localization signal	NATURE BIOTECHNOLOGY			English	Article						peptide nucleic acid (PNA); anti-gene; nuclear localization signal (NLS) peptide; c-myc; lymphomas	LYMPHOMA CELLS; ACIDS PNA; PEPTIDE; DNA; STABILITY; INVASION; SEQUENCE; TRANSCRIPTION; LOCATION; BINDING	Peptide nucleic acids (PNA) are synthetic homologs of nucleic acids in which the phosphate-sugar polynucleotide backbone is replaced by a flexible polyamide. In this study, a PNA construct was employed as an anti-gene agent in intact cells in culture. The cell lines studied were derived from Burkitt's lymphomas (BL) that presented a translocated and hyperexpressed c-myc oncogene. A 17-mer anti-myc PNA, complementary to a unique sequence located at the beginning of the second exon of the oncogene, and was covalently linked at its N terminus to a nuclear localization signal (NLS) (PNA-myc(wt)-NLS). When BL cells were exposed to PNA-myc(wt)-NLS, the anti-gene construct was localized predominantly in the cell nuclei and a rapid consequent downregulation of c-myc expression occurred. Under these conditions, both completion of a productive cell cycle and apoptosis were inhibited.	Natl Canc Inst, Serv Oncol Sperimentale, Genoa, Italy; Natl Canc Inst, Serv Immunol Clin, Genoa, Italy; Osped St Andrea, Serv Anat Patol, La Spezia, Italy; TIB MOLBIOL, D-10829 Berlin, Germany; Univ Genoa, Dipartimento Oncol Biol & Genet, Genoa, Italy	University of Genoa	Boffa, LC (corresponding author), Natl Canc Inst, Serv Oncol Sperimentale, Genoa, Italy.	boffa@hp380.ist.unige.it	Cutrona, Giovanna/I-7868-2018	Cutrona, Giovanna/0000-0002-3335-1101; Ferrarini, Manlio/0000-0002-6154-2570				ABE M, 1988, CANCER, V61, P483, DOI 10.1002/1097-0142(19880201)61:3<483::AID-CNCR2820610313>3.0.CO;2-L; AUSUBEL FM, 1994, CURRENT PROTOCOLS MO, V1, P492; Bentin T, 1996, BIOCHEMISTRY-US, V35, P8863, DOI 10.1021/bi960436k; BIRD RC, 1994, CELL BIOL LAB HDB, P278; Boffa LC, 1996, J BIOL CHEM, V271, P13228, DOI 10.1074/jbc.271.22.13228; Boffa LC, 1997, ONCOL RES, V9, P41; BOFFA LC, 1995, P NATL ACAD SCI USA, V92, P1901, DOI 10.1073/pnas.92.6.1901; Branden LJ, 1999, NAT BIOTECHNOL, V17, P784, DOI 10.1038/11726; CLEMENTS GB, 1975, INT J CANCER, V16, P125, DOI 10.1002/ijc.2910160114; COLLEDGE WH, 1986, MOL CELL BIOL, V6, P4136, DOI 10.1128/MCB.6.11.4136; CUTRONA G, 1995, J EXP MED, V181, P699, DOI 10.1084/jem.181.2.699; DEMIDOV VV, 1994, BIOCHEM PHARMACOL, V48, P1310, DOI 10.1016/0006-2952(94)90171-6; EGHOLM M, 1993, NATURE, V365, P566, DOI 10.1038/365566a0; EGHOLM M, 1992, J AM CHEM SOC, V114, P1895, DOI 10.1021/ja00031a062; FRIED J, 1978, J HISTOCHEM CYTOCHEM, V26, P921, DOI 10.1177/26.11.82573; Gangamani BP, 1997, BIOCHEM BIOPH RES CO, V240, P778, DOI 10.1006/bbrc.1997.7745; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; Gray GD, 1997, BIOCHEM PHARMACOL, V53, P1465, DOI 10.1016/S0006-2952(97)82440-9; GRAZIN C, 1984, EMBO J, V3, P383; HANVEY JC, 1992, SCIENCE, V258, P1481, DOI 10.1126/science.1279811; HUEBER AO, 1998, SCIENCE, V278, P1205; Hyrup B, 1996, BIOORGAN MED CHEM, V4, P5, DOI 10.1016/0968-0896(95)00171-9; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; Magrath I, 1990, Adv Cancer Res, V55, P133, DOI 10.1016/S0065-230X(08)60470-4; MAKY LA, 1987, BIOPOLYMERS, V26, P1601; Pooga M, 1998, NAT BIOTECHNOL, V16, P857, DOI 10.1038/nbt0998-857; Roncella S, 1996, BLOOD, V88, P599, DOI 10.1182/blood.V88.2.599.bloodjournal882599; Saphire ACS, 1998, J BIOL CHEM, V273, P29764, DOI 10.1074/jbc.273.45.29764; SPENCER CA, 1991, ADV CANCER RES, V56, P1; Tomac S, 1996, J AM CHEM SOC, V118, P5544, DOI 10.1021/ja960495l; Tyler BM, 1999, P NATL ACAD SCI USA, V96, P7053, DOI 10.1073/pnas.96.12.7053	31	209	221	0	24	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	MAR	2000	18	3					300	303		10.1038/73745	http://dx.doi.org/10.1038/73745			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	292AC	10700145				2022-12-25	WOS:000085771100027
J	Shackleton, S; Lloyd, DJ; Jackson, SNJ; Evans, R; Niermeijer, MF; Singh, BM; Schmidt, H; Brabant, G; Kumar, S; Durrington, PN; Gregory, S; O'Rahilly, S; Trembath, RC				Shackleton, S; Lloyd, DJ; Jackson, SNJ; Evans, R; Niermeijer, MF; Singh, BM; Schmidt, H; Brabant, G; Kumar, S; Durrington, PN; Gregory, S; O'Rahilly, S; Trembath, RC			LMNA, encoding lamin A/C, is mutated in partial lipodystrophy	NATURE GENETICS			English	Article							INTERMEDIATE FILAMENT PROTEINS; FAMILIAL PARTIAL LIPODYSTROPHY; GENE; HOMOLOGY	The lipodystrophies are a group of disorders characterized by the absence or reduction of subcutaneous adipose tissue. Partial lipodystrophy (PLD; MIM 151660) is an inherited condition in which a regional (trunk and limbs) loss of fat occurs during the peri-pubertal phase(1,2). Additionally, variable degrees of resistance to insulin action, together with a hyperlipidaemic state, may occur and simulate the metabolic features commonly associated with predisposition to atherosclerotic disease(3). The PLD locus has been mapped to chromosome 1q with no evidence of genetic heterogeneity(4). We, and others, have refined the location to a 5.3-cM interval between markers D1S305 and D1S1600 (refs 5,6). Through a positional cloning approach we have identified five different missense mutations in LMNA among ten kindreds and three individuals with PLD. The protein product of LMNA is lamin AIC, which is a component of the nuclear envelope. Heterozygous mutations in LMNA have recently been identified in kindreds with the variant form of muscular dystrophy (MD) known as autosomal dominant Emery-Dreifuss MD (EDMD-AD; ref. 7) and dilated cardiomyopathy and conduction-system diseases (CMD1A). As LMNA is ubiquitously expressed, the finding of site-specific amino acid substitutions in PLD, EDMD-AD and CMD1A reveals distinct functional domains of the lamin A/C protein required for the maintenance and integrity of different cell types.	Univ Leicester, Dept Med, Div Med Genet, Leicester, Leics, England; Univ Leicester, Dept Genet, Div Med Genet, Leicester, Leics, England; Sanger Ctr, Cambridge, England; Erasmus Univ, Dept Clin Genet, Rotterdam, Netherlands; Acad Hosp Dijkzigt, NL-3000 DR Rotterdam, Netherlands; New Cross Hosp, Ctr Diabet, Wolverhampton, England; 4 Med Klin mS Gastroenterol, Hepatol & Endokrinol, Berlin, Germany; Med Hsch Hannover, Abt Klin Endokrinol, Hannover, Germany; Univ Birmingham, Brimingham Heartlands Hosp, Div Med Sci, Birmingham B15 2TT, W Midlands, England; Univ Manchester, Manchester Royal Infirm, Dept Med, Manchester M13 9WL, Lancs, England; Univ Cambridge, Addenbrookes Hosp, Dept Med, Cambridge, England; Univ Cambridge, Addenbrookes Hosp, Dept Clin Biochem, Cambridge, England	University of Leicester; University of Leicester; Wellcome Trust Sanger Institute; Erasmus University Rotterdam; Erasmus University Rotterdam; Erasmus MC; New Cross Hospital; Hannover Medical School; Heart of England NHS Foundation Trust; University of Birmingham; University of Manchester; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge	Trembath, RC (corresponding author), Univ Leicester, Dept Med, Div Med Genet, Leicester, Leics, England.		O'Rahilly, Stephen/ABF-6509-2020; kumar, sudhesh/D-6945-2013	O'Rahilly, Stephen/0000-0003-2199-4449; Gregory, Simon/0000-0002-7805-1743; kumar, sudhesh/0000-0003-4326-5941; Trembath, Richard/0000-0003-0550-3400; Lloyd, David/0000-0001-5924-0672				Anderson JL, 1999, AM J MED GENET, V82, P161, DOI 10.1002/(SICI)1096-8628(19990115)82:2<161::AID-AJMG12>3.3.CO;2-S; Bonne G, 1999, NAT GENET, V21, P285, DOI 10.1038/6799; Cao H, 2000, HUM MOL GENET, V9, P109, DOI 10.1093/hmg/9.1.109; Coyle B, 1996, NAT GENET, V12, P421, DOI 10.1038/ng0496-421; Fatkin D, 1999, NEW ENGL J MED, V341, P1715, DOI 10.1056/NEJM199912023412302; FISHER DZ, 1986, P NATL ACAD SCI USA, V83, P6450, DOI 10.1073/pnas.83.17.6450; Garg A, 1999, J CLIN ENDOCR METAB, V84, P170, DOI 10.1210/jc.84.1.170; Gregory SG, 1997, GENOME RES, V7, P1162, DOI 10.1101/gr.7.12.1162; Jackson SNJ, 1997, QJM-INT J MED, V90, P27; Jackson SNJ, 1998, AM J HUM GENET, V63, P534, DOI 10.1086/301971; KOBBERLING J, 1986, J MED GENET, V23, P120, DOI 10.1136/jmg.23.2.120; LIN F, 1993, J BIOL CHEM, V268, P16321; MCKEON FD, 1986, NATURE, V319, P463, DOI 10.1038/319463a0; Morris GE, 1999, HUM MOL GENET, V8, P1847, DOI 10.1093/hmg/8.10.1847; Peters JM, 1998, NAT GENET, V18, P292, DOI 10.1038/ng0398-292; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; SHIZUYA H, 1992, P NATL ACAD SCI USA, V89, P8794, DOI 10.1073/pnas.89.18.8794; South AP, 1999, J INVEST DERMATOL, V112, P910, DOI 10.1046/j.1523-1747.1999.00613.x; Stuurman N, 1998, J STRUCT BIOL, V122, P42, DOI 10.1006/jsbi.1998.3987; Sullivan T, 1999, J CELL BIOL, V147, P913, DOI 10.1083/jcb.147.5.913; WOLIN SL, 1987, EMBO J, V6, P3809, DOI 10.1002/j.1460-2075.1987.tb02717.x	21	530	554	0	11	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	FEB	2000	24	2					153	156		10.1038/72807	http://dx.doi.org/10.1038/72807			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	280LQ	10655060				2022-12-25	WOS:000085104600015
J	Sblattero, D; Bradbury, A				Sblattero, D; Bradbury, A			Exploiting recombination in single bacteria to make large phage antibody libraries	NATURE BIOTECHNOLOGY			English	Article						antibody engineering; phage display; recombination; Cre recombinase; filamentous phage; single-chain Fv (scFv)	SITE-SPECIFIC RECOMBINATION; AFFINITY HUMAN-ANTIBODIES; DISPLAY LIBRARY; REPERTOIRES; SELECTION; FRAGMENTS; PROTEIN; GENE; CONSTRUCTION; IMMUNIZATION	The creation of large phage antibody libraries has become an important goal in selecting antibodies against any antigen. Here we describe a method for making libraries so large that the complete diversity cannot be accessed using traditional phage technology. This involves the creation of a primary phage scFv library in a phagemid vector containing two nonhomologous lox sites. Contrary to the current dogma, we found that infecting Ore recombinase-expressing bacteria by such a primary library at a high multiplicity of infection results in the entry of many different phagemid into the cell. Exchange of VH and VL genes between such phagemids creates many new VH/VL combinations, all of which are functional. On the basis of the observed recombination, the library is calculated to have a diversity of 3 x 10(11). A library created using this method was validated by the selection of high affinity antibodies against a large number of different protein antigens.	Int Sch Adv Studies, SISSA, Biophys Sector, I-34014 Trieste, Italy	International School for Advanced Studies (SISSA)	Bradbury, A (corresponding author), Los Alaamos Natl Lab, Div biosci, MS M888, Los Alamos, NM 87545 USA.			Sblattero, Daniele/0000-0003-4309-242X				BARBAS CF, 1991, P NATL ACAD SCI USA, V88, P7978, DOI 10.1073/pnas.88.18.7978; CLACKSON T, 1994, TRENDS BIOTECHNOL, V12, P173, DOI 10.1016/0167-7799(94)90079-5; de Bruin R, 1999, NAT BIOTECHNOL, V17, P397, DOI 10.1038/7959; de Haard HJ, 1999, J BIOL CHEM, V274, P18218, DOI 10.1074/jbc.274.26.18218; DEKRUIF J, 1995, J MOL BIOL, V248, P97, DOI 10.1006/jmbi.1995.0204; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GEOFFROY F, 1994, GENE, V151, P109, DOI 10.1016/0378-1119(94)90639-4; GRIFFITHS AD, 1994, EMBO J, V13, P3245, DOI 10.1002/j.1460-2075.1994.tb06626.x; GRIFFITHS AD, 1993, EMBO J, V12, P725, DOI 10.1002/j.1460-2075.1993.tb05706.x; HANKE T, 1992, J GEN VIROL, V73, P653, DOI 10.1099/0022-1317-73-3-653; HOESS RH, 1986, NUCLEIC ACIDS RES, V14, P2287, DOI 10.1093/nar/14.5.2287; HOLLIGER P, 1993, P NATL ACAD SCI USA, V90, P6444, DOI 10.1073/pnas.90.14.6444; Krebber A, 1997, J IMMUNOL METHODS, V201, P35, DOI 10.1016/S0022-1759(96)00208-6; MARIUZZA RA, 1983, J MOL BIOL, V170, P1055, DOI 10.1016/S0022-2836(83)80206-X; MARKS JD, 1991, J MOL BIOL, V222, P581, DOI 10.1016/0022-2836(91)90498-U; MARKS JD, 1992, BIO-TECHNOL, V10, P779, DOI 10.1038/nbt0792-779; NISSIM A, 1994, EMBO J, V13, P692, DOI 10.1002/j.1460-2075.1994.tb06308.x; PERELSON AS, 1979, J THEOR BIOL, V81, P645, DOI 10.1016/0022-5193(79)90275-3; Sambrook J., 2002, MOL CLONING LAB MANU; SAUER B, 1988, GENE, V70, P331, DOI 10.1016/0378-1119(88)90205-3; Sblattero D, 1998, IMMUNOTECHNOLOGY, V3, P271, DOI 10.1016/S1380-2933(97)10004-5; Schier R, 1996, J MOL BIOL, V255, P28, DOI 10.1006/jmbi.1996.0004; Schier Robert, 1996, Human Antibodies and Hybridomas, V7, P97; Sheets MD, 1998, P NATL ACAD SCI USA, V95, P6157, DOI 10.1073/pnas.95.11.6157; Tomlinson I. M., 1996, VBASE SEQUENCE DIREC; Tsurushita N, 1996, GENE, V172, P59, DOI 10.1016/0378-1119(96)00170-9; Vaughan TJ, 1996, NAT BIOTECHNOL, V14, P309, DOI 10.1038/nbt0396-309; WATERHOUSE P, 1993, NUCLEIC ACIDS RES, V21, P2265, DOI 10.1093/nar/21.9.2265; WERGE TM, 1992, ONCOGENE, V7, P1033	29	255	303	0	37	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JAN	2000	18	1					75	80		10.1038/71958	http://dx.doi.org/10.1038/71958			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	273GQ	10625396				2022-12-25	WOS:000084699900030
J	Chattergoon, MA; Kim, JJ; Yang, JS; Robinson, TM; Lee, DJ; Dentchev, T; Wilson, DM; Ayyavoo, V; Weiner, DB				Chattergoon, MA; Kim, JJ; Yang, JS; Robinson, TM; Lee, DJ; Dentchev, T; Wilson, DM; Ayyavoo, V; Weiner, DB			Targeted antigen delivery to antigen-presenting cells including dendritic cells by engineered Fas-mediated apoptosis	NATURE BIOTECHNOLOGY			English	Article						dendritic cells; apoptosis; Fas; cytotoxic T-lymphocytes; vaccines	VIVO IMMUNE-RESPONSES; IN-VIVO; T-CELLS; EXOGENOUS ANTIGEN; INDUCTION; IMMUNIZATION; EXPRESSION; CHEMOKINES; DANGER	Immunity to tumors as well as to viral and bacterial pathogens is often mediated by cytotoxic T lymphocytes (CTLs), Thus, the ability to induce a strong cell-mediated immune response is an important requirement of novel immunotherapies, Antigen-presenting cells (APCs), including dendritic cells (DCs), are specialized in initiating T-cell immunity. Harnessing this innate ability of these cells to acquire and present antigens, we sought to improve antigen presentation by targeting antigens directly to DCs in vivo through apoptosis. We engineered Fas-mediated apoptotic death of antigen-bearing cells in vivo by cc-expressing the immunogen and Fas in the same cell. We then observed that the death of antigen-bearing cells results in increased antigen acquisition by APCs including DCs. This in vivo strategy led to enhanced antigen-specific CTLs, and the elaboration of T helper-1 (Th1) type cytokines and chemokines. This adjuvant approach has important implications for viral and nonviral delivery strategies for vaccines or gene therapies.	Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA	University of Pennsylvania	Weiner, DB (corresponding author), Univ Penn, Sch Med, Dept Pathol & Lab Med, 422 Curie Blvd, Philadelphia, PA 19104 USA.	dbweiner@mail.med.upenn.edu	Weiner, David B/H-8579-2014					Agadjanyan MG, 1999, J IMMUNOL, V162, P3417; Albert ML, 1998, NATURE, V392, P86, DOI 10.1038/32183; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Celluzzi CM, 1996, J EXP MED, V183, P283, DOI 10.1084/jem.183.1.283; Chattergoon MA, 1998, J IMMUNOL, V160, P5707; CONEY L, 1994, VACCINE, V12, P1545, DOI 10.1016/0264-410X(94)90082-5; Gallucci S, 1999, NAT MED, V5, P1249, DOI 10.1038/15200; Hsu FJ, 1996, NAT MED, V2, P52, DOI 10.1038/nm0196-52; JANEWAY CA, 1992, IMMUNOL TODAY, V13, P11, DOI 10.1016/0167-5699(92)90198-G; Kim JJ, 1999, J CLIN INVEST, V103, P869, DOI 10.1172/JCI6024; Kim JJ, 1997, NAT BIOTECHNOL, V15, P641; Kim JJ, 1998, ONCOGENE, V17, P3125, DOI 10.1038/sj.onc.1201736; Kim JJ, 1998, EUR J IMMUNOL, V28, P1089, DOI 10.1002/(SICI)1521-4141(199803)28:03<1089::AID-IMMU1089>3.0.CO;2-L; Kim JJ, 1998, J CLIN INVEST, V102, P1112, DOI 10.1172/JCI3986; Matzinger P, 1998, SEMIN IMMUNOL, V10, P399, DOI 10.1006/smim.1998.0143; MATZINGER P, 1994, ANNU REV IMMUNOL, V12, P991, DOI 10.1146/annurev.immunol.12.1.991; Mayordomo JI, 1997, STEM CELLS, V15, P94, DOI 10.1002/stem.150094; Mitchell DA, 1998, EUR J IMMUNOL, V28, P1923, DOI 10.1002/(SICI)1521-4141(199806)28:06<1923::AID-IMMU1923>3.0.CO;2-9; Mogensen S C, 1987, Interferon, V8, P55; Murphy G, 1996, PROSTATE, V29, P371; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; Nestle FO, 1998, NAT MED, V4, P328, DOI 10.1038/nm0398-328; Porgador A, 1998, J EXP MED, V188, P1075, DOI 10.1084/jem.188.6.1075; Porgador A, 1996, J IMMUNOL, V156, P2918; SEDER RA, 1994, ANNU REV IMMUNOL, V12, P635, DOI 10.1146/annurev.iy.12.040194.003223; SHIRAI M, 1992, J IMMUNOL, V148, P1657; Sigal LJ, 1999, NATURE, V398, P77, DOI 10.1038/18038; TAKAHASHI H, 1992, SCIENCE, V255, P333, DOI 10.1126/science.1372448; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; VIGNAUX F, 1995, J EXP MED, V181, P781, DOI 10.1084/jem.181.2.781	30	102	115	2	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	SEP	2000	18	9					974	979		10.1038/79470	http://dx.doi.org/10.1038/79470			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	350AN	10973219				2022-12-25	WOS:000089078300027
J	de Angelis, MH; Flaswinkel, H; Fuchs, H; Rathkolb, B; Soewarto, D; Marschall, S; Heffner, S; Pargent, W; Wuensch, K; Jung, M; Reis, A; Richter, T; Alessandrini, F; Jakob, T; Fuchs, E; Kolb, H; Kremmer, E; Schaeble, K; Rollinski, B; Roscher, A; Peters, C; Meitinger, T; Strom, T; Steckler, T; Holsboer, F; Klopstock, T; Gekeler, F; Schindewolf, C; Jung, T; Avraham, K; Behrendt, H; Ring, J; Zimmer, A; Schughart, K; Pfeffer, K; Wolf, E; Balling, R				de Angelis, MH; Flaswinkel, H; Fuchs, H; Rathkolb, B; Soewarto, D; Marschall, S; Heffner, S; Pargent, W; Wuensch, K; Jung, M; Reis, A; Richter, T; Alessandrini, F; Jakob, T; Fuchs, E; Kolb, H; Kremmer, E; Schaeble, K; Rollinski, B; Roscher, A; Peters, C; Meitinger, T; Strom, T; Steckler, T; Holsboer, F; Klopstock, T; Gekeler, F; Schindewolf, C; Jung, T; Avraham, K; Behrendt, H; Ring, J; Zimmer, A; Schughart, K; Pfeffer, K; Wolf, E; Balling, R			Genome-wide, large-scale production of mutant mice by ENU mutagenesis	NATURE GENETICS			English	Article							MOUSE; SPERMATOZOA	In the post-genome era, the mouse will have a major role as a model system for functional genome analysis. This requires a large number of mutants similar to the collections available from other model organisms such as Drosophila melanogaster and Caenorhabditis elegans. Here we report on a systematic, genome-wide, mutagenesis screen in mice. As part of the German Human Genome Project, we have undertaken a large-scale ENU-mutagenesis screen for dominant mutations and a limited screen for recessive mutations'. In screening over 14,000 mice for a large number of clinically relevant parameters, we recovered 182 mouse mutants for a variety of phenotypes. In addition, 247 variant mouse mutants are currently in genetic confirmation testing and will result in additional new mutant lines. This mutagenesis screen, along with the screen described in the accompanying paper(2), leads to a significant increase in the number of mouse models(3) available to the scientific community. Our mutant lines are freely accessible to non-commercial users (for information, see http://www.gsf.de/ieg/groups/enu-mouse.html).	GSF, Res Ctr Environm & Hlth, Inst Expt Genet, Neuherberg, Germany; GSF, Res Ctr Environm & Hlth, Inst Pathol, Neuherberg, Germany; GSF, Res Ctr Environm & Hlth, Inst Immunol, Neuherberg, Germany; GSF, Res Ctr Environm & Hlth, Inst Mammalian Genet, Neuherberg, Germany; Tech Univ Munich, Inst Med Microbiol Immunol & Hyg, Munich, Germany; Univ Munich, Gene Ctr, Inst Mol Anim Breeding, Munich, Germany; Ingenium Pharmaceut AG, Martinsried, Germany; Max Delbrueck Ctr, Mol Genet & Mikrosatellitenzentrum, Berlin, Germany; GSF Munich, TUM, Div Environm Dermatol & Allergol, Munich, Germany; Clin Harlaching, Inst Clin Chem, Munich, Germany; Dr Von Haunerschen Kinderspital, Kinderklin, Abt Klin Chem Biochem & Stoffwechsel, Munich, Germany; Dr Von Haunerschen Kinderspital, Kinderpoliklin, Munich, Germany; Univ Klin Freiburg, Freiburg, Germany; Univ Munich, Klinikum Grosshadern, Dept Neurobiol, Munich, Germany; Univ Munich, Kinderklin, Abt Med Genet, Munich, Germany; Max Planck Inst Psychiat, D-80804 Munich, Germany; Bundesamt Strahlenschutz, Inst Strahlenhyg, Oberschleissheim, Germany; Tel Aviv Univ, Sackler Sch Med, Dept Human Genet, Tel Aviv, Israel; NIMH, Genet Lab, Bethesda, MD USA; Transgene SA, Strasbourg, France	Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Technical University of Munich; University of Munich; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Technical University of Munich; Munchen Klinik; University of Munich; University of Munich; University of Freiburg; University of Munich; University of Munich; Max Planck Society; Tel Aviv University; Sackler Faculty of Medicine; National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); Transgene SA	de Angelis, MH (corresponding author), GSF, Res Ctr Environm & Hlth, Inst Expt Genet, Neuherberg, Germany.	hrabe@gsf.de	Balling, Rudi/E-9680-2010; de Angelis, Martin Hrabe/F-5531-2012; Reis, André/D-2309-2009; Zimmer, Andreas/B-8357-2009; Meitinger, Thomas/O-1318-2015; Fuchs, Helmut/M-7347-2014; Ring, Johannes/GLN-4341-2022; Steckler, Thomas/AAF-3975-2020; Jakob, Thilo/J-1621-2012; Rathkolb, Birgit/F-7041-2013	Balling, Rudi/0000-0003-2902-5650; de Angelis, Martin Hrabe/0000-0002-7898-2353; Reis, André/0000-0002-6301-6363; Fuchs, Helmut/0000-0002-5143-2677; Ring, Johannes/0000-0001-8236-3152; Schughart, Klaus/0000-0002-6824-7523; Meitinger, Thomas/0000-0002-8838-8403; Pfeffer, Klaus/0000-0002-5652-6330; Wolf, Eckhard/0000-0002-0430-9510; Avraham, Karen B/0000-0002-4913-251X				Ahearn JM, 1996, IMMUNITY, V4, P251, DOI 10.1016/S1074-7613(00)80433-1; Brown SDM, 1996, TRENDS GENET, V12, P433, DOI 10.1016/0168-9525(96)30094-2; de Angelis MH, 1998, MUTAT RES-FUND MOL M, V400, P25, DOI 10.1016/S0027-5107(98)00061-X; Graw J, 1999, GENOMICS, V62, P67, DOI 10.1006/geno.1999.5974; Justice MJ, 1999, HUM MOL GENET, V8, P1955, DOI 10.1093/hmg/8.10.1955; Marschall S, 1999, TRENDS GENET, V15, P128, DOI 10.1016/S0168-9525(99)01715-1; Marschall S, 1999, MAMM GENOME, V10, P773, DOI 10.1007/s003359901090; Molina H, 1996, P NATL ACAD SCI USA, V93, P3357, DOI 10.1073/pnas.93.8.3357; Nolan PM, 1997, METHODS, V13, P379, DOI 10.1006/meth.1997.0545; Nolan PM, 2000, NAT GENET, V25, P440, DOI 10.1038/78140; RUSSELL WL, 1979, P NATL ACAD SCI USA, V76, P5918; Spickett GP, 1997, IMMUNOL TODAY, V18, P325, DOI 10.1016/S0167-5699(97)01086-4; WHYTE MP, 1979, MEDICINE, V58, P329, DOI 10.1097/00005792-197909000-00001	13	518	527	0	25	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	AUG	2000	25	4					444	447		10.1038/78146	http://dx.doi.org/10.1038/78146			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	341WY	10932192				2022-12-25	WOS:000088615000023
J	Soderlind, E; Strandberg, L; Jirholt, P; Kobayashi, N; Alexeiva, V; Aberg, AM; Nilsson, A; Jansson, B; Ohlin, M; Wingren, C; Danielsson, L; Carlsson, R; Borrebaeck, CAK				Soderlind, E; Strandberg, L; Jirholt, P; Kobayashi, N; Alexeiva, V; Aberg, AM; Nilsson, A; Jansson, B; Ohlin, M; Wingren, C; Danielsson, L; Carlsson, R; Borrebaeck, CAK			Recombining germline-derived CDR sequences for creating diverse single-framework antibody libraries	NATURE BIOTECHNOLOGY			English	Article						antibody engineering; recombination; diversity; in vitro evolution	PHAGE-DISPLAY LIBRARY; BY-PASSING IMMUNIZATION; SYNTHETIC REPERTOIRES; ANTIGEN INTERACTIONS; IN-VIVO; AFFINITY; FRAGMENTS; GENES; SELECTION; REGIONS	We constructed a single-chain Fv antibody library that permits human complementarity-determining region (CDR) gene fragments of any germline to be incorporated combinatorially into the appropriate positions of the variable-region frameworks VH-DP47 and VL-DPL3. A library of 2 x 10(9) independent transformants was screened against haptens, peptides, carbohydrates, and proteins, and the selected antibody fragments exhibited dissociation constants in the subnanomolar range. The antibody genes in this library were built on a single master framework into which diverse CDRs were allowed to recombine, These CDRs were sampled from in vivo-processed gene sequences, thus potentially optimizing the levels of correctly folded and functional molecules, and resulting in a molecule exhibiting a lower computed immunogenicity compared to naive immunoglobulins. Using the modularized assembly process to incorporate foreign sequences into an immunoglobulin scaffold, it is possible to vary as many as six CDRs at the same time, creating genetic and functional variation in antibody molecules.	BioInvent Therapeut AB, SE-22370 Lund, Sweden; Lund Univ, Dept Immunotechnol, SE-22007 Lund, Sweden	Lund University	Soderlind, E (corresponding author), BioInvent Therapeut AB, SE-22370 Lund, Sweden.	es@bioinvent.com	Ohlin, Mats/A-7307-2010	Ohlin, Mats/0000-0002-5105-1938				BARBAS CF, 1992, P NATL ACAD SCI USA, V89, P4457, DOI 10.1073/pnas.89.10.4457; BARBAS CF, 1991, P NATL ACAD SCI USA, V88, P7978, DOI 10.1073/pnas.88.18.7978; Chang CCJ, 1999, NAT BIOTECHNOL, V17, P793, DOI 10.1038/11737; CLACKSON T, 1991, NATURE, V352, P624, DOI 10.1038/352624a0; Crameri A, 1998, NATURE, V391, P288, DOI 10.1038/34663; CRMAERI A, 1996, BIOTECHNIQUES, V18, P194; de Haard HJ, 1999, J BIOL CHEM, V274, P18218, DOI 10.1074/jbc.274.26.18218; de Wildt RMT, 1999, J MOL BIOL, V285, P895, DOI 10.1006/jmbi.1998.2396; DEKRUIF J, 1995, J MOL BIOL, V248, P97, DOI 10.1006/jmbi.1995.0204; Ditzel HJ, 1996, J IMMUNOL, V157, P739; Engberg J, 1996, MOL BIOTECHNOL, V6, P287, DOI 10.1007/BF02761708; FOTHERGILL J, Patent No. 59244; FRIGUET B, 1985, J IMMUNOL METHODS, V77, P305, DOI 10.1016/0022-1759(85)90044-4; GRIFFITHS AD, 1994, EMBO J, V13, P3245, DOI 10.1002/j.1460-2075.1994.tb06626.x; HAWKINS RE, 1992, J MOL BIOL, V226, P889, DOI 10.1016/0022-2836(92)90639-2; HAYASHI N, 1994, BIOTECHNIQUES, V17, P310; HERRON JN, 1989, PROTEINS, V5, P271, DOI 10.1002/prot.340050404; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; HONIG B, 1995, SCIENCE, V268, P1144, DOI 10.1126/science.7761829; HOOGENBOOM HR, 1992, J MOL BIOL, V227, P381, DOI 10.1016/0022-2836(92)90894-P; Huang SC, 1996, MOL IMMUNOL, V33, P553, DOI 10.1016/0161-5890(95)00162-X; Ignatovich O, 1997, J MOL BIOL, V268, P69, DOI 10.1006/jmbi.1997.0956; Jirholt P, 1998, GENE, V215, P471, DOI 10.1016/S0378-1119(98)00317-5; Kobayashi N, 1997, BIOTECHNIQUES, V23, P500, DOI 10.2144/97233st09; MacCallum RM, 1996, J MOL BIOL, V262, P732, DOI 10.1006/jmbi.1996.0548; Mao SL, 1999, P NATL ACAD SCI USA, V96, P6953, DOI 10.1073/pnas.96.12.6953; MARKS JD, 1991, J MOL BIOL, V222, P581, DOI 10.1016/0022-2836(91)90498-U; Meyer A, 1997, Int Rev Immunol, V15, P165, DOI 10.3109/08830189709068175; Ohlin M, 1996, MOL IMMUNOL, V33, P583, DOI 10.1016/0161-5890(96)00018-1; Pallares N, 1999, EXP CLIN IMMUNOGENET, V16, P36, DOI 10.1159/000019095; Pallares N, 1998, EXP CLIN IMMUNOGENET, V15, P8, DOI 10.1159/000019054; Pini A, 1998, J BIOL CHEM, V273, P21769, DOI 10.1074/jbc.273.34.21769; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Sheets MD, 1998, P NATL ACAD SCI USA, V95, P6157, DOI 10.1073/pnas.95.11.6157; SODERLIND E, 1995, GENE, V160, P269, DOI 10.1016/0378-1119(95)00200-P; SODERLIND E, 1993, BIO-TECHNOL, V11, P503, DOI 10.1038/nbt0493-503; STEMMER WPC, 1994, NATURE, V370, P389, DOI 10.1038/370389a0; Vaughan TJ, 1996, NAT BIOTECHNOL, V14, P309, DOI 10.1038/nbt0396-309; VIRNEKAS B, 1994, NUCLEIC ACIDS RES, V22, P5600, DOI 10.1093/nar/22.25.5600; WEBSTER DM, 1994, CURR OPIN STRUC BIOL, V4, P123, DOI 10.1016/S0959-440X(94)90070-1	40	254	365	1	22	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	AUG	2000	18	8					852	856		10.1038/78458	http://dx.doi.org/10.1038/78458			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	342VX	10932154				2022-12-25	WOS:000088666800021
J	Yao, XB; Abrieu, A; Zheng, Y; Sullivan, KF; Cleveland, DW				Yao, XB; Abrieu, A; Zheng, Y; Sullivan, KF; Cleveland, DW			CENP-E forms a link between attachment of spindle microtubules to kinetochores and the mitotic checkpoint	NATURE CELL BIOLOGY			English	Article							CENTROMERE-ASSOCIATED KINESIN; CELL-CYCLE ARREST; NEWT LUNG-CELLS; CYTOPLASMIC DYNEIN; CHROMOSOME ALIGNMENT; UNATTACHED KINETOCHORES; MITOSIS; ANAPHASE; PROTEIN; MOTOR	Here we show that suppression of synthesis of the microtubule motor CENP-E (centromere-associated protein E), a component of the kinetochore corona fibres of mammalian centromeres, yields chromosomes that are chronically mono-orientated, with spindles that are flattened along the plane of the substrate. Despite apparently normal microtubule numbers and the continued presence at kinetochores of other microtubule motors, spindle poles fragment in the absence of CENP-E, which implicates this protein in delivery of components from kinetochores to poles. CENP-E represents a link between attachment of spindle microtubules and the mitotic checkpoint signalling cascade, as depletion of this motor leads to profound checkpoint activation, whereas immunoprecipitation reveals a nearly stoichiometric association of CENP-E with the checkpoint kinase BubR1 during mitosis.	Univ Calif San Diego, Ludwig Inst Canc Res, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA; Univ Wisconsin, Dept Physiol, Madison, WI 53706 USA; Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA	Ludwig Institute for Cancer Research; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of Wisconsin System; University of Wisconsin Madison; Scripps Research Institute	Cleveland, DW (corresponding author), Univ Calif San Diego, Ludwig Inst Canc Res, 9500 Gilman Dr, La Jolla, CA 92093 USA.		Yao, Xuebiao/P-5771-2014; Abrieu, Ariane/G-6336-2013; Abrieu, Ariane/P-3307-2019; Cleveland, Don/AAN-9783-2021	Abrieu, Ariane/0000-0002-0942-8877; Cleveland, Don/0000-0002-1934-3682; Sullivan, Kevin/0000-0002-5374-8245	NIGMS NIH HHS [GM29513] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029513, R37GM029513] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALEXANDER SP, 1991, J CELL BIOL, V113, P805, DOI 10.1083/jcb.113.4.805; BAJER AS, 1982, J CELL BIOL, V93, P33, DOI 10.1083/jcb.93.1.33; BRINKLEY BR, 1966, CHROMOSOMA, V19, P28, DOI 10.1007/BF00332792; Brown KD, 1996, J CELL SCI, V109, P961; BROWN KD, 1994, J CELL BIOL, V125, P1303, DOI 10.1083/jcb.125.6.1303; CACERES A, 1990, NATURE, V343, P461, DOI 10.1038/343461a0; CASSIMERIS L, 1990, J CELL SCI, V96, P9; Chan GKT, 1999, J CELL BIOL, V146, P941, DOI 10.1083/jcb.146.5.941; Chan GKT, 1998, J CELL BIOL, V143, P49, DOI 10.1083/jcb.143.1.49; Chen RH, 1996, SCIENCE, V274, P242, DOI 10.1126/science.274.5285.242; Desai A, 1999, CELL, V96, P69, DOI 10.1016/S0092-8674(00)80960-5; Duesbery NS, 1997, P NATL ACAD SCI USA, V94, P9165, DOI 10.1073/pnas.94.17.9165; Echeverri CJ, 1996, J CELL BIOL, V132, P617, DOI 10.1083/jcb.132.4.617; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Fang GW, 1998, GENE DEV, V12, P1871, DOI 10.1101/gad.12.12.1871; HOYT MA, 1991, CELL, V66, P507, DOI 10.1016/0092-8674(81)90014-3; HYMAN AA, 1991, NATURE, V351, P206, DOI 10.1038/351206a0; Jablonski SA, 1998, CHROMOSOMA, V107, P386, DOI 10.1007/s004120050322; Khodjakov A, 1996, J CELL BIOL, V135, P315, DOI 10.1083/jcb.135.2.315; KILMARTIN JV, 1982, J CELL BIOL, V93, P576, DOI 10.1083/jcb.93.3.576; LI R, 1991, CELL, V66, P519, DOI 10.1016/0092-8674(81)90015-5; LI XT, 1995, NATURE, V373, P630, DOI 10.1038/373630a0; Li Y, 1996, SCIENCE, V274, P246, DOI 10.1126/science.274.5285.246; LOMBILLO VA, 1995, J CELL BIOL, V128, P107, DOI 10.1083/jcb.128.1.107; Maney T, 1998, J CELL BIOL, V142, P787, DOI 10.1083/jcb.142.3.787; Martinez-Exposito MJ, 1999, P NATL ACAD SCI USA, V96, P8493, DOI 10.1073/pnas.96.15.8493; Merdes A, 1996, CELL, V87, P447, DOI 10.1016/S0092-8674(00)81365-3; MERDES A, UNPUB J CELL BIOL; NICKLAS RB, 1989, J CELL BIOL, V109, P2245, DOI 10.1083/jcb.109.5.2245; PFARR CM, 1990, NATURE, V345, P263, DOI 10.1038/345263a0; RIEDER CL, 1981, CHROMOSOMA, V84, P145, DOI 10.1007/BF00293368; RIEDER CL, 1990, J CELL BIOL, V110, P81, DOI 10.1083/jcb.110.1.81; RIEDER CL, 1995, J CELL BIOL, V130, P941, DOI 10.1083/jcb.130.4.941; ROOS UP, 1976, CHROMOSOMA, V54, P363, DOI 10.1007/BF00292816; Schaar BT, 1997, J CELL BIOL, V139, P1373, DOI 10.1083/jcb.139.6.1373; SKIBBENS RV, 1993, J CELL BIOL, V122, P859, DOI 10.1083/jcb.122.4.859; Starr DA, 1998, J CELL BIOL, V142, P763, DOI 10.1083/jcb.142.3.763; STEUER ER, 1990, NATURE, V345, P266, DOI 10.1038/345266a0; Taylor SS, 1997, CELL, V89, P727, DOI 10.1016/S0092-8674(00)80255-X; Taylor SS, 1998, J CELL BIOL, V142, P1, DOI 10.1083/jcb.142.1.1; VAISBERG EA, 1993, J CELL BIOL, V123, P849, DOI 10.1083/jcb.123.4.849; Walczak CE, 1996, CELL, V84, P37, DOI 10.1016/S0092-8674(00)80991-5; Waters JC, 1996, J CELL SCI, V109, P2823; Wood KW, 1997, CELL, V91, P357, DOI 10.1016/S0092-8674(00)80419-5; WORDEMAN L, 1995, J CELL BIOL, V128, P95, DOI 10.1083/jcb.128.1.95; Yao XB, 1997, J CELL BIOL, V139, P435, DOI 10.1083/jcb.139.2.435; YEN TJ, 1991, EMBO J, V10, P1245, DOI 10.1002/j.1460-2075.1991.tb08066.x; Zhang DH, 1996, NATURE, V382, P466, DOI 10.1038/382466a0	48	302	317	1	15	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	AUG	2000	2	8					484	491		10.1038/35019518	http://dx.doi.org/10.1038/35019518			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	341TE	10934468				2022-12-25	WOS:000088605000013
J	Borg, JP; Marchetto, S; Le Bivic, A; Ollendorff, V; Jaulin-Bastard, F; Saito, H; Fournier, E; Adelaide, J; Margolis, B; Birnbaum, D				Borg, JP; Marchetto, S; Le Bivic, A; Ollendorff, V; Jaulin-Bastard, F; Saito, H; Fournier, E; Adelaide, J; Margolis, B; Birnbaum, D			ERBIN: a basolateral PDZ protein that interacts with the mammalian ERBB2/HER2 receptor	NATURE CELL BIOLOGY			English	Article							NITRIC-OXIDE SYNTHASE; ELEGANS VULVAR INDUCTION; RAS-BINDING PROTEIN; EPITHELIAL-CELLS; DOMAIN PROTEIN; C-ELEGANS; PLASMA-MEMBRANE; KINASE-ACTIVITY; LOCALIZATION; COMPLEX	The ERBB receptors have a crucial role in morphogenesis and oncogenesis. We have identified a new PDZ protein we named ERBIN (ERBB2 interacting protein) that acts as an adaptor for the receptor ERBB2/HER2 in epithelia. ERBIN contains 16 leucine-rich repeats (LRRs) in its amino terminus and a PDZ (PSD-95/DLG/ZO-1) domain at its carboxy terminus, and belongs to a new PDZ protein family. The PDZ domain directly and specifically interacts with ERBB2/ HER2. ERBIN and ERBB2/HER2 colocalize to the lateral membrane of human intestinal epithelial cells. The ERBIN-binding site in ERBB2/HER2 has a critical role in restricting this receptor to the basolateral membrane of epithelial cells, as mutation of the ERBIN-binding site leads to the mislocalization of the receptor in these cells. We suggest that ERBIN acts in the localization and signalling of ERBB2/HER2 in epithelia.	INSERM, U119, F-13009 Marseille, France; Fac Sci Luminy, IBDM, F-13288 Marseille 09, France; Inst J Paoli I Calmettes, F-13009 Marseille, France; Univ Michigan, Howard Hughes Med Inst, Ann Arbor, MI 48109 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; UNICANCER; Institut Paoli-Calmette (IPC); Howard Hughes Medical Institute; University of Michigan System; University of Michigan	Borg, JP (corresponding author), INSERM, U119, 27 Blvd Lei Roure, F-13009 Marseille, France.	borg@marseille.inserm.fr	Jaulin, Fanny/D-7152-2017; Borg, Jean-Paul/AAX-8096-2020; ADELAIDE, José JA/O-4390-2017	Jaulin, Fanny/0000-0002-5110-1800; Borg, Jean-Paul/0000-0001-8418-3382; ADELAIDE, José JA/0000-0003-4364-9857; Ollendorff, Vincent/0000-0001-9751-2202; Birnbaum, Daniel/0000-0001-7920-9883				Apperson ML, 1996, J NEUROSCI, V16, P6839; Bateman A, 2000, NUCLEIC ACIDS RES, V28, P263, DOI 10.1093/nar/28.1.263; Bhat MA, 1999, CELL, V96, P833, DOI 10.1016/S0092-8674(00)80593-0; Bilder D, 2000, NATURE, V403, P676, DOI 10.1038/35001108; Borg JP, 1998, CURR TOP MICROBIOL, V228, P23; Borg JP, 1996, MOL CELL BIOL, V16, P6229; Borg JP, 1998, J BIOL CHEM, V273, P31633, DOI 10.1074/jbc.273.48.31633; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; Butz S, 1998, CELL, V94, P773, DOI 10.1016/S0092-8674(00)81736-5; Caplan MJ, 1997, AM J PHYSIOL-RENAL, V272, pF425, DOI 10.1152/ajprenal.1997.272.4.F425; Cereijido M, 1998, ANNU REV PHYSIOL, V60, P161, DOI 10.1146/annurev.physiol.60.1.161; Chevesich J, 1997, NEURON, V18, P95, DOI 10.1016/S0896-6273(01)80049-0; Cohen AR, 1998, J CELL BIOL, V142, P129, DOI 10.1083/jcb.142.1.129; DEPOTTER CR, 1989, INT J CANCER, V44, P969, DOI 10.1002/ijc.2910440604; Drubin DG, 1996, CELL, V84, P335, DOI 10.1016/S0092-8674(00)81278-7; Fanning AS, 1998, CURR TOP MICROBIOL, V228, P209; FEDI P, 1994, MOL CELL BIOL, V14, P492, DOI 10.1128/MCB.14.1.492; Hata Y, 1996, J NEUROSCI, V16, P2488; Hildebrand JD, 1999, CELL, V99, P485, DOI 10.1016/S0092-8674(00)81537-8; Hillier BJ, 1999, SCIENCE, V284, P812, DOI 10.1126/science.284.5415.812; Hock B, 1998, P NATL ACAD SCI USA, V95, P9779, DOI 10.1073/pnas.95.17.9779; Hoskins R, 1996, DEVELOPMENT, V122, P97; Hsueh YP, 1998, J CELL BIOL, V142, P139, DOI 10.1083/jcb.142.1.139; Irie M, 1999, ONCOGENE, V18, P2811, DOI 10.1038/sj.onc.1202652; Irie M, 1997, SCIENCE, V277, P1511, DOI 10.1126/science.277.5331.1511; Jo K, 1999, J NEUROSCI, V19, P4189, DOI 10.1523/jneurosci.19-11-04189.1999; Kaech SM, 1998, CELL, V94, P761, DOI 10.1016/S0092-8674(00)81735-3; Kim SK, 1997, CURR OPIN CELL BIOL, V9, P853, DOI 10.1016/S0955-0674(97)80088-9; Klapper LN, 2000, ADV CANCER RES, V77, P25; Kornau HC, 1997, CURR OPIN NEUROBIOL, V7, P368, DOI 10.1016/S0959-4388(97)80064-5; LEBIVIC A, 1988, EUR J CELL BIOL, V46, P113; LEBIVIC A, 1990, J CELL BIOL, V110, P1533, DOI 10.1083/jcb.110.5.1533; LEBIVIC A, 1989, P NATL ACAD SCI USA, V86, P9313; LEGALL AH, 1995, SEMIN NEPHROL, V15, P272; Levkowitz G, 1996, ONCOGENE, V12, P1117; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Perego C, 1999, EMBO J, V18, P2384, DOI 10.1093/emboj/18.9.2384; Rongo C, 1998, CELL, V94, P751, DOI 10.1016/S0092-8674(00)81734-1; Sieburth DS, 1998, CELL, V94, P119, DOI 10.1016/S0092-8674(00)81227-1; Simske JS, 1996, CELL, V85, P195, DOI 10.1016/S0092-8674(00)81096-X; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Sternberg PW, 1998, CELL, V95, P447, DOI 10.1016/S0092-8674(00)81612-8; Straight SW, 2000, AM J PHYSIOL-RENAL, V278, pF464, DOI 10.1152/ajprenal.2000.278.3.F464; Stricker NL, 1997, NAT BIOTECHNOL, V15, P336, DOI 10.1038/nbt0497-336; Tochio H, 1999, NAT STRUCT BIOL, V6, P417; Tsunoda S, 1997, NATURE, V388, P243, DOI 10.1038/40805; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; Whitfield CW, 1999, MOL BIOL CELL, V10, P2087, DOI 10.1091/mbc.10.6.2087; WOODS DF, 1991, CELL, V66, P451, DOI 10.1016/0092-8674(81)90009-X; Wu HJ, 1998, J CELL SCI, V111, P2365	50	239	260	2	13	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	JUL	2000	2	7					407	414		10.1038/35017038	http://dx.doi.org/10.1038/35017038			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	333MK	10878805	Green Published			2022-12-25	WOS:000088133700016
J	Steinborn, R; Schinogl, P; Zakhartchenko, V; Achmann, R; Schernthaner, W; Stojkovic, M; Wolf, E; Muller, M; Brem, G				Steinborn, R; Schinogl, P; Zakhartchenko, V; Achmann, R; Schernthaner, W; Stojkovic, M; Wolf, E; Muller, M; Brem, G			Mitochondrial DNA heteroplasmy in cloned cattle produced by fetal and adult cell cloning	NATURE GENETICS			English	Article							NUCLEI; FIBROBLASTS; SHEEP; MICE		Univ Vet Med, Inst Genet & Anim Breeding, Vienna, Austria; Ludwig Boltzmann Inst Immuno Cyto & Mol Genet, Vienna, Austria; Inst Agrobiotechnol, Dept Biotechnol Anim Prod, Tulln, Austria; Univ Munich, Gene Ctr, Dept Mol Anim Breeding & Genet, Munich, Germany	University of Veterinary Medicine Vienna; Ludwig Boltzmann Institute; University of Natural Resources & Life Sciences, Vienna; University of Munich	Steinborn, R (corresponding author), Univ Vet Med, Inst Genet & Anim Breeding, Vienna, Austria.	Ralf.Steinborn@vu-wien.ac.at		Zakhartchenko, Valeri/0000-0002-5974-9759; Muller, Mathias/0000-0002-7879-3552; Stojkovic, Miodrag/0000-0001-7526-6573; Wolf, Eckhard/0000-0002-0430-9510				Evans MJ, 1999, NAT GENET, V23, P90, DOI 10.1038/12696; Hiendleder S, 1999, MOL REPROD DEV, V54, P24, DOI 10.1002/(SICI)1098-2795(199909)54:1&lt;24::AID-MRD4&gt;3.0.CO;2-S; Irwin MH, 1999, TRANSGENIC RES, V8, P119, DOI 10.1023/A:1008925419758; Kato Y, 1998, SCIENCE, V282, P2095, DOI 10.1126/science.282.5396.2095; PLANTE Y, 1992, THERIOGENOLOGY, V38, P887; Schnieke AE, 1997, SCIENCE, V278, P2130, DOI 10.1126/science.278.5346.2130; Steinborn R, 1998, FEBS LETT, V426, P357, DOI 10.1016/S0014-5793(98)00351-2; Steinborn R, 1998, FEBS LETT, V426, P352, DOI 10.1016/S0014-5793(98)00350-0; Sutovsky P, 1999, NATURE, V402, P371, DOI 10.1038/46466; Wakayama T, 1998, NATURE, V394, P369, DOI 10.1038/28615; Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482; Wilmut I, 1997, NATURE, V385, P810, DOI 10.1038/385810a0; Zakhartchenko V, 1999, MOL REPROD DEV, V54, P264, DOI 10.1002/(SICI)1098-2795(199911)54:3&lt;264::AID-MRD7&gt;3.0.CO;2-Y; Zakhartchenko V, 1999, J REPROD FERTIL, V115, P325, DOI 10.1530/jrf.0.1150325	14	134	141	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JUL	2000	25	3					255	257		10.1038/77000	http://dx.doi.org/10.1038/77000			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	329RD	10888867				2022-12-25	WOS:000087920900008
J	Stojdl, DF; Lichty, B; Knowles, S; Marius, R; Atkins, H; Sonenberg, N; Bell, JC				Stojdl, DF; Lichty, B; Knowles, S; Marius, R; Atkins, H; Sonenberg, N; Bell, JC			Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus	NATURE MEDICINE			English	Article							VESICULAR STOMATITIS-VIRUS; COMPLETE REGRESSION; CELL-LINE; ALPHA; RESISTANCE; THERAPY; MICE; REPLICATION; XENOGRAFTS; EXPRESSION	Interferons are circulating factors that bind to cell surface receptors, activating a signaling cascade, ultimately leading to both an antiviral response and an induction of growth inhibitory and/or apoptotic signals in normal and tumor cells(1). Attempts to exploit the ability of interferons to limit the growth of tumors in patients has met with limited results(2) because of cancer-specific mutations of gene products in the interferon pathway(3-7). Although interferon-non-responsive cancer cells may have acquired a growth/survival advantage over their normal counterparts, they may have simultaneously compromised their antiviral response. To test this, we used vesicular stomatitis virus (VSV), an enveloped, negative-sense RNA virus(8) exquisitely sensitive to treatment with interferon(9) VSV rapidly replicated in and selectively killed a variety of human tumor cell lines even in the presence of doses of interferon that completely protected normal human primary cell cultures. A single intratumoral injection of VSV was effective in reducing the tumor burden of nude mice bearing subcutaneous human melanoma xenografts. Our results support the use of VSV as a replication-competent oncolytic virus and demonstrate a new strategy for the treatment of interferon non-responsive tumors.	Ottawa Reg Canc Ctr, Res Labs, Ottawa, ON K1H 8L6, Canada; Univ Ottawa, Dept Biochem Microbiol & Immunol, Ottawa, ON K1H 8M5, Canada; McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada	University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; McGill University	Bell, JC (corresponding author), Ottawa Reg Canc Ctr, Res Labs, 501 Smyth Rd, Ottawa, ON K1H 8L6, Canada.	jbell@med.uottawa.ca	Lichty, Brian/J-2008-2012	Lichty, Brian/0000-0003-4514-1037				Abril E, 1996, TISSUE ANTIGENS, V47, P391, DOI 10.1111/j.1399-0039.1996.tb02574.x; BELKOWSKI LS, 1987, J VIROL, V61, P653, DOI 10.1128/JVI.61.3.653-660.1987; Burke F, 1999, CYTOKINES CELL MOL T, V5, P51; Cassady KA, 1998, J VIROL, V72, P7005; CAVE DR, 1985, J VIROL, V55, P366, DOI 10.1128/JVI.55.2.366-373.1985; COLAMONICI OR, 1992, BLOOD, V80, P744; Coukos G, 1999, CLIN CANCER RES, V5, P1523; HUNEYCUTT BS, 1993, J VIROL, V67, P6698, DOI 10.1128/JVI.67.11.6698-6706.1993; KLOKE O, 1990, CANCER TREAT REV, V17, P81, DOI 10.1016/0305-7372(90)90019-C; Letchworth GJ, 1999, VET J, V157, P239, DOI 10.1053/tvjl.1998.0303; LORENCE RM, 1994, JNCI-J NATL CANCER I, V86, P1228, DOI 10.1093/jnci/86.16.1228; LORENCE RM, 1994, CANCER RES, V54, P6017; Rothmann T, 1998, J VIROL, V72, P9470, DOI 10.1128/JVI.72.12.9470-9478.1998; Shimada A, 1998, CANCER RES, V58, P4434; SMITH RR, 1956, CANCER, V9, P1211, DOI 10.1002/1097-0142(195611/12)9:6<1211::AID-CNCR2820090624>3.0.CO;2-7; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Strong JE, 1998, EMBO J, V17, P3351, DOI 10.1093/emboj/17.12.3351; Sun WH, 1998, BLOOD, V91, P570, DOI 10.1182/blood.V91.2.570.570_570_576; Thomsen AR, 1997, INT IMMUNOL, V9, P1757, DOI 10.1093/intimm/9.11.1757; Wong LH, 1997, J BIOL CHEM, V272, P28779, DOI 10.1074/jbc.272.45.28779; XU B, 1994, BLOOD, V84, P1942	21	638	694	0	71	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2000	6	7					821	825		10.1038/77558	http://dx.doi.org/10.1038/77558			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	331VV	10888934				2022-12-25	WOS:000088040100042
J	Svensson, EC; Huggins, GS; Lin, H; Clendenin, C; Jiang, F; Tufts, R; Dardik, FB; Leiden, JM				Svensson, EC; Huggins, GS; Lin, H; Clendenin, C; Jiang, F; Tufts, R; Dardik, FB; Leiden, JM			A syndrome of tricuspid atresia in mice with a targeted mutation of the gene encoding Fog-2	NATURE GENETICS			English	Article							TRANSCRIPTION FACTOR GATA-4; HEART TUBE FORMATION; ATRIOVENTRICULAR JUNCTION; VENTRAL MORPHOGENESIS; NF-ATC; MOUSE; TRISOMY-16; COFACTOR; NKX2-5; VALVE	Tricuspid atresia (TA) is a common form of congenital heart disease, accounting for 1-3% of congenital cardiac disorders(1). TA is characterized by the congenital agenesis of the tricuspid valve connecting the right atrium to the right ventricle and both an atrial septal defect (ASD) and a ventricular septal defect(2) (VSD). Some patients also have pulmonic stenosis. persistence of a left-sided superior vena cava or transposition of the great arteries. Most cases of TA are sporadic, but familiar occurrences with disease in multiple siblings have been reported(3-5). Gata4 is a zinc-finger transcription factor with a role in early cardiac development. Gata4-deficient mice fail to form a ventral heart tube and die of circulatory failure at embryonic day (E) 8.5 (refs 6,7). Zfpm2 (also known as Fog-2) is a multi-zinc-finger protein that is co-expressed with Gata4 in the developing heart beginning at E8.5 (refs 8-10). Zfpm2 interacts specifically with the N-terminal zinc finger of Gata4 and represses Gata4-dependent transcription(8-10). Here we use targeted mutagenesis to explore the role of Zfpm2 in normal cardiac development. Zfpm2-deficient mice died of congestive heart failure at E13 with a syndrome of tricuspid atresia that includes an absent tricuspid valve, a large ASD, a VSD, an elongated left ventricular outflow tract, rightward displacement of the aortic valve and pulmonic stenosis. These mice also display hypoplasia of the compact zone of the left ventricle. Our findings indicate the importance of Zfpm2 in the normal looping and septation of the heart and suggest a genetic basis for the syndrome of tricuspid atresia.	Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Univ Chicago, Dept Med, Chicago, IL 60637 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; University of Chicago	Leiden, JM (corresponding author), Harvard Univ, Sch Publ Hlth, 665 Huntington Ave, Boston, MA 02115 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL003667, R01HL054592] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL54592, HL03667, R01 HL054592] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Anderson RH, 1998, CARDIOVASC RES, V39, P155, DOI 10.1016/S0008-6363(98)00037-6; Biben C, 1997, GENE DEV, V11, P1357, DOI 10.1101/gad.11.11.1357; Bonnet D, 1999, J MED GENET, V36, P349; de la Pompa JL, 1998, NATURE, V392, P182, DOI 10.1038/32419; GELB BD, 1991, AM J MED GENET, V40, P471, DOI 10.1002/ajmg.1320400420; KUMAR A, 1994, PEDIATR CARDIOL, V15, P201, DOI 10.1007/BF00800676; Kuo CT, 1997, GENE DEV, V11, P2996, DOI 10.1101/gad.11.22.2996; Kuo CT, 1997, GENE DEV, V11, P1048, DOI 10.1101/gad.11.8.1048; LAMERS WH, 1995, CIRCULATION, V91, P111, DOI 10.1161/01.CIR.91.1.111; Lee RY, 1997, CIRC RES, V80, P757; Lin AE, 1998, J MED GENET, V35, P1055, DOI 10.1136/jmg.35.12.1055; Lu JR, 1999, MOL CELL BIOL, V19, P4495; LYONS I, 1995, GENE DEV, V9, P1654, DOI 10.1101/gad.9.13.1654; Molkentin JD, 1997, GENE DEV, V11, P1061, DOI 10.1101/gad.11.8.1061; Morrisey EE, 1997, DEV BIOL, V183, P21, DOI 10.1006/dbio.1996.8485; Ranger AM, 1998, NATURE, V392, P186, DOI 10.1038/32426; RAO PS, 1980, AM HEART J, V99, P799, DOI 10.1016/0002-8703(80)90632-8; SADE RM, 1990, PEDIATR CLIN N AM, V37, P151; SOUDAIS C, 1995, DEVELOPMENT, V121, P3877; Srivastava D, 1997, NAT GENET, V16, P154, DOI 10.1038/ng0697-154; SUJANSKY E, 1993, AM J MED GENET, V47, P512, DOI 10.1002/ajmg.1320470415; SVENSSON E, IN PRESS J BIOL CHEM; Svensson EC, 1999, P NATL ACAD SCI USA, V96, P956, DOI 10.1073/pnas.96.3.956; Tevosian SG, 1999, P NATL ACAD SCI USA, V96, P950, DOI 10.1073/pnas.96.3.950; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; Webb S, 1997, CARDIOVASC RES, V34, P515, DOI 10.1016/S0008-6363(97)00064-3; Webb S, 1999, CIRC RES, V84, P897; Webb S, 1998, CIRC RES, V82, P645, DOI 10.1161/01.RES.82.6.645	28	138	142	0	10	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUL	2000	25	3					353	356		10.1038/77146	http://dx.doi.org/10.1038/77146			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	329RD	10888889				2022-12-25	WOS:000087920900029
J	Tretter, YP; Hertel, M; Munz, B; ten Bruggencate, G; Werner, S; Alzheimer, C				Tretter, YP; Hertel, M; Munz, B; ten Bruggencate, G; Werner, S; Alzheimer, C			Induction of activin A is essential for the neuroprotective action of basic fibroblast growth factor in vivo	NATURE MEDICINE			English	Article							MIDBRAIN DOPAMINERGIC-NEURONS; TRANSGENIC MICE REVEALS; BRAIN INJURY; EXPRESSION; RAT; FOLLISTATIN; BINDING; PROTECTS; LESION; REPAIR	Exogenous application of neurotrophic growth factors has emerged as a new and particularly promising approach not only to promote functional recovery after acute brain injury but also to protect neurons against the immediate effect of the injury. Among the various growth factors and cytokines studied so far, the neuroprotective and neurotrophic profile of basic fibroblast growth factor (bFGF) Is the best documented(1-5). Using an animal model of acute excitotoxic brain injury(6), we report here that the neuroprotective action of bFGF, which is now being tested in stroke patients, depends on the induction of activin A, a member of the transforming growth factor-beta superfamily. Our evidence for this previously unknown mechanism of action of bFGF is that bFGF strongly enhanced lesion-associated induction of activin A; in the presence of the activin-neutralizing protein follistatin, bFGF was no longer capable of rescuing neurons from excitotoxic death; and recombinant activin A exerted a neuroprotective effect by itself. Our data indicate that the development of substances influencing activin expression or receptor binding should offer new ways to fight neuronal loss in ischemic and traumatic brain injury.	Univ Munich, Dept Physiol, D-80336 Munich, Germany; Max Planck Inst Biochem, D-82152 Martinsried, Germany; Swiss Fed Inst Technol, Dept Cell Biol, CH-8093 Zurich, Switzerland	University of Munich; Max Planck Society; Swiss Federal Institutes of Technology Domain; ETH Zurich	Alzheimer, C (corresponding author), Univ Munich, Dept Physiol, Pettenkoferstr 12, D-80336 Munich, Germany.			Werner, Sabine/0000-0001-7397-8710				ANDERSON KJ, 1988, NATURE, V332, P360, DOI 10.1038/332360a0; Ay H, 1999, CEREBROVASC DIS, V9, P131, DOI 10.1159/000015941; Bethel A, 1997, STROKE, V28, P609, DOI 10.1161/01.STR.28.3.609; deWinter JP, 1996, MOL CELL ENDOCRINOL, V116, P105, DOI 10.1016/0303-7207(95)03705-5; Fainsod A, 1997, MECH DEVELOP, V63, P39, DOI 10.1016/S0925-4773(97)00673-4; Hubner G, 1996, EXP CELL RES, V228, P106, DOI 10.1006/excr.1996.0305; Hughes PE, 1999, NEUROSCIENCE, V92, P197, DOI 10.1016/S0306-4522(98)00724-6; Iemura S, 1998, P NATL ACAD SCI USA, V95, P9337, DOI 10.1073/pnas.95.16.9337; KIRSCHNER PB, 1995, J CEREBR BLOOD F MET, V15, P619, DOI 10.1038/jcbfm.1995.76; Krieglstein K, 1998, EUR J NEUROSCI, V10, P2746, DOI 10.1046/j.1460-9568.1998.00324.x; KRIEGLSTEIN K, 1995, EMBO J, V14, P736, DOI 10.1002/j.1460-2075.1995.tb07052.x; Lai M, 1997, NEUROREPORT, V8, P2691, DOI 10.1097/00001756-199708180-00011; McDowell N, 1997, CURR BIOL, V7, P671, DOI 10.1016/S0960-9822(06)00294-6; Munz B, 1999, EMBO J, V18, P5205, DOI 10.1093/emboj/18.19.5205; Munz B, 1999, J ENDOCRINOL, V161, P187, DOI 10.1677/joe.0.1610187; NADLER JV, 1980, J COMP NEUROL, V192, P333, DOI 10.1002/cne.901920209; NAKAMURA T, 1990, SCIENCE, V247, P836, DOI 10.1126/science.2106159; Peterson DA, 1996, J NEUROSCI, V16, P886; RIVA MA, 1994, NEUROSCIENCE, V59, P55, DOI 10.1016/0306-4522(94)90098-1; Sugino Hiromu, 1997, Journal of Medical Investigation, V44, P1; Tretter YP, 1996, NEUROREPORT, V7, P1819, DOI 10.1097/00001756-199607290-00026; WERNER S, 1993, EMBO J, V12, P2635, DOI 10.1002/j.1460-2075.1993.tb05924.x; WISDEN W, 1991, MOL NEUROBIOLOGY PRA, P205; Wu DD, 1999, BRAIN RES, V835, P369, DOI 10.1016/S0006-8993(99)01638-8; YASUDA H, 1993, J CLIN INVEST, V92, P1491, DOI 10.1172/JCI116727	25	130	137	0	4	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUL	2000	6	7					812	+		10.1038/77548	http://dx.doi.org/10.1038/77548			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	331VV	10888932				2022-12-25	WOS:000088040100040
J	Crespi, RS				Crespi, RS			Patents on genes: clarifying the issues	NATURE BIOTECHNOLOGY			English	Editorial Material												R.S.Crespi@btinternet.com						EISENBERG RE, 1995, AM INTELL PROP L ASS, V1, P3; Eisenberg RS, 1997, NAT GENET, V15, P125, DOI 10.1038/ng0297-125; Flores MA, 1999, NAT BIOTECHNOL, V17, P819, DOI 10.1038/11774; MAYS TD, 1999, BIOSCI LAW REV, V2, P56; 1998, J EUROPEAN COMM 0730; 1990, OFICIAL J EUROPEAN P, V8, P335	6	3	3	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JUN	2000	18	6					683	684		10.1038/76548	http://dx.doi.org/10.1038/76548			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	325EK	10835611				2022-12-25	WOS:000087663200033
J	Le Saux, O; Urban, Z; Tschuch, C; Csiszar, K; Bacchelli, B; Quaglino, D; Pasquali-Ronchetti, I; Pope, FM; Richards, A; Terry, S; Bercovitch, L; de Paepe, A; Boyd, CD				Le Saux, O; Urban, Z; Tschuch, C; Csiszar, K; Bacchelli, B; Quaglino, D; Pasquali-Ronchetti, I; Pope, FM; Richards, A; Terry, S; Bercovitch, L; de Paepe, A; Boyd, CD			Mutations in a gene encoding an ABC transporter cause pseudoxanthoma elasticum	NATURE GENETICS			English	Article							CHROMOSOME 16P13.1; BETA-THALASSEMIA; EXPRESSION; DISEASE; MAPS	Pseudoxanthoma elasticum (PXE) is a heritable disorder characterized by calcification of elastic fibres in skin, arteries and retina that results in dermal lesions with associated laxity and loss of elasticity, arterial insufficiency and retinal haemorrhages leading to macular degefieration(1-5). PXE is usually found as a sporadic disorder, but examples of both autosomal recessive and autosomal dominant forms of PXE have been observed(6). Partial manifestations of the PXE phenotype have also been described in presumed carriers in PXE families(7,8). Linkage of both dominant and recessive forms of PXE to a 5-cM domain on chromosome 16013.1 has been reported (refs 8,9). We have refined this locus to an 820-kb region containing 6 candidate genes(10). Here we report the exclusion of five of these genes and the identification of the first mutations responsible for the development of PXE in a gene encoding a protein associated with multidrug resistance (ABCC6).	Univ Hawaii, Pacific Biomed Res Ctr, Lab Matrix Pathobiol, Honolulu, HI 96822 USA; Univ Modena, Dept Biomed Sci, Modena, Italy; Univ Wales Hosp, Inst Med Genet, MRC, Connect Tissue Genet Grp, Cardiff CF4 4XN, S Glam, Wales; Univ Cambridge, Dept Pathol, MRC, Connect Tissue Genet Grp, Cambridge CB2 1QP, England; PXE Int Inc, Sharon, MA USA; Brown Univ, Dept Dermatol, Providence, RI 02912 USA; Univ Hosp, Univ Ziekenhuis, Ctr Med Genet, Ghent, Belgium	University of Hawaii System; Universita di Modena e Reggio Emilia; Cardiff University; University of Cambridge; Brown University; Ghent University; Ghent University Hospital	Boyd, CD (corresponding author), Univ Hawaii, Pacific Biomed Res Ctr, Lab Matrix Pathobiol, Honolulu, HI 96822 USA.		Le Saux, Olivier/P-4668-2017; Urban, Zsolt/B-1977-2008; Urban, Zsolt/A-2018-2013; Quaglino, Daniela/A-9381-2010	Le Saux, Olivier/0000-0002-5605-3617; Urban, Zsolt/0000-0003-3890-1843; Quaglino, Daniela/0000-0002-4302-5078	NCRR NIH HHS [RR03061] Funding Source: Medline; NEI NIH HHS [EY13019] Funding Source: Medline; NHLBI NIH HHS [HL50665] Funding Source: Medline; Telethon [E.0696] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY013019] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050665] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Telethon(Fondazione Telethon); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aessopos A, 1998, ANGIOLOGY, V49, P137, DOI 10.1177/000331979804900206; Bacchelli B, 1999, MODERN PATHOL, V12, P1112; Bakos E, 1996, J BIOL CHEM, V271, P12322, DOI 10.1074/jbc.271.21.12322; Belinsky MG, 1999, BRIT J CANCER, V80, P1342, DOI 10.1038/sj.bjc.6690527; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; Jones PM, 1998, J MEMBRANE BIOL, V166, P133, DOI 10.1007/s002329900455; Klein I, 1999, BBA-BIOMEMBRANES, V1461, P237, DOI 10.1016/S0005-2736(99)00161-3; Kool M, 1999, CANCER RES, V59, P175; Le Saux O, 1999, GENOMICS, V62, P1, DOI 10.1006/geno.1999.5925; LEBWOHL M, 1993, NEW ENGL J MED, V329, P1237, DOI 10.1056/NEJM199310213291705; MENDELSOHN G, 1978, ARCH PATHOL LAB MED, V102, P298; NAGAMINE CM, 1989, AM J HUM GENET, V45, P337; Neldner K H, 1988, Clin Dermatol, V6, P1; Nikko AP, 1996, AM J DERMATOPATH, V18, P396, DOI 10.1097/00000372-199608000-00011; Ong-ajyooth L, 1998, NEPHRON, V78, P156, DOI 10.1159/000044904; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; POPE FM, 1975, BRIT J DERMATOL, V92, P493; Sapadin AN, 1998, J AM ACAD DERMATOL, V39, P338, DOI 10.1016/S0190-9622(98)70385-8; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; Struk B, 1997, HUM MOL GENET, V6, P1823, DOI 10.1093/hmg/6.11.1823; Tusnady GE, 1998, J MOL BIOL, V283, P489, DOI 10.1006/jmbi.1998.2107; Urban Z, 1999, HUM GENET, V104, P135, DOI 10.1007/s004390050926; vanSoest S, 1997, GENOME RES, V7, P830, DOI 10.1101/gr.7.8.830; Weenink AC, 1996, NETH J MED, V49, P24, DOI 10.1016/0300-2977(95)00079-8; Wilton SD, 1998, HUM MUTAT, V11, P252, DOI 10.1002/(SICI)1098-1004(1998)11:3<252::AID-HUMU11>3.3.CO;2-Z; YAP EY, 1992, RETINA-J RET VIT DIS, V12, P315, DOI 10.1097/00006982-199212040-00004	26	400	416	1	9	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUN	2000	25	2					223	227		10.1038/76102	http://dx.doi.org/10.1038/76102			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	321ML	10835642				2022-12-25	WOS:000087459200026
J	Seiler, S; Kirchner, J; Horn, C; Kallipolitou, A; Woehlke, G; Schliwa, M				Seiler, S; Kirchner, J; Horn, C; Kallipolitou, A; Woehlke, G; Schliwa, M			Cargo binding and regulatory sites in the tail of fungal conventional kinesin	NATURE CELL BIOLOGY			English	Article							MICROTUBULE-BASED MOTILITY; HEAVY-CHAIN; MOTOR DOMAIN; LIGHT-CHAIN; MONOCLONAL-ANTIBODIES; ELECTRON-MICROSCOPY; CELL MORPHOGENESIS; NEUROSPORA-CRASSA; AXONAL-TRANSPORT; IDENTIFICATION	Here, using a quantitative in vivo assay, we map three regions in the carboxy terminus of conventional kinesin that are involved in cargo association, folding and regulation, respectively. Using C-terminal and internal deletions, point mutations, localization studies, and an engineered 'minimal' kinesin, we identify five heptads of a coiled-coil domain in the kinesin tail that are necessary and sufficient for cargo association. Mutational analysis and in vitro ATPase assays highlight a conserved motif in the globular tail that is involved in regulation of the motor domain; a region preceding this motif participates in folding. Although these sites are spatially and functionally distinct, they probably cooperate during activation of the motor for cargo transport.	Univ Munich, Adolf Butenandt Inst, D-80336 Munich, Germany	University of Munich	Schliwa, M (corresponding author), Univ Munich, Adolf Butenandt Inst, D-80336 Munich, Germany.			Woehlke, Gunther/0000-0001-8462-9962				AMOS LA, 1987, J CELL SCI, V87, P105; BERGER B, 1995, P NATL ACAD SCI USA, V92, P8259, DOI 10.1073/pnas.92.18.8259; BLOOM GS, 1995, PROTEIN PROFILE, V2, P105; BRADY ST, 1985, NATURE, V317, P73, DOI 10.1038/317073a0; Case RB, 1997, CELL, V90, P959, DOI 10.1016/S0092-8674(00)80360-8; Coy DL, 1999, NAT CELL BIOL, V1, P288, DOI 10.1038/13001; Diefenbach RJ, 1998, BIOCHEMISTRY-US, V37, P16663, DOI 10.1021/bi981163r; Endow SA, 1998, SCIENCE, V281, P1200, DOI 10.1126/science.281.5380.1200; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Friedman DS, 1999, NAT CELL BIOL, V1, P293, DOI 10.1038/13008; Gindhart JG, 1998, J CELL BIOL, V141, P443, DOI 10.1083/jcb.141.2.443; GOLDSTEIN LSB, 1993, ANNU REV GENET, V27, P319; Grummt M, 1998, EMBO J, V17, P5536, DOI 10.1093/emboj/17.19.5536; HACKNEY DD, 1992, J BIOL CHEM, V267, P8696; Henningsen U, 1997, NATURE, V389, P93, DOI 10.1038/38022; HIROKAWA N, 1991, J CELL BIOL, V114, P295, DOI 10.1083/jcb.114.2.295; HIROKAWA N, 1989, CELL, V56, P867, DOI 10.1016/0092-8674(89)90691-0; Hirokawa N, 1998, SCIENCE, V279, P519, DOI 10.1126/science.279.5350.519; Howard J, 1996, ANNU REV PHYSIOL, V58, P703, DOI 10.1146/annurev.ph.58.030196.003415; HUANG TG, 1994, J BIOL CHEM, V269, P16493; JELLALI A, 1994, CELL MOTIL CYTOSKEL, V28, P79, DOI 10.1002/cm.970280108; Kirchner J, 1999, BIOL CHEM, V380, P915, DOI 10.1515/BC.1999.113; Kirchner J, 1999, EMBO J, V18, P4404, DOI 10.1093/emboj/18.16.4404; KUZNETSOV SA, 1989, J BIOL CHEM, V264, P589; Lane J, 1998, BBA-REV BIOMEMBRANES, V1376, P27, DOI 10.1016/S0304-4157(97)00010-5; Lane JD, 1999, MOL BIOL CELL, V10, P1909, DOI 10.1091/mbc.10.6.1909; Lehmler C, 1997, EMBO J, V16, P3464, DOI 10.1093/emboj/16.12.3464; LEOPOLD PL, 1992, CELL MOTIL CYTOSKEL, V23, P19, DOI 10.1002/cm.970230104; PFISTER KK, 1989, J CELL BIOL, V108, P1453, DOI 10.1083/jcb.108.4.1453; Rahman A, 1999, J CELL BIOL, V146, P1277, DOI 10.1083/jcb.146.6.1277; Rice S, 1999, NATURE, V402, P778, DOI 10.1038/45483; Romberg L, 1998, J CELL BIOL, V140, P1407, DOI 10.1083/jcb.140.6.1407; SCHNAPP BJ, 1992, J CELL BIOL, V119, P389, DOI 10.1083/jcb.119.2.389; SCHOLEY JM, 1985, NATURE, V318, P483, DOI 10.1038/318483a0; Seiler S, 1999, CURR BIOL, V9, P779, DOI 10.1016/S0960-9822(99)80360-1; Seiler S, 1997, EMBO J, V16, P3025, DOI 10.1093/emboj/16.11.3025; SKOUFIAS DA, 1994, J BIOL CHEM, V269, P1477; Steinberg G, 1997, EUR J CELL BIOL, V73, P124; STEINBERG G, 1995, MOL BIOL CELL, V6, P1605, DOI 10.1091/mbc.6.11.1605; STENOIEN DS, 1997, MOL BIOL CELL, V146, P1277; Stock MF, 1999, J BIOL CHEM, V274, P14617, DOI 10.1074/jbc.274.21.14617; Tinsley JH, 1996, MOL BIOL CELL, V7, P731, DOI 10.1091/mbc.7.5.731; VALE RD, 1985, CELL, V42, P39, DOI 10.1016/S0092-8674(85)80099-4; Vale RD, 1997, ANNU REV CELL DEV BI, V13, P745, DOI 10.1146/annurev.cellbio.13.1.745; Verhey KJ, 1998, J CELL BIOL, V143, P1053, DOI 10.1083/jcb.143.4.1053; Woehlke G, 1997, CELL, V90, P207, DOI 10.1016/S0092-8674(00)80329-3; WRIGHT BD, 1991, J CELL BIOL, V113, P817, DOI 10.1083/jcb.113.4.817; Wu QD, 1998, MOL BIOL CELL, V9, P89, DOI 10.1091/mbc.9.1.89; YANG JT, 1990, SCIENCE, V249, P42, DOI 10.1126/science.2142332; YU H, 1992, J BIOL CHEM, V267, P20457	50	112	114	0	4	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	JUN	2000	2	6					333	338		10.1038/35014022	http://dx.doi.org/10.1038/35014022			6	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	321KE	10854323				2022-12-25	WOS:000087454000014
J	Cook, B; Bar-Yaacov, M; Ben-Ami, HC; Goldstein, RE; Paroush, Z; Selinger, Z; Minke, B				Cook, B; Bar-Yaacov, M; Ben-Ami, HC; Goldstein, RE; Paroush, Z; Selinger, Z; Minke, B			Phospholipase C and termination of G-protein-mediated signalling in vivo	NATURE CELL BIOLOGY			English	Article							PDZ-DOMAIN PROTEIN; DROSOPHILA PHOTORECEPTORS; SIGNALING COMPLEX; CA2+ CHANNEL; IN-VIVO; LIGHT RESPONSE; PHOTOTRANSDUCTION; NORPA; TRP; CALCIUM	In Drosophila photoreceptors, phospholipase C (PLC) and other signalling components form multiprotein structures through the PDZ scaffold protein INAD. Association between PLC and INAD is important for termination of responses to light; the underlying mechanism is, however, unclear. Here we report that the maintenance of large amounts of PLC in the signalling membranes by association with INAD facilitates response termination, and show that PLC functions as a GTPase-activating protein (GAP). The inactivation of the G protein by its target, the PLC, is crucial for reliable production of single-photon responses and for the high temporal and intensity resolution of the response to light.	Hebrew Univ Jerusalem, Dept Physiol, IL-91120 Jerusalem, Israel; Hebrew Univ Jerusalem, Kuhne Minerva Ctr Studies Visual Transduct, IL-91120 Jerusalem, Israel; Hebrew Univ Jerusalem, Dept Biol Chem, IL-91904 Jerusalem, Israel; Hebrew Univ Jerusalem, Kuhne Minerva Ctr Studies Visual Transduct, IL-91904 Jerusalem, Israel; Hebrew Univ Jerusalem, Dept Biochem, IL-91120 Jerusalem, Israel; Hebrew Univ Jerusalem, Kuhne Minerva Ctr Studies Visual Transduct, IL-91120 Jerusalem, Israel	Hebrew University of Jerusalem; Hebrew University of Jerusalem; Hebrew University of Jerusalem; Hebrew University of Jerusalem; Hebrew University of Jerusalem; Hebrew University of Jerusalem	Minke, B (corresponding author), Hebrew Univ Jerusalem, Dept Physiol, IL-91120 Jerusalem, Israel.	Minke@md2.huji.ac.il			NATIONAL EYE INSTITUTE [R01EY003529] Funding Source: NIH RePORTER; NEI NIH HHS [EY-03529] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Arshavsky VY, 1998, NEURON, V20, P11, DOI 10.1016/S0896-6273(00)80430-4; Baylor D, 1996, P NATL ACAD SCI USA, V93, P560, DOI 10.1073/pnas.93.2.560; BAYLOR DA, 1979, J PHYSIOL-LONDON, V288, P613; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BERRIDGE MJ, 1995, BIOCHEM J, V312, P1, DOI 10.1042/bj3120001; BERSTEIN G, 1992, CELL, V70, P411, DOI 10.1016/0092-8674(92)90165-9; BLOOMQUIST BT, 1988, CELL, V54, P723, DOI 10.1016/S0092-8674(88)80017-5; BLUMENFELD A, 1985, P NATL ACAD SCI USA, V82, P7116, DOI 10.1073/pnas.82.20.7116; Chen CK, 2000, NATURE, V403, P557, DOI 10.1038/35000601; Chevesich J, 1997, NEURON, V18, P95, DOI 10.1016/S0896-6273(01)80049-0; DEVARY O, 1987, P NATL ACAD SCI USA, V84, P6939, DOI 10.1073/pnas.84.19.6939; DODGE FA, 1968, SCIENCE, V160, P88, DOI 10.1126/science.160.3823.88; FEIN A, 1984, NATURE, V311, P157, DOI 10.1038/311157a0; HARDIE RC, 1993, P ROY SOC B-BIOL SCI, V252, P223, DOI 10.1098/rspb.1993.0069; HARDIE RC, 1991, P ROY SOC B-BIOL SCI, V245, P203, DOI 10.1098/rspb.1991.0110; HARDIE RC, 1992, NEURON, V8, P643, DOI 10.1016/0896-6273(92)90086-S; He W, 1998, NEURON, V20, P95, DOI 10.1016/S0896-6273(00)80437-7; Huber A, 1996, EMBO J, V15, P7036, DOI 10.1002/j.1460-2075.1996.tb01095.x; KIRKWOOD A, 1989, P NATL ACAD SCI USA, V86, P3872, DOI 10.1073/pnas.86.10.3872; LEE YJ, 1990, NEURON, V5, P889, DOI 10.1016/0896-6273(90)90349-K; Makino ER, 1999, P NATL ACAD SCI USA, V96, P1947, DOI 10.1073/pnas.96.5.1947; Meij JTA, 1996, BIOCHEM BIOPH RES CO, V225, P705, DOI 10.1006/bbrc.1996.1239; MINKE B, 1985, J COMP PHYSIOL A, V156, P339, DOI 10.1007/BF00610727; MINKE B, 1991, PROG RETIN RES, V11, P99, DOI 10.1016/0278-4327(91)90026-X; Mukhopadhyay S, 1999, P NATL ACAD SCI USA, V96, P9539, DOI 10.1073/pnas.96.17.9539; Pak W.L., 1979, P67; PAK WL, 1976, SCIENCE, V194, P956, DOI 10.1126/science.824732; Pearn MT, 1996, J BIOL CHEM, V271, P4937; PERETZ A, 1994, NEURON, V12, P1257, DOI 10.1016/0896-6273(94)90442-1; SCHRAMM M, 1982, MEMBRANES TRANSPORT, P555; Scott K, 1998, NATURE, V395, P805, DOI 10.1038/27448; SCOTT K, 1995, NEURON, V15, P919, DOI 10.1016/0896-6273(95)90182-5; SELINGER Z, 1988, COLD SPRING HARB SYM, V53, P333, DOI 10.1101/SQB.1988.053.01.040; Shieh BH, 1997, P NATL ACAD SCI USA, V94, P12682, DOI 10.1073/pnas.94.23.12682; Shieh BH, 1996, NEURON, V16, P991, DOI 10.1016/S0896-6273(00)80122-1; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; STIEVE H, 1986, MOL MECHANISM PHOTOR, P199; Tsang SH, 1998, SCIENCE, V282, P117, DOI 10.1126/science.282.5386.117; Tsunoda S, 1997, NATURE, V388, P243, DOI 10.1038/40805; van Huizen R, 1998, EMBO J, V17, P2285, DOI 10.1093/emboj/17.8.2285; WU CF, 1978, J GEN PHYSIOL, V71, P249, DOI 10.1085/jgp.71.3.249; Xu XZS, 1998, J CELL BIOL, V142, P545, DOI 10.1083/jcb.142.2.545; YAU KW, 1989, ANNU REV NEUROSCI, V12, P289, DOI 10.1146/annurev.ne.12.030189.001445; YEANDLE S, 1973, J GEN PHYSIOL, V61, P552, DOI 10.1085/jgp.61.5.552	44	85	85	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	MAY	2000	2	5					296	301		10.1038/35010571	http://dx.doi.org/10.1038/35010571			6	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	313FX	10806481				2022-12-25	WOS:000086990600019
J	Lamb, RF; Roy, C; Diefenbach, TJ; Vinters, HV; Johnson, MW; Jay, DG; Hall, A				Lamb, RF; Roy, C; Diefenbach, TJ; Vinters, HV; Johnson, MW; Jay, DG; Hall, A			The TSC1 tumour suppressor hamartin regulates cell adhesion through ERM proteins and the GTPase Rho	NATURE CELL BIOLOGY			English	Article							ASSISTED LASER INACTIVATION; ACTIN STRESS FIBERS; TUBEROUS-SCLEROSIS; TERMINAL DOMAIN; F-ACTIN; EZRIN; GENE; BINDING; MOESIN; RADIXIN	Loss of the tumour-suppressor gene TSC1 is responsible for hamartoma development in tuberous sclerosis complex (TSC), which renders several organs susceptible to benign tumours. Hamartin, the protein encoded by TSC1, contains a coiled-coil domain and is expressed in most adult tissues, although its function is unknown. Here we show that hamartin interacts with the ezrin-radixin-moesin (ERM) family of actin-binding proteins. Inhibition of hamartin function in cells containing focal adhesions results in loss of adhesion to the cell substrate, whereas overexpression of hamartin in cells lacking focal adhesions results in activation of the small GTP-binding protein Rho, assembly of actin stress fibres and formation of focal adhesions. interaction of endogenous hamartin with ERM-family proteins is required for activation of Rho by serum or by lysophosphatidic acid (LPA). Our data indicate that disruption of adhesion to the cell matrix through loss of hamartin may initiate the development of TSC hamartomas and that a Rho-mediated signalling pathway regulating cell adhesion may constitute a rate-limiting step in tumour formation.	UCL, MRC, Mol Cell Biol Lab, London WC1E 6BT, England; UCL, Dept Biochem, London WC1E 6BT, England; Univ Montpellier 2, CNRS, UMR 5539, F-34095 Montpellier 05, France; Univ Calif Los Angeles, Med Ctr, Brain Res Inst, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA; Tufts Univ, Sch Med, Dept Physiol, Boston, MA 02111 USA	University of London; University College London; University of London; University College London; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; Tufts University	Lamb, RF (corresponding author), UCL, MRC, Mol Cell Biol Lab, Gower St, London WC1E 6BT, England.	r.lamb@ucl.ac.uk						ASPENSTROM P, 1995, METHOD ENZYMOL, V256, P228; Assoian RK, 1997, CURR OPIN CELL BIOL, V9, P93, DOI 10.1016/S0955-0674(97)80157-3; Bretscher A, 1999, CURR OPIN CELL BIOL, V11, P109, DOI 10.1016/S0955-0674(99)80013-1; Bretscher A, 1997, J CELL SCI, V110, P3011; Chishti AH, 1998, TRENDS BIOCHEM SCI, V23, P281, DOI 10.1016/S0968-0004(98)01237-7; Dransfield DT, 1997, EMBO J, V16, P35, DOI 10.1093/emboj/16.1.35; FRANCK Z, 1993, J CELL SCI, V105, P219; Frisch SM, 1997, CURR OPIN CELL BIOL, V9, P701, DOI 10.1016/S0955-0674(97)80124-X; GARY R, 1995, MOL BIOL CELL, V6, P1061, DOI 10.1091/mbc.6.8.1061; GOMEZ MR, 1999, TUBEROUS SCLEROSIS; Guilford P, 1998, NATURE, V392, P402, DOI 10.1038/32918; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Hirao M, 1996, J CELL BIOL, V135, P37, DOI 10.1083/jcb.135.1.37; Huynh DP, 1996, ONCOGENE, V13, P73; Ito N, 1999, CELL, V96, P529, DOI 10.1016/S0092-8674(00)80657-1; Jin F, 1996, P NATL ACAD SCI USA, V93, P9154, DOI 10.1073/pnas.93.17.9154; Johnson MW, 1999, BRAIN PATHOL, V9, P45; Jones AC, 1997, HUM MOL GENET, V6, P2155, DOI 10.1093/hmg/6.12.2155; KANDT RS, 1992, NAT GENET, V2, P37, DOI 10.1038/ng0992-37; Koga H, 1998, ONCOGENE, V17, P801, DOI 10.1038/sj.onc.1202010; Lamb RF, 1997, CURR BIOL, V7, P682, DOI 10.1016/S0960-9822(06)00295-8; LIAO JC, 1995, PHOTOCHEM PHOTOBIOL, V62, P923; Matsui T, 1998, J CELL BIOL, V140, P647, DOI 10.1083/jcb.140.3.647; McClatchey AI, 1998, GENE DEV, V12, P1121, DOI 10.1101/gad.12.8.1121; MCKAY DJG, 1997, J CELL BIOL, V138, P927; NELLIST M, 1993, CELL, V75, P1305; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Pietromonaco SF, 1998, J BIOL CHEM, V273, P7594, DOI 10.1074/jbc.273.13.7594; POVEY S, 1994, ANN HUM GENET, V58, P107, DOI 10.1111/j.1469-1809.1994.tb01881.x; Reczek D, 1997, J CELL BIOL, V139, P169, DOI 10.1083/jcb.139.1.169; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; ROBERTSON D, 1995, J HISTOCHEM CYTOCHEM, V43, P471, DOI 10.1177/43.5.7537292; Roy C, 1997, J BIOL CHEM, V272, P20088, DOI 10.1074/jbc.272.32.20088; SELF AJ, 1995, METHOD ENZYMOL, V256, P3; TACHEUCHI K, 1994, J CELL BIOL, V125, P1371; Takahashi K, 1998, ONCOGENE, V16, P3279, DOI 10.1038/sj.onc.1201874; Takahashi K, 1997, J BIOL CHEM, V272, P23371, DOI 10.1074/jbc.272.37.23371; Tlsty TD, 1998, CURR OPIN CELL BIOL, V10, P647, DOI 10.1016/S0955-0674(98)80041-0; TROFATTER JA, 1993, CELL, V72, P791, DOI 10.1016/0092-8674(93)90406-G; van Slegtenhorst M, 1998, HUM MOL GENET, V7, P1053, DOI 10.1093/hmg/7.6.1053; vanSlegtenhorst M, 1997, SCIENCE, V277, P805, DOI 10.1126/science.277.5327.805; Wang FS, 1996, TRENDS CELL BIOL, V6, P442, DOI 10.1016/S0962-8924(96)40005-8	44	262	272	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	MAY	2000	2	5					281	287		10.1038/35010550	http://dx.doi.org/10.1038/35010550			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	313FX	10806479				2022-12-25	WOS:000086990600017
J	Sun, X; Lewandoski, M; Meyers, EN; Liu, YH; Maxson, RE; Martin, GR				Sun, X; Lewandoski, M; Meyers, EN; Liu, YH; Maxson, RE; Martin, GR			Conditional inactivation of Fgf4 reveals complexity of signalling during limb bud development	NATURE GENETICS			English	Article							APICAL ECTODERMAL RIDGE; VERTEBRATE LIMB; SONIC-HEDGEHOG; FEEDBACK LOOP; MEDIATED RECOMBINATION; GENE-FUNCTION; MOUSE; EXPRESSION; GROWTH; OUTGROWTH	Development of the vertebrate limb bud depends on reciprocal interactions between the zone of polarizing activity (ZPA) and the apical ectodermal ridge(1) (AER). Sonic hedgehog (SHH) and fibroblast growth factors (FGFs) are key signalling molecules produced in the ZPA and AER, respectively(1,2). Experiments in chicks suggested that SHH expression in the ZPA is maintained by FGF4 expression in the AER, acid vice versa(3,4), providing a molecular mechanism for coordinating the activities of these two signalling centres. This SHH/FGF4 feedback loop model is supported by genetic evidence showing that Fgf4 expression is not maintained in Shh(-/-) mouse limbs(5). We report here that Shh expression is maintained and limb formation is normal when Fgf4 is inactivated in mouse limbs, thus contradicting the model. We also found that maintenance of Fgf9 and Fgf17 expression is dependent on Shh, whereas Fgf8 expression is not. We discuss a model in which no individual Fgf expressed in the AER (AER-Fgf) is solely necessary to maintain Shh expression, but, instead, the combined activities of two or more AER-Fgfs function in a positive feedback loop with Shh to control limb development.	Univ Calif San Francisco, Sch Med, Dept Anat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Sch Med, Program Dev Biol, San Francisco, CA 94143 USA; USC Norris Canc Ctr, Dept Biochem & Mol Biol, Los Angeles, CA USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of Southern California	Martin, GR (corresponding author), Univ Calif San Francisco, Sch Med, Dept Anat, San Francisco, CA 94143 USA.			Lewandoski, Mark/0000-0002-1066-3735	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD034380] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE012450] Funding Source: NIH RePORTER; NICHD NIH HHS [R01 HD34380, HD01216] Funding Source: Medline; NIDCR NIH HHS [R01 DE12450] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Bellusci S, 1997, DEVELOPMENT, V124, P4867; Chiang C, 1996, NATURE, V383, P407, DOI 10.1038/383407a0; Colvin JS, 1999, DEV DYNAM, V216, P72; CROSSLEY PH, 1995, DEVELOPMENT, V121, P439; Dymecki SM, 1996, P NATL ACAD SCI USA, V93, P6191, DOI 10.1073/pnas.93.12.6191; ECHELARD Y, 1993, CELL, V75, P1417, DOI 10.1016/0092-8674(93)90627-3; FELDMAN B, 1995, SCIENCE, V267, P246, DOI 10.1126/science.7809630; Hsu DR, 1998, MOL CELL, V1, P673, DOI 10.1016/S1097-2765(00)80067-2; Johnson RL, 1997, CELL, V90, P979, DOI 10.1016/S0092-8674(00)80364-5; JONES CM, 1991, DEVELOPMENT, V111, P531; LAUFER E, 1994, CELL, V79, P993, DOI 10.1016/0092-8674(94)90030-2; Lewandoski M, 1997, COLD SPRING HARB SYM, V62, P159; Lewandoski M, 1997, CURR BIOL, V7, P148, DOI 10.1016/S0960-9822(06)00059-5; LIU YH, 1994, MECH DEVELOP, V48, P187, DOI 10.1016/0925-4773(94)90059-0; Lobe CG, 1999, DEV BIOL, V208, P281, DOI 10.1006/dbio.1999.9209; LYONS KM, 1990, DEVELOPMENT, V109, P833; Martin GR, 1998, GENE DEV, V12, P1571, DOI 10.1101/gad.12.11.1571; Maruoka Y, 1998, MECH DEVELOP, V74, P175, DOI 10.1016/S0925-4773(98)00061-6; Meyers EN, 1998, NAT GENET, V18, P136, DOI 10.1038/ng0298-136; Minowada G, 1999, DEVELOPMENT, V126, P4465; Moon AM, 2000, DEVELOPMENT, V127, P989; MOUNTFORD P, 1994, P NATL ACAD SCI USA, V91, P4303, DOI 10.1073/pnas.91.10.4303; NISWANDER L, 1993, CELL, V75, P579, DOI 10.1016/0092-8674(93)90391-3; NISWANDER L, 1992, DEVELOPMENT, V114, P755; NISWANDER L, 1994, NATURE, V371, P609, DOI 10.1038/371609a0; NISWANDER L, 1993, NATURE, V361, P68, DOI 10.1038/361068a0; Ohuchi H, 1997, DEVELOPMENT, V124, P2235; Sauer B, 1998, METHODS, V14, P381, DOI 10.1006/meth.1998.0593; XU J, IN PRESS DEVELOPMENT; Zuniga A, 1999, NATURE, V401, P598, DOI 10.1038/44157	30	236	251	0	11	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAY	2000	25	1					83	86		10.1038/75644	http://dx.doi.org/10.1038/75644			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	311KU	10802662				2022-12-25	WOS:000086884000022
J	Esnault, C; Maestre, J; Heidmann, T				Esnault, C; Maestre, J; Heidmann, T			Human LINE retrotransposons generate processed pseudogenes	NATURE GENETICS			English	Article							SACCHAROMYCES-CEREVISIAE; TRANSPOSABLE ELEMENTS; INDICATOR GENE; RNA; GENOME; CELLS; INFECTION; TRANSPOSITION; PARTICLES; SEQUENCE	Long interspersed elements (LINEs) are endogenous mobile genetic elements(1-4) that have dispersed and accumulated in the genomes of higher eukaryotes via germline transposition, with up to 100,000 copies in mammalian genomes. In humans, LINEs are the major source of insertional mutagenesis, being involved in both germinal and somatic mutant phenotypes(4). Here we show that the human LINE retrotransposons, which transpose through the reverse transcription of their own transcript(2), can also mobilize transcribed DNA not associated with a LIME sequence by a process involving the diversion of the LINE enzymatic machinery by the corresponding mRNA transcripts. This results in the 'retroposition' of the transcribed gene and the formation of new copies that disclose features characteristic of the widespread and naturally occurring processed pseudogenes: loss of intron and promoter, acquisition of a poly(A) 3' end and presence of target-site duplications of varying length(5,6). We further show-by introducing deletions within either coding sequence of the human LINE-that both ORFs are necessary for the formation of the processed pseudogenes, and that retroviral-like elements are not able to produce similar structures in the same assay. Our results strengthen the unique versatility of LINEs as genome modellers.	Inst Gustave Roussy, CNRS, UMR 1573, Unite Retrovirus Endogenes & Elements Retroides E, Villejuif, France	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy	Heidmann, T (corresponding author), Inst Gustave Roussy, CNRS, UMR 1573, Unite Retrovirus Endogenes & Elements Retroides E, Rue Camille Desmoulins, Villejuif, France.							Boeke J. D., 1997, P343; BOEKE JD, 1985, CELL, V40, P491, DOI 10.1016/0092-8674(85)90197-7; Boeke JD, 1997, NAT GENET, V16, P6, DOI 10.1038/ng0597-6; BROSIUS J, 1991, SCIENCE, V251, P753, DOI 10.1126/science.1990437; CARLTON MBL, 1995, MAMM GENOME, V6, P90, DOI 10.1007/BF00303250; DERR LK, 1991, CELL, V67, P355, DOI 10.1016/0092-8674(91)90187-4; Dhellin O, 1997, EMBO J, V16, P6590, DOI 10.1093/emboj/16.21.6590; DOMBROSKI BA, 1991, SCIENCE, V254, P1805, DOI 10.1126/science.1662412; DORNBURG R, 1990, MOL CELL BIOL, V10, P68, DOI 10.1128/MCB.10.1.68; Eickbush T, 1999, SCIENCE, V283, P1465, DOI 10.1126/science.283.5407.1465; FINNEGAN DJ, 1989, MOBILE DNA, P503; Gabriel A, 1998, TRENDS GENET, V14, P220, DOI 10.1016/S0168-9525(98)01474-7; HEIDMANN O, 1991, CELL, V64, P159, DOI 10.1016/0092-8674(91)90217-M; Hohjoh H, 1996, EMBO J, V15, P630, DOI 10.1002/j.1460-2075.1996.tb00395.x; JENSEN S, 1991, EMBO J, V10, P1927, DOI 10.1002/j.1460-2075.1991.tb07719.x; Kazazian HH, 1999, NAT GENET, V22, P130, DOI 10.1038/9638; Kazazian HH, 1998, NAT GENET, V19, P19, DOI 10.1038/ng0598-19; Kim JM, 1998, GENOME RES, V8, P464, DOI 10.1101/gr.8.5.464; Klenerman P, 1997, NATURE, V390, P298, DOI 10.1038/36876; Lahn BT, 1999, NAT GENET, V21, P429, DOI 10.1038/7771; LEVINE KL, 1990, MOL CELL BIOL, V10, P1891, DOI 10.1128/MCB.10.5.1891; Maestre J, 1995, EMBO J, V14, P6333, DOI 10.1002/j.1460-2075.1995.tb00324.x; MARTIN SL, 1991, MOL CELL BIOL, V11, P4804, DOI 10.1128/MCB.11.9.4804; Moran JV, 1999, SCIENCE, V283, P1530, DOI 10.1126/science.283.5407.1530; Moran JV, 1996, CELL, V87, P917, DOI 10.1016/S0092-8674(00)81998-4; Sandmeyer S, 1998, GENOME RES, V8, P416, DOI 10.1101/gr.8.5.416; TCHENIO T, 1993, EMBO J, V12, P1487, DOI 10.1002/j.1460-2075.1993.tb05792.x; VANIN EF, 1985, ANNU REV GENET, V19, P253, DOI 10.1146/annurev.genet.19.1.253; WEINER AM, 1986, ANNU REV BIOCHEM, V55, P631, DOI 10.1146/annurev.bi.55.070186.003215; Weiss RA, 1997, NATURE, V390, P235, DOI 10.1038/36740	30	607	625	1	33	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	APR	2000	24	4					363	367		10.1038/74184	http://dx.doi.org/10.1038/74184			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	299HK	10742098				2022-12-25	WOS:000086192800013
J	Gibbons, RJ; McDowell, TL; Raman, S; O'Rourke, DM; Garrick, D; Ayyub, H; Higgs, DR				Gibbons, RJ; McDowell, TL; Raman, S; O'Rourke, DM; Garrick, D; Ayyub, H; Higgs, DR			Mutations in ATRX, encoding a SWI/SNF-like protein, cause diverse changes in the pattern of DNA methylation	NATURE GENETICS			English	Article							SEQUENCES; REGION	A goal of molecular genetics is to understand the relationship between basic nuclear processes, epigenetic changes and the numerous proteins that orchestrate these effects. One such protein, ATRX, contains a highly conserved plant homeodomain (PHD)-like domain, present in many chromatin-associated proteins, and a carboxy-terminal domain which identifies it as a member of the SNF2 family of helicase/ATPases(1,2). Mutations in ATRX give rise to characteristic developmental abnormalities including severe mental retardation, facial dysmorphism, urogenital abnormalities and alpha-thalassaemia(1). This circumstantial evidence suggests that ATRX may act as a transcriptional regulator through an effect on chromatin. We have recently shown that ATRX is localized to pericentromeric heterochromatin during interphase and mitosis, suggesting that ATRX might exert other chromatin-mediated effects in the nucleus. Moreover, at metaphase, some ATRX is localized at or close to the ribosomal DNA (rDNA) arrays on the short arms of human acrocentric chromosomes(3). Here we show that mutations in ATRX give rise to changes in the pattern of methylation of several highly repeated sequences including the rDNA arrays, a Y-specific satellite and subtelomeric repeats. Our findings provide a potential link between the processes of chromatin remodelling, DNA methylation and gene expression in mammalian development.	John Radcliffe Hosp, Inst Mol Med, MRC Mol Haematol, Oxford OX3 9DU, England; Univ Oxford, Nuffield Dept Clin Lab, Oxford, England	University of Oxford; University of Oxford	Higgs, DR (corresponding author), John Radcliffe Hosp, Inst Mol Med, MRC Mol Haematol, Oxford OX3 9DU, England.		GARRICK, David/O-5734-2019; Garrick, David/F-1728-2017	GARRICK, David/0000-0001-7422-7986; Garrick, David/0000-0001-7422-7986				BROWN WRA, 1990, CELL, V63, P119, DOI 10.1016/0092-8674(90)90293-N; COOKE HJ, 1982, CHROMOSOMA, V87, P491, DOI 10.1007/BF00333470; Flint J, 1997, NAT GENET, V15, P252, DOI 10.1038/ng0397-252; FROMMER M, 1984, NUCLEIC ACIDS RES, V12, P2887, DOI 10.1093/nar/12.6.2887; GIBBONS RJ, 1995, CELL, V80, P837, DOI 10.1016/0092-8674(95)90287-2; Gibbons RJ, 1997, NAT GENET, V17, P146, DOI 10.1038/ng1097-146; Goenechea L. G., 1992, Cellular and Molecular Biology (Noisy-Le-Grand), V38, P841; Jacobsen SE, 1999, CURR BIOL, V9, pR617, DOI 10.1016/S0960-9822(99)80388-1; Jeddeloh JA, 1999, NAT GENET, V22, P94, DOI 10.1038/8803; KAKUTANI T, 1995, NUCLEIC ACIDS RES, V23, P130, DOI 10.1093/nar/23.1.130; Kakutani T, 1999, GENETICS, V151, P831; McDowell TL, 1999, P NATL ACAD SCI USA, V96, P13983, DOI 10.1073/pnas.96.24.13983; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; SULLIVAN BA, 1995, HUM MOL GENET, V4, P2189, DOI 10.1093/hmg/4.12.2189; TASSERONDEJONG JG, 1988, GENE, V74, P147, DOI 10.1016/0378-1119(88)90272-7; VONGS A, 1993, SCIENCE, V260, P1926, DOI 10.1126/science.8316832; Wade PA, 1999, NAT GENET, V23, P62, DOI 10.1038/12664; Xie SP, 1999, GENE, V236, P87, DOI 10.1016/S0378-1119(99)00252-8; Xu GL, 1999, NATURE, V402, P187, DOI 10.1038/46052; Zhang Y, 1999, GENE DEV, V13, P1924, DOI 10.1101/gad.13.15.1924	20	391	407	0	16	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	APR	2000	24	4					368	371		10.1038/74191	http://dx.doi.org/10.1038/74191			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	299HK	10742099				2022-12-25	WOS:000086192800014
J	Otterbein, LE; Bach, FH; Alam, J; Soares, M; Lu, HT; Wysk, M; Davis, RJ; Flavell, RA; Choi, AMK				Otterbein, LE; Bach, FH; Alam, J; Soares, M; Lu, HT; Wysk, M; Davis, RJ; Flavell, RA; Choi, AMK			Carbon monoxide has anti-inflammatory effects involving the mitogen-activated protein kinase pathway	NATURE MEDICINE			English	Article							TUMOR-NECROSIS-FACTOR; HEME OXYGENASE-1; SIGNAL-TRANSDUCTION; PROVIDES PROTECTION; FACTOR BIOSYNTHESIS; LETHAL ENDOTOXEMIA; OXIDATIVE STRESS; IL-12 PRODUCTION; LUNG INJURY; EXPRESSION	The stress-inducible protein heme oxygenase-1 provides protection against oxidative stress. The antiinflammatory properties of heme oxygenase-1 may serve as a basis for this cytoprotection. We demonstrate here that carbon monoxide, a by-product of heme catabolism by heme oxygenase, mediates potent anti-inflammatory effects. Both in vivo and in vitro, carbon monoxide at low concentrations differentially and selectively inhibited the expression of lipopolysaccharide-induced pro-inflammatory cytokines tumor necrosis factor-alpha, interleukin-1 beta, and macrophage inflammatory protein-lp and increased the lipopolysaccharide-induced expression of the anti-inflammatory cytokine interleukin-10. Carbon monoxide mediated these anti-inflammatory effects not through a guanylyl cyclase-cGMP or nitric oxide pathway, but instead through a pathway involving the mitogen-activated protein kinases. These data indicate the possibility that carbon monoxide may have an important protective function in inflammatory disease states and thus has potential therapeutic uses.	Yale Univ, Sch Med, Pulm & Crit Care Med Sect, New Haven, CT 06520 USA; Connecticut Healthcare Syst, Connecticut Vet Affairs, W Haven, CT 06516 USA; Johns Hopkins Univ, Baltimore, MD 21205 USA; Yale Univ, Sch Med, Howard Hughes Med Inst, New Haven, CT 06520 USA; Yale Univ, Sch Med, Immunobiol Sect, New Haven, CT 06520 USA; Univ Massachusetts, Sch Med, Dept Biochem & Mol Biol, Howard Hughes Med Inst, Worcester, MA 01605 USA; Univ Massachusetts, Sch Med, Dept Biochem & Mol Biol, Program Mol Med, Worcester, MA 01605 USA; Alton Ochsner Med Fdn & Ochsner Clin, Dept Mol Genet, New Orleans, LA 70121 USA; Louisiana State Univ, Med Ctr, Dept Biochem & Mol Biol, New Orleans, LA 70121 USA; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Immunobiol Res Ctr, Boston, MA 02215 USA	Yale University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Connecticut Healthcare System; Johns Hopkins University; Howard Hughes Medical Institute; Yale University; Yale University; Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; Ochsner Health System; Louisiana State University System; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Choi, AMK (corresponding author), Yale Univ, Sch Med, Pulm & Crit Care Med Sect, 333 Cedar St, New Haven, CT 06520 USA.		Alam, Jawed/F-2596-2010	Alam, Jawed/0000-0001-6520-482X; Soares, Miguel/0000-0002-9314-4833	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060234, R01HL055330, R29HL055330] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI042365] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL55330, HL60234] Funding Source: Medline; NIAID NIH HHS [AI42365] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALAM J, 1994, J BIOL CHEM, V269, P25049; Badger AM, 1996, J PHARMACOL EXP THER, V279, P1453; BALLA J, 1993, P NATL ACAD SCI USA, V90, P9285, DOI 10.1073/pnas.90.20.9285; BAUSS F, 1987, INFECT IMMUN, V55, P1622, DOI 10.1128/IAI.55.7.1622-1625.1987; BEUTLER B, 1986, SCIENCE, V232, P977, DOI 10.1126/science.3754653; Chow JC, 1999, J BIOL CHEM, V274, P10689, DOI 10.1074/jbc.274.16.10689; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; Elbirt KK, 1998, J BIOL CHEM, V273, P8922, DOI 10.1074/jbc.273.15.8922; Foey AD, 1998, J IMMUNOL, V160, P920; FUHLBRIGGE RC, 1988, P NATL ACAD SCI USA, V85, P5649, DOI 10.1073/pnas.85.15.5649; GEPPERT TD, 1994, MOL MED, V1, P93; GUNTHER S, 1982, J CELL BIOL, V92, P289, DOI 10.1083/jcb.92.2.289; HAMBLETON J, 1996, P NATL ACAD SCI USA, V93, P2274; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HAN J, 1990, J EXP MED, V171, P465, DOI 10.1084/jem.171.2.465; HAN JH, 1991, BIOCHIM BIOPHYS ACTA, V1090, P22, DOI 10.1016/0167-4781(91)90032-H; Hasko G, 1998, EUR J IMMUNOL, V28, P468, DOI 10.1002/(SICI)1521-4141(199802)28:02<468::AID-IMMU468>3.0.CO;2-Z; HOWARD M, 1993, J EXP MED, V177, P1205, DOI 10.1084/jem.177.4.1205; Jongeneel C V, 1994, Prog Clin Biol Res, V388, P367; Lee PJ, 1996, P NATL ACAD SCI USA, V93, P10393, DOI 10.1073/pnas.93.19.10393; LLESUY SF, 1994, BBA-MOL CELL RES, V1223, P9, DOI 10.1016/0167-4889(94)90067-1; Lu HT, 1999, EMBO J, V18, P1845, DOI 10.1093/emboj/18.7.1845; MORITA T, 1995, P NATL ACAD SCI USA, V92, P1475, DOI 10.1073/pnas.92.5.1475; NATH KA, 1992, J CLIN INVEST, V90, P267, DOI 10.1172/JCI115847; Nemeth ZH, 1997, SHOCK, V7, P371, DOI 10.1097/00024382-199705000-00010; Netea MG, 1998, IMMUNOLOGY, V94, P340, DOI 10.1046/j.1365-2567.1998.00532.x; OTTERBEIN L, 1995, AM J RESP CELL MOL, V13, P595, DOI 10.1165/ajrcmb.13.5.7576696; Otterbein LE, 1999, J CLIN INVEST, V103, P1047, DOI 10.1172/JCI5342; Otterbein LE, 1999, AM J PHYSIOL-LUNG C, V276, pL688; PARILLO JE, 1992, ANN INTERN MED, V113, P991; Poss KD, 1997, P NATL ACAD SCI USA, V94, P10925, DOI 10.1073/pnas.94.20.10925; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; SHIBAHARA S, 1985, P NATL ACAD SCI USA, V82, P7865, DOI 10.1073/pnas.82.23.7865; Soares MP, 1998, NAT MED, V4, P1073, DOI 10.1038/2063; STOCKER R, 1987, SCIENCE, V235, P1043, DOI 10.1126/science.3029864; STUPFEL M, 1970, ANN NY ACAD SCI, V174, P342, DOI 10.1111/j.1749-6632.1970.tb49799.x; Szabo C, 1997, SHOCK, V7, P304, DOI 10.1097/00024382-199704000-00011; TENHUNEN R, 1968, P NATL ACAD SCI USA, V61, P748, DOI 10.1073/pnas.61.2.748; Tetreau C, 1999, BIOCHEMISTRY-US, V38, P7210, DOI 10.1021/bi9901026; Thomassen MJ, 1997, AM J RESP CELL MOL, V17, P279, DOI 10.1165/ajrcmb.17.3.2998m; VERMA A, 1993, SCIENCE, V259, P381, DOI 10.1126/science.7678352; Wysk M, 1999, P NATL ACAD SCI USA, V96, P3763, DOI 10.1073/pnas.96.7.3763; Yachie A, 1999, J CLIN INVEST, V103, P129, DOI 10.1172/JCI4165; Yang RB, 1998, NATURE, V395, P284, DOI 10.1038/26239	45	1765	1882	8	185	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	APR	2000	6	4					422	428		10.1038/74680	http://dx.doi.org/10.1038/74680			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	376UA	10742149				2022-12-25	WOS:000165474100036
J	Persidis, A				Persidis, A			Progress against AIDS	NATURE BIOTECHNOLOGY			English	Editorial Material									RheoGene, Charlottesville, VA 22903 USA		Persidis, A (corresponding author), RheoGene, 706 Forest St, Charlottesville, VA 22903 USA.							Henry K, 2000, ANN INTERN MED, V132, P306, DOI 10.7326/0003-4819-132-4-200002150-00009	1	2	2	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	APR	2000	18	4					466	467		10.1038/74566	http://dx.doi.org/10.1038/74566			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	303UY	10748537				2022-12-25	WOS:000086444300036
J	Satokata, I; Ma, L; Ohshima, H; Bei, M; Woo, I; Nishizawa, K; Maeda, T; Takano, Y; Uchiyama, M; Heaney, S; Peters, H; Tang, ZQ; Maxson, R; Maas, R				Satokata, I; Ma, L; Ohshima, H; Bei, M; Woo, I; Nishizawa, K; Maeda, T; Takano, Y; Uchiyama, M; Heaney, S; Peters, H; Tang, ZQ; Maxson, R; Maas, R			Msx2 deficiency in mice causes pleiotropic defects in bone growth and ectodermal organ formation	NATURE GENETICS			English	Article							PARIETAL FORAMINA; TOOTH DEVELOPMENT; INDIAN HEDGEHOG; HOMEODOMAIN; GENE; CRANIOSYNOSTOSIS; EXPRESSION; MUTATION; FAMILY; FETAL	The composite structure of the mammalian skull, which forms predominantly via intramembranous ossification, requires precise pre- and post-natal growth regulation of individual calvarial elements. Disturbances of this process frequently cause severe clinical manifestations in humans. Enhanced DNA binding by a mutant MSX2 homeodomain results in a gain of function and produces craniosynostosis in humans(1,2). Here we show that Msx2-deficient mice have defects of skull ossification and persistent calvarial foramen, This phenotype results from defective proliferation of osteoprogenitors at the osteogenic front during calvarial morphogenesis, and closely resembles that associated with human MSX2 haploinsufficiency in parietal foramina(3) (PFM), Msx2(-/-) mice also have defects in endochondral bone formation. In the axial and appendicular skeleton, post-natal deficits in Pth/Pthrp receptor (Pthr) signalling and in expression of marker genes for bone differentiation indicate that Msx2 is required for both chondrogenesis and osteogenesis, Consistent with phenotypes associated with PFM, Msx2-mutant mice also display defective tooth, hair follicle and mammary gland development, and seizures, the latter accompanied by abnormal development of the cerebellum. Most Msx2-mutant phenotypes, including calvarial defects, are enhanced by genetic combination with Msx1 loss of function, indicating that Msx gene dosage can modify expression of the PFM phenotype. Our results provide a developmental basis for PFM and demonstrate that Msx2 is essential at multiple sites during organogenesis.	Univ So Calif, Sch Med, Dept Biochem & Mol Biol, Los Angeles, CA 90089 USA; Norris Canc Ctr, Los Angeles, CA USA; Brigham & Womens Hosp, Dept Med, Div Genet, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Niigata Univ, Sch Med, Dept Pediat, Asahimachi, Japan; Niigata Univ, Fac Dent, Dept Oral Anat, Niigata, Japan; Tokyo Med & Dent Univ, Fac Dent, Dept Oral Anat, Tokyo, Japan	University of Southern California; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Niigata University; Niigata University; Tokyo Medical & Dental University (TMDU)	Maas, R (corresponding author), Univ So Calif, Sch Med, Dept Biochem & Mol Biol, Los Angeles, CA 90089 USA.		Ohshima, Hayato/AAW-5545-2020	Ohshima, Hayato/0000-0001-8571-9900	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE011697] Funding Source: NIH RePORTER; NIDCR NIH HHS [R01 DE11697] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Amizuka N, 1996, DEV BIOL, V175, P166, DOI 10.1006/dbio.1996.0104; Bei M, 1998, DEVELOPMENT, V125, P4325; Chrzanowska K, 1998, AM J MED GENET, V78, P401, DOI 10.1002/(SICI)1096-8628(19980806)78:5<401::AID-AJMG1>3.0.CO;2-O; Dodig M, 1999, DEV BIOL, V209, P298, DOI 10.1006/dbio.1999.9258; Goldowitz D, 1998, TRENDS NEUROSCI, V21, P375, DOI 10.1016/S0166-2236(98)01313-7; HEBERT JM, 1994, CELL, V78, P1017, DOI 10.1016/0092-8674(94)90276-3; JABS EW, 1993, CELL, V75, P443, DOI 10.1016/0092-8674(93)90379-5; KARAPLIS AC, 1994, GENE DEV, V8, P277, DOI 10.1101/gad.8.3.277; KITE WC, 1961, NEUROLOGY, V11, P345, DOI 10.1097/00132985-196104000-00010; Lanske B, 1996, SCIENCE, V273, P663, DOI 10.1126/science.273.5275.663; LITTLE BB, 1990, AM J MED GENET, V35, P453, DOI 10.1002/ajmg.1320350402; Liu YH, 1999, DEV BIOL, V205, P260, DOI 10.1006/dbio.1998.9114; Ma L, 1996, HUM MOL GENET, V5, P1915, DOI 10.1093/hmg/5.12.1915; MACKENZIE A, 1992, DEVELOPMENT, V115, P403; McKusick V.A., 1998, MENDELIAN INHERITANC; Newberry EP, 1998, BIOCHEMISTRY-US, V37, P16360, DOI 10.1021/bi981878u; Oro AE, 1997, SCIENCE, V276, P817, DOI 10.1126/science.276.5313.817; Paus R, 1999, J INVEST DERMATOL, V113, P523, DOI 10.1046/j.1523-1747.1999.00740.x; Pennacchio LA, 1998, NAT GENET, V20, P251, DOI 10.1038/3059; Phippard DJ, 1996, DEVELOPMENT, V122, P2729; PREIS S, 1995, ACTA PAEDIATR, V84, P701, DOI 10.1111/j.1651-2227.1995.tb13735.x; REGINELLI AD, 1995, DEVELOPMENT, V121, P1065; Sakakura T., 1987, The mammary gland. Development, regulation, and function., P37; SAKAKURA Y, 1989, AM J ANAT, V184, P287, DOI 10.1002/aja.1001840404; SATOKATA I, 1994, NAT GENET, V6, P348, DOI 10.1038/ng0494-348; VANGENDEREN C, 1994, GENE DEV, V8, P2691, DOI 10.1101/gad.8.22.2691; Vortkamp A, 1996, SCIENCE, V273, P613, DOI 10.1126/science.273.5275.613; Wilkie AOM, 2000, NAT GENET, V24, P387, DOI 10.1038/74224; Xu PX, 1999, NAT GENET, V23, P113, DOI 10.1038/12722	29	584	603	1	32	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	APR	2000	24	4					391	395		10.1038/74231	http://dx.doi.org/10.1038/74231			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	299HK	10742104				2022-12-25	WOS:000086192800019
J	van den Boogaard, MJH; Dorland, M; Beemer, FA; van Amstel, HKP				van den Boogaard, MJH; Dorland, M; Beemer, FA; van Amstel, HKP			MSX1 mutation is associated with orofacial clefting and tooth agenesis in humans	NATURE GENETICS			English	Article							PALATE; LIP; PREVALENCE		Univ Utrecht, Med Ctr, Dept Med Genet, Utrecht, Netherlands	Utrecht University	van den Boogaard, MJH (corresponding author), Univ Utrecht, Med Ctr, Dept Med Genet, Utrecht, Netherlands.							Christensen K, 1996, AM J HUM GENET, V58, P182; Croen LA, 1998, AM J MED GENET, V79, P42, DOI 10.1002/(SICI)1096-8628(19980827)79:1<42::AID-AJMG11>3.0.CO;2-M; FITZPATRICK D, 1993, J CRAN GENET DEV BIO, V13, P230; FRASER FC, 1970, AM J HUM GENET, V22, P336; HEWITT JE, 1991, GENOMICS, V11, P670, DOI 10.1016/0888-7543(91)90074-O; Hu GZ, 1998, MOL CELL BIOL, V18, P6044, DOI 10.1128/MCB.18.10.6044; Lidral AC, 1998, AM J HUM GENET, V63, P557, DOI 10.1086/301956; Murray JC, 1997, CLEFT PALATE-CRAN J, V34, P7, DOI 10.1597/1545-1569(1997)034<0007:CAESOC>2.3.CO;2; SATOKATA I, 1994, NAT GENET, V6, P348, DOI 10.1038/ng0494-348; Satokata I, 2000, NAT GENET, V24, P391, DOI 10.1038/74231; Schutte BC, 1999, HUM MOL GENET, V8, P1853, DOI 10.1093/hmg/8.10.1853; Tolarova MM, 1998, AM J MED GENET, V75, P126; VANDERAS AP, 1987, CLEFT PALATE J, V24, P216; Vastardis H, 1996, NAT GENET, V13, P417, DOI 10.1038/ng0896-417; Wilkie AOM, 2000, NAT GENET, V24, P387, DOI 10.1038/74224	15	421	430	0	25	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	APR	2000	24	4					342	343		10.1038/74155	http://dx.doi.org/10.1038/74155			2	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	299HK	10742093				2022-12-25	WOS:000086192800009
J	Baiker, A; Maercker, C; Piechaczek, C; Schmidt, SBA; Bode, J; Benham, C; Lipps, HJ				Baiker, A; Maercker, C; Piechaczek, C; Schmidt, SBA; Bode, J; Benham, C; Lipps, HJ			Mitotic stability of an episomal vector containing a human scaffold/matrix-attached region is provided by association with nuclear matrix	NATURE CELL BIOLOGY			English	Article							DNA; AMPLIFICATION; CHROMOSOME; SEQUENCE		Univ Witten Herdecke, Inst Zellbiol, D-58448 Witten, Germany; Gesell Biotechnol Forsch mbH, D-38124 Braunschweig, Germany; Mt Sinai Sch Med, Dept Biomath Sci, New York, NY 10029 USA	Witten Herdecke University; Gesellschaft fur Biotechnologische Forschung mbH; Icahn School of Medicine at Mount Sinai	Lipps, HJ (corresponding author), Univ Witten Herdecke, Inst Zellbiol, Stockumer Str 10, D-58448 Witten, Germany.	lipps@uni-wh.de	Baiker, Alfons/S-6912-2017; Benham, Craig J/G-1512-2013	Baiker, Alfons/0000-0003-1408-464X; 	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047012] Funding Source: NIH RePORTER; NIGMS NIH HHS [R0I-GM47012] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ballestas ME, 1999, SCIENCE, V284, P641, DOI 10.1126/science.284.5414.641; Benham C, 1997, J MOL BIOL, V274, P181, DOI 10.1006/jmbi.1997.1385; BODE J, IN PRESS CRIT REV EU; Calos MP, 1998, P NATL ACAD SCI USA, V95, P4084, DOI 10.1073/pnas.95.8.4084; Cook PR, 1999, SCIENCE, V284, P1790, DOI 10.1126/science.284.5421.1790; Cossons N, 1997, J CELL BIOCHEM, V67, P439, DOI 10.1002/(SICI)1097-4644(19971215)67:4<439::AID-JCB3>3.0.CO;2-T; Dijkwel PA, 1995, INT REV CYTOL, V162A, P455; FANNING E, 1992, ANNU REV BIOCHEM, V61, P55; Ferraro A, 1996, J CELL BIOCHEM, V62, P495; KAY V, 1995, METHOD MOL CELL BIOL, V5, P186; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lehman CW, 1998, P NATL ACAD SCI USA, V95, P4338, DOI 10.1073/pnas.95.8.4338; Liu CG, 1996, P NATL ACAD SCI USA, V93, P4278, DOI 10.1073/pnas.93.9.4278; MIELKE C, 1990, BIOCHEMISTRY-US, V29, P7475, DOI 10.1021/bi00484a017; MISKIMIS WK, 1985, P NATL ACAD SCI USA, V82, P6791; Nickerson JA, 1998, CELL BIOLOGY - A LABORATORY HANDBOOK, 2ND EDITION, VOL 2, P184; Piechaczek C, 1999, NUCLEIC ACIDS RES, V27, P426, DOI 10.1093/nar/27.2.426; ROBINS DM, 1981, CELL, V23, P29, DOI 10.1016/0092-8674(81)90267-1; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; WEGNER M, 1989, NUCLEIC ACIDS RES, V17, P9909, DOI 10.1093/nar/17.23.9909	20	115	124	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	MAR	2000	2	3					182	184		10.1038/35004061	http://dx.doi.org/10.1038/35004061			3	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	292AE	10707091				2022-12-25	WOS:000085771300020
J	Boussiotis, VA; Freeman, GJ; Taylor, PA; Berezovskaya, A; Grass, I; Blazar, BR; Nadler, LM				Boussiotis, VA; Freeman, GJ; Taylor, PA; Berezovskaya, A; Grass, I; Blazar, BR; Nadler, LM			p27(kip1) functions as an anergy factor inhibiting interleukin 2 transcription and clonal expansion of alloreactive human and mouse helper T lymphocytes	NATURE MEDICINE			English	Article							DEPENDENT KINASE INHIBITOR; PROTEIN-TYROSINE KINASES; VERSUS-HOST DISEASE; CELL-CYCLE; SIGNALING PATHWAY; IL-2 GENE; ACTIVATION; EXPRESSION; INDUCTION; BLOCKADE	Although recent in vitro studies have begun to decipher the molecular events that characterize the anergic state, their in vivo biologic relevance and potential clinical importance remain unclear. Here, using anergic human T-cell clones and tolerant alloreactive mouse T cells that do not induce graft-versus-host disease, we show that p27(kip1) cyclin-dependent kinase inhibitor is an essential regulator responsible for the blockade of clonal expansion of anergic T cells in vitro and in vivo. Moreover, in anergic cells, p27(kip1) associates with the c-Jun co-activator JAB1, resulting in defective transactivation of AP-1 and interleukin 2 transcription. Therefore, pharmacological agents that upregulate the expression of or prevent the degradation of p27(kip1) during antigen recognition should be part of new therapeutic strategies to induce antigen-specific T-cell unresponsiveness.	Brigham & Womens Hosp, Dept Adult Oncol, Dana Farber Canc Inst, Div Med Oncol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; Univ Minnesota, Ctr Canc, Dept Pediat, Minneapolis, MN 55455 USA	Harvard University; Brigham & Women's Hospital; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; University of Minnesota System; University of Minnesota Twin Cities	Boussiotis, VA (corresponding author), Brigham & Womens Hosp, Dept Adult Oncol, Dana Farber Canc Inst, Div Med Oncol, 75 Francis St, Boston, MA 02115 USA.		Freeman, Gordon/AAC-5380-2019	Freeman, Gordon/0000-0002-7210-5616	NHLBI NIH HHS [HL 54785] Funding Source: Medline; NIAID NIH HHS [AI 43552, AI 41584] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL054785] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI043552, R56AI043552, R01AI043552, P01AI041584] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AJCHENBAUM F, 1993, J BIOL CHEM, V268, P4113; BEVERLY B, 1992, INT IMMUNOL, V4, P661, DOI 10.1093/intimm/4.6.661; Blazar BR, 1998, J CLIN INVEST, V102, P473, DOI 10.1172/JCI3741; BLAZAR BR, 1994, BLOOD, V83, P3815; Boussiotis VA, 1996, J EXP MED, V184, P365, DOI 10.1084/jem.184.2.365; Boussiotis VA, 1997, SCIENCE, V278, P124, DOI 10.1126/science.278.5335.124; CHAN FKM, 1995, MOL CELL BIOL, V15, P2682; CHO EA, 1993, J IMMUNOL, V151, P20; Claret FX, 1996, NATURE, V383, P453, DOI 10.1038/383453a0; de Rooij J, 1998, NATURE, V396, P474, DOI 10.1038/24884; DECAPRIO JA, 1992, P NATL ACAD SCI USA, V89, P1795, DOI 10.1073/pnas.89.5.1795; Elliott G, 1997, CELL, V88, P223, DOI 10.1016/S0092-8674(00)81843-7; Fields PE, 1996, SCIENCE, V271, P1276, DOI 10.1126/science.271.5253.1276; GAJEWSKI TF, 1995, EUR J IMMUNOL, V25, P1836, DOI 10.1002/eji.1830250707; GAJEWSKI TF, 1994, P NATL ACAD SCI USA, V91, P38, DOI 10.1073/pnas.91.1.38; GILBERT KM, 1993, J IMMUNOL, V151, P1245; GRANGER DK, 1994, SURGERY, V116, P236; Grewal IS, 1998, ANNU REV IMMUNOL, V16, P111, DOI 10.1146/annurev.immunol.16.1.111; Guinan EC, 1999, NEW ENGL J MED, V340, P1704, DOI 10.1056/NEJM199906033402202; Kamesaki H, 1998, J IMMUNOL, V160, P770; KANG SM, 1992, SCIENCE, V257, P1134, DOI 10.1126/science.257.5073.1134; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; Kawada M, 1997, ONCOGENE, V15, P629, DOI 10.1038/sj.onc.1201228; Kirk AD, 1997, P NATL ACAD SCI USA, V94, P8789, DOI 10.1073/pnas.94.16.8789; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; Kwon TK, 1997, J IMMUNOL, V158, P5642; Larsen CP, 1996, NATURE, V381, P434, DOI 10.1038/381434a0; Li LS, 1999, SCIENCE, V283, P848, DOI 10.1126/science.283.5403.848; Li YS, 1998, TRANSPLANTATION, V66, P1387, DOI 10.1097/00007890-199811270-00021; MADRENAS J, 1995, SCIENCE, V267, P515, DOI 10.1126/science.7824949; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; Mondino A, 1996, J IMMUNOL, V157, P2048; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; NUNES JA, 1994, J EXP MED, V180, P1067, DOI 10.1084/jem.180.3.1067; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; Powell JD, 1999, J IMMUNOL, V162, P2775; QUILL H, 1992, J IMMUNOL, V149, P2887; Schwartz RH, 1997, CURR OPIN IMMUNOL, V9, P351, DOI 10.1016/S0952-7915(97)80081-7; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SloanLancaster J, 1996, J EXP MED, V184, P1525, DOI 10.1084/jem.184.4.1525; Tamir A, 1996, J IMMUNOL, V157, P1514; Tomoda K, 1999, NATURE, V398, P160, DOI 10.1038/18230; Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0	45	200	205	0	5	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAR	2000	6	3					290	297		10.1038/73144	http://dx.doi.org/10.1038/73144			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	288TL	10700231				2022-12-25	WOS:000085580500039
J	Eroglu, A; Russo, MJ; Bieganski, R; Fowler, A; Cheley, S; Bayley, H; Toner, M				Eroglu, A; Russo, MJ; Bieganski, R; Fowler, A; Cheley, S; Bayley, H; Toner, M			Intracellular trehalose improves the survival of cryopreserved mammalian cells	NATURE BIOTECHNOLOGY			English	Article						trehalose; alpha-toxin; cryopreservation; fibroblasts; keratinocytes	PORE-FORMING PROTEIN; ALPHA-TOXIN; STABILIZATION; MEMBRANE; SWITCH	We report that the introduction of low concentrations of intracellular trehalose can greatly improve the survival of mammalian cells during cryopreservation. Using a genetically engineered mutant of Staphylococcus aureus alpha-hemolysin to create pores in the cellular membrane, we were able to load trehalose into cells. Low concentrations (0.2 M) of trehalose permitted long-term post-thaw survival of more than 80% of 3T3 fibroblasts and 70% of human keratinocytes. These results indicate that simplified and widely applicable freezing protocols may be possible using sugars as intracellular cryoprotective additives.	Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Engn Med, Boston, MA 02114 USA; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Surg Serv, Boston, MA 02114 USA; Shriners Hosp Crippled Children, Boston, MA 02114 USA; Texas A&M Univ, Dept Med Biochem & Genet, College Stn, TX 77843 USA; Univ Massachusetts, Dept Mech Engn, N Dartmouth, MA 02747 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; Texas A&M University System; Texas A&M University College Station; University of Massachusetts System; University Massachusetts Dartmouth	Toner, M (corresponding author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Engn Med, Boston, MA 02114 USA.		Fowler, Alex/AAC-3573-2019	Bayley, Hagan/0000-0003-2499-6116	NIDDK NIH HHS [DK46270] Funding Source: Medline; NINDS NIH HHS [NS26760] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK046270, R01DK046270] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS026760] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bayley H, 1997, SCI AM, V277, P62, DOI 10.1038/scientificamerican0997-62; Beattie GM, 1997, DIABETES, V46, P519, DOI 10.2337/diabetes.46.3.519; Bieganski RM, 1998, BIOTECHNOL PROGR, V14, P615, DOI 10.1021/bp980057d; CARPENTER JF, 1987, BIOCHIM BIOPHYS ACTA, V923, P109, DOI 10.1016/0304-4165(87)90133-4; CROWE LM, 1984, BIOCHIM BIOPHYS ACTA, V769, P141, DOI 10.1016/0005-2736(84)90017-8; CROWE LM, 1985, ARCH BIOCHEM BIOPHYS, V242, P240, DOI 10.1016/0003-9861(85)90498-9; EMING SA, 1997, METHODS MOL MED GENE, P266; GREEN JL, 1989, J PHYS CHEM-US, V93, P2880, DOI 10.1021/j100345a006; HILDEBRAND A, 1991, J BIOL CHEM, V266, P17195; ISRAELI E, 1993, CRYOBIOLOGY, V30, P519, DOI 10.1006/cryo.1993.1052; LANGER R, 1993, SCIENCE, V260, P920, DOI 10.1126/science.8493529; MAZUR P, 1984, AM J PHYSIOL, V247, pC125, DOI 10.1152/ajpcell.1984.247.3.C125; MAZUR P, 1969, CRYOBIOLOGY, V6, P1, DOI 10.1016/S0011-2240(69)80002-7; MAZUR P, 1972, EXP CELL RES, V71, P345, DOI 10.1016/0014-4827(72)90303-5; Miller DP, 1997, PHARMACEUT RES, V14, P578, DOI 10.1023/A:1012192725996; MULLIGAN RC, 1993, SCIENCE, V260, P926, DOI 10.1126/science.8493530; Rossi S, 1997, BIOTECHNOL PROGR, V13, P609, DOI 10.1021/bp970061+; Russo MJ, 1997, NAT BIOTECHNOL, V15, P278, DOI 10.1038/nbt0397-278; Song LZ, 1996, SCIENCE, V274, P1859, DOI 10.1126/science.274.5294.1859; URITANI M, 1995, J BIOCHEM-TOKYO, V117, P774, DOI 10.1093/oxfordjournals.jbchem.a124775; WALEV I, 1993, INFECT IMMUN, V61, P4972, DOI 10.1128/IAI.61.12.4972-4979.1993; WALKER B, 1995, CHEM BIOL, V2, P99, DOI 10.1016/1074-5521(95)90282-1; WALKER B, 1994, PROTEIN ENG, V7, P655, DOI 10.1093/protein/7.5.655	23	388	432	6	87	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	FEB	2000	18	2					163	167		10.1038/72608	http://dx.doi.org/10.1038/72608			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	281FH	10657121				2022-12-25	WOS:000085146900022
J	Tanoue, T; Adachi, M; Moriguchi, T; Nishida, E				Tanoue, T; Adachi, M; Moriguchi, T; Nishida, E			A conserved docking motif in MAP kinases common to substrates, activators and regulators	NATURE CELL BIOLOGY			English	Article							OF-FUNCTION MUTATION; PROTEIN-KINASE; ERK2; TRANSCRIPTION; SPECIFICITY; PATHWAYS; CASCADES; CELLS; MNK1; JNK	Mitogen-activated protein kinases (MAPKs) are specifically phosphorylated and activated by the MAPK kinases, phosphorylate various targets such as MARK-activated protein kinases and transcription factors, and are inactivated by specific phosphatases. Recently, docking interactions via the non-catalytic regions of MAPKs have been suggested to be important in regulating these reactions. Here we identify docking sites in MAPKs and in MAPK-interacting enzymes. A docking domain in extracellular-signal-regulated kinase (ERK), a MAPK, serves as a common site for binding to the MAPK kinase MEK1, the MARK-activated protein kinase MNK1 and the MAPK phosphatase MKP3. Two aspartic acids in this domain are essential for docking, one of which is mutated in the sevenmaker mutant of Drosophila ERK/Rolled. A corresponding domain in the MAPKs p38 and JNK/SAPK also serves as a common docking site for their MEKs, MAPK-activated protein kinases and MKPs. These docking interactions increase the efficiency of the enzymatic reactions. These findings reveal a hitherto unidentified docking motif in MAPKs that is used in common for recognition of their activators, substrates and regulators.	Kyoto Univ, Dept Biophys, Grad Sch Sci, Sakyo Ku, Kyoto 6068502, Japan; Kyoto Univ, Dept Cell & Dev Biol, Grad Sch Biostudies, Sakyo Ku, Kyoto 6068502, Japan	Kyoto University; Kyoto University	Nishida, E (corresponding author), Kyoto Univ, Dept Biophys, Grad Sch Sci, Sakyo Ku, Kyoto 6068502, Japan.	L50174@sakura.kudpc.kyoto-u.ac.jp	Moriguchi, Tetsuo/D-7061-2012	Moriguchi, Tetsuo/0000-0002-9598-4991				Ahn Natalie G., 1992, Current Opinion in Cell Biology, V4, P992, DOI 10.1016/0955-0674(92)90131-U; Bardwell L, 1996, TRENDS BIOCHEM SCI, V21, P373, DOI 10.1016/S0968-0004(96)30032-7; BOTT CM, 1994, FEBS LETT, V352, P201, DOI 10.1016/0014-5793(94)00958-9; Brunet A, 1996, SCIENCE, V272, P1652, DOI 10.1126/science.272.5268.1652; BRUNNER D, 1994, CELL, V76, P875, DOI 10.1016/0092-8674(94)90362-X; Camps M, 1998, SCIENCE, V280, P1262, DOI 10.1126/science.280.5367.1262; Chu YF, 1996, J BIOL CHEM, V271, P6497, DOI 10.1074/jbc.271.11.6497; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; Duesbery NS, 1998, SCIENCE, V280, P734, DOI 10.1126/science.280.5364.734; Fukuda M, 1997, EMBO J, V16, P1901, DOI 10.1093/emboj/16.8.1901; Fukunaga R, 1997, EMBO J, V16, P1921, DOI 10.1093/emboj/16.8.1921; Gavin AC, 1999, CURR BIOL, V9, P281, DOI 10.1016/S0960-9822(99)80120-1; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; Holland PM, 1999, CURR BIOL, V9, pR329, DOI 10.1016/S0960-9822(99)80205-X; Jacobs D, 1999, GENE DEV, V13, P163, DOI 10.1101/gad.13.2.163; Kallunki T, 1996, CELL, V87, P929, DOI 10.1016/S0092-8674(00)81999-6; Karim FD, 1999, MOL CELL, V3, P741, DOI 10.1016/S1097-2765(01)80006-X; Khokhlatchev AV, 1998, CELL, V93, P605, DOI 10.1016/S0092-8674(00)81189-7; Kyriakis JM, 1996, BIOESSAYS, V18, P567, DOI 10.1002/bies.950180708; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Moriguchi T, 1996, J BIOL CHEM, V271, P26981, DOI 10.1074/jbc.271.43.26981; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; PRITCHARD CA, 1995, MOL CELL BIOL, V15, P6430; Pulido R, 1998, EMBO J, V17, P7337, DOI 10.1093/emboj/17.24.7337; Smith JA, 1999, J BIOL CHEM, V274, P2893, DOI 10.1074/jbc.274.5.2893; STURGILL TW, 1994, BIOCHIM BIOPHYS ACTA, V1092, P350; Tanoue T, 1999, J BIOL CHEM, V274, P19949, DOI 10.1074/jbc.274.28.19949; Tournier C, 1999, MOL CELL BIOL, V19, P1569; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; WANG X, 1997, STRUCTURE, V94, P2327; Waskiewicz AJ, 1997, EMBO J, V16, P1909, DOI 10.1093/emboj/16.8.1909; Wilsbacher JL, 1999, J BIOL CHEM, V274, P16988, DOI 10.1074/jbc.274.24.16988; Wilson KP, 1996, J BIOL CHEM, V271, P27696, DOI 10.1074/jbc.271.44.27696; Xia Y, 1998, GENE DEV, V12, P3369, DOI 10.1101/gad.12.21.3369; Yang SH, 1999, MOL CELL BIOL, V19, P4028; Yang SH, 1998, EMBO J, V17, P1740, DOI 10.1093/emboj/17.6.1740; ZHANG FM, 1994, NATURE, V367, P704, DOI 10.1038/367704a0; Zuniga A, 1999, J BIOL CHEM, V274, P21900, DOI 10.1074/jbc.274.31.21900	39	662	679	5	48	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	FEB	2000	2	2					110	116		10.1038/35000065	http://dx.doi.org/10.1038/35000065			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	281GA	10655591				2022-12-25	WOS:000085148500016
J	Amanuma, K; Takeda, H; Amanuma, H; Aoki, Y				Amanuma, K; Takeda, H; Amanuma, H; Aoki, Y			Transgenic zebrafish for detecting mutations caused by compounds in aquatic environments	NATURE BIOTECHNOLOGY			English	Article						transgenic zebrafish; mutation assay; rpsL gene; N-ethyl-N-nitrosourea; benzo[a]pyrene; 2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline; aquatic environments	GERM-LINE TRANSMISSION; MICE; MUTAGENESIS; SEQUENCES; GENE; ENU; MUTAGENICITY; GENOTOXICITY; FREQUENCY; RECOVERY	We have established a transgenic zebrafish line carrying a shuttle vector plasmid (pML4) for detecting mutagens in aquatic environments. The plasmid contains the rpsL gene of Escherichia coli as a mutational target gene, and the kanamycin-resistance gene for recovering the plasmid from the chromosomal DNA. To evaluate the system, we treated embryos of the transgenic fish with N-ethyl-N-nitrosourea (ENU), which induces a dose-dependent increase in the mutation frequency of the target gene. The mutation spectrum was consistent with the proposed mechanism of ENU mutagenesis. Similarly, treating the embryos with benzo[a]pyrene or 2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline, which are found in naturally polluted water, significantly increased the frequency of mutations in the target gene.	Natl Inst Environm Studies, Div Environm Hlth Sci, Tsukuba, Ibaraki 3050053, Japan; Nagoya Univ, Sch Sci, Dept Mol Biol, Nagoya, Aichi 4648602, Japan	National Institute for Environmental Studies - Japan; Nagoya University	Amanuma, K (corresponding author), Natl Inst Environm Studies, Div Environm Hlth Sci, Tsukuba, Ibaraki 3050053, Japan.							AMES BN, 1975, MUTAT RES, V31, P347, DOI 10.1016/0165-1161(75)90046-1; BURKHART JG, 1993, MUTAT RES, V292, P69, DOI 10.1016/0165-1161(93)90009-O; CULP P, 1991, P NATL ACAD SCI USA, V88, P7953, DOI 10.1073/pnas.88.18.7953; Driever W, 1996, DEVELOPMENT, V123, P37; FAIRBAIRN DW, 1995, MUTAT RES-REV GENET, V339, P37, DOI 10.1016/0165-1110(94)00013-3; Gondo Y, 1996, MUTAT RES-ENVIR MUTA, V360, P1, DOI 10.1016/S0165-1161(96)90231-9; GOSSEN JA, 1989, P NATL ACAD SCI USA, V86, P7971, DOI 10.1073/pnas.86.20.7971; HEDDLE JA, 1973, MUTAT RES, V18, P187, DOI 10.1016/0027-5107(73)90035-3; KOHLER SW, 1991, P NATL ACAD SCI USA, V88, P7958, DOI 10.1073/pnas.88.18.7958; MO JY, 1991, J MOL BIOL, V222, P925, DOI 10.1016/0022-2836(91)90586-U; Nohmi T, 1996, ENVIRON MOL MUTAGEN, V28, P465, DOI 10.1002/(SICI)1098-2280(1996)28:4<465::AID-EM24>3.0.CO;2-C; Ohe T, 1997, MUTAT RES-GEN TOX EN, V393, P73, DOI 10.1016/S1383-5718(97)00087-9; RILEY BB, 1995, P NATL ACAD SCI USA, V92, P5997, DOI 10.1073/pnas.92.13.5997; SCHMID W, 1975, MUTAT RES, V31, P9, DOI 10.1016/0165-1161(75)90058-8; Shelby MD, 1997, MUTAT RES-GEN TOX EN, V388, P99, DOI 10.1016/S1383-5718(96)00106-4; SHIBUYA T, 1993, MUTAT RES, V297, P3, DOI 10.1016/0165-1110(93)90005-8; SINGH NP, 1988, EXP CELL RES, V175, P184, DOI 10.1016/0014-4827(88)90265-0; SOLNICAKREZEL L, 1994, GENETICS, V136, P1401; STUART GW, 1990, DEVELOPMENT, V109, P577; STUART GW, 1988, DEVELOPMENT, V103, P403; TALBOT WS, 1995, NATURE, V378, P150, DOI 10.1038/378150a0; White PA, 1998, MUTAT RES-REV MUTAT, V410, P223, DOI 10.1016/S1383-5742(98)00002-7; Willett KL, 1997, ARCH ENVIRON CON TOX, V32, P442, DOI 10.1007/s002449900211; WINN RN, 1995, MAR ENVIRON RES, V40, P247, DOI 10.1016/0141-1136(94)00144-E	24	64	70	1	12	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JAN	2000	18	1					62	65		10.1038/71938	http://dx.doi.org/10.1038/71938			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	273GQ	10625393				2022-12-25	WOS:000084699900027
J	Dove, A				Dove, A			Isis and antisense face crucial test without Novartis	NATURE BIOTECHNOLOGY			English	News Item																			0	8	8	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JAN	2000	18	1					19	19		10.1038/71852	http://dx.doi.org/10.1038/71852			1	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	273GQ	10625379	Bronze			2022-12-25	WOS:000084699900013
J	de Wildt, RMT; Mundy, CR; Gorick, BD; Tomlinson, IM				de Wildt, RMT; Mundy, CR; Gorick, BD; Tomlinson, IM			Antibody arrays for high-throughput screening of antibody-antigen interactions	NATURE BIOTECHNOLOGY			English	Article						antibody; array screening; high throughput; single-chain variable fragment (scFv); phage display	PHAGE DISPLAY LIBRARIES; AFFINITY HUMAN-ANTIBODIES; SINGLE-CHAIN ANTIBODIES; SELECTION; FRAGMENTS; PROTEIN; BINDING; MICROARRAYS; EXPRESSION; REPERTOIRE	We have developed a novel technique for high-throughput screening of recombinant antibodies, based on the creation of antibody arrays. Our method uses robotic picking and high-density gridding of bacteria containing antibody genes followed by filter-based enzyme-linked immunosorbent assay (ELISA) screening to identify clones that express binding antibody fragments. By eliminating the need for liquid handling, we can thereby screen up to 18,342 different antibody clones at a time and, because the clones are arrayed from master stocks, the same antibodies can be double spotted and screened simultaneously against 15 different antigens. We have used our technique in several different applications, including isolating antibodies against impure proteins and complex antigens, where several rounds of phage display often fail. Our results indicate that antibody arrays can be used to identify differentially expressed proteins.	MRC, Mol Biol Lab, Cambridge CB2 2QH, England; MRC, Ctr Prot Engn, Cambridge CB2 2QH, England; UK Human Genome Mapping Project Resource Ctr, Cambridge CB10 1SB, England	MRC Laboratory Molecular Biology; University of Cambridge	de Wildt, RMT (corresponding author), MRC, Mol Biol Lab, Hills Rd, Cambridge CB2 2QH, England.							Blackstock WP, 1999, TRENDS BIOTECHNOL, V17, P121, DOI 10.1016/S0167-7799(98)01245-1; BOBROW MN, 1989, J IMMUNOL METHODS, V125, P279, DOI 10.1016/0022-1759(89)90104-X; Brown PO, 1999, NAT GENET, V21, P33, DOI 10.1038/4462; Bussow K, 1998, NUCLEIC ACIDS RES, V26, P5007, DOI 10.1093/nar/26.21.5007; CAI XH, 1995, P NATL ACAD SCI USA, V92, P6537, DOI 10.1073/pnas.92.14.6537; CLACKSON T, 1991, NATURE, V352, P624, DOI 10.1038/352624a0; de Haard HJ, 1999, J BIOL CHEM, V274, P18218, DOI 10.1074/jbc.274.26.18218; de Wildt RMT, 1999, J MOL BIOL, V285, P895, DOI 10.1006/jmbi.1998.2396; DEKRUIF J, 1995, P NATL ACAD SCI USA, V92, P3938, DOI 10.1073/pnas.92.9.3938; deWildt RMT, 1996, EUR J IMMUNOL, V26, P629, DOI 10.1002/eji.1830260319; Dinh Q, 1996, J IMMUNOL, V157, P732; FRIGUET B, 1985, J IMMUNOL METHODS, V77, P305, DOI 10.1016/0022-1759(85)90044-4; Graus YF, 1997, J IMMUNOL, V158, P1919; GRIFFITHS AD, 1994, EMBO J, V13, P3245, DOI 10.1002/j.1460-2075.1994.tb06626.x; GRIFFITHS AD, 1993, EMBO J, V12, P725, DOI 10.1002/j.1460-2075.1993.tb05706.x; Harlow E., 1988, ANTIBODIES LAB MANUA; HAWKINS RE, 1992, J MOL BIOL, V226, P889, DOI 10.1016/0022-2836(92)90639-2; Hoet RMA, 1998, MOL IMMUNOL, V35, P1045, DOI 10.1016/S0161-5890(98)00093-5; HOFFMANN A, 1991, NUCLEIC ACIDS RES, V19, P6337, DOI 10.1093/nar/19.22.6337; HOLLIGER P, 1993, P NATL ACAD SCI USA, V90, P6444, DOI 10.1073/pnas.90.14.6444; Hoogenboom HR, 1999, EUR J BIOCHEM, V260, P774, DOI 10.1046/j.1432-1327.1999.00214.x; HUSE WD, 1989, SCIENCE, V246, P1275, DOI 10.1126/science.2531466; Iliades P, 1997, FEBS LETT, V409, P437, DOI 10.1016/S0014-5793(97)00475-4; Kristensen P, 1998, FOLD DES, V3, P321, DOI 10.1016/S1359-0278(98)00044-3; Lueking A, 1999, ANAL BIOCHEM, V270, P103, DOI 10.1006/abio.1999.4063; Mao SL, 1999, P NATL ACAD SCI USA, V96, P6953, DOI 10.1073/pnas.96.12.6953; MARKS JD, 1992, BIO-TECHNOL, V10, P779, DOI 10.1038/nbt0792-779; MULLINAX RL, 1990, P NATL ACAD SCI USA, V87, P8095, DOI 10.1073/pnas.87.20.8095; Nieba L, 1996, ANAL BIOCHEM, V234, P155, DOI 10.1006/abio.1996.0067; Noronha EJ, 1998, J IMMUNOL, V161, P2968; Osbourn JK, 1998, IMMUNOTECHNOLOGY, V3, P293, DOI 10.1016/S1380-2933(97)10007-0; Parsons HL, 1996, PROTEIN ENG, V9, P1043, DOI 10.1093/protein/9.11.1043; Rodenburg CM, 1998, HYBRIDOMA, V17, P1, DOI 10.1089/hyb.1998.17.1; Schier R, 1996, J MOL BIOL, V255, P28, DOI 10.1006/jmbi.1996.0004; Sheets MD, 1998, P NATL ACAD SCI USA, V95, P6157, DOI 10.1073/pnas.95.11.6157; SKERRA A, 1991, ANAL BIOCHEM, V196, P151, DOI 10.1016/0003-2697(91)90131-C; Vaughan TJ, 1996, NAT BIOTECHNOL, V14, P309, DOI 10.1038/nbt0396-309; VERHEIJEN R, 1994, J IMMUNOL METHODS, V169, P173, DOI 10.1016/0022-1759(94)90261-5; Watkins JD, 1998, ANAL BIOCHEM, V256, P169, DOI 10.1006/abio.1997.2523; WINTER G, 1994, ANNU REV IMMUNOL, V12, P433, DOI 10.1146/annurev.iy.12.040194.002245; YOUNG RA, 1983, P NATL ACAD SCI-BIOL, V80, P1194, DOI 10.1073/pnas.80.5.1194	41	531	659	2	79	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	SEP	2000	18	9					989	994		10.1038/79494	http://dx.doi.org/10.1038/79494			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	350AN	10973222				2022-12-25	WOS:000089078300030
J	Slavotinek, AM; Stone, EM; Mykytyn, K; Heckenlively, JR; Green, JS; Heon, E; Musarella, MA; Parfrey, PS; Sheffield, VC; Biesecker, LG				Slavotinek, AM; Stone, EM; Mykytyn, K; Heckenlively, JR; Green, JS; Heon, E; Musarella, MA; Parfrey, PS; Sheffield, VC; Biesecker, LG			Mutations in MKKS cause Bardet-Biedl syndrome	NATURE GENETICS			English	Article							SYNDROME LOCUS; LINKAGE		Univ Iowa, Howard Hughes Med Inst, Iowa City, IA 52242 USA; Univ Iowa, Dept Pediat, Iowa City, IA 52242 USA; NHGRI, Genet Dis Res Branch, NIH, Bethesda, MD 20892 USA; Univ Iowa, Dept Ophthalmol, Iowa City, IA 52242 USA; Harbor UCLA Med Ctr, Dept Ophthalmol, Torrance, CA 90509 USA; Mem Univ St Johns, Fac Med, St Johns, NF, Canada; Univ Toronto, Dept Ophthalmol, Toronto, ON M5S 1A1, Canada; Univ Toronto, Vis Sci Res Program, Toronto, ON M5S 1A1, Canada; Long Isl Coll Hosp, Brooklyn, NY 11201 USA	Howard Hughes Medical Institute; University of Iowa; University of Iowa; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); University of Iowa; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; Memorial University Newfoundland; University of Toronto; University of Toronto; Long Island College Hospital	Sheffield, VC (corresponding author), Univ Iowa, Howard Hughes Med Inst, Iowa City, IA 52242 USA.		Slavotinek, Anne/AAK-6794-2020	Stone, Edwin M./0000-0003-3343-4414; Sheffield, Val/0000-0002-6282-0835	NATIONAL EYE INSTITUTE [R01EY011298] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [Z01HG000009] Funding Source: NIH RePORTER; NEI NIH HHS [EY11298] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Beales PL, 1999, J MED GENET, V36, P437; Bruford EA, 1997, GENOMICS, V41, P93, DOI 10.1006/geno.1997.4613; CARMI R, 1995, HUM MOL GENET, V4, P9, DOI 10.1093/hmg/4.1.9; David A, 1999, J MED GENET, V36, P599; GREEN JS, 1989, NEW ENGL J MED, V321, P1002, DOI 10.1056/NEJM198910123211503; KWITEKBLACK AE, 1993, NAT GENET, V5, P392, DOI 10.1038/ng1293-392; LEPPERT M, 1994, NAT GENET, V7, P108, DOI 10.1038/ng0594-108; MCKUSICK VA, 1978, AM J HUM GENET, V30, P105; MCKUSICK VA, 1964, JAMA-J AM MED ASSOC, V189, P813; Rosenberg MJ, 2000, AM J HUM GENET, V66, P419, DOI 10.1086/302743; SHEFFIELD VC, 1994, HUM MOL GENET, V3, P1331, DOI 10.1093/hmg/3.8.1331; Stone DL, 1998, HUM MOL GENET, V7, P475, DOI 10.1093/hmg/7.3.475; Stone DL, 2000, NAT GENET, V25, P79, DOI 10.1038/75637; Young TL, 1999, AM J HUM GENET, V64, P900, DOI 10.1086/302301	14	206	212	1	10	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	SEP	2000	26	1					15	16		10.1038/79116	http://dx.doi.org/10.1038/79116			2	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	350AK	10973238				2022-12-25	WOS:000089078000008
J	Afzal, AR; Rajab, A; Fenske, CD; Oldridge, M; Elanko, N; Ternes-Pereira, E; Tuysuz, B; Murday, VA; Patton, MA; Wilkie, AOM; Jeffery, S				Afzal, AR; Rajab, A; Fenske, CD; Oldridge, M; Elanko, N; Ternes-Pereira, E; Tuysuz, B; Murday, VA; Patton, MA; Wilkie, AOM; Jeffery, S			Recessive Robinow syndrome, allelic to dominant brachydactyly type B, is caused by mutation of ROR2	NATURE GENETICS			English	Article							X-LINKED AGAMMAGLOBULINEMIA; FETAL FACE SYNDROME; LIGNEOUS CONJUNCTIVITIS; PLASMINOGEN GENE; TYROSINE; DISEASE; DISRUPTION; FAMILY; DOMAIN; CDMP1	The autosomal recessive form of Robinow syndrome (RRS; MIM 268310) is a severe skeletal dysplasia with generalized limb bone shortening, segmental defects of the spine, brachydactyly and a dysmorphic facial appearance(1-3). We previously mapped the gene mutated in RRS to chromosome 9q22 (ref. 4), a region that overlaps the locus for autosomal dominant brachydactyly type B (refs 5,6). The recent identification of ROR2, encoding an orphan receptor tyrosine kinase, as the gene mutated in brachydactyly type B (BDB1; ref. 7) and the mesomelic dwarfing in mice homozygous for a lacZ and/or a neo insertion into Ror2 (refs 8.9) made this gene a candidate for RRS. Here we report homozygous missense mutations in both intracellular and extracellular domains of ROR2 in affected individuals from 3 unrelated consanguineous families, and a nonsense mutation that removes the tyrosine kinase domain and all subsequent 3' regions of the gene in 14 patients from 7 families from Oman. The nature of these mutations suggests that RRS is caused by loss of ROR2 activity. The identification of mutations in three distinct domains (containing Frizzled-like, kringle and tyrosine kinase motifs) indicates that these are all essential for ROR2 function.	Univ London St Georges Hosp, Sch Med, Med Genet Unit, London, England; Minist Hlth, DGHA, Med Genet Unit, Muscat, Oman; John Radcliffe Hosp, Inst Mol Med, Oxford, England; Univ Fed Santa Catarina, Dept Clin Med, Florianopolis, SC, Brazil; Univ Istanbul, Cerrahpasa Med Fac, Dept Paediat, Istanbul, Turkey	St Georges University London; University of Oxford; Universidade Federal de Santa Catarina (UFSC); Istanbul University; Istanbul University - Cerrahpasa	Jeffery, S (corresponding author), Univ London St Georges Hosp, Sch Med, Med Genet Unit, London, England.		Tüysüz, Beyhan/AAN-4858-2020; Wilkie, Andrew/AAC-3820-2020	Wilkie, Andrew/0000-0002-2972-5481; Tuysuz, Beyhan/0000-0002-9620-5021				Afzal AR, 2000, HUM GENET, V106, P351, DOI 10.1007/s004390051049; Aksit S, 1997, CLIN GENET, V52, P226; Castellino FJ, 1997, CIBA F SYMP, V212, P46; DeChiara TM, 2000, NAT GENET, V24, P271, DOI 10.1038/73488; Forrester WC, 1999, NATURE, V400, P881, DOI 10.1038/23722; Frischmeyer PA, 1999, HUM MOL GENET, V8, P1893, DOI 10.1093/hmg/8.10.1893; Gherardi E, 1997, CIBA F SYMP, V212, P24; Gong YQ, 1999, AM J HUM GENET, V64, P570, DOI 10.1086/302249; Kantaputra PN, 1999, AM J MED GENET, V84, P1, DOI 10.1002/(SICI)1096-8628(19990507)84:1<1::AID-AJMG1>3.0.CO;2-C; Masiakowski P, 1998, CURR BIOL, V8, pR407, DOI 10.1016/S0960-9822(98)70263-5; MASIAKOWSKI P, 1992, J BIOL CHEM, V267, P26181; Oishi I, 1997, J BIOL CHEM, V272, P11916, DOI 10.1074/jbc.272.18.11916; Oldridge M, 2000, NAT GENET, V24, P275, DOI 10.1038/73495; Oldridge M, 1999, AM J HUM GENET, V64, P578, DOI 10.1086/302255; Polinkovsky A, 1997, NAT GENET, V17, P18, DOI 10.1038/ng0997-18; Robertson SC, 1998, P NATL ACAD SCI USA, V95, P4567, DOI 10.1073/pnas.95.8.4567; Robinow M, 1993, Clin Dysmorphol, V2, P189; Schuster V, 1997, BLOOD, V90, P958, DOI 10.1182/blood.V90.3.958.958_958_966; Schuster V, 1999, BLOOD, V93, P3457, DOI 10.1182/blood.V93.10.3457.410k03_3457_3466; Soliman AT, 1998, METABOLISM, V47, P1337, DOI 10.1016/S0026-0495(98)90301-8; Takeuchi S, 2000, GENES CELLS, V5, P71, DOI 10.1046/j.1365-2443.2000.00300.x; TAYLOR SI, 1991, J CLIN ENDOCR METAB, V73, P1158, DOI 10.1210/jcem-73-6-1158; TEEBI AS, 1990, AM J MED GENET, V35, P64, DOI 10.1002/ajmg.1320350112; Thomas JT, 1997, NAT GENET, V17, P58, DOI 10.1038/ng0997-58; Thomas JT, 1996, NAT GENET, V12, P315, DOI 10.1038/ng0396-315; VIHINEN M, 1994, P NATL ACAD SCI USA, V91, P12803, DOI 10.1073/pnas.91.26.12803; VORECHOVSKY I, 1995, HUM MOL GENET, V4, P51, DOI 10.1093/hmg/4.1.51; WADIA RS, 1978, J MED GENET, V15, P123, DOI 10.1136/jmg.15.2.123; WILSON C, 1993, P NATL ACAD SCI USA, V90, P7109, DOI 10.1073/pnas.90.15.7109; Xu YK, 1998, CURR BIOL, V8, pR405, DOI 10.1016/S0960-9822(98)70262-3	30	227	240	0	7	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	AUG	2000	25	4					419	422		10.1038/78107	http://dx.doi.org/10.1038/78107			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	341WY	10932186				2022-12-25	WOS:000088615000017
J	Bard, F; Cannon, C; Barbour, R; Burke, RL; Games, D; Grajeda, H; Guido, T; Hu, K; Huang, JP; Johnson-Wood, K; Khan, K; Kholodenko, D; Lee, M; Lieberburg, I; Motter, R; Nguyen, M; Soriano, F; Vasquez, N; Weiss, K; Welch, B; Seubert, P; Schenk, D; Yednock, T				Bard, F; Cannon, C; Barbour, R; Burke, RL; Games, D; Grajeda, H; Guido, T; Hu, K; Huang, JP; Johnson-Wood, K; Khan, K; Kholodenko, D; Lee, M; Lieberburg, I; Motter, R; Nguyen, M; Soriano, F; Vasquez, N; Weiss, K; Welch, B; Seubert, P; Schenk, D; Yednock, T			Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease	NATURE MEDICINE			English	Article							PRECURSOR PROTEIN; MICROGLIAL CELLS; DEGRADATION	One hallmark of Alzheimer disease is the accumulation of amyloid beta -peptide in the brain and its deposition as plaques. Mice transgenic for an amyloid beta precursor protein (APP) mini-gene driven by a platelet-derived (PD) growth factor promoter (PDAPP mice), which overexpress one of the disease-linked mutant forms of the human amyloid precursor protein, show many of the pathological features of Alzheimer disease, including extensive deposition of extracellular amyloid plaques, astrocytosis and neuritic dystrophy(1,2). Active immunization of PDAPP mice with human amyloid beta -peptide reduces plaque burden and its associated pathologies(3). Several hypotheses have been proposed regarding the mechanism of this response(4,5). Here we report that peripheral administration of antibodies against amyloid beta -peptide, was sufficient to reduce amyloid burden. Despite their relatively modest serum levels, the passively administered antibodies were able to enter the central nervous system, decorate plaques and induce clearance of preexisting amyloid. When examined in an ex vivo assay with sections of PDAPP or Alzheimer disease brain tissue, antibodies against amyloid beta -peptide triggered microglial cells to clear plaques through Fc receptor-mediated phagocytosis and subsequent peptide degradation. These results indicate that antibodies can cross the blood-brain barrier to act directly in the central nervous system and should be considered as a therapeutic approach for the treatment of Alzheimer disease and other neurological disorders.	Elan Pharmaceut, S San Francisco, CA 94080 USA		Bard, F (corresponding author), Elan Pharmaceut, 800 Gateway Blvd, S San Francisco, CA 94080 USA.							Chung HY, 1999, J BIOL CHEM, V274, P32301, DOI 10.1074/jbc.274.45.32301; Duff K, 1999, TRENDS NEUROSCI, V22, P485, DOI 10.1016/S0166-2236(99)01489-7; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; HYMAN BT, 1992, J NEUROPATH EXP NEUR, V51, P76, DOI 10.1097/00005072-199201000-00009; Johnson D, 1997, EDN, V42, P94; Masliah E, 1996, J NEUROSCI, V16, P5795; Paresce DM, 1997, J BIOL CHEM, V272, P29390, DOI 10.1074/jbc.272.46.29390; Schenk D, 1999, NATURE, V400, P173, DOI 10.1038/22124; St George-Hyslop PH, 1999, NATURE, V400, P116; THOMPSON EJ, 1990, ANN CLIN BIOCHEM, V27, P425, DOI 10.1177/000456329002700503	10	1655	1877	1	175	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	AUG	2000	6	8					916	919		10.1038/78682	http://dx.doi.org/10.1038/78682			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	376TX	10932230	Bronze			2022-12-25	WOS:000165473800036
J	Nolan, PM; Peters, J; Strivens, M; Rogers, D; Hagan, J; Spurr, N; Gray, IC; Vizor, L; Brooker, D; Whitehill, E; Washbourne, R; Hough, T; Greenaway, S; Hewitt, M; Liu, XH; McCormack, S; Pickford, K; Selley, R; Wells, C; Tymowska-Lalanne, Z; Roby, P; Glenister, P; Thornton, C; Thaung, C; Stevenson, JA; Arkell, R; Mburu, P; Hardisty, R; Kiernan, A; Erven, H; Steel, KP; Voegeling, S; Guenet, JL; Nickols, C; Sadri, R; Naase, M; Isaacs, A; Davies, K; Browne, M; Fisher, EMC; Martin, J; Rastan, S; Brown, SDM; Hunter, J				Nolan, PM; Peters, J; Strivens, M; Rogers, D; Hagan, J; Spurr, N; Gray, IC; Vizor, L; Brooker, D; Whitehill, E; Washbourne, R; Hough, T; Greenaway, S; Hewitt, M; Liu, XH; McCormack, S; Pickford, K; Selley, R; Wells, C; Tymowska-Lalanne, Z; Roby, P; Glenister, P; Thornton, C; Thaung, C; Stevenson, JA; Arkell, R; Mburu, P; Hardisty, R; Kiernan, A; Erven, H; Steel, KP; Voegeling, S; Guenet, JL; Nickols, C; Sadri, R; Naase, M; Isaacs, A; Davies, K; Browne, M; Fisher, EMC; Martin, J; Rastan, S; Brown, SDM; Hunter, J			A systematic, genome-wide, phenotype-driven mutagenesis programme for gene function studies in the mouse	NATURE GENETICS			English	Article							MUTATIONS; MODELS; MICE	As the human genome project approaches completion, the challenge for mammalian geneticists is to develop approaches for the systematic determination of mammalian gene function. Mouse mutagenesis will be a key element of studies of gene function(1-3). Phenotype-driven approaches using the chemical mutagen ethylnitrosourea(4-6) (ENU) represent a potentially efficient route for the generation of large numbers of mutant mice that can be screened for novel phenotypes. The advantage of this approach is that, in assessing gene function, no a priori assumptions are made about the genes involved in any pathway. Phenotype-driven mutagenesis is thus an effective method for the identification of novel genes and pathways(1,2). We have undertaken a genome-wide, phenotype-driven screen for dominant mutations in the mouse. We generated and screened over 26,000 mice, and recovered some 500 new mouse mutants. Our work along with the programme reported in the accompanying paper(7), has led to a substantial increase in the mouse mutant resource and represents a first step towards systematic studies of gene function in mammalian genetics.	MRC, Mammalian Genet Unit, Harwell, Berks, England; Mouse Genome Ctr, Harwell, Berks, England; SmithKline Beecham Pharmaceut, Dept Neurosci, Harlow, Essex, England; SmithKline Beecham Pharmaceut, Dept Biotechnol & Genet, Harlow, Essex, England; MRC, Inst Hearing Res, Nottingham, England; Inst Pasteur, Paris, France; Univ London Queen Mary & Westfield Coll, Dept Morbid Anat, London, England; Univ Oxford, Dept Human Anat & Genet, Oxford, England; Univ London Imperial Coll Sci Technol & Med, Dept Neurogenet, London, England; MRC, Human Genet Unit, Edinburgh, Midlothian, Scotland	GlaxoSmithKline; GlaxoSmithKline; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; University of London; Queen Mary University London; University of Oxford; Imperial College London; University of Edinburgh	Brown, SDM (corresponding author), MRC, Mammalian Genet Unit, Harwell, Berks, England.		arkell, ruth m/D-1525-2009; Nolan, Patrick/W-3918-2019; Thaung, Caroline/C-2180-2008; Arkell, Ruth/AAR-8471-2021; Fisher, Elizabeth MC/C-2168-2008; Wells, Christine A/A-5071-2010	arkell, ruth m/0000-0002-6213-7323; Nolan, Patrick/0000-0001-5550-0334; Thaung, Caroline/0000-0002-8318-046X; Arkell, Ruth/0000-0002-6213-7323; Fisher, Elizabeth MC/0000-0003-2850-9936; Wells, Christine A/0000-0003-3133-3628				Brown SDM, 1996, TRENDS GENET, V12, P433, DOI 10.1016/0168-9525(96)30094-2; Brown SDM, 1998, HUM MOL GENET, V7, P1627, DOI 10.1093/hmg/7.10.1627; CANDY CJ, 1997, J REPROD FERTIL, V110, P1; de Angelis MH, 2000, NAT GENET, V25, P444, DOI 10.1038/78146; GEYER MA, 1987, SCHIZOPHRENIA BULL, V13, P643, DOI 10.1093/schbul/13.4.643; IRWIN S, 1968, PSYCHOPHARMACOLOGIA, V13, P222, DOI 10.1007/BF00401402; Justice MJ, 1999, HUM MOL GENET, V8, P1955, DOI 10.1093/hmg/8.10.1955; *MED RES COUNC, 1993, MED RES COUNC RESP U; Nolan PM, 1997, METHODS, V13, P379, DOI 10.1006/meth.1997.0545; NOLAN PM, 1995, GENETICS, V140, P245; Rinchik EM, 1999, GENETICS, V152, P373; Rogers DC, 1997, MAMM GENOME, V8, P711, DOI 10.1007/s003359900551; RUSSELL WL, 1979, P NATL ACAD SCI USA, V76, P5918; SHEDLOVSKY A, 1993, GENETICS, V134, P1205; Thornton CE, 1999, MAMM GENOME, V10, P987, DOI 10.1007/s003359901145	15	476	496	0	14	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	AUG	2000	25	4					440	443		10.1038/78140	http://dx.doi.org/10.1038/78140			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	341WY	10932191				2022-12-25	WOS:000088615000022
J	Wei, J; Hemmings, GP				Wei, J; Hemmings, GP			The NOTCH4 locus is associated with susceptibility to schizophrenia	NATURE GENETICS			English	Article							LINKAGE DISEQUILIBRIUM; GENE		Schizophrenia Assoc Great Britain, Inst Biol Psychiat, Bangor, Gwynedd, Wales		Wei, J (corresponding author), Schizophrenia Assoc Great Britain, Inst Biol Psychiat, Bangor, Gwynedd, Wales.			Wei, Jun/0000-0002-2916-4944				FORTINI ME, 1993, CELL, V75, P1245, DOI 10.1016/0092-8674(93)90611-S; Levinson DF, 1996, AM J MED GENET, V67, P580; Li LH, 1998, GENOMICS, V51, P45, DOI 10.1006/geno.1998.5330; SCHWAB SG, 1995, NAT GENET, V11, P325, DOI 10.1038/ng1195-325; Song WH, 1999, P NATL ACAD SCI USA, V96, P6959, DOI 10.1073/pnas.96.12.6959; Spielman RS, 1996, AM J HUM GENET, V59, P983; SPIELMAN RS, 1993, AM J HUM GENET, V52, P506; STRAUB RE, 1995, NAT GENET, V11, P235; TERWILLIGER JD, 1995, AM J HUM GENET, V56, P777; Uyttendaele H, 1996, DEVELOPMENT, V122, P2251; WANG SB, 1995, NAT GENET, V10, P41, DOI 10.1038/ng0595-41	11	134	147	0	9	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	AUG	2000	25	4					376	377		10.1038/78044	http://dx.doi.org/10.1038/78044			2	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	341WY	10932176				2022-12-25	WOS:000088615000008
J	Attaran, A; Roberts, DR; Curtis, CF; Kilama, WL				Attaran, A; Roberts, DR; Curtis, CF; Kilama, WL			Balancing risks on the backs of the poor	NATURE MEDICINE			English	Editorial Material							BREAST-CANCER RISK; MALARIA CONTROL; COST-EFFECTIVENESS; BLOOD-LEVELS; DDT; AFRICA; ORGANOCHLORINES; AMERICA; WOMEN	Malaria kills over one million people, mainly children, in the tropics each year, and DDT remains one of the few affordable, effective tools against the mosquitoes that transmit the disease. Attaran et al. explain that the scientific literature on the need to withdraw DDT is unpersuasive, and the benefits of DDT in saving lives from malaria are well worth the risks.	Harvard Univ, John F Kennedy Sch Govt, Ctr Int Dev, Cambridge, MA 02138 USA; Uniformed Serv Univ Hlth Sci, Dept Prevent Med & Biometr, Bethesda, MD 20814 USA; Univ London London Sch Hyg & Trop Med, London WC1E 7HT, England; C2627 Tanzania Commiss Sci & Technol, African Malaria Vaccine Testing Network, Dar Es Salaam, Tanzania; Malaria Fdn Int, Dar Es Salaam, Tanzania	Harvard University; Uniformed Services University of the Health Sciences - USA; University of London; London School of Hygiene & Tropical Medicine	Attaran, A (corresponding author), Harvard Univ, John F Kennedy Sch Govt, Ctr Int Dev, Cambridge, MA 02138 USA.							Baris D, 1998, OCCUP ENVIRON MED, V55, P522, DOI 10.1136/oem.55.8.522; Chareonviriyaphap T, 1997, J AM MOSQUITO CONTR, V13, P171; DEZULUETA J, 1963, NATURE, V200, P860, DOI [10.1038/200860a0, 10.1038/200861a0]; GALLUP JL, 1998, EC BURDEN MALARIA; GLADEN BC, 1995, AM J PUBLIC HEALTH, V85, P504, DOI 10.2105/AJPH.85.4.504; Goodman CA, 1999, LANCET, V354, P378, DOI 10.1016/S0140-6736(99)02141-8; Goodman CA, 1999, HEALTH POLICY PLANN, V14, P301, DOI 10.1093/heapol/14.4.301; Grieco JP, 2000, J VECTOR ECOL, V25, P62; Helzlsouer KJ, 1999, CANCER EPIDEM BIOMAR, V8, P525; Hunter DJ, 1997, NEW ENGL J MED, V337, P1253, DOI 10.1056/NEJM199710303371801; Kouznetsov R L, 1977, Trop Doct, V7, P81; KRIEGER N, 1994, JNCI-J NATL CANCER I, V86, P589, DOI 10.1093/jnci/86.8.589; Longnecker MP, 1997, ANNU REV PUBL HEALTH, V18, P211, DOI 10.1146/annurev.publhealth.18.1.211; LopezCarrillo L, 1997, CANCER RES, V57, P3728; Macdonald G., 1957, EPIDEMIOLOGY CONTROL; Metcalf CL., 1962, DESTRUCTIVE USEFUL I; Mouchet J, 1998, J AM MOSQUITO CONTR, V14, P121; Moysich KB, 1998, CANCER EPIDEM BIOMAR, V7, P181; *PHYS SOC RESP, 1999, MOD MAL CONTR HDB; Roberts DR, 1997, EMERG INFECT DIS, V3, P295, DOI 10.3201/eid0303.970305; Roberts DR, 2000, J VECTOR ECOL, V25, P48; Schecter A, 1997, ARCH ENVIRON CON TOX, V33, P453, DOI 10.1007/s002449900276; vantVeer P, 1997, BMJ-BRIT MED J, V315, P81, DOI 10.1136/bmj.315.7100.81; *WHO, 1999, SDEPHEDP04; *WHO, 1999, SDEPHEDP02 WHO; *WHO EXP COMM MAL, 1979, WHO TECH REP SER, V640; *WHO UN ENV PROGR, 1979, ENV CRIT WHO, V9; WOLFF MS, 1993, JNCI-J NATL CANCER I, V85, P648, DOI 10.1093/jnci/85.8.648; *WORLD WILDL FUND, 1998, RES DDT DIL; Zheng TZ, 1999, AM J EPIDEMIOL, V150, P453, DOI 10.1093/oxfordjournals.aje.a010033	30	52	55	0	14	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUL	2000	6	7					729	+		10.1038/77438	http://dx.doi.org/10.1038/77438			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	331VV	10888909				2022-12-25	WOS:000088040100019
J	Coljee, VW; Murray, HL; Donahue, WF; Jarrell, KA				Coljee, VW; Murray, HL; Donahue, WF; Jarrell, KA			Seamless gene engineering using RNA- and DNA-overhang cloning	NATURE BIOTECHNOLOGY			English	Article							AMPLIFICATION; POLYMERASES		Boston Univ, Med Ctr, Dept Pharmacol & Expt Therapeut, Boston, MA 02118 USA	Boston University	Jarrell, KA (corresponding author), Boston Univ, Med Ctr, Dept Pharmacol & Expt Therapeut, 80 E Concord St, Boston, MA 02118 USA.							Cline J, 1996, NUCLEIC ACIDS RES, V24, P3546, DOI 10.1093/nar/24.18.3546; KRAINER AR, 1984, CELL, V36, P993, DOI 10.1016/0092-8674(84)90049-7; MEAD DA, 1991, BIO-TECHNOL, V9, P657, DOI 10.1038/nbt0791-657; MYERS TW, 1991, BIOCHEMISTRY-US, V30, P7661, DOI 10.1021/bi00245a001; Perler FB, 1996, ADV PROTEIN CHEM, V48, P377; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SOMMER B, 1990, SCIENCE, V249, P1580, DOI 10.1126/science.1699275	7	17	33	0	5	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUL	2000	18	7					789	791		10.1038/77363	http://dx.doi.org/10.1038/77363			3	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	331YN	10888851				2022-12-25	WOS:000088046400032
J	Sundin, OH; Yang, JM; Li, YY; Zhu, DP; Hurd, JN; Mitchell, TN; Silva, ED; Maumenee, IH				Sundin, OH; Yang, JM; Li, YY; Zhu, DP; Hurd, JN; Mitchell, TN; Silva, ED; Maumenee, IH			Genetic basis of total colourblindness among the Pingelapese islanders	NATURE GENETICS			English	Article							GATED CATION CHANNEL; ALPHA-SUBUNIT; BETA-SUBUNIT; ACHROMATOPSIA; PHOTORECEPTORS; MUTATIONS; DATABASE; LOCUS	Complete achromatopsia is a rare, autosomal recessive disorder characterized by photophobia, low visual acuity. nystagmus and a total inability to distinguish colours. In this disease, cone photoreceptors. the retinal sensory neurons mediating colour vision, seem viable but fail to generate an electrical response to light(1,2). Achromatopsia, or rod monochromatism, was first mapped to 2p11-2q12 (MIM 216900; ref. 3), where it is associated with missense mutations in CNGA3 (ref. 4). CNGA3 encodes the a-subunit of the cone cyclic nucleotide-gated cation channel, which generates the light-evoked electrical responses of cone photoreceptors(5-7). A second locus at 8q21-q22 has been identified among the Pingelapese islanders of Micronesia(8,9), who have a high incidence of recessive achromatopsia(10,11) (MIM 262300). Here we narrow the achromatopsia locus to 1.4 cM and show that Pingelapese achromatopsia segregates with a missense mutation at a highly conserved site in CNGB3. a new gene that encodes the beta-subunit of the cone cyclic nucleotide-gated cation channel. Two independent frameshift deletions establish that achromatopsia is the null phenotype of CNGB3. Combined with earlier findings, our results demonstrate that both alpha- and beta-subunits of the cGMP-gated channel are essential for phototransduction in all three classes of cones.	Johns Hopkins Univ, Sch Med, Lab Dev Genet, Baltimore, MD 21218 USA; Johns Hopkins Univ, Sch Med, Johns Hopkins Ctr Hereditary Eye Dis, Dept Ophthalmol, Baltimore, MD 21218 USA; Johns Hopkins Univ, Sch Med, Dept Genet & Mol Biol, Baltimore, MD 21218 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Sundin, OH (corresponding author), Johns Hopkins Univ, Sch Med, Lab Dev Genet, Baltimore, MD 21218 USA.			Silva, Eduardo/0000-0002-2739-9854	NEI NIH HHS [R01-EY10813] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY010813] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Arbour NC, 1997, HUM MOL GENET, V6, P689, DOI 10.1093/hmg/6.5.689; Ardell MD, 1996, FEBS LETT, V389, P213, DOI 10.1016/0014-5793(96)00588-1; BOGUSKI MS, 1993, NAT GENET, V4, P332, DOI 10.1038/ng0893-332; BRODY JA, 1970, LANCET, V1, P1253; CHEN TY, 1993, NATURE, V362, P764, DOI 10.1038/362764a0; DRYJA TP, 1995, P NATL ACAD SCI USA, V92, P10177, DOI 10.1073/pnas.92.22.10177; Grunwald ME, 1998, J BIOL CHEM, V273, P9148, DOI 10.1074/jbc.273.15.9148; HURD JN, 1977, THESIS U HAWAII; HUSSELS IE, 1972, AM J HUM GENET, V24, P304; Kohl S, 1998, NAT GENET, V19, P257, DOI 10.1038/935; Korschen HG, 1999, NATURE, V400, P761, DOI 10.1038/23468; Krill A. E., 1977, HEREDITARY RETINAL C; Milunsky A, 1999, CLIN GENET, V56, P82, DOI 10.1034/j.1399-0004.1999.560112.x; MORTON NE, 1972, AM J HUM GENET, V24, P277; NATHANS J, 1986, SCIENCE, V232, P193, DOI 10.1126/science.2937147; Ott J., 1999, ANAL HUMAN GENETIC L; SHARPE LT, 1990, NIGHT VISION BASIC C; SHEFFIELD VC, 1995, HUM MOL GENET, V4, P1837, DOI 10.1093/hmg/4.10.1837; Winick JD, 1999, AM J HUM GENET, V64, P1679, DOI 10.1086/302423; Wissinger B, 1997, EUR J NEUROSCI, V9, P2512, DOI 10.1111/j.1460-9568.1997.tb01680.x; YAU KW, 1994, P NATL ACAD SCI USA, V91, P3481, DOI 10.1073/pnas.91.9.3481; Zagotta WN, 1996, ANNU REV NEUROSCI, V19, P235, DOI 10.1146/annurev.ne.19.030196.001315	23	168	176	0	124	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUL	2000	25	3					289	293		10.1038/77162	http://dx.doi.org/10.1038/77162			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	329RD	10888875				2022-12-25	WOS:000087920900015
J	Benoit, M; Gabriel, D; Gerisch, G; Gaub, HE				Benoit, M; Gabriel, D; Gerisch, G; Gaub, HE			Discrete interactions in cell adhesion measured by single-molecule force spectroscopy	NATURE CELL BIOLOGY			English	Article							SITE-A GLYCOPROTEIN; DICTYOSTELIUM-DISCOIDEUM; PHOSPHOLIPID-ANCHOR; CONTACT SITES; DNA-MOLECULES; MICROSCOPY; MEMBRANE; MECHANICS; PROTEIN; LIGANDS	Cell-cell adhesion mediated by specific cell-surface molecules is essential for multicellular development. Here we quantify de-adhesion forces at the resolution of individual cell-adhesion molecules, by controlling the interactions between single cells and combining single-molecule force spectroscopy with genetic manipulation. Our measurements are focused on a glycoprotein, contact site A (csA), as a prototype of cell-adhesion proteins, csA is expressed in aggregating cells of Dictyostelium discoideum, which are engaged in development of a multicellular organism. Adhesion between two adjacent cell surfaces involves discrete interactions characterized by an unbinding force of 23 +/-8 pN, measured at a rupture rate of 2.5+/-0.5 mu m s(-1).	Univ Munich, Ctr Nanosci, D-80799 Munich, Germany; Max Planck Inst Biochem, D-82152 Martinsried, Germany	University of Munich; Max Planck Society	Benoit, M (corresponding author), Univ Munich, Ctr Nanosci, Amalienstr 54, D-80799 Munich, Germany.							BARTH A, 1994, J CELL BIOL, V124, P205, DOI 10.1083/jcb.124.1.205; BELL GI, 1978, SCIENCE, V200, P618, DOI 10.1126/science.347575; BEUG H, 1973, J CELL BIOL, V56, P647, DOI 10.1083/jcb.56.3.647; BEUG H, 1973, P NATL ACAD SCI USA, V70, P3150, DOI 10.1073/pnas.70.11.3150; BINNIG G, 1986, PHYS REV LETT, V56, P930, DOI 10.1103/PhysRevLett.56.930; BOZZARO S, 1978, J MOL BIOL, V120, P265, DOI 10.1016/0022-2836(78)90067-0; BUTT HJ, 1995, NANOTECHNOLOGY, V6, P1, DOI 10.1088/0957-4484/6/1/001; Chen SQ, 1999, J CELL BIOL, V144, P185, DOI 10.1083/jcb.144.1.185; Curtis A. S. G., 1970, Symp. zool. Soc. Lond., VNo. 25, P335; DETTMANN W, IN PRESS ARCH BIOCH; EVANS E, 1991, BIOPHYS J, V59, P838, DOI 10.1016/S0006-3495(91)82296-2; EVANS E, 1998, R SOC CHEM FARADAY D, V3, P1; EVANS E, 1995, STRUCTURE DYNAMICS M, P723; EVANS EA, 1985, BIOPHYS J, V48, P185, DOI 10.1016/S0006-3495(85)83771-1; FAIX J, 1990, EMBO J, V9, P2709, DOI 10.1002/j.1460-2075.1990.tb07457.x; FAIX J, 1992, J CELL SCI, V102, P203; FAIX J, 1999, GUIDEBOOK EXTRACELLU, P177; FLORIN EL, 1994, SCIENCE, V264, P415, DOI 10.1126/science.8153628; FLORIN EL, 1995, BIOSENS BIOELECTRON, V10, P895, DOI 10.1016/0956-5663(95)99227-C; Fritz J, 1998, P NATL ACAD SCI USA, V95, P12283, DOI 10.1073/pnas.95.21.12283; GERISCH G, 1980, CELL ADHESION MOTILI, P293; Gimzewski JK, 1999, SCIENCE, V283, P1683, DOI 10.1126/science.283.5408.1683; Grubmuller H, 1996, SCIENCE, V271, P997, DOI 10.1126/science.271.5251.997; HARLOFF C, 1989, GENE DEV, V3, P2011, DOI 10.1101/gad.3.12a.2011; Hinterdorfer P, 1996, P NATL ACAD SCI USA, V93, P3477, DOI 10.1073/pnas.93.8.3477; Kloboucek A, 1999, BIOPHYS J, V77, P2311, DOI 10.1016/S0006-3495(99)77070-0; Kreis T, 1999, GUIDEBOOK EXTRACELLU; MALCHOW D, 1972, EUR J BIOCHEM, V28, P136, DOI 10.1111/j.1432-1033.1972.tb01894.x; Marszalek PE, 1999, P NATL ACAD SCI USA, V96, P7894, DOI 10.1073/pnas.96.14.7894; Merkel R, 1999, NATURE, V397, P50, DOI 10.1038/16219; MOY VT, 1994, SCIENCE, V266, P257, DOI 10.1126/science.7939660; Muller KM, 1998, ANAL BIOCHEM, V261, P149, DOI 10.1006/abio.1998.2725; MURRAY BA, 1981, J SUPRAMOL STR CELL, V17, P197, DOI 10.1002/jsscb.380170302; Oberhauser AF, 1998, NATURE, V393, P181, DOI 10.1038/30270; OESTERHELT F, IN PRESS SCIENCE; Ponte E, 1998, P NATL ACAD SCI USA, V95, P9360, DOI 10.1073/pnas.95.16.9360; Rief M, 1997, SCIENCE, V275, P1295, DOI 10.1126/science.275.5304.1295; Rief M, 1998, BIOPHYS J, V75, P3008, DOI 10.1016/S0006-3495(98)77741-0; Rief M, 1999, NAT STRUCT BIOL, V6, P346; Rief M, 1998, PHYS REV LETT, V81, P4764, DOI 10.1103/PhysRevLett.81.4764; SIU CH, 1988, BIOCHEM CELL BIOL, V66, P1089, DOI 10.1139/o88-126; Smith BL, 1999, NATURE, V399, P761, DOI 10.1038/21607; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; STADLER J, 1989, EMBO J, V8, P371, DOI 10.1002/j.1460-2075.1989.tb03387.x; Strunz T, 1999, P NATL ACAD SCI USA, V96, P11277, DOI 10.1073/pnas.96.20.11277; Tomschy A, 1996, EMBO J, V15, P3507, DOI 10.1002/j.1460-2075.1996.tb00719.x; Vestweber D, 1999, PHYSIOL REV, V79, P181, DOI 10.1152/physrev.1999.79.1.181	47	457	471	2	140	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	JUN	2000	2	6					313	317		10.1038/35014000	http://dx.doi.org/10.1038/35014000			5	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	321KE	10854320				2022-12-25	WOS:000087454000011
J	Cowan, KN; Heilbut, A; Humpl, T; Lam, C; Ito, S; Rabinovitch, M				Cowan, KN; Heilbut, A; Humpl, T; Lam, C; Ito, S; Rabinovitch, M			Complete reversal of fatal pulmonary hypertension in rats by a serine elastase inhibitor	NATURE MEDICINE			English	Article							TENASCIN-C; INTEGRIN; ANGIOGENESIS; ALPHA(V)BETA(3); REGRESSION; SUPPRESSION; EXPRESSION; APOPTOSIS; CELLS	Progression of pulmonary hypertension is associated with increased serine elastase activity and the proteinase-dependent deposition of the extracellular matrix smooth muscle cell survival factor tenascin-C (refs. 1,2). Tenascin-C amplifies the response of smooth muscle cells to growth factors(3), which are also liberated through matrix proteolysis(4). Recent organ culture studies using hypertrophied rat pulmonary arteries have shown that elastase inhibitors suppress tenascin-C and induce smooth muscle cell apoptosis(5,6). This initiates complete regression of the hypertrophied vessel wall by a coordinated loss of cellularity and extracellular matrix. We now report that elastase inhibitors can reverse advanced pulmonary vascular disease produced in rats by injecting monocrotaline, an endothelial toxin. We began oral administration of the peptidyl trifluoromethylketone serine elastase inhibitors M249314 or ZD0892 21 days after injection of monocrotaline. A 1-week treatment resulted in 92% survival, compared with 39% survival in untreated or vehicle-treated rats. Pulmonary artery pressure and muscularization were reduced by myocyte apoptosis and loss of extracellular matrix, specifically elastin and tenascin-C. After 2 weeks, pulmonary artery pressure and structure normalized, and survival was 86%, compared with 0% in untreated or vehicle-treated rats. Although concomitant treatment with various agents can reduce pulmonary hypertension(7), we have documented complete regression after establishment of malignant monocrotaline-induced disease.	Univ Toronto, Dept Pediat, Div Cardiovasc Res, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Lab Med & Pathol, Toronto, ON M5G 1X8, Canada; Univ Toronto, Hosp Sick Children, Div Clin Pharmacol & Toxicol, Toronto, ON M5G 1X8, Canada	University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	Rabinovitch, M (corresponding author), Univ Toronto, Dept Pediat, Div Cardiovasc Res, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.		Lam, Catherine/K-6328-2014; Heilbut, Adrian M/J-9427-2012	Lam, Catherine/0000-0003-1363-5331; Heilbut, Adrian M/0000-0002-8169-7967; Cowan, Kyle/0000-0003-0109-7716				Bader BL, 1998, CELL, V95, P507, DOI 10.1016/S0092-8674(00)81618-9; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; CHOI ET, 1994, J VASC SURG, V19, P125, DOI 10.1016/S0741-5214(94)70127-X; Cowan KN, 2000, J CLIN INVEST, V105, P21, DOI 10.1172/JCI6539; Cowan KN, 1999, CIRC RES, V84, P1223, DOI 10.1161/01.RES.84.10.1223; Edwards PD, 1997, J MED CHEM, V40, P1876, DOI 10.1021/jm960819g; Eliceiri BP, 1998, J CELL BIOL, V140, P1255, DOI 10.1083/jcb.140.5.1255; FRIED R, 1984, J APPL PHYSIOL, V57, P1247, DOI 10.1152/jappl.1984.57.4.1247; Haas TL, 1999, TRENDS CARDIOVAS MED, V9, P70, DOI 10.1016/S1050-1738(99)00014-6; Jones PL, 1997, AM J PATHOL, V150, P1349; Jones PL, 1999, J CELL SCI, V112, P435; Jones PL, 1997, J CELL BIOL, V139, P279, DOI 10.1083/jcb.139.1.279; Lee JK, 1998, NAT MED, V4, P1383, DOI 10.1038/3973; Mitani Y, 1997, CIRCULATION, V96, P689; RABINOVITCH M, 1998, COMPREHENSIVE CARDIO, P3001; SELIEM MA, 1995, PEDIATR CARDIOL, V16, P53, DOI 10.1007/BF00796817; Stromblad S, 1996, J CLIN INVEST, V98, P426, DOI 10.1172/JCI118808; Thompson K, 1996, J CELL PHYSIOL, V166, P495, DOI 10.1002/(SICI)1097-4652(199603)166:3<495::AID-JCP4>3.0.CO;2-K; Wigle DA, 1998, CIRC RES, V83, P252, DOI 10.1161/01.RES.83.3.252; YE CL, 1991, AM J PHYSIOL, V261, pH1255, DOI 10.1152/ajpheart.1991.261.4.H1255	20	273	297	0	15	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUN	2000	6	6					698	702		10.1038/76282	http://dx.doi.org/10.1038/76282			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	321CX	10835689				2022-12-25	WOS:000087438300043
J	Glaser, V				Glaser, V			Cloned cows turn back the cellular clock	NATURE BIOTECHNOLOGY			English	News Item																			0	1	1	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUN	2000	18	6					594	594		10.1038/76420	http://dx.doi.org/10.1038/76420			1	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	325EK	10835590	Bronze			2022-12-25	WOS:000087663200012
J	Berry, V; Francis, P; Kaushal, S; Moore, A; Bhattacharya, S				Berry, V; Francis, P; Kaushal, S; Moore, A; Bhattacharya, S			Missense mutations in MIP underlie autosomal dominant 'polymorphic' and lamellar cataracts linked to 12q	NATURE GENETICS			English	Article							ZONULAR PULVERULENT CATARACT; FAMILY		Inst Ophthalmol, Dept Mol Genet, London, England; Moorfields Eye Hosp, London, England; Addenbrookes Hosp, Cambridge, England	University of London; University College London; University of London; University College London; Moorfields Eye Hospital NHS Foundation Trust; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge	Bhattacharya, S (corresponding author), Inst Ophthalmol, Dept Mol Genet, London, England.		Bhattacharya, Shom/N-2926-2016	Bhattacharya, Shom/0000-0002-1601-6344				Daniels G, 1999, BLOOD REV, V13, P14, DOI 10.1016/S0268-960X(99)90020-6; DENNING GM, 1992, NATURE, V358, P761, DOI 10.1038/358761a0; Echevarria M, 1998, J PHYSIOL BIOCHEM, V54, P107; Francis PJ, 1999, TRENDS GENET, V15, P191, DOI 10.1016/S0168-9525(99)01738-2; Heymann JB, 1998, J STRUCT BIOL, V121, P191, DOI 10.1006/jsbi.1997.3951; Ionides A, 1999, BRIT J OPHTHALMOL, V83, P802, DOI 10.1136/bjo.83.7.802; KAUSHAL S, 1994, BIOCHEMISTRY-US, V33, P6121, DOI 10.1021/bi00186a011; Lambert SR, 1996, SURV OPHTHALMOL, V40, P427, DOI 10.1016/S0039-6257(96)82011-X; Lee MD, 1997, MEDICINE, V76, P141, DOI 10.1097/00005792-199705000-00001; Mackay D, 1997, AM J HUM GENET, V60, P1474, DOI 10.1086/515468; Mackay D, 1999, AM J HUM GENET, V64, P1357, DOI 10.1086/302383; Shiels A, 1996, NAT GENET, V12, P212, DOI 10.1038/ng0296-212; Shiels A, 1998, AM J HUM GENET, V62, P526, DOI 10.1086/301762; Tamarappoo BK, 1999, J BIOL CHEM, V274, P34825, DOI 10.1074/jbc.274.49.34825	14	221	236	0	13	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAY	2000	25	1					15	17		10.1038/75538	http://dx.doi.org/10.1038/75538			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	311KU	10802646				2022-12-25	WOS:000086884000008
J	Favis, R; Day, JP; Gerry, NP; Phelan, C; Narod, S; Barany, F				Favis, R; Day, JP; Gerry, NP; Phelan, C; Narod, S; Barany, F			Universal DNA array detection of small insertions and deletions in BRCA1 and BRCA2	NATURE BIOTECHNOLOGY			English	Article							DENSITY OLIGONUCLEOTIDE ARRAYS; POINT MUTATIONS; LIGASE; SEQUENCE; GENETICS; FIDELITY	Array-based mutation detection methodology typically relies on direct hybridization of the fluorescently labeled query sequence to surface-bound oligonucleotide probes. These probes contain either small sequence variations or perfect-match sequence. The intensity of fluorescence bound to each oligonucleotide probe is intended to reveal which sequence is perfectly complementary to the query sequence(1). However, these approaches have not always been successful, especially for detection of small frameshift mutations. Here we describe a multiplex assay to detect small insertions and deletions by using a modified PCR to evenly amplify each amplicon (PCR/PCR)(2), followed by ligase detection reaction (LDR)(3). Mutations were identified by screening reaction products with a universal DNA microarray(4), which uncouples mutation detection from array hybridization and provides for high sensitivity. Using the three BRCA1 and BRCA2 founder mutations in the Ashkenazi Jewish population (BRCA1 185delAG; BRCA1 5382insC; BRCA2 6174delT)(5) as a model system, the assay readily detected these mutations in multiplexed reactions. Our results demonstrate that universal microarray analysis of PCR/PCR/LDR2 products permits rapid identification of small insertion and deletion mutations in the context of both clinical diagnosis and population studies.	Cornell Univ, Joan & Sanford I Weill Med Coll, Hearst Microbiol Res Ctr, Dept Microbiol, New York, NY 10021 USA; Cornell Univ, Joan & Sanford I Weill Med Coll, Strang Canc Prevent Ctr, New York, NY 10021 USA; Univ Toronto, Ctr Res Womens Hlth, Toronto, ON M5G 1N8, Canada	Cornell University; Cornell University; University of Toronto	Barany, F (corresponding author), Cornell Univ, Joan & Sanford I Weill Med Coll, Hearst Microbiol Res Ctr, Dept Microbiol, 1300 York Ave,Box 62, New York, NY 10021 USA.		Narod, Steven A/AAA-6112-2022		NCI NIH HHS [P01-CA65930, R01-CA81467] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA065930, R01CA081467] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahrendt SA, 1999, P NATL ACAD SCI USA, V96, P7382, DOI 10.1073/pnas.96.13.7382; BARANY F, 1991, GENE, V109, P1, DOI 10.1016/0378-1119(91)90582-V; Belgrader P, 1996, GENOME SCI TECHNOLOG, V1, P77, DOI [DOI 10.1089/GST.1996.1.77, 10.1089/gst.1996.1.77]; Chakravarti A, 1999, NAT GENET, V21, P56, DOI 10.1038/4482; Gerry NP, 1999, J MOL BIOL, V292, P251, DOI 10.1006/jmbi.1999.3063; Hacia JG, 1999, NAT GENET, V21, P42, DOI 10.1038/4469; Hacia JG, 1996, NAT GENET, V14, P441, DOI 10.1038/ng1296-441; Khanna M, 1999, ONCOGENE, V18, P27, DOI 10.1038/sj.onc.1202291; Kozal MJ, 1996, NAT MED, V2, P753, DOI 10.1038/nm0796-753; Luo JY, 1996, NUCLEIC ACIDS RES, V24, P3079, DOI 10.1093/nar/24.15.3079; Luo JY, 1996, NUCLEIC ACIDS RES, V24, P3071, DOI 10.1093/nar/24.15.3071; Rahman N, 1998, ANNU REV GENET, V32, P95, DOI 10.1146/annurev.genet.32.1.95; SYVANEN AC, 1994, HUM MUTAT, V3, P172, DOI 10.1002/humu.1380030303; Tong J, 1999, NUCLEIC ACIDS RES, V27, P788, DOI 10.1093/nar/27.3.788; Zirvi M, 1999, NUCLEIC ACIDS RES, V27, DOI 10.1093/nar/27.24.e40; Zirvi M, 1999, NUCLEIC ACIDS RES, V27, DOI 10.1093/nar/27.24.e41	16	167	188	0	12	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAY	2000	18	5					561	564		10.1038/75452	http://dx.doi.org/10.1038/75452			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	313UK	10802632				2022-12-25	WOS:000087017500038
J	Marin, MC; Jost, CA; Brooks, LA; Irwin, MS; O'Nions, J; Tidy, JA; James, N; McGregor, JM; Harwood, CA; Yulug, IG; Vousden, KH; Allday, MJ; Gusterson, B; Ikawa, S; Hinds, PW; Crook, T; Kaelin, WG				Marin, MC; Jost, CA; Brooks, LA; Irwin, MS; O'Nions, J; Tidy, JA; James, N; McGregor, JM; Harwood, CA; Yulug, IG; Vousden, KH; Allday, MJ; Gusterson, B; Ikawa, S; Hinds, PW; Crook, T; Kaelin, WG			A common polymorphism acts as an intragenic modifier of mutant p53 behaviour	NATURE GENETICS			English	Article							HUMAN LUNG-CANCER; CERVICAL-CANCER; CELL-LINES; WILD-TYPE; GENE; MUTATIONS; P73; SUPPRESSION; GROWTH; RISK	The p73 protein, a homologue of the tumour-suppressor protein p53, can activate p53-responsive promoters and induce apoptosis in p53-deficient cells. Here we report that some tumour-derived p53 mutants can bind to and inactivate p73. The binding of such mutants is influenced by whether TP53 (encoding p53) codon 72, by virtue of a common polymorphism in the human population, encodes Arg or Pro. The ability of mutant p53 to bind p73, neutralize p73-induced apoptosis and transform cells in cooperation with EJ-Ras was enhanced when codon 72 encoded Arg. We found that the Arg-containing allele was preferentially mutated and retained in squamous cell tumours arising in Arg/Pro germline heterozygotes. Thus, inactivation of p53 family members may contribute to the biological properties of a subset of p53 mutants, and a polymorphic residue within p53 affects mutant behaviour.	Dana Farber Canc Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA USA; London Sch Hyg & Trop Med, London WC1, England; Inst Canc Res, Sect Cell Biol & Expt Pathol, London SW3 6JB, England; Univ Sheffield, No Gen Hosp, Dept Gynecol Oncol, Sheffield S5 7AU, S Yorkshire, England; Univ Birmingham, CRC, Inst Canc Studies, Birmingham, W Midlands, England; Ctr Cutaneous Res, London, England; NCI, ABL Basic Res Program, Frederick Canc Res & Dev Ctr, Frederick, MD 21701 USA; St Marys Hosp, Imperial Coll Sci Technol & Med, Ludwig Inst Canc Res, London, England; Tohoku Univ, Inst Dev Aging & Canc, Dept Cell Biol, Sendai, Miyagi 980, Japan; Harvard Univ, Sch Med, Dept Pathol, Boston, MA USA; Howard Hughes Med Inst, Coconut Grove, FL 33133 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; University of London; London School of Hygiene & Tropical Medicine; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Northern General Hospital; University of Sheffield; University of Birmingham; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Imperial College London; Ludwig Institute for Cancer Research; Tohoku University; Harvard University; Harvard Medical School; Howard Hughes Medical Institute	Kaelin, WG (corresponding author), Dana Farber Canc Inst, Boston, MA 02115 USA.		Marin, Maria C/G-1040-2010; 井川, 俊太郎/L-5911-2015; Marín Vieira, María del Carmen/B-8108-2015; gusterson, barry a/D-3752-2009	Marin, Maria C/0000-0002-7149-287X; Marín Vieira, María del Carmen/0000-0002-7149-287X; Harwood, Catherine/0000-0002-1375-0965; Yulug, Isik/0000-0002-7577-2502				BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BECKMAN G, 1994, HUM HERED, V44, P266, DOI 10.1159/000154228; BIRGANDER R, 1995, CARCINOGENESIS, V16, P2233, DOI 10.1093/carcin/16.9.2233; Blandino G, 1999, ONCOGENE, V18, P477, DOI 10.1038/sj.onc.1202314; BRACHMAN DG, 1992, CANCER RES, V52, P4832; BRASH DE, 1991, P NATL ACAD SCI USA, V88, P10124, DOI 10.1073/pnas.88.22.10124; CROOK T, 1994, CELL, V79, P817, DOI 10.1016/0092-8674(94)90071-X; Davison TS, 1999, J BIOL CHEM, V274, P18709, DOI 10.1074/jbc.274.26.18709; De Laurenzi V, 1998, J EXP MED, V188, P1763, DOI 10.1084/jem.188.9.1763; Di Como CJ, 1999, MOL CELL BIOL, V19, P1438; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Gong JG, 1999, NATURE, V399, P806; HALEVY O, 1990, SCIENCE, V250, P113, DOI 10.1126/science.2218501; HARRIS N, 1986, MOL CELL BIOL, V6, P4650, DOI 10.1128/MCB.6.12.4650; Helland A, 1998, NATURE, V396, P530, DOI 10.1038/25034; Hildesheim A, 1998, NATURE, V396, P531, DOI 10.1038/25040; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; JIN XM, 1995, CARCINOGENESIS, V16, P2205, DOI 10.1093/carcin/16.9.2205; JONES M, 1992, GENE CHROMOSOME CANC, V1, P89; Josefsson AM, 1998, NATURE, V396, P531, DOI 10.1038/25037; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaelin WG, 1999, J NATL CANCER I, V91, P594, DOI 10.1093/jnci/91.7.594; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; KAWAJIRI K, 1993, CARCINOGENESIS, V14, P1085, DOI 10.1093/carcin/14.6.1085; Kovalev S, 1998, CELL GROWTH DIFFER, V9, P897; Lanham S, 1998, LANCET, V352, P1631, DOI 10.1016/S0140-6736(05)61083-5; Levine AJ, 1995, ANN NY ACAD SCI, V768, P111, DOI 10.1111/j.1749-6632.1995.tb12115.x; Li RZ, 1998, ONCOGENE, V16, P3269, DOI 10.1038/sj.onc.1201867; Marin MC, 1998, MOL CELL BIOL, V18, P6316, DOI 10.1128/MCB.18.11.6316; Mateu MG, 1999, P NATL ACAD SCI USA, V96, P3595, DOI 10.1073/pnas.96.7.3595; MCGREGOR J, 1997, ONCOGENE, V14, P1737; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; Minaguchi T, 1998, CANCER RES, V58, P4585; Murata M, 1996, CARCINOGENESIS, V17, P261, DOI 10.1093/carcin/17.2.261; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; ORFY K, 1994, EMBO J, V13, P3496; Rosenthal AN, 1998, LANCET, V352, P871, DOI 10.1016/S0140-6736(98)07357-7; Sakamuro D, 1997, ONCOGENE, V15, P887, DOI 10.1038/sj.onc.1201263; SHAULSKY G, 1991, CANCER RES, V51, P5232; Storey A, 1998, NATURE, V396, P532, DOI 10.1038/25043; UNGER T, 1993, MOL CELL BIOL, V13, P5186, DOI 10.1128/MCB.13.9.5186; Walker KK, 1996, P NATL ACAD SCI USA, V93, P15335, DOI 10.1073/pnas.93.26.15335; WESTON A, 1994, CARCINOGENESIS, V15, P583, DOI 10.1093/carcin/15.4.583; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; ZAMBETTI GP, 1993, FASEB J, V7, P855, DOI 10.1096/fasebj.7.10.8344485; ZHANG W, 1992, GENE, V117, P271, DOI 10.1016/0378-1119(92)90738-B	49	450	460	1	15	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAY	2000	25	1					47	54		10.1038/75586	http://dx.doi.org/10.1038/75586			8	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	311KU	10802655				2022-12-25	WOS:000086884000015
J	Aoki, H; Sadoshima, J; Izumo, S				Aoki, H; Sadoshima, J; Izumo, S			Myosin light chain kinase mediates sarcomere organization during cardiac hypertrophy in vitro	NATURE MEDICINE			English	Article							ACTIVATED PROTEIN-KINASE; RAT VENTRICULAR MYOCYTES; MUSCLE CELL HYPERTROPHY; ANGIOTENSIN-II; RHO-KINASE; TRANSCRIPTION FACTORS; S6 KINASE; PHOSPHORYLATION; GROWTH; STRESS	During the development of hypertrophy, cardiac myocytes increase organization of the sarcomere, a highly ordered contractile unit in striated muscle cells. Several hypertrophic agonists, such as angiotensin II, phenylephrine, and endothelin-1, have been shown to promote the sarcomere organization. However, the signaling pathway, which links extracellular stimuli to sarcomere organization, has not been clearly demonstrated. Here, we demonstrate that myosin light chain kinase specifically mediates agonist-induced sarcomere organization during early hypertrophic response. Acute administration of a hypertrophic agonist phenylephrine, or angiotensin II, causes phosphorylation of myosin light chain 2v both in cultured cardiac myocytes and in the adult heart in vivo. We also show that both sarcomere organization and myosin light chain 2v phosphorylation are dependent on the activation of Ca2+/calmodulin pathway, a known activator of myosin light chain kinase. These results define a new and specific role of myosin light chain kinase in cardiac myocytes, which may provide a rapid adaptive mechanism in response to hypertrophic stimuli.	Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Cardiovasc, Boston, MA 02215 USA; Penn State Univ, Coll Med, Weis Ctr Res, Danville, PA 17822 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Izumo, S (corresponding author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Cardiovasc, 330 Brookline Ave,SL-201, Boston, MA 02215 USA.			Sadoshima, Junichi/0000-0003-3724-4132				Amano M, 1996, J BIOL CHEM, V271, P20246, DOI 10.1074/jbc.271.34.20246; Aoki H, 1998, CIRC RES, V82, P666, DOI 10.1161/01.RES.82.6.666; BLANCHARD EM, 1990, PFLUG ARCH EUR J PHY, V416, P219, DOI 10.1007/BF00370248; Braunwald E, 1992, HEART DIS, V1, P393; CHIEN KR, 1993, ANNU REV PHYSIOL, V55, P77, DOI 10.1146/annurev.ph.55.030193.000453; Chihara K, 1997, J BIOL CHEM, V272, P25121, DOI 10.1074/jbc.272.40.25121; Choukroun G, 1998, J CLIN INVEST, V102, P1311, DOI 10.1172/JCI3512; Clerk A, 1997, BIOCHEM J, V325, P801, DOI 10.1042/bj3250801; ECKEL J, 1991, J MOL CELL CARDIOL, V23, P617, DOI 10.1016/0022-2828(91)90053-O; EPSTEIN HF, 1991, SCIENCE, V251, P1039, DOI 10.1126/science.1998120; Ferrari MB, 1998, J CELL BIOL, V141, P1349, DOI 10.1083/jcb.141.6.1349; Gallagher PJ, 1997, J MUSCLE RES CELL M, V18, P1, DOI 10.1023/A:1018616814417; GRUVER CL, 1993, ENDOCRINOLOGY, V133, P376, DOI 10.1210/en.133.1.376; HEACOCK CS, 1983, ANAL BIOCHEM, V135, P22, DOI 10.1016/0003-2697(83)90725-X; HONGO K, 1995, AM J PHYSIOL-CELL PH, V269, pC690, DOI 10.1152/ajpcell.1995.269.3.C690; Hoshijima M, 1998, J BIOL CHEM, V273, P7725, DOI 10.1074/jbc.273.13.7725; HU ZY, 1992, BIOCHEM PHARMACOL, V44, P1543, DOI 10.1016/0006-2952(92)90470-4; KATZ AM, 1990, NEW ENGL J MED, V322, P100; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; Kureishi Y, 1997, J BIOL CHEM, V272, P12257, DOI 10.1074/jbc.272.19.12257; MEBAZAA A, 1993, AM J PHYSIOL, V265, pH1841, DOI 10.1152/ajpheart.1993.265.5.H1841; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; MORANO I, 1985, FEBS LETT, V189, P221, DOI 10.1016/0014-5793(85)81027-9; NAKANISHI S, 1990, MOL PHARMACOL, V37, P482; PERRIE WT, 1970, BIOCHEM J, V119, P31, DOI 10.1042/bj1190031; Pracyk JB, 1998, J CLIN INVEST, V102, P929, DOI 10.1172/JCI2552; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SADOSHIMA J, 1995, CIRC RES, V77, P1040, DOI 10.1161/01.RES.77.6.1040; Sadoshima J, 1997, ANNU REV PHYSIOL, V59, P551, DOI 10.1146/annurev.physiol.59.1.551; SADOSHIMA J, 1992, J BIOL CHEM, V267, P10551; SADOSHIMA J, 1995, CIRC RES, V76, P1; Sanbe A, 1999, J BIOL CHEM, V274, P21085, DOI 10.1074/jbc.274.30.21085; SIMPSON P, 1983, J CLIN INVEST, V72, P732, DOI 10.1172/JCI111023; Small JV, 1999, CURR OPIN CELL BIOL, V11, P54, DOI 10.1016/S0955-0674(99)80007-6; SWEENEY HL, 1986, AM J PHYSIOL, V250, pC657, DOI 10.1152/ajpcell.1986.250.4.C657; SWEENEY HL, 1994, P NATL ACAD SCI USA, V91, P1490, DOI 10.1073/pnas.91.4.1490; SWEENEY HL, 1993, AM J PHYSIOL, V264, pC1085, DOI 10.1152/ajpcell.1993.264.5.C1085; THORBURN A, 1993, J BIOL CHEM, V268, P2244; Wang YB, 1998, J BIOL CHEM, V273, P2161, DOI 10.1074/jbc.273.4.2161; Wang YB, 1998, J BIOL CHEM, V273, P5423, DOI 10.1074/jbc.273.10.5423; Watanabe A, 1998, CARDIOVASC RES, V37, P524, DOI 10.1016/S0008-6363(97)00287-3; Zechner D, 1997, J CELL BIOL, V139, P115, DOI 10.1083/jcb.139.1.115; Zhi G, 1998, J BIOL CHEM, V273, P8951, DOI 10.1074/jbc.273.15.8951	44	117	123	1	10	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	FEB	2000	6	2					183	188		10.1038/72287	http://dx.doi.org/10.1038/72287			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	278YQ	10655107				2022-12-25	WOS:000085016900039
J	Baba, TW; Liska, V; Hofmann-Lehmann, R; Vlasak, J; Xu, WD; Ayehunie, S; Cavacini, LA; Posner, MR; Katinger, H; Stiegler, G; Bernacky, BJ; Rizvi, TA; Schmidt, R; Hill, LR; Keeling, ME; Lu, YC; Wright, JE; Chou, TC; Ruprecht, RM				Baba, TW; Liska, V; Hofmann-Lehmann, R; Vlasak, J; Xu, WD; Ayehunie, S; Cavacini, LA; Posner, MR; Katinger, H; Stiegler, G; Bernacky, BJ; Rizvi, TA; Schmidt, R; Hill, LR; Keeling, ME; Lu, YC; Wright, JE; Chou, TC; Ruprecht, RM			Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection	NATURE MEDICINE			English	Article							COMPLEMENT-MEDIATED LYSIS; CELL-FREE SIV; SYNERGISTIC NEUTRALIZATION; TYPE-1; MACAQUES; HIV-1; MONKEYS; EPITOPE; BINDING; GP120	Although maternal human immunodeficiency virus type 1 (HIV-1) transmission occurs during gestation, intrapartum and postpartum (by breast-feeding), 50-70% of all infected children seem to acquire HIV-1 shortly before or during delivery(1). Epidemiological evidence indicates that mucosal exposure is an important aspect of intrapartum HIV transmission(2,3). A simian immunodeficiency virus (SIV) macaque model has been developed(4) that mimics the mucosal exposure that can occur during intrapartum HIV-1 transmission. To develop immunoprophylaxis against intrapartum HIV-1 transmission, we used SHIV-vpu(+) (refs. 5,6), a chimeric simian-human virus that encodes the env gene of HIV-IIIB. Several combinations of human monoclonal antibodies against HIV-1. have been identified that neutralize SHIV-vpu(+) completely in vitro through synergistic interaction(7). Here, we treated four pregnant macaques with a triple combination of the human IgG1 monoclonal antibodies F105, 2G12 and 2F5. All four macaques were protected against intravenous SHIV-vpu(+) challenge after delivery. The infants received monoclonal antibodies after birth and were challenged orally with SHIV-vpu(+) shortly thereafter. We found no evidence of infection in any infant during 6 months of follow-up. This demonstrates that IgG1 monoclonal antibodies protect against mucosal lentivirus challenge in neonates. We conclude that epitopes recognized by the three monoclonal antibodies are important determinants for achieving substantial protection, thus providing a rational basis for AIDS vaccine development.	Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA; Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA; Tufts Univ, Sch Med, Dept Pediat, Div Newborn Med, Boston, MA 02111 USA; Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA; Inst Appl Microbiol, A-1190 Vienna, Austria; Univ Texas, MD Anderson Canc Ctr, Dept Vet Sci, Bastrop, TX 78602 USA; Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA; Mem Sloan Kettering Canc Ctr, Biochem Pharmacol Lab, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Preclin Pharmacol Core Facil, New York, NY 10021 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Tufts University; Harvard University; Beth Israel Deaconess Medical Center; University of Texas System; UTMD Anderson Cancer Center; Harvard University; Harvard T.H. Chan School of Public Health; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Ruprecht, RM (corresponding author), Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA.		Ayehunie, Seyoum/K-3514-2019; Hofmann-Lehmann, Regina/C-6528-2009; Chou, Ting-Chao/B-4111-2009; Chou, Ting-Chao/AAA-7881-2020	Hofmann-Lehmann, Regina/0000-0001-9750-4296; Chou, Ting-Chao/0000-0002-3340-1594; Chou, Ting-Chao/0000-0002-3340-1594; Rizvi, Tahir A/0000-0002-2572-1678	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI026926, R01AI032330, R01AI034266] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI32330, R01 AI34266, R01 AI26926] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BABA TW, 1994, AIDS RES HUM RETROV, V10, P351, DOI 10.1089/aid.1994.10.351; Baba TW, 1996, SCIENCE, V272, P1486, DOI 10.1126/science.272.5267.1486; CAVACINI LA, 1994, J IMMUNOTHER, V15, P251, DOI 10.1097/00002371-199405000-00003; COLLMAN R, 1992, J VIROL, V66, P7517, DOI 10.1128/JVI.66.12.7517-7521.1992; Conley AJ, 1996, J VIROL, V70, P6751, DOI 10.1128/JVI.70.10.6751-6758.1996; Joag SV, 1999, AIDS RES HUM RETROV, V15, P391, DOI 10.1089/088922299311367; Li A, 1998, J VIROL, V72, P3235, DOI 10.1128/JVI.72.4.3235-3240.1998; LI JT, 1995, J VIROL, V69, P7061, DOI 10.1128/JVI.69.11.7061-7067.1995; Liska V, 1999, AIDS RES HUM RETROV, V15, P445, DOI 10.1089/088922299311196; Lu YC, 1996, J ACQ IMMUN DEF SYND, V12, P99, DOI 10.1097/00042560-199606010-00001; Mascola JR, 1997, J VIROL, V71, P7198, DOI 10.1128/JVI.71.10.7198-7206.1997; Mascola JR, 1999, J VIROL, V73, P4009, DOI 10.1128/JVI.73.5.4009-4018.1999; MOFENSON L, 1998, PEDIAT AIDS CHALLENG, P487; MUSTER T, 1993, J VIROL, V67, P6642, DOI 10.1128/JVI.67.11.6642-6647.1993; POSNER MR, 1993, J ACQ IMMUN DEF SYND, V6, P7; POSNER MR, 1992, AIDS RES HUM RETROV, V8, P553, DOI 10.1089/aid.1992.8.553; POSNER MR, 1991, J IMMUNOL, V146, P4325; Rogers MF, 1999, NEW ENGL J MED, V341, P441, DOI 10.1056/NEJM199908053410609; Ruprecht RM, 1999, J INFECT DIS, V179, pS408, DOI 10.1086/314794; Shibata R, 1999, NAT MED, V5, P204, DOI 10.1038/5568; SPOUGE JL, 1992, P NATL ACAD SCI USA, V89, P7581, DOI 10.1073/pnas.89.16.7581; Sullivan BL, 1996, J IMMUNOL, V157, P1791; Trkola A, 1996, J VIROL, V70, P1100, DOI 10.1128/JVI.70.2.1100-1108.1996; Van Rompay KKA, 1998, J INFECT DIS, V177, P1247, DOI 10.1086/515270; WILLIAMSHERMAN D, 1993, INT C AIDS 6 11 JUN	25	745	793	0	35	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	FEB	2000	6	2					200	206		10.1038/72309	http://dx.doi.org/10.1038/72309			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	278YQ	10655110	Bronze			2022-12-25	WOS:000085016900042
J	Balomenos, D; Martin-Caballero, J; Garcia, MI; Prieto, I; Flores, JM; Serrano, M; Martinez, C				Balomenos, D; Martin-Caballero, J; Garcia, MI; Prieto, I; Flores, JM; Serrano, M; Martinez, C			The cell cycle inhibitor p21 controls T-cell proliferation and sex-linked lupus development	NATURE MEDICINE			English	Article							MICE; ERYTHEMATOSUS; KINASE; DEFICIENCY; RADIATION; MEMORY	Here we show that the cell-cycle regulator p21 is involved in immune system function. T lymphocytes from p21(-/-) mice exhibit significant proliferative advantage over wild-type cells following prolonged stimulation, but not after primary activation. Consistent with this, p27-deficient mice accumulate abnormal amounts of CD4(+) memory cells, and develop loss of tolerance towards nuclear antigens. Similar to human lupus, female p21-deficient mice develop antibodies against dsDNA, lymphadenopathy, and glomerulonephritis, leading to decreased viability. These data demonstrate a specialized role for p21 in the control of T-cell proliferation, tolerance to nuclear antigens, and female-prone lupus. These findings could be the basis for new therapeutic approaches to lupus.	CSIC, Ctr Nacl Biotecnol, Dept Immunol & Oncol, E-28049 Madrid, Spain; Univ Complutense Madrid, Fac Vet, Dept Patol Anim 2, E-28040 Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB); Complutense University of Madrid	Balomenos, D (corresponding author), CSIC, Ctr Nacl Biotecnol, Dept Immunol & Oncol, Plaza Murillo 2, E-28049 Madrid, Spain.		Serrano, Manuel/H-2634-2015; Balomenos, Dimitrios/I-3850-2015	Serrano, Manuel/0000-0001-7177-9312; Balomenos, Dimitrios/0000-0002-1252-0850				Balomenos D, 1998, J CLIN INVEST, V101, P364, DOI 10.1172/JCI750; BERDEN JHM, 1983, J IMMUNOL, V130, P1699; Bickerstaff MCM, 1999, NAT MED, V5, P694, DOI 10.1038/9544; Botto M, 1998, NAT GENET, V19, P56, DOI 10.1038/ng0598-56; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; CASCIOLAROSEN LA, 1994, J EXP MED, V179, P1317, DOI 10.1084/jem.179.4.1317; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Coats S, 1999, CURR BIOL, V9, P163, DOI 10.1016/S0960-9822(99)80086-4; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Dutton RW, 1998, ANNU REV IMMUNOL, V16, P201, DOI 10.1146/annurev.immunol.16.1.201; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Gaffney PM, 1998, P NATL ACAD SCI USA, V95, P14875, DOI 10.1073/pnas.95.25.14875; Kim YG, 1999, KIDNEY INT, V55, P2349, DOI 10.1046/j.1523-1755.1999.00504.x; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; London CA, 1999, J IMMUNOL, V162, P766; Megyesi J, 1998, J CLIN INVEST, V101, P777, DOI 10.1172/JCI1497; Moser KL, 1998, P NATL ACAD SCI USA, V95, P14869, DOI 10.1073/pnas.95.25.14869; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; OHASHI PS, 1997, CURR OPIN IMMUNOL, V8, P815; Ophascharoensuk V, 1998, NAT MED, V4, P575, DOI 10.1038/nm0598-575; Pape KA, 1997, IMMUNOL REV, V156, P67, DOI 10.1111/j.1600-065X.1997.tb00959.x; Paul E, 1999, NAT MED, V5, P607, DOI 10.1038/9450; Sabzevari H, 1997, EUR J IMMUNOL, V27, P1901, DOI 10.1002/eji.1830270813; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Takahashi S, 1996, J CLIN INVEST, V97, P1597, DOI 10.1172/JCI118584; Theofilopoulos AN, 1998, ANN NY ACAD SCI, V841, P225, DOI 10.1111/j.1749-6632.1998.tb10932.x; Wang YA, 1997, P NATL ACAD SCI USA, V94, P14590, DOI 10.1073/pnas.94.26.14590	27	167	170	0	3	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	FEB	2000	6	2					171	176		10.1038/72272	http://dx.doi.org/10.1038/72272			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	278YQ	10655105				2022-12-25	WOS:000085016900037
J	Potter, H; Dressler, D				Potter, H; Dressler, D			The potential of BACE inhibitors for Alzheimer's therapy	NATURE BIOTECHNOLOGY			English	Editorial Material									Univ S Florida, Coll Med, Tampa, FL 33612 USA; Univ Oxford, Dept Biochem, Oxford OX1 3QU, England; Univ Oxford Balliol Coll, Oxford OX1 3BJ, England	State University System of Florida; University of South Florida; University of Oxford; University of Oxford	Potter, H (corresponding author), Univ S Florida, Coll Med, Tampa, FL 33612 USA.							Hussain I, 1999, MOL CELL NEUROSCI, V14, P419, DOI 10.1006/mcne.1999.0811; Sinha S, 1999, NATURE, V402, P537, DOI 10.1038/990114; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Yan RQ, 1999, NATURE, V402, P533, DOI 10.1038/990107	4	21	24	0	3	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	FEB	2000	18	2					125	126		10.1038/72477	http://dx.doi.org/10.1038/72477			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	281FH	10657070				2022-12-25	WOS:000085146900003
J	Schuelke, M				Schuelke, M			An economic method for the fluorescent labeling of PCR fragments	NATURE BIOTECHNOLOGY			English	Editorial Material							DINUCLEOTIDE REPEAT		Charite Univ Hosp, Dept Neuropediat, D-13353 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Schuelke, M (corresponding author), Charite Univ Hosp, Dept Neuropediat, Augustenburger Pl 1, D-13353 Berlin, Germany.							BLACK GCM, 1991, NUCLEIC ACIDS RES, V19, P689; Hung SC, 1997, ANAL BIOCHEM, V252, P78, DOI 10.1006/abio.1997.2287; Ju JY, 1996, NAT MED, V2, P246, DOI 10.1038/nm0296-246; LITT M, 1989, AM J HUM GENET, V44, P397; SMITH LM, 1986, NATURE, V321, P674, DOI 10.1038/321674a0	5	2780	2889	2	284	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	FEB	2000	18	2					233	234		10.1038/72708	http://dx.doi.org/10.1038/72708			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	281FH	10657137				2022-12-25	WOS:000085146900036
J	Hodgson, J				Hodgson, J			Scientists avert new GMO crisis	NATURE BIOTECHNOLOGY			English	News Item																			0	16	17	0	6	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JAN	2000	18	1					13	13		10.1038/71838	http://dx.doi.org/10.1038/71838			1	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	273GQ	10625373	Bronze			2022-12-25	WOS:000084699900007
J	Hodgson, J				Hodgson, J			Crystal gazing the new biotechnologies	NATURE BIOTECHNOLOGY			English	Article								Several scientific, conceptual, and financial challenges face biotechnology if it is to overcome thus far intractable problems in human disease and agriculture.											0	2	2	0	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JAN	2000	18	1					29	31		10.1038/71884	http://dx.doi.org/10.1038/71884			3	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	273GQ	10625386				2022-12-25	WOS:000084699900020
J	Phimister, B				Phimister, B			Four companies announce discovery of beta-secretase gene	NATURE BIOTECHNOLOGY			English	News Item																			0	7	10	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JAN	2000	18	1					16	16		10.1038/71846	http://dx.doi.org/10.1038/71846			1	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	273GQ	10625376	Bronze			2022-12-25	WOS:000084699900010
J	Halford, MM; Armes, J; Buchert, M; Meskenaite, V; Grail, D; Hibbs, ML; Wilks, AF; Farlie, PG; Newgreen, DF; Hovens, CM; Stacker, SA				Halford, MM; Armes, J; Buchert, M; Meskenaite, V; Grail, D; Hibbs, ML; Wilks, AF; Farlie, PG; Newgreen, DF; Hovens, CM; Stacker, SA			Ryk-deficient mice exhibit craniofacial defects associated with perturbed Eph receptor crosstalk	NATURE GENETICS			English	Article							INVERSUS SYNDROME BPES; TYROSINE KINASE FAMILY; BLEPHAROPHIMOSIS; EXPRESSION; PTOSIS; DUPLICATION; SELECTION; DELETION; DOMAINS; TARGETS	Secondary palate formation is a complex process that is frequently disturbed in mammals, resulting in the birth defect cleft palate(1,2). Gene targeting has identified components of cytokine/growth factor signalling systems such as Tgf-alpha/Egfr, Eph receptors B2 and B3 (Ephb2 and Ephb3, respectively), Tgf-beta 2, Tgf-beta 3 and activin-beta A (ref. 3) as regulators of secondary palate development, Here we demonstrate that the mouse orphan receptor 'related to tyrosine kinases' (Ryk) is essential for normal development and morphogenesis of craniofacial structures including the secondary palate. Ryk belongs to a subclass of catalytically inactive, but otherwise distantly related, receptor protein tyrosine kinases(4-6) (RTKs). Mice homozygous for a null allele of Ryk have a distinctive craniofacial appearance, shortened limbs and postnatal mortality due to feeding and respiratory complications associated with a complete cleft of the secondary palate. Consistent with cleft palate phenocopy in Ephb2/Ephb3-deficient mice(7) and the role of a Drosophila melanogaster Ryk orthologue, Derailed, in the transduction of repulsive axon pathfinding cues(8,9), our biochemical data implicate Ryk in signalling mediated by Eph receptors and the cell-junction-associated Af-6 (also known as Afadin), Our findings highlight the importance of signal crosstalk between members of different RTK subfamilies.	Royal Melbourne Hosp, Ludwig Inst Canc Res, Melbourne, Vic, Australia; Cooperat Res Ctr Cellular Growth Factors, Melbourne, Vic, Australia; Peter MacCallum Canc Inst, Victorian Breast Canc Res Consortium, E Melbourne, Vic, Australia; Peter MacCallum Canc Inst, Dept Pathol, E Melbourne, Vic, Australia; Royal Melbourne Hosp, Dept Surg, Melbourne, Vic, Australia; Univ Zurich, ETH Zurich, Inst Neuroinformat, Zurich, Switzerland; Royal Childrens Hosp, Murdoch Inst, Parkville, Vic 3052, Australia	Ludwig Institute for Cancer Research; Royal Melbourne Hospital; Peter Maccallum Cancer Center; Peter Maccallum Cancer Center; Royal Melbourne Hospital; Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Zurich; Murdoch Children's Research Institute; Royal Children's Hospital Melbourne	Stacker, SA (corresponding author), Royal Melbourne Hosp, Ludwig Inst Canc Res, POB 2008, Melbourne, Vic, Australia.		Armes, Jane/D-6396-2012; Buchert, Michael/Z-1777-2019; Hibbs, Margaret L/D-7013-2011; Wilks, Andrew F/R-5542-2019	Armes, Jane/0000-0002-2215-0347; Buchert, Michael/0000-0003-2672-0148; Hibbs, Margaret L/0000-0002-3751-6751; Stacker, Steven/0000-0003-4096-9273; Wilks, Andrew F/0000-0002-8554-2399; Hovens, Christopher/0000-0002-0610-1289				Adams RH, 1999, GENE DEV, V13, P295, DOI 10.1101/gad.13.3.295; BOHME B, 1993, ONCOGENE, V82, P857; Bonkowsky JL, 1999, NATURE, V402, P540, DOI 10.1038/990122; Buchert M, 1999, J CELL BIOL, V144, P361, DOI 10.1083/jcb.144.2.361; CALLAHAN CA, 1995, NATURE, V376, P171, DOI 10.1038/376171a0; CIOSSEK T, 1995, ONCOGENE, V10, P97; FEAR C, 1979, ARCH DIS CHILD, V54, P135, DOI 10.1136/adc.54.2.135; FERGUSON MWJ, 1988, DEVELOPMENT, V103, P41; Francis-West P, 1998, MECH DEVELOP, V75, P3, DOI 10.1016/S0925-4773(98)00082-3; FRYNS JP, 1995, CLIN GENET, V48, P111; FUJITA H, 1992, AM J MED GENET, V44, P434, DOI 10.1002/ajmg.1320440409; Gorlin RJ, 1990, PLAST RECONSTR SURG; Halford MM, 1999, J BIOL CHEM, V274, P7379, DOI 10.1074/jbc.274.11.7379; Hockley D, 1998, JAVA REP, V3, P6; Hogan B, 1994, MANIPULATING MOUSE E; HOVENS CM, 1992, P NATL ACAD SCI USA, V89, P11818, DOI 10.1073/pnas.89.24.11818; ISHIKIRIYAMA S, 1994, AM J MED GENET, V52, P245, DOI 10.1002/ajmg.1320520228; JEWETT T, 1993, AM J MED GENET, V47, P1147, DOI 10.1002/ajmg.1320470802; Kamitori K, 1999, DEV BRAIN RES, V114, P149, DOI 10.1016/S0165-3806(99)00033-4; Katso RM, 1999, MOL CELL BIOL, V19, P6427; Koblizek TI, 1997, EUR J BIOCHEM, V244, P774, DOI 10.1111/j.1432-1033.1997.00774.x; Kuriyama M, 1996, J BIOL CHEM, V271, P607, DOI 10.1074/jbc.271.2.607; Linnemann T, 1999, J BIOL CHEM, V274, P13556, DOI 10.1074/jbc.274.19.13556; Orioli D, 1996, EMBO J, V15, P6035, DOI 10.1002/j.1460-2075.1996.tb00992.x; ROSENFELD W, 1981, AM J MED GENET, V10, P187, DOI 10.1002/ajmg.1320100212; SALAZAR D, 1979, AM J DIS CHILD, V133, P1006, DOI 10.1001/archpedi.1979.02130100030005; Schneider S, 1999, NAT BIOTECHNOL, V17, P170, DOI 10.1038/6172; Simon AF, 1998, MECH DEVELOP, V76, P45, DOI 10.1016/S0925-4773(98)00104-X; STACKER SA, 1993, ONCOGENE, V8, P1347; WILLIAMSON RA, 1981, AM J MED GENET, V9, P105, DOI 10.1002/ajmg.1320090204	30	137	142	1	6	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	AUG	2000	25	4					414	418		10.1038/78099	http://dx.doi.org/10.1038/78099			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	341WY	10932185				2022-12-25	WOS:000088615000016
J	Hotta, CT; Gazarini, ML; Beraldo, FH; Varotti, FP; Lopes, C; Markus, RP; Pozzan, T; Garcia, CRS				Hotta, CT; Gazarini, ML; Beraldo, FH; Varotti, FP; Lopes, C; Markus, RP; Pozzan, T; Garcia, CRS			Calcium-dependent modulation by melatonin of the circadian rhythm in malarial parasites.	NATURE CELL BIOLOGY			English	Article							HOMEOSTASIS; STORES; STAGE		Univ Sao Paulo, Inst Biociencias, Dept Fisiol, BR-0550890 Sao Paulo, Brazil; Univ Padua, Dipartimento Sci Biomed Sperimentali, CNR, Ctr Biomembrane, I-35121 Padua, Italy	Universidade de Sao Paulo; Consiglio Nazionale delle Ricerche (CNR); University of Padua	Garcia, CRS (corresponding author), Univ Sao Paulo, Inst Biociencias, Dept Fisiol, BR-0550890 Sao Paulo, Brazil.	cgarcia@usp.br	Hotta, Carlos Takeshi/G-9760-2012; Markus, Regina P/K-2954-2012; Garcia, Celia R. S./A-4093-2011; Varotti, Fernando/J-4764-2015; Lopes, Cristiane/D-3911-2014; Gazarini, Marcos L./O-7413-2019; Markus, Regina P./AAC-1505-2021; Gazarini, Marcos/AFR-3473-2022; Gazarini, Marcos L/D-6022-2012	Hotta, Carlos Takeshi/0000-0003-3349-6121; Markus, Regina P/0000-0003-4606-6120; Garcia, Celia R. S./0000-0003-2825-1701; Varotti, Fernando/0000-0002-2939-7780; Lopes, Cristiane/0000-0001-7147-1772; Markus, Regina P./0000-0003-4606-6120; Gazarini, Marcos/0000-0002-3882-6831; 				ARNOLD JD, 1969, J PARASITOL, V55, P609, DOI 10.2307/3277305; ARNOLD JD, 1969, J PARASITOL, V55, P597, DOI 10.2307/3277304; BELL A, 1994, BIOCHEM PHARMACOL, V48, P495, DOI 10.1016/0006-2952(94)90279-8; CAMBIE G, 1990, CR ACAD SCI III-VIE, V310, P183; Cassone VM, 1997, J BIOL RHYTHM, V12, P489, DOI 10.1177/074873049701200602; DAVID PH, 1978, P NATL ACAD SCI USA, V75, P5081, DOI 10.1073/pnas.75.10.5081; DIVIRGILIO F, 1988, J IMMUNOL, V140, P915; DOERIG CD, 1997, PARASITOL TODAY, V13, P297; Eison Arlene S., 1993, Life Sciences, V53, P393; Garcia CRS, 1998, EUR J CELL BIOL, V76, P133, DOI 10.1016/S0171-9335(98)80026-5; Garcia CRS, 1996, EUR J CELL BIOL, V71, P409; Garcia CRS, 1999, PARASITOL TODAY, V15, P488, DOI 10.1016/S0169-4758(99)01571-9; HAWKING F, 1972, PARASITOLOGY, V65, P189, DOI 10.1017/S003118200004498X; KLEIN DC, 1981, PINEAL GLAND ANATOMY, P199; Lopes C, 1997, J PINEAL RES, V23, P72, DOI 10.1111/j.1600-079X.1997.tb00338.x; Passos APD, 1998, BIOCHEM BIOPH RES CO, V245, P155, DOI 10.1006/bbrc.1998.8338; POPOVA JS, 1995, J NEUROCHEM, V64, P130; POZZAN T, 1994, PHYSIOL REV, V74, P595, DOI 10.1152/physrev.1994.74.3.595; TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840; Tsim ST, 1997, J CELL SCI, V110, P1387; Vivien-Roels B, 1998, J BIOL RHYTHM, V13, P403, DOI 10.1177/074873098129000228	21	147	151	0	14	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	JUL	2000	2	7					466	468		10.1038/35017112	http://dx.doi.org/10.1038/35017112			3	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	333MK	10878815				2022-12-25	WOS:000088133700026
J	Xu, WM; Liu, LZ; Smith, GCM; Charles, IG				Xu, WM; Liu, LZ; Smith, GCM; Charles, IG			Nitric oxide upregulates expression of DNA-PKcs to protect cells from DNA-damaging anti-tumour agents	NATURE CELL BIOLOGY			English	Article							SYNTHASE GENE-EXPRESSION; KINASE ACTIVITY; SENSITIVITY; CANCER; INHIBITION; SUBUNIT; GROWTH; REPAIR; TISSUE; LINES	Nitric-oxide synthase (NOS) activity has been detected in many human tumours, although its function is unclear. Here we show that exposure of cells to nitric oxide (NO) results in a 4-5-fold increase in expression of the DNA-dependent protein-kinase catalytic subunit (DNA-PKcs), one of the key enzymes involved in repairing double-stranded DNA breaks. This NO-mediated increase in enzymatically active DNA-PK not only protects cells from the toxic effects of NO, but also provides crossprotection against clinically important DNA-damaging agents, such as X-ray radiation, adriamycin, bleomycin and cisplatin. The NO-mediated increase in DNA-PKcs described here demonstrates the presence of a new and highly effective NO-mediated mechanism for DNA repair.	UCL, Wolfson Inst Biomed Res, London WC1E 6BT, England; Univ Cambridge, Wellcome Trust CRC Inst, Cambridge CB2 1QR, England; Univ Cambridge, Dept Zool, Cambridge CB2 1QR, England	University of London; University College London; University of Cambridge; University of Cambridge	Charles, IG (corresponding author), UCL, Wolfson Inst Biomed Res, Cruciform Bldg,Gower St, London WC1E 6BT, England.	rmgzigc@ucl.ac.uk	Xu, Weiming/A-6274-2008	Xu, Weiming/0000-0002-7085-7814				ALLALUNISTURNER MJ, 1993, RADIAT RES, V134, P349, DOI 10.2307/3578196; Ambs S, 1998, NAT MED, V4, P1371, DOI 10.1038/3957; Ambs S, 1998, CANCER RES, V58, P334; ASANO K, 1994, P NATL ACAD SCI USA, V91, P10089, DOI 10.1073/pnas.91.21.10089; Burney S, 1999, MUTAT RES-FUND MOL M, V424, P37, DOI 10.1016/S0027-5107(99)00006-8; CHARLES IG, 1993, P NATL ACAD SCI USA, V90, P11419, DOI 10.1073/pnas.90.23.11419; Connelly MA, 1998, GENOMICS, V47, P71, DOI 10.1006/geno.1997.5076; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DARIUS H, 1984, J CARDIOVASC PHARM, V6, P115; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FINNIE NJ, 1995, P NATL ACAD SCI USA, V92, P320, DOI 10.1073/pnas.92.1.320; Forrester K, 1996, P NATL ACAD SCI USA, V93, P2442, DOI 10.1073/pnas.93.6.2442; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; Izzard RA, 1999, CANCER RES, V59, P2581; JENKINS DC, 1995, P NATL ACAD SCI USA, V92, P4392, DOI 10.1073/pnas.92.10.4392; JENKINS DC, 1994, BRIT J CANCER, V70, P847, DOI 10.1038/bjc.1994.409; KNOWLES RG, 1994, BIOCHEM J, V298, P249, DOI 10.1042/bj2980249; LEESMILLER SP, 1995, SCIENCE, V267, P1183, DOI 10.1126/science.7855602; MONCADA S, 1991, PHARMACOL REV, V43, P109; Muller C, 1998, NUCLEIC ACIDS RES, V26, P1382, DOI 10.1093/nar/26.6.1382; Muller C, 1998, BLOOD, V92, P2213, DOI 10.1182/blood.V92.7.2213.2213_2213_2219; No D, 1996, P NATL ACAD SCI USA, V93, P3346, DOI 10.1073/pnas.93.8.3346; SALTER M, 1991, FEBS LETT, V291, P145, DOI 10.1016/0014-5793(91)81123-P; Shen HX, 1998, BBA-GEN SUBJECTS, V1381, P131, DOI 10.1016/S0304-4165(98)00020-8; Smith GCM, 1999, GENE DEV, V13, P916, DOI 10.1101/gad.13.8.916; Song QZ, 1996, EMBO J, V15, P3238, DOI 10.1002/j.1460-2075.1996.tb00688.x; Suschek CV, 1999, J BIOL CHEM, V274, P6130, DOI 10.1074/jbc.274.10.6130; Thomsen LL, 1998, BIOCHEM PHARMACOL, V56, P1365, DOI 10.1016/S0006-2952(98)00187-7; Woudstra EC, 1998, INT J RADIAT BIOL, V73, P495, DOI 10.1080/095530098142031; YAGLE MK, 1990, P NATL ACAD SCI USA, V87, P7255, DOI 10.1073/pnas.87.18.7255; Zhao HX, 1998, BLOOD, V92, P1031	31	122	128	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	JUN	2000	2	6					339	345		10.1038/35014028	http://dx.doi.org/10.1038/35014028			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	321KE	10854324				2022-12-25	WOS:000087454000015
J	Wraight, CJ; White, PJ; McKean, SC; Fogarty, RD; Venables, DJ; Liepe, IJ; Edmondson, SR; Werther, GA				Wraight, CJ; White, PJ; McKean, SC; Fogarty, RD; Venables, DJ; Liepe, IJ; Edmondson, SR; Werther, GA			Reversal of epidermal hyperproliferation in psoriasis by insulin-like growth factor I receptor antisense oligonucleotides	NATURE BIOTECHNOLOGY			English	Article						psoriasis; keratinocytes; hyperproliferation; IGFI receptor; antisense oligonucleotides	BINDING PROTEIN-3 IGFBP-3; KERATINOCYTE CELL-LINE; HUMAN-SKIN-GRAFTS; IGF-1 RECEPTOR; SOMATOMEDIN-C; NUDE-MICE; CULTURED KERATINOCYTES; GENE-EXPRESSION; OLIGODEOXYNUCLEOTIDES; PROLIFERATION	Epidermal hyperplasia is a key feature of the common skin disorder psoriasis. Stimulation of epidermal keratinocytes by insulin-like growth factor I (IGF-I) is essential for cell division, and increased sensitivity to IGF-I may occur in psoriasis. We hypothesized that inhibition of IGF-I receptor expression in the psoriasis lesion would reverse psoriatic epidermal hyperplasia by stowing the rate of keratinocyte cell division. Here we report the use of C5-propynyl-dU,dC-phosphorothioate antisense oligonucleotides to inhibit IGF-I receptor expression in keratinocytes. We identified several inhibitory antisense oligonucleotides and demonstrated IGF-I receptor inhibition in vitro through an mRNA targeting mechanism. Repeated injection of these oligonucleotides into human psoriasis lesions, grafted onto nude mice, caused a dramatic normalization of the hyperplastic epidermis. The findings indicate that IGF-I receptor stimulation is a rate-limiting step in psoriatic epidermal hyperplasia and that IGF-I receptor targeting by cutaneous administration of antisense oligonucleotides forms the basis of a potential new psoriasis therapy.	Royal Childrens Hosp, Ctr Hormone Res, Parkville, Vic 3052, Australia; Monash Univ, Victorian Coll Pharm, Dept Pharmaceut Biol & Pharmacol, Parkville, Vic 3052, Australia	Royal Children's Hospital Melbourne; Monash University	Wraight, CJ (corresponding author), Royal Childrens Hosp, Ctr Hormone Res, Flemington Rd, Parkville, Vic 3052, Australia.		Werther, George/B-3784-2012; White, Paul J/A-7038-2011	White, Paul/0000-0002-7524-1808; Venables, Ingrid/0000-0002-5258-6563				BARRECA A, 1992, J CELL PHYSIOL, V151, P262, DOI 10.1002/jcp.1041510207; BONNEKOH B, 1991, J AM ACAD DERMATOL, V25, P483, DOI 10.1016/0190-9622(91)70228-T; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; FINLAY AY, 1995, BRIT J DERMATOL, V132, P236; Flanagan WM, 1997, MOL CELL BIOCHEM, V172, P213, DOI 10.1023/A:1006852613083; Flanagan WM, 1996, NAT BIOTECHNOL, V14, P1139, DOI 10.1038/nbt0996-1139; GELLEN CC, 1997, J BIOL CHEM, V272, P8997; Gottlieb AB, 1997, ARCH DERMATOL, V133, P781, DOI 10.1001/archderm.133.6.781; HAFTEK M, 1981, J INVEST DERMATOL, V76, P48, DOI 10.1111/1523-1747.ep12524864; Hodak E, 1996, J INVEST DERMATOL, V106, P564, DOI 10.1111/1523-1747.ep12344044; KRANE JF, 1992, J EXP MED, V175, P1081, DOI 10.1084/jem.175.4.1081; KRANE JF, 1991, J INVEST DERMATOL, V96, P419, DOI 10.1111/1523-1747.ep12469799; KRUEGER GG, 1975, J INVEST DERMATOL, V64, P307, DOI 10.1111/1523-1747.ep12512256; KRUEGER JG, 1990, J INVEST DERMATOL S, V94, P135; LEIGH IM, 1985, BRIT J DERMATOL, V113, P53, DOI 10.1111/j.1365-2133.1985.tb02044.x; Lewis JG, 1996, P NATL ACAD SCI USA, V93, P3176, DOI 10.1073/pnas.93.8.3176; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/S0092-8674(05)80084-4; Michel G, 1997, INFLAMM RES, V46, P32, DOI 10.1007/s000110050042; MISRA P, 1986, J INVEST DERMATOL, V87, P264, DOI 10.1111/1523-1747.ep12696645; Monia BP, 1996, NAT MED, V2, P668, DOI 10.1038/nm0696-668; MONIA BP, 1993, J BIOL CHEM, V268, P14514; MOULDS C, 1995, BIOCHEMISTRY-US, V34, P5044, DOI 10.1021/bi00015a015; Muller K, 1997, J MED CHEM, V40, P2780, DOI 10.1021/jm9701785; NANNEY LB, 1992, J INVEST DERMATOL, V98, P296, DOI 10.1111/1523-1747.ep12497963; NICKOLOFF BJ, 1988, DERMATOLOGICA, V177, P265, DOI 10.1159/000248577; NICKOLOFF BJ, 1991, ARCH DERMATOL, V127, P871, DOI 10.1001/archderm.127.6.871; PIETRZKOWSKI Z, 1992, MOL CELL BIOL, V12, P3883, DOI 10.1128/MCB.12.9.3883; PORCU P, 1992, MOL CELL BIOL, V12, P5069, DOI 10.1128/MCB.12.11.5069; REISS K, 1992, ONCOGENE, V7, P2243; RESNICOFF M, 1994, CANCER RES, V54, P2218; RISTOW HJ, 1993, GROWTH REGULAT, V3, P129; Ristow HJ, 1997, DERMATOLOGY, V195, P213, DOI 10.1159/000245945; RISTOW HJ, 1988, J CELL PHYSIOL, V137, P277, DOI 10.1002/jcp.1041370210; SHULTZ J, 1994, J IMMUNOL METHODS, V167, P1; STEIN CA, 1993, SCIENCE, V261, P1004, DOI 10.1126/science.8351515; STEIN CA, 1994, ANTISENSE RES DEV, V4, P67, DOI 10.1089/ard.1994.4.67; TAVAKKOL A, 1992, J INVEST DERMATOL, V99, P343, DOI 10.1111/1523-1747.ep12616668; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; VANSCOTT EJ, 1963, ARCH DERMATOL, V88, P373, DOI 10.1001/archderm.1963.01590220005001; WAGNER RW, 1994, NATURE, V372, P333, DOI 10.1038/372333a0; WEINSTEIN GD, 1984, J INVEST DERMATOL, V82, P623, DOI 10.1111/1523-1747.ep12261462; White PJ, 1999, J INVEST DERMATOL, V112, P887, DOI 10.1046/j.1523-1747.1999.00593.x; White PJ, 1999, J INVEST DERMATOL, V112, P699, DOI 10.1046/j.1523-1747.1999.00578.x; WRAIGHT CJ, 1994, J INVEST DERMATOL, V103, P627, DOI 10.1111/1523-1747.ep12397667; WRAIGHT CJ, 1995, J INVEST DERMATOL, V105, P602, DOI 10.1111/1523-1747.ep12323716; Wraight CJ, 1997, J INVEST DERMATOL, V108, P452, DOI 10.1111/1523-1747.ep12289713; Xu S, 1996, J INVEST DERMATOL, V106, P109, DOI 10.1111/1523-1747.ep12328197	47	66	81	0	6	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAY	2000	18	5					521	526		10.1038/75382	http://dx.doi.org/10.1038/75382			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	313UK	10802619				2022-12-25	WOS:000087017500025
J	Zhang, D; Gaussin, V; Taffet, GE; Belaguli, NS; Yamada, M; Schwartz, RJ; Michael, LH; Overbeek, PA; Schneider, MD				Zhang, D; Gaussin, V; Taffet, GE; Belaguli, NS; Yamada, M; Schwartz, RJ; Michael, LH; Overbeek, PA; Schneider, MD			TAK1 is activated in the myocardium after pressure overload and is sufficient to provoke heart failure in transgenic mice	NATURE MEDICINE			English	Article							SERUM RESPONSE FACTOR; ALPHA-ACTIN GENE; RAT CARDIAC MYOCYTES; KINASE CASCADE; VENTRICULAR MYOCYTES; SIGNAL-TRANSDUCTION; MECHANICAL-STRESS; IN-VIVO; PROTEIN; EXPRESSION	The transforming-growth-factor-beta-activated kinase TAK1 is a member of the mitogen-activated protein kinase kinase kinase family, which couples extracellular stimuli to gene transcription. The in vivo function of TAK1 is not understood. Here, we investigated the potential involvement of TAK1 in cardiac hypertrophy. In adult mouse myocardium, TAK1 kinase activity was upregulated 7 days after aortic banding, a mechanical load that induces hypertrophy and expression of transforming growth factor beta. An activating mutation of TAK1 expressed in myocardium of transgenic mice was sufficient to produce p38 mitogen-activated protein kinase phosphorylation in vivo, cardiac hypertrophy, interstitial fibrosis, severe myocardial dysfunction, 'fetal' gene induction, apoptosis and early lethality. Thus, TAK1 activity is induced as a delayed response to mechanical stress, and can suffice to elicit myocardial hypertrophy and fulminant heart failure.	Baylor Coll Med, Ctr Cardiovasc Dev, Houston, TX 77030 USA; Baylor Coll Med, DeBakey Heart Ctr Grad Program Cardiovasc Sci, Houston, TX 77030 USA; Baylor Coll Med, Dept Med, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol Physiol & Biophys, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine	Schneider, MD (corresponding author), Baylor Coll Med, Ctr Cardiovasc Dev, Houston, TX 77030 USA.			Schneider, Michael/0000-0001-9645-1938; Overbeek, Paul/0000-0001-9784-2084				ABDELLATIF M, 1994, J BIOL CHEM, V269, P15423; Adams JW, 1998, P NATL ACAD SCI USA, V95, P10140, DOI 10.1073/pnas.95.17.10140; Agah R, 1997, J CLIN INVEST, V100, P169, DOI 10.1172/JCI119509; BOLUYT MO, 1994, CIRC RES, V75, P23, DOI 10.1161/01.RES.75.1.23; Brown TL, 1999, J BIOL CHEM, V274, P23256, DOI 10.1074/jbc.274.33.23256; Charng MJ, 1998, DEV BIOL, V199, P72, DOI 10.1006/dbio.1998.8905; Chen CY, 1996, MOL CELL BIOL, V16, P6372; Croissant JD, 1996, DEV BIOL, V177, P250, DOI 10.1006/dbio.1996.0160; Depre C, 1998, NAT MED, V4, P1269, DOI 10.1038/3253; Georgakopoulos D, 1999, NAT MED, V5, P327, DOI 10.1038/6549; HARTLEY CJ, 1995, AM J PHYSIOL-HEART C, V268, pH499, DOI 10.1152/ajpheart.1995.268.1.H499; Hirota H, 1999, CELL, V97, P189, DOI 10.1016/S0092-8674(00)80729-1; Jiang W, 1997, P NATL ACAD SCI USA, V94, P14320, DOI 10.1073/pnas.94.26.14320; JOHANSEN FE, 1993, MOL CELL BIOL, V13, P4640, DOI 10.1128/MCB.13.8.4640; Kapadia SR, 1997, CIRC RES, V81, P187, DOI 10.1161/01.RES.81.2.187; Kirshenbaum LA, 1996, DEV BIOL, V179, P402, DOI 10.1006/dbio.1996.0270; Kretzschmar M, 1998, CURR OPIN GENET DEV, V8, P103, DOI 10.1016/S0959-437X(98)80069-5; MACLELLAN WR, 1994, J BIOL CHEM, V269, P16754; MacLellan WR, 1997, CIRC RES, V81, P137, DOI 10.1161/01.RES.81.2.137; MACLELLAN WR, 1998, CARDIAC DEV, P405; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; Monzen K, 1999, MOL CELL BIOL, V19, P7096; Moriguchi T, 1996, J BIOL CHEM, V271, P13675, DOI 10.1074/jbc.271.23.13675; Nemoto S, 1998, MOL CELL BIOL, V18, P3518, DOI 10.1128/MCB.18.6.3518; Ninomiya-Tsuji J, 1999, NATURE, V398, P252, DOI 10.1038/18465; ORNITZ DM, 1991, P NATL ACAD SCI USA, V88, P698, DOI 10.1073/pnas.88.3.698; Paradis P, 1996, J BIOL CHEM, V271, P10827, DOI 10.1074/jbc.271.18.10827; PARKER TG, 1990, J CLIN INVEST, V85, P507, DOI 10.1172/JCI114466; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; RINDT H, 1993, J BIOL CHEM, V268, P5332; Ritter SJ, 1998, J BIOL CHEM, V273, P12798, DOI 10.1074/jbc.273.21.12798; Sadoshima J, 1997, ANNU REV PHYSIOL, V59, P551, DOI 10.1146/annurev.physiol.59.1.551; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; Sano Y, 1999, J BIOL CHEM, V274, P8949, DOI 10.1074/jbc.274.13.8949; Shioi T, 1997, CIRC RES, V81, P664; Shirakabe K, 1997, J BIOL CHEM, V272, P8141, DOI 10.1074/jbc.272.13.8141; SUBRAMANIAM A, 1991, J BIOL CHEM, V266, P24613; Taffet GE, 1996, AM J PHYSIOL-HEART C, V270, pH2204; Thuerauf DJ, 1998, J BIOL CHEM, V273, P20636, DOI 10.1074/jbc.273.32.20636; VILLARREAL FJ, 1992, AM J PHYSIOL, V262, pH1861, DOI 10.1152/ajpheart.1992.262.6.H1861; Wang YB, 1998, J BIOL CHEM, V273, P2161, DOI 10.1074/jbc.273.4.2161; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; YAMAZAKI T, 1995, J CLIN INVEST, V96, P438, DOI 10.1172/JCI118054; Zhu C, 1997, MOL CELL BIOL, V17, P4957, DOI 10.1128/MCB.17.9.4957	45	273	288	0	11	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAY	2000	6	5					556	563		10.1038/75037	http://dx.doi.org/10.1038/75037			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	309YB	10802712				2022-12-25	WOS:000086796200040
J	Krause, PR; Klinman, DM				Krause, PR; Klinman, DM			Varicella vaccination: Evidence for frequent reactivation of the vaccine strain in healthy children	NATURE MEDICINE			English	Article							ZOSTER VIRUS-INFECTIONS; FOLLOW-UP; EFFICACY; IMMUNIZATION; EPIDEMIOLOGY; CHICKENPOX; IMMUNITY	Wild-type varicella tester virus (VZV) causes chickenpox, a common childhood illness characterized by fever and a vesicular rash(1) and rare serious complications'. Wild-type VZV persists in a latent form in the sensory ganglia, and can re-activate to cause herpes zoster(3). More than 10 million American children have received the live attenuated Oka strain VZV vaccine (OkaVZV) since its licensure in 1995. Pre-licensure clinical studies showed that mean serum anti-VZV levels among vaccinees continued to increase with time after vaccination. This was attributed to immunologic boosting caused by exposure to wild-type VZV in the community(4,5). Here, we examine the alternative, that large-scale asymptomatic reactivation of OkaVZV might occur in vaccinees. We analyzed serum antibody levels and infection rates for 4 years of follow-up in 4,631 children immunized with OkaVZV. Anti-VZV titers decreased over time in high-responder subjects, but rose in vaccinees with low titers. Among subjects with low anti-VZV titers, the frequency of clinical infection and immunological boosting substantially exceeded the 13%-per-year rate of exposure to wild-type varicella. These findings indicate that OkaVZV persisted in vivo and reactivated as serum antibody titers decreased after vaccination. This has salient consequences for individuals immunized with OkaVZV.	US FDA, Lab DNA Viruses, Div Viral Prod, Ctr Biol Evaluat & Res, Bethesda, MD 20892 USA; US FDA, Sect Retroviral Res, Div Viral Prod, Ctr Biol Evaluat & Res, Bethesda, MD 20892 USA	US Food & Drug Administration (FDA); US Food & Drug Administration (FDA)	Krause, PR (corresponding author), US FDA, Lab DNA Viruses, Div Viral Prod, Ctr Biol Evaluat & Res, Bethesda, MD 20892 USA.	krause@cber.fda.gov		Krause, Philip/0000-0002-1045-7536				ARVIN AM, 1983, J INFECT DIS, V148, P200, DOI 10.1093/infdis/148.2.200; ASANO Y, 1994, PEDIATRICS, V94, P524; BERNSTEIN HH, 1993, PEDIATRICS, V92, P833; BRUNNER U, 1986, APPL GEOGR, V6, P77, DOI 10.1016/0143-6228(86)90030-5; CHOO PW, 1995, J INFECT DIS, V172, P706, DOI 10.1093/infdis/172.3.706; Cohen JI, 1999, ANN INTERN MED, V130, P922, DOI 10.7326/0003-4819-130-11-199906010-00017; COLTON T, 1974, STAT MED, P153; FINGER R, 1994, PUBLIC HEALTH REP, V109, P750; HARDY I, 1991, NEW ENGL J MED, V325, P1545, DOI 10.1056/NEJM199111283252204; HOPESIMPSON RE, 1965, P ROY SOC MED, V58, P9, DOI 10.1177/003591576505800106; KELLER PM, 1986, J VIROL METHODS, V14, P177, DOI 10.1016/0166-0934(86)90048-0; KRAUSE PR, 1995, J PEDIATR-US, V127, P518, DOI 10.1016/S0022-3476(95)70106-0; KUTER BJ, 1991, VACCINE, V9, P643, DOI 10.1016/0264-410X(91)90189-D; LJUNGMAN P, 1986, J INFECT DIS, V153, P840, DOI 10.1093/infdis/153.5.840; LUBY JP, 1977, J INFECT DIS, V135, P659, DOI 10.1093/infdis/135.4.659; *MERCK CO, 1998, PHYS DESK REF, P1762; Schenk LM, 1999, OBSTET GYN CLIN N AM, V26, P1, DOI 10.1016/S0889-8545(05)70054-1; STRAUS SE, 1984, NEW ENGL J MED, V311, P1362, DOI 10.1056/NEJM198411223112107; TOMITA H, 1988, ACTA OTO-LARYNGOL, P10; Varis T, 1996, J INFECT DIS, V174, pS330, DOI 10.1093/infdis/174.Supplement_3.S330; WASMUTH EH, 1990, J MED VIROL, V32, P189, DOI 10.1002/jmv.1890320310; WEIBEL RE, 1984, NEW ENGL J MED, V310, P1409, DOI 10.1056/NEJM198405313102201; Wharton M, 1996, INFECT DIS CLIN N AM, V10, P571, DOI 10.1016/S0891-5520(05)70313-5; WILSON A, 1992, J INFECT DIS, V165, P119, DOI 10.1093/infdis/165.1.119	24	69	76	0	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2000	6	4					451	454		10.1038/74715	http://dx.doi.org/10.1038/74715			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	376UA	10742154				2022-12-25	WOS:000165474100041
J	Lopez-Bucio, J; de la Vega, OM; Guevara-Garcia, A; Herrera-Estrella, L				Lopez-Bucio, J; de la Vega, OM; Guevara-Garcia, A; Herrera-Estrella, L			Enhanced phosphorus uptake in transgenic tobacco plants that overproduce citrate	NATURE BIOTECHNOLOGY			English	Article						transgenic plants; citrate overproduction; phosphorus acquisition; mycorrhiza	MYCORRHIZAL FUNGI; SOIL-PHOSPHORUS; ROOT EXUDATION; ORGANIC-ACIDS; PHOSPHATE; RAPE	Phosphorus (P) is one of the most important nutrients limiting agricultural production worldwide. In acid and alkaline soils, which make up over 70% of the world's arable land, P forms insoluble compounds that are not available for plant use. To reduce P deficiencies and ensure plant productivity, nearly 30 million tons of P fertilizer are applied every year. Up to 80% of the applied P fertilizer is lost because it becomes immobile and unavailable for plant uptake. Therefore, the development of novel plant varieties more efficient in the use of P represents the best alternative to reduce the use of P fertilizers and achieve a more sustainable agriculture. We show here that the ability to use insoluble P compounds can be significantly enhanced by engineering plants to produce more organic acids. Our results show that when compared to the controls, citrate-overproducing plants yield more leaf and fruit biomass when grown under P-limiting conditions and require less P fertilizer to achieve optimal growth.	IPN, Unidad Irapuato, Ctr Invest & Estudios Avanzados, Dept Ingn Genet Plantas, Irapuato 36500, Guanajuato, Mexico	CINVESTAV - Centro de Investigacion y de Estudios Avanzados del Instituto Politecnico Nacional; Instituto Politecnico Nacional - Mexico	Herrera-Estrella, L (corresponding author), IPN, Unidad Irapuato, Ctr Invest & Estudios Avanzados, Dept Ingn Genet Plantas, Apartado Postal 629, Irapuato 36500, Guanajuato, Mexico.	lherrera@irapuato.ira.cinvestav.mx	Herrera-Estrella, Luis/AAL-2472-2020; Herrera-Estrella, Luis/ABC-7431-2020; Martinez, Octavio/F-3951-2014; Estrella, Luis R Herrera/G-7351-2011	Herrera-Estrella, Luis/0000-0001-7936-3856; Martinez, Octavio/0000-0002-7590-0041; Estrella, Luis R Herrera/0000-0001-7936-3856				BARYOSEF B, 1991, PLANT ROOTS HIDDEN H, P529; BOLAN NS, 1991, PLANT SOIL, V134, P189, DOI 10.1007/BF00012037; delaFuente JM, 1997, SCIENCE, V276, P1566, DOI 10.1126/science.276.5318.1566; DINKELAKER B, 1989, PLANT CELL ENVIRON, V12, P285, DOI 10.1111/j.1365-3040.1989.tb01942.x; Dinkelaker Barbara, 1995, Botanica Acta, V108, P183; HOFFLAND E, 1989, PLANT SOIL, V113, P161, DOI 10.1007/BF02280176; Holford ICR, 1997, AUST J SOIL RES, V35, P227, DOI 10.1071/S96047; *INT IND AS, 1999, FERT DEM CROPS; Loneragan JF, 1997, PLANT SOIL, V196, P163, DOI 10.1023/A:1004208621263; Lowenstein JM, 1969, METHOD ENZYMOL, P3, DOI [10.1016/0076-6879(69)13005-0, DOI 10.1016/0076-6879(69)13005-0]; Marschner H., 1995, MINERAL NUTR HIGHER, Vsecond, DOI DOI 10.1016/B978-0-12-473542-2.X5000-7; MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473, DOI 10.1111/j.1399-3054.1962.tb08052.x; MURPHY J, 1962, ANAL CHIM ACTA, V26, P31; PATE JS, 1994, PLANT SOIL, V159, P1; PHILLIPS JM, 1970, T BRIT MYCOL SOC, V55, P158, DOI 10.1016/S0007-1536(70)80110-3; PICHA DH, 1985, J AGR FOOD CHEM, V33, P743, DOI 10.1021/jf00064a045; Schachtman DP, 1998, PLANT PHYSIOL, V116, P447, DOI 10.1104/pp.116.2.447; Sharpley AN, 1995, ECOL ENG, V5, P261, DOI 10.1016/0925-8574(95)00027-5; TYLER G, 1992, PLANT SOIL, V145, P65, DOI 10.1007/BF00009542; Zhang FS, 1997, PLANT SOIL, V196, P261, DOI 10.1023/A:1004214410785	20	208	232	1	56	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	APR	2000	18	4					450	453		10.1038/74531	http://dx.doi.org/10.1038/74531			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	303UY	10748530				2022-12-25	WOS:000086444300032
J	Roy, NS; Wang, S; Jiang, L; Kang, J; Benraiss, A; Harrison-Restelli, C; Fraser, RAR; Couldwell, WT; Kawaguchi, A; Okano, H; Nedergaard, M; Goldman, SA				Roy, NS; Wang, S; Jiang, L; Kang, J; Benraiss, A; Harrison-Restelli, C; Fraser, RAR; Couldwell, WT; Kawaguchi, A; Okano, H; Nedergaard, M; Goldman, SA			In vitro neurogenesis by progenitor cells isolated from the adult human hippocampus	NATURE MEDICINE			English	Article							GREEN FLUORESCENT PROTEIN; RAT DENTATE GYRUS; NEURAL STEM-CELLS; GENE-EXPRESSION; TUBULIN PROMOTER; ALPHA-TUBULIN; NEURONS; DIFFERENTIATION; PRECURSORS; ASTROCYTES	Neurogenesis persists in the adult mammalian hippocampus. To identify and isolate neuronal progenitor cells of the adult human hippocampus, we transfected ventricular zone-free dissociates of surgically-excised dentate gyrus with DNA encoding humanized green fluorescent protein (hGFP), placed under the control of either the nestin enhancer (E/nestin) or the T alpha 1 tubulin promoter (P/T alpha 1), two regulatory regions that direct transcription in neural progenitor cells. The resultant P/T alpha 1:hGFP(+) and E/nestin:enhanced (E)GFP(+) cells expressed beta III-tubulin or microtubule-associated protein-2; many incorporated bromodeoxyuridine, indicating their genesis in vitro. Using fluorescence-activated cell sorting, the E/nestin:EGFP(+) and P/T alpha 1:hGFP(+) cells were isolated to near purity, and matured antigenically and physiologically as neurons. Thus, the adult human hippocampus contains mitotically competent neuronal progenitors that can be selectively extracted. The isolation of these cells may provide a cellular substrate for re-populating the damaged or degenerated adult hippocampus.	Cornell Univ, Coll Med, Dept Neurol & Neurosci, New York, NY 10021 USA; Cornell Univ, Coll Med, Dept Neurosurg, New York, NY 10021 USA; New York Med Coll, Dept Neurosurg, Valhalla, NY 10585 USA; New York Med Coll, Dept Cell Biol, Valhalla, NY 10585 USA; Osaka Univ, Grad Sch Med, Div Neuroanat, Osaka 5650867, Japan; Japan Sci & Technol Corp, Core Res Evolut Sci & Technol, Osaka 5650867, Japan	Cornell University; Cornell University; New York Medical College; New York Medical College; Osaka University; Japan Science & Technology Agency (JST)	Goldman, SA (corresponding author), Cornell Univ, Coll Med, Dept Neurol & Neurosci, 1300 York Ave,Room E607, New York, NY 10021 USA.		Okano, Hideyuki/I-7584-2019; Benraiss, Abdellatif/AAI-8584-2021; Kawaguchi, Ayano/I-7286-2014	Benraiss, Abdellatif/0000-0002-0325-6234; Goldman, Steven/0000-0002-5498-4303; Kawaguchi, Ayano/0000-0002-0339-3992	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS029813, R01NS033106] Funding Source: NIH RePORTER; NINDS NIH HHS [R01NS29813, R01NS33106] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALTMAN J, 1965, J COMP NEUROL, V124, P319, DOI 10.1002/cne.901240303; BARAMI K, 1995, J NEUROBIOL, V28, P82, DOI 10.1002/neu.480280108; BARNEA A, 1994, P NATL ACAD SCI USA, V91, P11217, DOI 10.1073/pnas.91.23.11217; BAYER SA, 1982, SCIENCE, V216, P890, DOI 10.1126/science.7079742; BERNHARDT R, 1984, J COMP NEUROL, V226, P203, DOI 10.1002/cne.902260205; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; Doetsch F, 1999, CELL, V97, P703, DOI 10.1016/S0092-8674(00)80783-7; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; FREDERIKSEN K, 1988, J NEUROSCI, V8, P1144; GLOSTER A, 1994, J NEUROSCI, V14, P7319; Gould E, 1999, NAT NEUROSCI, V2, P260, DOI 10.1038/6365; GOULD E, 1992, J NEUROSCI, V12, P3642; Gould E, 1997, J NEUROSCI, V17, P2492; Gould E, 1998, P NATL ACAD SCI USA, V95, P3168, DOI 10.1073/pnas.95.6.3168; Kang J, 1998, NAT NEUROSCI, V1, P683, DOI 10.1038/3684; KAPLAN SL, 1992, INFECT DIS CLIN N AM, V6, P197; Kempermann G, 1997, NATURE, V386, P493, DOI 10.1038/386493a0; KIRSCHENBAUM B, 1994, CEREB CORTEX, V4, P576, DOI 10.1093/cercor/4.6.576; Kornack DR, 1999, P NATL ACAD SCI USA, V96, P5768, DOI 10.1073/pnas.96.10.5768; Kukekov VG, 1999, EXP NEUROL, V156, P333, DOI 10.1006/exnr.1999.7028; LEE WL, 1990, EPILEPSY RES, V6, P87, DOI 10.1016/0920-1211(90)90082-7; LENDAHL U, 1990, CELL, V60, P585, DOI 10.1016/0092-8674(90)90662-X; Levy JP, 1996, NAT BIOTECHNOL, V14, P610, DOI 10.1038/nbt0596-610; Lothian C, 1997, EUR J NEUROSCI, V9, P452, DOI 10.1111/j.1460-9568.1997.tb01622.x; McKay R, 1997, SCIENCE, V276, P66, DOI 10.1126/science.276.5309.66; MENEZES JRL, 1994, J NEUROSCI, V14, P5399; MILLER FD, 1987, J CELL BIOL, V105, P3065, DOI 10.1083/jcb.105.6.3065; Palmer TD, 1997, MOL CELL NEUROSCI, V8, P389, DOI 10.1006/mcne.1996.0595; Pincus DW, 1998, ANN NEUROL, V43, P576, DOI 10.1002/ana.410430505; ROSSANT J, 1991, GENE DEV, V5, P1333, DOI 10.1101/gad.5.8.1333; Roy NS, 2000, J NEUROSCI RES, V59, P321, DOI 10.1002/(SICI)1097-4547(20000201)59:3<321::AID-JNR5>3.0.CO;2-9; Roy NS, 1999, J NEUROSCI, V19, P9986, DOI 10.1523/jneurosci.19-22-09986.1999; SONTHEIMER H, 1991, J NEUROSCI RES, V30, P275, DOI 10.1002/jnr.490300202; SONTHEIMER H, 1992, J NEUROPHYSIOL, V68, P985, DOI 10.1152/jn.1992.68.4.985; Suhonen JO, 1996, NATURE, V383, P624, DOI 10.1038/383624a0; TSE FW, 1992, J NEUROSCI, V12, P1781; van Praag H, 1999, NAT NEUROSCI, V2, P266, DOI 10.1038/6368; Wang S, 1998, NAT BIOTECHNOL, V16, P196, DOI 10.1038/nbt0298-196; Wang S, 2000, DEV NEUROSCI-BASEL, V22, P167, DOI 10.1159/000017437; ZIMMERMAN L, 1994, NEURON, V12, P11, DOI 10.1016/0896-6273(94)90148-1	40	436	485	1	23	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAR	2000	6	3					271	277						7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	288TL	10700228				2022-12-25	WOS:000085580500036
J	Shimada, Y; Gulli, MP; Peter, M				Shimada, Y; Gulli, MP; Peter, M			Nuclear sequestration of the exchange factor Cdc24 by Far1 regulates cell polarity during yeast mating	NATURE CELL BIOLOGY			English	Article							NF-KAPPA-B; SACCHAROMYCES-CEREVISIAE; BUDDING YEAST; HETEROLOGOUS PROTEINS; CYCLE ARREST; KINASE; POLARIZATION; MORPHOGENESIS; LOCALIZATION; GENE	Cytoskeletal rearrangements during the cell cycle and in response to signals are regulated by small Rho-type GTPases, but it is not known how these GTPases are activated in a spatial and temporal manner. Here we show that Cdc24, the guanine-nucleotide exchange factor for the yeast GTPase Cdc42, is sequestered in the cell nucleus by Farl. Export of Cdc24 to a site of cell polarization is mediated by two mechanisms. At bud emergence, activation of the G1 cyclin-dependent kinase Cdc28-Cln triggers degradation of Farl and, as a result, relocation of Cdc24 to the cytoplasm. Cells overexpressing a non-degradable Farl were unable to polarize their actin cytoskeleton because they failed to relocate Cdc24 to the incipient bud site. In contrast, in response to mating pheromones, the Far1-Cdc24 complex is exported from the nucleus by Msn5. This mechanism ensures that Cdc24 is targeted to the site of receptor-associated heterotrimeric G-protein activation at the plasma membrane, thereby allowing polarization of the actin cytoskeleton along the morphogenetic gradient of pheromone. Either degradation of Farl or its nuclear export by Msn5 was sufficient for cell growth, suggesting that the two mechanisms are redundant for cell viability. Taken together, our results indicate that Farl functions as a nuclear anchor for Cdc24. This sequestration regulates cell polarity in response to pheromones by restricting activation of Cdc42 to the site of pheromone receptor activation.	Swiss Inst Expt Canc Res, CH-1066 Epalinges, VD, Switzerland	Swiss Institute Experimental Cancer Research	Peter, M (corresponding author), Swiss Inst Expt Canc Res, Chemin Boveresses 155, CH-1066 Epalinges, VD, Switzerland.							ADAMS AEM, 1990, J CELL BIOL, V111, P131, DOI 10.1083/jcb.111.1.131; Alepuz PM, 1999, GENETICS, V153, P1219; ArenzanaSeisdedos F, 1997, J CELL SCI, V110, P369; Arkowitz RA, 1999, TRENDS CELL BIOL, V9, P20, DOI 10.1016/S0962-8924(98)01412-3; Ausubel FM., 2006, ENZYMATIC MANIPULATI; BAHLER J, IN PRESS MICROBIOL M; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; BENDER A, 1989, P NATL ACAD SCI USA, V86, P9976, DOI 10.1073/pnas.86.24.9976; Bertagnolo V, 1998, FEBS LETT, V441, P480, DOI 10.1016/S0014-5793(98)01593-2; Blondel M, 1999, GENE DEV, V13, P2284, DOI 10.1101/gad.13.17.2284; Brown JL, 1997, GENE DEV, V11, P2972, DOI 10.1101/gad.11.22.2972; Butty AC, 1998, SCIENCE, V282, P1511, DOI 10.1126/science.282.5393.1511; CHANG F, 1990, CELL, V63, P999, DOI 10.1016/0092-8674(90)90503-7; Chant J, 1996, CURR OPIN CELL BIOL, V8, P557, DOI 10.1016/S0955-0674(96)80035-4; CHANT J, 1995, CELL, V81, P1, DOI 10.1016/0092-8674(95)90363-1; Chen CR, 1999, P NATL ACAD SCI USA, V96, P517, DOI 10.1073/pnas.96.2.517; CHENEVERT J, 1994, MOL BIOL CELL, V5, P1169, DOI 10.1091/mbc.5.11.1169; CHENEVERT J, 1992, NATURE, V356, P77, DOI 10.1038/356077a0; DORER R, 1995, J CELL BIOL, V131, P845, DOI 10.1083/jcb.131.4.845; EPSTEIN CB, 1992, GENE DEV, V6, P1695, DOI 10.1101/gad.6.9.1695; Gaits F, 1998, GENE DEV, V12, P1464, DOI 10.1101/gad.12.10.1464; Guthrie C, 1991, GUIDE YEAST GENETICS; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Harlow E., 1988, ANTIBODIES LAB MANUA; Henchoz S, 1997, GENE DEV, V11, P3046, DOI 10.1101/gad.11.22.3046; HENKEL T, 1992, CELL, V68, P1121, DOI 10.1016/0092-8674(92)90083-O; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; Hood JK, 1999, CURR OPIN CELL BIOL, V11, P241, DOI 10.1016/S0955-0674(99)80032-5; Johnston LH, 1997, METHOD ENZYMOL, V283, P342; KAFFMANN A, IN PRESS ANN REV CEL; LEEUW T, 1995, SCIENCE, V270, P1210, DOI 10.1126/science.270.5239.1210; LEW DJ, 1995, CURR OPIN GENET DEV, V5, P17, DOI 10.1016/S0959-437X(95)90048-9; LEW DJ, 1993, J CELL BIOL, V120, P1305, DOI 10.1083/jcb.120.6.1305; Mahanty SK, 1999, CELL, V98, P501, DOI 10.1016/S0092-8674(00)81978-9; MCKINNEY JD, 1993, GENE DEV, V7, P833, DOI 10.1101/gad.7.5.833; MCKINNEY JD, 1995, MOL CELL BIOL, V15, P2509; MUMBERG D, 1995, GENE, V156, P119, DOI 10.1016/0378-1119(95)00037-7; Nern A, 1999, J CELL BIOL, V144, P1187, DOI 10.1083/jcb.144.6.1187; Nern A, 1998, NATURE, V391, P195, DOI 10.1038/34458; Park HO, 1997, P NATL ACAD SCI USA, V94, P4463, DOI 10.1073/pnas.94.9.4463; PETER M, 1994, SCIENCE, V265, P1228, DOI 10.1126/science.8066461; PETERSON J, 1994, J CELL BIOL, V127, P1395, DOI 10.1083/jcb.127.5.1395; Posas F, 1998, MOL CELL BIOL, V18, P5788, DOI 10.1128/MCB.18.10.5788; Ronicke V, 1997, METHOD ENZYMOL, V283, P313; SEGALL JE, 1993, P NATL ACAD SCI USA, V90, P8332, DOI 10.1073/pnas.90.18.8332; Sprague GF, 1992, MOL CELLULAR BIOL YE, V2, P657; Toenjes KA, 1999, CURR BIOL, V9, P1183, DOI 10.1016/S0960-9822(00)80022-6; Valtz N, 1997, METHOD ENZYMOL, V283, P350; VALTZ N, 1995, J CELL BIOL, V131, P863, DOI 10.1083/jcb.131.4.863	49	143	144	1	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	FEB	2000	2	2					117	124		10.1038/35000073	http://dx.doi.org/10.1038/35000073			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	281GA	10655592				2022-12-25	WOS:000085148500017
J	Saegusa, A				Saegusa, A			Japan creeps toward proteomics	NATURE BIOTECHNOLOGY			English	News Item																			0	0	0	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JAN	2000	18	1					16	17		10.1038/71848	http://dx.doi.org/10.1038/71848			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	273GQ	10625377				2022-12-25	WOS:000084699900011
J	Zhang, ZW; Zhu, WG; Kodadek, T				Zhang, ZW; Zhu, WG; Kodadek, T			Selection and application of peptide-binding peptides	NATURE BIOTECHNOLOGY			English	Article						peptides; epitope binding; two-hybrid assay; lambda repressor	PROTEIN-PROTEIN INTERACTIONS; COMBINATORIAL LIBRARIES; REPRESSOR FUSIONS; RECEPTORS; COMPLEX; SYSTEM; REQUIREMENTS	Peptide-binding ligands would be useful for directing reagents to particular epitopes in a protein, the detection of peptide hormones, and many other applications. Here we show that peptides of modest size isolated from a library using a simple genetic assay can act as specific receptors for other peptides. The equilibrium dissociation constants of these peptide-peptide complexes are higher than those of typical monoclonal antibody-epitope complexes. Nonetheless, as shown here, these peptide-binding peptides can be used to detect or purify proteins containing the partner peptide.	Univ Texas, SW Med Ctr, Ctr Biomed Innovat, Dept Internal Med, Dallas, TX 75216 USA; Univ Texas, SW Med Ctr, Ctr Biomed Innovat, Dept Biochem, Dallas, TX 75216 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Kodadek, T (corresponding author), Univ Texas, SW Med Ctr, Ctr Biomed Innovat, Dept Internal Med, 5323 Harry Hines Blvd, Dallas, TX 75216 USA.			Kodadek, Thomas/0000-0003-1930-4795				BUNKER CA, 1995, NUCLEIC ACIDS RES, V23, P269, DOI 10.1093/nar/23.2.269; Burger MT, 1997, J ORG CHEM, V62, P4785, DOI 10.1021/jo970256w; Cairns MT, 1997, GENE, V185, P5, DOI 10.1016/S0378-1119(96)00601-4; Chen CT, 1998, SCIENCE, V279, P851, DOI 10.1126/science.279.5352.851; Cheng YA, 1996, J AM CHEM SOC, V118, P1813, DOI 10.1021/ja952976v; Dong DL, 1999, CHEM BIOL, V6, P133, DOI 10.1016/S1074-5521(99)89005-X; Drees BL, 1999, CURR OPIN CHEM BIOL, V3, P64, DOI 10.1016/S1367-5931(99)80012-X; ELLENBERGER TE, 1992, CELL, V71, P1223, DOI 10.1016/S0092-8674(05)80070-4; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FREIFELDER D, 1982, PHYSICAL BIOCH APPLI, P654; Hioki H, 1998, J ORG CHEM, V63, P904, DOI 10.1021/jo971782q; Hossain MA, 1998, J AM CHEM SOC, V120, P11208, DOI 10.1021/ja982435g; HOWARD AD, 1991, J IMMUNOL, V147, P2964; HU JC, 1995, STRUCTURE, V3, P431, DOI 10.1016/S0969-2126(01)00176-9; HU JC, 1990, SCIENCE, V250, P1400, DOI 10.1126/science.2147779; Jappelli R, 1996, J MOL BIOL, V259, P575, DOI 10.1006/jmbi.1996.0340; Miller J.H., 1972, EXPT MOL GENETICS; OHLMEYER MHJ, 1993, P NATL ACAD SCI USA, V90, P10922, DOI 10.1073/pnas.90.23.10922; PARKS TD, 1994, ANAL BIOCHEM, V216, P413, DOI 10.1006/abio.1994.1060; PHIZICKY EM, 1995, MICROBIOL REV, V59, P94, DOI 10.1128/MMBR.59.1.94-123.1995; PTASHNE MA, 1987, GENETIC SWITCH GENE, P18; Schneider S, 1999, NAT BIOTECHNOL, V17, P170, DOI 10.1038/6172; Shao YF, 1996, J ORG CHEM, V61, P6086, DOI 10.1021/jo960775j; Still WC, 1996, ACCOUNTS CHEM RES, V29, P155, DOI 10.1021/ar950166i; Zhang ZW, 1999, CURR BIOL, V9, P417, DOI 10.1016/S0960-9822(99)80188-2	25	35	40	1	16	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JAN	2000	18	1					71	74		10.1038/71951	http://dx.doi.org/10.1038/71951			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	273GQ	10625395				2022-12-25	WOS:000084699900029
J	Albrecht, M; Takaichi, S; Steiger, S; Wang, ZY; Sandmann, G				Albrecht, M; Takaichi, S; Steiger, S; Wang, ZY; Sandmann, G			Novel hydroxycarotenoids with improved antioxidative properties produced by gene combination in Escherichia coli	NATURE BIOTECHNOLOGY			English	Article						antioxidants; novel carotenoids; combinatorial biosynthesis; heterologous gene expression; metabolic engineering	BIOSYNTHETIC-PATHWAY; CAROTENOIDS; DERIVATIVES; DESATURASE; CLUSTER; ABILITY; CLONING	We have used combinatorial biosynthesis to synthesize novel lipophilic carotenoids that are powerful cellular antioxidants. By co-expressing three different carotenoid desaturases in combination with a carotenoid hydratase, a cyclase, and a hydroxylase on compatible plasmids in Escherichia coli, we synthesized four novel carotenoids not previously detected in biological material or chemically synthesized. Their identification was based on their relative retention times on HPLC, spectroscopic properties, molecular weights, number of hydroxy groups, and H-1-NMR spectra. The carotenoids were designated as 1-HO-3', 4'-didehydrolycopene, 3, 1'-(HO)(2)-gamma-carotene, 1,1'-(HO)(2)-3, 4, 3', 4'-tetradehydrolycopene, and 1, 1'-(HO)(2)-3, 4-didehydrolycopene. These novel acyclic derivatives differ from structurally related compounds by extension of the conjugated polyene chain as well as additional hydroxy groups at position C-1'. We determined their antioxidative activity in a liposome-membrane model system, which showed that their ability to protect against photooxidation and radical-mediated peroxidation reactions was linked to the length of the conjugated double-bond system and the presence of a single hydroxy group. The protection of membrane degradation was superior to the related 1-HO and 1, 1'-(HO)(2) lycopene derivatives, making them interesting pharmaceutical candidates.	Goethe Univ Frankfurt, Inst Bot, D-60054 Frankfurt, Germany; Nippon Med Sch, Biol Lab, Kawasaki, Kanagawa 2110063, Japan; Tohoku Univ, Dept Biochem & Engn, Sendai, Miyagi 9808577, Japan	Goethe University Frankfurt; Nippon Medical School; Tohoku University	Sandmann, G (corresponding author), Goethe Univ Frankfurt, Inst Bot, POB 111932, D-60054 Frankfurt, Germany.	sandmann@em.uni-frankfurt.de		, Wang-Otomo/0000-0003-1676-2002				Albrecht M, 1997, J BACTERIOL, V179, P7462, DOI 10.1128/jb.179.23.7462-7467.1997; Albrecht M, 1997, J BIOTECHNOL, V58, P177, DOI 10.1016/S0168-1656(97)00151-X; Britton G, 1995, FASEB J, V9, P1551, DOI 10.1096/fasebj.9.15.8529834; Buege J A, 1978, Methods Enzymol, V52, P302; CANFIELD LM, 1992, P SOC EXP BIOL MED, V200, P260; CONN PF, 1992, FREE RADICAL RES COM, V16, P401, DOI 10.3109/10715769209049190; Davies B. H., 1976, CHEM BIOCH PLANT PIG, V2, P38; Englert G., 1996, SPECTROSCOPY-US, V1B, P147; ERNST S, 1988, ARCH MICROBIOL, V150, P590, DOI 10.1007/BF00408255; GERSTER H, 1993, INT J VITAM NUTR RES, V63, P93; Hahn FM, 1996, J BACTERIOL, V178, P619, DOI 10.1128/jb.178.3.619-624.1996; HIRAYAMA O, 1994, LIPIDS, V29, P149, DOI 10.1007/BF02537155; Johnson E A, 1996, Adv Biochem Eng Biotechnol, V53, P119; KOVACH ME, 1995, GENE, V166, P175, DOI 10.1016/0378-1119(95)00584-1; KRINSKY NI, 1994, PURE APPL CHEM, V66, P1003, DOI 10.1351/pac199466051003; LINDEN H, 1993, FEMS MICROBIOL LETT, V106, P99, DOI 10.1016/0378-1097(93)90062-7; Miller NJ, 1996, FEBS LETT, V384, P240, DOI 10.1016/0014-5793(96)00323-7; MISAWA N, 1995, J BACTERIOL, V177, P6575, DOI 10.1128/jb.177.22.6575-6584.1995; OURISSON G, 1989, CAROTENOIDS, P237; RiceEvans CA, 1997, FREE RADICAL RES, V26, P381, DOI 10.3109/10715769709097818; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sandmann G, 1999, TRENDS BIOTECHNOL, V17, P233, DOI 10.1016/S0167-7799(99)01307-4; SCHMIDHAUSER TJ, 1990, MOL CELL BIOL, V10, P5064, DOI 10.1128/MCB.10.10.5064; Sprenger GA, 1997, P NATL ACAD SCI USA, V94, P12857, DOI 10.1073/pnas.94.24.12857; Steiger S, 1999, J PHOTOCH PHOTOBIO B, V52, P14, DOI 10.1016/S1011-1344(99)00094-9; SUBCZYNSKI WK, 1991, BIOCHIM BIOPHYS ACTA, V1068, P68, DOI 10.1016/0005-2736(91)90061-C; TAKAICHI S, 1992, METHOD ENZYMOL, V213, P374; Takaichi S, 1996, EUR J BIOCHEM, V241, P291, DOI 10.1111/j.1432-1033.1996.0291t.x; TAKAICHI S, 1993, ORG MASS SPECTROM, V28, P785, DOI 10.1002/oms.1210280711; Woodall AA, 1997, BBA-GEN SUBJECTS, V1336, P575, DOI 10.1016/S0304-4165(97)00007-X	30	103	114	1	14	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	AUG	2000	18	8					843	846		10.1038/78443	http://dx.doi.org/10.1038/78443			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	342VX	10932152				2022-12-25	WOS:000088666800019
J	Gerdts, V; Babiuk, LA; Littel-van den Hurk, SV; Griebel, PJ				Gerdts, V; Babiuk, LA; Littel-van den Hurk, SV; Griebel, PJ			Fetal immunization by a DNA vaccine delivered into the oral cavity	NATURE MEDICINE			English	Article							NEONATAL TOLERANCE; INDUCTION; INFANTS; VIRUS	Infectious diseases are the main cause of neonatal morbidity and mortality in humans. The World Health Organization estimated that in 1995 approximately 8 million infants died within the first year of life from infectious diseases, including 5 million during the first week of life. Some of the salient pathogens involved include herpes simplex virus, human immunodeficiency virus, hepatitis B virus, human cytomegalovirus, group B streptococcus, hemophilus and chlamydia(1,2). Infection with these pathogens usually occurs at the end of pregnancy, during birth or by breastfeeding. To reduce the risk of disease transmission, caesarian sections, prophylactic treatment with antibiotics or maternal antiviral therapy during the last trimester are used where available, together with improved neonatal care. None of these approaches, however, completely eliminates the risk of neonatal infection. Therefore, active or passive immunization of the fetus might represent an effective approach to reduce the high risk of neonatal diseases. Here, we demonstrate that a single immunization with a DNA vaccine delivered into the amniotic fluid in the oral cavity induces high serum antibody titers and a cell-mediated immune response, combined with induction of local immunity in the oral cavities of fetal lambs.	Univ Saskatchewan, Vet Infect Dis Org, Saskatoon, SK S7N 5E3, Canada	University of Saskatchewan	Griebel, PJ (corresponding author), Univ Saskatchewan, Vet Infect Dis Org, Saskatoon, SK S7N 5E3, Canada.	griebelp@sask.usask.ca		Gerdts, Volker/0000-0001-8229-1611				AUPHAN N, 1995, SCIENCE, V270, P286, DOI 10.1126/science.270.5234.286; Baba TW, 2000, NAT MED, V6, P200, DOI 10.1038/72309; BRAUN R, 1997, VACCINE RES, V6, P151; Butts C, 1998, VACCINE, V16, P1444, DOI 10.1016/S0264-410X(98)00106-6; Donnelly JJ, 1997, ANNU REV IMMUNOL, V15, P617, DOI 10.1146/annurev.immunol.15.1.617; Forsthuber T, 1996, SCIENCE, V271, P1728, DOI 10.1126/science.271.5256.1728; Gaensler KML, 1999, NAT BIOTECHNOL, V17, P1188, DOI 10.1038/70729; HEIN WR, 1995, IMMUNOLOGIST, V3, P12; Ichino M, 1999, J IMMUNOL, V162, P3814; Ishii KJ, 1999, VACCINE, V18, P703, DOI 10.1016/S0264-410X(99)00267-4; Iwamoto HS, 1999, GENE THER, V6, P98, DOI 10.1038/sj.gt.3300804; Littel-van den Hurk SV, 1999, VIRAL IMMUNOL, V12, P67, DOI 10.1089/vim.1999.12.67; Mascola JR, 2000, NAT MED, V6, P207, DOI 10.1038/72318; McCluskie MJ, 1999, CRIT REV IMMUNOL, V19, P303; Mor G, 1996, J CLIN INVEST, V98, P2700, DOI 10.1172/JCI119094; Mulholland K, 1998, VACCINE, V16, P1360, DOI 10.1016/S0264-410X(98)00092-9; Ridge JP, 1996, SCIENCE, V271, P1723, DOI 10.1126/science.271.5256.1723; Sarzotti M, 1996, SCIENCE, V271, P1726, DOI 10.1126/science.271.5256.1726; Watts AM, 1999, NAT MED, V5, P427, DOI 10.1038/7426; Wright PF, 1998, VACCINE, V16, P1355, DOI 10.1016/S0264-410X(98)00091-7	20	59	62	0	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	AUG	2000	6	8					929	932		10.1038/78699	http://dx.doi.org/10.1038/78699			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	376TX	10932233				2022-12-25	WOS:000165473800039
J	van Bokhoven, H; Celli, J; Kayserili, H; van Beusekom, E; Balci, S; Brussel, W; Skovby, F; Kerr, B; Percin, EF; Akarsu, N; Brunner, HG				van Bokhoven, H; Celli, J; Kayserili, H; van Beusekom, E; Balci, S; Brussel, W; Skovby, F; Kerr, B; Percin, EF; Akarsu, N; Brunner, HG			Mutation of the gene encoding the ROR2 tyrosine kinase causes autosomal recessive Robinow syndrome	NATURE GENETICS			English	Article							GROWTH-FACTOR RECEPTOR-3; NERVOUS-SYSTEM; DOMAIN; FAMILY; CRANIOSYNOSTOSIS; EXPRESSION; DYSPLASIA; FEATURES	Robinow syndrome is a short-limbed dwarfism characterized by abnormal morphogenesis of the face and external genitalia, and vertebral segmentation(1,2). The recessive form of Robinow syndrome (RRS; OMIM 268310). particularly frequent in Turkey(3-6), has a high incidence of abnormalities of the vertebral column such as hemivertebrae and rib fusions. which is not seen in the dominant form. Some patients have cardiac malformations or facial clefting. We have mapped a gene for RRS to 9q21-q23 in 11 families. Haplotype sharing was observed between three families from Turkey, which localized the gene to a 4.9-cM interval. The gene ROR2, which encodes an orphan membrane-bound tyrosine kinase, maps to this region. Heterozygous (presumed gain of function) mutations in ROR2 were previously shown to cause dominant brachydactyly type B (BDB; ref. 7). In contrast, Ror2(-/-) mice have a short-limbed phenotype that is more reminiscent of the mesomelic shortening observed in RRS. We detected several homozygous ROR2 mutations in our cohort of RRS patients that are located upstream from those previously found in BDB. The ROR2 mutations present in RRS result in premature stop codons and predict nonfunctional proteins.	Univ Nijmegen, Med Ctr, Dept Human Genet, Nijmegen, Netherlands; Istanbul Univ, Istanbul Fac Med, Div Med Genet, Dept Pediat, Istanbul, Turkey; Hacettepe Univ, Inst Child Hlth, Div Clin Genet, Ankara, Turkey; Rijnstate Hosp, Dept Pediat, Arnhem, Netherlands; Rigshosp, Dept Clin Genet, Copenhagen, Denmark; Royal Manchester Childrens Hosp, Reg Genet Serv, Manchester, Lancs, England; Cumhuriye Univ, Dept Med Biol & Genet, Sivas, Turkey	Radboud University Nijmegen; Istanbul University; Hacettepe University; Rijnstate Hospital; Rigshospitalet; University of Copenhagen; Royal Manchester Children's Hospital; Cumhuriyet University	Brunner, HG (corresponding author), Univ Nijmegen, Med Ctr, Dept Human Genet, Nijmegen, Netherlands.	h.brunner@antrg.azn.nl	van Bokhoven, Hans/D-8764-2012; Bokhoven, J.H.L.M. van van/H-8015-2014; Kayserili, Hülya/AAA-5593-2021; Percin, Ferda E/H-6850-2016; Akarsu, Nurten/E-9758-2013; van Beusekom, Ellen/AAF-2687-2019; Brunner, Han/C-9928-2013	Bokhoven, J.H.L.M. van van/0000-0002-2153-9254; Kayserili, Hülya/0000-0003-0376-499X; Percin, Ferda E/0000-0001-9317-8155; Akarsu, Nurten/0000-0001-5432-0032; 				Aksit S, 1997, CLIN GENET, V52, P226; Atalay S, 1993, Clin Dysmorphol, V2, P208; Balci S, 1993, Clin Dysmorphol, V2, P199; Balci S, 1998, AM J MED GENET, V79, P27, DOI 10.1002/(SICI)1096-8628(19980827)79:1<27::AID-AJMG7>3.0.CO;2-F; Bellus GA, 1996, NAT GENET, V14, P174, DOI 10.1038/ng1096-174; BUTLER MG, 1987, CLIN GENET, V31, P77; Cunningham ME, 1997, J BIOL CHEM, V272, P10957; DeChiara TM, 2000, NAT GENET, V24, P271, DOI 10.1038/73488; Deng CX, 1996, CELL, V84, P911, DOI 10.1016/S0092-8674(00)81069-7; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; Forrester WC, 1999, NATURE, V400, P881, DOI 10.1038/23722; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; KREMER H, 1994, HUM MOL GENET, V3, P299, DOI 10.1093/hmg/3.2.299; LATHROP GM, 1984, AM J HUM GENET, V36, P460; Li CL, 1999, HUM MOL GENET, V8, P35, DOI 10.1093/hmg/8.1.35; LOEB DM, 1994, J BIOL CHEM, V269, P8901; MASIAKOWSKI P, 1992, J BIOL CHEM, V267, P26181; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; OBERMEIER A, 1993, EMBO J, V12, P933, DOI 10.1002/j.1460-2075.1993.tb05734.x; Oishi I, 1999, GENES CELLS, V4, P41, DOI 10.1046/j.1365-2443.1999.00234.x; Oishi I, 1997, J BIOL CHEM, V272, P11916, DOI 10.1074/jbc.272.18.11916; Oldridge M, 2000, NAT GENET, V24, P275, DOI 10.1038/73495; ROBINOW M, 1969, AM J DIS CHILD, V117, P645, DOI 10.1001/archpedi.1969.02100030647005; SHIANG R, 1994, CELL, V78, P335, DOI 10.1016/0092-8674(94)90302-6; Takeuchi S, 2000, GENES CELLS, V5, P71, DOI 10.1046/j.1365-2443.2000.00300.x; Tavormina PL, 1999, AM J HUM GENET, V64, P722, DOI 10.1086/302275; TAVORMINA PL, 1995, NAT GENET, V9, P321, DOI 10.1038/ng0395-321; Wilkie AOM, 1997, HUM MOL GENET, V6, P1647, DOI 10.1093/hmg/6.10.1647; WILSON C, 1993, P NATL ACAD SCI USA, V90, P7109, DOI 10.1073/pnas.90.15.7109	30	203	213	0	11	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	AUG	2000	25	4					423	426		10.1038/78113	http://dx.doi.org/10.1038/78113			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	341WY	10932187				2022-12-25	WOS:000088615000018
J	Wengenack, TM; Curran, GL; Poduslo, JF				Wengenack, TM; Curran, GL; Poduslo, JF			Targeting Alzheimer amyloid plaques in vivo	NATURE BIOTECHNOLOGY			English	Article						Alzheimer disease; amyloid; labeling; imaging; diagnosis; transgenic	BLOOD-BRAIN BARRIERS; INCREASED PERMEABILITY; ENZYMATIC-ACTIVITY; TRANSGENIC MICE; IN-VIVO; NERVE; PUTRESCINE; DISEASE; POLYAMINE; PROTEINS	The only definitive diagnosis for Alzheimer disease (AD) at present is postmortem observation of neuritic plaques and neurofibrillary tangles in brain sections. Radiolabeled amyloid-beta peptide (A beta), which has been shown to label neuritic plaques in vitro, therefore could provide a diagnostic tool if it also labels neuritic plaques in vivo following intravenous injection. In this study we show that the permeability of A beta at the blood-brain barrier can be increased by at least twofold through covalent modification with the naturally occurring polyamine, putrescine. We also show that, following intravenous injection, radiolabeled, putrescine-modified A beta labels amyloid deposits in vivo in a transgenic mouse model of AD, as well as in vitro in human AD brain sections. This technology, when applied to humans, may be used to detect plaques in vivo, allowing early diagnosis of the disease and therapeutic intervention before cognitive decline occurs.	Mayo Clin & Mayo Fdn, Dept Neurol & Biochem Mol Biol, Mol Neurobiol Lab, Rochester, MN 55905 USA	Mayo Clinic	Poduslo, JF (corresponding author), Mayo Clin & Mayo Fdn, Dept Neurol & Biochem Mol Biol, Mol Neurobiol Lab, 200 1st St SW, Rochester, MN 55905 USA.							Abbott NJ, 1999, ADV DRUG DELIVER REV, V37, P253, DOI 10.1016/S0169-409X(98)00097-0; CUMMINGS BJ, 1995, LANCET, V346, P1524, DOI 10.1016/S0140-6736(95)92053-6; Ghilardi JR, 1996, NEUROREPORT, V7, P2607, DOI 10.1097/00001756-199611040-00040; Holcomb L, 1998, NAT MED, V4, P97, DOI 10.1038/nm0198-097; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; Maggio JE, 1996, BRAIN PATHOL, V6, P147, DOI 10.1111/j.1750-3639.1996.tb00797.x; MAGGIO JE, 1992, P NATL ACAD SCI USA, V89, P5462, DOI 10.1073/pnas.89.12.5462; MANELLI AM, 1995, BRAIN RES BULL, V38, P569, DOI 10.1016/0361-9230(95)02034-X; PODUSIO JF, 1997, NEUROBIOL DIS, V4, P274; Poduslo JF, 1999, NEUROBIOL DIS, V6, P190, DOI 10.1006/nbdi.1999.0238; PODUSLO JF, 1992, P NATL ACAD SCI USA, V89, P2218, DOI 10.1073/pnas.89.6.2218; Poduslo JF, 1998, J NEUROCHEM, V71, P1651; PODUSLO JF, 1994, MOL BRAIN RES, V23, P157, DOI 10.1016/0169-328X(94)90222-4; Poduslo JF, 1996, J NEUROCHEM, V66, P1599; Poduslo JF, 1996, J NEUROCHEM, V67, P734; Poduslo JF, 1999, J NEUROBIOL, V39, P371, DOI 10.1002/(SICI)1097-4695(19990605)39:3<371::AID-NEU4>3.3.CO;2-5; PODUSLO JF, 1994, P NATL ACAD SCI USA, V9, P5705; SELKOE DJ, 1997, SCIENCE, V275, P830; Soto C, 1996, BIOCHEM BIOPH RES CO, V226, P672, DOI 10.1006/bbrc.1996.1413; VINTERS HV, 1986, CAN J NEUROL SCI, V13, P446; WALKER LC, 1990, ACTA NEUROPATHOL, V80, P381, DOI 10.1007/BF00307691; Weldon DT, 1998, J NEUROSCI, V18, P2161; Wengenack TM, 1997, BRAIN RES, V767, P128, DOI 10.1016/S0006-8993(97)00565-9	23	84	107	0	9	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	AUG	2000	18	8					868	872		10.1038/78482	http://dx.doi.org/10.1038/78482			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	342VX	10932157				2022-12-25	WOS:000088666800024
J	Anson-Cartwright, L; Dawson, K; Holmyard, D; Fisher, SJ; Lazzarini, RA; Cross, JC				Anson-Cartwright, L; Dawson, K; Holmyard, D; Fisher, SJ; Lazzarini, RA; Cross, JC			The glial cells missing-1 protein is essential for branching morphogenesis in the chorioallantoic placenta	NATURE GENETICS			English	Article							TRANSCRIPTION FACTORS; MOUSE; DROSOPHILA; DIFFERENTIATION; EXPRESSION; GENE; IMPLANTATION; SWITCH; GCM1	Trophoblast cells of the placenta are established at the blastocyst stage and differentiate into specialized subtypes after implantation(1,2). In mice, the outer layer of the placenta consists of trophoblast giant cells that invade the uterus and promote maternal blood flow to the implantation site by producing cytokines with angiogenic(3) and vasodilatory(4) actions. The innermost layer, called the labyrinth, consists of branched villi that provide a large surface area for nutrient transport and are composed of trophoblast cells and underlying mesodermal cells derived from the allantois. The chorioallantoic villi develop after embryonic day (E) 8.5 through extensive folding and branching of an initially flat sheet of trophoblast cells, the chorionic plate, in response to contact with the allantois. We show here that Gcm1. encoding the transcription factor glial cells missing-1 (Gcm1). is expressed in small clusters of chorionic trophoblast cells at the flat chorionic plate stage and at sites of chorioallantoic folding and extension when morphogenesis begins. Mutation of Gcm1 in mice causes a complete block to branching of the chorioallantoic interface, resulting in embryonic mortality by E10 due to the absence of the placental labyrinth. In addition, chorionic trophoblast cells in Gcm1-deficient placentas do not fuse to form syncytiotrophoblast. Abnormal development of placental villi is frequently associated with fetal death and intrauterine growth restriction in humans, and our studies provide the earliest molecular insight into this aspect of placental development.	Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Program Dev & Fetal Hlth, Toronto, ON M5G 1X5, Canada; Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Stomatol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Obstet & Gynecol, San Francisco, CA 94143 USA; Mt Sinai Sch Med, Brookdale Ctr Dev & Mol Biol, New York, NY USA; Univ Toronto, Dept Obstet & Gynaecol, Toronto, ON, Canada; Univ Toronto, Dept Mol & Med Genet, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Icahn School of Medicine at Mount Sinai; University of Toronto; University of Toronto	Cross, JC (corresponding author), Univ Calgary, Dept Biochem & Mol Biol, Genes & Dev Res Grp, Calgary, AB, Canada.		Cross, James/F-4814-2011; Cross, James/AAU-2973-2020	Cross, James/0000-0003-0956-9378; Cross, James/0000-0003-0956-9378				Akiyama Y, 1996, P NATL ACAD SCI USA, V93, P14912, DOI 10.1073/pnas.93.25.14912; Altshuller Y, 1996, FEBS LETT, V393, P201, DOI 10.1016/0014-5793(96)00890-3; Basyuk E, 1999, DEV DYNAM, V214, P303, DOI 10.1002/(SICI)1097-0177(199904)214:4<303::AID-AJA3>3.3.CO;2-2; BECKER M, 1995, CREATIVITY RES J, V8, P219, DOI 10.1207/s15326934crj0803_2; Bernardoni R, 1998, DEVELOPMENT, V125, P3189; Bernardoni R, 1997, DEV BIOL, V191, P118; COLOSI P, 1987, MOL ENDOCRINOL, V1, P767, DOI 10.1210/mend-1-11-767; CROSS JC, 1994, SCIENCE, V266, P1508, DOI 10.1126/science.7985020; CROSS JC, IN PRESS SEMIN CELL; Cross JC, 1996, FETAL MATERNAL MED R, V8, P57, DOI DOI 10.1017/S0965539500001492; GUILLEMOT F, 1994, NATURE, V371, P333, DOI 10.1038/371333a0; HERNANDE.D, 1974, CELL TISSUE RES, V148, P381; HOSOYA T, 1995, CELL, V82, P1025, DOI 10.1016/0092-8674(95)90281-3; Hunter PJ, 1999, DEVELOPMENT, V126, P1247; JACKSON D, 1994, SCIENCE, V266, P1581, DOI 10.1126/science.7527157; Jacquemin P, 1998, DEV DYNAM, V212, P423, DOI 10.1002/(SICI)1097-0177(199807)212:3<423::AID-AJA10>3.0.CO;2-1; Janatpour MJ, 1999, DEV GENET, V25, P146, DOI 10.1002/(SICI)1520-6408(1999)25:2<146::AID-DVG9>3.0.CO;2-K; JONES BW, 1995, CELL, V82, P1013, DOI 10.1016/0092-8674(95)90280-5; KHONG TY, 1986, BRIT J OBSTET GYNAEC, V93, P1049, DOI 10.1111/j.1471-0528.1986.tb07830.x; Kim JS, 1998, P NATL ACAD SCI USA, V95, P12364, DOI 10.1073/pnas.95.21.12364; Krebs C, 1996, AM J OBSTET GYNECOL, V175, P1534, DOI 10.1016/S0002-9378(96)70103-5; LESCISIN KR, 1988, GENE DEV, V2, P1639, DOI 10.1101/gad.2.12a.1639; Luo JM, 1997, NATURE, V388, P778, DOI 10.1038/42022; Morasso MI, 1999, P NATL ACAD SCI USA, V96, P162, DOI 10.1073/pnas.96.1.162; Riley P, 1998, NAT GENET, V18, P271, DOI 10.1038/ng0398-271; ROSSANT J, 1977, J EMBRYOL EXP MORPH, V39, P183; Scott IC, 2000, MOL CELL BIOL, V20, P530, DOI 10.1128/MCB.20.2.530-541.2000; Tanaka S, 1998, SCIENCE, V282, P2072, DOI 10.1126/science.282.5396.2072; Wurst W., 1993, Gene targeting: a practical approach., P33; Yotsumoto S, 1998, DEV BIOL, V203, P264, DOI 10.1006/dbio.1998.9073	30	312	322	0	8	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUL	2000	25	3					311	314		10.1038/77076	http://dx.doi.org/10.1038/77076			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	329RD	10888880				2022-12-25	WOS:000087920900020
J	Avela, K; Lipsanen-Nyman, M; Idanheimo, N; Seemanova, E; Rosengren, S; Makela, TP; Perheentupa, J; de la Chapelle, A; Lehesjoki, AE				Avela, K; Lipsanen-Nyman, M; Idanheimo, N; Seemanova, E; Rosengren, S; Makela, TP; Perheentupa, J; de la Chapelle, A; Lehesjoki, AE			Gene encoding a new RING-B-box-Coiled-coil protein is mutated in mulibrey nanism	NATURE GENETICS			English	Article							NUCLEAR RECEPTORS; WILMS-TUMOR; IN-VIVO; FINGER; EXPRESSION; DOMAIN; IDENTIFICATION; MUTATIONS; PRODUCT; DISEASE	Mulibrey nanism (for muscle-liver-brain-eye nanism, MUL; MIM 253250) is an autosomal recessive disorder that involves several tissues of mesodermal origin, implying a defect in a highly pleiotropic gene(1). Characteristic features include severe growth failure of prenatal onset and constrictive pericardium with consequent hepatomegaly(1-3). In addition, muscle hypotonia, J-shaped sella turcica, yellowish dots in the ocular fundi, typical dysmorphic features and hypoplasia of various endocrine glands causing hormonal deficiency are (1-3). About 4% of RAUL patients develop Wilms' common tumour(2,4,5). MUL is enriched in the Finnish population, but is rare elsewhere(1-3). We previously assigned MUL to chromosome 17q22-q23 and constructed a physical contig over the critical MUL region(6,7). The region has now been further refined by haplotype analysis and new positional candidate genes have been localized. We identified a gene with four independent MUL-associated mutations that all cause a frameshift and predict a truncated protein. MUL is ubiquitously expressed and encodes a new member of the RINC-B-box-Coiled-coil (RBCC) family of zinc-finger proteins(8-10), whose members are involved in diverse cellular functions such as developmental patterning and oncogenesis.	Folkhalsan Inst Genet, Helsinki, Finland; Univ Helsinki, Dept Med Genet, Haartman Inst, FIN-00014 Helsinki, Finland; Univ Helsinki, Hosp Children & Adolescents, FIN-00014 Helsinki, Finland; Charles Univ, Sch Med 2, Inst Biol & Med Genet, Prague, Czech Republic; Univ Connecticut, Sch Med, Farmington, CT USA; Univ Helsinki, Bioctr, FIN-00014 Helsinki, Finland; Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA	University of Helsinki; University of Helsinki; Charles University Prague; University of Connecticut; University of Helsinki; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University	Avela, K (corresponding author), Folkhalsan Inst Genet, Helsinki, Finland.		makela, tomi/B-3734-2009	makela, tomi/0000-0002-4869-8044; Lipsanen-Nyman, Marita/0000-0003-4959-2310	NCI NIH HHS [P30CA16058] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016058] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Avela K, 1997, AM J HUM GENET, V60, P896; Bernot A, 1997, NAT GENET, V17, P25; Borden KLB, 1996, P NATL ACAD SCI USA, V93, P1601, DOI 10.1073/pnas.93.4.1601; BORDEN KLB, 1993, FEBS LETT, V335, P255, DOI 10.1016/0014-5793(93)80741-C; Cainarca S, 1999, HUM MOL GENET, V8, P1387, DOI 10.1093/hmg/8.8.1387; Chang CJ, 1998, MOL CELL BIOL, V18, P5880, DOI 10.1128/MCB.18.10.5880; COOPER DN, 1991, HUM GENET, V87, P409; Culbertson MR, 1999, TRENDS GENET, V15, P74, DOI 10.1016/S0168-9525(98)01658-8; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; Dow MR, 1998, GENETICS, V150, P119; LAPUNZINA P, 1995, AM J MED GENET, V55, P349, DOI 10.1002/ajmg.1320550320; Le Douarin B, 1998, J STEROID BIOCHEM, V65, P43, DOI 10.1016/S0960-0760(97)00175-1; LEDOUARIN B, 1995, EMBO J, V14, P2020, DOI 10.1002/j.1460-2075.1995.tb07194.x; LIPSANENNYMAN M, 1986, THESIS U HELSINKI; Nagai Y, 1997, FEBS LETT, V418, P23, DOI 10.1016/S0014-5793(97)01340-9; Nagase T, 1998, DNA Res, V5, P355, DOI 10.1093/dnares/5.6.355; Nakai K, 1999, TRENDS BIOCHEM SCI, V24, P34, DOI 10.1016/S0968-0004(98)01336-X; Paavola P, 1999, GENOME RES, V9, P267; Peltonen L, 1999, HUM MOL GENET, V8, P1913, DOI 10.1093/hmg/8.10.1913; PERHEENTUPA J, 1973, LANCET, V2, P351, DOI 10.1016/S0140-6736(73)93193-0; Quaderi NA, 1997, NAT GENET, V17, P285, DOI 10.1038/ng1197-285; Rahman N, 1996, NAT GENET, V13, P461, DOI 10.1038/ng0896-461; Ranta S, 1999, NAT GENET, V23, P233, DOI 10.1038/13868; REDDY BA, 1992, TRENDS BIOCHEM SCI, V17, P344, DOI 10.1016/0968-0004(92)90308-V; Saurin AJ, 1996, TRENDS BIOCHEM SCI, V21, P208, DOI 10.1016/S0968-0004(96)80017-X; Seemanova E, 1999, AM J MED GENET, V85, P76, DOI 10.1002/(SICI)1096-8628(19990702)85:1<76::AID-AJMG12>3.0.CO;2-Z; SIMILA S, 1980, CLIN GENET, V17, P29; Slack FJ, 1998, TRENDS BIOCHEM SCI, V23, P474, DOI 10.1016/S0968-0004(98)01299-7; TAKAHASHI M, 1988, MOL CELL BIOL, V8, P1853, DOI 10.1128/MCB.8.4.1853; Wu LJC, 1996, NAT GENET, V14, P430, DOI 10.1038/ng1296-430	31	124	127	0	5	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUL	2000	25	3					298	301		10.1038/77053	http://dx.doi.org/10.1038/77053			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	329RD	10888877				2022-12-25	WOS:000087920900017
J	Ferguson, JN; Young, LJ; Hearn, EF; Matzuk, MM; Insel, TR; Winslow, JT				Ferguson, JN; Young, LJ; Hearn, EF; Matzuk, MM; Insel, TR; Winslow, JT			Social amnesia in mice lacking the oxytocin gene	NATURE GENETICS			English	Article							OLFACTORY-BULB; NEUROHYPOPHYSEAL PEPTIDES; MATERNAL-BEHAVIOR; MALE-MOUSE; RECOGNITION; RATS; MEMORY; VASOPRESSIN; MODULATION; LESIONS	The development of social familiarity in rodents depends predominantly on olfactory cues and can critically influence reproductive success(1,2). Researchers have operationally defined this memory by a reliable decrease in olfactory investigation in repeated or prolonged encounters with a conspecific(3-6). Brain oxytocin (OT) and vasopressin (AVP) seem to modulate a range of social behaviour from parental care to mate guarding(7). Pharmacological studies indicate that AVP administration may enhance social memory(8-10), whereas OT administration may either inhibit or facilitate social memory depending on dose, route or paradigm(1,11-13). We found that male mice mutant for the oxytocin gene (Oxt(-/-)) failed to develop social memory, whereas wild-type (Oxt(+/+)) mice showed intact social memory. Measurement of both olfactory foraging and olfactory habituation tasks indicated that olfactory detection of non-social stimuli is intact in Oxt(-/-) mice. Spatial memory and behavioural inhibition measured in a Morris water-maze, Y-maze. or habituation of an acoustic startle also seemed intact. Treatment with OT but not AVP rescued social memory in Oxt(-/-) mice, and treatment with an OT antagonist produced a social amnesia-like effect in Oxt(+/+) mice. Our data indicate that OT is necessary for the normal development of social memory in mice and support the hypothesis that social memory has a neural basis distinct from other forms of memory.	Emory Univ, Sch Med, Dept Psychiat & Behav Sci, Ctr Behav Neurosci, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Yerkes Reg Primate Res Ctr, Atlanta, GA 30322 USA; Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Baylor Coll Med, Dept Cellular & Mol Biol, Houston, TX 77030 USA	Emory University; Emory University; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine	Winslow, JT (corresponding author), Emory Univ, Sch Med, Dept Psychiat & Behav Sci, Ctr Behav Neurosci, Atlanta, GA 30322 USA.		Young, Larry/HGE-5031-2022		NCRR NIH HHS [RR0016] Funding Source: Medline; NICHD NIH HHS [HD33438] Funding Source: Medline; PHS HHS [R01M56538-01] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD033438] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD033438] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BENELLI A, 1995, NEUROPEPTIDES, V28, P251, DOI 10.1016/0143-4179(95)90029-2; Contarino A, 1999, BRAIN RES, V835, P1, DOI 10.1016/S0006-8993(98)01158-5; DANTZER R, 1987, PSYCHOPHARMACOLOGY, V91, P363, DOI 10.1007/BF00518192; Dantzer R, 1998, PROG BRAIN RES, V119, P409; Dluzen DE, 1998, NEUROSCI LETT, V254, P161, DOI 10.1016/S0304-3940(98)00691-0; DLUZEN DE, 1993, BRAIN RES, V609, P98, DOI 10.1016/0006-8993(93)90860-P; Engelmann M, 1998, BEHAV BRAIN RES, V90, P89, DOI 10.1016/S0166-4328(97)00084-3; Engelmann M, 1996, NEUROSCI BIOBEHAV R, V20, P341, DOI 10.1016/0149-7634(95)00059-3; GHEUSI G, 1994, BEHAV PROCESS, V33, P59, DOI 10.1016/0376-6357(94)90060-4; Insel TR, 1998, ADV EXP MED BIOL, V449, P215; JIRIKOWSKI GF, 1991, CELL TISSUE RES, V266, P399, DOI 10.1007/BF00318196; Kendrick KM, 1997, BRAIN RES BULL, V44, P383, DOI 10.1016/S0361-9230(97)00218-9; Keverne EB, 1996, J PHYSIOLOGY-PARIS, V90, P399, DOI 10.1016/S0928-4257(97)87929-6; Keverne EB, 1999, SCIENCE, V286, P716, DOI 10.1126/science.286.5440.716; Kubota Y, 1996, MOL CELL ENDOCRINOL, V124, P25, DOI 10.1016/S0303-7207(96)03923-8; LEVY F, 1995, BRAIN RES, V669, P197, DOI 10.1016/0006-8993(94)01236-B; MENCIOWSZALEK T, 1992, BEHAV NEURAL BIOL, V57, P205, DOI 10.1016/0163-1047(92)90164-Y; Nishimori K, 1996, P NATL ACAD SCI USA, V93, P11699, DOI 10.1073/pnas.93.21.11699; PAOLINI AG, 1993, NEUROSCIENCE, V57, P717, DOI 10.1016/0306-4522(93)90017-A; Paolini AG, 1996, BEHAV BRAIN RES, V81, P223, DOI 10.1016/S0166-4328(96)89082-6; Popik P, 1991, Eur Neuropsychopharmacol, V1, P555, DOI 10.1016/0924-977X(91)90010-R; POPIK P, 1992, BEHAV PHARMACOL, V3, P351; Popik P, 1998, PROG BRAIN RES, V119, P415; POPIK P, 1992, PSYCHOPHARMACOLOGY, V106, P71, DOI 10.1007/BF02253591; POPIK P, 1991, NEUROPEPTIDES, V18, P23, DOI 10.1016/0143-4179(91)90159-G; POPIK P, 1993, EUR NEUROPSYCHOPHARM, V30, P200; Smith CP, 1997, J PHARMACOL EXP THER, V280, P710; THOR DH, 1981, ANIM LEARN BEHAV, V9, P28; WINSLOW JT, 1995, PSYCHOPHARMACOLOGY, V121, P164, DOI 10.1007/BF02245626; Yu GZ, 1996, NEUROSCIENCE, V72, P1083, DOI 10.1016/0306-4522(95)00600-1	30	772	789	2	119	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUL	2000	25	3					284	288		10.1038/77040	http://dx.doi.org/10.1038/77040			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	329RD	10888874				2022-12-25	WOS:000087920900014
J	Zhang, ZX; Yang, L; Young, KJ; DuTemple, B; Zhang, L				Zhang, ZX; Yang, L; Young, KJ; DuTemple, B; Zhang, L			Identification of a previously unknown antigen-specific regulatory T cell and its mechanism of suppression	NATURE MEDICINE			English	Article							IN-VIVO; TRANSPLANTATION TOLERANCE; RENAL-ALLOGRAFTS; TRANSGENIC MICE; RECEPTOR; CD8; ENCEPHALOMYELITIS; AUTOIMMUNITY; ASSOCIATION; LYMPHOCYTES	Despite increasing evidence for the existence of antigen-specific regulatory T cells, the mechanisms underlying suppression remain unclear. In this study we have identified and cloned a novel subset of antigen-specific regulatory T cells and demonstrated that these T cells possess a unique combination of cell surface markers and array of cytokines. The regulatory T cells are able to inhibit the function of T cells carrying the same T-cell receptor specificity and prevent skin allograft rejection in an antigen-specific, dose-dependent manner. The regulatory T cells are able to acquire alloantigen from antigen-presenting cells, present the alloantigen to activated syngeneic CD8(+) T cells and then send death signals to CD8(+) T cells. These findings provide a novel mechanism of regulatory T-cell-mediated, antigen-specific suppression.	Univ Toronto, Toronto Gen Hosp, Res Inst,Dept Lab Med & Pathol, UHN,Multi Organ Transplantat Program, Toronto, ON M5G 2C4, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital	Zhang, L (corresponding author), Univ Toronto, Toronto Gen Hosp, Res Inst,Dept Lab Med & Pathol, UHN,Multi Organ Transplantat Program, 100 Coll St, Toronto, ON M5G 2C4, Canada.		Zhang, Zhu-Xu/G-3361-2011	Zhang, Zhu-Xu/0000-0002-8335-3738				ABRAHAM VS, 1992, J IMMUNOL, V148, P3746; Baxter AG, 1997, DIABETES, V46, P572, DOI 10.2337/diabetes.46.4.572; Bushell A, 1999, J IMMUNOL, V162, P1359; CAI ZL, 1994, J EXP MED, V179, P2005, DOI 10.1084/jem.179.6.2005; Chai JG, 1999, EUR J IMMUNOL, V29, P686, DOI 10.1002/(SICI)1521-4141(199902)29:02<686::AID-IMMU686>3.0.CO;2-N; CHEN YH, 1994, SCIENCE, V265, P1237, DOI 10.1126/science.7520605; Cobbold S, 1998, CURR OPIN IMMUNOL, V10, P518, DOI 10.1016/S0952-7915(98)80217-3; ERARD F, 1993, SCIENCE, V260, P1802, DOI 10.1126/science.8511588; Groux H, 1997, NATURE, V389, P737, DOI 10.1038/39614; Han HS, 1996, J AUTOIMMUN, V9, P331, DOI 10.1006/jaut.1996.0045; Huang JF, 1999, SCIENCE, V286, P952, DOI 10.1126/science.286.5441.952; Ierino FL, 1999, J IMMUNOL, V162, P550; KAGI D, 1994, SCIENCE, V265, P528, DOI 10.1126/science.7518614; Khan Q, 1999, J IMMUNOL, V162, P5860; King C, 1998, IMMUNITY, V8, P601, DOI 10.1016/S1074-7613(00)80565-8; Kuwano K, 1996, CELL IMMUNOL, V169, P288, DOI 10.1006/cimm.1996.0120; LANCASTER F, 1985, NATURE, V315, P336, DOI 10.1038/315336a0; LOMBARDI G, 1994, SCIENCE, V264, P1587, DOI 10.1126/science.8202711; MATZINGER P, 1991, J IMMUNOL METHODS, V145, P185, DOI 10.1016/0022-1759(91)90325-A; Ohteki T, 1999, EUR J IMMUNOL, V29, P2886, DOI 10.1002/(SICI)1521-4141(199909)29:09<2886::AID-IMMU2886>3.0.CO;2-A; Olivares-Villagomez D, 1998, J EXP MED, V188, P1883, DOI 10.1084/jem.188.10.1883; Patel DM, 1999, J IMMUNOL, V163, P5201; QIN SX, 1993, SCIENCE, V259, P974, DOI 10.1126/science.8094901; SAMBHARA SR, 1991, SCIENCE, V252, P1424; Seddon B, 1999, J EXP MED, V189, P877, DOI 10.1084/jem.189.5.877; SHA WC, 1988, NATURE, V336, P73, DOI 10.1038/336073a0; Smyth MJ, 1998, EUR J IMMUNOL, V28, P4162, DOI 10.1002/(SICI)1521-4141(199812)28:12<4162::AID-IMMU4162>3.3.CO;2-5; Sprent J, 1999, J IMMUNOL, V163, P4629; STROBER S, 1987, J IMMUNOL, V138, P699; Strohmaier W, 1996, PTERIDINES, V7, P1; SYKES M, 1990, CELL IMMUNOL, V129, P478, DOI 10.1016/0008-8749(90)90222-D; Tanchot C, 1998, IMMUNITY, V8, P581, DOI 10.1016/S1074-7613(00)80563-4; Thilenius ARB, 1999, J IMMUNOL, V162, P643; WAHL SM, 1994, J EXP MED, V180, P1587, DOI 10.1084/jem.180.5.1587; Waldmann H, 1999, NAT MED, V5, P1245, DOI 10.1038/15197; Yang LM, 1999, TRANSPLANTATION, V67, P1404, DOI 10.1097/00007890-199906150-00003; Yang PY, 1998, J NUTR BIOCHEM, V9, P324, DOI 10.1016/S0955-2863(98)00010-2; Zhai Y, 1999, CURR OPIN IMMUNOL, V11, P497, DOI 10.1016/S0952-7915(99)00007-2; Zhang L, 1996, J EXP MED, V183, P2065, DOI 10.1084/jem.183.5.2065; Zhang XH, 1998, IMMUNITY, V8, P591, DOI 10.1016/S1074-7613(00)80564-6	40	348	377	1	12	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUL	2000	6	7					782	789		10.1038/77513	http://dx.doi.org/10.1038/77513			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	331VV	10888927				2022-12-25	WOS:000088040100035
J	Escayg, A; MacDonald, BT; Meisler, MH; Baulac, S; Huberfeld, G; An-Gourfinkel, I; Brice, A; LeGuern, E; Moulard, B; Chaigne, D; Buresi, C; Malafosse, A				Escayg, A; MacDonald, BT; Meisler, MH; Baulac, S; Huberfeld, G; An-Gourfinkel, I; Brice, A; LeGuern, E; Moulard, B; Chaigne, D; Buresi, C; Malafosse, A			Mutations of SCN1A, encoding a neuronal sodium channel, in two families with GEFS+2	NATURE GENETICS			English	Article							GENERALIZED EPILEPSY; FEBRILE SEIZURES		Univ Michigan, Dept Human Genet, Ann Arbor, MI 48109 USA; Hop La Pitie Salpetriere, INSERM, U289, Paris, France; Hop La Pitie Salpetriere, Ctr Epilepsie, Paris, France; Genethon, Evry, France; Hop Univ Geneve, Div Neuropsychiat, Chene Bourg, Switzerland; Clin St Odile, Strasbourg, France	University of Michigan System; University of Michigan; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; University of Geneva	Meisler, MH (corresponding author), Univ Michigan, Dept Human Genet, Ann Arbor, MI 48109 USA.		brice, alexis/AAE-8275-2019; Baulac, Stéphanie/O-2099-2016; Brice, Alexis/A-2170-2009	brice, alexis/0000-0002-0941-3990; Baulac, Stéphanie/0000-0001-6430-4693; 	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034509] Funding Source: NIH RePORTER; NINDS NIH HHS [NS34509] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Baulac S, 1999, AM J HUM GENET, V65, P1078, DOI 10.1086/302593; Bulman DE, 1997, HUM MOL GENET, V6, P1679, DOI 10.1093/hmg/6.10.1679; Catterall W A, 1999, Adv Neurol, V79, P441; ESCAYG A, IN PRESS AM J HUM GE; Kuhn FJP, 1999, J GEN PHYSIOL, V114, P167, DOI 10.1085/jgp.114.2.167; LEHMANNHORN F, 1999, PHYSIOL REV, V79, P137; Lopes-Cendes I, 2000, AM J HUM GENET, V66, P698, DOI 10.1086/302768; Moulard B, 1999, AM J HUM GENET, V65, P1396, DOI 10.1086/302621; NODA M, 1987, J RECEPTOR RES, V7, P467, DOI 10.3109/10799898709054998; Peiffer A, 1999, ANN NEUROL, V46, P671, DOI 10.1002/1531-8249(199910)46:4<671::AID-ANA20>3.0.CO;2-5; Plummer NW, 1999, GENOMICS, V57, P323, DOI 10.1006/geno.1998.5735; Scheffer IE, 1997, BRAIN, V120, P479, DOI 10.1093/brain/120.3.479; Smith RD, 1998, J NEUROSCI, V18, P811; Wallace RH, 1998, NAT GENET, V19, P366, DOI 10.1038/1252; Wattanasirichaigoon D, 1999, AM J MED GENET, V86, P470, DOI 10.1002/(SICI)1096-8628(19991029)86:5<470::AID-AJMG13>3.0.CO;2-Y	15	758	799	1	44	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	APR	2000	24	4					343	345		10.1038/74159	http://dx.doi.org/10.1038/74159			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	299HK	10742094				2022-12-25	WOS:000086192800010
J	McCallum, CM; Comai, L; Greene, EA; Henikoff, S				McCallum, CM; Comai, L; Greene, EA; Henikoff, S			Targeted screening for induced mutations	NATURE BIOTECHNOLOGY			English	Article							ARABIDOPSIS; DNA		Fred Hutchinson Canc Res Ctr, Div Basic Sci, Seattle, WA 98109 USA; Univ Washington, Dept Bot, Seattle, WA 98199 USA; Univ Washington, Mol & Cellular Biol Program, Seattle, WA 98199 USA; Fred Hutchinson Canc Res Ctr, Howard Hughes Med Inst, Res Labs, Seattle, WA 98109 USA	Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Fred Hutchinson Cancer Center; Howard Hughes Medical Institute	Henikoff, S (corresponding author), Fred Hutchinson Canc Res Ctr, Div Basic Sci, Seattle, WA 98109 USA.		Comai, Luca/F-4279-2010	Comai, Luca/0000-0003-2642-6619; Henikoff, Steven/0000-0002-7621-8685	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029009] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM29009] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aljanabi SM, 1997, NUCLEIC ACIDS RES, V25, P4692, DOI 10.1093/nar/25.22.4692; BOWMAN JL, 1989, PLANT CELL, V1, P37, DOI 10.1105/tpc.1.1.37; Gross E, 1999, HUM GENET, V105, P72, DOI 10.1007/s004390051066; Henikoff S, 1998, GENETICS, V149, P307; Jones AC, 1999, CLIN CHEM, V45, P1133; Kheterpal I, 1999, ANAL CHEM, V71, p31A, DOI 10.1021/ac990099w; KOORNNEEF M, 1982, MUTAT RES, V93, P109, DOI 10.1016/0027-5107(82)90129-4; Kuklin A, 1997, GENET TEST, V1, P201, DOI 10.1089/gte.1997.1.201; Larsen LA, 1999, HUM MUTAT, V13, P318, DOI 10.1002/(SICI)1098-1004(1999)13:4<318::AID-HUMU9>3.0.CO;2-F; Li-Sucholeiki XC, 1999, ELECTROPHORESIS, V20, P1224; Liu LX, 1999, GENOME RES, V9, P859, DOI 10.1101/gr.9.9.859; Oleykowski CA, 1998, NUCLEIC ACIDS RES, V26, P4597, DOI 10.1093/nar/26.20.4597; PLATERO JS, 1995, EMBO J, V14, P3977, DOI 10.1002/j.1460-2075.1995.tb00069.x; POSFAI J, 1989, NUCLEIC ACIDS RES, V17, P2421, DOI 10.1093/nar/17.7.2421; Rose TM, 1998, NUCLEIC ACIDS RES, V26, P1628, DOI 10.1093/nar/26.7.1628; Schimenti J, 1998, GENOME RES, V8, P698, DOI 10.1101/gr.8.7.698; Underhill PA, 1997, GENOME RES, V7, P996, DOI 10.1101/gr.7.10.996	17	451	664	2	110	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	APR	2000	18	4					455	457		10.1038/74542	http://dx.doi.org/10.1038/74542			3	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	303UY	10748531				2022-12-25	WOS:000086444300033
J	Goldstein, JC; Waterhouse, NJ; Juin, P; Evan, GI; Green, DR				Goldstein, JC; Waterhouse, NJ; Juin, P; Evan, GI; Green, DR			The coordinate release of cytochrome c during apoptosis is rapid, complete and kinetically invariant	NATURE CELL BIOLOGY			English	Article							PERMEABILITY TRANSITION PORE; CELL-DEATH; MITOCHONDRIA; NECROSIS; BAX; ACTIVATION; PROTEIN; PHOSPHATIDYLSERINE; CASPASES; CED-4	Release of cytochrome c from mitochondria triggers activation of caspase proteases and death of a cell by apoptosis, However, the mechanism and kinetics of cytochrome c release remain unknown. Here we study this event by using green fluorescent protein (GFP)-tagged cytochrome c, and find that the release of cytochrome-c-GFP always precedes exposure of phosphatidylserine and the loss of plasma-membrane integrity-characteristics of apoptotic cells. Once initiated, the release of cytochrome-c-GFP continues until all of the protein is released from all mitochondria in individual cells, within about 5 minutes, regardless of the type or strength of stimulus or the time elapsed since the stimulus was applied, Temperatures ranging from 24 degrees C to 37 degrees C do not change the duration of release, and nor does the addition of caspase inhibitors. Further, we find that the electron-transport chain can maintain the mitochondrial transmembrane potential even after cytochrome c has been released.	La Jolla Inst Allergy & Immunol, Div Cellular Immunol, San Diego, CA 92121 USA; Univ Calif San Diego, La Jolla, CA 92093 USA; Univ Calif San Francisco, Ctr Canc, San Francisco, CA 94143 USA	La Jolla Institute for Immunology; University of California System; University of California San Diego; University of California System; University of California San Francisco	Green, DR (corresponding author), La Jolla Inst Allergy & Immunol, Div Cellular Immunol, 10355 Sci Ctr Dr, San Diego, CA 92121 USA.	DGreen5240@aol.com	JUIN, Philippe P/H-3636-2014; Waterhouse, Nigel/I-9813-2016; JUIN, Philippe/Q-1338-2019; Green, Douglas R/N-8083-2018	JUIN, Philippe P/0000-0002-4997-3888; JUIN, Philippe/0000-0002-4997-3888; Green, Douglas R/0000-0002-7332-1417	NATIONAL CANCER INSTITUTE [T32CA009345, P01CA069381] Funding Source: NIH RePORTER; NCI NIH HHS [CA69381, CA09345] Funding Source: Medline; PHS HHS [A140646] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Basanez G, 1999, P NATL ACAD SCI USA, V96, P5492, DOI 10.1073/pnas.96.10.5492; Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; Cecconi F, 1998, CELL, V94, P727, DOI 10.1016/S0092-8674(00)81732-8; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Eguchi Y, 1997, CANCER RES, V57, P1835; Eskes R, 1998, J CELL BIOL, V143, P217, DOI 10.1083/jcb.143.1.217; Finucane DM, 1999, J BIOL CHEM, V274, P2225, DOI 10.1074/jbc.274.4.2225; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Heiskanen KM, 1999, J BIOL CHEM, V274, P5654, DOI 10.1074/jbc.274.9.5654; Hu YM, 1999, EMBO J, V18, P3586, DOI 10.1093/emboj/18.13.3586; Kennedy SG, 1999, MOL CELL BIOL, V19, P5800; Kluck RM, 1999, J CELL BIOL, V147, P809, DOI 10.1083/jcb.147.4.809; Kohler C, 1999, FEBS LETT, V447, P10, DOI 10.1016/S0014-5793(99)00251-3; Kroemer G, 1998, ANNU REV PHYSIOL, V60, P619, DOI 10.1146/annurev.physiol.60.1.619; Leist M, 1997, J EXP MED, V185, P1481, DOI 10.1084/jem.185.8.1481; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Marchetti P, 1996, J EXP MED, V184, P1155, DOI 10.1084/jem.184.3.1155; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; Marzo I, 1998, J EXP MED, V187, P1261, DOI 10.1084/jem.187.8.1261; Matsuyama S, 1998, MOL CELL, V1, P327, DOI 10.1016/S1097-2765(00)80033-7; Narita M, 1998, P NATL ACAD SCI USA, V95, P14681, DOI 10.1073/pnas.95.25.14681; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; Saleh A, 1999, J BIOL CHEM, V274, P17941, DOI 10.1074/jbc.274.25.17941; Single B, 1998, CELL DEATH DIFFER, V5, P1001, DOI 10.1038/sj.cdd.4400462; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Srinivasan A, 1998, J BIOL CHEM, V273, P4523, DOI 10.1074/jbc.273.8.4523; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Susin SA, 1999, J EXP MED, V189, P381, DOI 10.1084/jem.189.2.381; Vander Heiden MG, 1999, MOL CELL, V3, P159; VERMES I, 1995, J IMMUNOL METHODS, V184, P39, DOI 10.1016/0022-1759(95)00072-I; Wolf BB, 1999, J BIOL CHEM, V274, P20049, DOI 10.1074/jbc.274.29.20049; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	36	837	860	1	37	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	MAR	2000	2	3					156	162		10.1038/35004029	http://dx.doi.org/10.1038/35004029			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	292AE	10707086				2022-12-25	WOS:000085771300015
J	Liu, L; Oldenbourg, R; Trimarchi, JR; Keefe, DL				Liu, L; Oldenbourg, R; Trimarchi, JR; Keefe, DL			A reliable, noninvasive technique for spindle imaging and enucleation of mammalian oocytes	NATURE BIOTECHNOLOGY			English	Article							MATURED IN-VITRO; ULTRAVIOLET-IRRADIATION; NUCLEAR TRANSFER; EMBRYOS; MICROSCOPY; CYTOPLASM; FETAL; CELLS		Brown Univ, Women & Infants Hosp, Dept Obstet & Gynecol, Providence, RI 02905 USA; Marine Biol Lab, Woods Hole, MA 02543 USA	Brown University; Women & Infants Hospital Rhode Island; Marine Biological Laboratory - Woods Hole	Keefe, DL (corresponding author), Brown Univ, Women & Infants Hosp, Dept Obstet & Gynecol, Providence, RI 02905 USA.				PHS HHS [K081099] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Campbell K H, 1999, Cloning, V1, P3, DOI 10.1089/15204559950020058; CHEONG HT, 1994, MOL REPROD DEV, V37, P138, DOI 10.1002/mrd.1080370204; Cibelli JB, 1998, SCIENCE, V280, P1256, DOI 10.1126/science.280.5367.1256; Evans MJ, 1999, NAT GENET, V23, P90, DOI 10.1038/12696; HIRAMOTO Y, 1981, J CELL BIOL, V89, P121, DOI 10.1083/jcb.89.1.121; INOUE S, 1953, CHROMOSOMA, V5, P487, DOI 10.1007/BF01271498; Keefe D, 1997, HUM REPROD, V12, P1250; LATHAM KE, 1993, METHOD ENZYMOL, V225, P719; Liu L, 1997, MOL REPROD DEV, V47, P255, DOI 10.1002/(SICI)1098-2795(199707)47:3&lt;255::AID-MRD4&gt;3.0.CO;2-K; Liu Z, 1995, HUM REPROD, V10, P2985, DOI 10.1093/oxfordjournals.humrep.a135834; Oldenbourg R, 1999, METHOD CELL BIOL, V61, P175; Oldenbourg R, 1996, NATURE, V381, P811, DOI 10.1038/381811a0; Peura TT, 1998, MOL REPROD DEV, V50, P185, DOI 10.1002/(SICI)1098-2795(199806)50:2&lt;185::AID-MRD9&gt;3.0.CO;2-G; Robl JM, 1999, THERIOGENOLOGY, V51, P499, DOI 10.1016/S0093-691X(98)00243-X; Silva CP, 1999, FERTIL STERIL, V71, P719, DOI 10.1016/S0015-0282(98)00530-5; SMITH LC, 1993, J REPROD FERTIL, V99, P39, DOI 10.1530/jrf.0.0990039; TSUNODA Y, 1988, J REPROD FERTIL, V82, P173, DOI 10.1530/jrf.0.0820173; Wakayama T, 1998, NATURE, V394, P369, DOI 10.1038/28615; Wakayama T, 1998, ZYGOTE, V6, P341, DOI 10.1017/S096719949800029X; Wilmut I, 1997, NATURE, V385, P810, DOI 10.1038/385810a0	20	105	124	0	14	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	FEB	2000	18	2					223	225		10.1038/72692	http://dx.doi.org/10.1038/72692			3	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	281FH	10657133				2022-12-25	WOS:000085146900033
J	Mascola, JR; Stiegler, G; VanCott, TC; Katinger, H; Carpenter, CB; Hanson, CE; Beary, H; Hayes, D; Frankel, SS; Birx, DL; Lewis, MG				Mascola, JR; Stiegler, G; VanCott, TC; Katinger, H; Carpenter, CB; Hanson, CE; Beary, H; Hayes, D; Frankel, SS; Birx, DL; Lewis, MG			Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies	NATURE MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; TYPE-1 INFECTION; RHESUS MACAQUES; AIDS; HIV; INOCULATION; DISEASE; EPITOPE; MONKEYS; WOMEN	The development of the human immunodeficiency virus-1 (HIV-1)/simian immunodeficiency virus (SIV) chimeric virus macaque model (SHIV) permits the in vivo evaluation of anti-HIV-1. envelope glycoprotein immune responses(1-3), Using this model, others, and we have shown that passively infused antibody can protect against an intravenous challenge(4,5). However, HIV-1 is most often transmitted across mucosal surfaces(6-9) and the intravenous challenge model may not accurately predict the role of antibody in protection against mucosal exposure. After controlling the macaque estrous cycle with progesterone(10), anti-HIV-1 neutralizing monoclonal antibodies 2F5 and 2G12, and HIV immune globulin were tested(11-13). Whereas all five control monkeys displayed high plasma viremia and rapid CD4 cell decline, 14 antibody-treated macaques were either completely protected against infection or against pathogenic manifestations of SHIV-infection. Infusion of all three antibodies together provided the greatest amount of protection, but a single monoclonal antibody, with modest virus neutralizing activity, was also protective. Compared with our previous intravenous challenge study with the same virus and antibodies: the data indicated that greater protection was achieved after vaginal challenge. This study demonstrates that antibodies can affect transmission and subsequent disease course after vaginal SHIV-challenge; the data begin to define the type of antibody response that could play a role in protection against mucosal transmission of HIV-1.	Walter Reed Army Inst Res, Div Retrovirol, Rockville, MD 20850 USA; Henry M Jackson Fdn, Rockville, MD 20850 USA; Univ Agr Vienna, Inst Appl Microbiol, Vienna, Austria; USN, Med Res Ctr, Dept Infect Dis, Forrest Glenn, MD 20910 USA; Walter Reed Army Inst Res, Div Vet Med, Forrest Glenn, MD 20910 USA	United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR); Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc; University of Natural Resources & Life Sciences, Vienna; United States Department of Defense; United States Navy; United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR)	Mascola, JR (corresponding author), Walter Reed Army Inst Res, Div Retrovirol, 1 Taft Court,Suite 250, Rockville, MD 20850 USA.	jmascola@hiv.hif.org	Mascola, John/AAI-7193-2021					Artenstein AW, 1997, J INFECT DIS, V175, P265, DOI 10.1093/infdis/175.2.265; BURTON DR, 1997, AIDS SA, V11, P587; Frankel SS, 1998, J VIROL, V72, P9788, DOI 10.1128/JVI.72.12.9788-9794.1998; Frankel SS, 1996, SCIENCE, V272, P115, DOI 10.1126/science.272.5258.115; Kutteh WH, 1998, AIDS RES HUM RETROV, V14, pS51; Lambert G, 1997, J PEDIATR-US, V130, P890, DOI 10.1016/S0022-3476(97)70274-9; Lambert JS, 1997, J INFECT DIS, V175, P283, DOI 10.1093/infdis/175.2.283; Lewis MG, 1999, J VIROL, V73, P1262, DOI 10.1128/JVI.73.2.1262-1270.1999; Lu YC, 1998, J ACQ IMMUN DEF SYND, V19, P6, DOI 10.1097/00042560-199809010-00002; Marx PA, 1996, NAT MED, V2, P1084, DOI 10.1038/nm1096-1084; Mascola JR, 1997, J VIROL, V71, P7198, DOI 10.1128/JVI.71.10.7198-7206.1997; Mascola JR, 1999, J VIROL, V73, P4009, DOI 10.1128/JVI.73.5.4009-4018.1999; Miller CJ, 1996, NAT MED, V2, P751, DOI 10.1038/nm0796-751; MUSTER T, 1993, J VIROL, V67, P6642, DOI 10.1128/JVI.67.11.6642-6647.1993; Piot P, 1998, SCIENCE, V280, P1844, DOI 10.1126/science.280.5371.1844; Reimann KA, 1996, J VIROL, V70, P3198, DOI 10.1128/JVI.70.5.3198-3206.1996; Reimann KA, 1996, J VIROL, V70, P6922, DOI 10.1128/JVI.70.10.6922-6928.1996; Shibata R, 1997, J INFECT DIS, V176, P362, DOI 10.1086/514053; Shibata R, 1999, NAT MED, V5, P204, DOI 10.1038/5568; Spira AI, 1996, J EXP MED, V183, P215, DOI 10.1084/jem.183.1.215; Trkola A, 1996, J VIROL, V70, P1100, DOI 10.1128/JVI.70.2.1100-1108.1996; Vahey Maryanne T., 1995, P313	22	1081	1145	0	20	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2000	6	2					207	210		10.1038/72318	http://dx.doi.org/10.1038/72318			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	278YQ	10655111				2022-12-25	WOS:000085016900043
J	Matsuo, K; Owens, JM; Tonko, M; Elliott, C; Chambers, TJ; Wagner, EF				Matsuo, K; Owens, JM; Tonko, M; Elliott, C; Chambers, TJ; Wagner, EF			Fosl1 is a transcriptional target of c-Fos during osteoclast differentiation	NATURE GENETICS			English	Article							TERMINAL TRANSACTIVATION DOMAIN; ACTIVATION DOMAINS; BINDING PROTEIN; CELL-GROWTH; FRA-1 GENE; TRANSFORMATION; LIGAND; CYTOKINE; REQUIRES; MOUSE	Osteoclasts are bone-resorbing cells derived from haematopoietic precursors of the monocyte-macrophage lineage. Mice lacking Fos (encoding c-Fos) develop osteopetrosis due to an early differentiation block in the osteoclast lineage(1-3), c-Fos is a component of the dimeric transcription factor activator protein-1 (Ap-1), which is composed mainly of Fos (c-Fos, FosB, Fra-1 and Fra-2) and Jun proteins (c-Jun, JunB and JunD). Unlike Fra-1 (encoded by Fos/1), c-Fos contains transactivation domains required for oncogenesis and cellular transformation(4-6). The mechanism by which c-Fos exerts its specific function in osteoclast differentiation is not understood. Here we show by retroviral-gene transfer that all four Fos proteins, hut not the Jun proteins, rescue the differentiation block in vitro. Structure-function analysis demonstrated that the major carboxy-terminal transactivation domains of c-Fos and FosB are dispensable and that Fra-1 (which lacks transactivation domains(4,7)) has the highest rescue activity. Moreover, a transgene expressing Fra-1 rescues the osteopetrosis of c-fos-mutant mice in vivo. The osteoclast differentiation factor Rankl (also known as TRANCE, CUE and OPGL; refs 8-11) induces transcription of Fos/1 in a c-fos-dependent manner, thereby establishing a link between Rank signalling and the expression of Ap-1 proteins in osteoclast differentiation.	Res Inst Mol Pathol, A-1030 Vienna, Austria; St George Hosp, Sch Med, Dept Histopathol, London, England	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP); St Georges University London	Wagner, EF (corresponding author), Res Inst Mol Pathol, Dr Bohr Gasse 7, A-1030 Vienna, Austria.		Matsuo, Koichi/K-5695-2012; Elliott, Candace/F-1860-2011	Matsuo, Koichi/0000-0002-1490-8955; Elliott, Candace/0000-0002-9174-0244; Wagner, Erwin F/0000-0001-7872-0196				Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593; BERGERS G, 1995, MOL CELL BIOL, V15, P3748; BROWN HJ, 1995, EMBO J, V14, P124, DOI 10.1002/j.1460-2075.1995.tb06982.x; CHAMBERS TJ, 1993, P NATL ACAD SCI USA, V90, P5578, DOI 10.1073/pnas.90.12.5578; Dougall WC, 1999, GENE DEV, V13, P2412, DOI 10.1101/gad.13.18.2412; Funk M, 1997, MOL CELL BIOL, V17, P537, DOI 10.1128/MCB.17.2.537; GIUS D, 1990, MOL CELL BIOL, V10, P4243, DOI 10.1128/MCB.10.8.4243; GRIGORIADIS AE, 1993, J CELL BIOL, V122, P685, DOI 10.1083/jcb.122.3.685; GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685; Hsu HL, 1999, P NATL ACAD SCI USA, V96, P3540, DOI 10.1073/pnas.96.7.3540; JOHNSON RS, 1992, CELL, V71, P577, DOI 10.1016/0092-8674(92)90592-Z; JOOSS KU, 1994, EMBO J, V13, P1467, DOI 10.1002/j.1460-2075.1994.tb06401.x; Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852; Kustikova O, 1998, MOL CELL BIOL, V18, P7095, DOI 10.1128/MCB.18.12.7095; Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092-8674(00)81569-X; LIVAK KJ, 1995, PCR METH APPL, V4, P357; METZ R, 1994, MOL CELL BIOL, V14, P6021, DOI 10.1128/MCB.14.9.6021; METZ R, 1994, EMBO J, V13, P3832, DOI 10.1002/j.1460-2075.1994.tb06694.x; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; OLIVIERO S, 1992, GENE DEV, V6, P1799, DOI 10.1101/gad.6.9.1799; Owens JM, 1999, J CELL PHYSIOL, V179, P170, DOI 10.1002/(SICI)1097-4652(199905)179:2<170::AID-JCP7>3.0.CO;2-K; Russell RGG, 1999, BONE, V25, P97, DOI 10.1016/S8756-3282(99)00116-7; Schreiber M, 1997, ONCOGENE, V15, P1171, DOI 10.1038/sj.onc.1201460; SUTHERLAND JA, 1992, GENE DEV, V6, P1810, DOI 10.1101/gad.6.9.1810; WANG SJ, 1992, J OPT SOC AM B, V9, P360, DOI 10.1364/JOSAB.9.000360; WISDOM R, 1992, GENE DEV, V6, P667, DOI 10.1101/gad.6.4.667; WISDOM R, 1993, MOL CELL BIOL, V13, P7429, DOI 10.1128/MCB.13.12.7429; Wong BR, 1997, J EXP MED, V186, P2075, DOI 10.1084/jem.186.12.2075; WRIGHTON C, 1993, MOL CELL BIOL, V13, P4657, DOI 10.1128/MCB.13.8.4657; Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597	30	266	276	0	18	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	FEB	2000	24	2					184	187		10.1038/72855	http://dx.doi.org/10.1038/72855			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	280LQ	10655067				2022-12-25	WOS:000085104600022
J	Sibon, OCM; Kelkar, A; Lemstra, W; Theurkauf, WE				Sibon, OCM; Kelkar, A; Lemstra, W; Theurkauf, WE			DNA-replication/DNA-damage-dependent centrosome inactivation in Drosophila embryos	NATURE CELL BIOLOGY			English	Article							XENOPUS EGG EXTRACTS; KINESIN-LIKE PROTEIN; SELF-ORGANIZATION; MITOTIC-CYCLES; GAMMA-TUBULIN; SPINDLE; CHROMOSOMES; GENE; EMBRYOGENESIS; MELANOGASTER	During early embryogenesis of Drosophila melanogaster, mutations in the DNA-replication checkpoint lead to chromosome-segregation failures. Here we show that these segregation failures are associated with the assembly of an anastral microtubule spindle, a mitosis-specific loss of centrosome function, and dissociation of several components of the gamma-tubulin ring complex from a core centrosomal structure. The DNA-replication inhibitor aphidicolin and DNA-damaging agents trigger identical mitotic defects in wild-type embryos, indicating that centrosome inactivation is a checkpoint-independent and mitosis-specific response to damaged or incompletely replicated DNA, We propose that centrosome inactivation is part of a damage-control system that blocks chromosome segregation when replication/damage checkpoint control fails.	Univ Massachusetts, Med Ctr, Program Mol Med, Worcester, MA 01605 USA; Univ Groningen, Dept Radiobiol, Fac Med, Groningen, Netherlands; Univ Massachusetts, Med Ctr, Dept Mol Genet & Microbiol, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester; University of Groningen; University of Massachusetts System; University of Massachusetts Worcester	Theurkauf, WE (corresponding author), Univ Massachusetts, Med Ctr, Program Mol Med, 373 Plantat St, Worcester, MA 01605 USA.			Kelkar, Anju/0000-0001-7956-8210; Theurkauf, William/0000-0001-7342-1912; Sibon, Ody/0000-0002-6836-6063	NIGMS NIH HHS [R01GM50898] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050898] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Cadet J, 1997, BIOL CHEM, V378, P1275; Doxsey S, 1998, NAT GENET, V20, P104, DOI 10.1038/2392; EDGAR BA, 1986, CELL, V44, P871, DOI 10.1016/0092-8674(86)90009-7; EDGAR BA, 1994, GENE DEV, V8, P440, DOI 10.1101/gad.8.4.440; EDGAR BA, 1986, CELL, V44, P365, DOI 10.1016/0092-8674(86)90771-3; ERICKSON LC, 1980, BIOCHIM BIOPHYS ACTA, V610, P105, DOI 10.1016/0005-2787(80)90060-X; FOE VE, 1983, J CELL SCI, V61, P31; Foe Victoria E., 1993, P149; FOGARTY P, 1994, DEVELOPMENT, V120, P2131; Fogarty P, 1997, CURR BIOL, V7, P418, DOI 10.1016/S0960-9822(06)00189-8; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; HARI KL, 1995, CELL, V82, P815, DOI 10.1016/0092-8674(95)90478-6; Heald R, 1997, J CELL BIOL, V138, P615, DOI 10.1083/jcb.138.3.615; Heald R, 1996, NATURE, V382, P420, DOI 10.1038/382420a0; KELLOGG DR, 1988, DEVELOPMENT, V103, P675; KELLOGG DR, 1989, J CELL BIOL, V109, P2977, DOI 10.1083/jcb.109.6.2977; Li KJ, 1996, CELL, V85, P585, DOI 10.1016/S0092-8674(00)81258-1; Matthies HJG, 1996, J CELL BIOL, V134, P455, DOI 10.1083/jcb.134.2.455; Megraw TL, 1999, DEVELOPMENT, V126, P2829; Moore DP, 1998, J CELL BIOL, V140, P1003, DOI 10.1083/jcb.140.5.1003; Oegema K, 1999, J CELL BIOL, V144, P721, DOI 10.1083/jcb.144.4.721; OEGEMA K, 1995, J CELL BIOL, V131, P1261, DOI 10.1083/jcb.131.5.1261; RAFF JW, 1988, J CELL BIOL, V107, P2009, DOI 10.1083/jcb.107.6.2009; RIEDER CL, 1986, J CELL BIOL, V103, P581, DOI 10.1083/jcb.103.2.581; Sibon OCM, 1999, CURR BIOL, V9, P302, DOI 10.1016/S0960-9822(99)80138-9; Sibon OCM, 1997, NATURE, V388, P93, DOI 10.1038/40439; Theurkauf WE, 1999, METHOD CELL BIOL, V61, P317; THEURKAUF WE, 1994, METHOD CELL BIOL, V44, P489, DOI 10.1016/S0091-679X(08)60928-0; THEURKAUF WE, 1992, J CELL BIOL, V116, P1167, DOI 10.1083/jcb.116.5.1167; Vaizel-Ohayon D, 1999, CURR BIOL, V9, P889, DOI 10.1016/S0960-9822(99)80393-5; WHITFIELD WGF, 1995, J CELL SCI, V108, P3377; WIESCHAUS E, 1988, DEVELOPMENT, V104, P483; ZHENG YX, 1991, CELL, V65, P817, DOI 10.1016/0092-8674(91)90389-G; ZHENG YX, 1995, NATURE, V378, P578, DOI 10.1038/378578a0	34	135	135	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	FEB	2000	2	2					90	95		10.1038/35000041	http://dx.doi.org/10.1038/35000041			6	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	281GA	10655588				2022-12-25	WOS:000085148500013
J	Trainor, P; Krumlauf, R				Trainor, P; Krumlauf, R			Plasticity in mouse neural crest cells reveals a new patterning role for cranial mesoderm	NATURE CELL BIOLOGY			English	Article							HOX GENE INDUCTION; TRANSPOSED RHOMBOMERES; SEGMENTAL EXPRESSION; PARAXIAL MESODERM; CROSS-REGULATION; HINDBRAIN; MIGRATION; EMBRYO; CODE; IDENTITY	The anteroposterior identity of cranial neural crest cells is thought to be preprogrammed before these cells emigrate from the neural tube. Here we test this assumption by developing techniques for transposing cells in the hindbrain of mouse embryos, using small numbers of cells in combination with genetic and lineage markers. This technique has uncovered a surprising degree of plasticity with respect to the expression of Hox genes, which can be used as markers of different hindbrain segments and cells, in both hindbrain tissue and cranial neural crest cells. Our analysis shows that the patterning of cranial neural crest cells relies on a balance between permissive and instructive signals, and underscores the importance of cell-community effects. These results reveal a new role for the cranial mesoderm in patterning facial tissues. Furthermore, our findings argue against a permanently fixed prepatterning of the cranial neural crest that is maintained by passive transfer of positional information from the hindbrain to the periphery.	Natl Inst Med Res, Div Dev Neurobiol, London NW7 1AA, England	MRC National Institute for Medical Research	Krumlauf, R (corresponding author), Natl Inst Med Res, Div Dev Neurobiol, Ridgeway,Mill Hill, London NW7 1AA, England.	rkrumlauf@nimr.mrc.ac.uk	Krumlauf, Robb/AAH-5012-2019	Krumlauf, Robb/0000-0001-9102-7927; Trainor, Paul/0000-0003-2774-3624				Chazaud C, 1999, DEVELOPMENT, V126, P2589; Couly G, 1998, DEVELOPMENT, V125, P3445; FROHMAN MA, 1990, DEVELOPMENT, V110, P589; Golding JP, 2000, NAT CELL BIOL, V2, P103, DOI 10.1038/35000058; Gould A, 1998, NEURON, V21, P39, DOI 10.1016/S0896-6273(00)80513-9; Gould A, 1997, GENE DEV, V11, P900, DOI 10.1101/gad.11.7.900; GRAPINBOTTON A, 1995, DEVELOPMENT, V121, P2707; GrapinBotton A, 1997, DEVELOPMENT, V124, P849; GUTHRIE S, 1992, NATURE, V356, P157, DOI 10.1038/356157a0; Hunt P, 1998, DEV BIOL, V198, P82, DOI 10.1006/dbio.1998.8886; HUNT P, 1991, NATURE, V353, P861, DOI 10.1038/353861a0; Itasaki N, 1996, NEURON, V16, P487, DOI 10.1016/S0896-6273(00)80069-0; Kontges G, 1996, DEVELOPMENT, V122, P3229; KRUMLAUF R, 1994, CELL, V78, P191, DOI 10.1016/0092-8674(94)90290-9; Kulesa PM, 1998, DEV BIOL, V204, P327, DOI 10.1006/dbio.1998.9082; KURATANI SC, 1993, DEVELOPMENT, V117, P105; Le Douarin N., 1999, DEV CELL BIOL SERIES, V2nd, DOI [10.1017/CBO9780511897948, DOI 10.1017/CBO9780511897948, 10.1017/cbo9780511897948]; LEE YM, 1995, DEVELOPMENT, V121, P825; LUMSDEN A, 1989, NATURE, V337, P424, DOI 10.1038/337424a0; Lumsden A, 1996, SCIENCE, V274, P1109, DOI 10.1126/science.274.5290.1109; LUMSDEN A, 1991, DEVELOPMENT, V113, P1281; Maconochie M, 1999, DEVELOPMENT, V126, P1483; Maconochie MK, 1997, GENE DEV, V11, P1885, DOI 10.1101/gad.11.14.1885; Manzanares M, 1999, DEV BIOL, V211, P220, DOI 10.1006/dbio.1999.9318; MARSHALL H, 1992, NATURE, V360, P737, DOI 10.1038/360737a0; NODEN DM, 1986, DEV BIOL, V116, P347, DOI 10.1016/0012-1606(86)90138-7; NODEN DM, 1983, DEV BIOL, V96, P144, DOI 10.1016/0012-1606(83)90318-4; NODEN DM, 1986, J CRAN GENET DEV BIO, P15; Nonchev S, 1996, DEVELOPMENT, V122, P543; POPPERL H, 1995, CELL, V81, P1031, DOI 10.1016/S0092-8674(05)80008-X; PRINCE V, 1994, DEVELOPMENT, V120, P911; Saldivar JR, 1996, DEVELOPMENT, V122, P895; SECHRIST J, 1993, DEVELOPMENT, V118, P691; SERBEDZIJA GN, 1992, DEVELOPMENT, V116, P297; STURM K, 1993, METHOD ENZYMOL, V225, P164; TRAINOR PA, 1994, DEVELOPMENT, V120, P2397; TRAINOR PA, 1995, DEVELOPMENT, V121, P2569; WHITING J, 1991, GENE DEV, V5, P2048, DOI 10.1101/gad.5.11.2048; Xu QL, 1999, NATURE, V399, P267, DOI 10.1038/20452; Xu QL, 1995, DEVELOPMENT, V121, P4005	40	171	172	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	FEB	2000	2	2					96	102		10.1038/35000051	http://dx.doi.org/10.1038/35000051			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	281GA	10655589				2022-12-25	WOS:000085148500014
J	Bovenberg, JA				Bovenberg, JA			Should companies set up databases in Europe?	NATURE BIOTECHNOLOGY			English	Editorial Material									Nauta Dutilh, Amsterdam, Netherlands		Bovenberg, JA (corresponding author), Nauta Dutilh, Amsterdam, Netherlands.							GASTER JL, 1996, RECHTSSCHUTZ DATENBA; Lederberg J, 1999, NAT GENET, V23, P1; Maurer SM, 1999, SCIENCE, V284, P1129, DOI 10.1126/science.284.5417.1129; 2000, NATURE, V405, P719	4	4	4	0	3	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	SEP	2000	18	9					907	907		10.1038/79301	http://dx.doi.org/10.1038/79301			1	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	350AN	10973169	Bronze			2022-12-25	WOS:000089078300003
J	Locke, SD; Kalow, DA				Locke, SD; Kalow, DA			When the human genome project and State Street collide	NATURE BIOTECHNOLOGY			English	Editorial Material									Kalow & Springut LLP, New York, NY 10022 USA		Locke, SD (corresponding author), Kalow & Springut LLP, 488 Madison Ave, New York, NY 10022 USA.							Auth DR, 1997, NAT BIOTECHNOL, V15, P911, DOI 10.1038/nbt0997-911; Kowalski TJ, 2000, NAT BIOTECHNOL, V18, P349, DOI 10.1038/73820	2	0	0	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	SEP	2000	18	9					1009	1010		10.1038/79281	http://dx.doi.org/10.1038/79281			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	350AN	10973226				2022-12-25	WOS:000089078300034
J	Tretiakova, AP; Little, CS; Blank, KJ; Jameson, BA				Tretiakova, AP; Little, CS; Blank, KJ; Jameson, BA			Rational design of cytotoxic T-cell inhibitors	NATURE BIOTECHNOLOGY			English	Article						CD8; MHC class 1; synthetic peptide; rational design	LEUKEMIA-VIRUS INFECTION; CRYSTAL-STRUCTURE; COMPLEX; RECEPTOR; CD8; ACTIVATION; MICE; CD8-ALPHA-ALPHA; ASSOCIATIONS; GLYCOPROTEIN	This study describes the use of the CD8/major histocompatibility complex (MHC) class I crystal structure as a template for the de novo design of low-molecular-weight surface mimetics. The analogs were designed from a local surface region on the CD8 alpha-chain directly adjacent to the bound MHC class I, to block the protein associations in the T-cell activation cluster that occur upon stimulation of the cytotoxic T lymphocytes (CTLs). One small conformationally restrained peptide showed dose-dependent inhibition of a primary allogeneic CTL assay while having no effect on the CD4-dependent mixed lymphocyte reaction (MLR). The analog's activity could be modulated through subtle changes in its side chain composition. Administration of the analog prevented CD8-dependent clearance of a murine retrovirus in BALB/c mice. In C57BL/6 mice challenged with the same retrovirus, the analog selectively inhibited the antiviral CTL responses without affecting the ability of the CTLs to generate robust allogeneic responses.	Med Coll Penn & Hahnemann Univ, Sch Med, Ctr Canc, Dept Pathol & Lab Med, Philadelphia, PA 19102 USA	Drexel University	Jameson, BA (corresponding author), Med Coll Penn & Hahnemann Univ, Sch Med, Ctr Canc, Dept Pathol & Lab Med, Philadelphia, PA 19102 USA.	bjameson@drexel.edu						Avidan N, 1997, CLIN IMMUNOL IMMUNOP, V85, P282, DOI 10.1006/clin.1997.4447; BANNER DW, 1993, CELL, V73, P431, DOI 10.1016/0092-8674(93)90132-A; BEYERS AD, 1992, P NATL ACAD SCI USA, V89, P2945, DOI 10.1073/pnas.89.7.2945; Boriack-Sjodin PA, 1998, NATURE, V394, P337, DOI 10.1038/28548; Cheng YK, 1998, NATURE, V392, P696, DOI 10.1038/33653; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DiLorenzo TP, 1998, P NATL ACAD SCI USA, V95, P12538, DOI 10.1073/pnas.95.21.12538; Fowler DH, 1998, VOX SANG, V74, P331, DOI 10.1111/j.1423-0410.1998.tb05439.x; Gao GF, 1997, NATURE, V387, P630, DOI 10.1038/42523; He G, 1999, TRANSPLANT P, V31, P1239, DOI 10.1016/S0041-1345(98)01978-2; HEHMKE B, 1995, DIABETES, V44, P1414, DOI 10.2337/diabetes.44.12.1414; JAMESON BA, 1989, NATURE, V341, P465, DOI 10.1038/341465a0; JAMESON BA, 1994, NATURE, V368, P744, DOI 10.1038/368744a0; JANEWAY CA, 1992, ANNU REV IMMUNOL, V10, P645, DOI 10.1146/annurev.immunol.10.1.645; Kern PS, 1998, IMMUNITY, V9, P519, DOI 10.1016/S1074-7613(00)80635-4; Kwong PD, 1998, NATURE, V393, P648, DOI 10.1038/31405; LEAHY DJ, 1992, CELL, V68, P1145, DOI 10.1016/0092-8674(92)90085-Q; Lim GEK, 1998, EUR J IMMUNOL, V28, P745, DOI 10.1002/(SICI)1521-4141(199802)28:02<745::AID-IMMU745>3.0.CO;2-6; MATZINGER P, 1991, J IMMUNOL METHODS, V145, P185, DOI 10.1016/0022-1759(91)90325-A; Panoutsakopoulou V, 1998, J IMMUNOL, V161, P17; Pardanani A, 1998, J MOL BIOL, V284, P729, DOI 10.1006/jmbi.1998.2195; PARNES JR, 1989, ADV IMMUNOL, V44, P265, DOI 10.1016/S0065-2776(08)60644-6; Peakman M, 1996, DIABETES CARE, V19, P1177, DOI 10.2337/diacare.19.11.1177; Rabinovitch A, 1998, BIOCHEM PHARMACOL, V55, P1139, DOI 10.1016/S0006-2952(97)00492-9; Rittinger K, 1997, NATURE, V389, P758, DOI 10.1038/39651; Rockwell AL, 1999, BIOORG MED CHEM LETT, V9, P937, DOI 10.1016/S0960-894X(99)00114-6; Wheeler CJ, 1998, J IMMUNOL, V160, P4199; Wong FS, 1999, J AUTOIMMUN, V13, P290, DOI 10.1006/jaut.1999.0322; Xue CB, 1997, BIOORGAN MED CHEM, V5, P693, DOI 10.1016/S0968-0896(97)00013-8; Yoneda R, 1997, DIABETOLOGIA, V40, P1044, DOI 10.1007/s001250050786	30	6	7	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	SEP	2000	18	9					984	988		10.1038/79487	http://dx.doi.org/10.1038/79487			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	350AN	10973221				2022-12-25	WOS:000089078300029
J	Saito, M; Korsmeyer, SJ; Schlesinger, PH				Saito, M; Korsmeyer, SJ; Schlesinger, PH			BAX-dependent transport of cytochrome c reconstituted in pure liposomes	NATURE CELL BIOLOGY			English	Article							PORE FORMATION; MARKER MOLECULES; CELL-DEATH; RELEASE; MITOCHONDRIA; MEMBRANES; APOPTOSIS; KINETICS; BCL-2; MELITTIN		Washington Univ, Sch Med, Dept Physiol & Cell Biol, St Louis, MO 63110 USA; Harvard Univ, Sch Med, Howard Hughes Med Inst, Dana Farber Canc Inst, Boston, MA 02115 USA	Washington University (WUSTL); Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Howard Hughes Medical Institute	Schlesinger, PH (corresponding author), Washington Univ, Sch Med, Dept Physiol & Cell Biol, St Louis, MO 63110 USA.		Schlesinger, Paul H/C-6049-2012					Antonsson B, 2000, BIOCHEM J, V345, P271, DOI 10.1042/0264-6021:3450271; Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370; BADLEY RA, 1976, MODERN FLUORESCENCE, V2, P112; Basanez G, 1999, P NATL ACAD SCI USA, V96, P5492, DOI 10.1073/pnas.96.10.5492; CHEN RF, 1988, ANAL BIOCHEM, V172, P61, DOI 10.1016/0003-2697(88)90412-5; DUFOURCQ J, 1986, BIOCHIM BIOPHYS ACTA, V859, P33, DOI 10.1016/0005-2736(86)90315-9; EFTINK MR, 1981, ANAL BIOCHEM, V114, P199, DOI 10.1016/0003-2697(81)90474-7; Finucane DM, 1999, J BIOL CHEM, V274, P2225, DOI 10.1074/jbc.274.4.2225; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; HILLE B, 1968, J GEN PHYSIOL, V51, P199, DOI 10.1085/jgp.51.2.199; LEVITT DG, 1984, CURR TOP MEMBR TRANS, V21, P181; MILLER C, 1984, ANNU REV PHYSIOL, V46, P549, DOI 10.1146/annurev.ph.46.030184.003001; Pastorino JG, 1998, J BIOL CHEM, V273, P7770, DOI 10.1074/jbc.273.13.7770; Priault M, 1999, EUR J BIOCHEM, V260, P684, DOI 10.1046/j.1432-1327.1999.00198.x; RENKIN EM, 1954, J GEN PHYSIOL, V38, P225; Rex S, 1996, BIOPHYS CHEM, V58, P75, DOI 10.1016/0301-4622(95)00087-9; Schlesinger PH, 1997, P NATL ACAD SCI USA, V94, P11357, DOI 10.1073/pnas.94.21.11357; SCHWARZ G, 1990, BIOPHYS J, V58, P577, DOI 10.1016/S0006-3495(90)82401-2; SCHWARZ G, 1992, BIOCHIM BIOPHYS ACTA, V1110, P97, DOI 10.1016/0005-2736(92)90299-2; SCHWARZ G, 1992, BIOPHYS CHEM, V42, P291, DOI 10.1016/0301-4622(92)80021-V; Segel I., 1975, ENZYME KINETICS, P371; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	26	389	405	1	12	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	AUG	2000	2	8					553	555		10.1038/35019596	http://dx.doi.org/10.1038/35019596			3	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	341TE	10934477				2022-12-25	WOS:000088605000022
J	Schuchert, MJ; Wright, RD; Colson, YL				Schuchert, MJ; Wright, RD; Colson, YL			Characterization of a newly discovered T-cell receptor beta-chain heterodimer expressed on a CD8(+) bone marrow subpopulation that promotes allogeneic stem cell engraftment	NATURE MEDICINE			English	Article							VERSUS-HOST DISEASE; NATURAL-KILLER-CELLS; ANTIGEN RECEPTOR; GRAFT-REJECTION; IMMATURE THYMOCYTES; MONOCLONAL-ANTIBODY; SUBUNIT COMPOSITION; LYMPHOCYTE-SURFACE; FACILITATING CELLS; CD3 COMPLEXES	The facilitating cell is a rare CD8(+) bone marrow subpopulation that can enhance allogeneic hematopoietic stem cell engraftment across complete major histocompatibility complex barriers without inducing acute graft-versus-host disease. Here we describe a CD3 epsilon -associated complex on the facilitating cell surface that consists of the T-cell receptor beta -chain disulfide-linked to a previously unknown 33-kilodalton glycoprotein. Provisionally called FCp33, this glycoprotein does not represent any of the known protein chains or surrogates associated with CD3-T-cell receptor beta. Expression of this CD3-T-cell receptor beta -FCp33 complex directly correlates with the facilitating cell's functional ability to enhance allogeneic stem cell engraftment in vivo.	Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Thorac Surg, Boston, MA 02115 USA; Univ Pittsburgh, Med Ctr Hlth Syst, Dept Surg, Pittsburgh, PA 15261 USA; Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Harvard University; Dana-Farber Cancer Institute	Colson, YL (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Thorac Surg, Boston, MA 02115 USA.				NIAID NIH HHS [R29-AI4093] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALTIN JG, 1995, ANAL BIOCHEM, V224, P382, DOI 10.1006/abio.1995.1054; ARMITAGE JO, 1994, NEW ENGL J MED, V330, P827, DOI 10.1056/NEJM199403243301206; Barber DF, 1998, J IMMUNOL, V161, P11; BECKER MLB, 1989, CELL, V58, P911, DOI 10.1016/0092-8674(89)90943-4; Berger MA, 1997, J EXP MED, V186, P1461, DOI 10.1084/jem.186.9.1461; Chen B G, 1996, Transpl Immunol, V4, P158, DOI 10.1016/S0966-3274(96)80010-4; Drobyski W R, 1999, Biol Blood Marrow Transplant, V5, P222, DOI 10.1053/bbmt.1999.v5.pm10465102; El-Badri NS, 1998, EXP HEMATOL, V26, P110; Fowler DH, 1998, BLOOD, V91, P4045, DOI 10.1182/blood.V91.11.4045.411k17_4045_4050; Gaines BA, 1996, EXP HEMATOL, V24, P902; GALE RP, 1986, LANCET, V1, P1468; Gallardo D, 1997, BONE MARROW TRANSPL, V20, P945, DOI 10.1038/sj.bmt.1701008; GROETTRUP M, 1993, EUR J IMMUNOL, V23, P1393, DOI 10.1002/eji.1830230633; GROETTRUP M, 1992, EMBO J, V11, P2735, DOI 10.1002/j.1460-2075.1992.tb05339.x; GROETTRUP M, 1993, CELL, V75, P283, DOI 10.1016/0092-8674(93)80070-U; HOCHSTENBACH F, 1989, NATURE, V340, P562, DOI 10.1038/340562a0; ILDSTAD ST, 1984, NATURE, V307, P168, DOI 10.1038/307168a0; IOANNIDES CG, 1987, P NATL ACAD SCI USA, V84, P4244, DOI 10.1073/pnas.84.12.4244; JACOBS H, 1994, EUR J IMMUNOL, V24, P934, DOI 10.1002/eji.1830240423; KAUFMAN CL, 1994, BLOOD, V84, P2436; KISHI H, 1991, EMBO J, V10, P93, DOI 10.1002/j.1460-2075.1991.tb07924.x; Kosugi A, 1997, IMMUNOLOGY, V91, P618, DOI 10.1046/j.1365-2567.1997.00294.x; KUBO RT, 1989, J IMMUNOL, V142, P2336; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAPIDOT T, 1992, BLOOD, V80, P2406; LEY SC, 1989, EUR J IMMUNOL, V19, P2309, DOI 10.1002/eji.1830191220; MARRACK P, 1987, SCIENCE, V238, P1073, DOI 10.1126/science.3317824; MARTIN PJ, 1993, J EXP MED, V178, P703, DOI 10.1084/jem.178.2.703; MEIER T, 1992, ANAL BIOCHEM, V204, P220, DOI 10.1016/0003-2697(92)90165-4; MINAMI Y, 1987, P NATL ACAD SCI USA, V84, P2688, DOI 10.1073/pnas.84.9.2688; Modigliani Y, 1997, SCAND J IMMUNOL, V46, P117, DOI 10.1046/j.1365-3083.1997.d01-114.x; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; MURPHY WJ, 1992, J IMMUNOL, V148, P2953; MURPHY WJ, 1990, J IMMUNOL, V144, P3305; Neipp M, 1998, BLOOD, V92, P3177, DOI 10.1182/blood.V92.9.3177.421k51_3177_3188; OFARRELL PZ, 1977, CELL, V12, P1133, DOI 10.1016/0092-8674(77)90176-3; SAMELSON LE, 1985, CELL, V43, P223, DOI 10.1016/0092-8674(85)90027-3; SHINKAI Y, 1993, SCIENCE, V259, P822, DOI 10.1126/science.8430336; SPANGRUDE GJ, 1988, SCIENCE, V241, P58, DOI 10.1126/science.2898810; SYKES M, 1989, J IMMUNOL, V143, P3503; Tanaka Y, 1999, JPN J PSYCHOL, V70, P1, DOI 10.4992/jjpsy.70.1; vonBoehmer H, 1997, ANNU REV IMMUNOL, V15, P433, DOI 10.1146/annurev.immunol.15.1.433; WIEST DL, 1995, EMBO J, V14, P3425, DOI 10.1002/j.1460-2075.1995.tb07348.x	43	46	50	0	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	AUG	2000	6	8					904	909		10.1038/78667	http://dx.doi.org/10.1038/78667			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	376TX	10932228				2022-12-25	WOS:000165473800034
J	Shimizu, N; Sugimoto, K; Tang, JW; Nishi, T; Sato, I; Hiramoto, M; Aizawa, S; Hatakeyama, M; Ohba, R; Hatori, H; Yoshikawa, T; Suzuki, F; Oomori, A; Tanaka, H; Kawaguchi, H; Watanabe, H; Handa, H				Shimizu, N; Sugimoto, K; Tang, JW; Nishi, T; Sato, I; Hiramoto, M; Aizawa, S; Hatakeyama, M; Ohba, R; Hatori, H; Yoshikawa, T; Suzuki, F; Oomori, A; Tanaka, H; Kawaguchi, H; Watanabe, H; Handa, H			High-performance affinity beads for identifying drug receptors	NATURE BIOTECHNOLOGY			English	Article						affinity purification; NF-kappa B; Ref-1; FK506-binding protein (FKBP); FK506; drug receptor identification	PEPTIDYL-PROLYL ISOMERASE; IMMUNOSUPPRESSANT FK506; BINDING-PROTEIN; ACTIVATION; REDOX; PURIFICATION; EXPRESSION; LATEX	We have developed a method using novel latex beads for rapid identification of drug receptors using affinity purification. Composed of a glycidylmethacrylate (GMA) and styrene copolymer core with a GMA polymer surface, the beads minimize nonspecific protein binding and maximize purification efficiency. We demonstrated their performance by efficiently purifying FK506-binding protein using FK506-conjugated beads, and found that the amount of material needed was significantly reduced compared with previous methods. Using the latex beads, we identified a redox-related factor, Ref-1, as a target protein of an anti-NF-kappa B drug, E3330, demonstrating the existence of a new class of receptors of anti-NF-kappa B drugs. Our results suggest that the latex beads could provide a tool for the identification and analysis of drug receptors and should therefore be useful in drug development.	Tokyo Inst Technol, Fac Biosci & Biotechnol, Yokohama, Kanagawa 2268501, Japan; Nihon Univ, Sch Med, Dept Anat, Tokyo 1738601, Japan; Tokyo Inst Technol, Frontier Collaborat Res Ctr, Yokohama, Kanagawa 2268503, Japan; Mitsubishi Chem Corp, Inst Life Sci, Machida, Tokyo 1948511, Japan; Univ Tokyo, Inst Med Sci, Tokyo 1088639, Japan; Keio Univ, Fac Sci & Technol, Yokohama, Kanagawa 2238522, Japan	Tokyo Institute of Technology; Nihon University; Tokyo Institute of Technology; Mitsubishi Chemical Holdings Corporation; Mitsubishi Chemical; University of Tokyo; Keio University	Handa, H (corresponding author), Tokyo Inst Technol, Fac Biosci & Biotechnol, Yokohama, Kanagawa 2268501, Japan.		Watanabe, Hajime/S-8957-2019; WATANABE, Hajime/AAJ-8904-2021	Watanabe, Hajime/0000-0001-9657-6554				CUATRECA.P, 1968, P NATL ACAD SCI USA, V61, P636, DOI 10.1073/pnas.61.2.636; CUATRECASAS P, 1971, ANNU REV BIOCHEM, V40, P259, DOI 10.1146/annurev.bi.40.070171.001355; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; HARDING MW, 1989, NATURE, V341, P758, DOI 10.1038/341758a0; Hiramoto M, 1998, J IMMUNOL, V160, P810; Hogan JC, 1996, NATURE, V384, P17; Hoque M, 1999, J VIROL, V73, P7912, DOI 10.1128/JVI.73.9.7912-7915.1999; INOMATA Y, 1992, ANAL BIOCHEM, V206, P109, DOI 10.1016/S0003-2697(05)80018-1; INOMATA Y, 1994, J BIOMAT SCI-POLYM E, V5, P293, DOI 10.1163/156856294X00031; MATSUURA Y, 1987, J GEN VIROL, V68, P1233, DOI 10.1099/0022-1317-68-5-1233; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Nakamura H, 1997, ANNU REV IMMUNOL, V15, P351, DOI 10.1146/annurev.immunol.15.1.351; Sawada J, 1999, J BIOL CHEM, V274, P35475, DOI 10.1074/jbc.274.50.35475; SIEKIERKA JJ, 1989, NATURE, V341, P755, DOI 10.1038/341755a0; SPENCER DM, 1993, SCIENCE, V262, P1019, DOI 10.1126/science.7694365; WADA T, 1995, METHOD ENZYMOL, V254, P595; WATANABE H, 1990, EMBO J, V9, P841, DOI 10.1002/j.1460-2075.1990.tb08181.x; XANTHOUDAKIS S, 1994, P NATL ACAD SCI USA, V91, P23, DOI 10.1073/pnas.91.1.23; Zwacka RM, 1998, NAT MED, V4, P698, DOI 10.1038/nm0698-698	19	214	225	0	23	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	AUG	2000	18	8					877	881		10.1038/78496	http://dx.doi.org/10.1038/78496			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	342VX	10932159				2022-12-25	WOS:000088666800026
J	Pantaloni, D; Boujemaa, R; Didry, D; Gounon, P; Carlier, MF				Pantaloni, D; Boujemaa, R; Didry, D; Gounon, P; Carlier, MF			The Arp2/3 complex branches filament barbed ends: functional antagonism with capping proteins	NATURE CELL BIOLOGY			English	Article							ACTIN-BASED MOTILITY; ALDRICH-SYNDROME PROTEIN; LISTERIA-MONOCYTOGENES; CELL MOTILITY; SHIGELLA-FLEXNERI; N-WASP; NUCLEATION; POLYMERIZATION; DYNAMICS; GELSOLIN	The Arp2/3 complex is an essential regulator of actin polymerization in response to signalling and generates a dendritic array of filaments in lamellipodia. Here we show that the activated Arp2/3 complex interacts with the barbed ends of filaments to initiate barbed-end branching. Barbed-end branching by Arp2/3 quantitatively accounts for polymerization kinetics and for the length correlation of the branches of filaments observed by electron microscopy. Filament branching is Visualized at the surface of Listeria in a reconstituted motility assay. The functional antagonism between the Arp2/3 complex and capping proteins is essential in the maintenance of the steady state of actin assembly and actin-based motility.	CNRS, Lab Enzymol & Biochim Struct, F-91198 Gif Sur Yvette, France; Inst Pasteur, F-75724 Paris, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Carlier, MF (corresponding author), CNRS, Lab Enzymol & Biochim Struct, F-91198 Gif Sur Yvette, France.	carlier@lebs.cnrs-gif.fr		Boujemaa-Paterski, Rajaa/0000-0001-9645-387X				BORISY GG, IN PRESS CURR OPIN C; Carlier MF, 1999, J BIOL CHEM, V274, P33827, DOI 10.1074/jbc.274.48.33827; Carlier MF, 1998, CURR OPIN CELL BIOL, V10, P45, DOI 10.1016/S0955-0674(98)80085-9; Carlier MF, 1997, J MOL BIOL, V269, P459, DOI 10.1006/jmbi.1997.1062; CARLIER MF, J BIOL CHEM, V260, P6565; CASELLA JF, 1986, J BIOL CHEM, V261, P915; CUNNINGHAM CC, 1991, SCIENCE, V251, P1233, DOI 10.1126/science.1848726; Egile C, 1999, J CELL BIOL, V146, P1319, DOI 10.1083/jcb.146.6.1319; Gouin E, 1999, J CELL SCI, V112, P1697; HALSEY TC, 1994, PHYS REV LETT, V72, P1228, DOI 10.1103/PhysRevLett.72.1228; Higgs HN, 1999, J BIOL CHEM, V274, P32531, DOI 10.1074/jbc.274.46.32531; Higgs HN, 1999, BIOCHEMISTRY-US, V38, P15212, DOI 10.1021/bi991843+; Huang M, 1999, CURR BIOL, V9, P979, DOI 10.1016/S0960-9822(99)80428-X; HUG C, 1995, CELL, V81, P591, DOI 10.1016/0092-8674(95)90080-2; KOUYAMA T, 1981, EUR J BIOCHEM, V114, P33; Kuhlman PA, 1997, BIOCHEMISTRY-US, V36, P13461, DOI 10.1021/bi970601b; Laine RO, 1998, INFECT IMMUN, V66, P3775, DOI 10.1128/IAI.66.8.3775-3782.1998; Laurent V, 1999, J CELL BIOL, V144, P1245, DOI 10.1083/jcb.144.6.1245; Loisel TP, 1999, NATURE, V401, P613, DOI 10.1038/44183; Machesky LM, 1999, P NATL ACAD SCI USA, V96, P3739, DOI 10.1073/pnas.96.7.3739; Machesky LM, 1998, CURR BIOL, V8, P1347, DOI 10.1016/S0960-9822(98)00015-3; Mullins RD, 1998, P NATL ACAD SCI USA, V95, P6181, DOI 10.1073/pnas.95.11.6181; PANTALONI D, 1993, CELL, V75, P1009; POLLARD TD, 1986, ANNU REV BIOCHEM, V55, P987, DOI 10.1146/annurev.bi.55.070186.005011; Ressad F, 1999, J BIOL CHEM, V274, P20970, DOI 10.1074/jbc.274.30.20970; Rohatgi R, 1999, CELL, V97, P221, DOI 10.1016/S0092-8674(00)80732-1; Schafer DA, 1995, ANNU REV CELL DEV BI, V11, P497, DOI 10.1146/annurev.cellbio.11.1.497; SMALL JV, 1995, TRENDS CELL BIOL, V5, P52, DOI 10.1016/S0962-8924(00)88939-4; SUN HQ, 1995, J CELL BIOL, V129, P147, DOI 10.1083/jcb.129.1.147; Sun HQ, 1999, J BIOL CHEM, V274, P33179, DOI 10.1074/jbc.274.47.33179; Svitkina TM, 1999, J CELL BIOL, V145, P1009, DOI 10.1083/jcb.145.5.1009; THERIOT JA, 1991, NATURE, V352, P126, DOI 10.1038/352126a0; THERIOT JA, 1992, NATURE, V357, P257, DOI 10.1038/357257a0; Welch MD, 1998, SCIENCE, V281, P105, DOI 10.1126/science.281.5373.105; Winter D, 1999, CURR BIOL, V9, P501, DOI 10.1016/S0960-9822(99)80218-8; Yarar D, 1999, CURR BIOL, V9, P555, DOI 10.1016/S0960-9822(99)80243-7	36	198	202	0	6	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	JUL	2000	2	7					385	391		10.1038/35017011	http://dx.doi.org/10.1038/35017011			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	333MK	10878802				2022-12-25	WOS:000088133700013
J	Kreda, SM; Pickles, RJ; Lazarowski, ER; Boucher, RC				Kreda, SM; Pickles, RJ; Lazarowski, ER; Boucher, RC			G-protein-coupled receptors as targets for gene transfer vectors using natural small-molecule ligands	NATURE BIOTECHNOLOGY			English	Article						gene therapy; G-protein-coupled receptor; P2Y(2) receptor; ligand conjugates; adenoviral vector retargeting	AGONIST-INDUCED INTERNALIZATION; DIFFERENTIATED AIRWAY EPITHELIUM; SMOOTH-MUSCLE CELLS; CYSTIC-FIBROSIS; MEDIATED INTERNALIZATION; ADENOASSOCIATED VIRUS; ADENOVIRUS VECTORS; P2Y(2) RECEPTOR; EFFICIENCY; ENTRY	Gene therapy for cystic fibrosis (CF) has focused on correcting electrolyte transport in airway epithelia. However, success has been limited by the failure of vectors to attach and enter into airway epithelia, and may require redirecting vectors to targets on the apical membrane of airway cells that mediate these functions, The G-protein-coupled P2Y(2) receptor (P2Y(2)-R) is abundantly expressed on the airway lumenal surface and internalizes into coated pits upon agonist activation. We tested whether a small-molecule-agonist (UTP) could direct vectors to P2Y(2)-R and mediate attachment, internalization, and gene transfer, Fluorescein-UTP studies demonstrated that P2Y(2)-R agonists internalized with their receptor, and biotinylated UTP (BUTP) mediated P2Y(2)-R-specific internalization of fluorescently labeled streptavidin (SAF) or SAF conjugated to biotinylated Cy3 adenoviral-vector (BCAV). BUTP conjugated to BCAV mediated P2Y(2)-R-specific gene transfer in (1) adenoviral-resistant A9 and polarized MDCK cells by means of heterologous P2Y(2)-R, and (2) well-differentiated human airway epithelial cells by means of endogenous P2Y(2)-R. Targeting vectors with small-molecule-ligands to apical membrane G-protein-coupled receptors may be a feasible approach for successful CF gene therapy.	Univ N Carolina, CF Pulm Res & Treatment Ctr, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill	Kreda, SM (corresponding author), Univ N Carolina, CF Pulm Res & Treatment Ctr, Chapel Hill, NC 27599 USA.		Core, Vector/CAF-4832-2022		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL034322] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL34322, HL51818] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Arcasoy SM, 1997, AM J RESP CELL MOL, V17, P422, DOI 10.1165/ajrcmb.17.4.2714; Bais R, 1999, J VIROL, V73, P6085, DOI 10.1128/JVI.73.7.6085-6088.1999; Bergelson JM, 1997, SCIENCE, V275, P1320, DOI 10.1126/science.275.5304.1320; Boucher RC, 1996, TRENDS GENET, V12, P81, DOI 10.1016/0168-9525(96)81410-7; Boucher RC, 1999, J CLIN INVEST, V103, P441, DOI 10.1172/JCI6330; Fukushima Y, 1997, J BIOL CHEM, V272, P19464, DOI 10.1074/jbc.272.31.19464; GRUBB BR, 1994, NATURE, V371, P802, DOI 10.1038/371802a0; Hoganson DK, 1998, HUM GENE THER, V9, P2565, DOI 10.1089/10430349850019409; ICHER M, 1998, PEDIATR PULM, V17, P288; Johnson LG, 1996, HUM GENE THER, V7, P51, DOI 10.1089/hum.1996.7.1-51; JOHNSON LG, 1992, NAT GENET, V2, P21, DOI 10.1038/ng0992-21; LAZAROWSKI ER, 1995, BRIT J PHARMACOL, V116, P1619, DOI 10.1111/j.1476-5381.1995.tb16382.x; Lazarowski ER, 1997, P NATL ACAD SCI USA, V94, P2599, DOI 10.1073/pnas.94.6.2599; LeGouill C, 1997, J BIOL CHEM, V272, P21289, DOI 10.1074/jbc.272.34.21289; Leopold PL, 1998, HUM GENE THER, V9, P367, DOI 10.1089/hum.1998.9.3-367; MASON SJ, 1991, BRIT J PHARMACOL, V103, P1649, DOI 10.1111/j.1476-5381.1991.tb09842.x; Matsui H, 1998, CELL, V95, P1005, DOI 10.1016/S0092-8674(00)81724-9; Matsui H, 1997, J BIOL CHEM, V272, P1117, DOI 10.1074/jbc.272.2.1117; Mayr GA, 1997, J VIROL, V71, P412, DOI 10.1128/JVI.71.1.412-418.1997; MUNOZ CM, 1993, ARCH BIOCHEM BIOPHYS, V301, P336, DOI 10.1006/abbi.1993.1153; MUNOZ CM, 1992, J BIOL CHEM, V267, P303; Olivier KN, 1996, AM J RESP CRIT CARE, V154, P217, DOI 10.1164/ajrccm.154.1.8680683; PARADISO AM, 1995, NATURE, V377, P643, DOI 10.1038/377643a0; PARR CE, 1994, P NATL ACAD SCI USA, V91, P3275, DOI 10.1073/pnas.91.8.3275; PERKINS JP, 1991, BETA ADRENERGIC RECE, P73; Pickles RJ, 1998, J VIROL, V72, P6014, DOI 10.1128/JVI.72.7.6014-6023.1998; Pickles RJ, 1996, HUM GENE THER, V7, P921, DOI 10.1089/hum.1996.7.8-921; Pohl M, 1997, J BIOL CHEM, V272, P18179, DOI 10.1074/jbc.272.29.18179; Robinson Graham, 1996, P585; Sromek SM, 1998, MOL PHARMACOL, V54, P485, DOI 10.1124/mol.54.3.485; Teramoto S, 1998, J VIROL, V72, P8904, DOI 10.1128/JVI.72.11.8904-8912.1998; THOMAS WG, 1995, J BIOL CHEM, V270, P22153, DOI 10.1074/jbc.270.38.22153; Welsh MJ, 1995, METABOLIC MOL BASES, V3, P3799; WICKHAM TJ, 1993, CELL, V73, P309, DOI 10.1016/0092-8674(93)90231-E; Zabner J, 1996, J VIROL, V70, P6994, DOI 10.1128/JVI.70.10.6994-7003.1996	35	39	42	0	7	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUN	2000	18	6					635	640		10.1038/76479	http://dx.doi.org/10.1038/76479			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	325EK	10835601				2022-12-25	WOS:000087663200023
J	Zhao, XY; Malloy, PJ; Krishnan, AV; Swami, S; Navone, NM; Peehl, DM; Feldman, D				Zhao, XY; Malloy, PJ; Krishnan, AV; Swami, S; Navone, NM; Peehl, DM; Feldman, D			Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor	NATURE MEDICINE			English	Article							GENE-MUTATIONS; LNCAP CELLS; EXPRESSION; CORTISOL; ANTIGEN; MODEL	The androgen receptor (AR) is involved in the development, growth and progression of prostate cancer(1) (CaP). CaP often progresses from an androgen-dependent to an androgen-independent tumor, making androgen ablation therapy ineffective. However, the mechanisms for the development of androgen-independent CaP are unclear. More than 80% of clinically androgen-independent prostate tumors show high levels of AR expression(1). In some CaPs, AR levels are increased because of gene amplification(2) and/or overexpression, whereas in others, the AR is mutated(3-5). Nonetheless, the involvement of the AR in the transition of CaP to androgen-independent growth and the subsequent failure of endocrine therapy are not fully understood. Here we show that in CaP cells from a patient who failed androgen ablation therapy, a doubly mutated AR functioned as a high-affinity cortisol/cortisone receptor (AR(ccr)). Cortisol, the main circulating glucocorticoid, and its metabolite, cortisone, both equally stimulate the growth of these CaP cells and increase the secretion of prostate-specific antigen in the absence of androgens. The physiological concentrations of free cortisol and total cortisone in men(6,7) greatly exceed the binding affinity of the androgen and cortisol/cortisone receptor (AR(ccr)) and would activate the receptor, promoting CaP cell proliferation. Our data demonstrate a previously unknown mechanism for the androgen-independent growth of advanced CaP. Understanding this mechanism and recognizing the presence of glucocorticoid-responsive AR mutants are important for the development of new forms of therapy for the treatment of this subset of CaP.	Stanford Univ, Sch Med, Dept Med, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Urol, Stanford, CA 94305 USA; Univ Texas, MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX 77030 USA	Stanford University; Stanford University; University of Texas System; UTMD Anderson Cancer Center	Feldman, D (corresponding author), Stanford Univ, Sch Med, Dept Med, Stanford, CA 94305 USA.							Cleutjens CBJM, 1997, ENDOCRINOLOGY, V138, P5293, DOI 10.1210/en.138.12.5293; GADDIPATI JP, 1994, CANCER RES, V54, P2861; Gottlieb B, 1999, HUM MUTAT, V14, P103, DOI 10.1002/(SICI)1098-1004(1999)14:2<103::AID-HUMU2>3.0.CO;2-A; HOLLENBERG SM, 1985, NATURE, V318, P635, DOI 10.1038/318635a0; HOROSZEWICZ JS, 1983, CANCER RES, V43, P1809; LUBAHN DB, 1989, P NATL ACAD SCI USA, V86, P9534, DOI 10.1073/pnas.86.23.9534; Navone NM, 1997, CLIN CANCER RES, V3, P2493; Oakley RH, 1997, ENDOCRINOLOGY, V138, P5028, DOI 10.1210/en.138.11.5028; Roux S, 1996, MOL ENDOCRINOL, V10, P1214, DOI 10.1210/me.10.10.1214; STAMEY TA, 1987, NEW ENGL J MED, V317, P909, DOI 10.1056/NEJM198710083171501; SUZUKI H, 1993, J STEROID BIOCHEM, V46, P759, DOI 10.1016/0960-0760(93)90316-O; TAPLIN ME, 1995, NEW ENGL J MED, V332, P1393, DOI 10.1056/NEJM199505253322101; Trapman J, 1996, PATHOL RES PRACT, V192, P752, DOI 10.1016/S0344-0338(96)80097-5; VanCauter E, 1996, J CLIN ENDOCR METAB, V81, P2468, DOI 10.1210/jc.81.7.2468; VELDSCHOLTE J, 1990, BIOCHEM BIOPH RES CO, V173, P534, DOI 10.1016/S0006-291X(05)80067-1; VISAKORPI T, 1995, NAT GENET, V9, P401, DOI 10.1038/ng0495-401; Walker BR, 1997, J CLIN ENDOCR METAB, V82, P4015, DOI 10.1210/jc.82.12.4015; WARRIAR N, 1994, BIOCHEMISTRY-US, V33, P12837, DOI 10.1021/bi00209a015; Watanabe M, 1997, JPN J CLIN ONCOL, V27, P389, DOI 10.1093/jjco/27.6.389; Zhao XY, 1999, J UROLOGY, V162, P2192, DOI 10.1016/S0022-5347(05)68158-X	20	409	429	2	14	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUN	2000	6	6					703	706		10.1038/76287	http://dx.doi.org/10.1038/76287			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	321CX	10835690				2022-12-25	WOS:000087438300044
J	Xu, X; Peng, M; Fang, Z; Xu, XP				Xu, X; Peng, M; Fang, Z; Xu, XP			The direction of microsatellite mutations is dependent upon allele length	NATURE GENETICS			English	Article							REPEAT LOCI; INSTABILITY; FREQUENCIES; EVOLUTION; MODEL; YEAST; SIZE	Microsatellites, comprising tandemly repeated short nucleotide sequences, are ubiquitous in eukaryotic: genomes. Mutations within microsatellites are frequent, altering their overall length by insertion or deletion of a small number of repeat units, with a rate as high as 10(-3) in humans(1). Despite their high mutability, stable allele frequency distributions are typically observed for microsatellites in humans as well as other primates(2,3), although the mechanism maintaining these stable distributions remains unclear. Previous studies have suggested that microsatellite mutations occur more frequently in longer alleles and favour expansion(4-8). Generalizing these results has been hindered because the sample sizes were small, only a small subset of alleles for any marker was studied and the direction of mutation (expansion or contraction) was not rigorously determined. Here we examine 236 mutations at 122 tetranucleotide repeat markers and find that the rate of contraction mutations increases exponentially with allele size. whereas the rate of expansion mutations is constant across the entire allele distribution. The overall rate of expansion mutations does not differ from that of contractions. Our findings offer an explanation for the stationary allele distribution of microsatellites.	Harvard Univ, Sch Publ Hlth, Program Populat Genet, Boston, MA 02115 USA; Anhui Med Univ, Inst Biomed, Hefei, Anhui, Peoples R China	Harvard University; Harvard T.H. Chan School of Public Health; Anhui Medical University	Xu, X (corresponding author), Harvard Univ, Sch Publ Hlth, Program Populat Genet, 665 Huntington Ave, Boston, MA 02115 USA.		Xu, Xin/A-1687-2016	Xu, Xin/0000-0002-6324-5211				Amos W, 1996, NAT GENET, V13, P390, DOI 10.1038/ng0896-390; Brinkmann B, 1998, AM J HUM GENET, V62, P1408, DOI 10.1086/301869; DIRIENZO A, 1994, P NATL ACAD SCI USA, V91, P3166, DOI 10.1073/pnas.91.8.3166; GARZA JC, 1995, MOL BIOL EVOL, V12, P594; Goldstein DB, 1997, J HERED, V88, P335, DOI 10.1093/oxfordjournals.jhered.a023114; Horvath S, 1998, AM J HUM GENET, V63, P1886, DOI 10.1086/302137; Kimmel M, 1996, THEOR POPUL BIOL, V50, P345, DOI 10.1006/tpbi.1996.0035; Kruglyak L, 1996, AM J HUM GENET, V58, P1347; LEVINSON G, 1987, MOL BIOL EVOL, V4, P203; Primmer CR, 1996, NAT GENET, V13, P391, DOI 10.1038/ng0896-391; Sia EA, 1997, MOL CELL BIOL, V17, P2851, DOI 10.1128/MCB.17.5.2851; Twerdi CD, 1999, P NATL ACAD SCI USA, V96, P2875, DOI 10.1073/pnas.96.6.2875; VALDES AM, 1993, GENETICS, V133, P737; WEBER JL, 1993, HUM MOL GENET, V2, P1123, DOI 10.1093/hmg/2.8.1123; Wierdl M, 1997, GENETICS, V146, P769; Xu XP, 1999, AM J HUM GENET, V64, P1694, DOI 10.1086/302405; ZHIVOTOVSKY LA, 1995, P NATL ACAD SCI USA, V92, P11549, DOI 10.1073/pnas.92.25.11549	17	280	304	1	20	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	APR	2000	24	4					396	399		10.1038/74238	http://dx.doi.org/10.1038/74238			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	299HK	10742105				2022-12-25	WOS:000086192800020
J	Oldridge, M; Fortuna, AM; Maringa, M; Propping, P; Mansour, S; Pollitt, C; DeChiara, TM; Kimble, RB; Valenzuela, DM; Yancopoulos, GD; Wilkie, AOM				Oldridge, M; Fortuna, AM; Maringa, M; Propping, P; Mansour, S; Pollitt, C; DeChiara, TM; Kimble, RB; Valenzuela, DM; Yancopoulos, GD; Wilkie, AOM			Dominant mutations in ROR2, encoding an orphan receptor tyrosine kinase, cause brachydactyly type B	NATURE GENETICS			English	Article							MAP; FAMILY; FGFR2	Inherited limb malformations provide a valuable resource for the identification of genes involved in limb development(1,2). Brachydactyly type B (BDB), an autosomal dominant disorder, is the most severe of the brachydactylies(3) and characterized by terminal deficiency of the fingers and toes. In the typical form of BDB, the thumbs and big toes are spared, sometimes with broadening or partial duplication(4-8). The BDB1 locus was previously mapped to chromosome 9q22 within an interval of 7.5 cM (refs 9, 10). Here we describe mutations in ROR2, which encodes the orphan receptor tyrosine kinase ROR2 (ref. 11), in three unrelated families with BDB1. We identified distinct heterozygous mutations (2 nonsense, 1 frameshift) within a 7-amino-acid segment of the 943-amino-acid protein, all of which predict truncation of the intracellular portion of the protein immediately after the tyrosine kinase domain. The localized nature of these mutations suggests that they confer a specific gain of function. We obtained further evidence for this by demonstrating that two patients heterozygous for 9q22 deletions including ROR2 do not exhibit BDB. Expression of the mouse orthologue, Ror2, early in limb development indicates that BDB arises as a primary defect of skeletal patterning.	John Radcliffe Hosp, Inst Mol Med, Oxford OX3 9DU, England; Inst Med Genet, Porto, Portugal; Univ Bonn, Inst Human Genet, D-5300 Bonn, Germany; Univ London St Georges Hosp, Sch Med, SW Thames Reg Genet Serv, London SW17 0RE, England; Royal Victoria Infirm, No Reg Genet Serv, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England; Regeneron Pharmaceut Inc, Tarrytown, NY 10591 USA	University of Oxford; University of Bonn; St Georges University London; Newcastle University - UK; Regeneron	Wilkie, AOM (corresponding author), John Radcliffe Hosp, Inst Mol Med, Oxford OX3 9DU, England.		Wilkie, Andrew/AAC-3820-2020	Wilkie, Andrew/0000-0002-2972-5481; Fortuna, Ana/0000-0002-1296-5366				AFZAL AR, IN PRESS HUM GENET; BATTLE HI, 1973, ANN HUM GENET, V36, P415, DOI 10.1111/j.1469-1809.1973.tb00605.x; Blair IP, 1998, GENOMICS, V51, P277, DOI 10.1006/geno.1998.5373; DeChiara TM, 2000, NAT GENET, V24, P271, DOI 10.1038/73488; DEGENHARDT KH, 1954, Z MENSCHLICHE VERERB, V32, P227; Deloukas P, 1998, SCIENCE, V282, P744, DOI 10.1126/science.282.5389.744; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; FITCH N, 1979, J MED GENET, V16, P36, DOI 10.1136/jmg.16.1.36; Forrester WC, 1999, NATURE, V400, P881, DOI 10.1038/23722; Gong YQ, 1999, AM J HUM GENET, V64, P570, DOI 10.1086/302249; Houlston R S, 1994, Clin Dysmorphol, V3, P224; Innis JW, 1998, CLIN GENET, V53, P337; MacARTHUR J. W., 1932, HUMAN BIOL, V4, P179; MALLOCH JD, 1957, ANN HUM GENET, V22, P36, DOI 10.1111/j.1469-1809.1957.tb01297.x; Manouvrier-Hanu S, 1999, TRENDS GENET, V15, P409, DOI 10.1016/S0168-9525(99)01823-5; MASIAKOWSKI P, 1992, J BIOL CHEM, V267, P26181; Oishi I, 1999, GENES CELLS, V4, P41, DOI 10.1046/j.1365-2443.1999.00234.x; Oishi I, 1997, J BIOL CHEM, V272, P11916, DOI 10.1074/jbc.272.18.11916; Oldridge M, 1997, HUM MOL GENET, V6, P137, DOI 10.1093/hmg/6.1.137; Oldridge M, 1999, AM J HUM GENET, V64, P578, DOI 10.1086/302255; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; WILKIE AOM, 1995, NAT GENET, V9, P165, DOI 10.1038/ng0295-165; WILSON C, 1993, P NATL ACAD SCI USA, V90, P7109, DOI 10.1073/pnas.90.15.7109	23	161	181	0	4	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAR	2000	24	3					275	278		10.1038/73495	http://dx.doi.org/10.1038/73495			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	288XW	10700182				2022-12-25	WOS:000085590600019
J	Anderson, DE; Bieganowska, KD; Bar-Or, A; Oliveira, EML; Carreno, B; Collins, M; Hafler, DA				Anderson, DE; Bieganowska, KD; Bar-Or, A; Oliveira, EML; Carreno, B; Collins, M; Hafler, DA			Paradoxical inhibition of T-cell function in response to CTLA-4 blockade; heterogeneity within the human T-cell population	NATURE MEDICINE			English	Article							MULTIPLE-SCLEROSIS; COSTIMULATION; COEXPRESSION; ACTIVATION; INFECTION; PEPTIDE; CLONES; B7-1; CD28; VIVO	T-cell co-stimulation delivered by the molecules B7-1 or B7-2 through CD28 has a positive effect on T-cell activation(1), whereas engagement of cytotoxic T-lymphocyte antigen 4 (CTLA-4) by these molecules inhibits activation(2). In vivo administration to mice of blocking monoclonal antibodies or Fab fragments against CTLA-4 can augment antigen-specific T-cell responses(3,4) and, thus, therapy with monoclonal antibody against CTLA-4 has potential applications for tumor therapy and enhancement of vaccine immunization(5-7). The effects of B7-1 and B7-2 co-stimulation through CD28 depend on the strength of the signal delivered through the T-cell receptor (TCR)(8,9) and the activation state of T cells during activation(10,11). Thus, we sought to determine whether these factors similarly influence the effect of B7-mediated signals delivered through CTLA-4 during T-cell activation. Using freshly isolated human T cells and Fab fragments of a monoclonal antibody against CTLA-4 we demonstrate here that CTLA-4 blockade can enhance or inhibit the clonal expansion of different T cells that respond to the same antigen, depending on both the T-cell activation state and the strength of the T-cell receptor signal delivered during T-cell stimulation. Thus, for whole T-cell populations, blocking a negative signal may paradoxically inhibit immune responses. These results provide a theoretical framework for clinical trials in which co-stimulatory signals are manipulated in an attempt to modulate the immune response in human disease.	Harvard Univ, Sch Med, Div Med Sci, Comm Immunol, Boston, MA 02115 USA; Brigham & Womens Hosp, Ctr Neurol Dis, Boston, MA 02115 USA; Genet Inst, Cambridge, MA 02140 USA	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	Hafler, DA (corresponding author), Harvard Univ, Sch Med, Div Med Sci, Comm Immunol, Boston, MA 02115 USA.		Oliveira, Enedina M.L/B-2720-2016; Bar-Or, Amit/C-4213-2011	Oliveira, Enedina M.L/0000-0002-4939-7200; 	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052127] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS024247] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01DK52127] Funding Source: Medline; NINDS NIH HHS [R01NS2424710A2] Funding Source: Medline; PHS HHS [IPO1A139671-03] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Anderson DE, 1997, J IMMUNOL, V159, P1669; AZUMA M, 1993, NATURE, V366, P76, DOI 10.1038/366076a0; Bieganowska KD, 1997, J EXP MED, V185, P1585, DOI 10.1084/jem.185.9.1585; Fields PE, 1998, J IMMUNOL, V161, P5268; HATHCOCK KS, 1994, J EXP MED, V180, P631, DOI 10.1084/jem.180.2.631; Jeannin P, 1999, J IMMUNOL, V162, P2044; KEARNEY ER, 1995, J IMMUNOL, V155, P1032; Kwon ED, 1997, P NATL ACAD SCI USA, V94, P8099, DOI 10.1073/pnas.94.15.8099; LASALLE JM, 1991, CELL IMMUNOL, V138, P197, DOI 10.1016/0008-8749(91)90144-Z; Lenschow DJ, 1996, ANNU REV IMMUNOL, V14, P233, DOI 10.1146/annurev.immunol.14.1.233; LINSLEY PS, 1992, J EXP MED, V176, P1595, DOI 10.1084/jem.176.6.1595; Lovett-Racke AE, 1998, J CLIN INVEST, V101, P725, DOI 10.1172/JCI1528; McCoy K, 1997, J EXP MED, V186, P183, DOI 10.1084/jem.186.2.183; Metz DP, 1998, J IMMUNOL, V161, P5855; Murphy ML, 1998, J IMMUNOL, V161, P4153; Rissoan MC, 1999, SCIENCE, V283, P1183, DOI 10.1126/science.283.5405.1183; Saha B, 1998, EUR J IMMUNOL, V28, P4213, DOI 10.1002/(SICI)1521-4141(199812)28:12&lt;4213::AID-IMMU4213&gt;3.0.CO;2-C; Scholz C, 1998, J IMMUNOL, V160, P1532; Thompson CB, 1997, IMMUNITY, V7, P445, DOI 10.1016/S1074-7613(00)80366-0; Walunas TL, 1998, J IMMUNOL, V160, P3855; WUCHERPFENNIG KW, 1994, J EXP MED, V179, P279, DOI 10.1084/jem.179.1.279	21	58	92	0	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	FEB	2000	6	2					211	214		10.1038/72323	http://dx.doi.org/10.1038/72323			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	278YQ	10655112				2022-12-25	WOS:000085016900044
J	Kale, S; Biermann, S; Edwards, C; Tarnowski, C; Morris, M; Long, MW				Kale, S; Biermann, S; Edwards, C; Tarnowski, C; Morris, M; Long, MW			Three-dimensional cellular development is essential for ex vivo formation of human bone	NATURE BIOTECHNOLOGY			English	Article						osteogenesis; bone-formation; ex vivo; three-dimensional; tissue aggregates	MESENCHYMAL PROGENITOR CELLS; DIFFERENTIATION IN-VITRO; COLLAGEN-SYNTHESIS; RAT BONE; EXPRESSION; PROTEINS; CHONDROGENESIS; OSTEOGENESIS; CULTURES; GROWTH	Tissue engineering of human bone is a complex process, as the functional development of bone cells requires that regulatory signals be temporally and spatially ordered. The role of three-dimensional cellular interactions is well understood in embryonic osteogenesis, but in vitro correlates are lacking. Here we report that in vitro serum-free transforming growth factor (TGF)-beta 1 stimulation of osteogenic cells immediately after passage results in the formation of three-dimensional cellular condensations (bone cell spheroids) within 24 to 48 hours. In turn, bone cell spheroid formation results in the up-regulation of several bone-related proteins (e.g., alkaline phosphatase, type I collagen, osteonectin) during days 3-7, and the concomitant formation of micro-crystalline bone. This system of ex vivo bone formation should provide important information on the physiological, biological and molecular basis of osteogenesis.	Univ Michigan, Dept Pediat, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Surg, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Chem, Ann Arbor, MI 48109 USA; Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Long, MW (corresponding author), Univ Michigan, Dept Pediat, Ann Arbor, MI 48109 USA.		Morris, Michael D/A-9327-2009		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059495] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 59495] Funding Source: Medline; NIA NIH HHS [AG 43460] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		CENTRELLA M, 1987, J BIOL CHEM, V262, P2869; DENKER AE, 1995, DIFFERENTIATION, V59, P25, DOI 10.1046/j.1432-0436.1995.5910025.x; Ducy P, 1996, NATURE, V382, P448, DOI 10.1038/382448a0; DUNLOP LLT, 1995, INT J DEV BIOL, V39, P357; FANG JM, 1995, INT J DEV BIOL, V39, P519; FEDARKO NS, 1992, J CELL PHYSIOL, V151, P215, DOI 10.1002/jcp.1041510202; FRANCESCHI RT, 1988, J BIOL CHEM, V263, P18938; Gronthos S, 1997, J BONE MINER RES, V12, P1189, DOI 10.1359/jbmr.1997.12.8.1189; Hall BK, 1995, INT J DEV BIOL, V39, P881; Hunter GK, 1996, BIOCHEM J, V317, P59, DOI 10.1042/bj3170059; Johnstone B, 1998, EXP CELL RES, V238, P265, DOI 10.1006/excr.1997.3858; Johnstone B, 1999, CLIN ORTHOP RELAT R, pS156, DOI 10.1097/00003086-199910001-00017; LIAN JB, 1992, CRIT REV ORAL BIOL M, V3, P269, DOI 10.1177/10454411920030030501; LONG MW, 1990, J CLIN INVEST, V86, P1387, DOI 10.1172/JCI114852; LONG MW, 1995, J CLIN INVEST, V95, P881, DOI 10.1172/JCI117738; MALAVAL L, 1994, J CELL PHYSIOL, V158, P555, DOI 10.1002/jcp.1041580322; MENDELSOHN R, 1989, CALCIFIED TISSUE INT, V44, P20, DOI 10.1007/BF02556236; Moursi AM, 1997, J CELL SCI, V110, P2187; PASTOUREAU P, 1993, J BONE MINER RES, V8, P1417; Timlin JA, 1999, J BIOMED OPT, V4, P28, DOI 10.1117/1.429918; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WONG M, 1995, DEV BIOL, V167, P130, DOI 10.1006/dbio.1995.1012; Woodward WA, 1999, DEV GENET, V24, P178, DOI 10.1002/(SICI)1520-6408(1999)24:1/2<178::AID-DVG16>3.0.CO;2-M; Yoo JU, 1998, J BONE JOINT SURG AM, V80A, P1745, DOI 10.2106/00004623-199812000-00004	24	219	238	6	36	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	SEP	2000	18	9					954	958		10.1038/79439	http://dx.doi.org/10.1038/79439			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	350AN	10973215				2022-12-25	WOS:000089078300023
J	Ikemoto, M; Takita, M; Imamura, T; Inoue, K				Ikemoto, M; Takita, M; Imamura, T; Inoue, K			Increased sensitivity to the stimulant effects of morphine conferred by anti-adhesive glycoprotein SPARC in amygdala	NATURE MEDICINE			English	Article							VENTRAL TEGMENTAL AREA; MU-OPIOID-RECEPTOR; EXTRACELLULAR-MATRIX GLYCOPROTEIN; NUCLEUS-ACCUMBENS; BEHAVIORAL SENSITIZATION; IMMUNOHISTOCHEMICAL LOCALIZATION; MOLECULAR-CLONING; REVERSE TOLERANCE; PREFRONTAL CORTEX; PROTEIN-SYNTHESIS	Repeated administration of morphine substantially increases its locomotor-enhancing activity, a phenomenon termed locomotor sensitization. Here we show that secreted protein acidic and rich in cysteine (SPARC), an anti-adhesive glycoprotein present in the basolateral amygdala, contributes to the establishment of locomotor sensitization. The morphine-induced increase in SPARC levels in the basolateral amygdala persisted after morphine withdrawal and coincided with the duration of locomotor sensitization. Moreover, a single injection of morphine after SPARC infusion into the basolateral amygdala of previously uninjected mice substantially enhanced locomotor activity. Thus, SPARC may be an important element for establishing locomotor sensitization to morphine.	Minist Int Trade & Ind, Agcy Ind Sci & Technol, Natl Inst Biosci & Human Technol, Dept Biomol Engn, Tsukuba, Ibaraki 3058566, Japan; Minist Int Trade & Ind, Agcy Ind Sci & Technol, Natl Inst Biosci & Human Technol, Dept Biosignaling, Tsukuba, Ibaraki 3058566, Japan	National Institute of Advanced Industrial Science & Technology (AIST); National Institute of Advanced Industrial Science & Technology (AIST)	Ikemoto, M (corresponding author), Minist Int Trade & Ind, Agcy Ind Sci & Technol, Natl Inst Biosci & Human Technol, Dept Biomol Engn, 1-1 Higashi, Tsukuba, Ibaraki 3058566, Japan.		IKEMOTO, Mitsushi J/L-8861-2018; Takita, Masatoshi/N-3378-2016	IKEMOTO, Mitsushi J/0000-0001-5799-0672; Takita, Masatoshi/0000-0003-1140-5268				Akirav I, 1999, NEUROSCI LETT, V270, P83, DOI 10.1016/S0304-3940(99)00488-7; Bassuk JA, 1996, ARCH BIOCHEM BIOPHYS, V325, P8, DOI 10.1006/abbi.1996.0002; BRADY LS, 1981, PHARMACOL BIOCHEM BE, V14, P361, DOI 10.1016/0091-3057(81)90403-2; BUNNEY WC, 1984, PSYCHOPHARMACOLOGY, V82, P318, DOI 10.1007/BF00427677; Carlezon WA, 1997, SCIENCE, V277, P812, DOI 10.1126/science.277.5327.812; Collins DR, 1999, J NEUROSCI, V19, P836; CRISWELL HE, 1990, BRAIN RES, V512, P284, DOI 10.1016/0006-8993(90)90638-R; Ding YQ, 1996, J COMP NEUROL, V367, P375; DOU CL, 1994, J NEUROSCI, V14, P7616; ELLINWOO.EH, 1971, SCIENCE, V171, P420, DOI 10.1126/science.171.3969.420; GUITART X, 1992, J NEUROCHEM, V58, P1168, DOI 10.1111/j.1471-4159.1992.tb09377.x; Hatfield T, 1996, J NEUROSCI, V16, P5256; IKEMOTO M, 1995, NEUROREPORT, V6, P262, DOI 10.1097/00001756-199501000-00009; JOHNSTON IG, 1990, NEURON, V4, P165, DOI 10.1016/0896-6273(90)90452-L; KANETO H, 1973, JPN J PHARMACOL, V23, P701, DOI 10.1254/jjp.23.701; KARLER R, 1993, BRAIN RES, V603, P19, DOI 10.1016/0006-8993(93)91294-3; KARLER R, 1989, LIFE SCI, V45, P599, DOI 10.1016/0024-3205(89)90045-3; KELLEY AE, 1982, NEUROSCIENCE, V7, P615, DOI 10.1016/0306-4522(82)90067-7; Killcross S, 1997, NATURE, V388, P377, DOI 10.1038/41097; KURIBARA H, 1989, JPN J PHARMACOL, V49, P197, DOI 10.1254/jjp.49.197; MANN K, 1987, FEBS LETT, V218, P167, DOI 10.1016/0014-5793(87)81040-2; MANSOUR A, 1995, J CHEM NEUROANAT, V8, P283, DOI 10.1016/0891-0618(95)00055-C; MASON IJ, 1986, EMBO J, V5, P1465, DOI 10.1002/j.1460-2075.1986.tb04383.x; MATSUI M, 1996, NEUROSCIENCE PROTOCO, V20, P1; Matthes HWD, 1996, NATURE, V383, P819, DOI 10.1038/383819a0; Mendis DB, 1996, BRAIN RES, V713, P53, DOI 10.1016/0006-8993(95)01472-1; MENDIS DB, 1995, BRAIN RES, V676, P69, DOI 10.1016/0006-8993(95)00101-U; MURAMOTO K, 1993, NEUROSCIENCE, V52, P621, DOI 10.1016/0306-4522(93)90411-8; NAKAMURA H, 1978, PSYCHOPHARMACOLOGY, V56, P269, DOI 10.1007/BF00432849; NAKAYAMA H, 1992, NUCLEIC ACIDS RES, V20, P4939, DOI 10.1093/nar/20.18.4939; NESTLER EJ, 1993, NEURON, V11, P995, DOI 10.1016/0896-6273(93)90213-B; PHILLIPSON OT, 1979, J COMP NEUROL, V187, P117, DOI 10.1002/cne.901870108; POST RM, 1976, NATURE, V260, P731, DOI 10.1038/260731a0; SAGE EH, 1991, J BIOL CHEM, V266, P14831; SAGE H, 1989, J CELL BIOL, V109, P341, DOI 10.1083/jcb.109.1.341; SHARMA SK, 1975, P NATL ACAD SCI USA, V72, P3092, DOI 10.1073/pnas.72.8.3092; SHINONAGA Y, 1994, NEUROSCIENCE, V58, P389, DOI 10.1016/0306-4522(94)90045-0; Soderling JA, 1997, J HISTOCHEM CYTOCHEM, V45, P823, DOI 10.1177/002215549704500607; Sora I, 1997, P NATL ACAD SCI USA, V94, P1544, DOI 10.1073/pnas.94.4.1544; SORG BA, 1995, SYNAPSE, V20, P217, DOI 10.1002/syn.890200305; SPANAGEL R, 1995, BEHAV BRAIN RES, V70, P37, DOI 10.1016/0166-4328(94)00176-G; TERMINE JD, 1981, CELL, V26, P99, DOI 10.1016/0092-8674(81)90037-4; TRUJILLO KA, 1991, SCIENCE, V251, P85, DOI 10.1126/science.1824728; VEZINA P, 1987, BRAIN RES, V417, P51, DOI 10.1016/0006-8993(87)90178-8; WALLACE DM, 1992, BRAIN RES BULL, V28, P447, DOI 10.1016/0361-9230(92)90046-Z; Wang SJ, 1999, J NEUROSCI, V19, P10656, DOI 10.1523/JNEUROSCI.19-24-10656.1999; Wang XB, 1997, J NEUROSCI, V17, P5993; WOLF ME, 1995, NEUROSCIENCE, V69, P417, DOI 10.1016/0306-4522(95)00248-H; YAMAGATA K, 1993, NEURON, V11, P371, DOI 10.1016/0896-6273(93)90192-T	49	25	29	0	4	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	AUG	2000	6	8					910	915		10.1038/78675	http://dx.doi.org/10.1038/78675			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	376TX	10932229				2022-12-25	WOS:000165473800035
J	Suzuki, K; Hu, D; Bustos, T; Zlotogora, J; Richieri-Costa, A; Helms, JA; Spritz, RA				Suzuki, K; Hu, D; Bustos, T; Zlotogora, J; Richieri-Costa, A; Helms, JA; Spritz, RA			Mutations of PVRL1, encoding a cell-cell adhesion molecule/herpesvirus receptor, in cleft lip/palate-ectodermal dysplasia	NATURE GENETICS			English	Article							POLIOVIRUS RECEPTOR; NUCLEOTIDE-SEQUENCE; MENTAL-RETARDATION; BINDING PROTEIN; PALATE; LIP; GENE; ASSOCIATION; FAMILIES; HOMOLOG	Cleft lip, with:or without cleft palate (CL/P), is one of the most common birth defects, occurring in 0.4 to 2.0 per 1,000 infants born alive(1). Approximately 70% of CL/P cases are non-syndromic (MIM 119530), but CL/P also occurs in many single-gene syndromes, each affecting a protein critical for orofacial development. Here we describe positional cloning of the gene responsible for an autosomal recessive CL/P-ectodermal dysplasia (ED) syndrome (CLPED1; previously ED4; ref. 2), which we identify as PVRL1, encoding nectin-1, an immunoglobulin (Ig)-related transmembrane cell-cell adhesion molecule that is part of the NAP cell adhesion system(3-6). Nectin-1 is also the principal cell surface receptor for cr-herpesviruses (HveC; ref. 7), and the high frequency of CLPED1 on Margarita island in the Caribbean Sea might result from resistance of heterozygotes to infection by these viruses.	Univ Colorado, Hlth Sci Ctr, Human Med Genet Program, Denver, CO 80262 USA; Univ Calif San Francisco, Dept Orthoped Surg, San Francisco, CA USA; Cent Univ Venezuela, Ctr Nacl Genet Humana & Expt, Caracas, Venezuela; Hebrew Univ Jerusalem, Sch Med, IL-91010 Jerusalem, Israel; USP, HRAC, Dept Genet, Bauru, SP, Brazil	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of California System; University of California San Francisco; University of Central Venezuela; Hebrew University of Jerusalem; Universidade de Sao Paulo	Spritz, RA (corresponding author), Univ Colorado, Hlth Sci Ctr, Human Med Genet Program, Denver, CO 80262 USA.		Richieri-Costa, Antonio/B-2514-2013	Zlotogora, Joel/0000-0001-6293-2979	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [K08HD001079] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE012462, R29DE012462] Funding Source: NIH RePORTER; NICHD NIH HHS [HD01079] Funding Source: Medline; NIDCR NIH HHS [DE12462] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Amos C, 1996, AM J HUM GENET, V59, P743; Asakura T, 1999, GENES CELLS, V4, P573, DOI 10.1046/j.1365-2443.1999.00283.x; BUCKLER AJ, 1991, P NATL ACAD SCI USA, V88, P4005, DOI 10.1073/pnas.88.9.4005; BUSTOS T, 1991, AM J MED GENET, V41, P398, DOI 10.1002/ajmg.1320410403; Celli J, 1999, CELL, V99, P143, DOI 10.1016/S0092-8674(00)81646-3; Cocchi F, 1998, P NATL ACAD SCI USA, V95, P15700, DOI 10.1073/pnas.95.26.15700; EBERLE F, 1995, GENE, V159, P267, DOI 10.1016/0378-1119(95)00180-E; Geraghty RJ, 1998, SCIENCE, V280, P1618, DOI 10.1126/science.280.5369.1618; Helms JA, 1997, DEV BIOL, V187, P25, DOI 10.1006/dbio.1997.8589; KOIKE S, 1990, EMBO J, V9, P3217, DOI 10.1002/j.1460-2075.1990.tb07520.x; Lee ST, 1995, MOL CELLS, V5, P668; LEONHARDT EA, 1994, GENOMICS, V19, P130, DOI 10.1006/geno.1994.1022; LOPEZ M, 1995, GENE, V155, P261, DOI 10.1016/0378-1119(94)00842-G; Mandai K, 1999, J CELL BIOL, V144, P1001, DOI 10.1083/jcb.144.5.1001; Mandai K, 1997, J CELL BIOL, V139, P517, DOI 10.1083/jcb.139.2.517; MENDELSOHN CL, 1989, CELL, V56, P855, DOI 10.1016/0092-8674(89)90690-9; OGUR G, 1988, J MED GENET, V25, P37, DOI 10.1136/jmg.25.1.37; RODINI ESO, 1990, AM J MED GENET, V36, P473, DOI 10.1002/ajmg.1320360420; Schollmeyer P, 1990, APMIS Suppl, V19, P54; Schutte BC, 1999, HUM MOL GENET, V8, P1853, DOI 10.1093/hmg/8.10.1853; STEIN J, 1995, AM J HUM GENET, V57, P257; Suzuki K, 1998, AM J HUM GENET, V63, P1102, DOI 10.1086/302072; TAKAHASHI K, 1999, J CELL BIOL, V139, P517; TRASK B, 1993, GENOMICS, V15, P133, DOI 10.1006/geno.1993.1021; van den Boogaard MJH, 2000, NAT GENET, V24, P342, DOI 10.1038/74155; Wyszynski DF, 1997, HUM GENET, V99, P22; ZLOTOGORA J, 1988, J MED GENET, V25, P503, DOI 10.1136/jmg.25.7.503; ZLOTOGORA J, 1994, J MED GENET, V31, P957, DOI 10.1136/jmg.31.12.957; ZLOTOGORA J, 1987, J MED GENET, V24, P291, DOI 10.1136/jmg.24.5.291	30	247	256	0	17	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	AUG	2000	25	4					427	430		10.1038/78119	http://dx.doi.org/10.1038/78119			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	341WY	10932188				2022-12-25	WOS:000088615000019
J	Frattini, A; Orchard, PJ; Sobacchi, C; Giliani, S; Abinun, M; Mattsson, JP; Keeling, DJ; Andersson, AK; Wallbrandt, P; Zecca, L; Notarangelo, LD; Vezzoni, P; Villa, A				Frattini, A; Orchard, PJ; Sobacchi, C; Giliani, S; Abinun, M; Mattsson, JP; Keeling, DJ; Andersson, AK; Wallbrandt, P; Zecca, L; Notarangelo, LD; Vezzoni, P; Villa, A			Defects in TCIRG1 subunit of the vacuolar proton pump are responsible for a subset of human autosomal recessive osteopetrosis	NATURE GENETICS			English	Article							MEDIATED EXTRACELLULAR ACIDIFICATION; OSTEOCLASTIC BONE-RESORPTION; MEMBRANE-PROTEIN; LEADS; MICE; OSTEOSCLEROSIS; MUTATION; TIRC7; GENE	Osteopetrosis includes a group of inherited diseases in which inadequate bone resorption is caused by osteoclast dysfunction. Although molecular defects have been described for many animal models of osteopetrosis. the gene responsible for most cases of the severe human form of the disease (infantile malignant osteopetrosis) is unknown. Infantile malignant autosomal recessive osteopetrosis (MIM 259700) is a severe bone disease with a fatal outcome, generally within the first decade of life. Osteoclasts are present in normal or elevated numbers in individuals affected by autosomal recessive osteopetrosis(1), suggesting that the defect is not in osteoclast differentiation, but in a gene involved in the functional capacity of mature osteoclasts. Some of the mouse mutants have a decreased number of osteoclasts. which suggests that the defect directly interferes with osteoclast differentiation(2,3). In other mutants, it is the function of the osteoclast that seems to be affected, as they show normal or elevated numbers of non-functioning osteoclasts(2,4-6). Here we show that TCIRG1, encoding the osteoclast-specific 116-kD subunit of the vacuolar proton pump, is mutated in five of nine patients with a diagnosis of infantile malignant osteopetrosis. Our data indicate that mutations in TCIRG1 are a frequent cause of autosomal recessive osteopetrosis in humans.	CNR, Ist Tecnol Biomed Avanzate, Segrate, Italy; Univ Minnesota, Dept Pediat, Div Bone Marrow Transplantat, Minneapolis, MN 55455 USA; Univ Brescia, Pediat Clin, Ist Med Mol Angelo Nocivelli, I-25121 Brescia, Italy; Newcastle Gen Hosp, Dept Pediat Immunol & Infect Dis, Newcastle Upon Tyne NE4 6BE, Tyne & Wear, England; AstraZeneca R&D, Dept Cell Biol & Biochem, Molndal, Sweden; AstraZeneca R&D, Dept Biol Mol, Molndal, Sweden	Consiglio Nazionale delle Ricerche (CNR); Istituto di Tecnologie Biomediche (ITB-CNR); University of Minnesota System; University of Minnesota Twin Cities; University of Brescia; Newcastle General Hospital; AstraZeneca; AstraZeneca	Vezzoni, P (corresponding author), CNR, Ist Tecnol Biomed Avanzate, Segrate, Italy.	vezzoni@itba.mi.cnr.it	SOBACCHI, CRISTINA/J-9345-2018; Frattini, Annalisa/B-7684-2015; Notarangelo, Luigi D/F-9718-2016; Vezzoni, Paolo/K-3197-2018; Vezzoni, Paolo/R-3416-2019; Giliani, Silvia/AAX-8843-2020	SOBACCHI, CRISTINA/0000-0002-2684-7184; Frattini, Annalisa/0000-0002-1166-3091; Notarangelo, Luigi D/0000-0002-8335-0262; Giliani, Silvia/0000-0001-8137-4642; Villa, Anna/0000-0003-4428-9013; Vezzoni, Paolo/0000-0002-6382-3923	Telethon [E.0917] Funding Source: Medline	Telethon(Fondazione Telethon)		BARON R, 1985, J CELL BIOL, V101, P2210, DOI 10.1083/jcb.101.6.2210; BLAIR HC, 1989, SCIENCE, V245, P855, DOI 10.1126/science.2528207; Eapen M, 1998, BONE MARROW TRANSPL, V22, P941, DOI 10.1038/sj.bmt.1701474; Forgac M, 1999, J BIOL CHEM, V274, P12951, DOI 10.1074/jbc.274.19.12951; GERRITSEN EJA, 1994, PEDIATRICS, V93, P247; Heaney C, 1998, HUM MOL GENET, V7, P1407, DOI 10.1093/hmg/7.9.1407; Heinemann T, 1999, GENOMICS, V57, P398, DOI 10.1006/geno.1999.5751; Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852; Lazner F, 1999, HUM MOL GENET, V8, P1839, DOI 10.1093/hmg/8.10.1839; Li YP, 1996, BIOCHEM BIOPH RES CO, V218, P813, DOI 10.1006/bbrc.1996.0145; Li YP, 1999, NAT GENET, V23, P447, DOI 10.1038/70563; MACCHI P, 1995, NATURE, V377, P65, DOI 10.1038/377065a0; Maquat LE, 1996, AM J HUM GENET, V59, P279; MARKS SC, 1985, J HERED, V76, P171, DOI 10.1093/oxfordjournals.jhered.a110059; Saftig P, 1998, P NATL ACAD SCI USA, V95, P13453, DOI 10.1073/pnas.95.23.13453; Scimeca JC, 2000, BONE, V26, P207, DOI 10.1016/S8756-3282(99)00278-1; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; Utku N, 1998, IMMUNITY, V9, P509, DOI 10.1016/S1074-7613(00)80634-2; Vaananen HK, 2000, J CELL SCI, V113, P377; Villa A, 1998, CELL, V93, P885, DOI 10.1016/S0092-8674(00)81448-8	20	512	539	2	17	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1061-4036	1546-1718		NAT GENET	Nature Genet.	JUL	2000	25	3					343	346		10.1038/77131	http://dx.doi.org/10.1038/77131			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	329RD	10888887				2022-12-25	WOS:000087920900027
J	Lakkis, FG; Arakelov, A; Konieczny, BT; Inoue, Y				Lakkis, FG; Arakelov, A; Konieczny, BT; Inoue, Y			Immunologic 'ignorance' of vascularized organ transplants in the absence of secondary lymphoid tissue	NATURE MEDICINE			English	Article							T-CELLS; ENDOTHELIAL-CELLS; IMMUNE-RESPONSES; IFN-GAMMA; MOUSE; MICE; REJECTION; MUTATION; ROLES; CD40	Secondary lymphoid organs (the spleen, lymph nodes and mucosal lymphoid tissues) provide the proper environment for antigen-presenting cells to interact with and activate naive T and B lymphocytes(1). Although it is generally accepted that secondary lymphoid organs are essential for initiating immune responses to microbial antigens and to skin allografts(2-6), the prevailing view has been that the immune response to primarily vascularized organ transplants such as hearts and kidneys does not require the presence of secondary lymphoid tissue. The assumption has been that the immune response to such organs is initiated in the graft itself when recipient lymphocytes encounter foreign histocompatibility antigens presented by the graft's endothelial cells(7-13). In contrast to this view, we show here that cardiac allografts are accepted indefinitely in recipient mice that lack secondary lymphoid tissue, indicating that the alloimmune response to a vascularized organ transplant cannot be initiated in the graft itself. Moreover, we demonstrate that the permanent acceptance of these grafts is not due to tolerance but is because of immunologic 'ignorance'.	Vet Affairs Med Ctr, Atlanta, GA 30033 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Atlanta VA Health Care System	Lakkis, FG (corresponding author), Emory Univ, Sch Med, Dept Med, Div Renal, 1670 Clairmont Rd, Atlanta, GA 30033 USA.				NIAID NIH HHS [AI41643, AI44644] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI041643] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARKER CF, 1968, J EXP MED, V128, P197, DOI 10.1084/jem.128.1.197; BRENT L, 1967, BRIT MED BULL, V23, P55, DOI 10.1093/oxfordjournals.bmb.a070517; Briscoe DM, 1998, CURR OPIN IMMUNOL, V10, P525, DOI 10.1016/S0952-7915(98)80218-5; CORRY RJ, 1973, TRANSPLANTATION, V16, P343, DOI 10.1097/00007890-197310000-00010; GOES N, 1995, J IMMUNOL, V155, P4559; Goodnow CC, 1997, IMMUNOL REV, V156, P5, DOI 10.1111/j.1600-065X.1997.tb00954.x; Grewal IS, 1998, ANNU REV IMMUNOL, V16, P111, DOI 10.1146/annurev.immunol.16.1.111; Karrer U, 1997, J EXP MED, V185, P2157, DOI 10.1084/jem.185.12.2157; Konieczny BT, 1998, J IMMUNOL, V160, P2059; Ma WL, 1998, J IMMUNOL, V161, P2158; MEDAWAR PB, 1957, P ROY SOC LOND B BIO, V149, P145; MIYAWAKI S, 1994, EUR J IMMUNOL, V24, P429, DOI 10.1002/eji.1830240224; MOMBAERTS P, 1993, NATURE, V365, P53, DOI 10.1038/365053a0; Ochsenbein AF, 1999, P NATL ACAD SCI USA, V96, P2233, DOI 10.1073/pnas.96.5.2233; PEDERSEN NC, 1970, J EXP MED, V131, P936, DOI 10.1084/jem.131.5.936; Perez VL, 1998, CELL IMMUNOL, V189, P31, DOI 10.1006/cimm.1998.1362; Picker L.J., 1999, FUNDAMENTAL IMMUNOLO, P479; Pober JS, 1996, TRANSPLANTATION, V61, P343, DOI 10.1097/00007890-199602150-00001; ROBERTS CWM, 1994, NATURE, V368, P747, DOI 10.1038/368747a0; Shinkura R, 1999, NAT GENET, V22, P74, DOI 10.1038/8780; STROBER S, 1965, J EXP MED, V122, P347, DOI 10.1084/jem.122.2.347; VETTO RM, 1967, TRANSPLANTATION, V5, P1537; Zinkernagel RM, 1997, IMMUNOL REV, V156, P199, DOI 10.1111/j.1600-065X.1997.tb00969.x	23	332	334	0	4	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUN	2000	6	6					686	688		10.1038/76267	http://dx.doi.org/10.1038/76267			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	321CX	10835686				2022-12-25	WOS:000087438300040
J	Wiese, C; Zheng, YX				Wiese, C; Zheng, YX			A new function for the gamma-tubulin ring complex as a microtubule minus-end cap	NATURE CELL BIOLOGY			English	Article							CENTROSOME; NUCLEATION; CELLS; IDENTIFICATION; PROTEIN; FAMILY; INVITRO; BINDING; MEMBER; SPC98P	Microtubule nucleation from centrosomes involves a lockwasher-shaped protein complex containing gamma-tubulin, named the gamma-tubulin ring complex (gamma TuRC). Here we investigate the mechanism by which the gamma TuRC nucleates microtubules, using a direct labelling method to visualize the behaviour of individual gamma TuRCs. A fluorescently-labelled version of the gamma TuRC binds to the minus ends of microtubules nucleated in vitro. Both gamma TuRC-mediated nucleation and binding of the gamma TuRC to preformed microtubules block further minus-end growth and prevent microtubule depolymerization. The gamma TuRC therefore acts as a minus-end-capping protein, as confirmed by electron-microscopic examination of gold-labelled gamma TuRCs. These data support a nucleation model for gamma TuRC function that involves capping of microtubules.	Carnegie Inst Sci, Dept Embryol, Baltimore, MD 21210 USA	Carnegie Institution for Science	Wiese, C (corresponding author), Carnegie Inst Sci, Dept Embryol, 115 W Univ Pkwy, Baltimore, MD 21210 USA.	wiese@ciwemb.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056312] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM56312-01] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERGEN LG, 1980, J CELL BIOL, V84, P151, DOI 10.1083/jcb.84.1.151; BURNS RG, 1995, CELL MOTIL CYTOSKEL, V31, P255, DOI 10.1002/cm.970310402; BYERS B, 1978, J CELL SCI, V30, P331; Desai A, 1999, CELL, V96, P69, DOI 10.1016/S0092-8674(00)80960-5; Erickson HP, 1996, J CELL BIOL, V135, P5, DOI 10.1083/jcb.135.1.5; EVANS L, 1985, J CELL BIOL, V100, P1185, DOI 10.1083/jcb.100.4.1185; Fava F, 1999, J CELL BIOL, V147, P857, DOI 10.1083/jcb.147.4.857; HYMAN A, 1991, METHOD ENZYMOL, V196, P478; HYMAN AA, 1991, J CELL SCI, P125; Keating TJ, 1997, P NATL ACAD SCI USA, V94, P5078, DOI 10.1073/pnas.94.10.5078; Martin OC, 1998, J CELL BIOL, V141, P675, DOI 10.1083/jcb.141.3.675; McNally FJ, 1996, J CELL SCI, V109, P561; MITCHISON TJ, 1985, J CELL BIOL, V101, P755, DOI 10.1083/jcb.101.3.755; Moritz M, 1998, J CELL BIOL, V142, P775, DOI 10.1083/jcb.142.3.775; MORITZ M, 1995, NATURE, V378, P638, DOI 10.1038/378638a0; Moudjou M, 1996, J CELL SCI, V109, P875; Murphy SM, 1998, J CELL BIOL, V141, P663, DOI 10.1083/jcb.141.3.663; MURRAY AW, 1991, METHOD CELL BIOL, V36, P581; OAKLEY BR, 1995, NATURE, V378, P555, DOI 10.1038/378555a0; OAKLEY CE, 1989, NATURE, V338, P662, DOI 10.1038/338662a0; Oegema K, 1999, J CELL BIOL, V144, P721, DOI 10.1083/jcb.144.4.721; Tassin AM, 1997, J CELL SCI, V110, P2533; Tassin AM, 1998, J CELL BIOL, V141, P689, DOI 10.1083/jcb.141.3.689; Vorobjev IA, 1997, J CELL SCI, V110, P2635; VOTER WA, 1984, J BIOL CHEM, V259, P430; Waterman-Storer C, 1999, METHOD CELL BIOL, V61, P155; WEBER PC, 1989, SCIENCE, V243, P85, DOI 10.1126/science.2911722; Wiese C, 1999, CURR OPIN STRUC BIOL, V9, P250, DOI 10.1016/S0959-440X(99)80035-9; Yvon AMC, 1997, J CELL SCI, V110, P2391; ZHENG YX, 1995, NATURE, V378, P578, DOI 10.1038/378578a0	30	189	194	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	JUN	2000	2	6					358	364		10.1038/35014051	http://dx.doi.org/10.1038/35014051			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	321KE	10854327				2022-12-25	WOS:000087454000018
J	Stone, DL; Slavotinek, R; Bouffard, GG; Banerjee-Basu, S; Baxevanis, AD; Barr, M; Biesecker, LG				Stone, DL; Slavotinek, R; Bouffard, GG; Banerjee-Basu, S; Baxevanis, AD; Barr, M; Biesecker, LG			Mutation of a gene encoding a putative chaperonin causes McKusick-Kaufman syndrome	NATURE GENETICS			English	Article							CCT	McKusick-Kaufman syndrome (MKKS, MIM 236700) is a human developmental anomaly syndrome comprising hydrometrocolpos (HMC), postaxial polydactyly (PAP) and congenital heart disease(1,2) (CHD). MKKS has been mapped in the Old Order Amish population to 20p12, between D20S162 and D20S894 (ref. 3). Here we describe the identification of a gene mutated in MKKS. We analysed the approximately 450-kb candidate region by sample sequencing, which revealed the presence of several known genes and EST clusters. We evaluated candidate transcripts by northern-blot analysis of adult and fetal tissues. We selected one transcript with widespread expression, MKKS, for analysis in a patient from the Amish pedigree and a sporadic, non-Amish case. The Old Order Amish patient was found to be homozygous for an allele that had two missense substitutions and the non-Amish patient was a compound heterozygote for a frameshift mutation predicting premature protein truncation and a distinct missense mutation. The MKKS predicted protein shows amino acid similarity to the chaperonin family of proteins, suggesting a role for protein processing in limb, cardiac and reproductive system development. We believe that this is the first description of a human disorder caused by mutations affecting a putative chaperonin molecule.	Natl Human Genome Res Inst, Genet Dis Res Branch, NIH, Bethesda, MD USA; NIH Intramural Sequencing Ctr, Gaithersburg, MD USA; Univ Michigan, Med Ctr, NIH,NHGRI, Genome Technol Branch, Ann Arbor, MI USA; Univ Michigan, Med Ctr, Dept Pediat, Ann Arbor, MI 48109 USA; Univ Michigan, Med Ctr, Dept Obstet, Ann Arbor, MI 48109 USA	National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Biesecker, LG (corresponding author), Natl Human Genome Res Inst, Genet Dis Res Branch, NIH, Bethesda, MD USA.	leslieb@helix.nih.gov	Biesecker, Leslie/AAG-2526-2021	Baxevanis, Andy/0000-0002-5370-0014	NATIONAL HUMAN GENOME RESEARCH INSTITUTE [Z01HG000009] Funding Source: NIH RePORTER	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		Agarwala R, 1998, GENOME RES, V8, P211, DOI 10.1101/gr.8.3.211; Braig K, 1998, CURR OPIN STRUC BIOL, V8, P159, DOI 10.1016/S0959-440X(98)80033-X; David A, 1999, J MED GENET, V36, P599; Ditzel L, 1998, CELL, V93, P125, DOI 10.1016/S0092-8674(00)81152-6; Ewing B, 1998, GENOME RES, V8, P186, DOI 10.1101/gr.8.3.186; Ewing B, 1998, GENOME RES, V8, P175, DOI 10.1101/gr.8.3.175; Gordon D, 1998, GENOME RES, V8, P195, DOI 10.1101/gr.8.3.195; Horwich AL, 1999, P NATL ACAD SCI USA, V96, P11033, DOI 10.1073/pnas.96.20.11033; KAUFMAN R L, 1972, Birth Defects Original Article Series, V8, P85; Li LH, 1997, NAT GENET, V16, P243, DOI 10.1038/ng0797-243; Llorca O, 1999, NATURE, V402, P693, DOI 10.1038/45294; MCKUSICK VA, 1964, JAMA-J AM MED ASSOC, V189, P813; Oda T, 1997, NAT GENET, V16, P235, DOI 10.1038/ng0797-235; RILEY J, 1990, NUCLEIC ACIDS RES, V18, P2887, DOI 10.1093/nar/18.10.2887; ROSENBERG MJ, IN PRESS AM J HUM GE; Slavotinek AM, 1999, AM J HUM GENET, V65, pA36; Stone DL, 1998, HUM MOL GENET, V7, P475, DOI 10.1093/hmg/7.3.475; Wickner S, 1999, SCIENCE, V286, P1888, DOI 10.1126/science.286.5446.1888; WILSON RK, 1997, ANAL DNA; ZHAO ND, 1994, GENE, V145, P313	20	151	158	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAY	2000	25	1					79	82		10.1038/75637	http://dx.doi.org/10.1038/75637			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	311KU	10802661				2022-12-25	WOS:000086884000021
J	Domashenko, A; Gupta, S; Cotsarelis, G				Domashenko, A; Gupta, S; Cotsarelis, G			Efficient delivery of transgenes to human hair follicle progenitor cells using topical lipoplex	NATURE BIOTECHNOLOGY			English	Article						gene therapy; hair follicle; liposomes; xenograft; progenitor cells; alopecia	MEDIATED GENE-TRANSFER; ALOPECIA-AREATA; STEM-CELLS; SKIN; CYCLE	The topical delivery of transgenes to hair follicles has potential for treating disorders of the skin and hair. Here we show that the topical administration of liposome-DNA mixtures (lipoplex) to mouse skin and to human skin xenografts resulted in efficient in vivo transfection of hair follicle cells. Transfection depended on liposome composition, and occurred only at the onset of a new growing stage of the hair cycle. Manipulating the hair follicle cycle with depilation and retinoic acid treatment resulted in nearly 50% transfection efficiency-defined as the proportion of transfected, newly growing follicles within the xenograft. Transgenes administered in this-fashion are selectively expressed in hair progenitor cells and therefore have the potential to affect the characteristics of the follicle. These findings form a foundation for the future use of topical lipoplex applications to alter hair follicle phenotype and treat diseases of the hair and skin.	Univ Penn, Med Ctr, Dept Dermatol, Philadelphia, PA 19104 USA	University of Pennsylvania	Cotsarelis, G (corresponding author), Univ Penn, Med Ctr, Dept Dermatol, Philadelphia, PA 19104 USA.							ALEXANDER MY, 1995, HUM MOL GENET, V4, P2279, DOI 10.1093/hmg/4.12.2279; ARGYRIS TS, 1976, AM J PATHOL, V83, P329; CHASE HB, 1954, PHYSIOL REV, V34, P113, DOI 10.1152/physrev.1954.34.1.113; COTSARELIS G, 1990, CELL, V61, P1329, DOI 10.1016/0092-8674(90)90696-C; Cotsarelis G, 1997, AM J PATHOL, V151, P1505; EGLIMEZ NK, 1996, BIOCHEM BIOPH RES CO, V221, P169; Fan HR, 1999, NAT BIOTECHNOL, V17, P870, DOI 10.1038/12856; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; Gilhar A, 1998, J CLIN INVEST, V101, P62, DOI 10.1172/JCI551; HEADINGTON JT, 1984, CURR THER RES CLIN E, V36, P1098; LI LN, 1995, NAT MED, V1, P705, DOI 10.1038/nm0795-705; Lyle S, 1998, J CELL SCI, V111, P3179; NICOLAU C, 1982, BIOCHIM BIOPHYS ACTA, V721, P185, DOI 10.1016/0167-4889(82)90067-2; PAUS R, 1990, BRIT J DERMATOL, V122, P777, DOI 10.1111/j.1365-2133.1990.tb06266.x; Paus R, 1999, NEW ENGL J MED, V341, P491, DOI 10.1056/NEJM199908123410706; SAFAVI KH, 1995, MAYO CLIN PROC, V70, P628, DOI 10.4065/70.7.628; Sato N, 1999, J CLIN INVEST, V104, P855, DOI 10.1172/JCI7691; Shi ZK, 1999, VACCINE, V17, P2136, DOI 10.1016/S0264-410X(98)00488-5; SLOIMINSKI A, 1993, J INVEST DERMATOL, V101, pS90; Sorgi FL, 1997, GENE THER, V4, P961, DOI 10.1038/sj.gt.3300484; VANSCOTT E, 1958, J INVEST DERMATOL, V41, P269; VANSCOTT EJ, 1958, J INVEST DERMATOL, V31, P35, DOI 10.1038/jid.1958.73; WILSON C, 1994, DIFFERENTIATION, V55, P127, DOI 10.1046/j.1432-0436.1994.5520127.x; WroneSmith T, 1996, J CLIN INVEST, V98, P1878, DOI 10.1172/JCI118989; Yu WH, 1999, J INVEST DERMATOL, V112, P370, DOI 10.1046/j.1523-1747.1999.00513.x	25	108	115	2	14	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	APR	2000	18	4					420	423		10.1038/74480	http://dx.doi.org/10.1038/74480			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	303UY	10748523				2022-12-25	WOS:000086444300025
J	Latouche, JB; Sadelain, M				Latouche, JB; Sadelain, M			Induction of human cytotoxic T lymphocytes by artificial antigen-presenting cells	NATURE BIOTECHNOLOGY			English	Article						adoptive cell therapy; CD8(+) T cell; costimulation; dendritic cells; immunotherapy; retrovirus-mediated gene transfer	TUMOR-INFILTRATING LYMPHOCYTES; DENDRITIC CELLS; HUMAN BLOOD; ADOPTIVE IMMUNOTHERAPY; MATRIX PROTEIN; PEPTIDE; COSTIMULATION; HLA-A2; IDENTIFICATION; PROLIFERATION	The adoptive transfer of antigen-specific cytotoxic T lymphocytes (CTLs) is a promising therapeutic approach for a number of diseases. To overcome the difficulty in generating specific CTLs, we established stable artificial antigen-presenting cells (AAPCs) that can be used to stimulate T cells of any patient of a given human leukocyte antigen (HLA) type. Mouse fibroblasts were retrovirally transduced with a single HLA-peptide complex along with the human accessory molecules B7.1, ICAM-1, and LFA-3. These AAPCs consistently elicit strong stimulation and expansion of HLA-restricted CTLs. Owing to the high efficiency of retrovirus-mediated gene transfer, stable AAPCs can be readily engineered for any HLA molecule and any specific peptide.	Mem Sloan Kettering Canc Ctr, Dept Human Genet, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Program Immunol, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Sadelain, M (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Human Genet, 1275 York Ave, New York, NY 10021 USA.			Latouche, Jean-Baptiste/0000-0003-4802-5429	NATIONAL CANCER INSTITUTE [P01CA059350] Funding Source: NIH RePORTER; NCI NIH HHS [CA-59350] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON K, 1991, J EXP MED, V174, P489, DOI 10.1084/jem.174.2.489; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; BEDNAREK MA, 1991, J IMMUNOL, V147, P4047; Bender A, 1996, J IMMUNOL METHODS, V196, P121, DOI 10.1016/0022-1759(96)00079-8; BHARDWAJ N, 1994, J CLIN INVEST, V94, P797, DOI 10.1172/JCI117399; Brenner MK, 1998, VOX SANG, V74, P87, DOI 10.1111/j.1423-0410.1998.tb05401.x; BRYANT J, 1992, J IMMUNOL METHODS, V146, P91, DOI 10.1016/0022-1759(92)90052-U; Chen YT, 1996, P NATL ACAD SCI USA, V93, P5915, DOI 10.1073/pnas.93.12.5915; DAVIS MM, 1993, CURR OPIN IMMUNOL, V5, P45, DOI 10.1016/0952-7915(93)90079-8; Deeths MJ, 1999, EUR J IMMUNOL, V29, P45, DOI 10.1002/(SICI)1521-4141(199901)29:01<45::AID-IMMU45>3.0.CO;2-I; Dustin ML, 1999, SCIENCE, V283, P649, DOI 10.1126/science.283.5402.649; Fields PE, 1998, J IMMUNOL, V161, P5268; Gallardo HF, 1997, GENE THER, V4, P1115, DOI 10.1038/sj.gt.3300506; Gong Michael C., 1999, Neoplasia (New York), V1, P123, DOI 10.1038/sj.neo.7900018; Grakoui A, 1999, SCIENCE, V285, P221, DOI 10.1126/science.285.5425.221; Heslop HE, 1996, NAT MED, V2, P551, DOI 10.1038/nm0596-551; KAWAKAMI Y, 1994, J EXP MED, V180, P347, DOI 10.1084/jem.180.1.347; Kawakami Y, 1997, Int Rev Immunol, V14, P173, DOI 10.3109/08830189709116851; Krause A, 1998, J EXP MED, V188, P619, DOI 10.1084/jem.188.4.619; Lanzavecchia A, 1999, CELL, V96, P1, DOI 10.1016/S0092-8674(00)80952-6; Lehner PJ, 1996, CURR OPIN IMMUNOL, V8, P59, DOI 10.1016/S0952-7915(96)80106-3; Lenschow DJ, 1996, ANNU REV IMMUNOL, V14, P233, DOI 10.1146/annurev.immunol.14.1.233; Levine BL, 1997, J IMMUNOL, V159, P5921; MELIEF CJM, 1995, IMMUNOL REV, V145, P167, DOI 10.1111/j.1600-065X.1995.tb00081.x; Mellman I, 1998, TRENDS CELL BIOL, V8, P231, DOI 10.1016/S0962-8924(98)01276-8; MORRISON J, 1992, EUR J IMMUNOL, V22, P903, DOI 10.1002/eji.1830220404; O'Reilly RJ, 1998, SPRINGER SEMIN IMMUN, V20, P455, DOI 10.1007/BF00838055; ODOHERTY U, 1993, J EXP MED, V178, P1067, DOI 10.1084/jem.178.3.1067; Ory DS, 1996, P NATL ACAD SCI USA, V93, P11400, DOI 10.1073/pnas.93.21.11400; Parkhurst MR, 1996, J IMMUNOL, V157, P2539; Parra E, 1997, J IMMUNOL, V158, P637; RIDDELL SR, 1995, ANNU REV IMMUNOL, V13, P545; RIVIERE I, 1995, P NATL ACAD SCI USA, V92, P6733, DOI 10.1073/pnas.92.15.6733; RIVLERE I, 1997, GENE THERAPY PROTOCO, P59; Rivoltini L, 1996, J IMMUNOL, V156, P3882; Romani N, 1996, J IMMUNOL METHODS, V196, P137, DOI 10.1016/0022-1759(96)00078-6; Rooney CM, 1998, VOX SANG, V74, P497, DOI 10.1111/j.1423-0410.1998.tb05463.x; ROSENBERG SA, 1991, CANCER RES, V51, pS5074; Schultze JL, 1997, J CLIN INVEST, V100, P2757, DOI 10.1172/JCI119822; Shaw AS, 1997, IMMUNITY, V6, P361, DOI 10.1016/S1074-7613(00)80279-4; SPAGNOLI GC, 1995, INT J CANCER, V64, P309, DOI 10.1002/ijc.2910640505; SPRENT J, 1995, CURR BIOL, V5, P1095, DOI 10.1016/S0960-9822(95)00219-3; Sprent J, 1997, ADV EXP MED BIOL, V417, P249; Watts TH, 1999, CURR OPIN IMMUNOL, V11, P286, DOI 10.1016/S0952-7915(99)80046-6; YOUNG JW, 1990, J EXP MED, V171, P1315, DOI 10.1084/jem.171.4.1315	45	143	173	0	12	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	APR	2000	18	4					405	409		10.1038/74455	http://dx.doi.org/10.1038/74455			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	303UY	10748520				2022-12-25	WOS:000086444300022
J	Werkele, T; Kurtz, J; Ito, H; Ronquillo, JV; Dong, V; Zhao, GL; Shaffer, J; Sayegh, MH; Sykes, M				Werkele, T; Kurtz, J; Ito, H; Ronquillo, JV; Dong, V; Zhao, GL; Shaffer, J; Sayegh, MH; Sykes, M			Allogeneic bone marrow transplantation with co-stimulatory blockade induces macrochimerism and tolerance without cytoreductive host treatment	NATURE MEDICINE			English	Article							NONLETHAL PREPARATIVE REGIMEN; RENAL-ALLOGRAFT REJECTION; T-CELLS; CLONAL DELETION; CHIMERISM; MICE; ENGRAFTMENT; INDUCTION; ACCEPTANCE; RECONSTITUTION	Allogeneic bone marrow transplantation tin immunocompetent adults) has always required cytoreductive treatment of recipients with irradiation or cytotoxic drugs to achieve lasting engraftment at levels detectable by non-PCR-based techniques ('macrochimerism' or 'mixed chimerism')(1-11). Only syngeneic marrow engraftment at such levels has been achieved in unconditioned hosts(12,13). This requirement for potentially toxic myelosuppressive host pre-conditioning has precluded the clinical use of allogeneic bone marrow transplantation for many indications other than malignancies, including tolerance induction. We demonstrate here that treatment of naive mice with a high dose of fully major histocompatibility complex-mismatched allogeneic bone marrow, followed by one injection each of monoclonal antibody against CD154 and cytotoxic T-lymphocyte antigen 4 immunoglobulin, resulted in multi-lineage hematopoietic macrochimerism (of about 15%) that persisted for up to 34 weeks. Long-term chimeras developed donor-specific tolerance (donor skin graft survival of more than 145 days) and demonstrated ongoing intrathymic deletion of donor-reactive T cells. A protocol of high-dose bone marrow transplantation and co-stimulatory blockade can thus achieve allogeneic bone marrow engraftment without cytoreduction or T-cell depletion of the host, and eliminates a principal barrier to the more widespread use of allogeneic bone marrow transplantation(14-18). Although efforts have been made to minimize host pre-treatment for allogeneic bone marrow transplantation for tolerance induction, so far none have succeeded in eliminating pre-treatment completely. Our demonstration that this can be achieved provides the rationale for a safe approach for inducing robust transplantation tolerance in large animals and humans.	Harvard Univ, Sch Med, Massachusetts Gen Hosp, Transplantat Biol Res Ctr,BMT Sect, Boston, MA 02129 USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Med,Lab Immunogenet & Transplantat, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Sykes, M (corresponding author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Transplantat Biol Res Ctr,BMT Sect, MGH E,Bldg 149-5102,13th St, Boston, MA 02129 USA.			Wekerle, Thomas/0000-0001-5159-2796	NHLBI NIH HHS [R01HL49915] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049915] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abrams JR, 1999, J CLIN INVEST, V103, P1243, DOI 10.1172/JCI5857; ACHAORBEA H, 1991, IMMUNOL TODAY, V12, P356, DOI 10.1016/0167-5699(91)90066-3; BACHARLUSTIG E, 1995, NAT MED, V1, P1268, DOI 10.1038/nm1295-1268; BILL J, 1989, J EXP MED, V169, P1405, DOI 10.1084/jem.169.4.1405; Brocker T, 1997, J EXP MED, V185, P541, DOI 10.1084/jem.185.3.541; Colson YL, 1996, J IMMUNOL, V157, P2820; COLSON YL, 1997, BLOOD, V88, P4601; deVriesvanderZwan A, 1997, BLOOD, V89, P2596, DOI 10.1182/blood.V89.7.2596; DOWN JD, 1993, EXP HEMATOL, V21, P913; DYSON PJ, 1991, NATURE, V349, P531, DOI 10.1038/349531a0; Elwood ET, 1998, TRANSPLANTATION, V65, P1422, DOI 10.1097/00007890-199806150-00002; ILDSTAD ST, 1984, NATURE, V307, P168, DOI 10.1038/307168a0; KAWAI T, 1995, TRANSPLANTATION, V59, P256, DOI 10.1097/00007890-199501270-00018; Kirk AD, 1997, P NATL ACAD SCI USA, V94, P8789, DOI 10.1073/pnas.94.16.8789; Kirk AD, 1999, NAT MED, V5, P686, DOI 10.1038/9536; Krivit W, 1999, Curr Opin Neurol, V12, P167, DOI 10.1097/00019052-199904000-00007; KRIVIT W, 1994, BONE MARROW TRANSPL, P883; Larsen CP, 1996, NATURE, V381, P434, DOI 10.1038/381434a0; Li H, 1996, J IMMUNOL, V156, P380; MAYUMI H, 1989, J EXP MED, V169, P213, DOI 10.1084/jem.169.1.213; Messner RP, 1997, J RHEUMATOL, V24, P819; NOMOTO K, 1995, TRANSPLANTATION, V59, P395, DOI 10.1097/00007890-199502150-00015; Sayegh MH, 1998, NEW ENGL J MED, V338, P1813, DOI 10.1056/NEJM199806183382506; SHARABI Y, 1989, J EXP MED, V169, P493, DOI 10.1084/jem.169.2.493; SHARABI Y, 1990, J EXP MED, V172, P195, DOI 10.1084/jem.172.1.195; STEWART FM, 1993, BLOOD, V81, P2566; Storb R, 1997, BLOOD, V89, P3048, DOI 10.1182/blood.V89.8.3048; Sykes M, 1997, NAT MED, V3, P783, DOI 10.1038/nm0797-783; Sykes M, 1998, EXP HEMATOL, V26, P457; Sykes M, 1996, CURR OPIN IMMUNOL, V8, P694, DOI 10.1016/S0952-7915(96)80088-4; TOMITA Y, 1994, J IMMUNOL, V153, P1087; TOMONARI K, 1991, IMMUNOGENETICS, V33, P157, DOI 10.1007/BF01719234; Trambley J, 1999, J CLIN INVEST, V104, P1715, DOI 10.1172/JCI8082; Wang BY, 1997, P NATL ACAD SCI USA, V94, P12065, DOI 10.1073/pnas.94.22.12065; Wekerle T, 1998, J EXP MED, V187, P2037, DOI 10.1084/jem.187.12.2037	35	400	417	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	APR	2000	6	4					464	469		10.1038/74731	http://dx.doi.org/10.1038/74731			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	376UA	10742157				2022-12-25	WOS:000165474100044
J	Chen, YJ; Yee, D; Dains, K; Chatterjee, A; Cavalcoli, J; Schneider, E; Om, J; Woychik, RP; Magnuson, T				Chen, YJ; Yee, D; Dains, K; Chatterjee, A; Cavalcoli, J; Schneider, E; Om, J; Woychik, RP; Magnuson, T			Genotype-based screen for ENU-induced mutations in mouse embryonic stem cells	NATURE GENETICS			English	Article							ETHYL-N-NITROSOUREA; HPRT GENE; ETHYLNITROSOUREA; MUTAGENESIS; LOCUS; DNA; REPAIR; ALKYLTRANSFERASE; SPERMATOGONIA; INDUCTION	The ability to generate mutations is a prerequisite to functional genetic analysis. Despite a long history of using mice as a model system for genetic analysis, the scientific community has not generated a comprehensive collection of multiple alleles for most mouse genes. The chemical mutagen of choice for mouse has been N-ethyl-N-nitrosourea (ENU). an alkylating agent that mainly causes base substitutions in DNA, and therefore allows for recovery of complete and partial loss-, as well as gain-, of-function alleles', Specific locus tests designed to detect recessive mutations showed that ENU is the most efficient mutagen in mouse with an approximate mutation rate of 1 in 1,000 gametes(2,3). In fact, several genome-wide(4-7) and region-specific(8-10) screens based on phenotypes have been carried out. The anticipation of the completion of the human and mouse genome projects, however, now emphasizes genotype-driven genetics-from sequence to mutants. To take advantage of the mutagenicity of ENU and its ability to create allelic series of mutations, we have developed a complementary approach to generating mutations using mouse embryonic stem (ES) cells. We show that a high mutation frequency can be achieved and that modulating DNA-repair activities can enhance this frequency. The treated cells retain germline competency, thereby rendering this approach applicable for efficient generation of an allelic series of mutations pivotal to a fine-tuned dissection of biological pathways.	Case Western Reserve Univ, Dept Genet, Cleveland, OH 44106 USA; Parke Davis Lab Mol Genet, Alameda, CA USA	Case Western Reserve University; Pfizer	Magnuson, T (corresponding author), Case Western Reserve Univ, Dept Genet, Cleveland, OH 44106 USA.		Woychik, Richard P/C-8345-2019	Woychik, Richard P/0000-0001-8196-1732				BRONSTEIN SM, 1991, CANCER RES, V51, P5188; Brown SDM, 1998, HUM MOL GENET, V7, P1627, DOI 10.1093/hmg/7.10.1627; de Angelis MH, 1998, MUTAT RES-FUND MOL M, V400, P25, DOI 10.1016/S0027-5107(98)00061-X; DOUGLAS GR, 1995, P NATL ACAD SCI USA, V92, P7485, DOI 10.1073/pnas.92.16.7485; FAVOR J, 1991, MUTAT RES, V249, P293, DOI 10.1016/0027-5107(91)90003-7; GERSON SL, 1986, CARCINOGENESIS, V7, P745, DOI 10.1093/carcin/7.5.745; HITOTSUMACHI S, 1985, P NATL ACAD SCI USA, V82, P6619, DOI 10.1073/pnas.82.19.6619; JANSEN JG, 1994, MUTAGENESIS, V9, P417, DOI 10.1093/mutage/9.5.417; Justice MJ, 1999, HUM MOL GENET, V8, P1955, DOI 10.1093/hmg/8.10.1955; JUSTICE MJ, 1986, GENET RES, V47, P187, DOI 10.1017/S0016672300023119; Kasarskis A, 1998, P NATL ACAD SCI USA, V95, P7485, DOI 10.1073/pnas.95.13.7485; KONECKI DS, 1982, NUCLEIC ACIDS RES, V10, P6763, DOI 10.1093/nar/10.21.6763; Munroe RJ, 2000, NAT GENET, V24, P318, DOI 10.1038/73563; PEGG AE, 1992, FASEB J, V6, P2302, DOI 10.1096/fasebj.6.6.1544541; Rinchik EM, 1999, GENETICS, V152, P373; RUSSELL LB, 1990, BANBURY REPORT, V34, P271; RUSSELL WL, 1979, P NATL ACAD SCI USA, V76, P5818, DOI 10.1073/pnas.76.11.5818; SHEDLOVSKY A, 1988, P NATL ACAD SCI USA, V85, P180, DOI 10.1073/pnas.85.1.180; SHEDLOVSKY A, 1993, GENETICS, V134, P1205; Threadgill DW, 1997, MAMM GENOME, V8, P390, DOI 10.1007/s003359900453; Tong HH, 1997, ENVIRON MOL MUTAGEN, V29, P168; Veld CWOH, 1997, MUTAGENESIS, V12, P417, DOI 10.1093/mutage/12.6.417; VITATERNA MH, 1994, SCIENCE, V264, P719, DOI 10.1126/science.8171325	23	107	114	0	4	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAR	2000	24	3					314	317		10.1038/73557	http://dx.doi.org/10.1038/73557			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	288XW	10700191				2022-12-25	WOS:000085590600028
J	della-Cioppa, G; Callan, M				della-Cioppa, G; Callan, M			Sex, lies, and herbicides	NATURE BIOTECHNOLOGY			English	Editorial Material									Large Scale Biol Corp, Genom, Vacaville, CA 95688 USA; Large Scale Biol Corp, Business Dev, Vacaville, CA 95688 USA		della-Cioppa, G (corresponding author), Large Scale Biol Corp, Genom, Vacaville, CA 95688 USA.								0	0	0	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAR	2000	18	3					241	241		10.1038/73584	http://dx.doi.org/10.1038/73584			1	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	292AC	10700090				2022-12-25	WOS:000085771100003
J	Satoh, S; Daigo, Y; Furukawa, Y; Kato, T; Miwa, N; Nishiwaki, T; Kawasoe, T; Ishiguro, H; Fujita, M; Tokino, T; Sasaki, Y; Imaoka, S; Murata, M; Shimano, T; Yamaoka, Y; Nakamura, Y				Satoh, S; Daigo, Y; Furukawa, Y; Kato, T; Miwa, N; Nishiwaki, T; Kawasoe, T; Ishiguro, H; Fujita, M; Tokino, T; Sasaki, Y; Imaoka, S; Murata, M; Shimano, T; Yamaoka, Y; Nakamura, Y			AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1	NATURE GENETICS			English	Article							BETA-CATENIN GENE; TUMOR-SUPPRESSOR; APC; ACTIVATION; ADENOVIRUS; APOPTOSIS; PATHWAY; EXON-3	The Wnt signalling pathway is essential for development and organogenesis(1-3). Wnt signalling stabilizes beta-catenin, which accumulates in the cytoplasm, binds to T-cell factor (TCF; also known as lymphocyte enhancer-binding factor, LEF) and then upregulates downstream genes(4-6). Mutations in CTNNB1 (encoding beta-catenin) or ape (adenomatous polyposis coli) have been reported in human neoplasms including colon cancers and hepatocellular carcinomas(7-13) (HCCs), Because HCCs tend to show accumulation of beta-catenin more often than mutations in CTNNB1, we looked for mutations in AXIN1, encoding a key factor for Wnt signalling, in 6 HCC cell lines and 100 primary HCCs. Among the 4 cell lines and 87 HCCs in which we did not detect CTNNB1 mutations, we identified AXIN1 mutations in 3 cell lines and 6 mutations in 5 of the primary HCCs. In cell lines containing mutations in either gene, we observed increased DNA binding of TCF associated with beta-catenin in nuclei. Adenovirus mediated gene transfer of wild-type AXIN1 induced apoptosis in hepatocellular and colorectal cancer cells that had accumulated beta-catenin as a consequence of either APC, CTNNB1 or AXIN1 mutation, suggesting that axin may be an effective therapeutic molecule for suppressing growth of hepatocellular and colorectal cancers.	Univ Tokyo, Inst Med Sci, Ctr Human Genome, Mol Med Lab, Tokyo, Japan; Sapporo Med Univ, Sch Med, Canc Res Inst, Dept Mol Biol, Sapporo, Hokkaido, Japan; Osaka Med Ctr Canc & Cardiovasc Dis, Osaka, Japan; Municipal Ikeda Hosp, Osaka, Japan; Kyoto Univ, Grad Sch Med, Dept Surg Gastroenterol, Kyoto, Japan	University of Tokyo; Sapporo Medical University; Osaka Medical Center for Cancer & Cardiovascular Diseases; Kyoto University	Nakamura, Y (corresponding author), Univ Tokyo, Inst Med Sci, Ctr Human Genome, Mol Med Lab, Tokyo, Japan.		Tokino, Takashi/AAI-9887-2021	Daigo, Yataro/0000-0002-0915-3025				Chan EF, 1999, NAT GENET, V21, P410, DOI 10.1038/7747; de La Coste A, 1998, P NATL ACAD SCI USA, V95, P8847; DING SF, 1993, CANCER DETECT PREV, V17, P405; Fukuchi T, 1998, CANCER RES, V58, P3526; Hart MJ, 1998, CURR BIOL, V8, P573, DOI 10.1016/S0960-9822(98)70226-X; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Ihara A, 1996, HEPATOLOGY, V23, P1441, DOI 10.1053/jhep.1996.v23.pm0008675162; Itoh K, 1998, CURR BIOL, V8, P591, DOI 10.1016/S0960-9822(98)70229-5; Iwao K, 1998, CANCER RES, V58, P1021; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Lee YJ, 1999, J BIOL CHEM, V274, P1566, DOI 10.1074/jbc.274.3.1566; MCGRORY WJ, 1988, VIROLOGY, V163, P614, DOI 10.1016/0042-6822(88)90302-9; Miyoshi Y, 1998, CANCER RES, V58, P2524; Morin PJ, 1996, P NATL ACAD SCI USA, V93, P7950, DOI 10.1073/pnas.93.15.7950; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Nagai H, 1997, ONCOGENE, V14, P2927, DOI 10.1038/sj.onc.1201136; Nakamura T, 1998, GENES CELLS, V3, P395, DOI 10.1046/j.1365-2443.1998.00198.x; Nakamura Y, 1997, NAT MED, V3, P499, DOI 10.1038/nm0597-499; Orford K, 1999, J CELL BIOL, V146, P855, DOI 10.1083/jcb.146.4.855; Polakis P, 1997, BBA-REV CANCER, V1332, pF127, DOI 10.1016/S0304-419X(97)00008-5; Smalley MJ, 1999, EMBO J, V18, P2823, DOI 10.1093/emboj/18.10.2823; Takahashi M, 1996, J BIOL CHEM, V271, P26536, DOI 10.1074/jbc.271.43.26536; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Tsuda M, 1999, NATURE, V400, P276, DOI 10.1038/22336; vandeWetering M, 1996, MOL CELL BIOL, V16, P745; Voeller HJ, 1998, CANCER RES, V58, P2520; Zhang ZH, 1998, NATURE, V395, P698, DOI 10.1038/27208; Zurawel RH, 1998, CANCER RES, V58, P896	28	839	891	0	23	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAR	2000	24	3					245	250		10.1038/73448	http://dx.doi.org/10.1038/73448			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	288XW	10700176				2022-12-25	WOS:000085590600013
J	Shelton, AM; Tang, JD; Roush, RT; Metz, TD; Earle, ED				Shelton, AM; Tang, JD; Roush, RT; Metz, TD; Earle, ED			Field tests on managing resistance to Bt-engineered plants	NATURE BIOTECHNOLOGY			English	Article						Insecta; Plutella xylostella; Bacillus thuringiensis; resistance; transgenic plants	DIAMONDBACK MOTH LEPIDOPTERA; BACILLUS-THURINGIENSIS; TRANSGENIC PLANTS; INSECT RESISTANCE; CRYSTAL PROTEIN; PLUTELLIDAE; MANAGEMENT	Several important crops have been engineered to express toxins of Bacillus thuringiensis (Bt) for insect control. In 1999, US farmers planted nearly 8 million hectares (nearly 20 million acres) of transgenic St crops approved by the EPA. Bf-transgenic plants can greatly reduce the use of broader spectrum insecticides, but insect resistance may hinder this technology. Present resistance management strategies rely on a "refuge" composed of non-Bt plants to conserve susceptible alleles. We have used Bf-transgenic broccoli plants and the diamondback moth as a model system to examine resistance management strategies. The higher number of larvae on refuge plants in our field tests indicate that a "separate refuge" will be more effective at conserving susceptible larvae than a "mixed refuge" and would thereby reduce the number of homozygous resistant (RR) offspring. Our field tests also examined the strategy of spraying the refuge to prevent economic loss to the crop while maintaining susceptible alleles in the population. Results indicate that great care must be taken to ensure that refuges, particularly those sprayed with efficacious insecticides, produce adequate numbers of susceptible alleles. Each insect/Bt crop system may have unique management requirements because of the biology of the insect, but our studies validate the need for a refuge. As we learn more about how to refine our present resistance management strategies, it is important to also develop the next generation of technology and implementation strategies.	Cornell Univ, New York State Agr Expt Stn, Dept Entomol, Geneva, NY 14456 USA; Cornell Univ, Dept Entomol, Ithaca, NY 14853 USA; Cornell Univ, Dept Plant Breeding, Ithaca, NY 14853 USA	Cornell University; Cornell University; Cornell University	Shelton, AM (corresponding author), Cornell Univ, New York State Agr Expt Stn, Dept Entomol, Geneva, NY 14456 USA.							ALSTAD DN, 1995, SCIENCE, V268, P1894, DOI 10.1126/science.268.5219.1894; Gould F, 1998, NOW NEVER SERIOUS NE, P67; Hargrove TR, 1999, AM SCI, V87, P24; KRATTIGER A, 1997, 2 ISAAA; LeOra Software, 1987, POL PC US GUID PROB; LLEWELLYN D, 1998, P 6 AUSTR APPL ENT R; MCGAUGHEY WH, 1992, SCIENCE, V258, P1451, DOI 10.1126/science.258.5087.1451; MELLON M, 1998, NOW NEVER SERIOUS PL; Metz TD, 1995, PLANT CELL REP, V15, P287, DOI 10.1007/BF00193738; METZ TD, 1995, MOL BREEDING, V1, P309, DOI 10.1007/BF01248408; Perez CJ, 1997, J ECON ENTOMOL, V90, P94, DOI 10.1093/jee/90.1.94; Roush R. T., 1997, ADV INSECT CONTROL R, P271; Roush Richard T., 1996, V15, P242; Roush RT, 1997, NAT BIOTECHNOL, V15, P816, DOI 10.1038/nbt0997-816; Roush RT, 1997, PESTIC SCI, V51, P328, DOI 10.1002/(SICI)1096-9063(199711)51:3&lt;328::AID-PS650&gt;3.0.CO;2-B; ROUSH RT, 1994, BIOCONTROL SCI TECHN, V4, P501, DOI 10.1080/09583159409355364; SHELTON AM, 1993, J ECON ENTOMOL, V86, P697, DOI 10.1093/jee/86.3.697; Shelton AM, 1998, PEST MANAGEMENT - FUTURE CHALLENGES, VOLS 1 AND 2, PROCEEDINGS, P258; Tabashnik BE, 1997, P NATL ACAD SCI USA, V94, P12780, DOI 10.1073/pnas.94.24.12780; TABASHNIK BE, 1994, P ROY SOC B-BIOL SCI, V255, P7, DOI 10.1098/rspb.1994.0002; TALEKAR NS, 1993, ANNU REV ENTOMOL, V38, P275, DOI 10.1146/annurev.en.38.010193.001423; Tang JD, 1996, APPL ENVIRON MICROB, V62, P564, DOI 10.1128/AEM.62.2.564-569.1996; Tang JD, 1997, J ECON ENTOMOL, V90, P732, DOI 10.1093/jee/90.3.732; Tang JD, 1999, J ECON ENTOMOL, V92, P47, DOI 10.1093/jee/92.1.47	24	162	186	0	27	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAR	2000	18	3					339	342		10.1038/73804	http://dx.doi.org/10.1038/73804			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	292AC	10700153				2022-12-25	WOS:000085771100035
J	Engert, JC; Berube, P; Mercier, J; Dore, C; Lepage, P; Ge, B; Bouchard, JP; Mathieu, J; Melancon, SB; Schalling, M; Lander, ES; Morgan, K; Hudson, TJ; Richter, A				Engert, JC; Berube, P; Mercier, J; Dore, C; Lepage, P; Ge, B; Bouchard, JP; Mathieu, J; Melancon, SB; Schalling, M; Lander, ES; Morgan, K; Hudson, TJ; Richter, A			ARSACS, a spastic ataxia common in northeastern Quebec, is caused by mutations in a new gene encoding an 11.5-kb ORF	NATURE GENETICS			English	Article							DISEQUILIBRIUM; LINKAGE; CHAPERONE; POPULATIONS; FREQUENCY; DISORDERS; SAGUENAY; FINLAND; ALLELE; BASE	Autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS or SACS) is an early onset neurodegenerative disease with high prevalence (carrier frequency 1/22) in the Charlevoix-Saguenay-Lac-Saint-Jean (CSLSJ) region of Quebec. We previously mapped the gene responsible for ARSACS to chromosome 13q11 and identified two ancestral haplotypes. Here we report the cloning of this gene, SAGS, which encodes the protein sacsin. The ORF of SAGS is 11,487 bp and is encoded by a single gigantic exon spanning 12,794 bp. This exon is the largest to be identified in any vertebrate organism. The ORF is conserved in human and mouse. The putative protein contains three large segments with sequence similarity to each other and to the predicted protein of an Arabidopsis thaliana ORF. The presence of heat-shock domains suggests a function for sacsin in chaperone-mediated protein folding. SAGS is expressed in a variety of tissues, including the central nervous system. We identified two SAGS mutations in ARSACS families that lead to protein truncation, consistent with haplotype analysis.	Univ Montreal, Hop St Justine, Gen Med Serv, Dept Pediat, Montreal, PQ H3T 1C5, Canada; McGill Univ, Montreal Genome Ctr, Hlth Ctr Res Inst, Montreal, PQ, Canada; Hop Enfants Jesus, Serv Neurol, Quebec City, PQ G1J 1Z4, Canada; Hop Chicoutimi, Serv Neurol, Chicoutimi, PQ, Canada; Karolinska Inst, Neurogen Unit, Dept Mol Med, Stockholm, Sweden; MIT, Whitehead Inst Biomed Res, Cambridge, MA USA; McGill Univ, Dept Human Genet & Med, Montreal, PQ, Canada	Universite de Montreal; McGill University; Laval University; Karolinska Institutet; Massachusetts Institute of Technology (MIT); Whitehead Institute; McGill University	Richter, A (corresponding author), Univ Montreal, Hop St Justine, Gen Med Serv, Dept Pediat, Montreal, PQ H3T 1C5, Canada.	thudson@genome.wi.mit.edu; richtera@ere.umontreal.ca	Schalling, Martin/F-1518-2015	Schalling, Martin/0000-0001-5011-2922; Berube, Pierre/0000-0002-1008-192X; Engert, James/0000-0001-8411-4790; Hudson, Thomas/0000-0002-1376-4849				Austerlitz F, 1998, P NATL ACAD SCI USA, V95, P15140, DOI 10.1073/pnas.95.25.15140; Austerlitz F, 1999, GENET EPIDEMIOL, V16, P2, DOI 10.1002/(SICI)1098-2272(1999)16:1<2::AID-GEPI2>3.0.CO;2-9; Birren Bruce, 1999, P241; BOEHNKE M, 1994, AM J HUM GENET, V55, P379; Bonfield JK, 1995, NUCLEIC ACIDS RES, V23, P4992, DOI 10.1093/nar/23.24.4992; Bonfield JK, 1996, DNA SEQUENCE, V6, P109, DOI 10.3109/10425179609010197; Bouchard JP, 1998, NEUROMUSCULAR DISORD, V8, P474, DOI 10.1016/S0960-8966(98)00055-8; Bouchard JP., 1991, HDB CLIN NEUROLOGY H, V60, P451; Boysen C, 1997, BIOTECHNIQUES, V23, P978, DOI 10.2144/97236bm01; BROWN CJ, 1992, CELL, V71, P527, DOI 10.1016/0092-8674(92)90520-M; Buchner J, 1999, TRENDS BIOCHEM SCI, V24, P136, DOI 10.1016/S0968-0004(99)01373-0; Charbonneau H., 1987, HIST ATLAS CANADA, V1; Cummings CJ, 1998, NAT GENET, V19, P148, DOI 10.1038/502; De La Chapelle A, 1998, P NATL ACAD SCI USA, V95, P12416, DOI 10.1073/pnas.95.21.12416; DEBRAEKELEER M, 1995, ANN HUM BIOL, V22, P111, DOI 10.1080/03014469500003772; Desseyn JL, 1997, J BIOL CHEM, V272, P3168, DOI 10.1074/jbc.272.6.3168; DEVLIN B, 1995, GENOMICS, V29, P311, DOI 10.1006/geno.1995.9003; DICKIE MM, 1965, MOUSE NEWS LETT, V32, P45; Dittmar KD, 1998, J BIOL CHEM, V273, P7358, DOI 10.1074/jbc.273.13.7358; Engert JC, 1999, GENOMICS, V62, P156, DOI 10.1006/geno.1999.6003; Fink AL, 1999, PHYSIOL REV, V79, P425, DOI 10.1152/physrev.1999.79.2.425; Graham J, 1998, AM J HUM GENET, V63, P1517, DOI 10.1086/302102; GRAHAM J, 1998, THESIS U WASHINGTON; GUPTA RS, 1995, MOL BIOL EVOL, V12, P1063; HASTBACKA J, 1992, NAT GENET, V2, P204, DOI 10.1038/ng1192-204; Heyer E, 1999, HUM BIOL, V71, P99; KIMURA Y, 1995, SCIENCE, V268, P1362, DOI 10.1126/science.7761857; KNOPPERS BM, 1991, CAN MED ASSOC J, V144, P128; Kruglyak L, 1999, NAT GENET, V22, P139, DOI 10.1038/9642; Marcotte EM, 1999, SCIENCE, V285, P751, DOI 10.1126/science.285.5428.751; McCarthy LC, 1997, GENOME RES, V7, P1153, DOI 10.1101/gr.7.12.1153; McNally EM, 1996, AM J HUM GENET, V59, P1040; Nagase T, 1998, DNA Res, V5, P277, DOI 10.1093/dnares/5.5.277; NAKAI K, 1992, GENOMICS, V14, P897, DOI 10.1016/S0888-7543(05)80111-9; Prodromou C, 1997, CELL, V90, P65, DOI 10.1016/S0092-8674(00)80314-1; Richter A, 1999, AM J HUM GENET, V64, P768, DOI 10.1086/302274; SCHALLING M, 1991, NEUROSCIENCE, V41, P753, DOI 10.1016/0306-4522(91)90365-U; Smith RF, 1996, GENOME RES, V6, P454, DOI 10.1101/gr.6.5.454; Thompson EA, 1997, AM J HUM GENET, V60, P197; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Van Etten WJ, 1999, NAT GENET, V22, P384, DOI 10.1038/11962; WEEKS DE, 1995, AM J HUM GENET, V56, P1506	42	286	298	0	13	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	FEB	2000	24	2					120	125		10.1038/72769	http://dx.doi.org/10.1038/72769			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	280LQ	10655055				2022-12-25	WOS:000085104600010
J	Hicks, GG; Singh, N; Nashabi, A; Mai, S; Bozek, G; Klewes, L; Arapovic, D; White, EK; Koury, MJ; Oltz, EM; Van Kaer, L; Ruley, HE				Hicks, GG; Singh, N; Nashabi, A; Mai, S; Bozek, G; Klewes, L; Arapovic, D; White, EK; Koury, MJ; Oltz, EM; Van Kaer, L; Ruley, HE			Fus deficiency in mice results in defective B-lymphocyte development and activation, high levels of chromosomal instability and perinatal death	NATURE GENETICS			English	Article							HUMAN MYELOID-LEUKEMIA; C-ABL; ATAXIA-TELANGIECTASIA; TLS; PROTEIN; CELLS; ATM; TLS/FUS; ERG; DNA	The gene FUS (also known as TLS (for translocated in liposarcoma) and hnRNP P-2) is translocated with the gene encoding the transcription factor ERG-1 in human myeloid leukaemias(1-3) Although the functions of wild-type FUS are unknown, the protein contains an RNA-recognition motif and is a component of nuclear riboprotein complexes(4,5). FUS resembles a transcription factor in that it binds DNA. contributes a transcriptional activation domain to the FUS-ERG oncoprotein and interacts with several transcription factors in vitro(6-8). TO better understand FUS function in vivo, we examined the consequences of disrupting Fus in mice. Our results indicate that Fus is essential for viability of neonatal animals, influences lymphocyte development in a non-cell-intrinsic manner, has an intrinsic role in the proliferative responses of B cells to specific mitogenic stimuli and is required for the maintenance of genomic stability. The involvement of a nuclear riboprotein in these processes in vivo indicates that Fus is important in genome maintenance.	Manitoba Inst Cell Biol, Winnipeg, MB R3E 0V9, Canada; Univ Manitoba, Winnipeg, MB, Canada; Vanderbilt Univ, Sch Med, Dept Microbiol & Immunol, Nashville, TN USA; Vanderbilt Univ, Sch Med, Howard Hughes Med Inst, Nashville, TN 37212 USA; Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37212 USA; Dept Vet Affairs, Nashville, TN USA	University of Manitoba; Vanderbilt University; Howard Hughes Medical Institute; Vanderbilt University; Vanderbilt University	Hicks, GG (corresponding author), Manitoba Inst Cell Biol, 100 Olivia St, Winnipeg, MB R3E 0V9, Canada.		Van Kaer, Luc/H-1033-2015; Mai, Sabine/E-5667-2017	Van Kaer, Luc/0000-0001-5275-2309; Mai, Sabine/0000-0002-5797-2201; Hicks, Geoffrey/0000-0003-4688-2312	NATIONAL CANCER INSTITUTE [P30CA042014] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [R01RR013166] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG000684] Funding Source: NIH RePORTER; NCI NIH HHS [P30CA42014] Funding Source: Medline; NCRR NIH HHS [R01RR13166] Funding Source: Medline; NHGRI NIH HHS [R01HG00684] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		Aman P, 1996, GENOMICS, V37, P1, DOI 10.1006/geno.1996.0513; Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0; Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; Bertrand P, 1999, ONCOGENE, V18, P4515, DOI 10.1038/sj.onc.1203048; CALVIO C, 1995, RNA, V1, P724; CARSETTI R, 1995, J EXP MED, V181, P2129, DOI 10.1084/jem.181.6.2129; DERR LK, 1991, CELL, V67, P355, DOI 10.1016/0092-8674(91)90187-4; Fukatsu K, 1997, SEN-I GAKKAISHI, V53, P15, DOI 10.2115/fiber.53.15; GAUBATZ JW, 1990, MUTAT RES, V237, P271, DOI 10.1016/0921-8734(90)90009-G; Hallier M, 1998, J BIOL CHEM, V273, P4838, DOI 10.1074/jbc.273.9.4838; HARDIN JD, 1995, CELL IMMUNOL, V165, P44, DOI 10.1006/cimm.1995.1185; Hicks GG, 1997, NAT GENET, V16, P338, DOI 10.1038/ng0897-338; HIYOSHI M, 1995, CLIN LAB HAEMATOL, V17, P243; Horwitz BH, 1997, IMMUNITY, V6, P765, DOI 10.1016/S1074-7613(00)80451-3; ICHIKAWA H, 1994, CANCER RES, V54, P2865; Maldonado E, 1996, NATURE, V381, P86, DOI 10.1038/381086a0; Moore JK, 1996, NATURE, V383, P644, DOI 10.1038/383644a0; Pereira DS, 1998, P NATL ACAD SCI USA, V95, P8239, DOI 10.1073/pnas.95.14.8239; Perrotti D, 1998, EMBO J, V17, P4442, DOI 10.1093/emboj/17.15.4442; Powers CA, 1998, MOL ENDOCRINOL, V12, P4, DOI 10.1210/mend.12.1.0043; PRASAD DDK, 1994, ONCOGENE, V9, P3717; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SCHWARTZBERG PL, 1991, CELL, V65, P1165, DOI 10.1016/0092-8674(91)90012-N; Shafman T, 1997, NATURE, V387, P520, DOI 10.1038/387520a0; Singh N, 1999, J IMMUNOL, V163, P2373; Teng SC, 1996, NATURE, V383, P641, DOI 10.1038/383641a0; Xu Y, 1996, GENE DEV, V10, P2401, DOI 10.1101/gad.10.19.2401; Xu Y, 1996, GENE DEV, V10, P2411, DOI 10.1101/gad.10.19.2411; ZINSZNER H, 1994, GENE DEV, V8, P2513, DOI 10.1101/gad.8.21.2513; Zinszner H, 1997, ONCOGENE, V14, P451, DOI 10.1038/sj.onc.1200854	30	220	226	0	5	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	FEB	2000	24	2					175	179		10.1038/72842	http://dx.doi.org/10.1038/72842			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	280LQ	10655065				2022-12-25	WOS:000085104600020
J	Alexeev, V; Igoucheva, O; Domashenko, A; Cotsarelis, G; Yoon, K				Alexeev, V; Igoucheva, O; Domashenko, A; Cotsarelis, G; Yoon, K			Localized in vivo genotypic and phenotypic correction of the albino mutation in skin by RNA-DNA oligonucleotide	NATURE BIOTECHNOLOGY			English	Article						gene correction; epidermis; intradermal injection; topical application	CHIMERIC RNA/DNA OLIGONUCLEOTIDE; HUMAN HAIR-FOLLICLES; TYROSINASE GENE; STEM-CELLS; MOUSE TYROSINASE; BULGE AREA; MELANOCYTES; MICE; EXPRESSION; EPIDERMIS	We recently demonstrated that an RNA-DNA oligonucleotide corrected a point mutation in the mouse tyrosinase gene, resulting in permanent and inheritable restoration of tyrosinase enzymatic activity, melanin synthesis, and pigmentation changes in cultured melanocytes. In this study, we extended gene correction of melanocytes from tissue culture to live animals, using a chimeric oligonucleotide designed to correct a point mutation in the tyrosinase gene, Both topical application and intradermal injection of this oligonucleotide to albino BALB/c mouse skin resulted in dark pigmentation of several hairs in a localized area. The restored tyrosinase enzymatic activity was detected by dihydroxyphenylacetic acid (DOPA) staining of hair follicles in the treated skin, Tyrosinase gene correction was also confirmed by restriction fragment length polymorphism analysis and DNA sequencing from skin that was positive for DOPA staining and melanin synthesis. Localized gene correction was maintained three months after the last application of the chimeric oligonucleotides, These results demonstrated correction of the tyrosinase gene point mutation by chimeric oligonucleotides in vivo.	Thomas Jefferson Univ, Jefferson Inst Mol Med, Dept Dermatol & Cutaneous Biol, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Jefferson Inst Mol Med, Dept Biochem & Mol Pharmacol, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Jefferson Med Coll, Philadelphia, PA 19107 USA; Univ Penn, Sch Med, Dept Dermatol, Philadelphia, PA 19104 USA	Jefferson University; Jefferson University; Jefferson University; University of Pennsylvania	Yoon, K (corresponding author), Thomas Jefferson Univ, Jefferson Inst Mol Med, Dept Dermatol & Cutaneous Biol, Philadelphia, PA 19107 USA.	Kyonggeun.Yoon@mail.tju.edu			NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR044350] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR44350] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Alexeev V, 1998, NAT BIOTECHNOL, V16, P1343, DOI 10.1038/4322; BEERMANN F, 1990, EMBO J, V9, P2819, DOI 10.1002/j.1460-2075.1990.tb07470.x; BENNETT DC, 1989, DEVELOPMENT, V105, P379; ColeStrauss A, 1996, SCIENCE, V273, P1386, DOI 10.1126/science.273.5280.1386; COTSARELIS G, 1990, CELL, V61, P1329, DOI 10.1016/0092-8674(90)90696-C; delMarmol V, 1996, FEBS LETT, V381, P165, DOI 10.1016/0014-5793(96)00109-3; Dry FW, 1926, J GENET, V16, P287, DOI 10.1007/BF02983004; FAVOR J, 1987, MUTAT RES, V177, P161, DOI 10.1016/0027-5107(87)90031-5; GAUDET SJ, 1993, J INVEST DERMATOL, V100, P537; HALABAN R, 1993, J INVEST DERMATOL, V100, pS176, DOI 10.1111/1523-1747.ep12465140; HENGGE UR, 1995, NAT GENET, V10, P161, DOI 10.1038/ng0695-161; HUSZAR D, 1991, DEVELOPMENT, V113, P653; JACKSON IJ, 1990, P NATL ACAD SCI USA, V87, P7010, DOI 10.1073/pnas.87.18.7010; JONES PH, 1993, CELL, V73, P713, DOI 10.1016/0092-8674(93)90251-K; Kren BT, 1997, HEPATOLOGY, V25, P1462, DOI 10.1002/hep.510250626; Kren BT, 1998, NAT MED, V4, P285, DOI 10.1038/nm0398-285; LI LN, 1995, NAT MED, V1, P705, DOI 10.1038/nm0795-705; MASON HS, 1968, MANUAL HISTOLOGIC ST, P104; Narisawa Y, 1997, ACTA DERM-VENEREOL, V77, P97; Paus R, 1999, NEW ENGL J MED, V341, P491, DOI 10.1056/NEJM199908123410706; ROCHAT A, 1994, CELL, V76, P1063, DOI 10.1016/0092-8674(94)90383-2; Santana E, 1998, J INVEST DERMATOL, V111, P1172, DOI 10.1046/j.1523-1747.1998.00403.x; SHIBAHARA S, 1990, EUR J BIOCHEM, V189, P455, DOI 10.1111/j.1432-1033.1990.tb15510.x; Silvers WK., 1979, COAT COLORS MICE, DOI [10.1007/978-1-4612-6164-3, DOI 10.1007/978-1-4612-6164-3]; SLOMINSKI A, 1994, J INVEST DERMATOL, V102, P862, DOI 10.1111/1523-1747.ep12382606; STRAILE WE, 1964, DEV BIOL, V10, P45, DOI 10.1016/0012-1606(64)90004-1; TANAKA S, 1990, DEVELOPMENT, V108, P223; TOBIN DJ, 1995, J INVEST DERMATOL, V104, P86, DOI 10.1111/1523-1747.ep12613573; Tobin DJ, 1996, PIGM CELL RES, V9, P304, DOI 10.1111/j.1600-0749.1996.tb00122.x; Tobin DJ, 1998, J INVEST DERMATOL, V111, P941, DOI 10.1046/j.1523-1747.1998.00417.x; Xiang YF, 1997, J MOL MED-JMM, V75, P829, DOI 10.1007/s001090050172; Yoon K, 1996, P NATL ACAD SCI USA, V93, P2071, DOI 10.1073/pnas.93.5.2071; Yoon K, 1999, BIOGENIC AMINES, V15, P137; Zhang ZP, 1998, ANTISENSE NUCLEIC A, V8, P531, DOI 10.1089/oli.1.1998.8.531	34	116	141	0	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JAN	2000	18	1					43	47		10.1038/71901	http://dx.doi.org/10.1038/71901			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	273GQ	10625389				2022-12-25	WOS:000084699900023
J	Usui-Aoki, K; Ito, H; Ui-Tei, K; Takahashi, K; Lukacsovich, T; Awano, W; Nakata, H; Piao, ZF; Nilsson, EE; Tomida, J; Yamamoto, D				Usui-Aoki, K; Ito, H; Ui-Tei, K; Takahashi, K; Lukacsovich, T; Awano, W; Nakata, H; Piao, ZF; Nilsson, EE; Tomida, J; Yamamoto, D			Formation of the male-specific muscle in female Drosophila by ectopic fruitless expression	NATURE CELL BIOLOGY			English	Article							SEX-DETERMINATION; DOSAGE COMPENSATION; MELANOGASTER; DOUBLESEX; LETHAL; GENES; BEHAVIOR; PROTEIN; DIFFERENTIATION; TRANSFORMER-2	The Drosophila fruitless (fru) gene product Fru has been postulated to be a neural sex-determination factor that directs the development of at least two male-specific characteristics, namely courtship behaviour and formation of the muscle of Lawrence (MOL). The fru gene encodes a putative transcription factor with a BTB domain and two zinc-finger motifs, and with consensus Tra-binding sequences. The binding of Tra to these sequences results in sex-specific alternative splicing of the fru mRNA, leading to production of the 'male-type' or 'female-type' Fru protein. We show here that the Fru protein is not detected in the female central nervous system (CNS), despite the similar level of expression of fru mRNA in both male and female CNS. As ectopic expression of both the 'male-type' (with the sequence for the aminoterminal extension) and 'female-type' (without the sequence for the amino-terminal extension) fru cDNA can induce formation of the MOL in females, the presence or absence of the Fru protein, and not its sex-specific structure, seems to be responsible for the sexually dimorphic actions of the fru gene.	Waseda Univ, Sch Human Sci, Tokorozawa, Saitama 3591192, Japan; Waseda Univ, Adv Res Inst Sci & Engn, Tokorozawa, Saitama 3591192, Japan; Mitsubishi Kaisei Inst Life Sci, Japan Sci & Technol Corp, Yamamoto Behav Genes Project, ERATO, Tokyo 1948511, Japan; Nippon Med Sch, Dept Pharmacol, Bunkyo Ku, Tokyo 1138602, Japan; Univ Osaka Prefecture, Grad Sch Integrated Arts & Sci, Osaka 5998531, Japan	Waseda University; Waseda University; Japan Science & Technology Agency (JST); Nippon Medical School; Osaka Metropolitan University	Usui-Aoki, K (corresponding author), Waseda Univ, Sch Human Sci, 2-579-15 Mikajima, Tokorozawa, Saitama 3591192, Japan.		Nilsson, Eric/AAR-5021-2020; Ito, Hiroki/ABC-9621-2020; Ito, Hiroki/E-4858-2017	, Daisuke/0000-0002-4623-0106; Ito, Hiroki/0000-0003-4745-5750; Tomida, Junya/0000-0002-0813-5757				Baba K, 1999, MOL CELL BIOL, V19, P4405; Bashaw GJ, 1997, CELL, V89, P789, DOI 10.1016/S0092-8674(00)80262-7; Bopp D, 1996, DEVELOPMENT, V122, P971; Charlesworth B, 1996, CURR BIOL, V6, P149, DOI 10.1016/S0960-9822(02)00448-7; Du C, 1998, MOL CELL, V2, P741, DOI 10.1016/S1097-2765(00)80289-0; Goodwin SF, 2000, GENETICS, V154, P725; Heinrichs V, 1998, MOL CELL BIOL, V18, P450, DOI 10.1128/MCB.18.1.450; INOUE K, 1992, P NATL ACAD SCI USA, V89, P8092, DOI 10.1073/pnas.89.17.8092; Ito H, 1996, P NATL ACAD SCI USA, V93, P9687, DOI 10.1073/pnas.93.18.9687; Ito K, 1997, CELL TISSUE RES, V290, P1, DOI 10.1007/s004410050901; KAUFMAN RJ, 1987, EMBO J, V6, P187, DOI 10.1002/j.1460-2075.1987.tb04737.x; Kelley RL, 1997, NATURE, V387, P195, DOI 10.1038/387195a0; LAWRENCE PA, 1984, CELL, V36, P775, DOI 10.1016/0092-8674(84)90357-X; LAWRENCE PA, 1986, CELL, V45, P505, DOI 10.1016/0092-8674(86)90282-5; Lukacsovich T, 1999, GENOMICS, V57, P43, DOI 10.1006/geno.1999.5746; Marin I, 1998, SCIENCE, V281, P1990, DOI 10.1126/science.281.5385.1990; Merendino L, 1999, NATURE, V402, P838, DOI 10.1038/45602; Parkes TL, 1998, NAT GENET, V19, P171, DOI 10.1038/534; Ryner LC, 1996, CELL, V87, P1079, DOI 10.1016/S0092-8674(00)81802-4; TAYLOR BJ, 1992, GENETICS, V132, P179; Villella A, 1996, GENETICS, V143, P331; Waterbury JA, 1999, GENETICS, V152, P1653; Yamamoto D, 1998, MECH DEVELOP, V73, P135, DOI 10.1016/S0925-4773(98)00042-2	23	128	130	2	6	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	AUG	2000	2	8					500	506		10.1038/35019537	http://dx.doi.org/10.1038/35019537			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	341TE	10934470				2022-12-25	WOS:000088605000015
J	Lee, SH; Lumelsky, N; Studer, L; Auerbach, JM; McKay, RD				Lee, SH; Lumelsky, N; Studer, L; Auerbach, JM; McKay, RD			Efficient generation of midbrain and hindbrain neurons from mouse embryonic stem cells	NATURE BIOTECHNOLOGY			English	Article							FETAL VENTRAL MESENCEPHALON; IN-VITRO; DOPAMINERGIC-NEURONS; MAMMALIAN BRAIN; PRECURSOR CELLS; NEURAL PLATE; PAX-GENES; TRANSPLANTATION; DIFFERENTIATION; EXPRESSION		NINDS, Mol Biol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)	McKay, RD (corresponding author), NINDS, Mol Biol Lab, NIH, Bethesda, MD 20892 USA.	mckay@codon.nih.gov	Studer, Lorenz/ABH-1491-2021	Studer, Lorenz/0000-0003-0741-7987				Acampora D, 1999, TRENDS NEUROSCI, V22, P116, DOI 10.1016/S0166-2236(98)01387-3; Auerbach JM, 2000, EUR J NEUROSCI, V12, P1696, DOI 10.1046/j.1460-9568.2000.00067.x; BAIN G, 1995, DEV BIOL, V168, P342, DOI 10.1006/dbio.1995.1085; Branton RL, 1998, NEUROREPORT, V9, P3223, DOI 10.1097/00001756-199810050-00017; Breier A, 1997, P NATL ACAD SCI USA, V94, P2569, DOI 10.1073/pnas.94.6.2569; Brustle O, 1997, P NATL ACAD SCI USA, V94, P14809, DOI 10.1073/pnas.94.26.14809; Brustle O, 1999, SCIENCE, V285, P754, DOI 10.1126/science.285.5428.754; Deacon T, 1998, EXP NEUROL, V149, P28, DOI 10.1006/exnr.1997.6674; FREDERIKSEN K, 1988, J NEUROSCI, V8, P1144; GRAM LF, 1994, NEW ENGL J MED, V331, P1354; Johe KK, 1996, GENE DEV, V10, P3129, DOI 10.1101/gad.10.24.3129; Joyner AL, 1996, TRENDS GENET, V12, P15, DOI 10.1016/0168-9525(96)81383-7; KALIR HH, 1991, J NEUROCHEM, V57, P458, DOI 10.1111/j.1471-4159.1991.tb03773.x; Keller G, 1998, BLOOD, V92, P877, DOI 10.1182/blood.V92.3.877.415k11_877_887; Klug MG, 1996, J CLIN INVEST, V98, P216, DOI 10.1172/JCI118769; LENDAHL U, 1990, CELL, V60, P585, DOI 10.1016/0092-8674(90)90662-X; Okabe S, 1996, MECH DEVELOP, V59, P89, DOI 10.1016/0925-4773(96)00572-2; Olanow CW, 1996, TRENDS NEUROSCI, V19, P102, DOI 10.1016/S0166-2236(96)80038-5; Reubinoff BE, 2000, NAT BIOTECHNOL, V18, P399, DOI 10.1038/74447; ROWITCH DH, 1995, MECH DEVELOP, V52, P3, DOI 10.1016/0925-4773(95)00380-J; Shamblott MJ, 1998, P NATL ACAD SCI USA, V95, P13726, DOI 10.1073/pnas.95.23.13726; Simeone A, 1998, EMBO J, V17, P6790, DOI 10.1093/emboj/17.23.6790; Spenger C, 1996, EXP BRAIN RES, V112, P47; STOYKOVA A, 1994, J NEUROSCI, V14, P1395, DOI 10.1523/JNEUROSCI.14-03-01395.1994; Studer L, 1996, BRAIN RES BULL, V41, P143, DOI 10.1016/0361-9230(96)00114-1; Studer L, 1998, NAT NEUROSCI, V1, P537, DOI 10.1038/2774; Studer L, 1998, NAT NEUROSCI, V1, P290, DOI 10.1038/1105; Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145; VICARIOABEJON C, 1995, NEURON, V15, P105, DOI 10.1016/0896-6273(95)90068-3; Volkow ND, 1997, NATURE, V386, P830, DOI 10.1038/386830a0; Volkow ND, 1997, NATURE, V386, P827, DOI 10.1038/386827a0; Wagner J, 1999, NAT BIOTECHNOL, V17, P653, DOI 10.1038/10862; Wobus AM, 1999, CELLS TISSUES ORGANS, V165, P129, DOI 10.1159/000016692; Ye WL, 1998, CELL, V93, P755, DOI 10.1016/S0092-8674(00)81437-3	34	997	1121	2	77	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JUN	2000	18	6					675	679		10.1038/76536	http://dx.doi.org/10.1038/76536			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	325EK	10835609				2022-12-25	WOS:000087663200031
J	Liang, F; Holt, I; Pertea, G; Karamycheva, S; Salzberg, SL; Quackenbush, J				Liang, F; Holt, I; Pertea, G; Karamycheva, S; Salzberg, SL; Quackenbush, J			Gene Index analysis of the human genome estimates approximately 120,000 genes	NATURE GENETICS			English	Article							DNA-SEQUENCE	Although sequencing of the human genome will soon be completed, gene identification and annotation remains a challenge. Early estimates suggested that there might be 60,000-100,000 (ref. 1) human genes, but recent analyses of the available data from EST sequencing projects have estimated as few as 45,000 (ref. 2) or as many as 140,000 (ref. 3) distinct genes. The Chromosome 22 Sequencing Consortium estimated a minimum of 45,000 genes based on their annotation of the complete chromosome, although their data suggests there may be additional genes(4). The nearly 2,000,000 human ESTs in dbEST provide an important resource for gene identification and genome annotation, but these single-pass sequences must be carefully analysed to remove contaminating sequences, including those from genomic DNA. spurious transcription, and vector and bacterial sequences. We have developed a highly refined and rigorously tested protocol for cleaning, clustering and assembling EST sequences to produce high-fidelity consensus sequences for the represented genes (F.L. et al.. manuscript submitted) and used this to create the TIGR Gene Indices(5)-databases of expressed genes for human, mouse, rat and other species (http://www.tigr.org/tdb/tgi.html). Using highly refined and tested algorithms for EST analysis, we have arrived at two independent estimates indicating the human genome contains approximately 120,000 genes.	Inst Genom Res, Rockville, MD USA	J. Craig Venter Institute	Quackenbush, J (corresponding author), Inst Genom Res, Rockville, MD USA.	johnq@tigr.org	Salzberg, Steven L/F-6162-2011; Salzberg, Steven/Q-6514-2019	Salzberg, Steven L/0000-0002-8859-7432; Salzberg, Steven/0000-0002-8859-7432; Quackenbush, John/0000-0002-2702-5879				Deloukas P, 1998, SCIENCE, V282, P744, DOI 10.1126/science.282.5389.744; Dunham I, 1999, NATURE, V402, P489, DOI 10.1038/990031; FIELDS C, 1994, NAT GENET, V7, P345, DOI 10.1038/ng0794-345; GREEN P, 1999, BRIDGING GAP SEQUENC; Huang XQ, 1999, GENOME RES, V9, P868, DOI 10.1101/gr.9.9.868; Huang XQ, 1997, GENOMICS, V46, P37, DOI 10.1006/geno.1997.4984; Quackenbush J, 2000, NUCLEIC ACIDS RES, V28, P141, DOI 10.1093/nar/28.1.141; Schuler GD, 1997, GENOME RES, V7, P541, DOI 10.1101/gr.7.5.541; SCOTT R, 1999, 11 INT GEN SEQ AN C	9	208	222	0	8	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1061-4036	1546-1718		NAT GENET	Nature Genet.	JUN	2000	25	2					239	240		10.1038/76126	http://dx.doi.org/10.1038/76126			2	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	321ML	10835646				2022-12-25	WOS:000087459200030
J	van Egmond, M; van Garderen, E; van Spriel, AB; Damen, CA; van Amersfoort, ES; van Zandbergen, G; van Hattum, J; Kuiper, J; van de Winkel, JGJ				van Egmond, M; van Garderen, E; van Spriel, AB; Damen, CA; van Amersfoort, ES; van Zandbergen, G; van Hattum, J; Kuiper, J; van de Winkel, JGJ			Fc alpha RI-positive liver Kupffer cells: Reappraisal of the function of immunoglobulin A in immunity	NATURE MEDICINE			English	Article							HUMAN-IGA; POLYMORPHONUCLEAR LEUKOCYTES; RECEPTOR EXPRESSION; PHAGOCYTOSIS; CD89; ANTIBODIES; CHEMILUMINESCENCE; NEUTROPHILS; ENHANCEMENT; MECHANISM	Despite the well-recognized involvement of immunoglobulin (Ig) A in mucosal immunity, the function of its receptor, Fc alpha RI (CD89), is poorly understood. The ability of Fc alpha RI to activate leukocytes seems to conflict with the proposed anti-inflammatory activity of secretory IgA. We show here that in a transgenic mouse model, inflammatory mediators induced expression of Fc alpha RI on Kupffer cells, which enabled efficient phagocytosis in vivo of bacteria coated with serum IgA. Secretory IgA did not initiate phagocytosis. Therefore, interactions between serum IgA and Fc alpha RI on Kupffer cells may provide a 'second line of defense' in mucosal immunity, by eliminating invasive bacteria entering through the portal circulation and thus preventing disease.	Univ Utrecht, Med Ctr, Dept Immunol & Medarex Europe, NL-3584 EA Utrecht, Netherlands; Univ Utrecht, Fac Vet Med, Dept Pathol, NL-3508 TD Utrecht, Netherlands; LACDR, Sylvius Labs, Div Biopharmaceut, NL-2333 AL Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Nephrol, NL-2300 RC Leiden, Netherlands; Univ Utrecht, Med Ctr, Dept Gastroenterol, NL-3584 EA Utrecht, Netherlands	Utrecht University; Utrecht University; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Utrecht University	van de Winkel, JGJ (corresponding author), Univ Utrecht, Med Ctr, Dept Immunol & Medarex Europe, Lundlaan 6, NL-3584 EA Utrecht, Netherlands.		van Spriel, Annemiek/Q-6044-2019; van Spriel, Annemiek/O-1639-2013; van Zandbergen, Ger/M-1571-2013; van Amersfoort, Edwin S/J-9944-2018	van Spriel, Annemiek/0000-0002-3590-2368; 				AVERY VM, 1991, EUR J CLIN MICROBIOL, V10, P1034, DOI 10.1007/BF01984925; Brandtzaeg P, 1999, IMMUNOL TODAY, V20, P141, DOI 10.1016/S0167-5699(98)01413-3; DECHATELET LR, 1982, J IMMUNOL, V129, P1589; DECKER K, 1990, EUR J BIOCHEM, V192, P245, DOI 10.1111/j.1432-1033.1990.tb19222.x; Deo YM, 1998, J IMMUNOL, V160, P1677; GORTER A, 1987, IMMUNOLOGY, V61, P303; HOSTOFFER RW, 1994, J INFECT DIS, V170, P82, DOI 10.1093/infdis/170.1.82; KAN ZX, 1995, HEPATOLOGY, V21, P487, DOI 10.1002/hep.1840210233; KERR MA, 1990, BIOCHEM J, V271, P285, DOI 10.1042/bj2710285; Kerr MA, 1998, MUCOSAL IMMUNOLOGY, P213; Kinet JP, 1999, ANNU REV IMMUNOL, V17, P931, DOI 10.1146/annurev.immunol.17.1.931; Lamm ME, 1997, ANNU REV MICROBIOL, V51, P311, DOI 10.1146/annurev.micro.51.1.311; MALISZEWSKI CR, 1990, J EXP MED, V172, P1665, DOI 10.1084/jem.172.6.1665; MAZANEC MB, 1992, P NATL ACAD SCI USA, V89, P6901, DOI 10.1073/pnas.89.15.6901; MAZANEC MB, 1993, IMMUNOL TODAY, V14, P430, DOI 10.1016/0167-5699(93)90245-G; MESTECKY J, 1986, CLIN IMMUNOL IMMUNOP, V40, P105, DOI 10.1016/0090-1229(86)90073-5; MONTEIRO RC, 1992, J IMMUNOL, V148, P1764; MONTEIRO RC, 1990, J EXP MED, V171, P597, DOI 10.1084/jem.171.3.597; Morton HC, 1996, CRIT REV IMMUNOL, V16, P423; NIKOLOVA EB, 1995, J LEUKOCYTE BIOL, V57, P875, DOI 10.1002/jlb.57.6.875; Ravetch JV, 1997, CURR OPIN IMMUNOL, V9, P121, DOI 10.1016/S0952-7915(97)80168-9; Russell MW, 1997, BIOCHEM SOC T, V25, P466, DOI 10.1042/bst0250466; RUSSELL MW, 1998, MUCOSAL IMMUNOLOGY, P225; SHEN L, 1994, J IMMUNOL, V152, P4080; SHEN L, 1989, IMMUNOLOGY, V68, P491; SHEN L, 1989, J IMMUNOL, V143, P4117; STEWART WW, 1990, IMMUNOLOGY, V71, P328; Valerius T, 1997, BLOOD, V90, P4485, DOI 10.1182/blood.V90.11.4485.4485_4485_4492; Van Berkel TJC, 1998, BIOCHEM J, V331, P29, DOI 10.1042/bj3310029; van Egmond M, 1999, IMMUNOL LETT, V68, P83, DOI 10.1016/S0165-2478(99)00034-6; van Egmond M, 1999, BLOOD, V93, P4387, DOI 10.1182/blood.V93.12.4387.412k08_4387_4394; VANDEWINKEL JGJ, 1998, IMMUNOGLOBULIN RECEP; WEISBART RH, 1988, NATURE, V332, P647, DOI 10.1038/332647a0; Westerhuis R, 1999, J AM SOC NEPHROL, V10, P770; Wisse E, 1996, TOXICOL PATHOL, V24, P100, DOI 10.1177/019262339602400114	35	177	184	0	9	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUN	2000	6	6					680	685		10.1038/76261	http://dx.doi.org/10.1038/76261			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	321CX	10835685				2022-12-25	WOS:000087438300039
J	Klesert, TR; Cho, DH; Clark, JI; Maylie, J; Adelman, J; Snider, L; Yuen, EC; Soriano, P; Tapscott, SJ				Klesert, TR; Cho, DH; Clark, JI; Maylie, J; Adelman, J; Snider, L; Yuen, EC; Soriano, P; Tapscott, SJ			Mice deficient in Six5 develop cataracts: implications for myotonic dystrophy	NATURE GENETICS			English	Article							HOMEODOMAIN-ENCODING GENE; CTG REPEAT; LENS OPACIFICATION; REDUCES EXPRESSION; PROTEIN; LOCUS; EXPANSION; FAMILY; INHIBITION; MUTATION	Expansion of a CTG trinucleotide repeat in the 3' UTR of the gene DMPK at the DM1 locus on chromosome 19 causes myotonic dystrophy(1-3), a dominantly inherited disease characterized by skeletal muscle dystrophy and myotonia, cataracts and cardiac conduction defects. Targeted deletion of Dm15, the mouse orthologue of human DMPK, produced mice with a mild myopathy(4,5) and cardiac conduction abnormalities(6), but without other features of myotonic dystrophy, such as myotonia and cataracts. We, and others, have demonstrated that repeat expansion decreases expression of the adjacent gene SIX5 (refs 7,8), which encodes a homeodomain transcription factor, To determine whether SIX5 deficiency contributes to the myotonic dystrophy phenotype, we disrupted mouse Six5 by replacing the first exon with a beta-galactosidase reporter. Six5-mutant mice showed reporter expression in multiple tissues, including the developing lens. Homozygous mutant mice had no apparent abnormalities of skeletal muscle function, but developed lenticular opacities at a higher rate than controls. Our results suggest that SIX5 deficiency contributes to the cataract phenotype in myotonic dystrophy, and that myotonic dystrophy represents a multigenic disorder.	Fred Hutchinson Canc Res Ctr, Program Dev Biol, Seattle, WA 98104 USA; Fred Hutchinson Canc Res Ctr, Div Human Biol, Seattle, WA 98104 USA; Fred Hutchinson Canc Res Ctr, Div Basic Sci, Seattle, WA 98104 USA; Univ Washington, Sch Med, Dept Pathol, Seattle, WA 98195 USA; Univ Washington, Sch Med, Dept Biol Struct, Seattle, WA 98195 USA; Univ Washington, Sch Med, Dept Neurol, Seattle, WA 98195 USA; Oregon Hlth Sci Univ, Dept Obstet & Gynecol, Portland, OR 97201 USA; Oregon Hlth Sci Univ, Dept Physiol, Portland, OR 97201 USA; Oregon Hlth Sci Univ, Dept Pharmacol, Portland, OR 97201 USA; Oregon Hlth Sci Univ, Vollum Inst, Portland, OR 97201 USA	Fred Hutchinson Cancer Center; Fred Hutchinson Cancer Center; Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University	Tapscott, SJ (corresponding author), Fred Hutchinson Canc Res Ctr, Program Dev Biol, 1124 Columbia St, Seattle, WA 98104 USA.		Soriano, Philippe M/E-5797-2015	Soriano, Philippe M/0000-0002-0427-926X; Tapscott, Stephen/0000-0002-0319-0968	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD024875] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY004542] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR045203] Funding Source: NIH RePORTER; NEI NIH HHS [EY04542, R01 EY004542] Funding Source: Medline; NIAMS NIH HHS [AR45203] Funding Source: Medline; NICHD NIH HHS [HD 24875] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Amack JD, 1999, HUM MOL GENET, V8, P1975, DOI 10.1093/hmg/8.11.1975; BEHRENS MI, 1994, MUSCLE NERVE, V17, P1264, DOI 10.1002/mus.880171104; Berul CI, 1999, J CLIN INVEST, V103, pR1, DOI 10.1172/JCI5346; BOUCHER CA, 1995, HUM MOL GENET, V4, P1919, DOI 10.1093/hmg/4.10.1919; BROOK JD, 1992, CELL, V68, P799, DOI 10.1016/0092-8674(92)90154-5; CHEYETTE BNR, 1994, NEURON, V12, P977, DOI 10.1016/0896-6273(94)90308-5; Clark JI, 1996, EXP EYE RES, V62, P75, DOI 10.1006/exer.1996.0009; Damiani E, 1996, NEUROMUSCULAR DISORD, V6, P33, DOI 10.1016/0960-8966(95)00016-X; Day JW, 1999, NEUROMUSCULAR DISORD, V9, P19, DOI 10.1016/S0960-8966(98)00094-7; FU YH, 1992, SCIENCE, V255, P1256, DOI 10.1126/science.1546326; Groenen P, 1998, BIOESSAYS, V20, P901, DOI 10.1002/(SICI)1521-1878(199811)20:11<901::AID-BIES5>3.0.CO;2-0; Harris S, 1996, HUM MOL GENET, V5, P1417, DOI 10.1093/hmg/5.Supplement_1.1417; Heath SK, 1997, HUM MOL GENET, V6, P651, DOI 10.1093/hmg/6.5.651; HIRAOKA T, 1995, INVEST OPHTH VIS SCI, V36, P2550; Jansen G, 1996, NAT GENET, V13, P316, DOI 10.1038/ng0796-316; Kawakami K, 1996, NUCLEIC ACIDS RES, V24, P303, DOI 10.1093/nar/24.2.303; Kawakami K, 1996, FEBS LETT, V393, P259, DOI 10.1016/0014-5793(96)00899-X; Klesert TR, 1997, NAT GENET, V16, P402, DOI 10.1038/ng0897-402; Korade-Mirnics Z, 1998, NUCLEIC ACIDS RES, V26, P1363, DOI 10.1093/nar/26.6.1363; Loosli F, 1999, GENE DEV, V13, P649, DOI 10.1101/gad.13.6.649; MAHADEVAN M, 1992, SCIENCE, V255, P1253, DOI 10.1126/science.1546325; Ohto H, 1999, MOL CELL BIOL, V19, P6815; Philips AV, 1998, SCIENCE, V280, P737, DOI 10.1126/science.280.5364.737; Pignoni F, 1997, CELL, V91, P881, DOI 10.1016/S0092-8674(00)80480-8; Ramirez BU, 1996, CELL MOL NEUROBIOL, V16, P39, DOI 10.1007/BF02578385; Ranum LPW, 1998, NAT GENET, V19, P196, DOI 10.1038/570; Reddy S, 1996, NAT GENET, V13, P325, DOI 10.1038/ng0796-325; Thornton CA, 1997, NAT GENET, V16, P407, DOI 10.1038/ng0897-407; Timchenko LT, 1999, AM J HUM GENET, V64, P360, DOI 10.1086/302268; Winchester CL, 1999, HUM MOL GENET, V8, P481, DOI 10.1093/hmg/8.3.481	30	172	183	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAY	2000	25	1					105	109		10.1038/75490	http://dx.doi.org/10.1038/75490			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	311KU	10802667				2022-12-25	WOS:000086884000027
J	Lavon, I; Goldberg, I; Amit, S; Landsman, L; Jung, S; Tsuberi, BZ; Barshack, I; Kopolovic, J; Galun, E; Bujard, H; Ben-Neriah, Y				Lavon, I; Goldberg, I; Amit, S; Landsman, L; Jung, S; Tsuberi, BZ; Barshack, I; Kopolovic, J; Galun, E; Bujard, H; Ben-Neriah, Y			High susceptibility to bacterial infection, but no liver dysfunction, in mice compromised for hepatocyte NF-kappa B activation	NATURE MEDICINE			English	Article							EMBRYONIC LETHALITY; GENE-EXPRESSION; TRANSGENIC MICE; APOPTOSIS; DEGENERATION; INHIBITION; PROTECTION; DEFICIENT; INJURY	Based on the essential involvement of NF-kappa B in immune and inflammatory responses and its apoptosis-rescue function in normal and malignant cells, inhibitors of this transcription factor are potential therapeutics for the treatment of a wide range of diseases, from bronchial asthma to cancer(1,2). Yet, given the essential function of NF-kappa B in the embryonic liver(3-6), it is important to determine its necessity in the liver beyond embryogenesis. NF-kappa B is normally retained in the cytoplasm by its inhibitor I kappa B, which is eliminated upon cell stimulation through phosphorylation-dependent ubiquitin degradation(7). Here, we directed a degradation-resistant I kappa B alpha transgene to mouse hepatocytes in an inducible manner and showed substantial tissue specificity using various means, including a new method for live-animal imaging. Transgene expression resulted in obstruction of NF-kappa B activation, yet produced no signs of liver dysfunction, even when implemented over 15 months. However, the transgene-expressing mice were very vulnerable both to a severe immune challenge and to a systemic bacterial infection. Despite having intact immunocytes and inflammatory cells, these mice were unable to clear Listeria monocytogenes from the liver and succumbed to sepsis. These findings indicate the essential function of the hepatocyte through NF-kappa B activation in certain systemic infections, possibly by coordinating innate immunity in the liver.	Hebrew Univ Jerusalem, Hadassah Med Sch, Lautenberg Ctr Immunol, IL-91120 Jerusalem, Israel; Tel Aviv Univ, Sackler Sch Med, Dept Pathol, Tel Hashomer, Israel; Chaim Sheba Med Ctr, IL-52621 Tel Hashomer, Israel; Hadassah Univ Hosp, Goldyne Savad Gene Therapy Inst, IL-91120 Jerusalem, Israel; Heidelberg Univ, Zentrum Mol Biol, D-69052 Heidelberg, Germany	Hebrew University of Jerusalem; Tel Aviv University; Sackler Faculty of Medicine; Chaim Sheba Medical Center; Hebrew University of Jerusalem; Ruprecht Karls University Heidelberg	Ben-Neriah, Y (corresponding author), Hebrew Univ Jerusalem, Hadassah Med Sch, Lautenberg Ctr Immunol, IL-91120 Jerusalem, Israel.	yinon@cc.huji.ac.il	Ben-Neriah, Yinon/L-6285-2019; Lavon, Iris/ABE-6651-2021; Jung, Steffen/K-1409-2012	Jung, Steffen/0000-0003-4290-5716; Landsman, Limor/0000-0002-8974-1344				Armstrong D, 1995, PRINCIPLES PRACTICE, P1880; Attar RM, 1997, SEMIN CANCER BIOL, V8, P93, DOI 10.1006/scbi.1997.0060; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Bellas RE, 1997, AM J PATHOL, V151, P891; Bradham CA, 1998, AM J PHYSIOL-GASTR L, V275, pG387, DOI 10.1152/ajpgi.1998.275.3.G387; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; CONLAN JW, 1994, J EXP MED, V179, P259, DOI 10.1084/jem.179.1.259; Contag CH, 1997, PHOTOCHEM PHOTOBIOL, V66, P523, DOI 10.1111/j.1751-1097.1997.tb03184.x; Endres R, 1997, IMMUNITY, V7, P419, DOI 10.1016/S1074-7613(00)80363-5; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; Iimuro Y, 1998, J CLIN INVEST, V101, P802, DOI 10.1172/JCI483; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; KAUFMANN SHE, 1993, ANNU REV IMMUNOL, V11, P129, DOI 10.1146/annurev.iy.11.040193.001021; Kistner A, 1996, P NATL ACAD SCI USA, V93, P10933, DOI 10.1073/pnas.93.20.10933; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Li ZW, 1999, J EXP MED, V189, P1839, DOI 10.1084/jem.189.11.1839; MIZUHARA H, 1994, J EXP MED, V179, P1529, DOI 10.1084/jem.179.5.1529; PFEFFER K, 1993, CELL, V73, P457, DOI 10.1016/0092-8674(93)90134-C; Rogers HW, 1996, J IMMUNOL, V156, P679; TALBOT D, 1994, NUCLEIC ACIDS RES, V22, P756, DOI 10.1093/nar/22.5.756; Tanaka M, 1999, IMMUNITY, V10, P421, DOI 10.1016/S1074-7613(00)80042-4; Taub R, 1998, HEPATOLOGY, V27, P1445, DOI 10.1002/hep.510270538; TIEGS G, 1992, J CLIN INVEST, V90, P196, DOI 10.1172/JCI115836; Wang CY, 1999, NAT MED, V5, P412, DOI 10.1038/7410	25	136	147	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2000	6	5					573	577		10.1038/75057	http://dx.doi.org/10.1038/75057			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	309YB	10802715				2022-12-25	WOS:000086796200043
J	Satoda, M; Zhao, F; Diaz, GA; Burn, J; Goodship, J; Davidson, HR; Pierpont, MEM; Gelb, BD				Satoda, M; Zhao, F; Diaz, GA; Burn, J; Goodship, J; Davidson, HR; Pierpont, MEM; Gelb, BD			Mutations in TFAP2B cause Char syndrome, a familial form of patent ductus arteriosus	NATURE GENETICS			English	Article							TRANSCRIPTION FACTOR AP-2; NEURAL CREST CELLS; PERSISTENT TRUNCUS ARTERIOSUS; CARDIAC MALFORMATION; MICE; MOUSE; HEART; EXPRESSION; AP-2-BETA; EMBRYOGENESIS	Char syndrome is an autosomal dominant trait characterized by patent ductus arteriosus, facial dysmorphism and hand anomalies. Using a positional candidacy strategy, we mapped TFAP2B, encoding a transcription factor expressed in neural crest cells, to the Char syndrome critical region and identified missense mutations altering conserved residues in two affected families. Mutant TFAP2B proteins dimerized properly in vitro, but showed abnormal binding to TFAP2 target sequence. Dimerization of both mutants with normal TFAP2B adversely affected transactivation, demonstrating a dominant-negative mechanism. Our work shows that TFAP2B has a role in ductal, facial and limb development and suggests that Char syndrome results from derangement of neural-crest-cell derivatives.	Mt Sinai Sch Med, Dept Pediat, New York, NY 10029 USA; Mt Sinai Sch Med, Dept Human Genet, New York, NY 10029 USA; Newcastle Univ, Sch Biochem & Genet, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; Duncan Guthrie Inst Med Genet, Glasgow G3 8SJ, Lanark, Scotland; Univ Minneapolis, Dept Pediat, Minneapolis, MN USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Newcastle University - UK	Gelb, BD (corresponding author), Mt Sinai Sch Med, Dept Pediat, New York, NY 10029 USA.	gelbb01@doc.mssm.edu	Diaz, George/AAF-6199-2021	Burn, John/0000-0002-9823-2322; Satoda, Masahiko/0000-0003-0804-860X	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD038018, K24HD001294] Funding Source: NIH RePORTER; NICHD NIH HHS [HD01294, HD38018] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Bamshad M, 1997, NAT GENET, V16, P311, DOI 10.1038/ng0797-311; Basson CT, 1997, NAT GENET, V15, P30, DOI 10.1038/ng0197-30; Char F, 1978, Birth Defects Orig Artic Ser, V14, P303; Conway SJ, 1997, DEVELOPMENT, V124, P505; DAVIDSON HR, 1993, J MED GENET, V30, P503, DOI 10.1136/jmg.30.6.503; EPSTEIN DJ, 1991, CELL, V67, P767, DOI 10.1016/0092-8674(91)90071-6; Ewart JL, 1997, DEVELOPMENT, V124, P1281; FRANZ T, 1989, ANAT EMBRYOL, V180, P457, DOI 10.1007/BF00305120; FUKIISHI Y, 1992, CELL TISSUE RES, V268, P1, DOI 10.1007/BF00338048; Kannan F, 1999, MOL CELL BIOL, V19, P899; Kannan P, 1999, NUCLEIC ACIDS RES, V27, P866, DOI 10.1093/nar/27.3.866; KIRBY ML, 1983, SCIENCE, V220, P1059, DOI 10.1126/science.6844926; Lens XM, 1997, GENOMICS, V41, P463, DOI 10.1006/geno.1997.4671; Li YH, 1997, CHINESE J CHEM, V15, P21; LUSCHER B, 1989, GENE DEV, V3, P1507, DOI 10.1101/gad.3.10.1507; MITCHELL PJ, 1991, GENE DEV, V5, P105, DOI 10.1101/gad.5.1.105; Moser M, 1997, GENE DEV, V11, P1938, DOI 10.1101/gad.11.15.1938; Moser M, 1997, DEV DYNAM, V208, P115, DOI 10.1002/(SICI)1097-0177(199701)208:1<115::AID-AJA11>3.0.CO;2-5; MOSER M, 1995, DEVELOPMENT, V121, P2779; MULLINS CE, 1998, SCI PRACTICE PEDIAT, P1181; NISHIBATAKE M, 1987, CIRCULATION, V75, P255, DOI 10.1161/01.CIR.75.1.255; NORA JJ, 1988, AM J MED GENET, V29, P137, DOI 10.1002/ajmg.1320290117; PHILIPP J, 1994, DEV BIOL, V165, P602, DOI 10.1006/dbio.1994.1279; REAUME AG, 1995, SCIENCE, V267, P1831, DOI 10.1126/science.7892609; Satoda M, 1999, CIRCULATION, V99, P3036, DOI 10.1161/01.CIR.99.23.3036; Sullivan R, 1998, DEV BIOL, V204, P224, DOI 10.1006/dbio.1998.9089; WALDO KL, 1993, ANAT RECORD, V237, P385, DOI 10.1002/ar.1092370312; Waldo KL, 1999, DEV BIOL, V208, P307, DOI 10.1006/dbio.1999.9219; WILLIAMS T, 1991, GENE DEV, V5, P670, DOI 10.1101/gad.5.4.670; Wilson GN, 1998, AM J MED GENET, V76, P297, DOI 10.1002/(SICI)1096-8628(19980401)76:4<297::AID-AJMG4>3.0.CO;2-N; Yanagisawa H, 1998, J CLIN INVEST, V102, P22, DOI 10.1172/JCI2698; ZETTERQVIST P, 1972, CLIN GENETIC STUDY C	32	177	184	0	8	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAY	2000	25	1					42	46		10.1038/75578	http://dx.doi.org/10.1038/75578			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	311KU	10802654				2022-12-25	WOS:000086884000014
J	Lewin, M; Carlesso, N; Tung, CH; Tang, XW; Cory, D; Scadden, DT; Weissleder, R				Lewin, M; Carlesso, N; Tung, CH; Tang, XW; Cory, D; Scadden, DT; Weissleder, R			Tat peptide-derivatized magnetic nanoparticles allow in vivo tracking and recovery of progenitor cells	NATURE BIOTECHNOLOGY			English	Article						stem cells; CD34; neural progenitor cells; magnetic resonance; iron oxide; homing	HEMATOPOIETIC STEM-CELLS; IRON-OXIDE; BONE-MARROW; LYMPH-NODES; IN-VIVO; MICROSCOPY; PROTEIN; SUSCEPTIBILITY; MIGRATION; DELIVERY	The ability to track the distribution and differentiation of progenitor and stem cells by high-resolution in vivo imaging techniques would have significant clinical and research implications. We have developed a cell labeling approach using short HIV-Tat peptides to derivatize superparamagnetic nanoparticles. The particles are efficiently internalized into hematopoietic and neural progenitor cells in quantities up to 10-30 pg of superparamagnetic iron per cell. Iron incorporation did not affect cell viability, differentiation, or proliferation of CD34(+) cells. Following intravenous injection into immunodeficient mice, 4% of magnetically CD34(+) cells homed to bone marrow per gram of tissue, and single cells could be detected by magnetic resonance (MR) imaging in tissue samples. In addition, magnetically labeled cells that had homed to bone marrow could be recovered by magnetic separation columns. Localization and retrieval of cell populations in vivo enable detailed analysis of specific stem cell and organ interactions critical for advancing the therapeutic use of stem cells.	Massachusetts Gen Hosp, Ctr Mol Imaging Res, Charlestown, MA 02129 USA; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Charlestown, MA 02129 USA; MIT, Dept Nucl Engn, NMR Facil, Cambridge, MA 02139 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Massachusetts Institute of Technology (MIT)	Weissleder, R (corresponding author), Massachusetts Gen Hosp, Ctr Mol Imaging Res, Charlestown, MA 02129 USA.		Tung, Ching-Hsuan/AIE-6009-2022; Tung, Ching-Hsuan/AHC-5070-2022	Tung, Ching-Hsuan/0000-0001-6648-6195; Tung, Ching-Hsuan/0000-0001-6648-6195; /0000-0003-0828-4143	NCI NIH HHS [R01 CA46973, R01 CA59649] Funding Source: Medline; NIAID NIH HHS [R01 AI/CA 46973] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA059649] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Asahara T, 1997, SCIENCE, V275, P964, DOI 10.1126/science.275.5302.964; Avrameas A, 1998, P NATL ACAD SCI USA, V95, P5601, DOI 10.1073/pnas.95.10.5601; Bulte JW, 1999, RADIOLOGY, V213P, P225; Choi SM, 1997, INT J IMAG SYST TECH, V8, P263, DOI 10.1002/(SICI)1098-1098(1997)8:3<263::AID-IMA4>3.0.CO;2-8; Derossi D, 1996, J BIOL CHEM, V271, P18188, DOI 10.1074/jbc.271.30.18188; Dodd SJ, 1999, BIOPHYS J, V76, P103, DOI 10.1016/S0006-3495(99)77182-1; ENSOLI B, 1993, J VIROL, V67, P277, DOI 10.1128/JVI.67.1.277-287.1993; FAWELL S, 1994, P NATL ACAD SCI USA, V91, P664, DOI 10.1073/pnas.91.2.664; Frenette PS, 1998, P NATL ACAD SCI USA, V95, P14423, DOI 10.1073/pnas.95.24.14423; HARDY CL, 1995, AM J MED SCI, V309, P260; Harisinghani MG, 1999, AM J ROENTGENOL, V172, P1347, DOI 10.2214/ajr.172.5.10227514; HAWRYLAK N, 1993, EXP NEUROL, V121, P181, DOI 10.1006/exnr.1993.1085; Hendrikx PJ, 1996, EXP HEMATOL, V24, P129; HOLT RW, 1994, JMRI-J MAGN RESON IM, V4, P809, DOI 10.1002/jmri.1880040612; Jacobs RE, 1999, TRENDS CELL BIOL, V9, P73, DOI 10.1016/S0962-8924(98)01435-4; JOHNSON GA, 1993, MAGN RESON QUART, V9, P1; Josephson L, 1999, BIOCONJUGATE CHEM, V10, P186, DOI 10.1021/bc980125h; Lanzkron SM, 1999, BLOOD, V93, P1916, DOI 10.1182/blood.V93.6.1916.406k15_1916_1921; Lynch WP, 1999, J VIROL, V73, P6841, DOI 10.1128/JVI.73.8.6841-6851.1999; MANN DA, 1991, EMBO J, V10, P1733, DOI 10.1002/j.1460-2075.1991.tb07697.x; MENGER MD, 1993, IMMUNOL TODAY, V14, P519, DOI 10.1016/0167-5699(93)90179-O; Miyoshi H, 1999, SCIENCE, V283, P682, DOI 10.1126/science.283.5402.682; Nagahara H, 1998, NAT MED, V4, P1449, DOI 10.1038/4042; Papayannopoulou T, 1997, ACTA HAEMATOL-BASEL, V97, P97; Peled A, 1999, SCIENCE, V283, P845, DOI 10.1126/science.283.5403.845; Phelan A, 1998, NAT BIOTECHNOL, V16, P440, DOI 10.1038/nbt0598-440; Rogers JM, 1998, MAGN RESON IMAGING, V16, P917, DOI 10.1016/S0730-725X(98)00090-3; Safarik I, 1999, J CHROMATOGR B, V722, P33, DOI 10.1016/S0378-4347(98)00338-7; Schoepf U, 1998, BIOTECHNIQUES, V24, P642, DOI 10.2144/98244rr01; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; SHEN T, 1993, MAGN RESON MED, V29, P599, DOI 10.1002/mrm.1910290504; von Andrian UH, 1998, CELL ADHES COMMUN, V6, P85; WEISSLEDER R, 1989, AM J ROENTGENOL, V152, P167, DOI 10.2214/ajr.152.1.167; Weissleder R, 1997, J MAGN RESON IMAGING, V7, P258, DOI 10.1002/jmri.1880070140; Weissleder Ralph, 2000, Nature Medicine, V6, P351, DOI 10.1038/73219; Wiesmann A, 1999, EXP HEMATOL, V27, P946, DOI 10.1016/S0301-472X(99)00029-6; Zandstra PW, 1997, P NATL ACAD SCI USA, V94, P4698, DOI 10.1073/pnas.94.9.4698; Zanjani ED, 1999, BLOOD, V94, P2515, DOI 10.1182/blood.V94.7.2515.419k15_2515_2522	38	1510	1644	6	392	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	APR	2000	18	4					410	414		10.1038/74464	http://dx.doi.org/10.1038/74464			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	303UY	10748521				2022-12-25	WOS:000086444300023
J	Okamoto, T; Suzuki, T; Yamamoto, N				Okamoto, T; Suzuki, T; Yamamoto, N			Microarray fabrication with covalent attachment of DNA using Bubble Jet technology	NATURE BIOTECHNOLOGY			English	Article						Bubble Jet; ink jet; microarray; DNA; single nucleotide polymorphism; p53 gene	GENOMICS	We have developed a method for fabricating DNA microarrays that uses a Bubble Jet ink jet device to eject 5'-terminal-thiolated oligonucleotides to a glass surface. The oligonucleotides are covalently attached to the glass surface by heterobifunctional crosslinkers that react with the amino group on the substrate and a thiol group on the oligonucleotide probe. Using this method, we fabricated DNA microarrays that carried 64 groups of 18-mer oligonucleotides encoding all possible three-base mutations in the mutational "hot spot" of the p53 tumor-suppressor gene. These were screened with a fluorescently labeled synthetic 18-mer oligonucleotide derived from the p53 gene, or segments of the p53 gene that had been PCR amplified from genomic DNA of two cell lines of human oral squamous cell carcinoma (SCC). This allowed us to discriminate between matched hybrids and 1 bp-mismatched hybrids.	Canon Res Ctr, Atsugi, Kanagawa 2430193, Japan	Canon Incorporated	Yamamoto, N (corresponding author), Canon Res Ctr, 5-1 Morinosato Wakamiya, Atsugi, Kanagawa 2430193, Japan.							ASAI A, 1988, J IMAGING TECHNOL, V14, P120; Chrisey LA, 1996, NUCLEIC ACIDS RES, V24, P3031, DOI 10.1093/nar/24.15.3031; Fodor SPA, 1997, SCIENCE, V277, P393, DOI 10.1126/science.277.5324.393; Gilles PN, 1999, NAT BIOTECHNOL, V17, P365, DOI 10.1038/7921; Hainaut P, 1997, NUCLEIC ACIDS RES, V25, P151, DOI 10.1093/nar/25.1.151; Hara T., 1982, J I IMAGE ELECT ENG, V11, P66; KITAGAWA T, 1981, CHEM PHARM BULL, V29, P1130; SAKAI E, 1992, ONCOGENE, V7, P927; Schena M, 1998, TRENDS BIOTECHNOL, V16, P301, DOI 10.1016/S0167-7799(98)01219-0; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467	10	348	380	1	51	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	APR	2000	18	4					438	441		10.1038/74507	http://dx.doi.org/10.1038/74507			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	303UY	10748527				2022-12-25	WOS:000086444300029
J	Piguet, V; Wan, L; Borel, C; Mangasarian, A; Demaurex, N; Thomas, G; Trono, D				Piguet, V; Wan, L; Borel, C; Mangasarian, A; Demaurex, N; Thomas, G; Trono, D			HIV-1 Nef protein binds to the cellular protein PACS-1 to downregulate class I major histocompatibility complexes	NATURE CELL BIOLOGY			English	Article							CD4 DOWN-REGULATION; DILEUCINE MOTIF; ADAPTER COMPLEXES; CLATHRIN ADAPTER; ENDOCYTOSIS; SURFACE; GOLGI; INTERNALIZATION; MECHANISM; MOLECULES	Major-histocompatibility-complex (MHC) proteins are used to display, on the surface of a cell, peptides derived from foreign material - such as a virus - that is infecting that cell. Cytotoxic T lymphocytes then recognize and kill the infected cell. The HIV-1 Nef protein downregulates the cell-surface expression of class I MHC proteins, and probably thereby promotes immune evasion by HIV-1, In the presence of Nef, class I MHC molecules are relocalized from the cell surface to the trans-Golgi network (TGN) through as-yet-unknown mechanisms. Here we show that Nef-induced downregulation of MHC-I expression and MHC-I targeting to the TGN require the binding of Nef to PACS-1, a molecule that controls the TGN localization of the cellular protein furin, This interaction is dependent on Nef's cluster of acidic amino acids. A chimaeric integral membrane protein containing Nef as its cytoplasmic domain localizes to the TGN after internalization, in an acidic-cluster- and PACS-1-dependent manner. These results support a model in which Nef relocalizes MHC-1 by acting as a connector between MHC-I's cytoplasmic tail and the PACS-1-dependent protein-sorting pathway.	Univ Geneva, Fac Med, Dept Genet & Microbiol, CH-1211 Geneva, Switzerland; Univ Geneva, Fac Med, Dept Dermatol, CH-1211 Geneva, Switzerland; Oregon Hlth Sci Univ, Vollum Inst, Portland, OR 97201 USA; Univ Geneva, Fac Med, Dept Physiol, CH-1211 Geneva, Switzerland	University of Geneva; University of Geneva; Oregon Health & Science University; University of Geneva	Trono, D (corresponding author), Univ Geneva, Fac Med, Dept Genet & Microbiol, CH-1211 Geneva, Switzerland.			Demaurex, Nicolas/0000-0002-9933-6772; Mangasarian, Aram/0000-0002-8087-7990; Piguet, Vincent/0000-0001-6079-4517	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI049793, R01AI048585] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI048585, R01 AI049793] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AIKEN C, 1994, CELL, V76, P853, DOI 10.1016/0092-8674(94)90360-3; Aiken C, 1996, VIROLOGY, V217, P293, DOI 10.1006/viro.1996.0116; Baur AS, 1997, IMMUNITY, V6, P283, DOI 10.1016/S1074-7613(00)80331-3; Bresnahan PA, 1998, CURR BIOL, V8, P1235, DOI 10.1016/S0960-9822(07)00517-9; Brodsky FM, 1999, IMMUNOL REV, V168, P199, DOI 10.1111/j.1600-065X.1999.tb01294.x; Collins KL, 1998, NATURE, V391, P397, DOI 10.1038/34929; Craig HM, 1998, P NATL ACAD SCI USA, V95, P11229, DOI 10.1073/pnas.95.19.11229; Demaurex N, 1998, J BIOL CHEM, V273, P2044, DOI 10.1074/jbc.273.4.2044; Greenberg M, 1998, CURR BIOL, V8, P1239, DOI 10.1016/S0960-9822(07)00518-0; Greenberg ME, 1997, EMBO J, V16, P6964, DOI 10.1093/emboj/16.23.6964; Greenberg ME, 1998, EMBO J, V17, P2777, DOI 10.1093/emboj/17.10.2777; Grzesiek S, 1996, BIOCHEMISTRY-US, V35, P10256, DOI 10.1021/bi9611164; Lama J, 1999, CURR BIOL, V9, P622, DOI 10.1016/S0960-9822(99)80284-X; Le Gall S, 1998, IMMUNITY, V8, P483, DOI 10.1016/S1074-7613(00)80553-1; Mangasarian A, 1997, IMMUNITY, V6, P67, DOI 10.1016/S1074-7613(00)80243-5; Mangasarian A, 1999, J VIROL, V73, P1964, DOI 10.1128/JVI.73.3.1964-1973.1999; Mukherjee S, 1997, PHYSIOL REV, V77, P759, DOI 10.1152/physrev.1997.77.3.759; Piguet V, 1999, CELL, V97, P63, DOI 10.1016/S0092-8674(00)80715-1; Piguet V, 1998, EMBO J, V17, P2472, DOI 10.1093/emboj/17.9.2472; Ploegh HL, 1998, SCIENCE, V280, P248, DOI 10.1126/science.280.5361.248; RHEE SS, 1994, J VIROL, V68, P5156, DOI 10.1128/JVI.68.8.5156-5163.1994; Ross TM, 1999, CURR BIOL, V9, P613, DOI 10.1016/S0960-9822(99)80283-8; SAKSELA K, 1995, EMBO J, V14, P484, DOI 10.1002/j.1460-2075.1995.tb07024.x; Schwartz O, 1996, NAT MED, V2, P338, DOI 10.1038/nm0396-338; Wan L, 1998, CELL, V94, P205, DOI 10.1016/S0092-8674(00)81420-8	25	240	249	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	MAR	2000	2	3					163	167		10.1038/35004038	http://dx.doi.org/10.1038/35004038			5	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	292AE	10707087	Green Accepted			2022-12-25	WOS:000085771300016
J	Tamada, K; Shimozaki, K; Chapoval, AI; Zhu, GF; Sica, G; Flies, D; Boone, T; Hsu, HL; Fu, YX; Nagata, S; Ni, J; Chen, LP				Tamada, K; Shimozaki, K; Chapoval, AI; Zhu, GF; Sica, G; Flies, D; Boone, T; Hsu, HL; Fu, YX; Nagata, S; Ni, J; Chen, LP			Modulation of T-cell-mediated immunity in tumor and graft-versus-host disease models through the LIGHT co-stimulatory pathway	NATURE MEDICINE			English	Article							HERPESVIRUS ENTRY MEDIATOR; LYMPHOTOXIN-BETA-RECEPTOR; CRYSTAL-STRUCTURE; ACTIVATION; MEMBER; COSTIMULATION; SUPERFAMILY; LIGAND; PROLIFERATION; LYMPHOCYTES	LIGHT was recently described as a member of the tumor necrosis factor (TNF) 'superfamily'. We have isolated a mouse homolog of human LIGHT and investigated its immunoregulatory functions in vitro and in vivo. LIGHT has potent, CD28-independent co-stimulatory activity leading to T-cell growth and secretion of gamma interferon and granulocyte-macrophage colony-stimulating factor. Gene transfer of LIGHT induced an antigen-specific cytolytic T-cell response and therapeutic immunity against established mouse P815 tumor. In contrast, blockade of LIGHT by administration of soluble receptor or antibody led to decreased cell-mediated immunity and ameliorated graft-versus-host disease. Our studies identify a previously unknown T-cell co-stimulatory pathway as a potential therapeutic target.	Mayo Clin & Mayo Fdn, Mayo Clin & Mayo Grad Sch Med, Dept Immunol, Rochester, MN 55905 USA; Osaka Univ, Sch Med, Dept Genet, Osaka, Japan; Amgen Inc, Thousand Oaks, CA 91320 USA; Univ Chicago, Dept Pathol, Chicago, IL 60637 USA; Human Genome Sci Inc, Rockville, MD 20850 USA	Mayo Clinic; Osaka University; Amgen; University of Chicago; GlaxoSmithKline; Human Genome Sciences Inc	Ni, J (corresponding author), Mayo Clin & Mayo Fdn, Mayo Clin & Mayo Grad Sch Med, Dept Immunol, 200 1st St SW, Rochester, MN 55905 USA.	jian_ni@hgsi.com; chen.lieping@mayo.edu	Nagata, Shigekazu/AAG-3203-2019; Chapoval, Andrei/N-9568-2013	Nagata, Shigekazu/0000-0001-9758-8426; Chapoval, Andrei/0000-0002-3426-1036; fu, yang-xin/0000-0001-8441-6617	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD073104] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P30CA015083, R01CA079915] Funding Source: NIH RePORTER; NCI NIH HHS [CA15083, CA79915] Funding Source: Medline; NICHD NIH HHS [HD73104] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BANNER DW, 1993, CELL, V73, P431, DOI 10.1016/0092-8674(93)90132-A; BLAZAR BR, 1994, BLOOD, V83, P3815; Browning JL, 1997, J IMMUNOL, V159, P3288; Browning JL, 1996, J EXP MED, V183, P867, DOI 10.1084/jem.183.3.867; Cha SS, 1999, IMMUNITY, V11, P253, DOI 10.1016/S1074-7613(00)80100-4; Chaplin DD, 1998, CURR OPIN IMMUNOL, V10, P289, DOI 10.1016/S0952-7915(98)80167-2; CHEN LP, 1994, J EXP MED, V179, P523, DOI 10.1084/jem.179.2.523; CHEN YM, 1993, MOL CRYST LIQ CRYS B, V4, P71; CROSS AH, 1995, J CLIN INVEST, V95, P2783, DOI 10.1172/JCI117982; DegliEsposti MA, 1997, J IMMUNOL, V158, P1756; DETOGNI P, 1994, SCIENCE, V264, P703, DOI 10.1126/science.8171322; FORCE WR, 1995, J IMMUNOL, V155, P5280; Harrop JA, 1998, J BIOL CHEM, V273, P27548, DOI 10.1074/jbc.273.42.27548; Harrop JA, 1998, J IMMUNOL, V161, P1786; Hsu HL, 1997, J BIOL CHEM, V272, P13471, DOI 10.1074/jbc.272.21.13471; Johnson AJ, 1999, J VIROL, V73, P3702, DOI 10.1128/JVI.73.5.3702-3708.1999; KARPUSAS M, 1995, STRUCTURE, V3, P1031, DOI 10.1016/S0969-2126(01)00239-8; Kwon BS, 1997, J BIOL CHEM, V272, P14272, DOI 10.1074/jbc.272.22.14272; LENSCHOW DJ, 1992, SCIENCE, V257, P789, DOI 10.1126/science.1323143; Mackay F, 1998, NATURE, V395, P26, DOI 10.1038/25630; Marsters SA, 1997, J BIOL CHEM, V272, P14029, DOI 10.1074/jbc.272.22.14029; Mauri DN, 1998, IMMUNITY, V8, P21, DOI 10.1016/S1074-7613(00)80455-0; Melero I, 1997, NAT MED, V3, P682, DOI 10.1038/nm0697-682; Montgomery RI, 1996, CELL, V87, P427, DOI 10.1016/S0092-8674(00)81363-X; Pitti RM, 1998, NATURE, V396, P699, DOI 10.1038/25387; SCHWARTZ RH, 1992, CELL, V71, P1065, DOI 10.1016/S0092-8674(05)80055-8; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; Speiser DE, 1997, J IMMUNOL, V158, P5185; VIA CS, 1988, IMMUNOL TODAY, V9, P207, DOI 10.1016/0167-5699(88)91215-7; Ware C F, 1995, Curr Top Microbiol Immunol, V198, P175; Watts TH, 1999, CURR OPIN IMMUNOL, V11, P286, DOI 10.1016/S0952-7915(99)80046-6; Yu KY, 1999, J BIOL CHEM, V274, P13733, DOI 10.1074/jbc.274.20.13733; Zhai YF, 1998, J CLIN INVEST, V102, P1142, DOI 10.1172/JCI3492	33	259	298	2	18	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2000	6	3					283	289						7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	288TL	10700230				2022-12-25	WOS:000085580500038
J	Bizily, SP; Rugh, CL; Meagher, RB				Bizily, SP; Rugh, CL; Meagher, RB			Phytodetoxification of hazardous organomercurials by genetically engineered plants	NATURE BIOTECHNOLOGY			English	Article						phytoremediation; mercury pollution; methylmercury; environment; transgenic; merA; merB	MERCURY; PHYTOREMEDIATION; RESISTANCE; REDUCTION	Methylmercury is a highly toxic, organic derivative found in mercury-polluted wetlands and coastal sediments worldwide. Though commonly present at low concentrations in the substrate, methylmercury can biomagnify to concentrations that poison predatory animals and humans. In the interest of developing an in situ detoxification strategy, a model plant system was transformed with bacterial genes (merA for mercuric reductase and merB for organomercurial lyase) for an organic mercury detoxification pathway. Arabidopsis thaliana plants expressing both genes grow on 50-fold higher methylmercury concentrations than wild-type plants and up to 10-fold higher concentrations than plants that express merB alone. An in vivo assay demonstrated that both transgenes are required for plants to detoxify organic mercury by converting it to volatile and much less toxic elemental mercury.	Univ Georgia, Dept Genet, Athens, GA 30602 USA; Michigan State Univ, Dept Crop & Soil Sci, E Lansing, MI 48824 USA	University System of Georgia; University of Georgia; Michigan State University	Meagher, RB (corresponding author), Univ Georgia, Dept Genet, Athens, GA 30602 USA.							ABERG B, 1969, ARCH ENVIRON HEALTH, V19, P478, DOI 10.1080/00039896.1969.10666872; *AG TOX SUBST DIS, 1994, TP9310 PHS US DEP HL; BEGLEY TP, 1986, BIOCHEMISTRY-US, V25, P7192, DOI 10.1021/bi00370a064; Bizily SP, 1999, P NATL ACAD SCI USA, V96, P6808, DOI 10.1073/pnas.96.12.6808; Chaney RL, 1997, CURR OPIN BIOTECH, V8, P279, DOI 10.1016/S0958-1669(97)80004-3; COMPEAU GC, 1985, APPL ENVIRON MICROB, V50, P498, DOI 10.1128/AEM.50.2.498-502.1985; Cunningham SD, 1996, PLANT PHYSIOL, V110, P715, DOI 10.1104/pp.110.3.715; FOX B, 1982, J BIOL CHEM, V257, P2498; GILMOUR CC, 1992, ENVIRON SCI TECHNOL, V26, P2281, DOI 10.1021/es00035a029; HARADA M, 1995, CRIT REV TOXICOL, V25, P1, DOI 10.3109/10408449509089885; JENSEN S, 1969, NATURE, V223, P753, DOI 10.1038/223753a0; KEATING MH, 1997, EPA452R9003; Mason RP, 1996, ENVIRON SCI TECHNOL, V30, P1835, DOI 10.1021/es950373d; MEAGHER RB, 1998, 4 INT C BIOG TRAC EL, P203; Miettinen J. -K., 1973, MERCURY MERCURIALS M, P233; *MIN DIS RES GROUP, 1968, MIN DIS; RAHOLA T, 1973, ANN CLIN RES, V5, P214; Rugh CL, 1996, P NATL ACAD SCI USA, V93, P3182, DOI 10.1073/pnas.93.8.3182; Rugh CL, 1998, NAT BIOTECHNOL, V16, P925, DOI 10.1038/nbt1098-925; Salt DE, 1998, ANNU REV PLANT PHYS, V49, P643, DOI 10.1146/annurev.arplant.49.1.643; SLEMR F, 1992, NATURE, V355, P434, DOI 10.1038/355434a0; SUMMERS AO, 1986, ANNU REV MICROBIOL, V40, P607, DOI 10.1146/annurev.mi.40.100186.003135; Tsubaki T., 1968, CLIN NEUROL, V8, P511; TSUZUKI T, 1977, MINAMATA DIS	24	214	249	1	69	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	FEB	2000	18	2					213	217		10.1038/72678	http://dx.doi.org/10.1038/72678			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	281FH	10657131				2022-12-25	WOS:000085146900031
J	Blume-Jensen, P; Jiang, GQ; Hyman, R; Lee, KF; O'Gorman, S; Hunter, T				Blume-Jensen, P; Jiang, GQ; Hyman, R; Lee, KF; O'Gorman, S; Hunter, T			Kit/stem cell factor receptor-induced activation of phosphatidylinositol 3 '-kinase is essential for male fertility	NATURE GENETICS			English	Article							PRIMORDIAL GERM-CELLS; PROTEIN-KINASE-C; KIT RECEPTOR; CULTURE; LIGAND; EXPRESSION; MOUSE; SPERMATOGONIA; SEQUENCES; SURVIVAL	The c-kit-encoded transmembrane tyrosine kinase receptor for stem cell factor (Kit/SCF-R) is required for normal haema-topoiesis, melanogenesis and gametogenesis(1-3). However, the roles of individual Kit/SCF-R-induced signalling pathways in the control of developmental processes in the intact animal are completely unknown. To examine the function of SCF-induced phosphatidylinositol (PI) 3'-kinase activation in vivo, we employed the Cre-IoxP system(4) to mutate the codon for Tyr719. the PI 3'-kinase binding site in Kit/SCF-R. to Phe in the genome of mice by homologous recombination. Homozygous (Y719F/Y719F) mutant mice are viable. The mutation completely disrupted PI 3'-kinase binding to Kit/SCF-R and reduced SCF-induced PI 3'-kinase-dependent activation of Akt by 90%. The mutation induced a gender- and tissue-specific defect. Although there are no haematopoietic or pigmentation defects in homozygous mutant mice, males are sterile due to a block in spermatogenesis. with initially decreased proliferation and subsequent extensive apoptosis occurring at the spermatogonial stem-cell level. In contrast, female homozygotes are fully Fertile. This is the first report so far demonstrating the role of an individual signalling pathway downstream of Kit/SCF-R in the intact animal. It provides the first in vivo model for male sterility caused by a discrete signalling pathway defect affecting early germ cells.	Salk Inst Biol Studies, Mol Biol & Virol Lab, La Jolla, CA 92037 USA; Salk Inst Biol Studies, Canc Biol Lab, La Jolla, CA 92037 USA; Salk Inst Biol Studies, Peptide Biol Lab, La Jolla, CA 92037 USA; Salk Inst Biol Studies, Gene Express Lab, La Jolla, CA 92037 USA	Salk Institute; Salk Institute; Salk Institute; Salk Institute	Blume-Jensen, P (corresponding author), Salk Inst Biol Studies, Mol Biol & Virol Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.							Alessi DR, 1998, CURR OPIN GENET DEV, V8, P55, DOI 10.1016/S0959-437X(98)80062-2; BELLVE AR, 1993, METHOD ENZYMOL, V225, P84; BESMER P, 1993, DEVELOPMENT, P125; Blume-Jensen P, 1998, CURR BIOL, V8, P779, DOI 10.1016/S0960-9822(98)70302-1; BLUMEJENSEN P, 1991, EMBO J, V10, P4121, DOI 10.1002/j.1460-2075.1991.tb04989.x; BLUMEJENSEN P, 1993, EMBO J, V12, P4199, DOI 10.1002/j.1460-2075.1993.tb06104.x; BLUMEJENSEN P, 1994, J BIOL CHEM, V269, P21793; COOKE JE, 1993, METHOD ENZYMOL, V225, P37; DOLCI S, 1991, NATURE, V352, P809, DOI 10.1038/352809a0; Downward J, 1998, CURR OPIN GENET DEV, V8, P49, DOI 10.1016/S0959-437X(98)80061-0; Fruman DA, 1998, ANNU REV BIOCHEM, V67, P481, DOI 10.1146/annurev.biochem.67.1.481; GALLI SJ, 1994, ADV IMMUNOL, V55, P1; GODIN I, 1991, NATURE, V352, P807, DOI 10.1038/352807a0; Heuchel R, 1999, P NATL ACAD SCI USA, V96, P11410, DOI 10.1073/pnas.96.20.11410; KOGAN SC, 1987, NEW ENGL J MED, V317, P985, DOI 10.1056/NEJM198710153171603; Leevers SJ, 1999, CURR OPIN CELL BIOL, V11, P219, DOI 10.1016/S0955-0674(99)80029-5; Lennartsson J, 1999, ONCOGENE, V18, P5546, DOI 10.1038/sj.onc.1202929; LEV S, 1992, P NATL ACAD SCI USA, V89, P678, DOI 10.1073/pnas.89.2.678; Lyman SD, 1998, BLOOD, V91, P1101, DOI 10.1182/blood.V91.4.1101; Maina F, 1996, CELL, V87, P531, DOI 10.1016/S0092-8674(00)81372-0; MANOVA K, 1993, DEV BIOL, V157, P85, DOI 10.1006/dbio.1993.1114; MANOVA K, 1990, DEVELOPMENT, V110, P1057; MATSUI Y, 1991, NATURE, V353, P750, DOI 10.1038/353750a0; Metzger D, 1999, CURR OPIN BIOTECH, V10, P470, DOI 10.1016/S0958-1669(99)00012-9; O'Gorman S, 1997, P NATL ACAD SCI USA, V94, P14602, DOI 10.1073/pnas.94.26.14602; Ogawa T, 2000, NAT MED, V6, P29, DOI 10.1038/71496; Rommel C, 1999, SCIENCE, V286, P1738, DOI 10.1126/science.286.5445.1738; Schrans-Stassen BHGJ, 1999, ENDOCRINOLOGY, V140, P5894, DOI 10.1210/en.140.12.5894; SERVE H, 1994, J BIOL CHEM, V269, P6026; YOSHINAGA K, 1991, DEVELOPMENT, V113, P689	30	249	269	0	11	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	FEB	2000	24	2					157	162		10.1038/72814	http://dx.doi.org/10.1038/72814			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	280LQ	10655061				2022-12-25	WOS:000085104600016
J	de Kruif, J; Tijmensen, M; Goldsein, J; Logtenberg, T				de Kruif, J; Tijmensen, M; Goldsein, J; Logtenberg, T			Recombinant lipid-tagged antibody fragments as functional cell-surface receptors	NATURE MEDICINE			English	Article							SINGLE-CHAIN ANTIBODY; ESCHERICHIA-COLI; DENDRITIC CELLS; DISPLAY; PHAGE; IMMUNOLIPOSOMES; EXPRESSION; LIBRARIES; SELECTION; ANTIGEN		Univ Utrecht Hosp, Dept Immunol, NL-3584 CX Utrecht, Netherlands; Utrecht Biotechnol Syst, Utrecht, Netherlands; Medarex Inc, Annandale, NJ USA	Utrecht University; Utrecht University Medical Center	de Kruif, J (corresponding author), Univ Utrecht Hosp, Dept Immunol, HP-F03-821,Heidelberglaan 100, NL-3584 CX Utrecht, Netherlands.							Bennett SRM, 1998, NATURE, V393, P478, DOI 10.1038/30996; Berd D, 1998, SEMIN ONCOL, V25, P646; Boder ET, 1997, NAT BIOTECHNOL, V15, P553, DOI 10.1038/nbt0697-553; DEKRUIF J, 1995, J MOL BIOL, V248, P97, DOI 10.1006/jmbi.1995.0204; DEKRUIF J, 1995, P NATL ACAD SCI USA, V92, P3938, DOI 10.1073/pnas.92.9.3938; deKruif J, 1996, FEBS LETT, V399, P232, DOI 10.1016/S0014-5793(96)01335-X; Devitt A, 1998, NATURE, V392, P505, DOI 10.1038/33169; Eshhar Z, 1997, CANCER IMMUNOL IMMUN, V45, P131, DOI 10.1007/s002620050415; FRANCISCO JA, 1992, P NATL ACAD SCI USA, V89, P2713, DOI 10.1073/pnas.89.7.2713; Gong JL, 1997, NAT MED, V3, P558, DOI 10.1038/nm0597-558; GOSSELIN EJ, 1992, J IMMUNOL, V149, P3477; GRAYEB J, 1984, J BIOL CHEM, V259, P463; GRAZIANO RF, 1995, J IMMUNOL, V155, P4996; GROUARD G, 1995, J IMMUNOL, V155, P3345; Haas C, 1999, CANCER GENE THER, V6, P254, DOI 10.1038/sj.cgt.7700048; Kwiatkowska K, 1999, BIOESSAYS, V21, P422, DOI 10.1002/(SICI)1521-1878(199905)21:5<422::AID-BIES9>3.0.CO;2-#; LAUKKANEN ML, 1993, PROTEIN ENG, V6, P449, DOI 10.1093/protein/6.4.449; LAUKKANEN ML, 1994, BIOCHEMISTRY-US, V33, P11664, DOI 10.1021/bi00204a031; Liu CL, 1996, J CLIN INVEST, V98, P2001, DOI 10.1172/JCI119004; Nawrocki S, 1999, CANCER TREAT REV, V25, P29, DOI 10.1053/ctrv.1998.0104; PACK P, 1993, BIO-TECHNOL, V11, P1271; Ridge JP, 1998, NATURE, V393, P474, DOI 10.1038/30989; SALLUSTO F, 1994, J EXP MED, V179, P1109, DOI 10.1084/jem.179.4.1109; Schirrmacher V, 1999, GENE THER, V6, P63, DOI 10.1038/sj.gt.3300787; Schoenberger SP, 1998, NATURE, V393, P480, DOI 10.1038/31002; SMITH GP, 1985, SCIENCE, V228, P1315, DOI 10.1126/science.4001944; Vermorken JB, 1999, LANCET, V353, P345, DOI 10.1016/S0140-6736(98)07186-4	27	24	25	0	7	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	FEB	2000	6	2					223	227		10.1038/72339	http://dx.doi.org/10.1038/72339			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	278YQ	10655115				2022-12-25	WOS:000085016900047
J	O'Hagan, RC; Schreiber-Agus, N; Chen, K; David, G; Engelman, JA; Schwab, R; Alland, L; Thomson, C; Ronning, DR; Sacchettini, JC; Meltzer, P; DePinho, RA				O'Hagan, RC; Schreiber-Agus, N; Chen, K; David, G; Engelman, JA; Schwab, R; Alland, L; Thomson, C; Ronning, DR; Sacchettini, JC; Meltzer, P; DePinho, RA			Gene-target recognition among members of the Myc superfamily and implications for oncogenesis	NATURE GENETICS			English	Article							C-MYC; DNA-BINDING; REPRESSES TRANSCRIPTION; CELL-GROWTH; IN-VIVO; MAX; PROTEIN; DOMAIN; DIFFERENTIATION; NETWORK	Myc and Mad family proteins regulate multiple biological processes through their capacity to influence gene expression directly. Here we show that the basic regions of Myc and Mad proteins are not functionally equivalent in oncogenesis, have separable E-box-binding activities and engage both common and distinct gene targets. Our data support the view that the opposing biological actions of Myc and Mxi1 extend beyond reciprocal regulation of common gene targets. Identification of differentially regulated gene targets provides a framework for understanding the mechanism through which the Myc superfamily governs the growth, proliferation and survival of normal and neoplastic cells.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med & Genet, Boston, MA 02115 USA; Albert Einstein Coll Med, Dept Mol Genet, Bronx, NY 10467 USA; Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10467 USA; Texas A&M Univ, Dept Biochem & Biophys, College Stn, TX 77843 USA; Natl Human Genome Res Inst, NIH, Bethesda, MD USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Texas A&M University System; Texas A&M University College Station; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI)	DePinho, RA (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Adult Oncol, 44 Binney St, Boston, MA 02115 USA.			Ronning, Donald/0000-0003-2583-8849; DePinho, Ronald/0000-0002-5625-577X; , gregory/0000-0002-3371-4558	NEI NIH HHS [R01EY09300] Funding Source: Medline; NICHD NIH HHS [R01HD28317] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD028317] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY009300] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		AMATI B, 1994, CURR OPIN GENET DEV, V4, P102, DOI 10.1016/0959-437X(94)90098-1; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; Blackwood EM, 1992, CURR OPIN GENET DEV, V2, P227, DOI 10.1016/S0959-437X(05)80278-3; Chen Y, 1997, J Biomed Opt, V2, P364, DOI 10.1117/12.281504; Chiorini JA, 1999, J BIOL CHEM, V274, P4195, DOI 10.1074/jbc.274.7.4195; Dang CV, 1999, MOL CELL BIOL, V19, P1; DeRisi J, 1996, NAT GENET, V14, P457; EVAN GI, 1993, CURR OPIN GENET DEV, V3, P44, DOI 10.1016/S0959-437X(05)80339-9; Felsher DW, 1999, P NATL ACAD SCI USA, V96, P3940, DOI 10.1073/pnas.96.7.3940; Ferre d'Amare AR, 1993, NATURE, V363, P38; FERREDAMARE AR, 1994, EMBO J, V13, P180, DOI 10.1002/j.1460-2075.1994.tb06247.x; FISHER F, 1992, EMBO J, V11, P4103, DOI 10.1002/j.1460-2075.1992.tb05503.x; Grandori C, 1996, EMBO J, V15, P4344, DOI 10.1002/j.1460-2075.1996.tb00808.x; Grandori C, 1997, TRENDS BIOCHEM SCI, V22, P177, DOI 10.1016/S0968-0004(97)01025-6; Greenberg RA, 1999, ONCOGENE, V18, P1219, DOI 10.1038/sj.onc.1202669; HALAZONETIS TD, 1991, P NATL ACAD SCI USA, V88, P6162, DOI 10.1073/pnas.88.14.6162; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hurlin PJ, 1997, GENE DEV, V11, P44, DOI 10.1101/gad.11.1.44; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Khan J, 1998, CANCER RES, V58, P5009; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; KRIKOS A, 1992, J BIOL CHEM, V267, P17971; Lee LA, 1997, CURR TOP MICROBIOL, V224, P131; Lee TC, 1997, P NATL ACAD SCI USA, V94, P12886, DOI 10.1073/pnas.94.24.12886; LI LH, 1994, EMBO J, V13, P4070, DOI 10.1002/j.1460-2075.1994.tb06724.x; Marhin WW, 1997, ONCOGENE, V14, P2825, DOI 10.1038/sj.onc.1201138; MUKHERJEE B, 1992, GENE DEV, V6, P1480, DOI 10.1101/gad.6.8.1480; Schreiber-Agus N, 1998, BIOESSAYS, V20, P808, DOI 10.1002/(SICI)1521-1878(199810)20:10<808::AID-BIES6>3.0.CO;2-U; SCHREIBERAGUS N, 1995, CELL, V80, P777, DOI 10.1016/0092-8674(95)90356-9; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Shimizu T, 1997, EMBO J, V16, P4689, DOI 10.1093/emboj/16.15.4689; SOLOMON DLC, 1993, NUCLEIC ACIDS RES, V21, P5372, DOI 10.1093/nar/21.23.5372; Wu KJ, 1999, SCIENCE, V283, P676, DOI 10.1126/science.283.5402.676; [No title captured]	37	121	125	0	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	FEB	2000	24	2					113	119		10.1038/72761	http://dx.doi.org/10.1038/72761			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	280LQ	10655054				2022-12-25	WOS:000085104600009
J	Steemers, FJ; Ferguson, JA; Walt, DR				Steemers, FJ; Ferguson, JA; Walt, DR			Screening unlabeled DNA targets with randomly ordered fiber-optic gene arrays	NATURE BIOTECHNOLOGY			English	Article						high-density oligonucleotide probe arrays; fluorescence detection; genotyping; DNA diagnosis	MOLECULAR BEACONS; HYBRIDIZATION; INFORMATION; MICROARRAY; EXPRESSION; SEQUENCE; DEVICE	We have developed a randomly ordered fiber-optic gene array for rapid, parallel detection of unlabeled DNA targets with surface immobilized molecular beacons (MB) that undergo a conformational change accompanied by a fluorescence change in the presence of a complementary DNA target. Microarrays are prepared by randomly distributing MB-functionalized 3-mu m diameter microspheres in an array of wells etched in a 500-mu m diameter optical imaging fiber. Using several MBs, each designed to recognize a different target, we demonstrate the selective detection of genomic cystic fibrosis related targets. Positional registration and fluorescence response monitoring of the microspheres was performed using an optical encoding scheme and an imaging fluorescence microscope system.	Tufts Univ, Dept Chem, Max Tishler Lab Organ Chem, Medford, MA 02155 USA	Tufts University	Walt, DR (corresponding author), Tufts Univ, Dept Chem, Max Tishler Lab Organ Chem, Medford, MA 02155 USA.				NIGMS NIH HHS [GM48142] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRONK KS, 1995, ANAL CHEM, V67, P2750, DOI 10.1021/ac00113a005; Burns MA, 1998, SCIENCE, V282, P484, DOI 10.1126/science.282.5388.484; Case-Green SC, 1998, CURR OPIN CHEM BIOL, V2, P404, DOI 10.1016/S1367-5931(98)80016-1; Chee M, 1996, SCIENCE, V274, P610, DOI 10.1126/science.274.5287.610; Cronin MT, 1996, HUM MUTAT, V7, P244, DOI 10.1002/(SICI)1098-1004(1996)7:3<244::AID-HUMU9>3.0.CO;2-A; EGNER BJ, 1997, CHEM COMMUN, V8, P735; Fang XH, 1999, J AM CHEM SOC, V121, P2921, DOI 10.1021/ja9837809; Ferguson JA, 1996, NAT BIOTECHNOL, V14, P1681, DOI 10.1038/nbt1296-1681; Fulton RJ, 1997, CLIN CHEM, V43, P1749; Kostrikis LG, 1998, SCIENCE, V279, P1228, DOI 10.1126/science.279.5354.1228; LONGO MC, 1990, GENE, V93, P125, DOI 10.1016/0378-1119(90)90145-H; Maldonado-Rodriguez R, 1999, MOL BIOTECHNOL, V11, P1, DOI 10.1007/BF02789172; McGall G, 1996, P NATL ACAD SCI USA, V93, P13555, DOI 10.1073/pnas.93.24.13555; Michael KL, 1998, ANAL CHEM, V70, P1242, DOI 10.1021/ac971343r; Ortiz E, 1998, MOL CELL PROBE, V12, P219, DOI 10.1006/mcpr.1998.0175; Pantano P, 1996, CHEM MATER, V8, P2832, DOI 10.1021/cm9603314; Piatek AS, 1998, NAT BIOTECHNOL, V16, P359, DOI 10.1038/nbt0498-359; Ramsay G, 1998, NAT BIOTECHNOL, V16, P40, DOI 10.1038/nbt0198-40; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; Slaterbeck AF, 1999, ANAL CHEM, V71, P1196, DOI 10.1021/ac9807464; Tyagi S, 1996, NAT BIOTECHNOL, V14, P303, DOI 10.1038/nbt0396-303; Tyagi S, 1998, NAT BIOTECHNOL, V16, P49, DOI 10.1038/nbt0198-49; Walt DR, 1998, ACCOUNTS CHEM RES, V31, P267, DOI 10.1021/ar970069k; Whitcombe D, 1998, CURR OPIN BIOTECH, V9, P602, DOI 10.1016/S0958-1669(98)80137-7; ZIELENSKI J, 1991, GENOMICS, V10, P214, DOI 10.1016/0888-7543(91)90503-7; ZIELENSKI J, 1991, GENOMICS, V10, P29; 1999, NATURE GENETICS S, V21, P3	27	226	296	0	27	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JAN	2000	18	1					91	94		10.1038/72006	http://dx.doi.org/10.1038/72006			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	273GQ	10625399				2022-12-25	WOS:000084699900033
J	Brown, CW; Houston-Hawkins, DE; Woodruff, TK; Matzuk, MM				Brown, CW; Houston-Hawkins, DE; Woodruff, TK; Matzuk, MM			Insertion of Inhbb into the Inhba locus rescues the Inhba-null phenotype and reveals new activin functions	NATURE GENETICS			English	Article							DEFICIENT MICE; MESSENGER-RNA; ALPHA-INHIBIN; EXPRESSION; RECEPTOR; DEFECTS; RAT; OVEREXPRESSION; PROLIFERATION; REPRODUCTION	The activins (dimers of beta A or beta B subunits, encoded by the genes Inhba and Inhbb, respectively) are TGF-beta superfamily members that have roles in reproduction and devetopment(1-3). Whereas mice homozygous for the Inhba-null allele demonstrate disruption of whisker, palate and tooth development, leading to neonatal lethality(4,5), homozygous Inhbb-null mice are viable, fertile and have eye defects(6,7). To determine if these phenotypes were due to spatiotemporal expression differences of the ligands or disruption of specific ligand-receptor interactions, we replaced the region of Inhba encoding the mature protein with Inhbb, creating the allele Inhba(tm2Zuk) thereafter designated Inhba(BK)). Although the craniofacial phenotypes of the Inhba-null mutation were rescued by the InhbaBK allele, somatic, testicular, genital and hair growth were grossly affected and influenced by the dosage and bioactivity of the allele. Thus, functional compensation within the TGF-beta superfamily can occur if the replacement gene is expressed appropriately. The novel phenotypes in these mice further illustrate the usefulness of insertion strategies for defining protein function.	Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; Northwestern Univ, Dept Neurobiol & Physiol, Evanston, IL 60208 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Northwestern University	Matzuk, MM (corresponding author), Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA.			Woodruff, Teresa/0000-0002-1197-3399	NICHD NIH HHS [HD32067, HD27823, HD01156] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD032067] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P30HD027823, K08HD001156] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ANTONIPILLAI I, 1995, MOL CELL ENDOCRINOL, V107, P99, DOI 10.1016/0303-7207(94)03430-2; BOITANI C, 1995, ENDOCRINOLOGY, V136, P5438, DOI 10.1210/en.136.12.5438; Bradley A, 1987, TERATOCARCINOMAS EMB, P113; Bunn HF, 1999, BLOOD, V93, P1787, DOI 10.1182/blood.V93.6.1787.406a34_1787_1789; Deconinck N, 1997, NAT MED, V3, P1216, DOI 10.1038/nm1197-1216; DEWINTER JP, 1992, MOL CELL ENDOCRINOL, V83, pR1, DOI 10.1016/0303-7207(92)90201-G; Dyson S, 1998, CELL, V93, P557, DOI 10.1016/S0092-8674(00)81185-X; Elvin JA, 1999, MOL ENDOCRINOL, V13, P1018, DOI 10.1210/me.13.6.1018; FEIJEN A, 1994, DEVELOPMENT, V120, P3621; FENG ZM, 1993, ENDOCRINOLOGY, V132, P2593, DOI 10.1210/en.132.6.2593; Ferguson CA, 1998, GENE DEV, V12, P2636, DOI 10.1101/gad.12.16.2636; Guo QX, 1998, MOL ENDOCRINOL, V12, P96, DOI 10.1210/mend.12.1.0053; KLUIN PM, 1984, ANAT EMBRYOL, V169, P73, DOI 10.1007/BF00300588; LAU AL, 1997, INHIBIN ACTIVIN FOLL, P220; Mather JP, 1997, P SOC EXP BIOL MED, V215, P209; MATHEWS LS, 1991, CELL, V65, P973, DOI 10.1016/0092-8674(91)90549-E; MATZUK MM, 1995, NATURE, V374, P354, DOI 10.1038/374354a0; Matzuk MM, 1996, RECENT PROG HORM RES, V51, P123; MATZUK MM, 1995, NATURE, V374, P356, DOI 10.1038/374356a0; MATZUK MM, 1992, NATURE, V360, P313, DOI 10.1038/360313a0; Rafael JA, 1998, NAT GENET, V19, P79, DOI 10.1038/ng0598-79; RAMIREZSOLIS R, 1992, ANAL BIOCHEM, V201, P331, DOI 10.1016/0003-2697(92)90347-A; SCHREWE H, 1994, MECH DEVELOP, V47, P43, DOI 10.1016/0925-4773(94)90094-9; TRUDEAU VL, 1994, BIOCHEM BIOPH RES CO, V203, P105, DOI 10.1006/bbrc.1994.2155; Vale Wylie, 1994, P1861; VASSALLI A, 1994, GENE DEV, V8, P414, DOI 10.1101/gad.8.4.414	26	163	169	0	7	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	AUG	2000	25	4					453	457		10.1038/78161	http://dx.doi.org/10.1038/78161			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	341WY	10932194				2022-12-25	WOS:000088615000025
J	Hofer, AM; Curci, S; Doble, MA; Brown, EM; Soybel, DI				Hofer, AM; Curci, S; Doble, MA; Brown, EM; Soybel, DI			Intercellular communication mediated by the extracellular calcium-sensing receptor	NATURE CELL BIOLOGY			English	Article							PANCREATIC ACINAR-CELLS; MEMBRANE CA2+ PUMP; INTRACELLULAR CA2+; CA2+-SENSING RECEPTOR; EPITHELIAL-CELLS; GLIAL-CELLS; EXPRESSION; ACTIVATION; EXTRUSION; RELEASE	Agonist-evoked, intracellular Ca2+-signalling events are associated with active extrusion of Ca2+ across the plasma membrane, implying a local increase in Ca2+ concentration ([Ca2+]) at the extracellular face of the cell. The possibility that these external [Ca2+] changes may have specific physiological functions has received little consideration in the past. Here we show that, at physiological ambient [Ca2+], Ca2+ mobilization in one cell produces an extracellular signal that can be detected in nearby cells expressing the extracellular Ca2+-sensing receptor (CaR), a cell-surface receptor for divalent cations with a widespread tissue distribution. The Can may therefore mediate a universal form of intercellular communication that allows cells to be informed of the Ca2+-signalling status of their neighbours.	Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Surg, Boston, MA 02115 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med, Boston, MA 02115 USA; Vet Adm Med Ctr W Roxbury, Dept Surg, Boston, MA 02132 USA; Univ Bari, Dipartimento Fisiol Gen & Ambientale, I-70126 Bari, Italy	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Universita degli Studi di Bari Aldo Moro	Hofer, AM (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Surg, Boston, MA 02115 USA.	ahofer@rics.bwh.harvard.edu			NIDDK NIH HHS [DK52005, DK48330, DK41415] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052005, R01DK041415, R01DK048330] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALONSO MT, 1991, BIOCHEM J, V280, P783, DOI 10.1042/bj2800783; Belan P, 1998, J BIOL CHEM, V273, P4106, DOI 10.1074/jbc.273.7.4106; BERGLINDH T, 1976, ACTA PHYSIOL SCAND, V96, P150, DOI 10.1111/j.1748-1716.1976.tb10184.x; BERRIDGE MJ, 1908, FASEB J, V15, P3074; BOITANO S, 1992, SCIENCE, V258, P292, DOI 10.1126/science.1411526; BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0; Brown EM, 1998, RECENT PROG HORM RES, V53, P257; BROWN EM, 1995, CELL, V83, P679, DOI 10.1016/0092-8674(95)90180-9; Bruce JIE, 1999, J BIOL CHEM, V274, P20561, DOI 10.1074/jbc.274.29.20561; Camello P, 1996, J PHYSIOL-LONDON, V490, P585, DOI 10.1113/jphysiol.1996.sp021169; Carafoli E, 1989, Adv Exp Med Biol, V255, P61; CHARLES AC, 1991, NEURON, V6, P983, DOI 10.1016/0896-6273(91)90238-U; Chattopadhyay N, 1998, GLIA, V24, P449, DOI 10.1002/(SICI)1098-1136(199812)24:4<449::AID-GLIA10>3.3.CO;2-0; Chattopadhyay N, 1998, AM J PHYSIOL-GASTR L, V274, pG122, DOI 10.1152/ajpgi.1998.274.1.G122; Cheng I, 1998, J CLIN ENDOCR METAB, V83, P703, DOI 10.1210/jc.83.2.703; Cheng I, 1999, GASTROENTEROLOGY, V116, P118, DOI 10.1016/S0016-5085(99)70235-0; Ennes HS, 1999, AM J PHYSIOL-CELL PH, V276, pC602, DOI 10.1152/ajpcell.1999.276.3.C602; Foster RH, 1999, GEN PHARMACOL, V32, P171, DOI 10.1016/S0306-3623(98)00092-5; GRIERSON JP, 1995, J BIOL CHEM, V270, P4451, DOI 10.1074/jbc.270.9.4451; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hofer AM, 1998, EMBO J, V17, P1986, DOI 10.1093/emboj/17.7.1986; HOFER AM, 1995, FASEB J, V9, P788, DOI 10.1096/fasebj.9.9.7601343; HOFER AM, 1999, IMAGING LIVING CELLS; Klishin A, 1998, AM J PHYSIOL-CELL PH, V274, pC1117, DOI 10.1152/ajpcell.1998.274.4.C1117; Kubo Y, 1998, SCIENCE, V279, P1722, DOI 10.1126/science.279.5357.1722; McNeil L, 1998, AM J OBSTET GYNECOL, V178, P305, DOI 10.1016/S0002-9378(98)80017-3; McNeil SE, 1998, J BIOL CHEM, V273, P1114, DOI 10.1074/jbc.273.2.1114; MUALLEM S, 1988, J MEMBRANE BIOL, V106, P57, DOI 10.1007/BF01871767; NELSON EJ, 1994, J BIOL CHEM, V269, P30854; Nemeth EF, 1998, P NATL ACAD SCI USA, V95, P4040, DOI 10.1073/pnas.95.7.4040; OSIPCHUK Y, 1992, NATURE, V359, P241, DOI 10.1038/359241a0; Petersen OH, 1999, BIOESSAYS, V21, P851, DOI 10.1002/(SICI)1521-1878(199910)21:10<851::AID-BIES7>3.3.CO;2-6; Pfeiffer F, 1998, AM J PHYSIOL-CELL PH, V274, pC663; POZZAN T, 1994, PHYSIOL REV, V74, P595, DOI 10.1152/physrev.1994.74.3.595; Quinn SJ, 1997, AM J PHYSIOL-CELL PH, V273, pC1315, DOI 10.1152/ajpcell.1997.273.4.C1315; Ray JM, 1997, J CLIN INVEST, V99, P2328, DOI 10.1172/JCI119413; RICCARDI D, 1995, P NATL ACAD SCI USA, V92, P131, DOI 10.1073/pnas.92.1.131; Ruat M, 1996, J BIOL CHEM, V271, P5972, DOI 10.1074/jbc.271.11.5972; Schlosser SF, 1996, P NATL ACAD SCI USA, V93, P9948, DOI 10.1073/pnas.93.18.9948; TEPIKIN AV, 1991, J MEMBRANE BIOL, V123, P43, DOI 10.1007/BF01993961; TEPIKIN AV, 1994, PFLUG ARCH EUR J PHY, V428, P664, DOI 10.1007/BF00374591; TEPIKIN AV, 1992, J BIOL CHEM, V267, P14073; TOESCU EC, 1995, J BIOL CHEM, V270, P8528, DOI 10.1074/jbc.270.15.8528; Vassilev PM, 1997, BIOPHYS J, V72, P2103, DOI 10.1016/S0006-3495(97)78853-2; Vescovi EG, 1997, J BIOL CHEM, V272, P1440, DOI 10.1074/jbc.272.3.1440; WOLFF T, 1993, PFLUG ARCH EUR J PHY, V424, P423, DOI 10.1007/BF00374904; Xiong ZG, 1997, P NATL ACAD SCI USA, V94, P7012, DOI 10.1073/pnas.94.13.7012; Yamoah EN, 1998, J NEUROSCI, V18, P610; Zanotti S, 1997, J NEUROCHEM, V69, P594; ZHANG BX, 1992, J BIOL CHEM, V267, P15419	50	114	115	2	6	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	JUL	2000	2	7					392	398		10.1038/35017020	http://dx.doi.org/10.1038/35017020			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	333MK	10878803				2022-12-25	WOS:000088133700014
J	Hoppe, HC; Ngo, HM; Yang, M; Joiner, KA				Hoppe, HC; Ngo, HM; Yang, M; Joiner, KA			Targeting to rhoptry organelles of Toxoplasma gondii involves evolutionarily conserved mechanisms.	NATURE CELL BIOLOGY			English	Article							TRANS-GOLGI NETWORK; DENSITY-LIPOPROTEIN RECEPTOR; INTRACELLULAR PARASITE; TRANSMEMBRANE DOMAINS; CYTOPLASMIC DOMAIN; SECRETORY PATHWAY; MEMBRANE-PROTEINS; SORTING SIGNALS; CELL-SURFACE; LDL RECEPTOR	Intracellular parasites of the phylum Apicomplexa contain specialized rhoptry secretory organelles that have a crucial function in host-cell invasion and establishment of the parasitophorous vacuole. Here we show that localization of the Toxoplasma gondii rhoptry protein ROP2 is dependent on a YEQL sequence in the cytoplasmic tail that binds to mu-chain subunits of T, gondii and mammalian adaptors, and conforms to the YXX phi mammalian sorting motif. Chimaeric reporters, containing the transmembrane domains and cytoplasmic tails of the low-density lipoprotein receptor and of Lamp-1, are sorted to the Golgi or the trans-Golgi network (TGN), and partially to apical microneme organelles of the parasite, respectively. Targeting of these reporters is mediated by YXX phi- and NPXY-type signals. This is the first demonstration of tyrosine-dependent sorting in protozoan parasites, indicating that T. gondii proteins may be targeted to, and involved in biogenesis of, morphologically unique organelles through the use of evolutionarily conserved signals and machinery.	Yale Univ, Sch Med, Dept Internal Med, Infect Dis Sect, New Haven, CT 06520 USA	Yale University	Joiner, KA (corresponding author), Yale Univ, Sch Med, Dept Internal Med, Infect Dis Sect, 333 Cedar St, New Haven, CT 06520 USA.	keith.joiner@yale.edu	Joiner, Keith/AAH-1059-2021	Hoppe, Heinrich/0000-0003-4409-1955; Joiner, Keith/0000-0003-3062-823X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [F32AI010044, T32AI007404, R01AI030060] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI30060, 5F32AI-10044, 5T32AI-07404] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ajioka JW, 1998, GENOME RES, V8, P18, DOI 10.1101/gr.8.1.18; BECKERS CJM, 1994, J CELL BIOL, V127, P947, DOI 10.1083/jcb.127.4.947; Beckers CJM, 1997, MOL BIOCHEM PARASIT, V89, P209, DOI 10.1016/S0166-6851(97)00120-5; BOMAN AL, 1995, TRENDS BIOCHEM SCI, V20, P147, DOI 10.1016/S0968-0004(00)88991-4; Bonifacino JS, 1999, J CELL BIOL, V145, P923, DOI 10.1083/jcb.145.5.923; Carruthers VB, 1997, EUR J CELL BIOL, V73, P114; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; Dittie AS, 1996, J CELL BIOL, V132, P523, DOI 10.1083/jcb.132.4.523; DUBEY JP, 1988, TAXOPLASMOSIS ANIMAL; Folsch H, 1999, CELL, V99, P189, DOI 10.1016/S0092-8674(00)81650-5; Ghosh RN, 1998, J CELL BIOL, V142, P923, DOI 10.1083/jcb.142.4.923; GREEN SA, 1992, J CELL BIOL, V117, P47, DOI 10.1083/jcb.117.1.47; Hager KM, 1999, J CELL SCI, V112, P2631; HARTER C, 1992, J CELL BIOL, V117, P311, DOI 10.1083/jcb.117.2.311; Hirst J, 1998, BBA-MOL CELL RES, V1404, P173, DOI 10.1016/S0167-4889(98)00056-1; HONING S, 1995, J CELL BIOL, V128, P321, DOI 10.1083/jcb.128.3.321; JAIKARIA NS, 1993, MOL BIOCHEM PARASIT, V57, P269, DOI 10.1016/0166-6851(93)90203-A; JOINER KA, 1990, SCIENCE, V249, P641, DOI 10.1126/science.2200126; Karsten V, 1998, J CELL BIOL, V141, P1323, DOI 10.1083/jcb.141.6.1323; Karsten V, 1997, METHODS, V13, P103, DOI 10.1006/meth.1997.0503; Kibbey RG, 1998, J CELL BIOL, V142, P59, DOI 10.1083/jcb.142.1.59; LIPPINCOTTSCHWARTZ J, 1991, CELL, V67, P601, DOI 10.1016/0092-8674(91)90534-6; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; Marks MS, 1997, TRENDS CELL BIOL, V7, P124, DOI 10.1016/S0962-8924(96)10057-X; MATHEWS PM, 1992, J CELL BIOL, V118, P1027, DOI 10.1083/jcb.118.5.1027; MATTER K, 1992, CELL, V71, P741, DOI 10.1016/0092-8674(92)90551-M; Moreno SNJ, 1996, BIOCHEM J, V313, P655, DOI 10.1042/bj3130655; MORRISSETTE NS, 1994, EXP PARASITOL, V79, P445, DOI 10.1006/expr.1994.1106; MUNRO S, 1995, EMBO J, V14, P4695, DOI 10.1002/j.1460-2075.1995.tb00151.x; Nakaar V, 1999, J BIOL CHEM, V274, P5083, DOI 10.1074/jbc.274.8.5083; Nesterov A, 1999, EMBO J, V18, P2489, DOI 10.1093/emboj/18.9.2489; Ngo HM, 2000, TRENDS CELL BIOL, V10, P67, DOI 10.1016/S0962-8924(99)01698-0; NICHOLS BA, 1994, PARASITOL RES, V80, P91, DOI 10.1007/BF00933773; NOTHWEHR SF, 1994, J BIOL CHEM, V269, P10185; Ohno H, 1997, VIROLOGY, V238, P305, DOI 10.1006/viro.1997.8839; Ohno H, 1996, J BIOL CHEM, V271, P29009, DOI 10.1074/jbc.271.46.29009; Ooi CE, 1997, EMBO J, V16, P4508; Owen DJ, 1998, SCIENCE, V282, P1327, DOI 10.1126/science.282.5392.1327; PONNAMBALAM S, 1994, J CELL BIOL, V125, P253, DOI 10.1083/jcb.125.2.253; REAVES B, 1992, J CELL BIOL, V116, P85, DOI 10.1083/jcb.116.1.85; Reaves BJ, 1998, MOL BIOL CELL, V9, P1107, DOI 10.1091/mbc.9.5.1107; ROOS DS, 1994, METHOD CELL BIOL, V45, P27; SADAK A, 1988, MOL BIOCHEM PARASIT, V29, P203, DOI 10.1016/0166-6851(88)90075-8; SamYellowe TY, 1996, PARASITOL TODAY, V12, P308, DOI 10.1016/0169-4758(96)10030-2; SEYMOR, 1997, MOL BIOL CELL S, V8, P227; Shaw MK, 1998, PARASITOLOGY, V117, P435, DOI 10.1017/S0031182098003278; Soldati D, 1998, MOL BIOCHEM PARASIT, V96, P37, DOI 10.1016/S0166-6851(98)00090-5; Soldati D, 1996, FEBS LETT, V389, P80, DOI 10.1016/0014-5793(96)00572-8; Stedman TT, 1999, ADV CELL MOL BIOL ME, V6, P233, DOI 10.1016/S1874-5172(99)80014-5; Swank RT, 1998, PIGM CELL RES, V11, P60, DOI 10.1111/j.1600-0749.1998.tb00713.x; VOORHEES P, 1995, EMBO J, V14, P4961, DOI 10.1002/j.1460-2075.1995.tb00179.x; WILLIAMS MA, 1990, J CELL BIOL, V111, P955, DOI 10.1083/jcb.111.3.955; WimerMackin S, 1996, BIOCHEM BIOPH RES CO, V229, P472, DOI 10.1006/bbrc.1996.1828; WONG SY, 1993, AIDS, V7, P299, DOI 10.1097/00002030-199303000-00001	54	112	117	0	5	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	JUL	2000	2	7					449	456		10.1038/35017090	http://dx.doi.org/10.1038/35017090			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	333MK	10878811				2022-12-25	WOS:000088133700022
J	Grisham, J				Grisham, J			Protein biopesticide may be next wave in pest control	NATURE BIOTECHNOLOGY			English	News Item																			0	3	6	0	4	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUN	2000	18	6					595	595		10.1038/76423	http://dx.doi.org/10.1038/76423			1	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	325EK	10835591	Bronze			2022-12-25	WOS:000087663200013
J	Camaschella, C; Roetto, A; Cali, A; De Gobbi, M; Garozzo, G; Carella, M; Majorano, N; Totaro, A; Gasparini, P				Camaschella, C; Roetto, A; Cali, A; De Gobbi, M; Garozzo, G; Carella, M; Majorano, N; Totaro, A; Gasparini, P			The gene TFR2 is mutated in a new type of haemochromatosis mapping to 7q22	NATURE GENETICS			English	Article							HEREDITARY HEMOCHROMATOSIS; TRANSFERRIN RECEPTOR; HLA-H; JUVENILE		IRCCS Osped CSS, Serv Genet Med, Foggia, Italy; Azienda Osped Civile M Paterno Arezzo, Serv Immunoematol & Med Trasfus, Ragusa, Italy; Univ Turin, Azienda Osped S Luigi, Dipartimento Sci Clin & Biol, Orbassano Torino, Italy	Civile M.P. Arezzo Hospital; University of Turin	Gasparini, P (corresponding author), IRCCS Osped CSS, Serv Genet Med, Foggia, Italy.		Camaschella, Clara/A-3289-2015; Gasparini, Paolo/B-6173-2014; Roetto, Antonella/K-4731-2016; De Gobbi, Marco/E-8136-2013; Carella, Massimo/A-2804-2014	Carella, Massimo/0000-0002-6830-6829; Gasparini, Paolo/0000-0002-0859-0856; ROETTO, Antonella/0000-0003-1188-7375; De Gobbi, Marco/0000-0003-4261-7642	Telethon [E.0679] Funding Source: Medline	Telethon(Fondazione Telethon)		Beutler Ernest, 1996, Blood Cells Molecules and Diseases, V22, P187, DOI 10.1006/bcmd.1996.0027; Camaschella C, 1997, EUR J HUM GENET, V5, P371, DOI 10.1159/000484794; Camaschella C, 1999, HEPATOLOGY, V29, P1563, DOI 10.1002/hep.510290509; Carella M, 1997, AM J HUM GENET, V60, P828; Feder JN, 1996, NAT GENET, V13, P399, DOI 10.1038/ng0896-399; Fleming RE, 2000, P NATL ACAD SCI USA, V97, P2214, DOI 10.1073/pnas.040548097; Glockner G, 1998, GENOME RES, V8, P1060; GORDEUK V, 1992, NEW ENGL J MED, V326, P95, DOI 10.1056/NEJM199201093260204; Jazwinska EC, 1996, NAT GENET, V14, P249, DOI 10.1038/ng1196-249; Kawabata H, 1999, J BIOL CHEM, V274, P20826, DOI 10.1074/jbc.274.30.20826; Levy JE, 1999, NAT GENET, V21, P396, DOI 10.1038/7727; Pietrangelo A, 1999, NEW ENGL J MED, V341, P725, DOI 10.1056/NEJM199909023411003; Piperno A, 1998, GASTROENTEROLOGY, V114, P996, DOI 10.1016/S0016-5085(98)70319-1; Robson KJH, 1997, GUT, V41, P841; Roetto A, 1999, AM J HUM GENET, V64, P1388, DOI 10.1086/302379	15	629	661	3	22	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAY	2000	25	1					14	15		10.1038/75534	http://dx.doi.org/10.1038/75534			2	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	311KU	10802645				2022-12-25	WOS:000086884000007
J	Murone, M; Luoh, SM; Stone, D; Li, WL; Gurney, A; Armanini, M; Grey, C; Rosenthal, A; de Sauvage, FJ				Murone, M; Luoh, SM; Stone, D; Li, WL; Gurney, A; Armanini, M; Grey, C; Rosenthal, A; de Sauvage, FJ			Gli regulation by the opposing activities of Fused and Suppressor of Fused	NATURE CELL BIOLOGY			English	Article							SIGNAL-TRANSDUCTION; HEDGEHOG; KINASE; COMPLEX; FAMILY; DOMAIN		Genentech Inc, Dept Mol Oncol, San Francisco, CA 94080 USA; Genentech Inc, Dept Mol Biol, San Francisco, CA 94080 USA; Genentech Inc, Dept Metab & Pharmacokinet, San Francisco, CA 94080 USA	Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech	de Sauvage, FJ (corresponding author), Genentech Inc, Dept Mol Oncol, 1 DNA Way, San Francisco, CA 94080 USA.	sauvage@gene.com	de Sauvage, Frederic/ABE-8400-2020	de Sauvage, Frederic/0000-0002-5275-2584				Carpenter D, 1998, P NATL ACAD SCI USA, V95, P13630, DOI 10.1073/pnas.95.23.13630; Hammerschmidt M, 1997, TRENDS GENET, V13, P14, DOI 10.1016/S0168-9525(96)10051-2; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; Kalderon D, 1997, CURR BIOL, V7, pR759, DOI 10.1016/S0960-9822(06)00398-8; Kogerman P, 1999, NAT CELL BIOL, V1, P312, DOI 10.1038/13031; Murone M, 1999, EXP CELL RES, V253, P25, DOI 10.1006/excr.1999.4676; Murone M, 1999, CURR BIOL, V9, P76, DOI 10.1016/S0960-9822(99)80018-9; Ohlmeyer JT, 1998, NATURE, V396, P749, DOI 10.1038/25533; PASTERIS NG, 1993, HUM MOL GENET, V2, P953, DOI 10.1093/hmg/2.7.953; Robbins DJ, 1997, CELL, V90, P225, DOI 10.1016/S0092-8674(00)80331-1; Sasaki H, 1999, DEVELOPMENT, V126, P3915; Stone DM, 1999, J CELL SCI, V112, P4437; Sun XQ, 1999, J BIOL CHEM, V274, P16871, DOI 10.1074/jbc.274.24.16871; Therond P, 1996, GENETICS, V142, P1181; Thomas JA, 1999, J IMMUNOL, V163, P978	15	113	131	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	MAY	2000	2	5					310	312		10.1038/35010610	http://dx.doi.org/10.1038/35010610			3	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	313FX	10806483				2022-12-25	WOS:000086990600021
J	Sun, LW; Li, J; Xiao, X				Sun, LW; Li, J; Xiao, X			Overcoming adeno-associated virus vector size limitation through viral DNA heterodimerization	NATURE MEDICINE			English	Article							RECOMBINANT ADENOASSOCIATED VIRUS; TRANSMEMBRANE CONDUCTANCE REGULATOR; IN-VIVO EXPRESSION; GENE-TRANSFER; MUSCULAR-DYSTROPHY; DETROIT-6 CELLS; MUSCLE-TISSUE; AAV VECTOR; PROTEIN; MICE		Univ Pittsburgh, Dept Mol Genet & Biochem, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Gene Therapy Ctr, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Duchenne Muscular Dystrophy Res Ctr, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Dept Orthoped Surg, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Xiao, X (corresponding author), Univ Pittsburgh, Dept Mol Genet & Biochem, Room W1213,BST, Pittsburgh, PA 15261 USA.				NIAMS NIH HHS [AR45967, AR 45925] Funding Source: Medline; NIDDK NIH HHS [R21 DK55966] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR045925, R01AR045967] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK055966] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CHEUNG AKM, 1980, J VIROL, V33, P739, DOI 10.1128/JVI.33.2.739-748.1980; Dong JY, 1996, HUM GENE THER, V7, P2101, DOI 10.1089/hum.1996.7.17-2101; Duan DS, 1998, J VIROL, V72, P8568, DOI 10.1128/JVI.72.11.8568-8577.1998; Duan DS, 1999, VIROLOGY, V261, P8, DOI 10.1006/viro.1999.9821; Duan DS, 1999, J VIROL, V73, P861, DOI 10.1128/JVI.73.1.861-861.1999; During MJ, 1998, GENE THER, V5, P820, DOI 10.1038/sj.gt.3300650; FLOTTE TR, 1993, P NATL ACAD SCI USA, V90, P10613, DOI 10.1073/pnas.90.22.10613; FLOTTE TR, 1993, J BIOL CHEM, V268, P3781; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; HOFFMAN EP, 1987, CELL, V51, P919, DOI 10.1016/0092-8674(87)90579-4; KAPLITT MG, 1994, NAT GENET, V8, P148, DOI 10.1038/ng1094-148; Kay MA, 2000, NAT GENET, V24, P257, DOI 10.1038/73464; Kessler PD, 1996, P NATL ACAD SCI USA, V93, P14082, DOI 10.1073/pnas.93.24.14082; KOTIN RM, 1989, VIROLOGY, V170, P460, DOI 10.1016/0042-6822(89)90437-6; Lewin AS, 1998, NAT MED, V4, P1081, DOI 10.1038/2077; Liu J, 1998, NAT GENET, V20, P31, DOI 10.1038/1682; MCLAUGHLIN SK, 1988, J VIROL, V62, P1963, DOI 10.1128/JVI.62.6.1963-1973.1988; Snyder RO, 1997, NAT GENET, V16, P270, DOI 10.1038/ng0797-270; TALMADGE K, 1984, NATURE, V307, P37, DOI 10.1038/307037a0; Xiao WD, 1998, J VIROL, V72, P10222, DOI 10.1128/JVI.72.12.10222-10226.1998; Xiao X, 2000, J VIROL, V74, P1436, DOI 10.1128/JVI.74.3.1436-1442.2000; Xiao X, 1997, BRAIN RES, V756, P76, DOI 10.1016/S0006-8993(97)00120-0; Xiao X, 1997, J VIROL, V71, P941, DOI 10.1128/JVI.71.2.941-948.1997; Xiao X, 1998, J VIROL, V72, P2224, DOI 10.1128/JVI.72.3.2224-2232.1998; Xiao XA, 1996, J VIROL, V70, P8098, DOI 10.1128/JVI.70.11.8098-8108.1996	25	171	179	0	11	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAY	2000	6	5					599	602		10.1038/75087	http://dx.doi.org/10.1038/75087			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	309YB	10802720				2022-12-25	WOS:000086796200048
J	Coste, SC; Kesterson, RA; Heldwein, KA; Stevens, SL; Heard, AD; Hollis, JH; Murray, SE; Hill, JK; Pantely, GA; Hohimer, AR; Hatton, DC; Phillips, TJ; Finn, DA; Low, MJ; Rittenberg, MB; Stenzel, P; Stenzel-Poore, MP				Coste, SC; Kesterson, RA; Heldwein, KA; Stevens, SL; Heard, AD; Hollis, JH; Murray, SE; Hill, JK; Pantely, GA; Hohimer, AR; Hatton, DC; Phillips, TJ; Finn, DA; Low, MJ; Rittenberg, MB; Stenzel, P; Stenzel-Poore, MP			Abnormal adaptations to stress and impaired cardiovascular function in mice lacking corticotropin-releasing hormone receptor-2	NATURE GENETICS			English	Article							CARDIAC MYOCYTES; FOOD-INTAKE; EXPRESSION; UROCORTIN; CELLS; NEUROPEPTIDE; PEPTIDE; ANXIETY; HEART; RATS	The actions of corticotropin-releasing hormone (Crh), a mediator of endocrine(1) and behavioural responses to stress(2), and the related hormone urocortin(3) (Ucn) are coordinated by two receptors, Crhr1 (encoded by Crhr) and Crhr2 (refs 4,5). These receptors may exhibit distinct functions due to unique tissue distribution(6) and pharmacology(4,5). Crhr-null mice have defined central functions for Crhr1 in anxiety and neuroendocrine stress responses(7,8). Here we generate Crhr2(-/-) mice and show that Crhr2 supplies regulatory features to the hypothalamic-pituitary-adrenal axis (HPA) stress response. Although initiation of the stress response appears to be normal. Crhr2(-/-) mice show early termination of adrenocorticotropic hormone (Acth) release, suggesting that Crhr2 is involved in maintaining HPA drive. Crhr2 also appears to modify the recovery phase of the HPA response, as corticosterone levels remain elevated 90 minutes after stress in Crhr2(-/-) mice. In addition, stress-coping behaviours associated with dearousal are reduced in Crhr2(-/-) mice. We also demonstrate that Crhr2 is essential for sustained feeding suppression (hypophagia) induced by Ucn. Feeding is initially suppressed in Crhr2(-/-) mice following Ucn, but Crhr2(-/-) mice recover more rapidly and completely than do wild-type mice. In addition to central nervous system effects, we found that, in contrast to wild-type mice, Crhr2(-/-) mice fail to show the enhanced cardiac performance or reduced blood pressure associated with systemic Ucn, suggesting that Crhr2 mediates these peripheral haemodynamic effects. Moreover, Crhr2(-/-) mice have elevated basal blood pressure, demonstrating that Crhr2(-/-) participates in cardiovascular homeostasis. Our results identify specific responses in the brain and periphery that involve Crhr2.	Oregon Hlth Sci Univ, Dept Mol Microbiol & Immunol, Portland, OR 97201 USA; Oregon Hlth Sci Univ, Dept Med, Portland, OR 97201 USA; Oregon Hlth Sci Univ, Dept Obstet & Physiol, Portland, OR 97201 USA; Oregon Hlth Sci Univ, Dept Behav Neurosci, Portland, OR 97201 USA; Oregon Hlth Sci Univ, Dept Pathol, Portland, OR 97201 USA; Oregon Hlth Sci Univ, Vollum Inst, Portland, OR 97201 USA; Oregon Hlth Sci Univ, Congenital Heart Res Ctr, Portland, OR 97201 USA; Vanderbilt Univ, Med Ctr, Dept Physiol & Mol Biophys, Nashville, TN USA; Vet Affairs Med Ctr, Portland, OR USA	Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University; Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Stenzel-Poore, MP (corresponding author), Oregon Hlth Sci Univ, Dept Mol Microbiol & Immunol, Portland, OR 97201 USA.			Murray, Susan/0000-0002-6470-3827; Low, Malcolm/0000-0002-9900-3708	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD030236] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL055512, R29HL045043, R01HL045043] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [P60AA010760] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL55512, HL45043] Funding Source: Medline; NIAAA NIH HHS [P60 AA010760] Funding Source: Medline; NICHD NIH HHS [HD30236] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ARASE K, 1988, AM J PHYSIOL, V255, pE255, DOI 10.1152/ajpendo.1988.255.3.E255; Bale TL, 2000, NAT GENET, V24, P410, DOI 10.1038/74263; CHALMERS DT, 1995, J NEUROSCI, V15, P6340; CHEN RP, 1993, P NATL ACAD SCI USA, V90, P8967, DOI 10.1073/pnas.90.19.8967; Fentzke RC, 1997, J AM SOC ECHOCARDIOG, V10, P915, DOI 10.1016/S0894-7317(97)80008-9; Franklin KBJ, 2008, MOUSE BRAIN STEREOTA, V3rd; FUKAMIZU A, 1993, J BIOL CHEM, V268, P11617; GRUNT M, 1992, HORM METAB RES, V24, P56, DOI 10.1055/s-2007-1003255; Gu GB, 1999, J NEUROSCI, V19, P3213; Heldwein KA, 1996, ENDOCRINOLOGY, V137, P3631, DOI 10.1210/en.137.9.3631; Liebsch G, 1999, J PSYCHIAT RES, V33, P153, DOI 10.1016/S0022-3956(98)80047-2; McEwen BS, 1998, ANN NY ACAD SCI, V840, P33, DOI 10.1111/j.1749-6632.1998.tb09546.x; MIYAKODA G, 1987, J BIOCHEM-TOKYO, V102, P211, DOI 10.1093/oxfordjournals.jbchem.a122034; Okosi A, 1998, NEUROPEPTIDES, V32, P167, DOI 10.1016/S0143-4179(98)90033-6; ONO N, 1985, P NATL ACAD SCI USA, V82, P3528, DOI 10.1073/pnas.82.10.3528; OVERTON JM, 1991, J AUTONOM NERV SYST, V35, P43, DOI 10.1016/0165-1838(91)90037-4; PARKES D, 1993, MOL ENDOCRINOL, V7, P1357, DOI 10.1210/me.7.10.1357; Parkes DG, 1997, AM J PHYSIOL-HEART C, V272, pH2115, DOI 10.1152/ajpheart.1997.272.5.H2115; Smith GW, 1998, NEURON, V20, P1093, DOI 10.1016/S0896-6273(00)80491-2; Spina M, 1996, SCIENCE, V273, P1561, DOI 10.1126/science.273.5281.1561; SPRUIJT BM, 1992, PHYSIOL REV, V72, P825, DOI 10.1152/physrev.1992.72.3.825; STENZEL P, 1995, MOL ENDOCRINOL, V9, P637, DOI 10.1210/me.9.5.637; SUTTON RE, 1982, J NEUROSCI, V10, P176; Timpl P, 1998, NAT GENET, V19, P162, DOI 10.1038/520; VALE W, 1981, SCIENCE, V213, P1394, DOI 10.1126/science.6267699; VAUGHAN J, 1995, NATURE, V378, P287, DOI 10.1038/378287a0; Wagoner LE, 1996, CIRCULATION, V93, P111, DOI 10.1161/01.CIR.93.1.111; WARLTIER DC, 1992, ANESTH ANALG, V75, pS17; Woods SC, 1998, SCIENCE, V280, P1378, DOI 10.1126/science.280.5368.1378	29	500	512	0	10	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	APR	2000	24	4					403	409		10.1038/74255	http://dx.doi.org/10.1038/74255			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	299HK	10742107				2022-12-25	WOS:000086192800022
J	Wilkie, AOM; Tang, ZQ; Elanko, N; Walsh, S; Twigg, SRF; Hurst, JA; Wall, SA; Chrzanowska, KH; Maxson, RE				Wilkie, AOM; Tang, ZQ; Elanko, N; Walsh, S; Twigg, SRF; Hurst, JA; Wall, SA; Chrzanowska, KH; Maxson, RE			Functional haploinsufficiency of the human homeobox gene MSX2 causes defects in skull ossification	NATURE GENETICS			English	Article							FORAMINA PARIETALIA PERMAGNA; SELECTIVE TOOTH AGENESIS; DNA-BINDING SPECIFICITY; MOLECULAR-BASIS; HOMEODOMAIN; FAMILY; CRANIOSYNOSTOSIS; MUTATION	The genetic analysis of congenital skull malformations provides insight into normal mechanisms of calvarial osteogenesis(1). Enlarged parietal foramina (PFM) are oval defects of the parietal bones caused by deficient ossification around the parietal notch, which is normally obliterated during the fifth fetal month(2), PFM are usually asymptomatic, but may be associated with headache, scalp defects and structural or vascular malformations of the brain(3,4). Inheritance is frequently autosomal dominant, but no causative mutations have been identified in non-syndromic cases. We describe here heterozygous mutations of the homeobox gene MSX2 (located on 5q34-q35) in three unrelated families with PFM. One is a deletion of approximately 206 kb including the entire gene and the others are intragenic mutations of the DNA-binding homeodomain (RK159-160del and R172H) that predict disruption of critical intramolecular and DNA contacts. Mouse Msx2 protein with either of the homeodomain mutations exhibited more than 85% reduction in binding to an optimal Msx2 DNA-binding site. Our findings contrast with the only described MSX2 homeodomain mutation(5) (P148H), associated with craniosynostosis, that binds with enhanced affinity to the same target(6). This demonstrates that MSX2 dosage is critical for human skull development and suggests that PFM and craniosynostosis result, respectively, from loss and gain of activity in an MSX2-mediated pathway of calvarial osteogenic differentiation.	John Radcliffe Hosp, Inst Mol Med, Oxford OX3 9DU, England; Dept Clin Genet, Oxford, England; Radcliffe Infirm, Craniofacial Unit, Oxford OX2 6HE, England; Univ So Calif, Norris Hosp, Sch Med, Los Angeles, CA 90089 USA; Childrens Mem Hlth Inst, Dept Med Genet, Warsaw, Poland	University of Oxford; Radcliffe Infirmary; University of Southern California; Children's Memorial Health Institute	Wilkie, AOM (corresponding author), John Radcliffe Hosp, Inst Mol Med, Oxford OX3 9DU, England.		Wilkie, Andrew/AAC-3820-2020; Twigg, Stephen/AAU-1135-2021	Wilkie, Andrew/0000-0002-2972-5481; Twigg, Stephen/0000-0001-5024-049X; Chrzanowska, Krystyna/0000-0003-3888-0624				Bartsch H, 1996, EUR J CANCER PREV, V5, P11, DOI 10.1097/00008469-199609001-00003; Burglin T.R, 1994, EVOLUTION HOMEOBOX G, P27; CATRON KM, 1993, MOL CELL BIOL, V13, P2354, DOI 10.1128/MCB.13.4.2354; CLARKE ND, 1995, PROTEIN SCI, V4, P2269, DOI 10.1002/pro.5560041104; CURRARINO G, 1976, AM J ROENTGENOL, V127, P487, DOI 10.2214/ajr.127.3.487; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; GEHRING WJ, 1994, CELL, V78, P211, DOI 10.1016/0092-8674(94)90292-5; GOLABI M, 1984, AM J DIS CHILD, V138, P596, DOI 10.1001/archpedi.1984.02140440080022; Gripp KW, 1999, AM J MED GENET, V82, P170, DOI 10.1002/(SICI)1096-8628(19990115)82:2<170::AID-AJMG14>3.0.CO;2-X; HODGKINSON JE, 1993, BIOCHIM BIOPHYS ACTA, V1174, P11, DOI 10.1016/0167-4781(93)90086-S; Hu GZ, 1998, MOL CELL BIOL, V18, P6044, DOI 10.1128/MCB.18.10.6044; Ioannou P.A., 1996, CURRENT PROTOCOLS HU; ISAAC VE, 1995, BIOCHEMISTRY-US, V34, P7127, DOI 10.1021/bi00021a026; JABS EW, 1993, CELL, V75, P443, DOI 10.1016/0092-8674(93)90379-5; Jaju RJ, 1999, BLOOD, V94, P773; Johnson D, 1998, AM J HUM GENET, V63, P1282, DOI 10.1086/302122; Kutilek S, 1997, J PAEDIATR CHILD H, V33, P168, DOI 10.1111/j.1440-1754.1997.tb01023.x; Li H, 1997, PROTEIN SCI, V6, P956, DOI 10.1002/pro.5560060502; Liu YH, 1999, DEV BIOL, V205, P260, DOI 10.1006/dbio.1998.9114; Ma L, 1996, HUM MOL GENET, V5, P1915, DOI 10.1093/hmg/5.12.1915; Mundlos S, 1997, CELL, V89, P773, DOI 10.1016/S0092-8674(00)80260-3; PANG D, 1982, NEUROSURGERY, V11, P33, DOI 10.1227/00006123-198207010-00007; PREIS S, 1995, ACTA PAEDIATR, V84, P701, DOI 10.1111/j.1651-2227.1995.tb13735.x; SALAMANCA A, 1994, PRENATAL DIAG, V14, P766, DOI 10.1002/pd.1970140820; Satokata I, 2000, NAT GENET, V24, P391, DOI 10.1038/74231; Stankiewicz P, 1998, EUR J HUM GENET, V6, P61; van den Boogaard MJH, 2000, NAT GENET, V24, P342, DOI 10.1038/74155; Vastardis H, 1996, NAT GENET, V13, P417, DOI 10.1038/ng0896-417; WILKIE AOM, 1995, J MED GENET, V32, P174, DOI 10.1136/jmg.32.3.174; WILKIE AOM, 1994, J MED GENET, V31, P89, DOI 10.1136/jmg.31.2.89; Wuyts W, 1999, EUR J HUM GENET, V7, P579, DOI 10.1038/sj.ejhg.5200339	31	214	222	0	5	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	APR	2000	24	4					387	390		10.1038/74224	http://dx.doi.org/10.1038/74224			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	299HK	10742103				2022-12-25	WOS:000086192800018
J	Galve-Roperh, I; Sanchez, C; Cortes, ML; del Pulgar, TG; Izquierdo, M; Guzman, M				Galve-Roperh, I; Sanchez, C; Cortes, ML; del Pulgar, TG; Izquierdo, M; Guzman, M			Anti-tumoral action of cannabinoids: Involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation	NATURE MEDICINE			English	Article							MALIGNANT BRAIN-TUMORS; NERVE GROWTH-FACTOR; PROTEIN-KINASE; SPHINGOMYELIN HYDROLYSIS; HIPPOCAMPAL-NEURONS; GLIOMA-CELLS; RECEPTOR; ANANDAMIDE; APOPTOSIS; DEATH	Delta(9)-Tetrahydrocannabinol, the main active component of marijuana, induces apoptosis of transformed neural cells in culture. Here, we show that intratumoral administration of Delta(9)-tetrahydrocannabinol and the synthetic cannabinoid agonist WIN-55,212-2 induced a considerable regression of malignant gliomas in Wistar rats and in mice deficient in recombination activating gene 2. Cannabinoid treatment did not produce any substantial neurotoxic effect in the conditions used. Experiments with two subclones of C6 glioma cells in culture showed that cannabinoids signal apoptosis by a pathway involving cannabinoid receptors, sustained ceramide accumulation and Raf1/extracellular signal-regulated kinase activation. These results may provide the basis for a new therapeutic approach for the treatment of malignant gliomas.	Univ Complutense, Sch Biol, Dept Biochem & Mol Biol 1, E-28040 Madrid, Spain; Univ Autonoma Madrid, Sch Sci, Severo Ochoa Mol Biol Ctr, Dept Mol Biol, E-28049 Madrid, Spain	Complutense University of Madrid; Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM)	Guzman, M (corresponding author), Univ Complutense, Sch Biol, Dept Biochem & Mol Biol 1, E-28040 Madrid, Spain.		Gomez del Pulgar, Teresa/GXV-5256-2022; Sanchez, Cristina/AFQ-4745-2022; Galve-Roperh, Ismael/AAG-2369-2020; Sanchez, Cristina/H-4980-2017	Sanchez, Cristina/0000-0002-1428-3078; Guzman, Manuel/0000-0001-7475-118X				Ariga T, 1998, J LIPID RES, V39, P1; Avgeropoulos N G, 1999, Oncologist, V4, P209; Barth RF, 1998, J NEURO-ONCOL, V36, P91, DOI 10.1023/A:1005805203044; Baudet C, 1996, J NEUROSCI RES, V46, P540, DOI 10.1002/(SICI)1097-4547(19961201)46:5<540::AID-JNR3>3.0.CO;2-J; Blazquez C, 1999, J NEUROCHEM, V72, P1759, DOI 10.1046/j.1471-4159.1999.721759.x; Brotchie JM, 1997, CURR OPIN NEUROL, V10, P340, DOI 10.1097/00019052-199708000-00010; Childers SR, 1998, DRUG ALCOHOL DEPEN, V51, P173, DOI 10.1016/S0376-8716(98)00075-1; Cortes ML, 1998, GENE THER, V5, P1499, DOI 10.1038/sj.gt.3300751; De Petrocellis L, 1998, P NATL ACAD SCI USA, V95, P8375, DOI 10.1073/pnas.95.14.8375; Derkinderen P, 1999, NEUROREPORT, V10, pR24; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; Di Marzo V, 1998, TRENDS NEUROSCI, V21, P521, DOI 10.1016/S0166-2236(98)01283-1; DIMARZO V, 1994, NATURE, V372, P686, DOI 10.1038/372686a0; Felder CC, 1998, ANNU REV PHARMACOL, V38, P179, DOI 10.1146/annurev.pharmtox.38.1.179; Galve-Roperh I, 1998, J NEUROCHEM, V71, P498; GRINSPOON L, 1995, JAMA-J AM MED ASSOC, V273, P1875, DOI 10.1001/jama.273.23.1875; Hampson AJ, 1998, P NATL ACAD SCI USA, V95, P8268, DOI 10.1073/pnas.95.14.8268; Huwiler A, 1996, P NATL ACAD SCI USA, V93, P6959, DOI 10.1073/pnas.93.14.6959; IZQUIERDO M, 1995, GENE THER, V2, P66; Kolesnick RN, 1998, ANNU REV PHYSIOL, V60, P643, DOI 10.1146/annurev.physiol.60.1.643; Laske DW, 1997, NAT MED, V3, P1362, DOI 10.1038/nm1297-1362; LOUIS DN, 1995, TRENDS GENET, V11, P412, DOI 10.1016/S0168-9525(00)89125-8; Maintz D, 1997, J NEUROPATH EXP NEUR, V56, P1098, DOI 10.1097/00005072-199710000-00003; Marshall CJ, 1998, NATURE, V392, P553, DOI 10.1038/33293; Martuza RL, 1997, NAT MED, V3, P1323, DOI 10.1038/nm1297-1323; Mason W, 1997, J CLIN ONCOL, V15, P3423, DOI 10.1200/JCO.1997.15.12.3423; MATSUDA LA, 1990, NATURE, V346, P561, DOI 10.1038/346561a0; Michaud NR, 1998, P NATL ACAD SCI USA, V95, P2714; Mohr S, 1998, P NATL ACAD SCI USA, V95, P5045, DOI 10.1073/pnas.95.9.5045; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; Muller G, 1998, EMBO J, V17, P732, DOI 10.1093/emboj/17.3.732; MUNRO S, 1993, NATURE, V365, P61, DOI 10.1038/365061a0; Murray B, 1998, P NATL ACAD SCI USA, V95, P11975, DOI 10.1073/pnas.95.20.11975; Nagayama T, 1999, J NEUROSCI, V19, P2987; Nicotera P, 1999, TRENDS PHARMACOL SCI, V20, P46, DOI 10.1016/S0165-6147(99)01304-8; Pertwee RG, 1997, PHARMACOL THERAPEUT, V74, P129, DOI 10.1016/S0163-7258(97)82001-3; Price DL, 1999, NATURE, V399, pA3, DOI 10.1038/399a003; Pumiglia KM, 1997, P NATL ACAD SCI USA, V94, P448, DOI 10.1073/pnas.94.2.448; Ram Z, 1997, NAT MED, V3, P1354, DOI 10.1038/nm1297-1354; ROSER K, 1991, EXP CELL RES, V197, P200, DOI 10.1016/0014-4827(91)90423-R; Sanchez C, 1998, FEBS LETT, V436, P6, DOI 10.1016/S0014-5793(98)01085-0; Sanchez C, 1998, MOL PHARMACOL, V54, P834, DOI 10.1124/mol.54.5.834; Shen MX, 1998, MOL PHARMACOL, V54, P459, DOI 10.1124/mol.54.3.459; Skaper SD, 1996, P NATL ACAD SCI USA, V93, P3984, DOI 10.1073/pnas.93.9.3984; Stella N, 1997, NATURE, V388, P773, DOI 10.1038/42015; Voth EA, 1997, ANN INTERN MED, V126, P791, DOI 10.7326/0003-4819-126-10-199705150-00008; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451; Zhang YH, 1997, CELL, V89, P63, DOI 10.1016/S0092-8674(00)80183-X	49	503	530	0	33	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAR	2000	6	3					313	319		10.1038/73171	http://dx.doi.org/10.1038/73171			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	288TL	10700234				2022-12-25	WOS:000085580500042
J	Manley, GT; Fujimura, M; Ma, TH; Noshita, N; Filiz, F; Bollen, AW; Chan, P; Verkman, AS				Manley, GT; Fujimura, M; Ma, TH; Noshita, N; Filiz, F; Bollen, AW; Chan, P; Verkman, AS			Aquaporin-4 deletion in mice reduces brain edema after acute water intoxication and ischemic stroke	NATURE MEDICINE			English	Article							FOCAL CEREBRAL-ISCHEMIA; ORTHOGONAL ARRAYS; CHANNEL AQUAPORIN-4; PLASMA-MEMBRANES; RAT-BRAIN; TISSUES; LACKING; VOLUME; KIDNEY; INJURY	Cerebral edema contributes significantly to morbidity and death associated with many common neurological disorders. However, current treatment options are limited to hyperosmolar agents and surgical decompression, therapies introduced more than 70 years ago. Here we show that mice deficient in aquaporin-4 (AQP4), a glial membrane water channel, have much better survival than wild-type mice in a model of brain edema caused by acute water intoxication. Brain tissue water content and swelling of pericapillary astrocytic foot processes in AQP4-deficient mice were significantly reduced. In another model of brain edema, focal ischemic stroke produced by middle cerebral artery occlusion, AQP4-deficient mice had improved neurological outcome. Cerebral edema, as measured by percentage of hemispheric enlargement at 24 h, was decreased by 35% in AQP4-deficient mice. These results implicate a key role for AQP4 in modulating brain water transport, and suggest that AQP4 inhibition may provide a new therapeutic option for reducing brain edema in a wide variety of cerebral disorders.	Univ Calif San Francisco, Dept Neurosurg, San Francisco, CA 94143 USA; Stanford Univ, Sch Med, Dept Neurosurg, Stanford, CA 94305 USA; Univ Calif San Francisco, Cardiovasc Res Inst, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Cardiovasc Res Inst, Dept Physiol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; Stanford University; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Manley, GT (corresponding author), Univ Calif San Francisco, Dept Neurosurg, San Francisco, CA 94143 USA.	manley@itsa.ucsf.edu		Ma, Tonghui/0000-0001-9338-1030				BULLOCK R, 1991, J NEUROL NEUROSUR PS, V54, P427, DOI 10.1136/jnnp.54.5.427; Carrillo P, 1998, J TRAUMA, V45, P239, DOI 10.1097/00005373-199808000-00007; FISHMAN RA, 1975, NEW ENGL J MED, V293, P706, DOI 10.1056/NEJM197510022931407; FRIGERI A, 1995, P NATL ACAD SCI USA, V92, P4328, DOI 10.1073/pnas.92.10.4328; FRIGERI A, 1995, J CELL SCI, V108, P2993; Fujimura M, 1999, J NEUROSCI, V19, P3414; GULLANS SR, 1993, ANNU REV MED, V44, P289, DOI 10.1146/annurev.me.44.020193.001445; HASEGAWA H, 1994, J BIOL CHEM, V269, P5497; HASEGAWA H, 1993, AM J PHYSIOL, V264, pC237, DOI 10.1152/ajpcell.1993.264.1.C237; HATTON JD, 1984, EPILEPSIA, V25, P145, DOI 10.1111/j.1528-1157.1984.tb04170.x; Hossmann KA, 1998, CARDIOVASC RES, V39, P106, DOI 10.1016/S0008-6363(98)00075-3; JUNG JS, 1994, P NATL ACAD SCI USA, V91, P13052, DOI 10.1073/pnas.91.26.13052; KIMELBERG HK, 1995, J NEUROSURG, V83, P1051, DOI 10.3171/jns.1995.83.6.1051; King LS, 1996, ANNU REV PHYSIOL, V58, P619, DOI 10.1146/annurev.ph.58.030196.003155; KLATZO I, 1994, ACTA NEUROCHIR, P3; Kondo T, 1997, J NEUROSCI, V17, P4180; LANDIS DMD, 1974, J CELL BIOL, V60, P316, DOI 10.1083/jcb.60.1.316; Ma TH, 1997, J CLIN INVEST, V100, P957, DOI 10.1172/JCI231; MARMAROU A, 1978, J NEUROSURG, V49, P530, DOI 10.3171/jns.1978.49.4.0530; Nagelhus EA, 1999, GLIA, V26, P47, DOI 10.1002/(SICI)1098-1136(199903)26:1<47::AID-GLIA5>3.0.CO;2-5; NELSON SR, 1971, J APPL PHYSIOL, V30, P268, DOI 10.1152/jappl.1971.30.2.268; NIELSEN S, 1993, P NATL ACAD SCI USA, V90, P7275, DOI 10.1073/pnas.90.15.7275; Nielsen S, 1997, J NEUROSCI, V17, P171; Rash JE, 1998, P NATL ACAD SCI USA, V95, P11981, DOI 10.1073/pnas.95.20.11981; SUZUKI M, 1984, BRAIN RES, V300, P141, DOI 10.1016/0006-8993(84)91348-9; SWANSON RA, 1990, J CEREBR BLOOD F MET, V10, P290, DOI 10.1038/jcbfm.1990.47; TRACHTMAN H, 1992, PEDIATR NEPHROL, V6, P104, DOI 10.1007/BF00856852; Verbavatz JM, 1997, J CELL SCI, V110, P2855; Verkman AS, 1996, AM J PHYSIOL-CELL PH, V270, pC12, DOI 10.1152/ajpcell.1996.270.1.C12; WASTERLAIN CG, 1968, ARCH NEUROL-CHICAGO, V19, P71, DOI 10.1001/archneur.1968.00480010089007; WASTERLAIN CG, 1968, ARCH NEUROL-CHICAGO, V19, P79, DOI 10.1001/archneur.1968.00480010097008; Weed LH, 1919, AM J PHYSIOL, V48, P531, DOI 10.1152/ajplegacy.1919.48.4.531; Yang BX, 1996, J BIOL CHEM, V271, P4577; YANG GY, 1994, STROKE, V25, P165, DOI 10.1161/01.STR.25.1.165	34	1187	1335	5	151	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2000	6	2					159	163		10.1038/72256	http://dx.doi.org/10.1038/72256			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	278YQ	10655103				2022-12-25	WOS:000085016900035
J	Rubakhin, SS; Garden, RW; Fuller, RR; Sweedler, JV				Rubakhin, SS; Garden, RW; Fuller, RR; Sweedler, JV			Measuring the peptides in individual organelles with mass spectrometry	NATURE BIOTECHNOLOGY			English	Article						dense-core vesicle; peptide; matrix-assisted laser desorption/ionization; Aplysia californica; atrial gland	PROHORMONE-RELATED PEPTIDES; MALDI-TOF MS; ATRIAL GLAND; APLYSIA-CALIFORNICA; LOCALIZATION; EXPRESSION; VESICLES; NEURONS; CELLS; IDENTIFICATION	New sampling protocols combined with matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) allow the assay of single dense core vesicles. Understanding the packaging of vesicles is important as vesicles are the quanta of information for intercellular communication. Using vesicles from the exocrine atrial gland of Aplysia californica as the model, a wide range of bioactive peptides are detected within each vesicle. Although the expression of the egg-laying hormone gene family of type 1 atrial gland cells has been previously examined, chemical characterization of individual 1-2 mu m diameter vesicles demonstrates that products from several genes are colocalized. The mass sensitivity of MALDI MS can be further improved to enable the analysis of even smaller subcellular organelles.	Univ Illinois, Dept Chem, Urbana, IL 61801 USA; Univ Illinois, Beckman Inst, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Sweedler, JV (corresponding author), Univ Illinois, Dept Chem, 1209 W Calif St, Urbana, IL 61801 USA.	jsweedle@uiuc.edu	Rubakhin, Stanislav S/E-6685-2017; Sweedler, Jonathan V/A-9405-2009	Rubakhin, Stanislav S/0000-0003-0437-1493; Sweedler, Jonathan V/0000-0003-3107-9922				Allmaier G, 1997, RAPID COMMUN MASS SP, V11, P1567, DOI 10.1002/(SICI)1097-0231(199709)11:14<1567::AID-RCM32>3.0.CO;2-0; Caprioli RM, 1997, ANAL CHEM, V69, P4751, DOI 10.1021/ac970888i; Cauli B, 1997, J NEUROSCI, V17, P3894; Chiu DT, 1998, SCIENCE, V279, P1190, DOI 10.1126/science.279.5354.1190; Chiu DT, 1998, P NATL ACAD SCI USA, V95, P3338, DOI 10.1073/pnas.95.7.3338; Dreisewerd K, 1997, INT J MASS SPECTROM, V169, P291, DOI 10.1016/S0168-1176(97)00220-6; Garden RW, 2000, ANAL CHEM, V72, P30, DOI 10.1021/ac9908997; Garden RW, 1996, J MASS SPECTROM, V31, P1126, DOI 10.1002/(SICI)1096-9888(199610)31:10<1126::AID-JMS403>3.3.CO;2-Z; Hirschberg K, 1998, J CELL BIOL, V143, P1485, DOI 10.1083/jcb.143.6.1485; JESPERSEN S, 1994, RAPID COMMUN MASS SP, V8, P581, DOI 10.1002/rcm.1290080802; Jespersen S, 1999, ANAL CHEM, V71, P660, DOI 10.1021/ac980841c; JIMENEZ CR, 1994, J NEUROCHEM, V62, P404; KARAS M, 1988, ANAL CHEM, V60, P2299, DOI 10.1021/ac00171a028; KREINER T, 1986, J CELL BIOL, V102, P769, DOI 10.1083/jcb.102.3.769; Kurosky Alexander, 1997, Invertebrate Neuroscience, V2, P261, DOI 10.1007/BF02211939; Li L, 1996, J AM CHEM SOC, V118, P11662, DOI 10.1021/ja9627499; Li LJ, 1999, ANAL CHEM, V71, P5451, DOI 10.1021/ac9907181; Li LJ, 1998, PEPTIDES, V19, P1425, DOI 10.1016/S0196-9781(98)00094-1; Lillard SJ, 1998, ANAL CHEM, V70, P3517, DOI 10.1021/ac980462j; MAHON AC, 1985, J NEUROSCI, V5, P1872; MOORE SK, 1996, SOC NEUR ABS, V22, P696; NAGLE GT, 1986, J BIOL CHEM, V261, P7853; NAGLE GT, 1988, J BIOL CHEM, V263, P9223; NAGLE GT, 1994, PEPTIDES, V15, P101, DOI 10.1016/0196-9781(94)90177-5; Onnerfjord P, 1998, ANAL CHEM, V70, P4755, DOI 10.1021/ac980207z; Redeker V, 1998, ANAL CHEM, V70, P1805, DOI 10.1021/ac971309c; ROTHMAN BS, 1986, J BIOL CHEM, V261, P1616; SOLOUKI T, 1995, ANAL CHEM, V67, P4139, DOI 10.1021/ac00118a017; Toomre D, 1999, J CELL SCI, V112, P21; VANHEUMEN WRA, 1995, CELL TISSUE RES, V279, P13, DOI 10.1007/BF00300687; vanStrien FJC, 1996, FEBS LETT, V379, P165, DOI 10.1016/0014-5793(95)01503-5; Worster BM, 1998, EUR J NEUROSCI, V10, P3498, DOI 10.1046/j.1460-9568.1998.00361.x; Zhang HY, 1995, J MASS SPECTROM, V30, P1768, DOI 10.1002/jms.1190301219	33	121	131	1	34	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	FEB	2000	18	2					172	175		10.1038/72622	http://dx.doi.org/10.1038/72622			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	281FH	10657123				2022-12-25	WOS:000085146900023
J	Beere, HM; Wolf, BB; Cain, K; Mosser, DD; Mahboubi, A; Kuwana, T; Tailor, P; Morimoto, RI; Cohen, GM; Green, DR				Beere, HM; Wolf, BB; Cain, K; Mosser, DD; Mahboubi, A; Kuwana, T; Tailor, P; Morimoto, RI; Cohen, GM; Green, DR			Heat-shock protein 70 inhibits apoptosis by preventing recruitment of procaspase-9 to the Apaf-1 apoptosome	NATURE CELL BIOLOGY			English	Article							CYTOCHROME-C; CELL-DEATH; ATPASE ACTIVITY; HSP70; THERMOTOLERANCE; ACTIVATION; CASPASE-9; COMPLEX; RELEASE; OVEREXPRESSION	The cellular-stress response can mediate cellular protection through expression of heat-shock protein (Hsp) 70, which can interfere with the process of apoptotic cell death. Stress-induced apoptosis proceeds through a defined biochemical process that involves cytochrome c, Apaf-1 and caspase proteases. Here we show, using a cell-free system, that Hsp70 prevents cytochrome c/dATP-mediated caspase activation, but allows the formation of Apaf-1 oligomers. Hsp70 binds to Apaf-1 but not to procaspase-9, and prevents recruitment of caspases to the apoptosome complex. Hsp70 therefore suppresses apoptosis by directly associating with Apaf-1 and blocking the assembly of a functional apoptosome.	La Jolla Inst Allergy & Immunol, San Diego, CA 92121 USA; Natl Res Council Canada, Biotechnol Res Inst, Montreal, PQ H4P 2R2, Canada; McGill Univ, Dept Biochem, Montreal, PQ H3G 1YG, Canada; Univ Leicester, MRC, Toxicol Unit, Leicester LE1 9HN, Leics, England; Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, Evanston, IL 60208 USA	La Jolla Institute for Immunology; National Research Council Canada; McGill University; University of Leicester; Northwestern University	Beere, HM (corresponding author), La Jolla Inst Allergy & Immunol, 10355 Sci Ctr Dr, San Diego, CA 92121 USA.		Green, Douglas R/N-8083-2018; Cohen, Gerald M/A-1687-2008; Mosser, Dick D/A-7391-2008	Green, Douglas R/0000-0002-7332-1417; Mosser, Richard/0000-0002-9183-2288	NIAID NIH HHS [AI47891, AI40646] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI047891, R01AI040646] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Benedict MA, 2000, J BIOL CHEM, V275, P8461, DOI 10.1074/jbc.275.12.8461; Cain K, 2000, J BIOL CHEM, V275, P6067, DOI 10.1074/jbc.275.9.6067; Cain K, 1999, J BIOL CHEM, V274, P22686, DOI 10.1074/jbc.274.32.22686; Cecconi F, 1998, CELL, V94, P727, DOI 10.1016/S0092-8674(00)81732-8; Creagh EM, 1999, IMMUNOLOGY, V97, P36; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FREEMAN BC, 1995, EMBO J, V14, P2281, DOI 10.1002/j.1460-2075.1995.tb07222.x; Gabai VL, 1997, J BIOL CHEM, V272, P18033, DOI 10.1074/jbc.272.29.18033; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; HAHN GM, 1982, RADIAT RES, V92, P452, DOI 10.2307/3575917; Hu YM, 1999, EMBO J, V18, P3586, DOI 10.1093/emboj/18.13.3586; Jaattela M, 1999, EXP CELL RES, V248, P30, DOI 10.1006/excr.1999.4455; JAATTELA M, 1992, EMBO J, V11, P3507, DOI 10.1002/j.1460-2075.1992.tb05433.x; Jaattela M, 1998, EMBO J, V17, P6124, DOI 10.1093/emboj/17.21.6124; Juin P, 1999, GENE DEV, V13, P1367, DOI 10.1101/gad.13.11.1367; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; LI CH, IN PRESS J BIOL CHEM; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; Liossis SNC, 1997, J IMMUNOL, V158, P5668; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Mehlen P, 1996, J BIOL CHEM, V271, P16510, DOI 10.1074/jbc.271.28.16510; MILARSKI KL, 1986, P NATL ACAD SCI USA, V83, P9517, DOI 10.1073/pnas.83.24.9517; MOSSER DD, 1992, J CELL PHYSIOL, V151, P561, DOI 10.1002/jcp.1041510316; Mosser DD, 1997, MOL CELL BIOL, V17, P5317, DOI 10.1128/MCB.17.9.5317; PARSELL DA, 1993, PHILOS T R SOC B, V339, P279, DOI 10.1098/rstb.1993.0026; PARSELL DA, 1993, ANNU REV GENET, V27, P437, DOI 10.1146/annurev.ge.27.120193.002253; PATRIARCA EJ, 1990, EXP CELL RES, V190, P57, DOI 10.1016/0014-4827(90)90143-X; Polla BS, 1996, P NATL ACAD SCI USA, V93, P6458, DOI 10.1073/pnas.93.13.6458; Rodriguez J, 1999, GENE DEV, V13, P3179, DOI 10.1101/gad.13.24.3179; Samali A, 1998, CELL STRESS CHAPERON, V3, P228, DOI 10.1054/csac.1998.0129; Samali A, 1996, EXP CELL RES, V223, P163, DOI 10.1006/excr.1996.0070; SIMON MM, 1995, J CLIN INVEST, V95, P926, DOI 10.1172/JCI117800; Soengas MS, 1999, SCIENCE, V284, P156, DOI 10.1126/science.284.5411.156; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; Stennicke HR, 1999, J BIOL CHEM, V274, P8359, DOI 10.1074/jbc.274.13.8359; Wolf BB, 1999, J BIOL CHEM, V274, P30651, DOI 10.1074/jbc.274.43.30651; Wolf BB, 1999, BLOOD, V94, P1683, DOI 10.1182/blood.V94.5.1683.417k37_1683_1692; Wolf BB, 1999, J BIOL CHEM, V274, P20049, DOI 10.1074/jbc.274.29.20049; Xanthoudakis S, 1999, EMBO J, V18, P2049, DOI 10.1093/emboj/18.8.2049; Yoshida H, 1998, CELL, V94, P739, DOI 10.1016/S0092-8674(00)81733-X; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	43	1239	1310	5	95	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	AUG	2000	2	8					469	475		10.1038/35019501	http://dx.doi.org/10.1038/35019501			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	341TE	10934466				2022-12-25	WOS:000088605000011
J	Chun, TW; Davey, RT; Ostrowski, M; Justement, JS; Engel, D; Mullins, JI; Fauci, AS				Chun, TW; Davey, RT; Ostrowski, M; Justement, JS; Engel, D; Mullins, JI; Fauci, AS			Relationship between pre-existing viral reservoirs and the re-emergence of plasma viremia after discontinuation of highly active anti-retroviral therapy	NATURE MEDICINE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; CD4(+) T-CELLS; POTENT ANTIRETROVIRAL THERAPY; HETERODUPLEX MOBILITY ASSAY; COMBINATION THERAPY; HIV-1 INFECTION; REPLICATION; ERADICATION; EVOLUTION; AIDS	We examined the pathogenic significance of the latent viral reservoir in the resting CD4(+) T cell compartment of HIV-1-infected individuals as well as its involvement in the rebound of plasma viremia after discontinuation of highly active anti-retroviral therapy (HAART). Using heteroduplex mobility and tracking assays, we show that the detectable pool of latently infected, resting CD4(+) T cells does not account entirely for the early rebounding plasma HIV in infected individuals in whom HAART has been discontinued. In the majority of patients examined, the rebounding plasma virus was genetically distinct from both the cell-associated HIV RNA and the replication-competent virus within the detectable pool of latently infected, resting CD4(+) T cells. These results indicate the existence of other persistent HIV reservoirs that could prompt rapid emergence of plasma viremia after cessation of HAART and underscore the necessity to develop therapies directed toward such populations of infected cells.	NIAID, Immunoregulat Lab, NIH, Bethesda, MD 20892 USA; Univ Washington, Dept Microbiol, Seattle, WA 98104 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of Washington; University of Washington Seattle	Chun, TW (corresponding author), NIAID, Immunoregulat Lab, NIH, Bldg 10, Bethesda, MD 20892 USA.		Chun, Tae-Wook/AAC-3101-2020; Chun, Tae-Wook/W-9187-2019	Chun, Tae-Wook/0000-0001-5153-7340	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000865, Z01AI000865] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Cavert W, 1998, SCIENCE, V280, P1865, DOI 10.1126/science.280.5371.1865; Cavert W, 1997, SCIENCE, V276, P960, DOI 10.1126/science.276.5314.960; CHUN TW, 1995, NAT MED, V1, P1284, DOI 10.1038/nm1295-1284; Chun TW, 1999, NATURE, V401, P874, DOI 10.1038/44755; Chun TW, 1997, NATURE, V387, P183, DOI 10.1038/387183a0; Chun TW, 1998, J EXP MED, V188, P83, DOI 10.1084/jem.188.1.83; Chun TW, 1997, P NATL ACAD SCI USA, V94, P13193, DOI 10.1073/pnas.94.24.13193; Chun TW, 1999, P NATL ACAD SCI USA, V96, P10958, DOI 10.1073/pnas.96.20.10958; Chun TW, 1999, NAT MED, V5, P651, DOI 10.1038/9498; Chun TW, 1998, P NATL ACAD SCI USA, V95, P8869, DOI 10.1073/pnas.95.15.8869; Cohen J, 1998, SCIENCE, V279, P1854, DOI 10.1126/science.279.5358.1854; Cohen OJ, 1998, JAMA-J AM MED ASSOC, V280, P87, DOI 10.1001/jama.280.1.87; Davey RT, 1999, P NATL ACAD SCI USA, V96, P15109, DOI 10.1073/pnas.96.26.15109; Delwart EL, 1997, METHODS, V12, P348, DOI 10.1006/meth.1997.0489; DELWART EL, 1993, SCIENCE, V262, P1257, DOI 10.1126/science.8235655; DELWART EL, 1995, PCR METH APPL, V4, pS202; DELWART EL, 1994, J VIROL, V68, P6672, DOI 10.1128/JVI.68.10.6672-6683.1994; Detels R, 1998, JAMA-J AM MED ASSOC, V280, P1497, DOI 10.1001/jama.280.17.1497; Dore G J, 1998, AIDS, V12 Suppl B, pS1; Finzi D, 1999, NAT MED, V5, P512, DOI 10.1038/8394; Finzi D, 1997, SCIENCE, V278, P1295, DOI 10.1126/science.278.5341.1295; Furtado MR, 1999, NEW ENGL J MED, V340, P1614, DOI 10.1056/NEJM199905273402102; Gulick RM, 1997, NEW ENGL J MED, V337, P734, DOI 10.1056/NEJM199709113371102; Gunthard HF, 1999, J VIROL, V73, P9404; Hammer SM, 1997, NEW ENGL J MED, V337, P725, DOI 10.1056/NEJM199709113371101; Ho DD, 1998, SCIENCE, V280, P1866, DOI 10.1126/science.280.5371.1866; Hoyert D L, 1999, Natl Vital Stat Rep, V47, P1; Lewin SR, 1999, J VIROL, V73, P6099, DOI 10.1128/JVI.73.7.6099-6103.1999; Lukashov V V, 1998, AIDS, V12 Suppl A, pS43; Mocroft A, 1998, LANCET, V352, P1725, DOI 10.1016/S0140-6736(98)03201-2; Natarajan V, 1999, LANCET, V353, P119, DOI 10.1016/S0140-6736(05)76156-0; Ostrowski MA, 1998, J VIROL, V72, P7772, DOI 10.1128/JVI.72.10.7772-7784.1998; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; Perelson AS, 1997, NATURE, V387, P188, DOI 10.1038/387188a0; Schrager LK, 1998, JAMA-J AM MED ASSOC, V280, P67, DOI 10.1001/jama.280.1.67; WOLINSKY SM, 1992, SCIENCE, V255, P1134, DOI 10.1126/science.1546316; Wolinsky SM, 1996, SCIENCE, V272, P537, DOI 10.1126/science.272.5261.537; Wong JK, 1997, SCIENCE, V278, P1291, DOI 10.1126/science.278.5341.1291; Zhang H, 1998, NEW ENGL J MED, V339, P1803, DOI 10.1056/NEJM199812173392502; ZHANG LQ, 1993, J VIROL, V67, P3345, DOI 10.1128/JVI.67.6.3345-3356.1993; Zhang LQ, 1999, NEW ENGL J MED, V340, P1605, DOI 10.1056/NEJM199905273402101; ZHU TF, 1993, SCIENCE, V261, P1179, DOI 10.1126/science.8356453	42	354	359	0	9	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUL	2000	6	7					757	761		10.1038/77481	http://dx.doi.org/10.1038/77481			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	331VV	10888923				2022-12-25	WOS:000088040100031
J	Poznansky, MC; Evans, RH; Foxall, RB; Olszak, IT; Piascik, AH; Hartman, KE; Brander, C; Meyer, TH; Pykett, MJ; Chabner, KT; Kalams, SA; Rosenzweig, M; Scadden, DT				Poznansky, MC; Evans, RH; Foxall, RB; Olszak, IT; Piascik, AH; Hartman, KE; Brander, C; Meyer, TH; Pykett, MJ; Chabner, KT; Kalams, SA; Rosenzweig, M; Scadden, DT			Efficient generation of human T cells from a tissue-engineered thymic organoid	NATURE BIOTECHNOLOGY			English	Article						T lymphocytes; stem cells; hematopoiesis; thymus	FETAL LIVER; STEM-CELLS; BONE-MARROW; IN-VITRO; MICROENVIRONMENTS; DIFFERENTIATION; PRECURSORS; EXPRESSION; PRODUCTS; CULTURE	Biocompatible inorganic matrices have been used to enhance bone repair by integrating with endogenous bone architecture. Hypothesizing that a three-dimensional framework might support reconstruction of other tissues as well, we assessed the capacity of a tantalum-coated carbon matrix to support reconstitution of functioning thymic tissue. We engineered a thymic organoid by seeding matrices with murine thymic stroma. Co-culture of human bone marrow-derived hematopoietic progenitor cells within this xenogeneic environment generated mature functional T cells within 14 days. The proportionate T-cell yield from this system was highly reproducible, generating over 70% CD3(+) T cells from either AC133(+) or CD34(+) progenitor cells. Cultured T cells expressed a high level of T-cell receptor excision circles (TREC), demonstrating de novo T lymphopoiesis, and function of fully mature T cells. This system not only facilitates analysis of the T-lymphopoietic potential of progenitor cell populations; it also permits ex vivo genesis of T cells for possible applications in treatment of immunodeficiency.	Harvard Univ, Sch Med, Massachusetts Gen Hosp, AIDS Res Ctr,Div Infect Dis, Boston, MA 02129 USA; Harvard Univ, Sch Med, Massachusetts Gen Hosp, MGH Canc Ctr, Boston, MA 02129 USA; Cytomatrix, Woburn, MA 01801 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital	Scadden, DT (corresponding author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, AIDS Res Ctr,Div Infect Dis, Boston, MA 02129 USA.		Poznansky, Mark C/M-4996-2015	Poznansky, Mark C/0000-0003-1344-7103; Brander, Christian/0000-0002-0548-5778; Foxall, Russell/0000-0001-9821-0708				ANDERSON G, 1993, NATURE, V362, P70, DOI 10.1038/362070a0; BARCENA A, 1994, J EXP MED, V180, P123, DOI 10.1084/jem.180.1.123; BARCENA A, 1993, BLOOD, V82, P3401; Black Jonathan, 1994, Clinical Materials, V16, P167, DOI 10.1016/0267-6605(94)90113-9; Bobyn JD, 1999, J BONE JOINT SURG BR, V81B, P907, DOI 10.1302/0301-620X.81B5.9283; BOYD RL, 1993, IMMUNOL TODAY, V14, P445, DOI 10.1016/0167-5699(93)90248-J; Douek DC, 1998, NATURE, V396, P690, DOI 10.1038/25374; FISHER AG, 1990, INT IMMUNOL, V2, P571, DOI 10.1093/intimm/2.6.571; Freedman AR, 1996, NAT MED, V2, P46, DOI 10.1038/nm0196-46; FUJIMOTO S, 1987, NATURE, V327, P242, DOI 10.1038/327242a0; GALY A, 1993, J EXP MED, V178, P391, DOI 10.1084/jem.178.2.391; Gardner JP, 1998, EXP HEMATOL, V26, P991; GENEVEE C, 1992, EUR J IMMUNOL, V22, P1261, DOI 10.1002/eji.1830220522; Livak F, 1996, MOL CELL BIOL, V16, P609; OKAZAKI K, 1987, CELL, V49, P477, DOI 10.1016/0092-8674(87)90450-8; Pawelec G, 1998, J LEUKOCYTE BIOL, V64, P733, DOI 10.1002/jlb.64.6.733; PLUM J, 1994, BLOOD, V84, P1587; Res P, 1996, BLOOD, V87, P5196, DOI 10.1182/blood.V87.12.5196.bloodjournal87125196; Shortman K, 1990, Semin Immunol, V2, P3; TAKESHITA S, 1989, EMBO J, V8, P3261, DOI 10.1002/j.1460-2075.1989.tb08486.x; van Ewijk W, 1999, SEMIN IMMUNOL, V11, P57, DOI 10.1006/smim.1998.0158; VANEWIJK W, 1988, LAB INVEST, V59, P579; VANEWIJK W, 1991, ANNU REV IMMUNOL, V9, P591, DOI 10.1146/annurev.iy.09.040191.003111; VANVLIET E, 1984, EUR J IMMUNOL, V14, P524, DOI 10.1002/eji.1830140608; VANVLIET E, 1985, EUR J IMMUNOL, V15, P675, DOI 10.1002/eji.1830150707; YEOMAN H, 1993, P NATL ACAD SCI USA, V90, P10778, DOI 10.1073/pnas.90.22.10778; Zhang XM, 1996, IMMUNOGENETICS, V43, P196, DOI 10.1007/BF00587300	27	105	122	2	37	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUL	2000	18	7					729	734		10.1038/77288	http://dx.doi.org/10.1038/77288			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	331YN	10888839				2022-12-25	WOS:000088046400020
J	Bergen, AAB; Plomp, AS; Schuurman, EJ; Terry, S; Breuning, M; Dauwerse, H; Swart, J; Kool, M; van Soest, S; Baas, F; ten Brink, JB; de Jong, PTVM				Bergen, AAB; Plomp, AS; Schuurman, EJ; Terry, S; Breuning, M; Dauwerse, H; Swart, J; Kool, M; van Soest, S; Baas, F; ten Brink, JB; de Jong, PTVM			Mutations in ABCC6 cause pseudoxanthoma elasticum	NATURE GENETICS			English	Article							CHROMOSOME 16P13.1; REGION; GENE; EXPRESSION; CLONING; CANCER; TISSUE; MAPS	Pseudoxanthoma elasticum (PXE) is a heritable disorder of the connective tissue. PXE patients frequently experience visual field loss and skin lesions, and occasionally cardiovascular complication(1-4). Histopathological findings reveal calcification of the elastic fibres and abnormalities of the collagen fibrils(5). Most PXE patients are sporadic, but autosomal recessive and dominant inheritance are also observed(6,7). We previously localized the PXE gene to chromosome 16p13.1 (refs 8,9) and constructed a physical map(10). Here we describe homozygosity mapping in five PXE families and the detection of deletions or mutations in ABCC6 (formerly MRP6) associated with all genetic forms of PXE in seven patients or families.	Netherlands Ophthalm Res Inst, NL-1100 AC Amsterdam, Netherlands; AMC, Dept Clin Genet, Amsterdam, Netherlands; AMC, Dept Neurol, Amsterdam, Netherlands; AMC, Dept Ophthalmol, Amsterdam, Netherlands; PXE Int Inc, Sharon, MA USA; Leiden Univ, Ctr Med Genet, Dept Human Genet, Leiden, Netherlands; EUR, Dept Epidemiol & Stat, Rotterdam, Netherlands	Royal Netherlands Academy of Arts & Sciences; Netherlands Institute for Neuroscience (NIN-KNAW); University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; Leiden University; Leiden University - Excl LUMC; Erasmus University Rotterdam	Bergen, AAB (corresponding author), Netherlands Ophthalm Res Inst, POB 12141, NL-1100 AC Amsterdam, Netherlands.		Breuning, Martijn H/E-3429-2010; Bergen, Arthur/J-3637-2013; Kool, Marcel/H-2541-2013; Baas, Frank/F-9574-2010	Baas, Frank/0000-0003-3912-5428; Bergen, Arthur/0000-0002-6333-9576; /0000-0002-4903-8232				Allikmets R, 1996, HUM MOL GENET, V5, P1649, DOI 10.1093/hmg/5.10.1649; BERGEN AAB, 1993, CYTOGENET CELL GENET, V62, P231, DOI 10.1159/000133484; Christiano AM, 1996, AM J HUM GENET, V58, P671; CHRISTIANO AM, 1992, J INVEST DERMATOL, V99, P660, DOI 10.1111/1523-1747.ep12668156; CHRISTIANO AM, 1994, J INVEST DERMATOL, V103, P535; Culbertson MR, 1999, TRENDS GENET, V15, P74, DOI 10.1016/S0168-9525(98)01658-8; DAUWERSE JG, 1993, HUM MOL GENET, V2, P1527, DOI 10.1093/hmg/2.10.1527; DIETZ HC, 1994, NAT GENET, V8, P183, DOI 10.1038/ng1094-183; DIETZ HC, 1993, SCIENCE, V259, P680, DOI 10.1126/science.8430317; HAUSSER I, 1991, HUM GENET, V87, P693; Hipfner DR, 1999, BBA-BIOMEMBRANES, V1461, P359, DOI 10.1016/S0005-2736(99)00168-6; HOOGENDIJK JE, 1992, LANCET, V339, P1081, DOI 10.1016/0140-6736(92)90668-S; Kool M, 1999, CANCER RES, V59, P175; Le Saux O, 1999, GENOMICS, V62, P1, DOI 10.1006/geno.1999.5925; LEBWOHL M, 1993, ARCH DERMATOL RES, V285, P121, DOI 10.1007/BF01112912; LEBWOHL M, 1994, J AM ACAD DERMATOL, V30, P103, DOI 10.1016/S0190-9622(08)81894-4; LEEDS P, 1991, GENE DEV, V5, P2303, DOI 10.1101/gad.5.12a.2303; MENDELSOHN G, 1978, ARCH PATHOL LAB MED, V102, P298; Struk B, 1997, HUM MOL GENET, V6, P1823, DOI 10.1093/hmg/6.11.1823; Van Soest S, 1999, SURV OPHTHALMOL, V43, P321, DOI 10.1016/S0039-6257(98)00046-0; VANOMMEN GB, 1987, AM J HUM GENET, V41, P689; vanSoest S, 1997, GENOME RES, V7, P830, DOI 10.1101/gr.7.8.830; YAP EY, 1992, RETINA-J RET VIT DIS, V12, P315, DOI 10.1097/00006982-199212040-00004	23	401	417	1	17	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUN	2000	25	2					228	231		10.1038/76109	http://dx.doi.org/10.1038/76109			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	321ML	10835643				2022-12-25	WOS:000087459200027
J	Karkkainen, MJ; Ferrell, RE; Lawrence, EC; Kimak, MA; Levinson, KL; McTigue, MA; Alitalo, K; Finegold, DN				Karkkainen, MJ; Ferrell, RE; Lawrence, EC; Kimak, MA; Levinson, KL; McTigue, MA; Alitalo, K; Finegold, DN			Missense mutations interfere with VEGFR-3 signalling in primary lymphoedema	NATURE GENETICS			English	Article							ENDOTHELIAL GROWTH-FACTOR; RECEPTOR TYROSINE KINASE; CRYSTAL-STRUCTURE; LYMPHATIC ENDOTHELIUM; FLT4; LYMPHEDEMA; ANGIOGENESIS; PROTEIN; LIGAND; DOMAIN	Primary lymphoedema is a rare, autosomal dominant disorder that leads to a disabling and disfiguring swelling of the extremities and, when untreated, tends to worsen with time. Here we link primary human lymphoedema to the FLT4 locus, encoding vascular endothelial growth factor receptor-3 (VEGFR-3). in several families. All disease-associated alleles analysed had missense mutations and encoded proteins with an inactive tyrosine kinase, preventing downstream gene activation, Our study establishes that VEGFR-3 is important for normal lymphatic vascular function and that mutations interfering with VEGFR-3 signal transduction are a cause of primary lymphoedema.	Univ Pittsburgh, Dept Human Genet, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Pediat, Pittsburgh, PA USA; Univ Helsinki, Haartman Inst, Ludwig Inst Canc Res, Mol Canc Biol Lab, Helsinki, Finland; Agouron Pharmaceut Inc, San Diego, CA USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Ludwig Institute for Cancer Research; University of Helsinki; Pfizer	Ferrell, RE (corresponding author), Univ Pittsburgh, Dept Human Genet, Pittsburgh, PA 15260 USA.	rferrell@helex.hgen.pitt.edu	Alitalo, Kari K/J-5013-2014	Alitalo, Kari K/0000-0002-7331-0902; Finegold, David/0000-0001-9901-2578	NICHD NIH HHS [HD35174] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R03HD035174] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Achen MG, 1998, P NATL ACAD SCI USA, V95, P548, DOI 10.1073/pnas.95.2.548; Barber JCK, 1996, AM J MED GENET, V62, P84, DOI 10.1002/(SICI)1096-8628(19960301)62:1<84::AID-AJMG17>3.3.CO;2-C; Bardelli A, 1997, BBA-REV CANCER, V1333, pM41, DOI 10.1016/S0304-419X(97)00026-7; BESMER P, 1993, DEVELOPMENT, P125; Brunger A.T., 1992, X PLOR VERSION 3 1 M; Burke D, 1998, TRENDS BIOCHEM SCI, V23, P59, DOI 10.1016/S0968-0004(97)01170-5; Dumont DJ, 1998, SCIENCE, V282, P946, DOI 10.1126/science.282.5390.946; Evans AL, 1999, AM J HUM GENET, V64, P547, DOI 10.1086/302248; FELDER S, 1992, J CELL BIOL, V117, P203, DOI 10.1083/jcb.117.1.203; Ferrara N, 1999, J MOL MED, V77, P527, DOI 10.1007/s001099900019; Ferrell RE, 1998, HUM MOL GENET, V7, P2073, DOI 10.1093/hmg/7.13.2073; GALLAND F, 1993, ONCOGENE, V8, P1233; Groen SE, 1998, AM J MED GENET, V80, P448, DOI 10.1002/(SICI)1096-8628(19981228)80:5<448::AID-AJMG3>3.0.CO;2-Q; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; Hardie G., 1995, PROTEIN KINASE FACTS; Hubbard SR, 1997, EMBO J, V16, P5572, DOI 10.1093/emboj/16.18.5572; Jeltsch M, 1997, SCIENCE, V276, P1423, DOI 10.1126/science.276.5317.1423; Joukov V, 1997, EMBO J, V16, P3898, DOI 10.1093/emboj/16.13.3898; Joukov V, 1996, EMBO J, V15, P290; Jussila L, 1998, CANCER RES, V58, P1599; KAIPAINEN A, 1995, P NATL ACAD SCI USA, V92, P3566, DOI 10.1073/pnas.92.8.3566; Korpelainen EI, 1999, ONCOGENE, V18, P1, DOI 10.1038/sj.onc.1202288; Kukk E, 1996, DEVELOPMENT, V122, P3829; Lee J, 1996, P NATL ACAD SCI USA, V93, P1988, DOI 10.1073/pnas.93.5.1988; LEU JJ, 1995, VASCULAR PATHOLOGY, P489; Mangion J, 1999, AM J HUM GENET, V65, P427, DOI 10.1086/302500; McTigue MA, 1999, STRUCT FOLD DES, V7, P319, DOI 10.1016/S0969-2126(99)80042-2; Meige H., 1898, PRESSE MED, V6, P341; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; Milroy WF., 1892, N Y MED J, V56, P505; Mowat D, 1999, AM J MED GENET, V83, P361, DOI 10.1002/(SICI)1096-8628(19990423)83:5<361::AID-AJMG3>3.0.CO;2-W; MUENKE M, 1995, TRENDS GENET, V11, P308, DOI 10.1016/S0168-9525(00)89088-5; Oh SJ, 1997, DEV BIOL, V188, P96, DOI 10.1006/dbio.1997.8639; PAJUSOLA K, 1992, CANCER RES, V52, P5738; PAJUSOLA K, 1994, ONCOGENE, V9, P3545; PAJUSOLA K, 1993, ONCOGENE, V8, P2931; Pasini B, 1996, TRENDS GENET, V12, P138, DOI 10.1016/0168-9525(96)10012-3; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Robertson K, 1997, GUT, V41, P436, DOI 10.1136/gut.41.4.436; SCHINZEL A, 1983, CATALOG UNBALANCED C; Schmidt L, 1997, NAT GENET, V16, P68, DOI 10.1038/ng0597-68; SPRITZ RA, 1994, J INVEST DERMATOL, V103, P1375; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; Veikkola T, 2000, CANCER RES, V60, P203; Witte MH, 1998, LYMPHOLOGY, V31, P145; ZHENG JH, 1993, BIOCHEMISTRY-US, V32, P2154, DOI 10.1021/bi00060a005	46	455	485	0	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JUN	2000	25	2					153	159		10.1038/75997	http://dx.doi.org/10.1038/75997			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	321ML	10835628				2022-12-25	WOS:000087459200012
J	Kramer, KJ; Morgan, TD; Throne, JE; Dowell, FE; Bailey, M; Howard, JA				Kramer, KJ; Morgan, TD; Throne, JE; Dowell, FE; Bailey, M; Howard, JA			Transgenic avidin maize is resistant to storage insect pests	NATURE BIOTECHNOLOGY			English	Article						genetic engineering; insect biology; stored grain; insect resistance; corn; host plant resistance; biotin; transgenic plants	BACILLUS-THURINGIENSIS; STORED-CORN; BIOTIN; INFESTATION; COLEOPTERA; PROTEINS; FARM; BOSTRICHIDAE; SPECTROSCOPY; REPRODUCTION	Avidin is a glycoprotein found in chicken egg white, that sequesters the vitamin biotin. Here we show that when present in maize at levels of greater than or equal to 100 p.p.m., avidin is toxic to and prevents development of insects that damage grains during storage. Insect toxicity is caused by a biotin deficiency, as shown by prevention of toxicity with biotin supplementation. The avidin maize is not, however, toxic to mice when administered as the sole component of their diet for 21 days, These dates suggest that avidin expression in food or feed grain crops can be used as a biopesticide against a spectrum of stored-produce insect pests.	USDA ARS, Grain Mkt & Prod Res Ctr, Manhattan, KS 66502 USA; ProdiGene Inc, College Stn, TX 77845 USA	United States Department of Agriculture (USDA)	Kramer, KJ (corresponding author), USDA ARS, Grain Mkt & Prod Res Ctr, Manhattan, KS 66502 USA.	kramer@usgmrl.ksu.edu						Arbogast RT, 1997, J STORED PROD RES, V33, P187, DOI 10.1016/S0022-474X(97)00006-4; ARBOGAST RT, 1988, ANN ENTOMOL SOC AM, V81, P899, DOI 10.1093/aesa/81.6.899; Baez-Saldana A, 1998, AM J CLIN NUTR, V67, P431, DOI 10.1093/ajcn/67.3.431; Baker J. E., 1996, Postharvest News and Information, V7, p11N; BELL CH, 1994, J STORED PROD RES, V30, P99, DOI 10.1016/0022-474X(94)90189-9; BRUINS BG, 1991, INSECT BIOCHEM, V21, P535, DOI 10.1016/0020-1790(91)90107-P; Carozzi N.B., 1997, ADV INSECT CONTROL R; CUPERUS G, 1995, STORED PRODUCT MANAG, V912, P199; DEMIANYK CJ, 1987, ENVIRON ENTOMOL, V16, P618, DOI 10.1093/ee/16.3.618; Dowell FE, 1999, J ECON ENTOMOL, V92, P165, DOI 10.1093/jee/92.1.165; Dowell FE, 1998, J ECON ENTOMOL, V91, P899, DOI 10.1093/jee/91.4.899; DU C, 1995, 1995 M SOC INV PATH, P70; DURANCE TD, 1991, J FOOD SCI, V56, P707, DOI 10.1111/j.1365-2621.1991.tb05361.x; Estruch JJ, 1997, NAT BIOTECHNOL, V15, P137, DOI 10.1038/nbt0297-137; FINNEY D, 1964, PROBIT ANAL STAT TRE; Gonzalez M, 1999, BIOMOL ENG, V16, P67, DOI 10.1016/S1050-3862(99)00041-8; Hilder VA, 1999, CROP PROT, V18, P177, DOI 10.1016/S0261-2194(99)00028-9; Hood EE, 1997, MOL BREEDING, V3, P291, DOI 10.1023/A:1009676322162; Hood EE, 1999, ADV EXP MED BIOL, V464, P127; KNOWLES JR, 1989, ANNU REV BIOCHEM, V58, P195, DOI 10.1146/annurev.bi.58.070189.001211; *LEORA SOFTW, 1994, POLO PC PROB LOG AN; LEVINSON H. Z., 1967, Journal of Stored Products Research, V3, P345, DOI 10.1016/0022-474X(67)90037-9; LEVINSON HZ, 1992, EXPERIENTIA, V48, P721, DOI 10.1007/BF02124287; Levinson HZ, 1959, J INSECT PHYSL, V3, P293; LIVNAH O, 1993, P NATL ACAD SCI USA, V90, P5076, DOI 10.1073/pnas.90.11.5076; MCGAUGHEY WH, 1985, SCIENCE, V229, P193, DOI 10.1126/science.229.4709.193; MIURA K, 1967, ARCH INT PHYS BIOCH, V75, P65, DOI 10.3109/13813456709084919; MORGAN TD, 1993, ENTOMOL EXP APPL, V69, P97, DOI 10.1007/BF02380637; Murray I., 1990, NEAR INFRARED TECHNO, P17; PAI CH, 1964, P SOC EXP BIOL MED, V116, P197; Pei R, 1964, P SOC EXP BIOL MED, V117, P341; PUGLIESE L, 1993, J MOL BIOL, V231, P698, DOI 10.1006/jmbi.1993.1321; RICHARDS A, 1997, UNPUB NATL SURVEY ST; SAMOLS D, 1988, J BIOL CHEM, V263, P6461; SAS Institute, 1990, SAS STAT US GUID VER; Schnepf E, 1998, MICROBIOL MOL BIOL R, V62, P775, DOI 10.1128/MMBR.62.3.775-806.1998; Sedlacek JD, 1998, J ENTOMOL SCI, V33, P171, DOI 10.18474/0749-8004-33.2.171; SINHA KK, 1992, J STORED PROD RES, V28, P211, DOI 10.1016/0022-474X(92)90043-P; Steel R.G., 1980, PRINCIPLES PROCEDURE, P481; STEVENS L, 1991, COMP BIOCHEM PHYS B, V100, P1, DOI 10.1016/0305-0491(91)90076-P; STOREY CL, 1983, J ECON ENTOMOL, V76, P1323, DOI 10.1093/jee/76.6.1323; THRONE JE, 1994, ENVIRON ENTOMOL, V23, P1459, DOI 10.1093/ee/23.6.1459; THRONE JE, 2000, IN PRESS ALTERNATIVE; TIGAR BJ, 1994, J STORED PROD RES, V30, P1, DOI 10.1016/0022-474X(94)90266-6; TIGAR BJ, 1994, J STORED PROD RES, V30, P267, DOI 10.1016/S0022-474X(94)90319-0; TSIROPOULOS GJ, 1985, Z ANGEW ENTOMOL, V100, P35; WATANABE T, 1993, J NUTR, V123, P2101; Watson S. A., 1987, CORN CHEM TECHNOLOGY; WRIGHT EJ, 1994, P 6 INT WORK C STOR, V1, P613; Wright V.F., 1984, P GASGA WORKSH LARG, P11	50	88	119	2	12	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUN	2000	18	6					670	674		10.1038/76531	http://dx.doi.org/10.1038/76531			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	325EK	10835608	Green Published			2022-12-25	WOS:000087663200030
J	Fox, JG; Beck, P; Dangler, CA; Whary, MT; Wang, TC; Shi, HN; Nagler-Anderson, C				Fox, JG; Beck, P; Dangler, CA; Whary, MT; Wang, TC; Shi, HN; Nagler-Anderson, C			Concurrent enteric helminth infection modulates inflammation and gastric immune responses and reduces helicobacter-induced gastric atrophy	NATURE MEDICINE			English	Article							DELAYED-TYPE HYPERSENSITIVITY; PYLORI INFECTION; C57BL/6 MICE; HELIGMOSOMOIDES-POLYGYRUS; T-LYMPHOCYTES; SOUTH-AFRICA; EXPRESSION; FELIS; CELLS; CANCER	Helicobacter pylori is causally associated with gastritis and gastric cancer. Some developing countries with a high prevalence of infection have high gastric cancer rates, whereas in others, these rates are low. The progression of helicobacter-induced gastritis and gastric atrophy mediated by type 1 T-helper cells may be modulated by concurrent parasitic infection. Here, in mice with concurrent helminth infection, helicobacter-associated gastric atrophy was reduced considerably despite chronic inflammation and high helicobacter colonization. This correlated with a substantial reduction in mRNA for cytokines and chemokines associated with a gastric inflammatory response of type 1 T-helper cells. Thus, concurrent enteric helminth infection can attenuate gastric atrophy, a premalignant lesion.	MIT, Div Comparat Med, Cambridge, MA 02139 USA; Massachusetts Gen Hosp, Dept Med, Mucosal Immunol Lab, Pediat Gastroenterol Unit, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Med, Mucosal Immunol Lab, Gastroenterol Unit, Boston, MA 02114 USA	Massachusetts Institute of Technology (MIT); Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital	Fox, JG (corresponding author), MIT, Div Comparat Med, 77 Massachusetts Ave, Cambridge, MA 02139 USA.				NCI NIH HHS [CA7529, CA74463] Funding Source: Medline; NIAID NIH HHS [AI37740] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abbas AK, 1996, NATURE, V383, P787, DOI 10.1038/383787a0; Ally R, 1999, GUT, V45, pA97; Appleton CC, 1996, ANN TROP MED PARASIT, V90, P181, DOI 10.1080/00034983.1996.11813042; Bamford KB, 1998, GASTROENTEROLOGY, V114, P482, DOI 10.1016/S0016-5085(98)70531-1; BARNISH G, 1990, PARASSITOLOGIA, V322, P245; BEHNKE JM, 1992, J PARASITOL, V22, P351; Berg DJ, 1998, AM J PATHOL, V152, P1377; Bonecchi R, 1998, J EXP MED, V187, P129, DOI 10.1084/jem.187.1.129; Chan MS, 1997, PARASITOL TODAY, V13, P438, DOI 10.1016/S0169-4758(97)01144-7; CORREA P, 1990, CANCER-AM CANCER SOC, V66, P2569, DOI 10.1002/1097-0142(19901215)66:12<2569::AID-CNCR2820661220>3.0.CO;2-I; Eaton KA, 1999, INFECT IMMUN, V67, P4594, DOI 10.1128/IAI.67.9.4594-4602.1999; Finkelman FD, 1997, ANNU REV IMMUNOL, V15, P505, DOI 10.1146/annurev.immunol.15.1.505; Fox JG, 1996, GASTROENTEROLOGY, V110, P155, DOI 10.1053/gast.1996.v110.pm8536852; Fox JG, 1999, CANCER RES, V59, P4823; GENTA RM, 1995, ANN MED, V27, P595, DOI 10.3109/07853899509002475; Goto T, 1999, INFECT IMMUN, V67, P2531, DOI 10.1128/IAI.67.5.2531-2539.1999; Graham DY, 1997, GASTROENTEROLOGY, V113, P1983, DOI 10.1016/S0016-5085(97)70019-2; HOLCOMBE C, 1992, GUT, V33, P429, DOI 10.1136/gut.33.4.429; Huang JQ, 1998, GASTROENTEROLOGY, V114, P1169, DOI 10.1016/S0016-5085(98)70422-6; Jemaneh L, 1998, ETHIOPIAN MED J, V36, P1; Loetscher P, 1998, NATURE, V391, P344, DOI 10.1038/34814; Marshall AJ, 1999, J IMMUNOL, V163, P2089; Mohammadi M, 1996, J IMMUNOL, V156, P4729; MONROY FG, 1992, PARASITOL TODAY, V8, P49, DOI 10.1016/0169-4758(92)90084-F; PRONOVOST AD, 1994, J CLIN MICROBIOL, V32, P46, DOI 10.1128/JCM.32.1.46-50.1994; Qin SX, 1998, J CLIN INVEST, V101, P746, DOI 10.1172/JCI1422; Roth KA, 1999, J IMMUNOL, V163, P1490; Sakagami T, 1996, GUT, V39, P639, DOI 10.1136/gut.39.5.639; Sallusto F, 1997, SCIENCE, V277, P2005, DOI 10.1126/science.277.5334.2005; Sawai N, 1999, INFECT IMMUN, V67, P279, DOI 10.1128/IAI.67.1.279-285.1999; SCHAAP HB, 1992, TROP GEOGR MED, V44, P19; Shi HN, 1998, J IMMUNOL, V160, P2449; SHI HN, 1995, PARASITOLOGY, V110, P599, DOI 10.1017/S003118200006532X; STELLATO C, 1995, J IMMUNOL, V155, P410; TAUB DD, 1993, J EXP MED, V177, P1809, DOI 10.1084/jem.177.6.1809; Wang TC, 2000, GASTROENTEROLOGY, V118, P36, DOI 10.1016/S0016-5085(00)70412-4; Whary MT, 1998, INFECT IMMUN, V66, P3142, DOI 10.1128/IAI.66.7.3142-3148.1998; WONG H, 1994, ANAL BIOCHEM, V223, P251, DOI 10.1006/abio.1994.1581; Zhou ZHL, 1998, J IMMUNOL, V160, P3908	39	380	392	0	10	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAY	2000	6	5					536	542		10.1038/75015	http://dx.doi.org/10.1038/75015			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	309YB	10802709				2022-12-25	WOS:000086796200037
J	Hanninen, P; Soini, A; Meltola, N; Soini, J; Soukka, J; Soini, E				Hanninen, P; Soini, A; Meltola, N; Soini, J; Soukka, J; Soini, E			A new microvolume technique for bioaffinity assays using two-photon excitation	NATURE BIOTECHNOLOGY			English	Article						two-photon excitation; immunoassay; microvolume detection; optical trapping; microchip laser	CORRELATION SPECTROSCOPY; FLUORESCENCE; IMMUNOASSAY	Bioaffinity binding assays such as the immunoassay are widely used in life science research. In an immunoassay, specific antibodies are used to bind target molecules in the sample, and quantification of the binding reaction reveals the amount of the target molecules. Here we present a method to measure bioaffinity assays using the two-photon excitation of fluorescence. In this method, microparticles are used as solid phase in binding the target molecules. The degree of binding is then quantified from individual microparticles by use of two photon excitation of fluorescence. We demonstrated the effectiveness of the method using the human alpha-fetoprotein (AFP) immunoassay, which is used to detect fetal disorders. The sensitivity and dynamic range we obtained with this assay indicate that this method can provide a cost-effective and simple way to measure various biomolecules in solution for research and clinical applications.	Univ Turku, Inst Biomed, Biophys Lab, FIN-20521 Turku, Finland	University of Turku	Hanninen, P (corresponding author), Univ Turku, Inst Biomed, Biophys Lab, POB 123, FIN-20521 Turku, Finland.		Hanninen, Pekka/C-7412-2012	Hanninen, Pekka/0000-0001-5481-3275; Soini, Juhani/0000-0002-5574-0650				ASHKIN A, 1986, OPT LETT, V11, P288, DOI 10.1364/OL.11.000288; BERLAND KM, 1995, BIOPHYS J, V68, P694, DOI 10.1016/S0006-3495(95)80230-4; BLACKBURN GF, 1991, CLIN CHEM, V37, P1534; COOK L, 1989, J CLIN IMMUNOASSAY, V12, P36; DENK W, 1990, SCIENCE, V248, P73, DOI 10.1126/science.2321027; EKINS RP, 1991, CLIN CHEM, V37, P1955; ELGEN M, 1994, P NATL ACAD SCI USA, V91, P5740; Hanninen P. E., 1995, Bioimaging, V3, P70, DOI 10.1002/1361-6374(199506)3:2<70::AID-BIO3>3.3.CO;2-N; KOPPEL DE, 1994, BIOPHYS J, V66, P502, DOI 10.1016/S0006-3495(94)80801-X; LYTLE FE, 1993, APPL SPECTROSC, V47, P2002, DOI 10.1366/0003702934066389; SIITARI H, 1983, NATURE, V301, P258, DOI 10.1038/301258a0; STREEFKERK JG, 1976, PROTIDES BIOL FLUIDS, V24, P811; Swartzman EE, 1999, ANAL BIOCHEM, V271, P143, DOI 10.1006/abio.1999.4128; WITTWER CT, 1990, ANAL BIOCHEM, V186, P328, DOI 10.1016/0003-2697(90)90090-V; XU C, 1997, TOPICS FLUORESCENCE, V5, P501	15	73	79	0	16	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAY	2000	18	5					548	550		10.1038/75421	http://dx.doi.org/10.1038/75421			3	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	313UK	10802624				2022-12-25	WOS:000087017500030
J	Lindblad-Toh, K; Winchester, E; Daly, MJ; Wang, DG; Hirschhorn, JN; Laviolette, JP; Ardlie, K; Reich, DE; Robinson, E; Sklar, P; Shah, N; Thomas, D; Fan, JB; Gingeras, T; Warrington, J; Patil, N; Hudson, TJ; Lander, ES				Lindblad-Toh, K; Winchester, E; Daly, MJ; Wang, DG; Hirschhorn, JN; Laviolette, JP; Ardlie, K; Reich, DE; Robinson, E; Sklar, P; Shah, N; Thomas, D; Fan, JB; Gingeras, T; Warrington, J; Patil, N; Hudson, TJ; Lander, ES			Large-scale discovery and genotyping of single-nucleotide polymorphisms in the mouse	NATURE GENETICS			English	Article							GENOME	Single-nucleotide polymorphisms (SNPs) have been the focus of much attention in human genetics because they are extremely abundant and well-suited for automated large-scale genotyping, Human SNPs, however, are less informative than other types of genetic markers (such as simple-sequence length polymorphisms or microsatellites) and thus more loci are required for mapping traits. SNPs offer similar advantages for experimental genetic organisms such as the mouse, but they entail no loss of informativeness because bi-allelic markers are fully informative in analysing crosses between inbred strains. Here we report a large-scale analysis of SNPs in the mouse genome. We characterized the rate of nucleotide polymorphism in eight mouse strains and identified a collection of 2,848 SNPs located in 1,755 sequence-tagged sites (STSs) using high-density oligonucleotide arrays. Three-quarters of these SNPs have been mapped on the mouse genome, providing a first-generation SNP map of the mouse. We have also developed a multiplex genotyping procedure by which a genome scan can be performed with only six genotyping reactions per animal.	MIT, Whitehead Inst Biomed Res, Ctr Genome Res, Cambridge, MA 02139 USA; Bristol Myers Squibb, Princeton, NJ USA; Childrens Hosp, Div Endocrinol, Boston, MA 02115 USA; Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA; Affymetrix Inc, Santa Clara, CA USA; McGill Univ, Ctr Hlth, Montreal Genome Ctr, Montreal, PQ H3A 2T5, Canada; MIT, Dept Biol, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Bristol-Myers Squibb; Harvard University; Boston Children's Hospital; Harvard University; Massachusetts General Hospital; Affymetrix; McGill University; Massachusetts Institute of Technology (MIT)	Lindblad-Toh, K (corresponding author), MIT, Whitehead Inst Biomed Res, Ctr Genome Res, Cambridge, MA 02139 USA.		Daly, Mark J/B-2453-2017	Daly, Mark J/0000-0002-0949-8752; Gingeras, Thomas/0000-0001-9106-3573	NHGRI NIH HHS [HG01806] Funding Source: Medline; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG001806] Funding Source: NIH RePORTER	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		ATCHLEY WR, 1993, MOL BIOL EVOL, V10, P1150; Beck JA, 2000, NAT GENET, V24, P23, DOI 10.1038/71641; Cargill M, 1999, NAT GENET, V22, P231, DOI 10.1038/10290; Chee M, 1996, SCIENCE, V274, P610, DOI 10.1126/science.274.5287.610; Dietrich WF, 1996, NATURE, V380, P149, DOI 10.1038/380149a0; FERRIS SD, 1983, GENETICS, V105, P681; Nusbaum C, 1999, NAT GENET, V22, P388, DOI 10.1038/11967; SAGE RD, 1981, MOUSE BIOMEDICAL RES, P40; Syvanen AC, 1999, HUM MUTAT, V13, P1; Van Etten WJ, 1999, NAT GENET, V22, P384, DOI 10.1038/11962; Wang DG, 1998, SCIENCE, V280, P1077, DOI 10.1126/science.280.5366.1077	11	323	360	0	29	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	APR	2000	24	4					381	386		10.1038/74215	http://dx.doi.org/10.1038/74215			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	299HK	10742102				2022-12-25	WOS:000086192800017
J	van Steensel, B; Henikoff, S				van Steensel, B; Henikoff, S			Identification of in vivo DNA targets of chromatin proteins using tethered Dam methyltransferase	NATURE BIOTECHNOLOGY			English	Article						protein-DNA interactions; DNA methyltransferase; targeted methylation; heterochromatin	IN-VIVO; DROSOPHILA-MELANOGASTER; GENE; METHYLATION; INVIVO; HETEROCHROMATIN; ACCESSIBILITY; FORMALDEHYDE; EXPRESSION; PATTERNS	We have developed a novel technique, named Dam1D, for the identification of DNA loci that interact in vivo with specific nuclear proteins in eukaryotes. By tethering Escherichia coli DNA adenine methyltransferase (Dam) to a chromatin protein, Dam can be targeted in vivo to native binding sites of this protein, resulting in local DNA methylation. Sites of methylation can subsequently be mapped using methylation-specific restriction enzymes or antibodies. We demonstrate the successful application of Dam1D both in Drosophila cell cultures and in whole flies. When Dam is tethered to the DNA-binding domain of GAL4, targeted methylation is limited to a region of a few kilobases surrounding a GAL4 binding sequence. Using Dam1D, we identified a number of expected and unexpected target loci for Drosophila heterochromatin protein 1. Dam1D has potential for genome-wide mapping of in vivo targets of chromatin proteins in various eukaryotes.	Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA; Howard Hughes Med Inst, Seattle, WA 98109 USA	Fred Hutchinson Cancer Center; Howard Hughes Medical Institute	van Steensel, B (corresponding author), Fred Hutchinson Canc Res Ctr, 1100 Fairview Ave N, Seattle, WA 98109 USA.			Henikoff, Steven/0000-0002-7621-8685				BARRAS F, 1989, TRENDS GENET, V5, P139, DOI 10.1016/0168-9525(89)90054-1; Boivin A, 1998, GENETICS, V150, P1539; BRINGMANN P, 1987, FEBS LETT, V213, P309, DOI 10.1016/0014-5793(87)81512-0; CAIZZI R, 1993, GENETICS, V133, P335; FISCHER JA, 1988, NATURE, V332, P853, DOI 10.1038/332853a0; FITCH DHA, 1990, CHROMOSOMA, V99, P118, DOI 10.1007/BF01735327; FROMMER G, 1994, CHROMOSOMA, V103, P82, DOI 10.1007/BF00352316; Goldstein A, 1964, BIOSTATISTICS INTRO; GOTTSCHLING DE, 1992, P NATL ACAD SCI USA, V89, P4062, DOI 10.1073/pnas.89.9.4062; Henikoff S, 2000, P NATL ACAD SCI USA, V97, P716, DOI 10.1073/pnas.97.2.716; HILLIKER AJ, 1980, CELL, V21, P607, DOI 10.1016/0092-8674(80)90424-9; JAMES TC, 1989, EUR J CELL BIOL, V50, P170; KLADDE MP, 1994, P NATL ACAD SCI USA, V91, P1361, DOI 10.1073/pnas.91.4.1361; Law A, 1998, NUCLEIC ACIDS RES, V26, P919, DOI 10.1093/nar/26.4.919; Lee JS, 1998, P NATL ACAD SCI USA, V95, P969, DOI 10.1073/pnas.95.3.969; Lie YS, 1998, CURR OPIN BIOTECH, V9, P43, DOI 10.1016/S0958-1669(98)80082-7; Lyko F, 1999, NAT GENET, V23, P363, DOI 10.1038/15551; Orlando V, 1997, METHODS, V11, P205, DOI 10.1006/meth.1996.0407; PEASE AC, 1994, P NATL ACAD SCI USA, V91, P5022, DOI 10.1073/pnas.91.11.5022; PLATERO JS, 1995, EMBO J, V14, P3977, DOI 10.1002/j.1460-2075.1995.tb00069.x; Rorth P, 1996, P NATL ACAD SCI USA, V93, P12418, DOI 10.1073/pnas.93.22.12418; Scheer U, 1999, CURR OPIN CELL BIOL, V11, P385, DOI 10.1016/S0955-0674(99)80054-4; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; Simpson RT, 1999, CURR OPIN GENET DEV, V9, P225, DOI 10.1016/S0959-437X(99)80033-1; SINGH J, 1992, GENE DEV, V6, P186, DOI 10.1101/gad.6.2.186; SOLOMON MJ, 1988, CELL, V53, P937, DOI 10.1016/S0092-8674(88)90469-2; VANSTEENSEL B, 1995, J CELL SCI, V108, P3003; Wines DR, 1996, CHROMOSOMA, V104, P332, DOI 10.1007/s004120050123; Xu GL, 1997, NAT GENET, V17, P376, DOI 10.1038/ng1297-376	29	393	431	0	37	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	APR	2000	18	4					424	428		10.1038/74487	http://dx.doi.org/10.1038/74487			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	303UY	10748524				2022-12-25	WOS:000086444300026
J	Iwata, N; Tsubuki, S; Takaki, Y; Watanabe, K; Sekiguchi, M; Hosoki, E; Kawashima-Morishima, M; Lee, HJ; Hama, E; Sekine-Aizawa, Y; Saido, TC				Iwata, N; Tsubuki, S; Takaki, Y; Watanabe, K; Sekiguchi, M; Hosoki, E; Kawashima-Morishima, M; Lee, HJ; Hama, E; Sekine-Aizawa, Y; Saido, TC			Identification of the major A beta(1-42)-degrading catabolic pathway in brain parenchyma: Suppression leads to biochemical and pathological deposition	NATURE MEDICINE			English	Article							AMYLOID BETA-PROTEIN; HUMAN NEUROBLASTOMA-CELLS; INSULIN-DEGRADING ENZYME; ALZHEIMERS-DISEASE; PRECURSOR PROTEIN; TRANSGENIC MICE; SENILE PLAQUES; A-BETA; DEGRADATION; INHIBITOR	Alzheimer amyloid beta-peptide (A beta) is a physiological peptide constantly anabolized and catabolized under normal conditions. We investigated the mechanism of catabolism by tracing multiple-radiolabeled synthetic peptide injected into rat hippocampus. The A beta(1-42) peptide underwent full degradation through limited proteolysis conducted by neutral endopeptidase (NEP) similar or identical to neprilysin as biochemically analyzed. Consistently, NEP inhibitor infusion resulted in both biochemical and pathological deposition of endogenous A beta(42) in brain. This NEP-catalyzed proteolysis therefore limits the rate of A beta(42) catabolism, up-regulation of which could reduce the risk of developing Alzheimer's disease by preventing A beta accumulation.	RIKEN, Brain Sci Inst, Lab Proteolyt Neurosci, Wako, Saitama 3510198, Japan; Univ Tokyo, Fac Med, Dept Neuropathol, Bunkyo Ku, Tokyo 1130033, Japan	RIKEN; University of Tokyo	Saido, TC (corresponding author), RIKEN, Brain Sci Inst, Lab Proteolyt Neurosci, Wako, Saitama 3510198, Japan.		Saido, Takaomi C/N-5472-2015; Sado, Takaomi/AAN-2759-2021	Saido, Takaomi C/0000-0003-1970-6903; Sado, Takaomi/0000-0003-1970-6903				BEAVIS RC, 1992, ORG MASS SPECTROM, V27, P156, DOI 10.1002/oms.1210270217; CHANG CD, 1978, INT J PEPT PROT RES, V11, P246; Duff K, 1996, NATURE, V383, P710, DOI 10.1038/383710a0; Funato H, 1998, AM J PATHOL, V152, P1633; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; Hardy J, 1997, TRENDS NEUROSCI, V20, P154, DOI 10.1016/S0166-2236(96)01030-2; HERSH LB, 1986, J BIOL CHEM, V261, P6433; HOWELL S, 1995, PEPTIDES, V16, P647, DOI 10.1016/0196-9781(95)00021-B; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; Ida N, 1996, FEBS LETT, V394, P174, DOI 10.1016/0014-5793(96)00948-9; MacPherson LJ, 1997, J MED CHEM, V40, P2525, DOI 10.1021/jm960871c; McDermott JR, 1997, NEUROCHEM RES, V22, P49, DOI 10.1023/A:1027325304203; Morishima-Kawashima M, 1998, BIOCHEMISTRY-US, V37, P15247, DOI 10.1021/bi981843u; Naslund J, 1996, J NEUROCHEM, V67, P294; NISHIMURA K, 1993, BIOCHEM BIOPH RES CO, V194, P713, DOI 10.1006/bbrc.1993.1880; OCUINN G, 1995, METABOLISM BRAIN PEP, P99; ORLOWSKI M, 1981, BIOCHEMISTRY-US, V20, P4942, DOI 10.1021/bi00520a021; Paxinos G., 1986, RAT BRAIN STEREOTAXI, V2nd; POZSGAY M, 1986, BIOCHEMISTRY-US, V25, P1292, DOI 10.1021/bi00354a015; Price DL, 1998, ANNU REV GENET, V32, P461, DOI 10.1146/annurev.genet.32.1.461; Qiu WQ, 1998, J BIOL CHEM, V273, P32730, DOI 10.1074/jbc.273.49.32730; ROQUES BP, 1995, METHOD ENZYMOL, V248, P263; ROQUES BP, 1993, PHARMACOL REV, V45, P87; SAIDO TC, 1995, NEURON, V14, P457, DOI 10.1016/0896-6273(95)90301-1; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; Selkoe DJ, 1998, TRENDS CELL BIOL, V8, P447, DOI 10.1016/S0962-8924(98)01363-4; SELKOE DJ, 1993, TRENDS NEUROSCI, V16, P403, DOI 10.1016/0166-2236(93)90008-A; SISODIA SS, 1995, FASEB J, V9, P366, DOI 10.1096/fasebj.9.5.7896005; Turner AJ, 1997, FASEB J, V11, P355, DOI 10.1096/fasebj.11.5.9141502; Turner AJ, 1996, BIOCHEM PHARMACOL, V51, P91, DOI 10.1016/0006-2952(95)02036-5; Turner AJ, 1996, ADV EXP MED BIOL, V389, P141; VORM O, 1994, ANAL CHEM, V66, P3281, DOI 10.1021/ac00091a044; Yamin R, 1999, J BIOL CHEM, V274, P18777, DOI 10.1074/jbc.274.26.18777; Zini S, 1996, P NATL ACAD SCI USA, V93, P11968, DOI 10.1073/pnas.93.21.11968	34	696	738	0	24	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	FEB	2000	6	2					143	150		10.1038/72237	http://dx.doi.org/10.1038/72237			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	278YQ	10655101				2022-12-25	WOS:000085016900033
J	Ma, M; Benimetskaya, L; Lebedeva, I; Dignam, J; Takle, G; Stein, CA				Ma, M; Benimetskaya, L; Lebedeva, I; Dignam, J; Takle, G; Stein, CA			Intracellular mRNA cleavage induced through activation of RNase P by nuclease-resistant external guide sequences	NATURE BIOTECHNOLOGY			English	Article						external guide sequences; RNaseP	C-ALPHA EXPRESSION; ANTISENSE OLIGODEOXYNUCLEOTIDES; RIBONUCLEASE-H; MESSENGER-RNA; OLIGONUCLEOTIDES; INHIBITION; ENZYME; DNA; SPECIFICITY; NUCLEOSIDES	Most antisense oligonucleotide experiments are performed with molecules containing RNase H-competent backbones. However, RNase H may cleave nontargeted mRNAs bound to only partially complementary oligonucleotides. Decreasing such 'irrelevant cleavage" would be of critical importance to the ability of the antisense biotechnology to provide accurate assessment of gene function. RNase P is a ubiquitous endogenous cellular ribozyme whose function is to cleave the 5' terminus of precursor tRNAs to generate the mature tRNA. To recruit RNase P, complementary oligonucleotides called external guide sequences (EGS), which mimic structural features of precursor tRNA, were incorporated into an antisense 2'-O-methyl oligoribonucleotide targeted to the 3' region of the PKC-alpha mRNA. In T24 human bladder carcinoma cells, these EGSs, but not control sequences, were highly effective in downregulating PKC-alpha protein and mRNA expression. Furthermore, the downregulation is dependent on the presence of, and base sequence in, the T-loop. Similar observations were made with an EGS targeted to the bcl-xL mRNA.	Columbia Univ, Dept Med, New York, NY 10032 USA; Columbia Univ, Dept Pharmacol, New York, NY 10032 USA; VimRx Pharmaceut, Innovir Labs, Wilmington, DE 19808 USA	Columbia University; Columbia University	Stein, CA (corresponding author), Columbia Univ, Dept Med, New York, NY 10032 USA.		Lebedeva, Irina V/A-3156-2008	Lebedeva, Irina V/0000-0002-1693-9392				ALTMAN S, 1993, P NATL ACAD SCI USA, V90, P10898, DOI 10.1073/pnas.90.23.10898; Benimetskaya L, 1998, NUCLEIC ACIDS RES, V26, P5310, DOI 10.1093/nar/26.23.5310; DEAN NM, 1994, P NATL ACAD SCI USA, V91, P11762, DOI 10.1073/pnas.91.24.11762; DEAN NM, 1994, J BIOL CHEM, V269, P16416; FORSTER AC, 1990, SCIENCE, V249, P783, DOI 10.1126/science.1697102; GILES RV, 1993, ANTI-CANCER DRUG DES, V8, P33; GILES RV, 1995, NUCLEIC ACIDS RES, V23, P954, DOI 10.1093/nar/23.6.954; GILES RV, 1992, NUCLEIC ACIDS RES, V20, P763, DOI 10.1093/nar/20.4.763; HAUSEN P, 1970, EUR J BIOCHEM, V14, P278, DOI 10.1111/j.1432-1033.1970.tb00287.x; HEIDENREICH O, 1994, J BIOL CHEM, V269, P2131; KAHLE D, 1990, EMBO J, V9, P1929, DOI 10.1002/j.1460-2075.1990.tb08320.x; Loria A, 1997, BIOCHEMISTRY-US, V36, P6317, DOI 10.1021/bi970115o; Ma MYX, 1998, ANTISENSE NUCLEIC A, V8, P415; MINSHULL J, 1986, NUCLEIC ACIDS RES, V14, P6433, DOI 10.1093/nar/14.16.6433; MONIA B, 1993, J BIOL CHEM, V268, P14154; Mulamba GB, 1998, ANTIMICROB AGENTS CH, V42, P971, DOI 10.1128/AAC.42.4.971; Ortigao J F, 1992, Antisense Res Dev, V2, P129; SINHA ND, 1993, BIOCHIMIE, V75, P13, DOI 10.1016/0300-9084(93)90019-O; Stein C. A., 1998, APPL ANTISENSE OLIGO; STEIN CA, 1988, NUCLEIC ACIDS RES, V16, P3209, DOI 10.1093/nar/16.8.3209; STEIN CA, 1993, SCIENCE, V261, P1004, DOI 10.1126/science.8351515; WAGNER RW, 1994, NATURE, V372, P333, DOI 10.1038/372333a0; WALDER RY, 1988, P NATL ACAD SCI USA, V85, P5011, DOI 10.1073/pnas.85.14.5011; Werner M, 1998, RNA, V4, P847, DOI 10.1017/S1355838298980323; Werner M, 1999, ANTISENSE NUCLEIC A, V9, P81, DOI 10.1089/oli.1.1999.9.81; YUAN Y, 1992, P NATL ACAD SCI USA, V89, P8006, DOI 10.1073/pnas.89.17.8006	26	73	81	0	9	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JAN	2000	18	1					58	61		10.1038/71924	http://dx.doi.org/10.1038/71924			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	273GQ	10625392				2022-12-25	WOS:000084699900026
J	Hughes, TR; Roberts, CJ; Dai, HY; Jones, AR; Meyer, MR; Slade, D; Burchard, J; Dow, S; Ward, TR; Kidd, MJ; Friend, SH; Marton, MJ				Hughes, TR; Roberts, CJ; Dai, HY; Jones, AR; Meyer, MR; Slade, D; Burchard, J; Dow, S; Ward, TR; Kidd, MJ; Friend, SH; Marton, MJ			Widespread aneuploidy revealed by DNA microarray expression profiling	NATURE GENETICS			English	Article							SACCHAROMYCES-CEREVISIAE; GENE-EXPRESSION; YEAST; GENOME; IDENTIFICATION; BIOSYNTHESIS; EVOLUTION; SCALE	Expression profiling using DNA microarrays holds great promise for a variety of research applications, including the systematic characterization of genes discovered by sequencing projects(1,2) To demonstrate the general usefulness of this approach, we recently obtained expression profiles for nearly 300 Saccharomyces cerevisiae deletion mutants(3). Approximately 8% of the mutants profiled exhibited chromosome-wide expression biases, leading to spurious correlations among profiles. Competitive hybridization of genomic DNA from the mutant strains and their isogenic parental wild-type strains showed they were aneuploid for whole chromosomes or chromosomal segments. Expression profile data published by several other laboratories also suggest the use of aneuploid strains. In five separate cases. the extra chromosome harboured a close homologue of the deleted gene; in two cases, a clear growth advantage for cells acquiring the extra chromosome was demonstrated. Our results have implications for interpreting whole-genome expression data, particularly from cells known to suffer genomic instability, such as malignant or immortalized cells.	Rosetta Inpharmat Inc, Kirkland, WA USA		Marton, MJ (corresponding author), Rosetta Inpharmat Inc, Kirkland, WA USA.							Chu S, 1998, SCIENCE, V282, P699, DOI 10.1126/science.282.5389.699; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; Ferea TL, 1999, P NATL ACAD SCI USA, V96, P9721, DOI 10.1073/pnas.96.17.9721; Galitski T, 1999, SCIENCE, V285, P251, DOI 10.1126/science.285.5425.251; HARTWELL LH, 1985, GENETICS, V110, P381; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; Holstege FCP, 1998, CELL, V95, P717, DOI 10.1016/S0092-8674(00)81641-4; HOYT MA, 1991, CELL, V66, P507, DOI 10.1016/0092-8674(81)90014-3; HUGHES TR, IN PRESS CELL; Jelinsky SA, 1999, P NATL ACAD SCI USA, V96, P1486, DOI 10.1073/pnas.96.4.1486; JOHNSON AD, 1995, CURR OPIN GENET DEV, V5, P552, DOI 10.1016/0959-437X(95)80022-0; Kal AJ, 1999, MOL BIOL CELL, V10, P1859, DOI 10.1091/mbc.10.6.1859; LAI MH, 1994, GENE, V140, P41; Lussier M, 1997, GENETICS, V147, P435; Marton MJ, 1998, NAT MED, V4, P1293, DOI 10.1038/3282; Pennisi E, 1998, SCIENCE, V282, P1972, DOI 10.1126/science.282.5396.1972; Pollack JR, 1999, NAT GENET, V23, P41, DOI 10.1038/12640; Schwartz K, 1997, MOL BIOL CELL, V8, P2677, DOI 10.1091/mbc.8.12.2677; Smith NGC, 1999, BIOESSAYS, V21, P697, DOI 10.1002/(SICI)1521-1878(199908)21:8<697::AID-BIES9>3.0.CO;2-X; Somerville C, 1999, SCIENCE, V285, P380, DOI 10.1126/science.285.5426.380; Spellman PT, 1998, MOL BIOL CELL, V9, P3273, DOI 10.1091/mbc.9.12.3273; Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901; Wolfe KH, 1997, NATURE, V387, P708, DOI 10.1038/42711; Wyrick JJ, 1999, NATURE, V402, P418, DOI 10.1038/46567	24	375	385	0	11	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUL	2000	25	3					333	337		10.1038/77116	http://dx.doi.org/10.1038/77116			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	329RD	10888885				2022-12-25	WOS:000087920900025
J	Rountree, MR; Bachman, KE; Baylin, SB				Rountree, MR; Bachman, KE; Baylin, SB			DNMT1 binds HDAC2 and a new co-repressor, DMAP1, to form a complex at replication foci	NATURE GENETICS			English	Article							HISTONE DEACETYLASE COMPLEX; DNA METHYLTRANSFERASE; METHYLATION; CHROMATIN; CELLS; TRANSCRIPTION; ORGANIZATION; DOMAIN; MECP2; (CYTOSINE-5)-METHYLTRANSFERASE	DNA methylation can contribute to transcriptional silencing through several transcriptionally repressive complexes, which include methyl-CpG binding domain proteins (MBDs) and histone deacetylases (HDACs). We show here that the chief enzyme that maintains mammalian DNA methylation, DNMT1, can also establish a repressive transcription complex. The non-catalytic amino terminus of DNMT1 binds to HDAC2 and a new protein, DMAP1 (for DNMT1 associated protein), and can mediate transcriptional repression. DMAP1 has intrinsic transcription repressive activity, and binds to the transcriptional co-repressor TSG101. DMAP1 is targeted to replication foci through interaction with the far N terminus of DNMT1 throughout S phase, whereas HDAC2 joins DNMT1 and DMAP1 only during late S phase, providing a platform for how histones may become deacetylated in heterochromatin following replication. Thus, DNMT1 not only maintains DNA methylation, but also may directly target, in a heritable manner, transcriptionally repressive chromatin to the genome during DNA replication.	Johns Hopkins Univ, Sch Med, Ctr Oncol, Tumor Biol Lab, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Grad Program Cellular & Mol Med, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University	Rountree, MR (corresponding author), Johns Hopkins Univ, Sch Med, Ctr Oncol, Tumor Biol Lab, Baltimore, MD 21205 USA.	rountree@jhmi.edu	Rountree, Michael R/C-6332-2018	Rountree, Michael R/0000-0003-2371-6389	NATIONAL CANCER INSTITUTE [R01CA043318, R01CA054396] Funding Source: NIH RePORTER; NCI NIH HHS [CA43318, CA54396] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANNUNZIATO AT, 1983, J BIOL CHEM, V258, P2675; Bakin AV, 1999, SCIENCE, V283, P387, DOI 10.1126/science.283.5400.387; BarPeled M, 1996, ANAL BIOCHEM, V241, P140, DOI 10.1006/abio.1996.0390; BESTOR T, 1988, J MOL BIOL, V203, P971, DOI 10.1016/0022-2836(88)90122-2; BESTOR TH, 1992, EMBO J, V11, P2611, DOI 10.1002/j.1460-2075.1992.tb05326.x; BIRD A, 1992, CELL, V70, P5, DOI 10.1016/0092-8674(92)90526-I; Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Chuang LSH, 1997, SCIENCE, V277, P1996, DOI 10.1126/science.277.5334.1996; Collingwood TN, 1999, J MOL ENDOCRINOL, V23, P255, DOI 10.1677/jme.0.0230255; EDEN S, 1994, CURR OPIN GENET DEV, V4, P255, DOI 10.1016/S0959-437X(05)80052-8; Fuks F, 2000, NAT GENET, V24, P88, DOI 10.1038/71750; Gaudet F, 1998, J BIOL CHEM, V273, P32725, DOI 10.1074/jbc.273.49.32725; Grunstein M, 1998, CELL, V93, P325, DOI 10.1016/S0092-8674(00)81160-5; Hittelman AB, 1999, EMBO J, V18, P5380, DOI 10.1093/emboj/18.19.5380; Hsieh JJD, 1999, P NATL ACAD SCI USA, V96, P23, DOI 10.1073/pnas.96.1.23; Johnson CA, 1999, SEMIN CELL DEV BIOL, V10, P179, DOI 10.1006/scdb.1999.0299; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; Jones PL, 1999, SEMIN CANCER BIOL, V9, P339, DOI 10.1006/scbi.1999.0134; KASS SU, 1996, EPIGENETIC MECH GENE, P529; Krude T, 1999, CURR BIOL, V9, pR394, DOI 10.1016/S0960-9822(99)80251-6; Krude T, 1999, EXP CELL RES, V247, P148, DOI 10.1006/excr.1998.4342; Leonhardt H., 1993, Experientia Supplementum (Basel), V64, P109; LEONHARDT H, 1992, CELL, V71, P865, DOI 10.1016/0092-8674(92)90561-P; Lewin B, 1998, CELL, V93, P301, DOI 10.1016/S0092-8674(00)81154-X; Li E, 1999, NAT GENET, V23, P5, DOI 10.1038/12595; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; Li LM, 1996, CELL, V85, P319, DOI 10.1016/S0092-8674(00)81111-3; Liu YL, 1998, NUCLEIC ACIDS RES, V26, P1038, DOI 10.1093/nar/26.4.1038; Mertineit C, 1998, DEVELOPMENT, V125, P889; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Ng HH, 1999, NAT GENET, V23, P58, DOI 10.1038/12659; OKEEFE RT, 1992, J CELL BIOL, V116, P1095, DOI 10.1083/jcb.116.5.1095; Rein T, 1999, J BIOL CHEM, V274, P25792, DOI 10.1074/jbc.274.36.25792; Sadoni N, 1999, J CELL BIOL, V146, P1211, DOI 10.1083/jcb.146.6.1211; Selker EU, 1998, P NATL ACAD SCI USA, V95, P9430, DOI 10.1073/pnas.95.16.9430; Shibahara K, 1999, CELL, V96, P575, DOI 10.1016/S0092-8674(00)80661-3; SOBEL RE, 1995, P NATL ACAD SCI USA, V92, P1237, DOI 10.1073/pnas.92.4.1237; Sun ZJ, 1999, CANCER-AM CANCER SOC, V86, P689, DOI 10.1002/(SICI)1097-0142(19990815)86:4<689::AID-CNCR19>3.0.CO;2-P; Taddei A, 1999, J CELL BIOL, V147, P1153, DOI 10.1083/jcb.147.6.1153; Tucker KL, 1996, P NATL ACAD SCI USA, V93, P12920, DOI 10.1073/pnas.93.23.12920; Vertino PM, 1996, MOL CELL BIOL, V16, P4555, DOI 10.1128/mcb.16.8.4555; Wade PA, 1998, COLD SPRING HARB SYM, V63, P435, DOI 10.1101/sqb.1998.63.435; Watanabe M, 1998, BIOCHEM BIOPH RES CO, V245, P900, DOI 10.1006/bbrc.1998.8547; WU JJ, 1993, P NATL ACAD SCI USA, V90, P8891, DOI 10.1073/pnas.90.19.8891; YEN RWC, 1992, NUCLEIC ACIDS RES, V20, P2287, DOI 10.1093/nar/20.9.2287; Yoder JA, 1996, J BIOL CHEM, V271, P31092, DOI 10.1074/jbc.271.49.31092; Zhong Q, 1998, CANCER RES, V58, P2699	48	820	846	2	66	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JUL	2000	25	3					269	277		10.1038/77023	http://dx.doi.org/10.1038/77023			9	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	329RD	10888872				2022-12-25	WOS:000087920900012
J	Zhang, ZH; Nadeau, P; Song, WH; Donoviel, D; Yuan, ML; Bernstein, A; Yankner, BA				Zhang, ZH; Nadeau, P; Song, WH; Donoviel, D; Yuan, ML; Bernstein, A; Yankner, BA			Presenilins are required for gamma-secretase cleavage of beta-APP and transmembrane cleavage of Notch-1	NATURE CELL BIOLOGY			English	Article							FAMILIAL ALZHEIMERS-DISEASE; INTRACELLULAR DOMAIN; PROTEOLYTIC RELEASE; MUTATIONS; GENE; DEFICIENCY		Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02115 USA; Childrens Hosp, Div Neurosci, Boston, MA 02115 USA; Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Med Genet & Microbiol, Toronto, ON M5S 1A8, Canada	Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto	Yankner, BA (corresponding author), Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02115 USA.	Yankner@A1.tch.harvard.edu	Song, Weihong/O-7623-2017	Song, Weihong/0000-0001-9928-889X				BUSCIGLIO J, 1993, P NATL ACAD SCI USA, V90, P2092, DOI 10.1073/pnas.90.5.2092; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; DONOVIEL D, 1999, GENE DEV, V13, P280; HERREMAN, 1999, P NATL ACAD SCI US, V96, P11872; Kimberly WT, 2000, J BIOL CHEM, V275, P3173, DOI 10.1074/jbc.275.5.3173; Klafki HW, 1996, ANAL BIOCHEM, V237, P24, DOI 10.1006/abio.1996.0195; LEVITAN D, 1995, NATURE, V377, P351, DOI 10.1038/377351a0; LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622; Naruse S, 1998, NEURON, V21, P1213, DOI 10.1016/S0896-6273(00)80637-6; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; Shen J, 1997, CELL, V89, P629, DOI 10.1016/S0092-8674(00)80244-5; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; Song WH, 1999, P NATL ACAD SCI USA, V96, P6959, DOI 10.1073/pnas.96.12.6959; Steiner H, 1999, J BIOL CHEM, V274, P28669, DOI 10.1074/jbc.274.40.28669; Struhl G, 1999, NATURE, V398, P522, DOI 10.1038/19091; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Wong PC, 1997, NATURE, V387, P288, DOI 10.1038/387288a0; Yankner BA, 1996, NEURON, V16, P921, DOI 10.1016/S0896-6273(00)80115-4; Ye YH, 1999, NATURE, V398, P525, DOI 10.1038/19096	20	347	357	0	8	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	JUL	2000	2	7					463	465		10.1038/35017108	http://dx.doi.org/10.1038/35017108			3	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	333MK	10878814				2022-12-25	WOS:000088133700025
J	Follenzi, A; Ailles, LE; Bakovic, S; Geuna, M; Naldini, L				Follenzi, A; Ailles, LE; Bakovic, S; Geuna, M; Naldini, L			Gene transfer by lentiviral vectors is limited by nuclear translocation and rescued by HIV-1 pol sequences	NATURE GENETICS			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; HEMATOPOIETIC STEM-CELLS; MURINE LEUKEMIA-VIRUS; IN-VIVO; NONDIVIDING CELLS; POLYPURINE TRACT; REVERSE TRANSCRIPTION; STABLE TRANSDUCTION; MATRIX PROTEIN; CD34(+) CELLS	Gene-transfer vectors based on lentiviruses are distinguished by their ability to transduce non-dividing cells(1,2). The HIV-1 proteins Matrix, Vpr and Integrase have been implicated in the nuclear import of the viral genome in non-dividing cells(3-5). Here we show that a sequence within polis also required in cis. It contains structural elements previously associated with the progress of reverse transcription in target cells(6-9). We restored these elements in cis within late-generation lentiviral vectors(10,11). The new vector transduced to a much higher efficiency several types of human primary cells, when both growing and growth-arrested, including haematopoietic stem cells assayed by longterm repopulation of NOD/SCID mice. On in vivo administration into SCID mice, the vector induced higher plasma levels of human clotting factor IX (F.IX) than non-modified vector. Our results indicate that nuclear translocation of the genome is a rate-limiting step in lentiviral infection of both dividing and non-dividing cells, and that it depends on protein and nucleic acid sequence determinants. Full rescue of this step in lentivirus-based vectors improves performance for gene-therapy applications.	Univ Turin, Sch Med, Labs Gene Transfer & Therapy, Turin, Italy; Univ Turin, IRCCS, Labs Tumor Immunol, Inst Canc Res & Treatment, Turin, Italy	University of Turin; University of Turin	Naldini, L (corresponding author), Univ Turin, Sch Med, Labs Gene Transfer & Therapy, Turin, Italy.		Naldini, Luigi/E-9083-2012; Geuna, Massimo/AAY-1441-2021	Follenzi, Antonia/0000-0001-9780-300X; NALDINI, Luigi/0000-0002-7835-527X; Geuna, Massimo/0000-0002-6475-5547	Telethon [A.143] Funding Source: Medline	Telethon(Fondazione Telethon)		Akkina RK, 1996, J VIROL, V70, P2581, DOI 10.1128/JVI.70.4.2581-2585.1996; Andreadis ST, 1997, J VIROL, V71, P7541, DOI 10.1128/JVI.71.10.7541-7548.1997; Bukrinskaya A, 1998, J EXP MED, V188, P2113, DOI 10.1084/jem.188.11.2113; BUKRINSKY MI, 1993, NATURE, V365, P666, DOI 10.1038/365666a0; Case SS, 1999, P NATL ACAD SCI USA, V96, P2988, DOI 10.1073/pnas.96.6.2988; CHARNEAU P, 1991, J VIROL, V65, P2415, DOI 10.1128/JVI.65.5.2415-2421.1991; CHARNEAU P, 1992, J VIROL, V66, P2814, DOI 10.1128/JVI.66.5.2814-2820.1992; CHARNEAU P, 1994, J MOL BIOL, V241, P651, DOI 10.1006/jmbi.1994.1542; Conneally E, 1998, BLOOD, V91, P3487, DOI 10.1182/blood.V91.9.3487.3487_3487_3493; Dull T, 1998, J VIROL, V72, P8463, DOI 10.1128/JVI.72.11.8463-8471.1998; GALLAY P, 1995, CELL, V80, P379, DOI 10.1016/0092-8674(95)90488-3; Hansen MST, 1999, NAT BIOTECHNOL, V17, P578, DOI 10.1038/9886; Ilyinskii PO, 1998, EMBO J, V17, P3766, DOI 10.1093/emboj/17.13.3766; Kay MA, 1999, P NATL ACAD SCI USA, V96, P9973, DOI 10.1073/pnas.96.18.9973; Kiernan RE, 1998, J VIROL, V72, P4116, DOI 10.1128/JVI.72.5.4116-4126.1998; LEWIS P, 1992, EMBO J, V11, P3053, DOI 10.1002/j.1460-2075.1992.tb05376.x; Marandin A, 1998, HUM GENE THER, V9, P1497, DOI 10.1089/hum.1998.9.10-1497; Miller MD, 1997, J VIROL, V71, P5382, DOI 10.1128/JVI.71.7.5382-5390.1997; Miyoshi H, 1999, SCIENCE, V283, P682, DOI 10.1126/science.283.5402.682; Naldini L, 1998, CURR OPIN BIOTECH, V9, P457, DOI 10.1016/S0958-1669(98)80029-3; Naldini L, 1996, SCIENCE, V272, P263, DOI 10.1126/science.272.5259.263; Nie ZL, 1998, J VIROL, V72, P4104, DOI 10.1128/JVI.72.5.4104-4115.1998; Popov S, 1998, EMBO J, V17, P909, DOI 10.1093/emboj/17.4.909; Powell MD, 1996, J VIROL, V70, P5288, DOI 10.1128/JVI.70.8.5288-5296.1996; Schmidtmayerova H, 1998, J VIROL, V72, P4633, DOI 10.1128/JVI.72.6.4633-4642.1998; Schwartz O, 1998, J VIROL, V72, P3845, DOI 10.1128/JVI.72.5.3845-3850.1998; Sutton RE, 1998, J VIROL, V72, P5781, DOI 10.1128/JVI.72.7.5781-5788.1998; Uchida N, 1998, P NATL ACAD SCI USA, V95, P11939, DOI 10.1073/pnas.95.20.11939; Zufferey R, 1997, NAT BIOTECHNOL, V15, P871, DOI 10.1038/nbt0997-871; Zufferey R, 1998, J VIROL, V72, P9873, DOI 10.1128/JVI.72.12.9873-9880.1998	30	755	832	0	33	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUN	2000	25	2					217	+		10.1038/76095	http://dx.doi.org/10.1038/76095			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	321ML	10835641				2022-12-25	WOS:000087459200025
J	Shih, IM; Torrance, C; Sokoll, LJ; Chan, DW; Kinzler, KW; Vogelstein, B				Shih, IM; Torrance, C; Sokoll, LJ; Chan, DW; Kinzler, KW; Vogelstein, B			Assessing tumors in living animals through measurement of urinary beta-human chorionic gonadotropin	NATURE MEDICINE			English	Article							ORGAN ENVIRONMENT; CARCINOMA CELLS; GROWTH; GENE; KINETICS; MODEL; MICE		Johns Hopkins Med Inst, Johns Hopkins Oncol Ctr, Baltimore, MD 21231 USA; Johns Hopkins Med Inst, Dept Pathol, Baltimore, MD 21231 USA; Johns Hopkins Med Inst, Howard Hughes Med Inst, Baltimore, MD 21231 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Howard Hughes Medical Institute; Johns Hopkins University; Johns Hopkins Medicine	Vogelstein, B (corresponding author), Johns Hopkins Med Inst, Johns Hopkins Oncol Ctr, Baltimore, MD 21231 USA.	vogelbe@welchlink.welch.jhu.edu	sdsd, shihieih/ABE-6190-2020		NCI NIH HHS [CA 62924, CA 57345, CA 43460] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA057345, R37CA057345, R37CA043460, P50CA062924, R01CA043460] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CARUSO M, 1993, P NATL ACAD SCI USA, V90, P7024, DOI 10.1073/pnas.90.15.7024; Cole LA, 1998, J REPROD MED, V43, P3; CULVER KW, 1992, SCIENCE, V256, P1550, DOI 10.1126/science.1317968; DIPERSIO L, 1979, J NATL CANCER I, V62, P375; FIDLER IJ, 1994, CANCER METAST REV, V13, P209, DOI 10.1007/BF00689637; Galons Jean-Philippe, 1999, Neoplasia (New York), V1, P113, DOI 10.1038/sj.neo.7900009; Jacobs Andreas, 1999, Neoplasia (New York), V1, P154, DOI 10.1038/sj.neo.7900007; KANAZAWA K, 1989, ACTA OBSTET GYN SCAN, V68, P429, DOI 10.3109/00016348909021015; KELLEN JA, 1982, CANCER-AM CANCER SOC, V49, P2300, DOI 10.1002/1097-0142(19820601)49:11<2300::AID-CNCR2820491117>3.0.CO;2-Y; Kerbel RS, 1998, CANCER METAST REV, V17, P301, DOI 10.1023/A:1006152915959; Killion JJ, 1998, CANCER METAST REV, V17, P279, DOI 10.1023/A:1006140513233; MacLaren DC, 1999, GENE THER, V6, P785, DOI 10.1038/sj.gt.3300877; MARINI FC, 1995, GENE THER, V2, P655; Newman D.J., 1999, TIETZ TXB CLIN CHEM, P1204; PESCE AJ, 1977, CANCER RES, V37, P1998; RAIKOW RB, 1986, AM J REPROD IMMUNOL, V12, P99; Shih I-M, 1999, DIAGNOSTIC SURG PATH, P2067; STAROSELSKY AN, 1992, INT J CANCER, V51, P130, DOI 10.1002/ijc.2910510123; Stegman LD, 1999, P NATL ACAD SCI USA, V96, P9821, DOI 10.1073/pnas.96.17.9821; Sweeney TJ, 1999, P NATL ACAD SCI USA, V96, P12044, DOI 10.1073/pnas.96.21.12044; TAKAHASHI Y, 1991, J SURG ONCOL, V48, P96, DOI 10.1002/jso.2930480205; WILLIAMS NN, 1992, INT J CANCER, V50, P274, DOI 10.1002/ijc.2910500218; WILMANNS C, 1992, INT J CANCER, V52, P98, DOI 10.1002/ijc.2910520118; WU AHB, 1987, CLIN CHEM, V33, P1424; Yang M, 1999, CANCER RES, V59, P781	25	29	30	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2000	6	6					711	714		10.1038/76299	http://dx.doi.org/10.1038/76299			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	321CX	10835692				2022-12-25	WOS:000087438300046
J	Holland, EC; Celestino, J; Dai, CK; Schaefer, L; Sawaya, RE; Fuller, GN				Holland, EC; Celestino, J; Dai, CK; Schaefer, L; Sawaya, RE; Fuller, GN			Combined activation of Ras and Akt in neural progenitors induces glioblastoma formation in mice	NATURE GENETICS			English	Article							GROWTH-FACTOR-I; HUMAN ASTROCYTOMAS; RECEPTOR; PATHWAYS; PROLIFERATION; EXPRESSION; PROTEIN	Gliomas are the most common primary malignant brain tumours and are classified into four clinical grades', with the most aggressive tumours being grade 4 astrocytomas (also known as glioblastoma multiforme; GBM). Frequent genetic alterations in GBMs (refs 2-5) result in stimulation of common signal transduction pathways involving Ras, Akt and other proteins(6-10). It is not known which of these pathways, if any, are sufficient to induce GBM formation, Here we transfer, in a tissue-specific manner, genes encoding activated forms of Ras and Akt to astrocytes and neural progenitors in mice. We found that although neither activated Ras nor Akt alone is sufficient to induce GBM formation, the combination of activated Ras and Akt induces high-grade gliomas with the histological features of human GBMs. These tumours appear to arise after gene transfer to neural progenitors, but not after transfer to differentiated astrocytes. Increased activity of RAS is found in many human GBMs (ref. 11), and we show here that Akt activity is increased in most of these tumours, implying that combined activation of these two pathways accurately models the biology of this disease.	Univ Texas, MD Anderson Canc Ctr, Dept Neurosurg, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Holland, EC (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Neurosurg, 1515 Holcombe Blvd, Houston, TX 77030 USA.			Fuller, Gregory/0000-0001-9447-2647	NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER; NCI NIH HHS [CA16672] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANTONIADES HN, 1992, INT J CANCER, V50, P215, DOI 10.1002/ijc.2910500210; Aoki M, 1998, P NATL ACAD SCI USA, V95, P14950, DOI 10.1073/pnas.95.25.14950; Feldkamp MM, 1997, J NEURO-ONCOL, V35, P223, DOI 10.1023/A:1005800114912; GROSS JL, 1990, J NEUROSCI RES, V27, P689, DOI 10.1002/jnr.490270429; Guha A, 1997, ONCOGENE, V15, P2755, DOI 10.1038/sj.onc.1201455; Hermanson M, 1996, CANCER RES, V56, P164; Holland EC, 1998, P NATL ACAD SCI USA, V95, P1218, DOI 10.1073/pnas.95.3.1218; Holland EC, 1998, GENE DEV, V12, P3675, DOI 10.1101/gad.12.23.3675; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; Kim BS, 1998, J BIOL CHEM, V273, P34543, DOI 10.1074/jbc.273.51.34543; KLEHUES P, 1993, HISTOLOGICAL TYPING; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; Kulik G, 1998, MOL CELL BIOL, V18, P6711, DOI 10.1128/MCB.18.11.6711; Li J, 1998, CANCER RES, V58, P5667; SCHLEGEL J, 1994, INT J CANCER, V56, P72	15	689	714	0	18	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAY	2000	25	1					55	57		10.1038/75596	http://dx.doi.org/10.1038/75596			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	311KU	10802656				2022-12-25	WOS:000086884000016
J	Honore, P; Luger, NM; Sabino, MAC; Schwei, MJ; Rogers, SD; Mach, DB; O'Keefe, PF; Ramnaraine, ML; Clohisy, DR; Mantyh, PW				Honore, P; Luger, NM; Sabino, MAC; Schwei, MJ; Rogers, SD; Mach, DB; O'Keefe, PF; Ramnaraine, ML; Clohisy, DR; Mantyh, PW			Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord	NATURE MEDICINE			English	Article							NECROSIS-FACTOR-ALPHA; SUBSTANCE-P RECEPTOR; C-FOS EXPRESSION; IMMUNOREACTIVE NERVES; BREAKTHROUGH PAIN; BREAST-CANCER; GROWTH-FACTOR; DORSAL HORN; LAMINA-I; RAT	Bone cancer pain is common among cancer patients and can have a devastating effect on their quality of life. A chief problem in designing new therapies for bone cancer pain is that it is unclear what mechanisms drive this distinct pain condition. Here we show that osteoprotegerin, a secreted 'decoy' receptor that inhibits osteoclast activity, also blocks behaviors indicative of pain in mice with bone cancer. A substantial part of the actions of osteoprotegerin seems to result from inhibition of tumor-induced bone destruction that in turn inhibits the neurochemical changes in the spinal cord that are thought to be involved in the generation and maintenance of cancer pain. These results demonstrate that excessive tumor-induced bone destruction is involved in the generation of bone cancer pain and that osteoprotegerin may provide an effective treatment for this common human condition.	Univ Minnesota, Neurosyst Ctr, Minneapolis, MN 55455 USA; Univ Minnesota, Dept Prevent Sci, Minneapolis, MN 55455 USA; Univ Minnesota, Dept Neurosci, Minneapolis, MN 55455 USA; Univ Minnesota, Ctr Canc, Minneapolis, MN 55455 USA; Vet Adm Med Ctr, Minneapolis, MN 55417 USA; Univ Minnesota, Dept Orthoped Surg, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; US Department of Veterans Affairs; Veterans Health Administration (VHA); Minneapolis VA Health Care System; University of Minnesota System; University of Minnesota Twin Cities	Clohisy, DR (corresponding author), Univ Minnesota, Neurosyst Ctr, Minneapolis, MN 55455 USA.				NIDA NIH HHS [DA11986] Funding Source: Medline; NIDCR NIH HHS [DEO7288] Funding Source: Medline; NINDS NIH HHS [NS23970] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS023970, R37NS023970] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA011986] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		ABBADIE C, 1993, BRAIN RES, V607, P195, DOI 10.1016/0006-8993(93)91507-O; Abbadie C, 1997, J NEUROSCI, V17, P8049; BANNING A, 1991, PAIN, V45, P45, DOI 10.1016/0304-3959(91)90163-R; Bekker PJ, 1999, J BONE MINER RES, V14, pS180; BJURHOLM A, 1988, PEPTIDES, V9, P165, DOI 10.1016/0196-9781(88)90023-X; Catheline G, 1999, PAIN, V80, P347, DOI 10.1016/S0304-3959(98)00234-6; Clohisy DR, 1998, J ORTHOPAED RES, V16, P660, DOI 10.1002/jor.1100160606; Colburn RW, 1999, EXP NEUROL, V157, P289, DOI 10.1006/exnr.1999.7065; Colburn RW, 1997, J NEUROIMMUNOL, V79, P163, DOI 10.1016/S0165-5728(97)00119-7; COLEMAN RE, 1987, BRIT J CANCER, V55, P61, DOI 10.1038/bjc.1987.13; Coleman RE, 1998, EUR J CANCER, V34, P820, DOI 10.1016/S0959-8049(97)10155-1; Coleman Robert E., 1998, Current Opinion in Oncology, V10, pS7; Delaisse Jean-Marie, 1992, P289; Doyle CA, 1999, NEUROSCIENCE, V89, P17, DOI 10.1016/S0306-4522(98)00276-0; DRAISCI G, 1991, BRAIN RES, V560, P186, DOI 10.1016/0006-8993(91)91231-O; Fulfaro F, 1998, PAIN, V78, P157, DOI 10.1016/S0304-3959(98)00135-3; GONI MH, 1993, ANTICANCER RES, V13, P1155; HILL EL, 1991, CELL TISSUE RES, V264, P469, DOI 10.1007/BF00319037; Honore P, 1996, J PHARMACOL EXP THER, V278, P393; Honore P, 1999, J NEUROSCI, V19, P7670, DOI 10.1523/JNEUROSCI.19-17-07670.1999; HUNT SP, 1987, NATURE, V328, P632, DOI 10.1038/328632a0; Josien R, 1999, J IMMUNOL, V162, P2562; KONG, 1999, NATURE, V402, P304; Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852; Kostenuik PJ, 1999, J BONE MINER RES, V14, pS166; Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092-8674(00)81569-X; Lipton A, 1997, CANCER, V80, P1668, DOI 10.1002/(SICI)1097-0142(19971015)80:8+<1668::AID-CNCR17>3.3.CO;2-5; Mantyh PW, 1997, SCIENCE, V278, P275, DOI 10.1126/science.278.5336.275; MANTYH PW, 1995, P NATL ACAD SCI USA, V92, P2622, DOI 10.1073/pnas.92.7.2622; MANTYH PW, 1995, SCIENCE, V268, P1629, DOI 10.1126/science.7539937; Mercadante S, 1997, PAIN, V69, P1, DOI 10.1016/S0304-3959(96)03267-8; Mercadante S, 1998, CANCER TREAT REV, V24, P425, DOI 10.1016/S0305-7372(98)90005-6; MOLANDER C, 1984, J COMP NEUROL, V230, P133, DOI 10.1002/cne.902300112; O'Connell JX, 1998, MODERN PATHOL, V11, P175; Olson TH, 1998, NEUROREPORT, V9, P1109, DOI 10.1097/00001756-199804200-00028; Payne R, 1998, Oncology (Williston Park), V12, P169; Payne R, 1997, CANCER, V80, P1608, DOI 10.1002/(SICI)1097-0142(19971015)80:8+<1608::AID-CNCR11>3.0.CO;2-3; Portenoy RK, 1999, PAIN, V81, P129, DOI 10.1016/S0304-3959(99)00006-8; Rosier R, 1992, Am J Hosp Palliat Care, V9, P37, DOI 10.1177/104990919200900610; RUDA MA, 1988, P NATL ACAD SCI USA, V85, P622, DOI 10.1073/pnas.85.2.622; SAFIEHGARABEDIAN B, 1995, BRIT J PHARMACOL, V115, P1265, DOI 10.1111/j.1476-5381.1995.tb15035.x; Schwei MJ, 1999, J NEUROSCI, V19, P10886, DOI 10.1523/JNEUROSCI.19-24-10886.1999; Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092-8674(00)80209-3; Sorkin LS, 1997, NEUROSCIENCE, V81, P255, DOI 10.1016/S0306-4522(97)00147-4; SUZUKI K, 1994, BONE MINER, V27, P219, DOI 10.1016/S0169-6009(08)80195-X; Tabarowski Z, 1996, ACTA HISTOCHEM, V98, P453, DOI 10.1016/S0065-1281(96)80013-4; Tonussi CR, 1999, PAIN, V82, P81, DOI 10.1016/S0304-3959(99)00035-4; WATKINS LR, 1994, BRAIN RES, V654, P15, DOI 10.1016/0006-8993(94)91566-0; Woolf CJ, 1998, PAIN, V77, P227, DOI 10.1016/S0304-3959(98)00099-2; Woolf CJ, 1997, BRIT J PHARMACOL, V121, P417, DOI 10.1038/sj.bjp.0701148	50	388	430	3	26	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAY	2000	6	5					521	528		10.1038/74999	http://dx.doi.org/10.1038/74999			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	309YB	10802707				2022-12-25	WOS:000086796200035
J	Anand, A; Chada, K				Anand, A; Chada, K			In vivo modulation of Hmgic reduces obesity	NATURE GENETICS			English	Article							MESENCHYMAL TUMORS; ADIPOSE-TISSUE; DNA-BINDING; EXPRESSION; MOUSE; GENE; PROTEIN; ENHANCEOSOME; DISRUPTION; PATHWAYS	The HMGI family of proteins consists of three members(1,2), HMGIC, HMGI and HMGI(Y), that function as architectural factors(3-5) and are essential components of the enhancesome(6,7) HMGIC is predominantly expressed in proliferating, undifferentiated mesenchymal cells and is not detected in adult tissues(8,9). It is disrupted and misexpressed in a number of mesenchymal tumour cell types(10-12), including fat-cell tumours(12) (lipomas), In addition Hmgic(-/-) mice have a deficiency in fat tissue(13), To study its role in adipogenesis and obesity, we examined Hmgic expression in the adipose tissue of adult, obese mice. Mice with a partial or complete deficiency of Hmgic resisted diet-induced obesity. Disruption of Hmgic caused a reduction in the obesity induced by leptin deficiency (Lep(Ob)/Lep(Ob)) in a gene-dose-dependent manner, Our studies implicate a role for HMGIC in fat-cell proliferation, indicating that it may be an adipose-specific target for the treatment of obesity.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Chada, K (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, Piscataway, NJ 08854 USA.				NATIONAL CANCER INSTITUTE [R01CA077929] Funding Source: NIH RePORTER; NCI NIH HHS [CA77929] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AILHAUD G, 1992, ANNU REV NUTR, V12, P207, DOI 10.1146/annurev.nu.12.070192.001231; ASHAR HR, 1995, CELL, V82, P57; BATES MARGARET W., 1955, AMER JOUR PHYSIOL, V180, P301; BENSON KF, 1994, GENET RES, V64, P27, DOI 10.1017/S0016672300032511; BUSTIN M, 1990, BIOCHIM BIOPHYS ACTA, V1049, P231, DOI 10.1016/0167-4781(90)90092-G; Carey M, 1998, CELL, V92, P5, DOI 10.1016/S0092-8674(00)80893-4; Cummings DE, 1996, NATURE, V382, P622, DOI 10.1038/382622a0; Flegal KM, 1998, INT J OBESITY, V22, P39, DOI 10.1038/sj.ijo.0800541; Flier JS, 1998, CELL, V92, P437, DOI 10.1016/S0092-8674(00)80937-X; Frankel WN, 1996, NAT GENET, V14, P371, DOI 10.1038/ng1296-371; GREEN MC, 1989, GENETIC VARIANTS STR; GROSSCHEDL R, 1994, TRENDS GENET, V10, P94, DOI 10.1016/0168-9525(94)90232-1; HERBERG L, 1977, METABOLISM, V26, P59, DOI 10.1016/0026-0495(77)90128-7; Hirning-Folz U, 1998, GENE CHROMOSOME CANC, V23, P350, DOI 10.1002/(SICI)1098-2264(199812)23:4<350::AID-GCC10>3.0.CO;2-E; JOHNSON PR, 1972, J LIPID RES, V13, P2; KLYDE BJ, 1979, J LIPID RES, V20, P705; Mantovani F, 1998, NUCLEIC ACIDS RES, V26, P1433, DOI 10.1093/nar/26.6.1433; PISUNYER FX, 1993, ANN INTERN MED, V119, P655, DOI 10.7326/0003-4819-119-7_Part_2-199310011-00006; REEVES R, 1991, P NATL ACAD SCI USA, V88, P1671, DOI 10.1073/pnas.88.5.1671; Rogalla P, 1996, AM J PATHOL, V149, P775; SCHOENMAKERS EFPM, 1995, NAT GENET, V10, P436, DOI 10.1038/ng0895-436; TAVTIGIAN SV, 1994, MOL BIOL CELL, V5, P375, DOI 10.1091/mbc.5.3.375; Thanos D, 1995, CELL, V83, P1091, DOI 10.1016/0092-8674(95)90136-1; Tkachenko A, 1997, CANCER RES, V57, P2276; WEST DB, 1992, AM J PHYSIOL, V262, pR1025, DOI 10.1152/ajpregu.1992.262.6.R1025; WOLFFE AP, 1994, SCIENCE, V264, P1100, DOI 10.1126/science.8178167; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0; Zhou X, 1998, Keio J Med, V47, P73; ZHOU XJ, 1995, NATURE, V376, P771, DOI 10.1038/376771a0	29	168	175	1	3	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	APR	2000	24	4					377	380		10.1038/74207	http://dx.doi.org/10.1038/74207			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	299HK	10742101				2022-12-25	WOS:000086192800016
J	Boute, N; Gribouval, O; Roselli, S; Benessy, F; Lee, H; Fuchshuber, A; Dahan, K; Gubler, MC; Niaudet, P; Antignac, C				Boute, N; Gribouval, O; Roselli, S; Benessy, F; Lee, H; Fuchshuber, A; Dahan, K; Gubler, MC; Niaudet, P; Antignac, C			NPHS2, encoding the glomerular protein podocin, is mutated in autosomal recessive steroid-resistant nephrotic syndrome	NATURE GENETICS			English	Article							INTEGRAL MEMBRANE-PROTEIN; FOCAL SEGMENTAL GLOMERULOSCLEROSIS; IN-SITU HYBRIDIZATION; MESSENGER-RNA; GENE; ALIGNMENT; SEQUENCES; MATRIX	Familial idiopathic nephrotic syndromes represent a heterogeneous group of kidney disorders, and include autosomal recessive steroid-resistant nephrotic syndrome, which is characterized by early childhood onset of proteinuria, rapid progression to end-stage renal disease and focal segmental glomerulosclerosis. A causative gene for this disease, NPHS2, was mapped to 1q25-31 and we report here its identification by positional cloning. NPHS2 is almost exclusively expressed in the podocytes of fetal and mature kidney glomeruli, and encodes a new integral membrane protein, podocin, belonging to the stomatin protein family. We found ten different NPHS2 mutations, comprising nonsense, frameshift and missense mutations, to segregate with the disease, demonstrating a crucial role for podocin in the function of the glomerular filtration barrier.	INSERM, U423, Paris, France; Univ Paris 05, Hop Necker Enfants Malad, Serv Nephrol Pediat, Paris, France; Univ Louvain, Sch Med, Ctr Human Genet, Brussels, Belgium	Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Universite Catholique Louvain; Cliniques Universitaires Saint-Luc; Universite Libre de Bruxelles; Vrije Universiteit Brussel	Antignac, C (corresponding author), INSERM, U423, Tour Lavoisier, Paris, France.		ANTIGNAC, Corinne/H-8945-2017; Gribouval, Olivier/A-7689-2015	ANTIGNAC, Corinne/0000-0002-9934-4940; Gribouval, Olivier/0000-0003-0238-8224; Gubler, Marie-Claire/0000-0002-3526-5661; roselli, severine/0000-0001-7896-9127				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Antonarakis SE, 1998, HUM MUTAT, V11, P1; Bairoch A, 1996, NUCLEIC ACIDS RES, V24, P189, DOI 10.1093/nar/24.1.189; Brandenberger AW, 1997, J CLIN ENDOCR METAB, V82, P3509, DOI 10.1210/jc.82.10.3509; Broyer M., 1998, OXFORD TXB CLIN NEPH, P493; CONNOLLY JO, 1995, QJM-MON J ASSOC PHYS, V88, P627; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; Engelman JA, 1999, J BIOL CHEM, V274, P32333, DOI 10.1074/jbc.274.45.32333; Fuchshuber A, 1996, LANCET, V347, P1050, DOI 10.1016/S0140-6736(96)90193-2; FUCHSHUBER A, 1995, HUM MOL GENET, V4, P2155, DOI 10.1093/hmg/4.11.2155; Heidet L, 1997, LAB INVEST, V76, P233; Holthofer H, 1999, AM J PATHOL, V155, P1681, DOI 10.1016/S0002-9440(10)65483-1; Holzman LB, 1999, KIDNEY INT, V56, P1481, DOI 10.1046/j.1523-1755.1999.00719.x; HUANG MX, 1995, NATURE, V378, P292, DOI 10.1038/378292a0; IOANNOU PA, 1994, NAT GENET, V6, P84, DOI 10.1038/ng0194-84; Kalatzis V, 1998, DEV DYNAM, V213, P486, DOI 10.1002/(SICI)1097-0177(199812)213:4<486::AID-AJA13>3.0.CO;2-L; Kaplan JM, 2000, NAT GENET, V24, P251, DOI 10.1038/73456; Kestila M, 1998, MOL CELL, V1, P575, DOI 10.1016/S1097-2765(00)80057-X; Kirsch KH, 1999, P NATL ACAD SCI USA, V96, P6211, DOI 10.1073/pnas.96.11.6211; Kozak M, 1996, MAMM GENOME, V7, P563, DOI 10.1007/s003359900171; Li BL, 1999, J BIOL CHEM, V274, P11060, DOI 10.1074/jbc.274.16.11060; Mannsfeldt AG, 1999, MOL CELL NEUROSCI, V13, P391, DOI 10.1006/mcne.1999.0761; Mathis BJ, 1998, KIDNEY INT, V53, P282, DOI 10.1046/j.1523-1755.1998.00828.x; NAKAI K, 1992, GENOMICS, V14, P897, DOI 10.1016/S0888-7543(05)80111-9; NOAKES PG, 1995, NAT GENET, V10, P400, DOI 10.1038/ng0895-400; OLSON JL, 1998, HEPTINSTALLS PATHOLO, P187; PARVING HH, 1992, KIDNEY INT, V41, P758, DOI 10.1038/ki.1992.118; PRESTRIDGE DS, 1995, J MOL BIOL, V249, P923, DOI 10.1006/jmbi.1995.0349; Ruotsalainen V, 1999, P NATL ACAD SCI USA, V96, P7962, DOI 10.1073/pnas.96.14.7962; SALZER U, 1993, BIOCHIM BIOPHYS ACTA, V1151, P149, DOI 10.1016/0005-2736(93)90098-K; Shih NY, 1999, SCIENCE, V286, P312, DOI 10.1126/science.286.5438.312; SIBONY M, 1995, LAB INVEST, V73, P586; Snyers L, 1999, FEBS LETT, V449, P101, DOI 10.1016/S0014-5793(99)00417-2; Snyers L, 1998, J BIOL CHEM, V273, P17221, DOI 10.1074/jbc.273.27.17221; STEWART GW, 1992, BLOOD, V79, P1593, DOI 10.1182/blood.V79.6.1593.bloodjournal7961593; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Town M, 1998, NAT GENET, V18, P319, DOI 10.1038/ng0498-319; TRASK BJ, 1991, SOMAT CELL MOLEC GEN, V17, P117, DOI 10.1007/BF01232970; VERANI RR, 1992, AM J KIDNEY DIS, V20, P629, DOI 10.1016/S0272-6386(12)70230-5; Winn MP, 1999, GENOMICS, V58, P113, DOI 10.1006/geno.1999.5828	40	1082	1173	2	43	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	APR	2000	24	4					349	354		10.1038/74166	http://dx.doi.org/10.1038/74166			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	299HK	10742096				2022-12-25	WOS:000086192800011
J	Anderson, RP; Degano, P; Godkin, AJ; Jewell, DP; Hill, AVS				Anderson, RP; Degano, P; Godkin, AJ; Jewell, DP; Hill, AVS			In vivo antigen challenge in celiac disease identifies a single transglutaminase-modified peptide as the dominant A-gliadin T-cell epitope	NATURE MEDICINE			English	Article							SEQUENCE-SPECIFIC PRIMERS; PCR-SSP; DEAMIDATION; TOXICITY; HLA-DQB1	Celiac disease (CD) is an increasingly diagnosed enteropathy (prevalence, 1:200-1:300)(1) that is induced by dietary exposure to wheat gliadins(2) (as well as related proteins in rye and barley) and is strongly associated with HLA-DQ2 (alpha 1*0501, beta 1*0201), which is present in over 90% of CD patients(3). Because a variety of gliadin peptides have been identified as epitopes for gliadin-specific T-cell clones(4-6) and as bioactive sequences in feeding studies and in ex vivo CD intestinal biopsy challenge(7-9), it has been unclear whether a 'dominant' T-cell epitope is associated with CD. Here, we used fresh peripheral blood lymphocytes from individual subjects undergoing shortterm antigen challenge and tissue transglutaminase-treated, overlapping synthetic peptides spanning A-gliadin to demonstrate a transient, disease-specific, DQ2-restricted, CD4 T-cell response to a single dominant epitope. Optimal gamma interferon release in an ELISPOT assay was elicited by a 17-amino-acid peptide corresponding to the partially deamidated peptide of A-gliadin amino acids 57-73 (Q65E). Consistent with earlier reports indicating that host tissue transglutaminase modification of gliadin enhances gliadin-specific CD T-cell responses(10), tissue transglutaminase specifically deamidated Q65 in the peptide of A-gliadin amino acids 56-75. Discovery of this dominant epitope may allow development of antigen-specific immunotherapy for CD.	Univ Oxford, John Radcliffe Hosp, Nuffield Dept Med, Inst Mol Med, Oxford OX3 9DU, England; Univ Oxford, John Radcliffe Hosp, Nuffield Dept Med, Gastroenterol Unit, Oxford OX3 9DU, England	University of Oxford; University of Oxford	Anderson, RP (corresponding author), Univ Oxford, John Radcliffe Hosp, Nuffield Dept Med, Inst Mol Med, Oxford OX3 9DU, England.		HILL, Adrian V>S>/C-1306-2008	Anderson, Robert/0000-0002-0764-7267; Godkin, Andrew/0000-0002-1910-7567				Bunce M, 1995, TISSUE ANTIGENS, V46, P355, DOI 10.1111/j.1399-0039.1995.tb03127.x; DERITIS G, 1988, GASTROENTEROLOGY, V94, P41, DOI 10.1016/0016-5085(88)90607-5; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; Gutgemann I, 1998, IMMUNITY, V8, P667, DOI 10.1016/S1074-7613(00)80571-3; Hin H, 1999, BMJ-BRIT MED J, V318, P164, DOI 10.1136/bmj.318.7177.164; KASARDA DD, 1984, P NATL ACAD SCI-BIOL, V81, P4712, DOI 10.1073/pnas.81.15.4712; KENDALL MJ, 1972, LANCET, V2, P1065; Lahat N, 1999, SCAND J IMMUNOL, V49, P441; LEHMANN PV, 1992, NATURE, V358, P155, DOI 10.1038/358155a0; MANTZARIS G, 1991, SCAND J GASTROENTERO, V26, P392, DOI 10.3109/00365529108996500; MAURI L, 1996, SCAND J GASTROENTERO, V31, P247; Molberg O, 1998, NAT MED, V4, P713, DOI 10.1038/nm0698-713; Molberg O, 1997, SCAND J IMMUNOL, V46, P103, DOI 10.1046/j.1365-3083.1997.d01-93.x; MOSKOPHIDIS D, 1993, NATURE, V362, P758, DOI 10.1038/362758a0; Mullighan CG, 1997, TISSUE ANTIGENS, V50, P688, DOI 10.1111/j.1399-0039.1997.tb02936.x; OLERUP O, 1993, TISSUE ANTIGENS, V41, P119, DOI 10.1111/j.1399-0039.1993.tb01991.x; Plebanski M, 1998, EUR J IMMUNOL, V28, P4345, DOI 10.1002/(SICI)1521-4141(199812)28:12&lt;4345::AID-IMMU4345&gt;3.0.CO;2-P; Sjostrom H, 1998, SCAND J IMMUNOL, V48, P111; SOLLID LM, 1993, GASTROENTEROLOGY, V105, P910, DOI 10.1016/0016-5085(93)90912-V; van de Wal Y, 1998, J IMMUNOL, V161, P1585; Vartdal F, 1996, EUR J IMMUNOL, V26, P2764, DOI 10.1002/eji.1830261132; WARD R, 1999, CODEX ALIMENTARIUS P	22	445	464	0	23	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAR	2000	6	3					337	342		10.1038/73200	http://dx.doi.org/10.1038/73200			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	288TL	10700238				2022-12-25	WOS:000085580500046
J	Meredith, GD; Sims, CE; Soughayer, JS; Allbritton, NL				Meredith, GD; Sims, CE; Soughayer, JS; Allbritton, NL			Measurement of kinase activation in single mammalian cells	NATURE BIOTECHNOLOGY			English	Article						kinase; capillary zone electrophoresis; peptide; laser-micropipette	DEPENDENT PROTEIN-KINASE; SERINE THREONINE PHOSPHATASES; LIGHT-CHAIN PHOSPHORYLATION; SUBSTRATE RECOGNITION; FIREFLY LUCIFERASE; CALCIUM SIGNALS; GENE-EXPRESSION; MAST-CELLS; MYOSIN-II; PEPTIDE	We demonstrate a new method for the simultaneous measurement of the activation of key regulatory enzymes within single cells. To illustrate the capabilities of the technique, the activation of protein kinase C (PKC), protein kinase A (PKA), calcium-calmodulin activated kinase II (CamKII), and cdc2 protein kinase (cdc2K) was measured in response to both pharmacological or physiological stimuli. This assay strategy should be applicable to a broad range of intracellular enzymes, including phosphatases, proteases, nucleases, and other kinases.	Univ Calif Irvine, Dept Physiol & Biophys, Irvine, CA 92697 USA	University of California System; University of California Irvine	Allbritton, NL (corresponding author), Univ Calif Irvine, Dept Physiol & Biophys, Irvine, CA 92697 USA.	nlallbri@uci.edu			NCI NIH HHS [CA09054, R01 CA78858] Funding Source: Medline; NIAID NIH HHS [KO8AI01513] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA078858] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K08AI001513] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALLBRITTON NL, 1994, P NATL ACAD SCI USA, V91, P12458, DOI 10.1073/pnas.91.26.12458; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BRIDGES AJ, 1997, ENCY CANC, P1314; CHEN SJ, 1993, BIOCHEMISTRY-US, V32, P1032, DOI 10.1021/bi00055a006; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; COLBRAN JL, 1992, BIOCHEM CELL BIOL, V70, P1277, DOI 10.1139/o92-174; Dolmetsch RE, 1998, NATURE, V392, P933, DOI 10.1038/31960; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; FISHMAN HA, 1994, ANAL CHEM, V66, P2318, DOI 10.1021/ac00086a018; HANSON PI, 1989, NEURON, V3, P59, DOI 10.1016/0896-6273(89)90115-3; HEASLEY LE, 1989, MOL PHARMACOL, V35, P331; Higashi H, 1997, FEBS LETT, V414, P55, DOI 10.1016/S0014-5793(97)00970-8; HOUSE C, 1987, SCIENCE, V238, P1726, DOI 10.1126/science.3686012; Johnson LN, 1998, FEBS LETT, V430, P1, DOI 10.1016/S0014-5793(98)00606-1; KARIN M, 1992, FASEB J, V6, P2581, DOI 10.1096/fasebj.6.8.1317309; Kim TD, 1997, J BIOL CHEM, V272, P31225, DOI 10.1074/jbc.272.50.31225; Kinet JP, 1999, ANNU REV IMMUNOL, V17, P931, DOI 10.1146/annurev.immunol.17.1.931; Kitano T, 1986, Methods Enzymol, V124, P349; KLANN E, 1993, P NATL ACAD SCI USA, V90, P8337, DOI 10.1073/pnas.90.18.8337; Klee CB, 1998, J BIOL CHEM, V273, P13367, DOI 10.1074/jbc.273.22.13367; Kuchtey J, 1996, J CELL PHYSIOL, V166, P643, DOI 10.1002/(SICI)1097-4652(199603)166:3<643::AID-JCP20>3.0.CO;2-6; Lee CL, 1999, NAT BIOTECHNOL, V17, P759, DOI 10.1038/11691; LORCA T, 1993, NATURE, V366, P270, DOI 10.1038/366270a0; LUTZ MP, 1994, ANAL BIOCHEM, V220, P268, DOI 10.1006/abio.1994.1337; McNeil PL, 1997, J CELL BIOL, V137, P1, DOI 10.1083/jcb.137.1.1; MUMBY MC, 1993, PHYSIOL REV, V73, P673, DOI 10.1152/physrev.1993.73.4.673; NEGULESCU PA, 1994, P NATL ACAD SCI USA, V91, P2873, DOI 10.1073/pnas.91.7.2873; Ng T, 1999, SCIENCE, V283, P2085, DOI 10.1126/science.283.5410.2085; Oancea E, 1998, CELL, V95, P307, DOI 10.1016/S0092-8674(00)81763-8; OSIPCHUK Y, 1992, NATURE, V359, P241, DOI 10.1038/359241a0; PANTONEY SL, 1997, HDB CAPILLARY ELECTR, P380; POST PL, 1994, J BIOL CHEM, V269, P12880; POST PL, 1995, MOL BIOL CELL, V6, P1755, DOI 10.1091/mbc.6.12.1755; SALANEWBY G, 1992, FEBS LETT, V307, P241, DOI 10.1016/0014-5793(92)80776-D; Sims CE, 1998, ANAL CHEM, V70, P4570, DOI 10.1021/ac9802269; SRINIVASAN J, 1995, BIOCHEM J, V309, P927, DOI 10.1042/bj3090927; Togo T, 1999, J CELL SCI, V112, P719; WALTER G, 1993, BIOCHIM BIOPHYS ACTA, V1155, P207, DOI 10.1016/0304-419X(93)90005-W; Waud JP, 1996, BBA-PROTEIN STRUCT M, V1292, P89, DOI 10.1016/0167-4838(95)00199-9; Weinberger R., 1993, PRACTICAL CAPILLARY; WOODGETT JR, 1986, EUR J BIOCHEM, V161, P177, DOI 10.1111/j.1432-1033.1986.tb10139.x; ZHOU SY, 1994, CURR BIOL, V4, P973, DOI 10.1016/S0960-9822(00)00221-9	42	115	123	0	19	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	MAR	2000	18	3					309	312		10.1038/73760	http://dx.doi.org/10.1038/73760			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	292AC	10700147				2022-12-25	WOS:000085771100029
J	Shirasawa, S; Arata, A; Onimaru, H; Roth, KA; Brown, GA; Horning, S; Arata, S; Okumura, K; Sasazuki, T; Korsmeyer, SJ				Shirasawa, S; Arata, A; Onimaru, H; Roth, KA; Brown, GA; Horning, S; Arata, S; Okumura, K; Sasazuki, T; Korsmeyer, SJ			Rnx deficiency results in congenital central hypoventilation	NATURE GENETICS			English	Article							HOMEOBOX GENE-EXPRESSION; SPINAL CORD PREPARATIONS; ONDINES-CURSE; DEVELOPMENTAL EXPRESSION; NEWBORN RATS; CHICK-EMBRYO; HOX11 GENE; BRAIN; MEDULLA; HINDBRAIN	The genes Tlx1 (Hox11), Enx (Hox11L1, Tlx-2) and Rnx (Hox11L2, Tlx-3) constitute a family of orphan homeobox genes(1-10). In situ hybridization has revealed considerable overlap in their expression within the nervous system, but Rnx is singularly expressed in the developing dorsal and ventral region of the medulla oblongata. Tlx1-deficient and Enx-deficient mice display phenotypes in tissues where the mutated gene is singularly expressed, resulting in asplenogenesis(3,4) and hyperganglionic megacolon(8), respectively. To determine the developmental role of Rnx. we disrupted the locus in mouse embryonic stem (ES) cells. Rnx-deficient mice developed to term, but all died within 24 hours after birth from a central respiratory failure. The electromyographic activity of intercostal muscles coupled with the C4 ventral root activity assessed in a medulla-spinal cord preparation revealed a high respiratory rate with short inspiratory duration and frequent apnea. Furthermore, a coordinate pattern existed between the abnormal activity of inspiratory neurons in the ventrolateral medulla and C4 motorneuron output, indicating a central respiratory defect in Rnx(-/-) mice. Thus, Rnx is critical for the development of the ventral medullary respiratory centre and its deficiency results in a syndrome resembling congenital central hypoventilation.	Washington Univ, Sch Med, Dept Med, Howard Hughes Med Inst, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Pathol, Howard Hughes Med Inst, St Louis, MO 63110 USA; Kyushu Univ, Med Inst Bioregulat, Dept Genet, Fukuoka 812, Japan; Tokyo Metropolitan Inst Neurosci, Dept Neurobiol, Tokyo 138, Japan; Showa Univ, Sch Med, Dept Physiol, Tokyo 142, Japan; Showa Univ, Ctr Biotechnol, Tokyo 142, Japan; Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA	Howard Hughes Medical Institute; Washington University (WUSTL); Howard Hughes Medical Institute; Washington University (WUSTL); Kyushu University; Tokyo Metropolitan Institute for Neuroscience; Tokyo Metropolitan Institute of Medical Science; Showa University; Showa University; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Korsmeyer, SJ (corresponding author), Washington Univ, Sch Med, Dept Med, Howard Hughes Med Inst, St Louis, MO 63110 USA.			Arata, Akiko/0000-0001-7418-8294; Roth, Kevin/0000-0002-0643-995X				Amiel J, 1998, AM J HUM GENET, V62, P715, DOI 10.1086/301759; ARATA A, 1990, BRAIN RES BULL, V24, P599, DOI 10.1016/0361-9230(90)90165-V; BIANCHI AL, 1995, PHYSIOL REV, V75, P1, DOI 10.1152/physrev.1995.75.1.1; Bolk S, 1996, NAT GENET, V13, P395, DOI 10.1038/ng0896-395; DEAR TN, 1993, P NATL ACAD SCI USA, V90, P4431, DOI 10.1073/pnas.90.10.4431; DEAR TN, 1995, DEVELOPMENT, V121, P2909; HATANO M, 1991, SCIENCE, V253, P79, DOI 10.1126/science.1676542; Jacquin TD, 1996, NEURON, V17, P747, DOI 10.1016/S0896-6273(00)80206-8; KENNEDY MA, 1991, P NATL ACAD SCI USA, V88, P8900, DOI 10.1073/pnas.88.20.8900; Logan C, 1998, J NEUROSCI, V18, P5389, DOI 10.1523/JNEUROSCI.18-14-05389.1998; LUMSDEN A, 1994, DEVELOPMENT, V120, P1581; Masson N, 1998, MOL CELL BIOL, V18, P3502, DOI 10.1128/MCB.18.6.3502; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; MELLINS RB, 1970, MEDICINE, V49, P487, DOI 10.1097/00005792-197011000-00003; NAKAHARA S, 1995, J PEDIATR SURG, V30, P1481, DOI 10.1016/0022-3468(95)90413-1; ONIMARU H, 1992, PFLUG ARCH EUR J PHY, V420, P399, DOI 10.1007/BF00374476; ONIMARU H, 1995, NEUROSCI RES, V21, P183, DOI 10.1016/0168-0102(94)00863-B; ONIMARU H, 1988, BRAIN RES, V445, P314, DOI 10.1016/0006-8993(88)91194-8; RAJU K, 1993, MECH DEVELOP, V44, P51, DOI 10.1016/0925-4773(93)90016-Q; RICKLING JC, 1996, J NEUROPHYSIOL, V75, P795; ROBEL P, 1994, TRENDS ENDOCRIN MET, V5, P1, DOI 10.1016/1043-2760(94)90114-7; ROBERTS CWM, 1995, AM J PATHOL, V146, P1089; RUBENSTEIN JLR, 1994, CURR TOP DEV BIOL, V29, P1, DOI 10.1016/S0070-2153(08)60546-3; Shirasawa S, 1997, NAT MED, V3, P646, DOI 10.1038/nm0697-646; SUZUE T, 1984, J PHYSIOL-LONDON, V354, P173, DOI 10.1113/jphysiol.1984.sp015370; VERLOES A, 1993, EUR J PEDIATR, V152, P75, DOI 10.1007/BF02072522; WEESEMAYER DE, 1993, AM J MED GENET, V47, P360, DOI 10.1002/ajmg.1320470313	27	131	138	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAR	2000	24	3					287	290		10.1038/73516	http://dx.doi.org/10.1038/73516			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	288XW	10700185				2022-12-25	WOS:000085590600022
J	Wang, L; Ho, CL; Sun, DM; Liem, RKH; Brown, A				Wang, L; Ho, CL; Sun, DM; Liem, RKH; Brown, A			Rapid movement of axonal neurofilaments interrupted by prolonged pauses	NATURE CELL BIOLOGY			English	Article							NEURONAL INTERMEDIATE FILAMENTS; TRANSPORT MODEL; SLOW TRANSPORT; GROWING AXONS; FROG NEURONS; MICROTUBULES; TUBULIN; CELLS; MECHANISMS; ELONGATION	Axonal cytoskeletal and cytosolic proteins are synthesized in the neuronal cell body and transported along axons by slow axonal transport, but attempts to observe this movement directly in living cells have yielded conflicting results. Here we report the direct observation of the axonal transport of neurofilament protein tagged with green fluorescent protein in cultured nerve cells. Live-cell imaging of naturally occurring gaps in the axonal neurofilament array reveals rapid, intermittent and highly asynchronous movement of fluorescent neurofilaments. The movement is bidirectional, but predominantly anterograde. Our data indicate that the slow rate of slow axonal transport may be the result of rapid movements interrupted by prolonged pauses.	Ohio Univ, Neurosci Programme, Dept Biol Sci, Athens, OH 45701 USA; Columbia Univ Coll Phys & Surg, Dept Pathol, New York, NY 10032 USA	University System of Ohio; Ohio University; Columbia University	Brown, A (corresponding author), Ohio Univ, Neurosci Programme, Dept Biol Sci, Athens, OH 45701 USA.			Brown, Anthony/0000-0003-2295-2929	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS038526] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS038526-02, R01 NS038526] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Baas PW, 1997, TRENDS CELL BIOL, V7, P380, DOI 10.1016/S0962-8924(97)01148-3; BLACK MM, 1986, J NEUROSCI, V6, P1004; Bray D, 1997, TRENDS CELL BIOL, V7, P379, DOI 10.1016/S0962-8924(97)01134-3; BROWN A, 1992, J CELL BIOL, V119, P867, DOI 10.1083/jcb.119.4.867; Brown A, 1997, CELL MOTIL CYTOSKEL, V38, P133, DOI 10.1002/(SICI)1097-0169(1997)38:2<133::AID-CM3>3.3.CO;2-C; Chang SH, 1999, NAT CELL BIOL, V1, P399, DOI 10.1038/15629; Chang SH, 1998, J NEUROSCI, V18, P821; CHING GY, 1993, J CELL BIOL, V122, P1323, DOI 10.1083/jcb.122.6.1323; Dent EW, 1999, J NEUROSCI, V19, P8894, DOI 10.1523/JNEUROSCI.19-20-08894.1999; GARCIA I, 1992, SCIENCE, V258, P302, DOI 10.1126/science.1411528; GEORGE EB, 1988, CELL MOTIL CYTOSKEL, V9, P48, DOI 10.1002/cm.970090106; Hirokawa N, 1997, TRENDS CELL BIOL, V7, P384, DOI 10.1016/S0962-8924(97)01133-1; KEITH CH, 1987, SCIENCE, V235, P337, DOI 10.1126/science.2432662; Koehnle TJ, 1999, J CELL BIOL, V144, P447, DOI 10.1083/jcb.144.3.447; LASEK RJ, 1992, J CELL BIOL, V117, P607, DOI 10.1083/jcb.117.3.607; LASEK RJ, 1984, J CELL BIOL, V99, pS212, DOI 10.1083/jcb.99.1.212s; LASEK RJ, 1993, BRAIN RES, V616, P58, DOI 10.1016/0006-8993(93)90192-P; LASEK RJ, 1976, CELL MOTILITY, P1021; LEE MK, 1993, J CELL BIOL, V122, P1337, DOI 10.1083/jcb.122.6.1337; LIM SS, 1989, J CELL BIOL, V109, P253, DOI 10.1083/jcb.109.1.253; LIM SS, 1990, J CELL BIOL, V111, P123, DOI 10.1083/jcb.111.1.123; MIKHAILOV AV, 1995, CELL MOTIL CYTOSKEL, V32, P173, DOI 10.1002/cm.970320303; NAPOLITANO EW, 1987, J NEUROSCI, V7, P2590; OHARA O, 1993, J CELL BIOL, V121, P387, DOI 10.1083/jcb.121.2.387; OKABE S, 1992, J CELL BIOL, V117, P105, DOI 10.1083/jcb.117.1.105; OKABE S, 1993, J CELL BIOL, V120, P1177, DOI 10.1083/jcb.120.5.1177; OKABE S, 1990, NATURE, V343, P479, DOI 10.1038/343479a0; OKABE S, 1993, J CELL BIOL, V121, P375, DOI 10.1083/jcb.121.2.375; REINSCH SS, 1991, J CELL BIOL, V115, P365, DOI 10.1083/jcb.115.2.365; SABRY J, 1995, NEURON, V14, P1247, DOI 10.1016/0896-6273(95)90271-6; TAKEDA S, 1995, NEURON, V14, P1257, DOI 10.1016/0896-6273(95)90272-4; TAKEDA S, 1994, J CELL BIOL, V127, P173, DOI 10.1083/jcb.127.1.173; TANAKA EM, 1991, J CELL BIOL, V115, P345, DOI 10.1083/jcb.115.2.345; Yabe JT, 1999, J CELL SCI, V112, P3799; Zhu QZ, 1997, EXP NEUROL, V148, P299, DOI 10.1006/exnr.1997.6654	35	265	265	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	MAR	2000	2	3					137	141		10.1038/35004008	http://dx.doi.org/10.1038/35004008			5	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	292AE	10707083				2022-12-25	WOS:000085771300012
J	Guo, N; Puhlev, I; Brown, DR; Mansbridge, J; Levine, F				Guo, N; Puhlev, I; Brown, DR; Mansbridge, J; Levine, F			Trehalose expression confers desiccation tolerance on human cells	NATURE BIOTECHNOLOGY			English	Article						trehalose; adenovirus vector; desiccation tolerance	PROTEINS; YEAST; ANHYDROBIOSIS	Many organisms that withstand desiccation express the disaccharide trehalose. We have now expressed the otsA and otsB genes of Escherichia coli, which encode trehalose biosynthetic enzymes, in human primary fibroblasts using a recombinant adenovirus vector. Infected cells produced increased amounts of trehalose with increasing multiplicity of infection (MOI). Human primary fibroblasts expressing trehalose could be maintained in the dry state for up to five days. Fourier transform infrared spectroscopy indicated that dry, but viable, human cells contained no detectable water. This study shows that mammalian cells can be engineered to retain viability in the absence of water.	Univ Calif San Diego, Ctr Mol Genet, Sch Med, La Jolla, CA 92093 USA; SW Coll, Dept Chem, Chula Vista, CA 91910 USA; Adv Tissue Sci Inc, La Jolla, CA 92037 USA	University of California System; University of California San Diego	Levine, F (corresponding author), Univ Calif San Diego, Ctr Mol Genet, Sch Med, La Jolla, CA 92093 USA.	flevine@ucsd.edu	Levine, Fred/L-2693-2013	Levine, Fred/0000-0002-7336-2526				Allison SD, 1999, ARCH BIOCHEM BIOPHYS, V365, P289, DOI 10.1006/abbi.1999.1175; ARAKAWA T, 1990, CRYOBIOLOGY, V27, P401, DOI 10.1016/0011-2240(90)90017-X; Beattie GM, 1997, DIABETES, V46, P519, DOI 10.2337/diabetes.46.3.519; BERKNER KL, 1992, CURR TOP MICROBIOL, V158, P39; CROWE JH, 1987, BIOCHEM J, V242, P1, DOI 10.1042/bj2420001; Crowe JH, 1998, ANNU REV PHYSIOL, V60, P73, DOI 10.1146/annurev.physiol.60.1.73; CROWE JH, 1992, ANNU REV PHYSIOL, V54, P579, DOI 10.1146/annurev.ph.54.030192.003051; CROWE LM, 1992, DEV BIOLOGICALS, V74, P285; HIRATA T, 1994, SURGERY, V115, P102; KAASEN I, 1994, GENE, V145, P9, DOI 10.1016/0378-1119(94)90316-6; Leibowitz G, 1999, DIABETES, V48, P745, DOI 10.2337/diabetes.48.4.745; LESLIE SB, 1995, APPL ENVIRON MICROB, V61, P3592, DOI 10.1128/AEM.61.10.3592-3597.1995; LESLIE SB, 1994, BBA-BIOMEMBRANES, V1192, P7, DOI 10.1016/0005-2736(94)90136-8; Naughton G, 1997, ARTIF ORGANS, V21, P1203; PELLETIER J, 1988, NATURE, V334, P320, DOI 10.1038/334320a0; Singer MA, 1998, MOL CELL, V1, P639, DOI 10.1016/S1097-2765(00)80064-7; SLADE L, 1991, ADV EXP MED BIOL, P29; SPESSOT R, 1989, VIROLOGY, V168, P378, DOI 10.1016/0042-6822(89)90279-1; Sun WQ, 1996, BIOPHYS J, V70, P1769, DOI 10.1016/S0006-3495(96)79740-0; THEVELEIN JM, 1995, TRENDS BIOCHEM SCI, V20, P3, DOI 10.1016/S0968-0004(00)88938-0; WIEMKEN A, 1990, ANTON LEEUW INT J G, V58, P209, DOI 10.1007/BF00548935	21	301	331	2	42	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	FEB	2000	18	2					168	171		10.1038/72616	http://dx.doi.org/10.1038/72616			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	281FH	10657122				2022-12-25	WOS:000085146900038
J	Zuber, J; Tchernitsa, OI; Hinzmann, B; Schmitz, AC; Grips, M; Hellriegel, M; Sers, C; Rosenthal, A; Schafer, R				Zuber, J; Tchernitsa, OI; Hinzmann, B; Schmitz, AC; Grips, M; Hellriegel, M; Sers, C; Rosenthal, A; Schafer, R			A genome-wide survey of RAS transformation targets	NATURE GENETICS			English	Article							HA-RAS; SIGNAL-TRANSDUCTION; GENE-EXPRESSION; DOWN-REGULATION; CANCER-CELLS; INSTABILITY; FIBROBLASTS; SUPPRESSION; ACTIVATION; H-REV107	An important aspect of multi-step tumorigenesis is the mutational activation of genes of the RAS family, particularly in sporadic cancers of the pancreas, colon, lung and myeloid system(1). RAS genes encode small GTP-binding proteins that affect gene expression in a global way by acting as major switches in signal transduction processes, coupling extracellular signals with transcription factors(2-4). Oncogenic farms of RAS are locked in their active state and transduce signals essential for transformation, angiogenesis, invasion and metastasis via downstream pathways involving the RAF/MEK/ERK cascade of cytoplasmic kinases, the small GTP-binding proteins RAC and RHO, phosphatidylinositol 3-kinase and others(5,6). We have used subtractive suppression hybridization (SSH), a PCR-based cDNA subtraction technique(7), to contrast differential gene expression profiles in immortalized, non-tumorigenic rat embryo fibroblasts and in HRAS-transformed cells. Sequence and expression analysis of more than 1,200 subtracted cDNA fragments revealed transcriptional stimulation or repression of 104 ESTs, 45 navel sequences and 244 known genes in HRAS-transformed cells compared with normal cells. Furthermore, we identified common and distinct targets in cells transformed by mutant HRAS, KRAS and NRAS, as well as 61 putative target genes controlled by the RAF/MEK/ERK pathway in reverted cells treated with the MEK-specific inhibitor PD 98059.	Humboldt Univ, Charite, Inst Pathol, Lab Mol Tumour Pathol, D-10117 Berlin, Germany; Gesell Genomforsch mbH, MetaGen, D-14195 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Schafer, R (corresponding author), Humboldt Univ, Charite, Inst Pathol, Lab Mol Tumour Pathol, D-10117 Berlin, Germany.	reinhold.schaefer@charite.de	Schäfer, Reinhold/AAB-5110-2021; Sers, Christine/B-5438-2010; Zuber, Johannes/E-7517-2011	Zuber, Johannes/0000-0001-8810-6835; Sers, christine/0000-0002-6219-1514; Schafer, Reinhold/0000-0001-7952-2124				ABDELLATIF M, 1994, J BIOL CHEM, V269, P15423; ADAMS AT, 1985, EXP CELL BIOL, V53, P181; AUGENLICHT LH, 1987, CANCER RES, V47, P6017; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOS JL, 1989, CANCER RES, V49, P4682; Chang DD, 1998, ONCOGENE, V16, P1921, DOI 10.1038/sj.onc.1201715; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARK GJ, 1995, BREAST CANCER RES TR, V35, P133, DOI 10.1007/BF00694753; DECLUE JE, 1992, CELL, V69, P265, DOI 10.1016/0092-8674(92)90407-4; DENKO N, 1995, SOMAT CELL MOLEC GEN, V21, P241, DOI 10.1007/BF02255779; DENKO NC, 1994, P NATL ACAD SCI USA, V91, P5124, DOI 10.1073/pnas.91.11.5124; Diatchenko L, 1996, P NATL ACAD SCI USA, V93, P6025, DOI 10.1073/pnas.93.12.6025; DOWNWARD J, 1998, MOL B INT U, V3, P171; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Fambrough D, 1999, CELL, V97, P727, DOI 10.1016/S0092-8674(00)80785-0; GRIEGEL S, 1986, INT J CANCER, V38, P697, DOI 10.1002/ijc.2910380513; GROUDINE M, 1980, P NATL ACAD SCI-BIOL, V77, P5351, DOI 10.1073/pnas.77.9.5351; Husmann K, 1998, ONCOGENE, V17, P1305, DOI 10.1038/sj.onc.1202060; Iyer VR, 1999, SCIENCE, V283, P83, DOI 10.1126/science.283.5398.83; JUNG JU, 1995, MOL CELL BIOL, V15, P6506; KhosraviFar R, 1998, ADV CANCER RES, V72, P57; LIU HS, 1992, CANCER RES, V52, P983; Malumbres M, 1998, FRONT BIOSCI-LANDMRK, V3, P887; Patton SE, 1998, CANCER RES, V58, P2253; PUIL L, 1994, EMBO J, V13, P764, DOI 10.1002/j.1460-2075.1994.tb06319.x; QUADE K, 1979, VIROLOGY, V98, P461, DOI 10.1016/0042-6822(79)90569-5; Sager R, 1997, P NATL ACAD SCI USA, V94, P952, DOI 10.1073/pnas.94.3.952; Sers C, 1997, J CELL BIOL, V136, P935, DOI 10.1083/jcb.136.4.935; SOUYRI M, 1987, VIROLOGY, V158, P69, DOI 10.1016/0042-6822(87)90239-X; vonStein OD, 1997, NUCLEIC ACIDS RES, V25, P2598, DOI 10.1093/nar/25.13.2598; Zhang L, 1997, SCIENCE, V276, P1268, DOI 10.1126/science.276.5316.1268	31	228	242	0	16	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	FEB	2000	24	2					144	152		10.1038/72799	http://dx.doi.org/10.1038/72799			9	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	280LQ	10655059				2022-12-25	WOS:000085104600014
J	Al-Kaff, NS; Kreike, MM; Covey, SN; Pitcher, R; Page, AM; Dale, PJ				Al-Kaff, NS; Kreike, MM; Covey, SN; Pitcher, R; Page, AM; Dale, PJ			Plants rendered herbicide-susceptible by cauliflower mosaic virus-elicited suppression of a 35S promoter-regulated transgene	NATURE BIOTECHNOLOGY			English	Article						35S promoter; oilseed rape; transgene expression; CaMV; herbicide tolerance gene	MULTIPLICATION CYCLE; TRANSCRIPTION; RESISTANCE; EXPRESSION; INFECTION; PATHOGEN; DISEASES; GENES	Crop plants genetically modified for herbicide tolerance were some of the first to be released into the environment, Frequently, the cauliflower mosaic virus (CaMV) 35S promoter is used to drive expression of the herbicide tolerance transgene. We analyzed the response to CaMV infection of a transgenic oilseed rape line containing the bialaphos tolerance gene (BAR) from Streptomyces hygroscopicus, regulated by the 35S promoter. Oilseed rape is susceptible to CaMV, but plants recover from infection. CaMV infection altered the expression of the herbicide tolerance gene such that plants became susceptible to the herbicide, The effect on transgene expression differed in infections with viral pathogenic variants typical of those found in natural situations worldwide. Susceptibility to the herbicide was most likely a result of transcriptional gene silencing of the transgene, Our results show that transgene phenotypes can be modified by pathogen invasion.	John Innes Ctr, Norwich NR4 7UH, Norfolk, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center	Al-Kaff, NS (corresponding author), John Innes Ctr, Norwich Res Pk,Colney, Norwich NR4 7UH, Norfolk, England.	alkaff@bbsrc.ac.uk						Al-Kaff NS, 1998, SCIENCE, V279, P2113, DOI 10.1126/science.279.5359.2113; ALKAFF NS, 1995, PLANT PATHOL, V44, P516, DOI 10.1111/j.1365-3059.1995.tb01674.x; Baulcombe DC, 1999, CURR BIOL, V9, pR599, DOI 10.1016/S0960-9822(99)80383-2; BENFEY PN, 1990, SCIENCE, V250, P959, DOI 10.1126/science.250.4983.959; COVEY SN, 1981, NUCLEIC ACIDS RES, V9, P6735, DOI 10.1093/nar/9.24.6735; COVEY SN, 1990, P NATL ACAD SCI USA, V87, P1633, DOI 10.1073/pnas.87.5.1633; Covey SN, 1997, NATURE, V385, P781, DOI 10.1038/385781a0; DEBLOCK M, 1987, EMBO J, V6, P2513, DOI 10.1002/j.1460-2075.1987.tb02537.x; HARDWICK NV, 1994, PLANT PATHOL, V43, P1045, DOI 10.1111/j.1365-3059.1994.tb01656.x; HULL R, 1980, VIROLOGY, V100, P76, DOI 10.1016/0042-6822(80)90553-X; Jones Jonathan D. G., 1992, Transgenic Research, V1, P285, DOI 10.1007/BF02525170; Kooter JM, 1999, TRENDS PLANT SCI, V4, P340, DOI 10.1016/S1360-1385(99)01467-3; ODELL JT, 1985, NATURE, V313, P810, DOI 10.1038/313810a0; QIN XF, 1994, PLANT CELL, V6, P863, DOI 10.1105/tpc.6.6.863; Ratcliff F, 1997, SCIENCE, V276, P1558, DOI 10.1126/science.276.5318.1558; Raybould AF, 1999, NEW PHYTOL, V141, P265, DOI 10.1046/j.1469-8137.1999.00339.x; SAUNDERS K, 1990, J GEN VIROL, V71, P1641, DOI 10.1099/0022-1317-71-8-1641; Selker EU, 1999, CELL, V97, P157, DOI 10.1016/S0092-8674(00)80725-4; SHEPHERD RJ, 1979, ANNU REV PLANT PHYS, V30, P405, DOI 10.1146/annurev.pp.30.060179.002201; TOMLINSON JA, 1987, ANN APPL BIOL, V110, P661, DOI 10.1111/j.1744-7348.1987.tb04187.x; Vaucheret H, 1998, PLANT J, V16, P651, DOI 10.1046/j.1365-313x.1998.00337.x; Waterhouse PM, 1999, TRENDS PLANT SCI, V4, P452, DOI 10.1016/S1360-1385(99)01493-4	22	45	83	1	9	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	SEP	2000	18	9					995	999		10.1038/79501	http://dx.doi.org/10.1038/79501			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	350AN	10973223				2022-12-25	WOS:000089078300031
J	Bonday, ZQ; Dhanasekaran, S; Rangarajan, PN; Padmanaban, G				Bonday, ZQ; Dhanasekaran, S; Rangarajan, PN; Padmanaban, G			Import of host delta-aminolevulinate dehydratase into the malarial parasite: Identification of a new drug target	NATURE MEDICINE			English	Article							PLASMODIUM-FALCIPARUM; INFECTED ERYTHROCYTES; PURIFICATION; BIOSYNTHESIS; PROTEINS; VACUOLE; CELL; DUCT	The parasite Plasmodium berghei imports the enzyme delta -aminolevulinate dehydratase (ALAD), and perhaps the subsequent enzymes of the pathway from the host red blood cell to sustain heme synthesis. Here we have studied the mechanism of this import. A 65-kDa protein on the P. berghei membrane specifically bound to mouse red blood cell ALAD, and a 93-amino-acid fragment (ALAD-Delta NC) of the host erythrocyte ALAD was able to compete with the full-length enzyme for binding to the P. berghei membrane. ALAD-Delta NC was taken up by the infected red blood cell when added to a culture of P. falciparum and this led to a substantial decrease in ALAD protein and enzyme activity and, subsequently, heme synthesis in the parasite, resulting in its death.	Indian Inst Sci, Dept Biochem, Bangalore 560012, Karnataka, India	Indian Institute of Science (IISC) - Bangalore	Padmanaban, G (corresponding author), Indian Inst Sci, Dept Biochem, Bangalore 560012, Karnataka, India.	geepee@biochem.iisc.ernet.in	Rangarajan, Pundi/A-7365-2009	Rangarajan, Pundi/0000-0002-6536-9891				ANDERSON PM, 1979, J BIOL CHEM, V254, P6924; Bonday ZQ, 1997, J BIOL CHEM, V272, P21839, DOI 10.1074/jbc.272.35.21839; GOLDBERG DE, 1990, P NATL ACAD SCI USA, V87, P2931, DOI 10.1073/pnas.87.8.2931; HALDAR K, 1994, PARASITOL TODAY, V10, P393, DOI 10.1016/0169-4758(94)90230-5; Hibbs AR, 1997, EUR J CELL BIOL, V72, P182; HIBBS AR, 1994, EXP PARASITOL, V79, P260, DOI 10.1006/expr.1994.1089; JENSEN JB, 1977, J PARASITOL, V63, P883, DOI 10.2307/3279900; Le Bonniec S, 1999, J BIOL CHEM, V274, P14218, DOI 10.1074/jbc.274.20.14218; Lingelbach K, 1998, J CELL SCI, V111, P1467; MAUZERALL D, 1956, J BIOL CHEM, V219, P435; POUVELLE B, 1994, MOL BIOCHEM PARASIT, V66, P83, DOI 10.1016/0166-6851(94)90038-8; REECE RJ, 1993, GENE, V126, P105, DOI 10.1016/0378-1119(93)90596-U; SANTIYANONT R, 1985, PARASITE IDENTIFICAT, P413; SCHMITT J, 1993, MOL BIOL REP, V18, P223, DOI 10.1007/BF01674434; SLATER AFG, 1992, EXP PARASITOL, V74, P362, DOI 10.1016/0014-4894(92)90162-4; SOKHANEKOVA TL, 1984, MED PARASITOL MOSC, V1, P46; Sullivan DJ, 1996, SCIENCE, V271, P219, DOI 10.1126/science.271.5246.219; SUROLIA N, 1992, BIOCHEM BIOPH RES CO, V187, P744, DOI 10.1016/0006-291X(92)91258-R; SUROLIA N, 1991, P NATL ACAD SCI USA, V88, P4786, DOI 10.1073/pnas.88.11.4786; TRAGER W, 1995, PARASITOL TODAY, V11, P69, DOI 10.1016/0169-4758(95)80121-9; Wilson CM, 1996, MOL BIOCHEM PARASIT, V79, P135, DOI 10.1016/0166-6851(96)02690-4	21	70	70	0	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	AUG	2000	6	8					898	903		10.1038/78659	http://dx.doi.org/10.1038/78659			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	376TX	10932227				2022-12-25	WOS:000165473800033
J	Mann, V; Harker, M; Pecker, I; Hirschberg, J				Mann, V; Harker, M; Pecker, I; Hirschberg, J			Metabolic engineering of astaxanthin production in tobacco flowers	NATURE BIOTECHNOLOGY			English	Article						chromoplasts; plant biotechnology; isoprenoids; nectary; transit peptide; protein import; cartenoid biosynthesis	CAROTENOID BIOSYNTHESIS; ESCHERICHIA-COLI; BETA-CAROTENE; HAEMATOCOCCUS-PLUVIALIS; POLYPHENOL OXIDASE; PHAFFIA-RHODOZYMA; GENE; CANTHAXANTHIN; PLANTS; BETA-C-4-OXYGENASE	Using metabolic engineering, we have modified the carotenoid biosynthesis pathway in tobacco (Nicotiana tabacum) to produce astaxanthin, a red pigment of considerable economic value. To alter the carotenoid pathway in chromoplasts of higher plants, the cDNA of the gene CrtO from the alga Haematococcus pluvialis, encoding beta-carotene ketolase, was transferred to tobacco under the regulation of the tomato Pds (phytoene desaturase) promoter. The transit peptide of PDS from tomato was used to target the CRTO polypeptide to the plastids. Chromoplasts in the nectary tissue of transgenic plants accumulated (3S,3'S) astaxanthin and other ketocarotenoids, changing the color of the nectary from yellow to red. This accomplishment demonstrates that plants can be used as a source of novel carotenoid pigments such as astaxanthin, The procedures described in this work can serve as a platform technology for future genetic manipulations of pigmentation of fruits and flowers of horticultural and floricultural importance.	Hebrew Univ Jerusalem, Inst Life Sci, Dept Genet, IL-91904 Jerusalem, Israel	Hebrew University of Jerusalem	Hirschberg, J (corresponding author), Hebrew Univ Jerusalem, Inst Life Sci, Dept Genet, IL-91904 Jerusalem, Israel.							Ausich RL, 1997, PURE APPL CHEM, V69, P2169, DOI 10.1351/pac199769102169; BECKER D, 1990, NUCLEIC ACIDS RES, V18, P203, DOI 10.1093/nar/18.1.203; Bon JA, 1997, BIOTECHNOL LETT, V19, P109, DOI 10.1023/A:1018391726206; Bonk M, 1997, EUR J BIOCHEM, V247, P942, DOI 10.1111/j.1432-1033.1997.00942.x; Boussiba S, 1999, BIOTECHNOL LETT, V21, P601, DOI 10.1023/A:1005507514694; CHAMOVITZ D, 1991, PLANT MOL BIOL, V16, P967, DOI 10.1007/BF00016069; Chew BP, 1999, ANTICANCER RES, V19, P1849; Chumpolkulwong N, 1997, J FERMENT BIOENG, V83, P429, DOI 10.1016/S0922-338X(97)82996-0; Corona V, 1996, PLANT J, V9, P505, DOI 10.1046/j.1365-313X.1996.09040505.x; CRAIK JC, 1985, AQUACULTURE, V112, P217; Cunningham FX, 1998, ANNU REV PLANT PHYS, V49, P557, DOI 10.1146/annurev.arplant.49.1.557; FAHN A, 1988, NEW PHYTOL, V108, P229, DOI 10.1111/j.1469-8137.1988.tb04159.x; GIULIANO G, 1993, PLANT CELL, V5, P379, DOI 10.1105/tpc.5.4.379; GRAY J, 1992, PLANT MOL BIOL, V19, P69, DOI 10.1007/BF00015607; Harker M, 1997, FEBS LETT, V404, P129, DOI 10.1016/S0014-5793(97)00110-5; HORSCH RB, 1985, COLD SPRING HARB SYM, V50, P433, DOI 10.1101/SQB.1985.050.01.054; JEFFERSON RA, 1987, EMBO J, V6, P3901; JYONOUCHI H, 1995, NUTR CANCER, V23, P171, DOI 10.1080/01635589509514373; Kobayashi M, 1999, BIOTECHNOL LETT, V21, P265, DOI 10.1023/A:1005445927433; Koussevitzky S, 1998, J BIOL CHEM, V273, P27064, DOI 10.1074/jbc.273.42.27064; LAWLOR SM, 1995, NUTR RES, V15, P1695, DOI 10.1016/0271-5317(95)02040-9; LOTAN T, 1995, FEBS LETT, V364, P125, DOI 10.1016/0014-5793(95)00368-J; MANN V, 1994, PLANT MOL BIOL, V24, P429, DOI 10.1007/BF00024111; Mayne ST, 1996, FASEB J, V10, P690, DOI 10.1096/fasebj.10.7.8635686; Misawa N, 1998, J BIOTECHNOL, V59, P169, DOI 10.1016/S0168-1656(97)00154-5; PALOZZA P, 1992, ARCH BIOCHEM BIOPHYS, V297, P291, DOI 10.1016/0003-9861(92)90675-M; PECKER I, 1992, P NATL ACAD SCI USA, V89, P4962, DOI 10.1073/pnas.89.11.4962; PECKER I, 1993, RES PHOTOSYNTHESIS, V3, P11; Pettersson A, 1999, AMBIO, V28, P43; Piccaglia R, 1998, IND CROP PROD, V8, P45, DOI 10.1016/S0926-6690(97)10005-X; Ronen G, 1999, PLANT J, V17, P341, DOI 10.1046/j.1365-313X.1999.00381.x; Sandmann G, 1999, TRENDS BIOTECHNOL, V17, P233, DOI 10.1016/S0167-7799(99)01307-4; Shewmaker CK, 1999, PLANT J, V20, P401, DOI 10.1046/j.1365-313x.1999.00611.x; SOMMER A, 1994, PLANT PHYSIOL, V105, P1301, DOI 10.1104/pp.105.4.1301; TANAKA T, 1995, CANCER RES, V55, P4059; TORRISSEN OJ, 1984, AQUACULTURE, V43, P185, DOI 10.1016/0044-8486(84)90021-8; Wang CW, 1999, BIOTECHNOL BIOENG, V62, P235, DOI 10.1002/(SICI)1097-0290(19990120)62:2<235::AID-BIT14>3.0.CO;2-U; Ye XD, 2000, SCIENCE, V287, P303, DOI 10.1126/science.287.5451.303; Yuan JP, 2000, FOOD CHEM, V68, P443, DOI 10.1016/S0308-8146(99)00219-8	39	171	212	5	71	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	AUG	2000	18	8					888	892		10.1038/78515	http://dx.doi.org/10.1038/78515			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	342VX	10932161				2022-12-25	WOS:000088666800028
J	Zisman, A; Peroni, OD; Abel, ED; Michael, MD; Mauvais-Jarvis, F; Lowell, BB; Wojtaszewski, JFP; Hirshman, MF; Virkamaki, A; Goodyear, LJ; Kahn, CR; Kahn, BB				Zisman, A; Peroni, OD; Abel, ED; Michael, MD; Mauvais-Jarvis, F; Lowell, BB; Wojtaszewski, JFP; Hirshman, MF; Virkamaki, A; Goodyear, LJ; Kahn, CR; Kahn, BB			Targeted disruption of the glucose transporter 4 selectively in muscle causes insulin resistance and glucose intolerance	NATURE MEDICINE			English	Article							KNOCKOUT MICE; GLUT4; GLYCOGEN; EXPRESSION; METABOLISM; EXERCISE; TISSUES; BRAIN	The prevalence of type 2 diabetes mellitus is growing worldwide. By the year 2020, 250 million people will be afflicted(1). Most forms of type 2 diabetes are polygenic with complex inheritance patterns, and penetrance is strongly influenced by environmental factors(2). The specific genes involved are not yet known, but impaired glucose uptake in skeletal muscle is an early, genetically determined defect that is present in nondiabetic relatives of diabetic subjects(3). The rate-limiting step in muscle glucose use is the transmembrane transport of glucose mediated by glucose transporter (GLUT) 4 (ref. 4), which is expressed mainly in skeletal muscle, heart and adipose tissues. GLUT4 mediates glucose transport stimulated by insulin and contraction/exercise. The importance of GLUT4 and glucose uptake in muscle, however, was challenged by two recent observations. Whereas heterozygous GLUT4 knockout mice show moderate glucose intolerance(6), homozygous whole-body GLUT4 knockout (GLUT4-null) mice have only mild perturbations in glucose homeostasis and have growth retardation, depletion of fat stores, cardiac hypertrophy and failure, and a shortened life span(7). Moreover, muscle-specific inactivation of the insulin receptor results in minimal, if any, change in glucose tolerances. To determine the importance of glucose uptake into muscle for glucose homeostasis, we disrupted GLUT4 selectively in mouse muscles. A profound reduction in basal glucose transport and near-absence of stimulation by insulin or contraction resulted. These mice showed severe insulin resistance and glucose intolerance from an early age. Thus, GLUT4-mediated glucose transport in muscle is essential to the maintenance of normal glucose homeostasis.	Beth Israel Deaconess Med Ctr, Div Endocrine, Boston, MA 02215 USA; Joslin Diabet Ctr, Div Res, Boston, MA 02215 USA; Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02215 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Joslin Diabetes Center, Inc.; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Kahn, BB (corresponding author), Beth Israel Deaconess Med Ctr, Div Endocrine, Boston, MA 02215 USA.		Wojtaszewski, Jørgen FP/P-6583-2014; Kahn, Ronald/AAY-2435-2021	Wojtaszewski, Jørgen FP/0000-0001-9785-6830; Kahn, Ronald/0000-0002-7583-9228; wojtaszewski, jorgen/0000-0001-8185-3408; Abel, E. Dale/0000-0001-5290-0738; Michael, Mervyn/0000-0002-0224-1065	NIDDK NIH HHS [DK46200, R01 DK043051, DK43051, DK33201] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK046200, R01DK043051, R01DK033201, R37DK043051] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abel ED, 1999, J CLIN INVEST, V104, P1703, DOI 10.1172/JCI7605; BELL GI, 1990, DIABETES CARE, V13, P198, DOI 10.2337/diacare.13.3.198; BROSIUS FC, 1992, KIDNEY INT, V42, P1086, DOI 10.1038/ki.1992.391; Bruning JC, 1998, MOL CELL, V2, P559, DOI 10.1016/S1097-2765(00)80155-0; CARRUTHERS A, 1990, PHYSIOL REV, V70, P1135, DOI 10.1152/physrev.1990.70.4.1135; CHARRON MJ, 1989, P NATL ACAD SCI USA, V86, P2535, DOI 10.1073/pnas.86.8.2535; Cline GW, 1999, NEW ENGL J MED, V341, P240, DOI 10.1056/NEJM199907223410404; DeFronzo RA, 1997, DIABETES REV, V5, P1; Etgen GJ, 1997, DIABETES, V46, P1915, DOI 10.2337/diabetes.46.11.1915; Frevert EU, 1996, BIOCHEM J, V316, P865, DOI 10.1042/bj3160865; Goodyear LJ, 1998, ANNU REV MED, V49, P235, DOI 10.1146/annurev.med.49.1.235; Hayashi T, 1998, DIABETES, V47, P1369, DOI 10.2337/diabetes.47.8.1369; HOLMAN GD, 1990, J BIOL CHEM, V265, P18172; HOM FG, 1984, DIABETES, V33, P141, DOI 10.2337/diabetes.33.2.141; KATZ EB, 1995, NATURE, V377, P151, DOI 10.1038/377151a0; Kim JK, 2000, J CLIN INVEST, V105, P1791, DOI 10.1172/JCI8305; Leloup C, 1996, MOL BRAIN RES, V38, P45, DOI 10.1016/0169-328X(95)00306-D; ORahilly S, 1997, NAT MED, V3, P1080, DOI 10.1038/nm1097-1080; PARNIAK M, 1985, CAN J BIOCHEM CELL B, V63, P333, DOI 10.1139/o85-049; Stenbit AE, 1997, NAT MED, V3, P1096, DOI 10.1038/nm1097-1096; TRASK RV, 1990, BIOCHIM BIOPHYS ACTA, V1049, P182, DOI 10.1016/0167-4781(90)90039-5; Virkamaki A, 1997, DIABETES, V46, P1106, DOI 10.2337/diabetes.46.7.1106; WARRAM JH, 1995, JOSLINS DIABETES MEL; Wojtaszewski JFP, 1999, J CLIN INVEST, V104, P1257, DOI 10.1172/JCI7961; Young ME, 1997, BIOCHEM J, V322, P223, DOI 10.1042/bj3220223	25	524	556	1	55	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	AUG	2000	6	8					924	928		10.1038/78693	http://dx.doi.org/10.1038/78693			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	376TX	10932232				2022-12-25	WOS:000165473800038
J	Eaves, IA; Merriman, TR; Barber, RA; Nutland, S; Tuomilehto-Wolf, E; Tuomilehto, J; Cucca, F; Todd, JA				Eaves, IA; Merriman, TR; Barber, RA; Nutland, S; Tuomilehto-Wolf, E; Tuomilehto, J; Cucca, F; Todd, JA			The genetically isolated populations of Finland and Sardinia may not be a panacea for linkage disequilibrium mapping of common disease genes	NATURE GENETICS			English	Article							ALLELIC ASSOCIATION; GENOMEWIDE SCAN; LOCI; FAMILIES; IDDM6	The choice of which population to study in the mapping of common disease genes may be critical(1,2). Isolated founder populations, such as that found in Finland, have already proved extremely useful for mapping the genes for specific rare monogenic disorders(3,4) and are being used in attempts to map the genes underlying common, complex diseases(5-8). But simulation results suggest that, under the common disease-common variant hypothesis(9-13), most isolated populations will prove no more useful for linkage disequilibrium (LD) mapping of common disease genes than large outbred populations(12). There is very little empirical data to either support or refute this conclusion at present(14-16) Therefore, we evaluated LD between 21 common microsatellite polymorphisms on chromosome 18q21 in 2 genetic isolates (Finland and Sardinia) and compared the results with those observed in two mixed populations (United Kingdom and United States of America). Mean levels of LD were similar across all four populations. Our results provide empirical support for the expectation that genetic isolates like Finland and Sardinia will not prove significantly more valuable than general populations for LD mapping of common variants underlying complex disease.	Cambridge Inst Med Res, Dept Med Genet, Wellcome Trust Ctr Mol Mechanisms Dis, Cambridge, England; Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford, England; Natl Publ Hlth Inst, Diabet & Genet Epidemiol Unit, Helsinki, Finland; Univ Cagliari, Ist Clin & Biol Eta Evolut, I-09100 Cagliari, Italy	University of Cambridge; University of Oxford; Wellcome Centre for Human Genetics; Finland National Institute for Health & Welfare; University of Cagliari	Todd, JA (corresponding author), Cambridge Inst Med Res, Dept Med Genet, Wellcome Trust Ctr Mol Mechanisms Dis, Wellcome Trust MRC Bldg, Cambridge, England.		Todd, John A/A-3542-2010	Todd, John A/0000-0003-2740-8148	NIDDK NIH HHS [DK73957] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Collins A, 1999, P NATL ACAD SCI USA, V96, P15173, DOI 10.1073/pnas.96.26.15173; Collins FS, 1997, SCIENCE, V278, P1580, DOI 10.1126/science.278.5343.1580; De La Chapelle A, 1998, P NATL ACAD SCI USA, V95, P12416, DOI 10.1073/pnas.95.21.12416; Escamilla MA, 1999, AM J HUM GENET, V64, P1670, DOI 10.1086/302400; Ghosh S, 1999, P NATL ACAD SCI USA, V96, P2198, DOI 10.1073/pnas.96.5.2198; HEDRICK PW, 1987, GENETICS, V117, P331; Huttley GA, 1999, GENETICS, V152, P1711; Jorde LB, 2000, HUM HERED, V50, P57, DOI 10.1159/000022891; Kruglyak L, 1999, NAT GENET, V22, P139, DOI 10.1038/9642; Kuokkanen S, 1997, AM J HUM GENET, V61, P1379, DOI 10.1086/301637; Laan M, 1997, NAT GENET, V17, P435, DOI 10.1038/ng1297-435; Lander ES, 1996, SCIENCE, V274, P536, DOI 10.1126/science.274.5287.536; LEWONTIN RC, 1964, GENETICS, V49, P49; Lonjou C, 1999, P NATL ACAD SCI USA, V96, P1621, DOI 10.1073/pnas.96.4.1621; Merriman T, 1997, HUM MOL GENET, V6, P1003, DOI 10.1093/hmg/6.7.1003; Merriman TR, 1998, HUM MOL GENET, V7, P517, DOI 10.1093/hmg/7.3.517; Pajukanta P, 1999, AM J HUM GENET, V64, P1453, DOI 10.1086/302365; Peltonen L, 1999, HUM MOL GENET, V8, P1913, DOI 10.1093/hmg/8.10.1913; REED PW, 1994, NAT GENET, V7, P390, DOI 10.1038/ng0794-390; Risch N, 1996, SCIENCE, V273, P1516, DOI 10.1126/science.273.5281.1516; Terwilliger JD, 1998, CURR OPIN BIOTECH, V9, P578, DOI 10.1016/S0958-1669(98)80135-3; THOMSON G, 1995, AM J HUM GENET, V57, P487; TODD JA, IN PRESS METABOLIC M; Weir B. S., 1996, GENETIC DATA ANAL; Wright AF, 1999, NAT GENET, V23, P397, DOI 10.1038/70501	25	135	136	0	3	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUL	2000	25	3					320	323						4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	329RD	10888882				2022-12-25	WOS:000087920900022
J	Witt, H; Luck, W; Hennies, HC; Classen, M; Kage, A; Lass, U; Landt, O; Becker, M				Witt, H; Luck, W; Hennies, HC; Classen, M; Kage, A; Lass, U; Landt, O; Becker, M			Mutations in the gene encoding the serine protease inhibitor, Kazal type 1 are associated with chronic pancreatitis	NATURE GENETICS			English	Article							CATIONIC TRYPSINOGEN GENE; CYSTIC-FIBROSIS GENE; HEREDITARY PANCREATITIS; LINKAGE DISEQUILIBRIUM	Chronic pancreatitis (CP) is a continuing or relapsing inflammatory disease of the pancreas. In approximately one-third of all cases, no aetiological factor can be found, and these patients are classified as having idiopathic disease. Pathophysiologically, autodigestion and inflammation may be caused by either increased proteolytic activity or decreased protease inhibition. Several studies have demonstrated mutations in the cationic trypsinogen gene (PRSS1) in patients with hereditary(1-3) or idiopathic(4) CP. It is thought that these mutations result in increased trypsin activity within the pancreatic parenchyma. Most patients with idiopathic or hereditary CP. however, do not have mutations in PRSS1 (ref. 4). Here we analysed 96 unrelated children and adolescents with CP for mutations in the gene encoding the serine protease inhibitor. Kazal type 1 (SPINK1). a pancreatic trypsin inhibitor. We found mutations in 23% of the patients. In 18 patients. 6 of whom were homozygous. we detected a missense mutation of codon 34 (N34S). We also found four other sequence variants. Our results indicate that mutations in SPINK1 are associated with chronic pancreatitis.	Humboldt Univ, Dept Pediat, Charite, Berlin, Germany; Max Delbruck Ctr Mol Med, Dept Mol Genet, Berlin, Germany; Max Delbruck Ctr Mol Med, Gene Mapping Ctr, Berlin, Germany; Zent Krankenhaus Links der Weser, Dept Pediat, Bremen, Germany; Humboldt Univ, Inst Lab Med & Pathobiochem, Berlin, Germany; TIB MOLBIOL, Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Humboldt University of Berlin	Witt, H (corresponding author), Humboldt Univ, Dept Pediat, Charite, Campus Virchow Klinikum, Berlin, Germany.		Hennies, Hans C/G-9424-2014	Hennies, Hans C/0000-0001-7210-2389				BARTELT DC, 1977, ARCH BIOCHEM BIOPHYS, V179, P189, DOI 10.1016/0003-9861(77)90103-5; Cohn JA, 1998, NEW ENGL J MED, V339, P653, DOI 10.1056/NEJM199809033391002; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; FALK CT, 1987, ANN HUM GENET, V51, P227, DOI 10.1111/j.1469-1809.1987.tb00875.x; Ferec C, 1999, J MED GENET, V36, P228; Gorry MC, 1997, GASTROENTEROLOGY, V113, P1063, DOI 10.1053/gast.1997.v113.pm9322498; HORII A, 1987, BIOCHEM BIOPH RES CO, V149, P635, DOI 10.1016/0006-291X(87)90415-3; LASKOWSKI M, 1980, ANNU REV BIOCHEM, V49, P593, DOI 10.1146/annurev.bi.49.070180.003113; Marchbank T, 1998, DIGESTION, V59, P167, DOI 10.1159/000007485; RINDERKNECHT H, 1986, DIGEST DIS SCI, V31, P314, DOI 10.1007/BF01318124; Rinderknecht Heinrich, 1993, P219; Sharer N, 1998, NEW ENGL J MED, V339, P645, DOI 10.1056/NEJM199809033391001; SPIELMAN RS, 1993, AM J HUM GENET, V52, P506; TERWILLIGER JD, 1995, AM J HUM GENET, V56, P777; Whitcomb DC, 1996, NAT GENET, V14, P141, DOI 10.1038/ng1096-141; Witt H, 1999, GASTROENTEROLOGY, V117, P7, DOI 10.1016/S0016-5085(99)70543-3	16	725	746	0	42	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUN	2000	25	2					213	216		10.1038/76088	http://dx.doi.org/10.1038/76088			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	321ML	10835640				2022-12-25	WOS:000087459200024
J	Ashburner, M; Ball, CA; Blake, JA; Botstein, D; Butler, H; Cherry, JM; Davis, AP; Dolinski, K; Dwight, SS; Eppig, JT; Harris, MA; Hill, DP; Issel-Tarver, L; Kasarskis, A; Lewis, S; Matese, JC; Richardson, JE; Ringwald, M; Rubin, GM; Sherlock, G				Ashburner, M; Ball, CA; Blake, JA; Botstein, D; Butler, H; Cherry, JM; Davis, AP; Dolinski, K; Dwight, SS; Eppig, JT; Harris, MA; Hill, DP; Issel-Tarver, L; Kasarskis, A; Lewis, S; Matese, JC; Richardson, JE; Ringwald, M; Rubin, GM; Sherlock, G		Gene Ontology Consortium	Gene Ontology: tool for the unification of biology	NATURE GENETICS			English	Editorial Material							YEAST; IDENTIFICATION; ANNOTATION; PROTEINS	Genomic sequencing has made it clear that a large fraction of the genes specifying the core biological functions are shared by all eukaryotes. Knowledge of the biological role of such shared proteins in one organism can often be transferred to other organisms. The goal of the Gene Ontology Consortium is to produce a dynamic, controlled vocabulary that can be applied to all eukaryotes even as knowledge of gene and protein roles in cells is accumulating and changing. To this end, three independent ontologies accessible on the World-Wide Web (http://www.geneontology.org) are being constructed: biological process, molecular function and cellular component.	Stanford Univ, Sch Med, Dept Genet, Stanford, CA 94305 USA	Stanford University	Botstein, D (corresponding author), Stanford Univ, Sch Med, Dept Genet, Stanford, CA 94305 USA.		yang, xiao-jun/B-1927-2009; Kessenbrock, Kai/B-6936-2011; Sherlock, Gavin J/E-9110-2012; Sherlock, Gavin J/B-1831-2009; Dolinski, Kara/GPP-4026-2022	Rubin, Gerald/0000-0001-8762-8703; Lewis, Suzanna/0000-0002-8343-612X; Dolinski, Kara/0000-0002-7010-0264; Cherry, J. Michael/0000-0001-9163-5180; Matese, John/0000-0002-9432-8909; Blake, Judith/0000-0001-8522-334X; Sherlock, Gavin/0000-0002-1692-4983; Harris, Midori/0000-0003-4148-4606	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD033745] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [P41HG000330, P41HG001315, P41HG000739] Funding Source: NIH RePORTER; NHGRI NIH HHS [P41 HG001315, P41 HG00330, U41 HG000739, P41 HG000739, P41 HG000739-19, P41 HG01315, P41 HG000330-22, U41 HG001315, P41 HG000330, P41 HG001315-16] Funding Source: Medline; NICHD NIH HHS [HD33745, R01 HD033745-11, R01 HD033745] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; Andrade MA, 1999, BIOINFORMATICS, V15, P391, DOI 10.1093/bioinformatics/15.5.391; Bairoch A, 2000, NUCLEIC ACIDS RES, V28, P304, DOI 10.1093/nar/28.1.304; Bairoch A, 2000, NUCLEIC ACIDS RES, V28, P45, DOI 10.1093/nar/28.1.45; Baker W, 2000, NUCLEIC ACIDS RES, V28, P19, DOI 10.1093/nar/28.1.19; Ball CA, 2000, NUCLEIC ACIDS RES, V28, P77, DOI 10.1093/nar/28.1.77; Barker WC, 2000, NUCLEIC ACIDS RES, V28, P41, DOI 10.1093/nar/28.1.41; Bassett DE, 1997, NAT GENET, V15, P339, DOI 10.1038/ng0497-339; Bateman A, 2000, NUCLEIC ACIDS RES, V28, P263, DOI 10.1093/nar/28.1.263; Benson DA, 2000, NUCLEIC ACIDS RES, V28, P15, DOI 10.1093/nar/28.1.15; Blake JA, 2000, NUCLEIC ACIDS RES, V28, P108, DOI 10.1093/nar/28.1.108; BOTSTEIN D, 1988, SCIENCE, V240, P1439, DOI 10.1126/science.3287619; Chervitz SA, 1999, NUCLEIC ACIDS RES, V27, P74, DOI 10.1093/nar/27.1.74; Costanzo MC, 2000, NUCLEIC ACIDS RES, V28, P73, DOI 10.1093/nar/28.1.73; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Fleischmann W, 1999, BIOINFORMATICS, V15, P228, DOI 10.1093/bioinformatics/15.3.228; Gelbart WM, 1999, NUCLEIC ACIDS RES, V27, P85, DOI 10.1093/nar/27.1.85; Goffeau A, 1996, SCIENCE, V274, P546, DOI 10.1126/science.274.5287.546; KATAOKA T, 1985, CELL, V40, P19, DOI 10.1016/0092-8674(85)90304-6; Lo Conte L, 2000, NUCLEIC ACIDS RES, V28, P257, DOI 10.1093/nar/28.1.257; Meinke DW, 1998, SCIENCE, V282, P662, DOI 10.1126/science.282.5389.662; Mewes HW, 2000, NUCLEIC ACIDS RES, V28, P37, DOI 10.1093/nar/28.1.37; NC-IUBMB, 1992, ENZ NOM REC NOM COMM; Ohi R, 1998, MOL CELL BIOL, V18, P4097, DOI 10.1128/MCB.18.7.4097; Ringwald M, 2000, NUCLEIC ACIDS RES, V28, P115, DOI 10.1093/nar/28.1.115; Rubin GM, 2000, SCIENCE, V287, P2204, DOI 10.1126/science.287.5461.2204; Spellman PT, 1998, MOL BIOL CELL, V9, P3273, DOI 10.1091/mbc.9.12.3273; Tang ZH, 2000, MOL CELL BIOL, V20, P816, DOI 10.1128/MCB.20.3.816-824.2000; Tateno Y, 2000, NUCLEIC ACIDS RES, V28, P24, DOI 10.1093/nar/28.1.24; Tatusov RL, 2000, NUCLEIC ACIDS RES, V28, P33, DOI 10.1093/nar/28.1.33; Tye BK, 1999, ANNU REV BIOCHEM, V68, P649, DOI 10.1146/annurev.biochem.68.1.649; Vajo Z, 1999, MAMM GENOME, V10, P1000, DOI 10.1007/s003359901147; *WORM SEQ CONS, 1998, SCIENCE, V282, P2012	33	25299	26057	102	1887	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAY	2000	25	1					25	29		10.1038/75556	http://dx.doi.org/10.1038/75556			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	311KU	10802651	Green Accepted			2022-12-25	WOS:000086884000011
J	Grimm, C; Wenzel, A; Hafezi, F; Yu, S; Redmond, TM; Reme, CE				Grimm, C; Wenzel, A; Hafezi, F; Yu, S; Redmond, TM; Reme, CE			Protection of Rpe65-deficient mice identifies rhodopsin as a mediator of light-induced retinal degeneration	NATURE GENETICS			English	Article							APOPTOTIC CELL-DEATH; PHOTORECEPTOR DEGENERATION; MACULAR DEGENERATION; PIGMENT EPITHELIUM; DIFFUSIBLE FACTOR; MUTANT RHODOPSIN; TRANSGENIC MICE; BLUE-LIGHT; C-FOS; SURVIVAL	Light-induced apoptosis of photoreceptors represents an animal model for retinal degeneration(1). Major human diseases that affect vision, such as age-related macular degeneration (AMD) and some forms of retinitis pigmentosa (RP), may be promoted by light(2-7). The receptor mediating light damage, however, has not yet been conclusively identified; candidate molecules include prostaglandin synthase(8), cytochrome oxidase(9), rhodopsin(10), and opsins of the cones and the retinal pigment epithelium(11) (PE). We exposed to bright light two groups of genetically altered mice that lack the visual pigment rhodopsin (Rpe65(-/-) and Rho(-/-)). The gene Rpe65 is specifically expressed in the PE and essential for the re-isomerization of all-trans retinol in the visual cycle and thus for the regeneration of rhodopsin after bleaching(12). Rho(-/-) mice do not express the apoprotein opsin in photoreceptors, which, consequently, do not contain rhodopsin(13). We show that photoreceptors lacking rhodopsin in these mice are completely protected against light-induced apoptosis. The transcription factor AP-1, a central element in the apoptotic response to light(14,15), is not activated in the absence of rhodopsin, indicating that rhodopsin is essential for the generation or transduction of the intracellular death signal induced by light.	Univ Zurich Hosp, Dept Ophthalmol, Lab Retinal Cell Biol, CH-8091 Zurich, Switzerland; NEI, Retinal Cell & Mol Biol Lab, NIH, Bethesda, MD 20892 USA	University of Zurich; University Zurich Hospital; National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI)	Grimm, C (corresponding author), Univ Zurich Hosp, Dept Ophthalmol, Lab Retinal Cell Biol, CH-8091 Zurich, Switzerland.		Hafezi, Farhad/A-1446-2010	Hafezi, Farhad/0000-0001-8935-4558; Redmond, T. Michael/0000-0002-1813-5291; Grimm, Christian/0000-0001-9318-4352	NATIONAL EYE INSTITUTE [Z01EY000260, ZIAEY000260] Funding Source: NIH RePORTER	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Campochiaro PA, 1996, J NEUROSCI, V16, P1679; Chen CK, 1999, P NATL ACAD SCI USA, V96, P3718, DOI 10.1073/pnas.96.7.3718; CHEN EP, 1993, GRAEF ARCH CLIN EXP, V231, P416, DOI 10.1007/BF00919652; Chen J, 1999, INVEST OPHTH VIS SCI, V40, P2978; Cideciyan AV, 1998, P NATL ACAD SCI USA, V95, P7103, DOI 10.1073/pnas.95.12.7103; CRUICKSHANKS KJ, 1993, ARCH OPHTHALMOL-CHIC, V111, P514, DOI 10.1001/archopht.1993.01090040106042; GAUR VP, 1992, EXP EYE RES, V54, P645, DOI 10.1016/0014-4835(92)90020-S; Hafezi F, 1997, NAT MED, V3, P346, DOI 10.1038/nm0397-346; Hafezi F, 1999, VISION RES, V39, P2511, DOI 10.1016/S0042-6989(98)00313-7; Hanna N, 1997, FREE RADICAL BIO MED, V23, P885, DOI 10.1016/S0891-5849(97)00083-X; Hao WS, 1996, BIOCHEMISTRY-US, V35, P6251, DOI 10.1021/bi952420k; Humphries MM, 1997, NAT GENET, V15, P216, DOI 10.1038/ng0297-216; LaVail MM, 1999, INVEST OPHTH VIS SCI, V40, P1020; LAVAIL MM, 1987, CURR EYE RES, V6, P825, DOI 10.3109/02713688709034850; LI AR, 1995, J NEUROSCI, V15, P385; Mohand-Said S, 1998, P NATL ACAD SCI USA, V95, P8357, DOI 10.1073/pnas.95.14.8357; Naash ML, 1996, INVEST OPHTH VIS SCI, V37, P775; NIR I, 1993, MOL BRAIN RES, V19, P47, DOI 10.1016/0169-328X(93)90147-H; Organisciak DT, 1999, CURR EYE RES, V19, P188, DOI 10.1076/ceyr.19.2.188.5333; Pang JJ, 1998, GRAEF ARCH CLIN EXP, V236, P696, DOI 10.1007/s004170050143; Redmond TM, 1998, NAT GENET, V20, P344, DOI 10.1038/3813; Reme CE, 1998, PROG RETIN EYE RES, V17, P443, DOI 10.1016/S1350-9462(98)00009-3; SANYAL S, 1986, VISION RES, V26, P1177, DOI 10.1016/0042-6989(86)90099-4; SIMONS K, 1993, ARCH OPHTHALMOL-CHIC, V111, P297, DOI 10.1001/archopht.1993.01090030015002; Streichert LC, 1999, J NEUROBIOL, V39, P475, DOI 10.1002/(SICI)1097-4695(19990615)39:4<475::AID-NEU2>3.0.CO;2-#; Taylor H R, 1990, Trans Am Ophthalmol Soc, V88, P163; Weng J, 1999, CELL, V98, P13, DOI 10.1016/S0092-8674(00)80602-9; Wenzel A, 2000, J NEUROSCI, V20, P81, DOI 10.1523/JNEUROSCI.20-01-00081.2000; WILLIAMS TP, 1983, INVEST OPHTH VIS SCI, V24, P285	29	212	220	0	17	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAY	2000	25	1					63	66		10.1038/75614	http://dx.doi.org/10.1038/75614			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	311KU	10802658				2022-12-25	WOS:000086884000018
J	Lu, DC; Rabizadeh, S; Chandra, S; Shayya, RF; Ellerby, LM; Ye, X; Salvesen, GS; Koo, EH; Bredesen, DE				Lu, DC; Rabizadeh, S; Chandra, S; Shayya, RF; Ellerby, LM; Ye, X; Salvesen, GS; Koo, EH; Bredesen, DE			A second cytotoxic proteolytic peptide derived from amyloid beta-protein precursor	NATURE MEDICINE			English	Article							APOPTOTIC CELL-DEATH; ALZHEIMERS-DISEASE; NEURONAL APOPTOSIS; RECEPTOR; DEGENERATION; ACTIVATION; CLEAVAGE; CASPASES; MICE; IDENTIFICATION	The amyloid beta -protein precursor gives rise to the amyloid beta -protein, the principal constituent of senile plaques and a cytotoxic fragment involved in the pathogenesis of Alzheimer disease. Here we show that amyloid beta -protein precursor was proteolytically cleaved by caspases in the C terminus to generate a second unrelated peptide, called C31. The resultant C31 peptide was a potent inducer of apoptosis. Both caspase-cleaved amyloid beta -protein precursor and activated caspase-9 were present in brains of Alzheimer disease patients but not in control brains. These findings indicate the possibility that caspase cleavage of amyloid beta -protein precursor with the generation of C31 may be involved in the neuronal death associated with Alzheimer disease.	Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA; Burnham Inst, Program Aging, La Jolla, CA 92037 USA; Univ Calif Los Angeles, Interdepartmental Program Neurosci, Los Angeles, CA 90024 USA; Buck Ctr Res Aging, Novato, CA 94948 USA	University of California System; University of California San Diego; Sanford Burnham Prebys Medical Discovery Institute; University of California System; University of California Los Angeles; Buck Institute for Research on Aging	Koo, EH (corresponding author), Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA.	edkoo@ucsd.edu; dbredesen@buckcenter.org			NIA NIH HHS [AG05131, AG12282] Funding Source: Medline; NINDS NIH HHS [NS37776] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG012282] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Barnes NY, 1998, J NEUROSCI, V18, P5869; Bredesen DE, 1998, CELL DEATH DIFFER, V5, P365, DOI 10.1038/sj.cdd.4400378; CAPORASO GL, 1994, J NEUROSCI, V14, P3122; Chan SL, 1999, J NEUROSCI RES, V57, P315, DOI 10.1002/(SICI)1097-4547(19990801)57:3<315::AID-JNR3>3.3.CO;2-R; Cotman CW, 1998, NEUROBIOL AGING, V19, pS29, DOI 10.1016/S0197-4580(98)00042-6; Ellerby LM, 1999, J NEUROCHEM, V72, P185, DOI 10.1046/j.1471-4159.1999.0720185.x; FUKUCHI K, 1993, NEUROSCI LETT, V154, P145, DOI 10.1016/0304-3940(93)90192-N; Gervais FG, 1999, CELL, V97, P395, DOI 10.1016/S0092-8674(00)80748-5; Hui KS, 1998, J BIOL CHEM, V273, P31053, DOI 10.1074/jbc.273.47.31053; KOO EH, 1994, J BIOL CHEM, V269, P17386; Krajewski S, 1999, P NATL ACAD SCI USA, V96, P5752, DOI 10.1073/pnas.96.10.5752; LAFERLA FM, 1995, NAT GENET, V9, P21, DOI 10.1038/ng0195-21; LeBlanc A, 1999, J BIOL CHEM, V274, P23426, DOI 10.1074/jbc.274.33.23426; MarquezSterling NR, 1997, J NEUROSCI, V17, P140, DOI 10.1523/JNEUROSCI.17-01-00140.1997; Masliah E, 1998, J NEURAL TRANSM-SUPP, P147; Mattson MP, 1998, BRAIN RES, V807, P167, DOI 10.1016/S0006-8993(98)00763-X; McPhie DL, 1997, J BIOL CHEM, V272, P24743, DOI 10.1074/jbc.272.40.24743; Mehlen P, 1998, NATURE, V395, P801, DOI 10.1038/27441; OsterGranite ML, 1996, J NEUROSCI, V16, P6732; Pellegrini L, 1999, J BIOL CHEM, V274, P21011, DOI 10.1074/jbc.274.30.21011; RABIZADEH S, 1993, SCIENCE, V261, P345, DOI 10.1126/science.8332899; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Selkoe DJ, 1998, TRENDS CELL BIOL, V8, P447, DOI 10.1016/S0962-8924(98)01363-4; Selznick LA, 1999, J NEUROPATH EXP NEUR, V58, P1020, DOI 10.1097/00005072-199909000-00012; Shindler KS, 1997, J NEUROSCI, V17, P3112; SISODIA SS, 1993, J NEUROSCI, V13, P3136; SOPHER BL, 1994, MOL BRAIN RES, V26, P207, DOI 10.1016/0169-328X(94)90092-2; Stadelmann C, 1999, AM J PATHOL, V155, P1459, DOI 10.1016/S0002-9440(10)65460-0; Stennicke HR, 1998, J BIOL CHEM, V273, P27084, DOI 10.1074/jbc.273.42.27084; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Weidemann A, 1999, J BIOL CHEM, V274, P5823, DOI 10.1074/jbc.274.9.5823; Wolf BB, 1999, BLOOD, V94, P1683, DOI 10.1182/blood.V94.5.1683.417k37_1683_1692; Yang FS, 1998, AM J PATHOL, V152, P379; YANKNER BA, 1989, SCIENCE, V245, P417, DOI 10.1126/science.2474201; Yankner BA, 1996, NEURON, V16, P921, DOI 10.1016/S0896-6273(00)80115-4	35	335	355	0	11	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2000	6	4					397	404		10.1038/74656	http://dx.doi.org/10.1038/74656			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	376UA	10742146				2022-12-25	WOS:000165474100033
J	Kretz-Rommel, A; Rubin, RL				Kretz-Rommel, A; Rubin, RL			Disruption of positive selection of thymocytes causes autoimmunity	NATURE MEDICINE			English	Article							T-CELL-RECEPTOR; INTERCELLULAR-ADHESION MOLECULE-1; PIGEON CYTOCHROME-C; DRUG-INDUCED LUPUS; NEGATIVE SELECTION; CLASS-II; SELF-PEPTIDES; ANTIGEN RECEPTOR; TRANSGENIC MICE; CLONAL DELETION	To differentiate into T cells, immature thymocytes must engage, through their antigen-specific T-cell receptor, peptides derived from self proteins presented by cortical epithelial cells in the thymus, a process called positive selection. Despite this requirement for self-recognition during development, mature T cells do not normally show autoreactivity. Mice injected in the thymus with procainamide-hydroxylamine, a metabolite of procainamide, develop autoimmune features resembling drug-induced lupus. Here, we show that when thymocytes undergo positive selection in the presence of procainamide-hydroxylamine, they fail to establish unresponsiveness to low affinity selecting self antigens, resulting in systemic autoimmunity.	Scripps Res Inst, Dept Mol & Expt Med, Wm Keck Autoimmune Dis Ctr, La Jolla, CA 92037 USA	Scripps Research Institute	Rubin, RL (corresponding author), Scripps Res Inst, Dept Mol & Expt Med, Wm Keck Autoimmune Dis Ctr, MEM 131,10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	rrubin@scripps.edu			NIAID NIH HHS [AI45978] Funding Source: Medline; NIEHS NIH HHS [ES06334] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI045978] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES006334] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ALBEROLAILA J, 1995, NATURE, V373, P620, DOI 10.1038/373620a0; ALLEN PM, 1994, CELL, V76, P593, DOI 10.1016/0092-8674(94)90497-9; Barton GM, 1999, SCIENCE, V283, P67, DOI 10.1126/science.283.5398.67; BURLINGAME RW, 1990, J IMMUNOL METHODS, V134, P187, DOI 10.1016/0022-1759(90)90380-E; Cavenagh JD, 1997, BRIT J HAEMATOL, V97, P673, DOI 10.1046/j.1365-2141.1997.982913.x; Chmielowski B, 1999, J IMMUNOL, V162, P95; Davey GM, 1998, J EXP MED, V188, P1867, DOI 10.1084/jem.188.10.1867; Douek DC, 1998, NATURE, V396, P690, DOI 10.1038/25374; FINK PJ, 1986, NATURE, V321, P219, DOI 10.1038/321219a0; Gapin L, 1998, J EXP MED, V187, P1871, DOI 10.1084/jem.187.11.1871; GONZALEZQUINTIAL R, 1992, J IMMUNOL, V149, P230; Grossman Z, 1996, P NATL ACAD SCI USA, V93, P14747, DOI 10.1073/pnas.93.25.14747; Grubin CE, 1997, IMMUNITY, V7, P197, DOI 10.1016/S1074-7613(00)80523-3; HESS EV, 1991, B RHEUM DIS, V40, P1; Ignatowicz L, 1996, CELL, V84, P521, DOI 10.1016/S0092-8674(00)81028-4; JANEWAY CA, 1991, ADV IMMUNOL, V50, P1; JARDETZKY TS, 1991, NATURE, V353, P326, DOI 10.1038/353326a0; JENKINSON EJ, 1992, J EXP MED, V176, P845, DOI 10.1084/jem.176.3.845; KAPPLER JW, 1987, CELL, V49, P273, DOI 10.1016/0092-8674(87)90568-X; KAYE J, 1992, CELL, V71, P423, DOI 10.1016/0092-8674(92)90512-B; KAYE J, 1989, NATURE, V341, P746, DOI 10.1038/341746a0; Kishimoto H, 1996, J EXP MED, V184, P531, DOI 10.1084/jem.184.2.531; KISIELOW P, 1988, NATURE, V333, P742, DOI 10.1038/333742a0; Kretz-Rommel A, 1999, J IMMUNOL, V162, P813; KretzRommel A, 1997, J IMMUNOL, V158, P4465; KretzRommel A, 1997, J CLIN INVEST, V99, P1888, DOI 10.1172/JCI119356; KUHLMAN P, 1991, J IMMUNOL, V146, P1773; Liu CP, 1997, J EXP MED, V186, P1441, DOI 10.1084/jem.186.9.1441; Liu CP, 1998, P NATL ACAD SCI USA, V95, P4522, DOI 10.1073/pnas.95.8.4522; LUCAS B, 1999, CELL, V10, P367; LYONS AB, 1994, J IMMUNOL METHODS, V171, P131, DOI 10.1016/0022-1759(94)90236-4; MACKALL CL, 1995, NEW ENGL J MED, V332, P143, DOI 10.1056/NEJM199501193320303; Mackall CL, 1998, EUR J IMMUNOL, V28, P1886, DOI 10.1002/(SICI)1521-4141(199806)28:06<1886::AID-IMMU1886>3.0.CO;2-M; MARRACK P, 1993, J EXP MED, V178, P2173, DOI 10.1084/jem.178.6.2173; Matechak EO, 1996, IMMUNITY, V4, P337, DOI 10.1016/S1074-7613(00)80247-2; MURPHY KM, 1990, SCIENCE, V250, P1720, DOI 10.1126/science.2125367; Nakano N, 1997, SCIENCE, V275, P678, DOI 10.1126/science.275.5300.678; Oehen S, 1996, J EXP MED, V183, P2617, DOI 10.1084/jem.183.6.2617; OGASAWARA K, 1989, J IMMUNOL, V142, P1448; Ohashi PS, 1996, CURR OPIN IMMUNOL, V8, P808, DOI 10.1016/S0952-7915(96)80009-4; PAGE DM, 1994, P NATL ACAD SCI USA, V91, P4057, DOI 10.1073/pnas.91.9.4057; Pawlowski TJ, 1996, EUR J IMMUNOL, V26, P851, DOI 10.1002/eji.1830260419; RUBIN RL, 1987, J PHARMACOL EXP THER, V242, P833; Rubin RL, 1999, CRIT REV IMMUNOL, V19, P199; RUBIN RL, 1997, DUBOIS LUPUS ERYTHEM, P871; SantAngelo DB, 1997, IMMUNITY, V7, P517, DOI 10.1016/S1074-7613(00)80373-8; Sugawara T, 1998, IMMUNITY, V9, P565, DOI 10.1016/S1074-7613(00)80639-1; Surh CD, 1997, IMMUNITY, V7, P209, DOI 10.1016/S1074-7613(00)80524-5; SUZUKI G, 1986, J IMMUNOL, V136, P230; Tourne S, 1997, IMMUNITY, V7, P187, DOI 10.1016/S1074-7613(00)80522-1; VASQUEZ NJ, 1992, J EXP MED, V175, P1307, DOI 10.1084/jem.175.5.1307; VASQUEZ NJ, 1994, IMMUNITY, V1, P45, DOI 10.1016/1074-7613(94)90008-6; VONBOEHMER H, 1994, CELL, V76, P219, DOI 10.1016/0092-8674(94)90330-1; Weinberg K, 1995, Biol Blood Marrow Transplant, V1, P18; WHITE J, 1989, CELL, V56, P27, DOI 10.1016/0092-8674(89)90980-X; YUNG RL, 1994, RHEUM DIS CLIN N AM, V20, P61	56	58	62	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2000	6	3					298	305						8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	288TL	10700232				2022-12-25	WOS:000085580500040
J	Murgia, M; Serrano, AL; Calabria, E; Pallafacchina, G; Lomo, T; Schiaffino, S				Murgia, M; Serrano, AL; Calabria, E; Pallafacchina, G; Lomo, T; Schiaffino, S			Ras is involved in nerve-activity-dependent regulation of muscle genes	NATURE CELL BIOLOGY			English	Article							ACTIVATED PROTEIN-KINASE; MYOSIN HEAVY-CHAIN; HUMAN SKELETAL-MUSCLE; FIBER-TYPE; ELECTRICAL-ACTIVITY; REGENERATING MUSCLE; SATELLITE CELLS; SLOW MYOSIN; EXPRESSION; PATHWAY	Gene expression in skeletal muscle is regulated by the firing pattern of motor neurons, but the signalling systems involved in excitation-transcription coupling are unknown. Here, using in vivo transfection in regenerating muscle, we show that constitutively active pas and a Ras mutant that selectively activates the MAPK(ERK) pathway are able to mimic the effects of slow motor neurons on expression of myosin genes. Conversely, the effect of slow motor neurons is inhibited by a dominant-negative Has mutant. MAPK(ERK) activity is increased by innervation and by low-frequency electrical stimulation. These results indicate that Ras-MAPK signalling is involved in promoting nerve-activity-dependent differentiation of slow muscle fibres in vivo.	Univ Padua, Dept Biomed Sci, I-35121 Padua, Italy; Univ Padua, CNR, Ctr Muscle Biol & Physiopathol, I-35121 Padua, Italy; Univ Oslo, Dept Physiol, N-0317 Oslo, Norway	University of Padua; Consiglio Nazionale delle Ricerche (CNR); University of Padua; University of Oslo	Schiaffino, S (corresponding author), Univ Padua, Dept Biomed Sci, Via G Colombo 3, I-35121 Padua, Italy.	schiaffi@civ.bio.unipd.it	Pallafacchina, Giorgia/K-4056-2016; Calabria, Elisa/K-3849-2014; Serrano, A/I-9198-2014	Pallafacchina, Giorgia/0000-0001-9766-5970; Calabria, Elisa/0000-0001-6557-0379; Schiaffino, Stefano/0000-0002-5607-6421	Telethon [A.058] Funding Source: Medline	Telethon(Fondazione Telethon)		Aronson D, 1997, J BIOL CHEM, V272, P25636, DOI 10.1074/jbc.272.41.25636; Aronson D, 1997, J CLIN INVEST, V99, P1251, DOI 10.1172/JCI119282; AUSONI S, 1990, J NEUROSCI, V10, P153; Barjot C, 1995, J MUSCLE RES CELL M, V16, P619, DOI 10.1007/BF00130243; Bennett AM, 1997, SCIENCE, V278, P1288, DOI 10.1126/science.278.5341.1288; Calvo S, 1999, MOL CELL BIOL, V19, P515; CHAHINE KG, 1993, J BIOL CHEM, V268, P2893; Chin ER, 1998, GENE DEV, V12, P2499, DOI 10.1101/gad.12.16.2499; CRESPO P, 1994, J BIOL CHEM, V269, P21103; DENARDI C, 1993, J CELL BIOL, V123, P823, DOI 10.1083/jcb.123.4.823; DEVLIN BH, 1989, J BIOL CHEM, V264, P13896; DiMario JX, 1997, DEV BIOL, V188, P167, DOI 10.1006/dbio.1997.8619; Dolmetsch RE, 1997, NATURE, V386, P855, DOI 10.1038/386855a0; DUDERT A, 1995, PHYSIOL REV, V75, P339; DUSTERHOFT S, 1993, DIFFERENTIATION, V53, P25, DOI 10.1111/j.1432-0436.1993.tb00642.x; EFTIMIE R, 1991, P NATL ACAD SCI USA, V88, P1349, DOI 10.1073/pnas.88.4.1349; ESSER K, 1993, DEV BIOL, V159, P173, DOI 10.1006/dbio.1993.1231; FELDMAN JL, 1991, DEV BIOL, V143, P320, DOI 10.1016/0012-1606(91)90083-F; Fields RD, 1997, J NEUROSCI, V17, P7252; Finkbeiner S, 1996, NEURON, V16, P233, DOI 10.1016/S0896-6273(00)80040-9; Goodyear LJ, 1996, AM J PHYSIOL-ENDOC M, V271, pE403, DOI 10.1152/ajpendo.1996.271.2.E403; Gredinger E, 1998, J BIOL CHEM, V273, P10436, DOI 10.1074/jbc.273.17.10436; GU XN, 1995, NATURE, V375, P784, DOI 10.1038/375784a0; Hasegawa K, 1997, CIRCULATION, V96, P3943; HENNIG R, 1985, NATURE, V314, P164, DOI 10.1038/314164a0; HUANG CF, 1992, NEURON, V9, P671, DOI 10.1016/0896-6273(92)90030-H; Hughes SM, 1999, J CELL BIOL, V145, P633, DOI 10.1083/jcb.145.3.633; HUGHES SM, 1993, DEVELOPMENT, V118, P1137; Jerkovic R, 1997, CELL STRUCT FUNCT, V22, P147, DOI 10.1247/csf.22.147; Jerkovic R, 1997, J MUSCLE RES CELL M, V18, P369, DOI 10.1023/A:1018630311208; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; KLARSFELD A, 1989, NEURON, V2, P1229, DOI 10.1016/0896-6273(89)90307-3; Naya FJ, 2000, J BIOL CHEM, V275, P4545, DOI 10.1074/jbc.275.7.4545; OLSON EN, 1987, MOL CELL BIOL, V7, P2104, DOI 10.1128/MCB.7.6.2104; Ramocki MB, 1997, MOL CELL BIOL, V17, P3547, DOI 10.1128/MCB.17.7.3547; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; Rosenblatt JD, 1996, DIFFERENTIATION, V60, P39, DOI 10.1046/j.1432-0436.1996.6010039.x; SCHIAFFINO S, 1989, J MUSCLE RES CELL M, V10, P197, DOI 10.1007/BF01739810; Schiaffino S, 1996, PHYSIOL REV, V76, P371, DOI 10.1152/physrev.1996.76.2.371; Semsarian C, 1999, NATURE, V400, P576, DOI 10.1038/23054; Sherwood DJ, 1999, AM J PHYSIOL-ENDOC M, V276, pE870, DOI 10.1152/ajpendo.1999.276.5.E870; VITADELLO M, 1994, HUM GENE THER, V5, P11, DOI 10.1089/hum.1994.5.1-11; VOYTIK SL, 1993, DEV DYNAM, V198, P214, DOI 10.1002/aja.1001980307; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; Widegren U, 1998, FASEB J, V12, P1379, DOI 10.1096/fasebj.12.13.1379; WOLFF JA, 1990, SCIENCE, V247, P1465, DOI 10.1126/science.1690918	46	173	188	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	MAR	2000	2	3					142	147		10.1038/35004013	http://dx.doi.org/10.1038/35004013			6	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	292AE	10707084				2022-12-25	WOS:000085771300013
J	Haider, NB; Jacobson, SG; Cideciyan, AV; Swiderski, R; Streb, LM; Searby, C; Beck, G; Hockey, R; Hanna, DB; Gorman, S; Duhl, D; Carmi, R; Bennett, J; Weleber, RG; Fishman, GA; Wright, AF; Stone, EM; Sheffield, VC				Haider, NB; Jacobson, SG; Cideciyan, AV; Swiderski, R; Streb, LM; Searby, C; Beck, G; Hockey, R; Hanna, DB; Gorman, S; Duhl, D; Carmi, R; Bennett, J; Weleber, RG; Fishman, GA; Wright, AF; Stone, EM; Sheffield, VC			Mutation of a nuclear receptor gene, NR2E3, causes enhanced S cone syndrome, a disorder of retinal cell fate	NATURE GENETICS			English	Article							SENSITIVITY	Hereditary human retinal degenerative diseases usually affect the mature photoreceptor topography by reducing the number of cells through apoptosis, resulting in loss of visual function(1). Only one inherited retinal disease, the enhanced S-cone syndrome (ESCS), manifests a gain in function of photoreceptors. ESCS is an autosomal recessive retinopathy in which patients have an increased sensitivity to blue light; perception of blue light is mediated by what is normally the least populous cone photoreceptor subtype, the S (short wavelength, blue) cones(2-8). People with ESCS also suffer visual loss, with night blindness occurring from early in life, varying degrees of L (long, red)- and M (middle, green)-cone vision, and retinal degeneration. The altered ratio of S- to L/M-cone photoreceptor sensitivity in ESCS may be due to abnormal cone cell fate determination during retinal development(7). In 94% of a cohort of ESCS probands we found mutations in NR2E3 (also known as PNR), which encodes a retinal nuclear receptor recently discovered to be a ligand-dependent transcription factor(9). Expression of NR2E3 was limited to the outer nuclear layer of the human retina. Our results suggest that NR2E3 has a role in determining photoreceptor phenotype during human retinogenesis.	Univ Iowa, Howard Hughes Med Inst, Dept Pediat, Iowa City, IA 52242 USA; Univ Iowa, Howard Hughes Med Inst, Dept Ophthalmol, Iowa City, IA 52242 USA; Univ Penn, Scheie Eye Inst, Dept Ophthalmol, Philadelphia, PA 19104 USA; Chiron Corp, Emeryville, CA 94608 USA; Ben Gurion Univ Negev, Inst Genet, Soroka Med Ctr, IL-84105 Beer Sheva, Israel; Oregon Hlth & Sci Univ, Casey Eye Inst, Portland, OR 97201 USA; Univ Illinois, Coll Med, Dept Ophthalmol, Chicago, IL USA; Western Gen Hosp, MRC Human Genet Unit, Edinburgh EH4 2XU, Midlothian, Scotland	Howard Hughes Medical Institute; University of Iowa; Howard Hughes Medical Institute; University of Iowa; University of Pennsylvania; Pennsylvania Medicine; Novartis; Ben Gurion University; Soroka Medical Center; Oregon Health & Science University; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Edinburgh	Sheffield, VC (corresponding author), Univ Iowa, Howard Hughes Med Inst, Dept Pediat, Iowa City, IA 52242 USA.	val-sheffield@uiowa.edu	Cideciyan, Artur V/A-1075-2007	Cideciyan, Artur V/0000-0002-2018-0905; Searby, Charles/0000-0002-8108-8782; Jacobson, Samuel/0000-0003-2122-169X; Stone, Edwin M./0000-0003-3343-4414; Sheffield, Val/0000-0002-6282-0835	NEI NIH HHS [EY05627, EY11298, EY10539] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY010539, R01EY011298] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ADLER R, 1993, INVEST OPHTH VIS SCI, V34, P1677; BASSAM BJ, 1991, ANAL BIOCHEM, V196, P80, DOI 10.1016/0003-2697(91)90120-I; Blumberg B, 1998, GENE DEV, V12, P3149, DOI 10.1101/gad.12.20.3149; Bumsted K, 1999, J COMP NEUROL, V403, P502; CARMI R, 1995, AM J MED GENET, V59, P199, DOI 10.1002/ajmg.1320590216; CEPKO CL, 1993, PROG RETIN RES, V12, P1, DOI 10.1016/0278-4327(93)90002-B; Cepko CL, 1999, CURR OPIN NEUROBIOL, V9, P37, DOI 10.1016/S0959-4388(99)80005-1; Chen F, 1999, P NATL ACAD SCI USA, V96, P15149, DOI 10.1073/pnas.96.26.15149; Daniel A, 1999, DEVELOPMENT, V126, P2945; FAVRE M, 1958, Ophthalmologica, V135, P604; FISHMAN GA, 1976, BRIT J OPHTHALMOL, V60, P345, DOI 10.1136/bjo.60.5.345; FISHMAN GA, 1989, OPHTHALMOLOGY, V96, P913; Freund C, 1996, HUM MOL GENET, V5, P1471, DOI 10.1093/hmg/5.Supplement_1.1471; Greenstein VC, 1996, VISION RES, V36, P3711, DOI 10.1016/0042-6989(96)00073-9; HENDRICKSON A, 1996, GREAT BAS VIS SCI S, P42; HOOD DC, 1995, VISION RES, V35, P1473, DOI 10.1016/0042-6989(95)98727-Q; JACOB JB, 1991, 6TH P WORLD TEL FOR, V1, P111; JACOBSON SG, 1990, INVEST OPHTH VIS SCI, V31, P827; Jacobson SG, 1998, INVEST OPHTH VIS SCI, V39, P2417; KELLNER U, 1993, CLIN VISION SCI, V8, P425; Kobayashi M, 1999, P NATL ACAD SCI USA, V96, P4814, DOI 10.1073/pnas.96.9.4814; MARMOR MF, 1990, AM J OPHTHALMOL, V110, P124, DOI 10.1016/S0002-9394(14)76980-6; Rattner A, 1999, ANNU REV GENET, V33, P89, DOI 10.1146/annurev.genet.33.1.89; ROMAN AJ, 1991, EXP EYE RES, V53, P685, DOI 10.1016/0014-4835(91)90230-C; Swiderski RE, 1999, MOL BRAIN RES, V68, P64, DOI 10.1016/S0169-328X(99)00085-6; SZEL A, 1994, DEV BRAIN RES, V81, P1, DOI 10.1016/0165-3806(94)90062-0; SZEL A, 1994, NATURE, V370, P336, DOI 10.1038/370336a0; WIKLER KC, 1994, P NATL ACAD SCI USA, V91, P6534, DOI 10.1073/pnas.91.14.6534; Wikler KC, 1996, PERSPECT DEV NEUROBI, V3, P161; WILLY PJ, 1998, HORMONES SIGNALING, V1, P307	30	352	367	0	11	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	FEB	2000	24	2					127	131		10.1038/72777	http://dx.doi.org/10.1038/72777			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	280LQ	10655056				2022-12-25	WOS:000085104600011
J	Westin, L; Xu, X; Miller, C; Wang, L; Edman, CF; Nerenberg, M				Westin, L; Xu, X; Miller, C; Wang, L; Edman, CF; Nerenberg, M			Anchored multiplex amplification on a microelectronic chip array	NATURE BIOTECHNOLOGY			English	Article						multiplex amplification; anchored amplification; SDA; microelectronic chip	STRAND DISPLACEMENT AMPLIFICATION; GENE-EXPRESSION; DNA; HYBRIDIZATION; DIAGNOSTICS; MICROARRAY; MUTATION; PCR	We have developed a method for anchored amplification on a microchip array that allows amplification and detection of multiple targets in an open format. Electronic anchoring of sets of amplification primers in distinct areas on the microchip permitted primer-primer interactions to be reduced and distinct zones of amplification created, thereby increasing the efficiency of the multiplex amplification reactions. We found strand displacement amplification (SDA) to be ideal for use in our microelectronic chip system because of the isothermal nature of the assay, which provides a rapid amplification system readily compatible with simple instrumentation. Anchored SDA supported multiplex DNA or RNA amplification without decreases in amplification efficiency, This microelectronic chip-based amplification system allows multiplexed amplification and detection to be performed on the same platform, streamlining development of any nucleic acid-based assay.	Nanogen Inc, Dept Mol Biol, San Diego, CA USA; Nanogen Inc, Dept Genom, San Diego, CA USA; Nanotron Inc, San Diego, CA USA		Westin, L (corresponding author), Nanogen Inc, Dept Mol Biol, San Diego, CA USA.			EDMAN, CARL/0000-0002-1596-3016				ADAMS CP, 1997, Patent No. 5641658; BERTINA RM, 1994, NATURE, V369, P64, DOI 10.1038/369064a0; Brownie J, 1997, NUCLEIC ACIDS RES, V25, P3235, DOI 10.1093/nar/25.16.3235; Chee M, 1996, SCIENCE, V274, P610, DOI 10.1126/science.274.5287.610; Debouck C, 1999, NAT GENET, V21, P48, DOI 10.1038/4475; Edman CF, 1997, NUCLEIC ACIDS RES, V25, P4907, DOI 10.1093/nar/25.24.4907; EDWARDS MC, 1994, PCR METH APPL, V3, pS65; EGGERS M, 1995, HEMATOL PATHOL, V9, P1; Ferguson JA, 1996, NAT BIOTECHNOL, V14, P1681, DOI 10.1038/nbt1296-1681; Halpern NA, 1999, CRIT CARE CLIN, V15, P577, DOI 10.1016/S0749-0704(05)70072-5; Hatch A, 1999, GENET ANAL-BIOMOL E, V15, P35, DOI 10.1016/S1050-3862(98)00014-X; Lizardi PM, 1998, NAT GENET, V19, P225, DOI 10.1038/898; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; Nycz CM, 1998, ANAL BIOCHEM, V259, P226, DOI 10.1006/abio.1998.2641; Pasternack R, 1997, J CLIN MICROBIOL, V35, P676, DOI 10.1128/JCM.35.3.676-678.1997; Romano JW, 1997, IMMUNOL INVEST, V26, P15, DOI 10.3109/08820139709048912; RYCHLIK W, 1995, MOL BIOTECHNOL, V3, P129, DOI 10.1007/BF02789108; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; Shuber AP, 1995, GENOME RES, V5, P488, DOI 10.1101/gr.5.5.488; Sosnowski RG, 1997, P NATL ACAD SCI USA, V94, P1119, DOI 10.1073/pnas.94.4.1119; Spargo CA, 1996, MOL CELL PROBE, V10, P247, DOI 10.1006/mcpr.1996.0034; SVENSSON PJ, 1994, NEW ENGL J MED, V330, P517, DOI 10.1056/NEJM199402243300801; VANGELDER RN, 1990, P NATL ACAD SCI USA, V87, P1663, DOI 10.1073/pnas.87.5.1663; WALKER GT, 1992, P NATL ACAD SCI USA, V89, P392, DOI 10.1073/pnas.89.1.392; Weiler J, 1996, ANAL BIOCHEM, V243, P218, DOI 10.1006/abio.1996.0509	25	82	184	0	18	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	FEB	2000	18	2					199	204		10.1038/72658	http://dx.doi.org/10.1038/72658			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	281FH	10657128				2022-12-25	WOS:000085146900028
J	Grady, WM; Willis, J; Guilford, PJ; Dunbier, AK; Toro, TT; Lynch, H; Wiesner, G; Ferguson, K; Eng, C; Park, JG; Kim, SJ; Markowitz, S				Grady, WM; Willis, J; Guilford, PJ; Dunbier, AK; Toro, TT; Lynch, H; Wiesner, G; Ferguson, K; Eng, C; Park, JG; Kim, SJ; Markowitz, S			Methylation of the CDH1 promoter as the second genetic hit in hereditary diffuse gastric cancer	NATURE GENETICS			English	Article							CADHERIN GERMLINE MUTATIONS; CPG ISLAND METHYLATION; DNA METHYLATION; COLORECTAL-CANCER; HYPERMETHYLATION; TUMORS; CELLS		Case Western Reserve Univ, Sch Med, Dept Med, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Pathol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Human Genet, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Ireland Canc Ctr, Cleveland, OH 44106 USA; Univ Hosp Cleveland, Cleveland, OH 44106 USA; Univ Otago, Dept Biochem, Canc Genet Lab, Dunedin, New Zealand; Creighton Univ, Sch Med, Dept Prevent Med, Omaha, NE 68178 USA; Ohio State Univ, Sch Med, Clin Canc Genet Program, Ctr Comprehens Canc, Columbus, OH 43210 USA; Ohio State Univ, Sch Med, Human Canc Genet Program, Ctr Comprehens Canc, Columbus, OH 43210 USA; Ohio State Univ, Sch Med, Div Human Genet, Dept Internal Med, Columbus, OH 43210 USA; Seoul Natl Univ Hosp, Dept Surg, Seoul 110744, South Korea; NCI, Lab Cell Regulat & Carcinogenesis, NIH, Bethesda, MD 20892 USA; Howard Hughes Med Inst, Cleveland, OH USA	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; University Hospitals of Cleveland; University of Otago; Creighton University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; Seoul National University (SNU); Seoul National University Hospital; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Howard Hughes Medical Institute	Markowitz, S (corresponding author), Case Western Reserve Univ, Sch Med, Dept Med, Cleveland, OH 44106 USA.		Park, Jae-Gahb/J-5494-2012	Guilford, Parry/0000-0002-7256-9576; Dunbier, Anita/0000-0003-4621-7419; Eng, Charis/0000-0002-3693-5145	NCI NIH HHS [KO8 CA77676, R01 CA67409, R01 CA72160] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K08CA077676, R01CA072160, R01CA067409] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahuja N, 1998, CANCER RES, V58, P5489; Graff JR, 1997, J BIOL CHEM, V272, P22322, DOI 10.1074/jbc.272.35.22322; GRAFF JR, 1995, CANCER RES, V55, P5195; Guilford P, 1998, NATURE, V392, P402, DOI 10.1038/32918; Guilford PJ, 1999, HUM MUTAT, V14, P249, DOI 10.1002/(SICI)1098-1004(1999)14:3<249::AID-HUMU8>3.0.CO;2-9; Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; Lengauer C, 1997, P NATL ACAD SCI USA, V94, P2545, DOI 10.1073/pnas.94.6.2545; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; Myohanen SK, 1998, CANCER RES, V58, P591; Prowse AH, 1997, AM J HUM GENET, V60, P765; Richards FM, 1999, HUM MOL GENET, V8, P607, DOI 10.1093/hmg/8.4.607; Stirzaker C, 1997, CANCER RES, V57, P2229; Toyota M, 1999, CANCER RES, V59, P5438	15	330	348	0	31	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	SEP	2000	26	1					16	17		10.1038/79120	http://dx.doi.org/10.1038/79120			2	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	350AK	10973239				2022-12-25	WOS:000089078000009
J	Xu, L; Chen, YG; Massague, J				Xu, L; Chen, YG; Massague, J			The nuclear import function of Smad2 is masked by SARA and unmasked by TGF beta-dependent phosphorylation	NATURE CELL BIOLOGY			English	Article							PROTEIN IMPORT; RECEPTOR; SUBSTRATE; PATHWAY; BINDING; SIGNAL; CELLS; MADR2; ALPHA		Mem Sloan Kettering Canc Ctr, Cell Biol Program, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Howard Hughes Med Inst, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center	Massague, J (corresponding author), Mem Sloan Kettering Canc Ctr, Cell Biol Program, 1275 York Ave, New York, NY 10021 USA.			Massague, Joan/0000-0001-9324-8408	NATIONAL CANCER INSTITUTE [R37CA034610, R01CA034610] Funding Source: NIH RePORTER; NCI NIH HHS [CA34610] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAM SA, 1992, METHOD ENZYMOL, V219, P97; ADAM SA, 1990, J CELL BIOL, V111, P807, DOI 10.1083/jcb.111.3.807; Baker JC, 1996, GENE DEV, V10, P1880, DOI 10.1101/gad.10.15.1880; Conti E, 1998, CELL, V94, P193, DOI 10.1016/S0092-8674(00)81419-1; Dong CM, 2000, MOL CELL, V5, P27, DOI 10.1016/S1097-2765(00)80400-1; Gorlich D, 1996, EMBO J, V15, P1810, DOI 10.1002/j.1460-2075.1996.tb00530.x; Kretzschmar M, 1999, GENE DEV, V13, P804, DOI 10.1101/gad.13.7.804; Kretzschmar M, 1997, GENE DEV, V11, P984, DOI 10.1101/gad.11.8.984; Liu F, 1997, GENE DEV, V11, P3157, DOI 10.1101/gad.11.23.3157; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Massague J, 2000, GENE DEV, V14, P627; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; Nakielny S, 1999, CELL, V99, P677, DOI 10.1016/S0092-8674(00)81666-9; Pollard VW, 1996, CELL, V86, P985, DOI 10.1016/S0092-8674(00)80173-7; REXACH M, 1995, CELL, V83, P683, DOI 10.1016/0092-8674(95)90181-7; Shi YG, 1998, CELL, V94, P585, DOI 10.1016/S0092-8674(00)81600-1; Tsukazaki T, 1998, CELL, V95, P779, DOI 10.1016/S0092-8674(00)81701-8; WIESER R, 1995, EMBO J, V14, P2199, DOI 10.1002/j.1460-2075.1995.tb07214.x; Wu G, 2000, SCIENCE, V287, P92, DOI 10.1126/science.287.5450.92	20	119	131	0	11	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	AUG	2000	2	8					559	562		10.1038/35019649	http://dx.doi.org/10.1038/35019649			4	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	341TE	10934479				2022-12-25	WOS:000088605000024
J	Alexander, CM; Reichsman, F; Hinkes, MT; Lincecum, J; Becker, KA; Cumberledge, S; Bernfield, M				Alexander, CM; Reichsman, F; Hinkes, MT; Lincecum, J; Becker, KA; Cumberledge, S; Bernfield, M			Syndecan-1 is required for Wnt-1-induced mammary tumorigenesis in mice	NATURE GENETICS			English	Article							HEPARAN-SULFATE PROTEOGLYCANS; CELL-SURFACE PROTEOGLYCAN; TRANSGENIC MICE; EPITHELIAL-CELLS; DROSOPHILA; FAMILY; GENE; TRANSFORMATION; RECEPTOR; WNT-1	Syndecan-1 is a cell-surface, heparan-sulphate proteoglycan (HSPG) predominantly expressed by epithelial cells. It binds specifically to many proteins, including oncoproteins. For example, it induces the assembly of a signalling complex between FCF ligands and their cognate receptors(1). But so far there has been no direct evidence that this proteoglycan contributes to tumorigenesis. Here we have examined the role of syndecan-1 (encoded by Sdc1) during mammary tumour formation in response to the ectopic expression of the proto-oncogene Wnt1. We crossed syndecan-1-deficient mice with transgenic mice that express Wnt1 in mammary gland (TgN(Wnt-1)1Hev; ref. 2). Ectopic Wnt-1 expression induces generalized mammary hyperplasia, followed by the development of solitary tumours (median time 22 weeks(3)). We show that in Sdc1(-/-) mice, Wnt-1-induced hyperplasia in virgin mammary gland was reduced by 70%, indicating that the Wnt-1 signalling pathway was inhibited. Of the 39 tumours that developed in a test cohort of mice, only 1 evolved in the Sdc1(-/-) background. In addition, we show that soluble syndecan-1 ectodomain purified from mouse mammary epithelial cells stimulates the activity of a Wnt-1 homologue in a tissue culture assay. Our results provide both genetic and biochemical evidence that syndecan-1 can modulate Wnt signalling, and is critical for Wnt-1-induced tumorigenesis of the mouse mammary gland.	Childrens Hosp, Div Newborn Med, Boston, MA 02115 USA; Univ Massachusetts, Dept Biochem & Mol Biol, Amherst, MA 01003 USA	Harvard University; Boston Children's Hospital; University of Massachusetts System; University of Massachusetts Amherst	Alexander, CM (corresponding author), Childrens Hosp, Div Newborn Med, Enders 950, Boston, MA 02115 USA.							Bellaiche Y, 1998, NATURE, V394, P85, DOI 10.1038/27932; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0; Binari RC, 1997, DEVELOPMENT, V124, P2623; BRADLEY RS, 1990, EMBO J, V9, P1569, DOI 10.1002/j.1460-2075.1990.tb08276.x; BROWN AMC, 1986, CELL, V46, P1001, DOI 10.1016/0092-8674(86)90699-9; BURRUS LW, 1995, EXP CELL RES, V220, P363, DOI 10.1006/excr.1995.1327; Cardiff RD, 1999, J MAMMARY GLAND BIOL, V4, P105, DOI 10.1023/A:1018712905244; Conrad H. E., 1998, HEPARIN BINDING PROT; GUIMOND S, 1993, J BIOL CHEM, V268, P23906; Hacker U, 1997, DEVELOPMENT, V124, P3565; Haerry TE, 1997, DEVELOPMENT, V124, P3055; Jackson D, 1997, J MAMMARY GLAND BIOL, V2, P385, DOI 10.1023/A:1026351414004; Jackson SM, 1997, DEVELOPMENT, V124, P4113; JALKANEN M, 1987, J CELL BIOL, V105, P3087, DOI 10.1083/jcb.105.6.3087; JUE SF, 1992, MOL CELL BIOL, V12, P321, DOI 10.1128/MCB.12.1.321; KATO M, 1995, MOL BIOL CELL, V6, P559, DOI 10.1091/mbc.6.5.559; LEE FS, 1995, P NATL ACAD SCI USA, V92, P2268, DOI 10.1073/pnas.92.6.2268; Lin XH, 1999, NATURE, V400, P281, DOI 10.1038/22343; Lin XH, 1999, DEVELOPMENT, V126, P3715; Pennica D, 1998, P NATL ACAD SCI USA, V95, P14717, DOI 10.1073/pnas.95.25.14717; RAMAKRISHNA NR, 1993, DEVELOPMENT S, V119, P95; RAPRAEGER AC, 1995, CHEM BIOL, V2, P645, DOI 10.1016/1074-5521(95)90025-X; Reichsman F, 1996, J CELL BIOL, V135, P819, DOI 10.1083/jcb.135.3.819; SHACKLEFORD GM, 1993, P NATL ACAD SCI USA, V90, P740, DOI 10.1073/pnas.90.2.740; Shimizu H, 1997, CELL GROWTH DIFFER, V8, P1349; THOMAS KR, 1991, CELL, V67, P969, DOI 10.1016/0092-8674(91)90369-A; Tsuda M, 1999, NATURE, V400, P276, DOI 10.1038/22336; TSUKAMOTO AS, 1988, CELL, V55, P619, DOI 10.1016/0092-8674(88)90220-6; Ugolini F, 1999, ONCOGENE, V18, P1903, DOI 10.1038/sj.onc.1202739; Uren A, 2000, J BIOL CHEM, V275, P4374, DOI 10.1074/jbc.275.6.4374	32	278	285	0	11	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUL	2000	25	3					329	332		10.1038/77108	http://dx.doi.org/10.1038/77108			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	329RD	10888884				2022-12-25	WOS:000087920900024
J	Brinkmeier, H; Aulkemeyer, P; Wollinsky, KH; Rudel, R				Brinkmeier, H; Aulkemeyer, P; Wollinsky, KH; Rudel, R			An endogenous pentapeptide acting as a sodium channel blocker in inflammatory autoimmune disorders of the central nervous system	NATURE MEDICINE			English	Article							GUILLAIN-BARRE-SYNDROME; CEREBROSPINAL-FLUID; MULTIPLE-SCLEROSIS; NEUROLOGICAL DISEASE; ANTIBODIES; SERUM	Reversible blockade of sodium channels by endogenous substances has been claimed to account for the fast exacerbations and relapses commonly seen in demyelinating autoimmune diseases(1-4). Evidence has been provided that in the cerebrospinal fluid of patients with multiple sclerosis(5) or Guillain-Barre syndrome(6), a sodium-channel-blocking factor exists that has properties of local anesthetic agents(7,8). This factor could contribute to the nerve conduction block and paresis seen in these disorders(9-11). We describe here a previously unknown endogenous substance in human cerebrospinal fluid with distinct channel-blocking properties even at very tow (0.00001 M) concentrations. The pentapeptide with the sequence Gln-Tyr-Asn-Ala-Asp exerted its blocking action by shifting the steady-state inactivation curve of the sodium channels to more-negative potentials, as most local anesthetics do. In the cerebrospinal fluid of healthy individuals, its concentration was about 3 mu M, whereas in patients with multiple sclerosis and Guillain-Barre syndrome, it increased 300-1,400%. At these concentrations, the peptide's blocking efficacy was higher than that of 50 mu M lidocaine. At a concentration of 10 mu M, lidocaine is able to 'unmask' subclinical lesions in multiple sclerosis(12); thus, the endogenous pentapeptide may well contribute to the fast changes of symptoms. Furthermore, it may become valuable as a marker of disease activity.	Univ Ulm, Dept Gen Physiol, D-89069 Ulm, Germany; Rehabil Hosp Ulm, Dept Anaesthesiol & Intens Care, D-89081 Ulm, Germany	Ulm University	Rudel, R (corresponding author), Univ Ulm, Dept Gen Physiol, D-89069 Ulm, Germany.							Aulkemeyer P, 2000, J NEUROL SCI, V172, P49, DOI 10.1016/S0022-510X(99)00285-3; Aulkemeyer P, 1996, NEUROSCI LETT, V216, P37; BRINKMEIER H, 1992, PFLUG ARCH EUR J PHY, V421, P552, DOI 10.1007/BF00375050; Brinkmeier H, 1996, MUSCLE NERVE, V19, P54, DOI 10.1002/(SICI)1097-4598(199601)19:1<54::AID-MUS7>3.0.CO;2-7; BRINKMEIER H, 1993, NEUROSCI LETT, V156, P172, DOI 10.1016/0304-3940(93)90465-W; CATTERALL WA, 1992, PHYSIOL REV, V72, P515; Griffin JW, 1996, ANN NEUROL, V39, P17, DOI 10.1002/ana.410390105; Gutmann L, 1996, NEUROLOGY, V47, P18, DOI 10.1212/WNL.47.1.18; HAMPRECHT B, 1985, METHOD ENZYMOL, V109, P316; Koller H, 1996, BRAIN, V119, P457, DOI 10.1093/brain/119.2.457; Koller H, 1997, PROG NEUROBIOL, V52, P1, DOI 10.1016/S0301-0082(96)00065-2; PARRY GJ, 1993, GUILLAINBARRE SYNDRO, P1; RAGSDALE DS, 1991, MOL PHARMACOL, V40, P756; SAKURAI M, 1992, NEUROLOGY, V42, P2088, DOI 10.1212/WNL.42.11.2088; TAKIGAWA T, 1995, ANN NEUROL, V37, P436, DOI 10.1002/ana.410370405; WAXMAN SG, 1995, ANN NEUROL, V37, P421, DOI 10.1002/ana.410370403; Weber F, 1999, J NEUROL, V246, P955, DOI 10.1007/s004150050490; WURZ A, 1995, MUSCLE NERVE, V18, P772, DOI 10.1002/mus.880180715	18	64	67	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUL	2000	6	7					808	811		10.1038/77543	http://dx.doi.org/10.1038/77543			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	331VV	10888931				2022-12-25	WOS:000088040100039
J	Morton, WM; Ayscough, KR; McLaughlin, PJ				Morton, WM; Ayscough, KR; McLaughlin, PJ			Latrunculin alters the actin-monomer subunit interface to prevent polymerization	NATURE CELL BIOLOGY			English	Article							FILAMENT; REFINEMENT; MOLSCRIPT; COMPLEX; YEAST		Univ Edinburgh, Inst Cell & Mol Biol, Wellcome Trust Ctr Cell Biol, Edinburgh EH9 3JR, Midlothian, Scotland; Univ Glasgow, Inst Biomed & Life Sci, Glasgow G12 8QQ, Lanark, Scotland	University of Edinburgh; University of Glasgow	McLaughlin, PJ (corresponding author), Univ Edinburgh, Inst Cell & Mol Biol, Wellcome Trust Ctr Cell Biol, Swann Bldg,Kings Bldg,Mayfield Rd, Edinburgh EH9 3JR, Midlothian, Scotland.							Ayscough KR, 1997, J CELL BIOL, V137, P399, DOI 10.1083/jcb.137.2.399; Belmont LD, 1999, J CELL SCI, V112, P1325; COUE M, 1987, FEBS LETT, V213, P316, DOI 10.1016/0014-5793(87)81513-2; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; HOLMES KC, 1990, NATURE, V347, P44, DOI 10.1038/347044a0; KASHMAN Y, 1980, TETRAHEDRON LETT, V21, P3629, DOI 10.1016/0040-4039(80)80255-3; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; MANNHERZ HG, 1992, J MOL BIOL, V226, P899, DOI 10.1016/0022-2836(92)90641-V; MCLAUGHLIN PJ, 1993, NATURE, V364, P685, DOI 10.1038/364685a0; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NEEMAN I, 1975, MAR BIOL, V30, P293, DOI 10.1007/BF00390634; Page R, 1998, J MOL BIOL, V280, P463, DOI 10.1006/jmbi.1998.1879; Sheldrick GM, 1997, METHOD ENZYMOL, V277, P319, DOI 10.1016/S0076-6879(97)77018-6; SPECTOR I, 1983, SCIENCE, V219, P493, DOI 10.1126/science.6681676; WERTMAN KF, 1992, GENETICS, V132, P337	16	377	381	2	20	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	JUN	2000	2	6					376	378		10.1038/35014075	http://dx.doi.org/10.1038/35014075			3	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	321KE	10854330	Green Published			2022-12-25	WOS:000087454000021
J	Duan, DS; Yue, YP; Yan, ZY; Engelhardt, JF				Duan, DS; Yue, YP; Yan, ZY; Engelhardt, JF			A new dual-vector approach to enhance recombinant adeno-associated virus-mediated gene expression through intermolecular cis activation	NATURE MEDICINE			English	Article							ADENOASSOCIATED VIRUS		Univ Iowa, Coll Med, Dept Anat & Cell Biol, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Ctr Gene Therapy, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Dept Internal Med, Iowa City, IA 52242 USA	University of Iowa; University of Iowa; University of Iowa	Engelhardt, JF (corresponding author), Univ Iowa, Coll Med, Dept Anat & Cell Biol, 51 Newton Rd,Room 1-101 BSB, Iowa City, IA 52242 USA.			Engelhardt, John/0000-0003-2389-9277; Yan, Ziying/0000-0001-8210-5567; Duan, Dongsheng/0000-0003-4109-1132	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058340] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK054759] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL58430, R01 HL058340] Funding Source: Medline; NIDDK NIH HHS [P30 DK054759, P30 DK54759] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Duan DS, 1998, J VIROL, V72, P8568, DOI 10.1128/JVI.72.11.8568-8577.1998; Duan DS, 1999, VIROLOGY, V261, P8, DOI 10.1006/viro.1999.9821; Duan DS, 1997, VIRUS RES, V48, P41, DOI 10.1016/S0168-1702(96)01425-6; Duan DS, 1999, J VIROL, V73, P161, DOI 10.1128/JVI.73.1.161-169.1999; FLOTTE TR, 1993, J BIOL CHEM, V268, P3781; LEWIN B, 1997, GENES, V6, P1260; SAMULSKI RJ, 1987, J VIROL, V61, P3096, DOI 10.1128/JVI.61.10.3096-3101.1987; Wagner JA, 1998, LANCET, V351, P1702, DOI 10.1016/S0140-6736(05)77740-0; Yang JS, 1999, J VIROL, V73, P9468, DOI 10.1128/JVI.73.11.9468-9477.1999	9	135	142	0	5	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAY	2000	6	5					595	598		10.1038/75080	http://dx.doi.org/10.1038/75080			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	309YB	10802719				2022-12-25	WOS:000086796200047
J	Guleria, I; Pollard, JW				Guleria, I; Pollard, JW			The trophoblast is a component of the innate immune system during pregnancy	NATURE MEDICINE			English	Article							COLONY-STIMULATING FACTOR; PLACENTAL DEVELOPMENT; FACTOR-I; MACROPHAGES; MOUSE; DIFFERENTIATION; LISTERIOSIS; EXPRESSION; CSF-1; CELLS	Systemic infection with Listeria monocytogenes, a Gram-positive intracellular bacterium, has been used extensively to analyze the innate immune response(1,2). Macrophages are central to this response, acting as both the host for and principal defense against this bacterium. During pregnancy L. monocytogenes has a predilection for replication at the maternal-placental interface and consequently is an important cause of fetal morbidity and mortality(3,4). However, macrophages are mostly excluded from the murine placenta with neutrophils acting as the main immune effector cell against this bacterium(3,5,6). Colony stimulating factor (CSF)-1, a macrophage growth factor, is synthesized in high concentrations by the uterine epithelium during pregnancy, where it is targeted to trophoblast bearing CSF-1-receptors(7,8). To define the involvement of CSF-1 in placental immunity, we infected pregnant mice either homozygous or heterozygous for an inactivating recessive mutation in the gene for CSF-1 (osteopetrotic; Csfm(op)) with L. monocytogenes(9). CSF-1 was required to recruit neutrophils to the site of listerial infection in the decidua basalis, and infection by Listeria remained unrestrained in its absence. CSF-1 acted by inducing the trophoblast to synthesize the neutrophil chemoattractants (KC) and macrophage inflammatory protein (MIP)-2. Thus, during pregnancy, trophoblast responsive to CSF-1 acts to organize the maternal immune response to bacterial infection at the utero-placental interface. This previously unknown function indicates that the trophoblast acts as a pregnancy-specific component of the innate immune system.	Yeshiva Univ Albert Einstein Coll Med, Dept Dev, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Obstet & Gynecol, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Mol Biol, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Womens Hlth, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Pollard, JW (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Dev, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	pollard@aecom.yu.edu		GULERIA, INDIRA/0000-0002-0622-3585	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD030280] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P30CA013330] Funding Source: NIH RePORTER; NCI NIH HHS [P30-CA13330] Funding Source: Medline; NICHD NIH HHS [HD30280] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ARCECI RJ, 1989, P NATL ACAD SCI USA, V86, P8818, DOI 10.1073/pnas.86.22.8818; Ashkar AA, 1999, BIOL REPROD, V61, P493, DOI 10.1095/biolreprod61.2.493; BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; CECCHINI MG, 1994, DEVELOPMENT, V120, P1357; GUILBERT L, 1993, IMMUNOL CELL BIOL, V71, P49, DOI 10.1038/icb.1993.5; KAUFMANN SHE, 1993, ANNU REV IMMUNOL, V11, P129, DOI 10.1146/annurev.iy.11.040193.001021; KISO Y, 1992, EXPERIENTIA, V48, P973, DOI 10.1007/BF01919144; Lorber B, 1997, CLIN INFECT DIS, V24, P1, DOI 10.1093/clinids/24.1.1; LU CY, 1991, MOLECULAR AND CELLULAR IMMUNOBIOLOGY OF THE MATERNAL FETAL INTERFACE, P141; NILSSON SK, 1995, BLOOD, V86, P66, DOI 10.1182/blood.V86.1.66.bloodjournal86166; ORLOFSKY A, 1987, EMBO J, V6, P2947, DOI 10.1002/j.1460-2075.1987.tb02599.x; Pollard JW, 1998, CONT ENDOCRINOL, V9, P59; POLLARD JW, 1987, NATURE, V330, P484, DOI 10.1038/330484a0; Pollard JW., 1996, ADV D BIOCH, V4, P153; REDLINE RW, 1988, J IMMUNOL, V140, P3947; REINER SL, 1994, J IMMUNOL METHODS, V175, P275, DOI 10.1016/0022-1759(94)90370-0; REINER SL, 1994, J IMMUNOL METHODS, V173, P133, DOI 10.1016/0022-1759(94)90291-7; REINER SL, 1993, J IMMUNOL METHODS, V165, P37, DOI 10.1016/0022-1759(93)90104-F; SCHAIBLE U, 1999, ADV IMMUNOL, P267; TAKAHASHI K, 1991, J LEUKOCYTE BIOL, V50, P57, DOI 10.1002/jlb.50.1.57; Unanue ER, 1997, IMMUNOL REV, V158, P11, DOI 10.1111/j.1600-065X.1997.tb00988.x; Unanue ER, 1996, RES IMMUNOL, V147, P499, DOI 10.1016/S0923-2494(97)85214-5; WEGMANN TG, 1993, IMMUNOL TODAY, V14, P353, DOI 10.1016/0167-5699(93)90235-D	23	147	154	0	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2000	6	5					589	593		10.1038/75074	http://dx.doi.org/10.1038/75074			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	309YB	10802718				2022-12-25	WOS:000086796200046
J	Ellegren, H				Ellegren, H			Heterogeneous mutation processes in human microsatellite DNA sequences	NATURE GENETICS			English	Article							MALE-DRIVEN EVOLUTION; MOLECULAR EVOLUTION; DIRECTIONALITY; INSTABILITY; LENGTH; BIAS; LOCI	Although microsatellite polymorphisms are one of the most commonly used tools in genetic analyses(1-3), it remains to be understood how microsatellite DNA has evolved as a ubiquitous and highly abundant class of repetitive sequences in eukaryotic genomes(4). On the basis of analyses of spontaneous human microsatellite mutations of germline origin, I show here that different mutation biases underlie the evolution of microsatellite repeats. The within-locus mutation rate increases with allele length, but is not affected by the size difference between an individual's two alleles (allele span). Within loci, long alleles tend to mutate to shorter lengths, thereby acting to prevent infinite growth. Expansions are more common than contractions among dinucleotide repeats, whereas no such trend is evident among tetranucleotide repeats. This observation is consistent with the longer repeat lengths and higher frequency of di- compared with tetranucleotide repeats. An excess of paternally transmitted mutations (male-to-female ratio of 4.9) supports a male-biased mutation rate in the human genome.	Uppsala Univ, Evolutionary Biol Ctr, Dept Evolutionary Biol, SE-75236 Uppsala, Sweden	Uppsala University	Ellegren, H (corresponding author), Uppsala Univ, Evolutionary Biol Ctr, Dept Evolutionary Biol, Norbyvagen 18D, SE-75236 Uppsala, Sweden.	Hans.Ellegren@evolution.uu.se						Amos W, 1996, NAT GENET, V13, P390, DOI 10.1038/ng0896-390; BANCHS I, 1994, HUM MUTAT, V3, P365, DOI 10.1002/humu.1380030407; BOWCOCK AM, 1994, NATURE, V368, P455, DOI 10.1038/368455a0; Brinkmann B, 1998, AM J HUM GENET, V62, P1408, DOI 10.1086/301869; Chakraborty R, 1997, P NATL ACAD SCI USA, V94, P1041, DOI 10.1073/pnas.94.3.1041; Crow JF, 1997, P NATL ACAD SCI USA, V94, P8380, DOI 10.1073/pnas.94.16.8380; Crow JF, 1997, NAT GENET, V17, P129, DOI 10.1038/ng1097-129; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; El-Maarri O, 1998, AM J HUM GENET, V63, P1001, DOI 10.1086/302065; Ellegren H, 1997, NATURE, V389, P593, DOI 10.1038/39303; Ellegren H, 1997, NAT GENET, V17, P182, DOI 10.1038/ng1097-182; ELLEGREN H, 1995, NAT GENET, V11, P360, DOI 10.1038/ng1295-360; Farbman Albert I., 1994, Seminars in Cell Biology, V5, P3; Farrall M, 1998, AM J HUM GENET, V62, P1260, DOI 10.1086/301829; HAMADA H, 1982, P NATL ACAD SCI-BIOL, V79, P6465, DOI 10.1073/pnas.79.21.6465; Hurst LD, 1998, TRENDS GENET, V14, P446, DOI 10.1016/S0168-9525(98)01577-7; Jones AG, 1999, GENETICS, V152, P1057; Kimura MA, 1985, NEUTRAL THEORY MOL E; McVean GT, 1997, NATURE, V386, P388, DOI 10.1038/386388a0; MIYATA T, 1987, COLD SPRING HARB SYM, V52, P863, DOI 10.1101/SQB.1987.052.01.094; Primmer CR, 1998, MOL BIOL EVOL, V15, P1047, DOI 10.1093/oxfordjournals.molbev.a026003; Primmer CR, 1996, NAT GENET, V13, P391, DOI 10.1038/ng0896-391; RUBINSZTEIN DC, 1995, NAT GENET, V10, P337, DOI 10.1038/ng0795-337; SCHLOTTERER C, 1992, NUCLEIC ACIDS RES, V20, P211, DOI 10.1093/nar/20.2.211; SHIMMIN LC, 1993, NATURE, V362, P745, DOI 10.1038/362745a0; Smith NGC, 1999, GENETICS, V152, P661; Vogel F., 1997, HUMAN GENETICS; WEBER JL, 1990, GENOMICS, V7, P524, DOI 10.1016/0888-7543(90)90195-Z; WEBER JL, 1993, HUM MOL GENET, V2, P1123, DOI 10.1093/hmg/2.8.1123; Wierdl M, 1997, GENETICS, V146, P769	30	251	260	0	14	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	APR	2000	24	4					400	402		10.1038/74249	http://dx.doi.org/10.1038/74249			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	299HK	10742106				2022-12-25	WOS:000086192800021
J	Jordan, KC; Clegg, NJ; Blasi, JA; Morimoto, AM; Sen, J; Stein, D; McNeill, H; Deng, WM; Tworoger, M; Ruohola-Baker, H				Jordan, KC; Clegg, NJ; Blasi, JA; Morimoto, AM; Sen, J; Stein, D; McNeill, H; Deng, WM; Tworoger, M; Ruohola-Baker, H			The homeobox gene mirror links EGF signalling to embryonic dorso-ventral axis formation through Notch activation	NATURE GENETICS			English	Article							ANTERIOR-POSTERIOR AXIS; DROSOPHILA OOGENESIS; STEM-CELLS; BODY AXES; RECEPTOR; EXPRESSION; POLARITY; ESTABLISHMENT; POLARIZATION; PATHWAY	Recent studies in vertebrates and Drosophila melanogaster have revealed that Fringe-mediated activation of the Notch pathway has a role in patterning cell layers during organogenesis(1,2). In these processes, a homeobox-containing transcription factor is responsible for spatially regulating fringe (fng) expression and thus directing activation of the Notch pathway along the fng expression border. Here we show that this may be a general mechanism for patterning epithelial cell layers. At three stages in Drosophila oogenesis, mirror (mirr) and fng have complementary expression patterns in the follicle-cell epithelial layer, and at all three stages loss of mirr enlarges, and ectopic expression of mirr restricts, fng expression, with consequences for follicle-cell patterning. These morphological changes are similar to those caused by Notch mutations. Ectopic expression of mirr in the posterior follicle cells induces a stripe of rhomboid (rho) expression and represses pipe (pip), a gene with a role in the establishment of the dorsal-ventral axis, at a distance. Ectopic Notch activation has a similar long-range effect on pip. Our results suggest that Mirror and Notch induce secretion of diffusible morphogens and we have identified TGF-beta (encoded by dpp) as such a molecule in germarium. We also found that mirr expression in dorsal follicle cells is induced by the EGF-receptor (EGFR) pathway and that mirr then represses pip expression in all but the ventral follicle cells, connecting EGFR activation in the dorsal follicle cells to repression of pip in the dorsal and lateral follicle cells. Our results suggest that the differentiation of ventral follicle cells is not a direct consequence of germline signalling, but depends on long-range signals from dorsal follicle cells, and provide a link between early and late events in Drosophila embryonic dorsal-ventral axis formation.	Univ Washington, Mol & Cellular Biol Program, Seattle, WA 98195 USA; Univ Washington, Dept Biochem, Seattle, WA 98195 USA; Univ Washington, Ctr Dev Biol, Seattle, WA 98195 USA; Albert Einstein Coll Med, Dept Mol Genet, Bronx, NY 10467 USA; Imperial Canc Res Fund, Dev Patterning Lab, London WC2A 3PX, England	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Yeshiva University; Albert Einstein College of Medicine; Cancer Research UK	Ruohola-Baker, H (corresponding author), Univ Washington, Mol & Cellular Biol Program, Seattle, WA 98195 USA.	hannele@u.washington.edu	McNeill, Helen/E-4579-2013	McNeill, Helen/0000-0003-1126-5154				Belvin MP, 1996, ANNU REV CELL DEV BI, V12, P393, DOI 10.1146/annurev.cellbio.12.1.393; BRAND AH, 1994, GENE DEV, V8, P629, DOI 10.1101/gad.8.5.629; Brodsky MH, 1996, DEV BIOL, V173, P428, DOI 10.1006/dbio.1996.0038; Bryant Z, 1999, P NATL ACAD SCI USA, V96, P5559, DOI 10.1073/pnas.96.10.5559; Duffy JB, 1998, DEVELOPMENT, V125, P2263; Gonzalez-Reyes A, 1998, DEVELOPMENT, V125, P2837; GONZALEZREYES A, 1995, NATURE, V375, P654, DOI 10.1038/375654a0; Irvine KD, 1999, CURR OPIN GENET DEV, V9, P434, DOI 10.1016/S0959-437X(99)80066-5; Kehl BT, 1998, DEVELOPMENT, V125, P1217; Larkin MK, 1999, DEV GENES EVOL, V209, P301, DOI 10.1007/s004270050256; Larkin MK, 1996, DEVELOPMENT, V122, P3639; Lawrence PA, 1996, CELL, V85, P951, DOI 10.1016/S0092-8674(00)81297-0; MARGOLIS J, 1995, DEVELOPMENT, V121, P3797; McNeill H, 1997, GENE DEV, V11, P1073, DOI 10.1101/gad.11.8.1073; Morimoto AM, 1996, DEVELOPMENT, V122, P3745; NEUMANSILBERBERG FS, 1993, CELL, V75, P165, DOI 10.1016/S0092-8674(05)80093-5; O'Donohue MF, 1998, BIOTECHNIQUES, V24, P910, DOI 10.2144/98246bm01; Queenan AM, 1997, DEVELOPMENT, V124, P3871; Raftery LA, 1999, DEV BIOL, V210, P251, DOI 10.1006/dbio.1999.9282; Ray RP, 1996, GENE DEV, V10, P1711, DOI 10.1101/gad.10.14.1711; ROTH S, 1995, CELL, V81, P967, DOI 10.1016/0092-8674(95)90016-0; RUOHOLA H, 1991, CELL, V66, P433, DOI 10.1016/0092-8674(81)90008-8; RUOHOLABAKER H, 1993, CELL, V73, P953, DOI 10.1016/0092-8674(93)90273-S; Sen J, 1998, CELL, V95, P471, DOI 10.1016/S0092-8674(00)81615-3; Struhl G, 1998, CELL, V93, P649, DOI 10.1016/S0092-8674(00)81193-9; Tworoger M, 1999, GENETICS, V151, P739; Wasserman JD, 1998, CELL, V95, P355, DOI 10.1016/S0092-8674(00)81767-5; Wu JY, 1999, CURR OPIN NEUROBIOL, V9, P537, DOI 10.1016/S0959-4388(99)00020-3; Xie T, 1998, CELL, V94, P251, DOI 10.1016/S0092-8674(00)81424-5; XU T, 1992, DEVELOPMENT, V115, P913	30	69	69	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	APR	2000	24	4					429	433		10.1038/74294	http://dx.doi.org/10.1038/74294			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	299HK	10742112				2022-12-25	WOS:000086192800027
J	Zamir, E; Katz, M; Posen, Y; Erez, N; Yamada, KM; Katz, BZ; Lin, S; Lin, DC; Bershadsky, A; Kam, Z; Geiger, B				Zamir, E; Katz, M; Posen, Y; Erez, N; Yamada, KM; Katz, BZ; Lin, S; Lin, DC; Bershadsky, A; Kam, Z; Geiger, B			Dynamics and segregation of cell-matrix adhesions in cultured fibroblasts	NATURE CELL BIOLOGY			English	Article							TO-SUBSTRATE CONTACTS; KINASE RHO-KINASE; SIGNAL-TRANSDUCTION; MOLECULAR-INTERACTIONS; FOCAL ADHESIONS; STRESS FIBERS; INTEGRINS; FIBRONECTIN; ACTIN; COMPLEXES	Here we use time-lapse microscopy to analyse cell-matrix adhesions in cells expressing one of two different cytoskeletal proteins, paxillin or tensin, tagged with green fluorescent protein (GFP), Use of GFP-paxillin to analyse focal contacts and GFP-tensin to study fibrillar adhesions reveals that both types of major adhesion are highly dynamic, Small focal contacts often translocate, by extending centripetally and contracting peripherally, at a mean rate of 19 micrometres per hour. Fibrillar adhesions arise from the medial ends of stationary focal contacts, contain alpha(5)beta(1) integrin and tensin but not other focal-contact components, and associate with fibronectin fibrils, Fibrillar adhesions translocate centripetally at a mean rate of 18 micrometres per hour in an actomyosin-dependent manner. We propose a dynamic model for the regulation of cell-matrix adhesions and for transitions between focal contacts and fibrillar adhesions, with the ability of the matrix to deform functioning as a mechanical switch.	Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel; NIDCR, Craniofacial Dev Biol & Regenerat Branch, NIH, Bethesda, MD 20892 USA; Tel Aviv Med Ctr, Inst Hematol, IL-64239 Tel Aviv, Israel; Univ Calif Irvine, Dept Dev & Cell Biol, Irvine, CA 92697 USA	Weizmann Institute of Science; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); Tel Aviv University; Sackler Faculty of Medicine; University of California System; University of California Irvine	Geiger, B (corresponding author), Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel.		Erez, Noam/AAW-4953-2021	Erez, Noam/0000-0001-5241-8028; Bershadsky, Alexander/0000-0002-9571-7375; Zamir, Eli/0000-0001-8226-5480; Yamada, Kenneth/0000-0003-1512-6805	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000525, ZIADE000524] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [ZIADE000336, Z01DE000524, Z01DE000525, Z01DE000336] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		AKIYAMA SK, 1989, J CELL BIOL, V109, P863, DOI 10.1083/jcb.109.2.863; Amano M, 1996, J BIOL CHEM, V271, P20246, DOI 10.1074/jbc.271.34.20246; AVNUR Z, 1981, CELL, V25, P121, DOI 10.1016/0092-8674(81)90236-1; BEGG DA, 1978, J CELL BIOL, V79, P846, DOI 10.1083/jcb.79.3.846; Bershadsky A, 1996, CURR BIOL, V6, P1279, DOI 10.1016/S0960-9822(02)70714-8; CHEN WT, 1982, J CELL BIOL, V95, P205, DOI 10.1083/jcb.95.1.205; ChrzanowskaWodnicka M, 1996, J CELL BIOL, V133, P1403, DOI 10.1083/jcb.133.6.1403; CHUANG JZ, 1995, J CELL BIOL, V128, P1095, DOI 10.1083/jcb.128.6.1095; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; DAVIES PF, 1993, J CLIN INVEST, V91, P2640, DOI 10.1172/JCI116503; FATH KR, 1989, J CELL SCI, V92, P67; Geiger B, 1995, ACTA ANAT, V154, P46; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; HOCK RS, 1989, CELL MOTIL CYTOSKEL, V14, P271, DOI 10.1002/cm.970140213; Howe A, 1998, CURR OPIN CELL BIOL, V10, P220, DOI 10.1016/S0955-0674(98)80144-0; HYNES RO, 1978, CELL, V15, P875, DOI 10.1016/0092-8674(78)90272-6; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; IZZARD CS, 1980, J CELL SCI, V42, P81; IZZARD CS, 1976, J CELL SCI, V21, P129; Jockusch BM, 1995, ANNU REV CELL DEV BI, V11, P379, DOI 10.1146/annurev.cellbio.11.1.379; KATZ BZ, IN PRESS MOL BIOL CE; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; Kioka N, 1999, J CELL BIOL, V144, P59, DOI 10.1083/jcb.144.1.59; KREIS TE, 1985, MOL BIOL CYTOSKELETO, P45; LAFLAMME SE, 1994, J CELL BIOL, V126, P1287, DOI 10.1083/jcb.126.5.1287; MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; PLOPPER G, 1993, BIOCHEM BIOPH RES CO, V193, P571, DOI 10.1006/bbrc.1993.1662; Rottner K, 1999, CURR BIOL, V9, P640, DOI 10.1016/S0960-9822(99)80286-3; Schoenwaelder SM, 1999, CURR OPIN CELL BIOL, V11, P274, DOI 10.1016/S0955-0674(99)80037-4; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; SINGER II, 1988, J CELL BIOL, V106, P2171, DOI 10.1083/jcb.106.6.2171; Smilenov LB, 1999, SCIENCE, V286, P1172, DOI 10.1126/science.286.5442.1172; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; Yamada KM, 1997, CURR OPIN CELL BIOL, V9, P76, DOI 10.1016/S0955-0674(97)80155-X; Zamir E, 1999, J CELL SCI, V112, P1655	36	437	446	1	63	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	APR	2000	2	4					191	196		10.1038/35008607	http://dx.doi.org/10.1038/35008607			6	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	302ZU	10783236				2022-12-25	WOS:000086397000011
J	Tavernarakis, N; Wang, SL; Dorovkov, M; Ryazanov, A; Driscoll, M				Tavernarakis, N; Wang, SL; Dorovkov, M; Ryazanov, A; Driscoll, M			Heritable and inducible genetic interference by double-stranded RNA encoded by transgenes	NATURE GENETICS			English	Article							CAENORHABDITIS-ELEGANS; EXPRESSION; SEQUENCE; IDENTIFICATION; DEGRADATION; MORPHOLOGY; PLANTS	Double-stranded RNA interference (RNAi) is an effective method for disrupting expression of specific genes in Caenorhabditis elegans and other organisms(1-5). Applications of this reverse-genetics tool, however, am somewhat restricted in nematodes because introduced dsRNA is not stably inherited(5). Another difficulty is that RNAi disruption of late-acting genes has been generally less consistent than that of embryonically expressed genes, perhaps because the concentration of dsRNA becomes lower as cellular division proceeds or as developmental time advances(1). In particular, some neuronally expressed genes appear refractory to dsRNA-mediated interference. We sought to extend the applicability of RNAi by in vivo expression of heritable inverted-repeat (IR) genes. We assayed the efficacy of in vivo-driven RNAi in three situations for which heritable, inducible RNAi would be advantageous: (i) production of large numbers of animals deficient for gene activities required for viability or reproduction; (ii) generation of large populations of phenocopy mutants for biochemical analysis; and (iii) effective gene inactivation in the nervous system. We report that heritable IR genes confer potent and specific gene inactivation for each of these applications. We suggest that a similar strategy might be used to test for dsRNA interference effects in higher organisms in which it is feasible to construct transgenic animals, but impossible to directly or transiently introduce high concentrations of dsRNA.	Rutgers State Univ, Dept Mol Biol & Biochem, Piscataway, NJ 08855 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Pharmacol, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University New Brunswick; Rutgers State University Medical Center	Driscoll, M (corresponding author), Rutgers State Univ, Dept Mol Biol & Biochem, Piscataway, NJ 08855 USA.		Tavernarakis, Nektarios/B-9684-2013; ryazanov, alexey/J-8081-2017	Tavernarakis, Nektarios/0000-0002-5253-1466; 	NIGMS NIH HHS [GM57300] Funding Source: Medline; NINDS NIH HHS [NS344435, NS37955] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057300] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037955] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Alvarado AS, 1999, P NATL ACAD SCI USA, V96, P5049, DOI 10.1073/pnas.96.9.5049; BRENNER S, 1974, GENETICS, V77, P71; DIBB NJ, 1989, J MOL BIOL, V205, P603, DOI 10.1016/0022-2836(89)90229-5; FIRE A, 1990, GENE, V93, P189, DOI 10.1016/0378-1119(90)90224-F; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; JONES D, 1986, J BIOL CHEM, V261, P2006; Kennerdell JR, 1998, CELL, V95, P1017, DOI 10.1016/S0092-8674(00)81725-0; KRAMER JM, 1990, MOL CELL BIOL, V10, P2081, DOI 10.1128/MCB.10.5.2081; Lu XW, 1998, CELL, V95, P981, DOI 10.1016/S0092-8674(00)81722-5; MADURO M, 1995, GENETICS, V141, P977; MELLO CC, 1994, METHODS CELL BIOL CA, P451; MITANI S, 1993, DEVELOPMENT, V119, P773; Montgomery MK, 1998, P NATL ACAD SCI USA, V95, P15502, DOI 10.1073/pnas.95.26.15502; Montgomery MK, 1998, TRENDS GENET, V14, P255, DOI 10.1016/S0168-9525(98)01510-8; Ngo H, 1998, P NATL ACAD SCI USA, V95, P14687, DOI 10.1073/pnas.95.25.14687; PARK EC, 1986, GENETICS, V113, P821; Ren XC, 1999, J NEUROBIOL, V39, P107, DOI 10.1002/(SICI)1097-4695(199904)39:1&lt;107::AID-NEU9&gt;3.0.CO;2-7; Ryazanov AG, 1997, P NATL ACAD SCI USA, V94, P4884, DOI 10.1073/pnas.94.10.4884; STRINGHAM EG, 1992, MOL BIOL CELL, V3, P221, DOI 10.1091/mbc.3.2.221; Tabara H, 1999, CELL, V99, P123, DOI 10.1016/S0092-8674(00)81644-X; Tabara H, 1998, SCIENCE, V282, P430, DOI 10.1126/science.282.5388.430; Timmons L, 1998, NATURE, V395, P854, DOI 10.1038/27579; Voinnet O, 1998, CELL, V95, P177, DOI 10.1016/S0092-8674(00)81749-3; Waterhouse PM, 1998, P NATL ACAD SCI USA, V95, P13959, DOI 10.1073/pnas.95.23.13959; Zhang Y, 1998, CELL, V95, P279, DOI 10.1016/S0092-8674(00)81758-4	25	329	446	1	35	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	FEB	2000	24	2					180	183		10.1038/72850	http://dx.doi.org/10.1038/72850			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	280LQ	10655066				2022-12-25	WOS:000085104600021
J	Wakayama, T; Tateno, H; Mombaerts, P; Yanagimachi, R				Wakayama, T; Tateno, H; Mombaerts, P; Yanagimachi, R			Nuclear transfer into mouse zygotes	NATURE GENETICS			English	Article							EMBRYOS; TRANSPLANTATION		Rockefeller Univ, New York, NY 10021 USA; Univ Hawaii, John A Burns Sch Med, Dept Anat & Reprod Biol, Honolulu, HI 96822 USA	Rockefeller University; University of Hawaii System	Wakayama, T (corresponding author), Rockefeller Univ, 1230 York Ave, New York, NY 10021 USA.	wakayat@rockvax.rockefeller.edu						Campbell KHS, 1996, NATURE, V380, P64, DOI 10.1038/380064a0; HOWLETT SK, 1987, DEVELOPMENT, V101, P915; Illmensee K, 1999, NATURE, V398, P19, DOI 10.1038/17905; ILLMENSEE K, 1981, CELL, V23, P9, DOI 10.1016/0092-8674(81)90265-8; MCGRATH J, 1984, SCIENCE, V226, P1317, DOI 10.1126/science.6542249; Sasaki, 1983, RAD INDUCED CHROMOSO, P411; Solter D, 1999, NATURE, V399, P13, DOI 10.1038/19841; STICE SL, 1994, MOL REPROD DEV, V38, P61, DOI 10.1002/mrd.1080380111; Wakayama T, 1998, NATURE, V394, P369, DOI 10.1038/28615; Wakayama T, 1999, P NATL ACAD SCI USA, V96, P14984, DOI 10.1073/pnas.96.26.14984; Wakayama T, 1999, NAT GENET, V22, P127, DOI 10.1038/9632	11	113	118	0	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	FEB	2000	24	2					108	109		10.1038/72749	http://dx.doi.org/10.1038/72749			2	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	280LQ	10655051				2022-12-25	WOS:000085104600007
J	Thomas, M; Yang, LQ; Hornsby, PJ				Thomas, M; Yang, LQ; Hornsby, PJ			Formation of functional tissue from transplanted adrenocortical cells expressing telomerase reverse transcriptase	NATURE BIOTECHNOLOGY			English	Article						telomerase reverse transcriptase; adrenocortical cells; xenotransplantation; SCID	DIFFERENTIATED FUNCTION GENE; LIFE-SPAN; SENESCENCE; IMMORTALIZATION; CULTURE; SV40; DNA	We report the first use of human telomerase reverse transcriptase (hTERT) expression in experimental xenotransplantation. Previously, we showed that bovine adrenocortical cells can be transplanted into severe combined immunodeficient (SCID) mice, and that these cells form functional tissue that replaces the animals' own adrenal glands. We cotransfected primary bovine adrenocortical cells with plasmids encoding hTERT, SV40 T antigen, neo, and green fluorescent protein. These clones do not undergo loss of telomeric DNA and appear to be immortalized. Two clones were transplanted beneath the kidney capsule of SCID mice. Animals that received cell transplants survived indefinitely despite adrenalectomy. The mouse glucocorticoid, corticosterone, was replaced by the bovine glucocorticoid, cortisol, in the plasma of these animals. The tissue formed from the transplanted cells resembled that formed by transplantation of cells that were not genetically modified and was similar to normal bovine adrenal cortex. The proliferation rate in tissues formed from these clones was low and there were no indications of malignant transformation.	Baylor Coll Med, Huffington Ctr Aging, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine	Hornsby, PJ (corresponding author), Baylor Coll Med, Huffington Ctr Aging, Houston, TX 77030 USA.	phornsby@bcm.tmc.edu	Thomas, Michael/N-5468-2018	Thomas, Michael/0000-0003-2901-824X	NIA NIH HHS [AG13663, AG12287] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG012287, R37AG012287, P01AG013663] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; BOSMA MJ, 1989, SCLD MOUSE CHARACTER; CHENG CY, 1989, EXP CELL RES, V180, P49, DOI 10.1016/0014-4827(89)90211-5; Counter CM, 1998, P NATL ACAD SCI USA, V95, P14723, DOI 10.1073/pnas.95.25.14723; de Lange T, 1999, SCIENCE, V283, P947, DOI 10.1126/science.283.5404.947; GREIDER CW, 1990, BIOESSAYS, V12, P363, DOI 10.1002/bies.950120803; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HARLEY CB, 1991, MUTAT RES, V256, P271, DOI 10.1016/0921-8734(91)90018-7; HASTIE ND, 1990, NATURE, V346, P866, DOI 10.1038/346866a0; HORNSBY PJ, 1991, METHOD ENZYMOL, V206, P371; HORNSBY PJ, 1987, P NATL ACAD SCI USA, V84, P1580, DOI 10.1073/pnas.84.6.1580; HORNSBY PJ, 1992, MUTAT RES, V275, P13, DOI 10.1016/0921-8734(92)90004-9; HORNSBY PJ, 1986, J CELL PHYSIOL, V129, P395, DOI 10.1002/jcp.1041290319; HORNSBY PJ, 1992, J STEROID BIOCHEM, V43, P385; Jiang XR, 1999, NAT GENET, V21, P111, DOI 10.1038/5056; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kolquist KA, 1998, NAT GENET, V19, P182, DOI 10.1038/554; Kozik A, 1998, MOL REPROD DEV, V51, P98, DOI 10.1002/(SICI)1098-2795(199809)51:1&lt;98::AID-MRD12&gt;3.0.CO;2-Q; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; Morales CP, 1999, NAT GENET, V21, P115, DOI 10.1038/5063; MOYZIS RK, 1988, P NATL ACAD SCI USA, V85, P6622, DOI 10.1073/pnas.85.18.6622; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; Norton JC, 1998, DNA CELL BIOL, V17, P217, DOI 10.1089/dna.1998.17.217; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SEPULVEDA AR, 1989, CANCER RES, V49, P6108; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; Thomas M, 1997, NAT MED, V3, P978, DOI 10.1038/nm0997-978; Vaziri H, 1999, MOL CELL BIOL, V19, P2373; Vaziri H, 1998, CURR BIOL, V8, P279, DOI 10.1016/S0960-9822(98)70109-5; Weinberg RA, 1998, NATURE, V396, P23, DOI 10.1038/23825	30	108	117	0	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JAN	2000	18	1					39	42		10.1038/71894	http://dx.doi.org/10.1038/71894			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	273GQ	10625388				2022-12-25	WOS:000084699900022
J	Eppich, HM; Foxall, R; Gaynor, K; Dombkowski, D; Miura, N; Cheng, T; Silva-Arrieta, S; Evans, RH; Mangano, JA; Preffer, FI; Scadden, DT				Eppich, HM; Foxall, R; Gaynor, K; Dombkowski, D; Miura, N; Cheng, T; Silva-Arrieta, S; Evans, RH; Mangano, JA; Preffer, FI; Scadden, DT			Pulsed electric fields for selection of hematopoietic cells and depletion of tumor cell contaminants	NATURE BIOTECHNOLOGY			English	Article						stem cells; cell selection; cell purging; electroporation; hematopoiesis	HUMAN-BONE-MARROW; BREAST-CANCER CELLS; STEM-CELLS; IN-VIVO; ELIMINATION; 4-HYDROPEROXYCYCLOPHOSPHAMIDE; MICROMETASTASES; TRANSPLANTATION; CHEMOTHERAPY; INVITRO	Purging of tumor cells and selection of stem cells are key technologies for enabling stem cell transplantation and stem cell gene therapy. Here we report a strategy for cell selection based on physical properties of the cells. Exposing cells to an external pulsed electric field (PEF) increases the natural potential difference across the cell membrane until a critical threshold is reached and pore formation occurs, resulting in fatal perturbation of cell physiology. Attaining this threshold is a function of the applied field intensity and cell size, with larger cells porated at lower field intensities than smaller cells. Since hematopoietic stem cells are smaller than other hematopoietic cells and tumor cells, we found that exposure of peripheral blood mononuclear cells (PBMCs) to PEFs caused stepwise elimination of monocytes without affecting the function of smaller lymphocyte populations. Mobilized peripheral blood exposed to PEFs was enriched for CD34(+)/CD38(-) cells and stem cell function was preserved. Furthermore, PEF treatment was able to selectively purge blood preparations of tumor cells and eradicate transplantable tumor.	Harvard Univ, Massachusetts Gen Hosp, Sch Med, AIDS Res Ctr, Boston, MA 02129 USA; Harvard Univ, Massachusetts Gen Hosp, Sch Med, MGH Canc Ctr, Boston, MA 02129 USA; Sci Res Lab Inc, Somerville, MA 02143 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital	Scadden, DT (corresponding author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, AIDS Res Ctr, Boston, MA 02129 USA.			Foxall, Russell/0000-0001-9821-0708; Cheng, Tao/0000-0002-5925-2769	NCI NIH HHS [CA7936401] Funding Source: Medline; NHLBI NIH HHS [HL55718] Funding Source: Medline; NIDDK NIH HHS [DK50234] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R43CA079364, R44CA079364] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055718] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050234] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abkowitz JL, 1996, NAT MED, V2, P190, DOI 10.1038/nm0296-190; ANDERSON IC, 1989, CANCER RES, V49, P4659; BERARDI AC, 1995, SCIENCE, V267, P104, DOI 10.1126/science.7528940; Bertolini F, 1997, EXP HEMATOL, V25, P350; Bradford GB, 1997, EXP HEMATOL, V25, P445; Chen L, 1996, J CLIN INVEST, V98, P2539, DOI 10.1172/JCI119072; COTE RJ, 1991, J CLIN ONCOL, V9, P1749, DOI 10.1200/JCO.1991.9.10.1749; Coulson C. A., 1951, ELECTRICITY; DIEL IJ, 1992, J CLIN ONCOL, V10, P1534, DOI 10.1200/JCO.1992.10.10.1534; ELMASHAK EM, 1985, BIOCHEMISTRY-US, V24, P2284; GARRETT TJ, 1976, CANCER-AM CANCER SOC, V38, P2401, DOI 10.1002/1097-0142(197612)38:6<2401::AID-CNCR2820380628>3.0.CO;2-F; Gothot A, 1998, EXP HEMATOL, V26, P562; Holman J., 1981, HEAT TRANSF; HULSHEGER H, 1981, RADIAT ENVIRON BIOPH, V20, P53, DOI 10.1007/BF01323926; JACOB J, 1990, NEW DISCHARGE PUMPIN; KINOSITA K, 1977, BIOCHIM BIOPHYS ACTA, V471, P227, DOI 10.1016/0005-2736(77)90252-8; Lanzkron SM, 1999, BLOOD, V93, P1916, DOI 10.1182/blood.V93.6.1916.406k15_1916_1921; MAUCH P, 1989, BONE MARROW TRANSPL, V4, P601; MYKLEBUST AT, 1994, CANCER RES, V54, P209; PASSOSCOELHO J, 1994, CANCER RES, V54, P2366; Radley JM, 1999, EXP HEMATOL, V27, P365, DOI 10.1016/S0301-472X(98)00017-4; ROSS AA, 1993, BLOOD, V82, P2605; SALE AJH, 1968, BIOCHIM BIOPHYS ACTA, V163, P37, DOI 10.1016/0005-2736(68)90030-8; SHPALL EJ, 1991, BONE MARROW TRANSPL, V7, P145; SHPALL EJ, 1991, J CLIN ONCOL, V9, P85, DOI 10.1200/JCO.1991.9.1.85; SINGH G, 1977, CANCER-AM CANCER SOC, V40, P2317, DOI 10.1002/1097-0142(197711)40:5<2317::AID-CNCR2820400546>3.0.CO;2-Z; SIXOU S, 1990, BIOCHIM BIOPHYS ACTA, V1028, P154, DOI 10.1016/0005-2736(90)90149-I; SUTHERLAND HJ, 1990, P NATL ACAD SCI USA, V87, P3584, DOI 10.1073/pnas.87.9.3584; SUTHERLAND HJ, 1989, BLOOD, V74, P1563; Teoh G, 1998, BLOOD, V92, P4591, DOI 10.1182/blood.V92.12.4591.424k08_4591_4601; TONDINI C, 1990, CANCER RES, V50, P1170	31	29	63	1	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	AUG	2000	18	8					882	887		10.1038/78504	http://dx.doi.org/10.1038/78504			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	342VX	10932160				2022-12-25	WOS:000088666800027
J	Kornblum, HI; Araujo, DM; Annala, AJ; Tatsukawa, KJ; Phelps, ME; Cherry, SR				Kornblum, HI; Araujo, DM; Annala, AJ; Tatsukawa, KJ; Phelps, ME; Cherry, SR			In vivo imaging of neuronal activation and plasticity in the rat brain by high resolution positron emission tomography (microPET)	NATURE BIOTECHNOLOGY			English	Article						seizure; vibrissal stimulation; hemispherectomy; brain; glucose metabolism	CEREBRAL GLUCOSE-UTILIZATION; METABOLIC-RATE; KAINIC ACID; COMPUTED-TOMOGRAPHY; SMALL ANIMALS; PET SCANNER; RECOVERY; HUMANS; SYSTEM; HEMIDECORTICATION	The study of neural repair and neuroplasticity in rodents would be enhanced by the ability to assess neuronal function in vivo. Positron emission tomography (PET) is used to study brain plasticity in humans, but the limited resolution and sensitivity of conventional scanners have generally precluded the use of PET to study neuroplasticity in rodents. We now demonstrate that microPET, a PET scanner developed for use with small animals, can be used to assess metabolic activity in different regions of the conscious rodent brain using [F-18]fluorodeoxyglucose (FDG) as the tracer, and to monitor changes in neuronal activity. Limbic seizures result in dramatically elevated metabolic activity in the hippocampus, whereas vibrissal stimulation results in more modest increases in FDG uptake in the contralateral neocortex. We also show that microPET can be used to study lesion-induced plasticity of the brain. Cerebral hemidecortication resulted in diminished relative glucose metabolism in the neostriatum and thalamus ipsilateral to the lesion, with subsequent, significant recovery of metabolic function. These studies demonstrate that microPET can be used for serial assessment of metabolic function of individual, awake rats with a minimal degree of invasiveness, and therefore, has the potential for use in the study of brain disorders and repair.	Univ Calif Los Angeles, Sch Med, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Dept Pediat, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Crump Inst Biol Imaging, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Dept Energy, Lab Struct Biol & Mol Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Brain Res Inst, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Kornblum, HI (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA.		Cherry, Simon/AAH-1000-2019	Cherry, Simon/0000-0002-0155-5644; Annala, Alexandra Jacqueline/0000-0002-5967-6596	NCI NIH HHS [CA69370-03] Funding Source: Medline; NINDS NIH HHS [NS01837-01A1] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA069370] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K08NS001837] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ACKERMANN RF, 1989, J CEREBR BLOOD F MET, V9, P774, DOI 10.1038/jcbfm.1989.111; Albala B.J., 1984, BRAIN RES, V315, P139; BENARI Y, 1981, NEUROSCIENCE, V6, P1361, DOI 10.1016/0306-4522(81)90193-7; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; BROWNELL AL, 1991, J COMPUT ASSIST TOMO, V15, P376, DOI 10.1097/00004728-199105000-00006; BRUEHL C, 1995, ANN NEUROL, V38, P414, DOI 10.1002/ana.410380311; Chatziioannou AF, 1999, J NUCL MED, V40, P1164; CHATZIOANNOU A, 2000, IN PRESS IEEE T MED; Cherry SR, 1997, IEEE T NUCL SCI, V44, P1161, DOI 10.1109/23.596981; CHUGANI HT, 1994, EPILEPSIA, V35, P813, DOI 10.1111/j.1528-1157.1994.tb02517.x; CHUGANI HT, 1991, J CEREBR BLOOD F MET, V11, P35, DOI 10.1038/jcbfm.1991.4; CHUGANI HT, 1986, SCIENCE, V231, P840, DOI 10.1126/science.3945811; CHUGANI HT, 1994, ANN NEUROL, V36, P794, DOI 10.1002/ana.410360518; CHUGANI HT, 1988, NEUROLOGY, V38, P1178, DOI 10.1212/WNL.38.8.1178; COLLINS RC, 1980, LIFE SCI, V27, P855, DOI 10.1016/0024-3205(80)90080-6; COYLE JT, 1983, J NEUROCHEM, V41, P1; CUTLER PD, 1992, J NUCL MED, V33, P595; DIETRICH WD, 1985, J NEUROSCI, V5, P874; DUNNMEYNELL AA, 1995, BRAIN RES, V675, P143, DOI 10.1016/0006-8993(95)00050-Z; FOWLER J S, 1986, P391; GREER CA, 1981, BRAIN RES, V217, P279, DOI 10.1016/0006-8993(81)90004-4; HOFFMAN EJ, 1979, J COMPUT ASSIST TOMO, V3, P299, DOI 10.1097/00004728-197906000-00001; Hovda DA, 1996, J CEREBR BLOOD F MET, V16, P134, DOI 10.1097/00004647-199601000-00016; Iglesias S, 1996, STROKE, V27, P1192, DOI 10.1161/01.STR.27.7.1192; KENNEDY C, 1975, SCIENCE, V187, P850, DOI 10.1126/science.1114332; KINAHAN PE, 1989, IEEE T NUCL SCI, V36, P964, DOI 10.1109/23.34585; KOLB B, 1987, BEHAV BRAIN RES, V25, P205, DOI 10.1016/0166-4328(87)90069-6; KOLB B, 1992, J COMP NEUROL, V322, P311, DOI 10.1002/cne.903220303; KORNBLUM HI, 1994, MOL BRAIN RES, V21, P107, DOI 10.1016/0169-328X(94)90383-2; KOSSUT M, 1985, PHYSIOL BOHEMOSLOV, V34, P79; KRYNAUW RA, 1950, J NEUROL NEUROSUR PS, V13, P243, DOI 10.1136/jnnp.13.4.243; Kuge Y, 1997, J CEREBR BLOOD F MET, V17, P116, DOI 10.1097/00004647-199701000-00015; KUHL DE, 1980, ANN NEUROL, V8, P348, DOI 10.1002/ana.410080403; MAGATA Y, 1995, BIOL PHARM BULL, V18, P753; Melega WP, 1997, BRAIN RES, V766, P113, DOI 10.1016/S0006-8993(97)00548-9; MILLER MW, 1993, J COMP NEUROL, V335, P283, DOI 10.1002/cne.903350211; MOORE A, 1999, J CEREB BLOOD FLO S1, V19, pS764; Muller RA, 1998, J CHILD NEUROL, V13, P16, DOI 10.1177/088307389801300103; Napieralski JA, 1996, J COMP NEUROL, V373, P484; Ouchi Y, 1996, J CEREBR BLOOD F MET, V16, P34, DOI 10.1097/00004647-199601000-00004; PHELPS ME, 1979, ANN NEUROL, V6, P371, DOI 10.1002/ana.410060502; Qi JY, 1998, PHYS MED BIOL, V43, P1001, DOI 10.1088/0031-9155/43/4/027; SCHWARTZ WJ, 1979, SCIENCE, V205, P723, DOI 10.1126/science.462184; SOKOLOFF L, 1977, J NEUROCHEM, V28, P897, DOI 10.1111/j.1471-4159.1977.tb10649.x; Tatsukawa K. J., 1997, Society for Neuroscience Abstracts, V23, P1447	45	153	155	0	16	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUN	2000	18	6					655	660		10.1038/76509	http://dx.doi.org/10.1038/76509			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	325EK	10835605				2022-12-25	WOS:000087663200027
J	Moritz, M; Braunfeld, MB; Guenebaut, V; Heuser, J; Agard, DA				Moritz, M; Braunfeld, MB; Guenebaut, V; Heuser, J; Agard, DA			Structure of the gamma-tubulin ring complex: a template for microtubule nucleation	NATURE CELL BIOLOGY			English	Article							SPINDLE POLE BODY; SACCHAROMYCES-CEREVISIAE; ELECTRON-MICROSCOPY; ASSEMBLED INVITRO; BETA-TUBULIN; CENTROSOME; PROTOFILAMENTS; SPC97P; ENDS; ORGANIZATION	The gamma-tubulin ring complex (gamma TuRC) is a protein complex of relative molecular mass -2.2x10(6) that nucleates microtubules at the centrosome. Here we use electron-microscopic tomography and metal shadowing to examine the structure of isolated Drosophila gamma TuRCs and the ends of microtubules nucleated by gamma TuRCs and by centrosomes. We show that the gamma TuRC is a lockwasher-like structure made up of repeating subunits, topped asymmetrically with a cap. A similar capped ring is also visible at one end of microtubules grown from isolated gamma TuRCs and from centrosomes. Antibodies against gamma-tubulin label microtubule ends, but not walls, in centrosomes. These data are consistent with a template-mediated mechanism for microtubule nucleation by the gamma TuRC.	Univ Calif San Francisco, Howard Hughes Med Inst, Dept Biochem & Biophys, San Francisco, CA 94143 USA; Washington Univ, Sch Med, Dept Cell Biol, St Louis, MO 63110 USA	Howard Hughes Medical Institute; University of California System; University of California San Francisco; Washington University (WUSTL)	Moritz, M (corresponding author), Univ Calif San Francisco, Howard Hughes Med Inst, Dept Biochem & Biophys, 513 Parnassus Ave, San Francisco, CA 94143 USA.			Moritz, Michelle/0000-0003-3811-5623	NIGMS NIH HHS [GM23928-22, GM 30127] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM023928] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOHM KJ, 1984, BIOCHIM BIOPHYS ACTA, V800, P119, DOI 10.1016/0304-4165(84)90049-7; Bullitt E, 1997, CELL, V89, P1077, DOI 10.1016/S0092-8674(00)80295-0; BYERS B, 1978, J CELL SCI, V30, P331; CHEN H, 1992, SPIE BIOMEDICAL IMAG, V1660, P784; CHEN H, 1990, HDB BIOL CONFOCAL MI, P141; CHRETIEN D, 1995, J CELL BIOL, V129, P1311, DOI 10.1083/jcb.129.5.1311; CHRETIEN D, 1992, J CELL BIOL, V117, P1031, DOI 10.1083/jcb.117.5.1031; Desai A, 1997, ANNU REV CELL DEV BI, V13, P83, DOI 10.1146/annurev.cellbio.13.1.83; DETRICH HW, 1985, J BIOL CHEM, V260, P9479; DUBOCHET J, 1988, Q REV BIOPHYS, V21, P129, DOI 10.1017/S0033583500004297; ERICKSON HP, 1974, J CELL BIOL, V60, P153, DOI 10.1083/jcb.60.1.153; Erickson HP, 1996, J CELL BIOL, V135, P5, DOI 10.1083/jcb.135.1.5; EVANS L, 1985, J CELL BIOL, V100, P1185, DOI 10.1083/jcb.100.4.1185; GOULD RR, 1977, J CELL BIOL, V73, P601, DOI 10.1083/jcb.73.3.601; Harris JR, 1996, MICROSC MICROANAL, V2, P43, DOI [10.1017/S1431927696210438, DOI 10.1017/S1431927696210438]; HEUSER J, 1989, J ELECTRON MICR TECH, V13, P244, DOI 10.1002/jemt.1060130310; Heuser J, 1981, Methods Cell Biol, V22, P97; Kilmartin JV, 1996, EMBO J, V15, P4592, DOI 10.1002/j.1460-2075.1996.tb00837.x; KILMARTIN JV, 1993, J CELL BIOL, V123, P1175, DOI 10.1083/jcb.123.5.1175; KIRSCHNER MW, 1975, J MOL BIOL, V99, P263, DOI 10.1016/S0022-2836(75)80144-6; Knop M, 1997, EMBO J, V16, P1550, DOI 10.1093/emboj/16.7.1550; Knop M, 1997, EMBO J, V16, P6985, DOI 10.1093/emboj/16.23.6985; Koster A. J., 1993, MICROSC SOC AM B, V23, P176; KOSTER AJ, 1992, ULTRAMICROSCOPY, V46, P207, DOI 10.1016/0304-3991(92)90016-D; Moritz M, 1999, METHOD CELL BIOL, V61, P1; Moritz M, 1998, J CELL BIOL, V142, P775, DOI 10.1083/jcb.142.3.775; MORITZ M, 1995, J CELL BIOL, V130, P1149, DOI 10.1083/jcb.130.5.1149; MORITZ M, 1995, NATURE, V378, P638, DOI 10.1038/378638a0; Murphy SM, 1998, J CELL BIOL, V141, P663, DOI 10.1083/jcb.141.3.663; Nogales E, 1998, NATURE, V391, P199, DOI 10.1038/34465; O'Toole ET, 1999, MOL BIOL CELL, V10, P2017, DOI 10.1091/mbc.10.6.2017; Oegema K, 1999, J CELL BIOL, V144, P721, DOI 10.1083/jcb.144.4.721; Pereira G, 1997, J CELL SCI, V110, P295; PIERSON GB, 1978, J CELL BIOL, V76, P223, DOI 10.1083/jcb.76.1.223; SIMON JR, 1990, J CELL SCI, V96, P571; TILNEY LG, 1973, J CELL BIOL, V59, P267, DOI 10.1083/jcb.59.2.267; Vogel JM, 1997, J CELL BIOL, V137, P193, DOI 10.1083/jcb.137.1.193; Wiese C, 1999, CURR OPIN STRUC BIOL, V9, P250, DOI 10.1016/S0959-440X(99)80035-9; Wigge PA, 1998, J CELL BIOL, V141, P967, DOI 10.1083/jcb.141.4.967; ZHENG YX, 1995, NATURE, V378, P578, DOI 10.1038/378578a0	40	213	214	0	16	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	JUN	2000	2	6					365	370		10.1038/35014058	http://dx.doi.org/10.1038/35014058			6	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	321KE	10854328				2022-12-25	WOS:000087454000019
J	Watnick, T; He, N; Wang, KR; Liang, Y; Parfrey, P; Hefferton, D; St George-Hyslop, P; Germino, G; Pei, Y				Watnick, T; He, N; Wang, KR; Liang, Y; Parfrey, P; Hefferton, D; St George-Hyslop, P; Germino, G; Pei, Y			Mutations of PKD1 in ADPKD2 cysts suggest a pathogenic effect of trans-heterozygous mutations	NATURE GENETICS			English	Article							POLYCYSTIC KIDNEY-DISEASE; MOLECULAR-BASIS; 2-HIT MODEL; GENE; CYSTOGENESIS		Johns Hopkins Univ, Sch Med, Dept Med, Div Nephrol, Baltimore, MD 21205 USA; Univ Hlth Network, Dept Med, Toronto, ON, Canada; Tanz Res Inst, Toronto, ON, Canada; Hlth Sci Ctr, Dept Med, Div Nephrol, St John, NF, Canada	Johns Hopkins University; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Memorial University Newfoundland; University of Manitoba; Children's Hospital Research Institute of Manitoba	Germino, G (corresponding author), Johns Hopkins Univ, Sch Med, Dept Med, Div Nephrol, Baltimore, MD 21205 USA.	ggermino@welch.jhu.edu; York.Pei@uhn.on.can		Germino, Gregory/0000-0002-3609-5588; St George-Hyslop, Peter/0000-0003-0796-7209	NIDDK NIH HHS [DK02562, DK48006] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048006, R37DK048006, K08DK002562] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Geng L, 1996, J CLIN INVEST, V98, P2674, DOI 10.1172/JCI119090; Koptides M, 1999, HUM MOL GENET, V8, P509, DOI 10.1093/hmg/8.3.509; Koptides M, 2000, HUM MOL GENET, V9, P447, DOI 10.1093/hmg/9.3.447; Lu WN, 1997, NAT GENET, V17, P179, DOI 10.1038/ng1097-179; Ong ACM, 1999, AM J PATHOL, V154, P1721, DOI 10.1016/S0002-9440(10)65428-4; Ong ACM, 1997, LANCET, V349, P1039, DOI 10.1016/S0140-6736(05)62286-6; Pei Y, 1999, J AM SOC NEPHROL, V10, P1524; Pei Y, 1998, J AM SOC NEPHROL, V9, P1853; Qian F, 1996, CELL, V87, P979, DOI 10.1016/S0092-8674(00)81793-6; Qian F, 1997, NAT GENET, V16, P179, DOI 10.1038/ng0697-179; Torra P, 1999, KIDNEY INT, V56, P28, DOI 10.1046/j.1523-1755.1999.00534.x; Watnick T, 1999, AM J HUM GENET, V65, P1561, DOI 10.1086/302657; Watnick TJ, 1997, HUM MOL GENET, V6, P1473, DOI 10.1093/hmg/6.9.1473; Watnick TJ, 1998, MOL CELL, V2, P247, DOI 10.1016/S1097-2765(00)80135-5; Wu GQ, 1998, CELL, V93, P177, DOI 10.1016/S0092-8674(00)81570-6	15	97	100	0	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JUN	2000	25	2					143	144		10.1038/75981	http://dx.doi.org/10.1038/75981			2	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	321ML	10835625				2022-12-25	WOS:000087459200009
J	Lyle, R; Watanabe, D; Vruchte, DT; Lerchner, W; Smrzka, OW; Wutz, A; Schageman, J; Hahner, L; Davies, C; Barlow, DP				Lyle, R; Watanabe, D; Vruchte, DT; Lerchner, W; Smrzka, OW; Wutz, A; Schageman, J; Hahner, L; Davies, C; Barlow, DP			The imprinted antisense RNA at the Igf2r locus overlaps but does not imprint Mas1	NATURE GENETICS			English	Article							CPG ISLAND; EXPRESSION; MOUSE; PROTOONCOGENE; TRANSCRIPT; GENE		Netherlands Canc Inst H5, Amsterdam, Netherlands; NIMR, London, England; Whitehead Inst, Cambridge, MA 02142 USA; Univ Texas, SW Med Ctr, Dallas, TX USA; Bayer Corp, Div Biotechnol, Berkeley, CA USA	Netherlands Cancer Institute; MRC National Institute for Medical Research; Massachusetts Institute of Technology (MIT); Whitehead Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Bayer AG	Barlow, DP (corresponding author), Netherlands Canc Inst H5, Amsterdam, Netherlands.			Lerchner, Walter/0000-0003-0842-4409				Barlow DP, 1997, EMBO J, V16, P6899, DOI 10.1093/emboj/16.23.6899; BARLOW DP, 1991, NATURE, V349, P84, DOI 10.1038/349084a0; Greger IH, 1998, NUCLEIC ACIDS RES, V26, P1294, DOI 10.1093/nar/26.5.1294; Kumar M, 1998, MICROBIOL MOL BIOL R, V62, P1415, DOI 10.1128/MMBR.62.4.1415-1434.1998; Lee JT, 1999, CELL, V99, P47, DOI 10.1016/S0092-8674(00)80061-6; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; METZGER R, 1995, FEBS LETT, V357, P27, DOI 10.1016/0014-5793(94)01292-9; Rougeulle C, 1998, NAT GENET, V19, P15, DOI 10.1038/ng0598-15; Schweifer N, 1997, GENOMICS, V43, P285, DOI 10.1006/geno.1997.4816; Smilinich NJ, 1999, P NATL ACAD SCI USA, V96, P8064, DOI 10.1073/pnas.96.14.8064; STOGER R, 1993, CELL, V73, P61, DOI 10.1016/0092-8674(93)90160-R; VILLAR AJ, 1994, NAT GENET, V8, P373, DOI 10.1038/ng1294-373; Wutz A, 1997, NATURE, V389, P745, DOI 10.1038/39631	13	218	228	0	6	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAY	2000	25	1					19	21		10.1038/75546	http://dx.doi.org/10.1038/75546			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	311KU	10802648				2022-12-25	WOS:000086884000010
J	Mills, AD; Coleman, N; Morris, LS; Laskey, RA				Mills, AD; Coleman, N; Morris, LS; Laskey, RA			Detection of S-phase cells in tissue sections by in situ DNA replication	NATURE CELL BIOLOGY			English	Article							NUCLEI		Wellcome CRC Inst, Cambridge CB2 1QR, England; Univ Cambridge, Dept Zool, Cambridge CB2 3EJ, England; Univ Cambridge, Dept Pathol, Cambridge CB2 1QP, England	University of Cambridge; University of Cambridge	Mills, AD (corresponding author), Wellcome CRC Inst, Tennis Court Rd, Cambridge CB2 1QR, England.							COVERLEY D, 1993, J CELL BIOL, V122, P985, DOI 10.1083/jcb.122.5.985; Freeman A, 1999, CLIN CANCER RES, V5, P2121; GURDON JB, 1976, J EMBRYOL EXP MORPH, V36, P523; Krude T, 1997, CELL, V88, P109, DOI 10.1016/S0092-8674(00)81863-2; MILLS AD, 1989, J CELL SCI, V94, P471; NAKAMURA H, 1984, EXP CELL RES, V151, P123, DOI 10.1016/0014-4827(84)90362-8; NAKAYASU H, 1989, J CELL BIOL, V108, P1, DOI 10.1083/jcb.108.1.1; Stoeber K, 1998, EMBO J, V17, P7219, DOI 10.1093/emboj/17.24.7219; Stoeber K, 1999, LANCET, V354, P1524, DOI 10.1016/S0140-6736(99)04265-8; Williams GH, 1998, P NATL ACAD SCI USA, V95, P14932, DOI 10.1073/pnas.95.25.14932	10	20	22	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	APR	2000	2	4					244	245		10.1038/35008670	http://dx.doi.org/10.1038/35008670			2	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	302ZU	10783244				2022-12-25	WOS:000086397000019
J	Schratzberger, P; Schratzberger, G; Silver, M; Curry, C; Kearney, M; Magner, M; Alroy, J; Adelman, LS; Weinberg, DH; Ropper, AH; Isner, JM				Schratzberger, P; Schratzberger, G; Silver, M; Curry, C; Kearney, M; Magner, M; Alroy, J; Adelman, LS; Weinberg, DH; Ropper, AH; Isner, JM			Favorable effect of VEGF gene transfer on ischemic peripheral neuropathy	NATURE MEDICINE			English	Article							ENDOTHELIAL GROWTH-FACTOR; CORONARY COLLATERAL DEVELOPMENT; THERAPEUTIC ANGIOGENESIS; HINDLIMB ISCHEMIA; VESSEL DEVELOPMENT; ARTERY OCCLUSION; CELL MIGRATION; RABBIT MODEL; TUMOR-CELLS; RAT MODEL	Ischemic peripheral neuropathy is a frequent, irreversible complication of lower extremity vascular insufficiency. We investigated whether ischemic peripheral neuropathy could be prevented and/or reversed by gene transfer of an endothelial cell mitogen designed to promote therapeutic angiogenesis. Intramuscular gene transfer of naked DNA encoding vascular endothelial growth factor (VEGF) simultaneously with induction of hindlimb ischemia in rabbits abrogated the substantial decrease in motor and sensory nerve parameters, and nerve function recovered promptly. When gene transfer was administered 10 days after induction of ischemia, nerve function was restored earlier and/or recovered faster than in untreated rabbits. These findings are due in part to enhanced hindlimb perfusion. In addition, however, the demonstration of functional VEGF receptor expression by Schwann cells indicates a direct effect of VEGF on neural integrity as well. These findings thus constitute a new paradigm for the treatment of ischemic peripheral neuropathy.	Tufts Univ, Sch Med, St Elizabeths Med Ctr, Div Cardiovasc Res, Boston, MA 02135 USA; Tufts Univ, Sch Med, St Elizabeths Med Ctr, Div Vasc Med, Boston, MA 02135 USA; Tufts Univ, Sch Med, St Elizabeths Med Ctr, Div Neurol, Boston, MA 02135 USA; Tufts Univ, Sch Med, Dept Pathol, Boston, MA 02111 USA; Tufts Univ, Sch Med, Dept Neuropathol, Boston, MA 02111 USA	St. Elizabeth's Medical Center; Tufts University; St. Elizabeth's Medical Center; Tufts University; St. Elizabeth's Medical Center; Tufts University; Tufts University; Tufts University	Isner, JM (corresponding author), Tufts Univ, Sch Med, St Elizabeths Med Ctr, Div Cardiovasc Res, 736 Cambridge St, Boston, MA 02135 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL057516, R01HL060911, R01HL053354, R37HL053354] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL57516, HL60911, HL53354] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANTON ES, 1994, P NATL ACAD SCI USA, V91, P2795, DOI 10.1073/pnas.91.7.2795; BAUTERS C, 1995, CIRCULATION, V91, P2802, DOI 10.1161/01.CIR.91.11.2802; BAUTERS C, 1995, J VASC SURG, V21, P314, DOI 10.1016/S0741-5214(95)70272-5; BAUTERS C, 1994, AM J PHYSIOL-HEART C, V267, pH1263, DOI 10.1152/ajpheart.1994.267.4.H1263; Bentley FH, 1943, J PHYSIOL-LONDON, V102, P62, DOI 10.1113/jphysiol.1943.sp004015; BLUNT MJ, 1960, ARCH NEUROL-CHICAGO, V2, P528, DOI 10.1001/archneur.1960.03840110042005; Brogi E, 1996, J CLIN INVEST, V97, P469, DOI 10.1172/JCI118437; BUTTKE TM, 1993, J IMMUNOL METHODS, V157, P233, DOI 10.1016/0022-1759(93)90092-L; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; CARROLL SM, 1993, CIRCULATION, V88, P198, DOI 10.1161/01.CIR.88.1.198; CHERVU A, 1989, J SURG RES, V47, P12, DOI 10.1016/0022-4804(89)90041-3; Couffinhal T, 1998, AM J PATHOL, V152, P1667; Couffinhal T, 1999, CIRCULATION, V99, P3188, DOI 10.1161/01.CIR.99.24.3188; EAMES RA, 1967, J NEUROL NEUROSUR PS, V30, P215, DOI 10.1136/jnnp.30.3.215; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; Hobson MI, 1997, BRIT J PLAST SURG, V50, P125, DOI 10.1016/S0007-1226(97)91325-4; HUNTER GC, 1988, J SURG RES, V45, P96, DOI 10.1016/0022-4804(88)90027-3; Isner JM, 1996, HUM GENE THER, V7, P959, DOI 10.1089/hum.1996.7.8-959; Kearney M, 1997, CIRCULATION, V95, P1998, DOI 10.1161/01.CIR.95.8.1998; MCCARTHY JB, 1983, J CELL BIOL, V97, P772, DOI 10.1083/jcb.97.3.772; MELLICK RS, 1968, BRAIN, V91, P141, DOI 10.1093/brain/91.1.141; Miglietta O, 1967, Arch Phys Med Rehabil, V48, P89; MORRISSEY TK, 1991, J NEUROSCI, V11, P2433; Murohara T, 1999, ARTERIOSCL THROM VAS, V19, P1156, DOI 10.1161/01.ATV.19.5.1156; Osborne W A, 1900, J Physiol, V25, P283; Patel MK, 1997, ARTERIOSCL THROM VAS, V17, P2107, DOI 10.1161/01.ATV.17.10.2107; Pu L Q, 1994, J Invest Surg, V7, P49, DOI 10.3109/08941939409018282; RALEVIC V, 1991, CIRCULATION, V84, P1, DOI 10.1161/01.CIR.84.1.1; Rivard A, 1999, AM J PATHOL, V154, P355, DOI 10.1016/S0002-9440(10)65282-0; Rivard A, 1999, CIRCULATION, V99, P111, DOI 10.1161/01.CIR.99.1.111; SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; Sondell M, 1999, BRAIN RES, V846, P219, DOI 10.1016/S0006-8993(99)02056-9; Sondell M, 1999, J NEUROSCI, V19, P5731, DOI 10.1523/JNEUROSCI.19-14-05731.1999; Spyridopoulos I, 1997, CIRCULATION, V95, P1505; Takeshita S, 1997, CIRCULATION, V95, P805; TAKESHITA S, 1994, CIRCULATION, V90, P228; Takeshita S, 1996, BIOCHEM BIOPH RES CO, V227, P628, DOI 10.1006/bbrc.1996.1556; Takeshita S, 1998, CIRCULATION, V98, P1261, DOI 10.1161/01.CIR.98.13.1261; TAKESHITA S, 1994, J CLIN INVEST, V93, P662, DOI 10.1172/JCI117018; Tsurumi Y, 1996, CIRCULATION, V94, P3281, DOI 10.1161/01.CIR.94.12.3281; VanBelle E, 1997, CIRCULATION, V96, P2667, DOI 10.1161/01.CIR.96.8.2667; WHITE FC, 1992, CIRC RES, V71, P1490, DOI 10.1161/01.RES.71.6.1490; ZIGMOND SH, 1973, J EXP MED, V137, P387, DOI 10.1084/jem.137.2.387	44	198	215	0	8	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	APR	2000	6	4					405	413		10.1038/74664	http://dx.doi.org/10.1038/74664			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	376UA	10742147				2022-12-25	WOS:000165474100034
J	Grachtchouk, M; Rong, M; Yu, S; Zhang, XY; Sasaki, H; Hui, CC; Dlugosz, AA				Grachtchouk, M; Rong, M; Yu, S; Zhang, XY; Sasaki, H; Hui, CC; Dlugosz, AA			Basal cell carcinomas in mice overexpressing Gli2 in skin	NATURE GENETICS			English	Article							SONIC HEDGEHOG; TRANSCRIPTION FACTOR; HUMAN HOMOLOG; NEURAL-TUBE; EXPRESSION; MUTATIONS; GENE		Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Dermatol, Ann Arbor, MI 48109 USA; Hosp Sick Children, Program Dev Biol, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Mol & Med Genet, Toronto, ON, Canada; Osaka Univ, Inst Mol & Cellular Biol, Dev Biol Lab, Osaka, Japan	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; Osaka University	Dlugosz, AA (corresponding author), Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA.				NATIONAL CANCER INSTITUTE [P30CA046592] Funding Source: NIH RePORTER; NCI NIH HHS [CA46592] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aszterbaum M, 1999, NAT MED, V5, P1285, DOI 10.1038/15242; Booth DR, 1999, CANCER METAST REV, V18, P261, DOI 10.1023/A:1006377425099; Chiang C, 1999, DEV BIOL, V205, P1, DOI 10.1006/dbio.1998.9103; Dahmane N, 1997, NATURE, V389, P876, DOI 10.1038/39918; Ding Q, 1998, DEVELOPMENT, V125, P2533; Hahn H, 1996, CELL, V85, P841, DOI 10.1016/S0092-8674(00)81268-4; Hynes M, 1997, NEURON, V19, P15, DOI 10.1016/S0896-6273(00)80344-X; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; Lee J, 1997, DEVELOPMENT, V124, P2537; MARKEY AC, 1992, BRIT J DERMATOL, V126, P154, DOI 10.1111/j.1365-2133.1992.tb07813.x; Matise MP, 1999, ONCOGENE, V18, P7852, DOI 10.1038/sj.onc.1203243; Motoyama J, 1998, NAT GENET, V20, P54, DOI 10.1038/1711; Oro AE, 1997, SCIENCE, V276, P817, DOI 10.1126/science.276.5313.817; RAMIREZ A, 1994, DIFFERENTIATION, V58, P53, DOI 10.1007/s002580050065; SMOLLER BR, 1994, BRIT J DERMATOL, V131, P28, DOI 10.1111/j.1365-2133.1994.tb08453.x; Xie JW, 1998, NATURE, V391, P90, DOI 10.1038/34201	16	314	328	0	7	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAR	2000	24	3					216	217		10.1038/73417	http://dx.doi.org/10.1038/73417			2	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	288XW	10700170				2022-12-25	WOS:000085590600009
J	Louie, AY; Huber, MM; Ahrens, ET; Rothbacher, U; Moats, R; Jacobs, RE; Fraser, SE; Meade, TJ				Louie, AY; Huber, MM; Ahrens, ET; Rothbacher, U; Moats, R; Jacobs, RE; Fraser, SE; Meade, TJ			In vivo visualization of gene expression using magnetic resonance imaging	NATURE BIOTECHNOLOGY			English	Article						MRI; gene expression; contrast agent; beta-galactosidase; gadolinium; lacZ; MRI	GREEN FLUORESCENT PROTEIN; CONTRAST AGENTS; NMR MICROSCOPY; IN-VIVO; REPORTER; EMBRYOS; SINGLE; NEURONS; CELLS; GFP	High-resolution in vivo imaging of gene expression is not possible in opaque animals by existing techniques. Here we present a new approach for obtaining such images by magnetic resonance imaging (MRI) using an MRI contrast agent that can indicate reporter gene expression in living animals. We have prepared MRI contrast agents in which the access of water to the first coordination sphere of a chelated paramagnetic ion is blocked with a substrate that can be removed by enzymatic cleavage. Following cleavage, the paramagnetic ion can interact directly with water protons to increase the MR signal. Here, we report an agent where galactopyranose is the blocking group. This group renders the MRI contrast agent sensitive to expression of the commonly used marker gene, P-galactosidase. To cellular resolution, regions of higher intensity in the MR image correlate with regions expressing marker enzyme. These results offer the promise of in vivo mapping of gene expression in transgenic animals and validate a general approach for constructing a family of MRI contrast agents that respond to biological activity.	CALTECH, Beckman Inst, Div Biol, Pasadena, CA 91125 USA	California Institute of Technology	Meade, TJ (corresponding author), CALTECH, Beckman Inst, Div Biol, Pasadena, CA 91125 USA.	sefraser@gg.caltech.edu; tmeade@gg.caltech.edu	Fraser, Scott/Y-3406-2019; Rothbächer, Ute/AAB-6901-2022; Moats, Rex A/F-5995-2015; Rothbächer, Ute/G-2688-2013	Fraser, Scott/0000-0002-5377-0223; Rothbächer, Ute/0000-0002-9989-6139; Rothbächer, Ute/0000-0002-9989-6139	NIAMS NIH HHS [AR42671] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR042671] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Ahrens ET, 1998, P NATL ACAD SCI USA, V95, P8443, DOI 10.1073/pnas.95.15.8443; Aime S, 1998, CHEM SOC REV, V27, P19, DOI 10.1039/a827019z; AMSTERDAM A, 1995, DEV BIOL, V171, P123, DOI 10.1006/dbio.1995.1265; Arnone MI, 1997, DEVELOPMENT, V124, P4649; BERTINI I, 1986, NMR PARAMAGNETIC MOL; Bogdanov A, 1998, TRENDS BIOTECHNOL, V16, P5, DOI 10.1016/S0167-7799(97)01150-5; BOWTELL RW, 1995, MAGNET RESON MED, V33, P790, DOI 10.1002/mrm.1910330608; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; Chiu WL, 1996, CURR BIOL, V6, P325, DOI 10.1016/S0960-9822(02)00483-9; Davidson E. H., 1986, GENE ACTIVITY EARLY; Gambhir SS, 1999, P NATL ACAD SCI USA, V96, P2333, DOI 10.1073/pnas.96.5.2333; Gerhart J, 1997, CELLS EMBRYOS EVOLUT; HORROCKS WD, 1979, J AM CHEM SOC, V101, P334, DOI 10.1021/ja00496a010; Huber MM, 1998, BIOCONJUGATE CHEM, V9, P242, DOI 10.1021/bc970153k; JACOBS RE, 1994, SCIENCE, V263, P681, DOI 10.1126/science.7508143; Josephson L, 1999, BIOCONJUGATE CHEM, V10, P186, DOI 10.1021/bc980125h; KAY BK, 1991, METHODS CELL BIOL, V6; KAYYEM JF, 1995, CHEM BIOL, V2, P615; Kroll KL, 1996, DEVELOPMENT, V122, P3173; Li WH, 1999, J AM CHEM SOC, V121, P1413, DOI 10.1021/ja983702l; LIANG ZP, 1994, IEEE T MED IMAGING, V13, P677, DOI 10.1109/42.363100; MELLIN AF, 1994, MAGNET RESON MED, V32, P199, DOI 10.1002/mrm.1910320208; Moats RA, 1997, ANGEW CHEM INT EDIT, V36, P726, DOI 10.1002/anie.199707261; Moore A, 1998, BBA-MOL CELL RES, V1402, P239, DOI 10.1016/S0167-4889(98)00002-0; Nunez L, 1998, P NATL ACAD SCI USA, V95, P9648, DOI 10.1073/pnas.95.16.9648; PRASHER DC, 1995, TRENDS GENET, V11, P320, DOI 10.1016/S0168-9525(00)89090-3; ROFE CJ, 1995, J MAGN RESON SER B, V108, P125, DOI 10.1006/jmrb.1995.1113; Shukla R, 1996, MAGNET RESON MED, V35, P928, DOI 10.1002/mrm.1910350623; Su MY, 1998, MAGN RESON MED, V39, P259, DOI 10.1002/mrm.1910390213; TJUVAJEV JG, 1995, CANCER RES, V55, P6126; Tjuvajev JG, 1996, CANCER RES, V56, P4087; Weissleder R, 1997, RADIOLOGY, V204, P425, DOI 10.1148/radiology.204.2.9240530; WETTS R, 1989, DEVELOPMENT, V105, P9; Wilson E. B., 1986, CELL DEV INHERITANCE; ZHANG X, 1992, INORG CHEM, V31, P5597, DOI 10.1021/ic00052a040; Zlokarnik G, 1998, SCIENCE, V279, P84, DOI 10.1126/science.279.5347.84	36	889	942	5	156	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	MAR	2000	18	3					321	325		10.1038/73780	http://dx.doi.org/10.1038/73780			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	292AC	10700150				2022-12-25	WOS:000085771100032
J	Paton, AW; Morona, R; Paton, JC				Paton, AW; Morona, R; Paton, JC			A new biological agent for treatment of Shiga toxigenic Escherichia coli infections and dysentery in humans	NATURE MEDICINE			English	Article							HEMOLYTIC-UREMIC SYNDROME; TOXIN TYPE-II; BACTERIAL LIPOPOLYSACCHARIDES; NEISSERIA-MENINGITIDIS; MOLECULAR MIMICRY; COLI STRAINS; MOUSE MODEL; LIPOOLIGOSACCHARIDE; DISEASE; CLONING	Gastrointestinal disease caused by Shiga toxin-producing bacteria (such as Escherichia coli O157:H7 and Shigella dysenteriae) is often complicated by life-threatening toxin-induced systemic sequelae, including hemolytic-uremic syndrome. Such infections can now be diagnosed very early in the course of the disease, but at present no effective therapeutic intervention is possible. Here, we constructed a recombinant bacterium that displayed a Shiga toxin receptor mimic on its surface, and it adsorbed and neutralized Shiga toxins with very high efficiency. Moreover, oral administration of the recombinant bacterium completely protected mice from challenge with an otherwise 100%-fatal dose of Shiga toxigenic E. coli. Thus, the bacterium shows great promise as a 'probiotic' treatment for Shiga toxigenic E. coli infections and dysentery.	Womens & Childrens Hosp, Mol Microbiol Unit, Adelaide, SA 5006, Australia; Univ Adelaide, Dept Microbiol & Immunol, Adelaide, SA 5005, Australia	Womens & Childrens Hospital Australia; University of Adelaide	Paton, JC (corresponding author), Womens & Childrens Hosp, Mol Microbiol Unit, Adelaide, SA 5006, Australia.	patonj@wch.sn.gov.au	Morona, Renato/B-7746-2013; Paton, James C/A-9920-2008	Morona, Renato/0000-0001-7009-7440; 				ARMSTRONG GD, 1991, J INFECT DIS, V164, P1160, DOI 10.1093/infdis/164.6.1160; ARMSTRONG GD, 1995, J INFECT DIS, V171, P1042, DOI 10.1093/infdis/171.4.1042; CLEMENTS JD, 1988, VACCINE, V6, P269, DOI 10.1016/0264-410X(88)90223-X; DARVEAU RP, 1983, J BACTERIOL, V155, P831, DOI 10.1128/JB.155.2.831-838.1983; DEGRANDIS S, 1989, J BIOL CHEM, V264, P12520; GOTSCHLICH EC, 1994, J EXP MED, V180, P2181, DOI 10.1084/jem.180.6.2181; Heinrichs DE, 1998, J BIOL CHEM, V273, P29497, DOI 10.1074/jbc.273.45.29497; ITO H, 1990, MICROB PATHOGENESIS, V8, P47, DOI 10.1016/0882-4010(90)90007-D; Jennings MP, 1995, MOL MICROBIOL, V18, P729, DOI 10.1111/j.1365-2958.1995.mmi_18040729.x; JOBLING MG, 1990, NUCLEIC ACIDS RES, V18, P5315, DOI 10.1093/nar/18.17.5315; KARMALI MA, 1989, CLIN MICROBIOL REV, V2, P15, DOI 10.1128/CMR.2.1.15-38.1989; KLAUSER T, 1990, EMBO J, V9, P1991, DOI 10.1002/j.1460-2075.1990.tb08327.x; Liljeqvist S, 1999, J BIOTECHNOL, V73, P1, DOI 10.1016/S0168-1656(99)00107-8; LINDGREN SW, 1993, INFECT IMMUN, V61, P3832, DOI 10.1128/IAI.61.9.3832-3842.1993; Lingwood CA, 1996, TRENDS MICROBIOL, V4, P147, DOI 10.1016/0966-842X(96)10017-2; MANDRELL RE, 1993, IMMUNOBIOLOGY, V187, P382, DOI 10.1016/S0171-2985(11)80352-9; Maniatis T, 1982, MOL CLONING LABORATO, P68; Masoud H, 1997, BIOCHEMISTRY-US, V36, P2091, DOI 10.1021/bi961989y; Moran AP, 1996, FEMS IMMUNOL MED MIC, V16, P105, DOI 10.1111/j.1574-695X.1996.tb00127.x; MORONA R, 1991, FEMS MICROBIOL LETT, V82, P279, DOI 10.1016/0378-1097(91)90274-E; Nataro JP, 1998, CLIN MICROBIOL REV, V11, P403; OBRIEN AD, 1984, SCIENCE, V226, P694, DOI 10.1126/science.6387911; OBRIEN AD, 1987, MICROBIOL REV, V51, P206, DOI 10.1128/MMBR.51.2.206-220.1987; Paton AW, 1999, J CLIN MICROBIOL, V37, P3357, DOI 10.1128/JCM.37.10.3357-3361.1999; Paton AW, 1996, J CLIN MICROBIOL, V34, P1622, DOI 10.1128/JCM.34.7.1622-1627.1996; PATON AW, 1993, MICROB PATHOGENESIS, V15, P77, DOI 10.1006/mpat.1993.1058; PATON AW, 1995, GENE, V153, P71, DOI 10.1016/0378-1119(94)00777-P; Paton JC, 1998, CLIN MICROBIOL REV, V11, P450, DOI 10.1128/CMR.11.3.450; Risberg A, 1999, EUR J BIOCHEM, V261, P171, DOI 10.1046/j.1432-1327.1999.00248.x; ROGERS JE, 1997, 3 INT S WORKSH SHIG; Takeda T, 1999, MICROBIOL IMMUNOL, V43, P331, DOI 10.1111/j.1348-0421.1999.tb02413.x; Vinogradov EV, 1999, EUR J BIOCHEM, V261, P629, DOI 10.1046/j.1432-1327.1999.00280.x; WADOLKOWSKI EA, 1990, INFECT IMMUN, V58, P3959, DOI 10.1128/IAI.58.12.3959-3965.1990; WADOLKOWSKI EA, 1990, INFECT IMMUN, V58, P2438, DOI 10.1128/IAI.58.8.2438-2445.1990; Wakarchuk WW, 1998, EUR J BIOCHEM, V254, P626, DOI 10.1046/j.1432-1327.1998.2540626.x; Yang QL, 1996, J EXP MED, V183, P323, DOI 10.1084/jem.183.1.323; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	37	161	170	1	20	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2000	6	3					265	270		10.1038/73111	http://dx.doi.org/10.1038/73111			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	288TL	10700227				2022-12-25	WOS:000085580500035
J	Schuster, S; Fell, DA; Dandekar, T				Schuster, S; Fell, DA; Dandekar, T			A general definition of metabolic pathways useful for systematic organization and analysis of complex metabolic networks	NATURE BIOTECHNOLOGY			English	Article						elementary modes; metabolic networks; functional genomics; stochiometric network analysis	BIOCHEMICAL PATHWAYS; TRYPANOSOMA-BRUCEI; GLUCOSE-METABOLISM; STEADY-STATES; FLUX ANALYSIS; BIOSYNTHESIS; GLYCOLYSIS; EVOLUTION; ALGORITHM; ENZYMES	A set of linear pathways often does not capture the full range of behaviors of a metabolic network. The concept of 'elementary flux modes' provides a mathematical tool to define and comprehensively describe all metabolic routes that are both stoichiometrically and thermodynamically feasible for a group of enzymes. We have used this concept to analyze the interplay between the pentose phosphate pathway (PPP) and glycolysis. The set of elementary modes for this system involves conventional glycolysis, a futile cycle, all the modes of PPP function described in biochemistry textbooks, and additional modes that are a priori equally entitled to pathway status. Applications include maximizing product yield in amino acid and antibiotic synthesis, reconstruction and consistency checks of metabolism from genome data, analysis of enzyme deficiencies, and drug target identification in metabolic networks.	Max Delbruck Ctr Mol Med, Dept Bioinformat, D-13092 Berlin, Germany; Oxford Brookes Univ, Sch Biol & Mol Sci, Oxford OX3 0BP, England; European Mol Biol Lab, Biocomp & Struct Program, D-69012 Heidelberg, Germany	Helmholtz Association; Max Delbruck Center for Molecular Medicine; Oxford Brookes University; European Molecular Biology Laboratory (EMBL)	Schuster, S (corresponding author), Max Delbruck Ctr Mol Med, Dept Bioinformat, D-13092 Berlin, Germany.		Fell, David A/B-2109-2009; Dandekar, Thomas/A-4431-2017	Fell, David A/0000-0001-6669-2247; Dandekar, Thomas/0000-0003-1886-7625				Bakker BM, 1997, J BIOL CHEM, V272, P3207, DOI 10.1074/jbc.272.6.3207; Bonarius HPJ, 1997, TRENDS BIOTECHNOL, V15, P308, DOI 10.1016/S0167-7799(97)01067-6; Bonarius HPJ, 1996, BIOTECHNOL BIOENG, V50, P299, DOI 10.1002/(SICI)1097-0290(19960505)50:3<299::AID-BIT9>3.0.CO;2-B; Bork P, 1998, J MOL BIOL, V283, P707, DOI 10.1006/jmbi.1998.2144; Boros LG, 1998, MED HYPOTHESES, V50, P55, DOI 10.1016/S0306-9877(98)90178-5; CLARKE BL, 1981, J CHEM PHYS, V75, P4970, DOI 10.1063/1.441885; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; Cronan Jr. J. E., 1996, ESCHERICHIA COLI SAL, VI, P206; Dandekar T, 1999, BIOCHEM J, V343, P115, DOI 10.1042/0264-6021:3430115; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; EISENTHAL R, 1985, FEBS LETT, V181, P23, DOI 10.1016/0014-5793(85)81106-6; Fell D., 1997, UNDERSTANDING CONTRO; FELL DA, 1993, MODERN TRENDS IN BIOTHERMOKINETICS, P97; FROST JW, 1995, ANNU REV MICROBIOL, V49, P557, DOI 10.1146/annurev.mi.49.100195.003013; Hartwell L, 1997, NATURE, V387, P855, DOI 10.1038/43072; HERS HG, 1983, ANNU REV BIOCHEM, V52, P617, DOI 10.1146/annurev.bi.52.070183.003153; KACSER H, 1993, EUR J BIOCHEM, V216, P361, DOI 10.1111/j.1432-1033.1993.tb18153.x; KLAIRA JK, 1994, BIOTECHNOL APPL BIOC, V20, P347; LEISER J, 1987, CELL BIOPHYS, V11, P123, DOI 10.1007/BF02797119; Liao JC, 1996, BIOTECHNOL BIOENG, V52, P129, DOI 10.1002/(SICI)1097-0290(19961005)52:1<129::AID-BIT13>3.0.CO;2-J; Martin JF, 1998, APPL MICROBIOL BIOT, V50, P1, DOI 10.1007/s002530051249; MAVROVOUNIOTIS ML, 1990, BIOTECHNOL BIOENG, V36, P1119, DOI 10.1002/bit.260361107; MELENDEZHEVIA E, 1994, J THEOR BIOL, V166, P201, DOI 10.1006/jtbi.1994.1018; Nuno JC, 1997, BIOCHEM J, V324, P103, DOI 10.1042/bj3240103; PANDOLFI PP, 1995, EMBO J, V14, P5209, DOI 10.1002/j.1460-2075.1995.tb00205.x; Pfeiffer T, 1999, BIOINFORMATICS, V15, P251, DOI 10.1093/bioinformatics/15.3.251; Rohwer JM, 2000, NATO ASI 3 HIGH TECH, V74, P73; RUWENDE C, 1995, NATURE, V376, P246, DOI 10.1038/376246a0; Sauer U, 1997, NAT BIOTECHNOL, V15, P448, DOI 10.1038/nbt0597-448; Schilling CH, 1999, BIOTECHNOL PROGR, V15, P296, DOI 10.1021/bp990048k; Schilling CH, 1998, P NATL ACAD SCI USA, V95, P4193, DOI 10.1073/pnas.95.8.4193; SCHUSTER R, 1993, COMPUT APPL BIOSCI, V9, P79; Schuster S, 1999, TRENDS BIOTECHNOL, V17, P53, DOI 10.1016/S0167-7799(98)01290-6; Schuster S., 1996, COMPUTATION CELLULAR, P151; SCHUTZ EA, 1994, SPORTS MED ARTHROSC, V2, P165; Selkov E, 1998, NUCLEIC ACIDS RES, V26, P43, DOI 10.1093/nar/26.1.43; SERESSIOTIS A, 1986, BIOTECHNOL LETT, V8, P837, DOI 10.1007/BF01078641; SIMPSON TW, 1995, BIOCHEM SOC T, V23, P381, DOI 10.1042/bst0230381; SMITH EL, 1983, PRINCIPLES BIOCH GEN; Stryer L., 1995, BIOCHEMISTRY-US, V4th ed.; Tatusov RL, 1996, CURR BIOL, V6, P279, DOI 10.1016/S0960-9822(02)00478-5; VOET D, 1997, BIOCHEMISTRY; Yarmush ML, 1997, NAT BIOTECHNOL, V15, P525, DOI 10.1038/nbt0697-525; Yudkin M., 1980, GUIDEBOOK BIOCH	44	648	682	1	121	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAR	2000	18	3					326	332		10.1038/73786	http://dx.doi.org/10.1038/73786			7	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	292AC	10700151				2022-12-25	WOS:000085771100033
J	Desbarats, J; Newell, MK				Desbarats, J; Newell, MK			Fas engagement accelerates liver regeneration after partial hepatectomy	NATURE MEDICINE			English	Article							EXPRESSION; APOPTOSIS; RECEPTOR; LIGAND; ACTIVATION; SIGNALS; CELLS; GENE	Fas (CD95) is a receptor involved in induction of apoptotic cell death of Fas-bearing cells, including hepatocytes(1,2) and T cells(3). Injection of Fas-specific antibodies into mice leads to fulminant hepatic failure and death(1). Fas also transduces growth-promoting signals in proliferating T cells(4,5), fibroblasts(6) and some tumor cells'. Here we show that partial hepatectomy, which triggers the immediate onset of liver regeneration(8), protected mice against the lethal effects of Fas-specific antibodies and prevented hepatocyte apoptosis in response to Fas engagement in vivo. Furthermore, Fas engagement accelerated liver regeneration after partial hepatectomy. Liver regeneration kinetics were delayed in mutant mice with decreased cell surface Fas expression (lpr mice(9)), in contrast, regeneration was not delayed in lpr-cg mutant mice, which have a Fas mutation that prevents Fas-induced death(10) but not Fas-dependent proliferative stimulation. Our results indicate that Fas engagement on cells in regenerating or healing tissues may promote cell growth.	Univ Vermont, Dept Med, Burlington, VT 05401 USA; Univ Colorado, Dept Biol, Colorado Springs, CO 80918 USA	University of Vermont; University of Colorado System; University of Colorado at Colorado Springs	Newell, MK (corresponding author), Univ Vermont, Dept Med, Burlington, VT 05401 USA.	mnewell@mail.uccs.edu		Desbarats, Julie/0000-0002-2495-7152	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062562] Funding Source: NIH RePORTER; NIGMS NIH HHS [1RO1GM62562] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADACHI M, 1993, P NATL ACAD SCI USA, V90, P1756, DOI 10.1073/pnas.90.5.1756; ALBRECHT JH, 1994, FEBS LETT, V347, P157, DOI 10.1016/0014-5793(94)00527-3; ALDERSON MR, 1993, J EXP MED, V178, P2231, DOI 10.1084/jem.178.6.2231; Biancone L, 1997, J EXP MED, V186, P147, DOI 10.1084/jem.186.1.147; Bradham CA, 1998, AM J PHYSIOL-GASTR L, V275, pG387, DOI 10.1152/ajpgi.1998.275.3.G387; Desbarats J, 1998, NAT MED, V4, P1377, DOI 10.1038/3965; Desbarats J, 1999, P NATL ACAD SCI USA, V96, P8104, DOI 10.1073/pnas.96.14.8104; Freiberg RA, 1997, J INVEST DERMATOL, V108, P215, DOI 10.1111/1523-1747.ep12334273; GALLE PR, 1995, J EXP MED, V182, P1223, DOI 10.1084/jem.182.5.1223; Higgins GM, 1931, ARCH PATHOL, V12, P186; Hikawa N, 1997, J NEUROL SCI, V149, P13, DOI 10.1016/S0022-510X(96)05216-1; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Kimura M, 1994, Int Rev Immunol, V11, P193, DOI 10.3109/08830189409061727; Kondo T, 1997, NAT MED, V3, P409, DOI 10.1038/nm0497-409; Lacronique V, 1996, NAT MED, V2, P80, DOI 10.1038/nm0196-80; Michalopoulos GK, 1997, SCIENCE, V276, P60, DOI 10.1126/science.276.5309.60; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; OWENSCHAUB LB, 1993, J IMMUNOTHER, V14, P234, DOI 10.1097/00002371-199310000-00011; Refaeli Y, 1998, IMMUNITY, V8, P615, DOI 10.1016/S1074-7613(00)80566-X; Sata M, 1998, J BIOL CHEM, V273, P33103, DOI 10.1074/jbc.273.50.33103; SATO Y, 1993, IMMUNOLOGY, V78, P86; SNELLER MC, 1992, J CLIN INVEST, V90, P334, DOI 10.1172/JCI115867; Tzung SP, 1997, AM J PATHOL, V150, P1985; Yamada Y, 1998, HEPATOLOGY, V28, P959, DOI 10.1002/hep.510280410	25	184	192	1	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	AUG	2000	6	8					920	923		10.1038/78688	http://dx.doi.org/10.1038/78688			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	376TX	10932231				2022-12-25	WOS:000165473800037
J	Zhang, H; Cook, J; Nickel, J; Yu, R; Stecker, K; Myers, K; Dean, NM				Zhang, H; Cook, J; Nickel, J; Yu, R; Stecker, K; Myers, K; Dean, NM			Reduction of liver Fas expression by an antisense oligonucleotide protects mice from fulminant hepatitis	NATURE BIOTECHNOLOGY			English	Article						Fas; antisense oligonucleotide; apoptosis; hepatitis	NECROSIS-FACTOR-ALPHA; ICAM-1 MESSENGER-RNA; A-INDUCED HEPATITIS; CONCANAVALIN-A; GENE-EXPRESSION; HASHIMOTOS-THYROIDITIS; ALLOGRAFT-REJECTION; ANTIGEN EXPRESSION; LIGAND EXPRESSION; SJOGRENS-SYNDROME	Aberrant apoptosis-mediated cell death is believed to result in a number of different human diseases. For example, excessive apoptosis in the liver can result in fulminant and autoimmune forms of hepatitis. We have explored the possibility that inhibition of Fas expression in mice would reduce the severity of fulminant hepatitis. To do this, we have developed a chemically modified 2'-O-(2-methoxy)ethyl antisense oligonucleotide (ISIS 22023) inhibitor of mouse Fas expression. In tissue culture, this oligonucleotide induced a reduction in Fas mRNA expression that was both concentration- and sequence-specific. In Balb/c mice, dosing with ISIS 22023 reduced Fas mRNA and protein expressions in liver by 90%, The ID50 for this response was 8-10 mg kg(-1) daily dosing, and the reduction was highly dependent on oligonucleotide sequence, oligonucleotide concentration in liver, and treatment time. Pretreatment with ISIS 22023 completely protected mice from fulminant hepatitis induced by agonistic Fas antibody, by a mechanism entirely consistent with an oligonucleotide antisense mechanism of action. In addition, oligonucleotide-mediated suppression of Fas expression reduced the severity of acetaminophen-mediated fulminant hepatitis, but was without effect on concanavalin A-mediated hepatitis. Our results demonstrate that 2'-O-(2-methoxy)ethyl containing antisense oligonucleotides targeting Fas can exert in vivo pharmacological activity in liver, and suggest that oligonucleotide inhibitors of Fas may be useful in the treatment of human liver disease.	ISIS Pharmaceut Inc, Dept Pharmacol, Carlsbad, CA 92008 USA	Isis Pharmaceuticals Inc	Zhang, H (corresponding author), ISIS Pharmaceut Inc, Dept Pharmacol, Carlsbad, CA 92008 USA.	hzhang@isisph.com						Afford SC, 1999, J EXP MED, V189, P441, DOI 10.1084/jem.189.2.441; Baker BF, 1997, J BIOL CHEM, V272, P11994, DOI 10.1074/jbc.272.18.11994; Bennett CF, 1997, J PHARMACOL EXP THER, V280, P988; Blazka ME, 1996, TOXICOL PATHOL, V24, P181, DOI 10.1177/019262339602400206; Cooper SR, 1999, PHARMACOL THERAPEUT, V82, P427, DOI 10.1016/S0163-7258(99)00002-9; Crooke ST, 1998, ANTISENSE NUCLEIC A, V8, P133, DOI 10.1089/oli.1.1998.8.133; Crooke ST, 1998, HANDB EXP PHARM, V131, P1; DEAN NM, 1994, J BIOL CHEM, V269, P16416; Dittel BN, 1999, J IMMUNOL, V162, P6392; Driver SE, 1999, NAT BIOTECHNOL, V17, P1184, DOI 10.1038/70724; Faubion WA, 1999, J CLIN INVEST, V103, P137, DOI 10.1172/JCI4765; Galle PR, 1998, SEMIN LIVER DIS, V18, P141, DOI 10.1055/s-2007-1007150; Geary RS, 1997, DRUG METAB DISPOS, V25, P1272; Giordano C, 1997, SCIENCE, V275, P960, DOI 10.1126/science.275.5302.960; Hanecak R, 1996, J VIROL, V70, P5203, DOI 10.1128/JVI.70.8.5203-5212.1996; HAYASHI N, 1997, J GASTROEN HEPATOL, V12, P9; Josien R, 1998, TRANSPLANTATION, V66, P887, DOI 10.1097/00007890-199810150-00013; Kole R, 1997, ACTA BIOCHIM POL, V44, P231; Kondo T, 1997, NAT MED, V3, P409, DOI 10.1038/nm0497-409; Kong LP, 1997, ARTHRITIS RHEUM, V40, P87, DOI 10.1002/art.1780400113; Ksontini R, 1998, J IMMUNOL, V160, P4082; Kuwano K, 1999, J CLIN INVEST, V104, P13, DOI 10.1172/JCI5628; Leeds JM, 1996, ANAL BIOCHEM, V235, P36, DOI 10.1006/abio.1996.0088; Luo KX, 1997, J VIRAL HEPATITIS, V4, P303, DOI 10.1046/j.1365-2893.1997.00053.x; Matsumura R, 1998, CLIN EXP RHEUMATOL, V16, P561; McKay RA, 1999, J BIOL CHEM, V274, P1715, DOI 10.1074/jbc.274.3.1715; Miwa K, 1999, INT IMMUNOL, V11, P925, DOI 10.1093/intimm/11.6.925; Mizuta T, 1999, NAT BIOTECHNOL, V17, P583, DOI 10.1038/9893; Mochizuki K, 1996, J HEPATOL, V24, P1, DOI 10.1016/S0168-8278(96)80178-4; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; Nagata S, 1996, Prog Mol Subcell Biol, V16, P87; Noiri E, 1996, J CLIN INVEST, V97, P2377, DOI 10.1172/JCI118681; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; Okazaki M, 1996, DIGEST DIS SCI, V41, P2453, DOI 10.1007/BF02100142; Ray SD, 1996, J PHARMACOL EXP THER, V279, P1470; Rudi J, 1998, J CLIN INVEST, V102, P1506, DOI 10.1172/JCI2808; Seino KI, 1997, GASTROENTEROLOGY, V113, P1315, DOI 10.1053/gast.1997.v113.pm9322527; Sekine K, 1997, Fukushima J Med Sci, V43, P51; Stassi G, 1999, J IMMUNOL, V162, P263; Strand S, 1998, NAT MED, V4, P588, DOI 10.1038/nm0598-588; Strater J, 1997, GASTROENTEROLOGY, V113, P160, DOI 10.1016/S0016-5085(97)70091-X; Tagawa Y, 1997, J IMMUNOL, V159, P1418; Taieb J, 1998, LANCET, V351, P1930, DOI 10.1016/S0140-6736(05)78614-1; Taylor JK, 1999, NAT BIOTECHNOL, V17, P1097, DOI 10.1038/15079; TIEGS G, 1992, J CLIN INVEST, V90, P196, DOI 10.1172/JCI115836; Viard I, 1998, SCIENCE, V282, P490, DOI 10.1126/science.282.5388.490; Watanabe Y, 1996, HEPATOLOGY, V24, P702, DOI 10.1002/hep.510240338; Zhang H, 1999, ANTIMICROB AGENTS CH, V43, P347, DOI 10.1128/AAC.43.2.347	48	187	214	0	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	AUG	2000	18	8					862	867		10.1038/78475	http://dx.doi.org/10.1038/78475			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	342VX	10932156				2022-12-25	WOS:000088666800023
J	Fornas, O; Garcia, J; Petriz, J				Fornas, O; Garcia, J; Petriz, J			Flow cytometry counting of CD34(+) cells in whole blood	NATURE MEDICINE			English	Article							HEMATOPOIETIC STEM-CELLS; VIABILITY		Canc Res Inst, Dept Cryobiol & Cell Therapy, Barcelona 08907, Spain		Petriz, J (corresponding author), Hosp Clin Barcelona, Lab Cryobiol, Villarroel 170, E-08036 Barcelona, Spain.		Fornas, Oscar/F-1456-2015; Petriz, Jordi/AAS-4943-2020; Petriz, Jordi/AAB-7293-2019	Fornas, Oscar/0000-0003-2017-9100; Petriz, Jordi/0000-0003-1085-0511; 				Barnett D, 1999, BRIT J HAEMATOL, V106, P1059; BRENNER MK, 1993, LANCET, V342, P1134, DOI 10.1016/0140-6736(93)92122-A; Broxterman HJ, 1997, BRIT J CANCER, V76, P1029, DOI 10.1038/bjc.1997.503; CANNAVO N, 1998, LEUCOCYTE TYPING, V6, P978; CHAUDHARY PM, 1991, CELL, V66, P85, DOI 10.1016/0092-8674(91)90141-K; Fritsch G, 1997, TRANSFUSION, V37, P775, DOI 10.1046/j.1537-2995.1997.37897424398.x; Goodell MA, 1997, NAT MED, V3, P1337, DOI 10.1038/nm1297-1337; GRATAMA JW, 1997, CYTOMETRY, V15, P166; Hubl W, 1998, CYTOMETRY, V34, P121; Keeney M, 1998, CYTOMETRY, V34, P61, DOI 10.1002/(SICI)1097-0320(19980415)34:2<61::AID-CYTO1>3.0.CO;2-F; Krause DS, 1996, BLOOD, V87, P1; Macey MG, 1997, J IMMUNOL METHODS, V204, P175, DOI 10.1016/S0022-1759(97)00045-8; MCCARTHY DA, 1993, J IMMUNOL METHODS, V163, P155, DOI 10.1016/0022-1759(93)90117-P; METCALF D, 1971, HAEMOPOIETIC CELLS, P550; QUESENBERRY P, 1979, NEW ENGL J MED, V301, P755, DOI 10.1056/NEJM197910043011404; SIENA S, 1989, BLOOD, V74, P1905; SPANGRUDE GJ, 1994, ANNU REV MED, V45, P93; STELZER GT, 1993, ANN NY ACAD SCI, V677, P265, DOI 10.1111/j.1749-6632.1993.tb38783.x; SUTHERLAND DR, 1994, EXP HEMATOL, V22, P1003; Yang HY, 1998, CELL TRANSPLANT, V7, P443, DOI 10.1016/S0963-6897(98)00032-3	20	41	49	0	3	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUL	2000	6	7					833	+		10.1038/77571	http://dx.doi.org/10.1038/77571			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	331VV	10888936				2022-12-25	WOS:000088040100044
J	Tang-Christensen, M; Larsen, PJ; Thulesen, J; Romer, J; Vrang, N				Tang-Christensen, M; Larsen, PJ; Thulesen, J; Romer, J; Vrang, N			The proglucagon-derived peptide, glucagon-like peptide-2, is a neurotransmitter involved in the regulation of food intake	NATURE MEDICINE			English	Article							NEUROPEPTIDE-Y; MESSENGER-RNA; HYPOTHALAMIC NUCLEUS; GENE-EXPRESSION; ARCUATE NUCLEUS; BRAIN-STEM; RAT; RECEPTOR; NEURONS; AGONIST	The dorsomedial hypothalamic nucleus harbors leptin sensitive neurons and is intrinsically connected to hypothalamic nuclei involved in feeding behavior. However, It also receives ascending input from the visceroceptive neurons of the brainstem. We have identified a unique glucagon-like-peptide-2 containing neuronal pathway connecting the nucleus of the solitary tract with the dorsomedial hypothalamic nucleus. A glucagon-like-peptide-2 fiber plexus targets neurons expressing its receptor within the dorsomedial hypothalamic nucleus. Pharmacological and behavioral studies confirmed that glucagon-like-peptide-2 signaling is a specific transmitter inhibiting rodent feeding behavior and with potential long-term effects on body weight homeostasis. The glucagon-like-peptide-1 receptor antagonist, Exendin (9-39) is also a functional antagonist of centrally applied glucagon-like-peptide-2.	Univ Copenhagen, Panum Inst, Dept Med Anat, Sect B, DK-1168 Copenhagen, Denmark; Novo Nordisk AS, Discovery, Pharmacol 4, DK-2880 Bagsvaerd, Denmark	University of Copenhagen; Novo Nordisk	Tang-Christensen, M (corresponding author), Univ Copenhagen, Panum Inst, Dept Med Anat, Sect B, DK-1168 Copenhagen, Denmark.	M.Tang@mal.ku.dk		Thulesen, Jesper/0000-0002-5355-8062				Bernardis LL, 1998, P SOC EXP BIOL MED, V218, P284; Brubaker PL, 1997, ENDOCRINOLOGY, V138, P4837, DOI 10.1210/en.138.11.4837; Drucker DJ, 1998, DIABETES, V47, P159, DOI 10.2337/diabetes.47.2.159; Elmquist JK, 1997, ENDOCRINOLOGY, V138, P839, DOI 10.1210/en.138.2.839; Gunn I, 1996, BIOCHEM SOC T, V24, P581, DOI 10.1042/bst0240581; Holst JJ, 1997, ANNU REV PHYSIOL, V59, P257, DOI 10.1146/annurev.physiol.59.1.257; Jensen J, 1996, J BIOL CHEM, V271, P18749, DOI 10.1074/jbc.271.31.18749; Kesterson RA, 1997, MOL ENDOCRINOL, V11, P630, DOI 10.1210/me.11.5.630; KRISTENSEN P, 1991, J HISTOCHEM CYTOCHEM, V39, P341, DOI 10.1177/39.3.1899685; Larsen PJ, 1997, NEUROSCIENCE, V77, P257, DOI 10.1016/S0306-4522(96)00434-4; Larsen PJ, 1997, ENDOCRINOLOGY, V138, P4445, DOI 10.1210/en.138.10.4445; Li C, 1998, REGUL PEPTIDES, V75-6, P93, DOI 10.1016/S0167-0115(98)00057-3; Li C, 1998, ENDOCRINOLOGY, V139, P1645, DOI 10.1210/en.139.4.1645; McMahon LR, 1998, AM J PHYSIOL-REG I, V274, pR23, DOI 10.1152/ajpregu.1998.274.1.R23; Merchenthaler I, 1999, J COMP NEUROL, V403, P261, DOI 10.1002/(SICI)1096-9861(19990111)403:2<261::AID-CNE8>3.0.CO;2-5; Munroe DG, 1999, P NATL ACAD SCI USA, V96, P1569, DOI 10.1073/pnas.96.4.1569; ORSKOV C, 1989, J BIOL CHEM, V264, P12826; Paxinos G, 1998, RAT BRAIN IN STEREOTAXIC COORDINATES, FOURTH ED., pix; PELLETIER G, 1990, ANN NY ACAD SCI, V611, P232; Rinaman L, 1999, AM J PHYSIOL-REG I, V277, pR1537, DOI 10.1152/ajpregu.1999.277.5.R1537; Schepp W, 1996, DIGESTION, V57, P398, DOI 10.1159/000201367; SCHEPP W, 1994, EUR J PHARM-MOLEC PH, V269, P183, DOI 10.1016/0922-4106(94)90085-X; SCHWARTZ MW, 1993, ANN NY ACAD SCI, V692, P60; Seeley RJ, 2000, J NEUROSCI, V20, P1616; Serre V, 1998, ENDOCRINOLOGY, V139, P4448, DOI 10.1210/en.139.11.4448; SMITH MS, 1993, ENDOCRINOLOGY, V133, P1258, DOI 10.1210/en.133.3.1258; STANLEY BG, 1985, P NATL ACAD SCI USA, V82, P3940, DOI 10.1073/pnas.82.11.3940; Tang-Christensen M, 1998, DIABETES, V47, P530, DOI 10.2337/diabetes.47.4.530; TangChristensen M, 1996, AM J PHYSIOL-REG I, V271, pR848, DOI 10.1152/ajpregu.1996.271.4.R848; TERHORST GJ, 1987, BRAIN RES BULL, V18, P191, DOI 10.1016/0361-9230(87)90190-0; Thiele TE, 1997, AM J PHYSIOL-REG I, V272, pR726, DOI 10.1152/ajpregu.1997.272.2.R726; Thim L, 1998, FEBS LETT, V428, P263, DOI 10.1016/S0014-5793(98)00543-2; THORENS B, 1993, DIABETES, V42, P1678, DOI 10.2337/diabetes.42.11.1678; Turton MD, 1996, NATURE, V379, P69, DOI 10.1038/379069a0; VALVERDE I, 1993, ENDOCRINOLOGY, V132, P75, DOI 10.1210/en.132.1.75; vanDijk G, 1996, AM J PHYSIOL-REG I, V271, pR1096, DOI 10.1152/ajpregu.1996.271.4.R1096; Vrang N, 1999, J Neurosci, V19, pRC5; Wilding JPH, 1997, J ENDOCRINOL, V152, P365, DOI 10.1677/joe.0.1520365; Woldbye DPD, 1996, BRAIN RES, V720, P111, DOI 10.1016/0006-8993(96)00158-8; Yusta B, 1999, J BIOL CHEM, V274, P30459, DOI 10.1074/jbc.274.43.30459	40	212	222	0	10	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2000	6	7					802	+		10.1038/77535	http://dx.doi.org/10.1038/77535			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	331VV	10888930				2022-12-25	WOS:000088040100038
J	Bartlett, RJ; Stockinger, S; Denis, MM; Bartlett, WT; Inverardi, L; Le, TT; Man, NT; Morris, GE; Bogan, DJ; Metcalf-Bogan, J; Kornegay, JN				Bartlett, RJ; Stockinger, S; Denis, MM; Bartlett, WT; Inverardi, L; Le, TT; Man, NT; Morris, GE; Bogan, DJ; Metcalf-Bogan, J; Kornegay, JN			In vivo targeted repair of a point mutation in the canine dystrophin gene by a chimeric RNA/DNA oligonucleotide	NATURE BIOTECHNOLOGY			English	Article						dystrophin; chimeric RNA/DNA oligonucleotide; invivo gene repair; quantitative RT/PCR; in situ RT/PCR; canine	RETRIEVER MUSCULAR-DYSTROPHY; MOUSE SKELETAL-MUSCLE; IN-VIVO; MDX MICE; MYOBLAST TRANSPLANTATION; IMMUNE-RESPONSES; VIRAL-ANTIGENS; EXPRESSION; INJECTION; TRANSCRIPTS	In the canine model of Duchenne muscular dystrophy in golden retrievers (GRMD), a point mutation within the splice acceptor site of intron 6 leads to deletion of exon 7 from the dystrophin mRNA, and the consequent frameshift causes early termination of translation. We have designed a DNA and RNA chimeric oligonucleotide to induce host cell mismatch repair mechanisms and correct the chromosomal mutation to wild type. Direct skeletal muscle injection of the chimeric oligonucleotide into the cranial tibialis compartment of a six-week-old affected male dog, and subsequent analysis of biopsy and necropsy samples, demonstrated in vivo repair of the GRMD mutation that was sustained for 48 weeks. Reverse transcription-polymerase chain reaction (RT-PCR) analysis of exons 5-10 demonstrated increasing levels of exon 7 inclusion with time. An isolated exon 7-specific dystrophin antibody confirmed synthesis of normal-sized dystrophin product and positive localization to the sarcolemma, Chromosomal repair in muscle tissue was confirmed by restriction fragment length polymorphism (RFLP)-PCR and sequencing the PCR product, This work provides evidence for the long-term repair of a specific dystrophin point mutation in muscle of a live animal using a chimeric oligonucleotide.	Univ Missouri, Coll Vet Med, Dept Vet Med & Surg, Dalton Cardiovasc Res Ctr, Columbia, MO 65202 USA; Univ Miami, Sch Med, Dept Med, Miami, FL 33136 USA; Univ Miami, Sch Med, Dept Neurol, Miami, FL 33136 USA; Ohio State Univ, Dept Med Biochem, Columbus, OH 43210 USA; NE Wales Inst, Wrexham LL11 2AW, Wales	University of Missouri System; University of Missouri Columbia; University of Miami; University of Miami; University System of Ohio; Ohio State University; Glyndwr University	Bartlett, RJ (corresponding author), NIAMS, Grants Review Branch, Bethesda, MD 20892 USA.		Le, Thanh/GRY-4094-2022; Deris, Mustafa Mat/D-4662-2013	Kornegay, Joe/0000-0002-5594-1882				ACSADI G, 1991, NATURE, V352, P815, DOI 10.1038/352815a0; ARAHATA K, 1989, P NATL ACAD SCI USA, V86, P7154, DOI 10.1073/pnas.86.18.7154; Bartlett RJ, 1996, AM J VET RES, V57, P650; Bartlett RJ, 1996, CELL TRANSPLANT, V5, P411, DOI 10.1016/0963-6897(95)02026-8; BARTLETT RJ, 1998, NATURE BIOL SHORT RE, V9, P163; BULFIELD G, 1984, P NATL ACAD SCI-BIOL, V81, P1189, DOI 10.1073/pnas.81.4.1189; Cole-Strauss A, 1999, NUCLEIC ACIDS RES, V27, P1323, DOI 10.1093/nar/27.5.1323; ColeStrauss A, 1996, SCIENCE, V273, P1386, DOI 10.1126/science.273.5280.1386; DANKO I, 1993, HUM MOL GENET, V2, P2055, DOI 10.1093/hmg/2.12.2055; Floyd SS, 1998, GENE THER, V5, P19, DOI 10.1038/sj.gt.3300549; FRITZ JD, 1995, PEDIATR RES, V37, P693, DOI 10.1203/00006450-199506000-00004; Huard J, 1996, J VIROL, V70, P8117, DOI 10.1128/JVI.70.11.8117-8123.1996; Kinoshita I, 1996, NEUROMUSCULAR DISORD, V6, P187, DOI 10.1016/0960-8966(96)00004-1; Kinoshita I, 1996, ACTA NEUROPATHOL, V91, P489, DOI 10.1007/s004010050456; KORNEGAY JN, 1994, J NEUROL SCI, V123, P100, DOI 10.1016/0022-510X(94)90210-0; KORNEGAY JN, 1988, MUSCLE NERVE, V11, P1056, DOI 10.1002/mus.880111008; Kren BT, 1998, NAT MED, V4, P285, DOI 10.1038/nm0398-285; MAN TT, 1996, PROTEIN PROTOCOLS HD, P783; MENDELL JR, 1995, NEW ENGL J MED, V333, P832, DOI 10.1056/NEJM199509283331303; Partridge T, 1998, NAT MED, V4, P1208, DOI 10.1038/3167; Schatzberg SJ, 1998, MUSCLE NERVE, V21, P991, DOI 10.1002/(SICI)1097-4598(199808)21:8<991::AID-MUS2>3.3.CO;2-S; SHARP NJH, 1992, GENOMICS, V13, P115, DOI 10.1016/0888-7543(92)90210-J; SICINSKI P, 1989, SCIENCE, V244, P1578, DOI 10.1126/science.2662404; THANH LT, 1995, AM J MED GENET, V58, P177, DOI 10.1002/ajmg.1320580217; WELLS DJ, 1993, FEBS LETT, V332, P179, DOI 10.1016/0014-5793(93)80508-R; Wilton SD, 1997, NEUROMUSCULAR DISORD, V7, P329, DOI 10.1016/S0960-8966(97)00058-8; Wilton SD, 1997, MUSCLE NERVE, V20, P728; Worgall S, 1997, HUM GENE THER, V8, P37, DOI 10.1089/hum.1997.8.1-37; Yang L, 1998, GENE THER, V5, P369, DOI 10.1038/sj.gt.3300600; Yang Y, 1996, GENE THER, V3, P137; Yang YP, 1996, J VIROL, V70, P7209, DOI 10.1128/JVI.70.10.7209-7212.1996; Yuasa K, 1998, FEBS LETT, V425, P329, DOI 10.1016/S0014-5793(98)00251-8	32	137	143	0	10	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUN	2000	18	6					615	622		10.1038/76448	http://dx.doi.org/10.1038/76448			8	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	325EK	10835598				2022-12-25	WOS:000087663200020
J	Brenner, S; Johnson, M; Bridgham, J; Golda, G; Lloyd, DH; Johnson, D; Luo, SJ; McCurdy, S; Foy, M; Ewan, M; Roth, R; George, D; Eletr, S; Albrecht, G; Vermaas, E; Williams, SR; Moon, K; Burcham, T; Pallas, M; DuBridge, RB; Kirchner, J; Fearon, K; Mao, J; Corcoran, K				Brenner, S; Johnson, M; Bridgham, J; Golda, G; Lloyd, DH; Johnson, D; Luo, SJ; McCurdy, S; Foy, M; Ewan, M; Roth, R; George, D; Eletr, S; Albrecht, G; Vermaas, E; Williams, SR; Moon, K; Burcham, T; Pallas, M; DuBridge, RB; Kirchner, J; Fearon, K; Mao, J; Corcoran, K			Gene expression analysis by massively parallel signature sequencing (MPSS) on microbead arrays	NATURE BIOTECHNOLOGY			English	Article						DNA sequencing; ligation; gene expression; fluid microarray; yeast	MICROARRAYS	We describe a novel sequencing approach that combines non-gel-based signature sequencing with in vitro cloning of millions of templates on separate 5 mu m diameter microbeads. After constructing a microbead library of DNA templates by in vitro cloning, we assembled a planar array of a million template-containing microbeads in a flow cell at a density greater than 3 x 10(6) microbeads/cm(2). Sequences of the free ends of the cloned templates on each microbead were then simultaneously analyzed using a fluorescence-based signature sequencing method that does not require DNA fragment separation. Signature sequences of 19-20 bases were obtained by repeated cycles of enzymatic cleavage with a type Ils restriction endonuclease, adaptor ligation, and sequence interrogation by encoded hybridization probes. The approach was validated by sequencing over 269,000 signatures from two cDNA libraries constructed from a fully sequenced strain of Saccharomyces cerevisiae, and by measuring gene expression levels in the human cell line THP-1. The approach provides an unprecedented depth of analysis permitting application of powerful statistical techniques for discovery of functional relationships among genes, whether known or unknown beforehand, or whether expressed at high or very low levels.	Lynx Therapeut Inc, Hayward, CA 94545 USA		Brenner, S (corresponding author), Lynx Therapeut Inc, 25861 Ind Blvd, Hayward, CA 94545 USA.	sbrenner@lynxgen.com	Martinez, Octavio/B-7375-2009; Pillay, Nischalan/F-9536-2012					Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Audic S, 1997, GENOME RES, V7, P986, DOI 10.1101/gr.7.10.986; Bachem CWB, 1996, PLANT J, V9, P745, DOI 10.1046/j.1365-313X.1996.9050745.x; Brenner S, 2000, P NATL ACAD SCI USA, V97, P1665, DOI 10.1073/pnas.97.4.1665; BREWSTER NK, 1994, ARCH BIOCHEM BIOPHYS, V311, P62, DOI 10.1006/abbi.1994.1209; Chervitz SA, 1999, NUCLEIC ACIDS RES, V27, P74, DOI 10.1093/nar/27.1.74; Collins FS, 1998, SCIENCE, V282, P682, DOI 10.1126/science.282.5389.682; Duggan DJ, 1999, NAT GENET, V21, P10, DOI 10.1038/4434; Hacia JG, 1999, NAT GENET, V21, P42, DOI 10.1038/4469; Lander ES, 1996, SCIENCE, V274, P536, DOI 10.1126/science.274.5287.536; Neilson L, 2000, GENOMICS, V63, P13, DOI 10.1006/geno.1999.6059; OKUBO K, 1992, NAT GENET, V2, P173, DOI 10.1038/ng1192-173; Richmond CS, 1999, NUCLEIC ACIDS RES, V27, P3821, DOI 10.1093/nar/27.19.3821; Shimkets RA, 1999, NAT BIOTECHNOL, V17, P798, DOI 10.1038/11743; VELCULESCU VE, 1995, SCIENCE, V270, P484, DOI 10.1126/science.270.5235.484; Velculescu VE, 1997, CELL, V88, P243, DOI 10.1016/S0092-8674(00)81845-0; Wittes J, 1999, J NATL CANCER I, V91, P400, DOI 10.1093/jnci/91.5.400	17	899	1256	5	110	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JUN	2000	18	6					630	634		10.1038/76469	http://dx.doi.org/10.1038/76469			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	325EK	10835600				2022-12-25	WOS:000087663200022
J	Trojan, A; Schultze, JL; Witzens, M; Vonderheide, RH; Ladetto, M; Donovan, JW; Gribben, JG				Trojan, A; Schultze, JL; Witzens, M; Vonderheide, RH; Ladetto, M; Donovan, JW; Gribben, JG			Immunoglobulin framework-derived peptides function as cytotoxic T-cell epitopes commonly expressed in B-cell malignancies	NATURE MEDICINE			English	Article							CLASS-I MOLECULES; MULTIPLE-MYELOMA; ENDOGENOUS IMMUNOGLOBULIN; PROTECTIVE IMMUNITY; IDIOTYPIC PROTEIN; BINDING PEPTIDES; DENDRITIC CELLS; LEUKEMIA CELLS; TUMOR-ANTIGEN; LYMPHOMA	Although the idiotypic structures of immunoglobulin from malignant B cells were the first tumor-specific determinants recognized, and clinical vaccination trials have demonstrated induction of tumor-specific immunity, the function of immunoglobulin-specific CD8(+) cytotoxic T lymphocytes in tumor rejection remains elusive. Here, we combined bioinformatics and a T cell-expansion system to identify human immunoglobulin-derived peptides capable of inducing cytotoxic T-lymphocyte responses. Immunogenic peptides were derived from framework regions of the variable regions of the immunoglobulin that were shared among patients. Human-leukocyte-antigen-matched and autologous cytotoxic T lymphocytes specific for these peptides killed primary malignant B cells, demonstrating that malignant B cells are capable of processing and presenting such peptides. Targeting shared peptides to induce T-cell responses might further improve current vaccination strategies in B-cell malignancies.	Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Trojan, A (corresponding author), Dana Farber Canc Inst, Dept Adult Oncol, 44 Binney St, Boston, MA 02115 USA.		Schultze, Joachim L./ABA-8176-2020; Schultze, Joachim L/D-7794-2011; ladetto, marco/AAA-5546-2022; Witzens-Harig, Mathias/N-1790-2017	Schultze, Joachim L./0000-0003-2812-9853; Schultze, Joachim L/0000-0003-2812-9853; ladetto, marco/0000-0002-8283-2681; Witzens-Harig, Mathias/0000-0002-2799-4661	NCI NIH HHS [P01 CA 66996, CA78378, CA81534] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA081534, P01CA078378, P01CA066996, P20CA081534] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bendandi M, 1999, NAT MED, V5, P1171, DOI 10.1038/13928; Bennett SRM, 1998, J EXP MED, V188, P1977, DOI 10.1084/jem.188.11.1977; Blake N, 1997, IMMUNITY, V7, P791, DOI 10.1016/S1074-7613(00)80397-0; BOGEN B, 1986, EUR J IMMUNOL, V16, P1373, DOI 10.1002/eji.1830161110; Brossart P, 1999, BLOOD, V93, P4309, DOI 10.1182/blood.V93.12.4309.412k19_4309_4317; CAMPBELL MJ, 1987, J IMMUNOL, V139, P2825; CAO WX, 1994, J EXP MED, V179, P195, DOI 10.1084/jem.179.1.195; COX AL, 1994, SCIENCE, V264, P716, DOI 10.1126/science.7513441; Fagerberg J, 1999, INT J CANCER, V80, P671, DOI 10.1002/(SICI)1097-0215(19990301)80:5<671::AID-IJC7>3.0.CO;2-E; FUCHS EJ, 1992, SCIENCE, V258, P1156, DOI 10.1126/science.1439825; GEORGE AJT, 1987, J IMMUNOL, V138, P628; Gulukota K, 1997, J MOL BIOL, V267, P1258, DOI 10.1006/jmbi.1997.0937; HAWKINS RE, 1994, BLOOD, V83, P3279; Hsu FJ, 1997, BLOOD, V89, P3129, DOI 10.1182/blood.V89.9.3129; JANEWAY CA, 1975, P NATL ACAD SCI USA, V72, P2357, DOI 10.1073/pnas.72.6.2357; Kessler BM, 1997, J EXP MED, V185, P629, DOI 10.1084/jem.185.4.629; King CA, 1998, NAT MED, V4, P1281, DOI 10.1038/3266; KWAK LW, 1992, NEW ENGL J MED, V327, P1209, DOI 10.1056/NEJM199210223271705; LAURITZSEN GF, 1994, P NATL ACAD SCI USA, V91, P5700, DOI 10.1073/pnas.91.12.5700; LAURITZSEN GF, 1993, SCAND J IMMUNOL, V37, P77, DOI 10.1111/j.1365-3083.1993.tb01668.x; Manici S, 1999, J EXP MED, V189, P871, DOI 10.1084/jem.189.5.871; Molldrem J, 1996, BLOOD, V88, P2450, DOI 10.1182/blood.V88.7.2450.bloodjournal8872450; Munthe LA, 1999, EUR J IMMUNOL, V29, P4043, DOI 10.1002/(SICI)1521-4141(199912)29:12<4043::AID-IMMU4043>3.0.CO;2-E; Nestle FO, 1998, NAT MED, V4, P328, DOI 10.1038/nm0398-328; NIJMAN HW, 1993, EUR J IMMUNOL, V23, P1215, DOI 10.1002/eji.1830230603; Osterroth F, 2000, BLOOD, V95, P1342, DOI 10.1182/blood.V95.4.1342.004k19_1342_1349; Pardoll DM, 1999, P NATL ACAD SCI USA, V96, P5340, DOI 10.1073/pnas.96.10.5340; PARKER KC, 1995, IMMUNOL RES, V14, P34, DOI 10.1007/BF02918496; PARKER KC, 1994, J IMMUNOL, V152, P163; Provan D, 1996, BLOOD, V88, P2228, DOI 10.1182/blood.V88.6.2228.bloodjournal8862228; Rammensee HG, 1999, IMMUNOGENETICS, V50, P213, DOI 10.1007/s002510050595; Rosenberg SA, 1998, NAT MED, V4, P321, DOI 10.1038/nm0398-321; Savage PA, 1999, IMMUNITY, V10, P485, DOI 10.1016/S1074-7613(00)80048-5; Schirmbeck R, 1998, EUR J IMMUNOL, V28, P4149, DOI 10.1002/(SICI)1521-4141(199812)28:12<4149::AID-IMMU4149>3.0.CO;2-D; Schultze JL, 1997, J CLIN INVEST, V100, P2757, DOI 10.1172/JCI119822; SETTE A, 1994, J IMMUNOL, V153, P5586; Syrengelas AD, 1996, NAT MED, V2, P1038, DOI 10.1038/nm0996-1038; vanderBurg SH, 1996, J IMMUNOL, V156, P3308; Vonderheide RH, 1999, IMMUNITY, V10, P673, DOI 10.1016/S1074-7613(00)80066-7; Wang RF, 1996, J EXP MED, V184, P2207, DOI 10.1084/jem.184.6.2207; WEISS S, 1991, CELL, V64, P767, DOI 10.1016/0092-8674(91)90506-T; WEISS S, 1989, P NATL ACAD SCI USA, V86, P282, DOI 10.1073/pnas.86.1.282; Wen YJ, 1998, BRIT J HAEMATOL, V100, P464, DOI 10.1046/j.1365-2141.1998.00592.x; Wen YJ, 1997, EUR J IMMUNOL, V27, P1043, DOI 10.1002/eji.1830270435; Wen YJ, 1998, CLIN CANCER RES, V4, P957	45	149	166	0	4	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUN	2000	6	6					667	672		10.1038/76243	http://dx.doi.org/10.1038/76243			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	321CX	10835683				2022-12-25	WOS:000087438300037
J	Clarke, G; Goldberg, AFX; Vidgen, D; Collins, L; Ploder, L; Schwarz, L; Molday, LL; Rossant, J; Szel, A; Molday, RS; Birch, DG; McInnes, RR				Clarke, G; Goldberg, AFX; Vidgen, D; Collins, L; Ploder, L; Schwarz, L; Molday, LL; Rossant, J; Szel, A; Molday, RS; Birch, DG; McInnes, RR			Rom-1 is required for rod photoreceptor viability and the regulation of disk morphogenesis	NATURE GENETICS			English	Article							RDS MUTANT MICE; MEMBRANE MORPHOGENESIS; RETINAL DEGENERATION; RETINITIS-PIGMENTOSA; RIM PROTEIN; PERIPHERIN/RDS; CLONING; CELLS; CONE; LOCALIZATION	The homologous membrane proteins Rom-1 and peripherin-2 are localized to the disk rims of photoreceptor outer segments (OSs), where they associate as tetramers and larger oligomers(1-3). Disk rims are thought to be critical for disk morphogenesis, OS renewal(4) and the maintenance of OS structure(5), but the molecules which regulate these processes are unknown. Although peripherin-2 is known to be required for OS formation (because Prph2(-/-) mice do not form OSs; ref. 6), and mutations in RDS (the human homologue of Prph2) cause retinal degeneration(7), the relationship of Rom-1 to these processes is uncertain. Here we show that Rom1(-/-) mice form OSs in which peripherin-2 homotetramers are localized to the disk rims, indicating that peripherin-2 alone is sufficient for both disk and OS morphogenesis, The disks produced in Rom1(-/-) mice were large, rod OSs were highly disorganized (a phenotype which largely normalized with age) and rod photoreceptors died slowly by apoptosis. Furthermore, the maximal photoresponse of Rom1(-/-) rod photoreceptors was lower than that of controls. We conclude that Rom-1 is required for the regulation of disk morphogenesis and the viability of mammalian rod photoreceptors, and that mutations in human ROM1 may cause recessive photoreceptor degeneration.	Hosp Sick Children, Res Inst, Program Dev Biol, Toronto, ON M5G 1X8, Canada; Hosp Sick Children, Res Inst, Genet Program, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Pediat, Toronto, ON, Canada; Univ Toronto, Dept Mol & Med Genet, Toronto, ON, Canada; Univ British Columbia, Dept Biochem & Mol Biol, Vancouver, BC V5Z 1M9, Canada; Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada; Semmelweis Univ, Sch Med, Electron Microscopy Lab, Dept Anat Histol & Embryol 2, Budapest, Hungary	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto; University of British Columbia; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; Semmelweis University	McInnes, RR (corresponding author), Hosp Sick Children, Res Inst, Program Dev Biol, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.			Birch, David/0000-0002-6594-2897	NATIONAL EYE INSTITUTE [R01EY002422] Funding Source: NIH RePORTER; NEI NIH HHS [EY02422] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ARIKAWA K, 1992, J CELL BIOL, V116, P659, DOI 10.1083/jcb.116.3.659; BASCOM RA, 1992, NEURON, V8, P1171, DOI 10.1016/0896-6273(92)90137-3; BASCOM RA, 1993, HUM MOL GENET, V2, P385, DOI 10.1093/hmg/2.4.385; Boesze-Battaglia K, 1998, BIOCHEMISTRY-US, V37, P9477, DOI 10.1021/bi980173p; CARTERDAWSON LD, 1979, J COMP NEUROL, V188, P245, DOI 10.1002/cne.901880204; CONNELL G, 1991, P NATL ACAD SCI USA, V88, P723, DOI 10.1073/pnas.88.3.723; Dryja TP, 1997, INVEST OPHTH VIS SCI, V38, P1972; Goldberg AFX, 1998, BIOCHEMISTRY-US, V37, P680, DOI 10.1021/bi972036i; Goldberg AFX, 1996, BIOCHEMISTRY-US, V35, P6144, DOI 10.1021/bi960259n; GOLDBERG AFX, 1995, BIOCHEMISTRY-US, V34, P14213, DOI 10.1021/bi00043a028; HAWKINS RK, 1985, EXP EYE RES, V41, P701, DOI 10.1016/0014-4835(85)90179-4; Illing M, 1997, J BIOL CHEM, V272, P10303, DOI 10.1074/jbc.272.15.10303; Kedzierski W, 1997, INVEST OPHTH VIS SCI, V38, P498; Kedzierski W, 1999, J BIOL CHEM, V274, P29181, DOI 10.1074/jbc.274.41.29181; Kohl S, 1998, ACTA ANAT, V162, P75; Loewen CJR, 2000, J BIOL CHEM, V275, P5370, DOI 10.1074/jbc.275.8.5370; MICHON JJ, 1991, INVEST OPHTH VIS SCI, V32, P280; MOLDAY RS, 1983, BIOCHEMISTRY-US, V22, P653, DOI 10.1021/bi00272a020; Moritz OL, 1996, INVEST OPHTH VIS SCI, V37, P352; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; Nagy A., 1993, Gene targeting: a practical approach., P147; ROHLICH P, 1993, CURR EYE RES, V12, P935, DOI 10.3109/02713689309020400; Sambrook J., 2002, MOL CLONING LAB MANU; SANYAL S, 1980, J COMP NEUROL, V194, P193, DOI 10.1002/cne.901940110; STEINBERG RH, 1980, J COMP NEUROL, V190, P501, DOI 10.1002/cne.901900307; Travis GH, 1998, AM J HUM GENET, V62, P503, DOI 10.1086/301772; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; WILLIAMS DS, 1991, BIOESSAYS, V13, P171, DOI 10.1002/bies.950130405; WILLIAMS DS, 1988, J COMP NEUROL, V272, P161, DOI 10.1002/cne.902720202; YOUNG RW, 1976, INVEST OPHTH VISUAL, V15, P700	30	129	130	0	9	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAY	2000	25	1					67	73		10.1038/75621	http://dx.doi.org/10.1038/75621			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	311KU	10802659				2022-12-25	WOS:000086884000019
J	Schnorrer, F; Bohmann, K; Nusslein-Volhard, C				Schnorrer, F; Bohmann, K; Nusslein-Volhard, C			The molecular motor dynein is involved in targeting Swallow and bicoid RNA to the anterior pole of Drosophila oocytes	NATURE CELL BIOLOGY			English	Article							MESSENGER-RNA; IN-VIVO; DEPENDENT MANNER; LIGHT-CHAIN; LOCALIZATION; PROTEIN; OOGENESIS; EMBRYO; GENE; MELANOGASTER	Localization of bicoid (bcd) messenger RNA to the anterior pole of the Drosophila oocyte requires the exuperantia (exu), swallow (swa) and staufen (stau) genes. We show here that Swa protein transiently co-localizes with bcd RNA in mid-oogenesis. Swa also localizes to the anterior pole of the oocyte in the absence of bcd RNA. This localization does not require Exu, but depends on intact microtubules. In mutant ovaries with duplicated polarity of microtubules, Swa and bcd RNA are ectopically localized at the posterior pole, as well as being present at the anterior pole. We identify dynein light chain-1 (Ddlc-1), a component of the minus-end-directed microtubule motor cytoplasmic dynein, as a Swa-binding protein. We propose that Swa acts as an adaptor for the dynein complex and thereby enables dynein to transport bcd RNA along microtubules to their minus ends at the anterior pole of the oocyte.	Max Planck Inst Entwicklungsbiol, Genet Abt, D-72076 Tubingen, Germany	Max Planck Society	Schnorrer, F (corresponding author), Max Planck Inst Entwicklungsbiol, Genet Abt, Spemannstr 35-3, D-72076 Tubingen, Germany.		Schnorrer, Frank/AIE-3578-2022	Schnorrer, Frank/0000-0002-9518-7263				BERLETH T, 1988, EMBO J, V7, P1749, DOI 10.1002/j.1460-2075.1988.tb03004.x; CHAO YC, 1991, DEV GENET, V12, P313; COOLEY L, 1994, SCIENCE, V266, P590, DOI 10.1126/science.7939713; Dick T, 1996, MOL CELL BIOL, V16, P1966; DRIEVER W, 1988, CELL, V54, P83, DOI 10.1016/0092-8674(88)90182-1; DRIEVER W, 1988, CELL, V54, P95, DOI 10.1016/0092-8674(88)90183-3; Ferrandon D, 1997, EMBO J, V16, P1751, DOI 10.1093/emboj/16.7.1751; FERRANDON D, 1994, CELL, V79, P1221, DOI 10.1016/0092-8674(94)90013-2; FRIGERIO G, 1986, CELL, V47, P735, DOI 10.1016/0092-8674(86)90516-7; FROHNHOFER HG, 1987, GENE DEV, V1, P880, DOI 10.1101/gad.1.8.880; GONZALEZREYES A, 1995, NATURE, V375, P654, DOI 10.1038/375654a0; Grosshans J, 1999, MECH DEVELOP, V81, P127, DOI 10.1016/S0925-4773(98)00236-6; HEGDE J, 1993, DEVELOPMENT, V119, P457; Holleran EA, 1998, INT REV CYTOL, V182, P69, DOI 10.1016/S0074-7696(08)62168-3; Karki S, 1999, CURR OPIN CELL BIOL, V11, P45, DOI 10.1016/S0955-0674(99)80006-4; King SM, 1996, J BIOL CHEM, V271, P19358, DOI 10.1074/jbc.271.32.19358; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/0968-0004(96)10052-9; MACDONALD PM, 1991, GENE DEV, V5, P2455, DOI 10.1101/gad.5.12b.2455; MCGRAIL M, 1995, J CELL BIOL, V131, P411, DOI 10.1083/jcb.131.2.411; PASCHAL BM, 1987, NATURE, V330, P181, DOI 10.1038/330181a0; PAYRE F, 1994, GENE DEV, V8, P2718, DOI 10.1101/gad.8.22.2718; Phillis R, 1996, DEVELOPMENT, V122, P2955; POKRYWKA NJ, 1995, DEV BIOL, V167, P363, DOI 10.1006/dbio.1995.1030; POKRYWKA NJ, 1991, DEVELOPMENT, V113, P55; SCHUPBACH T, 1986, ROUX ARCH DEV BIOL, V195, P302, DOI 10.1007/BF00376063; Spradling Allan C., 1993, P1; STEPHENSON EC, 1988, GENE DEV, V2, P1655, DOI 10.1101/gad.2.12a.1655; STJOHNSTON D, 1995, CELL, V81, P161, DOI 10.1016/0092-8674(95)90324-0; STJOHNSTON D, 1989, DEVELOPMENT, V107, P13; STRUHL G, 1989, CELL, V57, P1259, DOI 10.1016/0092-8674(89)90062-7; THEURKAUF WE, 1993, DEVELOPMENT, V118, P1169, DOI 10.1016/0168-9525(93)90134-4; Theurkauf WE, 1998, DEVELOPMENT, V125, P3655; Vallee RB, 1996, SCIENCE, V271, P1539, DOI 10.1126/science.271.5255.1539; van Eeden F, 1999, CURR OPIN GENET DEV, V9, P396, DOI 10.1016/S0959-437X(99)80060-4; WANG SX, 1994, NATURE, V369, P400, DOI 10.1038/369400a0; Whittaker KL, 1999, J CELL SCI, V112, P3385; WilschBrauninger M, 1997, J CELL BIOL, V139, P817, DOI 10.1083/jcb.139.3.817	37	206	208	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	APR	2000	2	4					185	190		10.1038/35008601	http://dx.doi.org/10.1038/35008601			6	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	302ZU	10783235				2022-12-25	WOS:000086397000010
J	DeChiara, TM; Kimble, RB; Poueymirou, WT; Rojas, J; Masiakowski, P; Valenzuela, DM; Yancopoulos, GD				DeChiara, TM; Kimble, RB; Poueymirou, WT; Rojas, J; Masiakowski, P; Valenzuela, DM; Yancopoulos, GD			Ror2, encoding a receptor-like tyrosine kinase, is required for cartilage and growth plate development	NATURE GENETICS			English	Article							HORMONE-RELATED PEPTIDE; ENDOCHONDRAL BONE-FORMATION; MICE LACKING; PARATHYROID-HORMONE; NEUROMUSCULAR-JUNCTION; INDIAN HEDGEHOG; TIE2 RECEPTOR; IN-VIVO; EXPRESSION; ANGIOPOIETIN-1	Receptor tyrosine kinases often have critical roles in particular cell lineages by initiating signalling cascades in those lineages. Examples include the neural-specific TRK receptors(1), the VEGF and angiopoietin endothelial-specific receptors(2-8), and the muscle-specific MUSK receptor(9-11). Many lineage-restricted receptor tyrosine kinases were initially identified as 'orphans' homologous to known receptors, and only subsequently used to identify their unknown growth factors. Some receptor-tyrosine-kinase-like orphans still lack identified ligands as well as biological roles. Here we characterize one such orphan, encoded by Ror2 (ref, 12). We report that disruption of mouse Ror2 leads to profound skeletal abnormalities, with essentially all endochondrally derived bones foreshortened or misshapen, albeit to differing degrees. Further, we find that Ror2 is selectively expressed in the chondrocytes of all developing cartilage anlagen, where it essential during initial growth and patterning, as well as subsequently in the proliferating chondrocytes of mature growth plates, where it is required for normal expansion. Thus, Ror2 encodes a receptor-like tyrosine kinase that is selectively expressed in, and particularly important for, the chondrocyte lineage.	Regeneron Pharmaceut Inc, Tarrytown, NY 10591 USA	Regeneron	Yancopoulos, GD (corresponding author), Regeneron Pharmaceut Inc, 777 Old Saw Mill River Rd, Tarrytown, NY 10591 USA.							BARBACID M, 1995, CURR OPIN CELL BIOL, V7, P148, DOI 10.1016/0955-0674(95)80022-0; Colvin JS, 1996, NAT GENET, V12, P390, DOI 10.1038/ng0496-390; CONOVER JC, 1995, NATURE, V375, P235, DOI 10.1038/375235a0; DAVIS AP, 1995, NATURE, V375, P791, DOI 10.1038/375791a0; Davis S, 1996, CELL, V87, P1161, DOI 10.1016/S0092-8674(00)81812-7; DeChiara TM, 1996, CELL, V85, P501, DOI 10.1016/S0092-8674(00)81251-9; DECHIARA TM, 1995, CELL, V83, P313, DOI 10.1016/0092-8674(95)90172-8; Deng CX, 1996, CELL, V84, P911, DOI 10.1016/S0092-8674(00)81069-7; DUMONT DJ, 1994, GENE DEV, V8, P1897, DOI 10.1101/gad.8.16.1897; Eriksson U, 1999, CURR TOP MICROBIOL, V237, P41; Ferrara N, 1999, CURR TOP MICROBIOL, V237, P1; Glass DJ, 1996, CELL, V85, P513, DOI 10.1016/S0092-8674(00)81252-0; KARAPLIS AC, 1994, GENE DEV, V8, P277, DOI 10.1101/gad.8.3.277; Lanske B, 1996, SCIENCE, V273, P663, DOI 10.1126/science.273.5275.663; Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55; MASIAKOWSKI P, 1992, J BIOL CHEM, V267, P26181; MCLEOD MJ, 1980, TERATOLOGY, V22, P299, DOI 10.1002/tera.1420220306; MERCER EH, 1991, NEURON, V7, P703, DOI 10.1016/0896-6273(91)90274-4; MUENKE M, 1995, TRENDS GENET, V11, P308, DOI 10.1016/S0168-9525(00)89088-5; Naski MC, 1998, DEVELOPMENT, V125, P4977; Oldridge M, 2000, NAT GENET, V24, P275, DOI 10.1038/73495; SATO TN, 1995, NATURE, V376, P70, DOI 10.1038/376070a0; Schipani E, 1997, P NATL ACAD SCI USA, V94, P13689, DOI 10.1073/pnas.94.25.13689; Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9; ten Berge D, 1998, DEVELOPMENT, V125, P3831; VALENZUELA DM, 1995, NEURON, V15, P573, DOI 10.1016/0896-6273(95)90146-9; Vanky P, 1998, BONE, V22, P331, DOI 10.1016/S8756-3282(97)00286-X; Vortkamp A, 1996, SCIENCE, V273, P613, DOI 10.1126/science.273.5275.613; Weir EC, 1996, P NATL ACAD SCI USA, V93, P10240, DOI 10.1073/pnas.93.19.10240; WILKIE AOM, 1995, CURR BIOL, V5, P500	30	181	195	1	7	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAR	2000	24	3					271	274		10.1038/73488	http://dx.doi.org/10.1038/73488			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	288XW	10700181				2022-12-25	WOS:000085590600018
J	Johnson, B; Hope, A				Johnson, B; Hope, A			GM crops and equivocal environmental benefits	NATURE BIOTECHNOLOGY			English	Editorial Material									English Nat, Taunton TA1 5AA, Somerset, England		Johnson, B (corresponding author), English Nat, Taunton TA1 5AA, Somerset, England.	brian.johnson@english-nature.org.uk						Lainsbury MA, 1999, 1999 BRIGHTON CONFERENCE: WEEDS, VOLS 1-3, P817; Owen MDK, 1997, PROC BRIGHTON CROP, P955; READ MA, 1998, ASPECTS APPL BIOL, V52, P401; SPRINGETT JA, 1992, SOIL BIOL BIOCHEM, V24, P1739, DOI 10.1016/0038-0717(92)90180-6; Sweet JB, 1998, ACTA HORTIC, P225, DOI 10.17660/ActaHortic.1998.459.25; WEVERS JDA, ASPECTS APPL BIOL, V52, P393; 1999, NEW SCI, V164, P27	7	13	13	0	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	MAR	2000	18	3					242	242		10.1038/73586	http://dx.doi.org/10.1038/73586			1	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	292AC	10700091				2022-12-25	WOS:000085771100004
J	Ramiya, VK; Maraist, M; Arfors, KE; Schatz, DA; Peck, AB; Cornelius, JG				Ramiya, VK; Maraist, M; Arfors, KE; Schatz, DA; Peck, AB; Cornelius, JG			Reversal of insulin-dependent diabetes using islets generated in vitro from pancreatic stem cells	NATURE MEDICINE			English	Article							HEPATOCYTE GROWTH-FACTOR; BETA-CELLS; NOD MOUSE; ENDOCRINE PANCREAS; PRECURSOR CELLS; SELF-RENEWAL; AR42J CELLS; DIFFERENTIATION; CULTURE; PROLIFERATION	Ductal structures of the adult pancreas contain stem cells that differentiate into islets of Langerhans. Here, we grew pancreatic ductal epithelial cells isolated from prediabetic adult non-obese diabetic mice in long-term cultures, where they were induced to produce functioning islets containing alpha, beta and delta cells. These in vitro-generated islets showed temporal changes in mRNA transcripts for islet cell-associated differentiation markers, responded in vitro to glucose challenge, and reversed insulin-dependent diabetes after being implanted into diabetic nonobese diabetic mice. The ability to control growth and differentiation of islet stem cells provides an abundant islet source for beta-cell reconstitution in type I diabetes.	Ixion Biotechnol, Alachua, FL 32615 USA; Q Med Scandinavia, San Diego, CA USA; Univ Florida, Coll Med, Dept Pediat, Gainesville, FL 32610 USA; Univ Florida, Coll Med, Dept Pathol Immunol & Lab Med, Gainesville, FL 32610 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida	Peck, AB (corresponding author), Ixion Biotechnol, 13709 Progr Blvd,Box 13, Alachua, FL 32615 USA.	peck.pathology@mail.health.ufl.edu						ANDERSON JT, 1993, AUTOIMMUNITY, V15, P113, DOI 10.3109/08916939309043886; BAUM J, 1962, DIABETES, V11, P371; BEATTIE GM, 1994, J CLIN ENDOCR METAB, V78, P1232, DOI 10.1210/jc.78.5.1232; BONNER G, 1993, PROTEIN ENG, V6, P41; BONNERWEIR S, 1994, TRENDS ENDOCRIN MET, V5, P60, DOI 10.1016/1043-2760(94)90003-5; Bouwens L, 1998, DIABETOLOGIA, V41, P629, DOI 10.1007/s001250050960; BRELJE TC, 1989, DIABETES, V38, P808, DOI 10.2337/diabetes.38.6.808; Cornelius JG, 1997, HORM METAB RES, V29, P271, DOI 10.1055/s-2007-979036; DRUCKER DJ, 1987, P NATL ACAD SCI USA, V84, P3434, DOI 10.1073/pnas.84.10.3434; DUBOIS MP, 1975, P NATL ACAD SCI USA, V72, P1340, DOI 10.1073/pnas.72.4.1340; EISENBARTH GS, 1986, NEW ENGL J MED, V314, P1360; GU DL, 1993, DEVELOPMENT, V118, P33; HELLERSTROM C, 1984, DIABETOLOGIA, V26, P393; LACY PE, 1957, DIABETES, V6, P354, DOI 10.2337/diab.6.4.354; LARSSON LI, 1975, CELL TISSUE RES, V156, P167; LEARY T, 1992, J INVEST DERMATOL, V99, P422, DOI 10.1111/1523-1747.ep12616134; Lefebvre VH, 1998, DIABETES, V47, P134, DOI 10.2337/diabetes.47.1.134; LEITER EH, 1987, AM J PATHOL, V128, P380; Mashima H, 1996, ENDOCRINOLOGY, V137, P3969, DOI 10.1210/en.137.9.3969; Mashima H, 1996, J CLIN INVEST, V97, P1647, DOI 10.1172/JCI118591; MENGER MD, 1994, J CLIN INVEST, V93, P2280, DOI 10.1172/JCI117228; OCONNOR NE, 1981, LANCET, V1, P75; OHGAWARA H, 1993, TOHOKU J EXP MED, V169, P159, DOI 10.1620/tjem.169.159; OTONKOSKI T, 1993, J CLIN INVEST, V92, P1459, DOI 10.1172/JCI116723; OTONKOSKI T, 1994, DIABETES, V43, P947, DOI 10.2337/diabetes.43.7.947; PELLETIER G, 1975, J HISTOCHEM CYTOCHEM, V23, P699, DOI 10.1177/23.9.1100709; PICTET R, 1972, HDB PHYSL ENDOCRINOL, V7, P25; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; Rafaeloff R, 1997, J CLIN INVEST, V99, P2100, DOI 10.1172/JCI119383; RAMRAKHA PS, 1989, TRANSPLANTATION, V48, P676; RAO MS, 1989, AM J PATHOL, V134, P1069; Rooman I, 1997, LAB INVEST, V76, P225; ROSENBERG L, 1992, ADV EXP MED BIOL, V321, P95; SCHOFIELD R, 1985, LEUKEMIA RES, V9, P305, DOI 10.1016/0145-2126(85)90093-1; SENER A, 1990, DIABETES RES CLIN EX, V13, P157; SLACK JMW, 1995, DEVELOPMENT, V121, P1569; SWENNE I, 1992, DIABETOLOGIA, V35, P193, DOI 10.1007/BF00400917; TEITELMAN G, 1993, DEVELOPMENT, V118, P1031; TEITELMAN G, 1988, CELL, V52, P97, DOI 10.1016/0092-8674(88)90534-X; Vogel G, 1999, SCIENCE, V283, P1432, DOI 10.1126/science.283.5407.1432; WANG TC, 1993, J CLIN INVEST, V92, P1349, DOI 10.1172/JCI116708; WATANABE T, 1994, P NATL ACAD SCI USA, V91, P3589, DOI 10.1073/pnas.91.9.3589; WEAVER CV, 1985, DIABETOLOGIA, V28, P781; WEIR GC, 1990, J CLIN INVEST, V85, P983, DOI 10.1172/JCI114574; WICKER LS, 1995, ANNU REV IMMUNOL, V13, P179, DOI 10.1146/annurev.iy.13.040195.001143	45	551	740	0	41	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2000	6	3					278	282						5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	288TL	10700229				2022-12-25	WOS:000085580500037
J	Rankin, CT; Bunton, T; Lawler, AM; Lee, SJ				Rankin, CT; Bunton, T; Lawler, AM; Lee, SJ			Regulation of left-right patterning in mice by growth/differentiation factor-1	NATURE GENETICS			English	Article							LEFT-RIGHT ASYMMETRY; SIGNALING PATHWAY; NODAL EXPRESSION; BETA SUPERFAMILY; MOUSE; MEMBER; DIFFERENTIATION; EMBRYOS; PITX2; GENE	The transforming growth factor-beta (TGF-beta) superfamily encompasses a large group of structurally related polypeptides that are capable of regulating cell growth and differentiation in a wide range of embryonic and adult tissues(1). Growth/differentiation factor-1 (Gdf-1. encoded by Gdf1) is a TGF-beta family member of unknown function that was originally isolated from an early mouse embryo cDNA library(2) and is expressed specifically in the nervous system in late-stage embryos and adult mice(3). Here we show that at early stages of mouse development, Gdf1 is expressed initially throughout the embryo proper and then most prominently in the primitive node, ventral neural tube, and intermediate and lateral plate mesoderm. To examine its biological function, we generated a mouse line carrying a targeted mutation in Gdf1. Gdf1(-/-) mice exhibited a spectrum of defects related to left-right axis formation, including visceral situs inversus, right pulmonary isomerism and a range of cardiac anomalies. In most Gdf1(-/-) embryos, the expression of Ebaf (formerly lefty-1) in the left side of the floor plate and Leftb (formerly lefty-2), nodal and Pitx2 in the left lateral plate mesoderm was absent, suggesting that Gdf1 acts upstream of these genes either directly or indirectly to activate their expression. Our findings suggest that Gdf1 acts early in the pathway of gene activation that leads to the establishment of left-right asymmetry.	Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Div Comparat Med, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Obstet & Gynecol, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Lee, SJ (corresponding author), Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Baltimore, MD 21205 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD035887, R01HD030740] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Collignon J, 1996, NATURE, V381, P155, DOI 10.1038/381155a0; Hummel K. P., 1959, Journal of Heredity, V50, P9; Ivemark B., 1955, ACTA PAEDIATR, V44, P590; KNECHT AK, 1995, DEVELOPMENT, V121, P1927; Kosaki K, 1998, SEMIN CELL DEV BIOL, V9, P89, DOI 10.1006/scdb.1997.0187; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; LAYTON WM, 1976, J HERED, V67, P336, DOI 10.1093/oxfordjournals.jhered.a108749; LEE SJ, 1991, P NATL ACAD SCI USA, V88, P4250, DOI 10.1073/pnas.88.10.4250; LEE SJ, 1990, MOL ENDOCRINOL, V4, P1034, DOI 10.1210/mend-4-7-1034; Lowe LA, 1996, NATURE, V381, P158, DOI 10.1038/381158a0; McPherron AC, 1997, NATURE, V387, P83, DOI 10.1038/387083a0; McPherron AC., 1996, GROWTH FACTORS CYTOK, P357, DOI [10.1016/s1874-5687(96)80016-4, DOI 10.1016/S1874-5687(96)80016-4]; Meno C, 1997, GENES CELLS, V2, P513, DOI 10.1046/j.1365-2443.1997.1400338.x; Meno C, 1996, NATURE, V381, P151, DOI 10.1038/381151a0; Nonaka S, 1998, CELL, V95, P829, DOI 10.1016/S0092-8674(00)81705-5; Oh SP, 1997, GENE DEV, V11, P1812, DOI 10.1101/gad.11.14.1812; Okada Y, 1999, MOL CELL, V4, P459, DOI 10.1016/S1097-2765(00)80197-5; Piedra ME, 1998, CELL, V94, P319, DOI 10.1016/S0092-8674(00)81475-0; Ramsdell AF, 1998, TRENDS GENET, V14, P459, DOI 10.1016/S0168-9525(98)01599-6; Yoshioka H, 1998, CELL, V94, P299, DOI 10.1016/S0092-8674(00)81473-7; ZHOU XL, 1993, NATURE, V361, P543, DOI 10.1038/361543a0	21	168	174	0	3	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAR	2000	24	3					262	265		10.1038/73472	http://dx.doi.org/10.1038/73472			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	288XW	10700179				2022-12-25	WOS:000085590600016
J	Kreitzer, G; Marmorstein, A; Okamoto, P; Vallee, R; Rodriguez-Boulan, E				Kreitzer, G; Marmorstein, A; Okamoto, P; Vallee, R; Rodriguez-Boulan, E			Kinesin and dynamin are required for post-Golgi transport of a plasma-membrane protein	NATURE CELL BIOLOGY			English	Article							LIVING CELLS; MICROTUBULE; VESICLES		Cornell Univ, Dyson Inst Vis Res, Joan & Sanford Weill Med Coll, New York, NY 10021 USA; Univ Massachusetts, Sch Med, Dept Cell Biol, Worcester, MA 01655 USA	Cornell University; Dyson; University of Massachusetts System; University of Massachusetts Worcester	Rodriguez-Boulan, E (corresponding author), Cornell Univ, Dyson Inst Vis Res, Joan & Sanford Weill Med Coll, New York, NY 10021 USA.				NIGMS NIH HHS [R01 GM034107] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034107] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altschuler Y, 1998, J CELL BIOL, V143, P1871, DOI 10.1083/jcb.143.7.1871; BALCH WE, 1994, CELL, V76, P841, DOI 10.1016/0092-8674(94)90359-X; Bloom GS, 1998, J CELL BIOL, V140, P1277, DOI 10.1083/jcb.140.6.1277; Cao H, 1998, MOL BIOL CELL, V9, P2595, DOI 10.1091/mbc.9.9.2595; Coleman DV, 1996, CYTOPATHOLOGY, V7, P1, DOI 10.1046/j.1365-2303.1995.40882408.x; Finger FP, 1998, J CELL BIOL, V142, P609, DOI 10.1083/jcb.142.3.609; GYOEVA FK, 1991, NATURE, V353, P445, DOI 10.1038/353445a0; Hirokawa N, 1998, SCIENCE, V279, P519, DOI 10.1126/science.279.5350.519; Hirschberg K, 1998, J CELL BIOL, V143, P1485, DOI 10.1083/jcb.143.6.1485; HOLLENBECK PJ, 1990, NATURE, V346, P864, DOI 10.1038/346864a0; INGOLD AL, 1988, J CELL BIOL, V107, P2657, DOI 10.1083/jcb.107.6.2657; Jones SM, 1998, SCIENCE, V279, P573, DOI 10.1126/science.279.5350.573; Kasai K, 1999, J BIOCHEM, V125, P780, DOI 10.1093/oxfordjournals.jbchem.a022349; LUBYPHELPS K, 1987, P NATL ACAD SCI USA, V84, P4910, DOI 10.1073/pnas.84.14.4910; MUESCH A, 1997, J CELL BIOL, V138, P291; Presley JF, 1997, NATURE, V389, P81, DOI 10.1038/38001; RODIONOV VI, 1993, J CELL BIOL, V123, P1811, DOI 10.1083/jcb.123.6.1811; RODIONOV VI, 1991, P NATL ACAD SCI USA, V88, P4956, DOI 10.1073/pnas.88.11.4956; Scales SJ, 1997, CELL, V90, P1137, DOI 10.1016/S0092-8674(00)80379-7; Seiler S, 1997, EMBO J, V16, P3025, DOI 10.1093/emboj/16.11.3025; Storrie B, 1998, J CELL BIOL, V143, P1505, DOI 10.1083/jcb.143.6.1505; Thyberg J, 1999, EXP CELL RES, V246, P263, DOI 10.1006/excr.1998.4326; Toomre D, 1999, J CELL SCI, V112, P21; Wacker I, 1997, J CELL SCI, V110, P1453	24	197	201	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	FEB	2000	2	2					125	127		10.1038/35000081	http://dx.doi.org/10.1038/35000081			3	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	281GA	10655593				2022-12-25	WOS:000085148500018
J	Brim, H; McFarlan, SC; Fredrickson, JK; Minton, KW; Zhai, M; Wackett, LP; Daly, MJ				Brim, H; McFarlan, SC; Fredrickson, JK; Minton, KW; Zhai, M; Wackett, LP; Daly, MJ			Engineering Deinococcus radiodurans for metal remediation in radioactive mixed waste environments	NATURE BIOTECHNOLOGY			English	Article						mercuric reductase; bioremediation	ESCHERICHIA-COLI; RECOMBINATION; RESISTANCE; PURIFICATION; REDUCTION; PLASMID; GENE	We have developed a radiation resistant bacterium for the treatment of mixed radioactive wastes containing ionic mercury. The high cost of remediating radioactive waste sites from nuclear weapons production has stimulated the development of bioremediation strategies using Deinococcos radiodurans, the most radiation resistant organism known. As a frequent constituent of these sites is the highly toxic ionic mercury (Hg) (II), we have generated several D. radiodurans strains expressing the cloned Hg (II) resistance gene (merA) from Escherichia coli strain BL308. We designed four different expression vectors for this purpose, and compared the relative advantages of each, The strains were shown to grow in the presence of both radiation and ionic mercury at concentrations well above those found in radioactive waste sites, and to effectively reduce Hg (II) to the less toxic volatile elemental mercury. We also demonstrated that different gene clusters could be used to engineer D. radiodurans for treatment of mixed radioactive wastes by developing a strain to detoxify both mercury and toluene. These expression systems could provide models to guide future D. radiodurans engineering efforts aimed at integrating several remediation functions into a single host.	Uniformed Serv Univ Hlth Sci, Dept Pathol, Bethesda, MD 20814 USA; Univ Minnesota, Biol Proc Technol Inst, Dept Biochem, St Paul, MN 55108 USA; Univ Minnesota, Ctr Biodegradat Res & Informat, Gortner Lab, St Paul, MN 55108 USA; Pacific NW Natl Lab, Richland, WA 99352 USA	Uniformed Services University of the Health Sciences - USA; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; United States Department of Energy (DOE); Pacific Northwest National Laboratory	Daly, MJ (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Pathol, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.							Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Barrineau P, 1985, Basic Life Sci, V30, P707; BROOKS BW, 1980, INT J SYST BACTERIOL, V30, P627, DOI 10.1099/00207713-30-4-627; Chang JS, 1998, J BIOTECHNOL, V64, P219, DOI 10.1016/S0168-1656(98)00112-6; DALY MJ, 1995, J BACTERIOL, V177, P5495, DOI 10.1128/jb.177.19.5495-5505.1995; DALY MJ, 1994, J BACTERIOL, V176, P3508, DOI 10.1128/JB.176.12.3508-3517.1994; DALY MJ, 1994, J BACTERIOL, V176, P7506, DOI 10.1128/JB.176.24.7506-7515.1994; Daly MJ, 1996, J BACTERIOL, V178, P4461, DOI 10.1128/jb.178.15.4461-4471.1996; FOX B, 1982, J BIOL CHEM, V257, P2498; GIBSON DT, 1970, BIOCHEMISTRY-US, V9, P1631, DOI 10.1021/bi00809a024; GORBY YA, 1992, ENVIRON SCI TECHNOL, V26, P205, DOI 10.1021/es00025a026; HANSEN MT, 1978, J BACTERIOL, V134, P71, DOI 10.1128/JB.134.1.71-75.1978; HIGHAM DP, 1984, SCIENCE, V225, P205; JI GY, 1992, J BACTERIOL, V174, P3684, DOI 10.1128/JB.174.11.3684-3694.1992; KOBAL VM, 1973, J AM CHEM SOC, V95, P4420, DOI 10.1021/ja00794a048; Lange CC, 1998, NAT BIOTECHNOL, V16, P929, DOI 10.1038/nbt1098-929; Lovely D. R., 1995, J IND MICROBIOL, V14, P85; Macilwain C, 1996, NATURE, V383, P375; MCCULLOUGH J, 1999, BIOREMEDIATION METAL; MINTON KW, 1996, MUTAT RES-DNA REPAIR, V362, P1; NAKAMURA K, 1988, APPL ENVIRON MICROB, V54, P2871, DOI 10.1128/AEM.54.11.2871-2873.1988; NIES DH, 1995, J IND MICROBIOL, V14, P186, DOI 10.1007/BF01569902; Riley, 1992, CHEM CONTAMINANTS DO; Rugh CL, 1996, P NATL ACAD SCI USA, V93, P3182, DOI 10.1073/pnas.93.8.3182; Rugh CL, 1998, NAT BIOTECHNOL, V16, P925, DOI 10.1038/nbt1098-925; SCHOTTEL JL, 1978, J BIOL CHEM, V253, P4341; SMITH MD, 1988, J BACTERIOL, V170, P2126, DOI 10.1128/jb.170.5.2126-2135.1988; SUMMERS AO, 1986, ANNU REV MICROBIOL, V40, P607, DOI 10.1146/annurev.mi.40.100186.003135; THORNLEY MJ, 1963, J APPL BACTERIOL, V26, P334, DOI 10.1111/j.1365-2672.1963.tb04784.x; Tsapin AI, 1996, J BACTERIOL, V178, P6386, DOI 10.1128/jb.178.21.6386-6388.1996; TURNER JS, 1995, J IND MICROBIOL, V14, P119, DOI 10.1007/BF01569893; VOORDOUW G, 1986, EUR J BIOCHEM, V159, P347, DOI 10.1111/j.1432-1033.1986.tb09874.x; White O, 1999, SCIENCE, V286, P1571, DOI 10.1126/science.286.5444.1571; 1996 BASELINE ENV MA	34	190	239	4	130	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JAN	2000	18	1					85	90		10.1038/71986	http://dx.doi.org/10.1038/71986			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	273GQ	10625398				2022-12-25	WOS:000084699900032
J	Bledsoe, AW; Jackson, CA; McPherson, S; Morrow, CD				Bledsoe, AW; Jackson, CA; McPherson, S; Morrow, CD			Cytokine production in motor neurons by poliovirus replicon vector gene delivery	NATURE BIOTECHNOLOGY			English	Article						replicon; central nervous system; neoron; gene delivery; tumor necrosis factor	TUMOR-NECROSIS-FACTOR; CENTRAL-NERVOUS-SYSTEM; VIRUS TYPE-1 GAG; EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; SPINAL-CORD INJURY; TRANSGENIC MICE; FACTOR-ALPHA; EXPRESSION; ENCAPSIDATION; PROTEINS	Poliovirus replicon vectors transiently express foreign proteins selectively in motor neurons of the anterior horn of the spinal cord. Here we intraspinally inoculated mice transgenic for the poliovirus receptor (PVR) with replicons encoding murine tumor necrosis factor alpha (mTNF-alpha). Mle detected high-level expression of mTNF-alpha in the spinal cords of these animals at 8-12 h post inoculation; this returned to background by 72 h. The mice exhibited ataxia and tail atony, whereas animals given a replicon encoding green fluorescent protein (GFP) exhibited no neurological symptoms. Histology of spinal cords from mice given the replicon encoding mTNF-alpha revealed neuronal chromatolysis, reactive astrogliosis, decreased expression of myelin basic protein, and demyelination. These animals recovered with only slight residual damage. This study shows that replicon vectors have potential for targeted delivery of therapeutic proteins to the central nervous system end provide a new approach for treatment of spinal cord trauma and neurological disease.	Univ Alabama, Dept Microbiol, Birmingham, AL 35294 USA; Univ Alabama, Dept Physiol Opt, Birmingham, AL 35294 USA; Univ Alabama, UAB AIDS Ctr, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Morrow, CD (corresponding author), Univ Alabama, Dept Microbiol, Birmingham, AL 35294 USA.				NIAID NIH HHS [T32AI07493] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007493] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABE S, 1995, VIROLOGY, V206, P1075, DOI 10.1006/viro.1995.1030; Akassoglou K, 1997, J IMMUNOL, V158, P438; ANDO DG, 1989, CELL IMMUNOL, V124, P132, DOI 10.1016/0008-8749(89)90117-2; ANSARDI DC, 1993, J VIROL, V67, P3684, DOI 10.1128/JVI.67.6.3684-3690.1993; ANSARDI DC, 1991, J VIROL, V65, P2088, DOI 10.1128/JVI.65.4.2088-2092.1991; BARGER SW, 1995, P NATL ACAD SCI USA, V92, P9328, DOI 10.1073/pnas.92.20.9328; BARGER SW, 1997, NEUROPROTECTIVE SIGN, P163; Basak S, 1998, J INTERF CYTOK RES, V18, P305, DOI 10.1089/jir.1998.18.305; Benveniste EN, 1997, CHEM IMMUNOL, V69, P31; Benveniste EN, 1997, J MOL MED-JMM, V75, P165, DOI 10.1007/s001090050101; BENVENISTE EN, 1997, CYTOKINES HLTH DIS, P531; Bethea JR, 1999, J NEUROTRAUM, V16, P851, DOI 10.1089/neu.1999.16.851; Bledsoe AW, 2000, J NEUROVIROL, V6, P95, DOI 10.3109/13550280009013153; BODIAN D, 1949, AM J MED, V6, P563, DOI 10.1016/0002-9343(49)90130-8; BODIAN D, 1965, VIRAL RICKETTSIAL IN, P479; CHOI WS, 1991, J VIROL, V65, P2875, DOI 10.1128/JVI.65.6.2875-2883.1991; DEALTY AM, 1999, VIROLOGY, V255, P221; Ellison D, 1998, NEUROPATHOLOGY; Girard S, 1999, J VIROL, V73, P6066, DOI 10.1128/JVI.73.7.6066-6072.1999; GRAHAM DI, 1995, COLOR ATLAS TEXT NEU; Grill RJ, 1997, EXP NEUROL, V148, P444, DOI 10.1006/exnr.1997.6704; Kim DH, 1996, NEUROREPORT, V7, P2221, DOI 10.1097/00001756-199609020-00033; KOIKE S, 1991, P NATL ACAD SCI USA, V88, P951, DOI 10.1073/pnas.88.3.951; Porter DC, 1997, VACCINE, V15, P257, DOI 10.1016/S0264-410X(96)00187-9; Porter DC, 1996, J VIROL, V70, P2643, DOI 10.1128/JVI.70.4.2643-2649.1996; PORTER DC, 1995, J VIROL, V69, P1548, DOI 10.1128/JVI.69.3.1548-1555.1995; PORTER DC, 1993, J VIROL, V67, P3712, DOI 10.1128/JVI.67.7.3712-3719.1993; Porter DC, 1998, VIROLOGY, V243, P1, DOI 10.1006/viro.1998.9046; Probert L, 1997, J NEUROIMMUNOL, V72, P137, DOI 10.1016/S0165-5728(96)00184-1; Probert L, 1996, J LEUKOCYTE BIOL, V59, P518, DOI 10.1002/jlb.59.4.518; PROBERT L, 1995, P NATL ACAD SCI USA, V92, P11294, DOI 10.1073/pnas.92.24.11294; REN R, 1992, J VIROL, V66, P296, DOI 10.1128/JVI.66.1.296-304.1992; REN R, 1990, CELL, V63, P353, DOI 10.1016/0092-8674(90)90168-E; Sternberg EM, 1997, J CLIN INVEST, V100, P2641, DOI 10.1172/JCI119807; STREIT WJ, 1990, J HISTOCHEM CYTOCHEM, V38, P1683, DOI 10.1177/38.11.2212623; Taupin VR, 1997, EUR J IMMUNOL, V27, P905, DOI 10.1002/eji.1830270416; ZIEGLERHEITBROCK HWL, 1984, J NATL CANCER I, V72, P23, DOI 10.1093/jnci/72.1.23	37	31	38	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	SEP	2000	18	9					964	969		10.1038/79455	http://dx.doi.org/10.1038/79455			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	350AN	10973217				2022-12-25	WOS:000089078300025
J	De Berardinis, P; Sartorius, R; Fanutti, C; Perham, RN; Del Pozzo, G; Guardiola, J				De Berardinis, P; Sartorius, R; Fanutti, C; Perham, RN; Del Pozzo, G; Guardiola, J			Phage display of peptide epitopes from HIV-1 elicits strong cytolytic responses	NATURE BIOTECHNOLOGY			English	Article						vaccine; AIDS/HIV; CTL; filamentous bacteriophage fd; MHC class I	CYTOTOXIC T-LYMPHOCYTES; MAJOR HISTOCOMPATIBILITY COMPLEX; FILAMENTOUS BACTERIOPHAGE; REVERSE-TRANSCRIPTASE; MULTIPLE DISPLAY; FOREIGN PEPTIDES; CELL; HELPER; GENERATION; MOLECULES	Although much effort has been expended on evaluating recombinant proteins and synthetic peptides as immunogens, they have generally proved incapable of inducing an efficient cytotoxic T-cell (CTL) response, Filamentous bacteriophage fd can display multiple copies of foreign peptides in the N-terminal region of its major coat protein pVIII, 2,700 copies of which make up the virus capsid, Here we show that fd virions displaying peptide RT2 (ILKEPVHGV), corresponding to residues 309-317 of the reverse transcriptase (RTase) of HIV-1, are able to prime a CTL response specific for this HIV-1 epitope in human cell lines. Successful priming also requires a T-helper epitope, pep23 (KDSWTVNDIQKLVGK), corresponding to residues 249-263 of HIV-1 RTase, Supplying this by displaying it on either the same or a separate bacteriophage virion led to activation of antigen-specific CD4(+) T cells. Likewise, HLA-A2 transgenic mice immunized with bacteriophage virions displaying peptide RT2 were shown to mount an effective, specific anti-HIV-RT2 CTL response. This unexpected ability to elicit a designated cytolytic T-cell response, in addition to a B-cell response, has important implications for access to the class I major histocompatibility complex (MHC) loading compartment and the development of recombinant vaccines.	CNR, Inst Prot Biochem & Enzymol, I-80125 Naples, Italy; Univ Cambridge, Dept Biochem, Cambridge CB2 1GA, England; Int Inst Genet & Biophys, I-80125 Naples, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Biochimica delle Proteine (IBP-CNR); University of Cambridge; Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica e Biofisica "Adriano Buzzati-Traverso" (IGB-CNR)	De Berardinis, P (corresponding author), CNR, Inst Prot Biochem & Enzymol, Via G Marconi 10, I-80125 Naples, Italy.	deberard@ibpe.na.cnr.it; r.n.perham@bioc.cam.ac.uk	Del Pozzo, Giovanna/AAW-9209-2020; De Berardinis, Piergiuseppe/AAX-1049-2020; SARTORIUS, ROSSELLA/G-8559-2016; De Berardinis, Piergiuseppe/HCI-0893-2022; sartorius, rossella/AAF-1623-2021	Del Pozzo, Giovanna/0000-0001-8937-9018; De Berardinis, Piergiuseppe/0000-0001-6579-1729; sartorius, rossella/0000-0003-0153-9377				Bennett SRM, 1998, NATURE, V393, P478, DOI 10.1038/30996; Bona CA, 1998, IMMUNOL TODAY, V19, P126, DOI 10.1016/S0167-5699(97)01218-8; Bot A, 1996, J IMMUNOL, V157, P3436; De Berardinis P, 1999, VACCINE, V17, P1434, DOI 10.1016/S0264-410X(98)00377-6; DEBOER M, 1993, EUR J IMMUNOL, V23, P3120, DOI 10.1002/eji.1830231212; DEMOTZ S, 1990, SCIENCE, V249, P1028, DOI 10.1126/science.2118680; DiModugno F, 1997, J IMMUNOTHER, V20, P431; GREENWOOD J, 1991, J MOL BIOL, V220, P821, DOI 10.1016/0022-2836(91)90354-9; GRIMISON B, 1995, J ACQ IMMUN DEF SYND, V9, P58; KEENE JA, 1982, J EXP MED, V155, P768, DOI 10.1084/jem.155.3.768; Malik P, 1997, NUCLEIC ACIDS RES, V25, P915, DOI 10.1093/nar/25.4.915; Malik P, 1996, GENE, V171, P49, DOI 10.1016/0378-1119(96)00070-4; Manca F, 1996, EUR J IMMUNOL, V26, P2461, DOI 10.1002/eji.1830261029; Menendez-Arias L, 1998, VIRAL IMMUNOL, V11, P167, DOI 10.1089/vim.1998.11.167; MINENKOVA OO, 1993, GENE, V128, P85, DOI 10.1016/0378-1119(93)90157-X; Ogg GS, 1998, SCIENCE, V279, P2103, DOI 10.1126/science.279.5359.2103; Ossendorp F, 1998, J EXP MED, V187, P693, DOI 10.1084/jem.187.5.693; Pascolo S, 1997, J EXP MED, V185, P2043, DOI 10.1084/jem.185.12.2043; REN JS, 1995, NAT STRUCT BIOL, V2, P293, DOI 10.1038/nsb0495-293; Ridge JP, 1998, NATURE, V393, P474, DOI 10.1038/30989; Schoenberger SP, 1998, NATURE, V393, P480, DOI 10.1038/31002; Stuhler G, 1997, P NATL ACAD SCI USA, V94, P622, DOI 10.1073/pnas.94.2.622; VERONESE FDM, 1994, J MOL BIOL, V243, P167, DOI 10.1006/jmbi.1994.1643; VITIELLO A, 1991, J EXP MED, V173, P1007, DOI 10.1084/jem.173.4.1007; WILLIS AE, 1993, GENE, V128, P79, DOI 10.1016/0378-1119(93)90156-W	25	81	90	0	11	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	AUG	2000	18	8					873	876		10.1038/78490	http://dx.doi.org/10.1038/78490			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	342VX	10932158				2022-12-25	WOS:000088666800025
J	Delepine, M; Nicolino, M; Barrett, T; Golamaully, M; Lathrop, GM; Julier, C				Delepine, M; Nicolino, M; Barrett, T; Golamaully, M; Lathrop, GM; Julier, C			EIF2AK3, encoding translation initiation factor 2-alpha kinase 3, is mutated in patients with Wolcott-Rallison syndrome	NATURE GENETICS			English	Article							DIABETES SUSCEPTIBILITY GENES; PANCREATIC EIF-2-ALPHA KINASE; GENOME-WIDE SEARCH; PAX4 GENE; MELLITUS; GLUCOSE; PROTEIN; LOCUS; CELLS; PEK	Wolcott-Rallison syndrome (WRS) is a rare, autosomal recessive disorder characterized by permanent neonatal or early infancy insulin-dependent diabetes. Epiphyseal dysplasia, osteoporosis and growth retardation occur at a later age. Other frequent multisystemic manifestations include hepatic and renal dysfunction, mental retardation and cardiovascular abnormalities(1-5). On the basis of two consanguineous families, we mapped WRS to a region of less than 3 cM on chromosome 2p12, with maximal evidence of linkage and homozygosity at 4 microsatellite markers within an interval of approximately 1 cM. The gene encoding the eukaryotic translation initiation factor 2-alpha kinase 3 (EIF2AK3) resides in this interval; thus we explored it as a candidate. We identified distinct mutations of EIF2AK3 that segregated with the disorder in each of the families, The first mutation produces a truncated protein in which the entire catalytic domain is missing. The other changes an amino acid, located in the catalytic domain of the protein, that is highly conserved among kinases from the same subfamily. Our results provide evidence for the role of EIF2AK3 in WRS, The identification of this gene may provide insight into the understanding of the more common forms of diabetes and other pathologic manifestations of WRS.	Inst Pasteur, Lab Genet Predisposit Malad Infect, Paris, France; Wellcome Trust Ctr Human Genet, Oxford, England; Birmingham Childrens Hosp, Dept Endocrinol, Birmingham, W Midlands, England; Hop Debrousse, Lyon, France; Ctr Natl Genotypage, Evry, France	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; University of Oxford; Wellcome Centre for Human Genetics; University of Birmingham; CHU Lyon; CEA; UDICE-French Research Universities; Universite Paris Saclay	Julier, C (corresponding author), Inst Pasteur, Lab Genet Predisposit Malad Infect, Paris, France.	cjulier@pasteur.fr	JULIER, Cécile/M-9824-2017; Barrett, Timothy/F-1682-2010	JULIER, Cécile/0000-0002-1538-0240; Barrett, Timothy/0000-0002-6873-0750				ALGAZALI LI, 1995, CLIN DYSMORPHOL, V4, P227; Barroso I, 1999, NATURE, V402, P880, DOI 10.1038/47254; Bonthron DT, 1998, J MED GENET, V35, P288, DOI 10.1136/jmg.35.4.288; Concannon P, 1998, NAT GENET, V19, P292, DOI 10.1038/985; DAVIES JL, 1994, NATURE, V371, P130, DOI 10.1038/371130a0; DETTMAN C, 1972, J PEDIATR-US, V80, P292, DOI 10.1016/S0022-3476(72)80596-1; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; Froguel P, 1999, TRENDS ENDOCRIN MET, V10, P142, DOI 10.1016/S1043-2760(98)00134-9; Gilligan M, 1996, J BIOL CHEM, V271, P2121, DOI 10.1074/jbc.271.4.2121; GOODISON S, 1992, BIOCHEM J, V285, P563, DOI 10.1042/bj2850563; GOUMY P, 1980, ARCH FR PEDIATR, V37, P323; Hanis CL, 1996, NAT GENET, V13, P161, DOI 10.1038/ng0696-161; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; HASHIMOTO L, 1994, NATURE, V371, P161, DOI 10.1038/371161a0; Hayes SE, 1999, CYTOGENET CELL GENET, V86, P327, DOI 10.1159/000015328; Inoue H, 1998, NAT GENET, V20, P143, DOI 10.1038/2441; LATHROP GM, 1984, P NATL ACAD SCI-BIOL, V81, P3443, DOI 10.1073/pnas.81.11.3443; Mein CA, 1998, NAT GENET, V19, P297, DOI 10.1038/991; NICOLINO PM, 1998, HORM RES, V50, pA215; Pratley RE, 1998, J CLIN INVEST, V101, P1757, DOI 10.1172/JCI1850; Rosenblum BB, 1997, NUCLEIC ACIDS RES, V25, P4500, DOI 10.1093/nar/25.22.4500; Shi YG, 1999, J BIOL CHEM, V274, P5723, DOI 10.1074/jbc.274.9.5723; Shi YG, 1998, MOL CELL BIOL, V18, P7499, DOI 10.1128/MCB.18.12.7499; SosaPineda B, 1997, NATURE, V386, P399, DOI 10.1038/386399a0; Srivastava SP, 1998, J BIOL CHEM, V273, P2416, DOI 10.1074/jbc.273.4.2416; Stewart FJ, 1996, CLIN GENET, V49, P152; STOSS H, 1982, EUR J PEDIATR, V138, P120, DOI 10.1007/BF00441137; Thornton CM, 1997, PEDIATR PATHOL LAB M, V17, P487, DOI 10.1080/107710497174778; Winter WE, 1999, ENDOCRIN METAB CLIN, V28, P765, DOI 10.1016/S0889-8529(05)70101-8	30	593	620	0	19	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	AUG	2000	25	4					406	409		10.1038/78085	http://dx.doi.org/10.1038/78085			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	341WY	10932183				2022-12-25	WOS:000088615000014
J	Joberty, G; Petersen, C; Gao, L; Macara, IG				Joberty, G; Petersen, C; Gao, L; Macara, IG			The cell-polarity protein Par6 links Par3 and atypical protein kinase C to Cdc42	NATURE CELL BIOLOGY			English	Article							GTPASE-BINDING DOMAIN; PDZ-DOMAIN; CAENORHABDITIS-ELEGANS; DROSOPHILA NEUROBLASTS; RHO-GTPASES; BAZOOKA; COLOCALIZES; COMPLEX; FAMILY; POLARIZATION	PAR (partitioning-defective) proteins, wh ich were first identified in the nematode Caenorhabditis elegans, are essential for asymmetric cell division and polarized growth, whereas Cdc42 mediates establishment of cell polarity. Here we describe an unexpected link between these two systems. We have identified a family of mammalian Pare proteins that are similar to the C. elegans PDZ-domain protein PAR-6. Par6 forms a complex with Cdc42-GTP, with a human homologue of the multi-PDZ protein PAR-3 and with the regulatory domains of atypical protein kinase C (PKC) proteins. This assembly is implicated in the formation of normal tight junctions at epithelial cell-cell contacts. Thus, Pare is a key adaptor that links Cdc42 and atypical PKCs to Par3.	Univ Virginia, Hlth Sci Ctr, Markey Ctr Cell Signaling, Charlottesville, VA 22908 USA	University of Virginia	Joberty, G (corresponding author), Univ Virginia, Hlth Sci Ctr, Markey Ctr Cell Signaling, Charlottesville, VA 22908 USA.				NATIONAL CANCER INSTITUTE [P01CA040042, R01CA038888] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA38888, P01CA40042] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abdul-Manan N, 1999, NATURE, V399, P379, DOI 10.1038/20726; Bruckner K, 1998, CURR OPIN NEUROBIOL, V8, P375, DOI 10.1016/S0959-4388(98)80064-0; BURHELO PD, 1995, J BIOL CHEM, V270, P29071; Cabib E, 1998, ANNU REV BIOCHEM, V67, P307, DOI 10.1146/annurev.biochem.67.1.307; Chen WN, 1996, J BIOL CHEM, V271, P26362, DOI 10.1074/jbc.271.42.26362; Coghlan MP, 2000, MOL CELL BIOL, V20, P2880, DOI 10.1128/MCB.20.8.2880-2889.2000; Daniels DL, 1998, NAT STRUCT BIOL, V5, P317, DOI 10.1038/nsb0498-317; Eaton S, 1996, J CELL BIOL, V135, P1277, DOI 10.1083/jcb.135.5.1277; ETEMADMOGHADAM B, 1995, CELL, V83, P743, DOI 10.1016/0092-8674(95)90187-6; Fanning AS, 1996, CURR BIOL, V6, P1385, DOI 10.1016/S0960-9822(96)00737-3; Hillier BJ, 1999, SCIENCE, V284, P812, DOI 10.1126/science.284.5415.812; Hing H, 1999, CELL, V97, P853, DOI 10.1016/S0092-8674(00)80798-9; Hotta K, 1996, BIOCHEM BIOPH RES CO, V225, P69, DOI 10.1006/bbrc.1996.1132; Hung TJ, 1999, DEVELOPMENT, V126, P127; Izumi Y, 1998, J CELL BIOL, V143, P95, DOI 10.1083/jcb.143.1.95; Joberty G, 1999, MOL CELL BIOL, V19, P6585; Johnson DI, 1999, MICROBIOL MOL BIOL R, V63, P54, DOI 10.1128/MMBR.63.1.54-105.1999; Kroschewski R, 1999, NAT CELL BIOL, V1, P8, DOI 10.1038/8977; Kuchinke U, 1998, CURR BIOL, V8, P1357, DOI 10.1016/S0960-9822(98)00016-5; Kuroda S, 1999, BIOCHEM BIOPH RES CO, V262, P1, DOI 10.1006/bbrc.1999.1122; Lin D, 1999, J BIOL CHEM, V274, P3726, DOI 10.1074/jbc.274.6.3726; Mott HR, 1999, NATURE, V399, P384, DOI 10.1038/20732; Muller HAJ, 1996, J CELL BIOL, V134, P149, DOI 10.1083/jcb.134.1.149; Nelson WJ, 1997, CURR BIOL, V7, pR562, DOI 10.1016/S0960-9822(06)00282-X; Neudauer CL, 1998, CURR BIOL, V8, P1151, DOI 10.1016/S0960-9822(07)00486-1; Nobes CD, 1999, J CELL BIOL, V144, P1235, DOI 10.1083/jcb.144.6.1235; Ponting CP, 1997, BIOESSAYS, V19, P469, DOI 10.1002/bies.950190606; Rousset R, 1998, ONCOGENE, V16, P643, DOI 10.1038/sj.onc.1201567; Sambrook J., 2002, MOL CLONING LAB MANU; Schaefer M, 2000, CURR BIOL, V10, P353, DOI 10.1016/S0960-9822(00)00401-2; Schober M, 1999, NATURE, V402, P548, DOI 10.1038/990135; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Stevens WK, 1999, BIOCHEMISTRY-US, V38, P5968, DOI 10.1021/bi990426u; Tabuse Y, 1998, DEVELOPMENT, V125, P3607; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295; Wodarz A, 1999, NATURE, V402, P544, DOI 10.1038/990128; Wu SL, 1998, J BIOL CHEM, V273, P1130, DOI 10.1074/jbc.273.2.1130; Yu FW, 2000, CELL, V100, P399, DOI 10.1016/S0092-8674(00)80676-5	38	737	761	0	40	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	AUG	2000	2	8					531	539		10.1038/35019573	http://dx.doi.org/10.1038/35019573			9	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	341TE	10934474				2022-12-25	WOS:000088605000019
J	Rogner, UC; Spyropoulos, DD; Le Novere, N; Changeux, JP; Avner, P				Rogner, UC; Spyropoulos, DD; Le Novere, N; Changeux, JP; Avner, P			Control of neurulation by the nucleosome assembly protein-1-like 2	NATURE GENETICS			English	Article							EMBRYONIC STEM-CELLS; NEURAL-TUBE DEFECTS; HISTONE CHAPERONE; MUTANT MOUSE; IN-VITRO; PROLIFERATION; NEURONS; GENE; DIFFERENTIATION; INHERITANCE	Neurulation is a complex process of histogenesis involving the precise temporal and spatial organization of gene expression(1,2) Genes influencing neurulation include proneural genes determining primary cell fate, neurogenic genes involved in lateral inhibition pathways and genes controlling the frequency of mitotic events. This is reflected in the aetiology and genetics of human and mouse neural tube defects, which are of both multifactorial and multigenic origin(3). The X-linked gene Nap1l2, specifically expressed in neurons, encodes a protein that is highly similar to the nucleosome assembly (NAP) and SET proteins. We inactivated Nap1l2 in mice by gene targeting, leading to embryonic lethality from mid-gestation onwards. Surviving mutant chimaeric embryos showed extensive surface ectoderm defects as well as the presence of open neural tubes and exposed brains similar to those observed in human spina bifida and anencephaly. These defects correlated with an overproduction of neuronal precursor cells. Protein expression studies showed that the Nap1l2 protein binds to condensing chromatin during S phase and in apoptotic cells, but remained cytoplasmic during G1 phase. Nap1l2 therefore likely represents a class of tissue-specific factors interacting with chromatin to regulate neuronal cell proliferation.	Inst Pasteur, CNRS, URA 1947, Paris 15, France; Inst Pasteur, CNRS, URA 1284, Paris 15, France; Med Univ S Carolina, Ctr Mol & Struct Biol, Charleston, SC USA	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Medical University of South Carolina	Rogner, UC (corresponding author), Inst Pasteur, CNRS, URA 1947, Paris 15, France.	urogner@pasteur.fr	Le Novère, Nicolas/F-9973-2010	Le Novère, Nicolas/0000-0002-6309-7327; Rogner, Ute Christine/0000-0001-9993-269X				Altman R, 1997, J CELL BIOL, V138, P119, DOI 10.1083/jcb.138.1.119; COPP AJ, 1994, DEV BIOL, V165, P20, DOI 10.1006/dbio.1994.1230; EMERY AEH, 1986, METHODOLOGY MED GENE, V58; FRAICHARD A, 1995, J CELL SCI, V108, P3181; GARDNER RL, 1968, NATURE, V220, P596, DOI 10.1038/220596a0; HOGAN B, 1994, MANIPULATING MOUSE E, P373; Ishibashi M, 1995, GENE DEV, V9, P3136, DOI 10.1101/gad.9.24.3136; Ito T, 1996, MOL CELL BIOL, V16, P3112; JENSSON O, 1988, J MED GENET, V25, P227, DOI 10.1136/jmg.25.4.227; KELLOGG DR, 1995, J CELL BIOL, V130, P661, DOI 10.1083/jcb.130.3.661; Kerszberg M, 1998, BIOESSAYS, V20, P758, DOI 10.1002/(SICI)1521-1878(199809)20:9<758::AID-BIES9>3.0.CO;2-C; KHOCHBIN S, 1994, EUR J BIOCHEM, V225, P501, DOI 10.1111/j.1432-1033.1994.00501.x; LASKEY RA, 1978, NATURE, V275, P416, DOI 10.1038/275416a0; LeNovere N, 1996, EUR J NEUROSCI, V8, P2428; MCBURNEY MW, 1993, INT J DEV BIOL, V37, P135; McQuibban GA, 1998, J BIOL CHEM, V273, P6582, DOI 10.1074/jbc.273.11.6582; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; NARUSE I, 1995, PROG NEUROBIOL, V47, P135, DOI 10.1016/0301-0082(95)00024-P; NEUMANN PE, 1994, NAT GENET, V6, P357, DOI 10.1038/ng0494-357; Papenbrock T, 1998, DEV DYNAM, V212, P540, DOI 10.1002/(SICI)1097-0177(199808)212:4<540::AID-AJA7>3.0.CO;2-H; Reyes JC, 1998, EMBO J, V17, P6979, DOI 10.1093/emboj/17.23.6979; Rodriguez P, 1997, GENOMICS, V44, P253, DOI 10.1006/geno.1997.4868; ROUGEULLE C, 1994, MAMM GENOME, V5, P416, DOI 10.1007/BF00357001; Rougeulle C, 1996, HUM MOL GENET, V5, P41, DOI 10.1093/hmg/5.1.41; SIMON HU, 1994, BIOCHEM J, V297, P389, DOI 10.1042/bj2970389; STRUBING C, 1995, MECH DEVELOP, V53, P275, DOI 10.1016/0925-4773(95)00446-8; WILSON DB, 1974, J COMP NEUROL, V154, P249, DOI 10.1002/cne.901540303; Wilson PA, 1997, NEURON, V18, P699, DOI 10.1016/S0896-6273(00)80311-6; WOOD SA, 1993, P NATL ACAD SCI USA, V90, P4582, DOI 10.1073/pnas.90.10.4582; YOUNG WS, 1986, P NATL ACAD SCI USA, V83, P9827, DOI 10.1073/pnas.83.24.9827	30	72	74	0	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	AUG	2000	25	4					431	435		10.1038/78124	http://dx.doi.org/10.1038/78124			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	341WY	10932189				2022-12-25	WOS:000088615000020
J	Takahashi, Y; Koizumi, K; Takagi, A; Kitajima, S; Inoue, T; Koseki, H; Saga, Y				Takahashi, Y; Koizumi, K; Takagi, A; Kitajima, S; Inoue, T; Koseki, H; Saga, Y			Mesp2 initiates somite segmentation through the Notch signalling pathway	NATURE GENETICS			English	Article							PARAXIAL MESODERM; DELTA-HOMOLOG; XENOPUS EMBRYOS; LUNATIC FRINGE; MOUSE GENE; EXPRESSION; DROSOPHILA; DII1; MICE; PRESENILIN	The Notch-signalling pathway is important in establishing metameric pattern during somitogenesis. In mice, the lack of either of two molecules involved in the Notch-signalling pathway. Mesp2 or presenilin-1 (Ps1), results in contrasting phenotypes: caudalized versus rostralized vertebra. Here we adopt a genetic approach to analyse the molecular mechanism underlying the establishment of rostro-caudal polarity in somites. By focusing on the fact that expression of a Notch ligand, DII1, is important for prefiguring somite identity, we found that Mesp2 initiates establishment of rostro-caudal polarity by controlling two Notch-signalling pathways. Initially, Mesp2 activates a Ps1-independent Notch-signalling cascade to suppress DII1 expression and specify the rostral half of the somite. Ps1-mediated Notch-signalling is required to induce DII1 expression in the caudal half of the somite. Therefore, Mesp2- and Ps1-dependent activation of Notch-signalling pathways might differentially regulate DII1 expression, resulting in the establishment of the rostro-caudal polarity of somites.	Natl Inst Hlth Sci, Cellular & Mol Toxicol Div, Setagaya Ku, Tokyo, Japan; Chiba Univ, Sch Med, Dept Dev Biol, Chuo Ku, Chiba, Japan	National Institute of Health Sciences - Japan; Chiba University	Koseki, H (corresponding author), Natl Inst Hlth Sci, Cellular & Mol Toxicol Div, Setagaya Ku, Tokyo, Japan.		Koseki, Haruhiko/I-3825-2014	Koseki, Haruhiko/0000-0001-8424-5854				Barrantes ID, 1999, CURR BIOL, V9, P470, DOI 10.1016/S0960-9822(99)80212-7; BETTENHAUSEN B, 1995, DEVELOPMENT, V121, P2407; CONLON RA, 1995, DEVELOPMENT, V121, P1533; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; deAngelis MH, 1997, NATURE, V386, P717, DOI 10.1038/386717a0; DELAMO FF, 1992, DEVELOPMENT, V115, P737; delaPompa J, 1997, DEVELOPMENT, V124, P1139; Donoviel DB, 1999, GENE DEV, V13, P2801, DOI 10.1101/gad.13.21.2801; Dunwoodie SL, 1997, DEVELOPMENT, V124, P3065; Evrard YA, 1998, NATURE, V394, P377, DOI 10.1038/28632; GOLDSTEIN RS, 1992, DEVELOPMENT, V116, P441; Ishii Y, 1997, DEV GROWTH DIFFER, V39, P643; Jen WC, 1999, GENE DEV, V13, P1486, DOI 10.1101/gad.13.11.1486; Jen WC, 1997, DEVELOPMENT, V124, P1169; Johnston SH, 1997, DEVELOPMENT, V124, P2245; Kusumi K, 1998, NAT GENET, V19, P274, DOI 10.1038/961; Neidhardt LM, 1997, DEV GENES EVOL, V207, P330, DOI 10.1007/s004270050120; OKA C, 1995, DEVELOPMENT, V121, P3291; Palmeirim I, 1997, CELL, V91, P639, DOI 10.1016/S0092-8674(00)80451-1; Saga Y, 1997, GENE DEV, V11, P1827, DOI 10.1101/gad.11.14.1827; Sparrow DB, 1998, DEVELOPMENT, V125, P2041; Struhl G, 1999, NATURE, V398, P522, DOI 10.1038/19091; SWIATEK PJ, 1994, GENE DEV, V8, P707, DOI 10.1101/gad.8.6.707; TAKEBAYASHI K, 1995, J BIOL CHEM, V270, P1342, DOI 10.1074/jbc.270.3.1342; Tam PPL, 2000, CURR TOP DEV BIOL, V47, P1; Wong PC, 1997, NATURE, V387, P288, DOI 10.1038/387288a0; YAGI T, 1993, ANAL BIOCHEM, V214, P70, DOI 10.1006/abio.1993.1458; Ye YH, 1999, NATURE, V398, P525, DOI 10.1038/19096; Zhang NA, 1998, NATURE, V394, P374, DOI 10.1038/28625	29	162	170	0	7	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	AUG	2000	25	4					390	396		10.1038/78062	http://dx.doi.org/10.1038/78062			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	341WY	10932180				2022-12-25	WOS:000088615000011
J	Fussenegger, M; Bailey, JE; Varner, J				Fussenegger, M; Bailey, JE; Varner, J			A mathematical model of caspase function in apoptosis	NATURE BIOTECHNOLOGY			English	Article						caspases; apoptosis; mechanistic mathematical models	INDUCED-PROXIMITY MODEL; HAMSTER OVARY CELLS; CYTOCHROME-C; DEATH DOMAIN; TNF RECEPTOR; BCL-2 FAMILY; ACTIVATION; MITOCHONDRIA; INTERACTS; PROTEIN	Caspases (cysteine-containing aspartate-specific proteases) are at the core of the cell's suicide machinery. These enzymes, once activated, dismantle the cell by selectively cleaving key proteins after aspartate residues. The events culminating in caspase activation are the subject of intense study because of their role in cancer, and neurodegenerative and autoimmune disorders. Here we present a mechanistic mathematical model, formulated on the basis of newly emerging information, describing key elements of receptor-mediated and stress-induced caspase activation. We have used mass-conservation principles in conjunction with kinetic rate laws to formulate ordinary differential equations that describe the temporal evolution of caspase activation. Qualitative strategies for the prevention of caspase activation are simulated and compared with experimental data. We show that model predictions are consistent with available information. Thus, the model could aid in better understanding caspase activation and identifying therapeutic approaches promoting or retarding apoptotic cell death.	ETH Zurich, Inst Biotechnol, CH-8093 Zurich, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich	Varner, J (corresponding author), Univ Minnesota, Dept Chem Engn & Mat Sci, 421 Washington Ave SE, Minneapolis, MN 55455 USA.							Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Amarante-Mendes GP, 1998, CELL DEATH DIFFER, V5, P298, DOI 10.1038/sj.cdd.4400354; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; BOLDIN MP, 1995, J BIOL CHEM, V270, P387, DOI 10.1074/jbc.270.1.387; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Davidson FF, 1998, NATURE, V391, P587, DOI 10.1038/35385; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; Goswami J, 1999, BIOTECHNOL BIOENG, V62, P632, DOI 10.1002/(SICI)1097-0290(19990320)62:6<632::AID-BIT2>3.0.CO;2-I; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Haass C, 1999, NATURE, V399, P204, DOI 10.1038/20314; Hsu YT, 1997, P NATL ACAD SCI USA, V94, P3668, DOI 10.1073/pnas.94.8.3668; Huang BH, 1996, NATURE, V384, P638, DOI 10.1038/384638a0; IRMLER M, 1997, NATURE, V388, P125; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Koseki T, 1998, P NATL ACAD SCI USA, V95, P5156, DOI 10.1073/pnas.95.9.5156; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; MIYASHITA T, 1995, CELL, V80, P293; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Newton K, 1998, CURR OPIN GENET DEV, V8, P68, DOI 10.1016/S0959-437X(98)80064-6; Ona VO, 1999, NATURE, V399, P263, DOI 10.1038/20446; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; Salvesen GS, 1999, P NATL ACAD SCI USA, V96, P10964, DOI 10.1073/pnas.96.20.10964; Sanfeliu A, 1999, BIOTECHNOL BIOENG, V64, P46, DOI 10.1002/(SICI)1097-0290(19990705)64:1&lt;46::AID-BIT5&gt;3.0.CO;2-9; Seshagiri S, 1997, P NATL ACAD SCI USA, V94, P13606, DOI 10.1073/pnas.94.25.13606; Shu HB, 1997, IMMUNITY, V6, P751, DOI 10.1016/S1074-7613(00)80450-1; Simpson NH, 1998, BIOTECHNOL BIOENG, V59, P90, DOI 10.1002/(SICI)1097-0290(19980705)59:1<90::AID-BIT12>3.0.CO;2-6; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954; Zhang JK, 1998, NATURE, V392, P296, DOI 10.1038/32681	37	180	182	2	15	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUL	2000	18	7					768	774		10.1038/77589	http://dx.doi.org/10.1038/77589			7	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	331YN	10888847				2022-12-25	WOS:000088046400028
J	Marino, M; Ruvo, M; De Falco, S; Fassina, G				Marino, M; Ruvo, M; De Falco, S; Fassina, G			Prevention of systemic lupus erythematosus in MRL/lpr mice by administration of an immunoglobulin-binding peptide	NATURE BIOTECHNOLOGY			English	Article						combinatorial chemistry; autoimmune diseases; lupus erythematosus; Fc gamma R inhibition; multimeric peptide	IMMUNE-COMPLEXES; AFFINITY PURIFICATION; FC-RECEPTORS; LIGAND; IGG; AUTOANTIBODIES; DISEASE; RECOGNITION; ANTIBODIES; SERA	Systemic lupus erythematosus (SLE) is a multisystem chronic inflammatory disease of unknown etiology that affects many organs, including the kidney. The presence of multiple autoantibodies and other immunological abnormalities point to basic defects in immunoregulatory controls that normally maintain self-tolerance. The deposition on kidney tissue of autoantibodies as immune complexes (ICs) through the interaction with Fc-receptor gamma-chains is thought to trigger an inflammatory response typical of SLE, leading to glomerulonephritis. Using combinatorial chemistry approaches, we have identified a peptide able to bind to immunoglobulins and to interfere with Fc gamma-receptor recognition. Administration of this peptide to MRL/lpr mice, an animal model used to study SLE, resulted in a remarkable enhancement of the survival rate (80%) compared to placebo-treated animals (10%). Consistent with this was a significant reduction of proteinuria, a clinical sign of SLE. Kidney histological examination of treated animals confirmed the preservation of tissue integrity and a remarkable reduction in IC deposition. These results support the role of Fc gamma receptors in SLE pathogenesis and open new avenues for the development of drugs to treat autoimmune disorders.	TECNOGEN SCpA, Biopharmaceut, I-81015 Piana Di Monte Verna, CE, Italy		Fassina, G (corresponding author), TECNOGEN SCpA, Biopharmaceut, I-81015 Piana Di Monte Verna, CE, Italy.		Fassina, Giorgio/I-7127-2012; De Falco, Sandro/P-6724-2015	Fassina, Giorgio/0000-0003-1845-2657; De Falco, Sandro/0000-0002-6501-1697				BACCALA R, 1989, P NATL ACAD SCI USA, V86, P4624, DOI 10.1073/pnas.86.12.4624; Baumann U, 2000, J IMMUNOL, V164, P1065, DOI 10.4049/jimmunol.164.2.1065; BAYLINK DJ, 1983, NEW ENGL J MED, V309, P306, DOI 10.1056/NEJM198308043090509; BURTON DR, 1988, MOL IMMUNOL, V25, P1175, DOI 10.1016/0161-5890(88)90153-8; Clynes R, 1998, SCIENCE, V279, P1052, DOI 10.1126/science.279.5353.1052; Fassina G, 1996, J MOL RECOGNIT, V9, P564, DOI 10.1002/(SICI)1099-1352(199634/12)9:5/6<564::AID-JMR302>3.0.CO;2-F; Fassina G, 1998, J MOL RECOGNIT, V11, P128, DOI 10.1002/(SICI)1099-1352(199812)11:1/6<128::AID-JMR408>3.0.CO;2-8; FEARON DT, 1983, ANNU REV IMMUNOL, V1, P243, DOI 10.1146/annurev.iy.01.040183.001331; Franceschini F, 1999, LUPUS, V8, P215, DOI 10.1191/096120399678847632; GAUTHIER VJ, 1986, J IMMUNOL, V136, P3266; Hasegawa H, 1999, LUPUS, V8, P439, DOI 10.1177/096120339900800605; HOOVER RG, 1995, J CLIN INVEST, V95, P241, DOI 10.1172/JCI117646; JAZWINSKA EC, 1991, CLIN EXP IMMUNOL, V86, P199; Lemay S, 1996, KIDNEY INT, V50, P85, DOI 10.1038/ki.1996.290; LUND J, 1995, FASEB J, V9, P115, DOI 10.1096/fasebj.9.1.7821750; MANNIK M, 1983, J EXP MED, V157, P1516, DOI 10.1084/jem.157.5.1516; MANNIK M, 1982, ARTHRITIS RHEUM, V25, P783, DOI 10.1002/art.1780250713; MARION TN, 1989, J IMMUNOL, V142, P4269; MATTIOLI M, 1974, ARTHRITIS RHEUM-US, V17, P421, DOI 10.1002/art.1780170413; ODELL JR, 1995, SAMTERS IMMUNOLOGIC, P667; PIPER JM, 1991, ANN INTERN MED, V114, P735, DOI 10.7326/0003-4819-114-9-735; Pryor BD, 1996, ARTHRITIS RHEUM, V39, P1475, DOI 10.1002/art.1780390906; Ravetch JV, 1998, ANNU REV IMMUNOL, V16, P421, DOI 10.1146/annurev.immunol.16.1.421; REICHLIN M, 1981, CLIN EXP IMMUNOL, V44, P1; Reichlin M, 1999, ARTHRITIS RHEUM, V42, P69, DOI 10.1002/1529-0131(199901)42:1<69::AID-ANR9>3.0.CO;2-J; Schett G, 2000, ARTHRITIS RHEUM-US, V43, P420, DOI 10.1002/1529-0131(200002)43:2<420::AID-ANR24>3.0.CO;2-Z; SYLVESTRE DL, 1994, SCIENCE, V265, P1095, DOI 10.1126/science.8066448; Szalai AJ, 2000, J IMMUNOL, V164, P463, DOI 10.4049/jimmunol.164.1.463; Theofilopoulos AN, 1992, SYSTEMIC LUPUS ERYTH, P121; TSAO BP, 1992, J IMMUNOL, V149, P350; Wang Y, 1996, P NATL ACAD SCI USA, V93, P8563, DOI 10.1073/pnas.93.16.8563; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0	32	56	78	0	8	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUL	2000	18	7					735	739		10.1038/77296	http://dx.doi.org/10.1038/77296			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	331YN	10888840				2022-12-25	WOS:000088046400021
J	Shusta, EV; Holler, PD; Kieke, MC; Kranz, DM; Wittrup, KD				Shusta, EV; Holler, PD; Kieke, MC; Kranz, DM; Wittrup, KD			Directed evolution of a stable scaffold for T-cell receptor engineering	NATURE BIOTECHNOLOGY			English	Article						yeast display; T-cell receptor; stability maturation; directed evolution	YEAST SURFACE-DISPLAY; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; POLYPEPTIDE LIBRARIES; ENDOPLASMIC-RETICULUM; LYMPHOCYTES-T; ANTIBODY; SECRETION; FRAGMENT; PROTEIN	Here we have constructed a single-chain T-cell receptor (scTCR) scaffold with high stability and soluble expression efficiency by directed evolution and yeast surface display. We evolved scTCRs in parallel for either enhanced resistance to thermal denaturation at 46 degrees C, or improved intracellular processing at 37 degrees C, with essentially equivalent results. This indicates that the efficiency of the consecutive kinetic processes of membrane translocation, protein folding, quality control, and vesicular transport can be well predicted by the single thermodynamic parameter of thermal stability. Selected mutations were recombined to create an scTCR scaffold that was stable for over an hour at 65 degrees C, had solubility of over 4 mg ml(-1), and shake-flask expression levels of 7.5 mg l(-1), while retaining specific ligand binding to peptide-major histocompatibility complexes (pMHCs) and bacterial superantigen. These properties are comparable to those for stable single-chain antibodies, but are markedly improved over existing scTCR constructs. Availability of this scaffold allows engineering of high-affinity soluble scTCRs as antigen-specific antagonists of cell-mediated immunity. Moreover, yeast displaying the scTCR formed specific conjugates with antigen-presenting cells (APCs), which could allow development of novel cell-to-cell selection strategies for evolving scTCRs with improved binding to various pMHC ligands in situ.	Univ Illinois, Dept Biochem, Urbana, IL 61801 USA; Univ Illinois, Dept Chem Engn, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Wittrup, KD (corresponding author), Univ Illinois, Dept Biochem, Urbana, IL 61801 USA.		Kieke, Michele (Shellie) C/GSJ-0910-2022		NIGMS NIH HHS [GM55757] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALEXANDER J, 1989, IMMUNOGENETICS, V29, P380, DOI 10.1007/BF00375866; Altman JD, 1998, SCIENCE, V280, P1821; Boder ET, 1998, BIOTECHNOL PROGR, V14, P55, DOI 10.1021/bp970144q; Boder ET, 1997, NAT BIOTECHNOL, V15, P553, DOI 10.1038/nbt0697-553; CHUNG S, 1994, P NATL ACAD SCI USA, V91, P12654, DOI 10.1073/pnas.91.26.12654; CLEMENTS JM, 1991, GENE, V106, P267, DOI 10.1016/0378-1119(91)90209-T; EILAT D, 1992, P NATL ACAD SCI USA, V89, P6871, DOI 10.1073/pnas.89.15.6871; ENGEL I, 1992, SCIENCE, V256, P1318, DOI 10.1126/science.1598575; Fields BA, 1996, NATURE, V384, P188, DOI 10.1038/384188a0; Garcia KC, 1996, SCIENCE, V274, P209, DOI 10.1126/science.274.5285.209; Gietz RD, 1995, METHOD MOL CELL BIOL, V5, P255; Holler PD, 2000, P NATL ACAD SCI USA, V97, P5387, DOI 10.1073/pnas.080078297; HOO WFS, 1992, P NATL ACAD SCI USA, V89, P4759, DOI 10.1073/pnas.89.10.4759; Kieke MC, 1997, PROTEIN ENG, V10, P1303, DOI 10.1093/protein/10.11.1303; Kieke MC, 1999, P NATL ACAD SCI USA, V96, P5651, DOI 10.1073/pnas.96.10.5651; KRANZ DM, 1984, P NATL ACAD SCI-BIOL, V81, P7922, DOI 10.1073/pnas.81.24.7922; LABOISSIERE MCA, 1995, J BIOL CHEM, V270, P28006; Lebowitz MS, 1999, CELL IMMUNOL, V192, P175, DOI 10.1006/cimm.1999.1441; Manning TC, 1998, IMMUNITY, V8, P413, DOI 10.1016/S1074-7613(00)80547-6; NECKER A, 1991, EUR J IMMUNOL, V21, P3035, DOI 10.1002/eji.1830211220; Nieba L, 1997, PROTEIN ENG, V10, P435, DOI 10.1093/protein/10.4.435; NOVOTNY J, 1991, P NATL ACAD SCI USA, V88, P8646, DOI 10.1073/pnas.88.19.8646; Parekh RN, 1996, BIOTECHNOL PROGR, V12, P16, DOI 10.1021/bp9500627; Plaksin D, 1997, J IMMUNOL, V158, P2218; REDDEHASE MJ, 1989, NATURE, V337, P651, DOI 10.1038/337651a0; REDDING K, 1991, J CELL BIOL, V113, P527, DOI 10.1083/jcb.113.3.527; Robinson AS, 1996, J BIOL CHEM, V271, P10017, DOI 10.1074/jbc.271.17.10017; Schodin BA, 1996, MOL IMMUNOL, V33, P819, DOI 10.1016/0161-5890(96)00038-7; SCOPES RK, 1974, ANAL BIOCHEM, V59, P277, DOI 10.1016/0003-2697(74)90034-7; SHIMBA N, 1995, FEBS LETT, V360, P247, DOI 10.1016/0014-5793(95)00113-N; Shusta EV, 1999, J MOL BIOL, V292, P949, DOI 10.1006/jmbi.1999.3130; Shusta EV, 1998, NAT BIOTECHNOL, V16, P773, DOI 10.1038/nbt0898-773; SUZUKI CK, 1991, J CELL BIOL, V114, P189, DOI 10.1083/jcb.114.2.189; SYKULEV Y, 1994, P NATL ACAD SCI USA, V91, P11487, DOI 10.1073/pnas.91.24.11487; TACHIBANA C, 1992, MOL CELL BIOL, V12, P4601, DOI 10.1128/MCB.12.10.4601; Udaka K, 1996, J IMMUNOL, V157, P670; VanLeeuwen JEM, 1996, J BIOL CHEM, V271, P25345, DOI 10.1074/jbc.271.41.25345; WEBBER KO, 1995, MOL IMMUNOL, V32, P249, DOI 10.1016/0161-5890(94)00150-Y; Weidanz JA, 1998, J IMMUNOL METHODS, V221, P59, DOI 10.1016/S0022-1759(98)00153-7; WULFING C, 1994, J MOL BIOL, V242, P655, DOI 10.1006/jmbi.1994.1615; Young NM, 1995, FEBS LETT, V377, P135, DOI 10.1016/0014-5793(95)01325-3	41	189	242	1	14	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUL	2000	18	7					754	759		10.1038/77325	http://dx.doi.org/10.1038/77325			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	331YN	10888844				2022-12-25	WOS:000088046400025
J	Barna, M; Hawe, N; Niswander, L; Pandolfi, PP				Barna, M; Hawe, N; Niswander, L; Pandolfi, PP			Plzf regulates limb and axial skeletal patterning	NATURE GENETICS			English	Article							ACUTE PROMYELOCYTIC LEUKEMIA; ZINC-FINGER PROTEIN; ALPHA RAR-ALPHA; HOMEOTIC TRANSFORMATIONS; RETINOIC ACID; TRANSCRIPTIONAL REPRESSOR; SONIC-HEDGEHOG; HOX GENES; MISEXPRESSION; MICE	The promyelocytic leukaemia zinc finger (Plzf) protein (encoded by the gene Zfp 145) belongs to the POZ/zinc-finger family of transcription factors. Here we generate Zfp 145(-/-) mice and show that Plzf is essential for patterning of the limb and axial skeleton. Plzf inactivation results in patterning defects affecting all skeletal structures of the limb, including homeotic transformations of anterior skeletal elements into posterior structures. We demonstrate that Plzf acts as a growth-inhibitory and pro-apoptotic factor in the limb bud. The expression of members of the abdominal b (Abdb) Hox gene complex, as well as genes encoding bone morphogenetic proteins (Bmps). is altered in the developing limb of Zfp 145(-/-) mice. Plzf regulates the expression of these genes in the absence of aberrant polarizing activity and independently of known patterning genes. Zfp145(-/-) mice also exhibit anterior-directed homeotic transformation throughout the axial skeleton with associated alterations in Hox gene expression. Plzf is therefore a mediator of anterior-to-posterior (AP) patterning in both the axial and appendicular skeleton and acts as a regulator of Hox gene expression.	Cornell Univ, Grad Sch Med Sci, Mem Sloan Kettering Canc Ctr, Sloan Kettering Div,Dept Human Genet, New York, NY 10021 USA; Cornell Univ, Grad Sch Med Sci, Mem Sloan Kettering Canc Ctr, Sloan Kettering Div,Mol Biol Program, New York, NY 10021 USA; Cornell Univ, Grad Sch Med Sci, Mem Sloan Kettering Canc Ctr, Sloan Kettering Div,Howard Hughes Med Inst, New York, NY 10021 USA	Cornell University; Memorial Sloan Kettering Cancer Center; Cornell University; Memorial Sloan Kettering Cancer Center; Cornell University; Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center	Pandolfi, PP (corresponding author), Cornell Univ, Grad Sch Med Sci, Mem Sloan Kettering Canc Ctr, Sloan Kettering Div,Dept Human Genet, New York, NY 10021 USA.		Niswander, Lee/D-3976-2013	Niswander, Lee/0000-0002-9959-0594; O'Connor, Nicola/0000-0003-1981-3055	NATIONAL CANCER INSTITUTE [R37CA071692, R01CA071692, P30CA008748] Funding Source: NIH RePORTER; NCI NIH HHS [CA71692, CA08748] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AVANTAGGIATO V, 1995, J NEUROSCI, V15, P4927; Bhatia M, 1999, J EXP MED, V189, P1139, DOI 10.1084/jem.189.7.1139; Chang CC, 1996, P NATL ACAD SCI USA, V93, P6947, DOI 10.1073/pnas.93.14.6947; CHEN Z, 1993, EMBO J, V12, P1161, DOI 10.1002/j.1460-2075.1993.tb05757.x; Davies JM, 1999, ONCOGENE, V18, P365, DOI 10.1038/sj.onc.1202332; DAVIS AP, 1995, NATURE, V375, P791, DOI 10.1038/375791a0; DUDLEY AT, 1995, GENE DEV, V9, P2795, DOI 10.1101/gad.9.22.2795; FromentalRamain C, 1996, DEVELOPMENT, V122, P2997; Goff DJ, 1997, DEVELOPMENT, V124, P627; He LZ, 1999, ONCOGENE, V18, P5278, DOI 10.1038/sj.onc.1203088; He LZ, 1998, NAT GENET, V18, P126, DOI 10.1038/ng0298-126; Hoatlin ME, 1999, BLOOD, V94, P3737, DOI 10.1182/blood.V94.11.3737.423k39_3737_3747; Hong SH, 1997, P NATL ACAD SCI USA, V94, P9028, DOI 10.1073/pnas.94.17.9028; JEGALIAN BG, 1992, CELL, V71, P901, DOI 10.1016/0092-8674(92)90387-R; KESSEL M, 1991, CELL, V67, P89, DOI 10.1016/0092-8674(91)90574-I; Knezevic V, 1997, DEVELOPMENT, V124, P4523; KRUMLAUF R, 1994, CELL, V78, P191, DOI 10.1016/0092-8674(94)90290-9; Li JY, 1997, J BIOL CHEM, V272, P22447, DOI 10.1074/jbc.272.36.22447; LUO G, 1995, GENE DEV, V9, P2808, DOI 10.1101/gad.9.22.2808; MORGAN BA, 1992, NATURE, V358, P236, DOI 10.1038/358236a0; Pearse RV, 1998, J EXP ZOOL, V282, P677, DOI 10.1002/(SICI)1097-010X(19981215)282:6<677::AID-JEZ4>3.0.CO;2-F; POLLOCK RA, 1992, CELL, V71, P911, DOI 10.1016/0092-8674(92)90388-S; REID A, 1995, BLOOD, V86, P4544, DOI 10.1182/blood.V86.12.4544.bloodjournal86124544; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; Ruthardt M, 1997, MOL CELL BIOL, V17, P4859, DOI 10.1128/MCB.17.8.4859; SMALL KM, 1993, GENE DEV, V7, P2318, DOI 10.1101/gad.7.12a.2318; TICKLE C, 1981, NATURE, V289, P295, DOI 10.1038/289295a0; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; van Oostveen JW, 1999, LEUKEMIA, V13, P1675, DOI 10.1038/sj.leu.2401562; WILKINSON DG, 1992, IN SITU HYBRIDIZATIO, P75; YOKOUCHI Y, 1995, GENE DEV, V9, P2509, DOI 10.1101/gad.9.20.2509; Zou HY, 1996, SCIENCE, V272, P738, DOI 10.1126/science.272.5262.738	32	231	240	0	7	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUN	2000	25	2					166	172		10.1038/76014	http://dx.doi.org/10.1038/76014			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	321ML	10835630				2022-12-25	WOS:000087459200014
J	Romer, S; Fraser, PD; Kiano, JW; Shipton, CA; Misawa, N; Schuch, W; Bramley, PM				Romer, S; Fraser, PD; Kiano, JW; Shipton, CA; Misawa, N; Schuch, W; Bramley, PM			Elevation of the provitamin A content of transgenic tomato plants	NATURE BIOTECHNOLOGY			English	Article						agricultural biotechnology; nutriceuticals; metabolic engineering	CAROTENOID BIOSYNTHESIS; PHYTOENE DESATURASE; ENZYME-ACTIVITY; BETA-CAROTENE; EXPRESSION; FRUIT; GENE; RESISTANCE; SYNTHASE; INCREASE	Tomato products are the principal dietary sources of lycopene and major source of beta-carotene, both of which have been shown to benefit human health. To enhance the carotenoid content and profile of tomato fruit, we have produced transgenic lines containing a bacterial carotenoid gene (crtl) encoding the enzyme phytoene desaturase, which converts phytoene into lycopene, Expression of this gene in transgenic tomatoes did not elevate total carotenoid levels. However, the beta-carotene content increased about threefold, up to 45% of the total carotenoid content, Endogenous carotenoid genes were concurrently upregulated, except for phytoene synthase, which was repressed. The alteration in carotenoid content of these plants did not affect growth and development. Levels of noncarotenoid isoprenoids were unchanged in the transformants, The phenotype has been found to be stable and reproducible over at least four generations.	Univ London Royal Holloway & Bedford New Coll, Sch Biol Sci, Egham TW20 0EX, Surrey, England; Zeneca Plant Sci, Jealotts Hill Res Stn, Bracknell RG42 6EY, Berks, England; Kirin Brewery Co Ltd, Cent Labs Key Technol, Kanazawa Ku, Yokohama, Kanagawa 236, Japan	University of London; Royal Holloway University London; Kirin Brewery Company Limited	Bramley, PM (corresponding author), Univ Konstanz, Fak Biol, D-78434 Constance, Germany.	p.bramley@rhbnc.ac.uk		Misawa, Norihiko/0000-0003-1373-0769				BIRD CR, 1988, PLANT MOL BIOL, V11, P651, DOI 10.1007/BF00017465; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Fraser PD, 1999, PLANT MOL BIOL, V40, P687, DOI 10.1023/A:1006256302570; FRASER PD, 1991, PHYTOCHEMISTRY, V30, P3971, DOI 10.1016/0031-9422(91)83447-S; FRASER PD, 1992, J BIOL CHEM, V267, P19891; FRASER PD, 1994, PLANT PHYSIOL, V105, P405, DOI 10.1104/pp.105.1.405; FRAY RG, 1995, PLANT J, V8, P693, DOI 10.1046/j.1365-313X.1995.08050693.x; HUMPHREY JH, 1992, B WORLD HEALTH ORGAN, V70, P225; KUNTZ M, 1992, PLANT J, V2, P25; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lichtenthaler H.K., 1983, ANALYSIS-UK, V11, P591, DOI [10.1042/bst0110591, DOI 10.1042/BST0110591]; Mayne ST, 1996, FASEB J, V10, P690, DOI 10.1096/fasebj.10.7.8635686; MCCORMICK DB, 1995, TIETZ FUNDAMENTALS C, P469; MISAWA N, 1993, PLANT J, V4, P833, DOI 10.1046/j.1365-313X.1993.04050833.x; MISAWA N, 1994, PLANT J, V6, P481, DOI 10.1046/j.1365-313X.1994.6040481.x; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANDMANN G, 1994, EUR J BIOCHEM, V223, P7, DOI 10.1111/j.1432-1033.1994.tb18961.x; SUBER A, 1992, 5 DAY BETTER HLTH BA; van den Berg H, 1999, NUTR REV, V57, P1, DOI 10.1111/j.1753-4887.1999.tb01769.x; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; Ye XD, 2000, SCIENCE, V287, P303, DOI 10.1126/science.287.5451.303; 1999, TOMATO NEWS      JAN	22	302	335	0	55	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JUN	2000	18	6					666	669		10.1038/76523	http://dx.doi.org/10.1038/76523			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	325EK	10835607				2022-12-25	WOS:000087663200029
J	Yoneda, A; Asada, M; Oda, Y; Suzuki, M; Imamura, T				Yoneda, A; Asada, M; Oda, Y; Suzuki, M; Imamura, T			Engineering of an FGF-proteoglycan fusion protein with heparin-independent, mitogenic activity	NATURE BIOTECHNOLOGY			English	Article						fibroblast growth factor; heparan sulfate; heparin; proteoglycan; fusion protein	FIBROBLAST GROWTH-FACTOR; ENDOTHELIAL-CELLS; GLYCOSYLATION; SEQUENCE; SULFATE; CLONING; BINDING; SITES	In the absence of heparan sulfate (HS) on the surface of target cells, or free heparin (HP) in the vicinity of their receptors, fibroblast growth factor (FGF) family members cannot exert their biological activity and are easily damaged by proteolysis. This limits the utility of FGFs in a variety of applications including treatment of surgical, burn, and periodontal tissue wounds, gastric ulcers, segmental bony defects, ligament and spinal cord injury. Here we describe an FGF analog engineered to overcome this limitation by fusing FGF-1 with HS proteoglycan (PG) core protein. The fusion protein (PG-FGF-1), which was expressed in Chinese hamster ovary cells and collected from the conditioned medium, possessed both MS and chondroitin sulfate sugar chains. After fractionation, intact PG-FGF-1 proteins with little affinity to immobilized HP and high-level HS modification, but not their heparitinase or heparinase digests, exerted mitogenic activity independent of exogenous MP toward MS-free Ba/F3 transfectants expressing FGF receptor. Although PG-FGF-1 was resistant to tryptic digestion, its physiological degradation with a combination of heparitinase and trypsin augmented its mitogenic activity toward human endothelial cells. The same treatment abolished the activity of simple FGF-1 protein. By constructing a biologically active proteoglycan-FGF-1 fusion protein, we have demonstrated an approach that may prove effective for engineering not only FGF family members, but other MP-binding molecules as well.	Natl Inst Biosci & Human Technol, Biosignaling Dept, Tsukuba, Ibaraki 3058566, Japan	National Institute of Advanced Industrial Science & Technology (AIST)	Imamura, T (corresponding author), Natl Inst Biosci & Human Technol, Biosignaling Dept, 1-1 Higashi, Tsukuba, Ibaraki 3058566, Japan.		ASADA, MASAHIRO/M-4086-2018; Suzuki, Masashi/M-1696-2018	ASADA, MASAHIRO/0000-0001-6092-2080; Suzuki, Masashi/0000-0002-7218-0923				Asada M, 1999, GLYCOCONJUGATE J, V16, P321, DOI 10.1023/A:1007092708666; DiGabriele AD, 1998, NATURE, V393, P812, DOI 10.1038/31741; ESKO JD, 1985, P NATL ACAD SCI USA, V82, P3197, DOI 10.1073/pnas.82.10.3197; IMAMURA T, 1990, SCIENCE, V249, P1567, DOI 10.1126/science.1699274; IMAMURA T, 1987, EXP CELL RES, V172, P92, DOI 10.1016/0014-4827(87)90096-6; Kato M, 1998, NAT MED, V4, P691, DOI 10.1038/nm0698-691; KOJIMA T, 1993, BIOCHEM BIOPH RES CO, V190, P814, DOI 10.1006/bbrc.1993.1122; McKeehan WL, 1998, PROG NUCLEIC ACID RE, V59, P135; ORRITZ DM, 1992, MOL CELL BIOL, V12, P240; PinedaLucena A, 1996, J MOL BIOL, V264, P162, DOI 10.1006/jmbi.1996.0631; ROSENGART TK, 1988, BIOCHEM BIOPH RES CO, V152, P432, DOI 10.1016/S0006-291X(88)80732-0; SCHREIBER AB, 1985, P NATL ACAD SCI USA, V82, P6138, DOI 10.1073/pnas.82.18.6138; SHWORAK NW, 1994, J BIOL CHEM, V269, P21204; THORNTON SC, 1983, SCIENCE, V222, P623, DOI 10.1126/science.6635659; Yoneda A, 1999, BIOTECHNIQUES, V27, P576, DOI 10.2144/99273rr05	15	29	44	1	5	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUN	2000	18	6					641	644		10.1038/76487	http://dx.doi.org/10.1038/76487			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	325EK	10835602				2022-12-25	WOS:000087663200024
J	Bielinska, B; Blaydes, SM; Buiting, K; Yang, T; Krajewska-Walasek, M; Horsthemke, B; Brannan, CI				Bielinska, B; Blaydes, SM; Buiting, K; Yang, T; Krajewska-Walasek, M; Horsthemke, B; Brannan, CI			De novo deletions of SNRPN exon 1 in early human and mouse embryos result in a paternal to maternal imprint switch	NATURE GENETICS			English	Article							PRADER-WILLI-SYNDROME; SYNDROME CRITICAL REGION; ANGELMAN-SYNDROMES; TARGETED MUTATION; DNA METHYLATION; EXPRESSED GENE; NECDIN GENE; TRANSCRIPT; LETHALITY; 15Q11-13	Prader-Willi syndrome (PWS) is a neurogenetic disease characterized by infantile hypotonia, gonadal hypoplasia, obsessive behaviour and neonatal feeding difficulties followed by hyperphagia, leading to profound obesity(1). PWS is due to a lack of paternal genetic information at 15q11-q13 (ref. 2). Five imprinted, paternally expressed genes map to the PWS region, MKRN3 (ref. 3), NDN (ref. 4), NDNL1 (ref. 5), SNRPN (refs 6-8) and IPW (ref. 9), as well as two poorly characterized framents designated PAR-1 and PAR-5 (ref. 10). Imprinting of this region involves a bipartite 'imprinting centre' (IC), which overlaps SNRPN (refs 10,11). Deletion of the SNRPN promoter/exon 1 region (the PWS IC element) appears to impair the establishment of the paternal imprint in the male germ line and leads to PWS. Here we report a PWS family in which the father is mosaic for an IC deletion on his paternal chromosome. The deletion chromosome has acquired a maternal methylation imprint in his somatic cells. We have made identical findings in chimaeric mice generated from two independent embryonic stem (ES) cell lines harbouring a similar deletion. Our studies demonstrate that the PWS IC element is not only required for the establishment of the paternal imprint, but also for its postzygotic maintenance.	Univ Essen Gesamthsch, Inst Human Genet, Essen, Germany; Childrens Mem Hlth Inst, Dept Genet, Warsaw, Poland; Univ Florida, Coll Med, Inst Brain, Gainesville, FL USA; Univ Florida, Coll Med, Ctr Mammalian Genet, Dept Mol Genet & Microbiol, Gainesville, FL USA	University of Duisburg Essen; Children's Memorial Health Institute; State University System of Florida; University of Florida; State University System of Florida; University of Florida	Horsthemke, B (corresponding author), Univ Essen Gesamthsch, Inst Human Genet, Essen, Germany.			Krajewska-Walasek, Malgorzata/0000-0001-8721-210X	NATIONAL CANCER INSTITUTE [T32CA009126] Funding Source: NIH RePORTER; NCI NIH HHS [T32 CA09126] Funding Source: Medline; NIGMS NIH HHS [GM55272] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Blaydes SM, 1999, MAMM GENOME, V10, P549, DOI 10.1007/s003359901042; Boccaccio I, 1999, HUM MOL GENET, V8, P2497, DOI 10.1093/hmg/8.13.2497; Buiting K, 1998, AM J HUM GENET, V63, P170, DOI 10.1086/301935; BUITING K, 1995, NAT GENET, V9, P395, DOI 10.1038/ng0495-395; BUITING K, 1994, HUM MOL GENET, V3, P893, DOI 10.1093/hmg/3.6.893; BULTMAN SJ, 1992, CELL, V71, P1195, DOI 10.1016/S0092-8674(05)80067-4; DITTRICH B, 1992, HUM GENET, V90, P313; DITTRICH B, 1994, HUM GENET, V94, P583; Farber C, 1999, HUM MOL GENET, V8, P337, DOI 10.1093/hmg/8.2.337; GLENN CC, 1993, HUM MOL GENET, V2, P2001, DOI 10.1093/hmg/2.12.2001; Hogan B, 1994, MANIPULATING MOUSE E; HOLM VA, 1993, PEDIATRICS, V91, P398; Jay P, 1997, NAT GENET, V17, P357, DOI 10.1038/ng1197-357; Jong MTC, 1999, HUM MOL GENET, V8, P795, DOI 10.1093/hmg/8.5.795; Jong MTC, 1999, HUM MOL GENET, V8, P783, DOI 10.1093/hmg/8.5.783; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; MacDonald HR, 1997, HUM MOL GENET, V6, P1873, DOI 10.1093/hmg/6.11.1873; Nicholls RD, 1998, TRENDS GENET, V14, P194, DOI 10.1016/S0168-9525(98)01432-2; OZCELIK T, 1992, NAT GENET, V2, P265, DOI 10.1038/ng1292-265; REED ML, 1994, NAT GENET, V6, P163, DOI 10.1038/ng0294-163; Robertson EJ, 1987, TERATOCARCINOMAS EMB, P71; Schumacher A, 1998, NAT GENET, V19, P324, DOI 10.1038/1211; SUTCLIFFE JS, 1994, NAT GENET, V8, P52, DOI 10.1038/ng0994-52; SWIATEK PJ, 1993, GENE DEV, V7, P2071, DOI 10.1101/gad.7.11.2071; Wevrick R, 1997, HUM MOL GENET, V6, P325, DOI 10.1093/hmg/6.2.325; WEVRICK R, 1994, HUM MOL GENET, V3, P1877, DOI 10.1093/hmg/3.10.1877; Yang T, 1998, NAT GENET, V19, P25, DOI 10.1038/ng0598-25; ZECHNIGK M, 1997, EUR J HUM GENET, V5, P94	29	124	124	0	13	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAY	2000	25	1					74	78		10.1038/75629	http://dx.doi.org/10.1038/75629			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	311KU	10802660				2022-12-25	WOS:000086884000020
J	Ferber, S; Halkin, A; Cohen, H; Ber, I; Einav, Y; Goldberg, I; Barshack, I; Seijffers, R; Kopolovic, J; Kaiser, N; Karasik, A				Ferber, S; Halkin, A; Cohen, H; Ber, I; Einav, Y; Goldberg, I; Barshack, I; Seijffers, R; Kopolovic, J; Kaiser, N; Karasik, A			Pancreatic and duodenal homeobox gene 1 induces expression of insulin genes in liver and ameliorates streptozotocin-induced hyperglycemia	NATURE MEDICINE			English	Article							HOMEODOMAIN PROTEIN IDX-1; STEM-CELLS; ACTIVATION; GLUCOSE; PROMOTER; AGENESIS; ISLETS; PDX-1	Insulin gene expression is restricted to islet beta cells of the mammalian pancreas through specific control mechanisms mediated in part by specific transcription factors(1,2). The protein encoded by the pancreatic and duodenal homeobox gene 1 (PDX-1) is central in regulating pancreatic development and islet cell function(3). PDX-1 regulates insulin gene expression and is involved in islet cell-specific expression of various genes(4-7). Involvement of PDX-1 in islet-cell differentiation and function has been demonstrated mainly by 'loss-of-function' studies(8-11). We used a 'gain-of-function' approach to test whether PDX-1 could endow a non-islet tissue with pancreatic beta-cell characteristics in vivo. Recombinant-adenovirus-mediated gene transfer of PDX-1 to the livers of BALB/C and C57BL/6 mice activated expression of the endogenous, otherwise silent, genes for mouse insulin 1 and 2 and prohormone convertase 1/3 (PC 1/3). Expression of PDX-1 resulted in a substantial increase in hepatic immunoreactive insulin content and an increase of 300% in plasma immunoreactive insulin levels, compared with that in mice treated with control adenovirus. Hepatic immunoreactive insulin induced by PDX-1 was processed to mature mouse insulin 1 and 2 and was biologically active; it ameliorated hyperglycemia in diabetic mice treated with streptozotocin. These data indicate the capacity of PDX-1 to reprogram extrapancreatic tissue towards a beta-cell phenotype, may provide a valuable approach for generating 'self' surrogate beta cells, suitable for replacing impaired islet-cell function in diabetics.	Chaim Sheba Med Ctr, Endocrine Inst, IL-64239 Tel Aviv, Israel; Chaim Sheba Med Ctr, Inst Pathol, IL-64239 Tel Aviv, Israel; Sourasky Med Ctr, Dept Cardiol, IL-64239 Tel Aviv, Israel; Tel Aviv Univ, Sackler Sch Med, IL-69978 Ramat Aviv, Israel; Tel Aviv Univ, Dept Life Sci, IL-69978 Ramat Aviv, Israel; Hebrew Univ Jerusalem, Hadassah Med Ctr, Dept Endocrinol & Metab, IL-91120 Jerusalem, Israel	Chaim Sheba Medical Center; Chaim Sheba Medical Center; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky Medical Center; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv University; Hebrew University of Jerusalem; Hadassah University Medical Center	Ferber, S (corresponding author), Chaim Sheba Med Ctr, Endocrine Inst, IL-64239 Tel Aviv, Israel.		Wilson, Matthew H/K-3193-2013	Ferber, Sarah/0000-0003-2764-2786				Alison M, 1998, CURR OPIN CELL BIOL, V10, P710, DOI 10.1016/S0955-0674(98)80111-7; Edlund H, 1998, DIABETES, V47, P1817, DOI 10.2337/diabetes.47.12.1817; EDLUND T, 1985, SCIENCE, V230, P912, DOI 10.1126/science.3904002; EMENS LA, 1992, P NATL ACAD SCI USA, V89, P7300, DOI 10.1073/pnas.89.16.7300; Gross DJ, 1996, ENDOCRINOLOGY, V137, P5610, DOI 10.1210/en.137.12.5610; Heller RS, 1998, GASTROENTEROLOGY, V115, P381, DOI 10.1016/S0016-5085(98)70204-5; JONSSON J, 1994, NATURE, V371, P606, DOI 10.1038/371606a0; Lekstrom-Himes J, 1998, J BIOL CHEM, V273, P28545, DOI 10.1074/jbc.273.44.28545; Marshak S, 1996, P NATL ACAD SCI USA, V93, P15057, DOI 10.1073/pnas.93.26.15057; MILLER CP, 1994, EMBO J, V13, P1145, DOI 10.1002/j.1460-2075.1994.tb06363.x; O'Doherty RM, 1999, DIABETES, V48, P2022, DOI 10.2337/diabetes.48.10.2022; Offield MF, 1996, DEVELOPMENT, V122, P983; Sander M, 1997, J MOL MED, V75, P327, DOI 10.1007/s001090050118; Seijffers R, 1999, ENDOCRINOLOGY, V140, P3311, DOI 10.1210/en.140.7.3311; Siegfried Z, 1997, CURR BIOL, V7, pR305, DOI 10.1016/S0960-9822(06)00144-8; STEINER DF, 1992, J BIOL CHEM, V267, P23435; STEINER DF, 1985, ANNU REV GENET, V19, P463, DOI 10.1146/annurev.ge.19.120185.002335; Stoffers DA, 1997, NAT GENET, V15, P106, DOI 10.1038/ng0197-106; Stoffers DA, 1997, TRENDS ENDOCRIN MET, V8, P145, DOI 10.1016/S1043-2760(97)00008-8; Thorgeirsson SS, 1996, FASEB J, V10, P1249, DOI 10.1096/fasebj.10.11.8836038; vanHolde KE, 1997, J BIOL CHEM, V272, P26073, DOI 10.1074/jbc.272.42.26073; VOLLENWEIDER F, 1992, J BIOL CHEM, V267, P14629; Waeber G, 1996, MOL ENDOCRINOL, V10, P1327, DOI 10.1210/me.10.11.1327; Watada H, 1996, DIABETES, V45, P1478, DOI 10.2337/diabetes.45.11.1478; WEINTRAUB H, 1989, P NATL ACAD SCI USA, V86, P5434, DOI 10.1073/pnas.86.14.5434	25	585	653	1	28	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAY	2000	6	5					568	572		10.1038/75050	http://dx.doi.org/10.1038/75050			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	309YB	10802714				2022-12-25	WOS:000086796200042
J	Schwall, GP; Safford, R; Westcott, RJ; Jeffcoat, R; Tayal, A; Shi, YC; Gidley, MJ; Jobling, SA				Schwall, GP; Safford, R; Westcott, RJ; Jeffcoat, R; Tayal, A; Shi, YC; Gidley, MJ; Jobling, SA			Production of very-high-amylose potato starch by inhibition of SBE A and B	NATURE BIOTECHNOLOGY			English	Article						biotechnology; starch structure; amylopectin; branching enzyme	BRANCHING ENZYME; AMYLOPECTIN; TUBERS; MAIZE	High-amylose starch is in great demand by the starch industry for its unique functional properties. However, very few high-amylose crop varieties are commercially available. In this paper we describe the generation of very-high-amylose potato starch by genetic modification. We achieved this by simultaneously inhibiting two isoforms of starch branching enzyme to below 1% of the wild-type activities. Starch granule morphology and composition were noticeably altered. Normal, high-molecular-weight amylopectin was absent, whereas the amylose content was increased to levels comparable to the highest commercially available maize starches. In addition, the phosphorus content of the starch was increased more than fivefold. This unique starch, with its high amylose, low amylopectin, and high phosphorus levels, offers novel properties for food and industrial applications.	Unilever Res Colworth, Sharnbrook MK44 1LQ, Beds, England; Natl Starch & Chem Co, Bridgewater, NJ 08807 USA	Unilever	Jobling, SA (corresponding author), Unilever Res Colworth, Colworth House, Sharnbrook MK44 1LQ, Beds, England.		Gidley, Mike/AAT-9543-2021; Jobling, Stephen A/B-6056-2009; gidley, mike/A-7266-2011	Jobling, Stephen A/0000-0001-6649-7329; Schwall, Gerhard/0000-0001-5046-1225				BURTON RA, 1995, PLANT J, V7, P3, DOI 10.1046/j.1365-313X.1995.07010003.x; Cheetham NWH, 1997, CARBOHYD POLYM, V33, P251, DOI 10.1016/S0144-8617(97)00033-7; *COMM PLANT GEN NO, 1994, PLANT MOL BIOL REP, V12, pC1; Edwards A, 1999, PLANT J, V17, P251, DOI 10.1046/j.1365-313X.1999.00371.x; Heyer AG, 1999, CURR OPIN BIOTECH, V10, P169, DOI 10.1016/S0958-1669(99)80030-5; Jobling SA, 1999, PLANT J, V18, P163, DOI 10.1046/j.1365-313X.1999.00441.x; Lillford PJ, 1997, STARCH STRUCTURE FUN, P1; Lloyd JR, 1999, BIOCHEM J, V338, P515, DOI 10.1042/0264-6021:3380515; MORRISON WR, 1983, J CEREAL SCI, V1, P9, DOI 10.1016/S0733-5210(83)80004-6; Safford R, 1998, CARBOHYD POLYM, V35, P155, DOI 10.1016/S0144-8617(97)00249-X; Shi YC, 1998, J CEREAL SCI, V27, P289, DOI 10.1006/jcrs.1997.9998; Sidebottom C, 1998, J CEREAL SCI, V27, P279, DOI 10.1006/jcrs.1997.0170; Smith AM, 1999, CURR OPIN PLANT BIOL, V2, P223, DOI 10.1016/S1369-5266(99)80039-9; Tjaden J, 1998, PLANT J, V16, P531, DOI 10.1046/j.1365-313X.1998.00317.x	14	196	257	2	69	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAY	2000	18	5					551	554		10.1038/75427	http://dx.doi.org/10.1038/75427			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	313UK	10802625				2022-12-25	WOS:000087017500031
J	Teitz, T; Wei, T; Valentine, MB; Vanin, EF; Grenet, J; Valentine, VA; Behm, FG; Look, AT; Lahti, JM; Kidd, VJ				Teitz, T; Wei, T; Valentine, MB; Vanin, EF; Grenet, J; Valentine, VA; Behm, FG; Look, AT; Lahti, JM; Kidd, VJ			Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN	NATURE MEDICINE			English	Article							DRUG-INDUCED APOPTOSIS; CELL-DEATH; ISLAND METHYLATION; SIGNALING COMPLEX; FAS; RECEPTOR; GENE; EXPRESSION; ACTIVATION; FAS/APO-1	Caspase 8 is a cysteine protease regulated in both a death-receptor-dependent and -independent manner during apoptosis. Here, we report that the gene for caspase 8 is frequently inactivated in neuroblastoma, a childhood tumor of the peripheral nervous system. The gene is silenced through DNA methylation as well as through gene deletion. Complete inactivation of CASP8 occurred almost exclusively in neuroblastomas with amplification of the oncogene MYCN. Caspase 8-null neuroblastoma cells were resistant to death receptor- and doxorubicin-mediated apoptosis, deficits that were corrected by programmed expression of the enzyme. Thus, caspase 8 acts as a tumor suppressor in neuroblastomas with amplification of MYCN.	St Jude Childrens Res Hosp, Dept Tumor Cell Biol, Memphis, TN 38101 USA; St Jude Childrens Res Hosp, Dept Expt Hematol, Memphis, TN 38101 USA; St Jude Childrens Res Hosp, Dept Expt Oncol, Memphis, TN 38101 USA; St Jude Childrens Res Hosp, Dept Pathol, Memphis, TN 38101 USA	St Jude Children's Research Hospital; St Jude Children's Research Hospital; St Jude Children's Research Hospital; St Jude Children's Research Hospital	Kidd, VJ (corresponding author), St Jude Childrens Res Hosp, Dept Tumor Cell Biol, 332 N Lauderdale, Memphis, TN 38101 USA.	vincent.kidd@stjude.org			NATIONAL CANCER INSTITUTE [R01CA067938, R56CA067938, P30CA021765, P01CA071907] Funding Source: NIH RePORTER; NCI NIH HHS [CA71907, CA 67938, CA 21765] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ASKEW DS, 1991, ONCOGENE, V6, P1915; Baylin SB, 1998, ADV CANCER RES, V72, P141; BELTINGER CP, 1995, CANCER RES, V55, P2053; BRODEUR GM, 1992, CANCER-AM CANCER SOC, V70, P1685, DOI 10.1002/1097-0142(19920915)70:4+<1685::AID-CNCR2820701607>3.0.CO;2-H; CHENG JH, 1994, SCIENCE, V263, P1759, DOI 10.1126/science.7510905; CHENG NC, 1995, ONCOGENE, V10, P291; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Corn PG, 1999, CANCER RES, V59, P3352; Easton J, 1998, CANCER RES, V58, P2624; Eischen CM, 1997, BLOOD, V90, P935, DOI 10.1182/blood.V90.3.935.935_935_943; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Friesen C, 1996, NAT MED, V2, P574, DOI 10.1038/nm0596-574; Fulda S, 1999, ONCOGENE, V18, P1479, DOI 10.1038/sj.onc.1202435; Fulda S, 1997, CANCER RES, V57, P3823; Grenet J, 1999, GENE, V226, P225, DOI 10.1016/S0378-1119(98)00565-4; Grenet J, 1998, GENOMICS, V49, P385, DOI 10.1006/geno.1998.5300; Gururajan R, 1998, GENOME RES, V8, P929, DOI 10.1101/gr.8.9.929; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Hueber AO, 1997, SCIENCE, V278, P1305, DOI 10.1126/science.278.5341.1305; JANICKE RU, 1994, MOL CELL BIOL, V14, P5661; Juin P, 1999, GENE DEV, V13, P1367, DOI 10.1101/gad.13.11.1367; Kitson J, 1996, NATURE, V384, P372, DOI 10.1038/384372a0; KOHNO T, 1994, ONCOGENE, V9, P103; Landowski TH, 1999, BLOOD, V94, P265, DOI 10.1182/blood.V94.1.265.413k37_265_274; Mandruzzato S, 1997, J EXP MED, V186, P785, DOI 10.1084/jem.186.5.785; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; MILLIGAN CE, 1995, NEURON, V15, P385, DOI 10.1016/0896-6273(95)90042-X; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; PARRA I, 1993, NAT GENET, V5, P17, DOI 10.1038/ng0993-17; Persons DA, 1999, BLOOD, V93, P488, DOI 10.1182/blood.V93.2.488.402k17_488_499; Rasper DM, 1998, CELL DEATH DIFFER, V5, P271, DOI 10.1038/sj.cdd.4400370; Rehemtulla A, 1997, J BIOL CHEM, V272, P25783, DOI 10.1074/jbc.272.41.25783; Scaffidi C, 1997, J BIOL CHEM, V272, P26953, DOI 10.1074/jbc.272.43.26953; Soengas MS, 1999, SCIENCE, V284, P156, DOI 10.1126/science.284.5411.156; Tang DM, 2000, J BIOL CHEM, V275, P9303, DOI 10.1074/jbc.275.13.9303; Tang DM, 1999, J BIOL CHEM, V274, P7245, DOI 10.1074/jbc.274.11.7245; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; Whang YE, 1998, P NATL ACAD SCI USA, V95, P5246, DOI 10.1073/pnas.95.9.5246; WHITE PS, 1995, P NATL ACAD SCI USA, V92, P5520, DOI 10.1073/pnas.92.12.5520; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954; ZORNIG M, 1995, ONCOGENE, V10, P2397	43	642	658	4	22	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2000	6	5					529	535		10.1038/75007	http://dx.doi.org/10.1038/75007			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	309YB	10802708				2022-12-25	WOS:000086796200036
J	Clausen, M; Krauter, R; Schachermayr, G; Potrykus, I; Sautter, C				Clausen, M; Krauter, R; Schachermayr, G; Potrykus, I; Sautter, C			Antifungal activity of a virally encoded gene in transgenic wheat	NATURE BIOTECHNOLOGY			English	Article						triticum aestivum L.; antifungal activity; Tilletia tritici; transformation; KP4	USTILAGO-MAYDIS; KILLER PROTEINS; TOBACCO PLANTS; EXPRESSION; TOXIN; SELECTION; SECRETION; SYSTEM	The cDNA encoding the antifungal protein KP4 from Ustilago maydis-infecting virus was inserted behind the ubiquitin promoter of maize and genetically transferred to wheat varieties particularly susceptible to stinking smut (Tilletia tritici) disease. The transgene was integrated and inherited over several generations. Of seven transgenic lines, three showed antifungal activity against U. maydis. The antifungal activity correlated with the presence of the KP4 transgene. KP4-transgenic, soil-grown wheat plants exhibit increased endogenous resistance against stinking smut.	Swiss Fed Inst Technol, CH-8092 Zurich, Switzerland; Fed Res Stn Agraecol & Agr, CH-8046 Zurich, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich	Sautter, C (corresponding author), Swiss Fed Inst Technol, Univ Str 2, CH-8092 Zurich, Switzerland.	christof.sautter@ipw.biol.ethz.ch						Altpeter F, 1996, NAT BIOTECHNOL, V14, P1155, DOI 10.1038/nbt0996-1155; Barro F, 1997, NAT BIOTECHNOL, V15, P1295, DOI 10.1038/nbt1197-1295; BEVAN EA, 1973, NATURE, V245, P81, DOI 10.1038/245081b0; Blechl AE, 1996, NAT BIOTECHNOL, V14, P875, DOI 10.1038/nbt0796-875; Bliffeld M, 1999, THEOR APPL GENET, V98, P1079, DOI 10.1007/s001220051170; Chen WP, 1999, THEOR APPL GENET, V99, P755, DOI 10.1007/s001220051294; CHRISTENSEN AH, 1992, PLANT MOL BIOL, V18, P675, DOI 10.1007/BF00020010; CHRISTOU P, 1995, TRANSGENIC RES, V4, P44, DOI 10.1007/BF01976501; DAY PR, 1973, PHYTOPATHOLOGY, V63, P1017, DOI 10.1094/Phyto-63-1017; DeBlock M, 1997, THEOR APPL GENET, V95, P125, DOI 10.1007/s001220050540; DEBLOCK M, 1987, EMBO J, V6, P2513, DOI 10.1002/j.1460-2075.1987.tb02537.x; FINER JJ, 1992, PLANT CELL REP, V11, P323, DOI 10.1007/BF00233358; Futterer J., 1995, P215; GRANER A, 1990, THEOR APPL GENET, V80, P826, DOI 10.1007/BF00224200; HANKIN L, 1971, PHYTOPATHOLOGY, V61, P50, DOI 10.1094/Phyto-61-50; KANDEL J, 1978, EXP MYCOL, V2, P270, DOI 10.1016/S0147-5975(78)80020-6; KINAL H, 1995, PLANT CELL, V7, P677, DOI 10.1105/tpc.7.6.677; KOLTIN Y, 1975, APPL MICROBIOL, V30, P694, DOI 10.1128/AEM.30.4.694-696.1975; KOLTIN Y, 1988, MYCOLOGY SERIES, V7, P209; KRAMER C, 1993, PLANTA, V190, P454, DOI 10.1007/BF00224783; LEMKE PA, 1974, BACTERIOL REV, V38, P29, DOI 10.1128/MMBR.38.1.29-56.1974; Oerke EC., 1994, CROP PRODUCTION CROP; Park CM, 1996, PLANT MOL BIOL, V30, P359, DOI 10.1007/BF00020122; SHEW DH, 1991, COMPENDIUM TOBACCO D; TAKIMOTO I, 1994, PLANT MOL BIOL, V26, P1007, DOI 10.1007/BF00028868; TAO JS, 1990, MOL CELL BIOL, V10, P1373, DOI 10.1128/MCB.10.4.1373; UTZ HF, 1995, PLABSTAT COMPUTERPRO; WEEKS JT, 1993, PLANT PHYSIOL, V102, P1077, DOI 10.1104/pp.102.4.1077; Winter W., 1995, Agrarforschung, V2, P325; [No title captured]	31	63	74	1	9	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	APR	2000	18	4					446	449		10.1038/74521	http://dx.doi.org/10.1038/74521			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	303UY	10748529				2022-12-25	WOS:000086444300031
J	Rhee, Y; Gurel, F; Gafni, Y; Dingwall, C; Citovsky, V				Rhee, Y; Gurel, F; Gafni, Y; Dingwall, C; Citovsky, V			A genetic system for detection of protein nuclear import and export	NATURE BIOTECHNOLOGY			English	Article						Agrobacterium; geminivirus; TYLCV; VirD2/VirE2; nucleotoplasmic shuttle protein	RNA-BINDING PROTEIN; LEAF CURL VIRUS; LOCALIZATION SIGNAL; AGROBACTERIUM-TUMEFACIENS; VIRD2 PROTEIN; SEQUENCE; TRANSPORT; DNA; IDENTIFICATION; TOBACCO	We have developed a simple genetic assay to detect active nuclear localization (NLS) and export signals (NES) on the basis of their function within yeast cells. The bacterial LexA protein was modified (mLexA) to abolish its intrinsic NLS and fused to the activation domain of the yeast Gal4p (Gal4AD) with or without the SV40 large T-antigen NLS. In the import assay, if a tested protein fused to mLexA-Gal4AD contains a functional NLS, it will enter the cell nucleus and activate the reporter gene expression. In the export assay, if a tested protein fused to mLexA-SV40 NLS-Gal4AD contains a functional NES, it will exit into the cytoplasm, decreasing the reporter gene expression. We tested this system with known NLS and NES and then used it to demonstrate a NES activity of the capsid protein of a plant geminivirus. This approach may help to identify, analyze, and select for proteins containing functional NLS and NES.	SUNY Stony Brook, Inst Cell & Dev Biol, Dept Biochem & Cell Biol, Stony Brook, NY 11794 USA; Agr Res Org, Dept Genet, IL-50250 Bet Dagan, Israel; SUNY Stony Brook, Dept Pharmacol, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; VOLCANI INSTITUTE OF AGRICULTURAL RESEARCH; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Citovsky, V (corresponding author), SUNY Stony Brook, Inst Cell & Dev Biol, Dept Biochem & Cell Biol, Stony Brook, NY 11794 USA.			Citovsky, Vitaly/0000-0003-2024-6844				Ballas N, 1997, P NATL ACAD SCI USA, V94, P10723, DOI 10.1073/pnas.94.20.10723; Bogerd HP, 1996, MOL CELL BIOL, V16, P4207; CITOVSKY V, 1994, P NATL ACAD SCI USA, V91, P3210, DOI 10.1073/pnas.91.8.3210; CITOVSKY V, 1988, SCIENCE, V240, P501, DOI 10.1126/science.240.4851.501; CITOVSKY V, 1992, SCIENCE, V256, P1803; CULLEN BR, 1988, J VIROL, V62, P2498, DOI 10.1128/JVI.62.7.2498-2501.1988; DAVIES JW, 1989, TRENDS GENET, V5, P77, DOI 10.1016/0168-9525(89)90030-9; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; DINGWALL C, 1991, BIOESSAYS, V13, P213, DOI 10.1002/bies.950130503; Dobbelstein M, 1997, EMBO J, V16, P4276, DOI 10.1093/emboj/16.14.4276; FISCHER U, 1994, EMBO J, V13, P4105, DOI 10.1002/j.1460-2075.1994.tb06728.x; GARCIABUSTOS J, 1991, BIOCHIM BIOPHYS ACTA, V1071, P83, DOI 10.1016/0304-4157(91)90013-M; Ghoshroy Soumitra, 1997, Annu Rev Plant Physiol Plant Mol Biol, V48, P27, DOI 10.1146/annurev.arplant.48.1.27; GOELET P, 1982, P NATL ACAD SCI-BIOL, V79, P5818, DOI 10.1073/pnas.79.19.5818; GOLDFARB DS, 1986, NATURE, V322, P641, DOI 10.1038/322641a0; Guralnick B, 1996, PLANT CELL, V8, P363, DOI 10.1105/tpc.8.3.363; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; HOWARD EA, 1992, CELL, V68, P109, DOI 10.1016/0092-8674(92)90210-4; JEFFERSON RA, 1986, P NATL ACAD SCI USA, V83, P8447, DOI 10.1073/pnas.83.22.8447; Kaiser C., 1994, METHODS YEAST GENETI; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; Kunik T, 1998, PLANT J, V13, P393, DOI 10.1046/j.1365-313X.1998.00037.x; Lazarowitz SG, 1999, PLANT CELL, V11, P535, DOI 10.1105/tpc.11.4.535; MALIM MH, 1989, CELL, V58, P205, DOI 10.1016/0092-8674(89)90416-9; MICHAEL WM, 1995, CELL, V83, P415; NAVOT N, 1991, VIROLOGY, V185, P151, DOI 10.1016/0042-6822(91)90763-2; NEWMEYER DD, 1988, CELL, V52, P641, DOI 10.1016/0092-8674(88)90402-3; Nigg EA, 1997, NATURE, V386, P779, DOI 10.1038/386779a0; OssarehNazari B, 1997, SCIENCE, V278, P141, DOI 10.1126/science.278.5335.141; Pollard VW, 1998, ANNU REV MICROBIOL, V52, P491, DOI 10.1146/annurev.micro.52.1.491; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; ROBERTS BL, 1987, CELL, V50, P465, DOI 10.1016/0092-8674(87)90500-9; Rosenblum JS, 1998, J CELL BIOL, V143, P887, DOI 10.1083/jcb.143.4.887; SCHLENSTEDT G, 1993, J CELL BIOL, V123, P785, DOI 10.1083/jcb.123.4.785; SILVER PA, 1988, GENE DEV, V2, P707, DOI 10.1101/gad.2.6.707; STACHEL SE, 1985, EMBO J, V4, P891, DOI 10.1002/j.1460-2075.1985.tb03715.x; STASWICK P, 1988, PLANT PHYSIOL, V89, P717; STASWICK PE, 1988, PLANT PHYSIOL, V87, P250, DOI 10.1104/pp.87.1.250; STASWICK PE, 1990, PLANT CELL, V2, P1, DOI 10.1105/tpc.2.1.1; Taagepera S, 1998, P NATL ACAD SCI USA, V95, P7457, DOI 10.1073/pnas.95.13.7457; Truant R, 1998, MOL CELL BIOL, V18, P1449, DOI 10.1128/MCB.18.3.1449; Ueki N, 1998, NAT BIOTECHNOL, V16, P1338, DOI 10.1038/4315; Ullman KS, 1997, CELL, V90, P967, DOI 10.1016/S0092-8674(00)80361-X; VARAGONA MJ, 1991, PLANT CELL, V3, P105, DOI 10.1105/tpc.3.2.105; Vidal M, 1996, P NATL ACAD SCI USA, V93, P10315, DOI 10.1073/pnas.93.19.10315; WINANS SC, 1994, RES MICROBIOL, V145, P461, DOI 10.1016/0923-2508(94)90095-7; WINANS SC, 1986, P NATL ACAD SCI USA, V83, P8278, DOI 10.1073/pnas.83.21.8278; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	48	88	97	0	14	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	APR	2000	18	4					433	437		10.1038/74500	http://dx.doi.org/10.1038/74500			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	303UY	10748526				2022-12-25	WOS:000086444300028
J	Saxton, TM; Ciruna, BG; Holmyard, D; Kulkarni, S; Harpal, K; Rossant, J; Pawson, T				Saxton, TM; Ciruna, BG; Holmyard, D; Kulkarni, S; Harpal, K; Rossant, J; Pawson, T			The SH2 tyrosine phosphatase Shp2 is required for mammalian limb development	NATURE GENETICS			English	Article							VERTEBRATE LIMB; CELL-ADHESION; MOUSE EMBRYOS; INDUCTION; BUD; EXPRESSION; CHIMERAS; MUTANT; BINDS; FGF8	The tyrosine phosphatase Shp2 is recruited into tyrosine-kinase signalling pathways through binding of its two amino-terminal SH2 domains to specific phosphotyrosine motifs, concurrent with its re-localization and stimulation of phosphatase activity(1) Shp2 can potentiate signalling through the MAP-kinase pathway(2-6) and is required during early mouse development for gastrulation(4,7). Chimaeric analysis can identify, by study of phenotypically normal embryos, tissues that tolerate mutant cells land therefore do not require the mutated gene) or lack mutant cells land presumably require the mutated gene during their developmental history(8)). We therefore generated chimaeric mouse embryos to explore the cellular requirements for Shp2. This analysis revealed an obligatory role for Shp2 during outgrowth of the limb. Shp2 is specifically required in mesenchyme cells of the progress zone (PZ), directly beneath the distal ectoderm of the limb bud. Comparison of Ptpn11 (encoding Shp2)-mutant and Fgfr1 (encoding fibroblast growth factor receptor-1)-mutant chimaeric limbs indicated that in both cases mutant cells fail to contribute to the PZ of phenotypically normal chimaeras, leading to the hypothesis that a signal transduction pathway, initiated by Fgfr1 and acting through Shp2, is essential within PZ cells. Rather than integrating proliferative signals, Shp2 probably exerts it effects on limb development by influencing cell shape, movement or adhesion. Furthermore, the branchial arches, which also use Fgfs during bud outgrowth, similarly require Shp2. Thus, Shp2 regulates phosphotyrosine-signalling events during the complex ectodermal-mesenchymal interactions that regulate mammalian budding morphogenesis.	Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Programme Mol Biol & Canc, Toronto, ON M5G 1X5, Canada; Univ Toronto, Dept Mol & Med Genet, Toronto, ON, Canada; Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Programme Dev & Fetal Hlth, Toronto, ON M5G 1X5, Canada	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute	Pawson, T (corresponding author), Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Programme Mol Biol & Canc, 600 Univ Ave, Toronto, ON M5G 1X5, Canada.		Pawson, Tony J/E-4578-2013					Bennett AM, 1996, MOL CELL BIOL, V16, P1189; BOWEN J, 1989, ANAT EMBRYOL, V179, P269, DOI 10.1007/BF00326592; Ciruna BG, 1997, DEVELOPMENT, V124, P2829; CONLON RA, 1992, DEVELOPMENT, V116, P357; CROSSLEY PH, 1995, DEVELOPMENT, V121, P439; Deng CX, 1997, DEV BIOL, V185, P42, DOI 10.1006/dbio.1997.8553; EDE DA, 1969, NATURE, V221, P244, DOI 10.1038/221244a0; Fujioka Y, 1996, MOL CELL BIOL, V16, P6887; Gardner RL, 1998, DEVELOPMENT, V125, P2397; Gertler FB, 1996, CELL, V87, P227, DOI 10.1016/S0092-8674(00)81341-0; Hof P, 1998, CELL, V92, P441, DOI 10.1016/S0092-8674(00)80938-1; Hogan BLM, 1999, CELL, V96, P225, DOI 10.1016/S0092-8674(00)80562-0; Jackson DE, 1997, J BIOL CHEM, V272, P6986, DOI 10.1074/jbc.272.11.6986; Johnson RL, 1997, CELL, V90, P979, DOI 10.1016/S0092-8674(00)80364-5; KIMURA Y, 1995, DEV BIOL, V169, P347, DOI 10.1006/dbio.1995.1149; Li SG, 1999, DEV BIOL, V211, P335, DOI 10.1006/dbio.1999.9317; Manes S, 1999, MOL CELL BIOL, V19, P3125; Martin GR, 1998, GENE DEV, V12, P1571, DOI 10.1101/gad.12.11.1571; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; O'Reilly AM, 1998, MOL CELL BIOL, V18, P161, DOI 10.1128/MCB.18.1.161; Oh ES, 1999, MOL CELL BIOL, V19, P3205; RIDDLE RD, 1995, CELL, V83, P631, DOI 10.1016/0092-8674(95)90103-5; Rossant J, 1998, TRENDS GENET, V14, P358, DOI 10.1016/S0168-9525(98)01552-2; Saxton TM, 1999, P NATL ACAD SCI USA, V96, P3790, DOI 10.1073/pnas.96.7.3790; Saxton TM, 1997, EMBO J, V16, P2352, DOI 10.1093/emboj/16.9.2352; TANG TL, 1995, CELL, V80, P473, DOI 10.1016/0092-8674(95)90498-0; VOGEL A, 1995, DEV BIOL, V171, P507, DOI 10.1006/dbio.1995.1300; WOOD SA, 1993, NATURE, V365, P87, DOI 10.1038/365025a0; Xu XL, 1998, DEVELOPMENT, V125, P753; Yu DH, 1998, J BIOL CHEM, V273, P21125, DOI 10.1074/jbc.273.33.21125	30	96	99	0	3	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	APR	2000	24	4					420	423		10.1038/74279	http://dx.doi.org/10.1038/74279			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	299HK	10742110				2022-12-25	WOS:000086192800025
J	Wang, E; Miller, LD; Ohnmacht, GA; Liu, ET; Marincola, FM				Wang, E; Miller, LD; Ohnmacht, GA; Liu, ET; Marincola, FM			High-fidelity mRNA amplification for gene profiling	NATURE BIOTECHNOLOGY			English	Article							EXPRESSION PATTERNS; CDNA MICROARRAY; ARRAYS		NCI, Surg Branch, Div Clin Sci, NIH, Bethesda, MD 20892 USA; NIH, Ctr Clin, Dept Transfus Med, Bethesda, MD 20892 USA; NCI, Med Branch, Div Clin Sci, NIH, Gaithersburg, MD USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH Clinical Center (CC); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Marincola, FM (corresponding author), NCI, Surg Branch, Div Clin Sci, NIH, Bethesda, MD 20892 USA.		Liu, Edison/C-4141-2008; Miller, Lance/A-5633-2009	Miller, Lance/0000-0003-3799-2528				Brown PO, 1999, NAT GENET, V21, P33, DOI 10.1038/4462; Chen JJW, 1998, GENOMICS, V51, P313, DOI 10.1006/geno.1998.5354; Collins FS, 1998, SCIENCE, V282, P682, DOI 10.1126/science.282.5389.682; DeRisi J, 1996, NAT GENET, V14, P457; Duggan DJ, 1999, NAT GENET, V21, P10, DOI 10.1038/4434; EBERWINE J, 1992, P NATL ACAD SCI USA, V89, P3010, DOI 10.1073/pnas.89.7.3010; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Kacharmina JE, 1999, METHOD ENZYMOL, V303, P3; Lander ES, 1996, SCIENCE, V274, P536, DOI 10.1126/science.274.5287.536; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; Luo L, 1999, NAT MED, V5, P117, DOI 10.1038/4806; Mahadevappa M, 1999, NAT BIOTECHNOL, V17, P1134, DOI 10.1038/15124; Matz M, 1999, NUCLEIC ACIDS RES, V27, P1558, DOI 10.1093/nar/27.6.1558; Perou CM, 1999, P NATL ACAD SCI USA, V96, P9212, DOI 10.1073/pnas.96.16.9212; Phillips Jennifer, 1996, Methods (Orlando), V10, P283, DOI 10.1006/meth.1996.0104; Rajeevan MS, 1999, J HISTOCHEM CYTOCHEM, V47, P337, DOI 10.1177/002215549904700307; Schena M, 1996, P NATL ACAD SCI USA, V93, P10614, DOI 10.1073/pnas.93.20.10614; Trenkle T, 1998, NUCLEIC ACIDS RES, V26, P3883, DOI 10.1093/nar/26.17.3883; VANGELDER RN, 1990, P NATL ACAD SCI USA, V87, P1663, DOI 10.1073/pnas.87.5.1663; Zejie Yin, 1998, Medical Engineering and Physics, V20, P149, DOI 10.1016/S1350-4533(97)00044-1	20	552	622	0	8	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	APR	2000	18	4					457	459		10.1038/74546	http://dx.doi.org/10.1038/74546			3	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	303UY	10748532				2022-12-25	WOS:000086444300034
J	Reddien, PW; Horvitz, HR				Reddien, PW; Horvitz, HR			CED-2/Crkll and CED-10/Rac control phagocytosis and cell migration in Caenorhabditis elegans	NATURE CELL BIOLOGY			English	Article							C-ELEGANS; APOPTOTIC CELLS; MYOBLAST CITY; MESSENGER-RNA; RHO-GTPASES; PROTEIN; GENE; DOCK180; ENGULFMENT; SEQUENCE	Engulfment of apoptotic cells in Caenorhabditis elegans is controlled by two partially redundant pathways. Mutations in genes in one of these pathways, defined by the genes ced-2, ced-5 and ced-10, result in defects both in the engulfment of dying cells and in the migrations of the two distal tip cells of the developing gonad. Here we find that ced-2 and ced-10 encode proteins similar to the human adaptor protein Crkll and the human GTPase Rac, respectively. Together with the previous observation that ced-5 encodes a protein similar to human DOCK180, our findings define a signalling pathway that controls phagocytosis and cell migration. We provide evidence that CED-2 and CED-10 function in engulfing rather than dying cells to control the phagocytosis of cell corpses, that CED-2 and CED-5 physically interact, and that ced-10 probably functions downstream of ced-2 and ced-5. We propose that CED-2/Crkll and CED-5/DOCK180 function to activate CED-10/Rac in a GTPase signalling pathway that controls the polarized extension of cell surfaces.	MIT, Howard Hughes Med Inst, Dept Biol, Cambridge, MA 02139 USA	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT)	Horvitz, HR (corresponding author), MIT, Howard Hughes Med Inst, Dept Biol, 68-425,77 Massachusetts Ave, Cambridge, MA 02139 USA.	horvitz@mit.edu						Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; ALFONSO A, 1993, SCIENCE, V261, P617, DOI 10.1126/science.8342028; Bloom L, 1997, P NATL ACAD SCI USA, V94, P3414, DOI 10.1073/pnas.94.7.3414; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; Caron E, 1998, SCIENCE, V282, P1717, DOI 10.1126/science.282.5394.1717; CHEN WI, 1993, J BIOL CHEM, V268, P320; ELLIS RE, 1991, GENETICS, V129, P79; Erickson MRS, 1997, J CELL BIOL, V138, P589, DOI 10.1083/jcb.138.3.589; Fadok VA, 1998, CURR BIOL, V8, pR693, DOI 10.1016/S0960-9822(98)70438-5; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Gumienny TL, 1999, DEVELOPMENT, V126, P1011; Hasegawa H, 1996, MOL CELL BIOL, V16, P1770; HEDGECOCK EM, 1983, SCIENCE, V220, P1277, DOI 10.1126/science.6857247; Imaizumi T, 1999, BIOCHEM BIOPH RES CO, V266, P569, DOI 10.1006/bbrc.1999.1869; KIMBLE J, 1979, DEV BIOL, V70, P396, DOI 10.1016/0012-1606(79)90035-6; Kiyokawa E, 1998, J BIOL CHEM, V273, P24479, DOI 10.1074/jbc.273.38.24479; Kiyokawa E, 1998, GENE DEV, V12, P3331, DOI 10.1101/gad.12.21.3331; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; KRAUSE M, 1987, CELL, V49, P753, DOI 10.1016/0092-8674(87)90613-1; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Li LM, 1996, CELL, V85, P319, DOI 10.1016/S0092-8674(00)81111-3; LI W, 1992, GENETICS, V132, P675; Liu QA, 1998, CELL, V93, P961, DOI 10.1016/S0092-8674(00)81202-7; Massol P, 1998, EMBO J, V17, P6219, DOI 10.1093/emboj/17.21.6219; MATSUDA M, 1992, MOL CELL BIOL, V12, P3482, DOI 10.1128/MCB.12.8.3482; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MELKO CC, 1991, EMBO J, V10, P3959; Metzstein MM, 1998, TRENDS GENET, V14, P410, DOI 10.1016/S0168-9525(98)01573-X; Nolan KM, 1998, GENE DEV, V12, P3337, DOI 10.1101/gad.12.21.3337; Platt N, 1998, TRENDS CELL BIOL, V8, P365, DOI 10.1016/S0962-8924(98)01329-4; REISS Y, 1991, P NATL ACAD SCI USA, V88, P732, DOI 10.1073/pnas.88.3.732; SPIETH J, 1993, CELL, V73, P521, DOI 10.1016/0092-8674(93)90139-H; Sugihara K, 1998, ONCOGENE, V17, P3427, DOI 10.1038/sj.onc.1202595; TENHOEVE J, 1993, ONCOGENE, V8, P2469; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295; Wu YC, 1998, NATURE, V392, P501, DOI 10.1038/33163; Wu YC, 1998, CELL, V93, P951, DOI 10.1016/S0092-8674(00)81201-5; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325	39	327	338	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	MAR	2000	2	3					131	136		10.1038/35004000	http://dx.doi.org/10.1038/35004000			6	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	292AE	10707082				2022-12-25	WOS:000085771300011
J	Montero, M; Alonso, MT; Carnicero, E; Cuchillo-Ibanez, I; Albillos, A; Garcia, AG; Garcia-Sancho, J; Alvarez, J				Montero, M; Alonso, MT; Carnicero, E; Cuchillo-Ibanez, I; Albillos, A; Garcia, AG; Garcia-Sancho, J; Alvarez, J			Chromaffin-cell stimulation triggers fast millimolar mitochondrial Ca2+ transients that modulate secretion	NATURE CELL BIOLOGY			English	Article							INTACT HELA-CELLS; ENDOPLASMIC-RETICULUM; MICRODOMAINS; HOMEOSTASIS; CLEARANCE; RELEASE; RESPONSES	Activation of calcium-ion (Ca2+) channels on the plasma membrane and on intracellular Ca2+ stores, such as the endoplasmic reticulum, generates local transient increases in the cytosolic Ca2+ concentration that induce Ca2+ uptake by neighbouring mitochondria. Here, by using mitochondrially targeted aequorin proteins with different Ca2+ affinities, we show that half of the chromaffin-cell mitochondria exhibit surprisingly rapid millimolar Ca2+ transients upon stimulation of cells with acetylcholine, caffeine or high concentrations of potassium ions. Our results show a tight functional coupling of voltage-dependent Ca2+ channels on the plasma membrane, ryanodine receptors on the endoplasmic reticulum, and mitochondria. Cell stimulation generates localized Ca2+ transients, with Ca2+ concentrations above 20-40 mu M, at these functional units. Protonophores abolish mitochondrial Ca2+ uptake and increase stimulated secretion of catecholamines by three- to fivefold. These results indicate that mitochondria modulate secretion by controlling the availability of Ca2+ for exocytosis.	Univ Valladolid, Inst Biol & Genet Mol, E-47005 Valladolid, Spain; Fac Med, CSIC, Dept Bioquim & Biol Mol & Fisiol, E-47005 Valladolid, Spain; Univ Autonoma Madrid, Fac Med, Inst Farmacol Teofilo Hernando, Dept Farmacol & Terapeut, E-28029 Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-UVA - Instituto de Biologia y Genetica Molecular (IBGM); Universidad de Valladolid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-UVA - Instituto de Biologia y Genetica Molecular (IBGM); Autonomous University of Madrid	Alvarez, J (corresponding author), Univ Valladolid, Inst Biol & Genet Mol, Ramon & Cajal 7, E-47005 Valladolid, Spain.		cuchillo, inmaculada/P-2975-2019; GARCIA, ANTONIO G/E-9961-2018; Montero, Mayte/K-8212-2014; Carnicero, Estela/D-3760-2013; Alonso Alonso, Maria Teresa/K-5003-2014; Carnicero, Estela/AAY-1518-2020; Alvarez, Javier/K-8210-2014; Albillos, Almudena/AAA-9098-2019; Garcia-Sancho, Javier/K-2975-2014	GARCIA, ANTONIO G/0000-0002-6517-3565; Montero, Mayte/0000-0001-7702-6653; Carnicero, Estela/0000-0002-9236-5503; Alvarez, Javier/0000-0003-0636-5521; Garcia-Sancho, Javier/0000-0003-4573-7930; ALBILLOS, ALMUDENA/0000-0003-3315-9715; /0000-0002-3689-5518				Alonso MT, 1998, CELL CALCIUM, V24, P87, DOI 10.1016/S0143-4160(98)90076-8; Alonso MT, 1999, J CELL BIOL, V144, P241, DOI 10.1083/jcb.144.2.241; Babcock DF, 1997, J CELL BIOL, V136, P833, DOI 10.1083/jcb.136.4.833; Barrero MJ, 1997, J BIOL CHEM, V272, P27694, DOI 10.1074/jbc.272.44.27694; BORGES R, 1986, J NEUROSCI METH, V16, P389; Brini M, 1997, MOL BIOL CELL, V8, P129, DOI 10.1091/mbc.8.1.129; Csordas G, 1999, EMBO J, V18, P96, DOI 10.1093/emboj/18.1.96; Di Lisa F, 1998, MOL CELL BIOCHEM, V184, P379, DOI 10.1023/A:1006810523586; Duchen MR, 1999, J PHYSIOL-LONDON, V516, P1, DOI 10.1111/j.1469-7793.1999.001aa.x; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Herrington J, 1996, NEURON, V16, P219, DOI 10.1016/S0896-6273(00)80038-0; Montero M, 1997, FASEB J, V11, P881, DOI 10.1096/fasebj.11.11.9285486; Montero M, 1997, J CELL BIOL, V139, P601, DOI 10.1083/jcb.139.3.601; MONTERO M, 1995, EMBO J, V14, P5467, DOI 10.1002/j.1460-2075.1995.tb00233.x; Neher E, 1998, NEURON, V20, P389, DOI 10.1016/S0896-6273(00)80983-6; Park YB, 1996, J PHYSIOL-LONDON, V492, P329, DOI 10.1113/jphysiol.1996.sp021312; Rizzuto R, 1998, SCIENCE, V280, P1763, DOI 10.1126/science.280.5370.1763; RIZZUTO R, 1994, J CELL BIOL, V126, P1183, DOI 10.1083/jcb.126.5.1183; RIZZUTO R, 1993, SCIENCE, V262, P744, DOI 10.1126/science.8235595; Robb-Gaspers LD, 1998, EMBO J, V17, P4987, DOI 10.1093/emboj/17.17.4987; Schinder AF, 1996, J NEUROSCI, V16, P6125; UCEDA G, 1995, EUR J PHARM-MOLEC PH, V289, P73, DOI 10.1016/0922-4106(95)90170-1; VONRUDEN L, 1993, SCIENCE, V262, P1061, DOI 10.1126/science.8235626; WERTH JL, 1994, J NEUROSCI, V14, P346; White RJ, 1997, J PHYSIOL-LONDON, V498, P31, DOI 10.1113/jphysiol.1997.sp021839; Xu T, 1997, BIOPHYS J, V73, P532, DOI 10.1016/S0006-3495(97)78091-3	26	385	393	0	25	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	FEB	2000	2	2					57	61		10.1038/35000001	http://dx.doi.org/10.1038/35000001			5	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	281GA	10655583	Green Published			2022-12-25	WOS:000085148500008
J	Cropp, TA; Wilson, DJ; Reynolds, KA				Cropp, TA; Wilson, DJ; Reynolds, KA			Identification of a cyclohexylcarbonyl CoA biosynthetic gene cluster and application in the production of doramectin	NATURE BIOTECHNOLOGY			English	Article						polyketide; avermectin; Streptomyces; biosynthesis	COENZYME-A REDUCTASE; POLYKETIDE SYNTHASE; STREPTOMYCES-HYGROSCOPICUS; MUTATIONAL BIOSYNTHESIS; AVERMITILIS; AVERMECTINS; EXPRESSION; COLLINUS; CLONING; STRAIN	The side chain of the antifungal antibiotic ansatrienin A from Streptomyces collinus contains a cyclohexanecarboxylic acid (CHC)-derived moiety. This moiety is also observed in trace amounts of omega-cyclohexyl fatty acids (typically less than 1% of total fatty acids) produced by S. collinus. Coenzyme A-activated CHC (CHC-CoA) is derived from shikimic acid through a reductive pathway involving a minimum of nine catalytic steps. Five putative CHC-CoA biosynthetic genes in the ansatrienin biosynthetic gene cluster of S. collinus have been identified. Plasmid-based heterologous expression of these five genes in Streptomyces avermitilis or Streptomyces lividans allows for production of significant amounts of omega-cyclohexyl fatty acids (as high as 49% of total fatty acids). In the absence of the plasmid these organisms are dependent on exogenously supplied CHC for omega-cyclohexyl fatty acid production. Doramectin is a commercial antiparasitic avermectin analog produced by fermenting a bkd mutant of S. avermitilis in the presence of CHC. introduction of the S. collinus CHC-CoA biosynthetic gene cassette into this organism resulted in an engineered strain able to produce doramectin without CHC supplementation. The CHC-CoA biosynthetic gene cluster represents an important genetic tool for precursor-directed biosynthesis of doramectin and has potential for directed biosynthesis in other important polyketide-producing organisms.	Virginia Commonwealth Univ, Dept Med Chem, Richmond, VA 23219 USA; Virginia Commonwealth Univ, Inst Struct Biol & Drug Discovery, Richmond, VA 23219 USA	Virginia Commonwealth University; Virginia Commonwealth University	Reynolds, KA (corresponding author), Virginia Commonwealth Univ, Dept Med Chem, 800 E Leigh St,Suite 212, Richmond, VA 23219 USA.	kareynol@hsc.vcu.edu						Aparicio JF, 1996, GENE, V169, P9, DOI 10.1016/0378-1119(95)00800-4; Chen S, 1999, EUR J BIOCHEM, V261, P98, DOI 10.1046/j.1432-1327.1999.00244.x; Cropp TA, 2000, CAN J MICROBIOL, V46, P506, DOI 10.1139/cjm-46-6-506; DENOYA CD, 1995, J BACTERIOL, V177, P3504, DOI 10.1128/jb.177.12.3504-3511.1995; DUTTON CJ, 1991, J ANTIBIOT, V44, P357, DOI 10.7164/antibiotics.44.357; He XY, 1997, EUR J BIOCHEM, V248, P516, DOI 10.1111/j.1432-1033.1997.00516.x; Hopwood D. A., 1985, GENETIC MANIPULATION; Jacobsen JR, 1997, SCIENCE, V277, P367, DOI 10.1126/science.277.5324.367; Katz L, 1997, CHEM REV, V97, P2557, DOI 10.1021/cr960025+; Khaw LE, 1998, J BACTERIOL, V180, P809, DOI 10.1128/JB.180.4.809-814.1998; MACNEIL DJ, 1987, J IND MICROBIOL, V2, P209, DOI 10.1007/BF01569542; Marsden AFA, 1998, SCIENCE, V279, P199, DOI 10.1126/science.279.5348.199; McArthur HAI, 1998, DEV IND MICROBIOL, V35, P43; McDaniel R, 1999, P NATL ACAD SCI USA, V96, P1846, DOI 10.1073/pnas.96.5.1846; Moore B. S., 1993, J AM CHEM SOC, V115, P1577; MOORE BS, 1993, J AM CHEM SOC, V115, P5267, DOI 10.1021/ja00065a043; Patton SM, 2000, BIOCHEMISTRY-US, V39, P7595, DOI 10.1021/bi0005714; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHMITTJOHN T, 1992, APPL MICROBIOL BIOT, V36, P493; Stassi DL, 1998, P NATL ACAD SCI USA, V95, P7305, DOI 10.1073/pnas.95.13.7305; WALLACE KK, 1995, FEMS MICROBIOL LETT, V131, P227, DOI 10.1016/0378-1097(95)00263-5; Wang P, 1996, J BACTERIOL, V178, P6873, DOI 10.1128/jb.178.23.6873-6881.1996; Zhao L, 1998, J AM CHEM SOC, V120, P9374, DOI 10.1021/ja981500j	23	74	97	0	22	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	SEP	2000	18	9					980	983		10.1038/79479	http://dx.doi.org/10.1038/79479			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	350AN	10973220				2022-12-25	WOS:000089078300028
J	Lin, D; Edwards, AS; Fawcett, JP; Mbamalu, G; Scott, JD; Pawson, T				Lin, D; Edwards, AS; Fawcett, JP; Mbamalu, G; Scott, JD; Pawson, T			A mammalian PAR-3-PAR-6 complex implicated in Cdc42/Rac1 and aPKC signalling and cell polarity	NATURE CELL BIOLOGY			English	Article							C-ELEGANS EMBRYOS; CENTRAL-NERVOUS-SYSTEM; PROTEIN-KINASE-C; CAENORHABDITIS-ELEGANS; DROSOPHILA-MELANOGASTER; SPINDLE ORIENTATION; NEURONAL POLARITY; TIGHT JUNCTIONS; BINDING MOTIF; DOMAIN	Cellular asymmetry is critical for the development of multicellular organisms. Here we show that homologues of proteins necessary for asymmetric cell division in Caenorhabditis elegans associate with each other in mammalian cells and tissues, mPAR-3 and mPAR-6 exhibit similar expression patterns and subcellular distributions in the CNS and associate through their PDZ (PSD-95/Dlg/ZO-1) domains. mPAR-6 binds to Cdc42/Rac1 GTPases, and mPAR-3 and mPAR-6 bind independently to atypical protein kinase C (aPKC) isoforms. In vitro, mPAR-3 acts as a substrate and an inhibitor of aPKC. We conclude that mPAR-3 and mPAR-6 have a scaffolding function, coordinating the activities of several signalling proteins that are implicated in mammalian cell polarity.	Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Program Mol Biol & Canc, Toronto, ON M5G 1X5, Canada; Univ Toronto, Dept Mol & Med Genet, Toronto, ON M5S 1A8, Canada; Oregon Hlth & Sci Univ, Vollum Inst, Howard Hughes Med Inst, Portland, OR 97201 USA	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; Howard Hughes Medical Institute; Oregon Health & Science University	Pawson, T (corresponding author), Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Program Mol Biol & Canc, 600 Univ Ave, Toronto, ON M5G 1X5, Canada.	pawson@mshri.on.ca	Pawson, Tony J/E-4578-2013	Fawcett, Jim/0000-0003-0043-2164	NIDDK NIH HHS [DK44239] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK044239] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bossing T, 1996, DEV BIOL, V179, P41, DOI 10.1006/dbio.1996.0240; Boyd L, 1996, DEVELOPMENT, V122, P3075; Bredt DS, 1998, CELL, V94, P691, DOI 10.1016/S0092-8674(00)81727-4; BURBELO PD, 1995, J BIOL CHEM, V270, P29071, DOI 10.1074/jbc.270.49.29071; Cereijido M, 1998, ANNU REV PHYSIOL, V60, P161, DOI 10.1146/annurev.physiol.60.1.161; CHENG NN, 1995, GENETICS, V139, P549; Colman DR, 1999, NEURON, V23, P649, DOI 10.1016/S0896-6273(01)80024-6; DOE CQ, 1992, DEVELOPMENT, V116, P855; DOTTI CG, 1990, CELL, V62, P63, DOI 10.1016/0092-8674(90)90240-F; ETEMADMOGHADAM B, 1995, CELL, V83, P743, DOI 10.1016/0092-8674(95)90187-6; GARCIA EP, 1995, J CELL BIOL, V129, P105, DOI 10.1083/jcb.129.1.105; GUO S, 1995, CELL, V81, P611, DOI 10.1016/0092-8674(95)90082-9; Guo S, 1996, CURR OPIN GENET DEV, V6, P408, DOI 10.1016/S0959-437X(96)80061-X; HART MJ, 1994, J BIOL CHEM, V269, P62; HARTENSTEIN V, 1984, ROUX ARCH DEV BIOL, V193, P308, DOI 10.1007/BF00848159; HELL JW, 1997, CELL BIOL LAB MANUAL, P567; Henkemeyer M, 1996, CELL, V86, P35, DOI 10.1016/S0092-8674(00)80075-6; HILL DP, 1988, DEV BIOL, V125, P75, DOI 10.1016/0012-1606(88)90060-7; Hillier BJ, 1999, SCIENCE, V284, P812, DOI 10.1126/science.284.5415.812; HIRD SN, 1993, J CELL BIOL, V121, P1343, DOI 10.1083/jcb.121.6.1343; Hung TJ, 1999, DEVELOPMENT, V126, P127; Huttner WB, 1997, CURR OPIN NEUROBIOL, V7, P29, DOI 10.1016/S0959-4388(97)80117-1; HUTTNER WB, 1983, J CELL BIOL, V96, P1374, DOI 10.1083/jcb.96.5.1374; Izumi Y, 1998, J CELL BIOL, V143, P95, DOI 10.1083/jcb.143.1.95; JOHNSTON PA, 1989, J BIOL CHEM, V264, P1268; Jou TS, 1998, J CELL BIOL, V142, P101, DOI 10.1083/jcb.142.1.101; KEMPHUES KJ, 1988, CELL, V52, P311, DOI 10.1016/S0092-8674(88)80024-2; Knoblich JA, 1997, CURR OPIN CELL BIOL, V9, P833, DOI 10.1016/S0955-0674(97)80085-3; Kraut R, 1996, NATURE, V383, P50, DOI 10.1038/383050a0; Kraut R, 1996, DEV BIOL, V174, P65, DOI 10.1006/dbio.1996.0052; Kroschewski R, 1999, NAT CELL BIOL, V1, P8, DOI 10.1038/8977; Kuchinke U, 1998, CURR BIOL, V8, P1357, DOI 10.1016/S0960-9822(98)00016-5; Lin D, 1999, J BIOL CHEM, V274, P3726, DOI 10.1074/jbc.274.6.3726; Lin HF, 1997, TRENDS GENET, V13, P33, DOI 10.1016/S0168-9525(96)10050-0; Mackay DJG, 1998, J BIOL CHEM, V273, P20685, DOI 10.1074/jbc.273.33.20685; Muller HAJ, 1996, J CELL BIOL, V134, P149, DOI 10.1083/jcb.134.1.149; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; Schober M, 1999, NATURE, V402, P548, DOI 10.1038/990135; SELF AJ, 1995, METHOD ENZYMOL, V256, P3; Standaert ML, 1997, J BIOL CHEM, V272, P30075, DOI 10.1074/jbc.272.48.30075; SUDHOF TC, 1987, SCIENCE, V238, P1142, DOI 10.1126/science.3120313; Tabuse Y, 1998, DEVELOPMENT, V125, P3607; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295; Watts JL, 1996, DEVELOPMENT, V122, P3133; Wodarz A, 1999, NATURE, V402, P544, DOI 10.1038/990128; Yeaman C, 1999, PHYSIOL REV, V79, P73, DOI 10.1152/physrev.1999.79.1.73; Yu FW, 2000, CELL, V100, P399, DOI 10.1016/S0092-8674(00)80676-5	47	601	615	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	AUG	2000	2	8					540	547		10.1038/35019582	http://dx.doi.org/10.1038/35019582			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	341TE	10934475				2022-12-25	WOS:000088605000020
J	Soong, NW; Nomura, L; Pekrun, K; Reed, M; Sheppard, L; Dawes, G; Stemmer, WPC				Soong, NW; Nomura, L; Pekrun, K; Reed, M; Sheppard, L; Dawes, G; Stemmer, WPC			Molecular breeding of viruses	NATURE GENETICS			English	Article							EVOLUTION; RETROVIRUSES; GLYCOSYLATION; DIVERSITY; RECEPTOR; PROTEIN; FAMILY	Genetic recombination is a major force driving the evolution of many viruses. Recombination between two copackaged retroviral genomes may occur at rates as high as 40% per replication cycle(1). This enables genetic information to be shuffled rapidly leading to recombinants with new patterns of mutations and phenotypes. The in vitro process of DNA shuffling(2,3) (molecular breeding) mimics this mechanism on a vastly parallel and accelerated scale. Multiple homologous parental sequences are recombined in parallel, leading to a diverse library of complex recombinants from which desired improvements can be selected. Different proteins and enzymes have been improved using DNA shuffling(4-6). We report here the first application of molecular breeding to viruses. A single round of shuffling envelope sequences from six murine leukaemia viruses (MLV) followed by selection yielded a chimaeric clone with a completely new tropism for Chinese Hamster Ovary (CHOK1) cells. The composition and properties of the selected clone indicated that this particular permutation of parental sequences cannot be readily attained by natural retroviral recombination. This example demonstrates that molecular breeding can enhance the inherently high evolutionary potential of retroviruses to obtain desired phenotypes. It can be an effective tool, when information is limited, to optimize viruses for gene therapy and vaccine applications when multiple complex functions must be simultaneously balanced.	Maxygen Inc, Redwood City, CA USA		Soong, NW (corresponding author), Maxygen Inc, Redwood City, CA USA.							Chang CCJ, 1999, NAT BIOTECHNOL, V17, P793, DOI 10.1038/11737; COFFIN JM, 1992, CURR TOP MICROBIOL, V176, P143; COLICELLI J, 1988, J MOL BIOL, V199, P47, DOI 10.1016/0022-2836(88)90378-6; Crameri A, 1996, NAT BIOTECHNOL, V14, P315, DOI 10.1038/nbt0396-315; Crameri A, 1998, NATURE, V391, P288, DOI 10.1038/34663; DEUTSCHERT SL, 1996, J BIOL CHEM, V261, P96; EIDEN MV, 1994, J VIROL, V68, P626, DOI 10.1128/JVI.68.2.626-631.1994; HU WS, 1990, SCIENCE, V250, P1227, DOI 10.1126/science.1700865; KATZ RA, 1990, ANNU REV GENET, V24, P409, DOI 10.1146/annurev.ge.24.120190.002205; Masuda M, 1996, J VIROL, V70, P8534, DOI 10.1128/JVI.70.12.8534-8539.1996; MILLER DG, 1992, J VIROL, V66, P78, DOI 10.1128/JVI.66.1.78-84.1992; Ness JE, 1999, NAT BIOTECHNOL, V17, P893, DOI 10.1038/12884; Patten PA, 1997, CURR OPIN BIOTECH, V8, P724, DOI 10.1016/S0958-1669(97)80127-9; STANLEY P, 1977, SOMAT CELL GENET, V3, P391, DOI 10.1007/BF01542968; STEMMER WPC, 1994, NATURE, V370, P389, DOI 10.1038/370389a0; Wang H, 1996, J VIROL, V70, P6884, DOI 10.1128/JVI.70.10.6884-6891.1996	16	83	96	0	7	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	AUG	2000	25	4					436	439		10.1038/78132	http://dx.doi.org/10.1038/78132			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	341WY	10932190				2022-12-25	WOS:000088615000021
J	Tanaka, TU; Fuchs, J; Loidl, J; Nasmyth, K				Tanaka, TU; Fuchs, J; Loidl, J; Nasmyth, K			Cohesin ensures bipolar attachment of microtubules to sister centromeres and resists their precocious separation	NATURE CELL BIOLOGY			English	Article							ANAPHASE-PROMOTING COMPLEX; CHROMATID COHESION; SACCHAROMYCES-CEREVISIAE; BUDDING YEAST; CHROMOSOME CONDENSATION; DNA-REPLICATION; FISSION YEAST; SPINDLE CHECKPOINT; CUT2 PROTEOLYSIS; PROTEIN	The multisubunit protein complex cohesin is required to establish cohesion between sister chromatids during S phase and to maintain it during G2 and M phases. Cohesin is essential for mitosis, and even partial defects cause very high rates of chromosome loss. In budding yeast, cohesin associates with specific sites which are distributed along the entire length of a chromosome but are more dense in the vicinity of the centromere. Real-time imaging of individual centromeres tagged with green fluorescent protein suggests that cohesin bound to centromeres is important for bipolar attachment to microtubules. This cohesin is, however, incapable of resisting the consequent force, which leads to sister centromere splitting and chromosome stretching. Meanwhile, cohesin bound to sequences flanking the centromeres prevents sister chromatids from completely unzipping and is required to pull back together sister centromeres that have already split. Cohesin therefore has a central role in generating a dynamic tension between microtubules and sister chromatid cohesion at centromeres, which lasts until chromosome segregation is finally promoted by separin-dependent cleavage of the cohesin subunit Scc1p.	Res Inst Mol Pathol, A-1030 Vienna, Austria; Univ Vienna, Inst Bot, A-1030 Vienna, Austria	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP); University of Vienna	Nasmyth, K (corresponding author), Res Inst Mol Pathol, Dr Bohr Gasse 7, A-1030 Vienna, Austria.	nasmyth@nt.imp.univie.ac.at	Tanaka, Tomoyuki U/A-4775-2008	Nasmyth, Kim/0000-0001-7030-4403; , Josef/0000-0002-2519-4484; Fuchs, Joerg/0000-0003-4171-5371; Tanaka, Tomoyuki/0000-0002-9886-5947				BAUM P, 1988, MOL CELL BIOL, V8, P5386, DOI 10.1128/MCB.8.12.5386; Bickel SE, 1996, BIOESSAYS, V18, P293, DOI 10.1002/bies.950180407; Blat Y, 1999, CELL, V98, P249, DOI 10.1016/S0092-8674(00)81019-3; Ciosk R, 1998, CELL, V93, P1067, DOI 10.1016/S0092-8674(00)81211-8; CLOSK R, 2000, MOL CELL, V5, P243; CohenFix O, 1996, GENE DEV, V10, P3081, DOI 10.1101/gad.10.24.3081; Fang GW, 1998, GENE DEV, V12, P1871, DOI 10.1101/gad.12.12.1871; Funabiki H, 1996, NATURE, V381, P438, DOI 10.1038/381438a0; Furuya K, 1998, GENE DEV, V12, P3408, DOI 10.1101/gad.12.21.3408; GOH PY, 1993, J CELL BIOL, V121, P503, DOI 10.1083/jcb.121.3.503; Goshima G, 2000, CELL, V100, P619, DOI 10.1016/S0092-8674(00)80699-6; GUACCI V, 1994, J CELL BIOL, V125, P517, DOI 10.1083/jcb.125.3.517; Guacci V, 1997, CELL, V91, P47, DOI 10.1016/S0092-8674(01)80008-8; He XW, 2000, CELL, V101, P763, DOI 10.1016/S0092-8674(00)80888-0; Hirano T, 1999, GENE DEV, V13, P11, DOI 10.1101/gad.13.1.11; Hwang LH, 1998, SCIENCE, V279, P1041, DOI 10.1126/science.279.5353.1041; Hyman AA, 1995, ANNU REV CELL DEV BI, V11, P471, DOI 10.1146/annurev.cb.11.110195.002351; INOUE S, 1995, MOL BIOL CELL, V6, P1619, DOI 10.1091/mbc.6.12.1619; Jin QW, 2000, J CELL SCI, V113, P1903; Kim SH, 1998, SCIENCE, V279, P1045, DOI 10.1126/science.279.5353.1045; Knop M, 1999, YEAST, V15, P963, DOI 10.1002/(SICI)1097-0061(199907)15:10B<963::AID-YEA399>3.0.CO;2-W; Kumada K, 1998, CURR BIOL, V8, P633, DOI 10.1016/S0960-9822(98)70250-7; Lim HH, 1998, CURR BIOL, V8, P231, DOI 10.1016/S0960-9822(98)70088-0; Loidl J, 1998, METHOD CELL BIOL, V53, P257; Losada A, 1998, GENE DEV, V12, P1986, DOI 10.1101/gad.12.13.1986; Megee PC, 1999, MOL CELL, V4, P445, DOI 10.1016/S1097-2765(00)80347-0; Michaelis C, 1997, CELL, V91, P35, DOI 10.1016/S0092-8674(01)80007-6; MIYAZAKI WY, 1994, ANNU REV GENET, V28, P167, DOI 10.1146/annurev.ge.28.120194.001123; Nabeshima K, 1998, MOL BIOL CELL, V9, P3211, DOI 10.1091/mbc.9.11.3211; Nasmyth K, 2000, SCIENCE, V288, P1379, DOI 10.1126/science.288.5470.1379; Nasmyth K, 1999, TRENDS BIOCHEM SCI, V24, P98, DOI 10.1016/S0968-0004(99)01358-4; Nicklas RB, 1997, SCIENCE, V275, P632, DOI 10.1126/science.275.5300.632; Pidoux AL, 2000, CURR OPIN CELL BIOL, V12, P308, DOI 10.1016/S0955-0674(00)00094-6; Rieder CL, 1999, J CELL SCI, V112, P2607; SCHERTHAN H, 1992, CHROMOSOMA, V101, P590, DOI 10.1007/BF00360535; Shirayama M, 1998, EMBO J, V17, P1336, DOI 10.1093/emboj/17.5.1336; Skibbens RV, 1999, GENE DEV, V13, P307, DOI 10.1101/gad.13.3.307; SKIBBENS RV, 1993, J CELL BIOL, V80, P674; Straight AF, 1996, CURR BIOL, V6, P1599, DOI 10.1016/S0960-9822(02)70783-5; Straight AF, 1997, SCIENCE, V277, P574, DOI 10.1126/science.277.5325.574; Tanaka K, 2000, MOL CELL BIOL, V20, P3459, DOI 10.1128/MCB.20.10.3459-3469.2000; Tanaka TU, 1999, CELL, V98, P847, DOI 10.1016/S0092-8674(00)81518-4; THIERRY A, 1995, YEAST, V11, P121, DOI 10.1002/yea.320110204; Uhlmann F, 1999, NATURE, V400, P37, DOI 10.1038/21831; Uhlmann F, 1998, CURR BIOL, V8, P1095, DOI 10.1016/S0960-9822(98)70463-4; Visintin R, 1997, SCIENCE, V278, P460, DOI 10.1126/science.278.5337.460; Waters JC, 1996, J CELL SCI, V109, P2823; WINEY M, 1995, J CELL BIOL, V129, P1601, DOI 10.1083/jcb.129.6.1601; Zachariae W, 1999, GENE DEV, V13, P2039, DOI 10.1101/gad.13.16.2039	50	259	263	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	AUG	2000	2	8					492	499		10.1038/35019529	http://dx.doi.org/10.1038/35019529			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	341TE	10934469				2022-12-25	WOS:000088605000014
J	Dequeker, E; Cassiman, JJ				Dequeker, E; Cassiman, JJ			Genetic testing and quality control in diagnostic laboratories	NATURE GENETICS			English	Article							CYSTIC-FIBROSIS		Katholieke Univ Leuven, Ctr Human Genet, Louvain, Belgium	KU Leuven	Dequeker, E (corresponding author), Katholieke Univ Leuven, Ctr Human Genet, Louvain, Belgium.							Dequeker E, 1998, EUR J HUM GENET, V6, P165, DOI 10.1038/sj.ejhg.5200195; DEQUEKER E, IN PRESS EUR J HUM G; ELLES R, 1996, METHODS MOL MED MOL; Estivill X, 1997, HUM MUTAT, V10, P135, DOI 10.1002/(SICI)1098-1004(1997)10:2<135::AID-HUMU6>3.3.CO;2-P; Grody WW, 1998, AM J HUM GENET, V62, P1252, DOI 10.1086/301842; Holtzman NA, 1999, CLIN CHEM, V45, P732; Holtzman NA, 1998, BMJ-BRIT MED J, V316, P852, DOI 10.1136/bmj.316.7134.852; Losekoot M, 1999, EUR J HUM GENET, V7, P217, DOI 10.1038/sj.ejhg.5200252; McGovern MM, 1999, JAMA-J AM MED ASSOC, V281, P835, DOI 10.1001/jama.281.9.835; Prence EM, 1999, GENET TEST, V3, P201, DOI 10.1089/gte.1999.3.201; Robinson RA, 1999, AM J CLIN PATHOL, V112, P11; Schwartz MK, 1999, CLIN CHEM, V45, P739	12	62	67	0	5	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUL	2000	25	3					259	260		10.1038/77008	http://dx.doi.org/10.1038/77008			2	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	329RD	10888869				2022-12-25	WOS:000087920900010
J	Filliol, D; Ghozland, S; Chluba, J; Martin, M; Matthes, HWD; Simonin, F; Befort, K; Gaveriaux-Ruff, C; Dierich, A; LeMeur, M; Valverde, O; Maldonado, R; Kieffer, BL				Filliol, D; Ghozland, S; Chluba, J; Martin, M; Matthes, HWD; Simonin, F; Befort, K; Gaveriaux-Ruff, C; Dierich, A; LeMeur, M; Valverde, O; Maldonado, R; Kieffer, BL			Mice deficient for delta- and gamma-opioid receptors exhibit opposing alterations of emotional responses	NATURE GENETICS			English	Article							ENDOGENOUS ENKEPHALINS; ANXIETY; LACKING; PAIN; RAT; ANTIDEPRESSANTS; INVOLVEMENT; EXPRESSION; WITHDRAWAL; ANALGESIA	The role of the opioid system in controlling pain(1), reward and addidion(2,3) is well established, but its role in regulating other emotional responses is poorly documented in pharmacology(4). The mu-. delta- and kappa- opioid receptors (encoded by Oprm, Oprd1 and Oprk1, respectively) mediate the biological activity of opioids(5) We have generated Oprd1-deficient mice and compared the behavioural responses of mice lacking Oprd1, Oprm (ref. 6) and Oprk1 (ref. 7) in several models of anxiety and depression. Our data show no detectable phenotype in Oprk1(-/-) mutants. suggesting that ic-receptors do not have a role in this aspect of opioid function; opposing phenotypes in Oprm(-/-) and Oprd1(-/-) mutants which contrasts with the classical notion of similar activities of mu-and delta-receptors; and consistent anxiogenic- and depressive-like responses in Oprd1(-/-) mice, indicating that delta-receptor activity contributes to improvement of mood states. We conclude that the Oprdl-encoded receptor, which has been proposed to be a promising target for the clinical management of pain(8,9), should also be considered in the treatment of drug addiction and other mood-related disorders.	Univ Strasbourg 1, ESBS, UPR 9050 CNRS, Strasbourg, France; Univ Pompeu Fabra, Fac Ciencies Salut & Vida, Lab Neurofarmacol, Barcelona, Spain; Inst Genet & Biol Mol & Cellulaire, Strasbourg, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Pompeu Fabra University; Institut National de la Sante et de la Recherche Medicale (Inserm)	Kieffer, BL (corresponding author), Univ Strasbourg 1, ESBS, UPR 9050 CNRS, Strasbourg, France.		Maldonado, Rafael/F-5657-2014; GAVERIAUX-RUFF, Claire/A-9671-2017; Valverde, Olga/D-8654-2012; Chluba, Johanna/D-1224-2012	Maldonado, Rafael/0000-0002-4359-8773; GAVERIAUX-RUFF, Claire/0000-0002-3523-8102; Valverde, Olga/0000-0003-2264-7852; Chluba, Johanna/0000-0001-8779-8016				Asakawa A, 1998, NEUROREPORT, V9, P2265, DOI 10.1097/00001756-199807130-00022; BAAMONDE A, 1992, EUR J PHARMACOL, V216, P157, DOI 10.1016/0014-2999(92)90356-9; CALENCOCHOUKROUN G, 1991, PSYCHOPHARMACOLOGY, V103, P493, DOI 10.1007/BF02244249; Crestani F, 1999, NAT NEUROSCI, V2, P833, DOI 10.1038/12207; DICKENSON AH, 1991, BRIT MED BULL, V47, P690, DOI 10.1093/oxfordjournals.bmb.a072501; Dondio G, 1997, EXPERT OPIN THER PAT, V7, P1075, DOI 10.1517/13543776.7.10.1075; KAMEYAMA T, 1985, NEUROPHARMACOLOGY, V24, P59; Kieffer BL, 1995, CELL MOL NEUROBIOL, V15, P615, DOI 10.1007/BF02071128; KIEFFER BL, 1992, P NATL ACAD SCI USA, V89, P12048, DOI 10.1073/pnas.89.24.12048; Konig M, 1996, NATURE, V383, P535, DOI 10.1038/383535a0; KOOB GF, 1992, TRENDS PHARMACOL SCI, V13, P177, DOI 10.1016/0165-6147(92)90060-J; LUFKIN T, 1991, CELL, V66, P1105, DOI 10.1016/0092-8674(91)90034-V; MANSOUR A, 1995, TRENDS NEUROSCI, V18, P22, DOI 10.1016/0166-2236(95)93946-U; Matthes HWD, 1998, J NEUROSCI, V18, P7285; Matthes HWD, 1996, NATURE, V383, P819, DOI 10.1038/383819a0; NABER D, 1993, HDB EXP PHARM OPIOID, V2, P781; PELLOW S, 1985, J NEUROSCI METH, V14, P149, DOI 10.1016/0165-0270(85)90031-7; PORSOLT RD, 1977, ARCH INT PHARMACOD T, V229, P327; RAPAKA RS, 1991, PHARM RES-DORDR, V8, P1, DOI 10.1023/A:1015809702296; Simonin F, 1998, EMBO J, V17, P886, DOI 10.1093/emboj/17.4.886; SMADJA C, 1995, PSYCHOPHARMACOLOGY, V120, P400, DOI 10.1007/BF02245811; Tejedor-Real P, 1998, EUR J PHARMACOL, V354, P1, DOI 10.1016/S0014-2999(98)00423-3; Timpl P, 1998, NAT GENET, V19, P162, DOI 10.1038/520; TRAYNOR JR, 1993, TRENDS PHARMACOL SCI, V14, P84, DOI 10.1016/0165-6147(93)90068-U; Valverde O, 1996, EUR J PHARMACOL, V312, P15, DOI 10.1016/0014-2999(96)00437-2; WALSH TD, 1983, CLIN NEUROPHARMACOL, V6, P271; Wise RA, 1996, CURR OPIN NEUROBIOL, V6, P243, DOI 10.1016/S0959-4388(96)80079-1; Zaki PA, 1996, ANNU REV PHARMACOL, V36, P379; Zhu YX, 1999, NEURON, V24, P243, DOI 10.1016/S0896-6273(00)80836-3; [No title captured]	30	528	546	1	33	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUN	2000	25	2					195	200		10.1038/76061	http://dx.doi.org/10.1038/76061			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	321ML	10835636				2022-12-25	WOS:000087459200020
J	Galperin, MY; Koonin, EV				Galperin, MY; Koonin, EV			Who's your neighbor? New computational approaches for functional genomics	NATURE BIOTECHNOLOGY			English	Review						protein function prediction; gene sequence; Rosetta Stone; clusters of orthologs; phylogenetic patterns	TRANSFER-RNA SYNTHETASE; PROTEIN SEQUENCES; BACTERIAL GENOMES; GENE; EVOLUTION; FAMILIES; PERSPECTIVE; ARCHAEAL; DOMAIN	Several recently developed computational approaches in comparative genomics go beyond sequence comparison. By analyzing phylogenetic profiles of protein families, domain fusions, gene adjacency in genomes, and expression patterns, these methods predict many functional interactions between proteins and help deduce specific functions for numerous proteins. Although some of the resultant predictions may not be highly specific, these developments herald a new era in genomics in which the benefits of comparative analysis of the rapidly growing collection of complete genomes will become increasingly obvious.	NIH, Natl Lib Med, Natl Ctr Biotechnol Informat, Bethesda, MD 20894 USA	National Institutes of Health (NIH) - USA; NIH National Library of Medicine (NLM)	Koonin, EV (corresponding author), NIH, Natl Lib Med, Natl Ctr Biotechnol Informat, Bethesda, MD 20894 USA.	koonin@ncbi.nlm.nih.gov	Galperin, Michael Y./B-5859-2013	Galperin, Michael Y./0000-0002-2265-5572	NATIONAL LIBRARY OF MEDICINE [Z01LM000073, ZIALM000073] Funding Source: NIH RePORTER	NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))		Aravind L, 1997, TRENDS BIOCHEM SCI, V22, P458, DOI 10.1016/S0968-0004(97)01148-1; Aravind L, 1998, TRENDS GENET, V14, P442, DOI 10.1016/S0168-9525(98)01553-4; Bork P, 1998, J MOL BIOL, V283, P707, DOI 10.1006/jmbi.1998.2144; Bork P, 1998, NAT GENET, V18, P313, DOI 10.1038/ng0498-313; Brown JR, 1997, MICROBIOL MOL BIOL R, V61, P456, DOI 10.1128/.61.4.456-502.1997; Dandekar T, 1999, BIOCHEM J, V343, P115, DOI 10.1042/0264-6021:3430115; Dandekar T, 1998, TRENDS BIOCHEM SCI, V23, P324, DOI 10.1016/S0968-0004(98)01274-2; Doolittle RF, 1999, NAT GENET, V23, P6, DOI 10.1038/12597; Doolittle WE, 1998, TRENDS GENET, V14, P307; Doolittle WF, 1999, SCIENCE, V284, P2124, DOI 10.1126/science.284.5423.2124; DYNES JL, 1989, P NATL ACAD SCI USA, V86, P7966, DOI 10.1073/pnas.86.20.7966; ERNIGHT AJ, 2000, TRNEDS GENET, V16, P9; FITCH WM, 1970, SYST ZOOL, V19, P99, DOI 10.2307/2412448; Gaasterland T, 1998, Microb Comp Genomics, V3, P199; Galperin Michael Y., 1999, Journal of Molecular Microbiology and Biotechnology, V1, P303; Galperin MY, 2000, FEMS MICROBIOL LETT, V183, P259, DOI 10.1016/S0378-1097(99)00612-6; Gelfand MS, 2000, NUCLEIC ACIDS RES, V28, P695, DOI 10.1093/nar/28.3.695; Henikoff S, 1997, SCIENCE, V278, P609, DOI 10.1126/science.278.5338.609; Huynen MA, 2000, ADV PROTEIN CHEM, V54, P345, DOI 10.1016/S0065-3233(00)54010-8; Huynen MA, 1999, TRENDS MICROBIOL, V7, P281, DOI 10.1016/S0966-842X(99)01539-5; Ibba M, 1997, P NATL ACAD SCI USA, V94, P14383, DOI 10.1073/pnas.94.26.14383; Ibba M, 1997, SCIENCE, V278, P1119, DOI 10.1126/science.278.5340.1119; Koonin EV, 1998, CURR OPIN STRUC BIOL, V8, P355, DOI 10.1016/S0959-440X(98)80070-5; Makarova KS, 1999, GENOME RES, V9, P608; Marcotte EM, 1999, NATURE, V402, P83, DOI 10.1038/47048; Marcotte EM, 1999, SCIENCE, V285, P751, DOI 10.1126/science.285.5428.751; Mewes HW, 1998, NUCLEIC ACIDS RES, V26, P33, DOI 10.1093/nar/26.1.33; Mironov AA, 1999, NUCLEIC ACIDS RES, V27, P2981, DOI 10.1093/nar/27.14.2981; Mushegian AR, 1996, P NATL ACAD SCI USA, V93, P10268, DOI 10.1073/pnas.93.19.10268; Overbeek R, 1999, P NATL ACAD SCI USA, V96, P2896, DOI 10.1073/pnas.96.6.2896; OVERBEEK R, 1998, SILICO BIOL; Pellegrini M, 1999, P NATL ACAD SCI USA, V96, P4285, DOI 10.1073/pnas.96.8.4285; Schiott T, 1997, J BACTERIOL, V179, P4523, DOI 10.1128/jb.179.14.4523-4529.1997; Tatusov RL, 1997, SCIENCE, V278, P631, DOI 10.1126/science.278.5338.631; Tatusov RL, 2000, NUCLEIC ACIDS RES, V28, P33, DOI 10.1093/nar/28.1.33; Thomson GJ, 1998, BIOCHEM J, V331, P437, DOI 10.1042/bj3310437; Walhout AJM, 2000, SCIENCE, V287, P116, DOI 10.1126/science.287.5450.116; Wolf YI, 1999, GENOME RES, V9, P689	38	236	255	0	6	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JUN	2000	18	6					609	613		10.1038/76443	http://dx.doi.org/10.1038/76443			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	325EK	10835597				2022-12-25	WOS:000087663200019
J	Menasche, G; Pastural, E; Feldmann, J; Certain, S; Ersoy, F; Dupuis, S; Wulffraat, N; Bianchi, D; Fischer, A; Le Deist, F; de Saint Basile, G				Menasche, G; Pastural, E; Feldmann, J; Certain, S; Ersoy, F; Dupuis, S; Wulffraat, N; Bianchi, D; Fischer, A; Le Deist, F; de Saint Basile, G			Mutations in RAB27A cause Griscelli syndrome associated with haemophagocytic syndrome	NATURE GENETICS			English	Article							BRAIN MYOSIN-V; HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS; UNCONVENTIONAL MYOSIN; PARTIAL ALBINISM; PROTEINS; GENE; IMMUNODEFICIENCY; TRANSPORT; GTPASES; CLONING	Griscelli syndrome (GS, MIM 214450), a rare, autosomal recessive disorder, results in pigmentary dilution of the skin and the hair, the presence of large clumps of pigment in hair shafts and an accumulation of melanosomes in melanocytes. Most patients also develop an uncontrolled T-lymphocyte and macrophage activation syndrome (known as haemophagocytic syndrome, HS), leading to death in the absence of bone-marrow transplantation(1,2). In contrast, early in life some GS patients show a severe neurological impairment without apparent immune abnormalities(3-5). We previously mapped the GS locus to chromosome 15q21 and found a mutation in a gene (MY05A) encoding a molecular motor in two patients(5). Further linkage analysis suggested a second gene associated with CS was in the same chromosomal region(6). Homozygosity mapping in additional families narrowed the candidate region to a 3.1-cM interval between D1551003 and D155962. We detected mutations in RAB27A, which lies within this interval, in 16 patients with CS. Unlike MYO5A, the GTP-binding protein RAB27A appears to be involved in the control of the immune system, as all patients with RAB27A mutations, but none with the MY05A mutation, developed HS. In addition, RAB27A-deficient T cells exhibited reduced cytotoxicity and cytolytic granule exocytosis, whereas MYO5A-defective T cells did not. RAB27A appears to be a key effector of cytotoxic granule exocytosis, a pathway essential for immune homeostasis.	INSERM, U429, Unite Rech Dev Normal & Pathol Syst Immunitaire, Paris, France; Hacettepe Univ, Hacettepe Childrens Hosp, Pediat Immunol Unit, Ankara, Turkey; Hop Necker Enfants Malad, Unite Immunol & Hematol Pediat, Paris, France; Wilhelmina Childrens Hosp, Utrecht, Netherlands; Tufts Univ New England Med Ctr, Boston, MA 02111 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); Hacettepe University; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Wilhelmina Kinderziekenhuis; Tufts Medical Center	de Saint Basile, G (corresponding author), INSERM, U429, Unite Rech Dev Normal & Pathol Syst Immunitaire, Paris, France.	sbasile@necker.fr	menasche, gael/D-8280-2017; de Saint Basile, Genevieve/G-9731-2017	DOGNIAUX, Stephanie/0000-0003-3309-1204; Menasche, Gael/0000-0001-6671-3642; de Saint Basile, Genevieve/0000-0002-1913-5269				Barrat FJ, 1999, P NATL ACAD SCI USA, V96, P8645, DOI 10.1073/pnas.96.15.8645; Chavrier P, 1999, CURR OPIN CELL BIOL, V11, P466, DOI 10.1016/S0955-0674(99)80067-2; Chen D, 1997, BIOCHEM MOL MED, V60, P27, DOI 10.1006/bmme.1996.2559; CHENEY RE, 1993, CELL, V75, P13, DOI 10.1016/0092-8674(93)90675-G; Dufourcq-Lagelouse R, 1999, INT J MOL MED, V4, P127; Echard A, 1998, SCIENCE, V279, P580, DOI 10.1126/science.279.5350.580; ELEJALDE BR, 1979, AM J MED GENET, V3, P65, DOI 10.1002/ajmg.1320030112; ESPREAFICO EM, 1992, J CELL BIOL, V119, P1541, DOI 10.1083/jcb.119.6.1541; GRISCELLI C, 1978, AM J MED, V65, P691, DOI 10.1016/0002-9343(78)90858-6; HURVITZ H, 1993, EUR J PEDIATR, V152, P402, DOI 10.1007/BF01955897; Kim S, 1998, CELL IMMUNOL, V183, P106, DOI 10.1006/cimm.1998.1252; KINSELLA BT, 1992, J BIOL CHEM, V267, P3940; KLEIN C, 1994, J PEDIATR-US, V125, P886, DOI 10.1016/S0022-3476(05)82003-7; Mazerolles F, 1998, INT IMMUNOL, V10, P1897, DOI 10.1093/intimm/10.12.1897; Novick P, 1997, CURR OPIN CELL BIOL, V9, P496, DOI 10.1016/S0955-0674(97)80025-7; Pastural E, 2000, GENOMICS, V63, P299, DOI 10.1006/geno.1999.6081; Pastural E, 1997, NAT GENET, V16, P289, DOI 10.1038/ng0797-289; PFEFFER SR, 1994, CURR OPIN CELL BIOL, V6, P522, DOI 10.1016/0955-0674(94)90071-X; Prekeris R, 1997, J CELL BIOL, V137, P1589, DOI 10.1083/jcb.137.7.1589; SEABRA MC, 1995, J BIOL CHEM, V270, P24420, DOI 10.1074/jbc.270.41.24420; Stepp SE, 1999, SCIENCE, V286, P1957, DOI 10.1126/science.286.5446.1957; Stinchcombe JC, 1999, J CELL BIOL, V147, P1, DOI 10.1083/jcb.147.1.1; Tolmachova T, 1999, GENE, V239, P109, DOI 10.1016/S0378-1119(99)00371-6	23	670	693	0	38	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JUN	2000	25	2					173	176		10.1038/76024	http://dx.doi.org/10.1038/76024			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	321ML	10835631				2022-12-25	WOS:000087459200015
J	Sarkar, PS; Appukuttan, B; Han, J; Ito, Y; Ai, CW; Tsai, WL; Chai, Y; Stout, JT; Reddy, S				Sarkar, PS; Appukuttan, B; Han, J; Ito, Y; Ai, CW; Tsai, WL; Chai, Y; Stout, JT; Reddy, S			Heterozygous loss of Six5 in mice is sufficient to cause ocular cataracts	NATURE GENETICS			English	Article							DYSTROPHY PROTEIN-KINASE; UNSTABLE CTG REPEAT; MYOTONIC-DYSTROPHY; REDUCES EXPRESSION; TRIPLET REPEAT; MESSENGER-RNAS; GENE; EXPANSION; MUTATION; DISRUPTION	Myotonic dystrophy (DM) is an autosomal dominant disorder characterized by skeletal muscle wasting, myotonia, cardiac arrhythmia, hyperinsulinaemia, mental retardation and ocular cataracts(1). The genetic defect in DM is a CTG repeat expansion located in the 3' untranslated region of DMPK and 5' of a homeodomain-encoding gene, SIX5 (formerly DMAHP; refs 2-5). There are three mechanisms by which CTG expansion can result in DM. First, repeat expansion may alter the processing or transport of the mutant DMPK mRNA and consequently reduce DMPK levels(6). Second, CTG expansion may establish a region of heterochromatin 3' of the repeat sequence and decrease SIX5 transcription(7-9). Third, toxic effects of the repeat expansion may be intrinsic to the repeated elements at the level of DNA or RNA (refs 10,11). Previous studies have demonstrated that a dose-dependent loss of Dm15 (the mouse DMPK homologue) in mice produces a partial DM phenotype characterized by decreased development of skeletal muscle force and cardiac conduction disorders(12-15). To test the role of Six5 loss in DM, we have analysed a strain of mice in which Six5 was deleted. Our results demonstrate that the rate and severity of cataract formation is inversely related to Six5 dosage and is temporally progressive. Six5(+/-) and Six(5-/-) mice show increased steady-state levels of the Na+/K+-ATPase alpha-1 subunit and decreased Dm15 mRNA levels. Thus, altered ion homeostasis within the lens may contribute to cataract formation. As ocular cataracts are a characteristic feature of DM, these results demonstrate that decreased SIX5 transcription is important in the aetiology of DM. Our data support the hypothesis that DM is a contiguous gene syndrome associated with the partial loss of both DMPK and SIX5.	Univ So Calif, Keck Sch med, Inst Med Genet, Los Angeles, CA 90089 USA; Univ So Calif, Childrens Hosp Los Angeles, Div Ophthalmol, Los Angeles, CA USA; Univ So Calif, Sch Dent, Ctr Craniofacial Mol Biol, Los Angeles, CA USA	University of Southern California; Children's Hospital Los Angeles; University of Southern California; University of Southern California	Reddy, S (corresponding author), Univ So Calif, Keck Sch med, Inst Med Genet, Los Angeles, CA 90089 USA.	sitaredd@hsc.usc.edu			NATIONAL EYE INSTITUTE [P30EY003040] Funding Source: NIH RePORTER; NEI NIH HHS [EYO3040] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Benders AAGM, 1997, J CLIN INVEST, V100, P1440, DOI 10.1172/JCI119664; Berul CI, 1999, J CLIN INVEST, V103, pR1, DOI 10.1172/JCI5346; BOUCHER CA, 1995, HUM MOL GENET, V4, P1919, DOI 10.1093/hmg/4.10.1919; BROOK JD, 1992, CELL, V68, P799, DOI 10.1016/0092-8674(92)90154-5; CHEYETTE BNR, 1994, NEURON, V12, P977, DOI 10.1016/0896-6273(94)90308-5; FU YH, 1992, SCIENCE, V255, P1256, DOI 10.1126/science.1546326; GRAW J, 1989, EXP EYE RES, V49, P469, DOI 10.1016/0014-4835(89)90055-9; HARLEY HG, 1993, AM J HUM GENET, V52, P1164; Harper P.S., 1989, MYOTONIC DYSTROPHY; HOFMANNRADVANYI H, 1993, HUM MOL GENET, V2, P1263, DOI 10.1093/hmg/2.8.1263; JANSEN G, 1992, NAT GENET, V1, P261, DOI 10.1038/ng0792-261; Jansen G, 1996, NAT GENET, V13, P316, DOI 10.1038/ng0796-316; JOHNS KJ, 1995, BASIC CLIN SCI COURS; Klesert TR, 1997, NAT GENET, V16, P402, DOI 10.1038/ng0897-402; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; MAHADEVAN M, 1992, SCIENCE, V255, P1253, DOI 10.1126/science.1546325; Murakami Y, 1998, HUM MOL GENET, V7, P2103, DOI 10.1093/hmg/7.13.2103; Ohto H, 1999, MOL CELL BIOL, V19, P6815; ORLOWSKI J, 1988, J BIOL CHEM, V263, P10436; OTTEN AD, 1995, P NATL ACAD SCI USA, V92, P5465, DOI 10.1073/pnas.92.12.5465; Philips AV, 1998, SCIENCE, V280, P737, DOI 10.1126/science.280.5364.737; Reddy S, 1996, NAT GENET, V13, P325, DOI 10.1038/ng0796-325; Steinbach P, 1998, AM J HUM GENET, V62, P278, DOI 10.1086/301711; TANEJA KL, 1995, J CELL BIOL, V128, P995, DOI 10.1083/jcb.128.6.995; Thornton CA, 1997, NAT GENET, V16, P407, DOI 10.1038/ng0897-407; Timchenko LT, 1996, HUM MOL GENET, V5, P115, DOI 10.1093/hmg/5.1.115; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; WILKINSON DG, 1998, PRACTICAL APPROACH S; Winchester CL, 1999, HUM MOL GENET, V8, P481, DOI 10.1093/hmg/8.3.481; Zhao JS, 1996, DEV BIOL, V180, P242, DOI 10.1006/dbio.1996.0298	30	130	134	1	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAY	2000	25	1					110	114		10.1038/75500	http://dx.doi.org/10.1038/75500			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	311KU	10802668				2022-12-25	WOS:000086884000028
J	Brandt, ER; Sriprakash, KS; Hobb, RI; Hayman, WA; Zeng, WG; Batzloff, MR; Jackson, DC; Good, MF				Brandt, ER; Sriprakash, KS; Hobb, RI; Hayman, WA; Zeng, WG; Batzloff, MR; Jackson, DC; Good, MF			New multi-determinant strategy for a group A streptococcal vaccine designed for the Australian Aboriginal population	NATURE MEDICINE			English	Article							GROUP-A STREPTOCOCCI; B-CELL EPITOPES; M-PROTEIN; SYNTHETIC PEPTIDES; T-CELL; INTRANASAL IMMUNIZATION; RHEUMATIC-FEVER; IDENTIFICATION; ANTIBODIES; POLYMERIZATION	Infection with group A streptococci can result in acute and postinfectious pathology, including rheumatic fever and rheumatic heart disease. These diseases are associated with poverty and are increasing in incidence, particularly in developing countries and amongst indigenous populations, such as Australia's Aboriginal population, who suffer the highest incidence worldwide(1). Immunity to group A streptococci is mediated by antibodies against the M protein, a coiled-coil alpha helical surface protein of the bacterium(2). Vaccine development(3-5) faces two substantial obstacles. Although opsonic antibodies directed against the N terminus of the protein are mostly responsible for serotypic immunity, more than 100 serotypes exist. Furthermore, whereas the pathogenesis of rheumatic fever is not well understood, increasing evidence indicates an autoimmune process(6,7). To develop a suitable vaccine candidate, we first identified a minimum, helical, non-host-cross-reactive peptide from the conserved C-terminal half of the protein and displayed this within a non-M-protein peptide sequence designed to maintain helical folding and antigenicity, J14 (refs. 8,9). As this region of the M protein is identical in only 70% of group A streptococci isolates(10), the optimal candidate might consist of the conserved determinant with common N-terminal sequences found in communities with endemic group A streptococci. We linked seven serotypic peptides with J14 using a new chemistry technique that enables the immunogen to display all the individual peptides pendant from an alkane backbone. This construct demonstrated excellent immunogenicity and protection in mice.	Queensland Inst Med Res, Cooperat Res Ctr Vaccine Technol, Brisbane, Qld 4029, Australia; Univ Queensland, Australian Ctr Int & Trop Hlth & Nutr, Brisbane, Qld 4029, Australia; Univ Melbourne, Dept Microbiol & Immunol, Parkville, Vic 3052, Australia	QIMR Berghofer Medical Research Institute; University of Queensland; University of Melbourne	Good, MF (corresponding author), Queensland Inst Med Res, Cooperat Res Ctr Vaccine Technol, PO Royal Brisbane Hosp, Brisbane, Qld 4029, Australia.			Jackson, David/0000-0001-7255-270X				BEACHEY EH, 1981, NATURE, V292, P457, DOI 10.1038/292457a0; BEACHEY EH, 1986, J IMMUNOL, V136, P2287; BESSEN D, 1988, INFECT IMMUN, V56, P2666, DOI 10.1128/IAI.56.10.2666-2672.1988; Brandt ER, 1996, IMMUNOLOGY, V89, P331, DOI 10.1046/j.1365-2567.1996.d01-754.x; BRANDT ER, 1997, VACCINE, V16, P1805; Carapetis JR, 1996, MED J AUSTRALIA, V164, P146, DOI 10.5694/j.1326-5377.1996.tb122012.x; COLIGAN JE, 1992, CURRENT PROTOCOLS IM, V2; Dale JB, 1996, VACCINE, V14, P944, DOI 10.1016/0264-410X(96)00050-3; DEMALMANCHE SA, 1994, MED MICROBIOL IMMUN, V183, P299, DOI 10.1007/BF00196680; GARDINER D, 1995, PCR METH APPL, V4, P288; Hayman WA, 1997, INT IMMUNOL, V9, P1723, DOI 10.1093/intimm/9.11.1723; HOUGHTEN RA, 1985, P NATL ACAD SCI USA, V82, P5231; Jackson DC, 1997, VACCINE, V15, P1697, DOI 10.1016/S0264-410X(97)00085-6; Ji YD, 1997, INFECT IMMUN, V65, P2080, DOI 10.1128/IAI.65.6.2080-2087.1997; KAPUR V, 1994, MICROB PATHOGENESIS, V16, P443, DOI 10.1006/mpat.1994.1044; KOTB M, 1989, J IMMUNOL, V142, P966; OBrienSimpson NM, 1997, J AM CHEM SOC, V119, P1183, DOI 10.1021/ja962707k; PRUKSAKORN S, 1994, INT IMMUNOL, V6, P1235, DOI 10.1093/intimm/6.8.1235; PRUKSAKORN S, 1994, LANCET, V344, P639, DOI 10.1016/S0140-6736(94)92083-4; PRUKSAKORN S, 1992, J IMMUNOL, V149, P2729; QUINN RW, 1985, PEDIATR INFECT DIS J, V4, P374, DOI 10.1097/00006454-198507000-00008; RELF WA, 1992, J CLIN MICROBIOL, V30, P3190, DOI 10.1128/JCM.30.12.3190-3194.1992; Relf WA, 1996, PEPTIDE RES, V9, P12; ROBINSON JH, 1992, IMMUNOL TODAY, V13, P362, DOI 10.1016/0167-5699(92)90173-5; SALVADORI LG, 1995, J INFECT DIS, V171, P593, DOI 10.1093/infdis/171.3.593	25	127	129	0	10	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	APR	2000	6	4					455	459		10.1038/74719	http://dx.doi.org/10.1038/74719			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	376UA	10742155				2022-12-25	WOS:000165474100042
J	Jedd, G; Chua, NH				Jedd, G; Chua, NH			A new self-assembled peroxisomal vesicle required for efficient resealing of the plasma membrane	NATURE CELL BIOLOGY			English	Article							NEUROSPORA-CRASSA; WORONIN BODIES; TARGETING SIGNAL; YEAST; PROTEINS; MICROBODIES; CELLS; MICROSCOPY; BIOGENESIS; HYPHAE	The Woronin body is a membrane-bound organelle that has been observed in over 50 species of filamentous fungi. However, neither the composition nor the precise function of the Woronin body has yet been determined. Here we purify the Woronin body from Neurospora crassa and isolate Hex1, a new protein containing a consensus sequence known as peroxisome-targeting signal-1 (PTSI). We show that Hex1 is localized to the matrix of the Woronin body by immunoelectron microscopy, and that a green fluorescent protein- (GFP-)Hex1 fusion protein is targeted to yeast peroxisomes in a PTS1- and peroxin-dependent manner. The expression of the HEX1 gene in yeast generates hexagonal vesicles that are morphologically similar to the native Woronin body, implying a Hex1-encoded mechanism of Woronin-body assembly. Deletion of HEX1 in N. crassa eliminates Woronin bodies from the cytoplasm and results in hyphae that exhibit a cytoplasmic-bleeding phenotype in response to cell lysis. Our results show that the Woronin body represents a new category of peroxisome with a function in the maintenance of cellular integrity.	Rockefeller Univ, Plant Mol Biol Lab, New York, NY 10021 USA	Rockefeller University	Chua, NH (corresponding author), Rockefeller Univ, Plant Mol Biol Lab, 1230 York Ave, New York, NY 10021 USA.	chua@rockvax.rockefeller.edu		Jedd, Gregory/0000-0002-5428-3873	NIGMS NIH HHS [GM 19828-02] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bi GQ, 1997, J CELL BIOL, V138, P999, DOI 10.1083/jcb.138.5.999; BYERS B, 1991, METHOD ENZYMOL, V194, P602; COLLINGE AJ, 1985, EXP MYCOL, V9, P80, DOI 10.1016/0147-5975(85)90051-9; DEZOYSA PA, 1994, CURR GENET, V26, P430, DOI 10.1007/BF00309930; ERDMANN R, 1995, J CELL BIOL, V128, P509, DOI 10.1083/jcb.128.4.509; Erdmann R, 1996, J CELL BIOL, V135, P111, DOI 10.1083/jcb.135.1.111; GARRISON RG, 1970, J BACTERIOL, V101, P628, DOI 10.1128/JB.101.2.628-635.1970; GOULD SJ, 1989, J CELL BIOL, V108, P1657, DOI 10.1083/jcb.108.5.1657; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HOCH HC, 1974, CAN J MICROBIOL, V20, P1029, DOI 10.1139/m74-159; Jedd G, 1997, J CELL BIOL, V137, P563, DOI 10.1083/jcb.137.3.563; KELLER GA, 1991, J CELL BIOL, V114, P893, DOI 10.1083/jcb.114.5.893; KIONKA C, 1985, J BACTERIOL, V161, P153, DOI 10.1128/JB.161.1.153-157.1985; LAZAROW PB, 1976, P NATL ACAD SCI USA, V73, P2043, DOI 10.1073/pnas.73.6.2043; Margolin BS, 1997, FUNGAL GENET NEWSLET, V44, P34, DOI [10.4148/1941-4765.1281, DOI 10.1128/EC.00244-07]; MARKHAM P, 1987, FEMS MICROBIOL LETT, V46, P1; MCKEEN WE, 1971, CAN J MICROBIOL, V17, P1557, DOI 10.1139/m71-248; Monosov EZ, 1996, J HISTOCHEM CYTOCHEM, V44, P581, DOI 10.1177/44.6.8666743; MUMBERG D, 1995, GENE, V156, P119, DOI 10.1016/0378-1119(95)00037-7; Nishimura M, 1996, CELL STRUCT FUNCT, V21, P387, DOI 10.1247/csf.21.387; Oancea E, 1998, CELL, V95, P307, DOI 10.1016/S0092-8674(00)81763-8; Olsen LJ, 1998, PLANT MOL BIOL, V38, P163, DOI 10.1023/A:1006092830670; PARK MH, 1993, BIOFACTORS, V4, P95; PRINGLE JR, 1989, METHOD CELL BIOL, V31, P357; Rose MD., 1990, METHODS YEAST GENETI; Schatz O, 1998, P NATL ACAD SCI USA, V95, P1607, DOI 10.1073/pnas.95.4.1607; Staben C, 1989, FUNGAL GENET NEWSL, V36, P79, DOI DOI 10.4148/1941-4765.1519; STEINHARDT RA, 1994, SCIENCE, V263, P390, DOI 10.1126/science.7904084; Subramani S, 1998, PHYSIOL REV, V78, P171, DOI 10.1152/physrev.1998.78.1.171; SWINKELS BW, 1991, EMBO J, V10, P3255, DOI 10.1002/j.1460-2075.1991.tb04889.x; Tabak HF, 1999, TRENDS CELL BIOL, V9, P447, DOI 10.1016/S0962-8924(99)01650-5; TRINCI APJ, 1973, PROTOPLASMA, V80, P57, DOI 10.1007/BF01666351; VOGEL HJ, 1964, AM NAT, V98, P435, DOI 10.1086/282338; WANNER G, 1982, ANN NY ACAD SCI, V386, P269, DOI 10.1111/j.1749-6632.1982.tb21422.x; WERGIN WP, 1973, PROTOPLASMA, V76, P249, DOI 10.1007/BF01280701; WORONIN M, 1864, ABH SENKENB NATURFOR, V5, P333; Zuk D, 1998, EMBO J, V17, P2914, DOI 10.1093/emboj/17.10.2914	37	199	208	1	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	APR	2000	2	4					226	231		10.1038/35008652	http://dx.doi.org/10.1038/35008652			6	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	302ZU	10783241				2022-12-25	WOS:000086397000016
J	Liu, P; Aitken, K; Kong, YY; Opavsky, MA; Martino, T; Dawood, F; Wen, WH; Kozieradzki, I; Bachmaier, K; Straus, D; Mak, TW; Penninger, JM				Liu, P; Aitken, K; Kong, YY; Opavsky, MA; Martino, T; Dawood, F; Wen, WH; Kozieradzki, I; Bachmaier, K; Straus, D; Mak, TW; Penninger, JM			The tyrosine kinase p56(lck) is essential in coxsackievirus B3-mediated heart disease	NATURE MEDICINE			English	Article							POLYMERASE-CHAIN-REACTION; DECAY-ACCELERATING FACTOR; CELL ANTIGEN RECEPTOR; MICE LACKING P56(LCK); DILATED CARDIOMYOPATHY; SIGNAL TRANSDUCTION; DIFFERENT STRAINS; T-CELLS; MYOCARDITIS; VIRUS	Infections are thought to be important in the pathogenesis of many heart diseases. Coxsackievirus B3 (CVB3) has been linked to chronic dilated cardiomyopathy, a common cause of progressive heart disease, heart failure and sudden death. We show here that the sarcoma (Src) family kinase Lck (p56(kk)) is required for efficient CVB3 replication in T-cell lines and for viral replication and persistence in vivo. Whereas infection of wild-type mice with human pathogenic CVB3 caused acute and very severe myocarditis, meningitis, hepatitis, pancreatitis and dilated cardiomyopathy, mice lacking the p56(lck) gene were completely protected from CVB3-induced acute pathogenicity and chronic heart disease. These data identify a previously unknown function of Src family kinases and indicate that p56(lck) is the essential host factor that controls the replication and pathogenicity of CVB3.	Ontario Canc Inst, Amgen Inst, Toronto, ON M5G 2C1, Canada; Univ Toronto, Univ Hlth Network, Heart & Stroke Lewar Ctr Excellence Cardiovasc Re, Toronto, ON M5G 2C4, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2C1, Canada; Univ Toronto, Dept Immunol, Toronto, ON M5G 2C1, Canada; Univ Chicago, Dept Med, Chicago, IL 60637 USA; Univ Chicago, Dept Pathol, Chicago, IL 60637 USA	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of Toronto; University of Chicago; University of Chicago	Penninger, JM (corresponding author), Ontario Canc Inst, Amgen Inst, 620 Univ Ave, Toronto, ON M5G 2C1, Canada.		Aitken, KJ/AAC-5383-2019; Bachmaier, Kurt/B-6331-2014; Penninger, Josef M/I-6860-2013	Bachmaier, Kurt/0000-0002-0299-2707; Penninger, Josef M/0000-0002-8194-3777; Aitken, Karen/0000-0003-2995-0205				Anderson DR, 1996, J VIROL, V70, P4632, DOI 10.1128/JVI.70.7.4632-4645.1996; Archard LC, 1998, HUM PATHOL, V29, P578, DOI 10.1016/S0046-8177(98)80006-3; Bachmaier K, 1999, SCIENCE, V283, P1335, DOI 10.1126/science.283.5406.1335; Bergelson JM, 1997, SCIENCE, V275, P1320, DOI 10.1126/science.275.5304.1320; Friman G, 1995, EUR HEART J, V16, P36, DOI 10.1093/eurheartj/16.suppl_O.36; FUNGLEUNG WP, 1991, CELL, V65, P443, DOI 10.1016/0092-8674(91)90462-8; Gauntt CJ, 1995, EUR HEART J, V16, P56, DOI 10.1093/eurheartj/16.suppl_O.56; Horwitz MS, 1998, NAT MED, V4, P781, DOI 10.1038/nm0798-781; Huber SA, 1997, LAB INVEST, V76, P691; HUBER SA, 1984, AM J PATHOL, V116, P21; Klingel K, 1996, J VIROL, V70, P8888, DOI 10.1128/JVI.70.12.8888-8895.1996; KORETZKY GA, 1991, P NATL ACAD SCI USA, V88, P2037, DOI 10.1073/pnas.88.6.2037; MARTINO TA, 1993, J CLIN MICROBIOL, V31, P2634, DOI 10.1128/JCM.31.10.2634-2640.1993; MARTINO TA, 1994, CIRC RES, V74, P182, DOI 10.1161/01.RES.74.2.182; MATSUMORI A, 1982, CIRCULATION, V65, P1230, DOI 10.1161/01.CIR.65.6.1230; MOLINA TJ, 1993, J IMMUNOL, V151, P699; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; RAHEMTULLA A, 1991, NATURE, V353, P180, DOI 10.1038/353180a0; ROSE NR, 1988, IMMUNOL TODAY, V9, P117, DOI 10.1016/0167-5699(88)91282-0; Shafren DR, 1998, J VIROL, V72, P9407, DOI 10.1128/JVI.72.11.9407-9412.1998; SHAHINIAN A, 1993, SCIENCE, V261, P609, DOI 10.1126/science.7688139; SHENOYSCARIA AM, 1992, J IMMUNOL, V149, P3535; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; Wang XH, 1999, J VIROL, V73, P2559, DOI 10.1128/JVI.73.3.2559-2562.1999; WOLFGRAM LJ, 1986, J IMMUNOL, V136, P1846; WOODRUFF JF, 1980, AM J PATHOL, V101, P425	27	120	134	0	3	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	APR	2000	6	4					429	434		10.1038/74689	http://dx.doi.org/10.1038/74689			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	376UA	10742150				2022-12-25	WOS:000165474100037
J	Niwa, H; Miyazaki, J; Smith, AG				Niwa, H; Miyazaki, J; Smith, AG			Quantitative expression of Oct-3/4 defines differentiation, dedifferentiation or self-renewal of ES cells	NATURE GENETICS			English	Article							EMBRYONIC STEM-CELLS; BINDING TRANSCRIPTION FACTOR; MOUSE EMBRYO; EXTRAEMBRYONIC MEMBRANES; MAMMALIAN EMBRYO; GENE-EXPRESSION; POU-DOMAIN; ACTIVATION; ENHANCER; DEPENDS	Cell fate during development is defined by transcription factors that act as molecular switches to activate or repress specific less than twofold increase in expression causes differentiation gene expression programmes. The POU transcription factor into primitive endoderm and mesoderm, In contrast, repression Oct-3/4 (encoded by Pou5f1) is a candidate regulator in pluripotent and germline cells(1-4) and is essential for the initial formation of a pluripotent founder cell population in the mammalian embryo(5). Here we use conditional expression and repression in embryonic stem (ES) cells to determine requirements for Oct-3/4 in the maintenance of developmental potency. Although transcriptional determination has usually been considered as a binary on-off control system, we found that the precise level of Oct-3/4 governs three distinct fates of ES cells, A less than twofold increase in expression causes differentiation of Oct-3/4 induces loss of pluripotency and dedifferentiation to trophectoderm. Thus a critical amount of Oct-3/4 is required to sustain stem-cell self-renewal, and up- or downregulation induce divergent developmental programmes. Our findings establish a pole for Oct-3/4 as a master regulator of pluripotency that controls lineage commitment and illustrate the sophistication of critical transcriptional regulators and the consequent importance of quantitative analyses.	Univ Edinburgh, Ctr Genome Res, Edinburgh, Midlothian, Scotland; Osaka Univ, Dept Nutr & Physiol Chem, Osaka, Japan	University of Edinburgh; Osaka University	Niwa, H (corresponding author), Univ Edinburgh, Ctr Genome Res, Kings Bldg, Edinburgh, Midlothian, Scotland.	hniwa@nutri.med.osaka-u.ac.jp; austin.smith@ed.ac.uk	Miyazaki, Jun-ichi/N-1976-2015	Miyazaki, Jun-ichi/0000-0003-2475-589X; Smith, Austin/0000-0002-3029-4682				Ambrosetti DC, 1997, MOL CELL BIOL, V17, P6321, DOI 10.1128/MCB.17.11.6321; ARCECI RJ, 1993, MOL CELL BIOL, V13, P2235, DOI 10.1128/MCB.13.4.2235; BECK F, 1995, DEV DYNAM, V204, P219, DOI 10.1002/aja.1002040302; BEDDINGTON RSP, 1989, DEVELOPMENT, V105, P733; Ben-Shushan E, 1998, MOL CELL BIOL, V18, P1866, DOI 10.1128/MCB.18.4.1866; Botquin V, 1998, GENE DEV, V12, P2073, DOI 10.1101/gad.12.13.2073; Brook FA, 1997, P NATL ACAD SCI USA, V94, P5709, DOI 10.1073/pnas.94.11.5709; Burdon T, 1999, CELLS TISSUES ORGANS, V165, P131, DOI 10.1159/000016693; CSERJESI P, 1995, DEV BIOL, V170, P664, DOI 10.1006/dbio.1995.1245; Dani C, 1998, DEV BIOL, V203, P149, DOI 10.1006/dbio.1998.9026; GASSMANN M, 1995, P NATL ACAD SCI USA, V92, P1292, DOI 10.1073/pnas.92.5.1292; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; HEBERT JM, 1991, DEVELOPMENT, V112, P407; MOUNTFORD P, 1994, P NATL ACAD SCI USA, V91, P4303, DOI 10.1073/pnas.91.10.4303; Nichols J, 1998, CELL, V95, P379, DOI 10.1016/S0092-8674(00)81769-9; Nishikawa S, 1998, DEVELOPMENT, V125, P1747; Nishimoto M, 1999, MOL CELL BIOL, V19, P5453; Niwa H, 1998, GENE DEV, V12, P2048, DOI 10.1101/gad.12.13.2048; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; OKAMOTO K, 1990, CELL, V60, P461, DOI 10.1016/0092-8674(90)90597-8; PALMIERI SL, 1994, DEV BIOL, V166, P259, DOI 10.1006/dbio.1994.1312; Pesce M, 1998, MECH DEVELOP, V71, P89, DOI 10.1016/S0925-4773(98)00002-1; ROSNER MH, 1990, NATURE, V345, P686, DOI 10.1038/345686a0; Saijoh Y, 1996, GENES CELLS, V1, P239, DOI 10.1046/j.1365-2443.1996.d01-237.x; SCHOLER HR, 1991, CELL, V66, P291, DOI 10.1016/0092-8674(91)90619-A; SCHOLER HR, 1990, NATURE, V344, P435, DOI 10.1038/344435a0; SHIMAZAKI T, 1993, EMBO J, V12, P4489, DOI 10.1002/j.1460-2075.1993.tb06138.x; SMITH AG, 1988, NATURE, V336, P688, DOI 10.1038/336688a0; Tanaka S, 1998, SCIENCE, V282, P2072, DOI 10.1126/science.282.5396.2072; WILKINSON DG, 1990, NATURE, V343, P657, DOI 10.1038/343657a0	30	2708	2896	9	258	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	APR	2000	24	4					372	376		10.1038/74199	http://dx.doi.org/10.1038/74199			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	299HK	10742100				2022-12-25	WOS:000086192800015
J	Yakushi, T; Masuda, K; Narita, S; Matsuyama, S; Tokuda, H				Yakushi, T; Masuda, K; Narita, S; Matsuyama, S; Tokuda, H			A new ABC transporter mediating the detachment of lipid-modified proteins from membranes	NATURE CELL BIOLOGY			English	Article							ESCHERICHIA-COLI LIPOPROTEINS; OUTER-MEMBRANE; LOCALIZATION; BACTERIA; LOLA; SEQUENCES; SUBUNITS; FAMILY	Lipoproteins in Escherichia coli are anchored to the periplasmic side of either the inner or the outer membrane by a lipid moiety that is covalently attached to the amino-terminal cysteine residue, Membrane specificity depends on a sorting signal at position 2 of the lipoprotein. Lipoproteins directed to the outer membrane are released from the inner membrane in an ATP-dependent manner through the formation of a complex with LolA, a periplasmic chaperone. However, the ATPase involved in this reaction has not been identified. Here we show, using reconstituted proteoliposomes, that a new complex, LolCDE, belonging to the ATP-binding cassette (ABC) transporter family, catalyses the release of lipoproteins in LolA- and sorting-signal-dependent manners. The LolCDE complex differs mechanistically from all other ABC transporters as it is not involved in the transmembrane transport of substrates. This new mechanism is evolutionarily conserved in other Gram-negative bacteria.	Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 1130032, Japan	University of Tokyo	Tokuda, H (corresponding author), Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1130032, Japan.			Narita, Shin-ichiro/0000-0001-9425-2943				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Fraser CM, 1997, NATURE, V390, P580, DOI 10.1038/37551; HAYASHI S, 1990, J BIOENERG BIOMEMBR, V22, P451, DOI 10.1007/BF00763177; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; HIGGINS CF, 1986, NATURE, V323, P448, DOI 10.1038/323448a0; Hung LW, 1998, NATURE, V396, P703, DOI 10.1038/25393; KOHARA Y, 1987, CELL, V50, P495, DOI 10.1016/0092-8674(87)90503-4; Linton KJ, 1998, MOL MICROBIOL, V28, P5, DOI 10.1046/j.1365-2958.1998.00764.x; MATSUYAMA S, 1995, EMBO J, V14, P3365, DOI 10.1002/j.1460-2075.1995.tb07342.x; Matsuyama S, 1997, EMBO J, V16, P6947, DOI 10.1093/emboj/16.23.6947; Nishiyama K, 1999, EMBO J, V18, P1049, DOI 10.1093/emboj/18.4.1049; PUGSLEY AP, 1993, MICROBIOL REV, V57, P50, DOI 10.1128/MMBR.57.1.50-108.1993; SHYAMALA V, 1991, J BIOL CHEM, V266, P18714; Tajima T, 1998, FEBS LETT, V439, P51, DOI 10.1016/S0014-5793(98)01334-9; Tjalsma H, 1999, J BIOL CHEM, V274, P1698, DOI 10.1074/jbc.274.3.1698; TOKUDA H, 1990, EUR J BIOCHEM, V192, P583, DOI 10.1111/j.1432-1033.1990.tb19264.x; Tusnady GE, 1998, J MOL BIOL, V283, P489, DOI 10.1006/jmbi.1998.2107; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; Yakushi T, 1998, J BIOL CHEM, V273, P32576, DOI 10.1074/jbc.273.49.32576; Yakushi T, 1997, J BACTERIOL, V179, P2857, DOI 10.1128/jb.179.9.2857-2862.1997; YAMAGUCHI K, 1988, CELL, V53, P423, DOI 10.1016/0092-8674(88)90162-6; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; Yokota N, 1999, J BIOL CHEM, V274, P30995, DOI 10.1074/jbc.274.43.30995; Zhou ZM, 1998, J BIOL CHEM, V273, P12466, DOI 10.1074/jbc.273.20.12466	24	204	216	0	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	APR	2000	2	4					212	218		10.1038/35008635	http://dx.doi.org/10.1038/35008635			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	302ZU	10783239				2022-12-25	WOS:000086397000014
J	Kost, J; Mitragotri, S; Gabbay, RA; Pishko, M; Langer, R				Kost, Joseph; Mitragotri, Samir; Gabbay, Robert A.; Pishko, Michael; Langer, Robert			Transdermal monitoring of glucose and other analytes using ultrasound	NATURE MEDICINE			English	Article									[Kost, Joseph] Ben Gur Univ, Dept Chem Engn, IL-84105 Beer Sheva, Israel; [Kost, Joseph; Langer, Robert] MIT, Dept Chem Engn, Cambridge, MA 02139 USA; [Mitragotri, Samir] Univ Calif Santa Barbara, Dept Chem Engn, Santa Barbara, CA 93106 USA; [Gabbay, Robert A.] Beth Israel Deaconess Med Ctr, Endocrine Div, Boston, MA 02215 USA; [Pishko, Michael] Texas A&M Univ, Dept Chem Engn, College Stn, TX 77843 USA; [Gabbay, Robert A.] Penn State Geisinger Hlth Syst, Sect Endocrinol & Diabet, Hershey, PA 17033 USA		Kost, J (corresponding author), Ben Gur Univ, Dept Chem Engn, IL-84105 Beer Sheva, Israel.; Kost, J; Langer, R (corresponding author), MIT, Dept Chem Engn, Cambridge, MA 02139 USA.	kost@bgumail.bgu.ac.il; rlanger@mit.edu	Kost, Joseph/F-2155-2012	Kost, Joseph/0000-0002-7854-533X	Juvenile Diabetic Foundation [197033]; United States-Israel Binational Science Foundation [93-00244]; Center for Disease Control; American Diabetes Association	Juvenile Diabetic Foundation; United States-Israel Binational Science Foundation(US-Israel Binational Science Foundation); Center for Disease Control; American Diabetes Association(American Diabetes Association)	We thank R. Rubin and A. Moses for advice; the Massachusetts Institute of Technology/Beth Israel Deaconess Medical Center Clinical Research Center teams and A. Patel for technical assistance; and Nicholas Warner and Tom Devlin for illustrations. This work was supported by American Diabetes Association and Juvenile Diabetic Foundation grants 197033, and the United States-Israel Binational Science Foundation grant 93-00244, and Center for Disease Control.	Antich T J, 1982, J Orthop Sports Phys Ther, V4, P99; Arnowitz J., 1998, NASA JDF TECHN WORKS; CLARKE WL, 1987, DIABETES CARE, V10, P622, DOI 10.2337/diacare.10.5.622; CSOREGI E, 1995, ANAL CHEM, V67, P1240; Eppstein J., 1995, US Patent, Patent No. [US5458140, 5458140]; Gutman S., 1998, REV CRITERIA ASSESSM; JOHNSON KW, 1992, BIOSENS BIOELECTRON, V7, P709, DOI 10.1016/0956-5663(92)85053-D; Klonoff DC, 1997, DIABETES CARE, V20, P433, DOI 10.2337/diacare.20.3.433; Kost J, 1993, TOPICAL DRUG BIOAVAI, P91; Kurnik RT, 1998, J ELECTROCHEM SOC, V145, P4119, DOI 10.1149/1.1838924; Liu J, 1998, PHARMACEUT RES, V15, P918, DOI 10.1023/A:1011984817567; Mastrototaro J., 1998, NASA JDF TECHN WORKS; MITRAGOTRI S, 1995, SCIENCE, V269, P850, DOI 10.1126/science.7638603; Rao G, 1995, PHARM RES-DORDR, V12, P1869, DOI 10.1023/A:1016271301814; Roe JN, 1998, CRIT REV THER DRUG, V15, P199; Ross D, 1997, BRIT MED J, V315, P288, DOI 10.1136/bmj.315.7103.288; TACHIBANA K, 1992, PHARMACEUT RES, V9, P952, DOI 10.1023/A:1015869420159; TAMADA JA, 1995, NAT MED, V1, P1198, DOI 10.1038/nm1195-1198; Wayforth H.B, 1992, EXPT SURG TECHNIQUES, P215	19	176	181	3	29	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2000	6	3					347	350		10.1038/73213	http://dx.doi.org/10.1038/73213			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	VK7ZM	10700240				2022-12-25	WOS:000755169100001
J	Sako, Y; Minoguchi, S; Yanagida, T				Sako, Y; Minoguchi, S; Yanagida, T			Single-molecule imaging of EGFR signalling on the surface of living cells	NATURE CELL BIOLOGY			English	Article							GROWTH-FACTOR RECEPTOR; PLASMA-MEMBRANES; A431 CELLS; MICROSCOPY; AGGREGATION; ACTIVATION; MODEL; STABILIZATION; DIFFUSION; SKELETON	The early events in signal transduction from the epidermal growth factor (EGF) receptor (EGFR) are dimerization and autophosphorylation of the receptor, induced by binding of EGF, Here we observe these events in living cells by visualizing single molecules of fluorescent-dye-labelled EGF in the plasma membrane of A431 carcinoma cells. Single-molecule tracking reveals that the predominant mechanism of dimerization involves the formation of a cell-surface complex of one EGF molecule and an EGFR dimer, followed by the direct arrest of a second EGF molecule, indicating that the EGFR dimers were probably preformed before the binding of the second EGF molecule. Single-molecule fluorescence-resonance energy transfer shows that EGF-EGFR complexes indeed form dimers at the molecular level. Use of a monoclonal antibody specific to the phosphorylated (activated) EGFR reveals that the EGFR becomes phosphorylated after dimerization.	Osaka Univ, Grad Sch Med, Dept Physiol & Biosignalling, Suita, Osaka 5650871, Japan; JST, ICORP, Single Mol Proc Project, Mino 5620035, Japan	Osaka University; Japan Science & Technology Agency (JST)	Yanagida, T (corresponding author), Osaka Univ, Grad Sch Med, Dept Physiol & Biosignalling, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	yanagida@phys1.med.osaka-u.ac.jp	Yanagida, Toshio/D-1919-2009; Sako, Yasushi/B-3253-2015	Sako, Yasushi/0000-0002-5707-5455				AZEVEDO JR, 1990, J MEMBRANE BIOL, V118, P215, DOI 10.1007/BF01868605; Campos-Gonzalez R, 1991, GROWTH FACTORS, V4, P305, DOI 10.3109/08977199109043916; CARRAWAY KL, 1991, J BIOL CHEM, V266, P8899; CARRAWAY KL, 1989, J BIOL CHEM, V264, P8699; Chung JC, 1997, BIOPHYS J, V73, P1089, DOI 10.1016/S0006-3495(97)78141-4; DENHARTIGH JC, 1992, J CELL BIOL, V119, P349, DOI 10.1083/jcb.119.2.349; FUNATSU T, 1995, NATURE, V374, P555, DOI 10.1038/374555a0; GADELLA TWJ, 1995, J CELL BIOL, V129, P1543, DOI 10.1083/jcb.129.6.1543; HURWITZ DR, 1991, J BIOL CHEM, V266, P22035; Ide T, 1999, BIOCHEM BIOPH RES CO, V265, P595, DOI 10.1006/bbrc.1999.1720; Ishii Y, 1999, CHEM PHYS, V247, P163, DOI 10.1016/S0301-0104(99)00174-3; KINOSITA K, 1991, J CELL BIOL, V115, P67, DOI 10.1083/jcb.115.1.67; Kusumi A, 1996, CURR OPIN CELL BIOL, V8, P566, DOI 10.1016/S0955-0674(96)80036-6; Lemmon MA, 1997, EMBO J, V16, P281, DOI 10.1093/emboj/16.2.281; PIMPLIKAR SW, 1994, J CELL BIOL, V125, P1025, DOI 10.1083/jcb.125.5.1025; Sako Y, 1998, J CELL BIOL, V140, P1227, DOI 10.1083/jcb.140.5.1227; SAKO Y, 1995, J CELL BIOL, V129, P1559, DOI 10.1083/jcb.129.6.1559; Schutz GJ, 1997, BIOPHYS J, V73, P1073, DOI 10.1016/S0006-3495(97)78139-6; SOROKIN A, 1994, J BIOL CHEM, V269, P9752; Tokunaga M, 1997, BIOCHEM BIOPH RES CO, V235, P47, DOI 10.1006/bbrc.1997.6732; Tzahar E, 1997, EMBO J, V16, P4938, DOI 10.1093/emboj/16.16.4938; WEIGANT FAC, 1986, J CELL BIOL, V103, P87; Weiss S, 1999, SCIENCE, V283, P1676, DOI 10.1126/science.283.5408.1676; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1443, DOI 10.1021/bi00379a035; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1434, DOI 10.1021/bi00379a034; ZIDOVETZKI R, 1986, EMBO J, V5, P247, DOI 10.1002/j.1460-2075.1986.tb04205.x	26	693	724	7	210	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	MAR	2000	2	3					168	172		10.1038/35004044	http://dx.doi.org/10.1038/35004044			5	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	292AE	10707088				2022-12-25	WOS:000085771300017
J	Song, YC; Khirabadi, BS; Lightfoot, F; Brockbank, KGM; Taylor, MJ				Song, YC; Khirabadi, BS; Lightfoot, F; Brockbank, KGM; Taylor, MJ			Vitreous cryopreservation maintains the function of vascular grafts	NATURE BIOTECHNOLOGY			English	Article						cryopreservation; vitrification; vascular graft; smooth muscle; tissue preservation	COMMON CAROTID-ARTERY; DIMETHYL-SULFOXIDE; VITRIFICATION; RABBIT	Avoidance of ice formation during cooling can be achieved by vitrification, which is defined as solidification in an amorphous glassy state that obviates ice nucleation and growth. We show that a vitrification approach to storing vascular tissue results in markedly improved tissue function compared with a standard method involving freezing. The maximum contractions achieved in vitrified vessels were >80% of fresh matched controls with similar drug sensitivities, whereas frozen vessels exhibited maximal contractions below 30% of controls and concomitant decreases in drug sensitivity. In vivo studies of vitrified vessel segments in an autologous transplant model showed no adverse effects of vitreous cryopreservation compared with fresh tissue grafts.	Organ Recovery Syst Inc, Charleston, SC 29403 USA		Taylor, MJ (corresponding author), Organ Recovery Syst Inc, 701 E Bay St, Charleston, SC 29403 USA.	mtaylor@organ-recovery.com	Brockbank, Kelvin/GWV-4265-2022					BATESON EAJ, 1994, CRYOBIOLOGY, V31, P393, DOI 10.1006/cryo.1994.1047; Bilfinger TV, 1997, ANN THORAC SURG, V63, P1063, DOI 10.1016/S0003-4975(97)00167-7; BROCKBANK KGM, 1994, CRYOBIOLOGY, V31, P71, DOI 10.1006/cryo.1994.1009; Davies MG, 1999, EUR J VASC ENDOVASC, V17, P493, DOI 10.1053/ejvs.1999.0793; ELFORD BC, 1972, CRYOBIOLOGY, V9, P82, DOI 10.1016/0011-2240(72)90015-6; ELFORD BC, 1972, NATURE-NEW BIOL, V236, P58, DOI 10.1038/newbio236058a0; ELFORD BC, 1970, J PHYSIOL-LONDON, V209, P187, DOI 10.1113/jphysiol.1970.sp009162; ELMORE JR, 1991, J VASC SURG, V13, P584; Faggioli G L, 1994, Cardiovasc Surg, V2, P259; FAHY GM, 1987, CRYOBIOLOGY, V24, P196, DOI 10.1016/0011-2240(87)90023-X; FAHY GM, 1984, CRYOBIOLOGY, V21, P407, DOI 10.1016/0011-2240(84)90079-8; FAHY GM, 1987, BIOPHYSICS ORGAN CRY, P265; FAHY GM, 1988, LOW TEMPERATURE BIOT, P113; FARRANT J, 1965, NATURE, V205, P1284, DOI 10.1038/2051284a0; FINNEY DJ, 1978, STATISTICAL METHOD B, P349; Horkheimer Max, 1985, GESAMMELTE SCHRIFTEN, V2; HUNT CJ, 1982, J MICROSC-OXFORD, V125, P177, DOI 10.1111/j.1365-2818.1982.tb00335.x; JACOBSEN IA, 1984, CRYOBIOLOGY, V21, P637, DOI 10.1016/0011-2240(84)90223-2; KENT KC, 1989, J VASC SURG, V9, P107, DOI 10.1067/mva.1989.vs0090107; McNally Robert T., 1992, Cryobiology, V29, P702; MCNALLY RT, 1992, Patent No. 5145769; MEHL PM, 1993, CRYOBIOLOGY, V30, P509, DOI 10.1006/cryo.1993.1051; Motulsky H., 1995, INTUITIVE BIOSTATIST; Pegg D.E., 1987, BIOPHYSICS ORGAN CRY, P117; PEGG DE, 1979, ORGAN PRESERVATION, V2, P132; RALL WF, 1985, NATURE, V313, P573, DOI 10.1038/313573a0; SONG YC, 1995, CRYOBIOLOGY, V32, P405, DOI 10.1006/cryo.1995.1040; SONG YC, 1994, CRYOBIOLOGY, V31, P317, DOI 10.1006/cryo.1994.1038; TAYLOR MJ, 1983, CRYOBIOLOGY, V20, P36, DOI 10.1016/0011-2240(83)90057-3; TAYLOR MJ, 1984, TRANSPLANTATION IMMU, P360; WALKER PJ, 1993, J VASC SURG, V18, P561, DOI 10.1016/0741-5214(93)90065-T	31	196	210	1	20	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	MAR	2000	18	3					296	299		10.1038/73737	http://dx.doi.org/10.1038/73737			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	292AC	10700144				2022-12-25	WOS:000085771100026
J	Jung, W; Yu, O; Lau, SMC; O'Keefe, DP; Odell, J; Fader, G; McGonigle, B				Jung, W; Yu, O; Lau, SMC; O'Keefe, DP; Odell, J; Fader, G; McGonigle, B			Identification and expression of isoflavone synthase, the key enzyme for biosynthesis of isoflavones in legumes	NATURE BIOTECHNOLOGY			English	Article						isoflavone; cytochrome P450; phenylpropanoid	SOYBEAN SEEDS; METABOLISM; SEQUENCES; PROMOTER; CANCER; YEAST; GENE; SOY	Isoflavones have drawn much attention because of their benefits to human health. These compounds, which are produced almost exclusively in legumes, have natural roles in plant defense and root nodulation, Isoflavone synthase catalyzes the first committed step of isoflavone biosynthesis, a branch of the phenylpropanoid pathway. To identify the gene encoding this enzyme, we used a yeast expression assay to screen soybean ESTs encoding cytochrome P450 proteins. We identified two soybean genes encoding isoflavone synthase, and used them to isolate homologous genes from other leguminous species including red clover, white clover, hairy vetch, mung bean, alfalfa, lentil, snow pea, and lupine, as well as from the nonleguminous sugarbeet, We expressed soybean isoflavone synthase in Arabidopsis thaliana, which led to production of the isoflavone genistein in this nonlegume plant. Identification of the isoflavone synthase gene should allow manipulation of the phenylpropanoid pathway for agronomic and nutritional purposes.	DuPont Co Inc, Expt Stn, Agr Biotechnol, Wilmington, DE 19880 USA; DuPont Co Inc, Expt Stn, Cent Res & Dev, Wilmington, DE 19880 USA	DuPont; DuPont	McGonigle, B (corresponding author), DuPont Co Inc, Expt Stn, Agr Biotechnol, POB 80402, Wilmington, DE 19880 USA.	Brian.McGonigle@usa.dupont.com		O'Keefe, Daniel/0000-0002-8234-5293				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BECHTOLD N, 1993, CR ACAD SCI III-VIE, V316, P1194; BLOUNT JW, 1992, PHYSIOL MOL PLANT P, V41, P333, DOI 10.1016/0885-5765(92)90020-V; BOLWELL GP, 1994, PHYTOCHEMISTRY, V37, P1491, DOI 10.1016/S0031-9422(00)89567-9; Civitelli R, 1997, CALCIFIED TISSUE INT, V61, pS12, DOI 10.1007/s002239900378; DEPICKER A, 1982, Journal of Molecular and Applied Genetics, V1, P561; DEWICK PM, 1982, ADV RES, P535; DIXON RA, 1995, PLANT CELL, V7, P1085, DOI 10.1105/tpc.7.7.1085; EBEL J, 1986, ANNU REV PHYTOPATHOL, V24, P235; ELDRIDGE AC, 1983, J AGR FOOD CHEM, V31, P394, DOI 10.1021/jf00116a052; Food and Drug Administation (FDA), 1999, FED REG         1026, V64, P57699; GEIGERT J, 1973, TETRAHEDRON, V29, P2703, DOI 10.1016/S0040-4020(01)93389-7; Gennari C, 1998, MENOPAUSE, V5, P9; Graham Terrence Lee, 1995, P85; GRAHAM TL, 2000, IN PRESS PLANT MICRO; HAJDUKIEWICZ P, 1994, PLANT MOL BIOL, V25, P989, DOI 10.1007/BF00014672; HASENFRATZ MP, 1992, CLONAGE NADPH CYTOCH; HASHIM MF, 1990, FEBS LETT, V271, P219, DOI 10.1016/0014-5793(90)80410-K; Hua SB, 1997, PLASMID, V38, P91, DOI 10.1006/plas.1997.1305; JOHNSTON M, 1984, MOL CELL BIOL, V4, P1440, DOI 10.1128/MCB.4.8.1440; KOCHS G, 1986, EUR J BIOCHEM, V155, P311, DOI 10.1111/j.1432-1033.1986.tb09492.x; MESSINA M, 1991, JNCI-J NATL CANCER I, V83, P541, DOI 10.1093/jnci/83.8.541; MURKIES AL, 1995, MATURITAS, V21, P189, DOI 10.1016/0378-5122(95)00899-V; Nestel PJ, 1999, J CLIN ENDOCR METAB, V84, P895, DOI 10.1210/jc.84.3.895; ODELL JT, 1985, NATURE, V313, P810, DOI 10.1038/313810a0; OKUBO K, 1992, BIOSCI BIOTECH BIOCH, V56, P99, DOI 10.1271/bbb.56.99; Padmavati M, 1999, J PLANT BIOCHEM BIOT, V8, P15, DOI 10.1007/BF03263051; PETERSON G, 1991, BIOCHEM BIOPH RES CO, V179, P661, DOI 10.1016/0006-291X(91)91423-A; Pompon D, 1996, METHOD ENZYMOL, V272, P51, DOI 10.1016/S0076-6879(96)72008-6; Pueppke SG, 1996, CRIT REV BIOTECHNOL, V16, P1, DOI 10.3109/07388559609146599; RIVERAVARGAS LI, 1993, PHYTOCHEMISTRY, V32, P851, DOI 10.1016/0031-9422(93)85219-H; Schopfer CR, 1998, MOL GEN GENET, V258, P315, DOI 10.1007/s004380050736; SHARMA RD, 1979, LIPIDS, V14, P535, DOI 10.1007/BF02533528; SIKORSKI RS, 1989, GENETICS, V122, P19; Siminszky B, 1999, P NATL ACAD SCI USA, V96, P1750, DOI 10.1073/pnas.96.4.1750; Steele CL, 1999, ARCH BIOCHEM BIOPHYS, V367, P146, DOI 10.1006/abbi.1999.1238; TSUKAMOTO C, 1995, J AGR FOOD CHEM, V43, P1184, DOI 10.1021/jf00053a012; Wang HJ, 1996, J AGR FOOD CHEM, V44, P2377, DOI 10.1021/jf950535p	38	313	373	4	99	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	FEB	2000	18	2					208	212		10.1038/72671	http://dx.doi.org/10.1038/72671			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	281FH	10657130				2022-12-25	WOS:000085146900030
J	Rapley, EA; Crockford, GP; Teare, D; Biggs, P; Seal, S; Barfoot, R; Edwards, S; Hamoudi, R; Heimdal, K; Fossa, SD; Tucker, K; Donald, J; Collins, F; Friedlander, M; Hogg, D; Goss, P; Heidenreich, A; Ormiston, W; Daly, PA; Forman, D; Oliver, RTD; Leahy, M; Huddart, R; Cooper, CS; Bodmer, JG; Easton, DF; Stratton, MR; Bishop, DT				Rapley, EA; Crockford, GP; Teare, D; Biggs, P; Seal, S; Barfoot, R; Edwards, S; Hamoudi, R; Heimdal, K; Fossa, SD; Tucker, K; Donald, J; Collins, F; Friedlander, M; Hogg, D; Goss, P; Heidenreich, A; Ormiston, W; Daly, PA; Forman, D; Oliver, RTD; Leahy, M; Huddart, R; Cooper, CS; Bodmer, JG; Easton, DF; Stratton, MR; Bishop, DT			Localization to Xq27 of a susceptibility gene for testicular germ-cell tumours	NATURE GENETICS			English	Article							KLINEFELTER SYNDROME; EUROPEAN COUNTRIES; CANCER INCIDENCE; CHROMOSOME; INCREASE; PATIENT; TESTIS	Testicular germ-cell tumours (TGCT) affect 1 in 500 men and are the most common cancer in males aged 15-40 in Western European populations(1). The incidence of TGCT has risen dramatically over the last century(2-5) Known risk factors for TGCT include a history of undescended testis (UDT), testicular dysgenesis, infertility(6), previously diagnosed TGCT (ref. 7) and a family history of the disease(8-10). Brothers of men with TGCT have an 8-10-fold risk of developing TGCT (refs 8,9), whereas the relative risk to fathers and sons is fourfold (ref. 9). This familial relative risk is much higher than that for most other types of cancer. We have collected samples from 134 families with two or mom cases of TGCT, 87 of which are affected sibpairs. A genome-wide linkage search yielded a heterogeneity Iod (hIod) score of 2.01 on chromosome Xq27 using all families compatible with X inheritance. We obtained a hIod score of 4.7 from families with at least one bilateral case, corresponding to a genome-wide significance level of P=0.034. The proportion of families with UDT linked to this locus was 73% compared with 26% of families without UDT (P=0.03). Our results provide evidence for a TGCT susceptibility gene on chromosome Xq27 that may also predispose to UDT.	Inst Canc Res, Haddow Labs, Sect Canc Genet, Sutton, Surrey, England; Inst Canc Res, Haddow Labs, Sect Mol Carcinogenesis, Sutton, Surrey, England; Imperial Canc Res Fund, Genet Epidemiol Lab, Leeds, W Yorkshire, England; CRC, Genet Epidemiol Unit, Strangeways Res Labs, Cambridge, England; Norwegian Radium Hosp, Dept Oncol, Unit Med Genet, Oslo, Norway; Norwegian Radium Hosp, Dept Oncol, Oslo, Norway; Prince Wales Hosp, Dept Oncol, Randwick, NSW 2031, Australia; Macquarie Univ, Dept Biol Sci, N Ryde, NSW, Australia; Univ Toronto, Dept Med, Toronto, ON, Canada; Univ Marburg, Dept Urol, Marburg, Germany; St James Hosp, Hope Directorate, Dept Med Oncol, Dublin, Ireland; John Radcliffe Hosp, Imperial Canc Res Fund, Canc Genet & Immunol Lab, Oxford OX3 9DU, England	University of London; Institute of Cancer Research - UK; University of London; Institute of Cancer Research - UK; University of Oslo; University of Oslo; Macquarie University; University of Toronto; Philipps University Marburg; Trinity College Dublin; University of Oxford	Stratton, MR (corresponding author), Inst Canc Res, Haddow Labs, Sect Canc Genet, Sutton, Surrey, England.	mikes@icr.ac.uk	Heimdal, Ketil Riddervold/H-3038-2019; Leahy, Michael G/K-8697-2015; Biggs, Patrick Jon/H-3355-2014	Heimdal, Ketil Riddervold/0000-0002-8911-3508; Leahy, Michael G/0000-0002-9936-0537; Biggs, Patrick Jon/0000-0002-0285-4101; huddart, robert/0000-0003-3604-1990; Bishop, Tim/0000-0002-8752-8785; Teare, Marion Dawn/0000-0003-3994-0051; Donald, Jennifer/0000-0002-2732-1379; Hamoudi, Rifat/0000-0002-1402-0868				ADAMI HO, 1994, INT J CANCER, V59, P33, DOI 10.1002/ijc.2910590108; Bergstrom R, 1996, J NATL CANCER I, V88, P727, DOI 10.1093/jnci/88.11.727; BOKEMEYER C, 1993, EUR J CANCER, V29A, P874, DOI 10.1016/S0959-8049(05)80429-0; Broman KW, 1998, AM J HUM GENET, V63, P861, DOI 10.1086/302011; CARROLL PR, 1988, UROLOGY, V31, P72, DOI 10.1016/0090-4295(88)90579-1; FORMAN D, 1994, BRIT MED J, V308, P1393, DOI 10.1136/bmj.308.6941.1393; FORMAN D, 1992, BRIT J CANCER, V65, P255, DOI 10.1038/bjc.1992.51; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; HASLE H, 1995, BRIT J CANCER, V71, P416, DOI 10.1038/bjc.1995.85; HASLE H, 1992, EUR J PEDIATR, V151, P735, DOI 10.1007/BF01959079; Heimdal K, 1997, BRIT J CANCER, V75, P1084, DOI 10.1038/bjc.1997.185; Heimdal K, 1996, BRIT J CANCER, V73, P964, DOI 10.1038/bjc.1996.173; Kruglyak L, 1996, AM J HUM GENET, V58, P1347; LANDER E, 1995, NAT GENET, V11, P241, DOI 10.1038/ng1195-241; LEAHY MG, 1995, HUM MOL GENET, V4, P1551, DOI 10.1093/hmg/4.9.1551; MORTON NE, 1992, ANN HUM GENET, V56, P223, DOI 10.1111/j.1469-1809.1992.tb01147.x; MULLER J, 1995, INT J ANDROL, V18, P57, DOI 10.1111/j.1365-2605.1995.tb00386.x; NICHOLS BS, 1995, NURS CONNECT, V8, P5; Okada H, 1999, HUM REPROD, V14, P946, DOI 10.1093/humrep/14.4.946; OLIVER RTD, 1990, CANCER SURV, V9, P263; PHELAN MC, 1988, AM J MED GENET, V30, P77, DOI 10.1002/ajmg.1320300106; Rapley E, 1998, APMIS, V106, P64; REDDY SR, 1991, SOUTHERN MED J, V84, P773, DOI 10.1097/00007611-199106000-00026; TOLLERUD DJ, 1985, CANCER, V55, P1849, DOI 10.1002/1097-0142(19850415)55:8<1849::AID-CNCR2820550834>3.0.CO;2-1; Wanderas EH, 1995, EUR J CANCER, V31A, P2044, DOI 10.1016/0959-8049(95)00321-5; WOOSTER R, 1992, NAT GENET, V2, P132, DOI 10.1038/ng1092-132; Xu JF, 1998, NAT GENET, V20, P175, DOI 10.1038/2477; Zheng TZ, 1996, INT J CANCER, V65, P723, DOI 10.1002/(SICI)1097-0215(19960315)65:6<723::AID-IJC2>3.0.CO;2-0	28	190	195	0	12	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	FEB	2000	24	2					197	200		10.1038/72877	http://dx.doi.org/10.1038/72877			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	280LQ	10655070				2022-12-25	WOS:000085104600025
J	Steinhoff, M; Vergnolle, N; Young, SH; Tognetto, M; Amadesi, S; Ennes, HS; Trevisani, M; Hollenberg, MD; Wallace, JL; Caughey, GH; Mitchell, SE; Williams, LM; Geppetti, P; Mayer, EA; Bunnett, NW				Steinhoff, M; Vergnolle, N; Young, SH; Tognetto, M; Amadesi, S; Ennes, HS; Trevisani, M; Hollenberg, MD; Wallace, JL; Caughey, GH; Mitchell, SE; Williams, LM; Geppetti, P; Mayer, EA; Bunnett, NW			Agonists of proteinase-activated receptor 2 induce inflammation by a neurogenic mechanism	NATURE MEDICINE			English	Article							GENE-RELATED PEPTIDE; MAST-CELL TRYPTASE; SPINAL DORSAL HORN; SUBSTANCE-P; ENDOTHELIAL-CELLS; THROMBIN RECEPTOR; IN-VITRO; SKIN; VASODILATOR; CGRP	Trypsin and mast cell tryptase cleave proteinase-activated receptor 2 and, by unknown mechanisms, induce widespread inflammation. We found that a large proportion of primary spinal afferent neurons, which express proteinase-activated receptor 2, also contain the proinflammatory neuropeptides calcitonin gene-related peptide and substance P. Trypsin and tryptase directly signal to neurons to stimulate release of these neuropeptides, which mediate inflammatory edema induced by agonists of proteinase-activated receptor 2. This new mechanism of protease-induced neurogenic inflammation may contribute to the proinflammatory effects of mast cells in human disease. Thus, tryptase inhibitors and antagonists of proteinase-activated receptor 2 may be useful anti-inflammatory agents.	Univ Calif San Francisco, Dept Surg, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Physiol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Inst Cardiovasc Res, San Francisco, CA 94143 USA; Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90073 USA; Univ Calif Los Angeles, CURE VA UCLA Digest Dis Res Ctr, Los Angeles, CA 90073 USA; Univ Calgary, Dept Pharmacol & Therapeut, Calgary, AB T2N 4N1, Canada; Rowett Res Inst, Aberdeen LS21 9JT, Scotland; Univ Ferrara, Dept Expt & Clin Med, Headache Ctr, Pharmacol Sect, I-44100 Ferrara, Italy	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of Calgary; University of Aberdeen; University of Ferrara	Bunnett, NW (corresponding author), Univ Calif San Francisco, Dept Surg, 513 Parnasus Ave, San Francisco, CA 94143 USA.		Steinhoff, Martin/F-6312-2013; Wallace, John/AAL-3763-2021; Geppetti, Pierangelo/AHA-7897-2022; Hollenberg, Morley/AFV-6966-2022; Vergnolle, Nathalie/C-7677-2018; Gw, Safwan/ABG-4675-2020	Vergnolle, Nathalie/0000-0003-1825-6015; Gw, Safwan/0000-0001-6764-1038; Bunnett, Nigel W./0000-0003-3367-0644; Steinhoff, Martin/0000-0002-7090-2187				BALUK P, 1995, AM J PHYSIOL-LUNG C, V268, pL263, DOI 10.1152/ajplung.1995.268.2.L263; BIELLA G, 1991, BRAIN RES, V559, P352, DOI 10.1016/0006-8993(91)90024-P; BOWDEN JJ, 1994, P NATL ACAD SCI USA, V91, P8964, DOI 10.1073/pnas.91.19.8964; BRAIN SD, 1988, NATURE, V335, P73, DOI 10.1038/335073a0; BRAIN SD, 1985, NATURE, V313, P54, DOI 10.1038/313054a0; Cocks TM, 1999, NATURE, V398, P156, DOI 10.1038/18223; Compton SJ, 1998, J IMMUNOL, V161, P1939; Corvera CU, 1999, J PHYSIOL-LONDON, V517, P741, DOI 10.1111/j.1469-7793.1999.0741s.x; Corvera CU, 1997, J CLIN INVEST, V100, P1383, DOI 10.1172/JCI119658; Dery O, 1998, AM J PHYSIOL-CELL PH, V274, pC1429, DOI 10.1152/ajpcell.1998.274.6.C1429; Emilsson K, 1997, J VASC RES, V34, P267, DOI 10.1159/000159233; Ennes HS, 1997, NEUROREPORT, V8, P733, DOI 10.1097/00001756-199702100-00031; GARDINER SM, 1991, EUR J PHARMACOL, V199, P375, DOI 10.1016/0014-2999(91)90504-J; GEPPETTI P, 1988, REGUL PEPTIDES, V23, P289, DOI 10.1016/0167-0115(88)90229-7; He SH, 1997, J IMMUNOL, V159, P6216; He SH, 1997, EUR J PHARMACOL, V328, P89, DOI 10.1016/S0014-2999(97)83033-6; Holzer P, 1998, GEN PHARMACOL, V30, P5, DOI 10.1016/S0306-3623(97)00078-5; Hou L, 1998, IMMUNOLOGY, V94, P356, DOI 10.1046/j.1365-2567.1998.00528.x; HUGHES SR, 1991, BRIT J PHARMACOL, V104, P738, DOI 10.1111/j.1476-5381.1991.tb12497.x; Ishihara H, 1997, NATURE, V386, P502, DOI 10.1038/386502a0; Kahn ML, 1998, NATURE, V394, P690, DOI 10.1038/29325; Kawabata A, 1998, BRIT J PHARMACOL, V125, P419, DOI 10.1038/sj.bjp.0702063; Kawabata A, 1999, J PHARMACOL EXP THER, V288, P358; Kong WY, 1997, P NATL ACAD SCI USA, V94, P8884, DOI 10.1073/pnas.94.16.8884; Koshikawa N, 1997, FEBS LETT, V409, P442, DOI 10.1016/S0014-5793(97)00565-6; LEGREVES P, 1985, EUR J PHARMACOL, V115, P309, DOI 10.1016/0014-2999(85)90706-X; McCafferty DM, 1997, AM J PHYSIOL-GASTR L, V272, pG272, DOI 10.1152/ajpgi.1997.272.2.G272; Metcalfe DD, 1997, PHYSIOL REV, V77, P1033, DOI 10.1152/physrev.1997.77.4.1033; Molino M, 1997, J BIOL CHEM, V272, P4043, DOI 10.1074/jbc.272.7.4043; NAUKKARINEN A, 1994, INT J DERMATOL, V33, P361, DOI 10.1111/j.1365-4362.1994.tb01069.x; NEWBOLD P, 1993, BRIT J PHARMACOL, V108, P705, DOI 10.1111/j.1476-5381.1993.tb12865.x; Nystedt S, 1996, J BIOL CHEM, V271, P14910, DOI 10.1074/jbc.271.25.14910; NYSTEDT S, 1994, P NATL ACAD SCI USA, V91, P9208, DOI 10.1073/pnas.91.20.9208; OKU R, 1987, BRAIN RES, V403, P350, DOI 10.1016/0006-8993(87)90074-6; Reinshagen M, 1996, AM J PHYSIOL-GASTR L, V270, pG79, DOI 10.1152/ajpgi.1996.270.1.G79; Reinshagen M, 1998, J PHARMACOL EXP THER, V286, P657; RENZI D, 1987, TRENDS CLUSTER HEADA, P125; Saifeddine M, 1996, BRIT J PHARMACOL, V118, P521, DOI 10.1111/j.1476-5381.1996.tb15433.x; STEAD RH, 1987, P NATL ACAD SCI USA, V84, P2975, DOI 10.1073/pnas.84.9.2975; TAM EK, 1990, AM J RESP CELL MOL, V3, P27, DOI 10.1165/ajrcmb/3.1.27; Vergnolle N, 1999, BRIT J PHARMACOL, V127, P1083, DOI 10.1038/sj.bjp.0702634; Vergnolle N, 1998, P NATL ACAD SCI USA, V95, P7766, DOI 10.1073/pnas.95.13.7766; Vu TH, 1991, CELL, V64, P1; Wallace JL, 1998, REGUL PEPTIDES, V73, P95, DOI 10.1016/S0167-0115(97)01064-1; WIEGAND U, 1993, GENE, V136, P167, DOI 10.1016/0378-1119(93)90460-K	45	733	766	0	35	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	FEB	2000	6	2					151	158		10.1038/72247	http://dx.doi.org/10.1038/72247			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	278YQ	10655102				2022-12-25	WOS:000085016900034
J	Bloecher, A; Venturi, GM; Tatchell, K				Bloecher, A; Venturi, GM; Tatchell, K			Anaphase spindle position is monitored by the BUB2 checkpoint	NATURE CELL BIOLOGY			English	Article							BUDDING YEAST; SACCHAROMYCES-CEREVISIAE; CELL-CYCLE; MITOTIC CHECKPOINT; PATHWAY; ORIENTATION; DYNAMICS; PROTEIN; DYNEIN		Louisiana State Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, Shreveport, LA 71130 USA	Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport	Tatchell, K (corresponding author), Louisiana State Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, 1501 Kings Highway, Shreveport, LA 71130 USA.		Tatchell, Kelly/A-9643-2009		NIGMS NIH HHS [GM-477899] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alexandru G, 1999, EMBO J, V18, P2707, DOI 10.1093/emboj/18.10.2707; Balasubramanian MK, 2000, J CELL SCI, V113, P1503; Bloecher A, 2000, J CELL BIOL, V149, P125, DOI 10.1083/jcb.149.1.125; Bloecher A, 1999, GENE DEV, V13, P517, DOI 10.1101/gad.13.5.517; Burke DJ, 2000, CURR OPIN GENET DEV, V10, P26, DOI 10.1016/S0959-437X(99)00040-4; ESHEL D, 1993, P NATL ACAD SCI USA, V90, P11172, DOI 10.1073/pnas.90.23.11172; Fesquet D, 1999, EMBO J, V18, P2424, DOI 10.1093/emboj/18.9.2424; Fraschini R, 1999, J CELL BIOL, V145, P979, DOI 10.1083/jcb.145.5.979; HOYT MA, 1991, CELL, V66, P507, DOI 10.1016/0092-8674(81)90014-3; Kahana JA, 1998, MOL BIOL CELL, V9, P1741, DOI 10.1091/mbc.9.7.1741; Korinek WS, 2000, SCIENCE, V287, P2257, DOI 10.1126/science.287.5461.2257; Lee L, 2000, SCIENCE, V287, P2260, DOI 10.1126/science.287.5461.2260; Lew DJ, 2000, CURR OPIN GENET DEV, V10, P47, DOI 10.1016/S0959-437X(99)00051-9; Li R, 1999, P NATL ACAD SCI USA, V96, P4989, DOI 10.1073/pnas.96.9.4989; LI R, 1991, CELL, V66, P519, DOI 10.1016/0092-8674(81)90015-5; MCMILLAN JN, 1994, J CELL BIOL, V125, P143, DOI 10.1083/jcb.125.1.143; Muhua L, 1998, NATURE, V393, P487, DOI 10.1038/31014; MUHUA L, 1994, CELL, V78, P669, DOI 10.1016/0092-8674(94)90531-2; RHYU MS, 1995, CELL, V82, P523, DOI 10.1016/0092-8674(95)90022-5; Schwartz K, 1997, MOL BIOL CELL, V8, P2677, DOI 10.1091/mbc.8.12.2677; Tirnauer JS, 1999, J CELL BIOL, V145, P993, DOI 10.1083/jcb.145.5.993; YEH E, 1995, J CELL BIOL, V130, P687, DOI 10.1083/jcb.130.3.687	22	98	98	0	1	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	AUG	2000	2	8					556	558		10.1038/35019601	http://dx.doi.org/10.1038/35019601			3	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	341TE	10934478				2022-12-25	WOS:000088605000023
J	Tazebay, UH; Wapnir, IL; Levy, O; Dohan, O; Zuckier, LS; Zhao, QH; Deng, HF; Amenta, PS; Fineberg, S; Pestell, RG; Carrasco, N				Tazebay, UH; Wapnir, IL; Levy, O; Dohan, O; Zuckier, LS; Zhao, QH; Deng, HF; Amenta, PS; Fineberg, S; Pestell, RG; Carrasco, N			The mammary gland iodide transporter is expressed during lactation and in breast cancer	NATURE MEDICINE			English	Article							THYROID NA+/I-SYMPORTER; TRANSGENIC MICE; PROLACTIN; GRANULOSA; OXYTOCIN; CLONING; AMPLIFICATION; INHIBITION; CARCINOMA; PREGNANCY	The sodium/iodide symporter mediates active iodide transport in both healthy and cancerous thyroid tissue. By exploiting this activity, radioiodide has been used for decades with considerable success in the detection and treatment of thyroid cancer. Here we show that a specialized form of the sodium/iodide symporter in the mammary gland mediates active iodide transport in healthy lactating (but not in nonlactating) mammary gland and in mammary tumors. In addition to characterizing the hormonal regulation of the mammary gland sodium/iodide symporter, we demonstrate by scintigraphy that mammary adenocarcinomas in transgenic mice bearing Ras or Neu oncogenes actively accumulate iodide by this symporter in vivo. Moreover, more than 80% of the human breast cancer samples we analyzed by immunohistochemistry expressed the symporter, compared with none of the normal (nonlactating) samples from reductive mammoplasties. These results indicate that the mammary gland sodium/iodide symporter may be an essential breast cancer marker and that radioiodide should be studied as a possible option in the diagnosis and treatment of breast cancer.	Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA; Albert Einstein Coll Med, Dept Nucl Med, Bronx, NY 10461 USA; Albert Einstein Coll Med, Dept Med & Dev & Mol Biol, Bronx, NY 10461 USA; Montefiore Med Ctr, Dept Pathol, Bronx, NY 10467 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Surg, New Brunswick, NJ 08903 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Pathol, New Brunswick, NJ 08903 USA; Wyeth Lederle Vaccines, Pearl River, NY 10965 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; Pfizer	Carrasco, N (corresponding author), Albert Einstein Coll Med, Dept Mol Pharmacol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	carrasco@aecom.yu.edu	Zuckier, Lionel Sydney/I-7114-2019; Carrasco, Nancy/AAH-1053-2019; Dohan, Orsolya/B-3750-2012	Zuckier, Lionel Sydney/0000-0002-7212-0437; Carrasco, Nancy/0000-0003-4137-6162; Dohan, Orsolya/0000-0001-6235-5657; TAZEBAY, UYGAR HALIS/0000-0003-1999-8213	NCI NIH HHS [R29CA70897, R01CA75503] Funding Source: Medline; NIDDK NIH HHS [DK-07218] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA070897, R01CA075503] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Villanueva LA, 1996, MOL HUM REPROD, V2, P725, DOI 10.1093/molehr/2.10.725; BALTER M, 1995, SCIENCE, V270, P1758, DOI 10.1126/science.270.5243.1758; BRAVERMAN LE, 2000, WERNER INGBARS THYRO, P295; CANCROFT ET, 1973, RADIOLOGY, V106, P441, DOI 10.1148/106.2.441; CARRASCO N, 1986, METHOD ENZYMOL, V125, P453; CARRASCO N, 1993, BIOCHIM BIOPHYS ACTA, V1154, P65, DOI 10.1016/0304-4157(93)90017-I; Dai G, 1996, NATURE, V379, P458, DOI 10.1038/379458a0; DEGROOT LJ, 1989, ENDOCRINOLOGY, P821; Digiuseppe JA, 1999, IN VIVO, V13, P1; DORRINGTON J, 1981, NATURE, V290, P600, DOI 10.1038/290600a0; Eskandari S, 1997, J BIOL CHEM, V272, P27230, DOI 10.1074/jbc.272.43.27230; FITZGERALD PJ, 1949, J CLIN ENDOCRINOL, V9, P1153, DOI 10.1210/jcem-9-11-1153; GITAYGOREN H, 1989, MOL CELL ENDOCRINOL, V61, P69, DOI 10.1016/0303-7207(89)90190-1; Grazzini E, 1998, NATURE, V392, P509, DOI 10.1038/33176; Greenlee RT, 2000, CA-CANCER J CLIN, V50, P7, DOI 10.3322/canjclin.50.1.7; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; HIGUCHI T, 1985, J ENDOCRINOL, V105, P339, DOI 10.1677/joe.0.1050339; HILL CR, 1986, NATURE, V321, P655, DOI 10.1038/321655a0; Hung MC, 1999, SEMIN ONCOL, V26, P51; KAMINSKY SM, 1994, P NATL ACAD SCI USA, V91, P3789, DOI 10.1073/pnas.91.9.3789; KRASNOW JS, 1990, MOL ENDOCRINOL, V4, P13, DOI 10.1210/mend-4-1-13; Levy O, 1997, P NATL ACAD SCI USA, V94, P5568, DOI 10.1073/pnas.94.11.5568; Levy O, 1998, J BIOL CHEM, V273, P22657, DOI 10.1074/jbc.273.35.22657; MATTHEIJ JAM, 1982, HORM RES, V16, P219, DOI 10.1159/000179505; Mazzaferri EL, 1999, ONCOLOGY-NY, V13, P391; MCCORMACK JT, 1974, J ENDOCRINOL, V62, P101, DOI 10.1677/joe.0.0620101; MOUNTFORD PJ, 1986, NATURE, V322, P600, DOI 10.1038/322600a0; Nishiwaki H, 1986, Pancreas, V1, P324, DOI 10.1097/00006676-198607000-00006; Ohno M, 1999, MOL CELL BIOL, V19, P2051; PATERSON MC, 1991, CANCER RES, V51, P556; POCHIN EE, 1954, J CLIN ENDOCR METAB, V14, P1300; ROSENBLATT JS, 1988, PSYCHONEUROENDOCRINO, V13, P29, DOI 10.1016/0306-4530(88)90005-4; Siegel PM, 1999, EMBO J, V18, P2149, DOI 10.1093/emboj/18.8.2149; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Smanik PA, 1996, BIOCHEM BIOPH RES CO, V226, P339, DOI 10.1006/bbrc.1996.1358; SOCOLOW EL, 1967, ENDOCRINOLOGY, V80, P337, DOI 10.1210/endo-80-2-337; Spitzweg C, 1998, J CLIN ENDOCR METAB, V83, P1746, DOI 10.1210/jc.83.5.1746; STUBBE P, 1986, BIBL NUTR DIET, V38, P206; VALENTA L, 1966, J CLIN ENDOCR METAB, V26, P1317, DOI 10.1210/jcem-26-12-1317; WAKERLEY JB, 1978, J ENDOCRINOL, V76, P493, DOI 10.1677/joe.0.0760493; Zingg HH, 1998, ADV EXP MED BIOL, V449, P287	42	383	409	0	18	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	AUG	2000	6	8					871	878		10.1038/78630	http://dx.doi.org/10.1038/78630			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	376TX	10932223				2022-12-25	WOS:000165473800029
J	Sosa-Pineda, B; Wigle, JT; Oliver, G				Sosa-Pineda, B; Wigle, JT; Oliver, G			Hepatocyte migration during liver development requires Prox1	NATURE GENETICS			English	Article							MOUSE DEVELOPMENT; ENDODERM; GENE; GUT		St Jude Childrens Res Hosp, Dept Genet, Memphis, TN 38105 USA	St Jude Children's Research Hospital	Oliver, G (corresponding author), St Jude Childrens Res Hosp, Dept Genet, 332 N Lauderdale St, Memphis, TN 38105 USA.		Wigle, J.t./G-2005-2014	Wigle, J.t./0000-0002-4985-7684	NATIONAL EYE INSTITUTE [R01EY012162] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058462] Funding Source: NIH RePORTER; NEI NIH HHS [EY12162] Funding Source: Medline; NIGMS NIH HHS [GM58462] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLADT F, 1995, NATURE, V376, P768, DOI 10.1038/376768a0; Gualdi R, 1996, GENE DEV, V10, P1670, DOI 10.1101/gad.10.13.1670; Hentsch B, 1996, GENE DEV, V10, P70, DOI 10.1101/gad.10.1.70; HILBERG F, 1993, NATURE, V365, P179, DOI 10.1038/365179a0; Jung JN, 1999, SCIENCE, V284, P1998, DOI 10.1126/science.284.5422.1998; LEDOUARIN NM, 1975, MED BIOL, V53, P427; OLIVER G, 1993, MECH DEVELOP, V44, P3, DOI 10.1016/0925-4773(93)90012-M; SCHMIDT C, 1995, NATURE, V373, P699, DOI 10.1038/373699a0; Wigle JT, 1999, NAT GENET, V21, P318, DOI 10.1038/6844; Wigle JT, 1999, CELL, V98, P769, DOI 10.1016/S0092-8674(00)81511-1; Zaret KS, 1996, ANNU REV PHYSIOL, V58, P231, DOI 10.1146/annurev.physiol.58.1.231; ZARET KS, 1988, CURR OPIN GENE DEV, V8, P526	12	270	278	0	12	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUL	2000	25	3					254	255		10.1038/76996	http://dx.doi.org/10.1038/76996			2	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	329RD	10888866				2022-12-25	WOS:000087920900007
J	Lim, KC; Lakshmanan, G; Crawford, SE; Gu, Y; Grosveld, F; Engel, JD				Lim, KC; Lakshmanan, G; Crawford, SE; Gu, Y; Grosveld, F; Engel, JD			Gata3 loss leads to embryonic lethality due to noradrenaline deficiency of the sympathetic nervous system	NATURE GENETICS			English	Article							TYROSINE-HYDROXYLASE GENE; MOUSE FETAL DEVELOPMENT; REGULATORY ELEMENTS; TARGETED DISRUPTION; EXPRESSION; TRANSCRIPTION; MICE; DIFFERENTIATION; LOCUS; PROMOTER	Mouse embryos deficient in Gata3 die by 11 days post coitum (d.p.c) from pathology of undetermined origin(1). We recently showed that Gata3-directed lacZ expression of a 625-kb Gata3 YAC transgene in mice mimics endogenous Gata3 expression, except in thymus and the sympathoadrenal system(2). As this transgene failed to overcome embryonic lethality (unpublished data and ref. 3) in Gata3(-/-) mice, we hypothesized that a neuroendocrine deficiency in the sympathetic nervous system (SNS) might cause embryonic lethality in these mutants. We find here that null mutation of Gata3 leads to reduced accumulation of Th (encoding tyrosine hydroxylase, Th) and Dbh (dopamine beta-hydroxylase. Dbh) mRNA. whereas several other SNS genes are unaffected. We show that Th and Dbh deficiencies lead to reduced noradrenaline in the SNS, and that noradrenaline deficiency is a proximal cause of death in mutants by feeding catechol intermediates to pregnant dams, thereby partially averting Gata3 mutation-induced lethality. These older, pharmacologically rescued mutants revealed abnormalities that previously could not be detected in untreated mutants. These late embryonic defects include renal hypoplasia and developmental defects in structures derived from cephalic neural crest cells. Thus we have shown that Gata3 has a role in the differentiation of multiple cell lineages during embryogenesis.	Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, Evanston, IL 60208 USA; Northwestern Univ, Sch Med, Childrens Mem Inst Educ & Res, Dept Pathol, Evanston, IL 60208 USA; Erasmus Univ, Dept Cell Biol & Genet, Rotterdam, Netherlands	Northwestern University; Northwestern University; Erasmus University Rotterdam	Engel, JD (corresponding author), Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, 2153 Sheridan Rd, Evanston, IL 60208 USA.				NATIONAL CANCER INSTITUTE [P30CA060553] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028896] Funding Source: NIH RePORTER; NCI NIH HHS [CA60553] Funding Source: Medline; NIGMS NIH HHS [GM28896] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Britsch S, 1998, GENE DEV, V12, P1825, DOI 10.1101/gad.12.12.1825; DRESSLER GR, 1992, P NATL ACAD SCI USA, V89, P1179, DOI 10.1073/pnas.89.4.1179; Esler M, 1997, AM J CARDIOL, V80, pL7, DOI 10.1016/S0002-9149(97)00844-8; GEORGE KM, 1994, DEVELOPMENT, V120, P2673; GROVES AK, 1995, DEVELOPMENT, V121, P887; Hirsch MR, 1998, DEVELOPMENT, V125, P599; HOYLE GW, 1994, J NEUROSCI, V14, P2455; Joh T H, 1998, Adv Pharmacol, V42, P33; Kitsukawa T, 1997, NEURON, V19, P995, DOI 10.1016/S0896-6273(00)80392-X; KOBAYASHI K, 1995, J BIOL CHEM, V270, P27235, DOI 10.1074/jbc.270.45.27235; Lakshmanan G, 1998, DEV BIOL, V204, P451, DOI 10.1006/dbio.1998.8991; Lakshmanan G, 1999, MOL CELL BIOL, V19, P1558; LEONARD MW, 1993, DEVELOPMENT, V119, P519; Lieuw KH, 1997, DEV BIOL, V188, P1, DOI 10.1006/dbio.1997.8575; Morin X, 1997, NEURON, V18, P411, DOI 10.1016/S0896-6273(00)81242-8; Nardelli J, 1999, DEV BIOL, V210, P305, DOI 10.1006/dbio.1999.9278; Onodera K, 2000, EMBO J, V19, P1335, DOI 10.1093/emboj/19.6.1335; OOSTERWEGEL M, 1992, DEV IMMUNOL, V3, P1, DOI 10.1155/1992/27903; PANDOLFI PP, 1995, NAT GENET, V11, P40, DOI 10.1038/ng0995-40; Pattyn A, 1999, NATURE, V399, P366, DOI 10.1038/20700; RAHMAN MK, 1981, BIOCHEM PHARMACOL, V30, P645, DOI 10.1016/0006-2952(81)90139-8; ten Berge D, 1998, DEVELOPMENT, V125, P3831; THOMAS SA, 1995, NATURE, V374, P643, DOI 10.1038/374643a0; Tiveron MC, 1996, J NEUROSCI, V16, P7649; Vainio S, 1997, CELL, V90, P975, DOI 10.1016/S0092-8674(00)80363-3; Yang CY, 1998, J NEUROCHEM, V71, P1358; ZHOU QY, 1995, NATURE, V374, P640, DOI 10.1038/374640a0	27	264	267	1	10	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUN	2000	25	2					209	212		10.1038/76080	http://dx.doi.org/10.1038/76080			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	321ML	10835639				2022-12-25	WOS:000087459200023
J	Streicher, J; Donat, MA; Strauss, B; Sporle, R; Schughart, K; Muller, GB				Streicher, J; Donat, MA; Strauss, B; Sporle, R; Schughart, K; Muller, GB			Computer-based three-dimensional visualization of developmental gene expression	NATURE GENETICS			English	Article							SERIAL SECTIONS; 3D RECONSTRUCTION; 3-DIMENSIONAL RECONSTRUCTION; MOUSE EMBRYOS; SYSTEM; SEGMENTATION; DERIVATIVES; DATABASE; DESIGN; MUTANT	A broad understanding of the relationship between gene activation, pattern formation and morphogenesis will require adequate tools for three-dimensional and, perhaps four-dimensional, representation and analysis of molecular developmental processes. We present a novel, computer-based method for the 3D visualization of embryonic gene expression and morphological structures from serial sections. The information from these automatically aligned 3D reconstructions exceeds that from single-section and whole-mount visualizations of in situ hybridizations. In addition, these 3D models of gene-expression patterns can become a central component of a future developmental database designed for the collection and presentation of digitized, morphological and gene-expression data. This work is accompanied by a web site (http://www. univie.ac.at/GeneEMAC).	Univ Vienna, Dept Anat, Integrat Morphol Grp, Vienna, Austria; GSF, Natl Res Ctr Environm & Hlth Neuherberg, Inst Mammalian Genet, F-75724 Paris 15, France; Inst Pasteur, CNRS, URA 1947, Dept Mol Biol, F-75724 Paris 15, France; Transgene SA, Dept Mol & Cellular Biol, Strasbourg, France	University of Vienna; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Transgene SA	Streicher, J (corresponding author), Univ Vienna, Dept Anat, Integrat Morphol Grp, Vienna, Austria.	johannes.streicher@univie.ac.at		Schughart, Klaus/0000-0002-6824-7523; Streicher, Johannes/0000-0002-4114-2246				ANDERSON DJ, 1985, CELL, V42, P649, DOI 10.1016/0092-8674(85)90122-9; ARNOLDS WJA, 1978, STAIN TECHNOL, V53, P287; ARRAEZAYBAR LA, 1994, SURG RADIOL ANAT, V16, P419, DOI 10.1007/BF01627664; Born G, 1883, ARCH MIKROSK ANAT, V22, P584, DOI 10.1007/bf02952679; BRANDLE K, 1989, COMPUT BIOMED RES, V22, P52, DOI 10.1016/0010-4809(89)90015-3; BRAVERMAN MS, 1986, J INVEST DERMATOL, V86, P290, DOI 10.1111/1523-1747.ep12285445; CANDIA AF, 1992, DEVELOPMENT, V116, P1123; HIBBARD LS, 1988, J NEUROSCI METH, V26, P55, DOI 10.1016/0165-0270(88)90129-X; His W., 1887, ANAT ANZEIGER, V2, P382; Holland Linda Z., 1996, P267; HOSONO M, 1995, J DIGIT IMAGING, V8, P105, DOI 10.1007/BF03168084; HUIJSMANS DP, 1986, ANAT RECORD, V216, P449, DOI 10.1002/ar.1092160402; IWAMOTO Y, 1995, ACTA ORTHOP SCAND, V66, P80, DOI 10.3109/17453679508994646; KERI C, 1991, J NEUROSCI METH, V37, P241, DOI 10.1016/0165-0270(91)90030-4; KNOX CK, 1990, P E MULT SOC COMP SI, P12; Krams R, 1997, ARTERIOSCL THROM VAS, V17, P2061, DOI 10.1161/01.ATV.17.10.2061; MITCHIE A, 1983, COMPUTER GRAPHICS IM, V22, P296; MOSS VA, 1990, J MICROSC-OXFORD, V158, P187, DOI 10.1111/j.1365-2818.1990.tb02992.x; Muller GB, 1996, AM ZOOL, V36, P4; OTT MO, 1991, DEVELOPMENT, V111, P1097; PROTHERO JS, 1986, COMPUT BIOMED RES, V19, P361, DOI 10.1016/0010-4809(86)90048-0; RINGWALD M, 1994, SCIENCE, V265, P2033, DOI 10.1126/science.8091224; Roush W, 1997, SCIENCE, V278, P1397, DOI 10.1126/science.278.5342.1397; RYDMARK M, 1992, J MICROSC-OXFORD, V165, P29, DOI 10.1111/j.1365-2818.1992.tb04303.x; Scarborough J, 1997, J ANAT, V191, P117, DOI 10.1046/j.1469-7580.1997.19110117.x; Seidler H, 1997, J HUM EVOL, V33, P691, DOI 10.1006/jhev.1997.0163; SJOSTRAND FS, 1958, J ULTRA MOL STRUCT R, V2, P122, DOI 10.1016/S0022-5320(58)90050-9; SKOGLUND TS, 1995, J NEUROSCI METH, V61, P105, DOI 10.1016/0165-0270(94)00031-B; Smith BR, 1999, SCI AM, V280, P76, DOI 10.1038/scientificamerican0399-76; Sporle R, 1996, DEVELOPMENT, V122, P79; Sporle R, 1998, DEV GENET, V22, P359, DOI 10.1002/(SICI)1520-6408(1998)22:4<359::AID-DVG6>3.0.CO;2-5; Sporle R, 1997, DEV DYNAM, V210, P216; STEIN R, 1988, NEURON, V1, P463, DOI 10.1016/0896-6273(88)90177-8; Stevens J. K., 1994, 3 DIMENSIONAL CONFOC; Streicher J, 1997, ANAT REC, V248, P583; Tajbakhsh S, 1998, CELL, V92, P9, DOI 10.1016/S0092-8674(00)80894-6; Theiler K., 1972, P1; Vazquez MD, 1998, ANAT HISTOL EMBRYOL, V27, P283, DOI 10.1111/j.1439-0264.1998.tb00194.x; VERBEEK FJ, 1995, MICROSC RES TECHNIQ, V30, P496, DOI 10.1002/jemt.1070300607; WRIGHT DE, 1995, J COMP NEUROL, V361, P321, DOI 10.1002/cne.903610209	40	73	76	0	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036			NAT GENET	Nature Genet.	JUN	2000	25	2					147	152		10.1038/75989	http://dx.doi.org/10.1038/75989			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	321ML	10835627				2022-12-25	WOS:000087459200011
J	Wickware, P				Wickware, P			$1 million study renews HIV/transplant research	NATURE MEDICINE			English	News Item																			0	3	3	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	APR	2000	6	4					365	365		10.1038/74602	http://dx.doi.org/10.1038/74602			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	376UA	10742128	Bronze			2022-12-25	WOS:000165474100014
J	May, O; Nguyen, PT; Arnold, FH				May, O; Nguyen, PT; Arnold, FH			Inverting enantioselectivity by directed evolution of hydantoinase for improved production of L-methionine	NATURE BIOTECHNOLOGY			English	Article						directed evolution; enantioselectivity; hydantoinase; biocatalysis; chiral chemicals	NUCLEOTIDE-SEQUENCE; AMINO-ACIDS	Using directed evolution, we have improved the hydantoinase process for production of L-methionine (L-met) in Escherichia coli. This was accomplished by inverting the enantioselectivity and increasing the total activity of a key enzyme in a whole-cell catalyst. The selectivity of all known hydantoinases for D-5-(2-methylthioethyl)hydantoin (D-MTEH) over the L-enantiomer leads to the accumulation of intermediates and reduced productivity for the L-amino acid. We used random mutagenesis, saturation mutagenesis, and screening to convert the D-selective hydantoinase from Arthrobacter sp. DSM 9771 into an L-selective enzyme and increased its total activity fivefold. Whole E. coli cells expressing the evolved L-hydantoinase, an L-N-carbamoylase, and a hydantoin racemase produced 91 mM L-met from 100 mM D,L-MTEH in less than 2 h. The improved hydantoinase increased productivity fivefold for >90% conversion of the substrate. The accumulation of the unwanted intermediate D-carbamoyl-methionine was reduced fourfold compared to cells with the wild-type pathway. Highly D-selective hydantoinase mutants were also discovered. Enantioselective enzymes rapidly optimized by directed evolution and introduced into multienzyme pathways may lead to improved whole-cell catalysts for efficient production of chiral compounds.	CALTECH, Div Chem & Chem Engn 210 41, Pasadena, CA 91125 USA	California Institute of Technology	Arnold, FH (corresponding author), CALTECH, Div Chem & Chem Engn 210 41, Pasadena, CA 91125 USA.			Arnold, Frances H./0000-0002-4027-364X				Arnold F H, 1997, Adv Biochem Eng Biotechnol, V58, P1; ARNOLD FH, 1999, ENCY BIOPROCESS TECH, P971; CHEN CS, 1982, J AM CHEM SOC, V104, P7294, DOI 10.1021/ja00389a064; Drauz K, 1997, CHIMIA, V51, P310; Fersht A., 1985, ENZYME STRUCTURE MEC; Handelsman J, 1998, CHEM BIOL, V5, pR245, DOI 10.1016/S1074-5521(98)90108-9; LURIA SE, 1960, VIROLOGY, V12, P348, DOI 10.1016/0042-6822(60)90161-6; Matcham GW, 1996, CHIM OGGI, V14, P20; May O, 1998, J BIOTECHNOL, V61, P1, DOI 10.1016/S0168-1656(98)00005-4; Miyazaki K, 1999, J MOL EVOL, V49, P716, DOI 10.1007/PL00006593; Reetz MT, 1997, ANGEW CHEM INT EDIT, V36, P2830, DOI 10.1002/anie.199728301; Reetz MT, 1999, TOP CURR CHEM, V200, P31; ROSE RE, 1988, NUCLEIC ACIDS RES, V16, P355, DOI 10.1093/nar/16.1.355; Stinson SC, 1998, CHEM ENG NEWS, V76, P83, DOI 10.1021/cen-v076n038.p083; SYLDATK C, 1992, HYDROLYSIS FORMATION, P131; SYLDATK C, 1992, HYDROLYSIS FORMATION, P75; Volff JN, 1996, MOL MICROBIOL, V21, P1037, DOI 10.1046/j.1365-2958.1996.761428.x; VOLKEL D, 1995, ANN NY ACAD SCI, V750, P1, DOI 10.1111/j.1749-6632.1995.tb19916.x; WAGNER F, 1998, Patent No. 5714355; Wagner T, 1996, J BIOTECHNOL, V46, P63, DOI 10.1016/0168-1656(95)00193-X; Wilms B, 1999, J BIOTECHNOL, V68, P101, DOI 10.1016/S0168-1656(98)00183-7; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	22	262	297	4	63	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAR	2000	18	3					317	320		10.1038/73773	http://dx.doi.org/10.1038/73773			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	292AC	10700149				2022-12-25	WOS:000085771100031
J	Ton-That, TT; Doron, D; Pollard, BS; Bacher, J; Pollard, HB				Ton-That, TT; Doron, D; Pollard, BS; Bacher, J; Pollard, HB			In vivo bypass of hemophilia A coagulation defect by Factor XIIa implant	NATURE BIOTECHNOLOGY			English	Article						hemophilia A; hemophilia B; coagulation; calcium; factor VII; factor VIIa; factor VIII; factor IX; factor Xa; factor XIIa; phospholipids; bypass activity	RECOMBINANT FACTOR-VIIA; EXTRINSIC PATHWAY INHIBITOR; ACTIVATED FACTOR-VII; HIGH-TITER INHIBITORS; ISLET TRANSPLANTATION; FACTOR-XA; MANAGEMENT; PATIENT; PURIFICATION; EXPERIENCE	Hemophilia A and B coagulation defects, which are caused by deficiencies of Factor VIII and Factor IX, respectively, can be bypassed by administration of recombinant Factor VIIa. However, the short half-life of recombinant Factor VIIa in vivo negates its routine clinical use. We report here an in vivo method for the continuous generation of Factor VIIa. The method depends on the implantation of a porous chamber that contains Factor Xa or XIIa, and continuously generates Factor VIIa bypass activity from the subject's own Factor VII, which enters the chamber by diffusion. Once inside, the Factor VII is cleaved to Factor VIIa by the immobilized Factor Xa or XIIa. The newly created Factor VIIa diffuses out of the chamber and back into the circulation, where it can bypass the deficient Factors VIII or IX, and enable coagulation to occur. In vitro, this method generates sufficient Factor VIIa to substantially correct Factor VIII-deficient plasma when assessed by the classical aPTT coagulation assay. In vivo, a Factor XIIa peritoneal implant generates bypass activity for up to one month when tested in rhesus monkeys. Implantation of such a chamber in a patient with hemophilia A or B could eventually provide a Viable alternative to replacement therapies using exogenous coagulation factors.	Uniformed Serv Univ Hlth Sci, Sch Med, Dept Anat & Cell Biol, Bethesda, MD 20814 USA; NIDDKD, Cell Biol & Genet Lab, NIH, Bethesda, MD 20892 USA; NIH, Off Director, Bethesda, MD 20892 USA; NIH, Vet Resources Program, Natl Ctr Res Resources, Bethesda, MD 20892 USA	Uniformed Services University of the Health Sciences - USA; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; National Institutes of Health (NIH) - USA	Pollard, HB (corresponding author), Uniformed Serv Univ Hlth Sci, Sch Med, Dept Anat & Cell Biol, Bethesda, MD 20814 USA.	hpollard@usuhs.mil						Abildgaard U, 1988, Folia Haematol Int Mag Klin Morphol Blutforsch, V115, P274; BELL BA, 1993, AM J PEDIAT HEMATOL, V15, P77; BLOOM AL, 1992, HAEMOSTASIS, V22, P268; BLOOM AL, 1991, THROMB HAEMOSTASIS, V66, P166; BRINKHOUS KM, 1989, P NATL ACAD SCI USA, V86, P1382, DOI 10.1073/pnas.86.4.1382; BROZE GJ, 1980, J BIOL CHEM, V255, P1242; CARPENTER CB, 1994, HARRISONS PRINCIPLES, P1281; Edgington T S, 1991, Curr Stud Hematol Blood Transfus, P15; Giles A R, 1987, Transfus Med Rev, V1, P131, DOI 10.1016/S0887-7963(87)70013-3; GILES AR, 1988, BRIT J HAEMATOL, V69, P491, DOI 10.1111/j.1365-2141.1988.tb02405.x; HANDIN RI, 1994, HARRISONS PRINCIPLES, P1804; HEDNER U, 1989, HAEMOSTASIS, V19, P335; HEDNER U, 1983, J CLIN INVEST, V71, P1836, DOI 10.1172/JCI110939; HEDNER U, 1992, HEMATOL ONCOL CLIN N, V6, P1035, DOI 10.1016/S0889-8588(18)30292-2; Hedner U, 1990, Blood Coagul Fibrinolysis, V1, P307, DOI 10.1097/00001721-199008000-00009; HEDNER U, 1991, CURR STUD HEMATOL BL, V58, P63; Hedner Ulla, 1993, Transfusion Medicine Reviews, V7, P78, DOI 10.1016/S0887-7963(93)70126-1; KASPER CK, 1991, ANN NY ACAD SCI, V614, P97, DOI 10.1111/j.1749-6632.1991.tb43695.x; KELLY P, 1976, JAMA-J AM MED ASSOC, V236, P2061, DOI 10.1001/jama.236.18.2061; KISIEL W, 1977, BIOCHEMISTRY-US, V16, P4189, DOI 10.1021/bi00638a009; KURCZYNSKI EM, 1974, NEW ENGL J MED, V291, P164, DOI 10.1056/NEJM197407252910402; LANZA RP, 1992, DIABETES, V41, P1503, DOI 10.2337/diabetes.41.12.1503; LUSHER JM, 1980, NEW ENGL J MED, V303, P421, DOI 10.1056/NEJM198008213030803; MACIK BG, 1989, AM J HEMATOL, V32, P232, DOI 10.1002/ajh.2830320315; MACIK BG, 1993, BLOOD COAGUL FIBRIN, V4, P521, DOI 10.1097/00001721-199308000-00001; Nilsson Inga Marie, 1992, Transfusion Medicine Reviews, V6, P285, DOI 10.1016/S0887-7963(92)70185-0; OSTERUD B, 1990, BLOOD COAGUL FIBRIN, V1, P749; POLLOCK A, 1976, LANCET, V2, P43; RAPAPORT SI, 1989, BLOOD, V73, P359; ROEGOECI E, 1989, AM J PHYSIOL, V256, pE447; ROSENDAAL FR, 1991, ANN HEMATOL, V62, P5, DOI 10.1007/BF01714977; SCHMIDT ML, 1991, BRIT J HAEMATOL, V78, P460, DOI 10.1111/j.1365-2141.1991.tb04468.x; SCHULMAN S, 1992, ACTA PAEDIATR, V81, P564, DOI 10.1111/j.1651-2227.1992.tb12297.x; SOONSHIONG P, 1994, LANCET, V343, P950, DOI 10.1016/S0140-6736(94)90067-1; Sullivan S J, 1992, ASAIO J, V38, pM450, DOI 10.1097/00002480-199207000-00074; Sultan Y, 1990, Blood Coagul Fibrinolysis, V1, P193; TELGT DSC, 1989, THROMB RES, V56, P603, DOI 10.1016/0049-3848(89)90268-5; Thompson A R, 1991, Prog Hemost Thromb, V10, P175; THOMSEN MK, 1993, THROMB HAEMOSTASIS, V70, P458; WARNCRAMER BJ, 1987, THROMB RES, V48, P11, DOI 10.1016/0049-3848(87)90341-0; WARR TA, 1989, BLOOD, V74, P201; WARR TA, 1989, BLOOD, V74, P994; WILDGOOSE P, 1992, BLOOD, V80, P3256; ZAELZNIK DF, 1994, HARRISONS PRINCIPLES, P526	44	11	11	0	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	MAR	2000	18	3					289	295		10.1038/73727	http://dx.doi.org/10.1038/73727			7	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	292AC	10700143				2022-12-25	WOS:000085771100025
J	Waeber, G; Delplanque, J; Bonny, C; Mooser, V; Steinmann, M; Widmann, C; Maillard, A; Miklossy, J; Dina, C; Hani, EH; Vionnet, N; Nicod, P; Boutin, P; Froguel, P				Waeber, G; Delplanque, J; Bonny, C; Mooser, V; Steinmann, M; Widmann, C; Maillard, A; Miklossy, J; Dina, C; Hani, EH; Vionnet, N; Nicod, P; Boutin, P; Froguel, P			The gene MAPK8IP1, encoding islet-brain-1, is a candidate for type 2 diabetes	NATURE GENETICS			English	Article							INSULIN CONTROL ELEMENT; TRANSCRIPTIONAL ACTIVATION; SIGNAL-TRANSDUCTION; LINKAGE ANALYSIS; MEK KINASE-1; BETA-CELLS; GLUT2 GENE; GLUCOSE; EXPRESSION; GLUCOKINASE	Type 2 diabetes is a polygenic and genetically heterogenous disease(1). The age of onset of the disease is usually late and environmental factors may be required to induce the complete diabetic phenotype. Susceptibility genes for diabetes have not yet been identified. Islet-brain-1 (IB1, encoded by MAPK8IP1), a novel DNA-binding transactivator of the glucose transporter GLUT2 (encoded by SLC2A2), is the homologue of the c-Jun amino-terminal kinase-interacting protein-1 (JIP-1; refs 2-5). We evaluated the role of IB1 in beta-cells by expression of a MAPK8IP1 antisense RNA in a stable insulinoma beta-cell line, A 38% decrease in IB1 protein content resulted in a 49% and a 41% reduction in SLC2A2 and INS (encoding insulin) mRNA expression, respectively. In addition, we detected MAPK8IP1 transcripts and IB1 protein in human pancreatic islets. These data establish MAPK8IP1 as a candidate gene for human diabetes. Sibpair analyses performed on 149 multiplex French families with type 2 diabetes excluded MAPK8IP1 as a major diabetogenic locus. We did, however, identify in one family a missense mutation located in the coding region of MAPK8IP1 (S59N) that segregated with diabetes. In vitro, this mutation was associated with an inability of IB1 to prevent apoptosis induced by MAPK/ERK kinase kinase 1 (MEKK1) and a reduced ability to counteract the inhibitory action of the activated c-JUN amino-terminal kinase (JNK) pathway on INS transcriptional activity. Identification of this novel non-maturity onset diabetes of the young (MODY) form of diabetes demonstrates that IB1 is a key regulator of beta-cell function.	CHUV Univ Hosp, Dept Internal Med, Lausanne, Switzerland; CHUV Univ Hosp, Dept Pathol, Lausanne, Switzerland; Inst Pasteur, Inst Biol, CNRS, F-59019 Lille, France; Univ Lausanne, Inst Morphol & Cellular Biol, CH-1015 Lausanne, Switzerland	University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; University of Lausanne	Waeber, G (corresponding author), CHUV Univ Hosp, Dept Internal Med, Lausanne, Switzerland.	gwaeber@chuv.hospvd.ch	Bonny, Christophe/AAV-7214-2021; Widmann, Christian/N-9851-2013; Dina, Christian R/D-3535-2015; FROGUEL, Philippe/O-6799-2017; Vionnet, Nathalie/N-6302-2017	Widmann, Christian/0000-0002-6881-0363; Dina, Christian R/0000-0002-7722-7348; FROGUEL, Philippe/0000-0003-2972-0784; Waeber, Gerard/0000-0003-4193-788X; Miklossy, Judith/0000-0003-4948-8708				Bonny C, 1998, J BIOL CHEM, V273, P1843, DOI 10.1074/jbc.273.4.1843; BONNY C, 1995, MOL ENDOCRINOL, V9, P1413, DOI 10.1210/me.9.10.1413; Dickens M, 1997, SCIENCE, V277, P693, DOI 10.1126/science.277.5326.693; Gavin JR, 1997, DIABETES CARE, V20, P1183; Gremlich S, 1997, J BIOL CHEM, V272, P30261, DOI 10.1074/jbc.272.48.30261; Guillam MT, 1997, NAT GENET, V17, P327, DOI 10.1038/ng1197-327; Hani EH, 1999, J CLIN INVEST, V104, pR41, DOI 10.1172/JCI7469; HASEMAN JK, 1972, BEHAV GENET, V2, P3, DOI 10.1007/BF01066731; HENDERSON E, 1994, MOL CELL BIOL, V14, P655, DOI 10.1128/MCB.14.1.655; INAGAKI N, 1992, P NATL ACAD SCI USA, V89, P1045, DOI 10.1073/pnas.89.3.1045; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Jonas JC, 1999, J BIOL CHEM, V274, P14112, DOI 10.1074/jbc.274.20.14112; Kahn BB, 1998, NAT GENET, V20, P223, DOI 10.1038/3018; Mooser V, 1999, GENOMICS, V55, P202, DOI 10.1006/geno.1998.5641; OCONNELL JR, 1995, NAT GENET, V11, P402, DOI 10.1038/ng1295-402; OHLSSON H, 1993, EMBO J, V12, P4251, DOI 10.1002/j.1460-2075.1993.tb06109.x; Pellet JB, 2000, EUR J NEUROSCI, V12, P621, DOI 10.1046/j.1460-9568.2000.00945.x; ROBINSON GLWG, 1995, MOL CELL BIOL, V15, P1398; THORENS B, 1990, P NATL ACAD SCI USA, V87, P6492, DOI 10.1073/pnas.87.17.6492; THORENS B, 1992, J CLIN INVEST, V90, P77, DOI 10.1172/JCI115858; Vionnet N, 1997, DIABETES, V46, P1062, DOI 10.2337/diabetes.46.6.1062; Waeber G, 1997, P NATL ACAD SCI USA, V94, P4782, DOI 10.1073/pnas.94.9.4782; WAEBER G, 1994, J BIOL CHEM, V269, P26912; Waeber G, 1996, MOL ENDOCRINOL, V10, P1327, DOI 10.1210/me.10.11.1327; Wang HY, 1997, P NATL ACAD SCI USA, V94, P4372, DOI 10.1073/pnas.94.9.4372; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; Widmann C, 1997, ONCOGENE, V15, P2439, DOI 10.1038/sj.onc.1201421; Widmann C, 1998, MOL CELL BIOL, V18, P2416, DOI 10.1128/MCB.18.4.2416; ZOUALI H, 1993, DIABETES, V42, P1238, DOI 10.2337/diabetes.42.9.1238	29	151	153	2	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAR	2000	24	3					291	295		10.1038/73523	http://dx.doi.org/10.1038/73523			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	288XW	10700186				2022-12-25	WOS:000085590600023
J	Xing, XM; Wang, SC; Xia, WY; Zou, YY; Shao, RP; Kwong, KY; Yu, ZM; Zhang, S; Miller, S; Huang, L; Hung, MC				Xing, XM; Wang, SC; Xia, WY; Zou, YY; Shao, RP; Kwong, KY; Yu, ZM; Zhang, S; Miller, S; Huang, L; Hung, MC			The Ets protein PEA3 suppresses HER-2/neu overexpression and inhibits tumorigenesis	NATURE MEDICINE			English	Article							HUMAN-BREAST-CANCER; E1A GENE-PRODUCTS; CELL LUNG-CANCER; OVARIAN-CANCER; C-ERBB-2 GENE; NEU ONCOGENE; 3T3 CELLS; EXPRESSION; TRANSCRIPTION; METASTASIS	Because HER-2/neu overexpression is important in cancer development, we looked for a method of suppressing the cell transformation mediated by HER-2/neu overexpression. We have identified that the DNA-binding protein PEA3, which is encoded by a previously isolated gene of the ets family, specifically targeted a DNA sequence on the HER-2/neu promoter and downregulated the promoter activity. Expression of PEA3 resulted in preferential inhibition of cell growth and tumor development of HER-2/neu-overexpressing cancer cells. This is a new approach to targeting HER-2/neu overexpression and also provides a rationale to the design for repressors of diseases caused by overexpression of pathogenic genes.	Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, Sect Mol Cell Biol, Houston, TX 77030 USA; Univ Pittsburgh, Dept Pharmacol, Pittsburgh, PA 15261 USA	University of Texas System; UTMD Anderson Cancer Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Hung, MC (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, Sect Mol Cell Biol, 1515 Holcombe Blvd, Houston, TX 77030 USA.		Hung, Mien-Chie/ABD-5911-2021; Wang, Shao-Chun/P-9904-2019	Hung, Mien-Chie/0000-0003-4317-4740; Wang, Shao-Chun/0000-0002-5477-1682				Baert JL, 1997, INT J CANCER, V70, P590, DOI 10.1002/(SICI)1097-0215(19970304)70:5<590::AID-IJC17>3.0.CO;2-H; Baselga J, 1998, CANCER RES, V58, P2825; Benz CC, 1997, ONCOGENE, V15, P1513, DOI 10.1038/sj.onc.1201331; BENZ CC, 1993, BREAST CANCER RES TR, V24, P85; BERCHUCK A, 1990, CANCER RES, V50, P4087; BOLD RJ, 1985, MOL CELL BIOL, V5, P3131, DOI 10.1128/MCB.5.11.3131; BUTTICE G, 1993, J BIOL CHEM, V268, P7196; Chang JY, 1997, ONCOGENE, V14, P561, DOI 10.1038/sj.onc.1200861; CHAZIN VR, 1992, ONCOGENE, V7, P1859; Chen H, 1997, J BIOL CHEM, V272, P6101, DOI 10.1074/jbc.272.10.6101; CHEN HM, 1995, MOL CELL BIOL, V15, P3840; DEMILIA J, 1989, ONCOGENE, V4, P1233; GIOVANE A, 1994, GENE DEV, V8, P1502, DOI 10.1101/gad.8.13.1502; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; GOLDBERG Y, 1994, J BIOL CHEM, V269, P16566; HUDZIAK RM, 1988, P NATL ACAD SCI USA, V85, P5102, DOI 10.1073/pnas.85.14.5102; HUNG MC, 1995, GENE, V159, P65, DOI 10.1016/0378-1119(94)00459-6; HUNG MC, 1999, TARGETING HER 2 NEUO; PARK JB, 1989, CANCER RES, V49, P6605; Pegram MD, 1998, J CLIN ONCOL, V16, P2659, DOI 10.1200/JCO.1998.16.8.2659; SCHNEIDER PM, 1989, CANCER RES, V49, P4968; SGOURAS DN, 1995, EMBO J, V14, P4781, DOI 10.1002/j.1460-2075.1995.tb00160.x; SHI DR, 1992, MOL CARCINOGEN, V5, P213, DOI 10.1002/mc.2940050308; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; TAL M, 1987, MOL CELL BIOL, V7, P2597, DOI 10.1128/MCB.7.7.2597; Tan M, 1997, CANCER RES, V57, P1199; TSAI CM, 1995, J NATL CANCER I, V87, P682, DOI 10.1093/jnci/87.9.682; TSAI CM, 1993, J NATL CANCER I, V85, P897, DOI 10.1093/jnci/85.11.897; WEINER DB, 1990, CANCER RES, V50, P421; WHITE MRA, 1992, ONCOGENE, V7, P677; Xia WY, 1997, CLIN CANCER RES, V3, P3; XIN JH, 1992, GENE DEV, V6, P481, DOI 10.1101/gad.6.3.481; Xing XM, 1996, CANCER GENE THER, V3, P168; YOKOTA J, 1988, ONCOGENE, V2, P283; YU DH, 1992, ONCOGENE, V7, P2263; Yu DH, 1998, CANCER METAST REV, V17, P195, DOI 10.1023/A:1006054421970; YU DH, 1990, P NATL ACAD SCI USA, V87, P4499, DOI 10.1073/pnas.87.12.4499; YU DH, 1991, ONCOGENE, V6, P1991; YU DH, 1994, CANCER RES, V54, P3260; YU DH, 1995, ONCOGENE, V11, P1383; Yu DH, 1998, ONCOGENE, V16, P2087, DOI 10.1038/sj.onc.1201729; Yu DH, 1998, MOL CELL, V2, P581, DOI 10.1016/S1097-2765(00)80157-4; ZHANG CT, 1989, CHINESE PHYS LETT, V6, P4, DOI 10.1088/0256-307X/6/1/002; Zhang M, 1997, P NATL ACAD SCI USA, V94, P5673, DOI 10.1073/pnas.94.11.5673; Zhang M, 1997, CELL GROWTH DIFFER, V8, P179; ZHANG YJ, 1995, ONCOGENE, V10, P1947	47	149	152	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	FEB	2000	6	2					189	195		10.1038/72294	http://dx.doi.org/10.1038/72294			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	278YQ	10655108				2022-12-25	WOS:000085016900040
J	Nadeau, JH; Frankel, WN				Nadeau, JH; Frankel, WN			The roads from phenotypic variation to gene discovery: mutagenesis versus QTLs	NATURE GENETICS			English	Editorial Material							QUANTITATIVE TRAIT LOCI; COMPLEX TRAITS; MOUSE GENOME; MICE; SUSCEPTIBILITY; DISSECTION	In model organisms, chemical mutagenesis provides a powerful alternative to natural, polygenic Variation (for example, quantitative trait loci (QTLs)) for identifying functional pathways and complex disease genes. Despite recent progress in QTLs, we expect that mutagenesis will ultimately prove more effective because the prospects of gene identification are high and every gene affecting a trait is potentially a target.	Case Western Reserve Univ, Sch Med, Dept Genet, Cleveland, OH 44106 USA; Univ Hosp Cleveland, Ctr Human Genet, Cleveland, OH 44106 USA; Jackson Lab, Bar Harbor, ME 04609 USA	Case Western Reserve University; University Hospitals of Cleveland; Jackson Laboratory	Nadeau, JH (corresponding author), Case Western Reserve Univ, Sch Med, Dept Genet, Cleveland, OH 44106 USA.	jhn4@po.cwru.edu; wnf@jax.org			NCI NIH HHS [CA75056] Funding Source: Medline; NCRR NIH HHS [RR12305] Funding Source: Medline; NHLBI NIH HHS [HL58982] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA075056] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P40RR012305] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058982] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Battey J, 1999, NAT GENET, V21, P73, DOI 10.1038/5012; Chen YJ, 2000, MAMM GENOME, V11, P598, DOI 10.1007/s003350010114; CHURCHILL GA, 1994, GENETICS, V138, P963; Cormier RT, 1997, NAT GENET, V17, P88, DOI 10.1038/ng0997-88; DARVASI A, 1995, GENETICS, V141, P1199; Darvasi A, 1998, NAT GENET, V18, P19, DOI 10.1038/ng0198-19; Davis AP, 1998, TRENDS GENET, V14, P438, DOI 10.1016/S0168-9525(98)01579-0; de Angelis MH, 2000, NAT GENET, V25, P444, DOI 10.1038/78146; DEMANT P, 1986, IMMUNOGENETICS, V24, P416, DOI 10.1007/BF00377961; Dietrich WF, 1996, NATURE, V380, P149, DOI 10.1038/380149a0; Fridman E, 2000, P NATL ACAD SCI USA, V97, P4718, DOI 10.1073/pnas.97.9.4718; Glenister PH, 2000, MAMM GENOME, V11, P565, DOI 10.1007/s003350010108; HALEY CS, 1992, HEREDITY, V69, P315, DOI 10.1038/hdy.1992.131; Justice MJ, 1999, HUM MOL GENET, V8, P1955, DOI 10.1093/hmg/8.10.1955; LANDER E, 1995, NAT GENET, V11, P241, DOI 10.1038/ng1195-241; LANDER ES, 1989, GENETICS, V121, P185; Legare ME, 2000, GENOME RES, V10, P42; MALO D, 1994, GENOMICS, V23, P51, DOI 10.1006/geno.1994.1458; Manenti G, 1999, GENOME RES, V9, P639; Marker PC, 1997, GENETICS, V145, P435; Matin A, 1999, NAT GENET, V23, P237, DOI 10.1038/13874; MUNROE RJ, 2000, MAMM GENOME, V11, P507; Nadeau JH, 2000, NAT GENET, V24, P221, DOI 10.1038/73427; Nolan PM, 2000, NAT GENET, V25, P440, DOI 10.1038/78140; Paterson A. H., 1998, MOL DISSECTION COMPL; RINCHIK EM, 1991, TRENDS GENET, V7, P15, DOI 10.1016/0168-9525(91)90016-J; Schimenti J, 1998, GENOME RES, V8, P698, DOI 10.1101/gr.8.7.698; Symula DJ, 1999, NAT GENET, V23, P241, DOI 10.1038/13880; Sztein J, 1998, BIOL REPROD, V58, P1071, DOI 10.1095/biolreprod58.4.1071; Sztein JM, 1997, CRYOBIOLOGY, V35, P46, DOI 10.1006/cryo.1997.2024; Talbot CJ, 1999, NAT GENET, V21, P305, DOI 10.1038/6825; Wang DG, 1998, SCIENCE, V280, P1077, DOI 10.1126/science.280.5366.1077; You Y, 1997, NAT GENET, V15, P285, DOI 10.1038/ng0397-285; ZENG ZB, 1994, GENETICS, V136, P1457	34	150	164	0	13	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	AUG	2000	25	4					381	384		10.1038/78051	http://dx.doi.org/10.1038/78051			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	341WY	10932178				2022-12-25	WOS:000088615000009
J	Reina-San-Martin, B; Degrave, W; Rougeot, C; Cosson, A; Chamond, N; Cordeiro-Da-Silva, A; Arala-Chaves, M; Coutinho, A; Minoprio, P				Reina-San-Martin, B; Degrave, W; Rougeot, C; Cosson, A; Chamond, N; Cordeiro-Da-Silva, A; Arala-Chaves, M; Coutinho, A; Minoprio, P			A B-cell mitogen from a pathogenic trypanosome is a eukaryotic proline racemase	NATURE MEDICINE			English	Article							CRUZI; ACTIVATION; MECHANISM; DIFFERENTIATION; PURIFICATION; PROTEIN	Lymphocyte polyclonal activation is a generalized mechanism of immune evasion among pathogens. In a mouse model of Trypanosoma cruzi infection (American trypanosomiasis), reduced levels of polyclonal lymphocyte responses correlate with resistance to infection and cardiopathy. We report here the characterization of a parasite protein with B-cell mitogenic properties in culture supernatants of infective forms, the cloning of the corresponding gene and the analysis of the biological properties of its product. We characterized the protein as a co-factor-independent proline racemase, and show that its expression as a cytoplasmic and/or membrane-associated protein is life-stage specific. Inhibition studies indicate that availability of the racemase active site is necessary for mitogenic activity. This is the first report to our knowledge of a eukaryotic amino acid racemase gene. Our findings have potential consequences for the development of new immune therapies and drug design against pathogens.	Inst Pasteur, Dept Immunol, CNRS, URA 1960, F-75724 Paris 15, France; Fiocruz MS, Inst Oswaldo Cruz, DBBM, BR-21045900 Rio De Janeiro, Brazil; Inst Pasteur, Dept Immunol, Unite Biochim & Genet Dev, CNRS,URA 1960, F-75724 Paris 15, France; Univ Porto, Inst Ciencias Biomed Abel Salazar, P-4099 Oporto, Portugal; CNRS, Inst Gulbenkian Ciencia, P-2782 Oeiras, Portugal; Inst Pasteur, Dept Immunol, Unite Immunochim Analyt, F-75724 Paris 15, France	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Fundacao Oswaldo Cruz; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Universidade do Porto; Instituto Gulbenkian de Ciencia; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Minoprio, P (corresponding author), Inst Pasteur, Dept Immunol, CNRS, URA 1960, 25 Rue Dr Roux, F-75724 Paris 15, France.	pmm@pasteur.fr	Cordeiro-da-Silva, Anabela/J-7807-2013; Chamond, Nathalie/C-5907-2018; Reina-San-Martin, Bernardo/I-9484-2016; Degrave, Wim/B-4162-2009	Cordeiro-da-Silva, Anabela/0000-0003-2392-6087; Reina-San-Martin, Bernardo/0000-0003-2083-6166; Minoprio, Paola/0000-0002-1659-833X; Chamond, Nathalie/0000-0002-0518-2929				ARALACHAVES M, 1992, MEM I OSWALDO CRUZ, V87, P35, DOI 10.1590/S0074-02761992000900005; BARRETT FM, 1974, COMP BIOCHEM PHYSIOL, V48, P241; CARDINALE GJ, 1968, BIOCHEMISTRY-US, V7, P3970, DOI 10.1021/bi00851a026; CONTRERAS VT, 1985, MOL BIOCHEM PARASIT, V16, P315, DOI 10.1016/0166-6851(85)90073-8; COUTINHO A, 1973, NATURE-NEW BIOL, V245, P12, DOI 10.1038/newbio245012a0; COUTINHO A, 1974, J EXP MED, V139, P74, DOI 10.1084/jem.139.1.74; DA Silva AC, 1998, IMMUNOLOGY, V94, P189, DOI 10.1046/j.1365-2567.1998.00498.x; DEISOLA ELD, 1981, J PARASITOL, V67, P53, DOI 10.2307/3280778; DOSSANTOS RR, 1992, J EXP MED, V175, P29, DOI 10.1084/jem.175.1.29; DRAGON EA, 1987, MOL CELL BIOL, V7, P1271, DOI 10.1128/MCB.7.3.1271; EISEN H, 1990, ORIGIN AUTOIMMUNE PA; Fisher G H, 1998, EXS, V85, P109; HERRERA EM, 1994, MOL BIOCHEM PARASIT, V65, P73, DOI 10.1016/0166-6851(94)90116-3; JANEWAY CA, 1970, FOLIA BIOL, V16, P156; Lamzin VS, 1995, CURR OPIN STRUC BIOL, V5, P830, DOI 10.1016/0959-440X(95)80018-2; Lima ECS, 1996, INFECT IMMUN, V64, P215, DOI 10.1128/IAI.64.1.215-221.1996; LIMA MRD, 1986, J IMMUNOL, V137, P353; MINOPRIO P, 1987, J IMMUNOL, V139, P545; MINOPRIO P, 1991, INT IMMUNOL, V3, P427, DOI 10.1093/intimm/3.5.427; MINOPRIO P, 1989, IMMUNOL REV, V112, P183, DOI 10.1111/j.1600-065X.1989.tb00558.x; MORO A, 1995, EMBO J, V14, P2483, DOI 10.1002/j.1460-2075.1995.tb07245.x; MOZES E, 1974, IMMUNOLOGY, V27, P641; ORTEGABARRIA E, 1991, CELL, V67, P411, DOI 10.1016/0092-8674(91)90192-2; Reina-San-Martin B, 2000, PARASITOL TODAY, V16, P62, DOI 10.1016/S0169-4758(99)01591-4; Rosenberg RD, 1997, J CLIN INVEST, V100, pS67; RUDNICK G, 1975, BIOCHEMISTRY-US, V14, P4515, DOI 10.1021/bi00691a028; Sela M, 1997, FASEB J, V11, P449; Shakibaei M, 1996, J EXP MED, V184, P1699, DOI 10.1084/jem.184.5.1699; SYLVESTER D, 1976, COMP BIOCHEM PHYS B, V55, P443, DOI 10.1016/0305-0491(76)90318-7; Tarleton RL, 1997, P NATL ACAD SCI USA, V94, P3932, DOI 10.1073/pnas.94.8.3932; TAVARES D, 1995, INT IMMUNOL, V7, P785, DOI 10.1093/intimm/7.5.785; Thompson RJ, 1998, INFECT IMMUN, V66, P3552, DOI 10.1128/IAI.66.8.3552-3561.1998; Wolosker H, 1999, P NATL ACAD SCI USA, V96, P721, DOI 10.1073/pnas.96.2.721	33	125	132	0	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	AUG	2000	6	8					890	897		10.1038/78651	http://dx.doi.org/10.1038/78651			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	376TX	10932226				2022-12-25	WOS:000165473800032
J	Esler, WP; Kimberly, WT; Ostaszewski, BL; Diehl, TS; Moore, CL; Tsai, JY; Rahmati, T; Xia, WM; Selkoe, DJ; Wolfe, MS				Esler, WP; Kimberly, WT; Ostaszewski, BL; Diehl, TS; Moore, CL; Tsai, JY; Rahmati, T; Xia, WM; Selkoe, DJ; Wolfe, MS			Transition-state analogue inhibitors of gamma-secretase bind directly to presenilin-1	NATURE CELL BIOLOGY			English	Article							AMYLOID PRECURSOR PROTEIN; FAMILIAL ALZHEIMERS-DISEASE; BETA-PEPTIDE PRODUCTION; C-TERMINAL FRAGMENTS; TRANSMEMBRANE DOMAIN; INTRACELLULAR DOMAIN; ASPARTYL PROTEASE; CLEAVAGE; ENDOPROTEOLYSIS; SPECIFICITY	The beta-amyloid precursor protein (beta-APP), which is involved in the pathogenesis of Alzheimer's disease, and the Notch receptor, which is responsible for critical signalling events during development, both undergo unusual proteolysis within their transmembrane domains by unknown gamma-secretases, Here we show that an affinity reagent designed to interact with the active site of gamma-secretase binds directly and specifically to heterodimeric forms of presenilins, polytopic proteins that are mutated in hereditary Alzheimer's and are known mediators of gamma-secretase cleavage of both beta-APP and Notch. These results provide evidence that heterodimeric presenilins contain the active site of gamma-secretase, and validate presenilins as principal targets for the design of drugs to treat and prevent Alzheimer's disease.	Harvard Univ, Sch Med, Ctr Neurol Dis, Boston, MA 02115 USA; Brigham & Womens Hosp, Boston, MA 02115 USA; Univ Tennessee, Dept Pharmaceut Sci, Memphis, TN 38163 USA	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; University of Tennessee System; University of Tennessee Health Science Center	Wolfe, MS (corresponding author), Harvard Univ, Sch Med, Ctr Neurol Dis, 77 Ave Louis Pasteur, Boston, MA 02115 USA.	wolfe@cnd.bwh.harvard.edu	xia, weiming/E-5465-2016	xia, weiming/0000-0002-7463-3295	NIA NIH HHS [AG12749] Funding Source: Medline; NINDS NIH HHS [NS37537] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS037537] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG012749] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ATLAS D, 1976, P NATL ACAD SCI USA, V73, P1921, DOI 10.1073/pnas.73.6.1921; BEREZOVSKA O, IN PRESS J NEUROCHEM; Brou C, 2000, MOL CELL, V5, P207, DOI 10.1016/S1097-2765(00)80417-7; Buxbaum JD, 1998, J BIOL CHEM, V273, P27765, DOI 10.1074/jbc.273.43.27765; Capell A, 1998, J BIOL CHEM, V273, P3205, DOI 10.1074/jbc.273.6.3205; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; ELKOE DJ, 2000, CURR OPIN NEUROBIOL, V10, P50; FEHRENTZ JA, 1983, SYNTHESIS-STUTTGART, P676; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; Hardy J, 1997, P NATL ACAD SCI USA, V94, P2095, DOI 10.1073/pnas.94.6.2095; Herreman A, 1999, P NATL ACAD SCI USA, V96, P11872, DOI 10.1073/pnas.96.21.11872; Hussain I, 1999, MOL CELL NEUROSCI, V14, P419, DOI 10.1006/mcne.1999.0811; Kimberly WT, 2000, J BIOL CHEM, V275, P3173, DOI 10.1074/jbc.275.5.3173; KOHRLE J, 1990, J BIOL CHEM, V265, P6155; KOO EH, 1994, J BIOL CHEM, V269, P17386; Leimer U, 1999, BIOCHEMISTRY-US, V38, P13602, DOI 10.1021/bi991453n; Li XJ, 1996, NEURON, V17, P1015, DOI 10.1016/S0896-6273(00)80231-7; Li XJ, 1998, P NATL ACAD SCI USA, V95, P7109, DOI 10.1073/pnas.95.12.7109; Lichtenthaler SF, 1997, BIOCHEMISTRY-US, V36, P15396, DOI 10.1021/bi971071m; Lichtenthaler SF, 1999, P NATL ACAD SCI USA, V96, P3053, DOI 10.1073/pnas.96.6.3053; Maruyama K, 1996, BIOCHEM BIOPH RES CO, V227, P730, DOI 10.1006/bbrc.1996.1577; Podlisny MB, 1997, NEUROBIOL DIS, V3, P325, DOI 10.1006/nbdi.1997.0129; Ratovitski T, 1997, J BIOL CHEM, V272, P24536, DOI 10.1074/jbc.272.39.24536; Ray WJ, 1999, J BIOL CHEM, V274, P36801, DOI 10.1074/jbc.274.51.36801; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; Selkoe DJ, 1997, SCIENCE, V275, P630, DOI 10.1126/science.275.5300.630; Selkoe DJ, 1999, NATURE, V399, pA23, DOI 10.1038/399a023; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; Sinha S, 1999, NATURE, V402, P537, DOI 10.1038/990114; SMAR MW, 1992, J MED CHEM, V35, P1117, DOI 10.1021/jm00084a017; Steiner H, 1999, J BIOL CHEM, V274, P28669, DOI 10.1074/jbc.274.40.28669; Struhl G, 1999, NATURE, V398, P522, DOI 10.1038/19091; Thinakaran G, 1997, J BIOL CHEM, V272, P28415, DOI 10.1074/jbc.272.45.28415; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; Tischer E, 1996, J BIOL CHEM, V271, P21914, DOI 10.1074/jbc.271.36.21914; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Wolfe MS, 1998, J MED CHEM, V41, P6, DOI 10.1021/jm970621b; Wolfe MS, 1999, BIOCHEMISTRY-US, V38, P4720, DOI 10.1021/bi982562p; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; WOLFE MS, 1999, SOC NEUROSCI, V25; XIA W, IN PRESS P NATL ACAD; Xia WM, 1997, P NATL ACAD SCI USA, V94, P8208, DOI 10.1073/pnas.94.15.8208; Xia WM, 1998, BIOCHEMISTRY-US, V37, P16465, DOI 10.1021/bi9816195; Yan RQ, 1999, NATURE, V402, P533, DOI 10.1038/990107; Ye YH, 1999, NATURE, V398, P525, DOI 10.1038/19096; Yu G, 1998, J BIOL CHEM, V273, P16470, DOI 10.1074/jbc.273.26.16470	47	485	513	0	13	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	JUL	2000	2	7					428	434		10.1038/35017062	http://dx.doi.org/10.1038/35017062			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	333MK	10878808				2022-12-25	WOS:000088133700019
J	Friedlander, R; Jarosch, E; Urban, J; Volkwein, C; Sommer, T				Friedlander, R; Jarosch, E; Urban, J; Volkwein, C; Sommer, T			A regulatory link between ER-associated protein degradation and the unfolded-protein response.	NATURE CELL BIOLOGY			English	Article							ENDOPLASMIC-RETICULUM DEGRADATION; UBIQUITIN-PROTEASOME PATHWAY; 3-HYDROXY-3-METHYLGLUTARYL-COA REDUCTASE; TRANSCRIPTION FACTOR; MEMBRANE-PROTEIN; YEAST; TRANSLOCATION; INDUCTION; NUCLEUS; IRE1P	Ubiquitin conjugation during endoplasmic-reticulum-associated degradation (ERAD) depends on the activity of Ubc7. Here we show that Ubc1 acts as a further ubiquitin-conjugating enzyme in this pathway. Absence of both enzymes results in marked stabilization of an ERAD substrate and induction of the unfolded-protein response (UPR). Furthermore, basic ERAD activity is sufficient to eliminate unfolded proteins under normal conditions. However, when stress is applied, the UPR is required to increase ERAD activity. We thus demonstrate, for the first time, st regulatory loop between ERAD and the UPR, which is essential for normal growth of yeast cells.	Max Delbruck Ctr Mol Med, D-13092 Berlin, Germany	Helmholtz Association; Max Delbruck Center for Molecular Medicine	Sommer, T (corresponding author), Max Delbruck Ctr Mol Med, Robert Rossle Str 10, D-13092 Berlin, Germany.	tsommer@mdc-berlin.de	Longo, Kenneth A/A-5631-2010; Geiss-Friedlander, Ruth/G-3569-2013; Geiss-Friedlander, Ruth/AAT-8768-2020	Geiss-Friedlander, Ruth/0000-0002-1720-3440; Geiss-Friedlander, Ruth/0000-0002-1720-3440; Jarosch, Ernst/0000-0002-5897-3492				Ausubel F. M., 1988, CURRENT PROTOCOLS MO; Biederer T, 1997, SCIENCE, V278, P1806, DOI 10.1126/science.278.5344.1806; Biederer T, 1996, EMBO J, V15, P2069, DOI 10.1002/j.1460-2075.1996.tb00560.x; Bonifacino JS, 1998, ANNU REV CELL DEV BI, V14, P19, DOI 10.1146/annurev.cellbio.14.1.19; Bordallo J, 1998, MOL BIOL CELL, V9, P209, DOI 10.1091/mbc.9.1.209; Bush KT, 1997, J BIOL CHEM, V272, P9086; Chapman R, 1998, ANNU REV CELL DEV BI, V14, P459, DOI 10.1146/annurev.cellbio.14.1.459; Cox JS, 1996, CELL, V87, P391, DOI 10.1016/S0092-8674(00)81360-4; Deshaies RJ, 1999, ANNU REV CELL DEV BI, V15, P435, DOI 10.1146/annurev.cellbio.15.1.435; Hampton RY, 1997, P NATL ACAD SCI USA, V94, P12944, DOI 10.1073/pnas.94.24.12944; Hampton RY, 1996, MOL BIOL CELL, V7, P2029, DOI 10.1091/mbc.7.12.2029; Hiller MM, 1996, SCIENCE, V273, P1725, DOI 10.1126/science.273.5282.1725; Jakob CA, 1998, J CELL BIOL, V142, P1223, DOI 10.1083/jcb.142.5.1223; JUNGMANN J, 1993, NATURE, V361, P369, DOI 10.1038/361369a0; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; Kawahara T, 1997, MOL BIOL CELL, V8, P1845, DOI 10.1091/mbc.8.10.1845; Knop M, 1996, EMBO J, V15, P753, DOI 10.1002/j.1460-2075.1996.tb00411.x; Kopito RR, 1997, CELL, V88, P427, DOI 10.1016/S0092-8674(00)81881-4; McCracken AA, 1996, J CELL BIOL, V132, P291, DOI 10.1083/jcb.132.3.291; MORI K, 1992, EMBO J, V11, P2583, DOI 10.1002/j.1460-2075.1992.tb05323.x; Plemper RK, 1997, NATURE, V388, P891, DOI 10.1038/42276; Plemper RK, 1999, TRENDS BIOCHEM SCI, V24, P266, DOI 10.1016/S0968-0004(99)01420-6; SEUFERT W, 1990, EMBO J, V9, P543, DOI 10.1002/j.1460-2075.1990.tb08141.x; SEUFERT W, 1990, EMBO J, V9, P4535, DOI 10.1002/j.1460-2075.1990.tb07905.x; Sidrauski C, 1997, CELL, V90, P1031, DOI 10.1016/S0092-8674(00)80369-4; Sommer T, 1997, FASEB J, V11, P1227, DOI 10.1096/fasebj.11.14.9409541; SOMMER T, 1993, NATURE, V365, P176, DOI 10.1038/365176a0; Tirasophon W, 1998, GENE DEV, V12, P1812, DOI 10.1101/gad.12.12.1812; Wiertz EJHJ, 1996, NATURE, V384, P432, DOI 10.1038/384432a0; Zhou MY, 1999, MOL CELL, V4, P925, DOI 10.1016/S1097-2765(00)80222-1	30	368	384	2	21	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	JUL	2000	2	7					379	384		10.1038/35017001	http://dx.doi.org/10.1038/35017001			6	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	333MK	10878801				2022-12-25	WOS:000088133700012
J	Katagiri, Y; Takeda, K; Yu, ZX; Ferrans, VJ; Ozato, K; Guroff, G				Katagiri, Y; Takeda, K; Yu, ZX; Ferrans, VJ; Ozato, K; Guroff, G			Modulation of retinoid signalling through NGF-induced nuclear export of NGFI-B	NATURE CELL BIOLOGY			English	Article							NERVE GROWTH-FACTOR; HORMONE RECEPTOR SUPERFAMILY; ORPHAN RECEPTORS; MEMBRANE DEPOLARIZATION; GENE-EXPRESSION; DNA-BINDING; PC12 CELLS; PROTEIN; IDENTIFICATION; STRESS	The retinoid-X receptor (RXR) regulates multiple hormonal pathways through heterodimerization with nuclear receptors such as the all-trans retinoic acid receptor (RAR). The orphan nuclear receptor NGFI-B (also called Nur77) can heterodimerize with RXR. Here we show that nerve growth factor (NGF) induces the phosphorylation of Ser 105 of NGFI-B in PC12 phaeochromocytoma cells, resulting in translocation of the NGFI-B-RXR heterodimer complex out of the nucleus using nuclear export signals within NGFI-B. As a consequence of the redistribution of RXR, the transcriptional activity of RXR-RAR is reduced. NGFI-B-mediated nuclear export of receptors may serve as a mechanism for crosstalk between NGF and retinoid pathways.	NICHD, Growth Factors Sect, NIH, Bethesda, MD 20892 USA; NHLBI, Pathol Sect, NIH, Bethesda, MD 20892 USA; NICHD, Lab Mol Growth Regulat, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Katagiri, Y (corresponding author), Amer Red Cross, Holland Lab, Dept Biochem, 15601 Crabbs Branch Way, Rockville, MD 20892 USA.	katagiriy@usa.redcross.org			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD001310] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD001310] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Ben-Levy R, 1998, CURR BIOL, V8, P1049, DOI 10.1016/S0960-9822(98)70442-7; Blanco JCG, 1998, GENE DEV, V12, P1638, DOI 10.1101/gad.12.11.1638; Blumberg B, 1998, GENE DEV, V12, P3149, DOI 10.1101/gad.12.20.3149; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; CHAN FKM, 1995, MOL CELL BIOL, V15, P2682; FAHRNER TJ, 1990, MOL CELL BIOL, V10, P6454, DOI 10.1128/MCB.10.12.6454; FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0; FORMAN BM, 1995, CELL, V81, P541, DOI 10.1016/0092-8674(95)90075-6; Fukuda M, 1997, J BIOL CHEM, V272, P32642, DOI 10.1074/jbc.272.51.32642; GREENE LA, 1995, CURR OPIN NEUROBIOL, V5, P579, DOI 10.1016/0959-4388(95)80062-X; HAMADA K, 1989, P NATL ACAD SCI USA, V86, P8289, DOI 10.1073/pnas.86.21.8289; HAZEL TG, 1988, P NATL ACAD SCI USA, V85, P8444, DOI 10.1073/pnas.85.22.8444; HAZEL TG, 1991, MOL CELL BIOL, V11, P3239, DOI 10.1128/MCB.11.6.3239; HONKANIEMI J, 1994, MOL BRAIN RES, V25, P234, DOI 10.1016/0169-328X(94)90158-9; Jans DA, 1996, PHYSIOL REV, V76, P651, DOI 10.1152/physrev.1996.76.3.651; Jehn BM, 1999, J IMMUNOL, V162, P635; Kaffman A, 1998, NATURE, V396, P482, DOI 10.1038/24898; Katagiri Y, 1997, J BIOL CHEM, V272, P31278, DOI 10.1074/jbc.272.50.31278; KOIZUMI S, 1988, J NEUROSCI, V8, P715; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MILBRANDT J, 1988, NEURON, V1, P183, DOI 10.1016/0896-6273(88)90138-9; Nigg EA, 1997, NATURE, V386, P779, DOI 10.1038/386779a0; NISHI K, 1994, J BIOL CHEM, V269, P6320; PERLMANN T, 1995, GENE DEV, V9, P769, DOI 10.1101/gad.9.7.769; Phillips A, 1997, MOL CELL BIOL, V17, P5946, DOI 10.1128/MCB.17.10.5946; RIVEST S, 1994, J NEUROENDOCRINOL, V6, P101, DOI 10.1111/j.1365-2826.1994.tb00559.x; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; Torchia J, 1998, CURR OPIN CELL BIOL, V10, P373, DOI 10.1016/S0955-0674(98)80014-8; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; WILSON TE, 1992, SCIENCE, V256, P107, DOI 10.1126/science.1314418; WILSON TE, 1991, SCIENCE, V252, P1296, DOI 10.1126/science.1925541; Wu Q, 1997, EMBO J, V16, P1656, DOI 10.1093/emboj/16.7.1656; Zetterstrom RH, 1996, MOL BRAIN RES, V41, P111, DOI 10.1016/0169-328X(96)00074-5	34	158	168	0	9	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	JUL	2000	2	7					435	440		10.1038/35017072	http://dx.doi.org/10.1038/35017072			6	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	333MK	10878809				2022-12-25	WOS:000088133700020
J	Shimura, H; Hattori, N; Kubo, S; Mizuno, Y; Asakawa, S; Minoshima, S; Shimizu, N; Iwai, K; Chiba, T; Tanaka, K; Suzuki, T				Shimura, H; Hattori, N; Kubo, S; Mizuno, Y; Asakawa, S; Minoshima, S; Shimizu, N; Iwai, K; Chiba, T; Tanaka, K; Suzuki, T			Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase	NATURE GENETICS			English	Article							ALPHA-SYNUCLEIN; LEWY BODIES; DEGRADATION; INCLUSIONS; PATHWAY; SPECIFICITY; PROTEASOME; MUTATIONS; ENZYMES; SYSTEM	Autosomal recessive juvenile parkinsonism (AR-JP). one of the most common familial forms of Parkinson disease, is characterized by selective dopaminergic neural cell death and the absence of the Lewy body, a cytoplasmic inclusion body consisting of aggregates of abnormally accumulated proteins(1). We previously cloned PARK2, mutations of which cause AR-JP (ref. 2). but the function of the gene product, parkin. remains unknown. We report here that parkin is involved in protein degradation as a ubiquitin-protein ligase collaborating with the ubiquitin-conjugating enzyme UbcH7. and that mutant parkins from AR-JP patients show loss of the ubiquitin-protein ligase activity. Our findings indicate that accumulation of proteins that have yet to be identified causes a selective neural cell death without formation of Lewy bodies. Our findings should enhance the exploration of the molecular mechanisms of neurodegeneration in Parkinson disease as well as in other neurodegenerative diseases that are characterized by involvement of abnormal protein ubiquitination. including Alzheimer disease, other tauopathies. CAG triplet repeat disorders and amyotrophic lateral sclerosis(3-10).	Tokyo Metropolitan Inst Med Sci, Tokyo 113, Japan; Japan Sci & Technol Corp, JST, CREST, Bunkyo Ku, Tokyo, Japan; Juntendo Univ, Sch Med, Dept Neurol, Bunkyo Ku, Tokyo 113, Japan; Keio Univ, Sch Med, Dept Mol Biol, Shinjuku Ku, Tokyo, Japan; Kyoto Univ, Grad Sch Biostudies, Dept Mol & Syst Biol, Kyoto, Japan	Tokyo Metropolitan Institute of Medical Science; Japan Science & Technology Agency (JST); Juntendo University; Keio University; Kyoto University	Tanaka, K (corresponding author), Tokyo Metropolitan Inst Med Sci, Bunkyo Ku, Tokyo 113, Japan.		shimura, hideki/AAA-2864-2020; Longo, Kenneth A/A-5631-2010; Hattori, Nobutaka/ACR-0069-2022; IWAI, KAZUHIRO/GSN-7385-2022	Iwai, Kazuhiro/0000-0001-5620-5951; Suzuki, Toshiaki/0000-0002-0650-6251; Minoshima, Satoshi/0000-0002-0043-3047				Alves-Rodrigues A, 1998, TRENDS NEUROSCI, V21, P516, DOI 10.1016/S0166-2236(98)01276-4; Bennett MC, 1999, J BIOL CHEM, V274, P33855, DOI 10.1074/jbc.274.48.33855; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; Cummings CJ, 1999, NEURON, V24, P879, DOI 10.1016/S0896-6273(00)81035-1; Deshaies RJ, 1999, ANNU REV CELL DEV BI, V15, P435, DOI 10.1146/annurev.cellbio.15.1.435; DiFiglia M, 1997, SCIENCE, V277, P1990, DOI 10.1126/science.277.5334.1990; Floyd JA, 1999, NEURON, V24, P765, DOI 10.1016/S0896-6273(00)81022-3; Harper JW, 1999, NAT CELL BIOL, V1, pE5, DOI 10.1038/8952; Hattori N, 1998, BIOCHEM BIOPH RES CO, V249, P754, DOI 10.1006/bbrc.1998.9134; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; Kitada T, 1998, NATURE, V392, P605, DOI 10.1038/33416; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; KUZUHARA S, 1988, ACTA NEUROPATHOL, V75, P345, DOI 10.1007/BF00687787; Larsen CN, 1998, BIOCHEMISTRY-US, V37, P3358, DOI 10.1021/bi972274d; LEIGH PN, 1991, BRAIN, V114, P775, DOI 10.1093/brain/114.2.775; Leroy E, 1998, NATURE, V395, P451, DOI 10.1038/26652; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; Martinez-Noel G, 1999, FEBS LETT, V454, P257, DOI 10.1016/S0014-5793(99)00823-6; MAYER RJ, 1998, UBIQUITIN BIOL CELL, P429; Mizuno Y, 1998, J NEUROCHEM, V71, P893; Morett E, 1999, TRENDS BIOCHEM SCI, V24, P229, DOI 10.1016/S0968-0004(99)01381-X; Moynihan TP, 1999, J BIOL CHEM, V274, P30963, DOI 10.1074/jbc.274.43.30963; Pallares-Trujillo J, 1998, INT J MOL MED, V2, P3; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Suzuki H, 1999, BIOCHEM BIOPH RES CO, V256, P127, DOI 10.1006/bbrc.1999.0289; Xie YM, 1999, EMBO J, V18, P6832, DOI 10.1093/emboj/18.23.6832	30	1558	1647	1	135	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUL	2000	25	3					302	305		10.1038/77060	http://dx.doi.org/10.1038/77060			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	329RD	10888878				2022-12-25	WOS:000087920900018
J	Arbour, NC; Lorenz, E; Schutte, BC; Zabner, J; Kline, JN; Jones, M; Frees, K; Watt, JL; Schwartz, DA				Arbour, NC; Lorenz, E; Schutte, BC; Zabner, J; Kline, JN; Jones, M; Frees, K; Watt, JL; Schwartz, DA			TLR4 mutations are associated with endotoxin hyporesponsiveness in humans	NATURE GENETICS			English	Article							TOLL-LIKE RECEPTOR-4; DROSOPHILA TOLL; GENE-TRANSFER; GRAIN DUST; LIPOPOLYSACCHARIDE; MICE; RESPONSIVENESS; INDUCTION	There is much variability between individuals in the response to inhaled toxins, but it is not known why certain people develop disease when challenged with environmental agents and others remain healthy. To address this, we investigated whether TLR4 (encoding the toll-like receptor-4), which has been shown to affect lipopolysaccharide (LPS) responsiveness in mice(1,2) underlies the variability in airway responsiveness to inhaled LPS in humans(3). Here we show that common, co-segregating missense mutations (Asp299Gly and Thr399Ile) affecting the extracellular domain of the TLR4 receptor are associated with a blunted response to inhaled LPS in humans. Transfection of THP-1 cells demonstrates that the Asp299Gly mutation (but not the Thr399Ile mutation) interrupts TLR4-mediated LPS signalling. Moreover. the wild-type allele of TLR4 rescues the LPS hyporesponsive phenotype in either primary airway epithelial cells or alveolar macrophages obtained from individuals with the TLR4 mutations. Our findings provide the first genetic evidence that common mutations in TLR4 are associated with differences in LPS responsiveness in humans, and demonstrate that gene-sequence changes can alter the ability of the host to respond to environmental stress.	Univ Iowa, Dept Vet Affairs Med Ctr, Dept Med, Iowa City, IA 52242 USA; Univ Iowa, Dept Vet Affairs Med Ctr, Dept Pediat, Iowa City, IA USA; Univ Iowa, Dept Vet Affairs Med Ctr, Dept Biostat, Iowa City, IA USA	University of Iowa; US Department of Veterans Affairs; Veterans Health Administration (VHA); Iowa City VA Health Care System; University of Iowa; US Department of Veterans Affairs; Veterans Health Administration (VHA); Iowa City VA Health Care System; University of Iowa; US Department of Veterans Affairs; Veterans Health Administration (VHA); Iowa City VA Health Care System	Schwartz, DA (corresponding author), Univ Iowa, Dept Vet Affairs Med Ctr, Dept Med, Iowa City, IA 52242 USA.			Zabner, Joseph/0000-0002-9606-1339; kline, joel/0000-0002-5523-8855	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P01ES009607, R01ES007498, R01ES006537] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES07498, ES06537, ES09607] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Becker S, 1999, AM J RESP CRIT CARE, V160, P1309, DOI 10.1164/ajrccm.160.4.9901062; Bonner JC, 1998, AM J RESP CELL MOL, V19, P672, DOI 10.1165/ajrcmb.19.4.3176; BRIGGS D, 1986, SURF INTERFACE ANAL, V8, P133, DOI 10.1002/sia.740080306; Chow JC, 1999, J BIOL CHEM, V274, P10689, DOI 10.1074/jbc.274.16.10689; DAVIDSON BL, 1994, EXP NEUROL, V125, P258, DOI 10.1006/exnr.1994.1028; Fasbender A, 1998, J CLIN INVEST, V102, P184, DOI 10.1172/JCI2732; Fisher L, 1993, BIOSTATISTICS METHOD; GIBRAT JF, 1987, J MOL BIOL, V198, P425, DOI 10.1016/0022-2836(87)90292-0; GUYER M, 1992, SCIENCE, V258, P67; Hoshino K, 1999, J IMMUNOL, V162, P3749; Kline JN, 1999, AM J RESP CRIT CARE, V160, P297, DOI 10.1164/ajrccm.160.1.9808144; Kuhns DB, 1997, J IMMUNOL, V158, P3959; Lidral AC, 1998, AM J HUM GENET, V63, P557, DOI 10.1086/301956; Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131; Michel O, 1996, AM J RESP CRIT CARE, V154, P1641, DOI 10.1164/ajrccm.154.6.8970348; OBRIEN AD, 1980, NATURE, V287, P440, DOI 10.1038/287440a0; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; RASKANDERSEN A, 1989, BRIT J IND MED, V46, P412; Rock FL, 1998, P NATL ACAD SCI USA, V95, P588, DOI 10.1073/pnas.95.2.588; SANTAMARIA P, 1989, J IMMUNOL, V143, P913; SCHWARTZ DA, 1995, AM J RESP CRIT CARE, V152, P603, DOI 10.1164/ajrccm.152.2.7633714; SCHWARTZ DA, 1995, AM J RESP CRIT CARE, V151, P47, DOI 10.1164/ajrccm.151.1.7812571; Shimazu R, 1999, J EXP MED, V189, P1777, DOI 10.1084/jem.189.11.1777; WARREN W, 1997, CURRENT PROTOCOLS HU; ZABNER J, 1996, J VIROL, V70, P6694	25	1609	1706	2	65	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUN	2000	25	2					187	+		10.1038/76048	http://dx.doi.org/10.1038/76048			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	321ML	10835634				2022-12-25	WOS:000087459200018
J	Schultz, J; Doerks, T; Ponting, CP; Copley, RR; Bork, P				Schultz, J; Doerks, T; Ponting, CP; Copley, RR; Bork, P			More than 1,000 putative new human signalling proteins revealed by EST data mining	NATURE GENETICS			English	Article							GENES	Cloning procedures aided by homology searches of EST databases have accelerated the pace of discovery of new genes' but EST database searching remains an involved and onerous task. More than 1.6 million human EST sequences have been deposited in public databases, making it difficult to identify ESTs that represent new genes. Compounding the problems of scale are difficulties in detection associated with a high sequencing error rate and low sequence similarity between distant homologues. We have developed a new method, coupling BLAST-based(2) searches with a domain identification protocol(3,4) that filters candidate homologues. Application of this method in a large-scale analysis of 100 signalling domain families has led to the identification of ESTs representing more than 1,000 novel human signalling genes. The 4,206 publicly available ESTs representing these genes are a valuable resource for rapid cloning of novel human signalling proteins. For example, we were able to identify ESTs of at least 106 new small GTPases, of which 6 are likely to belong to new subfamilies. In some cases, further analyses of genomic DNA led to the discovery of previously unidentified full-length protein sequences. This is exemplified by the in silico cloning (prediction of a gene product sequence using only genomic and EST sequence data) of a new type of GTPase with two catalytic domains.	EMBL, Heidelberg, Germany; Max Delbruck Ctr Mol Med, Berlin, Germany; Univ Oxford, MRC, Funct Genet Unit, Dept Human Anat & Genet, Oxford, England	European Molecular Biology Laboratory (EMBL); Helmholtz Association; Max Delbruck Center for Molecular Medicine; University of Oxford	Bork, P (corresponding author), EMBL, Heidelberg, Germany.		Bork, Peer/F-1813-2013; Ponting, Chris/AAV-2621-2021; Schultz, Joerg/B-9346-2008	Bork, Peer/0000-0002-2627-833X; Ponting, Chris/0000-0003-0202-7816				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BIRNEY E, 1997, ISMB, V5, P56; Bork P, 1996, METHOD ENZYMOL, V266, P162; Pandey A, 1999, TRENDS BIOCHEM SCI, V24, P276, DOI 10.1016/S0968-0004(99)01400-0; PRIGENT C, 1998, IN SILICO BIOL, V1, P11; Retief JD, 1999, GENOME RES, V9, P373; Schuler GD, 1997, J MOL MED, V75, P694, DOI 10.1007/s001090050155; Schultz J, 2000, NUCLEIC ACIDS RES, V28, P231, DOI 10.1093/nar/28.1.231; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; SUNYAEV S, IN PRESS ADV PROTEIN; Wadman M, 1999, NATURE, V398, P177, DOI 10.1038/18250; Wolff AM, 1999, YEAST, V15, P427, DOI 10.1002/(SICI)1097-0061(19990330)15:5<427::AID-YEA362>3.3.CO;2-X	12	35	46	0	4	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUN	2000	25	2					201	204		10.1038/76069	http://dx.doi.org/10.1038/76069			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	321ML	10835637				2022-12-25	WOS:000087459200021
J	Alimonti, J; Zhang, QJ; Gabathuler, R; Reid, G; Chen, SS; Jefferies, WA				Alimonti, J; Zhang, QJ; Gabathuler, R; Reid, G; Chen, SS; Jefferies, WA			TAP expression provides a general method for improving the recognition of malignant cells in vivo	NATURE BIOTECHNOLOGY			English	Article						TAP; MHC; CTL; cancer therapy; immunosurveillance; carcinoma	CLASS-I ANTIGENS; TRANSPORTER PROTEIN; TUMOR; LINES; BETA-2-MICROGLOBULIN; LYMPHOCYTES; CARCINOMAS; ESCAPE; GAMMA	A major class of tumors lack expression of the transporters associated with antigen processing (TAP). These proteins are essential for delivery of antigenic peptides into the lumen of the endoplasmic reticulum (ER) and subsequent assembly with nascent major histocompatibility complex (MHC) class I, which results in cell surface presentation of the trimeric complex to cytolytic T lymphocytes. Cytolytic T lymphocytes are major effector cells in immunosurveillance against tumors. Here we have tested the hypothesis that TAP downregulation in tumors allows immunosubversion of this effector mechanism, by establishing a model system to examine the role of TAP in vivo in restoring antigen presentation, immune recognition, and effects on malignancy of the TAP-deficient small-cell lung carcinoma, CMT.64. To test the potential of providing exogenous TAP in cancer therapies, we constructed a vaccinia virus (VV) containing the TAP1 gene and examined whether W-TAP1 could reduce tumors in mice. The results demonstrate that TAP should be considered for inclusion in cancer therapies, as it is likely to provide a general method for increasing immune responses against tumors regardless of the antigenic complement of the tumor or the MHC haplotypes of the host.	Univ British Columbia, Biomed Res Ctr, Biotechnol Lab, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Dept Med Genet, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Dept Microbiol & Immunol, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Dept Zool, Vancouver, BC V6T 1Z3, Canada	University of British Columbia; University of British Columbia; University of British Columbia; University of British Columbia	Jefferies, WA (corresponding author), Univ British Columbia, Biomed Res Ctr, Biotechnol Lab, 2222 Hlth Sci Mall, Vancouver, BC V6T 1Z3, Canada.		Reid, Gregor/F-6260-2011	Reid, Gregor/0000-0002-7567-3424				Braciale T J, 1992, Semin Immunol, V4, P81; CROMME FV, 1994, J EXP MED, V179, P335, DOI 10.1084/jem.179.1.335; FRANKS LM, 1976, CANCER RES, V36, P1049; GABATHULER R, 1994, J EXP MED, V180, P1415, DOI 10.1084/jem.180.4.1415; Garrido F, 1997, IMMUNOL TODAY, V18, P89, DOI 10.1016/S0167-5699(96)10075-X; HAMMERLING GJ, 1987, BIOCHIM BIOPHYS ACTA, V907, P245, DOI 10.1016/0304-419X(87)90008-4; INGLIS JR, 1983, T LYMPHOCYTE TODAY; JEFFERIES WA, 1993, J IMMUNOL, V151, P2974; KLAR D, 1989, EMBO J, V8, P475, DOI 10.1002/j.1460-2075.1989.tb03400.x; MACKETT M, 1986, J GEN VIROL, V67, P2067, DOI 10.1099/0022-1317-67-10-2067; Maeurer MJ, 1996, J CLIN INVEST, V98, P1633, DOI 10.1172/JCI118958; MOMBURG F, 1994, BEHRING I MITTEILUNG; NEEFJES J J, 1991, Current Opinion in Cell Biology, V3, P601, DOI 10.1016/0955-0674(91)90029-X; Rammensee HG, 1996, INT ARCH ALLERGY IMM, V110, P299, DOI 10.1159/000237320; REID GSD, 1997, THESIS U BRIT COLUMB; *SAS I INC, 1989, JMP IN VERS 3 2 1; Seliger B, 1997, EXP HEMATOL, V25, P608; Seliger B, 1997, IMMUNOL TODAY, V18, P292, DOI 10.1016/S0167-5699(97)01052-9; Singal DP, 1996, INT J CANCER, V68, P629, DOI 10.1002/(SICI)1097-0215(19961127)68:5<629::AID-IJC13>3.0.CO;2-X; TANAKA K, 1985, SCIENCE, V228, P26, DOI 10.1126/science.3975631; VOSE BM, 1985, SEMIN HEMATOL, V22, P27; WALLICH R, 1985, NATURE, V315, P301, DOI 10.1038/315301a0; Wang RF, 1996, J LEUKOCYTE BIOL, V60, P296, DOI 10.1002/jlb.60.3.296	23	64	77	0	4	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAY	2000	18	5					515	520		10.1038/75373	http://dx.doi.org/10.1038/75373			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	313UK	10802618				2022-12-25	WOS:000087017500024
J	Atreya, R; Mudter, J; Finotto, S; Mullberg, J; Jostock, T; Wirtz, S; Schutz, M; Bartsch, B; Holtmann, M; Becker, C; Strand, D; Czaja, J; Schlaak, JF; Lehr, HA; Autschbach, F; Schurmann, G; Nishimoto, N; Yoshizaki, K; Ito, H; Kishimoto, T; Galle, PR; Rose-John, S; Neurath, MF				Atreya, R; Mudter, J; Finotto, S; Mullberg, J; Jostock, T; Wirtz, S; Schutz, M; Bartsch, B; Holtmann, M; Becker, C; Strand, D; Czaja, J; Schlaak, JF; Lehr, HA; Autschbach, F; Schurmann, G; Nishimoto, N; Yoshizaki, K; Ito, H; Kishimoto, T; Galle, PR; Rose-John, S; Neurath, MF			Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: Evidence in Crohn disease and experimental colitis in vivo	NATURE MEDICINE			English	Article							NECROSIS-FACTOR-ALPHA; BOWEL-DISEASE; IL-6 RECEPTOR; MICE; STAT3; ACTIVATION; TERM	The pro-inflammatory cytokine interleukin (IL)-6 (refs. 1-5) can bind to cells lacking the IL-6 receptor (IL-6R) when it forms a complex with the soluble IL-6R (sIL-6R) (trans signaling)(5-7). Here, we have assessed the contribution of this system to the increased resistance of mucosal T cells against apoptosis in Crohn disease (CD), a chronic inflammatory disease of the gastrointestinal tract(8-12). A neutralizing antibody against IL-6R suppressed established experimental colitis in various animal models of CD mediated by type 1 T-helper cells, by inducing apoptosis of lamina propria T cells. Similarly, specific neutralization of sIL-6R in vivo by a newly designed gp130-Fc fusion protein caused suppression of colitis activity and induction of apoptosis, indicating that sIL-6R prevents mucosal T-cell apoptosis. In patients with Co, mucosal T cells showed strong evidence for IL-6 trans signaling, with activation of signal transducer and activator of transcription 3, bcl-2 and bcl-xl. Blockade of IL-6 trans signaling caused T-cell apoptosis, indicating that the IL-6-sIL-6R system mediates the resistance of T cells to apoptosis in CD. These data indicate that a pathway of T-cell activation driven by IL-6-sIL-6R contributes to the perpetuation of chronic intestinal inflammation. Specific targeting of this pathway may be a promising new approach for the treatment of CD.	Johannes Gutenberg Univ Mainz, Med Clin 1, Immunol Lab, D-55131 Mainz, Germany; Johannes Gutenberg Univ Mainz, Med Clin 1, Sect Pathophysiol, D-55131 Mainz, Germany; Osaka Univ, Suita, Osaka 5650871, Japan; Johannes Gutenberg Univ Mainz, Inst Pathol, D-55131 Mainz, Germany; Heidelberg Univ, Inst Pathol, D-69120 Heidelberg, Germany; Univ Munster, Dept Surg, D-48129 Munster, Germany	Johannes Gutenberg University of Mainz; Johannes Gutenberg University of Mainz; Osaka University; Johannes Gutenberg University of Mainz; Ruprecht Karls University Heidelberg; University of Munster	Neurath, MF (corresponding author), Johannes Gutenberg Univ Mainz, Med Clin 1, Immunol Lab, D-55131 Mainz, Germany.	neurath@1-med.klinik.uni-mainz.de	Becker, Christoph/A-6694-2008; Kishimoto, Tadamitsu/C-8470-2009; Galle, Peter R/T-5292-2018; Finotto, Susetta/H-2753-2019; Becker, Christoph/L-2996-2016; Eckhardt, Erik/G-1567-2010; Galle, Peter/ABE-2872-2021; Rose-John, Stefan/A-7998-2010	Becker, Christoph/0000-0002-1388-1041; Galle, Peter R/0000-0001-8294-0992; Galle, Peter/0000-0001-8294-0992; Rose-John, Stefan/0000-0002-7519-3279; Wirtz, Stefan/0000-0001-6936-7431; Schlaak, Joerg/0000-0002-9499-1014				Boirivant M, 1999, GASTROENTEROLOGY, V116, P557, DOI 10.1016/S0016-5085(99)70177-0; Bouhnik Y, 1996, LANCET, V347, P215, DOI 10.1016/S0140-6736(96)90402-X; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Fukada T, 1996, IMMUNITY, V5, P449, DOI 10.1016/S1074-7613(00)80501-4; GROSS V, 1992, GASTROENTEROLOGY, V102, P514, DOI 10.1016/0016-5085(92)90098-J; Ina K, 1999, J IMMUNOL, V163, P1081; KUHN R, 1993, CELL, V75, P263, DOI 10.1016/0092-8674(93)80068-P; Minami M, 1996, P NATL ACAD SCI USA, V93, P3963, DOI 10.1073/pnas.93.9.3963; MITSUYAMA K, 1995, GUT, V36, P45, DOI 10.1136/gut.36.1.45; MULLBERG J, 1995, J IMMUNOL, V155, P5198; NEURATH MF, 1995, J EXP MED, V182, P1281, DOI 10.1084/jem.182.5.1281; Peters M, 1996, J EXP MED, V183, P1399, DOI 10.1084/jem.183.4.1399; Peters M, 1998, BLOOD, V92, P3495, DOI 10.1182/blood.V92.10.3495.422k47_3495_3504; Peters M, 1997, J EXP MED, V185, P755, DOI 10.1084/jem.185.4.755; PODOLSKY DK, 1991, NEW ENGL J MED, V325, P928, DOI 10.1056/NEJM199109263251306; POWRIE F, 1994, IMMUNITY, V1, P553, DOI 10.1016/1074-7613(94)90045-0; REINECKER HC, 1993, CLIN EXP IMMUNOL, V94, P174; Romano M, 1997, IMMUNITY, V6, P315, DOI 10.1016/S1074-7613(00)80334-9; ROSEJOHN S, 1994, BIOCHEM J, V300, P281, DOI 10.1042/bj3000281; Sartor RB, 1998, GASTROENTEROLOGY, V114, P398, DOI 10.1016/S0016-5085(98)70492-5; STROBER W, 1995, CLIN IMMUNOLOGY, P1401; TAMURA T, 1993, P NATL ACAD SCI USA, V90, P11924, DOI 10.1073/pnas.90.24.11924; Targan SR, 1997, NEW ENGL J MED, V337, P1029, DOI 10.1056/NEJM199710093371502; Teague TK, 1997, J IMMUNOL, V158, P5791; Wirtz S, 1999, J IMMUNOL, V162, P1884	26	1037	1086	3	55	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2000	6	5					583	588		10.1038/75068	http://dx.doi.org/10.1038/75068			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	309YB	10802717				2022-12-25	WOS:000086796200045
J	Dantuma, NP; Lindsten, K; Glas, R; Jellne, M; Masucci, MG				Dantuma, NP; Lindsten, K; Glas, R; Jellne, M; Masucci, MG			Short-lived green fluorescent proteins for quantifying ubiquitin/proteasome-dependent proteolysis in living cells	NATURE BIOTECHNOLOGY			English	Article						ubiquitin/proteasome pathway; green fluorescent protein (GFP); proteasome inhibitor; cytotoxicity; cancer	MODULATES PROTEASOME ACTIVITY; N-END RULE; BETA-SUBUNITS; ANTIGEN PRESENTATION; UBIQUITIN SYSTEM; INHIBITORS; DEGRADATION; PATHWAY; EXPRESSION; CLEAVAGE	The ubiquitin/proteasome-dependent proteolytic pathway is an attractive target for therapeutics because of its critical involvement in cell cycle progression and antigen presentation. However, dissection of the pathway and development of modulators are hampered by the complexity of the system and the lack of easily detectable authentic substrates. We have developed a convenient reporter system by producing N-end rule and ubiquitin fusion degradation (UFD)-targeted green fluorescent proteins that allow quantification of ubiquitin/proteasome-dependent proteolysis in living cells. Accumulation of these reporters serves as an early predictor of G2/M arrest and apoptosis in cells treated with proteasome inhibitors. Comparison of reporter accumulation and cleavage of fluorogenic substrates demonstrates that the rate-limiting chymotrypsin-like activity of the proteasome can be substantially curtailed without significant effect on ubiquitin-dependent proteolysis. These reporters provide a new powerful tool for elucidation of the ubiquitin/proteasome pathway and for high throughput screening of compounds that selectively modify proteolysis in vivo.	Karolinska Inst, Ctr Microbiol & Tumor Biol, S-17177 Stockholm, Sweden	Karolinska Institutet	Masucci, MG (corresponding author), Karolinska Inst, Ctr Microbiol & Tumor Biol, S-17177 Stockholm, Sweden.		Masucci, Maria G/B-8588-2009; Masucci, Maria/AAC-6666-2019	Masucci, Maria/0000-0002-5541-2809; Dantuma, Nico/0000-0002-6090-4170				Adams J, 1999, CANCER RES, V59, P2615; Andre P, 1998, P NATL ACAD SCI USA, V95, P13120, DOI 10.1073/pnas.95.22.13120; BACHMAIR A, 1986, SCIENCE, V234, P179, DOI 10.1126/science.3018930; Bochtler M, 1999, ANNU REV BIOPH BIOM, V28, P295, DOI 10.1146/annurev.biophys.28.1.295; Bogyo M, 1997, BIOPOLYMERS, V43, P269, DOI 10.1002/(SICI)1097-0282(1997)43:4<269::AID-BIP2>3.0.CO;2-T; Bogyo M, 1997, P NATL ACAD SCI USA, V94, P6629, DOI 10.1073/pnas.94.13.6629; Bogyo M, 1998, CHEM BIOL, V5, P307, DOI 10.1016/S1074-5521(98)90169-7; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; Dick TP, 1998, J BIOL CHEM, V273, P25637, DOI 10.1074/jbc.273.40.25637; Dick TP, 1996, CELL, V86, P253, DOI 10.1016/S0092-8674(00)80097-5; Falnes PO, 1998, EMBO J, V17, P615, DOI 10.1093/emboj/17.2.615; FINLEY D, 1987, CELL, V48, P1035, DOI 10.1016/0092-8674(87)90711-2; GACZYNSKA M, 1993, NATURE, V365, P264, DOI 10.1038/365264a0; GONDA DK, 1989, J BIOL CHEM, V264, P16700; HEINEMEYER W, 1991, EMBO J, V10, P555, DOI 10.1002/j.1460-2075.1991.tb07982.x; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; JENSEN TJ, 1995, CELL, V83, P129, DOI 10.1016/0092-8674(95)90241-4; JOHNSON ES, 1995, J BIOL CHEM, V270, P17442, DOI 10.1074/jbc.270.29.17442; Kisselev AF, 1999, MOL CELL, V4, P395, DOI 10.1016/S1097-2765(00)80341-X; Laney JD, 1999, CELL, V97, P427, DOI 10.1016/S0092-8674(00)80752-7; Lee DH, 1998, TRENDS CELL BIOL, V8, P397, DOI 10.1016/S0962-8924(98)01346-4; Lee DH, 1998, MOL CELL BIOL, V18, P30, DOI 10.1128/MCB.18.1.30; Meng LH, 1999, P NATL ACAD SCI USA, V96, P10403, DOI 10.1073/pnas.96.18.10403; Meng LH, 1999, CANCER RES, V59, P2798; Nussbaum AK, 1998, P NATL ACAD SCI USA, V95, P12504, DOI 10.1073/pnas.95.21.12504; Orlowski RZ, 1999, CELL DEATH DIFFER, V6, P303, DOI 10.1038/sj.cdd.4400505; Rock KL, 1999, ANNU REV IMMUNOL, V17, P739, DOI 10.1146/annurev.immunol.17.1.739; Schmidtke G, 1999, J BIOL CHEM, V274, P35734, DOI 10.1074/jbc.274.50.35734; Schwartz AL, 1999, ANNU REV MED, V50, P57; Suzuki T, 1999, EMBO J, V18, P6017, DOI 10.1093/emboj/18.21.6017; Teicher BA, 1999, CLIN CANCER RES, V5, P2638	31	460	481	0	34	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAY	2000	18	5					538	543		10.1038/75406	http://dx.doi.org/10.1038/75406			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	313UK	10802622				2022-12-25	WOS:000087017500028
J	Gatei, M; Young, D; Cerosaletti, KM; Desai-Mehta, A; Spring, K; Kozlov, S; Lavin, MF; Gatti, RA; Concannon, P; Khanna, K				Gatei, M; Young, D; Cerosaletti, KM; Desai-Mehta, A; Spring, K; Kozlov, S; Lavin, MF; Gatti, RA; Concannon, P; Khanna, K			ATM-dependent phosphorylation of nibrin in response to radiation exposure	NATURE GENETICS			English	Article							STRAND BREAK REPAIR; DNA-DAMAGE RESPONSE; IONIZING-RADIATION; C-ABL; PROTEIN; KINASE; GENE; P53; PHENOTYPE; PRODUCT	Mutations in the gene ATM are responsible for the genetic disorder ataxia-telangiectasia (A-T), which is characterized by cerebellar dysfunction, radiosensitivity, chromosomal instability and cancer predisposition. Both the A-T phenotype and the similarity of the ATM protein to other DNA-damage sensors suggests a role for ATM in biochemical pathways involved in the recognition, signalling and repair of DNA double-strand breaks (DSBs). Them are strong parallels between the pattern of radiosensitivity, chromosomal instability and cancer predisposition in A-T patients and that in patients with Nijmegen breakage syndrome (NBS). The protein defective in NBS, nibrin (encoded by NBS1), forms a complex with MRE11 and RAD50 (refs 1,2). This complex localizes to DSBs within 30 minutes after cellular exposure to ionizing radiation (1R) and is observed in brightly staining nuclear foci after a longer period of time(3). The overlap between clinical and cellular phenotypes in A-T and NBS suggests that ATM and nibrin may function in the same biochemical pathway. Here we demonstrate that nibrin is phosphorylated within one hour of treatment of cells with IR. This response is abrogated in A-T cells that either do not express ATM protein or express near full-length mutant protein. We also show that ATM physically interacts with and phosphorylates nibrin on serine 343 both in vivo and in vitro. Phosphorylation of this site appears to be functionally important because mutated nibrin (S343A) does not completely complement radiosensitivity in NBS cells. ATM phosphorylation of nibrin does not affect nibrin-MRE11-RAD50 association as revealed by radiation-induced foci formation. Our data provide a biochemical explanation for the similarity in phenotype between A-T and NBS.	PO Royal Brisbane Hosp, Queensland Inst Med Res, Brisbane, Qld, Australia; Univ Washington, Sch Med, Dept Immunol, Seattle, WA USA; Univ Washington, Virginia Mason Res Ctr, Mol Genet Program, Seattle, WA USA; Univ Queensland, Dept Pathol, Joint Oncol Programme, Brisbane, Qld, Australia; Univ Queensland, Dept Surg, Brisbane, Qld, Australia; Univ Calif Los Angeles, Sch Med, Dept Pathol, Los Angeles, CA 90024 USA	QIMR Berghofer Medical Research Institute; Royal Brisbane & Women's Hospital; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Virginia Mason Medical Center; University of Queensland; University of Queensland; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Khanna, K (corresponding author), PO Royal Brisbane Hosp, Queensland Inst Med Res, Brisbane, Qld, Australia.		Khanna, Kum Kum/I-1747-2013; Kozlov, Sergei/M-2067-2014; Lavin, Martin F/F-5961-2014; Kozlov, Sergei/T-9779-2019	Kozlov, Sergei/0000-0001-6183-7339; Lavin, Martin F/0000-0002-5940-4769; Concannon, Patrick/0000-0002-5801-1859; Khanna, Kum Kum/0000-0001-8650-5381; Spring, Kevin/0000-0003-0601-924X	NATIONAL CANCER INSTITUTE [R01CA057569] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA057569, CA57569] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Carney JP, 1998, CELL, V93, P477, DOI 10.1016/S0092-8674(00)81175-7; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; FRANK JR, 1993, BIOMASS BIOENERG, V5, P1, DOI 10.1016/0961-9534(93)90002-L; GATEI M, IN PRESS CANCER; Khanna KK, 1998, NAT GENET, V20, P398, DOI 10.1038/3882; Kim ST, 1999, J BIOL CHEM, V274, P37538, DOI 10.1074/jbc.274.53.37538; Nelms BE, 1998, SCIENCE, V280, P590, DOI 10.1126/science.280.5363.590; PEAR WS, 1996, GENE THERAPY PROTOCO, P41; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; Shafman T, 1997, NATURE, V387, P520, DOI 10.1038/387520a0; Stewart GS, 1999, CELL, V99, P577, DOI 10.1016/S0092-8674(00)81547-0; Varon R, 1998, CELL, V93, P467, DOI 10.1016/S0092-8674(00)81174-5; Watters D, 1997, ONCOGENE, V14, P1911, DOI 10.1038/sj.onc.1201037; Wright JA, 1998, P NATL ACAD SCI USA, V95, P7445, DOI 10.1073/pnas.95.13.7445; Zhang N, 1997, P NATL ACAD SCI USA, V94, P8021, DOI 10.1073/pnas.94.15.8021; Ziv Y, 1997, ONCOGENE, V15, P159, DOI 10.1038/sj.onc.1201319	19	388	398	0	12	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAY	2000	25	1					115	119		10.1038/75508	http://dx.doi.org/10.1038/75508			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	311KU	10802669				2022-12-25	WOS:000086884000029
J	Poznansky, MC; Olszak, IT; Foxall, R; Evans, RH; Luster, AD; Scadden, DT				Poznansky, MC; Olszak, IT; Foxall, R; Evans, RH; Luster, AD; Scadden, DT			Active movement of T cells away from a chemokine	NATURE MEDICINE			English	Article							PROTEIN-COUPLED-RECEPTOR; AXON GUIDANCE; SIGNALING PATHWAYS; ATTRACTION; REPULSION; CHEMOTAXIS; CLONING; RANTES; GROWTH; SDF-1	Movement towards or away from a given stimulus guides the directional migration of prokaryotes, simple eukaryotes and neurons. As bi-directional cues may influence entry and exit of immune effector cells from tissue sites, we evaluated the migratory responses of T-cell subsets to varying concentrations of the chemokine stromal cell derived factor-1 (SDF-1). There was selective repulsion of subpopulations of T cells at high concentrations of recombinant SDF-1 or naturally occurring bone marrow-derived SDF-1, which could be inhibited by pertussis toxin and antibody against the chemokine receptor CXCR4. Distinct sensitivity profiles to genistein, herbimycin and 8-Br-cAMP biochemically distinguished movement of cells towards or away from an SDF-1 gradient. In vivo, antigen-induced T-cell recruitment into the peritoneal cavity was reversed by high but not low concentrations of SDF-1. The phenomenon of movement away from a chemokine represents a previously unknown mechanism regulating the localization of mature T cells. It adds to the functional repertoire of chemokines that may participate in immune physiology and may be applied therapeutically to alter the immune response.	Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr AIDS Res, Boston, MA 02129 USA; Harvard Univ, Massachusetts Gen Hosp, Sch Med, MGH Canc Ctr, Boston, MA 02129 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital	Scadden, DT (corresponding author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr AIDS Res, Boston, MA 02129 USA.		Poznansky, Mark C/M-4996-2015; Luster, Andrew/ABE-6504-2020	Poznansky, Mark C/0000-0003-1344-7103; Luster, Andrew/0000-0001-9679-7912; Foxall, Russell/0000-0001-9821-0708				BACON KB, 1995, SCIENCE, V269, P1727, DOI 10.1126/science.7569902; Baggiolini M, 1998, NATURE, V392, P565, DOI 10.1038/33340; BAILEY GB, 1985, J PROTOZOOL, V32, P341; Bashaw GJ, 1999, CELL, V97, P917, DOI 10.1016/S0092-8674(00)80803-X; Bleul CC, 1996, NATURE, V382, P829, DOI 10.1038/382829a0; Bleul CC, 1996, J EXP MED, V184, P1101, DOI 10.1084/jem.184.3.1101; COLOMARINO SA, 1995, CELL, V81, P621; Daaka Y, 1997, NATURE, V390, P88, DOI 10.1038/36362; DODD J, 1995, CELL, V81, P471, DOI 10.1016/0092-8674(95)90066-7; DUNN GA, 1990, BIOL CHEMOTACTIC RES, P1; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; Ganju RK, 1998, J BIOL CHEM, V273, P23169, DOI 10.1074/jbc.273.36.23169; Hong KS, 1999, CELL, V97, P927, DOI 10.1016/S0092-8674(00)80804-1; Hoogewerf AJ, 1997, BIOCHEMISTRY-US, V36, P13570, DOI 10.1021/bi971125s; KEATING MT, 1977, J BACTERIOL, V130, P144, DOI 10.1128/JB.130.1.144-147.1977; Kim CH, 1998, BLOOD, V91, P4434, DOI 10.1182/blood.V91.12.4434.412k45_4434_4443; Luster AD, 1998, NEW ENGL J MED, V338, P436, DOI 10.1056/NEJM199802123380706; Nagasawa T, 1996, NATURE, V382, P635, DOI 10.1038/382635a0; Oberlin E, 1996, NATURE, V382, P833, DOI 10.1038/382833a0; Seeger MA, 1999, CELL, V97, P821, DOI 10.1016/S0092-8674(00)80793-X; Selbie LA, 1998, TRENDS PHARMACOL SCI, V19, P87, DOI 10.1016/S0165-6147(97)01166-8; SHIROZU M, 1995, GENOMICS, V28, P495, DOI 10.1006/geno.1995.1180; Song HJ, 1998, SCIENCE, V281, P1515, DOI 10.1126/science.281.5382.1515; SUTHERLAND HJ, 1990, P NATL ACAD SCI USA, V87, P3584, DOI 10.1073/pnas.87.9.3584; TASHIRO K, 1993, SCIENCE, V261, P600, DOI 10.1126/science.8342023; Taylor BL, 1998, FEBS LETT, V425, P377, DOI 10.1016/S0014-5793(98)00253-1; TSO WW, 1974, J BACTERIOL, V118, P560, DOI 10.1128/JB.118.2.560-576.1974; TURNER L, 1995, J IMMUNOL, V155, P2437; TURNER SJ, 1977, BIOCHEM SOC T, V2, P2165; WARD AJI, 1985, LANGMUIR, V1, P24, DOI 10.1021/la00061a003; Wells TNC, 1998, TRENDS PHARMACOL SCI, V19, P376, DOI 10.1016/S0165-6147(98)01247-4; WILKINSON PC, 1990, BIOL CHEMOTACTIC RES, P323; Wu W, 1999, NATURE, V400, P331, DOI 10.1038/22477	33	243	272	0	5	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAY	2000	6	5					543	548		10.1038/75022	http://dx.doi.org/10.1038/75022			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	309YB	10802710				2022-12-25	WOS:000086796200038
J	Restifo, NP				Restifo, NP			Not so Fas: Re-evaluating the mechanisms of immune privilege and tumor escape	NATURE MEDICINE			English	Editorial Material							LIGAND EXPRESSION; CD95 LIGAND; ALLOGRAFT-REJECTION; GRAFT-REJECTION; MELANOMA-CELLS; T-LYMPHOCYTES; INHIBITION; APOPTOSIS; MYOBLASTS; ISLETS	Based on early studies, it was hypothesized that expression of Fas ligand (FasL) by tumor cells enabled them to counterattack the immune system, and that transplant rejection could be prevented by expressing FasL on transplanted organs. More recent studies have indicated that the notion of FasL as a mediator of immune privilege needed to be reconsidered, and taught a valuable lesson about making broad conclusions based on small amounts of data.	NCI, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Restifo, NP (corresponding author), NCI, NIH, Bethesda, MD 20892 USA.		Restifo, Nicholas Phillip/Z-1614-2019; Restifo, Nicholas Phillip/M-6549-2019; Restifo, Nicholas P/A-5713-2008	Restifo, Nicholas P./0000-0003-4229-4580	Intramural NIH HHS [Z99 CA999999, Z01 BC010763-01] Funding Source: Medline	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Allison J, 1997, P NATL ACAD SCI USA, V94, P3943, DOI 10.1073/pnas.94.8.3943; Arai H, 1997, P NATL ACAD SCI USA, V94, P13862, DOI 10.1073/pnas.94.25.13862; BELLGRAU D, 1995, NATURE, V377, P630, DOI 10.1038/377630a0; BELLGRAU D, 1998, NATURE, V394, P133; Chappell DB, 1998, CANCER IMMUNOL IMMUN, V47, P65, DOI 10.1007/s002620050505; Chappell DB, 1999, CANCER RES, V59, P59; DeMaria R, 1996, J CLIN INVEST, V97, P316, DOI 10.1172/JCI118418; Ekmekcioglu S, 1999, MELANOMA RES, V9, P261, DOI 10.1097/00008390-199906000-00008; FIEDLER P, 1998, SCIENCE, V279, pA2015; Gastman BR, 1999, CANCER RES, V59, P5356; GRIFFING JH, 1895, PSYCHOL REV MONOGRAP, V1, P1; Hahne M, 1996, SCIENCE, V274, P1363, DOI 10.1126/science.274.5291.1363; Henkart P A, 1997, Semin Immunol, V9, P135, DOI 10.1006/smim.1997.0063; Hohlbaum AM, 2000, J EXP MED, V191, P1209, DOI 10.1084/jem.191.7.1209; Kang SM, 1998, TRANSPLANT P, V30, P538, DOI 10.1016/S0041-1345(97)01396-1; Kang SM, 1997, NAT MED, V3, P738, DOI 10.1038/nm0797-738; Kang SM, 1997, SCIENCE, V278, P1322, DOI 10.1126/science.278.5341.1322; Lau HT, 1996, SCIENCE, V273, P109, DOI 10.1126/science.273.5271.109; Lenardo M, 1999, ANNU REV IMMUNOL, V17, P221, DOI 10.1146/annurev.immunol.17.1.221; LI P, 1995, CELL, V80, P401, DOI 10.1016/0092-8674(95)90490-5; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; O'Connell J, 1999, NAT MED, V5, P267, DOI 10.1038/6477; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; Seino K, 1998, J IMMUNOL, V161, P4484; Seino K, 1997, TRANSPL P, V29, P1092, DOI 10.1016/S0041-1345(96)00421-6; Seino K, 1996, INT IMMUNOL, V8, P1347, DOI 10.1093/intimm/8.9.1347; SELNO K, 1999, TRANSPLANT P, V31, P1942; Smith D, 1998, J IMMUNOL, V160, P4159; Vaux DL, 1998, NATURE, V394, P133, DOI 10.1038/28067; Yagita H, 1996, NATURE, V379, P682, DOI 10.1038/379682a0; Zaks TZ, 1999, J IMMUNOL, V162, P3273	31	207	229	0	7	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAY	2000	6	5					493	495		10.1038/74955	http://dx.doi.org/10.1038/74955			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	309YB	10802692	Green Accepted			2022-12-25	WOS:000086796200018
J	Morris, L; Allen, KE; La Thangue, NB				Morris, L; Allen, KE; La Thangue, NB			Regulation of E2F transcription by cyclinE-Cdk2 kinase mediated through p300/CBP co-activators	NATURE CELL BIOLOGY			English	Article							CELL-CYCLE CONTROL; RETINOBLASTOMA PROTEIN; HISTONE ACETYLTRANSFERASE; FUNCTIONAL INACTIVATION; NUCLEAR ACCUMULATION; FACTOR DRTF1/E2F; FAMILY PROTEINS; IN-VIVO; S-PHASE; CBP	The E2F proteins form a family of transcription factors that regulate the transition from the G1 to the S phase in the cell cycle. E2F activity is regulated by members of the retinoblastoma protein (pRb) family, ensuring the tight control of E2F-responsive genes. During the G1 phase, phosphorylation of pRb by cyclin-dependent kinases (CDKs), most notably cyclinD-CDK complexes, releases pRb from E2F, facilitating cell-cycle progression by the timely induction of E2F-targeted genes such as cyclinE However, it is not known whether E2F proteins are directly targeted by CDKs. Here we show that E2F-5 is phosphorylated by the cyclin E-Cdk2 complex, which functions in the late GS. phase, but not by the early-GI-phase-acting cyclinD-CDK complex. A phosphorylation site in the trans-activation domain of E2F-5 stimulates transcription and cell-cycle progression by the recruitment of the p300/CBP family of co-activators, whose binding to E2F-5 is stabilized upon phosphorylation by cyclin E-Cdk2, These results indicate that E2F activity may be directly regulated by cyclinE-Cdk2, and imply an autoregulatory mechanism for cell-cycle-dependent transcription through the CDK-stimulated interaction of E2F with p300/CBP co-activators.	Univ Glasgow, Div Biochem & Mol Biol, Glasgow G12 8QQ, Lanark, Scotland	University of Glasgow	La Thangue, NB (corresponding author), Univ Glasgow, Div Biochem & Mol Biol, Davidson Bldg, Glasgow G12 8QQ, Lanark, Scotland.			Allen, Liz/0000-0001-8579-7730				Alevizopoulos K, 1997, EMBO J, V16, P5322, DOI 10.1093/emboj/16.17.5322; Allen KE, 1997, J CELL SCI, V110, P2819; BANDARA LR, 1993, EMBO J, V12, P4317, DOI 10.1002/j.1460-2075.1993.tb06116.x; BANDARA LR, 1994, EMBO J, V13, P3104, DOI 10.1002/j.1460-2075.1994.tb06609.x; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BEIJERSBERGEN RL, 1994, GENE DEV, V8, P2680, DOI 10.1101/gad.8.22.2680; Botz J, 1996, MOL CELL BIOL, V16, P3401; BUCKLES R, 1995, J URBAN TECHNOL, V2, P31, DOI 10.1080/10630739508724497; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; de la Luna S, 1999, EMBO J, V18, P212, DOI 10.1093/emboj/18.1.212; delaLuna S, 1996, J CELL SCI, V109, P2443; DESAI D, 1995, MOL CELL BIOL, V15, P345, DOI 10.1128/MCB.15.1.345; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; GIRLING R, 1993, NATURE, V362, P83, DOI 10.1038/362083a0; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; HATAKEYAMA M, 1994, GENE DEV, V8, P1759, DOI 10.1101/gad.8.15.1759; Helin K, 1998, CURR OPIN GENET DEV, V8, P28, DOI 10.1016/S0959-437X(98)80058-0; HIJMANS EM, 1995, MOL CELL BIOL, V15, P3082; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; JOHNSTON LH, 1992, NUCLEIC ACIDS RES, V20, P2403, DOI 10.1093/nar/20.10.2403; KITAGAWA M, 1995, ONCOGENE, V10, P229; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; Krek W, 1995, CELL, V83, P1149, DOI 10.1016/0092-8674(95)90141-8; LAM EWF, 1994, CURR OPIN CELL BIOL, V6, P859; Lambert PF, 1998, J BIOL CHEM, V273, P33048, DOI 10.1074/jbc.273.49.33048; Lee CW, 1998, ONCOGENE, V16, P2695, DOI 10.1038/sj.onc.1201818; Lukas J, 1997, GENE DEV, V11, P1479, DOI 10.1101/gad.11.11.1479; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; LUO K, 1990, ONCOGENE, V5, P921; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Marti A, 1999, NAT CELL BIOL, V1, P14, DOI 10.1038/8984; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; PEEPER DS, 1995, ONCOGENE, V10, P39; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Shikama N, 1999, MOL CELL, V4, P365, DOI 10.1016/S1097-2765(00)80338-X; Shikama N, 1997, TRENDS CELL BIOL, V7, P230, DOI 10.1016/S0962-8924(97)01048-9; Slansky JE, 1996, CURR TOP MICROBIOL, V208, P1; Taylor IA, 1997, J MOL BIOL, V272, P1, DOI 10.1006/jmbi.1997.1229; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Trouche D, 1996, P NATL ACAD SCI USA, V93, P1439, DOI 10.1073/pnas.93.4.1439; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; ZerfassThome K, 1997, MOL CELL BIOL, V17, P407, DOI 10.1128/MCB.17.1.407; Zhang HS, 1999, CELL, V97, P53, DOI 10.1016/S0092-8674(00)80714-X; Zheng N, 1999, GENE DEV, V13, P666, DOI 10.1101/gad.13.6.666	50	122	125	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	APR	2000	2	4					232	239		10.1038/35008660	http://dx.doi.org/10.1038/35008660			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	302ZU	10783242				2022-12-25	WOS:000086397000017
J	Chen, BB; Bronson, RT; Klaman, LD; Hampton, TG; Wang, JF; Green, PJ; Magnuson, T; Douglas, PS; Morgan, JP; Neel, BG				Chen, BB; Bronson, RT; Klaman, LD; Hampton, TG; Wang, JF; Green, PJ; Magnuson, T; Douglas, PS; Morgan, JP; Neel, BG			Mice mutant for Egfr and Shp2 have defective cardiac semilunar valvulogenesis	NATURE GENETICS			English	Article							HUMAN EPIDERMOID CARCINOMA; TRANSCRIPTION FACTOR; NF-ATC; RECEPTOR; GROWTH; MUTATION; TRANSFORMATION; PHENOTYPE; LACKING; ERBB3	Atrioventricular and semilunar valve abnormalities are common birth defects, but how cardiac valvulogenesis is directed remains largely unknown. During studies of genetic interaction between Egfr, encoding the epidermal growth factor receptor, and Ptpn11, encoding the protein-tyrosine-phosphatase Shp2, we discovered that Egfr is required for semilunar, but not atrioventricular, valve development. Although unnoticed in earlier studies(1,2), 2, mice homozygous for the hypomorphic Egfr allele waved-2 (Egfr(wa2/wa2)) exhibit semilunar valve enlargement resulting from over-abundant mesenchymal cells. Egfr(-/-) mice (CD1 background) have similar defects. The penetrance and severity of the defects in Egfr(wa2/wa2) mice are enhanced by heterozygosity for a targeted mutation of exon 2 of Ptpn11 (ref. 3). Compound (Egfr(wa2/wa2):Ptpn11(+/-)) mutant mice also show premature lethality. Electrocardiography, echocardiography and haemodynamic analyses showed that affected mice develop aortic stenosis and regurgitation. Our results identify the Egfr and Shp2 as components of a growth-factor signalling pathway required specifically for semilunar valvulogenesis, support the hypothesis that Shp2 is required for Egfr signalling in vivo, and provide an animal model for aortic valve disease.	Beth Israel Deaconess Med Ctr, Div Hematol Oncol, Canc Biol Program, Boston, MA 02215 USA; Beth Israel Deaconess Med Ctr, Dept Med, Div Cardiol, Boston, MA USA; Harvard Univ, Sch Med, Boston, MA USA; Tufts Univ, Sch Vet Med, Dept Pathol, Boston, MA 02111 USA; Case Western Reserve Univ, Dept Genet, Cleveland, OH 44106 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Tufts University; Case Western Reserve University	Neel, BG (corresponding author), Beth Israel Deaconess Med Ctr, Div Hematol Oncol, Canc Biol Program, Boston, MA 02215 USA.			Douglas, Pamela/0000-0001-9876-4049	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD026722] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA049152] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL056993] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA49152] Funding Source: Medline; NHLBI NIH HHS [P50 HL56993-01] Funding Source: Medline; NICHD NIH HHS [HD26722] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Arrandale JM, 1996, J BIOL CHEM, V271, P21353, DOI 10.1074/jbc.271.35.21353; BARNES DW, 1982, J CELL BIOL, V93, P1, DOI 10.1083/jcb.93.1.1; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; Clarke Edward H., 1995, DEV MECH HEART DIS, P157; de la Pompa JL, 1998, NATURE, V392, P182, DOI 10.1038/32419; Erickson SL, 1997, DEVELOPMENT, V124, P4999; GILLIN FD, 1981, J ANTIMICROB CHEMOTH, V8, P305, DOI 10.1093/jac/8.4.305; Greco TL, 1996, GENE DEV, V10, P313, DOI 10.1101/gad.10.3.313; KIRBY ML, 1995, CIRC RES, V77, P211, DOI 10.1161/01.RES.77.2.211; Kretzschmar M, 1997, NATURE, V389, P618, DOI 10.1038/39348; Kupershmidt S, 1999, CIRC RES, V84, P146, DOI 10.1161/01.RES.84.2.146; Lakkis MM, 1998, DEVELOPMENT, V125, P4359; Lorenz JN, 1997, AM J PHYSIOL-HEART C, V272, pH1137, DOI 10.1152/ajpheart.1997.272.3.H1137; Luetteke NC, 1999, DEVELOPMENT, V126, P2739; LUETTEKE NC, 1994, GENE DEV, V8, P399, DOI 10.1101/gad.8.4.399; MACLEOD CL, 1986, J CELL PHYSIOL, V127, P175, DOI 10.1002/jcp.1041270121; MCLAREN A, 1971, GENET RES, V17, P257, DOI 10.1017/S0016672300012271; MCLAREN A, 1969, NATURE, V224, P238, DOI 10.1038/224238a0; MIETTINEN PJ, 1995, NATURE, V376, P337, DOI 10.1038/376337a0; POTTS JD, 1989, DEV BIOL, V134, P392, DOI 10.1016/0012-1606(89)90111-5; POTTS JD, 1991, P NATL ACAD SCI USA, V88, P1516, DOI 10.1073/pnas.88.4.1516; Qu CK, 1999, P NATL ACAD SCI USA, V96, P8528, DOI 10.1073/pnas.96.15.8528; Ranger AM, 1998, NATURE, V392, P186, DOI 10.1038/32426; Saxton TM, 1997, EMBO J, V16, P2352, DOI 10.1093/emboj/16.9.2352; Sibilia M, 1998, EMBO J, V17, P719, DOI 10.1093/emboj/17.3.719; SIBILIA M, 1995, SCIENCE, V269, P234, DOI 10.1126/science.7618085; TAKADA S, 1994, GENE DEV, V8, P174, DOI 10.1101/gad.8.2.174; THREADGILL DW, 1995, SCIENCE, V269, P230, DOI 10.1126/science.7618084; Van Vactor D, 1998, CURR OPIN GENET DEV, V8, P112, DOI 10.1016/S0959-437X(98)80070-1; Wang DZM, 1997, GENE DEV, V11, P309, DOI 10.1101/gad.11.3.309	30	215	225	0	11	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAR	2000	24	3					296	299		10.1038/73528	http://dx.doi.org/10.1038/73528			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	288XW	10700187				2022-12-25	WOS:000085590600024
J	Kung, C; Pingel, JT; Heikinheimo, M; Klemola, T; Varkila, K; Yoo, LI; Vuopala, K; Poyhonen, M; Uhari, M; Rogers, M; Speck, SH; Chatila, T; Thomas, ML				Kung, C; Pingel, JT; Heikinheimo, M; Klemola, T; Varkila, K; Yoo, LI; Vuopala, K; Poyhonen, M; Uhari, M; Rogers, M; Speck, SH; Chatila, T; Thomas, ML			Mutations in the tyrosine phosphatase CD45 gene in a child with severe combined immunodeficiency disease	NATURE MEDICINE			English	Article							CD4(+)CD8(+) THYMOCYTES; CELL MATURATION; LYMPHOCYTE; PROTEIN; MICE; DEFICIENCY; SELECTION; ZAP-70	The hematopoietic-specific transmembrane protein tyrosine phosphatase CD45 functions to regulate Src kinases required for T- and B-cell antigen receptor signal transduction(1,2). So far, there have been no reports to our knowledge of a human deficiency in a tyrosine-specific phosphatase. Here, we identified a male patient with a deficiency in CD45 due to a large deletion at one allele and a point mutation at the other. The point mutation resulted in the alteration of intervening sequence 13 donor splice site. The patient presented at 2 months of age with severe combined immunodeficiency disease. The population of peripheral blood T lymphocytes was greatly diminished and unresponsive to mitogen stimulation. Despite normal B-lymphocyte numbers, serum immunoglobulin levels decreased with age. Thus, CD45 deficiency in humans results in T- and B-lymphocyte dysfunction.	Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA; Washington Univ, Sch Med, Howard Hughes Med Inst, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Microbiol & Mol Pathol, St Louis, MO 63110 USA; Univ Helsinki, Childrens Hosp, FIN-00290 Helsinki, Finland; Natl Publ Hlth Inst, SF-00300 Helsinki, Finland; Oulu Univ Hosp, Dept Pathol, Oulu, Finland; Oulu Univ Hosp, Dept Clin Genet, Oulu, Finland; Univ Oulu, Dept Pediat, Oulu 90220, Finland; Lapland Cent Hosp, Dept Pathol, Rovaniemi 96101, Finland; Family Federat Finland, Dept Med Genet, Helsinki, Finland	Washington University (WUSTL); Howard Hughes Medical Institute; Washington University (WUSTL); Washington University (WUSTL); University of Helsinki; Finland National Institute for Health & Welfare; University of Oulu; University of Oulu; University of Oulu; Family Federation of Finland	Chatila, T (corresponding author), Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA.	chatila@kids.wustl.edu	Speck, Samuel/L-5893-2019; Poyhonen, Minna/K-4866-2018	Poyhonen, Minna/0000-0003-2037-2744; Chatila, Talal/0000-0001-7439-2762				Byth KF, 1996, J EXP MED, V183, P1707, DOI 10.1084/jem.183.4.1707; CHAN AC, 1994, SCIENCE, V264, P1599, DOI 10.1126/science.8202713; Cyster JG, 1996, NATURE, V381, P325, DOI 10.1038/381325a0; ELDER ME, 1994, SCIENCE, V264, P1596, DOI 10.1126/science.8202712; ERKELLERYUKSEL FM, 1992, J PEDIATR-US, V120, P216, DOI 10.1016/S0022-3476(05)80430-5; Jirapongsananuruk O, 1999, CLIN EXP IMMUNOL, V118, P1; Kirberg J, 1996, INT IMMUNOL, V8, P1743, DOI 10.1093/intimm/8.11.1743; KISHIHARA K, 1993, CELL, V74, P143, DOI 10.1016/0092-8674(93)90302-7; MACCHI P, 1995, NATURE, V377, P65, DOI 10.1038/377065a0; Okumura M, 1998, DNA CELL BIOL, V17, P779, DOI 10.1089/dna.1998.17.779; RUSSELL SM, 1995, SCIENCE, V270, P797, DOI 10.1126/science.270.5237.797; Sato T, 1996, INT IMMUNOL, V8, P1529, DOI 10.1093/intimm/8.10.1529; Seavitt JR, 1999, MOL CELL BIOL, V19, P4200; TROWBRIDGE IS, 1994, ANNU REV IMMUNOL, V12, P85, DOI 10.1146/annurev.iy.12.040194.000505; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4	15	217	229	0	10	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2000	6	3					343	345						3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	288TL	10700239				2022-12-25	WOS:000085580500047
J	Orso, E; Broccardo, C; Kaminski, WE; Bottcher, A; Liebisch, G; Drobnik, W; Gotz, A; Chambenoit, O; Diederich, W; Langmann, T; Spruss, T; Luciani, MF; Rothe, G; Lackner, KJ; Chimini, G; Schmitz, G				Orso, E; Broccardo, C; Kaminski, WE; Bottcher, A; Liebisch, G; Drobnik, W; Gotz, A; Chambenoit, O; Diederich, W; Langmann, T; Spruss, T; Luciani, MF; Rothe, G; Lackner, KJ; Chimini, G; Schmitz, G			Transport of lipids from Golgi to plasma membrane is defective in Tangier disease patients and Abc1-deficient mice	NATURE GENETICS			English	Article							FREE-CHOLESTEROL; A-I; LIPOPROTEINS; MACROPHAGES; METABOLISM; CAVEOLAE; EFFLUX; CELLS	Mutations in the gene encoding ATP-binding cassette transporter 1 (ABC1) have been reported in Tangier disease(1-3) (TD), an autosomal recessive disorder that is characterized by almost complete absence of plasma high-density lipoprotein (HDL), deposition of cholesteryl esters in the reticulo-endothelial system(4) (RES) and aberrant cellular lipid trafficking(5-12). We demonstrate here that mice with a targeted inactivation of Abc1 display morphologic abnormalities and perturbations in their lipoprotein metabolism concordant with TD. ABC1 is expressed on the plasma membrane and the Golgi complex, mediates apo-Al associated export of cholesterol and phospholipids from the cell, and is regulated by cholesterol flux. Structural and functional abnormalities in caveolar processing and the trans-Golgi secretory pathway of cells lacking functional ABC1 indicate that lipid export processes involving vesicular budding between the Golgi and the plasma membrane are severely disturbed.	Univ Regensburg, Inst Clin Chem & Lab Med, D-93042 Regensburg, Germany; CNRS Marseille Luminy, INSERM, Ctr Immunol, Marseille 9, France; Univ Regensburg, Lab Anim Facil, D-8400 Regensburg, Germany	University of Regensburg; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; University of Regensburg	Schmitz, G (corresponding author), Univ Regensburg, Inst Clin Chem & Lab Med, Franz Josef Str Allee 11, D-93042 Regensburg, Germany.		Liebisch, Gerhard/G-6130-2010; Broccardo, Cyril/G-2796-2017; Langmann, Thomas/HHZ-9814-2022	Liebisch, Gerhard/0000-0003-4886-0811; Broccardo, Cyril/0000-0003-3016-6549; Langmann, Thomas/0000-0001-6826-529X; Schmitz, Gerd/0000-0002-1325-1007				ASSMANN G, 1989, METABOLIC BASIS INHE, P1267; BHAKDI S, 1995, J EXP MED, V182, P1959, DOI 10.1084/jem.182.6.1959; Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914; BOJANOVSKI D, 1987, J CLIN INVEST, V80, P1742, DOI 10.1172/JCI113266; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; CONRAD PA, 1995, J CELL BIOL, V131, P1421, DOI 10.1083/jcb.131.6.1421; Drobnik W, 1999, ARTERIOSCL THROM VAS, V19, P28, DOI 10.1161/01.ATV.19.1.28; Fielding CJ, 1997, P NATL ACAD SCI USA, V94, P3753, DOI 10.1073/pnas.94.8.3753; FIELDING PE, 1995, BIOCHEMISTRY-US, V34, P14288, DOI 10.1021/bi00044a004; FRANCIS GA, 1995, J CLIN INVEST, V96, P78, DOI 10.1172/JCI118082; GINGRAS D, 1993, AM J PHYSIOL, V265, pF316, DOI 10.1152/ajprenal.1993.265.2.F316; Glauert AM., 1975, PRACTICAL METHODS EL; Huber AM, 1999, BBA-GEN SUBJECTS, V1426, P43, DOI 10.1016/S0304-4165(98)00121-4; Kurzchalia TV, 1999, CURR OPIN CELL BIOL, V11, P424, DOI 10.1016/S0955-0674(99)80061-1; Langmann T, 1999, BIOCHEM BIOPH RES CO, V257, P29, DOI 10.1006/bbrc.1999.0406; Li N, 1997, BRIT J HAEMATOL, V99, P808, DOI 10.1046/j.1365-2141.1997.4993305.x; Liu PS, 1999, NAT CELL BIOL, V1, P369, DOI 10.1038/14067; MARTIN OC, 1993, P NATL ACAD SCI USA, V90, P2661, DOI 10.1073/pnas.90.7.2661; ROBENEK H, 1991, ARTERIOSCLER THROMB, V11, P1007, DOI 10.1161/01.ATV.11.4.1007; ROGLER G, 1995, ARTERIOSCL THROM VAS, V15, P683, DOI 10.1161/01.ATV.15.5.683; Rust S, 1999, NAT GENET, V22, P352, DOI 10.1038/11921; SCHMITZ G, 1985, P NATL ACAD SCI USA, V82, P6305, DOI 10.1073/pnas.82.18.6305; Schmitz G, 1997, ELECTROPHORESIS, V18, P1807, DOI 10.1002/elps.1150181015; SCHMITZ G, 1985, EMBO J, V4, P613, DOI 10.1002/j.1460-2075.1985.tb03674.x; SCHMITZ G, 1990, ARTERIOSCLEROSIS, V10, P1010, DOI 10.1161/01.ATV.10.6.1010; SCHMITZ G, 1984, J CHROMATOGR, V307, P65, DOI 10.1016/S0378-4347(00)84073-6; Schmitz G, 1998, P SOC PHOTO-OPT INS, V3260, P127, DOI 10.1117/12.307088; Stohr J, 1998, ARTERIOSCL THROM VAS, V18, P1424, DOI 10.1161/01.ATV.18.9.1424; VAN MEER G, 1988, J CELL BIOCHEM, V36, P51, DOI 10.1002/jcb.240360106; WILLIAMS MA, 1977, PRACTICLA METHODS EL	30	412	434	0	11	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	FEB	2000	24	2					192	196		10.1038/72869	http://dx.doi.org/10.1038/72869			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	280LQ	10655069				2022-12-25	WOS:000085104600024
J	Rideout, WM; Wakayama, T; Wutz, A; Eggan, K; Jackson-Grusby, L; Dausman, J; Yanagimachi, R; Jaenisch, R				Rideout, WM; Wakayama, T; Wutz, A; Eggan, K; Jackson-Grusby, L; Dausman, J; Yanagimachi, R; Jaenisch, R			Generation of mice from wild-type and targeted ES cells by nuclear cloning	NATURE GENETICS			English	Article							ADULT		MIT, Whitehead Inst Biomed Res, Cambridge, MA 02139 USA; Univ Hawaii, John A Burns Sch Med, Dept Anat & Reprod Biol, Honolulu, HI 96822 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; University of Hawaii System	Jaenisch, R (corresponding author), MIT, Whitehead Inst Biomed Res, Cambridge, MA 02139 USA.		Eggan, Kevin/P-7119-2018					Baguisi A, 1999, NAT BIOTECHNOL, V17, P456, DOI 10.1038/8632; Campbell K H, 1996, Rev Reprod, V1, P40, DOI 10.1530/ror.0.0010040; Dean W, 1998, DEVELOPMENT, V125, P2273; Kato Y, 1998, SCIENCE, V282, P2095, DOI 10.1126/science.282.5396.2095; Simpson EM, 1997, NAT GENET, V16, P19, DOI 10.1038/ng0597-19; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; Wakayama T, 1998, NATURE, V394, P369, DOI 10.1038/28615; Wakayama T, 1999, P NATL ACAD SCI USA, V96, P14984, DOI 10.1073/pnas.96.26.14984; Wakayama T, 1999, NAT GENET, V22, P127, DOI 10.1038/9632; Wells DN, 1999, BIOL REPROD, V60, P996, DOI 10.1095/biolreprod60.4.996; Wilmut I, 1997, NATURE, V385, P810, DOI 10.1038/385810a0	11	248	277	0	12	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	FEB	2000	24	2					109	110		10.1038/72753	http://dx.doi.org/10.1038/72753			2	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	280LQ	10655052				2022-12-25	WOS:000085104600008
J	Zhang, M; Volpert, O; Shi, YH; Bouck, N				Zhang, M; Volpert, O; Shi, YH; Bouck, N			Maspin is an angiogenesis inhibitor	NATURE MEDICINE			English	Article							PLASMINOGEN-ACTIVATOR INHIBITOR-1; TUMOR-SUPPRESSOR; CANCER CELLS; GENE MASPIN; MAMMARY; EXPRESSION; GROWTH; PURIFICATION; INVASION; MOTILITY	Maspin, a unique member of the serpin family, is a secreted protein encoded by a class II tumor suppressor gene whose downregulation is associated with the development of breast and prostate cancers(1,2). Overexpression of maspin in breast tumor cells limits their growth and metastases in vivo. In this report we demonstrate that maspin is an effective inhibitor of angiogenesis. In vitro, it acted directly on cultured endothelial cells to stop their migration towards basic fibroblast growth factor and vascular endothelial growth factor and to limit mitogenesis and tube formation. In vivo, it blocked neovascularization in the rat cornea pocket model. Maspin derivatives mutated in the serpin reactive site lost their ability to inhibit the migration of fibroblasts, keratinocytes, and breast cancer cells but were still able to block angiogenesis in vitro and in vivo. When maspin was delivered locally to human prostate tumor cells in a xenograft mouse model, it blocked tumor growth and dramatically reduced the density of tumor-associated microvessels. These data suggest that the tumor suppressor activity of maspin may depend in large part on its ability to inhibit angiogenesis and raise the possibility that maspin and similar serpins may be excellent leads for the development of drugs that modulate angiogenesis.	Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; Northwestern Univ, Sch Med, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA; Northwestern Univ, Sch Med, Dept Immunol Microbiol, Chicago, IL 60611 USA	Baylor College of Medicine; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Robert H. Lurie Comprehensive Cancer Center; Northwestern University	Zhang, M (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA.	mzhang@bcm.tmc.edu		Volpert, Olga/0000-0003-1381-5543	NATIONAL CANCER INSTITUTE [R01CA064239] Funding Source: NIH RePORTER; NCI NIH HHS [CA 64239, CA 52750] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Dawson DW, 1999, SCIENCE, V285, P245, DOI 10.1126/science.285.5425.245; Dawson DW, 1997, J CELL BIOL, V138, P707, DOI 10.1083/jcb.138.3.707; Gately S, 1996, CANCER RES, V56, P4887; LAWRENCE DA, 1994, J BIOL CHEM, V269, P15223; Obermair A, 1997, J NATL CANCER I, V89, P1212, DOI 10.1093/jnci/89.16.1212; PEMBERTON PA, 1995, J BIOL CHEM, V270, P15832, DOI 10.1074/jbc.270.26.15832; POLVERINI PJ, 1991, METHOD ENZYMOL, V198, P440; Sheng S, 1996, P NATL ACAD SCI USA, V93, P11669, DOI 10.1073/pnas.93.21.11669; SHENG SJ, 1994, J BIOL CHEM, V269, P30988; Sheng SJ, 1998, P NATL ACAD SCI USA, V95, P499, DOI 10.1073/pnas.95.2.499; SILBERSTEIN GB, 1987, J DAIRY SCI, V70, P1981, DOI 10.3168/jds.S0022-0302(87)80240-0; Sternlicht MD, 1997, CLIN CANCER RES, V3, P1949; STRINGER HAR, 1995, J BIOL CHEM, V270, P11205, DOI 10.1074/jbc.270.19.11205; TALHOUK RS, 1992, J CELL BIOL, V118, P1271, DOI 10.1083/jcb.118.5.1271; Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6; Volpert OV, 1996, J CLIN INVEST, V98, P671, DOI 10.1172/JCI118838; Zhang M, 1997, MOL MED, V3, P49, DOI 10.1007/BF03401667; Zhang M, 1999, DEV BIOL, V215, P278, DOI 10.1006/dbio.1999.9442; Zhang M, 1997, CELL GROWTH DIFFER, V8, P179; ZOU ZQ, 1994, SCIENCE, V263, P526, DOI 10.1126/science.8290962	20	375	394	2	8	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2000	6	2					196	199		10.1038/72303	http://dx.doi.org/10.1038/72303			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	278YQ	10655109				2022-12-25	WOS:000085016900041
J	Barton, JH				Barton, JH			Rational limits on genomic patents	NATURE BIOTECHNOLOGY			English	Editorial Material									Stanford Univ, Stanford, CA 94305 USA	Stanford University	Barton, JH (corresponding author), Stanford Univ, Stanford, CA 94305 USA.								0	3	3	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	AUG	2000	18	8					805	805		10.1038/78319	http://dx.doi.org/10.1038/78319			1	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	342VX	10932127	hybrid			2022-12-25	WOS:000088666800002
J	Moreau, V; Frischknecht, F; Reckmann, I; Vincentelli, R; Rabut, G; Stewart, D; Way, M				Moreau, V; Frischknecht, F; Reckmann, I; Vincentelli, R; Rabut, G; Stewart, D; Way, M			A complex of N-WASP and WIP integrates signalling cascades that lead to actin polymerization	NATURE CELL BIOLOGY			English	Article							ALDRICH-SYNDROME PROTEIN; ARP2/3 COMPLEX; DEPOLYMERIZING PROTEIN; SHIGELLA-FLEXNERI; HOMOLOGY DOMAIN; MOTILITY; LISTERIA; NUCLEATION; VACCINIA; GTPASE	Wiskott-Aldrich syndrome protein (WASP) and N-WASP have emerged as key proteins connecting signalling cascades to actin polymerization. Here we show that the amino-terminal WH1 domain, and not the polyproline-rich region, of N-WASP is responsible for its recruitment to sites of actin polymerization during Cdc42-independent, actin-based motility of vaccinia virus. Recruitment of M-WASP to vaccinia is mediated by WASP-interacting protein (WIP), whereas in Shigella WIP is recruited by N-WASP. Our observations show that vaccinia and Shigella activate the Arp2/3 complex to achieve actin-based motility, by mimicking either the SH2/SH3-containing adaptor or Cdc42 signalling pathways to recruit the N-WASP-WIP complex. We propose that the N-WASP-WIP complex has a pivotal function in integrating signalling cascades that lead to actin polymerization.	European Mol Biol Lab, Meyerhofstr 1, D-69117 Heidelberg, Germany; NCI, NIH, Bethesda, MD 20892 USA	European Molecular Biology Laboratory (EMBL); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Way, M (corresponding author), European Mol Biol Lab, Meyerhofstr 1, D-69117 Heidelberg, Germany.	Way@EMBL-Heidelberg.de	Rabut, Gwenaël/E-7257-2011	Rabut, Gwenaël/0000-0003-2658-2769; Moreau, Violaine/0000-0002-4513-7022; Frischknecht, Friedrich/0000-0002-8332-6668; Way, Michael/0000-0001-7207-2722				Abdul-Manan N, 1999, NATURE, V399, P379, DOI 10.1038/20726; Aktories K, 1997, TRENDS MICROBIOL, V5, P282, DOI 10.1016/S0966-842X(97)01067-6; Anderson BL, 1998, J CELL BIOL, V141, P1357, DOI 10.1083/jcb.141.6.1357; Anton IM, 1998, J BIOL CHEM, V273, P20992, DOI 10.1074/jbc.273.33.20992; Aspenstrom P, 1996, CURR BIOL, V6, P70, DOI 10.1016/S0960-9822(02)00423-2; Banin S, 1996, CURR BIOL, V6, P981, DOI 10.1016/S0960-9822(02)00642-5; Blanchoin L, 2000, NATURE, V404, P1007, DOI 10.1038/35010008; Carlier MF, 1999, CHEM BIOL, V6, pR235, DOI 10.1016/S1074-5521(99)80107-0; Carlier MF, 1997, J CELL BIOL, V136, P1307, DOI 10.1083/jcb.136.6.1307; CARLIER MF, IN PRESS J BIOL CHEM; CLERC P, 1987, INFECT IMMUN, V55, P2681, DOI 10.1128/IAI.55.11.2681-2688.1987; Cudmore S, 1997, TRENDS MICROBIOL, V5, P142, DOI 10.1016/S0966-842X(97)01011-1; CUDMORE S, 1995, NATURE, V378, P636, DOI 10.1038/378636a0; DERRY JMJ, 1994, CELL, V78, P635, DOI 10.1016/0092-8674(94)90528-2; Dramsi S, 1998, ANNU REV CELL DEV BI, V14, P137, DOI 10.1146/annurev.cellbio.14.1.137; Drechsel DN, 1997, CURR BIOL, V7, P12, DOI 10.1016/S0960-9822(06)00023-6; Egile C, 1999, J CELL BIOL, V146, P1319, DOI 10.1083/jcb.146.6.1319; Evangelista M, 2000, J CELL BIOL, V148, P353, DOI 10.1083/jcb.148.2.353; Fedorov AA, 1999, NAT STRUCT BIOL, V6, P661, DOI 10.1038/10717; Frischknecht F, 1999, CURR BIOL, V9, P89, DOI 10.1016/S0960-9822(99)80020-7; Frischknecht F, 1999, NATURE, V401, P926, DOI 10.1038/44860; Imai K, 1999, CLIN IMMUNOL, V92, P128, DOI 10.1006/clim.1999.4746; Le Bot N, 1998, J CELL BIOL, V143, P1559, DOI 10.1083/jcb.143.6.1559; Lechler T, 2000, J CELL BIOL, V148, P363, DOI 10.1083/jcb.148.2.363; Li R, 1997, J CELL BIOL, V136, P649, DOI 10.1083/jcb.136.3.649; Loisel TP, 1999, NATURE, V401, P613, DOI 10.1038/44183; Ma L, 1999, MOL BIOL CELL, V10, p384A; Machesky LM, 1999, P NATL ACAD SCI USA, V96, P3739, DOI 10.1073/pnas.96.7.3739; Machesky LM, 1998, CURR BIOL, V8, P1347, DOI 10.1016/S0960-9822(98)00015-3; Madania A, 1999, MOL BIOL CELL, V10, P3521, DOI 10.1091/mbc.10.10.3521; May RC, 1999, CURR BIOL, V9, P759, DOI 10.1016/S0960-9822(99)80337-6; Miki H, 1998, NATURE, V391, P93, DOI 10.1038/34208; Miki H, 1996, EMBO J, V15, P5326, DOI 10.1002/j.1460-2075.1996.tb00917.x; Murray JM, 2000, GENETICS, V154, P155; Naqvi SN, 1998, CURR BIOL, V8, P959, DOI 10.1016/S0960-9822(98)70396-3; Ory S, 2000, J CELL SCI, V113, P1177; Prehoda KE, 1999, CELL, V97, P471, DOI 10.1016/S0092-8674(00)80757-6; Ramesh N, 1997, P NATL ACAD SCI USA, V94, P14671, DOI 10.1073/pnas.94.26.14671; RIVEROLEZCANO OM, 1995, MOL CELL BIOL, V15, P5725; Rohatgi R, 1999, CELL, V97, P221, DOI 10.1016/S0092-8674(00)80732-1; Rosenblatt J, 1997, J CELL BIOL, V136, P1323, DOI 10.1083/jcb.136.6.1323; Schindelhauer D, 1996, HUM GENET, V98, P68, DOI 10.1007/s004390050162; She HY, 1997, MOL BIOL CELL, V8, P1709, DOI 10.1091/mbc.8.9.1709; Stewart DM, 1999, J IMMUNOL, V162, P5019; Suzuki T, 1998, EMBO J, V17, P2767, DOI 10.1093/emboj/17.10.2767; Symons M, 1996, CELL, V84, P723, DOI 10.1016/S0092-8674(00)81050-8; Vaduva G, 1997, J CELL BIOL, V139, P1821, DOI 10.1083/jcb.139.7.1821; Welch MD, 1997, NATURE, V385, P265, DOI 10.1038/385265a0; Welch MD, 1998, SCIENCE, V281, P105, DOI 10.1126/science.281.5373.105; Yarar D, 1999, CURR BIOL, V9, P555, DOI 10.1016/S0960-9822(99)80243-7	50	265	275	0	15	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	JUL	2000	2	7					441	448		10.1038/35017080	http://dx.doi.org/10.1038/35017080			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	333MK	10878810				2022-12-25	WOS:000088133700021
J	Chavanas, S; Bodemer, C; Rochat, A; Hamel-Teillac, D; Ali, M; Irvine, AD; Bonafe, JL; Wilkinson, J; Taieb, A; Barrandon, Y; Harper, JI; de Prost, Y; Hovnanian, A				Chavanas, S; Bodemer, C; Rochat, A; Hamel-Teillac, D; Ali, M; Irvine, AD; Bonafe, JL; Wilkinson, J; Taieb, A; Barrandon, Y; Harper, JI; de Prost, Y; Hovnanian, A			Mutations in SPINK5, encoding a serine protease inhibitor, cause Netherton syndrome	NATURE GENETICS			English	Article							ACTIVATION; CONSEQUENCES; RECEPTOR; ATOPY		Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford, England; Necker Hosp, Dept Dermatol, Paris, France; Ecole Normale Super, Epithelial Differentiat Lab, F-75231 Paris, France; Amersham Hosp, Dept Dermatol, Amersham, England; Great Ormond St Hosp Children, Dept Paediat Dermatol, London WC1N 3JH, England; Rangueil Hosp, Dept Dermatol, Toulouse, France; St Andre Hosp, Dept Dermatol, Bordeaux, France	University of Oxford; Wellcome Centre for Human Genetics; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; PSL Research University Paris; Ecole Normale Superieure (ENS); University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; CHU de Toulouse; CHU Bordeaux	Hovnanian, A (corresponding author), Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford, England.		Hovnanian, Alain/I-4711-2017; TAIEB, ALAIN/AAB-1085-2021; Chavanas, stephane/K-1183-2014; Irvine, Alan D/A-3982-2008	Hovnanian, Alain/0000-0003-3412-7512; Irvine, Alan D/0000-0002-9048-2044; chavanas, stephane/0000-0003-4323-2656				Chavanas S, 2000, AM J HUM GENET, V66, P914, DOI 10.1086/302824; Culbertson MR, 1999, TRENDS GENET, V15, P74, DOI 10.1016/S0168-9525(98)01658-8; Fartasch M, 1999, ARCH DERMATOL, V135, P823, DOI 10.1001/archderm.135.7.823; Grand RJA, 1996, BIOCHEM J, V313, P353, DOI 10.1042/bj3130353; Heinzmann A, 2000, HUM MOL GENET, V9, P549, DOI 10.1093/hmg/9.4.549; Hershey GKK, 1997, NEW ENGL J MED, V337, P1720, DOI 10.1056/NEJM199712113372403; Lentsch AB, 1999, AM J PATHOL, V154, P239, DOI 10.1016/S0002-9440(10)65270-4; Magert HJ, 1999, J BIOL CHEM, V274, P21499, DOI 10.1074/jbc.274.31.21499; Ober C, 2000, AM J HUM GENET, V66, P517, DOI 10.1086/302781; Oettgen HC, 1999, J CLIN INVEST, V104, P829, DOI 10.1172/JCI8205; Rossi A, 1998, J BIOL CHEM, V273, P16446, DOI 10.1074/jbc.273.26.16446; Toomes C, 1999, NAT GENET, V23, P421, DOI 10.1038/70525; TRAUPE H, 1989, ICHTHYOSIS GUIDE CLI; Villa A, 1998, CELL, V93, P885, DOI 10.1016/S0092-8674(00)81448-8; Werb Z, 1997, CELL, V91, P439, DOI 10.1016/S0092-8674(00)80429-8	15	603	626	0	10	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUN	2000	25	2					141	142		10.1038/75977	http://dx.doi.org/10.1038/75977			2	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	321ML	10835624				2022-12-25	WOS:000087459200008
J	Talaat, AM; Hunter, P; Johnston, SA				Talaat, AM; Hunter, P; Johnston, SA			Genome-directed primers for selective labeling of bacterial transcripts for DNA microarray analysis	NATURE BIOTECHNOLOGY			English	Article							GENE-EXPRESSION; ARRAYS		Univ Texas, SW Med Ctr, Ctr Biomed Invent, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Med, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Johnston, SA (corresponding author), Univ Texas, SW Med Ctr, Ctr Biomed Invent, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.							Carulli JP, 1998, J CELL BIOCHEM, P286; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; de Saizieu A, 1998, NAT BIOTECHNOL, V16, P45, DOI 10.1038/nbt0198-45; Eisen MB, 1999, METHOD ENZYMOL, V303, P179; Eperon S, 1996, J IMMUNOL METHODS, V194, P121, DOI 10.1016/0022-1759(96)00073-7; Schena M, 1996, BIOESSAYS, V18, P427, DOI 10.1002/bies.950180513; Yao J, 1997, J BIOL CHEM, V272, P17795, DOI 10.1074/jbc.272.28.17795	7	90	135	0	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUN	2000	18	6					679	682		10.1038/76543	http://dx.doi.org/10.1038/76543			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	325EK	10835610				2022-12-25	WOS:000087663200032
J	Sieg, DJ; Hauck, CR; Ilic, D; Klingbeil, CK; Schaefer, E; Damsky, CH; Schlaepfer, DD				Sieg, DJ; Hauck, CR; Ilic, D; Klingbeil, CK; Schaefer, E; Damsky, CH; Schlaepfer, DD			FAK integrates growth-factor and integrin signals to promote cell migration	NATURE CELL BIOLOGY			English	Article							FOCAL ADHESION KINASE; PROTEIN-TYROSINE KINASES; C-SRC; PHOSPHORYLATION; ASSOCIATION; MOTILITY; IDENTIFICATION; FIBRONECTIN; PP125(FAK); PAXILLIN	Here we show that cells lacking focal adhesion kinase (FAK) are refractory to motility signals from platelet-derived and epidermal growth factors (PDGF and EGF respectively), and that stable re-expression of FAK rescues these defects. FAK associates with activated PDGF- and EGF-receptor (PDGFR and EGFR) signalling complexes, and expression of the band-4.1-like domain at the FAK amino terminus is sufficient to mediate an interaction with activated EGFR. However, efficient EGF-stimulated cell migration also requires FAK to be targeted, by its carboxy-terminal domain, to sites of integrin-receptor clustering. Although the kinase activity of FAK is not needed to promote PDGF- or EGF-stimulated cell motility, kinase-inactive FAK is transphosphorylated at the indispensable Src-kinase-binding site, FAK Y397, after EGF stimulation of cells. Our results establish that FAK is an important receptor-proximal link between growth-factor-receptor and integrin signalling pathways.	Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA; Univ Calif San Francisco, Dept Stomatol, San Francisco, CA 94143 USA; QCB A Div Biosource Int, Hopkinton, MA 01748 USA	Scripps Research Institute; University of California System; University of California San Francisco	Schlaepfer, DD (corresponding author), Scripps Res Inst, Dept Immunol, IMM 26,10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.			ILIC, DUSKO/0000-0003-1647-0026				Agochiya M, 1999, ONCOGENE, V18, P5646, DOI 10.1038/sj.onc.1202957; Brunton VG, 1997, ONCOGENE, V14, P283, DOI 10.1038/sj.onc.1200827; Cary LA, 1998, J CELL BIOL, V140, P211, DOI 10.1083/jcb.140.1.211; Chen HC, 1996, EUR J BIOCHEM, V235, P495, DOI 10.1111/j.1432-1033.1996.00495.x; CHEN HC, 1995, J BIOL CHEM, V270, P16995, DOI 10.1074/jbc.270.28.16995; Chen HC, 1996, J BIOL CHEM, V271, P26329, DOI 10.1074/jbc.271.42.26329; Cicala C, 1999, J IMMUNOL, V163, P420; Fincham VJ, 1998, EMBO J, V17, P81, DOI 10.1093/emboj/17.1.81; FURUTA Y, 1995, ONCOGENE, V11, P1989; GEORGE EL, 1993, DEVELOPMENT, V119, P1079; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Gilmore AP, 1996, MOL BIOL CELL, V7, P1209, DOI 10.1091/mbc.7.8.1209; Girault JA, 1999, TRENDS BIOCHEM SCI, V24, P54, DOI 10.1016/S0968-0004(98)01331-0; Gu JG, 1999, J CELL BIOL, V146, P389, DOI 10.1083/jcb.146.2.389; Han DC, 1999, J BIOL CHEM, V274, P24425, DOI 10.1074/jbc.274.34.24425; HILDEBRAND JD, 1993, J CELL BIOL, V123, P993, DOI 10.1083/jcb.123.4.993; Howe A, 1998, CURR OPIN CELL BIOL, V10, P220, DOI 10.1016/S0955-0674(98)80144-0; Ilic Dusko, 1995, Nature (London), V377, P539, DOI 10.1038/377539a0; Kornberg LJ, 1998, HEAD NECK-J SCI SPEC, V20, P745, DOI 10.1002/(SICI)1097-0347(199812)20:8<745::AID-HED14>3.0.CO;2-Z; Lev S, 1999, MOL CELL BIOL, V19, P2278; Liu S, 1999, NATURE, V402, P676, DOI 10.1038/45264; Manes S, 1999, MOL CELL BIOL, V19, P3125; Miao H, 2000, NAT CELL BIOL, V2, P62, DOI 10.1038/35000008; Miyamoto S, 1996, J CELL BIOL, V135, P1633, DOI 10.1083/jcb.135.6.1633; Owen JD, 1999, MOL CELL BIOL, V19, P4806; OWENS LV, 1995, CANCER RES, V55, P2752; Richardson A, 1996, NATURE, V380, P538, DOI 10.1038/380538a0; Salazar EP, 1999, J BIOL CHEM, V274, P28371, DOI 10.1074/jbc.274.40.28371; SCHALLER MD, 1995, J CELL BIOL, V130, P1181, DOI 10.1083/jcb.130.5.1181; Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079-6107(98)00052-2; Schlaepfer DD, 1998, MOL CELL BIOL, V18, P2571, DOI 10.1128/MCB.18.5.2571; Schlaepfer DD, 1996, MOL CELL BIOL, V16, P5623; Schlaepfer DD, 1997, MOL CELL BIOL, V17, P1702, DOI 10.1128/MCB.17.3.1702; Schneller M, 1997, EMBO J, V16, P5600, DOI 10.1093/emboj/16.18.5600; Schwartz MA, 1999, CURR OPIN CELL BIOL, V11, P197, DOI 10.1016/S0955-0674(99)80026-X; Sieg DJ, 1999, J CELL SCI, V112, P2677; Sieg DJ, 1998, EMBO J, V17, P5933, DOI 10.1093/emboj/17.20.5933; TACHIBANA K, 1995, J EXP MED, V182, P1089, DOI 10.1084/jem.182.4.1089; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; Zhang X, 1999, P NATL ACAD SCI USA, V96, P9021, DOI 10.1073/pnas.96.16.9021	40	1030	1054	6	91	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	MAY	2000	2	5					249	256		10.1038/35010517	http://dx.doi.org/10.1038/35010517			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	313FX	10806474	Green Published			2022-12-25	WOS:000086990600012
J	Zhu, T; Mettenburg, K; Peterson, DJ; Tagliani, L; Baszczynski, CL				Zhu, T; Mettenburg, K; Peterson, DJ; Tagliani, L; Baszczynski, CL			Engineering herbicide-resistant maize using chimeric RNA/DNA oligonucleotides	NATURE BIOTECHNOLOGY			English	Article						herbicide resistance; chimeraplasty; gene modification; genetic inheritance; acetohydroxyacid synthase	SITE-DIRECTED MUTAGENESIS; RNA-DNA OLIGONUCLEOTIDE; ACETOHYDROXYACID SYNTHASE; GENE; PLANTS; TRANSGENES	Maize plants resistant to imidazolinone herbicides were engineered through targeted modification of endogenous genes using chimeric RNA/DNA oligonucleotides. A precise single-point mutation was introduced into genes encoding acetohydroxyacid synthase (AHAS), at a position known to confer imidazolinone resistance. Phenotypically normal plants from the converted events (C-0) were regenerated from resistant calli and grown to maturity. Herbicide leaf painting confirmed the resistance phenotype in C-0 plants and demonstrated the anticipated segregation pattern in C-1 progeny. DNA cloning and sequencing of the targeted region in resistant calli and derived C-0 and C-1 plants confirmed the expected mutation. These results demonstrate that oligonucleotide-mediated gene manipulation can be applied to crop improvement. This approach does not involve genomic integration of transgenes. Since the new trait is obtained through modifying a gene within its normal chromosomal context, position effects, transgene silencing, or other concerns that arise as part of developing transgenic events are avoided.	Pioneer HiBred Int Inc, Trait & Technol Dev, Johnston, IA 50131 USA	DuPont	Baszczynski, CL (corresponding author), Pioneer HiBred Int Inc, Trait & Technol Dev, 7250 NW 62nd Ave, Johnston, IA 50131 USA.	baszczynski@phibred.com	Zhu, Tong/G-5202-2011	Zhu, Tong/0000-0002-8732-3499				Alexeev V, 1998, NAT BIOTECHNOL, V16, P1343, DOI 10.1038/4322; Armstrong C. L., 1991, Maize Genetics Cooperation News Letter, P92; Beetham PR, 1999, P NATL ACAD SCI USA, V96, P8774, DOI 10.1073/pnas.96.15.8774; Bergelson J, 1998, NATURE, V395, P25, DOI 10.1038/25626; ColeStrauss A, 1996, SCIENCE, V273, P1386, DOI 10.1126/science.273.5280.1386; ColeStrauss A, 1997, ANTISENSE NUCLEIC A, V7, P211, DOI 10.1089/oli.1.1997.7.211; FANG LY, 1992, PLANT MOL BIOL, V18, P1185, DOI 10.1007/BF00047723; KIRIHARA JA, 1994, MAIZE HDB, P663; Kren BT, 1997, HEPATOLOGY, V25, P1462, DOI 10.1002/hep.510250626; Kren BT, 1998, NAT MED, V4, P285, DOI 10.1038/nm0398-285; Matzke AJM, 1998, CURR OPIN PLANT BIOL, V1, P142, DOI 10.1016/S1369-5266(98)80016-2; Ohl S., 1994, Homologous recombination and gene silencing in plants., P191; Ott KH, 1996, J MOL BIOL, V263, P359, DOI 10.1006/jmbi.1996.0580; PASZKOWSKI J, 1988, EMBO J, V7, P4021, DOI 10.1002/j.1460-2075.1988.tb03295.x; Puchta H, 1998, TRENDS PLANT SCI, V3, P77; REGISTER JC, 1994, PLANT MOL BIOL, V25, P951, DOI 10.1007/BF00014669; SATHASIVAN K, 1991, PLANT PHYSIOL, V97, P1044, DOI 10.1104/pp.97.3.1044; SHANER DL, 1984, PLANT PHYSIOL, V76, P545, DOI 10.1104/pp.76.2.545; Stidham M. A., 1991, Imidazolinone herbicides., P71; Vaucheret H, 1998, PLANT J, V16, P651, DOI 10.1046/j.1365-313x.1998.00337.x; Xiang YF, 1997, J MOL MED-JMM, V75, P829, DOI 10.1007/s001090050172; Yoon K, 1996, P NATL ACAD SCI USA, V93, P2071, DOI 10.1073/pnas.93.5.2071; Zhu T, 1999, P NATL ACAD SCI USA, V96, P8768, DOI 10.1073/pnas.96.15.8768	23	107	134	0	20	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	MAY	2000	18	5					555	558		10.1038/75435	http://dx.doi.org/10.1038/75435			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	313UK	10802626				2022-12-25	WOS:000087017500032
J	Batlle, E; Sancho, E; Franci, C; Dominguez, D; Monfar, M; Baulida, J; de Herreros, AG				Batlle, E; Sancho, E; Franci, C; Dominguez, D; Monfar, M; Baulida, J; de Herreros, AG			The transcription factor Snail is a repressor of E-cadherin gene expression in epithelial tumour cells	NATURE CELL BIOLOGY			English	Article							ADHESION SYSTEM; BINDING SITE; DROSOPHILA; CANCER; GASTRULATION; TRANSITION; BEHAVIOR; ROLES	The adhesion protein E-cadherin plays a central part in the process of epithelial morphogenesis. Expression of this protein is downregulated during the acquisition of metastatic potential at late stages of epithelial tumour progression. There is evidence for a transcriptional blockage of E-cadherin gene expression in this process. Here we show that the transcription factor Snail, which is expressed by fibroblasts and some E-cadherin-negative epithelial tumour cell lines, binds to three E-boxes present in the human E-cadherin promoter and represses transcription of E-cadherin, Inhibition of Snail function in epithelial cancer cell lines lacking E-cadherin protein restores the expression of the E-cadherin gene.	Univ Pompeu Fabra, Unitat Biol Cellular & Mol, Inst Municipal Invest Med, Barcelona 08003, Spain	Pompeu Fabra University	de Herreros, AG (corresponding author), Univ Pompeu Fabra, Unitat Biol Cellular & Mol, Inst Municipal Invest Med, Dr Aiguader 80, Barcelona 08003, Spain.		Sancho, Elena/ABH-4867-2020; de Herreros, A Garcia/H-3104-2014; Batlle, Eduard/K-8080-2014; Ladoux, Benoit/A-9879-2013	Sancho, Elena/0000-0002-8182-513X; de Herreros, A Garcia/0000-0001-5270-0808; Batlle, Eduard/0000-0003-2422-0326; Dominguez-Sola, David/0000-0001-9569-8402				Birchmeier C, 1996, ACTA ANAT, V156, P217; BURDSAL CA, 1993, DEVELOPMENT, V118, P829; DAMJANOV I, 1986, DEV BIOL, V116, P194, DOI 10.1016/0012-1606(86)90056-4; Giroldi LA, 1997, BIOCHEM BIOPH RES CO, V241, P453, DOI 10.1006/bbrc.1997.7831; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Grimes HL, 1996, MOL CELL BIOL, V16, P6263; Hay ED, 1995, ACTA ANAT, V154, P8; Hennig G, 1996, J BIOL CHEM, V271, P595, DOI 10.1074/jbc.271.1.595; Ji XD, 1997, CELL GROWTH DIFFER, V8, P773; LEPTIN M, 1990, DEVELOPMENT, V110, P73; MAUHIN V, 1993, NUCLEIC ACIDS RES, V21, P3951, DOI 10.1093/nar/21.17.3951; Nakayama H, 1998, DEV BIOL, V199, P150, DOI 10.1006/dbio.1998.8914; NIETO MA, 1994, SCIENCE, V264, P835, DOI 10.1126/science.7513443; Oda H, 1998, DEV BIOL, V203, P435, DOI 10.1006/dbio.1998.9047; Perl AK, 1998, NATURE, V392, P190, DOI 10.1038/32433; ROUSSEAU S, 1989, NUCLEIC ACIDS RES, V17, P7495, DOI 10.1093/nar/17.18.7495; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Sefton M, 1998, DEVELOPMENT, V125, P3111; Shiozaki H, 1996, CANCER, V77, P1605, DOI 10.1002/(SICI)1097-0142(19960415)77:8+<1605::AID-CNCR4>3.3.CO;2-R; SMITH DE, 1992, DEVELOPMENT, V116, P1033; SOROKIN L, 1990, J CELL BIOL, V111, P1265, DOI 10.1083/jcb.111.3.1265; VIEMINCKX K, 1991, CELL, V66, P107	22	2069	2164	2	124	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	FEB	2000	2	2					84	89		10.1038/35000034	http://dx.doi.org/10.1038/35000034			6	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	281GA	10655587				2022-12-25	WOS:000085148500012
J	Calandra, T; Echtenacher, B; Le Roy, D; Pugin, J; Metz, CN; Hultner, L; Heumann, D; Mannel, D; Bucala, R; Glauser, MP				Calandra, T; Echtenacher, B; Le Roy, D; Pugin, J; Metz, CN; Hultner, L; Heumann, D; Mannel, D; Bucala, R; Glauser, MP			Protection from septic shock by neutralization of macrophage migration inhibitory factor	NATURE MEDICINE			English	Article							NECROSIS-FACTOR-ALPHA; CYTOKINE PRODUCTION; REGULATORY ROLE; MICE; EFFICACY; MIF; LIPOPOLYSACCHARIDE; MONOCYTOGENES; PATHOGENESIS; ENDOTOXEMIA	Identification of new therapeutic targets for the management of septic shock remains imperative as all investigational therapies, including anti-tumor necrosis factor (TNF) and anti-interleukin (IL)-1 agents, have uniformly failed to lower the mortality of critically ill patients with severe sepsis. We report here that macrophage migration inhibitory factor (MIF) is a critical mediator of septic shock. High concentrations of MIF were detected in the peritoneal exudate fluid and in the systemic circulation of mice with bacterial peritonitis. Experiments performed in TNF alpha knockout mice allowed a direct evaluation of the part played by MIF in sepsis in the absence of this pivotal cytokine of inflammation. Anti-MIF antibody protected TNF alpha knockout from lethal peritonitis induced by cecal ligation and puncture (CLP), providing evidence of an intrinsic contribution of MIF to the pathogenesis of sepsis. Anti-MIF antibody also protected normal mice from lethal peritonitis induced by both CLP and Escherichia coli, even when treatment was started up to 8 hours after CLP. Conversely co-injection of recombinant MIF and E. coli markedly increased the lethality of peritonitis. Finally, high concentrations of MIF were detected in the plasma of patients with severe sepsis or septic shock. These studies define a critical part for MIF in the pathogenesis of septic shock and identify a new target for therapeutic intervention.	CHU Vaudois, Div Infect Dis, CH-1011 Lausanne, Switzerland; Univ Regensburg, Dept Pathol, D-93042 Regensburg, Germany; Univ Hosp Geneva, Dept Med, Div Med Intens Care, CH-1211 Geneva 14, Switzerland; Picower Inst Med Res, Manhasset, NY 11030 USA; GSF Forschungszentrum Umwelt & Gesundheit GMBH, Inst Expt Hamatol, D-81337 Munich, Germany	University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Regensburg; University of Geneva; Northwell Health; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health	Calandra, T (corresponding author), CHU Vaudois, Div Infect Dis, CH-1011 Lausanne, Switzerland.	Thierry.Calandra@chuv.hospvd..ch	Calandra, Thierry/D-9017-2015	Calandra, Thierry/0000-0003-3051-1285; Christine, Metz/0000-0002-1013-1691				Abraham E, 1999, INTENS CARE MED, V25, P556, DOI 10.1007/s001340050903; Bacher M, 1996, P NATL ACAD SCI USA, V93, P7849, DOI 10.1073/pnas.93.15.7849; Bacher M, 1997, AM J PATHOL, V150, P235; BAGBY GJ, 1991, J INFECT DIS, V163, P83, DOI 10.1093/infdis/163.1.83; BAUMGARTNER JD, 1990, J EXP MED, V171, P889, DOI 10.1084/jem.171.3.889; BERNHAGEN J, 1993, NATURE, V365, P756, DOI 10.1038/365756a0; BERNHAGEN J, 1994, BIOCHEMISTRY-US, V33, P14144, DOI 10.1021/bi00251a025; BLOOM BR, 1966, SCIENCE, V153, P80, DOI 10.1126/science.153.3731.80; BONE RC, 1992, CHEST, V101, P1644, DOI 10.1378/chest.101.6.1644; Bozza M, 1999, J EXP MED, V189, P341, DOI 10.1084/jem.189.2.341; CALANDRA T, 1994, J EXP MED, V179, P1895, DOI 10.1084/jem.179.6.1895; Calandra T, 1998, P NATL ACAD SCI USA, V95, P11383, DOI 10.1073/pnas.95.19.11383; CALANDRA T, 1995, NATURE, V377, P68, DOI 10.1038/377068a0; Cohen J, 1999, J INFECT DIS, V180, P116, DOI 10.1086/314839; DAVID JR, 1966, P NATL ACAD SCI USA, V56, P72, DOI 10.1073/pnas.56.1.72; Donnelly SC, 1997, NAT MED, V3, P320, DOI 10.1038/nm0397-320; ECHTENACHER B, 1990, J IMMUNOL, V145, P3762; Friedman G, 1998, CRIT CARE MED, V26, P2078, DOI 10.1097/00003246-199812000-00045; GLAUSER MP, 1991, LANCET, V338, P732, DOI 10.1016/0140-6736(91)91452-Z; Heumann D, 1996, J INFLAMM, V47, P173; KOHLER J, 1993, J IMMUNOL, V151, P916; Lan HY, 1997, J EXP MED, V185, P1455, DOI 10.1084/jem.185.8.1455; Lan HY, 1998, TRANSPLANTATION, V66, P1465, DOI 10.1097/00007890-199812150-00009; Leech M, 1998, ARTHRITIS RHEUM-US, V41, P910, DOI 10.1002/1529-0131(199805)41:5<910::AID-ART19>3.0.CO;2-E; MARSHALL JC, 1998, SEPSIS, V2, P187; Maurer M, 1998, J EXP MED, V188, P2343, DOI 10.1084/jem.188.12.2343; Mikulowska A, 1997, J IMMUNOL, V158, P5514; Mitchell RA, 1999, J BIOL CHEM, V274, P18100, DOI 10.1074/jbc.274.25.18100; NATHAN CF, 1973, J EXP MED, V137, P275, DOI 10.1084/jem.137.2.275; NATHAN CF, 1971, J EXP MED, V133, P1356, DOI 10.1084/jem.133.6.1356; Pasparakis M, 1996, J EXP MED, V184, P1397, DOI 10.1084/jem.184.4.1397; PFEFFER K, 1993, CELL, V73, P457, DOI 10.1016/0092-8674(93)90134-C; PORAT R, 1991, SCIENCE, V254, P430, DOI 10.1126/science.1833820; ROTHE J, 1993, NATURE, V364, P798, DOI 10.1038/364798a0; Wang HC, 1999, SCIENCE, V285, P248, DOI 10.1126/science.285.5425.248; ZANETTI G, 1992, J IMMUNOL, V148, P1890	36	618	713	1	29	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2000	6	2					164	170		10.1038/72262	http://dx.doi.org/10.1038/72262			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	278YQ	10655104				2022-12-25	WOS:000085016900036
J	Simmler, MC; Cohen-Salmon, M; El-Amraoui, A; Guillaud, L; Benichou, JC; Petit, C; Panthier, JJ				Simmler, MC; Cohen-Salmon, M; El-Amraoui, A; Guillaud, L; Benichou, JC; Petit, C; Panthier, JJ			Targeted disruption of Otog results in deafness and severe imbalance	NATURE GENETICS			English	Article							TECTORIAL MEMBRANE; INNER-EAR; ULTRASTRUCTURAL ORGANIZATION; SENSORINEURAL DEAFNESS; MATRIX; GENE; PROTEOGLYCANS; LOCALIZATION; MUTATIONS; COLLAGEN	Genes specifically expressed in the inner ear are candidates to underlie hereditary nonsyndromic deafness(1). The gene Otog has been isolated from a mouse subtractive cDNA cochlear library(2). It encodes otogelin, an N-glycosylated protein that is present in the acellular membranes covering the six sensory epithelial patches of the inner ear: in the cochlea (the auditory sensory organ), the tectorial membrane (TM) over the organ of Corti; and in the vestibule (the balance sensory organ), the otoconial membranes over the utricular and saccular maculae as well as the cupulae over the cristae ampullares of the three semi-circular canals. These membranes are involved in the mechanotransduction process. Their movement, which is induced by sound in the cochlea or acceleration in the vestibule, results in the deflection of the stereocilia bundle at the apex of the sensory hair cells, which in turn opens the mechanotransduction channels located at the tip of the stereo-cilia(3). We sought to elucidate the role of otogelin in the auditory and vestibular functions by generating mice with a targeted disruption of Otog. In Otog(-/-) mice, both the vestibular and the auditory functions were impaired. Histological analysis of these mutants demonstrated that in the vestibule, otogelin is required for the anchoring of the otoconial membranes and cupulae to the neuroepithelia. In the cochlea, ultrastructural analysis of the TM indicated that otogelin is involved in the organization of its fibrillar network. Otogelin is likely to have a role in the resistance of this membrane to sound stimulation. These results support OTOG as a possible candidate gene for a human nonsyndromic form of deafness.	Ecole Natl Vet, INRA Genet Mol & Cellulaire, UMR 955, Maisons Alfort, France; Inst Pasteur, Unite Genet Deficits Sensoriels, CNRS, URA 1968, F-75724 Paris 15, France; Inst Pasteur, Unite Genet Dev, CNRS, URA 1960, F-75724 Paris, France	Ecole Nationale Veterinaire d'Alfort (ENVA); INRAE; Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Simmler, MC (corresponding author), Ecole Natl Vet, INRA Genet Mol & Cellulaire, UMR 955, Maisons Alfort, France.		PANTHIER, Jean-Jacques/I-4366-2014	PANTHIER, Jean-Jacques/0000-0002-7966-0663; Cohen-Salmon, Martine/0000-0002-5312-8476; EL-AMRAOUI, Aziz/0000-0003-2692-4984; Petit, Christine/0000-0002-9069-002X				Bernex F, 1996, DEVELOPMENT, V122, P3023; Cohen-Salmon M, 1999, MAMM GENOME, V10, P520, DOI 10.1007/s003359901033; Cohen-Salmon M, 1997, P NATL ACAD SCI USA, V94, P14450, DOI 10.1073/pnas.94.26.14450; COHENTANNOUDJI M, 1995, MAMM GENOME, V6, P844, DOI 10.1007/BF00292433; ERWAY LC, 1993, HEARING RES, V65, P125, DOI 10.1016/0378-5955(93)90207-H; Grifa A, 1999, NAT GENET, V23, P16, DOI 10.1038/12612; HASKO JA, 1988, HEARING RES, V35, P21, DOI 10.1016/0378-5955(88)90037-8; HENRY KR, 1979, AUDIOLOGY, V18, P93; HUDSPETH AJ, 1989, NATURE, V341, P397, DOI 10.1038/341397a0; Jain PK, 1998, GENOMICS, V50, P290, DOI 10.1006/geno.1998.5320; KEATS BJB, 1994, AM J HUM GENET, V54, P681; Kelsell DP, 1997, NATURE, V387, P80, DOI 10.1038/387080a0; KRONESTERFREI A, 1978, CELL TISSUE RES, V193, P11; Kubisch C, 1999, CELL, V96, P437, DOI 10.1016/S0092-8674(00)80556-5; Legan PK, 1997, J BIOL CHEM, V272, P8791, DOI 10.1074/jbc.272.13.8791; LIM DJ, 1972, ARCHIV OTOLARYNGOL, V96, P199; LLORENS J, 1993, TOXICOL APPL PHARM, V123, P199, DOI 10.1006/taap.1993.1238; MUNYER PD, 1994, HEARING RES, V79, P83, DOI 10.1016/0378-5955(94)90129-5; OSSENKOPP KP, 1990, PHARMACOL BIOCHEM BE, V36, P875, DOI 10.1016/0091-3057(90)90093-W; Petit C, 1996, NAT GENET, V14, P385, DOI 10.1038/ng1296-385; PORTER JD, 1990, PHYSIOL BEHAV, V48, P27, DOI 10.1016/0031-9384(90)90255-3; Rau A, 1999, J COMP NEUROL, V405, P271; SLEPECKY NB, 1992, CELL TISSUE RES, V267, P413, DOI 10.1007/BF00319363; SLEPECKY NB, 1992, MATRIX, V12, P80, DOI 10.1016/S0934-8832(11)80108-3; STEEL KP, 1996, WHATS WRONG MY MOUSE, P26; Tsuprun V, 1997, HEARING RES, V110, P107, DOI 10.1016/S0378-5955(97)00068-3; Verpy E, 1999, P NATL ACAD SCI USA, V96, P529, DOI 10.1073/pnas.96.2.529; Xia JH, 1998, NAT GENET, V20, P370, DOI 10.1038/3845; Zheng QY, 1999, HEARING RES, V130, P94, DOI 10.1016/S0378-5955(99)00003-9; ZWISLOCKI JJ, 1988, HEARING RES, V33, P207, DOI 10.1016/0378-5955(88)90151-7	30	111	112	0	6	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	FEB	2000	24	2					139	143		10.1038/72793	http://dx.doi.org/10.1038/72793			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	280LQ	10655058				2022-12-25	WOS:000085104600013
J	Kobrinsky, E; Mirshahi, T; Zhang, HL; Jin, TH; Logothetis, DE				Kobrinsky, E; Mirshahi, T; Zhang, HL; Jin, TH; Logothetis, DE			Receptor-mediated hydrolysis of plasma membrane messenger PIP2 leads to K+-current desensitization	NATURE CELL BIOLOGY			English	Article							GTP-BINDING PROTEINS; BETA-GAMMA-SUBUNITS; POTASSIUM CHANNELS; PHOSPHATIDYLINOSITOL PHOSPHATES; ATRIAL MYOCYTES; ATP CHANNELS; ACH CHANNEL; I-KACH; ACTIVATION; MECHANISM	Phosphatidylinositol bisphosphate (PIP2) directly regulates functions as diverse as the organization of the cytoskeleton, vesicular transport and ion channel activity. It is not known, however, whether dynamic changes in PIP2 levels have a regulatory role of physiological importance in such functions. Here, we show in both native cardiac cells and heterologous expression systems that receptor-regulated PIP2 hydrolysis results in desensitization of a GTP-binding protein-stimulated potassium current. Two receptor-regulated pathways in the plasma membrane cross-talk at the level of these channels to modulate potassium currents. One pathway signals through the beta gamma subunits of G proteins, which bind directly to the channel. G beta gamma subunits stabilize interactions with PIP2 and lead to persistent channel activation. The second pathway activates phospholipase C (PLC) which hydrolyses PIP2 and limits G beta gamma-stimulated activity. Our results provide evidence that PIP2 itself is a receptor-regulated second messenger, downregulation of which accounts for a new form of desensitization.	NYU, Mt Sinai Sch Med, Dept Physiol & Biophys, New York, NY 10029 USA; NYU, Mt Sinai Sch Med, Dept Med, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai; New York University; Icahn School of Medicine at Mount Sinai; New York University	Logothetis, DE (corresponding author), NYU, Mt Sinai Sch Med, Dept Physiol & Biophys, New York, NY 10029 USA.				NHLBI NIH HHS [HL59949, HL54185] Funding Source: Medline; NIDDK NIH HHS [DK07757] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054185, R01HL059949] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Baukrowitz T, 1998, SCIENCE, V282, P1141, DOI 10.1126/science.282.5391.1141; Caulfield MP, 1998, PHARMACOL REV, V50, P279; Chuang HH, 1998, P NATL ACAD SCI USA, V95, P11727, DOI 10.1073/pnas.95.20.11727; DASCAL N, 1993, P NATL ACAD SCI USA, V90, P10235, DOI 10.1073/pnas.90.21.10235; Fan Z, 1997, J BIOL CHEM, V272, P5388, DOI 10.1074/jbc.272.9.5388; Hilgemann DW, 1996, SCIENCE, V273, P956, DOI 10.1126/science.273.5277.956; Hilgemann DW, 1997, ANNU REV PHYSIOL, V59, P193, DOI 10.1146/annurev.physiol.59.1.193; Hirose K, 1999, SCIENCE, V284, P1527, DOI 10.1126/science.284.5419.1527; Ho IHM, 1999, J PHYSIOL-LONDON, V520, P645, DOI 10.1111/j.1469-7793.1999.00645.x; Huang CL, 1998, NATURE, V391, P803, DOI 10.1038/35882; Kim D, 2000, J GEN PHYSIOL, V115, P287, DOI 10.1085/jgp.115.3.287; KRAPIVINSKY G, 1995, NATURE, V374, P135, DOI 10.1038/374135a0; KRAPIVINSKY G, 1995, J BIOL CHEM, V270, P29059, DOI 10.1074/jbc.270.49.29059; KUBO Y, 1993, NATURE, V364, P802, DOI 10.1038/364802a0; KURACHI Y, 1987, PFLUG ARCH EUR J PHY, V410, P227, DOI 10.1007/BF00580270; LIMAN ER, 1992, NEURON, V9, P861, DOI 10.1016/0896-6273(92)90239-A; Liou HH, 1999, P NATL ACAD SCI USA, V96, P5820, DOI 10.1073/pnas.96.10.5820; Logothetis DE, 1999, J PHYSIOL-LONDON, V520, P630, DOI 10.1111/j.1469-7793.1999.00630.x; LOGOTHETIS DE, 1987, NATURE, V325, P321, DOI 10.1038/325321a0; MUIR TM, 1992, AM J PHYSIOL, V263, pH722, DOI 10.1152/ajpheart.1992.263.3.H722; PETERSEN CCH, 1994, J BIOL CHEM, V269, P32246; Petit-Jacques J, 1999, J GEN PHYSIOL, V114, P673, DOI 10.1085/jgp.114.5.673; Shyng SL, 1998, SCIENCE, V282, P1138, DOI 10.1126/science.282.5391.1138; Stauffer TP, 1998, CURR BIOL, V8, P343, DOI 10.1016/S0960-9822(98)70135-6; Sui JL, 1999, CURR TOP MEMBR, V46, P337; Sui JL, 1998, P NATL ACAD SCI USA, V95, P1307, DOI 10.1073/pnas.95.3.1307; Sui JL, 1996, J GEN PHYSIOL, V108, P381, DOI 10.1085/jgp.108.5.381; Varnai P, 1998, J CELL BIOL, V143, P501, DOI 10.1083/jcb.143.2.501; Vivaudou M, 1997, J BIOL CHEM, V272, P31553, DOI 10.1074/jbc.272.50.31553; WU DQ, 1993, J BIOL CHEM, V268, P3704; Xie LH, 1999, P NATL ACAD SCI USA, V96, P15292, DOI 10.1073/pnas.96.26.15292; Yamada M, 1998, PHARMACOL REV, V50, P723; YIM DL, 1994, DEV BIOL, V162, P41, DOI 10.1006/dbio.1994.1065; Zhang HL, 1999, NAT CELL BIOL, V1, P183, DOI 10.1038/11103	34	197	200	0	1	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	AUG	2000	2	8					507	514		10.1038/35019544	http://dx.doi.org/10.1038/35019544			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	341TE	10934471				2022-12-25	WOS:000088605000016
J	Molday, LL; Rabin, AR; Molday, RS				Molday, LL; Rabin, AR; Molday, RS			ABCR expression in foveal cone photoreceptors and its role in Stargardt macular dystrophy	NATURE GENETICS			English	Article							DISEASE GENE ABCR; ROD OUTER SEGMENTS; RETINITIS-PIGMENTOSA; RIM PROTEIN; DEGENERATION; MUTATIONS; MEMBRANE		Univ British Columbia, Dept Biochem & Mol Biol, Vancouver, BC V5Z 1M9, Canada	University of British Columbia	Molday, RS (corresponding author), Univ British Columbia, Dept Biochem & Mol Biol, Vancouver, BC V5Z 1M9, Canada.							Allikmets R, 1997, NAT GENET, V15, P236, DOI 10.1038/ng0397-236; Allikmets R, 1997, SCIENCE, V277, P1805, DOI 10.1126/science.277.5333.1805; Cremers FPM, 1998, HUM MOL GENET, V7, P355, DOI 10.1093/hmg/7.3.355; ELDRED GE, 1993, NATURE, V361, P724, DOI 10.1038/361724a0; Fishman GA, 1999, ARCH OPHTHALMOL-CHIC, V117, P504, DOI 10.1001/archopht.117.4.504; Illing M, 1997, J BIOL CHEM, V272, P10303, DOI 10.1074/jbc.272.15.10303; Klevering BJ, 1999, BRIT J OPHTHALMOL, V83, P914, DOI 10.1136/bjo.83.8.914; Lois N, 1999, INVEST OPHTH VIS SCI, V40, P2668; Martinez-Mir A, 1998, NAT GENET, V18, P11, DOI 10.1038/ng0198-11; Osterberg G., 1935, ACTA OPHTHALMOL    S, V13, P1; PAPERMASTER DS, 1982, VISION RES, V22, P1417, DOI 10.1016/0042-6989(82)90204-8; Stone EM, 1998, NAT GENET, V20, P328, DOI 10.1038/3798; Sun H, 1999, J BIOL CHEM, V274, P8269, DOI 10.1074/jbc.274.12.8269; Sun H, 1997, NAT GENET, V17, P15, DOI 10.1038/ng0997-15; Weng J, 1999, CELL, V98, P13, DOI 10.1016/S0092-8674(00)80602-9	15	188	194	0	5	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUL	2000	25	3					257	258		10.1038/77004	http://dx.doi.org/10.1038/77004			2	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	329RD	10888868				2022-12-25	WOS:000087920900009
J	Bodinier, M; Peyrat, MA; Tournay, C; Davodeau, F; Romagne, F; Bonneville, M; Lang, F				Bodinier, M; Peyrat, MA; Tournay, C; Davodeau, F; Romagne, F; Bonneville, M; Lang, F			Efficient detection and immunomagnetic sorting of specific T cells using multimers of MHC class I and peptide with reduced CD8 binding	NATURE MEDICINE			English	Article							ALPHA-3 DOMAIN; LYMPHOCYTES; AVIDITY; HLA-A2		INSERM, U463, Nantes, France; Immunotech SA, Beckman Coulter Co, Marshfield, WI USA	Institut National de la Sante et de la Recherche Medicale (Inserm); Beckman Coulter Inc.	Lang, F (corresponding author), INSERM, U463, 9 Quai 9 Quai Moncousu, Nantes, France.		Davodeau, Francois/M-1888-2015; LANG, François/K-7403-2015; François, Davodeau/GLU-4061-2022	LANG, François/0000-0002-0762-4647; François, Davodeau/0000-0001-8181-0192				Altman JD, 1996, SCIENCE, V274, P94, DOI 10.1126/science.274.5284.94; Bousso P, 1998, IMMUNITY, V9, P169, DOI 10.1016/S1074-7613(00)80599-3; Busch DH, 1998, IMMUNITY, V8, P353, DOI 10.1016/S1074-7613(00)80540-3; Callan MFC, 1998, J EXP MED, V187, P1395, DOI 10.1084/jem.187.9.1395; Couedel C, 1999, J IMMUNOL, V162, P6351; COULIE PG, 1994, J EXP MED, V180, P35, DOI 10.1084/jem.180.1.35; GARBOCZI DN, 1992, P NATL ACAD SCI USA, V89, P3429, DOI 10.1073/pnas.89.8.3429; Gervois N, 1996, J EXP MED, V183, P2403, DOI 10.1084/jem.183.5.2403; Lee PP, 1999, NAT MED, V5, P677, DOI 10.1038/9525; Luxembourg AT, 1998, NAT BIOTECHNOL, V16, P281, DOI 10.1038/nbt0398-281; Ogg GS, 1998, SCIENCE, V279, P2103, DOI 10.1126/science.279.5359.2103; SALTER RD, 1990, NATURE, V345, P41, DOI 10.1038/345041a0; SALTER RD, 1989, NATURE, V338, P345, DOI 10.1038/338345a0; Scotet E, 1996, J EXP MED, V184, P1791, DOI 10.1084/jem.184.5.1791	14	131	142	0	8	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUN	2000	6	6					707	710		10.1038/76292	http://dx.doi.org/10.1038/76292			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	321CX	10835691				2022-12-25	WOS:000087438300045
J	Conway, DJ; Cavanagh, DR; Tanabe, K; Roper, C; Mikes, ZS; Sakihama, N; Bojang, KA; Oduola, AMJ; Kremsner, PG; Arnot, DE; Greenwood, BM; McBride, JS				Conway, DJ; Cavanagh, DR; Tanabe, K; Roper, C; Mikes, ZS; Sakihama, N; Bojang, KA; Oduola, AMJ; Kremsner, PG; Arnot, DE; Greenwood, BM; McBride, JS			A principal target of human immunity to malaria identified by molecular population genetic and immunological analyses	NATURE MEDICINE			English	Article							MEROZOITE SURFACE PROTEIN-1; PLASMODIUM-FALCIPARUM MEROZOITES; CARBOXY-TERMINAL FRAGMENT; NATURAL-SELECTION; SERUM ANTIBODIES; SOUTHERN VIETNAM; ANTIGEN GENE; PARASITE; RECOMBINATION; RESPONSES	New strategies are required to identify the most important targets of protective immunity in complex eukaryotic pathogens. Natural selection maintains allelic variation in some antigens of the malaria parasite Plasmodium falciparum(1-3). Analysis of allele frequency distributions could identify the loci under most intense selection(4-7). The merozoite surface protein 1 (Msp1) is the most-abundant surface component on the erythrocyte-invading stage of P. falciparum(8-10). Immunization with whole Msp1 has protected monkeys completely against homologous(11) and partially against non-homologous(12) parasite strains. The single-copy msp1 gene, of about 5 kilobases, has highly divergent alleles(13) with stable frequencies in endemic populations(14,15). To identify the region of msp1 under strongest selection to maintain alleles within populations, we studied multiple intragenic sequence loci in populations in different regions of Africa and Southeast Asia. On both continents, the locus with the lowest inter-population variance in allele frequencies was block 2 indicating selection in this part of the gene. To test the hypothesis of immune selection, we undertook a large prospective longitudinal cohort study. This demonstrated that serum IgG antibodies against each of the two most frequent allelic types of block 2 of the protein were strongly associated with protection from P. falciparum malaria.	Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1E 7HT, England; Univ Edinburgh, Inst Cell Anim & Populat Biol, Edinburgh EH9 3JT, Midlothian, Scotland; Osaka Inst Technol, Biol Lab, Osaka 5358535, Japan; Osaka Inst Technol, Biol Lab, Osaka 5358535, Japan; MRC Labs, Banjul, Gambia; Univ Ibadan, Coll Med, Postgrad Inst Med Res & Training, Ibadan, Nigeria; Univ Tubingen, Inst Trop Med, Dept Parasitol, Tubingen, Germany	University of London; London School of Hygiene & Tropical Medicine; University of Edinburgh; Osaka Institute of Technology; Osaka Institute of Technology; MRC Laboratory Molecular Biology; University of Ibadan; Eberhard Karls University of Tubingen	Conway, DJ (corresponding author), Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Dis, Keppel St, London WC1E 7HT, England.	david.conway@lshtm.ac.uk	Roper, Cally/K-2989-2013; Arnot, David/S-1984-2019; Cavanagh, David R/A-1828-2008	Roper, Cally/0000-0002-6545-309X; Arnot, David/0000-0002-3027-1130; Conway, David/0000-0002-8711-3037; Bojang, Kalifa/0000-0001-7506-0938				AlYaman F, 1996, AM J TROP MED HYG, V54, P443, DOI 10.4269/ajtmh.1996.54.443; Anderson TJC, 1999, PARASITOLOGY, V119, P113, DOI 10.1017/S0031182099004552; Beaumont MA, 1996, P ROY SOC B-BIOL SCI, V263, P1619, DOI 10.1098/rspb.1996.0237; BERRY A, 1993, GENETICS, V134, P869; BLACKMAN MJ, 1990, J EXP MED, V172, P379, DOI 10.1084/jem.172.1.379; BURGHAUS PA, 1994, MOL BIOCHEM PARASIT, V64, P165, DOI 10.1016/0166-6851(94)90144-9; Cavanagh DR, 1997, MOL BIOCHEM PARASIT, V85, P197, DOI 10.1016/S0166-6851(96)02826-5; Cavanagh DR, 1998, J IMMUNOL, V161, P347; CONWAY DJ, 1991, PARASITOLOGY, V103, P1, DOI 10.1017/S0031182000059217; CONWAY DJ, 1992, INFECT IMMUN, V60, P1122, DOI 10.1128/IAI.60.3.1122-1127.1992; Conway DJ, 1997, PARASITOL TODAY, V13, P26, DOI 10.1016/S0169-4758(96)10077-6; Conway DJ, 1999, P NATL ACAD SCI USA, V96, P4506, DOI 10.1073/pnas.96.8.4506; DALESSANDRO U, 1995, LANCET, V346, P462, DOI 10.1016/S0140-6736(95)91321-1; Dodoo D, 1999, INFECT IMMUN, V67, P2131, DOI 10.1128/IAI.67.5.2131-2137.1999; EGAN AF, 1995, INFECT IMMUN, V63, P456, DOI 10.1128/IAI.63.2.456-466.1995; Egan AF, 1996, J INFECT DIS, V173, P765, DOI 10.1093/infdis/173.3.765; Escalante AA, 1998, GENETICS, V149, P189; Ferreira MU, 1998, J EUKARYOT MICROBIOL, V45, P131, DOI 10.1111/j.1550-7408.1998.tb05080.x; Guevara-Patino JA, 1997, J EXP MED, V186, P1689, DOI 10.1084/jem.186.10.1689; Gupta S, 1996, NAT MED, V2, P437, DOI 10.1038/nm0496-437; HALL R, 1984, NATURE, V311, P379, DOI 10.1038/311379a0; Hastings IM, 1996, PARASITOLOGY, V112, P155, DOI 10.1017/S0031182000084717; HOLDER AA, 1985, NATURE, V317, P270, DOI 10.1038/317270a0; HUGHES MK, 1995, MOL BIOCHEM PARASIT, V71, P99, DOI 10.1016/0166-6851(95)00037-2; Kaneko O, 1997, EXP PARASITOL, V86, P45, DOI 10.1006/expr.1997.4147; Locher CP, 1996, EXP PARASITOL, V84, P74, DOI 10.1006/expr.1996.0091; MCBRIDE JS, 1987, MOL BIOCHEM PARASIT, V23, P71, DOI 10.1016/0166-6851(87)90189-7; McDonald John H., 1994, P88; MILLER LH, 1993, MOL BIOCHEM PARASIT, V59, P1, DOI 10.1016/0166-6851(93)90002-F; Morgan WD, 1999, J MOL BIOL, V289, P113, DOI 10.1006/jmbi.1999.2753; RILEY EM, 1992, PARASITE IMMUNOL, V14, P321, DOI 10.1111/j.1365-3024.1992.tb00471.x; Sakihama N, 1999, GENE, V230, P47, DOI 10.1016/S0378-1119(99)00069-4; SIDDIQUI WA, 1987, P NATL ACAD SCI USA, V84, P3014, DOI 10.1073/pnas.84.9.3014; Su XZ, 1996, GENOMICS, V33, P430, DOI 10.1006/geno.1996.0218; TANABE K, 1987, J MOL BIOL, V195, P273, DOI 10.1016/0022-2836(87)90649-8; TAYLOR MFJ, 1995, SCIENCE, V270, P1497, DOI 10.1126/science.270.5241.1497; WEIR BS, 1984, EVOLUTION, V38, P1358, DOI [10.2307/2408641, 10.1111/j.1558-5646.1984.tb05657.x]	37	218	220	0	18	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2000	6	6					689	692		10.1038/76272	http://dx.doi.org/10.1038/76272			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	321CX	10835687	Green Published			2022-12-25	WOS:000087438300041
J	Keating, TJ; Borisy, GG				Keating, TJ; Borisy, GG			Immunostructural evidence for the template mechanism of microtubule nucleation	NATURE CELL BIOLOGY			English	Article							SPINDLE POLE BODY; GAMMA-TUBULIN COMPLEXES; RING COMPLEX; MOLECULAR CHARACTERIZATION; SACCHAROMYCES-CEREVISIAE; ASPERGILLUS-NIDULANS; CYTOPLASMIC DYNEIN; CENTROSOME; PROTEIN; BINDING	Two opposing models have been proposed to explain how the gamma-tubulin ring complex (gamma TuRC) induces microtubule nucleation. In the 'protofilament' model, the gamma TuRC induces nucleation as a partially or completely straightened protofilament that is incorporated longitudinally into the wall of the nascent microtubule, whereas the 'template' model proposes that the gamma TuRC acts as a helical template that constitutes the base of the newly-formed polymer. Here we appraise these two models, using high-resolution structural and immunolocalization methods. We show that components of the gamma TuRC localize to a narrow zone at the extreme minus end of the microtubule and that these ends terminate in a pointed cap. Together, these results strongly favour the template model of microtubule nucleation.	Univ Wisconsin, Mol Biol Lab, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Keating, TJ (corresponding author), Univ Wisconsin, Mol Biol Lab, Madison, WI 53706 USA.	tkeating@facstaff.wisc.edu		Borisy, Gary/0000-0002-0266-8018	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025062, R37GM025062] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM25062] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahmad FJ, 1998, J CELL BIOL, V140, P391, DOI 10.1083/jcb.140.2.391; Bullitt E, 1997, CELL, V89, P1077, DOI 10.1016/S0092-8674(00)80295-0; BYERS B, 1978, J CELL SCI, V30, P331; Echeverri CJ, 1996, J CELL BIOL, V132, P617, DOI 10.1083/jcb.132.4.617; Erickson HP, 1996, P NATL ACAD SCI USA, V93, P519, DOI 10.1073/pnas.93.1.519; Erickson HP, 1996, J CELL BIOL, V135, P5, DOI 10.1083/jcb.135.1.5; Fan J, 1996, J MOL BIOL, V259, P325, DOI 10.1006/jmbi.1996.0322; HORIO T, 1991, J CELL SCI, V99, P693; Hughes DA, 1998, METH MOL B, V80, P275; Jeng R, 1999, TRENDS CELL BIOL, V9, P339, DOI 10.1016/S0962-8924(99)01621-9; JOSHI HC, 1992, NATURE, V356, P80, DOI 10.1038/356080a0; Keating TJ, 1999, BIOL CELL, V91, P321, DOI 10.1016/S0248-4900(99)80093-8; Keating TJ, 1997, P NATL ACAD SCI USA, V94, P5078, DOI 10.1073/pnas.94.10.5078; Knop M, 1997, EMBO J, V16, P6985, DOI 10.1093/emboj/16.23.6985; LI QQ, 1995, J CELL BIOL, V131, P207, DOI 10.1083/jcb.131.1.207; Llanos R, 1999, BIOCHEMISTRY-US, V38, P15712, DOI 10.1021/bi990895w; Martin OC, 1998, J CELL BIOL, V141, P675, DOI 10.1083/jcb.141.3.675; MITCHISON TJ, 1989, J CELL BIOL, V109, P637, DOI 10.1083/jcb.109.2.637; Mogensen MM, 1997, CELL MOTIL CYTOSKEL, V36, P276, DOI 10.1002/(SICI)1097-0169(1997)36:3<276::AID-CM8>3.0.CO;2-5; Moritz M, 1998, J CELL BIOL, V142, P775, DOI 10.1083/jcb.142.3.775; MORITZ M, 1995, NATURE, V378, P638, DOI 10.1038/378638a0; Murphy SM, 1998, J CELL BIOL, V141, P663, DOI 10.1083/jcb.141.3.663; MURRAY AW, 1991, METHOD CELL BIOL, V36, P581; Nogales E, 1998, NATURE, V391, P199, DOI 10.1038/34465; O'Toole ET, 1999, MOL BIOL CELL, V10, P2017, DOI 10.1091/mbc.10.6.2017; OAKLEY BR, 1990, CELL, V61, P1289, DOI 10.1016/0092-8674(90)90693-9; OAKLEY CE, 1989, NATURE, V338, P662, DOI 10.1038/338662a0; Oegema K, 1999, J CELL BIOL, V144, P721, DOI 10.1083/jcb.144.4.721; Pereira G, 1997, J CELL SCI, V110, P295; Schiebel E, 2000, CURR OPIN CELL BIOL, V12, P113, DOI 10.1016/S0955-0674(99)00064-2; Sobel SG, 1995, J CELL BIOL, V131, P1775, DOI 10.1083/jcb.131.6.1775; STEARNS T, 1994, CELL, V76, P623, DOI 10.1016/0092-8674(94)90503-7; Svitkina TM, 1998, METHOD ENZYMOL, V298, P570, DOI 10.1016/S0076-6879(98)98045-4; VERDE F, 1991, J CELL BIOL, V112, P1177, DOI 10.1083/jcb.112.6.1177; WARNER FD, 1973, J CELL SCI, V12, P313; Wiese C, 1999, CURR OPIN STRUC BIOL, V9, P250, DOI 10.1016/S0959-440X(99)80035-9; Wittmann T, 1999, METHOD CELL BIOL, V61, P137; ZHENG YX, 1995, NATURE, V378, P578, DOI 10.1038/378578a0	38	86	87	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	JUN	2000	2	6					352	357		10.1038/35014045	http://dx.doi.org/10.1038/35014045			6	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	321KE	10854326				2022-12-25	WOS:000087454000017
J	Mirzabekov, T; Kontos, H; Farzan, M; Marasco, W; Sodroski, J				Mirzabekov, T; Kontos, H; Farzan, M; Marasco, W; Sodroski, J			Paramagnetic proteoliposomes containing a pure, native, and oriented seven-transmembrane segment protein, CCR5	NATURE BIOTECHNOLOGY			English	Article						seven-transmembrane protein; G protein-coupled receptor; CCR5; proteoliposomes; HIV-1 gp120; magnetic bead; antibody; screening assays	PLASMON RESONANCE SPECTROSCOPY; COUPLED RECEPTORS; CHEMOKINE RECEPTORS; HIV-1 CORECEPTOR; HEPARAN-SULFATE; ACTIVATION; INFECTION; RHODOPSIN; BINDING; GLYCOPROTEINS	Seven-transmembrane segment, G protein-coupled receptors play central roles in a wide range of biological processes, but their characterization has been hindered by the difficulty of obtaining homogeneous preparations of native protein, We have created paramagnetic proteoliposomes containing pure and oriented CCR5, a seven-transmembrane segment protein that serves as the principal coreceptor for human immunodeficiency virus (HIV-1). The CCR5 proteoliposomes bind the HIV-1 gp120 envelope glycoprotein and conformation-dependent antibodies against CCR5, The binding of gp120 was enhanced by a soluble form of the other HIV-1 receptor, CD4, but did not require additional cellular proteins. Paramagnetic proteoliposomes are uniform in size, stable in a broad range of salt concentrations and pH, and can be used in FACS and competition assays typically applied to cells. Integral membrane proteins can be inserted in either orientation into the liposomal membrane, The magnetic properties of these proteoliposomes facilitate rapid buffer exchange useful in multiple applications, As an example, the CCR5-proteoliposomes were used to select CCR5-specific antibodies from a recombinant phage display library, Thus, paramagnetic proteoliposomes should be useful tools in the analysis of membrane protein interactions with extracellular and intracellular ligands, particularly in establishing screens for inhibitors.	Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School	Sodroski, J (corresponding author), Dana Farber Canc Inst, Dept Canc Immunol & AIDS, 44 Binney St, Boston, MA 02115 USA.	joseph_sodroski@dfci.harvard.edu		Farzan, Michael/0000-0002-2990-5319	NIAID NIH HHS [AI 41851] Funding Source: Medline; NIGMS NIH HHS [GM 56550] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI041851] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM056550] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; Bieri C, 1999, NAT BIOTECHNOL, V17, P1105, DOI 10.1038/15090; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; Drews J, 1996, NAT BIOTECHNOL, V14, P1516, DOI 10.1038/nbt1196-1516; FOLCH J, 1957, J BIOL CHEM, V226, P497; Gether U, 1998, J BIOL CHEM, V273, P17979, DOI 10.1074/jbc.273.29.17979; Horn F, 1998, NUCLEIC ACIDS RES, V26, P275, DOI 10.1093/nar/26.1.275; Ji TH, 1998, J BIOL CHEM, V273, P17299, DOI 10.1074/jbc.273.28.17299; Kell Douglas, 1999, Trends in Biotechnology, V17, P89, DOI 10.1016/S0167-7799(98)01273-6; Lee B, 1999, J BIOL CHEM, V274, P9617, DOI 10.1074/jbc.274.14.9617; Lefkowitz RJ, 1996, NAT BIOTECHNOL, V14, P283, DOI 10.1038/nbt0396-283; Littman DR, 1998, CELL, V93, P677, DOI 10.1016/S0092-8674(00)81429-4; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; LUSTER AD, 1995, J EXP MED, V182, P219, DOI 10.1084/jem.182.1.219; Mellentin-Michelotti J, 1999, ANAL BIOCHEM, V272, P182, DOI 10.1006/abio.1999.4175; Mirzabekov T, 1999, J BIOL CHEM, V274, P28745, DOI 10.1074/jbc.274.40.28745; MOLDAY RS, 1983, BIOCHEMISTRY-US, V22, P653, DOI 10.1021/bi00272a020; SALAMON Z, 1994, BIOCHEMISTRY-US, V33, P13706, DOI 10.1021/bi00250a022; Salamon Z, 1996, BIOPHYS J, V71, P283, DOI 10.1016/S0006-3495(96)79224-X; Samson M, 1996, NATURE, V382, P722, DOI 10.1038/382722a0; Stadel JM, 1997, TRENDS PHARMACOL SCI, V18, P430, DOI 10.1016/S0165-6147(97)01117-6; TANAKA Y, 1993, NATURE, V361, P79, DOI 10.1038/361079a0; Tate CG, 1996, TRENDS BIOTECHNOL, V14, P426, DOI 10.1016/0167-7799(96)10059-7; Trkola A, 1996, NATURE, V384, P184, DOI 10.1038/384184a0; Watson S., 1994, G PROTEIN LINKED REC; WEBB LMC, 1993, P NATL ACAD SCI USA, V90, P7158, DOI 10.1073/pnas.90.15.7158; Wess J, 1997, FASEB J, V11, P346, DOI 10.1096/fasebj.11.5.9141501; WIENER MC, 1992, BIOPHYS J, V61, P437; Wilson S, 1998, BRIT J PHARMACOL, V125, P1387, DOI 10.1038/sj.bjp.0702238; Wu LJ, 1997, J EXP MED, V186, P1373, DOI 10.1084/jem.186.8.1373; Wu LJ, 1996, NATURE, V384, P179, DOI 10.1038/384179a0; Wyatt R, 1998, SCIENCE, V280, P1884, DOI 10.1126/science.280.5371.1884; Zeng FY, 1999, J BIOL CHEM, V274, P19487, DOI 10.1074/jbc.274.27.19487	36	100	115	0	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUN	2000	18	6					649	654		10.1038/76501	http://dx.doi.org/10.1038/76501			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	325EK	10835604				2022-12-25	WOS:000087663200026
J	Ahmad, FJ; Hughey, J; Wittmann, T; Hyman, A; Greaser, M; Baas, PW				Ahmad, FJ; Hughey, J; Wittmann, T; Hyman, A; Greaser, M; Baas, PW			Motor proteins regulate force interactions between microtubules and microfilaments in the axon	NATURE CELL BIOLOGY			English	Article							ACTIN FILAMENT BUNDLES; NERVE GROWTH CONES; CYTOPLASMIC DYNEIN; MITOTIC SPINDLE; CELL-DIVISION; ORGANIZATION; CYTOSKELETON; DYNACTIN; FIBROBLASTS; TRANSPORT	It has long been known that microtubule depletion causes axons to retract in a microfilament-dependent manner, although it was not known whether these effects are the result of motor-generated forces on these cytoskeletal elements. Here we show that inhibition of the motor activity of cytoplasmic dynein causes the axon to retract in the presence of microtubules. This response is obliterated if microfilaments are depleted or if myosin motors are inhibited. We conclude that axonal retraction results from myosin-mediated forces on the microfilament array, and that these forces are counterbalanced or attenuated by dynein-mediated forces between the microfilament and microtubule arrays.	Univ Wisconsin, Sch Med, Dept Anat, Madison, WI 53706 USA; European Mol Biol Lab, Cell Biol Program, D-69117 Heidelberg, Germany	University of Wisconsin System; University of Wisconsin Madison; European Molecular Biology Laboratory (EMBL)	Baas, PW (corresponding author), Univ Wisconsin, Sch Med, Dept Anat, 1300 Univ Ave, Madison, WI 53706 USA.	pwbaas@facstaff.wisc.edu	Hyman, Tony/F-1923-2011; Wittmann, Torsten/F-9833-2013; Greaser, Marion L/C-6147-2012	Wittmann, Torsten/0000-0001-9134-691X; Greaser, Marion L/0000-0002-6583-9566; Ahmad, Farhan/0000-0002-0740-8573				Ahmad FJ, 1998, J CELL BIOL, V140, P391, DOI 10.1083/jcb.140.2.391; Baas PW, 1999, NEURON, V22, P23, DOI 10.1016/S0896-6273(00)80675-3; BAAS PW, 1986, J CELL BIOL, V103, P917, DOI 10.1083/jcb.103.3.917; Bearer EL, 1999, J NEUROCYTOL, V28, P85, DOI 10.1023/A:1007025421849; BRAY D, 1981, J NEUROCYTOL, V10, P589, DOI 10.1007/BF01262592; Busson S, 1998, CURR BIOL, V8, P541, DOI 10.1016/S0960-9822(98)70208-8; Carminati JL, 1997, J CELL BIOL, V138, P629, DOI 10.1083/jcb.138.3.629; Challacombe JF, 1996, J CELL SCI, V109, P2031; Dillman JF, 1996, P NATL ACAD SCI USA, V93, P141, DOI 10.1073/pnas.93.1.141; Echeverri CJ, 1996, J CELL BIOL, V132, P617, DOI 10.1083/jcb.132.4.617; EVANS LL, 1995, P NATL ACAD SCI USA, V92, P10954, DOI 10.1073/pnas.92.24.10954; FATH KR, 1988, J CELL BIOL, V107, P613, DOI 10.1083/jcb.107.2.613; FORSCHER P, 1988, J CELL BIOL, V107, P1505, DOI 10.1083/jcb.107.4.1505; Garces JA, 1999, CURR BIOL, V9, P1497, DOI 10.1016/S0960-9822(00)80122-0; GEORGE EB, 1988, CELL MOTIL CYTOSKEL, V9, P48, DOI 10.1002/cm.970090106; Gonczy P, 1999, J CELL BIOL, V147, P135, DOI 10.1083/jcb.147.1.135; HALLORAN MC, 1994, J NEUROSCI, V14, P2161; HEIDEMANN SR, 1990, CELL MOTIL CYTOSKEL, V17, P6, DOI 10.1002/cm.970170103; Heidemann SR, 1999, J CELL BIOL, V145, P109, DOI 10.1083/jcb.145.1.109; Hirose M, 1998, J CELL BIOL, V141, P1625, DOI 10.1083/jcb.141.7.1625; Ingber DE, 1997, ANNU REV PHYSIOL, V59, P575, DOI 10.1146/annurev.physiol.59.1.575; Inoue S, 1998, J CELL SCI, V111, P2607; JOSHI HC, 1985, J CELL BIOL, V101, P697, DOI 10.1083/jcb.101.3.697; Karki S, 1999, CURR OPIN CELL BIOL, V11, P45, DOI 10.1016/S0955-0674(99)80006-4; KOLODNEY MS, 1995, P NATL ACAD SCI USA, V92, P10252, DOI 10.1073/pnas.92.22.10252; Koonce MP, 1999, EMBO J, V18, P6786, DOI 10.1093/emboj/18.23.6786; LETOURNEAU PC, 1987, CELL MOTIL CYTOSKEL, V8, P193, DOI 10.1002/cm.970080302; LETOURNEAU PC, 1983, J CELL BIOL, V97, P963, DOI 10.1083/jcb.97.4.963; LEWIS AK, 1992, J CELL BIOL, V119, P1219, DOI 10.1083/jcb.119.5.1219; Lin CH, 1996, NEURON, V16, P769, DOI 10.1016/S0896-6273(00)80097-5; LIN CH, 1993, J CELL BIOL, V121, P1369, DOI 10.1083/jcb.121.6.1369; Ma S, 1999, J CELL BIOL, V147, P1261, DOI 10.1083/jcb.147.6.1261; MEEUSEN RL, 1979, J CELL BIOL, V82, P57, DOI 10.1083/jcb.82.1.57; MEEUSEN RL, 1980, J CELL BIOL, V86, P858, DOI 10.1083/jcb.86.3.858; Olsson PA, 1999, J BIOL CHEM, V274, P36288, DOI 10.1074/jbc.274.51.36288; Rochlin MW, 1999, MOL BIOL CELL, V10, P2309, DOI 10.1091/mbc.10.7.2309; RODIONOV VI, 1993, J CELL BIOL, V123, P1811, DOI 10.1083/jcb.123.6.1811; SHAW G, 1977, EXP CELL RES, V104, P55, DOI 10.1016/0014-4827(77)90068-4; SOLOMON F, 1981, J CELL BIOL, V89, P157, DOI 10.1083/jcb.89.1.157; SPECTOR I, 1983, SCIENCE, V219, P493, DOI 10.1126/science.6681676; TANAKA E, 1995, CELL, V83, P171, DOI 10.1016/0092-8674(95)90158-2; Walczak CE, 1998, CURR BIOL, V8, P903, DOI 10.1016/S0960-9822(07)00370-3; Walczak CE, 1996, CELL, V85, P943, DOI 10.1016/S0092-8674(00)81295-7; Waterman-Storer CM, 1999, CURR OPIN CELL BIOL, V11, P61, DOI 10.1016/S0955-0674(99)80008-8; Waterman-Storer CM, 1999, NAT CELL BIOL, V1, P45, DOI 10.1038/9018; Wittmann T, 1999, METHOD CELL BIOL, V61, P137; YAMADA KM, 1970, P NATL ACAD SCI USA, V66, P1206, DOI 10.1073/pnas.66.4.1206; YAMADA KM, 1971, J CELL BIOL, V49, P614, DOI 10.1083/jcb.49.3.614; YU WQ, 1995, J NEUROSCI, V15, P6827; YU WQ, 1994, J NEUROSCI, V14, P2818	50	143	143	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	MAY	2000	2	5					276	280		10.1038/35010544	http://dx.doi.org/10.1038/35010544			5	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	313FX	10806478				2022-12-25	WOS:000086990600016
J	Cho, HJ; Takabayashi, K; Cheng, PM; Nguyen, MD; Corr, M; Tuck, S; Raz, E				Cho, HJ; Takabayashi, K; Cheng, PM; Nguyen, MD; Corr, M; Tuck, S; Raz, E			Immunostimulatory DNA-based vaccines induce cytotoxic lymphocyte activity by a T-helper cell-independent mechanism	NATURE BIOTECHNOLOGY			English	Article						immunostimulatory DNA sequences; CpG motif; CTL activation; AIDS	MHC CLASS-I; MYCOBACTERIUM-BOVIS BCG; DENDRITIC CELLS; B-CELL; SYNTHETIC OLIGONUCLEOTIDES; EXOGENOUS ANTIGENS; ANTITUMOR-ACTIVITY; MOLECULES; RESPONSES; ADJUVANTS	Immunostimulatory DNA sequences (ISS) contain unmethylated CpG dinucleotides within a defined motif. Immunization with ISS-based vaccines has been shown to induce high antigen-specific cytotoxic lymphocyte (CTL) activity and a T(h)1-biased immune response. We have developed a novel ISS-based vaccine composed of ovalbumin (OVA) chemically conjugated to ISS-oligodeoxynucleotide (ODN). Protein-ISS conjugate (PIC) is more potent in priming CTL activity and T(h)1-biased immunity than other ISS-based vaccines. Cytotoxic lymphocyte activation by ISS-ODN-based vaccines is preserved in both CD4(-/-) and MHC class II-/- gene-deficient animals. Furthermore, PIC provides protection against a lethal burden of OVA-expressing tumor cells in a CD8(+) cell-dependent manner. These results demonstrate that PIC acts through two unique mechanisms: T-helper-independent activation of CTL and facilitation of exogenous antigen presentation on MHC class I. This technology may have clinical applications in cancer therapy and in stimulating host defense in AIDS and chronic immunosuppression.	Univ Calif San Diego, Dept Internal Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Sam & Rose Stein Inst Res Aging, La Jolla, CA 92093 USA; Dynavax Technol Corp, Berkeley, CA 94710 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Raz, E (corresponding author), Univ Calif San Diego, Dept Internal Med, La Jolla, CA 92093 USA.				NIAID NIH HHS [AI 47078, AI 40682] Funding Source: Medline; NIAMS NIH HHS [AR 44850] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI040682, R21AI047078] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P50AR044850] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Bennett SRM, 1998, NATURE, V393, P478, DOI 10.1038/30996; Botti C, 1998, INT J BIOL MARKER, V13, P51; Carson DA, 1997, J EXP MED, V186, P1621, DOI 10.1084/jem.186.10.1621; Chu RS, 1997, J EXP MED, V186, P1623, DOI 10.1084/jem.186.10.1623; Corr M, 1996, J EXP MED, V184, P1555, DOI 10.1084/jem.184.4.1555; Davis HL, 1998, J IMMUNOL, V160, P870; Dejardin E, 1998, ONCOGENE, V16, P3299, DOI 10.1038/sj.onc.1201879; Grewal IS, 1996, IMMUNOL REV, V153, P85, DOI 10.1111/j.1600-065X.1996.tb00921.x; Gromme M, 1999, P NATL ACAD SCI USA, V96, P10326, DOI 10.1073/pnas.96.18.10326; HARDING FA, 1993, J EXP MED, V177, P1791, DOI 10.1084/jem.177.6.1791; Horner AA, 1998, CELL IMMUNOL, V190, P77, DOI 10.1006/cimm.1998.1400; Jakob T, 1998, J IMMUNOL, V161, P3042; KEENE JA, 1982, J EXP MED, V155, P768, DOI 10.1084/jem.155.3.768; Korkolopoulou P, 1996, BRIT J CANCER, V73, P148, DOI 10.1038/bjc.1996.28; KOVACSOVICSBANKOWSKI M, 1995, SCIENCE, V267, P243, DOI 10.1126/science.7809629; KRIEG AM, 1995, NATURE, V374, P546, DOI 10.1038/374546a0; Krieg AM, 1998, TRENDS MICROBIOL, V6, P23, DOI 10.1016/S0966-842X(97)01145-1; Lanzavecchia A, 1998, NATURE, V393, P413, DOI 10.1038/30845; LIN MS, 1993, CELL IMMUNOL, V150, P343, DOI 10.1006/cimm.1993.1202; Lipford GB, 1997, EUR J IMMUNOL, V27, P2340, DOI 10.1002/eji.1830270931; Martin-Orozco E, 1999, INT IMMUNOL, V11, P1111, DOI 10.1093/intimm/11.7.1111; MITCHISON NA, 1987, EUR J IMMUNOL, V17, P1579, DOI 10.1002/eji.1830171109; PFEIFER JD, 1993, NATURE, V361, P359, DOI 10.1038/361359a0; Porgador A, 1996, J IMMUNOL, V156, P2918; Reiss M, 1997, ONCOL RES, V9, P447; Ridge JP, 1998, NATURE, V393, P474, DOI 10.1038/30989; Roman M, 1997, NAT MED, V3, P849, DOI 10.1038/nm0897-849; Sato Y, 1996, SCIENCE, V273, P352, DOI 10.1126/science.273.5273.352; Schoenberger SP, 1998, NATURE, V393, P480, DOI 10.1038/31002; Seliger B, 1996, EXP HEMATOL, V24, P1275; Shen ZH, 1997, J IMMUNOL, V158, P2723; SHIMADA S, 1985, J NATL CANCER I, V74, P681; Sigal LJ, 1998, J IMMUNOL, V161, P2740; SOUZA CRE, 1995, J EXP MED, V182, P841; TOKUNAGA T, 1984, J NATL CANCER I, V72, P955; TRINCHIERI G, 1995, ANNU REV IMMUNOL, V13, P251, DOI 10.1146/annurev.immunol.13.1.251; YAMAMOTO S, 1992, J IMMUNOL, V148, P4072	37	226	256	0	22	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAY	2000	18	5					509	514		10.1038/75365	http://dx.doi.org/10.1038/75365			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	313UK	10802617				2022-12-25	WOS:000087017500023
J	Diehn, M; Eisen, MB; Botstein, D; Brown, PO				Diehn, M; Eisen, MB; Botstein, D; Brown, PO			Large-scale identification of secreted and membrane-associated gene products using DNA microarrays	NATURE GENETICS			English	Article							MESSENGER-RNA; BOUND POLYSOMES; SIGNAL PEPTIDES; PROTEINS; EXPRESSION; YEAST; CLONING; CELLS; LOCALIZATION; COMPLEXITY	Membrane-associated and secreted proteins are an important class of proteins and include receptors, transporters, adhesion molecules, hormones and cytokines. Although algorithms have been developed to recognize potential amino-terminal membrane-targeting signals or transmembrane domains in protein sequences, their accuracy is limited and they require knowledge of the entire coding sequence, including the N terminus(1), which is not currently available for most of the genes in most organisms, including human. Several experimental approaches for identifying secreted and membrane proteins have been described, but none have taken a comprehensive genomic approach(2-6). Furthermore, none of these methods allow easy classification of clones from arrayed cDNA libraries, for which large-scale gene-expression data are now becoming available through the use of DNA microarrays. We describe here a rapid and efficient method for identifying genes that encode secreted or membrane proteins. mRNA species bound to membrane-associated polysomes were separated from other mRNAs by sedimentation equilibrium or sedimentation velocity. The distribution of individual transcripts in the 'membrane-bound' and 'cytosolic' fractions was quantitated for thousands of genes by hybridization to DNA microarrays. Transcripts known to encode secreted or membrane proteins were enriched in the membrane-bound fractions, whereas those known to encode cytoplasmic proteins were enriched in the fractions containing mRNAs associated with free and cytoplasmic ribosomes. On this basis, we identified over 275 human genes and 285 yeast genes that are likely to encode previously unrecognized secreted or membrane proteins.	Stanford Univ, Sch Med, Dept Biochem, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Genet, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Howard Hughes Med Inst, Stanford, CA 94305 USA	Stanford University; Stanford University; Howard Hughes Medical Institute; Stanford University	Brown, PO (corresponding author), Stanford Univ, Sch Med, Dept Biochem, Stanford, CA 94305 USA.	pbrown@cmgm.stanford.edu		Eisen, Michael/0000-0002-7528-738X	NCI NIH HHS [CA77097] Funding Source: Medline; NHGRI NIH HHS [HG00983] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA077097] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG000983] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		Chapman RE, 1997, CURR BIOL, V7, P850, DOI 10.1016/S0960-9822(06)00373-3; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; Egea G, 1997, BIOCHEM J, V322, P557, DOI 10.1042/bj3220557; Eisen MB, 1999, METHOD ENZYMOL, V303, P179; Iyer VR, 1999, SCIENCE, V283, P83, DOI 10.1126/science.283.5398.83; Kacharmina JE, 1999, METHOD ENZYMOL, V303, P3; Klein RD, 1996, P NATL ACAD SCI USA, V93, P7108, DOI 10.1073/pnas.93.14.7108; Kopczynski CC, 1998, P NATL ACAD SCI USA, V95, P9973, DOI 10.1073/pnas.95.17.9973; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Lightowlers RN, 1996, BIOCHEM SOC T, V24, P527, DOI 10.1042/bst0240527; Lukyanetz EA, 1997, NEUROSCIENCE, V78, P625, DOI 10.1016/S0306-4522(97)00020-1; MECHLER B, 1981, J CELL BIOL, V88, P29, DOI 10.1083/jcb.88.1.29; MECHLER BM, 1987, METHOD ENZYMOL, V152, P241; MUECKLER MM, 1981, J CELL BIOL, V90, P495, DOI 10.1083/jcb.90.2.495; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Nielsen H, 1999, PROTEIN ENG, V12, P3, DOI 10.1093/protein/12.1.3; Perou CM, 1999, P NATL ACAD SCI USA, V96, P9212, DOI 10.1073/pnas.96.16.9212; PIETRINI G, 1992, J CELL BIOL, V117, P975, DOI 10.1083/jcb.117.5.975; Scherer PE, 1998, NAT BIOTECHNOL, V16, P581, DOI 10.1038/nbt0698-581; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; Sidrauski C, 1997, CELL, V90, P1031, DOI 10.1016/S0092-8674(00)80369-4; Spellman PT, 1998, MOL BIOL CELL, V9, P3273, DOI 10.1091/mbc.9.12.3273; STOLTENBURG R, 1995, BIOTECHNIQUES, V18, P564; Takizawa PA, 1997, NATURE, V389, P90, DOI 10.1038/38015; TASHIRO K, 1993, SCIENCE, V261, P600, DOI 10.1126/science.8342023; Zannettino ACW, 1996, J IMMUNOL, V156, P611	26	173	183	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAY	2000	25	1					58	62		10.1038/75603	http://dx.doi.org/10.1038/75603			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	311KU	10802657				2022-12-25	WOS:000086884000017
J	Hackney, DD; Stock, MF				Hackney, DD; Stock, MF			Kinesin's IAK tail domain inhibits initial microtubule-stimulated ADP release	NATURE CELL BIOLOGY			English	Article							ATP HYDROLYSIS; MOTOR DOMAIN; HEAD DOMAINS; LIGHT-CHAIN; BINDING; MOLECULES; MOVEMENT; MOTILITY; PROTEINS; SITE	Kinesin undergoes a global folding conformational change from an extended active conformation at high ionic concentrations to a compact inhibited conformation at physiological ionic concentrations. Here we show that much of the observed ATPase activity of folded kinesin is due to contamination with proteolysis fragments that can still fold, but retain an activated ATPase function. In contrast, kinesin that contains an intact IAK-homology region exhibits pronounced inhibition of its ATPase activity (140-fold in 50 mM KCl) and weak net affinity for microtubules in the presence of ATP, resulting from selective inhibition of the release of ADP upon initial interaction with a microtubule, Subsequent processive cycling is only partially inhibited. Fusion proteins containing residues 883-937 of the kinesin a-chain bind tightly to microtubules; exposure of this microtubule-binding site in proteolysed species is probably responsible for their activated ATPase activities at low microtubule concentrations.	Carnegie Mellon Univ, Dept Biol Sci, Pittsburgh, PA 15213 USA	Carnegie Mellon University	Hackney, DD (corresponding author), Carnegie Mellon Univ, Dept Biol Sci, 4400 5th Ave, Pittsburgh, PA 15213 USA.	ddh@andrew.cmu.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS028562] Funding Source: NIH RePORTER; NINDS NIH HHS [NS28562] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BLOCK SM, 1990, NATURE, V348, P348, DOI 10.1038/348348a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cheng JQ, 1998, BIOCHEMISTRY-US, V37, P5288, DOI 10.1021/bi972742j; Coy DL, 1999, NAT CELL BIOL, V1, P288, DOI 10.1038/13001; CROSS RA, 1988, J MOL BIOL, V203, P173, DOI 10.1016/0022-2836(88)90100-3; Diefenbach RJ, 1998, BIOCHEMISTRY-US, V37, P16663, DOI 10.1021/bi981163r; Friedman DS, 1999, NAT CELL BIOL, V1, P293, DOI 10.1038/13008; HACKNEY DD, 1992, J BIOL CHEM, V267, P8696; HACKNEY DD, 1994, P NATL ACAD SCI USA, V91, P6865, DOI 10.1073/pnas.91.15.6865; HACKNEY DD, 1991, BIOCHEM BIOPH RES CO, V174, P810, DOI 10.1016/0006-291X(91)91490-4; HACKNEY DD, 1994, J BIOL CHEM, V269, P16508; HACKNEY DD, 1995, NATURE, V377, P448, DOI 10.1038/377448a0; HACKNEY DD, 1991, METHOD ENZYMOL, V196, P175; Hirokawa N, 1998, CURR OPIN CELL BIOL, V10, P60, DOI 10.1016/S0955-0674(98)80087-2; HISANAGA S, 1989, CELL MOTIL CYTOSKEL, V12, P264, DOI 10.1002/cm.970120407; HOWARD J, 1989, NATURE, V342, P154, DOI 10.1038/342154a0; HUANG TG, 1994, J BIOL CHEM, V269, P16493; INGOLD AL, 1988, J CELL BIOL, V107, P2659; JIANG MY, 1995, BIOPHYS J S, V68, P283; Jiang W, 1997, J BIOL CHEM, V272, P7626, DOI 10.1074/jbc.272.12.7626; Kirchner J, 1999, BIOL CHEM, V380, P915, DOI 10.1515/BC.1999.113; Kirchner J, 1999, EMBO J, V18, P4404, DOI 10.1093/emboj/18.16.4404; Moraga D. E., 1997, Molecular Biology of the Cell, V8, p258A; NAVONE F, 1992, J CELL BIOL, V117, P1263, DOI 10.1083/jcb.117.6.1263; NEUHOFF V, 1988, ELECTROPHORESIS, V9, P255, DOI 10.1002/elps.1150090603; Rice S, 1999, NATURE, V402, P778, DOI 10.1038/45483; Stock MF, 1999, J BIOL CHEM, V274, P14617, DOI 10.1074/jbc.274.21.14617; Vale RD, 1997, ANNU REV CELL DEV BI, V13, P745, DOI 10.1146/annurev.cellbio.13.1.745; Verhey KJ, 1998, J CELL BIOL, V143, P1053, DOI 10.1083/jcb.143.4.1053; WAGNER MC, 1989, CELL MOTIL CYTOSKEL, V12, P195, DOI 10.1002/cm.970120403	30	142	143	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	MAY	2000	2	5					257	260		10.1038/35010525	http://dx.doi.org/10.1038/35010525			4	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	313FX	10806475				2022-12-25	WOS:000086990600013
J	Nakai, H; Storm, TA; Kay, MA				Nakai, H; Storm, TA; Kay, MA			Increasing the size of rAAV-mediated expression cassettes in vivo by intermolecular joining of two complementary vectors	NATURE BIOTECHNOLOGY			English	Article						adeno-associated virus vector; gene therapy; hepatocytes; intermolecular recombination; concatemer	RECOMBINANT ADENOASSOCIATED VIRUS; COAGULATION FACTOR-IX; GENE-TRANSFER; VIRAL VECTORS; SKELETAL-MUSCLE; HEMOPHILIA-B; MOUSE-LIVER; MICE; TRANSDUCTION; PROMOTER	A major shortcoming to the use of adeno-associated virus (rAAV) vectors is their limited packaging size. To overcome this hurdle, we split an expression cassette and cloned it into two separate vectors. The vectors contained either a nuclear localizing Escherichia coli lacZ transgene (nlslacZ) with a splice acceptor, or the human elongation factor 1 alpha (EF1 alpha) gene enhancer/promoter(s) (EF1 alpha EP) with a splice donor. We co-injected a promoter-less nlslacZ vector with a vector containing either a single EF1 alpha EP or a double copy of the EF1 alpha EP in a head-to-head orientation, into the portal vein of mice. Gene expression, measured by both transduction efficiency and quantitation of the recombinant protein, was as much as 60-70% of that obtained from mice that received a single vector containing a complete EF1 alpha EP/nlslacZ expression cassette. This two-vector approach may allow development of gene therapy strategies that will carry exogenous DNA sequences with large therapeutic cDNAs and/or regulatory elements.	Stanford Univ, Dept Pediat & Genet, Program Human Gene Therapy, Stanford, CA 94305 USA	Stanford University	Kay, MA (corresponding author), Stanford Univ, Dept Pediat & Genet, Program Human Gene Therapy, Stanford, CA 94305 USA.			Kay, Mark/0000-0002-2799-2615	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL053682] Funding Source: NIH RePORTER; NHLBI NIH HHS [R0I HL53682] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Burton M, 1999, P NATL ACAD SCI USA, V96, P12725, DOI 10.1073/pnas.96.22.12725; Duan DS, 1998, J VIROL, V72, P8568, DOI 10.1128/JVI.72.11.8568-8577.1998; Fan DS, 1998, HUM GENE THER, V9, P2527, DOI 10.1089/hum.1998.9.17-2527; FLOTTE TR, 1993, J BIOL CHEM, V268, P3781; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; Herzog RW, 1997, P NATL ACAD SCI USA, V94, P5804, DOI 10.1073/pnas.94.11.5804; KAY MA, 1992, HUM GENE THER, V3, P641, DOI 10.1089/hum.1992.3.6-641; Kessler PD, 1996, P NATL ACAD SCI USA, V93, P14082, DOI 10.1073/pnas.93.24.14082; KIM DW, 1990, GENE, V91, P217, DOI 10.1016/0378-1119(90)90091-5; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Matsushita T, 1998, GENE THER, V5, P938, DOI 10.1038/sj.gt.3300680; Miao CH, 1998, NAT GENET, V19, P13, DOI 10.1038/ng0598-13; Miao CH, 2000, J VIROL, V74, P3793, DOI 10.1128/JVI.74.8.3793-3803.2000; Nakai H, 1998, BLOOD, V91, P4600, DOI 10.1182/blood.V91.12.4600.412k22_4600_4607; Nakai H, 1999, J VIROL, V73, P5438, DOI 10.1128/JVI.73.7.5438-5447.1999; Naldini L, 1996, SCIENCE, V272, P263, DOI 10.1126/science.272.5259.263; Rendahl KG, 1998, NAT BIOTECHNOL, V16, P757, DOI 10.1038/nbt0898-757; Russell DW, 1999, BLOOD, V94, P864, DOI 10.1182/blood.V94.3.864.415k34_864_874; Russell DW, 1998, NAT GENET, V18, P325, DOI 10.1038/ng0498-325; Sambrook J., 2002, MOL CLONING LAB MANU; Snyder RO, 1997, NAT GENET, V16, P270, DOI 10.1038/ng0797-270; Snyder RO, 1999, NAT MED, V5, P64, DOI 10.1038/4751; Snyder RO, 1997, HUM GENE THER, V8, P1891, DOI 10.1089/hum.1997.8.16-1891; Watson GL, 1998, GENE THER, V5, P1642, DOI 10.1038/sj.gt.3300775; WIGLER M, 1980, P NATL ACAD SCI-BIOL, V77, P3567, DOI 10.1073/pnas.77.6.3567; Yang JS, 1999, J VIROL, V73, P9468, DOI 10.1128/JVI.73.11.9468-9477.1999	27	141	150	0	3	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAY	2000	18	5					527	532		10.1038/75390	http://dx.doi.org/10.1038/75390			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	313UK	10802620				2022-12-25	WOS:000087017500026
J	Takaki, A; Wiese, M; Maertens, G; Depla, E; Seifert, U; Liebetrau, A; Miller, JL; Manns, MP; Rehermann, B				Takaki, A; Wiese, M; Maertens, G; Depla, E; Seifert, U; Liebetrau, A; Miller, JL; Manns, MP; Rehermann, B			Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C	NATURE MEDICINE			English	Article							T-LYMPHOCYTE RESPONSE; VIRUS-INFECTION; NONSTRUCTURAL PROTEIN-3; CELLS; CLEARANCE; MICE	As acute hepatitis C virus (HCV) infection is clinically inapparent in most cases, the immunologic correlates of recovery are not well defined. The cellular immune response is thought to contribute to the elimination of HCV-infected cells(1) and a strong HCV-specific T-helper-cell (Th) response is associated with recovery from acute hepatitis C (ref. 2). However, diagnosis of resolved hepatitis C is based at present on the detection of HCV-specific antibodies and the absence of detectable HCV RNA, and detailed comparison of the humoral and cellular immune response has been hampered by the fact that patient cohorts as well as HCV strains are usually heterogeneous and that clinical data from acute-phase and long-term follow-up after infection generally are not available. We studied a cohort of women accidentally exposed to the same HCV strain of known sequence(3) and found that circulating HCV-specific antibodies were undetectable in many patients 18-20 years after recovery, whereas HCV-specific helper and cytotoxic T-cell responses with an interferon (IFN)-gamma-producing (Tc1) phenotype persisted. The data indicate these HCV-specific CD4(+) and CD8(+) T cells are biomarkers for a prior HCV exposure and recovery. Because of undetectable antibodies against HCV, the incidence of self-limited HCV infections and recovery may be underestimated in the general population.	Med Hsch Hannover, Dept Gastroenterol & Hepatol, D-30625 Hannover, Germany; Stadt Klinikum St Georg, Klin Innere Med 2, D-04129 Leipzig, Germany; Hepatitits Program, B-9052 Ghent, Belgium; NIDDK, Biol Chem Lab, NIH, Bethesda, MD 20892 USA; NIDDK, Liver Dis Sect, NIH, Bethesda, MD 20892 USA	Hannover Medical School; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Rehermann, B (corresponding author), Med Hsch Hannover, Dept Gastroenterol & Hepatol, Carl Neuberg Str 1, D-30625 Hannover, Germany.			Rehermann, Barbara/0000-0001-6832-9951	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK054509, Z01DK054508, ZIADK054509, ZIADK054508] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CERNY A, 1995, J CLIN INVEST, V95, P521, DOI 10.1172/JCI117694; Chang KM, 1999, J IMMUNOL, V162, P1156; Diepolder HM, 1997, J VIROL, V71, P6011, DOI 10.1128/JVI.71.8.6011-6019.1997; DIEPOLDER HM, 1995, LANCET, V346, P1006, DOI 10.1016/S0140-6736(95)91691-1; HENLE W, 1970, SCIENCE, V169, P188, DOI 10.1126/science.169.3941.188; Koziel MJ, 1997, J INFECT DIS, V176, P859, DOI 10.1086/516546; MAERTENS G, 1994, VIRAL HEPATITIS LIVE, P314; MAERTENS G, 1999, METHODS MOL BIOL HEP, P11; *MIN GES DDR, 1995, BER STAATL HYG INSP; Murali-Krishna K, 1999, SCIENCE, V286, P1377, DOI 10.1126/science.286.5443.1377; Rehermann B, 1996, NAT MED, V2, P1104, DOI 10.1038/nm1096-1104; Rehermann B, 2000, CURR TOP MICROBIOL, V242, P299; Rehermann B, 1996, J HEPATOL, V24, P15, DOI 10.1016/S0168-8278(96)80180-2; Rehermann B, 1996, J VIROL, V70, P7092, DOI 10.1128/JVI.70.10.7092-7102.1996; Scognamiglio P, 1999, J IMMUNOL, V162, P6681; Selin LK, 1997, J IMMUNOL, V158, P5366; Swain SL, 1999, SCIENCE, V286, P1381, DOI 10.1126/science.286.5443.1381; WIESE M, 1996, KASSENARZT, V5, P36; WIESE M, 1991, NON A NON B HEPATITI, P146	19	612	628	0	19	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAY	2000	6	5					578	582		10.1038/75063	http://dx.doi.org/10.1038/75063			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	309YB	10802716				2022-12-25	WOS:000086796200044
J	Reubinoff, BE; Pera, MF; Fong, CY; Trounson, A; Bongso, A				Reubinoff, BE; Pera, MF; Fong, CY; Trounson, A; Bongso, A			Embryonic stem cell lines from human blastocysts: somatic differentiation in vitro	NATURE BIOTECHNOLOGY			English	Article						embryonic stem cell; differentiation; Oct-4; neural progenitor; neuron	PRIMORDIAL GERM-CELLS; CARCINOMA-CELLS; HUMAN TERATOMAS; INDUCTION; ANTIGENS; CULTURE	We describe the derivation of pluripotent embryonic stem (ES) cells from human blastocysts. Two diploid ES cell lines have been cultivated in vitro for extended periods while maintaining expression of markers characteristic of pluripotent primate cells. Human ES cells express the transcription factor Oct-4, essential for development of pluripotential cells in the mouse. When grafted into SCID mice, both lines give rise to teratomas containing derivatives of all three embryonic germ layers. Both cell lines differentiate in vitro into extraembryonic and somatic cell lineages. Neural progenitor cells may be isolated from differentiating ES cell cultures and induced to form mature neurons. Embryonic stem cells provide a model to study early human embryology, an investigational tool for discovery of novel growth factors and medicines, and a potential source of cells for use in transplantation therapy.	Monash Univ, Monash Inst Reprod & Dev, Melbourne, Vic, Australia; Hadassah Univ Hosp, Dept Obstet & Gynaecol, IL-91120 Jerusalem, Israel; Natl Univ Singapore, Dept Obstet & Gynaecol, Singapore 117548, Singapore	Monash University; Hebrew University of Jerusalem; National University of Singapore	Pera, MF (corresponding author), Monash Univ, Monash Inst Reprod & Dev, Melbourne, Vic, Australia.	martin.pera@med.monash.edu.au	PERA, MARTIN/A-9812-2012	PERA, MARTIN/0000-0001-6239-0428; Reubinoff, Benjamin/0000-0003-0353-1299; Trounson, Alan/0000-0001-5469-0500				ANDREWS PW, 1994, LAB INVEST, V71, P243; ANDREWS PW, 1984, LAB INVEST, V50, P147; Andrews PW, 1996, INT J CANCER, V66, P806, DOI 10.1002/(SICI)1097-0215(19960611)66:6<806::AID-IJC17>3.0.CO;2-0; Badcock G, 1999, CANCER RES, V59, P4715; Beddington RSP, 1999, CELL, V96, P195, DOI 10.1016/S0092-8674(00)80560-7; BONGSO A, 1994, HUM REPROD, V9, P2110, DOI 10.1093/oxfordjournals.humrep.a138401; BUEHR M, 1993, METHOD ENZYMOL, V225, P58; CARICASOLE AD, 1997, INHIBIN ACTIVIN FOLL, P308; COOPER S, 1992, BIOCHEM J, V286, P959, DOI 10.1042/bj2860959; Dani C, 1998, DEV BIOL, V203, P149, DOI 10.1006/dbio.1998.9026; EVANS MJ, 1981, NATURE, V292, P151; Flax JD, 1998, NAT BIOTECHNOL, V16, P1033, DOI 10.1038/3473; Fong CY, 1997, HUM REPROD, V12, P557; Fong CY, 1999, HUM REPROD, V14, P774, DOI 10.1093/humrep/14.3.774; Kukekov VG, 1999, EXP NEUROL, V156, P333, DOI 10.1006/exnr.1999.7028; Li M, 1998, CURR BIOL, V8, P971, DOI 10.1016/S0960-9822(98)70399-9; MARTIN GR, 1981, P NATL ACAD SCI-BIOL, V78, P7634, DOI 10.1073/pnas.78.12.7634; McWhir J, 1996, NAT GENET, V14, P223, DOI 10.1038/ng1096-223; Neelands TR, 1998, J NEUROSCI, V18, P4993; Nichols J, 1998, CELL, V95, P379, DOI 10.1016/S0092-8674(00)81769-9; PERA MF, 1988, DIFFERENTIATION, V39, P139, DOI 10.1111/j.1432-0436.1988.tb00089.x; PERA MF, 1989, DIFFERENTIATION, V42, P10, DOI 10.1111/j.1432-0436.1989.tb00602.x; PERA MF, 1999, REPROD FERT DEVELOP, V10, P551; Rathjen J, 1999, J CELL SCI, V112, P601; ROACH S, 1993, EUR UROL, V23, P82; Shamblott MJ, 1998, P NATL ACAD SCI USA, V95, P13726, DOI 10.1073/pnas.95.23.13726; SOLTER D, 1975, P NATL ACAD SCI USA, V72, P5099, DOI 10.1073/pnas.72.12.5099; THOMPSON S, 1984, J CELL SCI, V72, P37; Thomson JA, 1996, BIOL REPROD, V55, P254, DOI 10.1095/biolreprod55.2.254; THOMSON JA, 1995, P NATL ACAD SCI USA, V92, P7844, DOI 10.1073/pnas.92.17.7844; Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145; van Eijk MJT, 1999, BIOL REPROD, V60, P1093, DOI 10.1095/biolreprod60.5.1093; Vescovi AL, 1999, EXP NEUROL, V156, P71, DOI 10.1006/exnr.1998.6998	33	2025	2417	5	253	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	APR	2000	18	4					399	404		10.1038/74447	http://dx.doi.org/10.1038/74447			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	303UY	10748519				2022-12-25	WOS:000086444300021
J	Schense, JC; Bloch, J; Aebischer, P; Hubbell, JA				Schense, JC; Bloch, J; Aebischer, P; Hubbell, JA			Enzymatic incorporation of bioactive peptides into fibrin matrices enhances neurite extension	NATURE BIOTECHNOLOGY			English	Article						fibrin; factor XIII; nerve regeneration; laminin; N-cadherin	CELL-ADHESION; ALPHA-2-PLASMIN INHIBITOR; CROSS-LINKING; LAMININ; IDENTIFICATION; MIGRATION; OUTGROWTH; SEQUENCE; RECEPTOR; BIOMATERIALS	Fibrin plays an important role in wound healing and regeneration, and enjoys widespread use in surgery and tissue engineering. The enzymatic activity of Factor XIIIa was employed to covalently incorporate exogenous bioactive peptides within fibrin during coagulation. Fibrin gels were formed with incorporated peptides from laminin and N-cadherin alone and in combination at concentrations up to 8.2 mol peptide per mole of fibrinogen. Neurite extension in vitro was enhanced when gels were augmented with exogenous peptide, with the maximal improvement reaching 75%. When this particular fibrin derivative was evaluated in rats in the repair of the severed dorsal root within polymeric tubes, the number of regenerated axons was enhanced by 85% relative to animals treated with tubes filled with unmodified fibrin. These results demonstrate that it is possible to enhance the biological activity of fibrin by enzymatically incorporating exogenous oligopeptide domains of morphoregulatory proteins.	ETH Zurich, Dept Mat, Zurich, Switzerland; ETH Zurich, Inst Biomed Engn, Zurich, Switzerland; Univ Zurich, Zurich, Switzerland; CALTECH, Div Chem & Chem Engn, Pasadena, CA 91125 USA; Univ Lausanne, Sch Med, CHU Vaudois, Div Surg Res, CH-1015 Lausanne, Switzerland; Univ Lausanne, Sch Med, CHU Vaudois, Gene Therapy Ctr, CH-1015 Lausanne, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich; Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Zurich; California Institute of Technology; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV)	Hubbell, JA (corresponding author), ETH Zurich, Dept Mat, Zurich, Switzerland.		Aebischer, Patrick/E-1387-2013; Bloch, Jocelyne/A-9668-2017; Hubbell, Jeffrey A/A-9266-2008	Bloch, Jocelyne/0000-0002-6405-1590; Hubbell, Jeffrey A/0000-0003-0276-5456				BLASCHUK OW, 1990, DEV BIOL, V139, P227, DOI 10.1016/0012-1606(90)90290-Y; FIELDS GB, 1990, INT J PEPT PROT RES, V35, P161, DOI 10.1111/j.1399-3011.1990.tb00939.x; GRAF J, 1987, CELL, V48, P989, DOI 10.1016/0092-8674(87)90707-0; Herbert CB, 1996, J COMP NEUROL, V365, P380, DOI 10.1002/(SICI)1096-9861(19960212)365:3<380::AID-CNE4>3.0.CO;2-0; HUBBELL JA, 1995, BIO-TECHNOL, V13, P565, DOI 10.1038/nbt0695-565; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; ICHINOSE A, 1983, FEBS LETT, V153, P369, DOI 10.1016/0014-5793(83)80645-0; KLEINMAN HK, 1989, ARCH BIOCHEM BIOPHYS, V272, P39, DOI 10.1016/0003-9861(89)90192-6; LANDER AD, 1989, TRENDS NEUROSCI, V12, P189, DOI 10.1016/0166-2236(89)90070-2; LANGER R, 1993, SCIENCE, V260, P920, DOI 10.1126/science.8493529; LETOURNEAU PC, 1990, DEV BIOL, V138, P430, DOI 10.1016/0012-1606(90)90209-2; LIESI P, 1989, FEBS LETT, V244, P141, DOI 10.1016/0014-5793(89)81180-9; LuckenbillEdds L, 1997, BRAIN RES REV, V23, P1, DOI 10.1016/S0165-0173(96)00013-6; Malinda KM, 1996, INT J BIOCHEM CELL B, V28, P957, DOI 10.1016/1357-2725(96)00042-8; MARTIN GR, 1987, ANNU REV CELL BIOL, V3, P57, DOI 10.1146/annurev.cellbio.3.1.57; MASSIA SP, 1993, J BIOL CHEM, V268, P8053; MCCORMACK ML, 1991, J COMP NEUROL, V313, P449, DOI 10.1002/cne.903130305; Palecek SP, 1997, NATURE, V385, P537, DOI 10.1038/385537a0; PEPPAS NA, 1994, SCIENCE, V263, P1715, DOI 10.1126/science.8134835; PITTMAN RN, 1989, DEV NEUROSCI-BASEL, V11, P361, DOI 10.1159/000111912; SAKATA Y, 1980, J CLIN INVEST, V65, P290, DOI 10.1172/JCI109671; Sakiyama SE, 1999, FASEB J, V13, P2214, DOI 10.1096/fasebj.13.15.2214; Sakiyama-Elbert SE, 2000, J CONTROL RELEASE, V65, P389, DOI 10.1016/S0168-3659(99)00221-7; Schense JC, 1999, BIOCONJUGATE CHEM, V10, P75, DOI 10.1021/bc9800769; SCHENSE JC, 2000, IN PRESS J BIOL CHEM; TASHIRO K, 1991, J CELL PHYSIOL, V146, P451, DOI 10.1002/jcp.1041460316; TASHIRO K, 1989, J BIOL CHEM, V264, P16174; VARON S, 1972, METHODS TECHNIQUES N, P203; WILLIAMS LR, 1985, J COMP NEUROL, V231, P209, DOI 10.1002/cne.902310208; YAMADA KM, 1991, J BIOL CHEM, V266, P12809; ZUTTER MM, 1990, AM J PATHOL, V137, P113	31	255	274	0	49	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	APR	2000	18	4					415	419		10.1038/74473	http://dx.doi.org/10.1038/74473			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	303UY	10748522				2022-12-25	WOS:000086444300024
J	Ohashi, K; Marion, PL; Nakai, H; Meuse, L; Cullen, JM; Bordier, BB; Schwall, R; Greenberg, HB; Glenn, JS; Kay, MA				Ohashi, K; Marion, PL; Nakai, H; Meuse, L; Cullen, JM; Bordier, BB; Schwall, R; Greenberg, HB; Glenn, JS; Kay, MA			Sustained survival of human hepatocytes in mice: A model for in vivo infection with human hepatitis B and hepatitis delta viruses	NATURE MEDICINE			English	Article							LIVER-REGENERATION; TRANSGENIC MICE; TRANSPLANTATION; EXPRESSION; GENOME; MOUSE; REPLICATION; DEFICIENT; SEQUENCE; DNA	Persistence of hepatocytes transplanted into the same or related species has been established(1-8). The long-term engraftment of human hepatocytes into rodents would be useful for the study of human viral hepatitis, where it might allow the species, technical and size limitations of the current animal models to be overcome. Although transgenic mice expressing the hepatitis B virus (HBV) genome produce infectious virus in their serum, the viral life cycle is not complete, in that the early stages of viral binding and entry into hepatocytes and production of an episomal transcriptional DNA template do not occur(9,10). As for hepatitis delta virus (HDV), another cause of liver disease(11,12), no effective therapy exists to eradicate infection, and it remains resistant even to recent regimens that have considerably changed the treatment of HBV (ref. 13). Here, we demonstrate long-term engraftment of primary human hepatocytes transplanted in a matrix under the kidney capsule of mice with administration of an agonistic antibody against c-Met. These mice were susceptible to HBV infection and completion of the viral life cycle. In addition, we demonstrate super-infection of the HBV-infected mice with HDV. Our results describe a new xenotransplant model that allows study of multiple aspects of human hepatitis viral infections, and may enhance studies of human liver diseases.	Stanford Univ, Sch Med, Program Human Gene Therapy, Dept Pediat & Genet, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Med, Stanford, CA 94305 USA; N Carolina State Univ, Coll Vet Med, Raleigh, NC 27606 USA; Stanford Univ, Sch Med, Div Gastroenterol, Stanford, CA 94305 USA; Vet Adm Med Ctr, Stanford, CA 94305 USA; Genentech Inc, Dept Mol Oncol, S San Francisco, CA 94080 USA	Stanford University; Stanford University; University of North Carolina; North Carolina State University; Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Roche Holding; Genentech	Kay, MA (corresponding author), Stanford Univ, Sch Med, Program Human Gene Therapy, Dept Pediat & Genet, Stanford, CA 94305 USA.		Cullen, John M/I-2051-2019	greenberg, harry/0000-0002-2128-9080; Kay, Mark/0000-0002-2799-2615	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI041320] Funding Source: NIH RePORTER; NIAID NIH HHS [AI41320] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARAKI K, 1989, P NATL ACAD SCI USA, V86, P207, DOI 10.1073/pnas.86.1.207; Casey JL, 1996, CLIN LAB MED, V16, P451, DOI 10.1016/S0272-2712(18)30279-8; Erhardt A, 1996, J CLIN MICROBIOL, V34, P1885, DOI 10.1128/JCM.34.8.1885-1891.1996; Fox IJ, 1998, NEW ENGL J MED, V338, P1422, DOI 10.1056/NEJM199805143382004; GALIBERT F, 1979, NATURE, V281, P646, DOI 10.1038/281646a0; GLENN JS, 1992, SCIENCE, V256, P1331, DOI 10.1126/science.1598578; GLENN JS, 1999, VIRAL HEPAT REV, V5, P13; GUIDOTTI LG, 1995, J VIROL, V69, P6158, DOI 10.1128/JVI.69.10.6158-6169.1995; GUPTA S, 1995, P NATL ACAD SCI USA, V92, P5860, DOI 10.1073/pnas.92.13.5860; Ilan E, 1999, HEPATOLOGY, V29, P553, DOI 10.1002/hep.510290228; LAI MMC, 1995, ANNU REV BIOCHEM, V64, P259, DOI 10.1146/annurev.bi.64.070195.001355; Lau DTY, 1999, HEPATOLOGY, V30, P546, DOI 10.1002/hep.510300217; Lieber A, 1996, J VIROL, V70, P8782, DOI 10.1128/JVI.70.12.8782-8791.1996; Michalopoulos GK, 1997, SCIENCE, V276, P60, DOI 10.1126/science.276.5309.60; NETTER HJ, 1993, J VIROL, V67, P3357, DOI 10.1128/JVI.67.6.3357-3362.1993; Overturf K, 1996, NAT GENET, V12, P266, DOI 10.1038/ng0396-266; Peeters MJTFDV, 1997, HEPATOLOGY, V25, P884, DOI 10.1002/hep.510250416; Petersen J, 1998, P NATL ACAD SCI USA, V95, P310, DOI 10.1073/pnas.95.1.310; PONDER KP, 1991, P NATL ACAD SCI USA, V88, P1217, DOI 10.1073/pnas.88.4.1217; RAY MB, 1979, HEPATITIS B VIRUS AN, P69; RHIM JA, 1994, SCIENCE, V263, P1149, DOI 10.1126/science.8108734; SANDGREN EP, 1991, CELL, V66, P245, DOI 10.1016/0092-8674(91)90615-6; SELLS MA, 1987, P NATL ACAD SCI USA, V84, P1005, DOI 10.1073/pnas.84.4.1005; VERME G, 1986, HEPATOLOGY, V6, P1303, DOI 10.1002/hep.1840060613; WANG KS, 1986, NATURE, V323, P508, DOI 10.1038/323508a0	25	134	157	0	10	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAR	2000	6	3					327	331						5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	288TL	10700236				2022-12-25	WOS:000085580500044
J	Staub, JM; Garcia, B; Graves, J; Hajdukiewicz, PTJ; Hunter, P; Nehra, N; Paradkar, V; Schlittler, M; Carroll, JA; Spatola, L; Ward, D; Ye, GN; Russell, DA				Staub, JM; Garcia, B; Graves, J; Hajdukiewicz, PTJ; Hunter, P; Nehra, N; Paradkar, V; Schlittler, M; Carroll, JA; Spatola, L; Ward, D; Ye, GN; Russell, DA			High-yield production of a human therapeutic protein in tobacco chloroplasts	NATURE BIOTECHNOLOGY			English	Article						pharmaceutical; plastid transformation; somatotropin; transplastomic; ubiquitin fusion	HUMAN GROWTH-HORMONE; PLASTID TRANSFORMATION; TRANSGENIC PLANTS; ESCHERICHIA-COLI; DIRECT EXPRESSION; GENE; TRANSLATION; METHIONINE; GENOME; RNA	Transgenic plants have become attractive systems for production of human therapeutic proteins because of the reduced risk of mammalian viral contaminants, the ability to do targe scale-up at low cost, and the tow maintenance requirements. Here we report a feasibility study for production of a human therapeutic protein through transplastomic transformation technology, which has the additional advantage of increased biological containment by apparent elimination of the transmission of transgenes through pollen. We show that chloroplasts can express a secretory protein, human somatotropin, in a soluble, biologically active, disulfide-bonded form. High concentrations of recombinant protein accumulation are observed (>7% total soluble protein), more than 300-fold higher than a similar gene expressed using a nuclear transgenic approach. The plastid-expressed somatotropin is nearly devoid of complex posttranslational modifications, effectively increasing the amount of usable recombinant protein. We also describe approaches to obtain a somatotropin with a non-methionine N terminus, similar to the native human protein. The results indicate that chloroplasts are a highly efficient vehicle for the potential production of pharmaceutical proteins in plants.	Monsanto Co, St Louis, MO 63198 USA; Monsanto Co, Integrated Prot Technol, Middleton, WI 53562 USA	Monsanto; Monsanto	Staub, JM (corresponding author), Monsanto Co, 700 Chesterfield Village Pkwy N, St Louis, MO 63198 USA.							Baker RT, 1996, CURR OPIN BIOTECH, V7, P541, DOI 10.1016/S0958-1669(96)80059-0; BECKER GW, 1986, FEBS LETT, V204, P145, DOI 10.1016/0014-5793(86)81403-X; BOSCH D, 1994, TRANSGENIC RES, V3, P304, DOI 10.1007/BF01973590; CHAWLA RK, 1983, ANNU REV MED, V34, P519, DOI 10.1146/annurev.me.34.020183.002511; CRAMER CL, 1996, ANN NY ACAD SCI, V792, P63; Cronin MJ, 1997, J PEDIATR-US, V131, pS5, DOI 10.1016/S0022-3476(97)70002-7; Daniell H, 1998, NAT BIOTECHNOL, V16, P345, DOI 10.1038/nbt0498-345; DATTANI MT, 1995, J BIOL CHEM, V270, P9222, DOI 10.1074/jbc.270.16.9222; GODDIJN OJM, 1995, TRENDS BIOTECHNOL, V13, P379, DOI 10.1016/S0167-7799(00)88985-4; GOEDDEL DV, 1979, NATURE, V281, P544, DOI 10.1038/281544a0; GRAY GL, 1984, BIO-TECHNOL, V2, P161, DOI 10.1038/nbt0284-161; Guda C, 2000, PLANT CELL REP, V19, P257, DOI 10.1007/s002990050008; Kim JM, 1997, SCIENCE, V278, P1954, DOI 10.1126/science.278.5345.1954; Lei JM, 1998, J CHROMATOGR A, V808, P121, DOI 10.1016/S0021-9673(98)00098-3; Ma J.K.C., 1996, ANN NY ACAD SCI, V792, P73; MALIGA P, 1993, TRENDS BIOTECHNOL, V11, P101, DOI 10.1016/0167-7799(93)90059-I; MASON HS, 1995, TRENDS BIOTECHNOL, V13, P388, DOI 10.1016/S0167-7799(00)88986-6; MCBRIDE KE, 1995, BIO-TECHNOL, V13, P362, DOI 10.1038/nbt0495-362; McCormick AA, 1999, P NATL ACAD SCI USA, V96, P703, DOI 10.1073/pnas.96.2.703; MEINNEL T, 1993, BIOCHIMIE, V75, P1061, DOI 10.1016/0300-9084(93)90005-D; MOORE JA, 1988, ENDOCRINOLOGY, V122, P2920, DOI 10.1210/endo-122-6-2920; Ruelland E, 1999, TRENDS PLANT SCI, V4, P136, DOI 10.1016/S1360-1385(99)01391-6; Scott SE, 1999, NAT BIOTECHNOL, V17, P390, DOI 10.1038/7952; Sidorov VA, 1999, PLANT J, V19, P209, DOI 10.1046/j.1365-313X.1999.00508.x; Sikdar SR, 1998, PLANT CELL REP, V18, P20, DOI 10.1007/s002990050525; Smyth DR, 1997, CURR BIOL, V7, pR793, DOI 10.1016/S0960-9822(06)00407-6; STAUB JM, 1994, PLANT J, V6, P547, DOI 10.1046/j.1365-313X.1994.6040547.x; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SVAB Z, 1993, P NATL ACAD SCI USA, V90, P913, DOI 10.1073/pnas.90.3.913; SVAB Z, 1990, P NATL ACAD SCI USA, V87, P8526, DOI 10.1073/pnas.87.21.8526; Tacket CO, 1998, NAT MED, V4, P607, DOI 10.1038/nm0598-607; Tritos NA, 1998, AM J MED, V105, P44, DOI 10.1016/S0002-9343(98)00135-1; Vierstra RD, 1996, PLANT MOL BIOL, V32, P275, DOI 10.1007/BF00039386; Zeitlin L, 1998, NAT BIOTECHNOL, V16, P1361, DOI 10.1038/4344; ZOUBENKO OV, 1994, NUCLEIC ACIDS RES, V22, P3819, DOI 10.1093/nar/22.19.3819	35	328	447	0	50	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAR	2000	18	3					333	338		10.1038/73796	http://dx.doi.org/10.1038/73796			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	292AC	10700152				2022-12-25	WOS:000085771100034
J	Blakely, BT; Rossi, FMV; Tillotson, B; Palmer, M; Estelles, A; Blau, HM				Blakely, BT; Rossi, FMV; Tillotson, B; Palmer, M; Estelles, A; Blau, HM			Epidermal growth factor receptor dimerization monitored in live cells	NATURE BIOTECHNOLOGY			English	Article						protein interactions; receptor dimerization; EGF receptor	PROTEIN-PROTEIN INTERACTIONS; EUKARYOTIC CELLS; MAMMALIAN-CELLS; KINASE-ACTIVITY; BINDING; COMPLEMENTATION; FLUORESCENCE; OLIGOMERIZATION; TRANSDUCTION; AGGREGATION	We present a method for monitoring receptor dimerization at the membrane of live cells. Chimeric proteins containing the epidermal growth factor (EGF) receptor extracellular and transmembrane domains fused to weakly complementing beta-galactosidase (beta-gal) deletion mutants were expressed in cells in culture. Treatment of the cells with EGF-like compounds for as little as 15 s resulted in chimeric receptor dimerization detectable as beta-gal enzymatic activity. The dose response of chimeric receptors was ligand specific. beta-galactosidase complementation was reversible upon removal of ligand and could be reinduced. Antibodies that block ligand binding inhibited receptor dimerization and beta-gal complementation. These results demonstrate that beta-gal complementation provides a rapid, simple, and sensitive assay for protein interactions and for detecting and monitoring the kinetics of receptor dimerization.	Stanford Univ, Sch Med, Dept Mol Pharmacol, Stanford, CA 94305 USA; PE Biosyst, Adv Discovery Sci, Bedford, MA 01730 USA	Stanford University	Blau, HM (corresponding author), Stanford Univ, Sch Med, Dept Mol Pharmacol, Stanford, CA 94305 USA.		rossi, francesca maria/S-8416-2019	rossi, francesca maria/0000-0001-8438-1661				ALBERTI S, 1987, CYTOMETRY, V8, P114, DOI 10.1002/cyto.990080203; Beerli RR, 1996, J BIOL CHEM, V271, P6071, DOI 10.1074/jbc.271.11.6071; CARRAWAY KL, 1993, J BIOL CHEM, V268, P23860; COCHET C, 1988, J BIOL CHEM, V263, P3290; COWLEY GP, 1986, BRIT J CANCER, V53, P223, DOI 10.1038/bjc.1986.39; FELDER S, 1992, J CELL BIOL, V117, P203, DOI 10.1083/jcb.117.1.203; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FIERING SN, 1991, CYTOMETRY, V12, P291, DOI 10.1002/cyto.990120402; GADELLA TWJ, 1995, J CELL BIOL, V129, P1543, DOI 10.1083/jcb.129.6.1543; GILL GN, 1984, J BIOL CHEM, V259, P7755; HAIGLER H, 1978, P NATL ACAD SCI USA, V75, P3317, DOI 10.1073/pnas.75.7.3317; Kiyokawa N, 1997, J BIOL CHEM, V272, P18656, DOI 10.1074/jbc.272.30.18656; LANGLEY KE, 1976, BIOCHEMISTRY-US, V15, P4866, DOI 10.1021/bi00667a018; LIVNEH E, 1986, J BIOL CHEM, V261, P2490; Miyawaki A, 1997, NATURE, V388, P882, DOI 10.1038/42264; Mohler WA, 1996, P NATL ACAD SCI USA, V93, P12423, DOI 10.1073/pnas.93.22.12423; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; NOLAN GP, 1988, P NATL ACAD SCI USA, V85, P2603, DOI 10.1073/pnas.85.8.2603; Pegram M, 1999, ONCOGENE, V18, P2241, DOI 10.1038/sj.onc.1202526; Pelletier JN, 1998, P NATL ACAD SCI USA, V95, P12141, DOI 10.1073/pnas.95.21.12141; Pollok BA, 1999, TRENDS CELL BIOL, V9, P57, DOI 10.1016/S0962-8924(98)01434-2; Remy I, 1999, SCIENCE, V283, P990, DOI 10.1126/science.283.5404.990; Rossi F, 1997, P NATL ACAD SCI USA, V94, P8405, DOI 10.1073/pnas.94.16.8405; Rossi FMV, 2000, TRENDS CELL BIOL, V10, P119, DOI 10.1016/S0962-8924(99)01707-9; ROSSI FMV, 2000, IN PRESS CHIMERIC PR; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; STOSCHECK CM, 1984, J CELL PHYSIOL, V120, P296, DOI 10.1002/jcp.1041200306; ULLMANN A, 1965, J MOL BIOL, V12, P918, DOI 10.1016/S0022-2836(65)80338-2; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; Weiss FU, 1997, CURR OPIN GENET DEV, V7, P80, DOI 10.1016/S0959-437X(97)80113-X; WINKLER ME, 1989, BIOCHEMISTRY-US, V28, P6373, DOI 10.1021/bi00441a033; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1443, DOI 10.1021/bi00379a035; ZABIN I, 1982, MOL CELL BIOCHEM, V49, P87	33	78	93	1	5	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	FEB	2000	18	2					218	222		10.1038/72686	http://dx.doi.org/10.1038/72686			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	281FH	10657132				2022-12-25	WOS:000085146900032
J	Lo, WF; Woods, AS; DeCloux, A; Cotter, RJ; Metcalf, ES; Soloski, MJ				Lo, WF; Woods, AS; DeCloux, A; Cotter, RJ; Metcalf, ES; Soloski, MJ			Molecular mimicry mediated by MHC class Ib molecules after infection with Gram-negative pathogens	NATURE MEDICINE			English	Article							HEAT-SHOCK PROTEINS; REACTIVE ARTHRITIS; T-CELLS; SALMONELLA INFECTIONS; AUTOIMMUNE-DISEASE; IDENTIFICATION; RECOGNITION; EXPRESSION; ANTIGEN; BINDING	The development of many autoimmune diseases has been etiologically linked to exposure to infectious agents(1). For example, a subset of patients with a history of Salmonella infection develop reactive arthritis(2-6). The persistence of bacterial antigen in arthritic tissue and the isolation of Salmonella or Yersinia reactive CD8(+) T cells from the joints of patients with reactive arthritis support the etiological link between Gram-negative bacterial infection and autoimmune disease(7,8). Models proposed to account for the link between infection and autoimmunity include inflammation-induced presentation of cryptic self-epitopes, antigen persistence and molecular mimicry(1). Several studies support molecular mimicry as a mechanism for the involvement of class II epitopes in infectious disease-induced self-reactivity(9-12). Here, we have identified an immunodominant epitope derived from the S. typhimurium GroEL molecule. This epitope is presented by the mouse H2-T23-encoded class Ib molecule Qa-l and was recognized by CD8(+) cytotoxic T lymphocytes induced after natural infection. S. typhimurium-stimulated cytotoxic T lymphocytes recognizing the GroEL epitope cross-reacted with a peptide derived from mouse heat shock protein 60 and recognized stressed macrophages. Our results indicate involvement of MHC class ib molecules in infection-induced autoimmune recognition and indicate a mechanism for the etiological link between Gram-negative bacterial infection and autoimmunity.	Johns Hopkins Univ, Sch Med, Dept Med, Div Rheumatol, Baltimore, MD 21218 USA; Johns Hopkins Univ, Sch Med, Grad Program Immunol, Baltimore, MD 21218 USA; Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21218 USA; Uniformed Serv Univ Hlth Sci, F Edward Hebert Sch Med, Dept Microbiol & Immunol, Bethesda, MD 20814 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Uniformed Services University of the Health Sciences - USA	Soloski, MJ (corresponding author), Johns Hopkins Univ, Sch Med, Dept Med, Div Rheumatol, Baltimore, MD 21218 USA.				NIAID NIH HHS [R01AI32951, R01AI42287, R01AI20922] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI042287, R01AI020922, R01AI032951] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALDRICH CJ, 1994, CELL, V79, P649, DOI 10.1016/0092-8674(94)90550-9; Braud VM, 1998, NATURE, V391, P795, DOI 10.1038/35869; COICO R, 1994, CURRENT PROTOCOLS IM; DECLOUX A, 1997, J IMMUNOL, V158, P2193; GRANFORS K, 1990, LANCET, V335, P685, DOI 10.1016/0140-6736(90)90804-E; Gross DM, 1998, SCIENCE, V281, P703, DOI 10.1126/science.281.5377.703; Hemmer B, 1997, J EXP MED, V185, P1651, DOI 10.1084/jem.185.9.1651; HERMANN E, 1993, APMIS, V101, P177, DOI 10.1111/j.1699-0463.1993.tb00099.x; HERMANN E, 1992, CELL IMMUNOL, V143, P253, DOI 10.1016/0008-8749(92)90023-I; IMANI F, 1991, P NATL ACAD SCI USA, V88, P10475, DOI 10.1073/pnas.88.23.10475; KOGA T, 1989, SCIENCE, V245, P1112, DOI 10.1126/science.2788923; KONDOWE GB, 1989, IRISH J MED SCI, V158, P274, DOI 10.1007/BF02942069; Kurepa Z, 1997, J IMMUNOL, V158, P3244; Lee N, 1998, J IMMUNOL, V160, P4951; LIFE PF, 1991, IMMUNOL REV, V121, P113, DOI 10.1111/j.1600-065X.1991.tb00825.x; MAKIIKOLA O, 1990, LANCET, V336, P1387, DOI 10.1016/0140-6736(90)92949-I; Rose NR, 1998, SEMIN IMMUNOL, V10, P5, DOI 10.1006/smim.1997.0100; Russmann H, 1998, SCIENCE, V281, P565, DOI 10.1126/science.281.5376.565; SIEPER J, 1995, ARTHRITIS RHEUM, V38, P1547, DOI 10.1002/art.1780381105; TAGGART AJ, 1989, BRIT MED J, V298, P674, DOI 10.1136/bmj.298.6674.674-a; WUCHERPFENNIG KW, 1995, CELL, V80, P695, DOI 10.1016/0092-8674(95)90348-8; YU D, 1991, Current Opinion in Rheumatology, V3, P581, DOI 10.1097/00002281-199108000-00004; Zhao ZS, 1998, SCIENCE, V279, P1344, DOI 10.1126/science.279.5355.1344; Zugel U, 1997, INFECT IMMUN, V65, P3947	25	129	133	0	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	FEB	2000	6	2					215	218		10.1038/72329	http://dx.doi.org/10.1038/72329			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	278YQ	10655113				2022-12-25	WOS:000085016900045
J	Miao, H; Burnett, E; Kinch, M; Simon, E; Wang, BC				Miao, H; Burnett, E; Kinch, M; Simon, E; Wang, BC			Activation of EphA2 kinase suppresses integrin function and causes focal-adhesion-kinase dephosphorylation	NATURE CELL BIOLOGY			English	Article							RECEPTOR TYROSINE KINASES; VASCULAR ENDOTHELIAL-CELLS; NEURAL CREST MIGRATION; SIGNAL-TRANSDUCTION; CYTOPLASMIC DOMAINS; AXON OUTGROWTH; PROTEIN; PHOSPHORYLATION; LIGANDS; FAMILY	Interactions between receptor tyrosine kinases of the Eph family and their ligands, ephrins, are implicated in establishment of organ boundaries and repulsive guidance of cell migration during development, but the mechanisms by which this is achieved are unclear. Here we show that activation of endogenous EphA2 kinase induces an inactive conformation of integrins and inhibits cell spreading, migration and integrin-mediated adhesion. Moreover, EphA2 is constitutively associated with focal-adhesion kinase (FAK) in vesting cells. Within one minute after stimulation of EphA2 with its ligand, ephrin-A1, the protein tyrosine phosphatase SHP2 is recruited to EphA2; this is followed by dephosphorylation of FAK and paxillin, and dissociation of the FAK-EphA2 complex. We conclude that Eph kinases mediate some of their functions by negatively regulating integrins and FAK.	Case Western Reserve Univ, Sch Med, Rammelkamp Ctr Res, Cleveland, OH 44109 USA; Purdue Univ, Dept Basic Med Sci, Ctr Canc, W Lafayette, IN 47907 USA	Case Western Reserve University; MetroHealth System; Purdue University System; Purdue University; Purdue University West Lafayette Campus	Wang, BC (corresponding author), Case Western Reserve Univ, Sch Med, Rammelkamp Ctr Res, MetroHlth Campus,2500 MetroHlth Dr, Cleveland, OH 44109 USA.			Kinch, Michael/0000-0003-3939-3756	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK054178] Funding Source: NIH RePORTER; NIDDK NIH HHS [P50 DK54178] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CALALB MB, 1995, MOL CELL BIOL, V15, P954; Cary LA, 1996, J CELL SCI, V109, P1787; Cirri P, 1998, J BIOL CHEM, V273, P32522, DOI 10.1074/jbc.273.49.32522; DAVIS S, 1994, SCIENCE, V266, P816, DOI 10.1126/science.7973638; DEFILIPPI P, 1995, EXP CELL RES, V221, P141, DOI 10.1006/excr.1995.1361; DRESCHER U, 1995, CELL, V82, P359, DOI 10.1016/0092-8674(95)90425-5; FAULL RJ, 1993, J CELL BIOL, V121, P155, DOI 10.1083/jcb.121.1.155; Flanagan JG, 1997, CELL, V90, P403; Flenniken AM, 1996, DEV BIOL, V179, P382, DOI 10.1006/dbio.1996.0269; GAILIT J, 1988, J BIOL CHEM, V263, P12927; Gale NW, 1997, CELL TISSUE RES, V290, P227, DOI 10.1007/s004410050927; Gale NW, 1996, NEURON, V17, P9, DOI 10.1016/S0896-6273(00)80276-7; Gilmore AP, 1996, MOL BIOL CELL, V7, P1209, DOI 10.1091/mbc.7.8.1209; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; Hock B, 1998, P NATL ACAD SCI USA, V95, P9779, DOI 10.1073/pnas.95.17.9779; Holland SJ, 1997, EMBO J, V16, P3877, DOI 10.1093/emboj/16.13.3877; Huynh-Do U, 1999, EMBO J, V18, P2165, DOI 10.1093/emboj/18.8.2165; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; Krull CE, 1997, CURR BIOL, V7, P571, DOI 10.1016/S0960-9822(06)00256-9; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; LEMMON V, 1989, NEURON, V2, P1597, DOI 10.1016/0896-6273(89)90048-2; LINDBERG RA, 1990, MOL CELL BIOL, V10, P6316, DOI 10.1128/MCB.10.12.6316; Meima L, 1997, MOL CELL NEUROSCI, V9, P314, DOI 10.1006/mcne.1997.0621; Meima L, 1997, EUR J NEUROSCI, V9, P177, DOI 10.1111/j.1460-9568.1997.tb01365.x; Mellitzer G, 1999, NATURE, V400, P77, DOI 10.1038/21907; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; OTOOLE TE, 1994, J CELL BIOL, V124, P1047, DOI 10.1083/jcb.124.6.1047; PANDEY A, 1994, J BIOL CHEM, V269, P30154; PANDEY A, 1995, CURR BIOL, V5, P986, DOI 10.1016/S0960-9822(95)00195-3; Retta SF, 1996, EXP CELL RES, V229, P307, DOI 10.1006/excr.1996.0376; Richardson A, 1997, MOL CELL BIOL, V17, P6906, DOI 10.1128/MCB.17.12.6906; RICHARDSON A, 1995, BIOESSAYS, V17, P229, DOI 10.1002/bies.950170309; Richardson A, 1996, NATURE, V380, P538, DOI 10.1038/380538a0; ROMER LH, 1994, MOL BIOL CELL, V5, P349, DOI 10.1091/mbc.5.3.349; SCHALLER MD, 1995, MOL CELL BIOL, V15, P2635; SCHALLER MD, 1995, J CELL BIOL, V130, P1181, DOI 10.1083/jcb.130.5.1181; Schlaepfer DD, 1998, TRENDS CELL BIOL, V8, P151, DOI 10.1016/S0962-8924(97)01172-0; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; Smith A, 1997, CURR BIOL, V7, P561, DOI 10.1016/S0960-9822(06)00255-7; Stein E, 1996, J BIOL CHEM, V271, P23588, DOI 10.1074/jbc.271.38.23588; Stein E, 1998, GENE DEV, V12, P667, DOI 10.1101/gad.12.5.667; Tonks NK, 1996, CELL, V87, P365, DOI 10.1016/S0092-8674(00)81357-4; Torres R, 1998, NEURON, V21, P1453, DOI 10.1016/S0896-6273(00)80663-7; VANDEWIELVANKEMENADE E, 1992, J CELL BIOL, V117, P461, DOI 10.1083/jcb.117.2.461; Wang HU, 1998, CELL, V93, P741, DOI 10.1016/S0092-8674(00)81436-1; Wang HU, 1997, NEURON, V18, P383, DOI 10.1016/S0896-6273(00)81240-4; Xu QL, 1999, NATURE, V399, P267, DOI 10.1038/20452; YAMAUCHI K, 1995, J BIOL CHEM, V270, P17716, DOI 10.1074/jbc.270.30.17716; Zisch AH, 1998, ONCOGENE, V16, P2657, DOI 10.1038/sj.onc.1201823	49	452	471	0	15	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	FEB	2000	2	2					62	69		10.1038/35000008	http://dx.doi.org/10.1038/35000008			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	281GA	10655584				2022-12-25	WOS:000085148500009
J	Wu, JY; Ribar, TJ; Cummings, DE; Burton, KA; McKnight, GS; Means, AR				Wu, JY; Ribar, TJ; Cummings, DE; Burton, KA; McKnight, GS; Means, AR			Spermiogenesis and exchange of basic nuclear proteins are impaired in male germ cells lacking Camk4	NATURE GENETICS			English	Article							KINASE-IV; MICE; PHOSPHORYLATION; ACTIVATION; PROTAMINE-1; EXPRESSION; PRECURSOR; COMPLEX; SPERM; MOUSE	Ca2+/calmodulin-dependent protein kinase IV (Camk4; also known as CaMKIV), a multifunctional serine/threonine protein kinase with limited tissue distribution, has been implicated in transcriptional regulation in lymphocytes, neurons and male germ cells(1-6). In the mouse testis, however, Camk4 is expressed in spermatids and associated with chromatin and nuclear matrix.(7) Elongating spermatids are not transcriptionally active(8), raising the possibility that Camk4 has a novel function in male germ cells. To investigate the role of Camk4 in spermatogenesis, we have generated mice with a targeted deletion of the gene Camk4. Male Camk4(-/-) mice are infertile with impairment of spermiogenesis in late elongating spermatids. The sequential deposition of sperm basic nuclear proteins on chromatin is disrupted, with a specific loss of protamine-2 and prolonged retention of transition protein-2 (Tnp2) in step-15 spermatids. Protamine-2 is phosphorylated by Camk4 in vitro, implicating a connection between Camk4 signalling and the exchange of basic nuclear proteins in mammalian male germ cells. Defects in protamine-2 have been identified in sperm of infertile men, suggesting that our results may have clinical implications for the understanding of human male infertility.	Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA; VA Med Ctr, Dept Med, Seattle, WA USA; Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA	Duke University; University of Washington; University of Washington Seattle	Means, AR (corresponding author), Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA.				NICHD NIH HHS [HD07503] Funding Source: Medline	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Anderson KA, 1997, MOL ENDOCRINOL, V11, P725, DOI 10.1210/me.11.6.725; Bench G, 1998, MOL REPROD DEV, V50, P345, DOI 10.1002/(SICI)1098-2795(199807)50:3<345::AID-MRD11>3.0.CO;2-3; Bito H, 1996, CELL, V87, P1203, DOI 10.1016/S0092-8674(00)81816-4; Blendy JA, 1996, NATURE, V380, P162, DOI 10.1038/380162a0; Chatila T, 1996, J BIOL CHEM, V271, P21542, DOI 10.1074/jbc.271.35.21542; de Yebra L, 1998, FERTIL STERIL, V69, P755, DOI 10.1016/S0015-0282(98)00012-0; Edelman AM, 1996, J BIOL CHEM, V271, P10806, DOI 10.1074/jbc.271.18.10806; ELSEVIER SM, 1991, EUR J BIOCHEM, V196, P167, DOI 10.1111/j.1432-1033.1991.tb15800.x; ENSLEN H, 1994, J BIOL CHEM, V269, P15520; GREEN D, 1994, APPL COGNITIVE PSYCH, V8, P37, DOI 10.1002/acp.2350080105; KENNEDY BP, 1981, J BIOL CHEM, V256, P9254; Lee K, 1995, P NATL ACAD SCI USA, V92, P12451, DOI 10.1073/pnas.92.26.12451; LOUIE AJ, 1972, J BIOL CHEM, V247, P7962; Meistrich M., 1989, HISTONES OTHER BASIC, P165; Nantel F, 1996, NATURE, V380, P159, DOI 10.1038/380159a0; PIRHONEN A, 1994, EUR J BIOCHEM, V223, P165, DOI 10.1111/j.1432-1033.1994.tb18979.x; Reyes JC, 1997, J CELL BIOL, V137, P263, DOI 10.1083/jcb.137.2.263; Russell L.D., 1990, HISTOLOGICAL HISTOPA, P119; SODERSTROM KO, 1976, MOL CELL ENDOCRINOL, V5, P181, DOI 10.1016/0303-7207(76)90082-4; SUN PQ, 1994, GENE DEV, V8, P2527, DOI 10.1101/gad.8.21.2527; SUN ZM, 1995, MOL CELL BIOL, V15, P561, DOI 10.1128/MCB.15.1.561; TOKUMITSU H, 1995, J BIOL CHEM, V270, P19320, DOI 10.1074/jbc.270.33.19320; Westphal RS, 1998, SCIENCE, V280, P1258, DOI 10.1126/science.280.5367.1258; Wu JY, 2000, J BIOL CHEM, V275, P7994, DOI 10.1074/jbc.275.11.7994; Xu X, 1999, NAT GENET, V23, P118, DOI 10.1038/12729; YELICK PC, 1987, MOL CELL BIOL, V7, P2173, DOI 10.1128/MCB.7.6.2173; Zhong J, 1999, NAT GENET, V22, P171, DOI 10.1038/9684	27	183	186	0	4	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	AUG	2000	25	4					448	452		10.1038/78153	http://dx.doi.org/10.1038/78153			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	341WY	10932193				2022-12-25	WOS:000088615000024
J	Herreman, A; Serneels, L; Annaert, W; Collen, D; Schoonjans, L; De Strooper, B				Herreman, A; Serneels, L; Annaert, W; Collen, D; Schoonjans, L; De Strooper, B			Total inactivation of gamma-secretase activity in presenilin-deficient embryonic stem cells	NATURE CELL BIOLOGY			English	Article							AMYLOID PRECURSOR PROTEIN; INTRACELLULAR DOMAIN; PROTEOLYTIC RELEASE; ALZHEIMERS-DISEASE; BETA-PROTEIN; NOTCH-1		Katholieke Univ Leuven, CME, Neuronal Cell Biol Lab, B-3000 Louvain, Belgium; Flanders Interuniv Inst Biotechnol VIB4, B-3000 Louvain, Belgium; Thromb X NV, B-3000 Louvain, Belgium	KU Leuven	De Strooper, B (corresponding author), Katholieke Univ Leuven, CME, Neuronal Cell Biol Lab, Herestr 49, B-3000 Louvain, Belgium.	Bart.Destrooper@med.kuleuven.ac.be	De Strooper, Bart/F-6507-2012	De Strooper, Bart/0000-0001-5455-5819; Serneels, Lutgarde/0000-0002-5463-4231				Annaert WG, 1999, J CELL BIOL, V147, P277, DOI 10.1083/jcb.147.2.277; Brown MS, 2000, CELL, V100, P391, DOI 10.1016/S0092-8674(00)80675-3; CAI XD, 1993, SCIENCE, V259, P514, DOI 10.1126/science.8424174; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; Donoviel DB, 1999, GENE DEV, V13, P2801, DOI 10.1101/gad.13.21.2801; Haass C, 1999, SCIENCE, V286, P916, DOI 10.1126/science.286.5441.916; Herreman A, 1999, P NATL ACAD SCI USA, V96, P11872, DOI 10.1073/pnas.96.21.11872; JARRIAULT S, 1995, NATURE, V377, P355, DOI 10.1038/377355a0; Kimberly WT, 2000, J BIOL CHEM, V275, P3173, DOI 10.1074/jbc.275.5.3173; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; Song WH, 1999, P NATL ACAD SCI USA, V96, P6959, DOI 10.1073/pnas.96.12.6959; TEINER H, 1999, J BIOL CHEM, V274, P28669; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077	15	433	455	0	2	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	JUL	2000	2	7					461	462		10.1038/35017105	http://dx.doi.org/10.1038/35017105			2	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	333MK	10878813				2022-12-25	WOS:000088133700024
J	Lee, CK; Weindruch, R; Prolla, TA				Lee, CK; Weindruch, R; Prolla, TA			Gene-expression profile of the ageing brain in mice	NATURE GENETICS			English	Article							DIETARY RESTRICTION; ALZHEIMERS-DISEASE; CALORIC RESTRICTION; NEURONS; INFLAMMATION; RESPONSES; LESIONS; ROLES; BETA; RAT	Ageing of the brain leads to impairments in cognitive and motor skills, and is the major risk factor for several common neurological disorders such as Alzheimer disease (AD) and Parkinson disease (PD). Recent studies suggest that normal brain ageing is associated with subtle morphological and functional alterations in specific neuronal circuits, as opposed to large-scale neuronal loss'. In fact, ageing of the central nervous system in diverse mammalian species shares many features, such as atrophy of pyramidal neurons, synaptic atrophy, decrease of striatal dopamine receptors. accumulation of fluorescent pigments, cytoskeletal abnormalities, and reactive astrocytes and microglia(2). To provide the first global analysis of brain ageing at the molecular level, we used oligonucleotide arrays representing 6,347 genes to determine the gene-expression profile of the ageing neocortex and cerebellum in mice. Ageing resulted in a gene-expression profile indicative of an inflammatory response, oxidative stress and reduced neurotrophic support in both brain regions. At the transcriptional level, brain ageing in mice displays parallels with human neurodegenerative disorders. Caloric restriction, which retards the ageing process in mammals, selectively attenuated the age-associated induction of genes encoding inflammatory and stress responses.	Univ Wisconsin, Dept Med, Madison, WI 53706 USA; Univ Wisconsin, Ctr Environm Toxicol, Madison, WI 53706 USA; Univ Wisconsin, Dept Genet, Madison, WI 53706 USA; Univ Wisconsin, Dept Med Genet, Madison, WI 53706 USA; Univ Wisconsin, Wisconsin Reg Primate Res Ctr, Madison, WI 53706 USA; Vet Adm Hosp, Ctr Geriatr Res Educ & Clin, Madison, WI USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Geriatric Research Education & Clinical Center	Weindruch, R (corresponding author), Univ Wisconsin, Dept Med, Madison, WI 53706 USA.		Lee, Cheol-Koo/F-2103-2013	Lee, Cheol-Koo/0000-0003-3927-9195	NCI NIH HHS [R01CA78723] Funding Source: Medline; NIA NIH HHS [P01AG11915] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA078723] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG011915] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Blumenthal HT, 1997, J GERONTOL A-BIOL, V52, pB1, DOI 10.1093/gerona/52A.1.B1; DISTERHOFT JF, 1994, CALCIUM HYPOTHESIS A; Duan WZ, 1999, J NEUROSCI RES, V57, P195, DOI 10.1002/(SICI)1097-4547(19990715)57:2&lt;195::AID-JNR5&gt;3.0.CO;2-P; Finch Caleb E., 1999, P613; Fox JW, 1998, NEURON, V21, P1315, DOI 10.1016/S0896-6273(00)80651-0; Gaubatz JW, 1995, MOL BASIS AGING, P71; HALLGREN R, 1982, INFLAMMATION, V6, P291, DOI 10.1007/BF00916410; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; Hermann DM, 1999, NEUROSCIENCE, V88, P599, DOI 10.1016/S0306-4522(98)00249-8; Huang J, 1999, SCIENCE, V285, P595, DOI 10.1126/science.285.5427.595; INGRAM DK, 1987, J GERONTOL, V42, P78, DOI 10.1093/geronj/42.1.78; Kaltschmidt B, 1999, ANTIOXID REDOX SIGN, V1, P129, DOI 10.1089/ars.1999.1.2-129; Lee CK, 1999, SCIENCE, V285, P1390, DOI 10.1126/science.285.5432.1390; LEMERE CA, 1995, AM J PATHOL, V146, P848; Lipshutz RJ, 1999, NAT GENET, V21, P20, DOI 10.1038/4447; Mattson MP, 1997, BRAIN RES REV, V23, P47, DOI 10.1016/S0165-0173(96)00014-8; McEwen BS, 1999, FRONT NEUROENDOCRIN, V20, P49, DOI 10.1006/frne.1998.0173; MOROIFETTERS SE, 1989, NEUROBIOL AGING, V10, P317, DOI 10.1016/0197-4580(89)90042-0; Morrison JH, 1997, SCIENCE, V278, P412, DOI 10.1126/science.278.5337.412; NICHOLS NR, 1993, NEUROBIOL AGING, V14, P421, DOI 10.1016/0197-4580(93)90100-P; Pasinetti GM, 1999, SYNAPSE, V31, P278, DOI 10.1002/(SICI)1098-2396(19990315)31:4<278::AID-SYN5>3.0.CO;2-0; Rogers J, 1996, NEUROBIOL AGING, V17, P681, DOI 10.1016/0197-4580(96)00115-7; Ryseck RP, 1996, BRAZ J MED BIOL RES, V29, P895; Sohal RS, 1996, SCIENCE, V273, P59, DOI 10.1126/science.273.5271.59; Suo ZM, 1998, BRAIN RES, V807, P110, DOI 10.1016/S0006-8993(98)00780-X; WEINDRUCH R, 1988, RETARDATION AGING DI	26	835	871	0	60	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUL	2000	25	3					294	297		10.1038/77046	http://dx.doi.org/10.1038/77046			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	329RD	10888876				2022-12-25	WOS:000087920900016
J	Ohh, M; Park, CW; Ivan, N; Hoffman, MA; Kim, TY; Huang, LE; Pavletich, N; Chau, V; Kaelin, WG				Ohh, M; Park, CW; Ivan, N; Hoffman, MA; Kim, TY; Huang, LE; Pavletich, N; Chau, V; Kaelin, WG			Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein	NATURE CELL BIOLOGY			English	Article							TUMOR-SUPPRESSOR PROTEIN; FACTOR 1-ALPHA; PROTEASOME PATHWAY; ELONGIN-B; TRANSCRIPTION; COMPLEX; GENE; IDENTIFICATION; STABILIZATION; DISEASE	von Hippel-Lindau (VHL) disease is a hereditary cancer syndrome that is characterized by the development of multiple vascular tumors and is caused by inactivation of the von Hippel-Lindau protein (pVHL). Here we show that pVHL, through its beta-domain, binds directly to hypoxia-inducible factor (HIF), thereby targeting HIF for ubiquitination in an alpha-domain-dependent manner. This is the first function to be ascribed to the pVHL beta-domain. Furthermore, we provide the first direct evidence that pVHL has a function analogous to that of an F-box protein, namely, to recruit substrates to a ubiquitination machine. These results strengthen the link between overaccumulation of HIF and development of VHL disease.	Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Howard Hughes Med Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Hematol, Boston, MA 02115 USA; Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA; Penn State Univ, Sch Med, Dept Cellular & Mol Physiol, Hershey, PA 17033 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Howard Hughes Medical Institute; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Memorial Sloan Kettering Cancer Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Kaelin, WG (corresponding author), Brigham & Womens Hosp, Dept Med, 75 Francis St, Boston, MA 02115 USA.	william_kaelin@dfci.harvard.edu	高, 雨莉/HGU-8187-2022; Ivan, Mircea/A-8109-2012; Kim, Tae-You/J-2750-2012	Huang, Eric/0000-0002-6444-1708; Ivan, Mircea/0000-0003-3424-6642				An WG, 1998, NATURE, V392, P405, DOI 10.1038/32925; Chandel NS, 1998, P NATL ACAD SCI USA, V95, P11715, DOI 10.1073/pnas.95.20.11715; CROSSEY PA, 1994, HUM MOL GENET, V3, P1303; DUAN DR, 1995, SCIENCE, V269, P1402, DOI 10.1126/science.7660122; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; ILIOPOULOS O, 1995, NAT MED, V1, P822, DOI 10.1038/nm0895-822; Iwai K, 1999, P NATL ACAD SCI USA, V96, P12436, DOI 10.1073/pnas.96.22.12436; Kaelin WG, 1999, NATURE, V399, P203, DOI 10.1038/20309; Kallio PJ, 1999, J BIOL CHEM, V274, P6519, DOI 10.1074/jbc.274.10.6519; Kamura T, 1998, GENE DEV, V12, P3872, DOI 10.1101/gad.12.24.3872; KIBEL A, 1995, SCIENCE, V269, P1444, DOI 10.1126/science.7660130; Lisztwan J, 1999, GENE DEV, V13, P1822, DOI 10.1101/gad.13.14.1822; Lonergan KM, 1998, MOL CELL BIOL, V18, P732, DOI 10.1128/MCB.18.2.732; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Ohh M, 1999, J CLIN INVEST, V104, P1583, DOI 10.1172/JCI8161; Ohh M, 1999, MOL MED TODAY, V5, P257, DOI 10.1016/S1357-4310(99)01481-1; Pugh CW, 1997, J BIOL CHEM, V272, P11205; Ritter MM, 1996, J CLIN ENDOCR METAB, V81, P1035, DOI 10.1210/jc.81.3.1035; Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642; Stebbins CE, 1999, SCIENCE, V284, P455, DOI 10.1126/science.284.5413.455	20	1207	1250	3	90	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	JUL	2000	2	7					423	427		10.1038/35017054	http://dx.doi.org/10.1038/35017054			5	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	333MK	10878807				2022-12-25	WOS:000088133700018
J	Paloneva, J; Kestila, M; Wu, J; Salminen, A; Bohling, T; Ruotsalainen, V; Hakola, P; Bakker, ABH; Phillips, JH; Pekkarinen, P; Lanier, LL; Timonen, T; Peltonen, L				Paloneva, J; Kestila, M; Wu, J; Salminen, A; Bohling, T; Ruotsalainen, V; Hakola, P; Bakker, ABH; Phillips, JH; Pekkarinen, P; Lanier, LL; Timonen, T; Peltonen, L			Loss-of-function mutations in TYROBP (DAP12) result in a presenile dementia with bone cysts	NATURE GENETICS			English	Article							POLYCYSTIC LIPOMEMBRANOUS OSTEODYSPLASIA; NATURAL-KILLER-CELLS; SCLEROSING LEUKOENCEPHALOPATHY; MEMBRANOUS LIPODYSTROPHY; CUTTING EDGE; PLO-SL; PROTEIN; GENE; RECEPTORS; ACTIVATION	Polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy (PLOSL; MIM 221770), also known as Nasu-Hakola disease, is a recessively inherited disease characterized by a combination of psychotic symptoms rapidly progressing to presenile dementia and bone cysts restricted to wrists and ankles(1-3). PLOSL has a global distribution, although most of the patients have been diagnosed in Finland(4) and Japan. with an estimated population prevalence of 2x10(-6) (ref. 2) in the Finns. We have previously identified a shared 153-kb ancestor haplotype in all Finnish disease alleles between markers D1951175 and D195608 on chromosome 19q13.1 (refs 5,6). Here we characterize the molecular defect in PLOSL by identifying one large deletion in all Finnish PLOSL alleles and another mutation in a Japanese patient, both representing loss-of-function mutations, in the gene encoding TYRO protein tyrosine kinase binding protein(7) (TYROBP; formerly DAP12). TYROBP is a transmembrane protein that has been recognized as a key activating signal transduction element in natural killer (NK) cells(8). On the plasma membrane of NK cells, TYROBP associates with activating receptors recognizing major histocompatibility complex (MHC) class I molecules(7,9). No abnormalities in NK cell function were detected in PLOSL patients homozygous for a null allele of TYROBP.	Natl Publ Hlth Inst, Dept Human Mol Genet, Helsinki, Finland; Univ Calif Los Angeles, Sch Med, Dept Human Genet, Gonda Ctr, Los Angeles, CA USA; Univ Helsinki, Haartman Inst, Dept Med Genet, Helsinki, Finland; Univ Helsinki, Haartman Inst, Dept Pathol, Helsinki, Finland; Univ Calif San Francisco, Dept Microbiol & Immunol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Canc Res Ctr, San Francisco, CA 94143 USA; Dept Biochem, Oulu, Finland; Bioctr Oulu, Oulu, Finland; Univ Kuopio, Dept Forens Psychiat, FIN-70211 Kuopio, Finland; DNAX Res Inst Molec & Cellular Biol Inc, Dept Immunobiol, Palo Alto, CA USA	Finland National Institute for Health & Welfare; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of Helsinki; University of Helsinki; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Finland National Institute for Health & Welfare; University of Oulu; University of Eastern Finland; Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.	Peltonen, L (corresponding author), Natl Publ Hlth Inst, Dept Human Mol Genet, Mannerheimintie 166, Helsinki, Finland.	lpeltonen@mednet.ucla.edu	Lanier, Lewis L/E-2139-2014; Paloneva, Juha/K-2419-2019; Bakker, Arnold B./F-8494-2010; Ijäs, Petra/F-8280-2015	Lanier, Lewis L/0000-0003-1308-3952; Bakker, Arnold B./0000-0003-1489-1847; Ijäs, Petra/0000-0002-7292-1971; Paloneva, Juha/0000-0003-3340-9390				ABRAMSKY O, 1989, DISSECTION TISSUE CU, P1; Bakker ABH, 1999, P NATL ACAD SCI USA, V96, P9792, DOI 10.1073/pnas.96.17.9792; Burge C, 1997, J MOL BIOL, V268, P78, DOI 10.1006/jmbi.1997.0951; Campbell KS, 1999, INT J BIOCHEM CELL B, V31, P631, DOI 10.1016/S1357-2725(99)00022-9; Chang CW, 1999, J IMMUNOL, V163, P4651; Colonna M, 1998, NATURE, V391, P642, DOI 10.1038/35515; Cuadros MA, 1998, PROG NEUROBIOL, V56, P173, DOI 10.1016/S0301-0082(98)00035-5; Dietrich J, 2000, J IMMUNOL, V164, P9, DOI 10.4049/jimmunol.164.1.9; EDVARDSEN P, 1983, INT ORTHOP, V7, P99; Hakola H P, 1972, Acta Psychiatr Scand Suppl, V232, P1; Hakola P., 1990, MONOGRAPHS PSYCHIAT, V17, P1; Harris NL, 1997, GENOME RES, V7, P754, DOI 10.1101/gr.7.7.754; Heymann D, 1998, CYTOKINE, V10, P155, DOI 10.1006/cyto.1997.0277; KALIMO H, 1994, ACTA NEUROL SCAND, V89, P353; Kestila M, 1998, MOL CELL, V1, P575, DOI 10.1016/S1097-2765(00)80057-X; Lanier LL, 1998, IMMUNITY, V8, P693, DOI 10.1016/S1074-7613(00)80574-9; Lanier LL, 1998, NATURE, V391, P703, DOI 10.1038/35642; Lenkkeri U, 1998, HUM GENET, V102, P192, DOI 10.1007/s004390050676; MAKELA P, 1982, SKELETAL RADIOL, V8, P51; McVicar DW, 1998, J BIOL CHEM, V273, P32934, DOI 10.1074/jbc.273.49.32934; NASU T, 1973, ACTA PATHOL JAPON, V23, P539; Nylander PO, 1996, CLIN GENET, V50, P353; Pekkarinen P, 1998, AM J HUM GENET, V62, P362, DOI 10.1086/301722; Pekkarinen P, 1998, GENOMICS, V54, P307, DOI 10.1006/geno.1998.5591; Peltonen L, 1999, HUM MOL GENET, V8, P1913, DOI 10.1093/hmg/8.10.1913; Rolstad B, 1998, SCAND J IMMUNOL, V47, P412; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Smith KM, 1998, J IMMUNOL, V161, P7; Verloes A, 1997, J MED GENET, V34, P753, DOI 10.1136/jmg.34.9.753; Wu J, 1999, SCIENCE, V285, P730, DOI 10.1126/science.285.5428.730	30	336	348	0	17	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JUL	2000	25	3					357	361		10.1038/77153	http://dx.doi.org/10.1038/77153			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	329RD	10888890				2022-12-25	WOS:000087920900030
J	Rogge, L; Bianchi, E; Biffi, M; Bono, E; Chang, SYP; Alexander, H; Santini, C; Ferrari, G; Sinigaglia, L; Seiler, M; Neeb, M; Mous, J; Sinigaglia, F; Certa, U				Rogge, L; Bianchi, E; Biffi, M; Bono, E; Chang, SYP; Alexander, H; Santini, C; Ferrari, G; Sinigaglia, L; Seiler, M; Neeb, M; Mous, J; Sinigaglia, F; Certa, U			Transcript imaging of the development of human T helper cells using oligonucleotide arrays	NATURE GENETICS			English	Article							REGULATORY FACTOR-I; SELECTIVE EXPRESSION; IMMUNE-RESPONSES; P-SELECTIN; INTERLEUKIN-12; T-HELPER-1; CYTOKINE; RECEPTOR; TYPE-1; LYMPHOCYTES	Many pathological processes, including those causing allergies and autoimmune diseases, are associated with the presence of specialized subsets of T helper cells at the site of inflammation(1) Understanding the genetic program that controls the functional properties of T helper type 1 (Th1) versus T helper type 2 (Th2) cells may provide insight into the pathophysiology of inflammatory diseases. We compared the gene-expression profiles of human Th1 and Th2 cells using high-density oligonucleotide arrays with the capacity to display transcript levels of 6,000 human genes'. Here we analyse the data sets derived from five independent experiments using statistical algorithms. This approach resulted in the identification of 215 differentially expressed genes, encoding proteins involved in transcriptional regulation, apoptosis, proteolysis, and cell adhesion and migration. A-subset of these genes was further upregulated by exposure of differentiated Th1 cells to interleukin-12 (IL-12), as confirmed by kinetic PCR analysis, indicating that IL-12 modulates the effector functions of Th1 cells in the absence of antigenic stimulation. Functional assays and in vivo expression of selected genes have validated the biological relevance of our study. Our results provide new insight into the transcriptional program controlling the functional diversity of subsets of T helper cells.	Roche Milano Ric, Milan, Italy; Ist Sci San Raffaele, DIBIT, Milan, Italy; Roche Mol Syst, Alameda, CA USA; TIGET HS Raffaele, Milan, Italy; Ist Ortoped Gaetano Pini, Chair Rheumatol, Milan, Italy; F Hoffmann La Roche & Co Ltd, PRPZB, CH-4002 Basel, Switzerland; F Hoffmann La Roche & Co Ltd, Roche Genet, CH-4002 Basel, Switzerland	Roche Holding; Vita-Salute San Raffaele University; Roche Holding; Fondazione Telethon; San Raffaele Telethon Institute For Gene Therapy (Sr-Tiget); ASST Gaetano Pini CTO; Roche Holding; Roche Holding	Rogge, L (corresponding author), Roche Milano Ric, Milan, Italy.		Rogge, Lars/GYJ-6142-2022; Ferrari, Giuliana/AAB-5546-2019	Ferrari, Giuliana/0000-0003-0790-3133; Biffi, Mauro/0000-0002-6914-2854; Rogge, Lars/0000-0003-1262-9204	Telethon [TGT06S01] Funding Source: Medline	Telethon(Fondazione Telethon)		Abbas AK, 1996, NATURE, V383, P787, DOI 10.1038/383787a0; Austrup F, 1997, NATURE, V385, P81, DOI 10.1038/385081a0; BERLIN C, 1993, CELL, V74, P185, DOI 10.1016/0092-8674(93)90305-A; Butcher EC, 1996, SCIENCE, V272, P60, DOI 10.1126/science.272.5258.60; Coccia EM, 1999, J BIOL CHEM, V274, P6698, DOI 10.1074/jbc.274.10.6698; Colantonio L, 1999, BLOOD, V94, P2981, DOI 10.1182/blood.V94.9.2981.421k27_2981_2989; Coligan JKA, 1991, CURRENT PROTOCOLS IM; Dolhain RJEM, 1996, ARTHRITIS RHEUM-US, V39, P1961, DOI 10.1002/art.1780391204; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Fambrough D, 1999, CELL, V97, P727, DOI 10.1016/S0092-8674(00)80785-0; Gately MK, 1998, ANNU REV IMMUNOL, V16, P495, DOI 10.1146/annurev.immunol.16.1.495; HIGUCHI R, 1999, PCR APPL PROTOCOLS F, P263; Lipshutz RJ, 1999, NAT GENET, V21, P20, DOI 10.1038/4447; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; Lohoff M, 1997, IMMUNITY, V6, P681, DOI 10.1016/S1074-7613(00)80444-6; Maly P, 1996, CELL, V86, P643, DOI 10.1016/S0092-8674(00)80137-3; O'Garra A, 1998, IMMUNITY, V8, P275, DOI 10.1016/S1074-7613(00)80533-6; Rogge L, 1997, J EXP MED, V185, P825, DOI 10.1084/jem.185.5.825; Rogge L, 1998, J IMMUNOL, V161, P6567; ROMAGNANI S, 1994, ANNU REV IMMUNOL, V12, P227, DOI 10.1146/annurev.iy.12.040194.001303; Sallusto F, 1998, IMMUNOL TODAY, V19, P568, DOI 10.1016/S0167-5699(98)01346-2; SEDER RA, 1994, ANNU REV IMMUNOL, V12, P635, DOI 10.1146/annurev.iy.12.040194.003223; SIMON AK, 1994, P NATL ACAD SCI USA, V91, P8562, DOI 10.1073/pnas.91.18.8562; Taki S, 1997, IMMUNITY, V6, P673, DOI 10.1016/S1074-7613(00)80443-4; TRINCHIERI G, 1995, ANNU REV IMMUNOL, V13, P251, DOI 10.1146/annurev.immunol.13.1.251; Van Damme J, 1999, Chem Immunol, V72, P42, DOI 10.1159/000058725; Verzeletti S, 1998, HUM GENE THER, V9, P2243, DOI 10.1089/hum.1998.9.15-2243; Xu DM, 1998, J EXP MED, V188, P1485, DOI 10.1084/jem.188.8.1485; Zheng WP, 1997, CELL, V89, P587, DOI 10.1016/S0092-8674(00)80240-8	29	188	200	0	5	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAY	2000	25	1					96	101		10.1038/75671	http://dx.doi.org/10.1038/75671			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	311KU	10802665				2022-12-25	WOS:000086884000025
J	Szczypka, MS; Rainey, MA; Palmiter, RD				Szczypka, MS; Rainey, MA; Palmiter, RD			Dopamine is required for hyperphagia in Lep(ob/ob) mice	NATURE GENETICS			English	Article							DEFICIENT MICE; NUCLEUS-ACCUMBENS; FEEDING-BEHAVIOR; BASAL GANGLIA; BODY-WEIGHT; FOOD REWARD; OBESE GENE; MECHANISMS; LEPTIN; MICRODIALYSIS	Feeding is a complex process responsive to sensory information related to sight and smell of food, previous feeding experiences, satiety signals elicited by ingestion and hormonal signals related to energy balance. Dopamine released in specific brain regions is associated with pleasurable and rewarding events(1,2) and may reinforce positive aspects of feeding. Dopamine also influences initiation and coordination of motor activity and is required for sensorimotor functions(3-5). Thus, dopamine may facilitate integration of sensory cues related to hunger, initiating the search for food and its consumption. Dopaminergic neurons in the substantia nigra and ventral tegmental area project to the caudate putamen and nucleus accumbens, where they modulate movement and reward(2,6-8). There are projections from the nucleus accumbens to the lateral hypothalamus that regulate feeding(9). Dopamine-deficient mice (Dbh(Th/s+), Th-/-; hereafter DD mice) cannot synthesize dopamine in dopaminergic neurons. They gradually become aphagic and die of starvation. Daily treatment of DD mice with L-3,4-dihydroxyphenylalanine (L-DOPA) transiently restores brain dopamine, locomotion and feeding. Leptin-null (Lep(ob/ob)) mice exhibit obesity, decreased energy expenditure and hyperphagia. As the hypothalamic leptin-melanocortin pathway appears to regulate appetite and metabolism(10), we generated mice lacking both dopamine and leptin (DDxLep(ob/ob)) to determine if leptin deficiency overcomes the aphagia of DD mice. DDxLep(ob/ob) mice became obese when treated daily with L-DOPA, but when L-DOPA treatment was terminated the double mutants were capable of movement, but did not feed. Our data show that dopamine is required for feeding in leptin-null mice.	Univ Washington, Howard Hughes Med Inst, Seattle, WA 98195 USA; Univ Washington, Dept Biochem, Seattle, WA 98195 USA	Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Palmiter, RD (corresponding author), Univ Washington, Howard Hughes Med Inst, Box 357370, Seattle, WA 98195 USA.				NICHD NIH HHS [HD-09172, HD-08121] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD009172, R37HD009172] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Ahima RS, 1996, NATURE, V382, P250, DOI 10.1038/382250a0; ALBIN RL, 1995, TRENDS NEUROSCI, V18, P63; Andretic R, 1999, SCIENCE, V285, P1066, DOI 10.1126/science.285.5430.1066; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; Chase TN, 1996, ADV NEUROL, V69, P497; Cousins MS, 1996, BRAIN RES, V732, P186, DOI 10.1016/0006-8993(96)00519-7; Elmquist JK, 1998, NAT NEUROSCI, V1, P445, DOI 10.1038/2164; Friedman JM, 1998, NATURE, V395, P763, DOI 10.1038/27376; GRAYBIEL AM, 1994, SCIENCE, V265, P1826, DOI 10.1126/science.8091209; GRAYBIEL AM, 1990, ADV NEUROL, V53, P17; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; HERNANDEZ L, 1988, PHYSIOL BEHAV, V44, P599, DOI 10.1016/0031-9384(88)90324-1; HERNANDEZ L, 1988, LIFE SCI, V42, P1705, DOI 10.1016/0024-3205(88)90036-7; Koob GF, 1999, ANN NY ACAD SCI, V877, P445, DOI 10.1111/j.1749-6632.1999.tb09282.x; MALDONADOIRIZARRY CS, 1995, J NEUROSCI, V15, P6779; Marsh DJ, 1999, NAT GENET, V21, P119, DOI 10.1038/5070; Martel P, 1996, PHARMACOL BIOCHEM BE, V53, P221, DOI 10.1016/0091-3057(95)00187-5; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; Robbins TW, 1996, CURR OPIN NEUROBIOL, V6, P228, DOI 10.1016/S0959-4388(96)80077-8; ROWLAND N, 1979, PHYSIOL BEHAV, V22, P635, DOI 10.1016/0031-9384(79)90222-1; SELF DW, 1995, ANNU REV NEUROSCI, V18, P463, DOI 10.1146/annurev.neuro.18.1.463; Spiegelman BM, 1996, CELL, V87, P377, DOI 10.1016/S0092-8674(00)81359-8; Szczypka MS, 1999, P NATL ACAD SCI USA, V96, P12138, DOI 10.1073/pnas.96.21.12138; Szczypka MS, 1999, NEURON, V22, P167, DOI 10.1016/S0896-6273(00)80688-1; Zhou QY, 1995, CELL, V83, P1197, DOI 10.1016/0092-8674(95)90145-0	25	114	116	0	4	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAY	2000	25	1					102	104		10.1038/75484	http://dx.doi.org/10.1038/75484			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	311KU	10802666				2022-12-25	WOS:000086884000026
J	Wasser, M; Chia, W				Wasser, M; Chia, W			The EAST protein of Drosophila controls an expandable nuclear endoskeleton	NATURE CELL BIOLOGY			English	Article							GENE-EXPRESSION; NERVOUS-SYSTEM; IDENTIFICATION; MATRIX; SITES; ACTIN; TRANSCRIPTION; LOCALIZATION; DOMAINS; CELLS	The high degree of structural order inside the nucleus suggests the existence of an internal nucleoskeleton. Our studies on the east gene of Drosophila, using the larval salivary gland polytene nucleus as a model, demonstrate the involvement of an extrachromosomal nuclear structure in modulating nuclear architecture. EAST, a novel ubiquitous protein, the product of the east (enhanced adult sensory threshold) locus, is localized to an extrachromosomal domain of the nucleus. Nuclear levels of EAST are increased in response to heat shock. Increase in nuclear EAST, whether caused by heat shock or by transgenic overexpression, results in the expansion of the extrachromosomal domain labelled by EAST, with a concomitant increase in the spacing between chromosomes. Moreover, EAST functions to promote the preferential accumulation of the proteins CP60 and actin in extrachromosomal regions of the nucleus. We propose that EAST mediates the assembly of an expandable nuclear endoskeleton which, through alterations of its volume, can modulate the spatial arrangement of chromosomes.	Natl Univ Singapore, Inst Mol & Cell Biol, Singapore 117609, Singapore	Agency for Science Technology & Research (ASTAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore	Chia, W (corresponding author), Natl Univ Singapore, Inst Mol & Cell Biol, 30 Med Dr, Singapore 117609, Singapore.			Wasser, Martin/0000-0002-8753-2346				Abney JR, 1997, J CELL BIOL, V137, P1459, DOI 10.1083/jcb.137.7.1459; AGARD DA, 1983, NATURE, V302, P676, DOI 10.1038/302676a0; ANAND A, 1990, J GENET, V69, P151, DOI 10.1007/BF02927976; Ashburner M., 1989, DROSOPHILA LAB HDB; BEREZNEY R, 1974, BIOCHEM BIOPH RES CO, V60, P1410, DOI 10.1016/0006-291X(74)90355-6; BRAND AH, 1995, CURR OPIN NEUROBIOL, V5, P572, DOI 10.1016/0959-4388(95)80061-1; BRAND AH, 1993, DEVELOPMENT, V118, P401; Bridger JM, 1998, J CELL SCI, V111, P1241; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; Chu A, 1998, FEBS LETT, V441, P165, DOI 10.1016/S0014-5793(98)01534-8; Clarkson M, 1999, DNA CELL BIOL, V18, P457, DOI 10.1089/104454999315178; CREMER T, 1993, COLD SPRING HARB SYM, V58, P777, DOI 10.1101/SQB.1993.058.01.085; Dynlacht JR, 1999, J CELL PHYSIOL, V178, P28, DOI 10.1002/(SICI)1097-4652(199901)178:1<28::AID-JCP4>3.3.CO;2-B; Fuller Margaret T., 1993, P71; Gonczy P, 1996, DEVELOPMENT, V122, P2437; GRUENBAUM Y, 1988, J CELL BIOL, V106, P2225; GRUENBAUM Y, 1988, J CELL BIOL, V106, P585, DOI 10.1083/jcb.106.3.585; Jackson DA, 1997, MOL BIOL REP, V24, P209, DOI 10.1023/A:1006873614521; KELLOGG DR, 1995, MOL BIOL CELL, V6, P1673, DOI 10.1091/mbc.6.12.1673; KELLOGG DR, 1992, MOL BIOL CELL, V3, P1, DOI 10.1091/mbc.3.1.1; LUNDELL MJ, 1994, BIOTECHNIQUES, V16, P434; Marshall WF, 1997, CURR OPIN GENET DEV, V7, P259, DOI 10.1016/S0959-437X(97)80136-0; Marshall WF, 1997, CURR BIOL, V7, P930, DOI 10.1016/S0960-9822(06)00412-X; Nakai K, 1999, TRENDS BIOCHEM SCI, V24, P34, DOI 10.1016/S0968-0004(98)01336-X; NAKAYASU H, 1983, EXP CELL RES, V143, P55, DOI 10.1016/0014-4827(83)90108-8; Nguyen E, 1998, MOL REPROD DEV, V50, P263, DOI 10.1002/(SICI)1098-2795(199807)50:3&lt;263::AID-MRD2&gt;3.0.CO;2-H; Oegema K, 1997, J CELL SCI, V110, P1573; Pederson T, 1998, J MOL BIOL, V277, P147, DOI 10.1006/jmbi.1997.1618; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; SoyerGobillard MO, 1996, BIOL CELL, V87, P17, DOI 10.1016/S0248-4900(97)89834-6; Spector DL, 1996, EXP CELL RES, V229, P189, DOI 10.1006/excr.1996.0358; Spradling AC, 1986, DROSOPHILA PRACTICAL, P175; Stuurman N, 1998, J STRUCT BIOL, V122, P42, DOI 10.1006/jsbi.1998.3987; TAMKUN JW, 1992, CELL, V68, P561, DOI 10.1016/0092-8674(92)90191-E; Van Doren M, 1998, CURR BIOL, V8, P243; vanDriel R, 1995, INT REV CYTOL, V162A, P151; VIJAYRAGHAVAN K, 1992, DEV BIOL, V154, P23, DOI 10.1016/0012-1606(92)90044-H; Wei XY, 1998, SCIENCE, V281, P1502, DOI 10.1126/science.281.5382.1502; ZACHAR Z, 1993, J CELL BIOL, V121, P729, DOI 10.1083/jcb.121.4.729; Zimowska G, 1997, J CELL SCI, V110, P927; Zirbel RM, 1993, CHROMOSOME RES, V1, P93, DOI 10.1007/BF00710032	41	59	63	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	MAY	2000	2	5					268	275		10.1038/35010535	http://dx.doi.org/10.1038/35010535			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	313FX	10806477				2022-12-25	WOS:000086990600015
J	Bale, TL; Contarino, AB; Smith, GW; Chan, R; Gold, LH; Sawchenko, PE; Koob, GF; Vale, WW; Lee, KF				Bale, TL; Contarino, AB; Smith, GW; Chan, R; Gold, LH; Sawchenko, PE; Koob, GF; Vale, WW; Lee, KF			Mice deficient for corticotropin-releasing hormone receptor-2 display anxiety-like behaviour and are hypersensitive to stress	NATURE GENETICS			English	Article							ACOUSTIC STARTLE REFLEX; CENTRAL NUCLEUS; ACTH-SECRETION; RAT-BRAIN; NEUROPEPTIDE; UROCORTIN; AMYGDALA; PARTICIPATION; HYPOTHALAMUS; EXPRESSION	Corticotropin-releasing hormone (Crh) is a critical coordinator of the hypothalamic-pituitary-adrenal (HPA) axis. In response to stress, Crh released from the paraventricular nucleus (PVN) of the hypothalamus activates Crh receptors on anterior pituitary corticotropes, resulting in release of adrenocorticotropic hormone (Acth) into the bloodstream. Acth in turn activates Acth receptors in the adrenal cortex to increase synthesis and release of glucocorticoids(1). The receptors for Crh, Crhr1 and Crhr2, are found throughout the central nervous system and periphery. Crh has a higher affinity for Crhr1 than for Crhr2, and urocortin (Ucn); a Crh-related peptide, is thought to be the endogenous ligand for Crhr2 because it binds with almost 40-fold higher affinity than does Crh (ref. 2). Crhr1 and Crhr2 share approximately 71% amino acid sequence similarity and are distinct in their localization within the brain and peripheral tissues(3-6). We generated mice deficient for Crhr2 to determine the physiological role of this receptor. Crhr2-mutant mice are hypersensitive to stress and display increased anxiety-like behaviour. Mutant mice have normal basal feeding and weight gain, but decreased food intake following food deprivation. intravenous Ucn produces no effect on mean arterial pressure in the mutant mice.	Salk Inst, Clayton Fdn Labs Peptide Biol, La Jolla, CA 92037 USA; Salk Inst, Neuronal Struct & Funct Lab, La Jolla, CA USA; Scripps Res Inst, Dept Neuropharmacol, La Jolla, CA USA	Salk Institute; Salk Institute; Scripps Research Institute	Lee, KF (corresponding author), Salk Inst, Clayton Fdn Labs Peptide Biol, La Jolla, CA 92037 USA.		Contarino, Angelo/C-9429-2014	Contarino, Angelo/0000-0002-7286-6941	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK009841, P01DK026741, F32DK009551] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK09551, DK-26741, DK09841] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLEN JP, 1975, NEUROENDOCRINOLOGY, V19, P115, DOI 10.1159/000122432; BALE TL, 1995, ENDOCRINOLOGY, V136, P27, DOI 10.1210/en.136.1.27; BEAULIEU S, 1987, NEUROENDOCRINOLOGY, V45, P37, DOI 10.1159/000124701; BEAULIEU S, 1986, NEUROENDOCRINOLOGY, V44, P247, DOI 10.1159/000124652; BELZUNG C, 1994, PHYSIOL BEHAV, V56, P623, DOI 10.1016/0031-9384(94)90311-5; CHALMERS DT, 1995, J NEUROSCI, V15, P6340; Coste SC, 2000, NAT GENET, V24, P403, DOI 10.1038/74255; Hogg S, 1996, PHARMACOL BIOCHEM BE, V54, P21, DOI 10.1016/0091-3057(95)02126-4; KING FA, 1958, SCIENCE, V128, P655, DOI 10.1126/science.128.3325.655; KISHIMOTO T, 1995, P NATL ACAD SCI USA, V92, P1108, DOI 10.1073/pnas.92.4.1108; Lee YL, 1997, J NEUROSCI, V17, P6424; LIANG KC, 1992, J NEUROSCI, V12, P2313; LOVENBERG TW, 1995, P NATL ACAD SCI USA, V92, P836, DOI 10.1073/pnas.92.3.836; Marcilhac A, 1996, EXP PHYSIOL, V81, P1035, DOI 10.1113/expphysiol.1996.sp003987; MELIA KR, 1991, PHYSIOL BEHAV, V49, P603, DOI 10.1016/0031-9384(91)90286-W; Moreau JL, 1997, NEUROREPORT, V8, P1697, DOI 10.1097/00001756-199705060-00027; PERRIN M, 1995, P NATL ACAD SCI USA, V92, P2969, DOI 10.1073/pnas.92.7.2969; Rodgers RJ, 1997, BEHAV PHARMACOL, V8, P477, DOI 10.1097/00008877-199711000-00003; Smith GW, 1998, NEURON, V20, P1093, DOI 10.1016/S0896-6273(00)80491-2; Spina M, 1996, SCIENCE, V273, P1561, DOI 10.1126/science.273.5281.1561; STENZEL P, 1995, MOL ENDOCRINOL, V9, P537; Timpl P, 1998, NAT GENET, V19, P162, DOI 10.1038/520; VALE W, 1981, SCIENCE, V213, P1394, DOI 10.1126/science.6267699; VAUGHAN J, 1995, NATURE, V378, P287, DOI 10.1038/378287a0	24	676	692	1	44	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	APR	2000	24	4					410	414		10.1038/74263	http://dx.doi.org/10.1038/74263			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	299HK	10742108				2022-12-25	WOS:000086192800023
J	Kishimoto, T; Radulovic, J; Radulovic, M; Lin, CR; Schrick, C; Hooshmand, F; Hermanson, O; Rosenfeld, MG; Spiess, J				Kishimoto, T; Radulovic, J; Radulovic, M; Lin, CR; Schrick, C; Hooshmand, F; Hermanson, O; Rosenfeld, MG; Spiess, J			Deletion of Crhr2 reveals an anxiolytic role for corticotropin-releasing hormone receptor-2	NATURE GENETICS			English	Article							IMPAIRED STRESS-RESPONSE; RAT-BRAIN; MICE; IDENTIFICATION; ANXIETY; MOUSE; HEART; NEUROENDOCRINE; EXPRESSION; SAUVAGINE	Corticotropin-releasing hormone(1,2) (Crh), a 41-residue polypeptide, activates two G-protein-coupled receptors, Crhr1 (refs 3-5) and Crhr2 (refs 6-9), causing (among other transductional events) phosphorylation of the transcription factor Creb (ref. 10). The physiologic;role of these receptors is only partially understood. Here we report that male, but not female, Crhr2-deficient mice exhibit enhanced anxious behaviour in several tests of anxiety in contrast to mice lacking Crhr1 (refs 11,12). The enhanced anxiety of Crhr2-deficient mice is not due to changes in hypothalamic-pituitary-adrenal (HPA) axis activity, but rather reflects impaired responses in specific brain regions involved in emotional and autonomic function, as monitored by a reduction of Creb phosphorylation in male, but not female, Crhr2(-/-) mice. We propose that Crhr2 predominantly mediates a central anxiolytic response, opposing the general anxiogenic effect of Crh mediated by Crhr1. Neither male nor female Crhr2-deficient mice show alterations of baseline feeding behaviour. Both respond with increased edema formation in response to thermal exposure, however, indicating that in contrast to its central role in anxiety, the peripheral role of Crhr2 in vascular permeability is independent of gender.	Max Planck Inst Expt Med, Dept Mol Neuroendocrinol, D-37075 Gottingen, Germany; Univ Calif San Diego, Howard Hughes Med Inst, Dept & Sch Med, La Jolla, CA 92093 USA	Max Planck Society; Howard Hughes Medical Institute; University of California System; University of California San Diego	Radulovic, J (corresponding author), Max Planck Inst Expt Med, Dept Mol Neuroendocrinol, Hermann Rein Str 3, D-37075 Gottingen, Germany.	radulovic@mail.mpiem.gwdg.de; mrosenfeld@ucsd.edu; spiess@mail.mpiem.gwdg.de	, Ola/AAF-5126-2021	Radulovic, Jelena/0000-0002-0268-2426; Hermanson, Ola/0000-0001-9320-7921; Radulovic, Marko/0000-0002-2314-7457				Allen E, 1922, AM J ANAT, V30, P297, DOI 10.1002/aja.1000300303; BALDWIN HA, 1991, PSYCHOPHARMACOLOGY, V103, P227, DOI 10.1007/BF02244208; CAREY MP, 1992, PHARMACOL BIOCHEM BE, V41, P719, DOI 10.1016/0091-3057(92)90218-5; CHALMERS DT, 1995, J NEUROSCI, V15, P6340; CHANG CP, 1993, NEURON, V11, P1187, DOI 10.1016/0896-6273(93)90230-O; CHEN Y, 1993, MOL PHARMACOL, V44, P8; FISHER LA, 1989, TRENDS PHARMACOL SCI, V10, P189, DOI 10.1016/0165-6147(89)90236-8; FOX MW, 1965, ANIM BEHAV, V13, P232, DOI 10.1016/0003-3472(65)90040-0; Hinks GL, 1996, EUR J PHARMACOL, V312, P153, DOI 10.1016/0014-2999(96)00471-2; KISHIMOTO T, 1995, P NATL ACAD SCI USA, V92, P1108, DOI 10.1073/pnas.92.4.1108; LEE EHY, 1989, BEHAV NEURAL BIOL, V51, P412, DOI 10.1016/S0163-1047(89)91052-2; LISTER RG, 1987, PSYCHOPHARMACOLOGY, V92, P180; LOVENBERG TW, 1995, P NATL ACAD SCI USA, V92, P836, DOI 10.1073/pnas.92.3.836; PERRIN M, 1995, P NATL ACAD SCI USA, V92, P2969, DOI 10.1073/pnas.92.7.2969; Radulovic J, 1998, J NEUROSCI, V18, P7452; Radulovic J, 1999, J NEUROSCI, V19, P5016; RODGERS RJ, 1995, PHARMACOL BIOCHEM BE, V52, P297, DOI 10.1016/0091-3057(95)00138-M; Rossant CJ, 1999, ENDOCRINOLOGY, V140, P1525, DOI 10.1210/en.140.4.1525; Ruhmann A, 1998, P NATL ACAD SCI USA, V95, P15264, DOI 10.1073/pnas.95.26.15264; Smith GW, 1998, NEURON, V20, P1093, DOI 10.1016/S0896-6273(00)80491-2; SPIESS J, 1981, P NATL ACAD SCI-BIOL, V78, P6517, DOI 10.1073/pnas.78.10.6517; STENZEL P, 1995, MOL ENDOCRINOL, V9, P637, DOI 10.1210/me.9.5.637; STENZELPOORE MP, 1994, J NEUROSCI, V14, P2579; TAKAHASHI LK, BEHAV NEUROSCI, V103, P645; Timpl P, 1998, NAT GENET, V19, P162, DOI 10.1038/520; Turnbull AV, 1996, EUR J PHARMACOL, V303, P213, DOI 10.1016/0014-2999(96)00141-0; VALE W, 1981, SCIENCE, V213, P1394, DOI 10.1126/science.6267699; VITA N, 1993, FEBS LETT, V335, P1, DOI 10.1016/0014-5793(93)80427-V; WEI ET, 1994, EUR J PHARMACOL, V263, P319, DOI 10.1016/0014-2999(94)90729-3	29	400	412	1	17	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	APR	2000	24	4					415	419		10.1038/74271	http://dx.doi.org/10.1038/74271			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	299HK	10742109				2022-12-25	WOS:000086192800024
J	Backes, BJ; Harris, JL; Leonetti, F; Craik, CS; Ellman, JA				Backes, BJ; Harris, JL; Leonetti, F; Craik, CS; Ellman, JA			Synthesis of positional-scanning libraries of fluorogenic peptide substrates to define the extended substrate specificity of plasmin and thrombin	NATURE BIOTECHNOLOGY			English	Article						serine protease; proteinase; blood coagulation; molecular recognition; combinatorial libraries	PRO-ARG CHLOROMETHYLKETONE; HUMAN ALPHA-THROMBIN; CRYSTAL-STRUCTURE; COMBINATORIAL LIBRARIES; ENZYME SPECIFICITY; FACTOR-V; ACTIVATION; PROTEIN; IDENTIFICATION; PROTEOLYSIS	We have developed a strategy for the synthesis of positional-scanning synthetic combinatorial libraries (PS-SCL) that does not depend on the identity of the P1 substituent, To demonstrate the strategy, we synthesized a tetrapeptide positional library in which the P1 amino acid is held constant as a lysine and the P4-P3-P2 positions are positionally randomized. The 6,859 members of the library were synthesized on solid support with an alkane sulfonamide linker, and then displaced from the solid support by condensation with a fluorogenic 7-amino-4-methylcoumarin-derivatized lysine. This library was used to determine the extended substrate specificities of two trypsin-like enzymes, plasmin and thrombin, which are involved in the blood coagulation pathway, The optimal P4 to P2 substrate specificity for plasmin was P4-Lys/Nle (norleucine)/Val/Ile/Phe, P3-Xaa, and P2-Tyr/Phe/Trp. This cleavage sequence has recently been identified in some of plasmin's physiological substrates. The optimal P4 to P2 extended substrate sequence determined for thrombin was P4-Nle/Leu/Ile/Phe/Val, P3-Xaa, and P2-Pro, a sequence found in many of the physiological substrates of thrombin, Single-substrate kinetic analysis of plasmin and thrombin was used to validate the substrate preferences resulting from the PS-SCL, By three-dimensional structural modeling of the substrates into the active sites of plasmin and thrombin, we identified potential determinants of the defined substrate specificity. This method is amenable to the incorporation of diverse substituents at the P1 position for exploring molecular recognition elements in proteolytic enzymes.	Univ Calif San Francisco, Dept Pharmaceut Chem, Program Chem & Chem Biol, San Francisco, CA 94143 USA; Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA	University of California System; University of California San Francisco; University of California System; University of California Berkeley	Ellman, JA (corresponding author), Univ Calif San Francisco, Dept Pharmaceut Chem, Program Chem & Chem Biol, San Francisco, CA 94143 USA.		Ellman, Jonathan A/C-7732-2013	Leonetti, Francesco/0000-0003-2043-7464	NCI NIH HHS [CA72006] Funding Source: Medline; NIGMS NIH HHS [GM 54051] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA072006] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Backes BJ, 1999, J ORG CHEM, V64, P2322, DOI 10.1021/jo981990y; BERMAN J, 1992, J BIOL CHEM, V267, P1434; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; Bevan A, 1998, P NATL ACAD SCI USA, V95, P10384, DOI 10.1073/pnas.95.18.10384; BIRKETT AJ, 1991, ANAL BIOCHEM, V196, P137, DOI 10.1016/0003-2697(91)90129-H; BODE W, 1989, EMBO J, V8, P3467, DOI 10.1002/j.1460-2075.1989.tb08511.x; BODE W, 1992, PROTEIN SCI, V1, P426; BUNIN BA, 1998, COMBINATORIAL INDEX, V12, P322; BURLEY SK, 1986, FEBS LETT, V203, P139, DOI 10.1016/0014-5793(86)80730-X; Campbell PG, 1997, AM J PHYSIOL-ENDOC M, V273, pE996, DOI 10.1152/ajpendo.1997.273.5.E996; CHAIN D, 1991, FEBS LETT, V285, P251, DOI 10.1016/0014-5793(91)80810-P; DelNery E, 1997, BIOCHEM J, V323, P427, DOI 10.1042/bj3230427; DING L, 1995, P NATL ACAD SCI USA, V92, P7627, DOI 10.1073/pnas.92.17.7627; Dooley CT, 1998, METH MOL B, V87, P13; EHRLICH HJ, 1990, EMBO J, V9, P2367, DOI 10.1002/j.1460-2075.1990.tb07411.x; FENTON JW, 1977, J BIOL CHEM, V252, P3587; Gillmor SA, 1997, PROTEIN SCI, V6, P1603, DOI 10.1002/pro.5560060801; Gundersen D, 1997, J IMMUNOL, V158, P1051; JAMESON GW, 1973, BIOCHEM J, V131, P107, DOI 10.1042/bj1310107; KAWABATA SI, 1988, EUR J BIOCHEM, V172, P17, DOI 10.1111/j.1432-1033.1988.tb13849.x; KELLER FG, 1995, BIOCHEMISTRY-US, V34, P4118, DOI 10.1021/bi00012a030; Kost C, 1996, EUR J BIOCHEM, V236, P682, DOI 10.1111/j.1432-1033.1996.0682d.x; Kothakota S, 1997, SCIENCE, V278, P294, DOI 10.1126/science.278.5336.294; Kuliopulos A, 1999, BIOCHEMISTRY-US, V38, P4572, DOI 10.1021/bi9824792; Lam KS, 1998, METH MOL B, V87, P1; LeBonniec BF, 1996, BIOCHEMISTRY-US, V35, P7114, DOI 10.1021/bi952701s; LOTTENBERG R, 1983, BIOCHIM BIOPHYS ACTA, V742, P539, DOI 10.1016/0167-4838(83)90272-8; Lustig KD, 1997, METHOD ENZYMOL, V283, P83; MATHEWS II, 1994, BIOCHEMISTRY-US, V33, P3266, DOI 10.1021/bi00177a018; MATTHEWS DJ, 1993, SCIENCE, V260, P1113, DOI 10.1126/science.8493554; MCGEEHAN GM, 1994, J BIOL CHEM, V269, P32814; MCKEE PA, 1975, ANN NY ACAD SCI, V240, P8; Meldal M, 1998, J PEPT SCI, V4, P83, DOI 10.1002/(SICI)1099-1387(199804)4:2<83::AID-PSC124>3.0.CO;2-Z; MELDAL M, 1994, P NATL ACAD SCI USA, V91, P3314, DOI 10.1073/pnas.91.8.3314; Novak JF, 1997, J BONE MINER RES, V12, P1035, DOI 10.1359/jbmr.1997.12.7.1035; OMAR MN, 1987, J BIOL CHEM, V262, P9750; OSTRESH JM, 1994, BIOPOLYMERS, V34, P1681, DOI 10.1002/bip.360341212; PETITHORY JR, 1991, P NATL ACAD SCI USA, V88, P11510, DOI 10.1073/pnas.88.24.11510; PINILLA C, 1992, BIOTECHNIQUES, V13, P901; PITTMAN DD, 1994, BIOCHEMISTRY-US, V33, P6952, DOI 10.1021/bi00188a026; POZSGAY M, 1981, EUR J BIOCHEM, V115, P491; Pryzdial ELG, 1999, J BIOL CHEM, V274, P8500, DOI 10.1074/jbc.274.13.8500; Rano TA, 1997, CHEM BIOL, V4, P149, DOI 10.1016/S1074-5521(97)90258-1; ROBBINS KC, 1981, METHOD ENZYMOL, V80, P379; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SCHELLENBERGER V, 1993, BIOCHEMISTRY-US, V32, P4349, DOI 10.1021/bi00067a026; St Hilaire PM, 1999, J COMB CHEM, V1, P509, DOI 10.1021/cc990031u; STILL WC, 1978, J ORG CHEM, V43, P2923, DOI 10.1021/jo00408a041; STUBBS MT, 1993, SEMIN THROMB HEMOST, V19, P344, DOI 10.1055/s-2007-993285; THOMAS KA, 1982, P NATL ACAD SCI-BIOL, V79, P4843, DOI 10.1073/pnas.79.16.4843; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Tsirka SE, 1997, P NATL ACAD SCI USA, V94, P9779, DOI 10.1073/pnas.94.18.9779; TSIRKA SE, 1997, P NATL ACAD SCI USA, V26, P14976; Vindigni A, 1997, NAT BIOTECHNOL, V15, P891, DOI 10.1038/nbt0997-891; VU TKH, 1991, NATURE, V353, P674, DOI 10.1038/353674a0; Wang XQ, 1998, SCIENCE, V281, P1662, DOI 10.1126/science.281.5383.1662; ZIMMERMAN M, 1977, ANAL BIOCHEM, V78, P47, DOI 10.1016/0003-2697(77)90006-9	57	231	245	0	19	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	FEB	2000	18	2					187	193		10.1038/72642	http://dx.doi.org/10.1038/72642			7	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	281FH	10657126				2022-12-25	WOS:000085146900026
J	Chaure, P; Gurr, SJ; Spanu, P				Chaure, P; Gurr, SJ; Spanu, P			Stable transformation of Erysiphe graminis, an obligate biotrophic pathogen of barley	NATURE BIOTECHNOLOGY			English	Article						Erysiphe graminis; barley; transformation; obligate biotrophs	F-SP HORDEI; BETA-TUBULIN; RESISTANCE; FUNGUS; GENE; MUTATIONS; DNA	Barley powdery mildew, Erysiphe graminis f.sp. hordei, is an obligate biotrophic pathogen and as such cannot complete its life cycle without a living host. The inability to transform this fungus and manipulate its genome has constrained research towards understanding its life cycle and pathogenicity. Here we describe an in planta transformation system based on delivery of DNA using a gold-particle gun and selection using benomyl or bialaphos. Using this method, we consistently obtained stable transformants with efficiencies comparable to other filamentous fungi. Stable expression of the beta-glucuronidase in E. graminis was demonstrated by cc-transforming the uidA gene with the selectable markers.	Univ London Imperial Coll Sci Technol & Med, Dept Biol, London SW7 2AZ, England; Univ Oxford, Dept Plant Sci, Oxford OX1 3RB, England	Imperial College London; University of Oxford	Spanu, P (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Biol, Imperial Coll Rd, London SW7 2AZ, England.		Spanu, Pietro/P-5859-2019; Bruening, Stefan/B-8505-2011	Spanu, Pietro/0000-0001-8928-6049; 				Christiansen SK, 1995, CURR GENET, V29, P100, DOI 10.1007/BF00313200; GOLD SE, 1994, GENE, V142, P225, DOI 10.1016/0378-1119(94)90265-8; HALL AA, 2000, ENCY MICROBIOLOGY, P269; HEWITT H, 1999, FUNGICIDES CROP PROT; JAVERZAT JP, 1993, NUCLEIC ACIDS RES, V21, P497, DOI 10.1093/nar/21.3.497; KISTLER HC, 1992, GENE, V117, P81, DOI 10.1016/0378-1119(92)90493-9; KOENRAADT H, 1993, PHYTOPATHOLOGY, V83, P850, DOI 10.1094/Phyto-83-850; Long DM, 1998, FUNGAL GENET BIOL, V24, P335, DOI 10.1006/fgbi.1998.1065; NEWTON AC, 1989, J PHYTOPATHOL, V126, P133, DOI 10.1111/j.1439-0434.1989.tb01097.x; OLIVER RP, 1999, FUNGAL GENET NEWSLET, V46, P86; Pall ML, 1993, FUNGAL GENET NEWSL, V40, P58; SHERWOOD JE, 1990, NUCLEIC ACIDS RES, V18, P1052, DOI 10.1093/nar/18.4.1052; Straubinger B., 1992, FUNGAL GENET NEWSLET, V39, P82; THOMPSON CJ, 1987, EMBO J, V6, P2519, DOI 10.1002/j.1460-2075.1987.tb02538.x; Wilmink A., 1993, Plant Molecular Biology Reporter, V11, P165, DOI 10.1007/BF02670474; YARDEN O, 1993, PHYTOPATHOLOGY, V83, P1478, DOI 10.1094/Phyto-83-1478	16	61	67	1	13	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	FEB	2000	18	2					205	207		10.1038/72666	http://dx.doi.org/10.1038/72666			3	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	281FH	10657129				2022-12-25	WOS:000085146900029
J	Costello, JF; Fruhwald, MC; Smiraglia, DJ; Rush, LJ; Robertson, GP; Gao, X; Wright, FA; Feramisco, JD; Peltomaki, P; Lang, JC; Schuller, DE; Yu, L; Bloomfield, CD; Caligiuri, MA; Yates, A; Nishikawa, R; Huang, HJS; Petrelli, NJ; Zhang, XL; O'Dorisio, MS; Held, WA; Cavenee, WK; Plass, C				Costello, JF; Fruhwald, MC; Smiraglia, DJ; Rush, LJ; Robertson, GP; Gao, X; Wright, FA; Feramisco, JD; Peltomaki, P; Lang, JC; Schuller, DE; Yu, L; Bloomfield, CD; Caligiuri, MA; Yates, A; Nishikawa, R; Huang, HJS; Petrelli, NJ; Zhang, XL; O'Dorisio, MS; Held, WA; Cavenee, WK; Plass, C			Aberrant CpG-island methylation has non-random and tumour-type-specific patterns	NATURE GENETICS			English	Article							DNA METHYLATION; MOUSE; GENES; GENOME; CELLS	CpG islands frequently contain gene promoters or exons(1) and are usually unmethylated in normal cells(1-3). Methylation of CPG islands is associated with delayed replication, condensed chromatin and inhibition of transcription initiation(4-7). The investigation of aberrant CpG-island methylation in human cancer has primarily taken a candidate gene approach, and has focused on less than 15 of the estimated 45,000 CpG islands(8) in the genome. Here we report a global analysis of the methylation status of 1,184 unselected CpG islands in each of 98 primary human rumours using restriction landmark genomic scanning(9) (RLGS). We estimate that an average of 600 CpG islands (range of 0 to 4,500) of the 45,000 in the genome were aberrantly methylated in the rumours, including early stage tumours. We identified patterns of CpG;island methylation that were shared within each tumour type, together with patterns and targets that displayed distinct tumour-type specificity. The expression of many of these genes was reactivated by experimental demethylation in cultured tumour cells. Thus, the methylation of particular subsets of CpG islands may have consequences for specific tumour types.	Univ Calif San Francisco, San Francisco, CA 94143 USA; Univ Calif San Diego, Ludwig Inst Canc Res, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr Genet Mol, La Jolla, CA 92093 USA; Ohio State Univ, Div Human Canc Genet, Dept Mol Virol Immunol & Med Genet, Columbus, OH 43210 USA; Ohio State Univ, Dept Vet Biosci, Columbus, OH 43210 USA; Ohio State Univ, Dept Otolaryngol, Columbus, OH 43210 USA; Ohio State Univ, Div Hematol & Oncol, Dept Internal Med, Columbus, OH 43210 USA; Ohio State Univ, Dept Pathol, Columbus, OH 43210 USA; Ohio State Univ, Dept Neurosci, Columbus, OH 43210 USA; Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA; Childrens Hosp, Dept Pediat, Columbus, OH 43205 USA; Saitama Med Sch, Dept Neurosurg, Iruma, Saitama, Japan; New York State Dept Hlth, Roswell Pk Canc Inst, Dept Surg Oncol, Buffalo, NY 14263 USA; New York State Dept Hlth, Roswell Pk Canc Inst, Dept Mol & Cellular Biol, Buffalo, NY 14263 USA	University of California System; University of California San Francisco; Ludwig Institute for Cancer Research; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; Nationwide Childrens Hospital; Saitama Medical University; Roswell Park Cancer Institute; Roswell Park Cancer Institute	Costello, JF (corresponding author), Univ Calif San Francisco, San Francisco, CA 94143 USA.		Plass, Christoph/H-7192-2014; Smiraglia, Dominic/R-2069-2019; Robertson, Gavin P./A-6106-2017	Smiraglia, Dominic/0000-0001-8852-1510; Robertson, Gavin P./0000-0003-0152-2997; Peltomaki, Paivi/0000-0001-8819-2980; O'Dorisio, M Sue/0000-0003-0690-1160	NCI NIH HHS [CA80912, 3U10CA31946-17S3, P30CA16058] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U10CA031946, P30CA016058, R21CA080912] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akama TO, 1997, CANCER RES, V57, P3294; ANTEQUERA F, 1993, P NATL ACAD SCI USA, V90, P11995, DOI 10.1073/pnas.90.24.11995; ANTEQUERA F, 1990, CELL, V62, P503, DOI 10.1016/0092-8674(90)90015-7; Bachman KE, 1999, CANCER RES, V59, P798; Barbour A.D., 1992, POISSON APPROXIMATIO; Baylin SB, 1998, ADV CANCER RES, V72, P141; BIRD A, 1985, CELL, V40, P91, DOI 10.1016/0092-8674(85)90312-5; Costello JF, 1997, CANCER RES, V57, P1250; CROSS SH, 1995, CURR OPIN GENET DEV, V5, P309, DOI 10.1016/0959-437X(95)80044-1; De Smet C, 1999, MOL CELL BIOL, V19, P7327; Delgado S, 1998, EMBO J, V17, P2426, DOI 10.1093/emboj/17.8.2426; FREUND RJ, 1997, STAT METHODS; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; Graff JR, 1997, J BIOL CHEM, V272, P22322, DOI 10.1074/jbc.272.35.22322; HATADA I, 1991, P NATL ACAD SCI USA, V88, P9523, DOI 10.1073/pnas.88.21.9523; HAYASHIZAKI Y, 1994, NAT GENET, V6, P33, DOI 10.1038/ng0194-33; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; Lehman EL, 1975, NONPARAMETRICS; NAMBU JR, 1990, CELL, V63, P63, DOI 10.1016/0092-8674(90)90288-P; Plass C, 1997, DNA Res, V4, P253, DOI 10.1093/dnares/4.3.253; Plass C, 1999, ONCOGENE, V18, P3159, DOI 10.1038/sj.onc.1202651; Ryan AK, 1997, GENE DEV, V11, P1207, DOI 10.1101/gad.11.10.1207; Smiraglia DJ, 1999, GENOMICS, V58, P254, DOI 10.1006/geno.1999.5840; Stirzaker C, 1997, CANCER RES, V57, P2229; Yoshikawa H, 1996, GENOMICS, V31, P28, DOI 10.1006/geno.1996.0005	25	1072	1175	1	72	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	FEB	2000	24	2					132	138		10.1038/72785	http://dx.doi.org/10.1038/72785			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	280LQ	10655057				2022-12-25	WOS:000085104600012
J	Golding, JP; Trainor, P; Krumlauf, R; Gassmann, M				Golding, JP; Trainor, P; Krumlauf, R; Gassmann, M			Defects in pathfinding by cranial neural crest cells in mice lacking the neuregulin receptor ErbB4	NATURE CELL BIOLOGY			English	Article							RETINOIC ACID; MOUSE EMBRYOGENESIS; MESSENGER-RNA; MIGRATION; EXPRESSION; HER4/P180(ERBB4); IDENTITY; GUIDANCE; PROTEIN; NEURONS	Mouse embryos with a loss-of-function mutation in the gene encoding the receptor tyrosine kinase ErbB4 exhibit misprojections of cranial sensory ganglion afferent axons. Here we analyse ErbB4-deficient mice, and find that morphological differences between wild-type and mutant cranial ganglia correlate with aberrant migration of a subpopulation of hindbrain-derived cranial neural crest cells within the paraxial mesenchyme environment. In transplantation experiments using new grafting techniques in cultured mouse embryos, we determine that this phenotype is non-cell-autonomous: wild-type and mutant neural crest cells both migrate in a pattern consistent with the host environment, deviating from their normal pathway only when transplanted into mutant embryos. ErbB4 signalling events within the hindbrain therefore provide patterning information to cranial paraxial mesenchyme that is essential for the proper migration of neural crest cells.	Natl Inst Med Res, Div Neurobiol, London NW7 1AA, England; Natl Inst Med Res, Div Dev Neurobiol, London NW7 1AA, England	MRC National Institute for Medical Research; MRC National Institute for Medical Research	Gassmann, M (corresponding author), Natl Inst Med Res, Div Neurobiol, Ridgeway,Mill Hill, London NW7 1AA, England.	mgassma@nimr.mrc.ac.uk	Krumlauf, Robb/AAH-5012-2019; Golding, Jon/L-2700-2017	Krumlauf, Robb/0000-0001-9102-7927; Golding, Jon/0000-0002-7910-7382; Gassmann, Martin/0000-0001-6201-3032; Trainor, Paul/0000-0003-2774-3624				Alexandre D, 1996, DEVELOPMENT, V122, P735; Beerli RR, 1996, J BIOL CHEM, V271, P6071, DOI 10.1074/jbc.271.11.6071; Bell E, 1999, SCIENCE, V284, P2168, DOI 10.1126/science.284.5423.2168; BIRGBAUER E, 1995, DEVELOPMENT, V121, P935; DAMICOMARTEL A, 1983, AM J ANAT, V166, P445, DOI 10.1002/aja.1001660406; Dixon M, 1999, MOL CELL NEUROSCI, V13, P237, DOI 10.1006/mcne.1999.0749; Eickholt BJ, 1999, DEVELOPMENT, V126, P2181; Farlie PG, 1999, DEV BIOL, V213, P70, DOI 10.1006/dbio.1999.9332; Fode C, 1998, NEURON, V20, P483, DOI 10.1016/S0896-6273(00)80989-7; Gale E, 1996, DEVELOPMENT, V122, P783; Gassmann M, 1997, CURR OPIN NEUROBIOL, V7, P87, DOI 10.1016/S0959-4388(97)80125-0; GASSMANN M, 1995, NATURE, V378, P390, DOI 10.1038/378390a0; Golding JP, 1999, DEV BIOL, V216, P85, DOI 10.1006/dbio.1999.9497; Harari D, 1999, ONCOGENE, V18, P2681, DOI 10.1038/sj.onc.1202631; Helbling PM, 1998, MECH DEVELOP, V78, P63, DOI 10.1016/S0925-4773(98)00148-8; Holder N, 1999, DEVELOPMENT, V126, P2033; KEYNES RJ, 1991, DEVELOPMENT, P131; Kuhlbrodt K, 1998, J NEUROSCI, V18, P237, DOI 10.1523/jneurosci.18-01-00237.1998; LEE JE, 1995, SCIENCE, V268, P836, DOI 10.1126/science.7754368; LEE YM, 1995, DEVELOPMENT, V121, P825; Lumsden A, 1996, SCIENCE, V274, P1109, DOI 10.1126/science.274.5290.1109; LUMSDEN A, 1991, DEVELOPMENT, V113, P1281; Ma QF, 1998, NEURON, V20, P469, DOI 10.1016/S0896-6273(00)80988-5; Maconochie MK, 1997, GENE DEV, V11, P1885, DOI 10.1101/gad.11.14.1885; Manzanares M, 1999, DEV BIOL, V211, P220, DOI 10.1006/dbio.1999.9318; Meyer D, 1997, DEVELOPMENT, V124, P3575; MEYER D, 1995, NATURE, V378, P386, DOI 10.1038/378386a0; MITCHELL PJ, 1991, GENE DEV, V5, P105, DOI 10.1101/gad.5.1.105; NODEN DM, 1975, DEV BIOL, V42, P106, DOI 10.1016/0012-1606(75)90318-8; O'Leary DDM, 1999, CURR OPIN NEUROBIOL, V9, P65, DOI 10.1016/S0959-4388(99)80008-7; Paria BC, 1999, DEVELOPMENT, V126, P1997; Pattyn A, 1997, DEVELOPMENT, V124, P4065; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; Quinlan GA, 1999, METH MOL B, V97, P41, DOI 10.1385/1-59259-270-8:41; Riese DJ, 1996, J BIOL CHEM, V271, P20047, DOI 10.1074/jbc.271.33.20047; RUBERTE E, 1992, DEVELOPMENT, V115, P973; SECHRIST J, 1993, DEVELOPMENT, V118, P691; SECHRIST J, 1994, DEVELOPMENT, V120, P1777; Shepherd I, 1996, DEV BIOL, V173, P185, DOI 10.1006/dbio.1996.0016; Smith A, 1997, CURR BIOL, V7, P561, DOI 10.1016/S0960-9822(06)00255-7; STURM K, 1993, METHOD ENZYMOL, V225, P164; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123; Trainor P, 2000, NAT CELL BIOL, V2, P96, DOI 10.1038/35000051; TRAINOR PA, 1994, DEVELOPMENT, V120, P2397; TRAINOR PA, 1995, DEVELOPMENT, V121, P2569; Ulupinar E, 1999, MOL CELL NEUROSCI, V13, P281, DOI 10.1006/mcne.1999.0747; Wang HU, 1997, NEURON, V18, P383, DOI 10.1016/S0896-6273(00)81240-4; WILKINSON DG, 1993, METHOD ENZYMOL, V225, P361; Zhang DX, 1997, P NATL ACAD SCI USA, V94, P9562, DOI 10.1073/pnas.94.18.9562	50	167	169	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	FEB	2000	2	2					103	109		10.1038/35000058	http://dx.doi.org/10.1038/35000058			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	281GA	10655590				2022-12-25	WOS:000085148500015
J	Mayfield, JA; Preuss, D				Mayfield, JA; Preuss, D			Rapid initiation of Arabidopsis pollination requires the oleosin-domain protein GRP17	NATURE CELL BIOLOGY			English	Article							POLLEN; THALIANA; GENES; RECOGNITION; COMPONENTS; EVOLUTION		Univ Chicago, Dept Mol Genet & Cell Biol, Chicago, IL 60637 USA	University of Chicago	Preuss, D (corresponding author), Univ Chicago, Dept Mol Genet & Cell Biol, 920 E 58Th St, Chicago, IL 60637 USA.			Mayfield, Jacob/0000-0002-5762-6755	NCRR NIH HHS [DRR-00480] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR000480] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		DEOLIVEIRA DE, 1993, PLANT J, V3, P495, DOI 10.1046/j.1365-313X.1993.03040495.x; ELLEMAN CJ, 1992, NEW PHYTOL, V121, P413, DOI 10.1111/j.1469-8137.1992.tb02941.x; Ferris PJ, 1997, P NATL ACAD SCI USA, V94, P8634, DOI 10.1073/pnas.94.16.8634; HANNOUFA A, 1993, PHYTOCHEMISTRY, V33, P851, DOI 10.1016/0031-9422(93)85289-4; Huang AHC, 1996, PLANT PHYSIOL, V110, P1055, DOI 10.1104/pp.110.4.1055; HULSKAMP M, 1995, PLANT J, V8, P703, DOI 10.1046/j.1365-313X.1995.08050703.x; LISTER C, 1993, PLANT J, V4, P745, DOI 10.1046/j.1365-313X.1993.04040745.x; MCKIBBEN B, 1995, WORLD WATCH, V8, P6; Murphy DJ, 1998, PLANT J, V13, P1; PREUSS D, 1993, GENE DEV, V7, P974, DOI 10.1101/gad.7.6.974; Shivanna K.R., 1992, POLLEN BIOL LAB MANU; Vacquier VD, 1998, SCIENCE, V281, P1995, DOI 10.1126/science.281.5385.1995; WEIGEL D, 1992, CELL, V69, P843, DOI 10.1016/0092-8674(92)90295-N; Wolters-Arts M, 1998, NATURE, V392, P818, DOI 10.1038/33929; Zinkl GM, 1999, DEVELOPMENT, V126, P5431	15	123	133	1	39	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	FEB	2000	2	2					128	130		10.1038/35000084	http://dx.doi.org/10.1038/35000084			3	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	281GA	10655594				2022-12-25	WOS:000085148500019
J	Thiele, C; Hannah, MJ; Fahrenholz, F; Huttner, WB				Thiele, C; Hannah, MJ; Fahrenholz, F; Huttner, WB			Cholesterol binds to synaptophysin and is required for biogenesis of synaptic vesicles	NATURE CELL BIOLOGY			English	Article							TRANS-GOLGI-NETWORK; VACUOLAR H+-ATPASE; MEMBRANE-PROTEIN; SECRETORY GRANULES; PLASMA-MEMBRANE; CELL-SURFACE; PC12 CELLS; IN-VITRO; MICROVESICLES; RECEPTOR	Here, to study lipid-protein interactions that contribute to the biogenesis of regulated secretory vesicles, we have developed new approaches by which to label proteins in vivo, using photoactivatable cholesterol and glycerophospholipids. We identify synaptophysin as a major specifically cholesterol-binding protein in PC12 cells and brain synaptic vesicles. Limited cholesterol depletion, which has little effect on total endocytic activity, blocks the biogenesis of synaptic-like microvesicles (SLMVs) from the plasma membrane. We propose that specific interactions between cholesterol and SLMV membrane proteins, such as synaptophysin, contribute to both the segregation of SLMV membrane constituents from plasma-membrane constituents, and the induction of synaptic-vesicle curvature.	Univ Heidelberg, Dept Neurobiol, D-69120 Heidelberg, Germany; Max Planck Inst Mol Cell Biol & Genet, D-01307 Dresden, Germany; Univ Mainz, Dept Biochem, D-55099 Mainz, Germany	Ruprecht Karls University Heidelberg; Max Planck Society; Johannes Gutenberg University of Mainz	Thiele, C (corresponding author), Univ Heidelberg, Dept Neurobiol, Im Neuenheimer Feld 364, D-69120 Heidelberg, Germany.		Huttner, Wieland B./P-4080-2018					BAUERFEIND R, 1995, FEBS LETT, V364, P328, DOI 10.1016/0014-5793(95)00419-A; BAUMERT M, 1989, EMBO J, V8, P379, DOI 10.1002/j.1460-2075.1989.tb03388.x; Beisswanger R, 1998, P NATL ACAD SCI USA, V95, P11134, DOI 10.1073/pnas.95.19.11134; BRAND SH, 1993, EMBO J, V12, P3753, DOI 10.1002/j.1460-2075.1993.tb06053.x; BRECKENRIDGE WC, 1973, BIOCHIM BIOPHYS ACTA, V320, P681, DOI 10.1016/0304-4165(73)90148-7; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; CHURCH RFR, 1970, J ORG CHEM, V35, P2465, DOI 10.1021/jo00833a001; CLIFTOGRADY L, 1990, J CELL BIOL, V110, P1693, DOI 10.1083/jcb.110.5.1693; Corradi N, 1996, J BIOL CHEM, V271, P27116, DOI 10.1074/jbc.271.43.27116; EVANS WH, 1985, BIOCHEM J, V232, P33, DOI 10.1042/bj2320033; Finbow ME, 1997, BIOCHEM J, V324, P697, DOI 10.1042/bj3240697; Goldberg AFX, 1996, BIOCHEMISTRY-US, V35, P6144, DOI 10.1021/bi960259n; Hannah MJ, 1998, METHODS, V16, P170, DOI 10.1006/meth.1998.0664; HEUMANN R, 1983, EXP CELL RES, V145, P179, DOI 10.1016/S0014-4827(83)80019-6; HUTTNER WB, 1983, J CELL BIOL, V96, P1374, DOI 10.1083/jcb.96.5.1374; Ikonen E, 1997, CURR OPIN LIPIDOL, V8, P60, DOI 10.1097/00041433-199704000-00002; IWATA S, 1995, NATURE, V376, P660, DOI 10.1038/376660a0; JAHN R, 1994, ANNU REV NEUROSCI, V17, P219, DOI 10.1146/annurev.ne.17.030194.001251; Keller P, 1998, J CELL BIOL, V140, P1357, DOI 10.1083/jcb.140.6.1357; Kirchhausen T, 1997, CURR OPIN CELL BIOL, V9, P488, DOI 10.1016/S0955-0674(97)80024-5; KLEIN U, 1995, BIOCHEMISTRY-US, V34, P13784, DOI 10.1021/bi00042a009; KURZCHALIA TV, 1992, J CELL BIOL, V118, P1003, DOI 10.1083/jcb.118.5.1003; Ledesma MD, 1998, P NATL ACAD SCI USA, V95, P3966, DOI 10.1073/pnas.95.7.3966; Lichtenstein Y, 1998, P NATL ACAD SCI USA, V95, P11223, DOI 10.1073/pnas.95.19.11223; MOLDAY RS, 1987, INVEST OPHTH VIS SCI, V28, P50; MONIER S, 1995, MOL BIOL CELL, V6, P911, DOI 10.1091/mbc.6.7.911; MURATA M, 1995, P NATL ACAD SCI USA, V92, P10339, DOI 10.1073/pnas.92.22.10339; Nickel W, 1998, SEMIN CELL DEV BIOL, V9, P493, DOI 10.1006/scdb.1998.0256; PEREZCASTINEIRA JR, 1990, BIOCHEM J, V271, P127, DOI 10.1042/bj2710127; PIMPLIKAR SW, 1994, J CELL BIOL, V125, P1025, DOI 10.1083/jcb.125.5.1025; PRYDE JG, 1986, BIOCHEM J, V233, P525, DOI 10.1042/bj2330525; Radhakrishnan R, 1980, Ann N Y Acad Sci, V346, P165, DOI 10.1111/j.1749-6632.1980.tb22099.x; Rodal SK, 1999, MOL BIOL CELL, V10, P961, DOI 10.1091/mbc.10.4.961; Schmidt A, 1998, METHODS, V16, P160, DOI 10.1006/meth.1998.0663; Schmidt A, 1997, J CELL BIOL, V137, P445, DOI 10.1083/jcb.137.2.445; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; SPECTOR AA, 1969, ANAL BIOCHEM, V32, P297, DOI 10.1016/0003-2697(69)90089-X; STOFFEL W, 1979, H-S Z PHYSIOL CHEM, V360, P197, DOI 10.1515/bchm2.1979.360.1.197; STOFFEL W, 1982, H-S Z PHYSIOL CHEM, V363, P1, DOI 10.1515/bchm2.1982.363.1.1; Subtil A, 1999, P NATL ACAD SCI USA, V96, P6775, DOI 10.1073/pnas.96.12.6775; Thiele C, 1998, SEMIN CELL DEV BIOL, V9, P511, DOI 10.1006/scdb.1998.0259; THOMAS L, 1988, SCIENCE, V242, P1050, DOI 10.1126/science.2461586; TOOZE SA, 1990, CELL, V60, P837, DOI 10.1016/0092-8674(90)90097-X; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; WESTERMAN J, 1983, EUR J BIOCHEM, V132, P441, DOI 10.1111/j.1432-1033.1983.tb07382.x; Wu TT, 1997, J CELL SCI, V110, P1533; Zacchetti D, 1995, FEBS LETT, V377, P465, DOI 10.1016/0014-5793(95)01396-2	48	455	459	0	30	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	JAN	2000	2	1					42	49		10.1038/71366	http://dx.doi.org/10.1038/71366			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	275WR	10620806				2022-12-25	WOS:000084843600018
J	Haracska, L; Yu, SL; Johnson, RE; Prakash, L; Prakash, S				Haracska, L; Yu, SL; Johnson, RE; Prakash, L; Prakash, S			Efficient and accurate replication in the presence of 7,8-dihydro-8-oxoguanine by DNA polymerase eta	NATURE GENETICS			English	Article							SACCHAROMYCES-CEREVISIAE; XERODERMA-PIGMENTOSUM; 8-OXO-GUANINE; TRANSVERSIONS; MUTAGENESIS; REQUIREMENT; FIDELITY; BYPASS; ASSAY; CELLS	Oxidative damage to DNA has been proposed to have a role in cancer and ageing(1). Oxygen-free radicals formed during normal aerobic cellular metabolism attack bases in DNA, and 7,8-dihydro-8-oxoguanine (8-oxoG) is one of the adducts formed(2,3). Eukaryotic replicative DNA polymerases replicate DNA containing 8-oxoG by inserting an adenine opposite the lesion(4); consequently. 8-oxoG is highly mutagenic and causes G:C to T:A transversions(5). Genetic studies in yeast have indicated a role for mismatch repair in minimizing the incidence of these mutations. In Saccharomyces cerevisiae, deletion of OGG1, encoding a DNA glycosylase that functions in the removal of 8-oxoG when paired with C, causes an increase in the rate of G:C to TA transversions(6). The ogg1 Delta msh2 Delta double mutant displays a higher rate of CAN1(S) to can1(r) forward mutations than the ogg1 Delta or msh2 Delta single mutants, and this enhanced mutagenesis is primarily due to C:C to T:A transversions(7). The gene RAD30 of S. cerevisiae encodes a DNA polymerase, Pol eta, that efficiently replicates DNA containing a cis-syn thymine-thymine (T-T) dimer by inserting two adenines across from the dimers. In humans, mutations in the yeast RAD30 counterpart, POLH, cause the variant form of xeroderma pigmentosum(9,10) (XP-V), and XP-V individuals suffer from a high incidence of sunlight-induced skin cancers. Here we show that yeast and human POL eta replicate DNA containing 8-oxoG efficiently and accurately by inserting a cytosine across from the lesion and by proficiently extending from this base pair. Consistent with these biochemical studies, a synergistic increase in the rate of spontaneous mutations occurs in the absence of POL eta in the yeast ogg1 Delta mutant. Our results suggest an additional role for Pol eta in the prevention of internal cancers in humans that would otherwise result from the mutagenic replication of 8-oxoG in DNA.	Univ Texas, Med Branch, Sealy Ctr Mol Sci, Galveston, TX 77550 USA	University of Texas System; University of Texas Medical Branch Galveston	Prakash, S (corresponding author), Univ Texas, Med Branch, Sealy Ctr Mol Sci, Galveston, TX 77550 USA.		Prakash, Satya/C-6420-2013	Prakash, Satya/0000-0001-7228-1444; Prakash, Louise/0000-0001-9143-6261	NATIONAL CANCER INSTITUTE [R01CA080882] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006676] Funding Source: NIH RePORTER; NCI NIH HHS [CA80882] Funding Source: Medline; NIEHS NIH HHS [P30-ES06676] Funding Source: Medline; NIGMS NIH HHS [GM19261] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALANI E, 1987, GENETICS, V116, P541, DOI 10.1534/genetics.112.541.test; AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915; Beckman KB, 1997, J BIOL CHEM, V272, P19633, DOI 10.1074/jbc.272.32.19633; Creighton S, 1995, METHOD ENZYMOL, V262, P232; Efrati E, 1999, J BIOL CHEM, V274, P15920, DOI 10.1074/jbc.274.22.15920; GOODMAN MF, 1993, CRIT REV BIOCHEM MOL, V28, P83, DOI 10.3109/10409239309086792; Helbock HJ, 1998, P NATL ACAD SCI USA, V95, P288, DOI 10.1073/pnas.95.1.288; HOFMANN H, 1978, B CANCER, V65, P347; Johnson RE, 1999, SCIENCE, V283, P1001, DOI 10.1126/science.283.5404.1001; Johnson RE, 1999, SCIENCE, V285, P263, DOI 10.1126/science.285.5425.263; Johnson RE, 1999, J BIOL CHEM, V274, P15975, DOI 10.1074/jbc.274.23.15975; LEA DE, 1949, J GENET, V49, P264, DOI 10.1007/BF02986080; Masutani C, 1999, NATURE, V399, P700, DOI 10.1038/21447; MENDELMAN LV, 1990, J BIOL CHEM, V265, P2338; MORIYA M, 1993, P NATL ACAD SCI USA, V90, P1122, DOI 10.1073/pnas.90.3.1122; Ni TT, 1999, MOL CELL, V4, P439, DOI 10.1016/S1097-2765(00)80346-9; Saparbaev M, 1996, GENETICS, V142, P727; SHIBUTANI S, 1991, NATURE, V349, P431, DOI 10.1038/349431a0; Thomas D, 1997, MOL GEN GENET, V254, P171, DOI 10.1007/s004380050405; Washington MT, 1999, J BIOL CHEM, V274, P36835, DOI 10.1074/jbc.274.52.36835	20	300	306	0	11	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	AUG	2000	25	4					458	461		10.1038/78169	http://dx.doi.org/10.1038/78169			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	341WY	10932195				2022-12-25	WOS:000088615000026
J	Ryoo, D; Shim, H; Canada, K; Barbieri, P; Wood, TK				Ryoo, D; Shim, H; Canada, K; Barbieri, P; Wood, TK			Aerobic degradation of tetrachloroethylene by toluene-o-xylene monooxygenase of Pseudomonas stutzeri OX1	NATURE BIOTECHNOLOGY			English	Article						PCE degradation; monoxygenase; Pseudomonas	METHYLOSINUS-TRICHOSPORIUM OB3B; SOLUBLE METHANE MONOOXYGENASE; CEPACIA G4; CHLORINATED SOLVENTS; TRICHLOROETHYLENE; OXIDATION; MINERALIZATION; STRAIN; PUTIDA; INACTIVATION	Tetrachloroethylene (PCE) is thought to have no natural source, so it is one of the most difficult contaminants to degrade biologically. This common groundwater pollutant was thought completely non-biodegradable in the presence of oxygen. Here we report that the wastewater bacterium Pseudomonas stutzeri OX1 degrades aerobically 0.56 mu mol of 2.0 mu mol PCE in 21 h (V-max approximate to 2.5 nmol min(-1) mg(-1) protein and K-M approximate to 34 mu M). These results were corroborated by the generation of 0.48 mu mol of the degradation product, chloride ions. This degradation was confirmed to be a result of expression of toluene-o-xylene monooxygenase (ToMO) by P. stutzeri OX1, since cloning and expressing this enzyme in Escherichia coli led to the aerobic degradation of 0.19 mu mol of 2.0 mu mol PCE and the generation of stoichiometric amounts of chloride. In addition, PCE induces formation of ToMO, which leads to its own degradation in P. stutzeri OX1. Degradation intermediates reduce the growth rate of this strain by 27%.	Univ Connecticut, Dept Chem Engn, Storrs, CT 06269 USA; Univ Milan, Dipartimento Genet & Biol Microrganismi, I-20133 Milan, Italy	University of Connecticut; University of Milan	Wood, TK (corresponding author), Univ Connecticut, Dept Chem Engn, Storrs, CT 06269 USA.	twood@engr.uconn.edu	Wood, Thomas/GWZ-2481-2022	Wood, Thomas/0000-0001-8962-8571; Wood, Thomas/0000-0002-6258-529X				Arenghi FLG, 1999, APPL ENVIRON MICROB, V65, P4057; BAGGI G, 1987, APPL ENVIRON MICROB, V53, P2129, DOI 10.1128/AEM.53.9.2129-2132.1987; BERGMANN JG, 1957, ANAL CHEM, V29, P241, DOI 10.1021/ac60122a018; Bertoni G, 1996, APPL ENVIRON MICROB, V62, P3704, DOI 10.1128/AEM.62.10.3704-3711.1996; Bertoni G, 1998, APPL ENVIRON MICROB, V64, P3626; Bolognese F, 1999, APPL ENVIRON MICROB, V65, P1876; Bradley PM, 1998, ENVIRON SCI TECHNOL, V32, P553, DOI 10.1021/es970498d; CARTER SR, 1993, WATER RES, V27, P607, DOI 10.1016/0043-1354(93)90170-M; Chauhan S, 1998, APPL ENVIRON MICROB, V64, P3023; ENSLEY BD, 1991, ANNU REV MICROBIOL, V45, P283; FOX BG, 1990, BIOCHEMISTRY-US, V29, P6419, DOI 10.1021/bi00479a013; HEALD S, 1994, APPL ENVIRON MICROB, V60, P4634, DOI 10.1128/AEM.60.12.4634-4637.1994; HOLLIGER C, 1993, APPL ENVIRON MICROB, V59, P2991, DOI 10.1128/AEM.59.9.2991-2997.1993; LEUNG SW, 1992, J ENVIRON QUAL, V21, P377, DOI 10.2134/jeq1992.00472425002100030012x; Luu PP, 1995, APPL MICROBIOL BIOT, V44, P259, DOI 10.1007/BF00164512; Mars AE, 1996, APPL ENVIRON MICROB, V62, P886, DOI 10.1128/AEM.62.3.886-891.1996; MaymoGatell X, 1997, SCIENCE, V276, P1568, DOI 10.1126/science.276.5318.1568; McCarty PL, 1997, SCIENCE, V276, P1521, DOI 10.1126/science.276.5318.1521; MCCLAY K, 1995, APPL ENVIRON MICROB, V61, P3479, DOI 10.1128/AEM.61.9.3479-3481.1995; MERCER J W, 1990, Journal of Contaminant Hydrology, V6, P107, DOI 10.1016/0169-7722(90)90043-G; NELSON MJK, 1987, APPL ENVIRON MICROB, V53, P949, DOI 10.1128/AEM.53.5.949-954.1987; Newman LM, 1997, J BACTERIOL, V179, P90, DOI 10.1128/jb.179.1.90-96.1997; PHELPS PA, 1992, APPL ENVIRON MICROB, V58, P3701, DOI 10.1128/AEM.58.11.3701-3708.1992; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sharma PK, 1996, APPL ENVIRON MICROB, V62, P761, DOI 10.1128/AEM.62.3.761-765.1996; SHIELDS MS, 1995, APPL ENVIRON MICROB, V61, P1352, DOI 10.1128/AEM.61.4.1352-1356.1995; SHIM H, 2000, IN PRESS BIOTECHNOL; Shingleton JT, 1998, APPL ENVIRON MICROB, V64, P5049; Sun AK, 1996, APPL MICROBIOL BIOT, V45, P248, DOI 10.1007/s002530050679; Vlieg JETV, 1996, APPL ENVIRON MICROB, V62, P3304, DOI 10.1128/AEM.62.9.3304-3312.1996; WACKETT LP, 1989, APPL ENVIRON MICROB, V55, P2723, DOI 10.1128/AEM.55.10.2723-2725.1989; WESTRICK JJ, 1984, J AM WATER WORKS ASS, V76, P52; Yee DC, 1998, APPL ENVIRON MICROB, V64, P112	33	103	106	2	46	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JUL	2000	18	7					775	778		10.1038/77344	http://dx.doi.org/10.1038/77344			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	331YN	10888848				2022-12-25	WOS:000088046400029
J	Netchine, I; Sobrier, ML; Krude, H; Schnabel, D; Maghnie, M; Marcos, E; Duriez, B; Cacheux, V; von Moers, A; Goossens, M; Gruters, A; Amselem, S				Netchine, I; Sobrier, ML; Krude, H; Schnabel, D; Maghnie, M; Marcos, E; Duriez, B; Cacheux, V; von Moers, A; Goossens, M; Gruters, A; Amselem, S			Mutations in LHX3 result in a new syndrome revealed by combined pituitary hormone deficiency	NATURE GENETICS			English	Article							GENOMIC STRUCTURE; GENE-EXPRESSION; MOTOR-NEURONS; LIM; SPECIFICATION; HYBRIDIZATION; SENSITIVITY; GLAND	Combined pituitary hormone deficiency (CPHD) has been linked with rare abnormalities in genes encoding transcription factors necessary for pituitary development(1). We have isolated LHX3, a gene involved in a new syndrome, using a candidate-gene approach developed on the basis of documented pituitary abnormalities of a recessive lethal mutation in mice generated by targeted disruption of Lhx3 (ref. 2). LHX3, encoding a member of the LIM class of homeodomain proteins(3), consists of at least six exons located at 9q34. We identified a homozygous LHX3 defect in patients of two unrelated consanguineous families displaying a complete deficit in all but one (adrenocorticotropin) anterior pituitary hormone and a rigid cervical spine leading to limited head rotation. Two of these patients also displayed a severe pituitary hypoplasia, whereas one patient presented secondarily with an enlarged anterior pituitary. These LHX3 mutations consist of a missense mutation (Y116C) in the LIM2 domain at a phylogenetically conserved residue and an intragenic deletion predicting a severely truncated protein lacking the entire homeodomain. These data are consistent with function of LHX3 in the proper development of all anterior pituitary cell types, except corticotropes, and extrapituitary structures.	Hop Henri Mondor, INSERM, U468, Lab Genet & Physiopathol, F-94010 Creteil, France; Humboldt Univ, Dept Pediat, Charite, Berlin, Germany; Humboldt Univ, Dept Pediat Neurol, Charite, Berlin, Germany; Univ Pavia, Policlin San Matteo, IRCCS, Dept Pediat, I-27100 Pavia, Italy	Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; IRCCS Fondazione San Matteo; University of Pavia	Amselem, S (corresponding author), Hop Henri Mondor, INSERM, U468, Lab Genet & Physiopathol, F-94010 Creteil, France.		Sobrier, Marie-Laure/L-4820-2017; Duriez, Benedicte/Z-4690-2019	Sobrier, Marie-Laure/0000-0001-6396-100X				Appel B, 1995, DEVELOPMENT, V121, P4117; BACH I, 1995, P NATL ACAD SCI USA, V92, P2720, DOI 10.1073/pnas.92.7.2720; Burrows HL, 1999, TRENDS ENDOCRIN MET, V10, P343, DOI 10.1016/S1043-2760(99)00189-7; COULY G, 1988, DEVELOPMENT, V103, P101; Dawid IB, 1998, TRENDS GENET, V14, P156, DOI 10.1016/S0168-9525(98)01424-3; Duquesnoy P, 1998, FEBS LETT, V437, P216, DOI 10.1016/S0014-5793(98)01234-4; EAGLESON GW, 1990, J NEUROBIOL, V21, P427, DOI 10.1002/neu.480210305; IKEDA H, 1988, ANAT EMBRYOL, V178, P327, DOI 10.1007/BF00698663; JAPON MA, 1994, J HISTOCHEM CYTOCHEM, V42, P1117, DOI 10.1177/42.8.8027530; Mendonca BB, 1999, J CLIN ENDOCR METAB, V84, P942, DOI 10.1210/jc.84.3.942; Parks JS, 1999, J CLIN ENDOCR METAB, V84, P4362, DOI 10.1210/jc.84.12.4362; PINKEL D, 1986, P NATL ACAD SCI USA, V83, P2934, DOI 10.1073/pnas.83.9.2934; SANCHEZGARCIA I, 1994, TRENDS GENET, V10, P315, DOI 10.1016/0168-9525(94)90034-5; Sharma K, 1998, CELL, V95, P817, DOI 10.1016/S0092-8674(00)81704-3; Sheng HZ, 1996, SCIENCE, V272, P1004, DOI 10.1126/science.272.5264.1004; TAIRA M, 1993, DEV BIOL, V159, P245, DOI 10.1006/dbio.1993.1237; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TSUCHIDA T, 1994, CELL, V79, P957, DOI 10.1016/0092-8674(94)90027-2; Wu W, 1998, NAT GENET, V18, P147, DOI 10.1038/ng0298-147; ZHADANOV AB, 1995, GENOMICS, V27, P27, DOI 10.1006/geno.1995.1004	20	235	242	1	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUN	2000	25	2					182	186		10.1038/76041	http://dx.doi.org/10.1038/76041			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	321ML	10835633				2022-12-25	WOS:000087459200017
J	Parveen, Z; Krupetsky, A; Engelstadter, M; Cichutek, K; Pomerantz, RJ; Dornburg, R				Parveen, Z; Krupetsky, A; Engelstadter, M; Cichutek, K; Pomerantz, RJ; Dornburg, R			Spleen necrosis virus-derived C-type retroviral vectors for gene transfer to quiescent cells	NATURE BIOTECHNOLOGY			English	Article						gene therapy; retroviral vectors; hematopoietic cells; gene transfer; T lymphocytes; macrophages	HUMAN-IMMUNODEFICIENCY-VIRUS; NUCLEAR-LOCALIZATION SIGNAL; SINGLE-CHAIN ANTIBODIES; MATRIX PROTEIN; NONDIVIDING CELLS; LENTIVIRUS VECTOR; ENVELOPE PROTEIN; HIV-1 INFECTION; THERAPY; MACROPHAGES	Gene therapy applications of retroviral vectors derived from C-type retroviruses have been limited to introducing genes into dividing target cells. Here, we report genetically engineered C-type retroviral vectors derived from spleen necrosis virus (SNV), which are capable of infecting nondividing cells, This has been achieved by introducing a nuclear localization signal (NLS) sequence into the matrix protein (MA) of SNV by site-directed mutagenesis. This increased the efficiency of infecting nondividing cells and was sufficient to endow the virus with the capability to efficiently infect growth-arrested human T lymphocytes and quiescent primary monocyte-derived macrophages. We demonstrate that this vector actively penetrates the nucleus of a target cell, and has potential use as a gene therapy vector to transfer genes into nondividing cells.	Thomas Jefferson Univ, Ctr Human Virol, Div Infect Dis, Dorrance H Hamilton Labs, Philadelphia, PA 19107 USA; Paul Ehrlich Inst, D-63225 Langen, Germany	Jefferson University; Paul Ehrlich Institute	Dornburg, R (corresponding author), Thomas Jefferson Univ, Ctr Human Virol, Div Infect Dis, Dorrance H Hamilton Labs, 1020 Locust St,Suite 329, Philadelphia, PA 19107 USA.	ralph.dornbur1@mail.tju.edu			NIAID NIH HHS [1RO1 AI 41899-01] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI041899] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Anderson WF, 1998, NATURE, V392, P25; BLAESE M, 1995, CANCER GENE THER, V2, P291; BLAESE RM, 1995, SCIENCE, V270, P475, DOI 10.1126/science.270.5235.475; Boulikas T, 1996, J CELL BIOCHEM, V60, P61, DOI 10.1002/(SICI)1097-4644(19960101)60:1<61::AID-JCB10>3.0.CO;2-N; BUKRINSKY MI, 1993, NATURE, V365, P666, DOI 10.1038/365666a0; CHU THT, 1994, GENE THER, V1, P292; CHU THT, 1995, J VIROL, V69, P2659, DOI 10.1128/JVI.69.4.2659-2663.1995; Chu THT, 1997, J VIROL, V71, P720, DOI 10.1128/JVI.71.1.720-725.1997; COFFIN JM, 1992, CURR TOP MICROBIOL, V176, P143; COLLMAN R, 1989, J EXP MED, V170, P1149, DOI 10.1084/jem.170.4.1149; DEMINIE CA, 1994, J VIROL, V68, P4442, DOI 10.1128/JVI.68.7.4442-4449.1994; DEMINIE CA, 1993, J VIROL, V67, P6499, DOI 10.1128/JVI.67.11.6499-6506.1993; DORNBURG R, 1995, GENE THER, V2, P301; Dornburg R, 1997, BIOL CHEM, V378, P457; Dull T, 1998, J VIROL, V72, P8463, DOI 10.1128/JVI.72.11.8463-8471.1998; Engelstadter M, 2000, HUM GENE THER, V11, P293, DOI 10.1089/10430340050016030; Fouchier RAM, 1997, EMBO J, V16, P4531, DOI 10.1093/emboj/16.15.4531; Gautier R, 2000, J VIROL, V74, P518, DOI 10.1128/JVI.74.1.518-522.2000; GILBOA E, 1994, TRENDS GENET, V10, P139, DOI 10.1016/0168-9525(94)90216-X; Gorlich D, 1997, CURR OPIN CELL BIOL, V9, P412, DOI 10.1016/S0955-0674(97)80015-4; HU WS, 1990, SCIENCE, V250, P1227, DOI 10.1126/science.1700865; HUANG ZB, 1993, J VIROL, V67, P6893, DOI 10.1128/JVI.67.11.6893-6896.1993; Jiang A, 1999, GENE THER, V6, P1982, DOI 10.1038/sj.gt.3301043; Jiang A, 1998, J VIROL, V72, P10148, DOI 10.1128/JVI.72.12.10148-10156.1998; KEWALRAMANI VN, 1992, J VIROL, V66, P3026, DOI 10.1128/JVI.66.5.3026-3031.1992; Kootstra NA, 1999, VIROLOGY, V253, P170, DOI 10.1006/viro.1998.9482; LEWIS PF, 1994, J VIROL, V68, P510, DOI 10.1128/JVI.68.1.510-516.1994; MARTINEZ I, 1995, VIROLOGY, V208, P234, DOI 10.1006/viro.1995.1147; Martinez I, 1996, HUM GENE THER, V7, P705, DOI 10.1089/hum.1996.7.6-705; MARTINEZ I, 1995, J VIROL, V69, P4339, DOI 10.1128/JVI.69.7.4339-4346.1995; Martinez I, 1996, J VIROL, V70, P6036, DOI 10.1128/JVI.70.9.6036-6043.1996; MIKAWA T, 1991, EXP CELL RES, V195, P516, DOI 10.1016/0014-4827(91)90404-I; MILLER AD, 1992, CURR TOP MICROBIOL, V158, P1; MILLER AD, 1990, HUM GENE THER, V1, P5, DOI 10.1089/hum.1990.1.1-5; Miyake K, 1998, HUM GENE THER, V9, P467, DOI 10.1089/hum.1998.9.4-467; Moroianu J, 1997, CRIT REV EUKAR GENE, V7, P61, DOI 10.1615/CritRevEukarGeneExpr.v7.i1-2.40; Naldini L, 1996, P NATL ACAD SCI USA, V93, P11382, DOI 10.1073/pnas.93.21.11382; PICARD V, 1994, NUCLEIC ACIDS RES, V22, P2587, DOI 10.1093/nar/22.13.2587; Poeschla E, 1996, P NATL ACAD SCI USA, V93, P11395, DOI 10.1073/pnas.93.21.11395; POMERANTZ RJ, 1995, AIDS, V9, P985, DOI 10.1097/00002030-199509000-00002; Robbins PD, 1998, TRENDS BIOTECHNOL, V16, P35, DOI 10.1016/S0167-7799(97)01137-2; Sambrook J, 1995, MOL CLONING LAB MANU; SCHWEDLER U, 1994, P NATL ACAD SCI USA, V91, P6992; STEVENSON M, 1994, J LEUKOCYTE BIOL, V56, P278, DOI 10.1002/jlb.56.3.278; Temin H M, 1971, J Natl Cancer Inst, V46, P3; TEMIN HM, 1991, TRENDS GENET, V7, P71, DOI 10.1016/0168-9525(91)90048-U; TEMIN HM, 1986, GENE TRANSFER, P144; Urban A, 1997, NUCLEIC ACIDS RES, V25, P2227, DOI 10.1093/nar/25.11.2227; VARMUS HE, 1988, MOBILE DNA, P53; VILE R, 1994, GENE THER, V1, P88; Vile RG, 1996, MOL BIOTECHNOL, V5, P139, DOI 10.1007/BF02789062; VONSCHWEDLER U, 1994, P NATL ACAD SCI USA, V91, P6992, DOI 10.1073/pnas.91.15.6992; Weichselbaum RR, 1997, LANCET, V349, pS10, DOI 10.1016/S0140-6736(97)90013-1; Yoneda Y, 1997, J BIOCHEM, V121, P811; Zufferey R, 1998, J VIROL, V72, P9873, DOI 10.1128/JVI.72.12.9873-9880.1998	55	26	31	0	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JUN	2000	18	6					623	629		10.1038/76458	http://dx.doi.org/10.1038/76458			7	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	325EK	10835599				2022-12-25	WOS:000087663200021
J	Arad, G; Levy, R; Hillman, D; Kaempfer, R				Arad, G; Levy, R; Hillman, D; Kaempfer, R			Superantigen antagonist protects against lethal shock and defines a new domain for T-cell activation	NATURE MEDICINE			English	Article							STAPHYLOCOCCAL-ENTEROTOXIN-B; TUMOR-NECROSIS-FACTOR; RECEPTOR-BETA-CHAIN; COMPLEX CLASS-II; INTERLEUKIN-2 GENE-EXPRESSION; AUREUS TOXIN SUPERANTIGENS; CRYSTAL-STRUCTURE; BINDING-SITES; HLA-DR; MICE	Superantigens trigger an excessive cellular immune response, leading to toxic shock. We have designed a peptide antagonist that inhibits superantigen-induced expression of human genes for interleukin-2, gamma interferon and tumor necrosis factor-b, which are cytokines that mediate shock. The peptide shows homology to a b-strand-hinge-a-helix domain that is structurally conserved in superantigens, yet is remote from known binding sites for the major histocompatibility class II molecule and T-cell receptor. Superantigens depend on this domain for T-cell activation. The peptide protected mice against lethal challenge with staphylococcal and streptococcal superantigens. Moreover, it rescued mice undergoing toxic shock. Surviving mice rapidly developed protective antibodies against superantigen that rendered them resistant to further lethal challenges, even with different superantigens. Thus, the lethal effect of superantigens can be blocked with a peptide antagonist that inhibits their action at the beginning of the toxicity cascade, before activation of T cells takes place.	Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Mol Virol, IL-91120 Jerusalem, Israel	Hebrew University of Jerusalem	Kaempfer, R (corresponding author), Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Mol Virol, IL-91120 Jerusalem, Israel.	kaempfer@cc.huji.ac.il		Kaempfer, Raymond/0000-0002-5865-4619				ABRAHMSEN L, 1995, EMBO J, V14, P2978, DOI 10.1002/j.1460-2075.1995.tb07300.x; ARAD G, 1995, CELL IMMUNOL, V160, P240, DOI 10.1016/0008-8749(95)80034-G; Basma H, 1999, INFECT IMMUN, V67, P1871; BEAN AGD, 1993, INFECT IMMUN, V61, P4937, DOI 10.1128/IAI.61.11.4937-4939.1993; BETLEY MJ, 1988, J BACTERIOL, V170, P34, DOI 10.1128/jb.170.1.34-41.1988; BOHACH GA, 1990, CRIT REV MICROBIOL, V17, P251, DOI 10.3109/10408419009105728; BUELOW R, 1992, J IMMUNOL, V148, P1; CHOI YW, 1990, NATURE, V346, P471, DOI 10.1038/346471a0; CHOI YW, 1989, P NATL ACAD SCI USA, V86, P8941, DOI 10.1073/pnas.86.22.8941; Earhart CA, 1998, BIOCHEMISTRY-US, V37, P7194, DOI 10.1021/bi9721896; Fields BA, 1996, NATURE, V384, P188, DOI 10.1038/384188a0; FIORENTINO DF, 1991, J IMMUNOL, V146, P3444; FRASER JD, 1989, NATURE, V339, P221, DOI 10.1038/339221a0; GALANOS C, 1979, P NATL ACAD SCI USA, V76, P5939, DOI 10.1073/pnas.76.11.5939; GEREZ L, 1991, CLIN IMMUNOL IMMUNOP, V58, P251, DOI 10.1016/0090-1229(91)90140-6; GEREZ L, 1995, J BIOL CHEM, V270, P19569, DOI 10.1074/jbc.270.33.19569; Groux H, 1996, J EXP MED, V184, P19, DOI 10.1084/jem.184.1.19; HACKETT SP, 1993, J INFECT DIS, V168, P232, DOI 10.1093/infdis/168.1.232; HERMAN A, 1991, ANNU REV IMMUNOL, V9, P745, DOI 10.1146/annurev.iy.09.040191.003525; HOFFMANN ML, 1994, INFECT IMMUN, V62, P3396, DOI 10.1128/IAI.62.8.3396-3407.1994; HUDSON KR, 1995, J EXP MED, V182, P711, DOI 10.1084/jem.182.3.711; JANEWAY CA, 1989, IMMUNOL REV, V107, P61, DOI 10.1111/j.1600-065X.1989.tb00003.x; JARDETZKY TS, 1994, NATURE, V368, P711, DOI 10.1038/368711a0; Jarrous N, 1996, MOL CELL BIOL, V16, P2814; JETT M, 1994, INFECT IMMUN, V62, P3408, DOI 10.1128/IAI.62.8.3408-3415.1994; Kaempfer R, 1996, J CLIN ONCOL, V14, P1778, DOI 10.1200/JCO.1996.14.6.1778; KAPPLER J, 1989, SCIENCE, V244, P811, DOI 10.1126/science.2524876; KAPPLER JW, 1992, J EXP MED, V175, P387, DOI 10.1084/jem.175.2.387; KOMISAR JL, 1994, INFECT IMMUN, V62, P4775, DOI 10.1128/IAI.62.11.4775-4780.1994; Leder L, 1998, J EXP MED, V187, P823, DOI 10.1084/jem.187.6.823; Lowell GH, 1996, INFECT IMMUN, V64, P1706, DOI 10.1128/IAI.64.5.1706-1713.1996; MARRACK P, 1990, SCIENCE, V248, P705, DOI 10.1126/science.2185544; MARRACK P, 1990, J EXP MED, V171, P455, DOI 10.1084/jem.171.2.455; MIETHKE T, 1992, J EXP MED, V175, P91, DOI 10.1084/jem.175.1.91; MURAILLE E, 1995, EUR J IMMUNOL, V25, P2111, DOI 10.1002/eji.1830250747; MURAILLE E, 1995, CELL IMMUNOL, V162, P315, DOI 10.1006/cimm.1995.1084; MURRAY DL, 1995, ASM NEWS, V61, P229; Papageorgiou AC, 1998, J MOL BIOL, V277, P61, DOI 10.1006/jmbi.1997.1577; PRASAD GS, 1993, BIOCHEMISTRY-US, V32, P13762, DOI 10.1021/bi00213a001; Saha B, 1996, J IMMUNOL, V157, P3869; SCHAD EM, 1995, EMBO J, V14, P3292, DOI 10.1002/j.1460-2075.1995.tb07336.x; SCHLIEVERT PM, 1993, J INFECT DIS, V167, P997, DOI 10.1093/infdis/167.5.997; SCHOLL P, 1989, P NATL ACAD SCI USA, V86, P4210, DOI 10.1073/pnas.86.11.4210; SWAMINATHAN S, 1992, NATURE, V359, P801, DOI 10.1038/359801a0; UCHIYAMA T, 1989, CLIN EXP IMMUNOL, V75, P239; Wang Z.-M., 1993, PSYCHOL DEV SOC, V5, P151, DOI [10. 1177/097133369300500204, DOI 10.1177/097133369300500204]	46	124	144	0	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2000	6	4					414	421		10.1038/74672	http://dx.doi.org/10.1038/74672			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	376UA	10742148				2022-12-25	WOS:000165474100035
J	Barembaum, M; Moreno, TA; LaBonne, C; Sechrist, J; Bronner-Fraser, M				Barembaum, M; Moreno, TA; LaBonne, C; Sechrist, J; Bronner-Fraser, M			Noelin-1 is a secreted glycoprotein involved in generation of the neural crest	NATURE CELL BIOLOGY			English	Article							CELLS; OLFACTOMEDIN; TUBE; ORIGINS; GENE; REGENERATION; MIGRATION; ECTODERM; SLUG	The vertebrate neural crest arises at the border of the neural plate during early stages of nervous system development; however, little is known about the molecular mechanisms underlying neural crest formation. Here we identify a secreted protein, Noelin-1, which has the ability to prolong neural crest production. Noelin-1 messenger RNA is expressed in a graded pattern in the closing neural tube. It subsequently becomes restricted to the dorsal neural folds and migrating neural crest. Over expression of Noelin-1 using recombinant retroviruses causes an excess of neural crest emigration and extends the time that the neural tube is competent to generate as well as regenerate neural crest cells. These results support an important role for Noelin-1 in regulating the production of neural crest cells by the neural tube.	CALTECH, Div Biol, Pasadena, CA 91125 USA	California Institute of Technology	Bronner-Fraser, M (corresponding author), CALTECH, Div Biol, 139-74, Pasadena, CA 91125 USA.			Bronner, Marianne/0000-0003-4274-1862	NINDS NIH HHS [NS 34671, NS 36585] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R37NS036585, R01NS036585, R01NS034671] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Baker CVH, 1997, MECH DEVELOP, V69, P3, DOI 10.1016/S0925-4773(97)00132-9; BRAY P, 1991, P NATL ACAD SCI USA, V88, P9563, DOI 10.1073/pnas.88.21.9563; BRONNERFRASER M, 1988, NATURE, V335, P161, DOI 10.1038/335161a0; BRONNERFRASER M, 1980, DEV BIOL, V77, P130, DOI 10.1016/0012-1606(80)90461-3; DANIELSON PE, 1994, J NEUROSCI RES, V38, P468, DOI 10.1002/jnr.490380413; DICKINSON ME, 1995, DEVELOPMENT, V121, P2099; Farlie PG, 1999, DEV BIOL, V213, P70, DOI 10.1006/dbio.1999.9332; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; HUNT P, 1995, DEV BIOL, V168, P584, DOI 10.1006/dbio.1995.1104; Krasnoperov VG, 1997, NEURON, V18, P925, DOI 10.1016/S0896-6273(00)80332-3; LALLIER T, 1991, DEVELOPMENT, V113, P1069; Le Douarin N.M., 1982, NEURAL CREST; LIEM KF, 1995, CELL, V82, P969, DOI 10.1016/0092-8674(95)90276-7; LUMSDEN A, 1991, DEVELOPMENT, V113, P1281; Martinsen BJ, 1998, SCIENCE, V281, P988, DOI 10.1126/science.281.5379.988; MORGAN BA, 1996, METHODS AVIAN EMBRYO, P185; MOURY JD, 1990, DEV BIOL, V141, P243, DOI 10.1016/0012-1606(90)90380-2; Nagano T, 1998, MOL BRAIN RES, V53, P13, DOI 10.1016/S0169-328X(97)00271-4; Nguyen TD, 1998, J BIOL CHEM, V273, P6341, DOI 10.1074/jbc.273.11.6341; NIETO MA, 1994, SCIENCE, V264, P835, DOI 10.1126/science.7513443; Raff MC, 1996, CELL, V86, P173, DOI 10.1016/S0092-8674(00)80087-2; Sambrook J., 2002, MOL CLONING LAB MANU; SCHERSON T, 1993, DEVELOPMENT, V118, P1049; Sechrist J, 1995, DEVELOPMENT, V121, P4103; SECHRIST J, 1993, DEVELOPMENT, V118, P691; SELLECK MAJ, 1995, DEVELOPMENT, V121, P525; SERBEDZIJA GN, 1989, DEVELOPMENT, V106, P809; SMITH WC, 1993, NATURE, V361, P547, DOI 10.1038/361547a0; Suzuki HR, 1997, DEV BIOL, V184, P222, DOI 10.1006/dbio.1997.8529; Tanabe Y, 1996, SCIENCE, V274, P1115, DOI 10.1126/science.274.5290.1115; VINCENT M, 1984, DEV BIOL, V103, P468, DOI 10.1016/0012-1606(84)90334-8; WILKINSON DG, 1992, IN SITU HYBRIDIZATIO, P75; YOKOE H, 1993, P NATL ACAD SCI USA, V90, P4655, DOI 10.1073/pnas.90.10.4655	34	114	118	1	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	APR	2000	2	4					219	225		10.1038/35008643	http://dx.doi.org/10.1038/35008643			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	302ZU	10783240				2022-12-25	WOS:000086397000015
J	Clynes, RA; Towers, TL; Presta, LG; Ravetch, JV				Clynes, RA; Towers, TL; Presta, LG; Ravetch, JV			Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets	NATURE MEDICINE			English	Article							MONOCLONAL-ANTIBODY; CELL-LINES; ANTITUMOR-ACTIVITY; GROWTH-INHIBITION; RESPONSES; LYMPHOMA; THERAPY; MICE	Inhibitory receptors have been proposed to modulate the in vivo cytotoxic response against tumor targets for both spontaneous and antibody-dependent pathways'. Using a variety of syngenic and xenograft models, we demonstrate here that the inhibitory Fc gamma RIIB molecule is a potent regulator of antibody-dependent cell-mediated cytotoxicity in vivo, modulating the activity of Fc gamma RIII on effector cells. Although many mechanisms have been proposed to account for the anti-tumor activities of therapeutic antibodies, including extended half-life, blockade of signaling pathways, activation of apoptosis and effector-cell-mediated cytotoxicity, we show here that engagement of Fc gamma receptors on effector cells is a dominant component of the in vivo activity of antibodies against tumors. Mouse monoclonal antibodies, as well as the humanized, clinically effective therapeutic agents trastuzumab (Herceptin(R)) and rituximab (Rituxan(R)), engaged both activation (Fc gamma RIII) and inhibitory (Fc gamma RIIB) antibody receptors on myeloid cells, thus modulating their cytotoxic potential. Mice deficient in Fc gamma RIIB showed much more antibody-dependent cell-mediated cytotoxicity; in contrast, mice deficient in activating Fc receptors as well as antibodies engineered to disrupt Fc binding to those receptors were unable to arrest tumor growth in vivo. These results demonstrate that Fc-receptor-dependent mechanisms contribute substantially to the action of cytotoxic antibodies against tumors and indicate that an optimal antibody against tumors would bind preferentially to activation Fc receptors and minimally to the inhibitory partner Fc gamma RIIB.	Rockefeller Univ, Lab Mol Genet & Immunol, New York, NY 10021 USA; Genentech Inc, Dept Immunol, S San Francisco, CA 94080 USA	Rockefeller University; Roche Holding; Genentech	Ravetch, JV (corresponding author), Rockefeller Univ, Lab Mol Genet & Immunol, 1230 York Ave, New York, NY 10021 USA.		Ravetch, Jeffrey/Z-1596-2019	Ravetch, Jeffrey/0000-0003-2024-9041				Baselga J, 1998, CANCER RES, V58, P2825; Bolland S, 1999, ADV IMMUNOL, V72, P149, DOI 10.1016/S0065-2776(08)60019-X; CARTER P, 1992, P NATL ACAD SCI USA, V89, P4285, DOI 10.1073/pnas.89.10.4285; Clynes R, 1998, P NATL ACAD SCI USA, V95, P652, DOI 10.1073/pnas.95.2.652; FAN Z, 1993, CANCER RES, V53, P4322; Funakoshi S, 1996, J IMMUNOTHER, V19, P93, DOI 10.1097/00002371-199603000-00002; HUDZIAK RM, 1989, MOL CELL BIOL, V9, P1165, DOI 10.1128/MCB.9.3.1165; Kopreski MS, 1996, ANTICANCER RES, V16, P433; Leget Gail A., 1998, Current Opinion in Oncology, V10, P548, DOI 10.1097/00001622-199811000-00012; LEWIS GD, 1993, CANCER IMMUNOL IMMUN, V37, P255, DOI 10.1007/BF01518520; LIU J, 1995, BIOCHEMISTRY-US, V34, P10474, DOI 10.1021/bi00033a020; MASUI H, 1986, CANCER RES, V46, P5592; Pegram MD, 1998, J CLIN ONCOL, V16, P2659, DOI 10.1200/JCO.1998.16.8.2659; Shan D, 1998, BLOOD, V91, P1644, DOI 10.1182/blood.V91.5.1644.1644_1644_1652; Taji H, 1998, JPN J CANCER RES, V89, P748, DOI 10.1111/j.1349-7006.1998.tb03280.x; TAKAI T, 1994, CELL, V76, P519, DOI 10.1016/0092-8674(94)90115-5; Takai T, 1996, NATURE, V379, P346, DOI 10.1038/379346a0; Tutt AL, 1998, J IMMUNOL, V161, P3176; WALDMANN TA, 1994, ANN ONCOL S13, V5, P1	19	2134	2399	3	137	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	APR	2000	6	4					443	446		10.1038/74704	http://dx.doi.org/10.1038/74704			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	376UA	10742152				2022-12-25	WOS:000165474100039
J	Collins, KB; Patterson, BK; Naus, GJ; Landers, DV; Gupta, P				Collins, KB; Patterson, BK; Naus, GJ; Landers, DV; Gupta, P			Development of an in vitro organ culture model to study transmission of HIV-1 in the female genital tract	NATURE MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; FLOW CYTOMETRIC ANALYSIS; EPITHELIAL-CELL LINE; INTRAVAGINAL INOCULATION; RHESUS MACAQUES; INFECTION; SEMEN; MEN; EXPRESSION; CARCINOMA		Univ Pittsburgh, Grad Sch Publ Hlth, Dept Infect Dis & Microbiol, Pittsburgh, PA 15261 USA; Northwestern Univ, Sch Med, Childrens Mem Hosp, Dept Pediat,Div Special Infect Dis, Chicago, IL 60614 USA; Univ Pittsburgh, Magee Womens Hosp, Dept Pathol, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Magee Womens Hosp, Dept Obstet Gynecol & Reprod Sci, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Gupta, P (corresponding author), Univ Pittsburgh, Grad Sch Publ Hlth, Dept Infect Dis & Microbiol, Pittsburgh, PA 15261 USA.		Abrams, William R/A-5782-2008		EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD032256] Funding Source: NIH RePORTER; NICHD NIH HHS [R01-HD-32256] Funding Source: Medline; PHS HHS [2P01A139061] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Atula S, 1997, EXP CELL RES, V235, P180, DOI 10.1006/excr.1997.3676; Bomsel M, 1997, NAT MED, V3, P42, DOI 10.1038/nm0197-42; Chackerian B, 1997, J VIROL, V71, P3932, DOI 10.1128/JVI.71.5.3932-3939.1997; DELVENNE P, 1995, AM J PATHOL, V146, P589; GOSSELIN EJ, 1995, ADV EXP MED BIOL, V371, P1003; Gupta P, 1997, J VIROL, V71, P6271, DOI 10.1128/JVI.71.8.6271-6275.1997; Howell AL, 1997, J VIROL, V71, P3498, DOI 10.1128/JVI.71.5.3498-3506.1997; LEVY J, 1998, HIV PATHOGENESIS, P29; MERMIN JH, 1991, J INFECT DIS, V164, P769, DOI 10.1093/infdis/164.4.769; Meyers Craig, 1996, Methods in Cell Science, V18, P201, DOI 10.1007/BF00132885; MILLER CJ, 1994, J VIROL, V68, P6391, DOI 10.1128/JVI.68.10.6391-6400.1994; MILLER CJ, 1989, J VIROL, V63, P4277, DOI 10.1128/JVI.63.10.4277-4284.1989; Patterson BK, 1999, LANCET, V353, P211, DOI 10.1016/S0140-6736(05)77222-6; Patterson BK, 1998, CYTOMETRY, V31, P265, DOI 10.1002/(SICI)1097-0320(19980401)31:4&lt;265::AID-CYTO6&gt;3.0.CO;2-I; Patterson BK, 1998, AM J PATHOL, V153, P481, DOI 10.1016/S0002-9440(10)65591-5; PUDNEY J, 1991, AM J PATHOL, V139, P149; SCHUTTE B, 1995, CYTOMETRY, V21, P177, DOI 10.1002/cyto.990210210; Scurry J, 1998, HISTOPATHOLOGY, V32, P399; Spira AI, 1996, J EXP MED, V183, P215, DOI 10.1084/jem.183.1.215; TAN X, 1993, J VIROL, V67, P6447, DOI 10.1128/JVI.67.11.6447-6452.1993; VERNAZZA PL, 1994, AIDS, V8, P1325, DOI 10.1097/00002030-199409000-00017; WATSON AJ, 1990, AIDS RES HUM RETROV, V6, P503, DOI 10.1089/aid.1990.6.503	22	158	167	1	6	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	APR	2000	6	4					475	479		10.1038/74743	http://dx.doi.org/10.1038/74743			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	376UA	10742159				2022-12-25	WOS:000165474100046
J	Pennisi, D; Gardner, J; Chambers, D; Hosking, B; Peters, J; Muscat, G; Abbott, C; Koopman, P				Pennisi, D; Gardner, J; Chambers, D; Hosking, B; Peters, J; Muscat, G; Abbott, C; Koopman, P			Mutations in Sox18 underlie cardiovascular and hair follicle defects in ragged mice	NATURE GENETICS			English	Article							DISTAL MOUSE CHROMOSOME-2; RECEPTOR TYROSINE KINASE; SONIC HEDGEHOG; MAPS	Analysis of classical mouse mutations has been useful in the identification and study of many genes. We previously mapped Sox18, encoding an SRY-related transcription factor(1), to distal mouse chromosome 2 (ref, 2), This region contains a known mouse mutation, ragged (Ra), that affects the coat and vasculature(3-5). Here we have directly evaluated Sox18 as a candidate for Ra, We found that Sox18 is expressed in the developing vascular endothelium and hair follicles in mouse embryos. Furthermore, we found no recombination between Sox18 and Ra in an interspecific backcross segregating for the Ra phenotype, We found point mutations in Sox18 in two different Ra alleles that result in missense translation and premature truncation of the encoded protein. Fusion proteins containing these mutations lack the ability to activate transcription relative to wild-type controls in an in vitro assay. Our observations implicate mutations in Sox18 as the underlying cause of the Ra phenotype, and identify Sox18 as a critical gene for cardiovascular and hair follicle formation.	Univ Queensland, Ctr Mol & Cellular Biol, Brisbane, Qld, Australia; Western Gen Hosp, Human Genet Unit, Edinburgh EH4 2XU, Midlothian, Scotland; MRC, Mammalian Genet Unit, Didcot, Oxon, England	University of Queensland; University of Edinburgh; MRC Harwell	Koopman, P (corresponding author), Univ Queensland, Ctr Mol & Cellular Biol, Brisbane, Qld, Australia.	p.koopman@cmcb.uq.edu.au	Abbott, Catherine M/C-7306-2013; Koopman, Peter A/C-9416-2009; Muscat, George/A-6401-2017	Koopman, Peter A/0000-0001-6939-0914; Muscat, George/0000-0002-5829-5695; Abbott, Catherine/0000-0001-8794-7173; Gardner, Jennifer/0000-0002-4215-955X; Pennisi, David/0000-0001-8247-2965				ABBOTT C, 1994, GENOMICS, V20, P94, DOI 10.1006/geno.1994.1131; CARTER TC, 1954, J HERED, V45, P150; CHRISTIANSEN JH, 1995, MECH DEVELOP, V51, P341, DOI 10.1016/0925-4773(95)00383-5; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; GREEN EL, 1961, J HERED, V52, P223, DOI 10.1093/oxfordjournals.jhered.a107077; Greenfield A, 1996, GENOMICS, V36, P558, DOI 10.1006/geno.1996.0510; Hahn H, 1996, J BIOL CHEM, V271, P12125, DOI 10.1074/jbc.271.21.12125; HERBERTSON B M, 1964, J Med Genet, V1, P10, DOI 10.1136/jmg.1.1.10; HOSKING BM, 1995, NUCLEIC ACIDS RES, V23, P2626, DOI 10.1093/nar/23.14.2626; Iseki S, 1996, BIOCHEM BIOPH RES CO, V218, P688, DOI 10.1006/bbrc.1996.0123; MANN SJ, 1963, GENET RES, V4, P1, DOI 10.1017/S0016672300003372; Pingault V, 1998, NAT GENET, V18, P171, DOI 10.1038/ng0298-171; ROELINK H, 1995, CELL, V81, P445, DOI 10.1016/0092-8674(95)90397-6; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; SLEE JOHN, 1957, JOUR GENETICS, V55, P570, DOI 10.1007/BF02984073; SLEE JOHN, 1957, JOUR GENETICS, V55, P100, DOI 10.1007/BF02981618; St-Jacques B, 1998, CURR BIOL, V8, P1058, DOI 10.1016/S0960-9822(98)70443-9; Theiler K., 1972, HOUSE MOUSE; WAGNER T, 1994, CELL, V79, P1111, DOI 10.1016/0092-8674(94)90041-8; WALLACE ME, 1979, HEREDITY, V43, P9, DOI 10.1038/hdy.1979.54; YAMAGUCHI TP, 1993, DEVELOPMENT, V118, P489	21	172	177	0	8	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1061-4036	1546-1718		NAT GENET	Nature Genet.	APR	2000	24	4					434	437		10.1038/74301	http://dx.doi.org/10.1038/74301			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	299HK	10742113				2022-12-25	WOS:000086192800028
J	Nagai, Y; Miyazaki, M; Aoki, R; Zama, T; Inouye, S; Hirose, K; Iino, M; Hagiwara, M				Nagai, Y; Miyazaki, M; Aoki, R; Zama, T; Inouye, S; Hirose, K; Iino, M; Hagiwara, M			A fluorescent indicator for visualizing cAMP-induced phosphorylation in vivo	NATURE BIOTECHNOLOGY			English	Article						phosphorylation; FRET; green fluorescent protein; imaging; PKA	RESONANCE ENERGY-TRANSFER; DEPENDENT PROTEIN-KINASE; CYCLIC-AMP; INHIBITOR; CELLS; CREB; EXPRESSION; BINDING; GENE	We have developed a method for visualizing phosphorylation of proteins in living cells using a novel fluorescent indicator composed of two green fluorescent protein (GFP) variants joined by the kinase-inducible domain (KID) of the transcription factor cyclic adenosine monophosphate (cAMP)-responsive element binding protein (CREB). Phosphorylation of KID by the cAMP-dependent protein kinase A (PKA) decreased the fluorescence resonance energy transfer (FRET) among the flanking GFPs, By transfecting COS-7 cells with an expression vector encoding this indicator protein (termed ART for cAMP-responsive tracer), we were able to visualize activation dynamics of PKA in living cells.	Tokyo Med & Dent Univ, Med Res Inst, Dept Funct Genom, Tokyo 1138510, Japan; Univ Calif San Diego, Scripps Inst Oceanog, La Jolla, CA 92093 USA; Univ Tokyo, Fac Med, Dept Pharmacol, Tokyo 1130033, Japan	Tokyo Medical & Dental University (TMDU); University of California System; University of California San Diego; Scripps Institution of Oceanography; University of Tokyo	Hagiwara, M (corresponding author), Tokyo Med & Dent Univ, Med Res Inst, Dept Funct Genom, Tokyo 1138510, Japan.		Inouye, Sharon/R-7216-2019	Inouye, Satoshi/0000-0001-8732-7839				ADAMS SR, 1991, NATURE, V349, P694, DOI 10.1038/349694a0; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; CHIJIWA T, 1989, J BIOL CHEM, V264, P4924; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; HAGIWARA M, 1992, CELL, V70, P105, DOI 10.1016/0092-8674(92)90537-M; HAGIWARA M, 1993, MOL CELL BIOL, V13, P4852, DOI 10.1128/MCB.13.8.4852; HAGIWARA M, 1987, MOL PHARMACOL, V31, P523; INOUYE S, 1994, FEBS LETT, V341, P277, DOI 10.1016/0014-5793(94)80472-9; KEMP BE, 1980, J BIOL CHEM, V255, P2914; Lee CL, 1999, NAT BIOTECHNOL, V17, P759, DOI 10.1038/11691; Mahajan NP, 1998, NAT BIOTECHNOL, V16, P547, DOI 10.1038/nbt0698-547; Mitra RD, 1996, GENE, V173, P13, DOI 10.1016/0378-1119(95)00768-7; MIYAWAKI A, 1997, NATURE, V388, P852; MORISE H, 1974, BIOCHEMISTRY-US, V13, P2656, DOI 10.1021/bi00709a028; Ng T, 1999, SCIENCE, V283, P2085, DOI 10.1126/science.283.5410.2085; PRASHER DC, 1992, GENE, V111, P229, DOI 10.1016/0378-1119(92)90691-H; Romoser VA, 1997, J BIOL CHEM, V272, P13270, DOI 10.1074/jbc.272.20.13270; Sakaguchi H, 1999, J NEUROSCI, V19, P3973; Suzuki Y, 1998, NATURE, V396, P380, DOI 10.1038/24640; TOKUMITSU H, 1990, J BIOL CHEM, V265, P4315	21	160	189	0	12	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAR	2000	18	3					313	316		10.1038/73767	http://dx.doi.org/10.1038/73767			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	292AC	10700148				2022-12-25	WOS:000085771100030
J	Petite, H; Viateau, V; Bensaid, W; Meunier, A; de Pollak, C; Bourguignon, M; Oudina, K; Sedel, L; Guillemin, G				Petite, H; Viateau, V; Bensaid, W; Meunier, A; de Pollak, C; Bourguignon, M; Oudina, K; Sedel, L; Guillemin, G			Tissue-engineered bone regeneration	NATURE BIOTECHNOLOGY			English	Article						tissue engineering; mesenchymal stem cells; bone repair; marrow stromal cells; coral	MESENCHYMAL STEM-CELLS; CORALLINE CALCIUM-CARBONATE; MARROW STROMAL CELLS; GRAFT SUBSTITUTES; DEFECTS; PHOSPHATE; DEXAMETHASONE; OSTEOCLASTS; RESORPTION	Bone lesions above a critical size become scarred rather than regenerated, leading to nonunion. We have attempted to obtain a greater degree of regeneration by using a resorbable scaffold with regeneration-competent cells to recreate an embryonic environment in injured adult tissues, and thus improve clinical outcome, We have used a combination of a coral scaffold with in vitro-expanded marrow stromal cells (MSC) to increase osteogenesis more than that obtained with the scaffold alone or the scaffold plus fresh bone marrow, The efficiency of the various combinations was assessed in a large segmental defect model in sheep, The tissue-engineered artificial bone underwent morphogenesis leading to complete recorticalization and the formation of a medullary canal with mature lamellar cortical bone in the most favorable cases. Clinical union never occurred when the defects were left empty or filled with the scaffold alone, In contrast, clinical union was obtained in three out of seven operated limbs when the defects were filled with the tissue-engineered bone.	Univ D Diderot, Fac Med Lariboisiere St Louis, CNRS UPRES A 7052, Lab Rech Orthoped, F-75010 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite	Petite, H (corresponding author), Univ D Diderot, Fac Med Lariboisiere St Louis, CNRS UPRES A 7052, Lab Rech Orthoped, 10 Ave Verdun, F-75010 Paris, France.		Petite, Herve/E-3478-2016; Bourguignon, Marianne/O-5854-2017	Petite, Herve/0000-0003-1694-5060; Bourguignon, Marianne/0000-0001-9824-1248				Bruder SP, 1998, J ORTHOPAED RES, V16, P155, DOI 10.1002/jor.1100160202; Bruder SP, 1998, J BONE JOINT SURG AM, V80A, P985, DOI 10.2106/00004623-199807000-00007; Caplan A., 1997, PRINCIPLES TISSUE EN, P603; CAPLAN AI, 1991, J ORTHOP RES, V9, P641, DOI 10.1002/jor.1100090504; Daculsi G, 1997, INT REV CYTOL, V172, P129, DOI 10.1016/S0074-7696(08)62360-8; DAMIEN CJ, 1991, J APPL BIOMATER, V2, P187, DOI 10.1002/jab.770020307; Gamou S, 1990, ANIMAL CELL CULTURE, P197; GAY CV, 1974, SCIENCE, V183, P432, DOI 10.1126/science.183.4123.432; GOSHIMA J, 1991, BIOMATERIALS, V12, P253, DOI 10.1016/0142-9612(91)90209-S; GROSS UM, 1991, BONE-BIOMATERIAL INTERFACE, P308; GRUNDEL RE, 1991, CLIN ORTHOP RELAT R, P244; GUILLEMIN G, 1989, J BIOMED MATER RES, V23, P765, DOI 10.1002/jbm.820230708; GUILLEMIN G, 1987, J BIOMED MATER RES, V21, P557, DOI 10.1002/jbm.820210503; GUILLEMIN G, 1995, CELL MATER, V5, P157; Guillemin G., 1995, Bulletin de l'Institut Oceanographique Numero Special (Monaco), V14, P67; HERBERTSON A, 1995, J BONE MINER RES, V10, P285; HULBERT S F, 1970, Journal of Biomedical Materials Research, V4, P433, DOI 10.1002/jbm.820040309; IRIGARAY JL, 1993, J THERM ANAL CALORIM, V39, P3, DOI 10.1007/BF02235441; Kadiyala S, 1997, TISSUE ENG, V3, P173, DOI 10.1089/ten.1997.3.173; LANGER R, 1993, SCIENCE, V260, P920, DOI 10.1126/science.8493529; Louisia S, 1999, J BONE JOINT SURG BR, V81B, P719, DOI 10.1302/0301-620X.81B4.9358; Marks Sandy C. Jr., 1996, P3; MOORE DC, 1987, J ORTHOP RES, V5, P356, DOI 10.1002/jor.1100050307; OHGUSHI H, 1989, ACTA ORTHOP SCAND, V60, P334, DOI 10.3109/17453678909149289; OSTRUM RF, 1994, ORTHOPAEDIC BASIC SC, P277; PACHENCE JM, 1997, PRINCIPLES TISSUE EN, P274; Petite H, 1996, J MATER SCI-MATER M, V7, P665, DOI 10.1007/BF00123405; PIECUCH JF, 1984, J BIOMED MATER RES, V18, P39, DOI 10.1002/jbm.820180106; POULIQUEN JC, 1989, FRENCH J ORTHOP SURG, V3, P272; Prockop DJ, 1997, SCIENCE, V276, P71, DOI 10.1126/science.276.5309.71; ROUX FX, 1988, J NEUROSURG, V69, P510, DOI 10.3171/jns.1988.69.4.0510; Shors EC, 1999, ORTHOP CLIN N AM, V30, P599, DOI 10.1016/S0030-5898(05)70113-9; Triffitt James T., 1996, P39; YUKNA RA, 1994, J PERIODONTOL, V65, P177, DOI 10.1902/jop.1994.65.2.177; Yukna RA, 1998, J CLIN PERIODONTOL, V25, P1036, DOI 10.1111/j.1600-051X.1998.tb02410.x; ZAWICKI DF, 1981, MICROVASC RES, V21, P27, DOI 10.1016/0026-2862(81)90003-0	36	1165	1244	13	427	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	SEP	2000	18	9					959	963		10.1038/79449	http://dx.doi.org/10.1038/79449			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	350AN	10973216				2022-12-25	WOS:000089078300024
J	Huttley, GA; Easteal, S; Southey, MC; Tesoriero, A; Giles, GG; McCredie, MRE; Hopper, JL; Venter, DJ				Huttley, GA; Easteal, S; Southey, MC; Tesoriero, A; Giles, GG; McCredie, MRE; Hopper, JL; Venter, DJ		Australian Breast Canc Family Stud	Adaptive evolution of the tumour suppressor BRCA1 in humans and chimpanzees	NATURE GENETICS			English	Article							BREAST-CANCER; NUCLEOTIDE SUBSTITUTION; SEQUENCE VARIANTS; AUSTRALIAN WOMEN; OVARIAN-CANCER; MEIOTIC CELLS; GENE BRCA1; POPULATION; SELECTION; SUSCEPTIBILITY	Mutations in BRCA1 (ref. 1) confer an increased risk of female breast cancer(2). In a genome-wide scan of linkage disequilibrium (LD), a high revel of LD was detected among microsatellite markers flanking BRCA1 (ref. 3), raising the prospect that positive natural selection may have acted on this gene. We have used the predictions of evolutionary genetic theory to investigate this further. Using phylogeny-based maximum likelihood analysis of the BRCA1 sequences from primates and other mammals, we found that the ratios of replacement to silent nucleotide substitutions on the human and chimpanzee lineages were not different from one another (P=0.8), were different from those of other primate lineages (P=0.004) and were greater than 1 (P=0.04). This is consistent with the historic occurrence of positive darwinian selection pressure on the BRCA1 protein in the human and chimpanzee lineages. Analysis of genetic variation in a sample of female Australians of Northern European origin showed evidence for Hardy-Weinberg (HW) disequilibrium at polymorphic sites in BRCA1, consistent with the possibility that natural selection is affecting genotype frequencies in modern Europeans. The clustering of between-species variation in the region of the gene encoding the RAD51-interaction domain of BRCA1 suggests the maintenance of genomic integrity as a possible target of selection.	Australian Natl Univ, John Curtin Sch Med Res, Human Genet Grp, Canberra, ACT 2601, Australia; Peter MacCallum Canc Inst, Dept Pathol, E Melbourne, Vic, Australia; Peter MacCallum Canc Inst, Res Dept, E Melbourne, Vic, Australia; Univ Melbourne, Dept Pathol, Parkville, Vic 3052, Australia; Anticanc Council Victoria, Canc Epidemiol Ctr, Carlton, Vic, Australia; New S Wales Canc Council, Canc & Epidemiol Res Unit, Woolloomooloo, NSW, Australia; Univ Otago, Dept Prevent & Social Med, Dunedin, New Zealand; Univ Melbourne, Ctr Genet Epidemiol, Carlton, Vic, Australia	Australian National University; John Curtin School of Medical Research; Peter Maccallum Cancer Center; Peter Maccallum Cancer Center; University of Melbourne; Cancer Council New South Wales; University of Otago; University of Melbourne	Huttley, GA (corresponding author), Australian Natl Univ, John Curtin Sch Med Res, Human Genet Grp, Canberra, ACT 2601, Australia.		Huttley, Gavin A/G-5169-2015	Huttley, Gavin A/0000-0001-7224-2074; Giles, Graham/0000-0003-4946-9099; Southey, Melissa/0000-0002-6313-9005; Easteal, Simon/0000-0002-0462-502X				Batterham P, 1996, BIOESSAYS, V18, P841, DOI 10.1002/bies.950181011; Cavalli-Sforza L. L., 1994, HIST GEOGRAPHY HUMAN; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; Chen JJ, 1998, MOL CELL, V2, P317, DOI 10.1016/S1097-2765(00)80276-2; Clark AG, 2000, NATURE, V403, P261, DOI 10.1038/35002236; Dunning AM, 1997, HUM MOL GENET, V6, P285, DOI 10.1093/hmg/6.2.285; Durocher F, 1996, HUM MOL GENET, V5, P835, DOI 10.1093/hmg/5.6.835; EXCOFFIER L, 1995, MOL BIOL EVOL, V12, P921; Ford D, 1998, AM J HUM GENET, V62, P676, DOI 10.1086/301749; Goodman M, 1998, MOL PHYLOGENET EVOL, V9, P585, DOI 10.1006/mpev.1998.0495; Gowen LC, 1996, NAT GENET, V12, P191, DOI 10.1038/ng0296-191; Gowen LC, 1998, SCIENCE, V281, P1009, DOI 10.1126/science.281.5379.1009; Hacia JG, 1998, NAT GENET, V18, P155, DOI 10.1038/ng0298-155; Hopper JL, 1994, BREAST, V3, P79; HUGHES AL, 1988, NATURE, V335, P167, DOI 10.1038/335167a0; Huttley GA, 1999, GENETICS, V152, P1711; Kimura MA, 1985, NEUTRAL THEORY MOL E; KREITMAN M, 1995, ANNU REV ECOL SYST, V26, P403, DOI 10.1146/annurev.es.26.110195.002155; LEWONTIN RC, 1959, EVOLUTION, V13, P561, DOI 10.2307/2406136; Li W. H, 1997, MOL EVOLUTION; McCredie MRE, 1998, CANCER CAUSE CONTROL, V9, P189, DOI 10.1023/A:1008886328352; Messler W, 1997, NATURE, V385, P151, DOI 10.1038/385151a0; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; MUSE SV, 1994, MOL BIOL EVOL, V11, P715; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Smith TM, 1996, GENOME RES, V6, P1029, DOI 10.1101/gr.6.11.1029; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Southey MC, 1999, BRIT J CANCER, V79, P34, DOI 10.1038/sj.bjc.6690008; Southey MC, 1998, J NATL CANCER I, V90, P532, DOI 10.1093/jnci/90.7.532; Swanson WJ, 1998, SCIENCE, V281, P710, DOI 10.1126/science.281.5377.710; Thakur S, 1997, MOL CELL BIOL, V17, P444, DOI 10.1128/MCB.17.1.444; Wyckoff GJ, 2000, NATURE, V403, P304, DOI 10.1038/35002070; Yang ZH, 1998, MOL BIOL EVOL, V15, P568, DOI 10.1093/oxfordjournals.molbev.a025957	33	90	97	0	13	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	AUG	2000	25	4					410	413		10.1038/78092	http://dx.doi.org/10.1038/78092			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	341WY	10932184				2022-12-25	WOS:000088615000015
J	Kennerdell, JR; Carthew, RW				Kennerdell, JR; Carthew, RW			Heritable gene silencing in Drosophila using double-stranded RNA	NATURE BIOTECHNOLOGY			English	Article							CELL; INTERFERENCE; EXPRESSION		Univ Pittsburgh, Dept Biol Sci, Pittsburgh, PA 15260 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Carthew, RW (corresponding author), Univ Pittsburgh, Dept Biol Sci, 4249 5th Ave,217 Clapp Hall, Pittsburgh, PA 15260 USA.							Ausubel F.M., 1993, CURRENT PROTOCOLS MO; Baulcombe DC, 1999, CURR BIOL, V9, pR599, DOI 10.1016/S0960-9822(99)80383-2; BRAND AH, 1993, DEVELOPMENT, V118, P401; DAVISON A, 1994, GENETICS, V137, P361; FOLEY KP, 1993, TRENDS GENET, V9, P380, DOI 10.1016/0168-9525(93)90137-7; HAMA C, 1990, GENE DEV, V4, P1079, DOI 10.1101/gad.4.7.1079; JARMAN AP, 1993, CELL, V73, P1307, DOI 10.1016/0092-8674(93)90358-W; Kauffmann RC, 1996, GENE DEV, V10, P2167, DOI 10.1101/gad.10.17.2167; Kennerdell JR, 1998, CELL, V95, P1017, DOI 10.1016/S0092-8674(00)81725-0; Li YX, 2000, DEV BIOL, V217, P394, DOI 10.1006/dbio.1999.9540; MARTINEK S, 2000, IN PRESS GENETICS; Misquitta L, 1999, P NATL ACAD SCI USA, V96, P1451, DOI 10.1073/pnas.96.4.1451; Montgomery MK, 1998, P NATL ACAD SCI USA, V95, P15502, DOI 10.1073/pnas.95.26.15502; SPRADLING AC, 1982, SCIENCE, V218, P341, DOI 10.1126/science.6289435; Tavernarakis N, 2000, NAT GENET, V24, P180, DOI 10.1038/72850; VINCENT JP, 1994, DEV BIOL, V164, P328, DOI 10.1006/dbio.1994.1203; Wang ZH, 1996, RNA, V2, P1241; WLANNY F, 2000, NAT CELL BIOL, V21, P70; RNAI DROSOPHILA EMBR	19	388	488	1	52	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	AUG	2000	18	8					896	898		10.1038/78531	http://dx.doi.org/10.1038/78531			3	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	342VX	10932163				2022-12-25	WOS:000088666800030
J	Saleh, A; Srinivasula, SM; Balkir, L; Robbins, PD; Alnemri, ES				Saleh, A; Srinivasula, SM; Balkir, L; Robbins, PD; Alnemri, ES			Negative regulation of the Apaf-1 apoptosome by Hsp70	NATURE CELL BIOLOGY			English	Article							SHOCK-PROTEIN HSP70; STRESS-INDUCED APOPTOSIS; HEAT-SHOCK; BREAST-CANCER; CYTOCHROME-C; TUMOR-CELLS; PROCASPASE-9; ACTIVATION; PROTEASES; COMPLEX	Release of cytochrome c from mitochondria by apoptotic signals induces ATP/dATP-dependent formation of the oligomeric Apaf-1-caspase-9 apoptosome. Here we show that the documented anti-apoptotic effect of the principal heat-shock protein, Hsp70, is mediated through its direct association with the caspase-recruitment domain (CARD) of Apaf-1 and through inhibition of apoptosome formation. The interaction between Hsp70 and Apaf-1 prevents oligomerization of Apaf-1 and association of Apaf-1 with procaspase-9, On the basis of these results, we propose that resistance to apoptosis exhibited by stressed cells and some tumours, which constitutively express high levels of Hsp70, may be due in part to modulation of Apaf-1 function by Hsp70.	Thomas Jefferson Univ, Kimmel Canc Inst, Ctr Apoptosis Res, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Kimmel Canc Inst, Dept Microbiol & Immunol, Philadelphia, PA 19107 USA; Univ Pittsburgh, Dept Mol Genet & Biochem, Pittsburgh, PA 15261 USA	Jefferson University; Jefferson University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Saleh, A (corresponding author), Thomas Jefferson Univ, Kimmel Canc Inst, Ctr Apoptosis Res, Philadelphia, PA 19107 USA.		Alnemri, Emad S/B-4526-2010	Saleh, Ayman M/0000-0003-1126-6018	NCI NIH HHS [CA55227] Funding Source: Medline; NIA NIH HHS [AG14357, AG13487] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA055227] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG013487, R01AG014357] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Alnemri ES, 1997, J CELL BIOCHEM, V64, P33, DOI 10.1002/(SICI)1097-4644(199701)64:1<33::AID-JCB6>3.0.CO;2-0; Buzzard KA, 1998, J BIOL CHEM, V273, P17147, DOI 10.1074/jbc.273.27.17147; Cain K, 1999, J BIOL CHEM, V274, P22686, DOI 10.1074/jbc.274.32.22686; CIOCCA DR, 1993, J NATL CANCER I, V85, P570, DOI 10.1093/jnci/85.7.570; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Creagh EM, 1999, IMMUNOLOGY, V97, P36; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; Dunning AM, 1999, CANCER EPIDEM BIOMAR, V8, P843; FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; Goldstein JC, 2000, NAT CELL BIOL, V2, P156, DOI 10.1038/35004029; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Hermawan A, 1999, ARCH BIOCHEM BIOPHYS, V369, P157, DOI 10.1006/abbi.1999.1354; Jaattela M, 1999, EXP CELL RES, V248, P30, DOI 10.1006/excr.1999.4455; JAATTELA M, 1992, EMBO J, V11, P3507, DOI 10.1002/j.1460-2075.1992.tb05433.x; JAATTELA M, 1993, J EXP MED, V177, P231, DOI 10.1084/jem.177.1.231; Jaattela M, 1998, EMBO J, V17, P6124, DOI 10.1093/emboj/17.21.6124; Kaur J, 2000, INT J CANCER, V85, P1; Kerr J.F., 1972, BRIT J CANCER, V4, P239; LI GC, 1995, INT J HYPERTHER, V11, P459, DOI 10.3109/02656739509022483; LI GC, 1992, P NATL ACAD SCI USA, V89, P2036, DOI 10.1073/pnas.89.6.2036; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Mosser DD, 1997, MOL CELL BIOL, V17, P5317, DOI 10.1128/MCB.17.9.5317; Polla BS, 1996, P NATL ACAD SCI USA, V93, P6458, DOI 10.1073/pnas.93.13.6458; Qin HX, 1999, NATURE, V399, P549, DOI 10.1038/21124; Robertson JD, 1999, BIOCHEM J, V344, P477, DOI 10.1042/0264-6021:3440477; Saleh A, 1999, J BIOL CHEM, V274, P17941, DOI 10.1074/jbc.274.25.17941; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; SCHMID D, 1994, SCIENCE, V263, P971, DOI 10.1126/science.8310296; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; Stennicke HR, 1998, J BIOL CHEM, V273, P27084, DOI 10.1074/jbc.273.42.27084; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; VAUX DL, 1994, CELL, V76, P777, DOI 10.1016/0092-8674(94)90350-6; WEI YQ, 1995, CANCER IMMUNOL IMMUN, V40, P73, DOI 10.1007/s002620050146; Wissing D, 1997, P NATL ACAD SCI USA, V94, P5073, DOI 10.1073/pnas.94.10.5073; Wong HR, 1998, AM J PHYSIOL-LUNG C, V275, pL836, DOI 10.1152/ajplung.1998.275.4.L836; Yin XM, 1999, NATURE, V400, P886, DOI 10.1038/23730; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	38	687	733	0	23	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	AUG	2000	2	8					476	483		10.1038/35019510	http://dx.doi.org/10.1038/35019510			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	341TE	10934467				2022-12-25	WOS:000088605000012
J	Dammann, R; Li, C; Yoon, JH; Chin, PL; Bates, S; Pfeifer, GP				Dammann, R; Li, C; Yoon, JH; Chin, PL; Bates, S; Pfeifer, GP			Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3	NATURE GENETICS			English	Article							CANCER; SEARCH; GENERATION; DELETIONS; CARCINOMA; GENES	Allelic loss at the short arm of chromosome 3 is one of the most common and earliest events in the pathogenesis of lung cancer, and is observed in more than 90% of small-cell lung cancers (SCLCs) and in 50-80% of non-small-cell lung cancers(1,2) (NSCLCs). Frequent and early loss of heterozygosity and the presence of homozygous deletions suggested a critical role of the region 3p21.3 in tumorigenesis(2-4) and a region of common homozygous deletion in 3p21.3 was narrowed to 120 kb (ref. 5). Several putative tumour-suppressor genes located at 3p21 have been characterized, but none of these genes appear to be altered in lung cancer. Here we describe the cloning and characterization of a human RAS effector homologue (RASSF1) located in the 120-kb region of minimal homozygous deletion. We identified three transcripts, A, B and C, derived from alternative splicing and promoter usage. The major transcripts A and C were expressed in all normal tissues. Transcript A was missing in all SCLC cell lines analysed and in several other cancer cell lines. loss of expression was correlated with methylation of the CpG-island promoter sequence of RASSF1A. The promoter was highly methylated in 24 of 60 (40%) primary lung tumours, and 4 of 41 tumours analysed carried missense mutations. Re-expression of transcript A in lung carcinoma cells reduced colony formation, suppressed anchorage-independent growth and inhibited tumour formation in nude mice. These characteristics indicate a potential role for RASSF1A asa lung tumour suppresor gene.	City Hope Natl Med Ctr, Beckman Res Inst, Dept Biol, Duarte, CA 91010 USA	City of Hope; Beckman Research Institute of City of Hope	Pfeifer, GP (corresponding author), City Hope Natl Med Ctr, Beckman Res Inst, Dept Biol, Duarte, CA 91010 USA.		jia, xu/A-8386-2016					Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Baylin SB, 1998, ADV CANCER RES, V72, P141; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785; Eng C, 2000, NAT GENET, V24, P101, DOI 10.1038/72730; HUNG J, 1995, JAMA-J AM MED ASSOC, V273, P558, DOI 10.1001/jama.273.7.558; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; Kok K, 1997, ADV CANCER RES, V71, P27, DOI 10.1016/S0065-230X(08)60096-2; NEWTON AC, 1995, CURR BIOL, V5, P973, DOI 10.1016/S0960-9822(95)00191-6; Ponting CP, 1996, TRENDS BIOCHEM SCI, V21, P422, DOI 10.1016/S0968-0004(96)30038-8; Sekido Y, 1998, ONCOGENE, V16, P3151, DOI 10.1038/sj.onc.1201858; SZABO PE, 1995, GENE DEV, V9, P1857, DOI 10.1101/gad.9.15.1857; Vavvas D, 1998, J BIOL CHEM, V273, P5439, DOI 10.1074/jbc.273.10.5439; Wei MH, 1996, CANCER RES, V56, P1487; WHANGPENG J, 1982, SCIENCE, V215, P181, DOI 10.1126/science.6274023; Wistuba II, 1999, ONCOGENE, V18, P643, DOI 10.1038/sj.onc.1202349	16	913	1048	0	41	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUL	2000	25	3					315	319		10.1038/77083	http://dx.doi.org/10.1038/77083			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	329RD	10888881				2022-12-25	WOS:000087920900021
J	Legouis, R; Gansmuller, A; Sookhareea, S; Bosher, JM; Baillie, DL; Labouesse, M				Legouis, R; Gansmuller, A; Sookhareea, S; Bosher, JM; Baillie, DL; Labouesse, M			LET-413 is a basolateral protein required for the assembly of adherens junctions in Caenorhabditis elegans	NATURE CELL BIOLOGY			English	Article							LEUCINE-RICH REPEATS; C-ELEGANS; CRYSTAL-STRUCTURE; SEPTATE JUNCTION; VULVAR INDUCTION; EPITHELIAL-CELLS; PDZ DOMAINS; POLARITY; EMBRYO; MORPHOGENESIS	Epithelial cells are polarized, with apical and basal compartments demarcated by tight and adherens junctions. Proper establishment of these subapical junctions is critical for normal development and histogenesis, We report the characterization of the gene let-413 which has a critical role in assembling adherens junctions in Caenorhabditis elegans, In let-413 mutants, adherens junctions are abnormal and mislocalized to more basolateral positions, epithelial cell polarity is affected and the actin cytoskeleton is disorganized. The LET-413 protein contains one PDZ domain and 16 leucine-rich repeats with high homology to proteins known to interact with small GTPases, Strikingly, LET-413 localizes to the basolateral membrane. We suggest that LET-413 acts as an adaptor protein involved in polarizing protein trafficking in epithelial cells.	ULP, INSERM, CNRS, Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch Graffenstaden, France; Simon Fraser Univ, Dept Biol Sci, Inst Mol Biol & Biochem, Burnaby, BC V5A 1S6, Canada	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Simon Fraser University	Labouesse, M (corresponding author), ULP, INSERM, CNRS, Inst Genet & Biol Mol & Cellulaire, BP163,1 Rue Laurent Fries, F-67404 Illkirch Graffenstaden, France.	lmichel@igbmc.u-strasbg.fr	Legouis, Renaud/G-9088-2014; Legouis, Renaud/S-1250-2017	Legouis, Renaud/0000-0002-2699-2584				Adamo JE, 1999, MOL BIOL CELL, V10, P4121, DOI 10.1091/mbc.10.12.4121; Apperson ML, 1996, J NEUROSCI, V16, P6839; Bateman A, 2000, NUCLEIC ACIDS RES, V28, P263, DOI 10.1093/nar/28.1.263; Baumgartner S, 1996, CELL, V87, P1059, DOI 10.1016/S0092-8674(00)81800-0; Bhat MA, 1999, CELL, V96, P833, DOI 10.1016/S0092-8674(00)80593-0; Bilder D, 2000, NATURE, V403, P676, DOI 10.1038/35001108; BRENNER S, 1974, GENETICS, V77, P71; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; Costa M, 1998, J CELL BIOL, V141, P297, DOI 10.1083/jcb.141.1.297; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; FRANCIS R, 1991, J CELL BIOL, V114, P465, DOI 10.1083/jcb.114.3.465; Grawe F, 1996, DEVELOPMENT, V122, P951; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hillig RC, 1999, MOL CELL, V3, P781, DOI 10.1016/S1097-2765(01)80010-1; Hoskins R, 1996, DEVELOPMENT, V122, P97; Hresko MC, 1999, J CELL BIOL, V146, P659, DOI 10.1083/jcb.146.3.659; JOHNSEN RC, 1991, GENETICS, V129, P735; Kaech SM, 1998, CELL, V94, P761, DOI 10.1016/S0092-8674(00)81735-3; Kajava AV, 1998, J MOL BIOL, V277, P519, DOI 10.1006/jmbi.1998.1643; Klebes A, 2000, CURR BIOL, V10, P76, DOI 10.1016/S0960-9822(99)00277-8; KOBE B, 1993, NATURE, V366, P751, DOI 10.1038/366751a0; Kroschewski R, 1999, NAT CELL BIOL, V1, P8, DOI 10.1038/8977; Labouesse M, 1996, DEVELOPMENT, V122, P2579; Labouesse M, 1997, DEV DYNAM, V210, P19, DOI 10.1002/(SICI)1097-0177(199709)210:1<19::AID-AJA3>3.0.CO;2-4; Leung B, 1999, DEV BIOL, V216, P114, DOI 10.1006/dbio.1999.9471; Martinez O, 1998, BBA-MOL CELL RES, V1404, P101, DOI 10.1016/S0167-4889(98)00050-0; Matter K, 2000, CURR BIOL, V10, pR39, DOI 10.1016/S0960-9822(99)00256-0; MCKIM KS, 1988, GENETICS, V118, P49; Mello C, 1995, METHOD CELL BIOL, V48, P451; Mohler WA, 1998, CURR BIOL, V8, P1087, DOI 10.1016/S0960-9822(98)70447-6; PODBILEWICZ B, 1994, DEV BIOL, V161, P408, DOI 10.1006/dbio.1994.1041; Ponting CP, 1997, BIOESSAYS, V19, P469, DOI 10.1002/bies.950190606; PRIESS JR, 1986, DEV BIOL, V117, P156, DOI 10.1016/0012-1606(86)90358-1; Raich WB, 1999, CURR BIOL, V9, P1139, DOI 10.1016/S0960-9822(00)80015-9; Selfors LM, 1998, P NATL ACAD SCI USA, V95, P6903, DOI 10.1073/pnas.95.12.6903; Sieburth DS, 1998, CELL, V94, P119, DOI 10.1016/S0092-8674(00)81227-1; Simske JS, 1996, CELL, V85, P195, DOI 10.1016/S0092-8674(00)81096-X; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Sternberg PW, 1998, TRENDS GENET, V14, P466, DOI 10.1016/S0168-9525(98)01592-3; Tabuse Y, 1998, DEVELOPMENT, V125, P3607; TEPASS U, 1990, CELL, V61, P787, DOI 10.1016/0092-8674(90)90189-L; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Ward RE, 1998, J CELL BIOL, V140, P1463, DOI 10.1083/jcb.140.6.1463; White J., 1988, NEMATODE CAENORHABDI, V17, P81; WILLIAMS BD, 1992, GENETICS, V131, P609; Wissmann A, 1997, GENE DEV, V11, P409, DOI 10.1101/gad.11.4.409; Woods DF, 1996, J CELL BIOL, V134, P1469, DOI 10.1083/jcb.134.6.1469; Yeaman C, 1999, CURR BIOL, V9, pR515, DOI 10.1016/S0960-9822(99)80324-8; Yeaman C, 1999, PHYSIOL REV, V79, P73, DOI 10.1152/physrev.1999.79.1.73	50	145	155	0	6	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	JUL	2000	2	7					415	422		10.1038/35017046	http://dx.doi.org/10.1038/35017046			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	333MK	10878806				2022-12-25	WOS:000088133700017
J	Schmidt-Dannert, C; Umeno, D; Arnold, FH				Schmidt-Dannert, C; Umeno, D; Arnold, FH			Molecular breeding of carotenoid biosynthetic pathways	NATURE BIOTECHNOLOGY			English	Article						carotenoid; molecular breeding; metabolic engineering; in vitro evolution	ESCHERICHIA-COLI; PHYTOENE DESATURASE; RHODOBACTER-CAPSULATUS; DIRECTED EVOLUTION; ERWINIA-UREDOVORA; CAPSICUM-ANNUUM; ANTIOXIDANTS; SEQUENCE; LYCOPENE; BIOLOGY	The burgeoning demand for complex, biologically active molecules for medicine, materials science, consumer products, and agrochemicals is driving efforts to engineer new biosynthetic pathways into microorganisms and plants. We have applied principles of breeding, including mixing genes and modifying catalytic functions by in vitro evolution, to create new metabolic pathways for biosynthesis of natural products in Escherichia coli. We expressed shuffled phytoene desaturases in the context of a carotenoid biosynthetic pathway assembled from different bacterial species and screened the resulting library for novel carotenoids. One desaturase chimera efficiently introduced six rather than four double bonds into phytoene, to favor production of the fully conjugated carotenoid, 3,4,3',4'-tetradehydrolycopene. This new pathway was extended with a second library of shuffled lycopene cyclases to produce a variety of colored products. One of the new pathways generates the cyclic carotenoid torulene, for the first time, in E. coli. This combined approach of rational pathway assembly and molecular breeding may allow the discovery and production, in simple laboratory organisms, of new compounds that are essentially inaccessible from natural sources or by synthetic chemistry.	Univ Minnesota, Dept Biochem Mol Biol & Biophys, St Paul, MN 55108 USA; CALTECH, Div Chem & Chem Engn 210 41, Pasadena, CA 91125 USA	University of Minnesota System; University of Minnesota Twin Cities; California Institute of Technology	Schmidt-Dannert, C (corresponding author), Univ Minnesota, Dept Biochem Mol Biol & Biophys, St Paul, MN 55108 USA.			Arnold, Frances H./0000-0002-4027-364X				Albrecht M, 1997, J BIOTECHNOL, V58, P177, DOI 10.1016/S0168-1656(97)00151-X; Altreuter DH, 1999, CURR OPIN BIOTECH, V10, P130, DOI 10.1016/S0958-1669(99)80022-6; An GH, 1999, J BIOSCI BIOENG, V88, P189, DOI 10.1016/S1389-1723(99)80200-X; Armstrong GA, 1996, FASEB J, V10, P228, DOI 10.1096/fasebj.10.2.8641556; ARMSTRONG GA, 1989, MOL GEN GENET, V216, P254, DOI 10.1007/BF00334364; Arnold FH, 1999, CURR OPIN CHEM BIOL, V3, P54, DOI 10.1016/S1367-5931(99)80010-6; AUSICH RL, 1994, PURE APPL CHEM, V66, P1057, DOI 10.1351/pac199466051057; BARTLEY GE, 1990, J BIOL CHEM, V265, P16020; Bertram JS, 1999, NUTR REV, V57, P182, DOI 10.1111/j.1753-4887.1999.tb06941.x; Britton G, 1998, CAROTENOIDS BIOSYNTH, P13; Cane DE, 1998, SCIENCE, V282, P63, DOI 10.1126/science.282.5386.63; Crameri A, 1998, NATURE, V391, P288, DOI 10.1038/34663; Cunningham FX, 1996, PLANT CELL, V8, P1613, DOI 10.2307/3870254; Edge R, 1997, J PHOTOCH PHOTOBIO B, V41, P189, DOI 10.1016/S1011-1344(97)00092-4; FRASER PD, 1992, J BIOL CHEM, V267, P19891; Garcia-Asua G, 1998, TRENDS PLANT SCI, V3, P445, DOI 10.1016/S1360-1385(98)01329-6; HIRSCHBERG J, 1998, CAROTENOIDS BIOSYNTH, V3, P148; HUGUENEY P, 1995, PLANT J, V8, P417, DOI 10.1046/j.1365-313X.1995.08030417.x; HUNTER CN, 1994, J BACTERIOL, V176, P3692, DOI 10.1128/JB.176.12.3692-3697.1994; Johnson E A, 1996, Adv Biochem Eng Biotechnol, V53, P119; Joo H, 1999, NATURE, V399, P670, DOI 10.1038/21395; Lau J, 1999, BIOCHEMISTRY-US, V38, P1643, DOI 10.1021/bi9820311; LINDEN H, 1991, Z NATURFORSCH C, V46, P1045; Misawa N, 1998, J BIOTECHNOL, V59, P169, DOI 10.1016/S0168-1656(97)00154-5; Reynolds KA, 1998, P NATL ACAD SCI USA, V95, P12744, DOI 10.1073/pnas.95.22.12744; Rock CL, 1997, PHARMACOL THERAPEUT, V75, P185, DOI 10.1016/S0163-7258(97)00054-5; Sandmann G, 1999, TRENDS BIOTECHNOL, V17, P233, DOI 10.1016/S0167-7799(99)01307-4; SANDMANN G, 1994, EUR J BIOCHEM, V223, P7, DOI 10.1111/j.1432-1033.1994.tb18961.x; Singh DK, 1998, ONCOLOGY-NY, V12, P1643; STEMMER WPC, 1994, NATURE, V370, P389, DOI 10.1038/370389a0; Takaichi S, 1996, EUR J BIOCHEM, V241, P291, DOI 10.1111/j.1432-1033.1996.0291t.x; WIERENGA RK, 1986, J MOL BIOL, V187, P101, DOI 10.1016/0022-2836(86)90409-2	32	255	300	2	62	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUL	2000	18	7					750	753		10.1038/77319	http://dx.doi.org/10.1038/77319			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	331YN	10888843				2022-12-25	WOS:000088046400024
J	Morano, I; Chai, GX; Baltas, LG; Lamounier-Zepter, V; Lutsch, G; Kott, M; Haase, H; Bader, M				Morano, I; Chai, GX; Baltas, LG; Lamounier-Zepter, V; Lutsch, G; Kott, M; Haase, H; Bader, M			Smooth-muscle contraction without smooth-muscle myosin	NATURE CELL BIOLOGY			English	Article							HEAVY-CHAIN; MOLECULAR-BIOLOGY; DUCTUS-ARTERIOSUS; PHOSPHORYLATION; RENIN; MICE	Here we have used gene-targeting to eliminate expression of smooth-muscle myosin heavy chain. Elimination of this gene does not affect expression of non-muscle myosin heavy chain, and knockout individuals typically survive for three days. Prolonged activation, by KCI depolarisation, of intact bladder preparations from wild-type neonatal mice produces an initial transient state (phase 1) of high force generation and maximal shortening velocity, which is followed by a sustained state (phase 2) characterized by low force generation and maximal shortening velocity. Similar preparations from knockout neonatal mice do not undergo phase 1, but exhibit a normal phase 2. We propose that, in neonatal smooth muscle phase 1 is generated by recruitment of smooth-muscle myosin heavy chain, whereas phase 2 can be generated by activation of non-muscle myosin heavy chain. We conclude that phase 1 becomes indispensable for survival and normal growth soon after birth, particularly for functions such as homeostasis and circulation.	Max Delbruck Ctr Mol Med, D-13092 Berlin, Germany; Humboldt Univ, Dept Physiol, Charite, D-10117 Berlin, Germany	Helmholtz Association; Max Delbruck Center for Molecular Medicine; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Morano, I (corresponding author), Max Delbruck Ctr Mol Med, Robert Rossle Str 10, D-13092 Berlin, Germany.	imorano@mdc-berlin.de; mbader@mdc-berlin.de	Bader, Michael/K-2124-2013	Bader, Michael/0000-0003-4780-4164				Amano M, 1996, J BIOL CHEM, V271, P20246, DOI 10.1074/jbc.271.34.20246; BABIJ P, 1993, NUCLEIC ACIDS RES, V21, P1467, DOI 10.1093/nar/21.6.1467; BARANY M, 1967, J GEN PHYSIOL, V50, P197, DOI 10.1085/jgp.50.6.197; Bresnick AR, 1999, CURR OPIN CELL BIOL, V11, P26, DOI 10.1016/S0955-0674(99)80004-0; DILLON PF, 1981, SCIENCE, V211, P495, DOI 10.1126/science.6893872; HACKENTHAL E, 1990, PHYSIOL REV, V70, P1067, DOI 10.1152/physrev.1990.70.4.1067; Hackney DD, 1996, ANNU REV PHYSIOL, V58, P731; Hill AV, 1938, PROC R SOC SER B-BIO, V126, P136, DOI 10.1098/rspb.1938.0050; KELLEY CA, 1993, J BIOL CHEM, V268, P12848; KISHIHARA K, 1993, CELL, V74, P143, DOI 10.1016/0092-8674(93)90302-7; Kolodney MS, 1999, J PHYSIOL-LONDON, V515, P87, DOI 10.1111/j.1469-7793.1999.087ad.x; LEE MA, 1995, HYPERTENSION, V25, P570, DOI 10.1161/01.HYP.25.4.570; MORANO IL, 1992, J HYPERTENS, V10, P411, DOI 10.1097/00004872-199205000-00002; NAGAI R, 1989, J BIOL CHEM, V264, P9734; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; Segi E, 1998, BIOCHEM BIOPH RES CO, V246, P7, DOI 10.1006/bbrc.1998.8461; Smith GCS, 1998, PHARMACOL REV, V50, P35; Somlyo A P, 1999, Rev Physiol Biochem Pharmacol, V134, P201; Suzuki T, 1996, CIRC RES, V78, P395, DOI 10.1161/01.RES.78.3.395; Tullio AN, 1997, P NATL ACAD SCI USA, V94, P12407, DOI 10.1073/pnas.94.23.12407; UMEMOTO S, 1989, J BIOL CHEM, V264, P1431; Wagner C, 1998, CURR OPIN NEPHROL HY, V7, P437, DOI 10.1097/00041552-199807000-00015; Weiss A, 1996, ANNU REV CELL DEV BI, V12, P417, DOI 10.1146/annurev.cellbio.12.1.417	23	109	111	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	JUN	2000	2	6					371	375		10.1038/35014065	http://dx.doi.org/10.1038/35014065			5	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	321KE	10854329				2022-12-25	WOS:000087454000020
J	Bolino, A; Muglia, M; Conforti, FL; LeGuern, E; Salih, MAM; Georgiou, DM; Christodoulou, K; Hausmanowa-Petrusewicz, I; Mandich, P; Schenone, A; Gambardella, A; Bono, F; Quattrone, A; Devoto, M; Monaco, AP				Bolino, A; Muglia, M; Conforti, FL; LeGuern, E; Salih, MAM; Georgiou, DM; Christodoulou, K; Hausmanowa-Petrusewicz, I; Mandich, P; Schenone, A; Gambardella, A; Bono, F; Quattrone, A; Devoto, M; Monaco, AP			Charcot-Marie-Tooth type 4B is caused by mutations in the gene encoding myotubularin-related protein-2	NATURE GENETICS			English	Article							FOLDED MYELIN SHEATHS; DEMYELINATING NEUROPATHY; FAMILY; YEAST		Wellcome Trust Ctr Human Genet, Oxford, England; Natl Res Council, Inst Expt Med & Biotechnol, Cosenza, Italy; Hop La Pitie Salpetriere, Paris, France; King Saud Univ, Dept Pediat, Riyadh, Saudi Arabia; Cyprus Inst Neurol & Genet, Mol Genet Unit D, Nicosia, Cyprus; Polish Acad Sci, MRC, Neuromuscular Unit, Warsaw, Poland; Univ Genoa, Dipartimento Sci Neurol & Riabilitaz, Genoa, Italy; Univ Genoa, Dipartimento Oncol Biol & Genet, Genoa, Italy; Univ Catanzaro, Inst Neurol, Catanzaro, Italy	University of Oxford; Wellcome Centre for Human Genetics; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; King Saud University; Polish Academy of Sciences; University of Genoa; University of Genoa; Magna Graecia University of Catanzaro	Monaco, AP (corresponding author), Wellcome Trust Ctr Human Genet, Oxford, England.		Salih, Mustafa/C-1222-2014; Bolino, Alessandra/AAN-5442-2020; Devoto, Marcella/AAP-7595-2021; schenone, angelo/I-3194-2012; Bolino, Alessandra/O-2933-2013; QUATTRONE, Aldo/A-6734-2016; Gambardella, Antonio/F-5295-2012; Conforti, Francesca Luisa/AAT-2428-2020; Monaco, Anthony P/A-4495-2010; Mandich, Paola/CAG-1105-2022; Conforti, Francesca Luisa/K-8877-2016	Salih, Mustafa/0000-0002-4379-2111; Bolino, Alessandra/0000-0002-8980-4878; schenone, angelo/0000-0002-2604-7830; QUATTRONE, Aldo/0000-0003-2001-957X; Gambardella, Antonio/0000-0001-7384-3074; Monaco, Anthony P/0000-0001-7480-3197; Mandich, Paola/0000-0003-3123-3512; Conforti, Francesca Luisa/0000-0001-8364-1783; DEVOTO, MARCELLA/0000-0002-4431-5114; MUGLIA, MARIA/0000-0001-6413-3935; Christodoulou, Kyproula/0000-0002-0622-7594	Telethon [293/B] Funding Source: Medline	Telethon(Fondazione Telethon)		Ben Othmane K, 1999, GENOMICS, V62, P344, DOI 10.1006/geno.1999.6028; Bolino A, 2000, GENOMICS, V63, P271, DOI 10.1006/geno.1999.6088; Bolino A, 1996, HUM MOL GENET, V5, P1051, DOI 10.1093/hmg/5.7.1051; Cui XM, 1998, NAT GENET, V18, P331, DOI 10.1038/ng0498-331; Gambardella A, 1997, BRAIN, V120, P2113, DOI 10.1093/brain/120.11.2113; Gambardella A, 1998, NEUROLOGY, V50, P799, DOI 10.1212/WNL.50.3.799; Hunter T, 1998, NAT GENET, V18, P303; Kikuno R, 1999, DNA Res, V6, P197, DOI 10.1093/dnares/6.3.197; Laporte J, 1998, HUM MOL GENET, V7, P1703, DOI 10.1093/hmg/7.11.1703; Laporte J, 1996, NAT GENET, V13, P175, DOI 10.1038/ng0696-175; Nakagawa M, 1999, NEUROLOGY, V52, P1271, DOI 10.1212/WNL.52.6.1271; Nelis E, 1999, HUM MUTAT, V13, P11, DOI 10.1002/(SICI)1098-1004(1999)13:1<11::AID-HUMU2>3.0.CO;2-A	12	356	376	0	19	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAY	2000	25	1					17	19		10.1038/75542	http://dx.doi.org/10.1038/75542			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	311KU	10802647				2022-12-25	WOS:000086884000009
J	Wagner, A				Wagner, A			Robustness against mutations in genetic networks of yeast	NATURE GENETICS			English	Article							FUNCTIONAL REDUNDANCY; SELECTIVE NEUTRALITY; EVOLUTION; GENOME; TRANSCRIPTION; TRANSPOSITION; DUPLICATION; DATABASE; FITNESS	There are two principal mechanisms that are responsible for the ability of an organism's physiological and developmental processes to compensate for mutations. In the first, genes have overlapping functions, and loss-of-function mutations in one gene will have little phenotypic effect if there are one or more additional genes with similar functions. The second mechanism has its origin in interactions between genes with unrelated functions, and has been documented in metabolic and regulatory gene networks. Here I analyse, on a genome-wide scale, which of these mechanisms of robustness against mutations is more prevalent. I used functional genomics data from the yeast Saccharomyces cerevisiae to test hypotheses related to the following: if gene duplications are mostly responsible for robustness, then a correlation is expected between the similarity of two duplicated genes and the effect of mutations in one of these genes. Wry results demonstrate that interactions among unrelated genes are the major cause of robustness against mutations. This type of robustness is probably an evolved response of genetic networks to stabilizing selection.	Univ New Mexico, Dept Biol, Albuquerque, NM 87131 USA; Santa Fe Inst, Albuquerque, NM USA	University of New Mexico; The Santa Fe Institute	Wagner, A (corresponding author), Univ New Mexico, Dept Biol, Albuquerque, NM 87131 USA.	wagnera@unm.edu						Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BRADSHAW VA, 1989, MOL GEN GENET, V218, P465, DOI 10.1007/BF00332411; CADIGAN KM, 1994, P NATL ACAD SCI USA, V91, P6324, DOI 10.1073/pnas.91.14.6324; Chu S, 1998, SCIENCE, V282, P699, DOI 10.1126/science.282.5389.699; Comeron JM, 1995, J MOL EVOL, V41, P1152, DOI 10.1007/BF00173196; Dayhoff M, 1978, ATLAS PROTEIN SEQ ST, P345; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; DOOLITTLE RF, 1994, TRENDS BIOCHEM SCI, V19, P15, DOI 10.1016/0968-0004(94)90167-8; DUN RB, 1958, NATURE, V181, P1018, DOI 10.1038/1811018a0; DYKHUIZEN D, 1980, GENETICS, V96, P801; DYKHUIZEN DE, 1987, GENETICS, V115, P25; Edwards JS, 1999, J BIOL CHEM, V274, P17410, DOI 10.1074/jbc.274.25.17410; Fell D., 1997, UNDERSTANDING CONTRO; Felsenstein J., 1989, CLADISTICS, V5, P164, DOI DOI 10.1111/J.1096-0031.1989.TB00562.X; Galperin MY, 1998, GENOME RES, V8, P779, DOI 10.1101/gr.8.8.779; GONZALEZGAITAN M, 1994, P NATL ACAD SCI USA, V91, P8567, DOI 10.1073/pnas.91.18.8567; HANKS M, 1995, SCIENCE, V269, P679, DOI 10.1126/science.7624797; HARTL DL, 1985, GENETICS, V111, P655; HENIKOFF S, 1992, P NATL ACAD SCI USA, V89, P10915, DOI 10.1073/pnas.89.22.10915; HOFFMANN FM, 1991, TRENDS GENET, V7, P351, DOI 10.1016/0168-9525(91)90254-F; Hubbard TJP, 1998, ACTA CRYSTALLOGR D, V54, P1147, DOI 10.1107/S0907444998009172; KACSER H, 1981, GENETICS, V97, P639; Kimura MA, 1985, NEUTRAL THEORY MOL E; LI XL, 1994, NATURE, V367, P83, DOI 10.1038/367083a0; Nadeau JH, 1997, GENETICS, V147, P1259; PAQUIN CE, 1984, SCIENCE, V226, P53, DOI 10.1126/science.226.4670.53; PEARSON WR, 1991, GENOMICS, V11, P635, DOI 10.1016/0888-7543(91)90071-L; RENDEL JM, 1959, EVOLUTION, V13, P425, DOI 10.1111/j.1558-5646.1959.tb03033.x; RENDEL JM, 1979, QUANTITATIVE GENETIC, P139; Rutherford SL, 1998, MOL BIOL CELL, V9, p433A; SAGA Y, 1992, GENE DEV, V6, P1821, DOI 10.1101/gad.6.10.1821; Seoighe C, 1999, CURR OPIN MICROBIOL, V2, P548, DOI 10.1016/S1369-5274(99)00015-6; Seoighe C, 1998, P NATL ACAD SCI USA, V95, P4447, DOI 10.1073/pnas.95.8.4447; Smith V, 1997, SCIENCE, V275, P464; Sokal R. R, 1981, BIOMETRY; Spellman PT, 1998, MOL BIOL CELL, V9, P3273, DOI 10.1091/mbc.9.12.3273; TAUTZ D, 1992, BIOESSAYS, V14, P263, DOI 10.1002/bies.950140410; Thatcher JW, 1998, P NATL ACAD SCI USA, V95, P253, DOI 10.1073/pnas.95.1.253; Waddington C. H., 1959, STRATEGY GENES; Wagner A, 1999, J EVOLUTION BIOL, V12, P1, DOI 10.1046/j.1420-9101.1999.00008.x; Wagner A, 1996, EVOLUTION, V50, P1008, DOI 10.1111/j.1558-5646.1996.tb02342.x; Wagner A, 2000, GENETICS, V154, P1389; Wagner GP, 1997, EVOLUTION, V51, P329, DOI [10.2307/2411105, 10.1111/j.1558-5646.1997.tb02420.x]; Wang YK, 1996, NATURE, V379, P823, DOI 10.1038/379823a0; WATERMAN MS, 1984, B MATH BIOL, V46, P473, DOI 10.1007/BF02459498; Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901; Wolfe KH, 1997, NATURE, V387, P708, DOI 10.1038/42711	48	301	308	0	25	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	APR	2000	24	4					355	361		10.1038/74174	http://dx.doi.org/10.1038/74174			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	299HK	10742097				2022-12-25	WOS:000086192800012
J	Yang, JH; Boerm, M; McCarty, M; Bucana, C; Fidler, IJ; Zhuang, Y; Su, B				Yang, JH; Boerm, M; McCarty, M; Bucana, C; Fidler, IJ; Zhuang, Y; Su, B			Mekk3 is essential for early embryonic cardiovascular development	NATURE GENETICS			English	Article							ACTIVATED PROTEIN-KINASE; RECEPTOR TYROSINE KINASE; TRANSCRIPTION FACTOR MEF2C; BLOOD-VESSEL FORMATION; MOLECULAR-CLONING; IN-VIVO; VASCULOGENESIS; ANGIOGENESIS; PATHWAYS; MORPHOGENESIS	The early development of blood vessels consists of two phases, vasculogenesis and angiogenesis, which involve distinct and also overlapping molecular regulators, but the intracellular signal transduction pathways involved in these processes have not been well defined(1-4). We disrupted Map3k3 (also known as Mekk3), which encodes Mekk3, a member of the Mekk/Ste11 family(5,6). in mice, Map3k3(-/-) embryos died at approximately embryonic day (E) 11, displaying disruption of blood vessel development and the structural integrity of the yolk sac. Angiogenesis was blocked at approximately E9.5 in mutant embryos. Map3k3 disruption did not alter the expression of the genes encoding Vegf-1, angiopoietin or their receptors. The development of embryonic, but not maternal, blood vessels in the placentas of Map3k3(-/-) embryos was impaired, revealing an intrinsic defect in Map3k3(-/-) endothelial cells. Moreover, Mekk3 activated myocyte-specific enhancer factor 2C (Mef2c), a transcription factor crucial for early embryonic cardiovascular development through the p38 mitogen-activated protein kinase (Mapk) cascade. We conclude that Mekk3 is necessary for blood vessel development and may be a possible target for drugs that control angiogenesis.	Univ Texas, MD Anderson Canc Ctr, Dept Immunol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA; Duke Univ, Med Ctr, Dept Immunol, Durham, NC USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Duke University	Su, B (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Immunol, Houston, TX 77030 USA.			zhuang, yuan/0000-0002-2964-3654				Bi WZ, 1999, DEV BIOL, V211, P255, DOI 10.1006/dbio.1999.9307; Blank JL, 1996, J BIOL CHEM, V271, P5361, DOI 10.1074/jbc.271.10.5361; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; Deacon K, 1999, J BIOL CHEM, V274, P16604, DOI 10.1074/jbc.274.23.16604; Deacon K, 1997, J BIOL CHEM, V272, P14489, DOI 10.1074/jbc.272.22.14489; DUMONT DJ, 1994, GENE DEV, V8, P1897, DOI 10.1101/gad.8.16.1897; EllingerZiegelbauer H, 1997, J BIOL CHEM, V272, P2668, DOI 10.1074/jbc.272.5.2668; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; Folkman J, 1996, CELL, V87, P1153, DOI 10.1016/S0092-8674(00)81810-3; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; Han J, 1997, NATURE, V386, P296, DOI 10.1038/386296a0; Hanahan D, 1997, SCIENCE, V277, P48, DOI 10.1126/science.277.5322.48; Lin Q, 1998, DEVELOPMENT, V125, P4565; Lin Q, 1997, SCIENCE, V276, P1404, DOI 10.1126/science.276.5317.1404; Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55; PURI MC, 1995, EMBO J, V14, P5884, DOI 10.1002/j.1460-2075.1995.tb00276.x; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; SATO TN, 1995, NATURE, V376, P70, DOI 10.1038/376070a0; Shalaby F, 1997, CELL, V89, P981, DOI 10.1016/S0092-8674(00)80283-4; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9; Yancopoulos GD, 1998, CELL, V93, P661, DOI 10.1016/S0092-8674(00)81426-9; Yang JH, 1998, GENE, V212, P95, DOI 10.1016/S0378-1119(98)00158-9	23	165	176	0	8	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAR	2000	24	3					309	313		10.1038/73550	http://dx.doi.org/10.1038/73550			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	288XW	10700190				2022-12-25	WOS:000085590600027
J	Kolusheva, S; Boyer, L; Jelinek, R				Kolusheva, S; Boyer, L; Jelinek, R			A colorimetric assay for rapid screening of antimicrobial peptides	NATURE BIOTECHNOLOGY			English	Article							POLYDIACETYLENE; TRANSITION; MEMBRANES; MELITTIN; VESICLES; ANALOGS; CHARGE; NMR		Ben Gurion Univ Negev, Dept Chem, IL-84105 Beer Sheva, Israel	Ben Gurion University	Kolusheva, S (corresponding author), Ben Gurion Univ Negev, Dept Chem, IL-84105 Beer Sheva, Israel.		JELINEK, RAZ/F-2023-2012	Kolusheva, Sofiya/0000-0002-4406-2241; jelinek, raz/0000-0002-0336-1384				BLONDELLE SE, 1991, BIOCHEMISTRY-US, V30, P4671, DOI 10.1021/bi00233a006; CHARYCH DH, 1993, SCIENCE, V261, P585, DOI 10.1126/science.8342021; Cheng Q, 1998, LANGMUIR, V14, P1974, DOI 10.1021/la980185b; Dathe M, 1998, BBA-BIOMEMBRANES, V1370, P175, DOI 10.1016/S0005-2736(97)00260-5; DEMPSEY CE, 1990, BIOCHIM BIOPHYS ACTA, V1031, P143, DOI 10.1016/0304-4157(90)90006-X; Hancock REW, 1999, DRUGS, V57, P469, DOI 10.2165/00003495-199957040-00002; Jelinek R, 1998, CHEM BIOL, V5, P619, DOI 10.1016/S1074-5521(98)90290-3; JEN WC, 1987, J APPL BACTERIOL, V63, P293, DOI 10.1111/j.1365-2672.1987.tb02705.x; Matsuzaki K, 1997, BBA-BIOMEMBRANES, V1327, P119, DOI 10.1016/S0005-2736(97)00051-5; Matsuzaki K, 1997, BIOCHEMISTRY-US, V36, P2104, DOI 10.1021/bi961870p; Okada S, 1998, ACCOUNTS CHEM RES, V31, P229, DOI 10.1021/ar970063v; Okada SY, 1999, ANGEW CHEM INT EDIT, V38, P655, DOI 10.1002/(SICI)1521-3773(19990301)38:5<655::AID-ANIE655>3.0.CO;2-4; PEREZPAYA E, 1995, J BIOL CHEM, V270, P1048, DOI 10.1074/jbc.270.3.1048; RAINA AK, 1989, SCIENCE, V244, P796, DOI 10.1126/science.244.4906.796; RINGSDORF H, 1988, ANGEW CHEM INT EDIT, V27, P113, DOI 10.1002/anie.198801131; SATAKE K, 1960, J BIOL CHEM, V235, P2801; TANAKA H, 1989, MACROMOLECULES, V22, P1208, DOI 10.1021/ma00193a036; Voet D VJ, 1990, BIOCHEMISTRY; ZASLOFF M, 1988, P NATL ACAD SCI USA, V85, P910, DOI 10.1073/pnas.85.3.910; [No title captured]	20	190	195	1	26	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	FEB	2000	18	2					225	227		10.1038/72697	http://dx.doi.org/10.1038/72697			3	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	281FH	10657134				2022-12-25	WOS:000085146900034
J	Hicks, C; Johnston, SH; diSibio, G; Collazo, A; Vogt, TF; Weinmaster, G				Hicks, C; Johnston, SH; diSibio, G; Collazo, A; Vogt, TF; Weinmaster, G			Fringe differentially modulates Jagged1 and Delta1 signalling through Notch1 and Notch2	NATURE CELL BIOLOGY			English	Article							LUNATIC FRINGE; INTRACELLULAR DOMAIN; SIGNALING MOLECULE; LIGAND; RECEPTOR; DROSOPHILA; ACTIVATION; EXPRESSION; SERRATE; MOUSE	Proteins encoded by the fringe family of genes are required to modulate Notch signalling in a wide range of developmental contexts. Using a cell co-culture assay, we find that mammalian Lunatic fringe (Lfng) inhibits Jagged1-mediated signalling and potentiates Delta1-mediated signalling through Notch1. Lfng localizes to the Golgi, and Lfng-dependent modulation of Notch signalling requires both expression of Lfng in the Notch-responsive cell and the Notch extracellular domain. Lfng does not prevent binding of soluble Jagged1 or Delta1 to Notch1-expressing cells. Lfng potentiates both Jagged1- and Delta1-mediated signalling via Notch2, in contrast to its actions with Notch1. Our data suggest that Fringe-dependent differential modulation of the interaction of Delta/Serrate/Lag2 (DSL) ligands with their Notch receptors is likely to have a significant role in the combinatorial repertoire of Notch signalling in mammals.	Univ Calif Los Angeles, Sch Med, Dept Biol Chem, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Dept Neurobiol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Inst Mol Biol, Los Angeles, CA 90095 USA; Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA; House Ear Inst, Los Angeles, CA 90057 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Princeton University; House Research Institute	Hicks, C (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Biol Chem, Los Angeles, CA 90095 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD030707] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R37NS031885, R01NS031885] Funding Source: NIH RePORTER; NICHD NIH HHS [HD 30707] Funding Source: Medline; NINDS NIH HHS [NS 31885-05] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Barrantes ID, 1999, CURR BIOL, V9, P470, DOI 10.1016/S0960-9822(99)80212-7; BLAIR SS, 1997, CURR BIOL, V7, P686; Brou C, 2000, MOL CELL, V5, P207, DOI 10.1016/S1097-2765(00)80417-7; Cohen B, 1997, NAT GENET, V16, P283, DOI 10.1038/ng0797-283; CONLON RA, 1995, DEVELOPMENT, V121, P1533; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; deAngelis MH, 1997, NATURE, V386, P717, DOI 10.1038/386717a0; Evrard YA, 1998, NATURE, V394, P377, DOI 10.1038/28632; Fleming RJ, 1997, DEVELOPMENT, V124, P2973; HEITZLER P, 1993, DEVELOPMENT, V117, P1113; Hsieh JJD, 1996, MOL CELL BIOL, V16, P952; Hukriede NA, 1997, DEVELOPMENT, V124, P3427; Irvine KD, 1999, CURR OPIN GENET DEV, V9, P434, DOI 10.1016/S0959-437X(99)80066-5; IRVINE KD, 1994, CELL, V79, P595, DOI 10.1016/0092-8674(94)90545-2; Jarriault S, 1998, MOL CELL BIOL, V18, P7423, DOI 10.1128/MCB.18.12.7423; Johnston SH, 1997, DEVELOPMENT, V124, P2245; Klueg KM, 1999, J CELL SCI, V112, P3289; Kuroda K, 1999, J BIOL CHEM, V274, P7238, DOI 10.1074/jbc.274.11.7238; Kusumi K, 1998, NAT GENET, V19, P274, DOI 10.1038/961; Laufer E, 1997, NATURE, V386, P366, DOI 10.1038/386366a0; Li LH, 1998, IMMUNITY, V8, P43, DOI 10.1016/S1074-7613(00)80457-4; LINDSELL CE, 1995, CELL, V80, P909, DOI 10.1016/0092-8674(95)90294-5; Lindsell CE, 1996, MOL CELL NEUROSCI, V8, P14, DOI 10.1006/mcne.1996.0040; Luo B, 1997, MOL CELL BIOL, V17, P6057, DOI 10.1128/MCB.17.10.6057; MACARTHUR CA, 1995, DEVELOPMENT, V121, P3603; May WA, 1997, NAT GENET, V17, P495, DOI 10.1038/ng1297-495; Moloney DJ, 2000, J BIOL CHEM, V275, P9604, DOI 10.1074/jbc.275.13.9604; Mumm JS, 2000, MOL CELL, V5, P197, DOI 10.1016/S1097-2765(00)80416-5; Nofziger D, 1999, DEVELOPMENT, V126, P1689; Panin VM, 1998, SEMIN CELL DEV BIOL, V9, P609, DOI 10.1006/scdb.1998.0263; Panin VM, 1997, NATURE, V387, P908, DOI 10.1038/43191; Qi HL, 1999, SCIENCE, V283, P91, DOI 10.1126/science.283.5398.91; RodriguezEsteban C, 1997, NATURE, V386, P360, DOI 10.1038/386360a0; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; Sestan N, 1999, SCIENCE, V286, P741, DOI 10.1126/science.286.5440.741; Shawber C, 1996, DEV BIOL, V180, P370, DOI 10.1006/dbio.1996.0310; Shawber C, 1996, DEVELOPMENT, V122, P3765; Shen J, 1997, CELL, V89, P629, DOI 10.1016/S0092-8674(00)80244-5; Shima DT, 1997, J CELL BIOL, V137, P1211, DOI 10.1083/jcb.137.6.1211; Shimizu K, 1999, J BIOL CHEM, V274, P32961, DOI 10.1074/jbc.274.46.32961; SWIATEK PJ, 1994, GENE DEV, V8, P707, DOI 10.1101/gad.8.6.707; Varnum-Finney B, 1998, BLOOD, V91, P4084, DOI 10.1182/blood.V91.11.4084.411k05_4084_4091; Wang SL, 1998, NEURON, V21, P63, DOI 10.1016/S0896-6273(00)80515-2; WATERS MG, 1992, J CELL BIOL, V118, P1015, DOI 10.1083/jcb.118.5.1015; Weinmaster G, 1997, MOL CELL NEUROSCI, V9, P91, DOI 10.1006/mcne.1997.0612; Wong PC, 1997, NATURE, V387, P288, DOI 10.1038/387288a0; Wu JY, 1996, SCIENCE, V273, P355, DOI 10.1126/science.273.5273.355; Yuan YP, 1997, CELL, V88, P9, DOI 10.1016/S0092-8674(00)81852-8; Zhang NA, 1998, NATURE, V394, P374, DOI 10.1038/28625	50	327	344	0	11	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	AUG	2000	2	8					515	520		10.1038/35019553	http://dx.doi.org/10.1038/35019553			6	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	341TE	10934472				2022-12-25	WOS:000088605000017
J	Long, QM; Huang, HG; Shafizadeh, E; Liu, NG; Lin, S				Long, QM; Huang, HG; Shafizadeh, E; Liu, NG; Lin, S			Stimulation of erythropoiesis by inhibiting a new hematopoietic death receptor in transgenic zebrafish	NATURE CELL BIOLOGY			English	Article							TRANSCRIPTION FACTOR GATA-1; DOMAIN-CONTAINING RECEPTOR; APOPTOSIS; CD95; GENE		Med Coll Georgia, Inst Mol Med & Genet, Augusta, GA 30912 USA	University System of Georgia; Augusta University	Lin, S (corresponding author), Med Coll Georgia, Inst Mol Med & Genet, Augusta, GA 30912 USA.		Long, Qiaoming/L-5074-2017	Long, Qiaoming/0000-0001-8243-589X	NATIONAL CENTER FOR RESEARCH RESOURCES [R01RR013227] Funding Source: NIH RePORTER; NCRR NIH HHS [R01RR13227] Funding Source: Medline; NIDDK NIH HHS [R01DK52355] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADACHI M, 1995, NAT GENET, V11, P394; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Chinnaiyan AM, 1996, SCIENCE, V274, P990, DOI 10.1126/science.274.5289.990; De Maria R, 1999, BLOOD, V93, P796, DOI 10.1182/blood.V93.3.796.403k23_796_803; De Maria R, 1999, NATURE, V401, P489, DOI 10.1038/46809; Dethloff GM, 1999, ECOTOX ENVIRON SAFE, V42, P253, DOI 10.1006/eesa.1998.1757; DETRICH HW, 1995, P NATL ACAD SCI USA, V92, P10713, DOI 10.1073/pnas.92.23.10713; Kitson J, 1996, NATURE, V384, P372, DOI 10.1038/384372a0; Kralovics R, 2000, CURR OPIN PEDIATR, V12, P29, DOI 10.1097/00008480-200002000-00006; Long QM, 1997, DEVELOPMENT, V124, P4105; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; PREHAL JF, 1999, CURR OPIN HEMATOL, V6, P100; Thompson MA, 1998, DEV BIOL, V197, P248, DOI 10.1006/dbio.1998.8887; WEISS MJ, 1995, EXP HEMATOL, V23, P99; WEISS MJ, 1995, P NATL ACAD SCI USA, V92, P9623, DOI 10.1073/pnas.92.21.9623; Willett CE, 1999, DEV DYNAM, V214, P323, DOI 10.1002/(SICI)1097-0177(199904)214:4<323::AID-AJA5>3.3.CO;2-V; WU H, 1995, CELL, V83, P59, DOI 10.1016/0092-8674(95)90234-1	20	50	52	0	8	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	AUG	2000	2	8					549	552		10.1038/35019592	http://dx.doi.org/10.1038/35019592			4	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	341TE	10934476				2022-12-25	WOS:000088605000021
J	Luo, D; Saltzman, WM				Luo, D; Saltzman, WM			Enhancement of transfection by physical concentration of DNA at the cell surface	NATURE BIOTECHNOLOGY			English	Article									Cornell Univ, Sch Chem Engn, Ithaca, NY 14853 USA	Cornell University	Saltzman, WM (corresponding author), Cornell Univ, Sch Chem Engn, Ithaca, NY 14853 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043873] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-43873] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Crank J., 1975, MATH DIFFUSION; HAENSLER J, 1993, BIOCONJUGATE CHEM, V4, P372, DOI 10.1021/bc00023a012; Jain RK, 1998, NAT MED, V4, P655, DOI 10.1038/nm0698-655; KULKOWSKALATALL.JF, 1996, P NATL ACAD SCI USA, V93, P4897; Luo D, 2000, NAT BIOTECHNOL, V18, P33, DOI 10.1038/71889; PASTAN IH, 1981, ANNU REV PHYSIOL, V43, P239, DOI 10.1146/annurev.ph.43.030181.001323; SALTZMAN WM, 2000, IN PRESS DRUG DELIVE	7	330	354	3	75	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	AUG	2000	18	8					893	895		10.1038/78523	http://dx.doi.org/10.1038/78523			3	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	342VX	10932162				2022-12-25	WOS:000088666800029
J	Velasco, J; Adrio, JL; Moreno, MA; Diez, B; Soler, G; Barredo, JL				Velasco, J; Adrio, JL; Moreno, MA; Diez, B; Soler, G; Barredo, JL			Environmentally safe production of 7-aminodeacetoxycephalosporanic acid (7-ADCA) using recombinant strains of Acremonium chrysogenum	NATURE BIOTECHNOLOGY			English	Article						cephalosporin; deacetoxycephalosporin C; 7-ADCA; cefEF; cefE; D-amino acid oxidase; glutaryl acylase	DEACETOXYCEPHALOSPORIN-C SYNTHETASE; STREPTOMYCES-CLAVULIGERUS NP1; ISOPENICILLIN N-SYNTHETASE; BETA-LACTAM BIOSYNTHESIS; PENICILLIUM-CHRYSOGENUM; CEPHALOSPORIUM-ACREMONIUM; RING-EXPANSION; ESCHERICHIA-COLI; RESTING CELLS; CEFE GENE	Medically useful semisynthetic cephalosporins are made from 7-aminodeacetoxycephalosporanic acid (7-ADCA) or 7-aminocephalosporanic acid (7-ACA). Here we describe a new industrially amenable bioprocess for the production of the important intermediate 7-ADCA that can replace the expensive and environmentally unfriendly chemical method classically used. The method is based on the disruption and one-step replacement of the cefEF gene, encoding the bifunctional expandase/hydroxylase activity, of an actual industrial cephalosporin C production strain of Acremonium chrysogenum. Subsequent cloning and expression of the cefE gene from Streptomyces clavuligerus in A. chrysogenum yield recombinant strains producing high titers of deacetoxycephalosporin C (DAOC). Production level of DAOC is nearly equivalent (75-80%) to the total p-lactams biosynthesized by the parental overproducing strain. DAOC deacylation is carried out by two final enzymatic bioconversions catalyzed by D-amino acid oxidase (DAO) and glutaryl acylase (GLA) yielding 7-ADCA, In contrast to the data reported for recombinant strains of Penicillium chrysogenum expressing ring expansion activity, no detectable contamination with other cephalosporin intermediates occurred.	Antibiot SA, Labs Biotecnol & Bioquim, Leon 24009, Spain		Barredo, JL (corresponding author), Antibiot SA, Labs Biotecnol & Bioquim, Avenida Antibiot 59-61, Leon 24009, Spain.			Velasco-Alvarez, Javier/0000-0002-4407-0620; Moreno Valle, Miguel Angel/0000-0002-1419-6898				Alonso J, 1998, MICROBIOL-SGM, V144, P1095, DOI 10.1099/00221287-144-4-1095; Alonso J, 1999, ENZYME MICROB TECH, V25, P88, DOI 10.1016/S0141-0229(99)00019-8; BALDWIN JE, 1987, TETRAHEDRON, V43, P3009, DOI 10.1016/S0040-4020(01)86840-X; BALLIO A, 1960, NATURE, V185, P97, DOI 10.1038/185097a0; BECKMANN R, 1993, INDUSTRIAL MICROORGANISMS: BASIC AND APPLIED MOLECULAR GENETICS, P177; CAMBIAGHI S, 1995, Patent No. 524196; CANTWELL C, 1992, P ROY SOC B-BIOL SCI, V248, P283, DOI 10.1098/rspb.1992.0073; CANTWELL CA, 1990, CURR GENET, V17, P213, DOI 10.1007/BF00312612; Cho H, 1998, P NATL ACAD SCI USA, V95, P11544, DOI 10.1073/pnas.95.20.11544; CRAWFORD L, 1995, BIO-TECHNOL, V13, P58, DOI 10.1038/nbt0195-58; Croux C., 1994, [No title captured], Patent No. [US 5354667A, 5354667]; DEMAIN A, 1995, BIO-TECHNOL, V13, P23, DOI 10.1038/nbt0195-23; Diez B, 1999, APPL MICROBIOL BIOT, V52, P196, DOI 10.1007/s002530051509; DOTZLAF JE, 1987, J BACTERIOL, V169, P1611, DOI 10.1128/jb.169.4.1611-1618.1987; FENG B, 1994, APPL ENVIRON MICROB, V60, P4432, DOI 10.1128/AEM.60.12.4432-4439.1994; Fernandez MJ, 1999, APPL MICROBIOL BIOT, V52, P484, DOI 10.1007/s002530051549; GUTIERREZ S, 1992, J BACTERIOL, V174, P3056; Gutierrez S, 1997, APPL MICROBIOL BIOT, V48, P606, DOI 10.1007/s002530051103; Hersbach G.J.M., 1984, BIOTECHNOLOGY IND AN, VVolume 22, P45; ISOGAI T, 1991, BIO-TECHNOL, V9, P188, DOI 10.1038/nbt0291-188; ISOGAI T, 1997, BIOTECHNOLOGY ANTIBI, P733; KOLAR M, 1991, J BIOTECHNOL, V17, P67, DOI 10.1016/0168-1656(91)90027-S; KOVACEVIC S, 1990, J BACTERIOL, V172, P3952, DOI 10.1128/jb.172.7.3952-3958.1990; KUPKA J, 1983, FEMS MICROBIOL LETT, V16, P1; LEPAGE GA, 1946, J BIOL CHEM, V162, P163; MAEDA K, 1995, ENZYME MICROB TECH, V17, P231, DOI 10.1016/0141-0229(94)00001-8; Maniatis T., 1989, MOL CLONING LAB MANU; MATSUDA A, 1985, J BACTERIOL, V163, P1222, DOI 10.1128/JB.163.3.1222-1228.1985; PUNT PJ, 1987, GENE, V56, P117, DOI 10.1016/0378-1119(87)90164-8; QUEENER SW, 1994, ANN NY ACAD SCI, V721, P178, DOI 10.1111/j.1749-6632.1994.tb47391.x; Queener SW, 1985, MICROBIOLOGY 1985, P468; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SAMSON SM, 1987, BIO-TECHNOL, V5, P1207, DOI 10.1038/nbt1187-1207; SHEN YQ, 1986, BIO-TECHNOL, V4, P61, DOI 10.1038/nbt0186-61; SPECHT CA, 1982, ANAL BIOCHEM, V119, P158, DOI 10.1016/0003-2697(82)90680-7; YEH WK, 1994, 50 YEARS PENICILLIN, P208	36	64	70	1	26	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	AUG	2000	18	8					857	861		10.1038/78467	http://dx.doi.org/10.1038/78467			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	342VX	10932155				2022-12-25	WOS:000088666800022
J	Vervoort, R; Lennon, A; Bird, AC; Tulloch, B; Axton, R; Miano, MG; Meindl, A; Meitinger, T; Ciccodicola, A; Wright, AF				Vervoort, R; Lennon, A; Bird, AC; Tulloch, B; Axton, R; Miano, MG; Meindl, A; Meitinger, T; Ciccodicola, A; Wright, AF			Mutational hot spot within a new RPGR exon in X-linked retinitis pigmentosa	NATURE GENETICS			English	Article							NUCLEOTIDE-EXCHANGE FACTOR; POSITIONAL CLONING; GENE; IDENTIFICATION; SEQUENCES; FAMILIES; DNA; RP3; TRANSCRIPTION; HOMOLOGY	The gene RPGR was previously identified in the RP3 region of Xp21.1 and shown to be mutated in 10-20% of patients with the progressive retinal degeneration X-linked retinitis pigmentosa(1,2) (XLRP). The mutations predominantly affected a domain homologous to RCC1, a guanine nucleotide exchange factor for the small GTPase Ran, although they were present in fewer than the 70-75% of XLRP patients predicted from linkage studies(3-6) Mutations in the RP2 locus at Xp11.3 were found in a further 10-20% of XLRP patients, as predicted from linkage studies(6-8). Because the mutations in the remainder of the XLRP patients may reside in undiscovered exons of RPGR, we sequenced a 172-kb region containing the entire gene. Analysis of the sequence disclosed a new 3' terminal exon that was mutated in 60% of XLRP patients examined. This exon encodes 567 amino acids, with a repetitive domain rich in glutamic acid residues. The sequence is conserved in the mouse, bovine and Fugu rubripes genes. it is preferentially expressed in mouse and bovine retina, further supporting its importance for retinal function. Our results suggest that mutations in RPGR are the only cause of RP3 type XLRP and account for the disease in over 70% of XLRP patients and an estimated 11% of all retinitis pigmentosa patients.	Western Gen Hosp, MRC, Human Genet Unit, Edinburgh, Midlothian, Scotland; UCL, Dept Clin Ophthalmol, London WC1E 6BT, England; Moorfields Eye Hosp, London, England; CNR, Int Inst Genet & Biophys, I-80125 Naples, Italy; Univ Munich, Dept Med Genet, Munich, Germany; GSF, Res Ctr, Clin Ophthalmol Res Cooperat, Neuherberg, Germany	University of Edinburgh; University of London; University College London; University of London; University College London; Moorfields Eye Hospital NHS Foundation Trust; Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica e Biofisica "Adriano Buzzati-Traverso" (IGB-CNR); University of Munich; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health	Wright, AF (corresponding author), Western Gen Hosp, MRC, Human Genet Unit, Edinburgh, Midlothian, Scotland.	alan.wright@hgu.mrc.ac.uk	Miano, Maria Giuseppina/AAX-8437-2020; Meitinger, Thomas/O-1318-2015; Giuseppina, Miano Maria/B-9169-2015; Miano, Maria Giuseppina/E-9056-2011	Miano, Maria Giuseppina/0000-0003-1396-9673; Miano, Maria Giuseppina/0000-0003-1396-9673; Meitinger, Thomas/0000-0002-8838-8403; Ciccodicola, Alfredo/0000-0002-9924-1482	Telethon [E.1093] Funding Source: Medline	Telethon(Fondazione Telethon)		Buraczynska M, 1997, AM J HUM GENET, V61, P1287, DOI 10.1086/301646; Burge C, 1997, J MOL BIOL, V268, P78, DOI 10.1006/jmbi.1997.0951; Cooper D. N., 1993, HUMAN GENE MUTATION; Dry KL, 1999, HUM MUTAT, V13, P141, DOI 10.1002/(SICI)1098-1004(1999)13:2<141::AID-HUMU6>3.3.CO;2-H; DRY KL, 1995, HUM MOL GENET, V4, P2347, DOI 10.1093/hmg/4.12.2347; Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020; Hardcastle AJ, 1999, AM J HUM GENET, V64, P1210, DOI 10.1086/302325; Jurka J, 1996, COMPUT CHEM, V20, P119, DOI 10.1016/S0097-8485(96)80013-1; Kirschner R, 1999, HUM MOL GENET, V8, P1571, DOI 10.1093/hmg/8.8.1571; Meindl A, 1996, NAT GENET, V13, P35, DOI 10.1038/ng0596-35; MEINDL A, 1995, HUM MOL GENET, V4, P2339, DOI 10.1093/hmg/4.12.2339; Miano MG, 1999, EUR J HUM GENET, V7, P687, DOI 10.1038/sj.ejhg.5200352; OTT J, 1990, P NATL ACAD SCI USA, V87, P701, DOI 10.1073/pnas.87.2.701; Reese MG, 1997, J COMPUT BIOL, V4, P311, DOI 10.1089/cmb.1997.4.311; Roepman R, 1996, HUM MOL GENET, V5, P1035, DOI 10.1093/hmg/5.7.1035; Roepman R, 1996, HUM MOL GENET, V5, P827, DOI 10.1093/hmg/5.6.827; Schwahn U, 1998, NAT GENET, V19, P327, DOI 10.1038/1214; TEAGUE PW, 1994, AM J HUM GENET, V55, P105; Wang G, 1996, SCIENCE, V271, P802, DOI 10.1126/science.271.5250.802; WEAVER DT, 1982, J BIOL CHEM, V257, P2075; WOOTTON JC, 1994, CURR OPIN STRUC BIOL, V4, P413, DOI 10.1016/S0959-440X(94)90111-2; Xu Y, 1994, Genet Eng (N Y), V16, P241; Zhang MQ, 1997, P NATL ACAD SCI USA, V94, P565, DOI 10.1073/pnas.94.2.565	23	318	333	0	8	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036			NAT GENET	Nature Genet.	AUG	2000	25	4					462	466		10.1038/78182	http://dx.doi.org/10.1038/78182			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	341WY	10932196				2022-12-25	WOS:000088615000027
J	Yang, ZY; Duckers, HJ; Sullivan, NJ; Sanchez, A; Nabel, EG; Nabel, GJ				Yang, ZY; Duckers, HJ; Sullivan, NJ; Sanchez, A; Nabel, EG; Nabel, GJ			Identification of the Ebola virus glycoprotein as the main viral determinant of vascular cell cytotoxicity and injury	NATURE MEDICINE			English	Article							TRANSIENT TRANSFECTION; INFECTION	Here we defined the main viral determinant of Ebola virus pathogenicity; synthesis of the virion glycoprotein (CP) of Ebola virus Zaire induced cytotoxic effects in human endothelial cells in vitro and in vivo. This effect mapped to a serine-threonine-rich, mucin-like domain of this type I transmembrane glycoprotein, one of seven gene products of the virus. Gene transfer of GP into explanted human or porcine blood vessels caused massive endothelial cell loss within 48 hours that led to a substantial increase in vascular permeability. Deletion of the mucin-like region of GP abolished these effects without affecting protein expression or function. CP derived from the Reston strain of virus, which causes disease in nonhuman primates but not in man, did not disrupt the vasculature of human blood vessels. In contrast, the Zaire CP induced endothelial cell disruption and cytotoxicity in both nonhuman primate and human blood vessels, and the mucin domain was required for this effect. These findings indicate that CP, through its mucin domain, is the viral determinant of Ebola pathogenicity and likely contributes to hemorrhage during infection.	NIH, Vaccine Res Ctr, Bethesda, MD 20892 USA; NHLBI, Vasc Biol Branch, NIH, Bethesda, MD 20892 USA; Ctr Dis Control & Prevent, Special Pathogens Branch, Div Viral & Rickettsial Dis, Natl Ctr Infect Dis, Atlanta, GA 30333 USA	National Institutes of Health (NIH) - USA; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Centers for Disease Control & Prevention - USA	Nabel, GJ (corresponding author), NIH, Vaccine Res Ctr, 40 Convent Dr, Bethesda, MD 20892 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL005601] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Baize S, 1999, NAT MED, V5, P423, DOI 10.1038/7422; BASKERVILLE A, 1978, J PATHOL, V125, P131, DOI 10.1002/path.1711250303; BASKERVILLE A, 1985, J PATHOL, V147, P199, DOI 10.1002/path.1711470308; BOWEN ETW, 1977, LANCET, V1, P571; CDC, 1995, MMWR-MORBID MORTAL W, V44, P381; FELDMANN H, 1994, VIROLOGY, V199, P469, DOI 10.1006/viro.1994.1147; Feldmann H, 1996, J VIROL, V70, P2208, DOI 10.1128/JVI.70.4.2208-2214.1996; Mbiene JP, 1997, J COMP NEUROL, V377, P324, DOI 10.1002/(SICI)1096-9861(19970120)377:3<324::AID-CNE2>3.0.CO;2-4; OHNO T, 1994, SCIENCE, V265, P781, DOI 10.1126/science.8047883; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Peters C.J., 1996, FIELDS VIROLOGY, P1161; Sanchez A, 1998, J VIROL, V72, P6442, DOI 10.1128/JVI.72.8.6442-6447.1998; Villinger F, 1999, J INFECT DIS, V179, pS188, DOI 10.1086/514283; Volchkov VE, 1998, P NATL ACAD SCI USA, V95, P5762, DOI 10.1073/pnas.95.10.5762; Weissenhorn W, 1998, P NATL ACAD SCI USA, V95, P6032, DOI 10.1073/pnas.95.11.6032; Xu L, 1998, NAT MED, V4, P37, DOI 10.1038/nm0198-037; Yang SL, 1999, HUM GENE THER, V10, P123, DOI 10.1089/10430349950019255; Yang ZY, 1998, SCIENCE, V279, P1034, DOI 10.1126/science.279.5353.1034	18	311	343	1	66	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	AUG	2000	6	8					886	889		10.1038/78654	http://dx.doi.org/10.1038/78654			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	376TX	10932225				2022-12-25	WOS:000165473800031
J	Tomancak, P; Piano, F; Riechmann, V; Gunsalus, KC; Kemphues, KJ; Ephrussi, A				Tomancak, P; Piano, F; Riechmann, V; Gunsalus, KC; Kemphues, KJ; Ephrussi, A			A Drosophila melanogaster homologue of Caenorhabditis elegans par-1 acts at an early step in embryonic-axis formation	NATURE CELL BIOLOGY			English	Article							OSKAR MESSENGER-RNA; C-ELEGANS; POSTERIOR POLE; GERM PLASM; LOCALIZATION; GRANULES		European Mol Biol Lab, Dev Biol Programme, D-69117 Heidelberg, Germany; Cornell Univ, Dept Mol Biol & Genet, Ithaca, NY 14853 USA	European Molecular Biology Laboratory (EMBL); Cornell University	Ephrussi, A (corresponding author), European Mol Biol Lab, Dev Biol Programme, Meyerhofstr 1, D-69117 Heidelberg, Germany.	ephrussi@embl-heidelberg.de	Ephrussi, Anne/ABD-4393-2021; Ephrussi, Anne/AAG-4075-2020; Tomancak, Pavel/C-2109-2009	Ephrussi, Anne/0000-0002-5061-4620; Tomancak, Pavel/0000-0002-2222-9370	NICHD NIH HHS [HD27689] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD027689] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Drewes G, 1997, CELL, V89, P297, DOI 10.1016/S0092-8674(00)80208-1; EPHRUSSI A, 1991, CELL, V66, P37, DOI 10.1016/0092-8674(91)90137-N; EPHRUSSI A, 1992, NATURE, V358, P387, DOI 10.1038/358387a0; ERDELYI M, 1995, NATURE, V377, P524, DOI 10.1038/377524a0; GLOTZER JB, 1999, COMP METHODS APPROAC, pCH23; Gunkel N, 1998, GENE DEV, V12, P1652, DOI 10.1101/gad.12.11.1652; Guo S, 1996, NATURE, V382, P455, DOI 10.1038/382455a0; Guo S, 1996, CURR OPIN GENET DEV, V6, P408, DOI 10.1016/S0959-437X(96)80061-X; Kawasaki I, 1998, CELL, V94, P635, DOI 10.1016/S0092-8674(00)81605-0; KIMHA J, 1991, CELL, V66, P23, DOI 10.1016/0092-8674(91)90136-M; Lantz VA, 1999, MECH DEVELOP, V85, P111, DOI 10.1016/S0925-4773(99)00096-9; LEHMANN R, 1994, CIBA F SYMP, V182, P282; MARKUSSEN FH, 1995, DEVELOPMENT, V121, P3723; Ray RP, 1996, GENE DEV, V10, P1711, DOI 10.1101/gad.10.14.1711; Rose LS, 1998, ANNU REV GENET, V32, P521, DOI 10.1146/annurev.genet.32.1.521; Sambrook J, 1989, MOL CLONING LAB MANU; STROME S, 1983, CELL, V35, P15, DOI 10.1016/0092-8674(83)90203-9; THEURKAUF WE, 1993, DEVELOPMENT, V118, P1169, DOI 10.1016/0168-9525(93)90134-4	18	140	140	2	5	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	JUL	2000	2	7					458	460		10.1038/35017101	http://dx.doi.org/10.1038/35017101			3	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	333MK	10878812				2022-12-25	WOS:000088133700023
J	Oritani, K; Medina, KL; Tomiyama, Y; Ishikawa, J; Okajima, Y; Ogawa, M; Yokota, T; Aoyama, K; Takahashi, I; Kincade, PW; Matsuzawa, Y				Oritani, K; Medina, KL; Tomiyama, Y; Ishikawa, J; Okajima, Y; Ogawa, M; Yokota, T; Aoyama, K; Takahashi, I; Kincade, PW; Matsuzawa, Y			Limitin: An interferon-like cytokine that preferentially influences B-lymphocyte precursors	NATURE MEDICINE			English	Article							HEMATOPOIETIC STEM-CELLS; PROTEIN-TYROSINE KINASE; BONE-MARROW; IFN-ALPHA; SIGNAL-TRANSDUCTION; INDUCED APOPTOSIS; PROGENITOR CELLS; GROWTH-FACTORS; STROMAL CELLS; IN-VITRO	We have identified an interferon-like cytokine, limitin, on the basis of its ability to arrest the growth of or kill lympho-hematopoietic cells. Limitin strongly inhibited B lymphopoiesis in vitro and in vivo but had little influence on either myelopoiesis or erythropoiesis. Because limitin uses the interferon alpha/beta receptors and induces interferon regulatory factor-1, it may represent a previously unknown type I interferon prototype. However, preferential B-lineage growth inhibition and activation of Janus kinase 2 in a myelomonocytic leukemia line have not been described for previously known interferons.	Osaka Univ, Grad Sch Med, Dept Internal Med & Mol Sci, Suita, Osaka 5650871, Japan; Oklahoma Med Res Fdn, Oklahoma City, OK 73104 USA	Osaka University; Oklahoma Medical Research Foundation	Oritani, K (corresponding author), Osaka Univ, Grad Sch Med, Dept Internal Med & Mol Sci, 2-2 Yamada-oka, Suita, Osaka 5650871, Japan.			Tomiyama, Yoshiaki/0000-0001-7645-0989	NIAID NIH HHS [AI-20069, AI-33085] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033085, R37AI020069, R01AI020069] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABRAMOVICH C, 1994, EMBO J, V13, P5871, DOI 10.1002/j.1460-2075.1994.tb06932.x; Borghesi LA, 1997, J IMMUNOL, V159, P4171; BROXMEYER HE, 1992, AM J PEDIAT HEMATOL, V14, P22; Burrows PD, 1997, CURR OPIN IMMUNOL, V9, P239, DOI 10.1016/S0952-7915(97)80142-2; COHEN PL, 1991, ANNU REV IMMUNOL, V9, P243, DOI 10.1146/annurev.iy.09.040191.001331; COLAMONICI O, 1994, MOL CELL BIOL, V14, P8133, DOI 10.1128/MCB.14.12.8133; Dexter T M, 1976, Methods Cell Biol, V14, P387, DOI 10.1016/S0091-679X(08)60498-7; Domanski Paul, 1996, Cytokine and Growth Factor Reviews, V7, P143, DOI 10.1016/1359-6101(96)00017-2; DORSHKIND K, 1988, J IMMUNOL, V141, P531; GIMBLE JM, 1993, EXP HEMATOL, V21, P224; GIMBLE JM, 1989, MOL CELL BIOL, V9, P4587, DOI 10.1128/MCB.9.11.4587; Graham GJ, 1997, INT J EXP PATHOL, V78, P197, DOI 10.1046/j.1365-2613.1997.270361.x; GRAWUNDER U, 1993, EUR J IMMUNOL, V23, P544, DOI 10.1002/eji.1830230237; Haque SJ, 1998, SEMIN ONCOL, V25, P14; HAUPTMANN R, 1985, NUCLEIC ACIDS RES, V13, P4739, DOI 10.1093/nar/13.13.4739; HIGASHI Y, 1983, J BIOL CHEM, V258, P9522; HIRAYAMA F, 1994, P NATL ACAD SCI USA, V91, P469, DOI 10.1073/pnas.91.2.469; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; ITRI LM, 1992, CANCER, V70, P940; Kelly KA, 1998, ENDOCRINOLOGY, V139, P2092, DOI 10.1210/en.139.4.2092; KIMURA T, 1994, SCIENCE, V264, P1921, DOI 10.1126/science.8009222; Kincade PW, 1998, CELL ADHES COMMUN, V6, P211, DOI 10.3109/15419069809004476; KINCADE PW, 1991, ADV EXP MED BIOL, V292, P227; KIRCHHOFF S, 1995, ONCOGENE, V11, P439; LEAMAN DW, 1992, J INTERFERON RES, V12, P1, DOI 10.1089/jir.1992.12.1; LEE G, 1987, J EXP MED, V166, P1290, DOI 10.1084/jem.166.5.1290; LENGYEL P, 1993, P NATL ACAD SCI USA, V90, P5893, DOI 10.1073/pnas.90.13.5893; Lyman SD, 1998, BLOOD, V91, P1101, DOI 10.1182/blood.V91.4.1101; Matsumura I, 1997, MOL CELL BIOL, V17, P2933, DOI 10.1128/MCB.17.5.2933; MAZUR EM, 1986, J INTERFERON RES, V6, P199, DOI 10.1089/jir.1986.6.199; MEDINA KL, 1994, P NATL ACAD SCI USA, V91, P5382, DOI 10.1073/pnas.91.12.5382; MEDINA KL, 1993, J EXP MED, V178, P1507, DOI 10.1084/jem.178.5.1507; Morrison SJ, 1997, CELL, V88, P287, DOI 10.1016/S0092-8674(00)81867-X; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; MULLER U, 1994, SCIENCE, V264, P1918, DOI 10.1126/science.8009221; Nguyen Hannah, 1997, Cytokine and Growth Factor Reviews, V8, P293, DOI 10.1016/S1359-6101(97)00019-1; NOVICK D, 1994, CELL, V77, P391, DOI 10.1016/0092-8674(94)90154-6; Oritani K, 1999, BLOOD, V93, P1346, DOI 10.1182/blood.V93.4.1346.404k15_1346_1354; Oritani K, 1996, J CELL BIOL, V134, P771, DOI 10.1083/jcb.134.3.771; Oritani K, 1998, LEUKEMIA LYMPHOMA, V32, P1; PIETRANGELI CE, 1988, EUR J IMMUNOL, V18, P863, DOI 10.1002/eji.1830180606; Platanias LC, 1996, J BIOL CHEM, V271, P23630, DOI 10.1074/jbc.271.39.23630; Rani MRS, 1996, J BIOL CHEM, V271, P22878, DOI 10.1074/jbc.271.37.22878; SHAW GD, 1983, NUCLEIC ACIDS RES, V11, P555, DOI 10.1093/nar/11.3.555; Shimozato T, 1997, J IMMUNOL, V158, P5178; SMITHSON G, 1995, J IMMUNOL, V155, P3409; TAMURA T, 1995, NATURE, V376, P596, DOI 10.1038/376596a0; TANIGUCHI T, 1995, J CANCER RES CLIN, V121, P516, DOI 10.1007/BF01197763; TOMIYAMA Y, 1992, BLOOD, V79, P2303; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; Verfaillie CM, 1996, J LAB CLIN MED, V127, P148; WANG JY, 1995, IMMUNITY, V3, P475, DOI 10.1016/1074-7613(95)90176-0; Weiss K, 1998, SEMIN ONCOL, V25, P9; Whetton AD, 1998, CURR OPIN CELL BIOL, V10, P721, DOI 10.1016/S0955-0674(98)80113-0; WHITLOCK CA, 1984, J IMMUNOL METHODS, V6, P7353; Yokota T, 1998, BLOOD, V91, P3263, DOI 10.1182/blood.V91.9.3263.3263_3263_3272; Zavyalov VP, 1997, APMIS, V105, P161, DOI 10.1111/j.1699-0463.1997.tb00556.x	57	100	105	0	5	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUN	2000	6	6					659	666		10.1038/76233	http://dx.doi.org/10.1038/76233			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	321CX	10835682				2022-12-25	WOS:000087438300036
J	Isacson, JP				Isacson, JP			Maximizing profits through intelligent planning and implementation - What every executive needs to know about intellectual asset management.	NATURE BIOTECHNOLOGY			English	Editorial Material									Foley & Lardner, Biotechnol & Pharmaceut Practice Grp, Washington, DC 20007 USA		Isacson, JP (corresponding author), Foley & Lardner, Biotechnol & Pharmaceut Practice Grp, 3000 K St NW,Suite 500, Washington, DC 20007 USA.								0	5	5	0	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAY	2000	18	5					565	566		10.1038/75458	http://dx.doi.org/10.1038/75458			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	313UK	10802633				2022-12-25	WOS:000087017500039
J	Asea, A; Kraeft, SK; Kurt-Jones, EA; Stevenson, MA; Chen, LB; Finberg, RW; Koo, GC; Calderwood, SK				Asea, A; Kraeft, SK; Kurt-Jones, EA; Stevenson, MA; Chen, LB; Finberg, RW; Koo, GC; Calderwood, SK			HSP70 stimulates cytokine production through a CD14-dependant pathway, demonstrating its dual role as a chaperone and cytokine	NATURE MEDICINE			English	Article							HEAT-SHOCK-PROTEIN; NF-KAPPA-B; HUMAN MONOCYTES; BACTERIAL LIPOPOLYSACCHARIDE; ANTIINFLAMMATORY DRUGS; INTRACELLULAR CALCIUM; LYMPHOCYTES-T; CUTTING EDGE; INDUCE HSP70; NK CELLS	Here, we demonstrate a previously unknown function for the 70-kDa heat-shock protein (HSP70) as a cytokine. HSP70 bound with high affinity to the plasma membrane, elicited a rapid intracellular calcium flux, activated nuclear factor (NF)-kappaB and upregulated the expression of pro-inflammatory cytokines tumor necrosis factor (TNF)-alpha, interleukin (IL)-1 beta and IL-6 in human monocytes. Furthermore, two different signal transduction pathways were activated by exogenous HSP70: one dependent on CD14 and intracellular calcium, which resulted in increased IL-1 beta, IL-6 and TNF-alpha; and the other independent of CD14 but dependent on intracellular calcium, which resulted in an increase in TNF-alpha but not IL-1 beta or IL-6. These findings indicate that CD14 is a co-receptor for HSP70-mediated signaling in human monocytes and are indicative of an previously unrecognized function for HSP70 as an extracellular protein with regulatory effects on human monocytes, having a dual role as chaperone and cytokine.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA; Merck Res Labs, Dept Immunol Res, Rahway, NJ 07065 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Merck & Company	Calderwood, SK (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Adult Oncol, 44 Binney St, Boston, MA 02115 USA.		Asea, Alexzander/X-6432-2019; Finberg, Robert W/E-3323-2010; Asea, Alexzander/I-4112-2013	Asea, Alexzander/0000-0003-3592-3481	NATIONAL CANCER INSTITUTE [P01CA031303, R01CA047407, R01CA050642] Funding Source: NIH RePORTER; NCI NIH HHS [CA31303, CA47407, CA50642] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arnold-Schild D, 1999, J IMMUNOL, V162, P3757; Asea A, 1996, CLIN EXP IMMUNOL, V105, P376, DOI 10.1046/j.1365-2249.1996.d01-755.x; ASEA A, 1995, THESIS U GOTEBORG GO; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; Baler R, 1996, CELL STRESS CHAPERON, V1, P33, DOI 10.1379/1466-1268(1996)001<0033:EFAROH>2.3.CO;2; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; CALDERWOOD SK, 1995, P 86 ANN M AM ASS CA, V682; Capra, 1997, IMMUNOBIOLOGY IMMUNE; CRAIG EA, 1991, TRENDS BIOCHEM SCI, V16, P135, DOI 10.1016/0968-0004(91)90055-Z; DUFF GW, 1982, J IMMUNOL METHODS, V52, P333, DOI 10.1016/0022-1759(82)90005-9; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; GOLENBOCK DT, 1991, J BIOL CHEM, V266, P19490; Hansson M, 1996, J IMMUNOL, V156, P42; HAREGEWOIN A, 1991, J INFECT DIS, V163, P156, DOI 10.1093/infdis/163.1.156; HAREGEWOIN A, 1989, NATURE, V340, P309, DOI 10.1038/340309a0; HOLOSHITZ J, 1984, J CLIN INVEST, V73, P211, DOI 10.1172/JCI111193; HOLOSHITZ J, 1989, NATURE, V339, P226, DOI 10.1038/339226a0; Hoshino K, 1999, J IMMUNOL, V162, P3749; Housby JN, 1999, CYTOKINE, V11, P347, DOI 10.1006/cyto.1998.0437; Kaufmann S., 1994, BIOL HEAT SHOCK PROT, P495; Kol A, 2000, J IMMUNOL, V164, P13, DOI 10.4049/jimmunol.164.1.13; Koo GC, 1996, CELL IMMUNOL, V174, P107, DOI 10.1006/cimm.1996.0300; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; MCLEISH KR, 1989, INFLAMMATION, V13, P681, DOI 10.1007/BF00914312; MINOTA S, 1988, J EXP MED, V168, P1475, DOI 10.1084/jem.168.4.1475; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; ROLLINS BJ, 1991, BLOOD, V78, P1112; Schletter J, 1995, ARCH MICROBIOL, V164, P383, DOI 10.1007/BF02529735; SISTONEN L, 1994, MOL CELL BIOL, V14, P2087, DOI 10.1128/MCB.14.3.2087; Solomon KR, 1998, J CLIN INVEST, V102, P2019, DOI 10.1172/JCI4317; Soncin F, 1996, BIOCHEM BIOPH RES CO, V229, P479, DOI 10.1006/bbrc.1996.1829; Srivastava PK, 1998, IMMUNITY, V8, P657, DOI 10.1016/S1074-7613(00)80570-1; SRIVASTAVA PK, 1994, CURR OPIN IMMUNOL, V6, P728, DOI 10.1016/0952-7915(94)90076-0; SRIVASTAVA PK, 1994, IMMUNOGENETICS, V39, P93; Stevenson MA, 1999, J IMMUNOL, V163, P5608; SUTO R, 1995, SCIENCE, V269, P1585, DOI 10.1126/science.7545313; Tamura Y, 1997, SCIENCE, V278, P117, DOI 10.1126/science.278.5335.117; Tapping RI, 1999, J IMMUNOL, V162, P5483; Todryk S, 1999, J IMMUNOL, V163, P1398; ULEVITCH RJ, 1994, CURR OPIN IMMUNOL, V6, P125, DOI 10.1016/0952-7915(94)90043-4; van Eden W, 1998, IMMUNOL REV, V164, P169; VANEDEN W, 1988, NATURE, V331, P171, DOI 10.1038/331171a0; Yang RB, 1998, NATURE, V395, P284, DOI 10.1038/26239; Zhang FX, 1999, J BIOL CHEM, V274, P7611, DOI 10.1074/jbc.274.12.7611	44	1273	1363	6	63	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	APR	2000	6	4					435	442		10.1038/74697	http://dx.doi.org/10.1038/74697			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	376UA	10742151				2022-12-25	WOS:000165474100038
J	Henegariu, O; Bray-Ward, P; Ward, DC				Henegariu, O; Bray-Ward, P; Ward, DC			Custom fluorescent-nucleotide synthesis as an alternative method for nucleic acid labeling	NATURE BIOTECHNOLOGY			English	Article							HUMAN-CHROMOSOMES; HYBRIDIZATION; SERIES		Yale Univ, Sch Med, Dept Genet, New Haven, CT 06510 USA	Yale University	Henegariu, O (corresponding author), Yale Univ, Sch Med, Dept Genet, 333 Cedar St, New Haven, CT 06510 USA.							COOK AF, 1988, NUCLEIC ACIDS RES, V16, P4077, DOI 10.1093/nar/16.9.4077; Henegariu O, 1999, NAT GENET, V23, P263, DOI 10.1038/15437; LANGER PR, 1981, P NATL ACAD SCI-BIOL, V78, P6633, DOI 10.1073/pnas.78.11.6633; Schrock E, 1996, SCIENCE, V273, P494, DOI 10.1126/science.273.5274.494; SHIMKUS ML, 1986, DNA-J MOLEC CELL BIO, V5, P247, DOI 10.1089/dna.1986.5.247; Speicher MR, 1996, NAT GENET, V12, P368, DOI 10.1038/ng0496-368; Tanke HJ, 1999, EUR J HUM GENET, V7, P2, DOI 10.1038/sj.ejhg.5200265; TELENIUS H, 1992, GENOMICS, V13, P718, DOI 10.1016/0888-7543(92)90147-K; Wiegant J, 1996, J HISTOCHEM CYTOCHEM, V44, P525, DOI 10.1177/44.5.8627009	9	42	68	0	10	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAR	2000	18	3					345	348		10.1038/73815	http://dx.doi.org/10.1038/73815			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	292AC	10700155				2022-12-25	WOS:000085771100037
J	Rosania, GR; Chang, YT; Perez, O; Sutherlin, D; Dong, HL; Lockhart, DJ; Schultz, PG				Rosania, GR; Chang, YT; Perez, O; Sutherlin, D; Dong, HL; Lockhart, DJ; Schultz, PG			Myoseverin, a microtubule-binding molecule with novel cellular effects	NATURE BIOTECHNOLOGY			English	Article						microtubule-binding molecule; morphological screen; purine library	MUSCLE DIFFERENTIATION; LIMB REGENERATION; EXPRESSION; CYCLE; ACTIVATION; PROTEINS	A new microtubule-binding molecule, myoseverin, was identified from a library of 2,6,9-trisubstituted purines in a morphological differentiation screen. Myoseverin induces the reversible fission of multinucleated myotubes into mononucleated fragments. Myotube fission promotes DNA synthesis and cell proliferation after removal of the compound and transfer of the cells to fresh growth medium. Transcriptional profiling and biochemical analysis indicate that myoseverin alone does not reverse the biochemical differentiation process. Instead, myoseverin affects the expression of a variety of growth factor, immunomodulatory, extracellular matrix-remodeling, and stress response genes, consistent with the activation of pathways involved in wound heeling and tissue regeneration.	Scripps Res Inst, La Jolla, CA 92037 USA; Novartis Res Fdn, Genom Inst, San Diego, CA 92121 USA	Scripps Research Institute; Novartis	Schultz, PG (corresponding author), Scripps Res Inst, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.		Chang, Young-Tae/B-2780-2010	Chang, Young-Tae/0000-0002-1927-3688				ALBANO RM, 1994, DEVELOPMENT, V120, P803; BAINS W, 1984, MOL CELL BIOL, V4, P1449, DOI 10.1128/MCB.4.8.1449; Belmont LD, 1996, CELL, V84, P623, DOI 10.1016/S0092-8674(00)81037-5; BISCHOFF R, 1968, J CELL BIOL, V36, P111, DOI 10.1083/jcb.36.1.111; Black BL, 1998, ANNU REV CELL DEV BI, V14, P167, DOI 10.1146/annurev.cellbio.14.1.167; Brockes JP, 1997, SCIENCE, V276, P81, DOI 10.1126/science.276.5309.81; BROXMEYER JE, 1999, ANN NY ACAD SCI, V872, P142; Chang YT, 1999, CHEM BIOL, V6, P361, DOI 10.1016/S1074-5521(99)80048-9; Dorfman J, 1998, J THORAC CARDIOV SUR, V116, P744, DOI 10.1016/S0022-5223(98)00451-6; Groskopf JC, 1997, ENDOCRINOLOGY, V138, P2835, DOI 10.1210/en.138.7.2835; Guo K, 1997, J BIOL CHEM, V272, P791, DOI 10.1074/jbc.272.2.791; Haelens A, 1996, IMMUNOBIOLOGY, V195, P499, DOI 10.1016/S0171-2985(96)80019-2; HANSEN MB, 1989, J IMMUNOL METHODS, V119, P203, DOI 10.1016/0022-1759(89)90397-9; Hung DT, 1996, CHEM BIOL, V3, P623, DOI 10.1016/S1074-5521(96)90129-5; Itoh N, 1996, DEVELOPMENT, V122, P291; Iyer VR, 1999, SCIENCE, V283, P83, DOI 10.1126/science.283.5398.83; LO DC, 1993, P NATL ACAD SCI USA, V90, P7230, DOI 10.1073/pnas.90.15.7230; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; OHUCHI H, 1995, BIOCHEM BIOPH RES CO, V209, P809, DOI 10.1006/bbrc.1995.1572; Robson LG, 1996, DEVELOPMENT, V122, P3899; Rosania GR, 1996, CELL MOTIL CYTOSKEL, V34, P230, DOI 10.1002/(SICI)1097-0169(1996)34:3<230::AID-CM6>3.0.CO;2-D; SAITOH O, 1988, CELL TISSUE RES, V252, P263; Shimokawa T, 1998, BIOCHEM BIOPH RES CO, V246, P287, DOI 10.1006/bbrc.1998.8600; Takekawa M, 1998, CELL, V95, P521, DOI 10.1016/S0092-8674(00)81619-0; TANAKA EM, 1998, WOUND REPAIR REGEN, V6, P301; Taylor DA, 1998, NAT MED, V4, P929, DOI 10.1038/nm0898-929; Walsh K, 1997, CURR OPIN GENET DEV, V7, P597, DOI 10.1016/S0959-437X(97)80005-6; Wodicka L, 1997, NAT BIOTECHNOL, V15, P1359, DOI 10.1038/nbt1297-1359	28	176	184	0	19	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAR	2000	18	3					304	308		10.1038/73753	http://dx.doi.org/10.1038/73753			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	292AC	10700146				2022-12-25	WOS:000085771100028
J	Blouin, MJ; Beauchemin, H; Wright, A; De Paepe, M; Sorette, M; Bleau, AM; Nakamoto, B; Ou, CN; Stamatoyannopoulos, G; Trudel, M				Blouin, MJ; Beauchemin, H; Wright, A; De Paepe, M; Sorette, M; Bleau, AM; Nakamoto, B; Ou, CN; Stamatoyannopoulos, G; Trudel, M			Genetic correction of sickle cell disease: Insights using transgenic mouse models	NATURE MEDICINE			English	Article							STAGE-SPECIFIC EXPRESSION; FETAL-GLOBIN GENE; GAMMA-GLOBIN; HEMOGLOBIN CONCENTRATION; LIGHT-SCATTERING; RISK-FACTORS; SAD MICE; ANEMIA; INDUCTION; VOLUME	Sickle cell disease is a hereditary disorder characterized by erythrocyte deformity due to hemoglobin polymerization. We assessed in vivo the potential curative threshold of fetal hemoglobin in the SAD transgenic mouse model of sickle cell disease using mating with mice expressing the human fetal A gamma-globin gene. With increasing levels of HbF, A gamma SAD mice showed considerable improvement in all hematologic parameters, morphopathologic features and life span/survival. We established the direct therapeutic effect of fetal hemoglobin on sickle cell disease end demonstrated correction by increasing fetal hemoglobin to about 9-16% in this mouse model. This in vivo study emphasizes the potential of the SAD mouse models for quantitative analysis of gene therapy approaches.	Univ Montreal, Fac Med, Inst Rech Clin Montreal, Montreal, PQ H3C 3J7, Canada; Bayer Corp, Tarrytown, NY USA; Brown Univ, Sch Med, Dept Pathol, Providence, RI 02912 USA; Univ Washington, Dept Med, Seattle, WA USA; Texas Childrens Hosp, Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA	Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; Bayer AG; Brown University; University of Washington; University of Washington Seattle; Baylor College of Medicine	Trudel, M (corresponding author), Univ Montreal, Fac Med, Inst Rech Clin Montreal, Montreal, PQ H3C 3J7, Canada.	trudelm@IRCM.qc.ca						ALTER BP, 1980, BRIT J HAEMATOL, V44, P527, DOI 10.1111/j.1365-2141.1980.tb08706.x; BERTLES JF, 1968, J CLIN INVEST, V47, P1731, DOI 10.1172/JCI105863; Blouin MJ, 1999, BLOOD, V94, P1451, DOI 10.1182/blood.V94.4.1451.416k02_1451_1459; BRUGNARA C, 1994, AM J CLIN PATHOL, V102, P623, DOI 10.1093/ajcp/102.5.623; BUNN HF, 1986, HEMOGLOBIN MOL GENET, P690; CHARACHE S, 1995, NEW ENGL J MED, V332, P1317, DOI 10.1056/NEJM199505183322001; CORASH LM, 1974, J LAB CLIN MED, V84, P147; CROIZAT H, 1990, BLOOD, V75, P1006; Croizat H, 1999, AM J HEMATOL, V60, P105, DOI 10.1002/(SICI)1096-8652(199902)60:2<105::AID-AJH4>3.0.CO;2-Z; CROIZAT H, 1988, EXP HEMATOL, V16, P946; DEFRANCESCHI L, 1994, J CLIN INVEST, V93, P1670, DOI 10.1172/JCI117149; DEPAEPE ME, 1994, KIDNEY INT, V46, P1337, DOI 10.1038/ki.1994.403; DOVER GJ, 1994, BLOOD, V84, P339; ENVER T, 1989, P NATL ACAD SCI USA, V86, P7033, DOI 10.1073/pnas.86.18.7033; FABRY ME, 1995, BLOOD, V86, P2419, DOI 10.1182/blood.V86.6.2419.bloodjournal8662419; GREAVES DR, 1990, NATURE, V343, P183, DOI 10.1038/343183a0; KIM YR, 1983, CYTOMETRY, V3, P419, DOI 10.1002/cyto.990030606; McCaffrey PG, 1997, BLOOD, V90, P2075, DOI 10.1182/blood.V90.5.2075; MOHANDAS N, 1989, BLOOD, V74, P442; MOHANDAS N, 1986, BLOOD, V68, P506; NOGUCHI CT, 1988, NEW ENGL J MED, V318, P96, DOI 10.1056/NEJM198801143180207; OU CN, 1993, CLIN CHEM, V39, P820; Paszty C, 1997, SCIENCE, V278, P876, DOI 10.1126/science.278.5339.876; PERRINE SP, 1993, NEW ENGL J MED, V328, P81, DOI 10.1056/NEJM199301143280202; PLATT OS, 1991, NEW ENGL J MED, V325, P11, DOI 10.1056/NEJM199107043250103; PLATT OS, 1994, NEW ENGL J MED, V330, P1639, DOI 10.1056/NEJM199406093302303; Popp RA, 1997, BLOOD, V89, P4204, DOI 10.1182/blood.V89.11.4204; POWARS DR, 1984, BLOOD, V63, P921, DOI 10.1182/blood.V63.4.921.921; Ryan TM, 1997, SCIENCE, V278, P873, DOI 10.1126/science.278.5339.873; SCHROEDER WA, 1985, HEMOGLOBIN, V9, P461, DOI 10.3109/03630268508997024; SERJEANT GR, 1970, BRIT J HAEMATOL, V19, P635, DOI 10.1111/j.1365-2141.1970.tb01647.x; STAMATOYANNOPOULOS G, 1993, MOL CELL BIOL, V13, P7636, DOI 10.1128/MCB.13.12.7636; STAMATOYANNOPOULOS G, 1994, BLOOD, V84, P3198, DOI 10.1182/blood.V84.9.3198.bloodjournal8493198; STAMATOYANNOPOULOS G, 1983, BLOOD, V61, P530; TRUDEL M, 1987, GENE DEV, V1, P954, DOI 10.1101/gad.1.9.954; TRUDEL M, 1987, MOL CELL BIOL, V7, P4024, DOI 10.1128/MCB.7.11.4024; TRUDEL M, 1994, BLOOD, V84, P3189; TRUDEL M, 1991, EMBO J, V10, P3157, DOI 10.1002/j.1460-2075.1991.tb04877.x; TYCKO DH, 1985, APPL OPTICS, V24, P1355, DOI 10.1364/AO.24.001355	39	44	45	0	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2000	6	2					177	182		10.1038/72279	http://dx.doi.org/10.1038/72279			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	278YQ	10655106				2022-12-25	WOS:000085016900038
J	Burton, DR; Parren, PWHI				Burton, DR; Parren, PWHI			Vaccines and the induction of functional antibodies: Time to look beyond the molecules of natural infection?	NATURE MEDICINE			English	Editorial Material							IMMUNODEFICIENCY-VIRUS TYPE-1; GP120 ENVELOPE GLYCOPROTEIN; NEUTRALIZATION SEROTYPES; EPITOPE; BINDING; COMPLEX; HIV-1		Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA	Scripps Research Institute; Scripps Research Institute	Burton, DR (corresponding author), Scripps Res Inst, Dept Immunol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	burton@scripps.edu; parren@scripps.edu		Parren, Paul/0000-0002-4365-3859				Baba TW, 2000, NAT MED, V6, P200, DOI 10.1038/72309; Barber B H, 1997, Semin Immunol, V9, P293, DOI 10.1006/smim.1997.0085; Binley JM, 2000, J VIROL, V74, P627, DOI 10.1128/JVI.74.2.627-643.2000; Casadevall A, 1998, TRENDS MICROBIOL, V6, P102, DOI 10.1016/S0966-842X(98)01208-6; Chargelegue D, 1998, J VIROL, V72, P2040, DOI 10.1128/JVI.72.3.2040-2046.1998; Connolly BM, 1999, J INFECT DIS, V179, pS203, DOI 10.1086/514305; Dempsey PW, 1996, SCIENCE, V271, P348, DOI 10.1126/science.271.5247.348; Edelson BT, 1999, J IMMUNOL, V163, P4087; Fouts TR, 1997, J VIROL, V71, P2779, DOI 10.1128/JVI.71.4.2779-2785.1997; Gauduin MC, 1997, NAT MED, V3, P1389, DOI 10.1038/nm1297-1389; Griffin D., 1996, FIELDS VIROLOGY, V3rd ed., P1267; Hilleman MR, 1998, NAT MED, V4, P507, DOI 10.1038/nm0598supp-507; Kostrikis LG, 1996, J VIROL, V70, P445, DOI 10.1128/JVI.70.1.445-458.1996; Kwong PD, 1998, NATURE, V393, P648, DOI 10.1038/31405; Maruyama T, 1999, J VIROL, V73, P6024, DOI 10.1128/JVI.73.7.6024-6030.1999; Mascola JR, 1999, J VIROL, V73, P4009, DOI 10.1128/JVI.73.5.4009-4018.1999; Mascola JR, 2000, NAT MED, V6, P207, DOI 10.1038/72318; Moog C, 1997, J VIROL, V71, P3734, DOI 10.1128/JVI.71.5.3734-3741.1997; Moore JP, 1996, J VIROL, V70, P427, DOI 10.1128/JVI.70.1.427-444.1996; Mulligan MJ, 1999, AIDS, V13, pS105; MURPHY N, 1996, LINGUA FRANCA, V6, P6; Nyambi PN, 1997, J VIROL, V71, P2320, DOI 10.1128/JVI.71.3.2320-2330.1997; Parren PWHI, 1998, J VIROL, V72, P3512, DOI 10.1128/JVI.72.5.3512-3519.1998; Patten PA, 1997, CURR OPIN BIOTECH, V8, P724, DOI 10.1016/S0958-1669(97)80127-9; Puntoriero G, 1998, EMBO J, V17, P3521, DOI 10.1093/emboj/17.13.3521; Reitter JN, 1998, NAT MED, V4, P679, DOI 10.1038/nm0698-679; ROBEN P, 1994, J VIROL, V68, P4821, DOI 10.1128/JVI.68.8.4821-4828.1994; Sanchez A, 1998, J VIROL, V72, P6442, DOI 10.1128/JVI.72.8.6442-6447.1998; SATTENTAU QJ, 1995, J EXP MED, V182, P185, DOI 10.1084/jem.182.1.185; STEWARD MW, 1995, J VIROL, V69, P7668, DOI 10.1128/JVI.69.12.7668-7673.1995; WANG H, IN PRESS P NATL ACAD; WOLINSKY JS, 1996, FIELDS VIROLOGY, P899; WRIN T, 1994, J ACQ IMMUN DEF SYND, V7, P211; Wyatt R, 1998, NATURE, V393, P705, DOI 10.1038/31514; Wyatt R, 1998, SCIENCE, V280, P1884, DOI 10.1126/science.280.5371.1884	35	58	61	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2000	6	2					123	125		10.1038/72200	http://dx.doi.org/10.1038/72200			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	278YQ	10655088				2022-12-25	WOS:000085016900018
J	Cano, A; Perez-Moreno, MA; Rodrigo, I; Locascio, A; Blanco, MJ; del Barrio, MG; Portillo, F; Nieto, MA				Cano, A; Perez-Moreno, MA; Rodrigo, I; Locascio, A; Blanco, MJ; del Barrio, MG; Portillo, F; Nieto, MA			The transcription factor Snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression	NATURE CELL BIOLOGY			English	Article							ZINC-FINGER GENE; MOUSE SKIN CARCINOGENESIS; NEURAL CREST DEVELOPMENT; SPINDLE CARCINOMA-CELLS; P-CADHERIN; TUMOR PROGRESSION; ADHESION MOLECULE; GROWTH; SLUG; PLAKOGLOBIN	The Snail family of transcription factors has previously been implicated in the differentiation of epithelial cells into mesenchymal cells (epithelial-mesenchymal transitions) during embryonic development. Epithelial-mesenchymal transitions are also determinants of the progression of carcinomas, occurring concomitantly with the cellular acquisition of migratory properties following downregulation of expression of the adhesion protein E-cadherin. Here we show that mouse Snail is a strong repressor of transcription of the E-cadherin gene. Epithelial cells that ectopically express Snail adopt a fibroblastoid phenotype and acquire tumorigenic and invasive properties. Endogenous Snail protein is present in invasive mouse and human carcinoma cell lines and tumours in which E-cadherin expression has been lost. Therefore, the same molecules are used to trigger epithelial-mesenchymal transitions during embryonic development and in tumour progression. Snail may thus be considered as a marker for malignancy, opening up new avenues for the design of specific anti-invasive drugs.	CSIC, Inst Cajal, E-28002 Madrid, Spain; Univ Autonoma Madrid, Inst Invest Biomed, CSIC, Madrid 28029, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto Cajal (IC); Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM)	Cano, A (corresponding author), CSIC, Inst Cajal, Doctor Arce 37, E-28002 Madrid, Spain.	acano@iib.uam.es; anieto@cajal.csic.es	Perez-Moreno, Mirna/I-3687-2015; Locascio, Annamaria/E-8714-2015; Nieto, M. Angela/A-6531-2008	Perez-Moreno, Mirna/0000-0002-0170-6406; Locascio, Annamaria/0000-0001-6956-2157; Nieto, M. Angela/0000-0002-3538-840X; Portillo Perez, Francisco/0000-0003-4922-346X				BEHRENS J, 1991, P NATL ACAD SCI USA, V88, P11495, DOI 10.1073/pnas.88.24.11495; BIRCHMEIER W, 1994, BBA-REV CANCER, V1198, P11, DOI 10.1016/0304-419X(94)90003-5; BURSDAL CA, 1993, DEVELOPMENT, V118, P829; BUSSEMAKERS MJG, 1994, BIOCHEM BIOPH RES CO, V203, P1284, DOI 10.1006/bbrc.1994.2321; Cano A, 1996, INT J CANCER, V65, P254; Cook DM, 1996, ONCOGENE, V13, P1789; Duband JL, 1995, ACTA ANAT, V154, P63; Faraldo MLM, 1997, MOL CARCINOGEN, V20, P33, DOI 10.1002/(SICI)1098-2744(199709)20:1<33::AID-MC5>3.0.CO;2-J; FRIXEN UH, 1991, J CELL BIOL, V113, P173, DOI 10.1083/jcb.113.1.173; Frontelo P, 1998, EXP CELL RES, V244, P420, DOI 10.1006/excr.1998.4219; FUSE N, 1994, GENE DEV, V8, P2270, DOI 10.1101/gad.8.19.2270; Giroldi LA, 1997, BIOCHEM BIOPH RES CO, V241, P453, DOI 10.1006/bbrc.1997.7831; GOMEZ M, 1994, INVAS METAST, V14, P17; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; Hay E.D., 1990, Seminars in Developmental Biology, V1, P347; Hay ED, 1995, ACTA ANAT, V154, P8; Hemavathy K, 1997, DEVELOPMENT, V124, P3683; Hennig G, 1996, J BIOL CHEM, V271, P595, DOI 10.1074/jbc.271.1.595; Huber O, 1996, CURR OPIN CELL BIOL, V8, P685, DOI 10.1016/S0955-0674(96)80110-4; Isaac A, 1997, SCIENCE, V275, P1301, DOI 10.1126/science.275.5304.1301; Jiang RL, 1998, DEV BIOL, V198, P277, DOI 10.1016/S0012-1606(98)80005-5; LARUE L, 1994, P NATL ACAD SCI USA, V91, P8263, DOI 10.1073/pnas.91.17.8263; LEVINE E, 1994, DEVELOPMENT, V120, P901; Llorens A, 1998, LAB INVEST, V78, P1131; Lozano E, 1998, MOL CARCINOGEN, V21, P273, DOI 10.1002/(SICI)1098-2744(199804)21:4<273::AID-MC6>3.0.CO;2-L; Lozano E, 1998, CELL ADHES COMMUN, V6, P51, DOI 10.3109/15419069809069760; MAUHIN V, 1993, NUCLEIC ACIDS RES, V21, P3951, DOI 10.1093/nar/21.17.3951; Miyaki M, 1995, ONCOGENE, V11, P2547; Nakayama H, 1998, DEV BIOL, V199, P150, DOI 10.1006/dbio.1998.8914; NAVARRO P, 1993, J CELL SCI, V105, P923; NAVARRO P, 1991, J CELL BIOL, V115, P517, DOI 10.1083/jcb.115.2.517; NIETO MA, 1992, DEVELOPMENT, V116, P227; NIETO MA, 1994, SCIENCE, V264, P835, DOI 10.1126/science.7513443; Nieto MA, 1996, METHOD CELL BIOL, V51, P219, DOI 10.1016/S0091-679X(08)60630-5; Oda H, 1998, DEV BIOL, V203, P435, DOI 10.1006/dbio.1998.9047; Perl AK, 1998, NATURE, V392, P190, DOI 10.1038/32433; RIETHMACHER D, 1995, P NATL ACAD SCI USA, V92, P855, DOI 10.1073/pnas.92.3.855; RINGWALD M, 1991, NUCLEIC ACIDS RES, V19, P6533, DOI 10.1093/nar/19.23.6533; Rodrigo I, 1999, EXP CELL RES, V248, P358, DOI 10.1006/excr.1999.4438; Ros MA, 1997, DEVELOPMENT, V124, P1821; Savagner P, 1997, J CELL BIOL, V137, P1403, DOI 10.1083/jcb.137.6.1403; Sefton M, 1998, DEVELOPMENT, V125, P3111; SMITH DE, 1992, DEVELOPMENT, V116, P1033; TAKEICHI M, 1995, CURR OPIN CELL BIOL, V7, P619, DOI 10.1016/0955-0674(95)80102-2; Takeichi M, 1993, CURR OPIN CELL BIOL, V5, P806, DOI 10.1016/0955-0674(93)90029-P; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; WHEELOCK MJ, 1992, J CELL BIOL, V117, P415, DOI 10.1083/jcb.117.2.415; YOSHIURA K, 1995, P NATL ACAD SCI USA, V92, P7416, DOI 10.1073/pnas.92.16.7416	48	2794	2909	2	226	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	FEB	2000	2	2					76	83		10.1038/35000025	http://dx.doi.org/10.1038/35000025			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	281GA	10655586				2022-12-25	WOS:000085148500011
J	James, R				James, R			Differentiating genomics companies	NATURE BIOTECHNOLOGY			English	Article								As the value of raw sequence data diminishes, genomics companies are evolving new competencies as providers of information, therapeutic products, or novel technology.	Prelude Technol Investments, Sycamore Studios, Cambridge CB4 5PJ, England		James, R (corresponding author), Prelude Technol Investments, Sycamore Studios, New Rd, Cambridge CB4 5PJ, England.								0	8	8	0	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	FEB	2000	18	2					153	155		10.1038/72597	http://dx.doi.org/10.1038/72597			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	281FH	10657119				2022-12-25	WOS:000085146900020
J	Thepen, T; van Vuuren, AJH; Kiekens, RCM; Damen, CA; Vooijs, WC; van de Winkel, JGJ				Thepen, T; van Vuuren, AJH; Kiekens, RCM; Damen, CA; Vooijs, WC; van de Winkel, JGJ			Resolution of cutaneous inflammation after local elimination of macrophages	NATURE BIOTECHNOLOGY			English	Article						Fc gamma RI; immunotoxin; macrophage; inflammation; transgenic	FC-GAMMA-RI; T-CELL; ALVEOLAR MACROPHAGES; MONOCLONAL-ANTIBODY; ATOPIC-DERMATITIS; RECEPTORS; LUNG	We constructed an immunotoxin, composed of an antibody directed against the high-affinity IgG receptor CD64 and Ricin-A, with the aim of resolving chronic inflammation through elimination of activated macrophages, In vitro, this immunotoxin proved very efficient in inducing apoptosis in activated macrophages, leaving resting and low CD64-expressing macrophages unaffected. We examined the activity of our immunotoxin in a sodium lauryl sulfate (SLS)-induced cutaneous inflammation model, using transgenic mice expressing human CD64. Upon intradermal injection of the immunotoxin (IT), cutaneous inflammation resolved in 24 h. This was demonstrated histologically by clearance of all CD64-expressing macrophages, followed by clearance of other inflammatory cells. Clinical parameters associated with inflammation, such as local skin temperature and vasodilation, also decreased.	Medarex Europe, Dept Immunol, Utrecht, Netherlands; Univ Utrecht, Med Ctr, Dept Dermatol, Utrecht, Netherlands; Netherlands Canc Inst, Div Immunol, NL-1066 CX Amsterdam, Netherlands	Utrecht University; Netherlands Cancer Institute	Thepen, T (corresponding author), Medarex Europe, Dept Immunol, Utrecht, Netherlands.							Avice MN, 1998, J IMMUNOL, V161, P3408; DAVIDSON NO, 1995, RNA, V1, P3; Deo YM, 1997, IMMUNOL TODAY, V18, P127, DOI 10.1016/S0167-5699(97)01007-4; Ganz T, 1993, New Horiz, V1, P23; GonzalezRamos A, 1996, J INVEST DERMATOL, V106, P305, DOI 10.1111/1523-1747.ep12342958; GORDON S, 1995, BIOESSAYS, V17, P977, DOI 10.1002/bies.950171111; GRAZIANO RF, 1995, J IMMUNOL, V155, P4996; Grewe M, 1998, IMMUNOL TODAY, V19, P359, DOI 10.1016/S0167-5699(98)01285-7; GUYRE PM, 1989, J IMMUNOL, V143, P1650; GUYRE PM, 1983, J CLIN INVEST, V72, P393, DOI 10.1172/JCI110980; Heijnen IAFM, 1996, J CLIN INVEST, V97, P331, DOI 10.1172/JCI118420; HOLT PG, 1993, J EXP MED, V177, P397, DOI 10.1084/jem.177.2.397; KRAAL G, 1987, SCAND J IMMUNOL, V26, P653, DOI 10.1111/j.1365-3083.1987.tb02301.x; KRAAL G, 1986, J EXP MED, V163, P981, DOI 10.1084/jem.163.4.981; LASKIN DL, 1995, ANNU REV PHARMACOL, V35, P655, DOI 10.1146/annurev.pharmtox.35.1.655; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; POST J, 1995, LEUKEMIA RES, V19, P241, DOI 10.1016/0145-2126(94)00142-W; Ravetch JV, 1997, CURR OPIN IMMUNOL, V9, P121, DOI 10.1016/S0952-7915(97)80168-9; STINGL G, 1993, RECENT RES CANCER, V128, P45; Strickland D, 1996, IMMUNOLOGY, V87, P250, DOI 10.1046/j.1365-2567.1996.459542.x; Thepen T, 1996, J ALLERGY CLIN IMMUN, V97, P828, DOI 10.1016/S0091-6749(96)80161-8; THEPEN T, 1994, ANN NY ACAD SCI, V725, P200, DOI 10.1111/j.1749-6632.1994.tb39802.x; TOMONARI K, 1988, IMMUNOGENETICS, V28, P455, DOI 10.1007/BF00355379; TRUSH PM, 1996, ANNU REV IMMUNOL, V14, P49; Van Vugt MJ, 1998, CLIN EXP IMMUNOL, V113, P415; Williams IR, 1996, LIFE SCI, V58, P1485, DOI 10.1016/0024-3205(96)00042-2	26	74	78	1	5	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JAN	2000	18	1					48	51		10.1038/71908	http://dx.doi.org/10.1038/71908			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	273GQ	10625390				2022-12-25	WOS:000084699900024
J	Imaizumi, T; Lankford, KL; Burton, WV; Fodor, WL; Kocsis, JD				Imaizumi, T; Lankford, KL; Burton, WV; Fodor, WL; Kocsis, JD			Xenotransplantation of transgenic pig olfactory ensheathing cells promotes axonal regeneration in rat spinal cord	NATURE BIOTECHNOLOGY			English	Article						olfactory ensheathing cells; axonal regeneration; cell transplantation; engineered cells	SCHWANN-CELLS; ADULT-RAT; TRANSPLANTATION; GROWTH; DEMYELINATION; REMYELINATE; EXPRESSION; CONDUCTION; AREAS; MODEL	Here we describe transplantation of olfactory ensheathing cells (OECs) or Schwann cells derived from transgenic pigs expressing the human complement inhibitory protein, CD59 (hCD59), into transected dorsal column lesions of the spinal cord of the immunosuppressed rat to induce axonal regeneration. Non-transplanted lesion-controlled rats exhibited no impulse conduction across the transection site, whereas in animals receiving transgenic pig OECs or Schwann cells impulse conduction was restored across and beyond the lesion site for more than a centimeter, Cell labeling indicated that the donor cells migrated into the denervated host tract. Conduction velocity measurements showed that the regenerated axons conducted impulses faster than normal axons. By morphological analysis, the axons seemed thickly myelinated with a peripheral pattern of myelin expected from the donor cell type. These results indicate that xenotranplantation of myelin-forming cells from pigs genetically altered to reduce the hyperacute response in humans are able to induce elongative axonal regeneration and remyelination and restore impulse conduction across the transected spinal cord.	Yale Univ, Sch Med, Dept Neurol, New Haven, CT 06510 USA; Dept Vet Affairs Med Ctr, Neurosci Res Ctr, W Haven, CT 06516 USA; Alex Pharmaceut Inc, New Haven, CT 06511 USA	Yale University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Connecticut Healthcare System	Kocsis, JD (corresponding author), Yale Univ, Sch Med, Dept Neurol, New Haven, CT 06510 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS010174, F05NS010174] Funding Source: NIH RePORTER; NICHD NIH HHS [R44 HD095784] Funding Source: Medline; NINDS NIH HHS [P50 NS010174-290027, F05 NS010174, NS 10174] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AGUAYO DA, 1981, SCIENCE, V214, P913; Auchincloss H, 1998, ANNU REV IMMUNOL, V16, P433, DOI 10.1146/annurev.immunol.16.1.433; BERTHOLD CH, 1978, PHYSL PATHOBIOLOGY A, P3; BLAKEMORE WF, 1985, J NEUROL SCI, V70, P207, DOI 10.1016/0022-510X(85)90088-7; Chen SC, 1997, ANN NY ACAD SCI, V831, P350; Costa C, 1999, XENOTRANSPLANTATION, V6, P6, DOI 10.1034/j.1399-3089.1999.00004.x; Deacon T, 1997, NAT MED, V3, P350, DOI 10.1038/nm0397-350; DEVON R, 1992, BRAIN RES, V589, P175; Edge ASB, 1998, CELL TRANSPLANT, V7, P525, DOI 10.1016/S0963-6897(98)00043-8; FODOR WL, 1994, P NATL ACAD SCI USA, V91, P11153, DOI 10.1073/pnas.91.23.11153; Franklin RJM, 1996, GLIA, V17, P217, DOI 10.1002/(SICI)1098-1136(199607)17:3<217::AID-GLIA4>3.0.CO;2-Y; FUJIOKA H, 1994, CELL TRANSPLANT, V3, P397, DOI 10.1177/096368979400300506; Honmou O, 1996, J NEUROSCI, V16, P3199; Imaizumi T, 2000, BRAIN RES, V854, P70, DOI 10.1016/S0006-8993(99)02285-4; Imaizumi T, 1998, J NEUROSCI, V18, P6176; KATO T, 2000, IN PRESS GLIA; KUHLENGEL KR, 1990, J COMP NEUROL, V293, P73; LEVI ADO, 1994, EXP NEUROL, V130, P41, DOI 10.1006/exnr.1994.1183; Li Y, 1997, SCIENCE, V277, P2000, DOI 10.1126/science.277.5334.2000; LI Y, 1994, J NEUROSCI, V14, P4050; Ramon-Cueto A, 1998, J NEUROSCI, V18, P3803; RAMONCUETO A, 1995, GLIA, V14, P163, DOI 10.1002/glia.440140302; SCHWAB ME, 1993, ANNU REV NEUROSCI, V16, P565, DOI 10.1146/annurev.ne.16.030193.003025; TANIUCHI M, 1988, J NEUROSCI, V8, P664; Trapp BD, 1998, NEW ENGL J MED, V338, P278, DOI 10.1056/NEJM199801293380502; Watanabe E, 1998, CELL TRANSPLANT, V7, P239, DOI 10.1016/S0963-6897(98)00011-6; WINDEBANK AJ, 1986, BRAIN RES, V385, P197, DOI 10.1016/0006-8993(86)91567-2	27	136	148	0	6	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	SEP	2000	18	9					949	953		10.1038/79432	http://dx.doi.org/10.1038/79432			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	350AN	10973214	Green Accepted			2022-12-25	WOS:000089078300022
J	Ueijma, H; Lee, MP; Cui, H; Feinberg, AP				Ueijma, H; Lee, MP; Cui, H; Feinberg, AP			Hot-stop PCR: a simple and general assay for linear quantitation of allele ratios	NATURE GENETICS			English	Article							COLORECTAL-CANCER; RELAXATION; TISSUE		Johns Hopkins Univ, Sch Med, Inst Med Genet, Baltimore, MD 21218 USA; Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Feinberg, AP (corresponding author), Johns Hopkins Univ, Sch Med, Inst Med Genet, Baltimore, MD 21218 USA.		Feinberg, Andrew/AAY-7666-2020; Cui, Hengmi/A-2598-2008	Feinberg, Andrew/0000-0002-8364-1991	NCI NIH HHS [R01 CA054358] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA054358] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Cui HM, 1998, NAT MED, V4, P1276, DOI 10.1038/3260; Greenwood AD, 1996, GENOME RES, V6, P336, DOI 10.1101/gr.6.4.336; Lee MP, 1997, NAT GENET, V15, P181, DOI 10.1038/ng0297-181; MANSFIELD ES, 1993, HUM MOL GENET, V2, P43, DOI 10.1093/hmg/2.1.43; MASHAL RD, 1995, NAT GENET, V9, P177, DOI 10.1038/ng0295-177; OGAWA O, 1993, NATURE, V362, P749, DOI 10.1038/362749a0; Ohlsson R., 1995, GENOMIC IMPRINTING C; Pushnova EA, 1998, ANAL BIOCHEM, V260, P24, DOI 10.1006/abio.1998.2682; Qian N, 1997, HUM MOL GENET, V6, P2021, DOI 10.1093/hmg/6.12.2021; RAINIER S, 1993, NATURE, V362, P747, DOI 10.1038/362747a0; TAKEDA S, 1993, HUM MUTAT, V2, P112, DOI 10.1002/humu.1380020209; Yun K, 1999, J PATHOL, V187, P518, DOI 10.1002/(SICI)1096-9896(199904)187:5<518::AID-PATH276>3.0.CO;2-3; 1995, ABI PRISM DNA SEQUEN	13	81	86	0	4	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	AUG	2000	25	4					375	376		10.1038/78040	http://dx.doi.org/10.1038/78040			2	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	341WY	10932175				2022-12-25	WOS:000088615000007
J	Chen, M; Ona, VO; Li, MW; Ferrante, RJ; Fink, KB; Zhu, S; Bian, J; Guo, L; Farrell, LA; Hersch, SM; Hobbs, W; Vonsattel, JP; Cha, JHJ; Friedlander, RM				Chen, M; Ona, VO; Li, MW; Ferrante, RJ; Fink, KB; Zhu, S; Bian, J; Guo, L; Farrell, LA; Hersch, SM; Hobbs, W; Vonsattel, JP; Cha, JHJ; Friedlander, RM			Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease	NATURE MEDICINE			English	Article							INTERLEUKIN-1-BETA CONVERTING-ENZYME; NEURONAL INTRANUCLEAR INCLUSIONS; POLYGLUTAMINE TRACT; MICE DEFICIENT; BRAIN; DYSFUNCTION; APOPTOSIS; PROTEASE; GENE; TETRACYCLINES	Huntington disease is an autosomal dominant neurodegenerative disease with no effective treatment. Minocycline is a tetracycline derivative with proven safety. After ischemia, minocycline inhibits caspase-1 and inducible nitric oxide synthetase upregulation, and reduces infarction. As caspase-1 and nitric oxide seem to play a role in Huntington disease, we evaluated the therapeutic efficacy of minocycline in the R6/2 mouse model of Huntington disease. We report that minocycline delays disease progression, inhibits caspase-1 and caspase-3 mRNA upregulation, and decreases inducible nitric oxide synthetase activity. In addition, effective pharmacotherapy in R6/2 mice requires caspase-1 and caspase-3 inhibition. This is the first demonstration of caspase-1 and caspase-3 transcriptional regulation in a Huntington disease model.	Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Surg,Neurosurg Serv,Neuroapoptosis Lab, Boston, MA 02115 USA; Bedford VA Med Ctr, Ctr Geriatr Res Educ & Clin, Bedford, MA USA; Boston Univ, Sch Med, Bedford, MA 01730 USA; Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Pathol, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Psychiat, Boston, MA 02118 USA; Univ Bonn, Sch Med, Dept Pharmacol, D-5300 Bonn, Germany; Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med, Boston, MA 02115 USA; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Neurol, Boston, MA 02114 USA; Emory Univ, Sch Med, Dept Neurol, Atlanta, GA 30322 USA; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Neuropathol, Boston, MA 02114 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Geriatric Research Education & Clinical Center; Boston University; Boston University; Boston University; Boston University; University of Bonn; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard Medical School; Massachusetts General Hospital; Emory University; Harvard University; Harvard Medical School; Massachusetts General Hospital	Friedlander, RM (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Surg,Neurosurg Serv,Neuroapoptosis Lab, Boston, MA 02115 USA.		Longo, Kenneth A/A-5631-2010; Friedlander, Robert M/A-2845-2016	Friedlander, Robert M/0000-0003-4423-9219				Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; ARONSON AL, 1980, J AM VET MED ASSOC, V176, P1061; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; Browne SE, 1997, ANN NEUROL, V41, P646, DOI 10.1002/ana.410410514; Cha JHJ, 1998, P NATL ACAD SCI USA, V95, P6480, DOI 10.1073/pnas.95.11.6480; Davies SW, 1997, CELL, V90, P537, DOI 10.1016/S0092-8674(00)80513-9; DiFiglia M, 1997, SCIENCE, V277, P1990, DOI 10.1126/science.277.5334.1990; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; Ferrante RJ, 1997, J NEUROSCI, V17, P3052; FORSYTH DA, 1990, INT J COMPUT VISION, V5, P5, DOI 10.1007/BF00056770; Friedlander RM, 1997, J EXP MED, V185, P933, DOI 10.1084/jem.185.5.933; Friedlander RM, 1998, CELL DEATH DIFFER, V5, P823, DOI 10.1038/sj.cdd.4400433; Goldberg YP, 1996, NAT GENET, V13, P442, DOI 10.1038/ng0896-442; Gottlieb A, 1997, LANCET, V349, P374, DOI 10.1016/S0140-6736(97)80006-2; Goulden V, 1996, BRIT J DERMATOL, V134, P693, DOI 10.1111/j.1365-2133.1996.tb06972.x; Hara H, 1997, P NATL ACAD SCI USA, V94, P2007, DOI 10.1073/pnas.94.5.2007; KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475; Li MW, 2000, SCIENCE, V288, P335, DOI 10.1126/science.288.5464.335; LI P, 1995, CELL, V80, P401, DOI 10.1016/0092-8674(95)90490-5; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; Mangiarini L, 1996, CELL, V87, P493, DOI 10.1016/S0092-8674(00)81369-0; Ona VO, 1999, NATURE, V399, P263, DOI 10.1038/20446; Schapira AHV, 1998, BBA-BIOENERGETICS, V1366, P225, DOI 10.1016/S0005-2728(98)00115-7; Tabrizi SJ, 2000, ANN NEUROL, V47, P80; Tabrizi SJ, 1999, ANN NEUROL, V45, P25, DOI 10.1002/1531-8249(199901)45:1<25::AID-ART6>3.0.CO;2-E; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; Wellington CL, 1998, J BIOL CHEM, V273, P9158, DOI 10.1074/jbc.273.15.9158; White JK, 1997, NAT GENET, V17, P404, DOI 10.1038/ng1297-404; YOSHIDA T, 1995, NEUROSCI LETT, V194, P214, DOI 10.1016/0304-3940(95)11752-I; Yrjanheikki J, 1999, P NATL ACAD SCI USA, V96, P13496, DOI 10.1073/pnas.96.23.13496; Yrjanheikki J, 1998, P NATL ACAD SCI USA, V95, P15769, DOI 10.1073/pnas.95.26.15769	31	856	902	2	57	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUL	2000	6	7					797	+		10.1038/77528	http://dx.doi.org/10.1038/77528			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	331VV	10888929				2022-12-25	WOS:000088040100037
J	Forsburg, SL; Hodson, JA				Forsburg, SL; Hodson, JA			Mitotic replication initiation proteins are not required for pre-meiotic S phase	NATURE GENETICS			English	Article							YEAST SCHIZOSACCHAROMYCES-POMBE; DNA-POLYMERASE-DELTA; CELL-CYCLE CONTROL; FISSION YEAST; GENE ENCODES; MEIOSIS; MITOSIS; FAMILY; KINASE; CHECKPOINT	Initiation of mitotic DNA replication in eukaryotes requires conserved factors, including Cdc18/CDC6 and minichromosome maintenance (MCM) proteins. We show here that these proteins are not essential for meiotic DNA replication or subsequent meiotic divisions in fission yeast. In addition, vegetative replication checkpoint genes are not required for the arrest of meiotic divisions in response to pre-meiotic S-phase delays. Genes essential for other aspects of vegetative DNA replication, however, including polymerases and DNA ligase, are also required for premeiotic DNA synthesis. Our results indicate that the process of replication initiation and checkpoint control may be fundamentally different in mitotic and meiotic cells.	Salk Inst Biol Studies, Mol Biol & Virol Lab, La Jolla, CA 92037 USA	Salk Institute	Forsburg, SL (corresponding author), Salk Inst Biol Studies, Mol Biol & Virol Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.	forsburg@salk.edu		Forsburg, Susan L/0000-0002-4895-8598	NIGMS NIH HHS [GM54797] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM054797] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AVES SJ, 1985, EMBO J, V4, P457, DOI 10.1002/j.1460-2075.1985.tb03651.x; BAKER BS, 1976, ANNU REV GENET, V10, P53, DOI 10.1146/annurev.ge.10.120176.000413; CALLAN HG, 1972, PROC R SOC SER B-BIO, V181, P19, DOI 10.1098/rspb.1972.0039; Carr AM, 1997, CURR OPIN GENET DEV, V7, P93, DOI 10.1016/S0959-437X(97)80115-3; COLLINS I, 1994, MOL CELL BIOL, V14, P3524, DOI 10.1128/MCB.14.5.3524; COXON A, 1992, NUCLEIC ACIDS RES, V20, P5571, DOI 10.1093/nar/20.21.5571; DAYAMAKIN M, 1992, BIOCHEM CELL BIOL, V70, P1088, DOI 10.1139/o92-154; Donaldson AD, 1999, CURR OPIN GENET DEV, V9, P62, DOI 10.1016/S0959-437X(99)80009-4; DURSO G, 1995, J CELL SCI, V108, P3109; DUrso G, 1997, P NATL ACAD SCI USA, V94, P12491, DOI 10.1073/pnas.94.23.12491; FENECH M, 1991, NUCLEIC ACIDS RES, V19, P6737, DOI 10.1093/nar/19.24.6737; FORSBURG SL, 1994, J CELL SCI, V107, P2779; Gould KL, 1998, GENETICS, V149, P1221; GRALLERT B, 1989, CURR GENET, V15, P231, DOI 10.1007/BF00435510; GRALLERT B, 1991, CURR GENET, V20, P199, DOI 10.1007/BF00326233; GRALLERT B, 1990, MOL GEN GENET, V222, P473, DOI 10.1007/BF00633860; Haber JE, 1999, TRENDS BIOCHEM SCI, V24, P271, DOI 10.1016/S0968-0004(99)01413-9; HOLLINGSWORTH RE, 1993, CHROMOSOMA, V102, P415, DOI 10.1007/BF00360406; Horie S, 1998, MOL CELL BIOL, V18, P2118, DOI 10.1128/MCB.18.4.2118; IINO Y, 1995, GENETICS, V140, P1235; Iino Y, 1997, MOL GEN GENET, V254, P93, DOI 10.1007/s004380050395; IINO Y, 1985, P NATL ACAD SCI USA, V82, P2447, DOI 10.1073/pnas.82.8.2447; IINO Y, 1985, MOL GEN GENET, V198, P416, DOI 10.1007/BF00332932; Johnston LH, 1999, TRENDS CELL BIOL, V9, P249, DOI 10.1016/S0962-8924(99)01586-X; JOHNSTON LH, 1986, GENE, V41, P321, DOI 10.1016/0378-1119(86)90114-9; Keeney S, 1997, CELL, V88, P375, DOI 10.1016/S0092-8674(00)81876-0; KELLY TJ, 1993, CELL, V74, P371, DOI 10.1016/0092-8674(93)90427-R; LI YF, 1997, GENETICS, V146, P146; Liang DT, 1999, J CELL SCI, V112, P559; LIN YK, 1994, GENETICS, V136, P769; MacNeill SA, 1996, EMBO J, V15, P4613, DOI 10.1002/j.1460-2075.1996.tb00839.x; Maiorano D, 1996, EMBO J, V15, P861, DOI 10.1002/j.1460-2075.1996.tb00421.x; MIYAKE S, 1993, MOL BIOL CELL, V4, P1003, DOI 10.1091/mbc.4.10.1003; MURAKAMI H, 1995, NATURE, V374, P817, DOI 10.1038/374817a0; NASMYTH K, 1981, MOL GEN GENET, V182, P119, DOI 10.1007/BF00422777; NIELSEN O, 1990, EMBO J, V9, P1401, DOI 10.1002/j.1460-2075.1990.tb08255.x; NURSE P, 1985, MOL GEN GENET, V198, P497, DOI 10.1007/BF00332946; Parker AE, 1997, MOL CELL BIOL, V17, P2381, DOI 10.1128/MCB.17.5.2381; Rhind N, 1998, CURR OPIN CELL BIOL, V10, P749, DOI 10.1016/S0955-0674(98)80118-X; SAKA Y, 1993, CELL, V74, P383, DOI 10.1016/0092-8674(93)90428-S; SARABIA MJF, 1993, MOL GEN GENET, V238, P241, DOI 10.1007/BF00279553; SCHILD D, 1978, CHROMOSOMA, V70, P109, DOI 10.1007/BF00292220; SEATON BL, 1992, GENE, V119, P83, DOI 10.1016/0378-1119(92)90069-2; SIMANIS V, 1986, CELL, V45, P261, DOI 10.1016/0092-8674(86)90390-9; Snaith HA, 1999, GENETICS, V152, P839; Stillman B, 1996, SCIENCE, V274, P1659, DOI 10.1126/science.274.5293.1659; WALWORTH N, 1993, NATURE, V363, P368, DOI 10.1038/363368a0; WILLIAMSON DH, 1983, EXP CELL RES, V145, P209, DOI 10.1016/S0014-4827(83)80022-6; Yamamoto M, 1996, TRENDS BIOCHEM SCI, V21, P18, DOI 10.1016/0968-0004(96)80880-2; You ZY, 1999, MOL CELL BIOL, V19, P8003	50	33	34	0	1	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1061-4036	1546-1718		NAT GENET	Nature Genet.	JUL	2000	25	3					263	268		10.1038/77015	http://dx.doi.org/10.1038/77015			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	329RD	10888871				2022-12-25	WOS:000087920900011
J	Goldberg, MS; Lansbury, PT				Goldberg, MS; Lansbury, PT			Is there a cause-and-effect relationship between alpha-synuclein fibrillization and Parkinson's disease?	NATURE CELL BIOLOGY			English	Editorial Material							BETA AMYLOID PROTOFIBRILS; ALZHEIMERS-DISEASE; LEWY BODIES; TRANSGENIC MICE; PRECURSOR PROTEIN; FIBRIL FORMATION; AGGREGATION; MUTATION; INCLUSIONS; HUNTINGTIN	The first gene to he linked to Parkinson's disease encodes the neuronal protein alpha-synuclein. Recent mouse and Drosophila models of Parkinson's disease support a central role for the process of alpha-synuclein fibrillization in pathogenesis. However, some evidence indicates that the fibril itself may not be the pathogenic species. Our own biophysical studies suggest that a structured fibrillization intermediate or an alternatively assembled oligomer may be responsible for neuronal death. This speculation can now be experimentally tested in the animal models. Such experiments will have implications for the development of new therapies for Parkinson's disease and related neurodegenerative diseases.	Harvard Univ, Brigham & Womens Hosp, Sch Med, Ctr Neurol Dis, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard Medical School	Goldberg, MS (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Ctr Neurol Dis, 77 Ave Louis Pasteur, Boston, MA 02115 USA.	lansbury@cnd.bwh.harvard.edu	Goldberg, Matthew/T-7827-2019	Goldberg, Matthew/0000-0002-5172-9841				Abeliovich A, 2000, NEURON, V25, P239, DOI 10.1016/S0896-6273(00)80886-7; Baba M, 1998, AM J PATHOL, V152, P879; Chai YH, 1999, J NEUROSCI, V19, P10338; Chiesa R, 1998, NEURON, V21, P1339, DOI 10.1016/S0896-6273(00)80653-4; Conway KA, 2000, BIOCHEMISTRY-US, V39, P2552, DOI 10.1021/bi991447r; Conway KA, 1998, NAT MED, V4, P1318, DOI 10.1038/3311; CONWAY KA, IN PRESS P NATL ACAD; Cummings CJ, 1999, NEURON, V24, P879, DOI 10.1016/S0896-6273(00)81035-1; Cummings CJ, 1998, NAT GENET, V19, P148, DOI 10.1038/502; Dawson TM, 2000, CELL, V101, P115, DOI 10.1016/S0092-8674(00)80629-7; Dunnett SB, 1999, NATURE, V399, pA32, DOI 10.1038/399a032; Engelender S, 1999, NAT GENET, V22, P110, DOI 10.1038/8820; Faber PW, 1999, P NATL ACAD SCI USA, V96, P179, DOI 10.1073/pnas.96.1.179; Feany MB, 2000, NATURE, V404, P394, DOI 10.1038/35006074; Forno LS, 1996, J NEUROPATH EXP NEUR, V55, P259, DOI 10.1097/00005072-199603000-00001; FORNO LS, 1993, NEURODEGENERATION, V2, P19; GEORGE JM, 1995, NEURON, V15, P361, DOI 10.1016/0896-6273(95)90040-3; Harper JD, 1999, BIOCHEMISTRY-US, V38, P8972, DOI 10.1021/bi9904149; Harper JD, 1997, CHEM BIOL, V4, P951, DOI 10.1016/S1074-5521(97)90303-3; Harper JD, 1997, CHEM BIOL, V4, P119, DOI 10.1016/S1074-5521(97)90255-6; Hsia AY, 1999, P NATL ACAD SCI USA, V96, P3228, DOI 10.1073/pnas.96.6.3228; IWAI A, 1995, NEURON, V14, P467, DOI 10.1016/0896-6273(95)90302-X; Jensen PH, 1998, J BIOL CHEM, V273, P26292, DOI 10.1074/jbc.273.41.26292; Kazemi-Esfarjani P, 2000, SCIENCE, V287, P1837, DOI 10.1126/science.287.5459.1837; Kitada T, 1998, NATURE, V392, P605, DOI 10.1038/33416; Klement IA, 1998, CELL, V95, P41, DOI 10.1016/S0092-8674(00)81781-X; Kobayashi Y, 2000, J BIOL CHEM, V275, P8772, DOI 10.1074/jbc.275.12.8772; Kosaka K, 1996, CURR OPIN NEUROL, V9, P271, DOI 10.1097/00019052-199608000-00005; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; Lansbury PT, 1997, NEURON, V19, P1151, DOI 10.1016/S0896-6273(00)80406-7; Lansbury PT, 1999, P NATL ACAD SCI USA, V96, P3342, DOI 10.1073/pnas.96.7.3342; Leroy E, 1998, NATURE, V395, P451, DOI 10.1038/26652; Li SH, 1998, HUM MOL GENET, V7, P777, DOI 10.1093/hmg/7.5.777; Masliah E, 2000, SCIENCE, V287, P1265, DOI 10.1126/science.287.5456.1265; Minton AP, 2000, CURR OPIN STRUC BIOL, V10, P34, DOI 10.1016/S0959-440X(99)00045-7; Moechars D, 1999, J BIOL CHEM, V274, P6483, DOI 10.1074/jbc.274.10.6483; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Rochet JC, 2000, CURR OPIN STRUC BIOL, V10, P60, DOI 10.1016/S0959-440X(99)00049-4; Saudou F, 1998, CELL, V95, P55, DOI 10.1016/S0092-8674(00)81782-1; SCHELLER RH, 1988, SCIENCE, V242, P13, DOI 10.1126/science.2902686; Scherzinger E, 1999, P NATL ACAD SCI USA, V96, P4604, DOI 10.1073/pnas.96.8.4604; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P6469, DOI 10.1073/pnas.95.11.6469; Tanner CM, 1999, JAMA-J AM MED ASSOC, V281, P341, DOI 10.1001/jama.281.4.341; Tompkins MM, 1997, BRAIN RES, V775, P24, DOI 10.1016/S0006-8993(97)00874-3; Tompkins MM, 1997, AM J PATHOL, V150, P119; Weinreb PH, 1996, BIOCHEMISTRY-US, V35, P13709, DOI 10.1021/bi961799n; Wyttenbach A, 2000, P NATL ACAD SCI USA, V97, P2898, DOI 10.1073/pnas.97.6.2898; Yamamoto A, 2000, CELL, V101, P57, DOI 10.1016/S0092-8674(00)80623-6	48	420	435	1	38	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	JUL	2000	2	7					E115	E119		10.1038/35017124	http://dx.doi.org/10.1038/35017124			5	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	333MK	10878819				2022-12-25	WOS:000088133700004
J	Mainguy, G; Montesinos, ML; Lesaffre, B; Zevnik, B; Karasawa, M; Kothary, R; Wurst, W; Prochiantz, A; Volovitch, M				Mainguy, G; Montesinos, ML; Lesaffre, B; Zevnik, B; Karasawa, M; Kothary, R; Wurst, W; Prochiantz, A; Volovitch, M			An induction gene trap for identifying a homeoprotein-regulated locus	NATURE BIOTECHNOLOGY			English	Article						gene trap; nervous system; electroporation; homeoprotein; BPAG1	ANTENNAPEDIA HOMEOBOX PEPTIDE; BULLOUS PEMPHIGOID ANTIGEN-1; EMBRYONIC STEM-CELLS; PATTERN-FORMATION; DNA RECOGNITION; MOUSE; EXPRESSION; PROTEIN; HOMEODOMAIN; DROSOPHILA	An important issue in developmental biology is the identification of homeoprotein target genes. We have developed a strategy based on the internalization and nuclear addressing of exogenous homeodomains, using an engrailed homeodomain (EnHD) to screen an embryonic stem (ES) cell gene trap library. Eight integrated gene trap loci responded to EnHD. One is within the bullous pemphigoid antigen 1 (BPAG1) locus, in a region that interrupts two neural isoforms. By combining in vivo electroporation with organotypic cultures, we show that an already identified BPAG1 enhancer/promoter is differentially regulated by homeoproteins Hoxc-8 and Engrailed in the embryonic spinal cord and mesencephalon. This strategy can therefore be used for identifying and mutating homeoprotein targets. Because homeodomain third helices can internalize proteins, peptides, phosphopeptides, and antisense oligonucleotides, this strategy should be applicable to other intracellular targets for characterizing genetic networks involved in a large number of physiopathological states.	Max Planck Inst Psychiat, D-80804 Munich, Germany; Ecole Normale Super, CNRS, UMR 8542, F-75230 Paris 05, France; GSF Forschungszentrum Umwelt & Gesundheit, D-85764 Oberschleissheim, Germany; Ottawa Gen Hosp, Res Inst, Ctr Mol Med, Ottawa, ON K1H 8L6, Canada; Univ Paris 07, UFR Biol, F-75005 Paris, France	Max Planck Society; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; Ecole Normale Superieure (ENS); Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Ottawa; Ottawa Hospital Research Institute; UDICE-French Research Universities; Universite Paris Cite	Wurst, W (corresponding author), Max Planck Inst Psychiat, Kraepelinstr 2-10, D-80804 Munich, Germany.		Montesinos, María Luz/H-3251-2015; Zevnik, Branko/AAB-7853-2020; IBIS, SINAPTICA/C-2547-2016	Montesinos, María Luz/0000-0003-3525-5874; Zevnik, Branko/0000-0001-7845-9522; Volovitch, Michel/0000-0002-7488-764X; Wurst, Wolfgang/0000-0003-4422-7410; Kothary, Rashmi/0000-0002-9239-7310				Biggin MD, 1997, DEVELOPMENT, V124, P4425; BLOCHGALLEGO E, 1993, J CELL BIOL, V120, P485, DOI 10.1083/jcb.120.2.485; Boncinelli E, 1997, CURR OPIN GENET DEV, V7, P331, DOI 10.1016/S0959-437X(97)80146-3; BROWN A, 1995, GENOMICS, V29, P777, DOI 10.1006/geno.1995.9936; BROWN A, 1995, NAT GENET, V10, P301, DOI 10.1038/ng0795-301; CHAMAK B, 1989, DEVELOPMENT, V106, P483; Chatelin L, 1996, MECH DEVELOP, V55, P111, DOI 10.1016/0925-4773(95)00478-5; Damante G, 1996, EMBO J, V15, P4992, DOI 10.1002/j.1460-2075.1996.tb00879.x; DAVIS CA, 1991, DEVELOPMENT, V111, P287; Derossi D, 1998, TRENDS CELL BIOL, V8, P84, DOI 10.1016/S0962-8924(97)01214-2; Ding M, 1997, J MOL NEUROSCI, V8, P93, DOI 10.1007/BF02736776; Forrester LM, 1996, P NATL ACAD SCI USA, V93, P1677, DOI 10.1073/pnas.93.4.1677; FRIEDRICH G, 1991, GENE DEV, V5, P1513, DOI 10.1101/gad.5.9.1513; GEHRING WJ, 1994, CELL, V78, P211, DOI 10.1016/0092-8674(94)90292-5; Gitton Y, 1999, J NEUROSCI, V19, P4889; GUO LF, 1995, CELL, V81, P233, DOI 10.1016/0092-8674(95)90333-X; HILL DP, 1993, METHOD ENZYMOL, V225, P664; HINZ U, 1992, DEVELOPMENT, V116, P543; Hogan B, 1994, MANIPULATING MOUSE E; Joliot A, 1998, CURR BIOL, V8, P856, DOI 10.1016/S0960-9822(07)00346-6; JOLIOT A, 1991, P NATL ACAD SCI USA, V88, P1864, DOI 10.1073/pnas.88.5.1864; JOLIOT AH, 1991, NEW BIOL, V3, P1121; LEMOUELLIC H, 1992, CELL, V69, P251, DOI 10.1016/0092-8674(92)90406-3; LEROUX I, 1995, FEBS LETT, V368, P311, DOI 10.1016/0014-5793(95)00681-X; LEROUX I, 1993, P NATL ACAD SCI USA, V90, P9120, DOI 10.1073/pnas.90.19.9120; Leung CL, 1999, J CELL BIOL, V144, P435, DOI 10.1083/jcb.144.3.435; Li KJ, 1996, CELL, V85, P585, DOI 10.1016/S0092-8674(00)81258-1; Mainguy G, 1999, J INVEST DERMATOL, V113, P643, DOI 10.1046/j.1523-1747.1999.00703.x; Muramatsu T, 1997, BIOCHEM BIOPH RES CO, V230, P376, DOI 10.1006/bbrc.1996.5882; Pooga M, 1998, NAT BIOTECHNOL, V16, P857, DOI 10.1038/nbt0998-857; Prochiantz A, 1996, CURR OPIN NEUROBIOL, V6, P629, DOI 10.1016/S0959-4388(96)80095-X; Saueressig H, 1999, DEVELOPMENT, V126, P4201; SAWAMURA D, 1994, J INVEST DERMATOL, V103, P651, DOI 10.1111/1523-1747.ep12398405; Serrano N, 1997, DEVELOPMENT, V124, P2527; Tiret L, 1998, DEVELOPMENT, V125, P279; Tolkunova EN, 1998, MOL CELL BIOL, V18, P2804, DOI 10.1128/MCB.18.5.2804; Winnier AR, 1999, GENE DEV, V13, P2774, DOI 10.1101/gad.13.21.2774; WURST W, 1993, GENE TARGETING PRACT; Yang YM, 1999, CELL, V98, P229, DOI 10.1016/S0092-8674(00)81017-X; Yang YM, 1996, CELL, V86, P655, DOI 10.1016/S0092-8674(00)80138-5	40	28	32	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUL	2000	18	7					746	749		10.1038/77312	http://dx.doi.org/10.1038/77312			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	331YN	10888842				2022-12-25	WOS:000088046400023
J	Schaub, FJ; Han, DKM; Liles, WC; Adams, LD; Coats, SA; Ramachandran, RK; Seifert, RA; Schwartz, SM; Bowen-Pope, DF				Schaub, FJ; Han, DKM; Liles, WC; Adams, LD; Coats, SA; Ramachandran, RK; Seifert, RA; Schwartz, SM; Bowen-Pope, DF			Fas/FADD-mediated activation of a specific program of inflammatory gene expression in vascular smooth muscle cells	NATURE MEDICINE			English	Article							MONOCYTE CHEMOATTRACTANT PROTEIN-1; RECEPTOR-DEFICIENT MICE; TUMOR-NECROSIS-FACTOR; IL-8 SECRETION; CD95 LIGAND; FAS LIGAND; IN-VIVO; APOPTOSIS; MACROPHAGES; INDUCTION	Apoptosis of smooth muscle cells is a common feature of vascular lesions but its pathophysiological significance is not known. We demonstrate that signals initiated by regulated Fas-associated death domain protein overexpression in rat vascular smooth muscle cells in the carotid artery induce expression of monocyte-chemoattractant protein-1 and interleukin-8, and cause massive immigration of macrophages in vivo. These chemokines, and a specific set of other pro-inflammatory genes, are also upregulated in human vascular smooth muscle cells during Fas-induced apoptosis, in part through a process that requires interleukin-1 alpha activation. Induction of a proinflammatory program by apoptotic vascular smooth muscle cells may thus contribute to the pathogenesis of vascular disease.	Univ Washington, Dept Pathol, Seattle, WA 98195 USA; Univ Washington, Dept Med, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Bowen-Pope, DF (corresponding author), Univ Washington, Dept Pathol, Box 357470, Seattle, WA 98195 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062995] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL03174, HL62995] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABREUMARTIN MT, 1995, J IMMUNOL, V155, P4147; Allison J, 1997, P NATL ACAD SCI USA, V94, P3943, DOI 10.1073/pnas.94.8.3943; AREND WP, 1993, ADV IMMUNOL, V54, P167, DOI 10.1016/S0065-2776(08)60535-0; Belvisi MG, 1997, BRIT J PHARMACOL, V120, P910, DOI 10.1038/sj.bjp.0700963; Biancone L, 1997, J EXP MED, V186, P147, DOI 10.1084/jem.186.1.147; Boisvert WA, 1998, J CLIN INVEST, V101, P353, DOI 10.1172/JCI1195; Boring L, 1998, NATURE, V394, P894, DOI 10.1038/29788; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; CLOWES MM, 1994, J CLIN INVEST, V93, P644, DOI 10.1172/JCI117016; Devitt A, 1998, NATURE, V392, P505, DOI 10.1038/33169; Frevert CW, 1998, J IMMUNOL METHODS, V213, P41, DOI 10.1016/S0022-1759(98)00016-7; GENG YJ, 1995, AM J PATHOL, V147, P251; Geng YJ, 1997, ARTERIOSCL THROM VAS, V17, P2200, DOI 10.1161/01.ATV.17.10.2200; Gerszten RE, 1999, NATURE, V398, P718, DOI 10.1038/19546; Gu L, 1998, MOL CELL, V2, P275, DOI 10.1016/S1097-2765(00)80139-2; HAN DKM, 1995, AM J PATHOL, V147, P267; HOPKINSONWOOLLEY J, 1994, J CELL SCI, V107, P1159; Huang DCS, 1999, P NATL ACAD SCI USA, V96, P14871, DOI 10.1073/pnas.96.26.14871; Kiener PA, 1997, J EXP MED, V185, P1511, DOI 10.1084/jem.185.8.1511; KOCH AE, 1993, AM J PATHOL, V142, P1423; Kockx MM, 1998, CIRCULATION, V97, P2307, DOI 10.1161/01.CIR.97.23.2307; Kollum M, 1997, ARTERIOSCL THROM VAS, V17, P2383, DOI 10.1161/01.ATV.17.11.2383; Lie YS, 1998, CURR OPIN BIOTECH, V9, P43, DOI 10.1016/S0958-1669(98)80082-7; Miwa K, 1998, NAT MED, V4, P1287, DOI 10.1038/3276; NELKEN NA, 1991, J CLIN INVEST, V88, P1121, DOI 10.1172/JCI115411; Newton K, 1998, EMBO J, V17, P706, DOI 10.1093/emboj/17.3.706; Perlman H, 1997, CIRCULATION, V95, P981; Reckless J, 1999, CIRCULATION, V99, P2310, DOI 10.1161/01.CIR.99.17.2310; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Saas P, 1999, J IMMUNOL, V162, P2326; SAVILL J, 1993, IMMUNOL TODAY, V14, P131, DOI 10.1016/0167-5699(93)90215-7; SAYERS TJ, 1988, J IMMUNOL, V141, P1670; Seino KI, 1997, NAT MED, V3, P165, DOI 10.1038/nm0297-165; Sekine C, 1996, BIOCHEM BIOPH RES CO, V228, P14, DOI 10.1006/bbrc.1996.1610; SHOCKETT P, 1995, P NATL ACAD SCI USA, V92, P6522, DOI 10.1073/pnas.92.14.6522; VERHEYEN AK, 1988, ARTERIOSCLEROSIS, V8, P759, DOI 10.1161/01.ATV.8.6.759; WANG JM, 1991, ARTERIOSCLER THROMB, V11, P1166, DOI 10.1161/01.ATV.11.5.1166; Wisniewski HG, 1996, J IMMUNOL, V156, P1609; Wu JC, 1999, METHODS, V17, P320, DOI 10.1006/meth.1999.0746; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954; ZAGORSKI J, 1993, BIOCHEM BIOPH RES CO, V190, P104, DOI 10.1006/bbrc.1993.1017; Zhang JK, 1998, NATURE, V392, P296, DOI 10.1038/32681	42	176	181	0	10	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUL	2000	6	7					790	796		10.1038/77521	http://dx.doi.org/10.1038/77521			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	331VV	10888928				2022-12-25	WOS:000088040100036
J	Verberne, MC; Verpoorte, R; Bol, JF; Mercado-Blanco, J; Linthorst, HJM				Verberne, MC; Verpoorte, R; Bol, JF; Mercado-Blanco, J; Linthorst, HJM			Overproduction of salicylic acid in plants by bacterial transgenes enhances pathogen resistance	NATURE BIOTECHNOLOGY			English	Article						salicylic acid; systemic acquired resistance; tobacco; tobacco mosaic virus; Oidium lycopersicon; PR gene expression	SYSTEMIC ACQUIRED-RESISTANCE; TOBACCO MOSAIC-VIRUS; ISOCHORISMATE SYNTHASE; DISEASE RESISTANCE; CELL-DEATH; INDUCTION; INFECTION; PROTEINS; SIGNAL; REPLICATION	After a hypersensitive response to invading pathogens, plants show elevated accumulation of salicylic acid (SA), induced expression of plant defense genes, and systemic acquired resistance (SAR) to further infection by a broad range of pathogens. There is compelling evidence that SA plays a crucial role in triggering SAR. We have transformed tobacco with two bacterial genes coding for enzymes that convert chorismate into SA by a two-step process. When the two enzymes were targeted to the chloroplasts, the transgenic (CSA, constitutive SA biosynthesis) plants showed a 500- to 1,000-fold increased accumulation of SA and SA glucoside compared to control plants. Defense genes, particularly those encoding acidic pathogenesis-related (PR) proteins, were constitutively expressed in CSA plants, This expression did not affect the plant phenotype, but the CSA plants showed a resistance to viral and fungal infection resembling SAR in nontransgenic plants.	Leiden Univ, Gorlaeus Labs, Inst Mol Plant Sci, NL-2300 RA Leiden, Netherlands; Leiden Univ, Gorlaeus Labs, Leiden Amsterdam Ctr Drug Res, NL-2300 RA Leiden, Netherlands; Univ Utrecht, Dept Plant Ecol & Evolutionary Biol, NL-3508 TB Utrecht, Netherlands	Leiden University; Leiden University - Excl LUMC; Leiden University; Leiden University - Excl LUMC; Utrecht University	Linthorst, HJM (corresponding author), Leiden Univ, Gorlaeus Labs, Inst Mol Plant Sci, POB 9502, NL-2300 RA Leiden, Netherlands.	linthors@chem.leidenuniv.nl	Verpoorte, Robert/Y-4363-2019; Mercado-Blanco, Jesús/F-3385-2011	Mercado-Blanco, Jesús/0000-0003-1895-5895; Verpoorte, Robert/0000-0001-6180-1424				BALANDIN T, 1995, PLANT MOL BIOL, V27, P1197, DOI 10.1007/BF00020893; BREDERODE FT, 1991, PLANT MOL BIOL, V17, P1117, DOI 10.1007/BF00028729; Chaerle L, 1999, NAT BIOTECHNOL, V17, P813, DOI 10.1038/11765; CHEN ZX, 1995, P NATL ACAD SCI USA, V92, P4134, DOI 10.1073/pnas.92.10.4134; Chivasa S, 1997, PLANT CELL, V9, P547, DOI 10.1105/tpc.9.4.547; Dangl JL, 1996, PLANT CELL, V8, P1793, DOI 10.1105/tpc.8.10.1793; DELANEY TP, 1994, SCIENCE, V266, P1247, DOI 10.1126/science.266.5188.1247; DIETRICH RA, 1994, CELL, V77, P565, DOI 10.1016/0092-8674(94)90218-6; ENYEDI AJ, 1992, P NATL ACAD SCI USA, V89, P2480, DOI 10.1073/pnas.89.6.2480; GAFFNEY T, 1993, SCIENCE, V261, P754, DOI 10.1126/science.261.5122.754; JOHAL GS, 1995, BIOESSAYS, V17, P685, DOI 10.1002/bies.950170805; LEE HI, 1995, P NATL ACAD SCI USA, V92, P4076, DOI 10.1073/pnas.92.10.4076; LINDROTH RL, 1988, OECOLOGIA, V75, P185, DOI 10.1007/BF00378595; LINTHORST HJM, 1991, CRIT REV PLANT SCI, V10, P123, DOI 10.1080/07352689109382309; LINTHORST HJM, 1989, PLANT CELL, V1, P285, DOI 10.1105/tpc.1.3.285; MALAMY J, 1992, PLANT CELL, V4, P359, DOI 10.1105/tpc.4.3.359; MALAMY J, 1990, SCIENCE, V250, P1002, DOI 10.1126/science.250.4983.1002; MAZUR BJ, 1985, NUCLEIC ACIDS RES, V13, P2373, DOI 10.1093/nar/13.7.2373; METRAUX JP, 1990, SCIENCE, V250, P1004, DOI 10.1126/science.250.4983.1004; MEUWLY P, 1993, ANAL BIOCHEM, V214, P500, DOI 10.1006/abio.1993.1529; MORENO PRH, 1994, PLANT CELL REP, V14, P188, DOI 10.1007/BF00233788; OZENBERGER BA, 1989, J BACTERIOL, V171, P775, DOI 10.1128/jb.171.2.775-783.1989; Pierpoint WS, 1997, INTERDISCIPL SCI REV, V22, P45; POULSEN C, 1991, PHYTOCHEMISTRY, V30, P377, DOI 10.1016/0031-9422(91)83688-H; RASKIN I, 1992, PLANT PHYSIOL, V99, P799, DOI 10.1104/pp.99.3.799; RASKIN I, 1989, P NATL ACAD SCI USA, V86, P2214, DOI 10.1073/pnas.86.7.2214; RASKIN I, 1992, ANNU REV PLANT PHYS, V43, P439, DOI 10.1146/annurev.pp.43.060192.002255; Ryals JA, 1996, PLANT CELL, V8, P1809, DOI 10.1105/tpc.8.10.1809; SELABUURLAGE MB, 1993, PLANT PHYSIOL, V101, P857, DOI 10.1104/pp.101.3.857; TASCHNER PEM, 1991, VIROLOGY, V181, P445, DOI 10.1016/0042-6822(91)90876-D; Verberne MC, 1999, N COMP BIOC, V33, P295; WARD ER, 1991, PLANT CELL, V3, P1085, DOI 10.1105/tpc.3.10.1085; WHITE RF, 1979, VIROLOGY, V99, P410, DOI 10.1016/0042-6822(79)90019-9; YALPANI N, 1991, PLANT CELL, V3, P809, DOI 10.1105/tpc.3.8.809; YOUNG IG, 1969, BIOCHIM BIOPHYS ACTA, V177, P389, DOI 10.1016/0304-4165(69)90301-8	35	152	186	2	26	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JUL	2000	18	7					779	783		10.1038/77347	http://dx.doi.org/10.1038/77347			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	331YN	10888849	Green Submitted			2022-12-25	WOS:000088046400030
J	Matsuyama, S; Llopis, J; Deveraux, QL; Tsien, RY; Reed, JC				Matsuyama, S; Llopis, J; Deveraux, QL; Tsien, RY; Reed, JC			Changes in intramitochondrial and cytosolic pH: early events that modulate caspase activation during apoptosis	NATURE CELL BIOLOGY			English	Article							PROAPOPTOTIC PROTEIN BAX; CYTOCHROME-C; CELL-DEATH; MITOCHONDRIAL-MEMBRANE; INTRACELLULAR ACIDIFICATION; MAMMALIAN-CELLS; BCL-2; RELEASE; YEAST; PREVENTION	Mitochondria trigger apoptosis by releasing caspase activators, including cytochrome c (cytC). Here we show, using a pH-sensitive green fluorescent protein (GFP), that mitochondria-dependent apoptotic stimuli (such as Bax, staurosporine and ultraviolet irradiation) induce rapid, Bcl-2-inhibitable mitochondrial alkalinization and cytosol acidification, followed by cytC release, caspase activation and mitochondrial swelling and depolarization. These events are not induced by mitochondria-independent apoptotic stimuli, such as Fas. Activation of cytosolic caspases by cytC in vitro is minimal at neutral pH, but maximal at acidic pH, indicating that mitochondria-induced acidification of the cytosol may be important for caspase activation; this finding is supported by results obtained from cells using protonophores. Cytosol acidification and cytC release are suppressed by oligomycin, a FoF1-ATPase/H+-pump inhibitor, but not by caspase inhibitors. Ectopic expression of Bax in wild-type, but not FoF1/H+-pump-deficient, yeast cells similarly results in mitochondrial matrix alkalinization, cytosol acidification and cell death. These findings indicate that mitochondria-mediated alteration of intracellular pH may be an early event that regulates caspase activation in the mitochondrial pathway for apoptosis.	Burnham Inst, Programme Apoptosis & Cell Death Regulat, La Jolla, CA 92037 USA; Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA; Univ Calif San Diego, Howard Hughes Med Inst, Div Cellular & Mol Med, La Jolla, CA 92093 USA	Sanford Burnham Prebys Medical Discovery Institute; University of California System; University of California San Diego; Howard Hughes Medical Institute; University of California System; University of California San Diego	Reed, JC (corresponding author), Burnham Inst, Programme Apoptosis & Cell Death Regulat, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	jreed@burnham-institute.org	Llopis, Juan/I-2622-2012	Llopis, Juan/0000-0002-9460-0642	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060554] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 60554-01] Funding Source: Medline; PHS HHS [N527177] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ALBERTS B, 1994, MOL BIOL CELL, V1, pCH14; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; BERNARDI P, 1994, J BIOENERG BIOMEMBR, V26, P509, DOI 10.1007/BF00762735; Bernardi P, 1998, BIOFACTORS, V8, P273, DOI 10.1002/biof.5520080315; Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; Chen Q, 1998, BLOOD, V92, P4545, DOI 10.1182/blood.V92.12.4545.424k41_4545_4553; Deshmukh M, 1998, NEURON, V21, P695, DOI 10.1016/S0896-6273(00)80587-5; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Eguchi Y, 1999, CANCER RES, V59, P2174; Gottlieb RA, 1996, P NATL ACAD SCI USA, V93, P654, DOI 10.1073/pnas.93.2.654; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; HAWORTH RS, 1993, MOL CELL BIOCHEM, V124, P131, DOI 10.1007/BF00929205; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; Khaled AR, 1999, P NATL ACAD SCI USA, V96, P14476, DOI 10.1073/pnas.96.25.14476; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Leist M, 1997, J EXP MED, V185, P1481, DOI 10.1084/jem.185.8.1481; LEMASTERS JJ, 1987, NATURE, V325, P78, DOI 10.1038/325078a0; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Llopis J, 1998, P NATL ACAD SCI USA, V95, P6803, DOI 10.1073/pnas.95.12.6803; Macho A, 1997, J IMMUNOL, V158, P4612; Manon S, 1997, FEBS LETT, V415, P29, DOI 10.1016/S0014-5793(97)01087-9; MARTIN SJ, 1995, EMBO J, V14, P5191, DOI 10.1002/j.1460-2075.1995.tb00203.x; Martinou I, 1999, J CELL BIOL, V144, P883, DOI 10.1083/jcb.144.5.883; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; Matsuyama S, 1998, J BIOL CHEM, V273, P30995, DOI 10.1074/jbc.273.47.30995; Matsuyama S, 1998, MOL CELL, V1, P327, DOI 10.1016/S1097-2765(00)80033-7; Minn AJ, 1999, EMBO J, V18, P632, DOI 10.1093/emboj/18.3.632; Nicholls DG, 2000, TRENDS NEUROSCI, V23, P166, DOI 10.1016/S0166-2236(99)01534-9; Nicholls DG, 2000, PHYSIOL REV, V80, P315, DOI 10.1152/physrev.2000.80.1.315; PEREZSALA D, 1995, J BIOL CHEM, V270, P6235, DOI 10.1074/jbc.270.11.6235; Petronilli V, 1998, BIOFACTORS, V8, P263, DOI 10.1002/biof.5520080314; RAJOTTE D, 1992, J BIOL CHEM, V267, P9980; Reed JC, 1997, CELL, V91, P559, DOI 10.1016/S0092-8674(00)80442-0; Rosse T, 1998, NATURE, V391, P496, DOI 10.1038/35160; Susin SA, 1998, BBA-BIOENERGETICS, V1366, P151, DOI 10.1016/S0005-2728(98)00110-8; Suzuki Y, 1998, FEBS LETT, V425, P209, DOI 10.1016/S0014-5793(98)00228-2; Thangaraju M, 1999, CANCER RES, V59, P1649; Thangaraju M, 1999, J BIOL CHEM, V274, P29549, DOI 10.1074/jbc.274.41.29549; THANGARAJU M, 1999, J BIOL CHEM, V59, P1649; Vander Heiden MG, 1999, NAT CELL BIOL, V1, pE209, DOI 10.1038/70237; vanRaaij MJ, 1996, P NATL ACAD SCI USA, V93, P6913, DOI 10.1073/pnas.93.14.6913; Vaux DL, 1999, CELL, V96, P245, DOI 10.1016/S0092-8674(00)80564-4; VELOURS J, 1989, BIOCHIMIE, V71, P903, DOI 10.1016/0300-9084(89)90073-4; Wachter RM, 1998, STRUCTURE, V6, P1267, DOI 10.1016/S0969-2126(98)00127-0; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zha HB, 1996, MOL CELL BIOL, V16, P6494; Zhivotovsky B, 1998, NATURE, V391, P449, DOI 10.1038/35060	50	614	628	1	61	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	JUN	2000	2	6					318	325		10.1038/35014006	http://dx.doi.org/10.1038/35014006			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	321KE	10854321				2022-12-25	WOS:000087454000012
J	Napirei, M; Karsunky, H; Zevnik, B; Stephan, H; Mannherz, HG; Moroy, T				Napirei, M; Karsunky, H; Zevnik, B; Stephan, H; Mannherz, HG; Moroy, T			Features of systemic lupus erythematosus in Dnase1-deficient mice	NATURE GENETICS			English	Article							DEOXYRIBONUCLEASE-I DNASE; AUTOANTIBODIES; TISSUES; SERUM; NEPHRITIS; APOPTOSIS	Systemic lupus erythematosus (SLE) is a multifactorial autoimmune disease that affects over one million people in the United States. SLE is characterized by the presence of anti-nuclear antibodies (ANA) directed against naked DNA and entire nucleosomes. It is thought that the resulting immune complexes accumulate in vessel walls, glomeruli and joints and cause a hypersensitivity reaction type ill, which manifests as glomerulonephritis, arthritis and general vasculitis, The aetiology of SLE is unknown, but several studies suggest that increased liberation or disturbed clearance of nuclear DNA-protein complexes after cell death may initiate and propagate the disease(1-6). Consequently, Dnase1, which is the major nuclease present in serum, urine and secreta, may be responsible for the removal of DNA from nuclear antigens at sites of high cell turnover and thus for the prevention of SLE (refs 7-11). To test this hypothesis, we have generated Dnase1-deficient mice by gene targeting. We report here that these animals show the classical symptoms of SLE. namely the presence of ANA, the deposition of immune complexes in glomeruli and full-blown glomerulonephritis in a Dnasel-dose-dependent manner. Moreover, in agreement with earlier reports(10), we found Dnase1 activities in serum to be lower in SLE patients than in normal subjects. Our findings suggest that lack or reduction of Dnase1 is a critical factor in the initiation of human SLE.	Ruhr Univ Bochum, Fak Med, Abt Anat & Embryol, D-4630 Bochum, Germany; Univ Essen Gesamthsch Klinikum, IFZ, Inst Zellbiol Tumorforsch, D-4300 Essen, Germany	Ruhr University Bochum; University of Duisburg Essen	Moroy, T (corresponding author), Ruhr Univ Bochum, Fak Med, Abt Anat & Embryol, Univ Str 150, D-4630 Bochum, Germany.	moeroey@uni-essen.de	Zevnik, Branko/AAB-7853-2020; Mannherz, Hans Georg/HHM-2867-2022; Moroy, Tarik/D-9923-2011; Stephan, Harald/AAT-6802-2021	Zevnik, Branko/0000-0001-7845-9522; Mannherz, Hans Georg/0000-0001-8158-5722				Berden JHM, 1999, CURR OPIN NEPHROL HY, V8, P299, DOI 10.1097/00041552-199905000-00005; Bickerstaff MCM, 1999, NAT MED, V5, P694, DOI 10.1038/9544; Botto M, 1998, NAT GENET, V19, P56, DOI 10.1038/ng0598-56; Carroll MC, 1998, NAT GENET, V19, P3, DOI 10.1038/ng0598-3; CHITRABAMRUNG S, 1981, RHEUMATOL INT, V1, P55, DOI 10.1007/BF00541153; Davis JC, 1999, LUPUS, V8, P68, DOI 10.1191/096120399678847380; Eilat D, 1999, IMMUNOL TODAY, V20, P339, DOI 10.1016/S0167-5699(99)01457-7; ELKON KB, 1985, J EXP MED, V162, P459, DOI 10.1084/jem.162.2.459; LACHMANN PJ, 1961, IMMUNOLOGY, V4, P153; LACKS SA, 1981, J BIOL CHEM, V256, P2644; Macanovic M, 1997, CLIN EXP IMMUNOL, V108, P220, DOI 10.1046/j.1365-2249.1997.3571249.x; Macanovic M, 1996, CLIN EXP IMMUNOL, V106, P243, DOI 10.1046/j.1365-2249.1996.d01-839.x; MOORE TL, 1981, SEMIN ARTHRITIS RHEU, V10, P309, DOI 10.1016/0049-0172(81)90007-X; NADANO D, 1993, CLIN CHEM, V39, P448; Peitsch M C, 1994, Cell Death Differ, V1, P1; PEITSCH MC, 1995, BIOCHEM BIOPH RES CO, V207, P62, DOI 10.1006/bbrc.1995.1153; POLZAR B, 1990, NUCLEIC ACIDS RES, V18, P7151, DOI 10.1093/nar/18.23.7151; POLZAR B, 1994, EUR J CELL BIOL, V64, P200; Rosen A, 1999, CELL DEATH DIFFER, V6, P6, DOI 10.1038/sj.cdd.4400460; RUMORE PM, 1990, J CLIN INVEST, V86, P69, DOI 10.1172/JCI114716; Shimoda M, 1998, IMMUNOLOGY, V95, P200; Takeshita H, 1997, BIOCHEM MOL BIOL INT, V42, P65; Vanholder R, 1998, EUR J DERMATOL, V8, P4; Verthelyi D, 1998, LUPUS, V7, P223, DOI 10.1191/096120398678920037	24	614	645	1	29	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JUN	2000	25	2					177	181		10.1038/76032	http://dx.doi.org/10.1038/76032			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	321ML	10835632				2022-12-25	WOS:000087459200016
J	Valls, M; Atrian, S; de Lorenzo, V; Fernandez, LA				Valls, M; Atrian, S; de Lorenzo, V; Fernandez, LA			Engineering a mouse metallothionein on the cell surface of Ralstonia eutropha CH34 for immobilization of heavy metals in soil	NATURE BIOTECHNOLOGY			English	Article						Alcaligenes; bioremediation; metallothionein; Ralstonia; surface display; heavy metals	DISULFIDE BOND FORMATION; ALCALIGENES-EUTROPHUS; RESISTANCE; SECRETION; METALLOADSORPTION; BIOREMEDIATION; PSEUDOMONAS; PROTEINS; CADMIUM	Here we describe targeting of the mouse metallothionein 1 (MT) protein to the cell surface of the heavy metal-tolerant Ralstonia eutropha (formerly Alcaligenes eutrophus) CH34 strain, which is adapted to thrive in soils highly polluted with metal ions. DNA sequences encoding MT were fused to the autotrans-porter beta-domain of the IgA protease of Neisseria gonorrhoeae, which targeted the hybrid protein toward the bacterial outer membrane. The translocation, surface display, and functionality of the chimeric MT beta protein was initially demonstrated in Escherichia coli before the transfer of its encoding gene (mtb) to R. eutropha. The resulting bacterial strain, named R. eutropha MTB, was found to have an enhanced ability for immobilizing Cd2+ ions from the external media. Furthermore, the inoculation of Cd2+-polluted soil with R. eutropha MTB decreased significantly the toxic effects of the heavy metal on the growth of tobacco plants (Nicotiana bentamiana).	Univ Barcelona, Fac Biol, Dept Genet, E-08028 Barcelona, Spain; Ctr Nacl Biotecnol, Dept Biotecnol Microbiana, Madrid 28049, Spain	University of Barcelona; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB)	de Lorenzo, V (corresponding author), Univ Barcelona, Fac Biol, Dept Genet, Av Diagonal 645, E-08028 Barcelona, Spain.	vdlorenzo@cnb.uam.es	Valls, Marc/I-7285-2015; Fernández-Herrero, Luis Ángel/AAA-2583-2021; Fernández, Luis Ángel/D-2713-2009	Valls, Marc/0000-0003-2312-0091; Fernández-Herrero, Luis Ángel/0000-0001-5920-0638; Fernández, Luis Ángel/0000-0001-5920-0638; de Lorenzo, Victor/0000-0002-6041-2731				Ausubel FM, 1994, CURRENT PROTOCOLS MO; BARDWELL JCA, 1991, CELL, V67, P581, DOI 10.1016/0092-8674(91)90532-4; BARDWELL JCA, 1994, MOL MICROBIOL, V14, P199, DOI 10.1111/j.1365-2958.1994.tb01281.x; Chaney RL, 1997, CURR OPIN BIOTECH, V8, P279, DOI 10.1016/S0958-1669(97)80004-3; de Lorenzo V, 1999, Environ Microbiol, V1, P275, DOI 10.1046/j.1462-2920.1999.00038.x; DELORENZO V, 1993, GENE, V130, P41, DOI 10.1016/0378-1119(93)90344-3; DELORENZO V, 1994, METHOD ENZYMOL, V235, P386; DIELS L, 1995, J IND MICROBIOL, V14, P142, DOI 10.1007/BF01569896; Diels L, 1999, MOL BIOTECHNOL, V12, P149, DOI 10.1385/MB:12:2:149; GADD GM, 1993, TRENDS BIOTECHNOL, V11, P353, DOI 10.1016/0167-7799(93)90158-6; Gilis A, 1998, J IND MICROBIOL BIOT, V20, P61, DOI 10.1038/sj.jim.2900478; Grimalt JO, 1999, SCI TOTAL ENVIRON, V242, P3, DOI 10.1016/S0048-9697(99)00372-1; Henderson IR, 1998, TRENDS MICROBIOL, V6, P370, DOI 10.1016/S0966-842X(98)01318-3; Jose J, 1996, GENE, V178, P107, DOI 10.1016/0378-1119(96)00343-5; KLAUSER T, 1993, J MOL BIOL, V234, P579, DOI 10.1006/jmbi.1993.1613; Kratochvil D, 1998, TRENDS BIOTECHNOL, V16, P291, DOI 10.1016/S0167-7799(98)01218-9; Lovley DR, 1997, CURR OPIN BIOTECH, V8, P285, DOI 10.1016/S0958-1669(97)80005-5; MERGEAY M, 1991, TRENDS BIOTECHNOL, V9, P17, DOI 10.1016/0167-7799(91)90007-5; MERGEAY M, 1985, J BACTERIOL, V162, P328, DOI 10.1128/JB.162.1.328-334.1985; Miller J.H., 1992, SHORT COURSE BACTERI, P150; NIES DH, 1989, J BACTERIOL, V171, P896, DOI 10.1128/jb.171.2.896-900.1989; NIKAIDO H, 1994, METHOD ENZYMOL, V235, P225; Nordberg M, 1998, TALANTA, V46, P243, DOI 10.1016/S0039-9140(97)00345-7; Ouzounidou G, 1997, ARCH ENVIRON CON TOX, V32, P154, DOI 10.1007/s002449900168; POHLNER J, 1987, NATURE, V325, P458, DOI 10.1038/325458a0; Ramos JL, 1997, ANNU REV MICROBIOL, V51, P341, DOI 10.1146/annurev.micro.51.1.341; Sousa C, 1996, NAT BIOTECHNOL, V14, P1017, DOI 10.1038/nbt0896-1017; Sousa C, 1998, J BACTERIOL, V180, P2280, DOI 10.1128/JB.180.9.2280-2284.1998; Tibazarwa C, 2000, J BACTERIOL, V182, P1399, DOI 10.1128/JB.182.5.1399-1409.2000; Valls M, 1998, BIOCHIMIE, V80, P855, DOI 10.1016/S0300-9084(00)88880-X; VanRoy S, 1997, RES MICROBIOL, V148, P526, DOI 10.1016/S0923-2508(97)88356-8; Veiga E, 1999, MOL MICROBIOL, V33, P1232, DOI 10.1046/j.1365-2958.1999.01571.x	32	185	200	5	66	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JUN	2000	18	6					661	665		10.1038/76516	http://dx.doi.org/10.1038/76516			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	325EK	10835606				2022-12-25	WOS:000087663200028
J	Yan, SD; Zhu, HJ; Zhu, AP; Golabek, A; Du, H; Roher, A; Yu, J; Soto, C; Schmidt, AM; Stern, D; Kindy, M				Yan, SD; Zhu, HJ; Zhu, AP; Golabek, A; Du, H; Roher, A; Yu, J; Soto, C; Schmidt, AM; Stern, D; Kindy, M			Receptor-dependent cell stress and amyloid accumulation in systemic amyloidosis	NATURE MEDICINE			English	Article							GLYCATION END-PRODUCTS; ACTIVATED MICROGLIAL CELLS; COLONY-STIMULATING FACTOR; E-DEFICIENT MICE; ALZHEIMERS-DISEASE; APOLIPOPROTEIN-E; DIABETIC VASCULOPATHY; SOLUBLE RECEPTOR; P-COMPONENT; IN-VIVO	Accumulation of fibrils composed of amyloid A in tissues resulting in displacement of normal structures and cellular dysfunction is the characteristic feature of systemic amyloidoses. Here we show that RAGE, a multiligand immunoglobulin superfamily cell surface molecule, is a receptor for the amyloidogenic form of serum amyloid A. Interactions between RAGE and amyloid A induced cellular perturbation. In a mouse model, amyloid A accumulation, evidence of cell stress and expression of RAGE were closely linked. Antagonizing RAGE suppressed cell stress and amyloid deposition in mouse spleens. These data indicate that RAGE is a potential target for inhibiting accumulation of amyloid A and for limiting cellular dysfunction induced by amyloid A.	Univ Kentucky, Sanders Brown Ctr Aging, Stroke Program, Dept Biochem, Lexington, KY 40506 USA; Columbia Univ Coll Phys & Surg, Dept Physiol, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Surg, New York, NY 10032 USA; New York State Inst Basic Res Dev Disabil, Staten Isl, NY 10314 USA; Sun Hlth Res inst, Haldeman Lab Alzheimers Dis Res, Sun City, AZ 85372 USA; Vet Adm Med Ctr, Lexington, KY 40506 USA; Serono Pharmaceut Res Inst, Geneva, Switzerland; Univ Chile, Santiago, Chile; Columbia Univ Coll Phys & Surg, Dept Pathol, New York, NY 10032 USA	University of Kentucky; Columbia University; Columbia University; Institute for Basic Research in Developmental Disabilities; Banner Research; Banner Health; Banner Sun Health Research Institute; US Department of Veterans Affairs; Veterans Health Administration (VHA); Lexington VA Medical Center; Universidad de Chile; Columbia University	Kindy, M (corresponding author), Univ Kentucky, Sanders Brown Ctr Aging, Stroke Program, Dept Biochem, Lexington, KY 40506 USA.				NIA NIH HHS [AG14103, AG12891, AG00690] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG014103, K01AG000690] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Ando Y, 1997, BIOCHEM BIOPH RES CO, V232, P497, DOI 10.1006/bbrc.1996.5997; BOCCHINI V, 1992, J NEUROSCI RES, V31, P616, DOI 10.1002/jnr.490310405; Botto M, 1997, NAT MED, V3, P855, DOI 10.1038/nm0897-855; BRETT J, 1993, AM J PATHOL, V143, P1699; COLLINS T, 1993, LAB INVEST, V68, P499; DEBEER MC, 1993, J BIOL CHEM, V268, P20606; Dickson DW, 1999, AM J PATHOL, V154, P1627, DOI 10.1016/S0002-9440(10)65416-8; Falk RH, 1997, NEW ENGL J MED, V337, P898, DOI 10.1056/NEJM199709253371306; Fixe P, 1998, CYTOKINE, V10, P32, DOI 10.1006/cyto.1997.0249; Gillmore JD, 1997, BRIT J HAEMATOL, V99, P245, DOI 10.1046/j.1365-2141.1997.303194.x; Hamilton JA, 1997, J LEUKOCYTE BIOL, V62, P145, DOI 10.1002/jlb.62.2.145; HAWKINS PN, 1991, CLIN EXP IMMUNOL, V84, P308; HOFMANNM, 1999, CELL, V97, P889; HORI O, 1995, J BIOL CHEM, V270, P25752, DOI 10.1074/jbc.270.43.25752; Hoshii Y, 1997, AM J PATHOL, V151, P911; Hume DA, 1997, MOL REPROD DEV, V46, P46; HUSEBEKK A, 1985, SCAND J IMMUNOL, V21, P283, DOI 10.1111/j.1365-3083.1985.tb01431.x; KIMBALL MR, 1979, BIOCHEM BIOPH RES CO, V88, P950, DOI 10.1016/0006-291X(79)91500-6; KINDY MS, 1995, LAB INVEST, V73, P469; Kindy MS, 1998, AM J PATHOL, V152, P1387; KIRSCHNER DA, 1986, P NATL ACAD SCI USA, V83, P503, DOI 10.1073/pnas.83.2.503; KISILEVSKY R, 1995, NAT MED, V1, P143, DOI 10.1038/nm0295-143; KLOTZ I, 1984, J BIOL CHEM, V258, P11442; Park' L, 1998, NAT MED, V4, P1025, DOI 10.1038/2012; PRELLI F, 1987, BIOCHEMISTRY-US, V26, P8251, DOI 10.1021/bi00399a035; RITTHALER U, 1995, AM J PATHOL, V146, P688; RUDDERMAN N, 1992, FASEB J, V6, P2905; Rysava R, 1999, BIOCHEM MOL BIOL INT, V47, P845; Schafer BW, 1996, TRENDS BIOCHEM SCI, V21, P134, DOI 10.1016/S0968-0004(96)80167-8; Schmidt AM, 1999, CIRC RES, V84, P489, DOI 10.1161/01.RES.84.5.489; SHIROO M, 1998, SCAND J IMMUNOL, V332, P721; SIPE JD, 1993, AM J PATHOL, V143, P1480; SIPE JD, 1992, ANNU REV BIOCHEM, V61, P947, DOI 10.1146/annurev.bi.61.070192.004503; STRACHAN AF, 1988, BIOCHEM J, V250, P203, DOI 10.1042/bj2500203; Suffredini AF, 1999, J CLIN IMMUNOL, V19, P203, DOI 10.1023/A:1020563913045; TAGUCHI A, IN PRESS NATURE; Uchihara T, 1997, STROKE, V28, P1948, DOI 10.1161/01.STR.28.10.1948; Wang HC, 1999, SCIENCE, V285, P248, DOI 10.1126/science.285.5425.248; Wautier JL, 1996, J CLIN INVEST, V97, P238, DOI 10.1172/JCI118397; WISNIEWSKI T, 1992, NEUROSCI LETT, V135, P235, DOI 10.1016/0304-3940(92)90444-C; Yan SD, 1999, AM J PATHOL, V155, P1403, DOI 10.1016/S0002-9440(10)65452-1; Yan SD, 1997, P NATL ACAD SCI USA, V94, P5296, DOI 10.1073/pnas.94.10.5296; Yan SD, 1996, NATURE, V382, P685, DOI 10.1038/382685a0	43	251	284	2	13	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUN	2000	6	6					643	651		10.1038/76216	http://dx.doi.org/10.1038/76216			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	321CX	10835680				2022-12-25	WOS:000087438300034
J	Benedetti, S; Pirola, B; Pollo, B; Magrassi, L; Bruzzone, MG; Rigamonti, D; Galli, R; Selleri, S; Di Meco, F; De Fraja, C; Vescovi, A; Cattaneo, E; Finocchiaro, G				Benedetti, S; Pirola, B; Pollo, B; Magrassi, L; Bruzzone, MG; Rigamonti, D; Galli, R; Selleri, S; Di Meco, F; De Fraja, C; Vescovi, A; Cattaneo, E; Finocchiaro, G			Gene therapy of experimental brain tumors using neural progenitor cells	NATURE MEDICINE			English	Article							MULTIPOTENTIAL STEM-CELLS; TRANSPLANTATION; INTEGRATION; LINES; DIFFERENTIATION; EXPRESSION; SURVIVAL	Glioblastomas, the most frequent and malignant of primary brain tumors, have a very poor prognosis'. Gene therapy of glioblastomas is limited by the short survival of viral vectors and by their difficulty in reaching glioblastoma cells infiltrating the brain parenchyma. Neural stem/progenitor cells can be engineered to produce therapeutic molecules and have the potential to overcome these limitations because they may travel along the white matter, like neoplastic cells, and engraft stably into the brain(2,3). Retrovirus-mediated transfer of the gene for interleukin-4 is an effective treatment for rat brain glioblastomas(4). Here, we transferred the gene for interleukin-4 into C57BL6J mouse primary neural progenitor cells and injected those cells into established syngeneic brain glioblastomas. This led to the survival of most tumor-bearing mice. We obtained similar results by implanting immortalized neural progenitor cells derived from Sprague-Dawley rats into C6 glioblastomas. We also documented by magnetic resonance imaging the progressive disappearance of large tumors, and detected 5-bromodeoxyuridine-labeled progenitor cells several weeks after the injection. These findings support a new approach for gene therapy of brain tumors, based on the grafting of neural stem cells producing therapeutic molecules.	Ist Nazl Neurol Carlo Besta, I-20133 Milan, Italy; Univ Pavia, IRCCS S Matteo, Neurosurg Dept Surg, I-27100 Pavia, Italy; Univ Milan, Inst Pharmacol Sci, I-20133 Milan, Italy	IRCCS Istituto Neurologico Besta; IRCCS Fondazione San Matteo; University of Pavia; University of Milan	Finocchiaro, G (corresponding author), Ist Nazl Neurol Carlo Besta, Via Celoria 11, I-20133 Milan, Italy.	finocchiaro@istituto-besta.it	Vescovi, Angelo Luigi/A-4919-2015; DiMeco, Francesco/Z-5431-2019; Bruzzone, Maria/AAM-4478-2021; Pollo, Bianca/K-5347-2018; Galli, Rossella/AAI-8028-2020; Magrassi, Lorenzo/AAJ-3105-2020; Finocchiaro, Gaetano/AAG-6791-2020; DiMeco, Francesco/Q-3785-2016	Vescovi, Angelo Luigi/0000-0002-1742-4112; Bruzzone, Maria/0000-0002-2786-1471; Pollo, Bianca/0000-0002-5523-4256; Galli, Rossella/0000-0001-9023-7033; CATTANEO, ELENA/0000-0002-0755-4917; DiMeco, Francesco/0000-0001-6213-5793; Magrassi, Lorenzo/0000-0002-8308-2720; Finocchiaro, Gaetano/0000-0003-3583-4040; Benedetti, Sara/0000-0003-2826-3040				AUSMAN JI, 1970, CANCER RES, V30, P2394; BARTH RF, 1998, RAT BRAIN TUMOR MODE, P313; Benedetti S, 1999, CANCER RES, V59, P645; Cattaneo E, 1996, J BIOL CHEM, V271, P23374, DOI 10.1074/jbc.271.38.23374; CATTANEO E, 1994, DEV BRAIN RES, V83, P197, DOI 10.1016/0165-3806(94)00137-5; Cattaneo E, 1998, J NEUROSCI RES, V53, P223, DOI 10.1002/(SICI)1097-4547(19980715)53:2<223::AID-JNR11>3.0.CO;2-7; Dewey RA, 1999, NAT MED, V5, P1256, DOI 10.1038/15207; Flax JD, 1998, NAT BIOTECHNOL, V16, P1033, DOI 10.1038/3473; Fricker RA, 1999, J NEUROSCI, V19, P5990, DOI 10.1523/JNEUROSCI.19-14-05990.1999; Gritti A, 1996, J NEUROSCI, V16, P1091; HOEBEN RC, 1991, J VIROL, V65, P904, DOI 10.1128/JVI.65.2.904-912.1991; Lacorazza HD, 1996, NAT MED, V2, P424, DOI 10.1038/nm0496-424; Lundberg C, 1997, EXP NEUROL, V145, P342, DOI 10.1006/exnr.1997.6503; Magrassi L, 1998, DEVELOPMENT, V125, P2847; Naldini L, 1996, P NATL ACAD SCI USA, V93, P11382, DOI 10.1073/pnas.93.21.11382; Pincus DW, 1998, NEUROSURGERY, V42, P858, DOI 10.1097/00006123-199804000-00103; Saleh M, 1999, J NATL CANCER I, V91, P438, DOI 10.1093/jnci/91.5.438; SANDMEYER SB, 1990, ANNU REV GENET, V24, P491; Surawicz TS, 1998, J NEURO-ONCOL, V40, P151, DOI 10.1023/A:1006091608586; Torchiana E, 1998, NEUROREPORT, V9, P3823, DOI 10.1097/00001756-199812010-00011; Vescovi AL, 1999, EXP NEUROL, V156, P71, DOI 10.1006/exnr.1998.6998	21	358	397	0	21	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2000	6	4					447	450		10.1038/74710	http://dx.doi.org/10.1038/74710			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	376UA	10742153				2022-12-25	WOS:000165474100040
J	Evans, AL; Muller, U				Evans, AL; Muller, U			Stereocilia defects in the sensory hair cells of the inner ear in mice deficient in integrin alpha 8 beta 1	NATURE GENETICS			English	Article							KIDNEY MORPHOGENESIS; OSTEOPONTIN; EXPRESSION; DEAFNESS; REGENERATION; FIBRONECTIN; ADHESION; RECEPTOR; TENASCIN; GENES	The mammalian inner ear contains organs for the detection of sound and acceleration, the cochlea and the vestibule, respectively. Mechanosensory hair cells within the neuroepithelia of these organs transduce mechanical force generated by sound waves or head movements into neuronal signals. Defects in hair cells lead to deafness and balance defects(1-3). Hair cells have stereocilia that are indispensable for mechanosensation, but the molecular mechanisms regulating stereocilia formation are poorly understood(4-6). We show here that integrin alpha 8 beta 1, its ligand fibronectin and the integrin-regulated focal adhesion kinase (FAK) co-localize to the apical hair-cell surface where stereocilia are forming. In mice homozygous for a targeted mutation of Itga8 (encoding the alpha 8 subunit; ref. 7), this co-localization is perturbed and hair cells in the utricle, a vestibular subcompartment, lack stereocilia or contain malformed stereocilia. Most integrin-alpha 8 beta 1-deficient mice die soon after birth due to kidney defects. Many of the survivors have difficulty balancing, consistent with the structural defects of the inner ear. Our data suggest that integrin alpha 8 beta 1, and potentially other integrins, regulates hair-cell differentiation and stereocilia maturation. Mutations affecting matrix molecules cause inherited forms of inner ear disease(1-3,8) and integrins may mediate some effects of matrix molecules in the ear: thus, mutations in integrin genes may lead to inner-ear diseases as well.	Friedrich Miescher Inst, CH-4002 Basel, Switzerland	Friedrich Miescher Institute for Biomedical Research	Evans, AL (corresponding author), Friedrich Miescher Inst, CH-4002 Basel, Switzerland.							Corwin JT, 1998, P NATL ACAD SCI USA, V95, P12080, DOI 10.1073/pnas.95.21.12080; CORWIN JT, 1991, ANNU REV NEUROSCI, V14, P301, DOI 10.1146/annurev.neuro.14.1.301; Cosgrove D, 1996, HEARING RES, V100, P21, DOI 10.1016/0378-5955(96)00114-1; Cremers FPM, 1998, CURR OPIN NEUROL, V11, P11, DOI 10.1097/00019052-199802000-00003; Denda S, 1998, MOL BIOL CELL, V9, P1425, DOI 10.1091/mbc.9.6.1425; Hasson T, 1997, J CELL BIOL, V137, P1287, DOI 10.1083/jcb.137.6.1287; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Legan PK, 1997, SEMIN CELL DEV BIOL, V8, P217, DOI 10.1006/scdb.1997.0145; LIM DJ, 1985, ACTA OTO-LARYNGOL, P1; LOPEZ CA, 1995, HEARING RES, V85, P210, DOI 10.1016/0378-5955(95)00046-7; Lynch ED, 1997, SCIENCE, V278, P1315, DOI 10.1126/science.278.5341.1315; McGuirt WT, 1999, NAT GENET, V23, P413, DOI 10.1038/70516; Muller U, 1997, CELL, V88, P603, DOI 10.1016/S0092-8674(00)81903-0; MULLER U, 1995, MOL BIOL CELL, V6, P433; Petit C, 1996, NAT GENET, V14, P385, DOI 10.1038/ng1296-385; Ruben R.J., 1967, ACTA OTO-LARYNGOL, DOI DOI 10.3109/00016486709127790; SCHAERENWIEMERS N, 1993, HISTOCHEMISTRY, V100, P431, DOI 10.1007/BF00267823; Schlaepfer DD, 1998, TRENDS CELL BIOL, V8, P151, DOI 10.1016/S0962-8924(97)01172-0; SCHNAPP LM, 1995, J BIOL CHEM, V270, P23196, DOI 10.1074/jbc.270.39.23196; Schoenwaelder SM, 1999, CURR OPIN CELL BIOL, V11, P274, DOI 10.1016/S0955-0674(99)80037-4; Sonnenberg A, 1993, Curr Top Microbiol Immunol, V184, P7; TAKEMURA T, 1994, HEARING RES, V79, P99, DOI 10.1016/0378-5955(94)90131-7; TILNEY LG, 1992, ANNU REV CELL BIOL, V8, P257, DOI 10.1146/annurev.cb.08.110192.001353; VARNUMFINNEY B, 1995, NEURON, V14, P1213, DOI 10.1016/0896-6273(95)90268-6; Whitlon DS, 1999, J COMP NEUROL, V406, P361, DOI 10.1002/(SICI)1096-9861(19990412)406:3<361::AID-CNE5>3.0.CO;2-O; Zheng JL, 1997, J NEUROSCI, V17, P8270	26	95	97	0	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	APR	2000	24	4					424	428		10.1038/74286	http://dx.doi.org/10.1038/74286			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	299HK	10742111				2022-12-25	WOS:000086192800026
J	May, RC; Caron, E; Hall, A; Machesky, LM				May, RC; Caron, E; Hall, A; Machesky, LM			Involvement of the Arp2/3 complex in phagocytosis mediated by Fc gamma R or CR3	NATURE CELL BIOLOGY			English	Article							MACROPHAGES; CDC42		Univ Birmingham, Sch Biosci, Birmingham B15 2TT, W Midlands, England; UCL, MRC, Mol Cell Biol Lab, London WC1E 6BT, England; UCL, Dept Biochem & Mol Biol, London WC1E 6BT, England	University of Birmingham; University of London; University College London; University of London; University College London	Machesky, LM (corresponding author), Univ Birmingham, Sch Biosci, Birmingham B15 2TT, W Midlands, England.	L.M.Machesky@bham.ac.uk	Machesky, Laura/Z-4554-2019; May, Robin Charles/ABA-9266-2021	Machesky, Laura/0000-0002-7592-9856; May, Robin Charles/0000-0001-5364-1838				Aderem A, 1999, ANNU REV IMMUNOL, V17, P593, DOI 10.1146/annurev.immunol.17.1.593; ALLEN LAH, 1995, J EXP MED, V182, P829, DOI 10.1084/jem.182.3.829; Allen LAH, 1996, J EXP MED, V184, P627, DOI 10.1084/jem.184.2.627; Araki N, 1996, J CELL BIOL, V135, P1249, DOI 10.1083/jcb.135.5.1249; Caron E, 1998, SCIENCE, V282, P1717, DOI 10.1126/science.282.5394.1717; Cox D, 1997, J EXP MED, V186, P1487, DOI 10.1084/jem.186.9.1487; Downey GP, 1999, J BIOL CHEM, V274, P28436, DOI 10.1074/jbc.274.40.28436; Evangelista M, 2000, J CELL BIOL, V148, P353, DOI 10.1083/jcb.148.2.353; KAPLAN G, 1977, SCAND J IMMUNOL, V6, P797, DOI 10.1111/j.1365-3083.1977.tb02153.x; Lamarche N, 1996, CELL, V87, P519, DOI 10.1016/S0092-8674(00)81371-9; Lechler T, 2000, J CELL BIOL, V148, P363, DOI 10.1083/jcb.148.2.363; Machesky LM, 1997, BIOCHEM J, V328, P105; Machesky LM, 1999, P NATL ACAD SCI USA, V96, P3739, DOI 10.1073/pnas.96.7.3739; Machesky LM, 1998, CURR BIOL, V8, P1347, DOI 10.1016/S0960-9822(98)00015-3; Machesky LM, 1999, CURR OPIN CELL BIOL, V11, P117, DOI 10.1016/S0955-0674(99)80014-3; May RC, 1999, CURR BIOL, V9, P759, DOI 10.1016/S0960-9822(99)80337-6; Roitt I.M, 1977, ESSENTIAL IMMUNOLOGY, V3rd; Swanson JA, 1999, J CELL SCI, V112, P307; VANSTRIJP JAG, 1993, J IMMUNOL, V151, P3324; WRIGHT SD, 1983, J EXP MED, V158, P1338, DOI 10.1084/jem.158.4.1338	20	249	256	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	APR	2000	2	4					246	248		10.1038/35008673	http://dx.doi.org/10.1038/35008673			3	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	302ZU	10783245				2022-12-25	WOS:000086397000020
J	Carnero, A; Hudson, JD; Price, CM; Beach, DH				Carnero, A; Hudson, JD; Price, CM; Beach, DH			p16(INK4A) and p19(ARF) act in overlapping pathways in cellular immortalization	NATURE CELL BIOLOGY			English	Article							TUMOR-SUPPRESSOR; RETINOBLASTOMA-PROTEIN; REPLICATIVE SENESCENCE; INK4A LOCUS; MDM2; P53; TELOMERASE; INHIBITION; EXPRESSION; APOPTOSIS	The INK4A locus encodes two independent but overlapping genes, p16(INK4A) and p19(ARF), and is frequently inactivated in human cancers. The unusual structure of this locus has lead to ambiguity regarding the biological role of each gene. Here we express, in primary mouse embryonic fibroblasts (MEFs), antisense RNA constructs directed specifically towards either p16(INK4A) or p19(ARF). Such constructs induce extended lifespan in primary MEFs; this lifespan extension is reversed upon subsequent elimination of the p16(INK4A) or p19(ARF) antisense constructs. In immortal derivatives of cell lines expressing antisense p16(INK4A) or p19(ARF) RNA, growth arrest induced by recovery of p16(INK4A) expression is bypassed by compromising the function of the retinoblastoma protein (Rb), whereas growth arrest induced by re-expression of p19(ARF) is overcome only by simultaneous inactivation of both the Rb and the p53 pathways. Thus, the physically overlapping p16(INK4A) and p19(ARF) genes act in partly overlapping pathways.	Inst Child Hlth, London WC1 1EH, England	University of London; University College London	Beach, DH (corresponding author), Inst Child Hlth, 30 Guilford St, London WC1 1EH, England.		IBIS, CANCER/P-3323-2015	Carnero, Amancio/0000-0003-4357-3979				Alcorta DA, 1996, P NATL ACAD SCI USA, V93, P13742, DOI 10.1073/pnas.93.24.13742; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Campisi J, 1997, EUR J CANCER, V33, P703, DOI 10.1016/S0959-8049(96)00058-5; Chin L, 1998, TRENDS BIOCHEM SCI, V23, P291, DOI 10.1016/S0968-0004(98)01236-5; Hannon GJ, 1999, SCIENCE, V283, P1129, DOI 10.1126/science.283.5405.1129; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; HIEBERT SW, 1995, MOL CELL BIOL, V15, P6864; Iravani M, 1997, ONCOGENE, V15, P2609, DOI 10.1038/sj.onc.1201428; Johnson BE, 1998, MATH MECH SOLIDS, V3, P447, DOI 10.1177/108128659800300405; Kamb A, 1998, CURR TOP MICROBIOL, V227, P139; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; Macleod K, 1999, CURR OPIN GENET DEV, V9, P31, DOI 10.1016/S0959-437X(99)80005-7; MEDEMA RH, 1995, P NATL ACAD SCI USA, V92, P6289, DOI 10.1073/pnas.92.14.6289; Nevins JR, 1997, J CELL PHYSIOL, V173, P233, DOI 10.1002/(SICI)1097-4652(199711)173:2<233::AID-JCP27>3.0.CO;2-F; Noble JR, 1996, ONCOGENE, V13, P1259; Pan HC, 1998, MOL CELL, V2, P283, DOI 10.1016/S1097-2765(00)80273-7; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; RITTLING SR, 1992, ONCOGENE, V7, P935; RUAS R, 1998, BIOCHIM BIOPHYS ACTA, V1378, P115; SERRANO M, 1995, SCIENCE, V267, P249, DOI 10.1126/science.7809631; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Sun PQ, 1998, SCIENCE, V282, P2270, DOI 10.1126/science.282.5397.2270; Wang XD, 1998, BIO-MED MATER ENG, V8, P1; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zindy F, 1997, ONCOGENE, V15, P203, DOI 10.1038/sj.onc.1201178	33	206	216	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	MAR	2000	2	3					148	155		10.1038/35004020	http://dx.doi.org/10.1038/35004020			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	292AE	10707085				2022-12-25	WOS:000085771300014
J	Triendl, R				Triendl, R			Genomics forges ahead in East Asia	NATURE BIOTECHNOLOGY			English	Article								National efforts to encourage genomics research in East Asia are providing impetus to the entire biotechnology sector.	Mitsubishi Kasei Inst Life Sci, Sci & Soc Program, Tokyo, Japan										0	4	4	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAR	2000	18	3					278	279		10.1038/73714	http://dx.doi.org/10.1038/73714			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	292AC	10700140				2022-12-25	WOS:000085771100022
J	Zheng, CY; Baum, BJ; Iadarola, MJ; O'Connell, BC				Zheng, CY; Baum, BJ; Iadarola, MJ; O'Connell, BC			Genomic integration and gene expression by a modified adenoviral vector	NATURE BIOTECHNOLOGY			English	Article						gene therapy; adeno-retrovirus vector	MURINE LEUKEMIA-VIRUS; NUCLEAR-PORE COMPLEX; RECOMBINANT ADENOVIRUS; RETROVIRAL DNA; CELL-LINE; POL GENE; IN-VIVO; INFECTION; THERAPY; ASSOCIATION	A replication-deficient recombinant adenovirus encoding luciferase was constructed using 5' and 3' long terminal repeat (LTR) sequences of the Moloney murine leukemia virus, Gene expression was observed in cultured cells in vitro and in submandibular gland, cortex, and caudate nucleus for as long as three months in vivo. The vector integrated randomly into the genome of both dividing and nondividing cells as determined by fluorescence in situ hybridization (FISH) (10-15% of cells in vitro and 5% in rat spleen in vivo), gene walking, Southern hybridization, and polymerase chain reaction (PCR), in the absence of transcomplementing reverse transcriptase or integrase activity. The new vector combines the high titer and versatility of adenoviral vectors with the long-term gene expression and integration of retroviral vectors.	Natl Inst Dent & Craniofacial Res, Gene Therapy & Therapeut Branch, NIH, Bethesda, MD 20892 USA; Natl Inst Dent & Craniofacial Res, Pain & Neurosensory Mechanisms Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Baum, BJ (corresponding author), Natl Inst Dent & Craniofacial Res, Gene Therapy & Therapeut Branch, NIH, Bethesda, MD 20892 USA.			O'Connell, Brian/0000-0003-4529-7664	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000688] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000688] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Adesanya MR, 1996, HUM GENE THER, V7, P1085, DOI 10.1089/hum.1996.7.9-1085; Anderson WF, 1998, NATURE, V392, P25; Asante-Appiah E, 1997, ANTIVIR RES, V36, P139, DOI 10.1016/S0166-3542(97)00046-6; BAJOCCHI G, 1993, NAT GENET, V3, P229, DOI 10.1038/ng0393-229; BECKER TC, 1994, METHOD CELL BIOL, V43, P161; BLAESE RM, 1995, SCIENCE, V270, P475, DOI 10.1126/science.270.5235.475; BOULTER CA, 1987, NUCLEIC ACIDS RES, V15, P7194, DOI 10.1093/nar/15.17.7194; BROWN AM, 1989, J ORAL PATHOL MED, V18, P206, DOI 10.1111/j.1600-0714.1989.tb00764.x; Brown P. O., 1997, P161; Caplen NJ, 1999, GENE THER, V6, P454, DOI 10.1038/sj.gt.3300835; Chen LM, 1997, HUM GENE THER, V8, P341, DOI 10.1089/hum.1997.8.3-341; COLICELLI J, 1985, CELL, V42, P573, DOI 10.1016/0092-8674(85)90114-X; CRYSTAL RG, 1995, SCIENCE, V270, P404, DOI 10.1126/science.270.5235.404; DALES S, 1973, VIROLOGY, V56, P465, DOI 10.1016/0042-6822(73)90050-0; Daniel R, 1999, SCIENCE, V284, P644, DOI 10.1126/science.284.5414.644; DONEHOWER LA, 1984, P NATL ACAD SCI-BIOL, V81, P6461, DOI 10.1073/pnas.81.20.6461; Dong JY, 1996, HUM GENE THER, V7, P319, DOI 10.1089/hum.1996.7.3-319; Feng MZ, 1997, NAT BIOTECHNOL, V15, P866, DOI 10.1038/nbt0997-866; GILGENKRANTZ H, 1995, HUM GENE THER, V6, P1265, DOI 10.1089/hum.1995.6.10-1265; GOFF SP, 1992, ANNU REV GENET, V26, P527, DOI 10.1146/annurev.ge.26.120192.002523; Greber UF, 1997, EMBO J, V16, P5998, DOI 10.1093/emboj/16.19.5998; Greber UF, 1996, EMBO J, V15, P1766, DOI 10.1002/j.1460-2075.1996.tb00525.x; HAGINOYAMAGISHI K, 1987, J VIROL, V61, P1964, DOI 10.1128/JVI.61.6.1964-1971.1987; HAREL J, 1981, VIROLOGY, V110, P202, DOI 10.1016/0042-6822(81)90022-2; Harui A, 1999, J VIROL, V73, P6141, DOI 10.1128/JVI.73.7.6141-6146.1999; HENG HHQ, 1992, P NATL ACAD SCI USA, V89, P9509, DOI 10.1073/pnas.89.20.9509; HODGSON CP, 1996, MED INTELL UNIT, P1; LEE MS, 1994, P NATL ACAD SCI USA, V91, P9823, DOI 10.1073/pnas.91.21.9823; Mannes AJ, 1998, BRAIN RES, V793, P1, DOI 10.1016/S0006-8993(97)01422-4; MILLER DG, 1990, MOL CELL BIOL, V10, P4239, DOI 10.1128/MCB.10.8.4239; MULLER HP, 1992, EMBO J, V66, P5092; MURPHY JE, 1992, J VIROL, V66, P5092, DOI 10.1128/JVI.66.8.5092-5095.1992; Nabel GJ, 1999, P NATL ACAD SCI USA, V96, P324, DOI 10.1073/pnas.96.2.324; PANGANIBAN AT, 1983, NATURE, V306, P155, DOI 10.1038/306155a0; PANGANIBAN AT, 1984, P NATL ACAD SCI-BIOL, V81, P7885, DOI 10.1073/pnas.81.24.7885; Ramsey WJ, 1998, BIOCHEM BIOPH RES CO, V246, P912, DOI 10.1006/bbrc.1998.8726; Roe T, 1997, J VIROL, V71, P1334, DOI 10.1128/JVI.71.2.1334-1340.1997; ROTH MJ, 1989, CELL, V58, P47, DOI 10.1016/0092-8674(89)90401-7; SCHAACK J, 1990, GENE DEV, V4, P1197, DOI 10.1101/gad.4.7.1197; SCHWARTZBERG P, 1984, CELL, V37, P1043, DOI 10.1016/0092-8674(84)90439-2; SHIRASUNA K, 1981, CANCER, V48, P745, DOI 10.1002/1097-0142(19810801)48:3<745::AID-CNCR2820480314>3.0.CO;2-7; SPRINGETT GM, 1989, J VIROL, V63, P3865, DOI 10.1128/JVI.63.9.3865-3869.1989; Suzuki M, 1998, HUM GENE THER, V9, P1223, DOI 10.1089/hum.1998.9.8-1223; TORRENT C, 1998, 1 ANN M AM SOC GEN T; Verma IM, 1997, NATURE, V389, P239, DOI 10.1038/38410; VILE RG, 1998, 1 ANN M AM SOC GEN T; YANAGAWA T, 1986, VIRCHOWS ARCH B, V51, P1871; YANG Y, 1995, NAT MED, V9, P890	48	62	73	0	3	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	FEB	2000	18	2					176	180		10.1038/72628	http://dx.doi.org/10.1038/72628			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	281FH	10657124				2022-12-25	WOS:000085146900024
